source_id@collection_memberships.#1@collection_memberships.#2@collection_memberships.#3@collection_memberships.#4@collection_memberships.#5@subscription.#1@subscription.#2@subscription.#3@subscription.#4@subscription.#5@Acronym@Administration@Asset_Classification@ONCO_ATC_Code@ATC_Level3@Black_Box@Company_HQ@Completion_Date@Current_Status@Drug_Description@Drug_Type@DynamicObjectID@ONCO_Full_Indication@Gender@ONCO_Hospital_Status@HTA_Decision_Date.RawValue@HTA_Decision_Date.Value@ICER_QALYs@Intervention@Intervention_Type@Length_Of_Trial@Level_Of_Reimbursement@Licensing_Status@Line_Of_Therapy@NCT_Code@No_Of_Patients@Official_Dosage@ONCO_Approval_Date.RawValue@ONCO_Approval_Date.Value@ONCO_Marketing_Date@ONCO_Orphan_Drug@Breakthrough_Therapy@ONCO_Start_Date@ONCO_Warnings@Other_IDs@ONCO_Parallel_Import@Patent_Expiration@Patient_Description@Patient_Profile@Patient_Profile_Age_Groups@Phase_Of_Trial@Portfolio_Pipeline_Status@ONCO_Regulatory_Submission_Date@Reimbursement_Guidance@Reimbursement_Plan@Results_Efficacy@Results_Safety_and_Adverse_Events@Sponsors@Study_Funded_By@ONCO_Therapeutic_Class@Type_Of_Therapy@API.#1@API.#2@API.#3@API.#4@API.#5@API_KEY@ONCO_Company.#1@ONCO_Company.#2@ONCO_Company.#3@ONCO_Company.#4@ONCO_Company.#5@ONCO_Company_KEY@Country_Clinical_Trial.#1@Country_Clinical_Trial.#2@Country_Clinical_Trial.#3@Country_Clinical_Trial.#4@Country_Clinical_Trial.#5@Country_Clinical_Trial_KEY@Disease_Area.#1@Disease_Area.#2@Disease_Area.#3@Disease_Area.#4@Disease_Area.#5@Disease_Area_KEY@Drug.#1@Drug.#2@Drug.#3@Drug.#4@Drug.#5@Drug_KEY@Drug_Class.#1@Drug_Class.#2@Drug_Class.#3@Drug_Class.#4@Drug_Class.#5@Drug_Class_KEY@Primary_Endpoint.#1@Primary_Endpoint.#2@Primary_Endpoint.#3@Primary_Endpoint.#4@Primary_Endpoint.#5@Secondary_Endpoints.#1@Secondary_Endpoints.#2@Secondary_Endpoints.#3@Secondary_Endpoints.#4@Secondary_Endpoints.#5@Stage_Of_Disease.#1@Stage_Of_Disease.#2@Stage_Of_Disease.#3@Stage_Of_Disease.#4@Stage_Of_Disease.#5@Trial_Design.#1@Trial_Design.#2@Trial_Design.#3@Trial_Design.#4@Trial_Design.#5@Assumption_value@Assumption_unit@ATC_Calculation_attempt@Average_Annual_Cost@Average_Cost_Per_Treatment_Cycle@Average_Duration_of_Use.Value@Average_Duration_of_Use.Unit@Average_Duration_of_Use.Comment@Average_Treatment_Cost.RawValue@Average_Treatment_Cost.Value@Cost_Per_Day@Number_of_Units@ONCO_Exchange_Rate@Factory_Price@Retail_Price@Wholesale_Price@PriceTimestamps.ManufacturerPriceDelta.TimeStamp@PriceTimestamps.ManufacturerPriceDelta.ValueChange@PriceTimestamps.ManufacturerPriceDelta.PercentageChange@PriceTimestamps.WholesalerPriceDelta.TimeStamp@PriceTimestamps.WholesalerPriceDelta.ValueChange@PriceTimestamps.WholesalerPriceDelta.PercentageChange@PriceTimestamps.RetailerPriceDelta.TimeStamp@PriceTimestamps.RetailerPriceDelta.ValueChange@PriceTimestamps.RetailerPriceDelta.PercentageChange@Price_Per_MG@Treatment_Phase_1.Cycle_Duration@Treatment_Phase_1.Cycle_Repetition@Treatment_Phase_1.Dosage_Unit@Treatment_Phase_1.Dosage_Value@Treatment_Phase_1.Treatment_Duration@Treatment_Phase_2.Cycle_Duration@Treatment_Phase_2.Cycle_Repetition@Treatment_Phase_2.Dosage_Unit@Treatment_Phase_2.Dosage_Value@Treatment_Phase_2.Treatment_Duration@Treatment_Phase_3.Cycle_Duration@Treatment_Phase_3.Cycle_Repetition@Treatment_Phase_3.Dosage_Unit@Treatment_Phase_3.Dosage_Value@Treatment_Phase_3.Treatment_Duration@Price_Date@ONCO_Price_per_Unit.RawValue@ONCO_Price_per_Unit.Value@Import_Id@Form@Currency@Active_Ingredients.Original.Active_Ingredient@Active_Ingredients.Original.Input_Language@Active_Ingredients.Original.Active_Ingredient_Translated@Active_Ingredients.Original.Volume@Active_Ingredients.Original.Volume_Unit@Active_Ingredients.Original.Dose@Active_Ingredients.Original.Dose_Unit@Active_Ingredients.Original.Strength@Active_Ingredients.Original.Strength_Unit@Active_Ingredients.Original.Strength_Comment@Active_Ingredients.Original.DDD@Active_Ingredients.Original.DDD_Unit@Active_Ingredients.Original.DDD_Comment@Active_Ingredients.Extracted.Active_Ingredient_Item.#1@Active_Ingredients.Extracted.Active_Ingredient_Item.#2@Active_Ingredients.Extracted.Active_Ingredient_Item.#3@Active_Ingredients.Extracted.Active_Ingredient_Item.#4@Active_Ingredients.Extracted.Active_Ingredient_Item.#5@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#1@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#2@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#3@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#4@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#5@Active_Ingredients.Extracted.Strength_Item.#1@Active_Ingredients.Extracted.Strength_Item.#2@Active_Ingredients.Extracted.Strength_Item.#3@Active_Ingredients.Extracted.Strength_Item.#4@Active_Ingredients.Extracted.Strength_Item.#5@Active_Ingredients.Extracted.Strength_CALC@Active_Ingredients.Extracted.Strength_unit@Active_Ingredients.Extracted.Strength_value@Active_Ingredients.Extracted.DDD@TimeStamp@geographic_location.#1.row_id@geographic_location.#1.name@geographic_location.#2.row_id@geographic_location.#2.name@geographic_location.#3.row_id@geographic_location.#3.name@geographic_location.#4.row_id@geographic_location.#4.name@geographic_location.#5.row_id@geographic_location.#5.name
0.01@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01XX11@L01X@NO@HOLZKIRCHEN, GERMANY@@@Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. The low level of clinical side effects may be due to the fact that estramustine binds to a protein present in the tumour tissue, so resulting in accumulation of the drug at the target site. Estracyt also has weak oestrogenic and anti-gonadotrophic properties. Estramustine causes little or no bone marrow depression at usual therapeutic dosage. Estramustine is effective in patients who have not previously received drug therapy, as well as in those who have shown no response to conventional hormone treatment.@@14918323@Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyestradiol phosphate etc.) or by orchidectomy.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Dosage range may be from 1 to 10 capsules a day by mouth. The capsules should be taken not less than 1 hour before or 2 hours after meals. The capsules should not be taken with milk or milk products. Standard starting dosage is 4-6 capsules a day in divided doses with later adjustment according to response and gastrointestinal tolerance.@@@@@@@Use with caution in patients with moderate to severe bone marrow depression, thrombophlebitis, thrombosis, thromboembolic disorders, cardiovascular disease, coronary artery disease and congestive heart failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ESTRAMUSTINE PHOSPHATE SODIUM@@@@@ESTRAMUSTINE PHOSPHATE SODIUM||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Oestrogen@Nitrogen Mustard Analogue@@@@Oestrogen|Nitrogen Mustard Analogue|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@113.33@154.27@117.6@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@2.27@2.27@882678@HARD CAPSULE@EURO@@@@@@@@280@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916569@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients enrolled in the trial will receive three weekly doses of 72 mg/m2 of voreloxin in a treatment cycle.@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@12/1/2009@@Voreloxin (also known as SNS-595) is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site- selective DNA damage, irreversible G2 arrest and rapid apoptosis. The topoisomerase II-associated DNA intercalation and DNA damage produced by voreloxin show greater selectivity for proliferating cells.  In nonclinical evaluations, voreloxin demonstrates broad and potent activity in tumor biopsies and in xenograft, syngeneic and drug-resistant tumor models. In addition to the REVEAL-1 Phase 2 clinical trial in elderly AML patients, voreloxin is being evaluated in combination with cytarabine in a Phase 1b clinical trial and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types. @@14916569@Untreated AML in patients older than 60@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00607997@55@-@-@@@-@@2/1/2008@-@REVEAL-1@@-@In order to qualify for the trial, patients must be at least age 60 with previously untreated AML and satisfy at least one of the following factors: poor performance status (PS 2); intermediate or unfavorable cytogenetics; prior antecedent hematologic disorder; or age greater than or equal to 70 years. @@@II; SPO-0014@II@@-@-@RESULTS PENDING@-@@@@MONO@VORELOXIN@@@@@VORELOXIN||||@SUNESIS PHARMACEUTICALS@@@@@SUNESIS PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@SNS-595@@@@@SNS-595||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16395657@Onco@@@@@300f1037ntsdm@@@@@@10 mg once daily or 10 mg once daily for 21 days every 28 days. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16395657@Indicated for the treatment of patients with transfusiondependent anaemia due to low or intermediate1risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.@@YES@@@NO REVIEW@@@@@@@@148@The recommended starting dose of lenalidomide is 10 mg orally once daily on days 121 of repeated 28day cycles. Dosing is continued or modified based upon clinical and laboratory findings.@EMA, 25 April 2013@4/25/2013@@Yes@@@@MDS003@No@@148 PATIENTS WHO HAD RBC TRANSFUSION DEPENDENT ANEMIA. RBCTRANSFUSION DEPENDENCE WAS DEFINED AS HAVING RECEIVED = 2 UNITS OF RBCS WITHIN 8 WEEKS PRIOR TO STUDY TREATMENT. THE STUDY ENROLLED PATIENTS WITH ABSOLUTE NEUTROPHIL COUNTS (ANC) = 500 CELLS/MM3,@@@III@APPROVED@@@SNS@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@OPEN-LABEL@SINGLE-ARM@MULTI-CENTRE@@@1@1@4837.415982@@@56@day@56 day@4837.42@4837.42@86.38@21@1.1511@6046.77@6346.79@6054.31@@@@@@@@@@11.52@28@@mg@10@21@@@@@@@@@@@8/4/2017@287.94@287.94@652652@CAPSULE@EURO@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921624@Onco@@@@@300f1018ntsdm@@@@@@AZD-2281 oral bid with cisplatin IV every 3 weeks [AstraZeneca]@@-@-@-@LONDON, UNITED KINGDOM@11/1/2010@@A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. PARP inhibitor AZD2281 selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.@@14921624@AZD2281 Administered Orally in Combination With Cisplatin, to Assess the Safety and Tolerability in Patients With Advanced Solid Tumours, and to Assess Efficacy in the Neoadjuvant Setting for Patients With Triple Negative Breast Cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@@NCT00782574@18@-@-@@@-@@11/1/2008@-@D0810C00021@@-@>> Life expectancy of at least 12 weeks     >> Histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent       >> Patients with measurable or non measurable disease according to RECIST@@@I/II@I@@-@-@Trial registered. [AstraZeneca, 29.10.2008]@-@@@@NEOADJUVANT@-@CISPLATIN@@@@-|CISPLATIN|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@HER2-@@@@Breast Cancer|HER2-||||||||@AZD-2281@@@@@AZD-2281||||@PARP Inhibitor@@@@@PARP Inhibitor||||@SAFETY@@@@@EXPOSURE@RESPONSE RATE@@@@METASTATIC@TRIPLE NEGATIVE@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16388209@Onco@@@@@@@@@@@"DC-PNAT/PMAT cells, Experimental, DC-PNAT/PMAT cells combined with Chemotherapy treatment: Chemotherapy:
once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT/PMAT cells：once per 3 weeks with a total of three periods.
Chemotherapy, Active Comparator, Chemotherapy:
once a week with a total of six times before 60 days prior to the start of drawing blood.
"@@@@@CHINA@3/1/2018@@@@16388209@A Clinical Study of Dendritic Cell-Precision Neoantigen T Cells/Precision Multiple Antigen T Cells Combined With Chemotherapy in Advanced Gastric Cancer@Both@@@@@Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.@@@@@-@NCT02862561@40@@@@@@@8/1/2016@@SIMC-20160104@@@-  Age 18~65 years old, male or female;  -  Life expectancy≥6 months;  -  ECOG score: 0-3;  -  Advanced Malignancies (gastric cancer) were diagnosed by pathological or clinical physicians;  -  Enough venous channel, no other contraindications to the separ@-@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@-@CISPLATIN@5-FU@@@-|CISPLATIN|5-FU||@SHANGHAI INTERNATIONAL MEDICAL CENTER@@@@@SHANGHAI INTERNATIONAL MEDICAL CENTER||||@China@@@@@China|||||||||@GIST@@@@@GIST|||||||||@DC-PNAT/PMAT@GENERIC@GENERIC@@@DC-PNAT/PMAT|GENERIC|GENERIC||@Other@@@@@Other||||@OVERALL SURVIVAL@Progress-free survival@@@@QUALITY OF LIFE@@@@@ADVANCED@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923498@Onco@@@@@@@@@@@Received standard first-line chemotherapy, carboplatin/paclitaxel (C/P), plus either oral talactoferrin or placebo.@@-@-@-@HOUSTON, TEXAS@@@Talactoferrin, a novel dendritic cell activator (DCA), is a unique recombinant form of human lactoferrin, an important immunomodulatory protein. Lactoferrin, found in the highest concentration in milk, is expressed throughout the body in immune cells and on all body surfaces exposed to the external environment. Lactoferrin plays an important role in helping to establish the immune system, including the Gut Associated Lymphoid Tissue (GALT), in infants. Talactoferrin is produced in Aspergillus niger, a filamentous fungus, and is structurally identical to native human lactoferrin in all material respects, differing only in its glycosylation.@@14923498@First-line@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@-@110@-@FDA confirmed that the Phase II trial provided the basis for moving forward with a large, pivotal Phase III trial in NSCLC and that the Phase II trial could provide supporting data for a BLA. The FDA also provided Fast Track designation for the development of talactoferrin as a first-line treatment in NSCLC. The FDA agreed that (i) the trial can be global without a requirement for any minimum number of patients from the U.S., provided that the standard of care is uniform across countries and that patients are appropriately stratified by region; (ii) it is appropriate to use carboplatin + paclitaxel (the chemotherapy used in Phase II) as the comparator arm even with the approval of Avastin, since Avastin's approval only applies to about 50% of patients with locally advanced or metastatic NSCLC and is associated with significant toxicities; (iii) PFS can be the primary endpoint for accelerated approval with the trial also powered to eventually look at overall survival for full approval; and (iv) a single pivotal trial powered for a high degree of statistical significance (p=0.01) for the PFS primary endpoint is acceptable. SPA package has been submitted.@@@-@@@-@-@@-@-@@@II@II@@-@-@ASCO 2006; the study met its primary endpoint with a substantial improvement in response rate. The median PFS in the ITT and evaluable patients increased by 2.8 months (67% improvement), from 4.2 months (C/P+placebo) to 7.0 months (C/P+talactoferrin). The median duration of response in the patients with a confirmed response increased by 2.1 months (39%) from 5.5 months (C/P+placebo) to 7.6 months (C/P+talactoferrin). The median overall survival in the ITT population increased by 1.9 months (22% improvement), from 8.5 months (C/P+placebo) to 10.4 months (C/P+talactoferrin), and in the prospectively defined evaluable population by 2.8 months (33% improvement) from 8.5 months to 11.3 months.@-@@@@COMBO@TALACTOFERRIN ALFA@CARBOPLATIN@PACLITAXEL@@@TALACTOFERRIN ALFA|CARBOPLATIN|PACLITAXEL||@AGENNIX@@@@@AGENNIX||||@India@@@@@India|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Immunotherapy@@@@@Immunotherapy||||@RECIST@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16668393@Onco@@@@@300f1020ntsdm@@@@@@Once daily@@L01XE27@L01X@@BEERSE, BELGIUM@5/1/2014@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16668393@Indicated for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy@Both@YES@30-Oct-16@10/30/2016@NO REVIEW@@@@@@@NCT01614821@63@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 3 July 2015@7/3/2015@@YES@@5/1/2012@@12-015@No@@Clinicopathological diagnosis of Waldenstrom's MacroglobulinemiaMeasurable disease; Have received at least one prior therapy for WM therapies@@ADULTS@II@APPROVED@@Included into the reimbursement list on 30 October 2016 [http://www.aifa.gov.it/content/pubblicazione-schede-di-monitoraggio-registro-imbruvica-05102016]@SSN@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Waldenstrom's Macroglobinaemia@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Waldenstrom's Macroglobinaemia|||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@OVERALL RESPONSE RATE@@@@@SAFETY@PROGRESSION-FREE SURVIVAL@@@@@@@@@OPEN LABEL@MULTICENTER@SINGLE-ARM@@@1@1@6150.267219@@@1@month@1 month@6150.27@6150.27@202.21@120@1.1229@8088.2@13348.76@8452.26@@@@@@@@@@0.48@1@@mg@420@1@@@@@@@@@@@6/7/2017@67.4@67.4@43693023@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921821@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@7mg/m2 on days 1,8 and 15 of a 28-day schedule (arm A) or 18mg/m2 every 21 days (arm B). The median number of cycles was 2 for each arm. @@-@-@-@BRENTFORD, UNITED KINGDOM@@@Ispinesib is a novel small molecule drug candidate that inhibits cell proliferation and promotes cancer cell death by specifically disrupting the function of a cytoskeletal protein known as kinesin spindle protein, or KSP. Current drugs that inhibit cell proliferation, such as paclitaxel and docetaxel, are standard treatments for many types of cancers, but these drugs also target other proteins that are essential to other important cellular functions and thus, their use is limited by side effects. @@14921821@-@@-@-@@NO REVIEW@@@@-@Part of wide-ranging 2001 partnership between Cytokinetics and GSK to discover and commercialise small moleculaes targeting mitotic kinesins in cancer; being positioned against Nexavar and Sutent@-@NCT00103311@76@-@-@@@-@@@-@CCC-PHII-51@@-@-@@@II@II@@-@-@>> Cytokinetics is discontinuing research activities related to oncology. [Cytokinetics, 16.09.2008]>> 8 patients had stable disease (3 in Arm A; 5 in Arm B) and 49 had progressive disease (25 in Arm A; 24 in Arm B). Response data were not available in 7 patients as they went off treatment too early to assess response. PFS was 49 days in Arm A (95% CI: 44 to 51) and 37 days in Arm B (95% CI: 35 to 42 days). Ispinesib did not manifest an objective response rate on the two schedules evaluated in heavily pretreated patients with colorectal cancer. The most common grade 3/4 toxicities in Arm A included neutropaenia (n=3), nausea (n=3), vomiting(n=2) and fatigue (n=2). The most common grade 3/4 toxicity in Arm B was neutropaenia (n=20), one of which was febrile. Weekly dose given for 3 weeks every 28 days (Arm A) appeared to have a more favorable toxicity profile compared to the once every 21 day schedule (Arm B). [Cytokinetics/ASCO, June 2007]@-@@@@MONO@ISPINESIB@@@@@ISPINESIB||||@GSK@CYTOKINETICS@@@@GSK|CYTOKINETICS|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@SB-715992@@@@@SB-715992||||@KSP Inhibitor@@@@@KSP Inhibitor||||@RESPONSE RATE@TIME TO PROGRESSION@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@METASTATIC@@@@@OPEN-LABEL@RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15399105@Onco@@@@@300f1015ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@15399105@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX.@@YES@@@@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@254@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 13 January 2012@1/13/2012@1/1/2008@No@@@@EMR 62 202-013@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@7/29/2011@@HAUTE AUTORITÉ DE SANTÉ@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@25179.65434@@@7.9@month@7.9 month@25179.65@25179.65@104.79@1@1.1511@823.92@@@@@@@@@@@@1.65@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/2/2017@823.92@823.92@9301111T@SOLUTION FOR PERFUSION 100 ML@EURO@@@@@@@@500@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922298@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will undergo mobilization with G-CSF (10 µg/kg) for 4 days. On Day 4, AMD3100 (240 µg/kg) will be administered in the evening prior to the first apheresis and each subsequent evening prior to apheresis thereafter, such that there is a 10 to 11 hour interval between dosing and the initiation of apheresis. Patients will continue to receive G-CSF on each day of apheresis. Patients will undergo a minimum of 2 and a maximum of 7 aphereses or until =2 x 10e6 CD34+ cells/kg are collected, whichever occurs first. In addition, the mobilization of NHL tumor cells and the pharmacokinetics of repeat doses of AMD3100 will be examined. SOURCE: Genzyme@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@8/1/2009@@Mozobil, a novel small molecule CXCR4 chemokine antagonist, has been shown in multiple earlier studies to rapidly and effectively increase the number of stem cells in circulation in the blood. Once circulating in the blood, stem cells can be collected for use in a stem cell transplant. Mozobil has been granted special protocol assessment and orphan drug status in the United States and European Union and the pivotal trials have undergone Special Protocol Assessment by the FDA and Protocol Assistance by the EMEA. Genzyme intends to commercialize Mozobil through its existing global transplant business to hematologists and hematopoietic stem cell transplant centers in more than 50 countries throughout the world. Genzyme has been developing Mozobil since its acquisition of AnorMED, Inc. in 2006.@@14922298@With GCSF in autologous stem cell transplant@@-@-@@NO REVIEW@@@@-@Acquired via takeover of AnorMED@MULTIPLE@NCT00396331@100@-@-@@@-@@7/1/2005@-@AMD31002112@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@PLERIXAFOR@@@@@PLERIXAFOR||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@@Haematological Malignancy|Myeloma|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma||||||@MOZOBIL@AMD-3100@@@@MOZOBIL|AMD-3100|||@CXCR4 Antagonist@@@@@CXCR4 Antagonist||||@SAFETY@@@@@@@@@@-@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16446638@Onco@@@@@300f1018ntsdm@@@@@@@@L01XX32@L01X@@@@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@16446638@VELCADE, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.@@YES@12-Mar@@NO REVIEW@@@@@@FIRST-LINE@@482@VELCADE plus dexamethasone: VELCADE (bortezomib) is administered as an IV injection in combination with oral dexamethasone for four 3-week treatment cycles as shown in Table 21.@TGA, 30 November 2011@11/30/2011@@No@@@@@No@@@@@III@APPROVED@@The PBAC recommended listing as a Section 100 (Efficient Funding of Chemotherapy) Public and Private Hospital Authority Required listing for the treatment in combination with chemotherapy, of a patient with newly diagnosed symptomatic multiple myeloma who is eligible for high dose chemotherapy and a primary stem cell transplant on a cost-minimisation basis compared with thalidomide.@PBS@@@@@@COMBO@BORTEZOMIB@DEXAMETHASONE@@@@BORTEZOMIB|DEXAMETHASONE|||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@VELCADE@GENERIC@@@@VELCADE|GENERIC|||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@@@@@@@@@@@@@@@@OPEN LABEL@MULTI-CENTRE@RANDOMISED@@@1.75@m²@16934.008@@@84@day@84 day@16934.01@16934.01@201.6@1@0.779@1395.66@@@@@@@@@@@@465.22@21@@mg/m²@1.3@4@@@@@@@@@@@8/1/2017@1395.66@1395.66@3554-2616-IN-JC@POWDER FOR SOLUTION FOR INFUSION/INJECTION@A$@@@@@@@@3@MG@3 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14918671@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918671@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Adult soft tissue sarcoma: For adult soft tissue sarcomas dacarbazine is given in daily doses of 250 mg/m2 body surface area i.v. (days 1-5) in combination with doxorubicin every 3 weeks (ADIC regimen). Restriction of food intake for 4-6 hours prior to treatment may reduce the severity of the nausea and vomiting which occurs in most patients particularly during the first two days of treatment. Because severe gastrointestinal and haematological disturbances can occur an extremely careful benefit-risk analysis has to be made before every course of therapy with dacarbazine.@EMA, November 1997@@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Sarcoma@Melanoma / Skin Cancer@@@@Sarcoma|Melanoma / Skin Cancer||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@37.5@@@@@@@@@@@@0.08@@@@@@@@@@@@@@@@7/28/2017@37.5@37.5@7.32E+15@POWDER FOR SOLUTION FOR INFUSION VIAL@GB£@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917088@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14917088@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@GEPEPHARM@@@@@GEPEPHARM||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@BLEMINOL@@@@@BLEMINOL||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@50@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917087@Onco@@@@@300f1015ntsdm@@@@@@Busulfex (16 doses of 0.8mg/kg every 6 hours as a 2-hour infusion for 4 days) followed by cyclophosphamide 60mg/kg once per day for two days.@@L01AB01@L01A@YES@CASTRES, FRANCE@@@@@14917087@Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option. Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.@@YES@@@NO REVIEW@@@@@@@@61@@@@10/1/2008@@@@Busulfex is a potent cytotoxic drug that causes profound myelosuppression at the recommended dosage. It should be administered under the supervision of a qualified physician who is experienced in allogeneic hematopoietic stem cell transplantation, the use of cancer chemotherapeutic drugs and the management of patients with severe pancytopenia. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available@LABEL@No@@@@@III@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@38% relapsed at a median of 183 days post-transplant. 62% were disease-free at median follow-up of 269 days.@@@@@COMBO@BUSULFAN@CYCLOPHOSPHAMIDE@@@@BUSULFAN|CYCLOPHOSPHAMIDE|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Supportive Care@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Supportive Care|||||||@BUSILVEX@@@@@BUSILVEX||||@Alkylating Agent@Alkylsulfonates@@@@Alkylating Agent|Alkylsulfonates|||@RATE OF RELAPSE@DISEASE-FREE SURVIVAL@@@@@@@@@@@@@@SINGLE-ARM@OPEN-LABEL@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@258.75@@@@@@@@@@@@4.31@@@@@@@@@@@@@@@@8/18/2017@258.75@258.75@9319358T@SOLUTION FOR PERFUSION  (VIAL 10 ML)@EURO@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921020@Onco@@@@@300f1012ntsdm@@@@@@Radiolabeled HumaniSed IMMU-LL2: Treatment With 90Y-hLL2 IgG@@-@-@-@MORRIS PLAINS, NEW JERSEY@@@Naked humanized antibody targeting CD22 receptors on B-lymphocytes.  Primary use is for the treatment of indolent and aggressive NHLs, and for autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren’s Syndrome.  Every year there are 56,000 newly diagnosed cases of NHL and 25,000 deaths.  SLE afflicts up to 1.4 million in the U.S.  In May 2006, epratuzumab was licensed to UCB, S.A. for all autoimmune disease indications worldwide.  A Phase IIb clinical trial for SLE is currently enrolling patients.  Additionally, there are three NCI-sponsored trials in oncology ongoing. @@14921020@B-Cell@@-@-@@NO REVIEW@@@@-@UCB Pharma holds non-oncology rights, with option for a buy-in. North American rights were licensed to Amgen, but returned to Immunomedics in April 2004.@-@NCT00421395@70@-@-@@@-@@8/1/2002@-@IM-T-hLL2-06EU@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@EPRATUZUMAB@@@@@EPRATUZUMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@LYMPHOCIDE@IMMU-102@@@@LYMPHOCIDE|IMMU-102|||@mAb@Humanised@CD22@@@mAb|Humanised|CD22||@MAXIMUM TOLERATED DOSE@SAFETY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916085@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@ARM1: Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle. Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days. ARM2: same dose of Gemzar and cisplatin, with cetuximab, which will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days. SOURCE: clinicaltrials.gov@@L01XC06@L01X@-@NEW YORK, NEW YORK@6/1/2013@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@14916085@Gemzar and cisplatin with or without Erbitux in urothelial cancer@@-@-@@NO REVIEW@@@@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]     >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@-@NCT00645593@81@-@-@@@-@@3/1/2008@-@UMCC 2007.097@@CURRENTLY IN DISPUTE; IMCLONE LOST PROCESS PATENT, EXPIRING IN 2017, TO YEDA IN 2006.@-@-@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@CETUXIMAB@GEMCITABINE@CISPLATIN@@@CETUXIMAB|GEMCITABINE|CISPLATIN||@BMS@IMCLONE@@@@BMS|IMCLONE|||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@ERBITUX@GEMZAR@@@@ERBITUX|GEMZAR|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@RESPONSE RATE@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921387@Onco@@@@@300f1015ntsdm@@@@@@N/A@@L01AB01@L01A@YES@BRENTFORD, UNITED KINGDOM@@@@@14921387@Myleran is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation in patients when the combination of high dose busulfan and cyclophosphamide is considered the best available option. Myleran is indicated for the palliative treatment of the chronic phase of chronic granulocytic leukaemia. Myleran is effective in producing prolonged remission in polycythaemia vera, particularly in cases with marked thrombocytosis. Myleran may be useful in selected cases of essential thrombocythaemia and myelofibrosis.@@NO@@@NO REVIEW@@@@@@@@N/A@• Adults: The recommended dose of busulfan in adult patients is 1 mg/kg every 6 hours for four days, starting seven days prior to transplantation. 60 mg/kg per day of cyclophosphamide is usually given for two days commencing 24 h after the final dose of Busulfan@@@8/11/2006@@@@Myleran is an active cytotoxic agent for use only under the direction of physicians experienced in the administration of such agents. Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, immunisations with live organism vaccines are not recommended. Myleran should be discontinued if lung toxicity develops.@LABEL@No@@@@@N/A@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@Approximately 90% of adults with previously untreated chronic myelogenous leukemia will obtain haematologic remission with regression or stabilization of organomegaly following the use of busulfan. It has been shown to be superior to splenic irradiation with respect to survival times and maintenance of haemoglobin levels, and to be equivalent to irradiation at controlling splenomegaly. It is not clear whether busulfan unequivocally prolongs the survival of responding patients beyond the 31 months experienced by an untreated group of historical controls. Median survival figures of 31 to 42 months have been reported for several groups of patients treated with busulfan, but concurrent control groups of comparable, untreated patients are not available.@@@@@MONO@BUSULFAN@@@@@BUSULFAN||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Supportive Care@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Supportive Care|||||||@MYLERAN@@@@@MYLERAN||||@Alkylating Agent@Alkylsulfonates@@@@Alkylating Agent|Alkylsulfonates|||@HAEMATOLOGIC RESPONSE@OVERALL SURVIVAL@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@1.1511@55@68.16@58.67@@@@@@@@@@1.1@@@@@@@@@@@@@@@@8/1/2017@2.2@2.2@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918231@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14918231@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.@@@12/1/2008@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@OXALIPLATIN@@@@@OXALIPLATIN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@153@@@@@@@@@@@@3.06@@@@@@@@@@@@@@@@8/2/2017@153@153@9312793R@CONCENTRATE FOR SOLUTION FOR INFUSION (ONCO-TAIN VIAL), 10 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916812@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@L01DC01@L01D@YES@BEDFORD, OHIO@@@@@14916812@It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's Disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. February 1996: has also been shown to be useful in the management of malignant pleural effusion and prevention of recurrent pleural effusions.@@NO@@@NO REVIEW@@@@@@@@@Hodgkin's Disease—0.25 to 0.50 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly. After a 50% response, a maintenance dose of 1 unit daily or 5 units weekly intravenously or intramuscularly should be given. Pulmonary toxicity of Blenoxane appears to be dose-related with a striking increase when the total dose is over 400 units. Total doses over 400 units should be given with great caution.@@@@@@@It is recommended that Blenoxane be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Pulmonary fibrosis is the most severe toxicity associated with Blenoxane. The most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis. Its occurrence is higher in elderly patients and in those receiving greater than 400 units total dose, but pulmonary toxicity has been observed in young patients and those treated with low doses. A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in approximately 1% of lymphoma patients treated with Blenoxane.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0006-01@POWDER FOR INJECTION@US$@@@@@@@@30@U@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916245@Onco@@@@@300f1010ntsdm@@@@@@Stable doses of either long-acting oral opioid or transdermal fentanyl with Actiq (200, 400, 600, 800, 1200 and 1600mcg)@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916245@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@257@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@257 OPIOID-TOLERANT ADULT CANCER PATIENTS@@@III; TWO DOSE TITRATION STUDIES@APPROVED@@NO NICE REVIEW@NHS@95 of 127 patients (75%) titrated to a successful dose of Actiq (could be used consistently for at least 2 days without unacceptable side-effects). 11% and 14% withdrew due to adverse events or other reasons respectively.@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOSE-RANGING@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.2961@210.41@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.01@7.01@2.69E+15@LOZENGE@GB£@@@@@@@@800@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921372@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are assigned to 1 of 2 groups according to timing of disease progression while enrolled on protocol FAV-ID-06 (disease progression after prior rituximab AND never randomized vs disease progression after randomization to placebo arm). Patients receive autologous immunoglobulin idiotype-KLH vaccine subcutaneously (SC) on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats monthly for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive additional treatment as above every 2 months for 1 year (6 treatments) and every 3 months until disease progression. After completion of study treatment, patients are followed for 30 days or until the start of subsequent treatment.@@-@-@-@-@@@Specifid (mitumprotimut-T, formerly FavId) is a personalized, active immunotherapy designed to stimulate a patient's immune system to mount a specific and sustained response to the patient's cancer. specifid is based upon a recombinant protein, called idiotype (Id), which is derived from genetic material obtained from a patient's own tumor, then conjugated to keyhole limpet hemocyanin (KLH), a protein commonly use.@@14921372@Progressive NHL@@-@-@@NO REVIEW@@@@-@-@-@NCT00104819@238@-@-@@@-@@9/1/2004@-@FAV-ID-09@@-@-@@@II; CWRU-FVID-2404, CWRU-100415, CASE-2404, FAV-WIRB-20041124; @DISCONTINUED@@-@-@All development discontinued following failure of pivotal FAV-ID-06 trial. SOURCE: Favrille, 27 May 2008@-@@@@COMBO@MITUMPROTIMUT-T@@@@@MITUMPROTIMUT-T||||@FAVRILLE@@@@@FAVRILLE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@FAVLD@SPECIFID@@@@FAVLD|SPECIFID|||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921523@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921523@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@YES@5-May@@NO REVIEW@@@@@@@@@In combination chemotherapy the usual dose (25-30 mg/m²) is usually maintained, while the frequency of administration is reduced e.g. day 1 and 5 every 3 weeks or day 1 and 8 every 3 weeks according to treatment protocol.@Apr-89@@9/1/1989@No@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@EXPIRED@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@COMBO@VINORELBINE TARTRATE@CISPLATIN@@@@VINORELBINE TARTRATE|CISPLATIN|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@ADVANCED@REFRACTORY@@@@@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@4993.66@4993.66@13.68@1@1.1511@103@@@@@@@@@@@@2.06@@@@@@@@@@@@@@@@8/2/2017@103@103@9137189R@INJECTABLE SOLUTION, 5 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16078284@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"Selinexor Plus HDM HCT, Experimental, The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.
"@@@@@@8/1/2019@@@@16078284@Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma@Both@@@@@Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.@@@@@@NCT02780609@46@@@@@@@7/1/2016@@MCC-18630@@@18 years of age or older with histologically confirmed multiple myeloma  -  Achieving partial response (PR) or very good partial response (VGPR) with systemic chemotherapy  -  Received less than 3 lines of anti-myeloma therapy.  -  Karnofsky performance status of >= 70%  -  Adequate pulmonary, cardiac, hepatic and renal function as outlined in the protocol  -  Signed informed consent form in accordance with institutional policies prior to the initiation of high-dose therapy@COMBO@Adult@Phase 1/Phase 2@I/II@@@@@@@@@@SELINEXOR@MELPHALAN@@@@SELINEXOR|MELPHALAN|||@KARYOPHARM THERAPEUTICS@@@@@KARYOPHARM THERAPEUTICS||||@United States@@@@@United States|||||||||@Myeloma@@@@@Myeloma|||||||||@-@ALKERAN@@@@-|ALKERAN|||@Other@@@@@Other||||@Phase I: Recommended Phase II Dose (RPh2D)@Phase II: Complete Response (CR)@@@@@@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920787@Onco@@@@@300f1012ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920787@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@@@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@APPROVED@@@GKV@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KEVATRIL@@@@@KEVATRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@UNCONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@15.19@30.19@16.37@@@@@@@@@@7.6@@@@@@@@@@@@@@@@8/1/2017@15.19@15.19@8532647@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15412799@Onco@@@@@@@@@@@Group 1, Experimental, Part 1: Sym015 dose titration cohorts followed byPart 2: a &quot;Basket Cohort&quot; of patients with MET-amplified solid tumor malignancies receiving Sym015 in the RP2D and selected dosing schedule (Q2W or Q3W)@@@@@@3/1/2019@@@@15412799@An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies@Both@@@@@@@@@@@NCT02648724@70@@@@@@@3/1/2016@@Sym015-01@@@Main inclusion criteria all patients, Part 1 and Part 2:  -  Male or female, at least 18 years of age at the time of informed consent  -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1  -  Life expectancy >3 months assessed during Screening  -  Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic, and that is refractory to standard therapy or for which no standard therapy is available  Additional main inclusion criteria applicable to Part 2, Basket Cohort patients ONLY:  -  Measurable disease according to RECIST v1.1 that has been confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks prior to Cycle 1/Day 1 (C1/D1)  -  Confirmed MET-amplification@MONO@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@@-@@@@@-||||@SYMPHOGEN@@@@@SYMPHOGEN||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@SYM015@@@@@SYM015||||@Other@@@@@Other||||@Part 1: Assess the safety and tolerability of Sym015 by occurrence of dose-limiting toxicities (DLT) measured during Cycle 1 of Sym015 administration on an every second week or every third week dosing schedule.@Part 2: Confirmed objective antitumor response by RECIST v1.1@@@@Determine dosing regimen for Sym015 by evaluating the patient data for DLT's from Part 1 of the study.@Evaluate the anti-drug antibody profile of patients treated with Sym015 for immunogencity@@@@ADVANCED@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16061251@Onco@@@@@@@@@@@LY3022855 + Durvalumab (Dose Escalation), Experimental, LY3022855 given intravenously (IV) in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.LY3022855 + Tremelimumab (Dose Escalation), Experimental, LY3022855 given IV in combination with tremelimumab given IV. Treatment may continue until disease progression or discontinuation.LY3022855 + Durvalumab (Expansion), Experimental, LY3022855 given IV in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.LY3022855 + Tremelimumab (Expansion), Experimental, LY3022855 given IV in combination with tremelimumab given IV. Treatment may continue until disease progression or discontinuation.@@@@@@11/1/2018@@@@16061251@A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors@Both@@@@@Administered IV@@@@@@NCT02718911@178@@@@@@@5/1/2016@@16348@@@Must have histological or cytological evidence of a diagnosis of cancer that is not amenable to curative therapy.  -  Part B: Must have a type of malignancy that is being studied.  -  Part A and Part B: Must be willing to undergo pretreatment and on-treatment core needle or excisional tumor biopsies.  -  Part A (all cohorts): Have the presence of measureable and /or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.  -  Part B (all cohorts): Have the presence of measurable disease as defined by the RECIST 1.1.  -  Have adequate normal organ and marrow function, including the following:  -  Absolute neutrophil count ≥ 1.5 x 10⁹/Liters (L) (1500/cubic millimeters)  -  Platelet count ≥ 100 x 10⁹/L (≥100,000/cubic millimeters)  -  Hemoglobin ≥9 grams per deciliter or ≥5.6 millimoles per liter  -  Serum Creatinine ≤1.5 × institutional upper limit of normal (ULN)  -  Total bilirubin ≤1.5 × institutional ULN  -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN OR ≤5 × institutional ULN for participants with liver metastases  -  International normalized ratio (INR) or prothrombin time (PT) INR ≤1.5 × institutional ULN or PT ≤5 seconds above institutional ULN  -  PTT or activated partial thromboplastin time (aPTT) ≤5 seconds above institutional ULN  -  Thyroid stimulating hormone (TSH) OR free thyroxine (T4) within the normal limits  -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.@COMBO@ADULTS@Phase 1@I@@@@@@@@@@-@DURVALUMAB@TREMELIMUMAB@@@-|DURVALUMAB|TREMELIMUMAB||@LILLY@ASTRAZENECA@@@@LILLY|ASTRAZENECA|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LY3022855@MEDI4736@CP-675,206@@@LY3022855|MEDI4736|CP-675,206||@Other@@@@@Other||||@Maximum Tolerated Dose (MTD) of LY3022855@@@@@Proportion of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]@Proportion of Participants who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]@@@@ADVANCED@@@@@NON-RANDOMIZED@Safety Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916256@Onco@@@@@300f1037ntsdm@@@@@@Vorinostat with Tarceva after Tarceva progression@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@9/1/2010@@"Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class
I) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removal
of acetyl groups from the lysine residues of proteins, including histones and transcription factors. In some
cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic
transcription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones is
associated with a condensed chromatin structure and repression of gene transcription. Inhibition of
HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an
open chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation of
acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The
mechanism of the antineoplastic effect of vorinostat has not been fully characterized."@@14916256@Stage IIIB or IV NSCLC after Tarceva@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00503971@50@-@-@@@-@@9/1/2007@-@TARZO@@-@-@@@I/II@III@@NO REVIEW@-@RESULTS PENDING@-@@@@COMBO@VORINOSTAT@ERLOTINIB@@@@VORINOSTAT|ERLOTINIB|||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZOLINZA@TARCEVA@@@@ZOLINZA|TARCEVA|||@HDAC@@@@@HDAC||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919423@Onco@@@@@300f1018ntsdm@@@@@@@@L01BC05@L01B@NO@@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14919423@Non-Small Cell Lung Cancer: Gemcitabine, in combination with cisplatin, is indicated as a first-line treatment of patients with locally advanced (inoperable Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.Pancreatic Cancer: Gemcitabine is indicated for the treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is indicated for patients with 5-FU refractory pancreatic cancer.Bladder Cancer: Gemcitabine is indicated for treatment of advanced bladder cancer (muscle invasive Stage IV tumours with or without metastases) in combination with cisplatin therapy.Breast Cancer: Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless clinically contra-indicated.@@YES@@@NO REVIEW@@@@100%@@SECOND-LINE@@@@@@@@@@Gemzar can suppress bone marrow function as manifested by leukopaenia, thrombocytopaenia, and anaemia, can increase toxicity when prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing. Pulmonary toxicity, Hemolytic Uremic Syndrome (HUS) and/or renal failure, leading to death or requiring dialysis, despite discontinuation of therapy have been reported. Occurence of rare cases of Serious hepatotoxicity, including liver failure and death.@@No@@@@@@APPROVED@@@PBS@@@@@@COMBO@GEMCITABINE HYDROCHLORIDE@@@@@GEMCITABINE HYDROCHLORIDE||||@EBEWE@@@@@EBEWE||||@@@@@@|||||||||@Breast Cancer@NSCLC@Ovarian Cancer@Pancreatic Cancer@@Breast Cancer|NSCLC|Ovarian Cancer|Pancreatic Cancer||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@A$@@@@@@@@200@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922689@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@300 mg or 450mg Intravenous (IV) infusions of natalizumab once every 28 days for 6 months. [Elan]@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@4/1/2012@@Tysabri is a treatment approved for relapsing forms of MS in the United States and relapsing-remitting MS in the European Union. According to data that have been published in the New England Journal of Medicine, after two years, Tysabri treatment led to a 68% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001). Tysabri was recently approved to induce and maintain clinical response and remission in adult patients with moderately to severely active Crohn's disease (CD) with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-alpha.@@14922689@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00675428@42@-@-@@@-@@5/1/2008@-@101MY201@@-@12 patients in Phase I portion, 30 patients in Phase II.@@@I/II@II@@-@-@>Trial commenced. [Elan, 05.09.2008]>Trial registered. [Elan, 06.05.2008]@-@@@@MONO@NATALIZUMAB@@@@@NATALIZUMAB||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@TYSABRI@@@@@TYSABRI||||@mAb@Humanised@@@@mAb|Humanised|||@SAFETY@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16159509@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: crizotinib 250mg orally continuous twice daily dosing Active Comparator: pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@12/1/2014@@@@16159509@XALKORI is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).@@NA@@@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@SECOND-LINE@NCT00932893@347@The recommended dose of XALKORI is 250 mg orally, twice daily until disease progression or no longer tolerated by the patient. The recommended dose of XALKORI in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis is 250 mg orally, once daily.@FDA, 26 August 2011@8/26/2011@@Yes@@9/1/2009@@PROFILE 1007@No@@Histologically or cytologically proven diagnosis of non-small cell lung cancer positive for the ALK fusion gene (test provided by a central laboratory). Must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug@(ALK)-positive@@III@APPROVED@@@NA@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE RATE@OVERALL SURVIVAL@@@@METASTATIC@@@@@OPEN-LABEL@RANDOMISED@PARALLEL ASSIGNMENT@@@1@1@149219.153@@@7.7@month@7.7 month@149219.15@149219.15@637.14@60@1@15291.25@@@@@@@@@@@@1.27@1@@mg@500@1@@@@@@@@@@@8/2/2017@254.85@254.85@00069-8141-20@HARD CAPSULE@US$@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918852@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01XA01@L01X@YES@UNITED STATES@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14918852@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@NO@@@NO REVIEW@@@@@@@@@Metastatic ovarian tumours; the usual dose is 75-100mg/m2 IV per cycle once every 4 weeks when used sequentially with Cytoxan (which is dosed at 600mg/m2 IV once every four weeks. As a single-agent, it should be administered at 100mg/m2 IV per cycle once every 4 weeks.@@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@APP PHARMACEUTICAL@@@@@APP PHARMACEUTICAL||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384844@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384844@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@YES@@@@@@@90%@@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@@@@Yes@@@@@No@@@@@@APPROVED@@@SNS@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@86420.9808@@@36@month@36 month@86420.98@86420.98@78.92@30@1.1511@2367.75@2520.61@2375.29@@@@@@@@@@0.2@1@@mg@400@1@@@@@@@@@@@8/4/2017@78.93@78.93@779660@TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14918228@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@CANONSBURG, PENNSYLVANIA@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14918228@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months).@@@7/1/2007@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@306@@@@@@@@@@@@3.06@@@@@@@@@@@@@@@@8/2/2017@306@306@9297349R@POWDER FOR SOLUTION FOR PERFUSION, 20 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919044@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Daily dose of Xanafide for five days in combination with a standard dose of ara-C as a continuous infusion for seven days.@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@AS1413 is a DNA intercalator that induces apoptotic signalling by blocking TopoII binding to DNA. Unlike classical TopoII inhibitors, which induce apoptosis by causing extensive DNA damage, AS1413 causes apoptosis by chromatin disorganisation. A further distinctive feature of AS1413 is its ability to evade PgP and related transporters responsible for multi-drug resistance. @@14919044@Secondary AML@@-@-@@NO REVIEW@@@@-@Antisoma acquired Xanthus in an all-share deal of GB£26.8 mil. SOURCE: Antisoma, 16 May 2008@SECOND-LINE@-@88@-@EMEA orphan drug designation. SOURCE: Xanthus, 26 October 2007SPA FROM THE FDA FOR THIS TRIAL.@10/26/2007@@EMEA orphan drug designation. SOURCE: Xanthus, 26 October 2007SPA FROM THE FDA FOR THIS TRIAL.@@@-@N/A@@-@-@@@II@II@@-@-@Final results: confirmed preliminary remission rate, which were seen in the overall population as well as in poor-risk subsets of secondary AML, including older patients and patients who previously received treatment for their prior MDS. SOURCE: Xanthus/ASCO, 2 June 2008Treatment with Xanafide was associated with a rate of complete remissions at 44%. SOURCE: Xanthus, ASCO, 2 June 2007@-@@@@COMBO@AMONAFIDE MALEATE@CYTARABINE@@@@AMONAFIDE MALEATE|CYTARABINE|||@XANTHUS PHARMACEUTICALS@ANTISOMA@@@@XANTHUS PHARMACEUTICALS|ANTISOMA|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@XANAFIDE@AS-1413@@@@XANAFIDE|AS-1413|||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@COMPLETE RESPONSE@@@@@@@@@@RELAPSED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16076437@Onco@@@@@300f1010ntsdm@@@@@@"[¹⁴C]LY2606368, Experimental, A single dose containing [¹⁴C]LY2606368 will be administered intravenously (IV) as a 1 hour continuous infusion
LY2606368, Experimental, A single dose of LY2606368 administered IV as a 1 hour continuous infusion once every 14 days (14 day cycles). Treatment may continue until discontinuation criteria are met.
"@@-@-@@INDIANAPOLIS, INDIANA@2/1/2017@@@@16076437@Disposition of [¹⁴C]LY2606368 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumours@Both@@@@@Administered IV@@@@@@NCT02778126@10@@@@@@@6/1/2016@@15556@@@Have a histological or cytological diagnosis of cancer (solid tumour), with clinical or radiologic evidence of locally advanced and/or metastatic disease, for which no life-prolonging therapy exists  -  Have the presence of measurable and/or nonmeasurable disease as defined by the Response Evaluation Criteria In Solid Tumours  -  Have Body Surface Area (BSA) greater than or equal to (≥)1.62 meter squared (m²) and less than or equal to (≤) 1.90 m²  -  Have adequate organ function  -  Have a performance status of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale  -  Have an estimated life expectancy, in the judgment of the investigator, that will permit the patient to complete 1 full cycle of treatment (beyond the initial [¹⁴C]LY2606368 dose)@MONO@ADULTS@Phase 1@I@@@@@@@@@@-@@@@@-||||@LILLY@@@@@LILLY||||@United Kingdom@@@@@United Kingdom|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@[¹⁴C]LY2606368@@@@@[¹⁴C]LY2606368||||@Other@@@@@Other||||@Urinary Excretion of LY2606368 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered@Fecal Excretion of LY2606368 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered@LY2606368 Radioactivity in Expired Air Over Time Expressed as a Percentage of the Total Radioactive Dose Administered@@@Maximum Concentration (Cmax)@Area Under the Concentration Time Curve from Time Zero to the Last Measured Concentration (AUC0-tlast)@@@@ADVANCED@METASTATIC@@@@NON-RANDOMIZED@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@Basic Science@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919294@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Lumiliximab in combination with fludarabine, cyclophosphamide and Rituxan versus this combination therapy without lumiliximab.@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14919294@-@@-@-@@NO REVIEW@@@@-@Biogen Idec and Seikagaku terminated their development partnership for lumiliximab for a variety of indications in January 2004.@-@NCT00391066@276@-@CLL:Orphan drug (EMEA COMP January 2008)Fast-track (FDA)Orphan drug (FDA)@@@CLL:Orphan drug (EMEA COMP January 2008)Fast-track (FDA)Orphan drug (FDA)@@11/1/2006@-@LUCID152CL201@@-@-@@@II/III@III@@-@-@Registrational trial started. SOURCE: Biogen, 7 February 2007@-@@@@COMBO@LUMILIXIMAB@RITUXIMAB@FLUDARABINE@CYCLOPHOSPHAMIDE@@LUMILIXIMAB|RITUXIMAB|FLUDARABINE|CYCLOPHOSPHAMIDE|@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ANTI-CD23 MAB@RITUXAN@FCR@@@ANTI-CD23 MAB|RITUXAN|FCR||@mAb@Chimeric@CD23@@@mAb|Chimeric|CD23||@COMPLETE RESPONSE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922624@Onco@@@@@300f1014ntsdm@@@@@@Casodex as immediate hormonal therapy or adjuvant to radical prostatectomy or radiotherapy.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14922624@In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), Casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Casodex 150 mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.@@NO@@@NO REVIEW@@@@100%@@@@8113@The dosage is one 150 mg tablet to be taken orally once a day. Casodex 150 mg should be taken continuously for at least 2 years or until disease progression.@@@@@@@Casodex 150 mg should be used with caution in patients with moderate to severe hepatic impairment.@@No@@@@@III; THREE TRIALS@APPROVED@@Unrestricted reimbursement.@RAMQ@27.4% and 30.7% of all Casodex and placebotreated patients, respectively, had experienced objective disease progression. In the subgroup of locally advanced prostate cancer who did not receive treatment with radical prostatectomy or radiotherapy, immediate therapy with Casodex 150 mg significantly reduced the risk of objective disease progression (Hazard Ratio (HR)= 0.60; 95% CI 0.49 to 0.73). PFS events was 57.6% in the Casodex watchful waiting group, compared to 68.9% in the placebo group, whilst deaths were 49% and 57% respectively.@@@@@@BICALUTAMIDE@@@@@BICALUTAMIDE||||@PHMSCIENCE@@@@@PHMSCIENCE||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PMS-BICALUTAMIDE@GENERIC@@@@PMS-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@DISEASE-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@@@@@100@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@C$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14924638@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@ROCKVILLE, MARYLAND@@@Panzem is an orally active, well-tolerated compound that has antiproliferative, antiangiogenic and anti-inflammatory properties. Panzem attacks tumor cells through multiple mechanisms of action (MOA) and blocks the development of new blood vessels that feed tumor cells. Panzem's MOAs include the disruption of angiogenesis through the inhibition of hypoxia inducible factor-1 alpha (HIF-1a), a protein required for angiogenesis and cell survival under stress. The inhibition of angiogenesis is an important approach to the treatment of both cancer and rheumatoid arthritis. Initial development of 2ME2 has been focused on various oncology indications. While modest antitumor activity has been demonstrated across most clinical studies, there is no clear development path that would allow the Company to narrow the indications for the next series of larger randomized studies. Panzem for oncology is a drug candidate that needs to be developed in combination with other chemotherapeutic agents, requiring the conduct of further non-randomized trials to clarify specific combinations and indications. Conversely, Panzem has potential as a single agent in rheumatoid arthritis based on its antiangiogenic, antiiflammatory, and antiosteoclastic (bone resorption) properties.@@14924638@Recurrent glioblastoma@@-@-@@NO REVIEW@@@@-@Entremed announces restructuring plan, including the loss of 60% of staff and core focus on development of ENMD-2076. [EntreMed, 19.12.2008]@-@-@27@-@FDA ORPHAN DRUG FOR GBM@@@FDA ORPHAN DRUG FOR GBM@@@-@-@@-@27 PATIENTS WITH RECURRENT GBM WHO FAILED PREVIOUS THERAPY.@@@II@DISCONTINUED@@-@-@Development discontinued; modest antitumor activity has been shown across most of the clinical studies, yet there is not a clear development path that would narrow the indications for larger randomized studies. Additional trial costs, the high doses required for use in oncology, and manufacturing/process development expenditures would together require the commitment of a disproportionate amount of resources and limit clinical development efforts on the remainder of the pipeline. SOURCE: Entremed press release, 13 March 2008ASCO 2007; 1 partial response (4%), and 7 patients with stable disease (26%).@-@@@@MONO@2-METHOXYESTRADIOL@@@@@2-METHOXYESTRADIOL||||@ENTREMED@@@@@ENTREMED||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@PANZEM NCD@@@@@PANZEM NCD||||@2ME2@Angiogenesis Inhibitor@@@@2ME2|Angiogenesis Inhibitor|||@PARTIAL RESPONSE@STABLE DISEASE@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918710@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@MUMBAI, INDIA@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918710@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@YES@@@NO REVIEW@@@@100%@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, September 2006@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@WOCKHARDT@@@@@WOCKHARDT||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR INJECTION@GB£@@@@@@@@1000@MG@50 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921032@Onco@@@@@@@@@@@Patients receive an infusion of technetium Tc 99m LL2 monoclonal antibody (LymphoScan) by IV injection or infused over 20-30 minutes after completion of therapy as part of the response evaluation procedures. Planar images are acquired between 4-8 hours and 18-24 hours following antibody injection, and single photon emission computerized tomography (SPECT) imaging is performed between 4-8 hours following antibody injection. Patients may receive a repeat injection of LymphoScan. Patients are followed for 3 to 6 months.@@-@-@-@MORRIS PLAINS, NEW JERSEY@@@Naked humanized antibody targeting CD22 receptors on B-lymphocytes.  Primary use is for the treatment of indolent and aggressive NHLs, and for autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren's Syndrome.  Every year there are 56,000 newly diagnosed cases of NHL and 25,000 deaths.  SLE afflicts up to 1.4 million in the U.S.  In May 2006, epratuzumab was licensed to UCB, S.A. for all autoimmune disease indications worldwide.  A Phase IIb clinical trial for SLE is currently enrolling patients.  Additionally, there are three NCI-sponsored trials in oncology ongoing.@@14921032@Diagnostic trial@@-@-@@NO REVIEW@@@@-@UCB Pharma holds non-oncology rights, with option for a buy-in. North American rights were licensed to Amgen, but returned to Immunomedics in April 2004.@-@NCT00003338@60@-@-@@@-@@3/1/1997@-@IM-D-LL2-06@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@MONO@EPRATUZUMAB@@@@@EPRATUZUMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@LYMPHOCIDE@IMMU-102@@@@LYMPHOCIDE|IMMU-102|||@mAb@Humanised@CD22@@@mAb|Humanised|CD22||@DIAGNOSTIC@RESPONSE RATE@SAFETY@@@SAFETY@@@@@-@@@@@DIAGNOSTIC@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924476@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@Hemopure [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the Company is developing Hemopure and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. @@14924476@Life-threatening Anemia Secondary to Induction Chemotherapy in Patients with AML who Refuse Red Blood Cell Transfusion@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@IND for Phase II trial filed with U.S. NDA. [Biopure, 17.12.2008]@-@@@@MONO@HAEMOGLOBIN GLUTAMER-250 (BOVINE)@@@@@HAEMOGLOBIN GLUTAMER-250 (BOVINE)||||@BIOPURE@@@@@BIOPURE||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Supportive Care@Anaemia@@Haematological Malignancy|Acute Myeloid Leukaemia|Supportive Care|Anaemia||||||@HEMOPURE@HBOC-201@@@@HEMOPURE|HBOC-201|||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917375@Onco@@@@@300f1008ntsdm@@@@@@NO LABELLED TRIAL@@H02CA01@H02C@NO@CAMBRIDGE, MASSACHUSSETTS@@@@@14917375@(a) For the control of the manifestation of adrenal cortical hyperfunction in such conditions as hypercortisolism and primary aldosteronism. (b) For the treatment of postmenopausal advanced breast cancer following relapse to initial hormone therapy e.g. oestrogen receptor antagonists.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Acquisition of Bioenvision by Genzyme completed in October 2007@@@@POSTMENOPAUSAL BREAST CANCER – The daily dose given in divided doses should increase stepwise every three days from 240 mg to 480 mg to 720 mg to 960 mg. This dose should be maintained but if it cannot be tolerated it may be reduced to 720 mg/day. From the start of Trilostane therapy a physiological replacement dose of a glucocorticoid should be given, e.g. Hydrocortisone 30 mg/day in divided doses.@@@@@@@Pregnancy should be excluded before beginning treatment and nonhormonal contraceptive methods should be used during therapy where appropriate. As with all drugs that are metabolised by the liver and excreted by the kidney, caution should be exercised when treating patients with gross hepatic or renal impairment. It is advisable to monitor response when treating adrenal cortical hyperfunction, by regular assays of blood electrolytes and circulating corticosteroids, and adjust the dose accordingly. In some patients the suppression of aldosterone production may cause hyperkalaemia and hyponatraemia with subsequent hypotension – under these circumstances a mineralocorticoid should be given, e.g. Fludro-cortisone 0.1 mg/day@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHI@NO LABELLED TRIAL@@@@@@TRILOSTANE@@@@@TRILOSTANE||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@DESOPAN@@@@@DESOPAN||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@828.6@828.6@@1@0.0091@518.47@611.4@@@@@@@@@@@8.64@@@@@@@@@@@@@@@@8/30/2017@518.47@518.47@2499008F1034@TABLETS@YEN@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918604@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14918604@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@HEUMANN@@@@@HEUMANN||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@100@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921376@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks >> FOLFOX6 cycles 4 onwards: Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks    >> Bevacizumab cycles 3 onwards: 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy [clinicaltrials.gov]@@-@-@-@SINGAPORE@12/1/2011@@SIR-Spheres yttrium-90 microspheres is a radiotherapy treatment being studied as part of chemoradiotherapy (chemo-SIRT) in cancer.@@14921376@FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma @@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00735241@30@-@-@@@-@@6/1/2008@-@FAST@@-@>> Histologically confirmed adenocarcinoma of the colon or rectum.    >> Unequivocal and measurable CT evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent.@@@II/III; STX0207@III@@-@-@Trial registered. [Sirtex, 13.08.2008]@-@@@@COMBO@SIR-SPHERES MICROSPHERES@BEVACIZUMAB@@@@SIR-SPHERES MICROSPHERES|BEVACIZUMAB|||@SIRTEX MEDICAL@@@@@SIRTEX MEDICAL||||@@@@@@|||||||||@Colorectal Cancer@Liver Cancer@@@@Colorectal Cancer|Liver Cancer||||||||@SIRT@AVASTIN@FOLFOX6@@@SIRT|AVASTIN|FOLFOX6||@Radiolabeled@@@@@Radiolabeled||||@TOXICITY@SAFETY@@@@-@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922103@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arm I: Brivanib Tablets, Oral, 800 mg, once daily, until disease progression or toxicityArm II: PlaceboTablets, Oral, 0 mg, once daily, until disease progression or toxicity SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@11/1/2011@@@@14922103@A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00825955@414@-@-@@@-@@2/1/2009@-@BRISK PS@@-@Histologic or cytologic confirmed diagnosis of HCCAdvanced disease defined as (i) disease not eligible for surgical or loco-regional therapy or (ii) disease progressive after surgical or loco-regional therapyPatient has failed = 14 days of Sorafenib treatment@@@III@III@@-@-@>>The trial did not meet primary endpoint of overall survival [BMS, 22 December 2011 http://www.bms.com/news/press_releases/pages/default.aspx ]>>Trial registered [BMS 20 January 2009]>>RESULTS PENDING@-@@@@MONO@BRIVANIB ALANINATE@@@@@BRIVANIB ALANINATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@BMS-582664@@@@@BMS-582664||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@OVERALL SURVIVAL@@@@@TIME TO PROGRESSION@RESPONSE@SAFETY@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16074357@Onco@@@@@@@@@@@Anetumab ravtansine, Experimental, Anetumab ravtansine in combination with pegylated liposomal doxorubicin 30 mg/m2 of body surface area in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.@@@@@LEVERKUSEN, GERMANY@6/1/2017@@@@16074357@An Open-label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin 30 mg/m2 Given Every 3 Weeks in Subjects With Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer@Female@@@@@Anetumab ravtansine will be administered by 1-hour IV infusion on Day 1 of every 21-day treatment cycle. The starting dose of anetumab ravtansine in the first dose cohort in Part 1 will be 5.5 mg/kg of body weight.@@@@@@NCT02751918@40@@@@@@@5/1/2016@@18326@@@Subject must provide a signed informed consent before any screening procedures.  -  Subject must be female and aged ≥18 years.  -  Subject must have histologically confirmed, locally invasive or metastatic, predominantly epithelial platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.  -  Subject must have recurrent, platinum-resistant cancer  -  Subject must have positive mesothelin expression in the archival tumor tissue.  -  Subject must have a life expectancy of at least 12 weeks.  -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.  -  Subject must have adequate bone marrow, kidney and liver function and coagulation, as assessed by the standard laboratory test results  -  Women of reproductive potential must have a negative serum beta human chorionic gonadotropin (beta HCG) pregnancy test obtained within 7 days before the start of anetumab ravtansine. Women not of reproductive potential are female subjects who are postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).  -  Women of reproductive potential must agree to consistently use adequate contraception / birth control between signing of the informed consent and 60 days after the last administration of the last study drug. The investigator or a designated associate should advise the subject how to achieve adequate contraception. Due to the lack of adequate reproductive toxicity data on anetumab ravtansine, subjects must concomitantly use 2 forms of adequate contraception.@COMBO@ADULTS@Phase 1@I@@@@@@@@@@ANETUMAB RAVTANSINE@DOXORUBICIN, PEGYLATED LIPOSOMAL @@@@ANETUMAB RAVTANSINE|DOXORUBICIN, PEGYLATED LIPOSOMAL |||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@BAY94-9343@CAELYX@@@@BAY94-9343|CAELYX|||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@Incidence of serious and non-serious adverse events (AEs)@@@@AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) of Anetumab ravtansine analytes (Antibody drug conjugates, Total Antibody, metabolites DM4, and DM4-Me)@AUC(0-tlast)@@@@@@@@@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14925103@Onco@@@@@@@@@@@Ponatinib: 45 mg tablet taken orally once daily@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@14925103@A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia@@-@-@@NO REVIEW@@@SEPTEMBER 2010 - OCTOBER 2020@-@@-@NCT01207440@440@-@MAA submitted [Ariad, 30 August 2012, http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1730090&highlight= ]@8/30/2012@@-@@@-@PACE@@-@-@@@II@FILED@@-@-@showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to prior tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD's ongoing Phase 3 EPIC trial comparing ponatinib to imatinib in newly diagnosed chronic-phase CML patients. [Ariad, 30 August 2012, http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1730090&highlight= ]@The most common side effects observed in the study to date were consistent with the known safety profile of ridaforolimus and included stomatitis (e.g., mouth sores), fatigue, diarrhea and thrombocytopenia. @@@@MONO@PONATINIB@@@@@PONATINIB||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@AP-24534@@@@@AP-24534||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921659@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intratumoral injection of VDC2008 post-cryotherapy. Subjects receive pre-therapy (-3 days), 300 mg/m2, IV (in the vein) cyclophosphamide and post- therapy (starting +2 weeks) 25 mg cyclophosphamide, PO, bid, in a 28 day cycle (7 day on, 7 day off, 7 day on, 7 day off) for up to 6 cycles. [clinicaltrials.gov]@@-@-@-@-@12/1/2010@@Dendritic cells injection.@@14921659@Autologous, Immature Dendritic Cells Injected Into the Prostate Following Cryoablation in Advanced Prostate Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00753220@26@-@-@@@-@@9/1/2008@-@CRITICAL@@-@>> Histologically documented primary adenocarcinoma of the prostate. A specimen of the primary tumor must be submitted to the Central Pathology Laboratory for confirmation of prostatic adenocarcinoma and determination of Gleason Sum grading. >> Prior history of Androgen Deprivation Therapy ; or Organ-preserving therapy (i.e., non-prostatectomy) for primary prostate cancer: e.g.radiation therapy@@@I/II@I@@-@-@Trial registered. [Bostwick, 12.09.2008]@-@@@@-@-@@@@@-||||@BOSTWICK THERAPEUTICS@@@@@BOSTWICK THERAPEUTICS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@VDC-2008@@@@@VDC-2008||||@Vaccine@@@@@Vaccine||||@CTCAE@@@@@TIME TO PROGRESSION@@@@@ADVANCED@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916805@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@R1507 16mg/kg iv every 3 weeks combined with letrozole 2.5mg po daily [Roche]@@-@-@-@BASEL, SWITZERLAND@5/1/2010@@R1507 is a fully human antibody created by Genmab under a collaboration with Roche. R1507 was selected from a large panel of antibodies and targets the Insulin-like Growth factor-1 Receptor (IGF-1R).  The IGF-1R molecule has been shown to be important in tumor growth and protecting tumor cells from being killed.  IGF-1R is over-expressed on a variety of tumors including breast, colon, prostate, lung, skin and pancreatic cancers and is a well validated target for an antibody therapeutic approach.  Roche filed an Investigational New Drug application with the US FDA for the antibody in December 2005. @@14916805@Postmenopausal Women With Advanced Breast Cancer@@-@-@@NO REVIEW@@@@-@In-licensed from Genmab@-@NCT00796107@43@-@-@@@-@@12/1/2008@-@NO21161@@-@Postmenopausal female patients with stage IV or locally advanced breast cancer@@@II@II@@-@-@Trial registered [Roche, 21.11.2008]@-@@@@COMBO@-@LETROZOLE@@@@-|LETROZOLE|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@R-1507@FEMARA@@@@R-1507|FEMARA|||@mAb@@@@@mAb||||@ADVERSE EVENTS@RESPONSE RATE@@@@PROGRESSION-FREE SURVIVAL@PHARMACOKINETICS@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917105@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@@@@@@14917105@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Squamous cell carcinoma and testicular teratoma: Used alone the normal dosage is 15 x 10³ IU (1 vial) three times a week or 30 x 10³ IU (2 vials) twice a week, either intramuscularly or intravenously. Treatment may continue on consecutive weeks, or more usually at intervals of 3-4 weeks, up to a total cumulative dose of 500 x 10³ IU although young men with testicular tumours have frequently tolerated twice this amount. Continuous intravenous infusion at a rate of 15 x 10³ IU (1 vial) per 24 hours for up to 10 days, or 30 x 10³ IU (2 vials) per 24 hours for up to 5 days may produce a therapeutic effect more rapidly. The development of stomatitis is the most useful guide to the determination of individual tolerance of maximum therapeutic response. The dose may need to be adjusted when bleomycin is used in combination chemotherapy. Use in elderly or children – see below.@@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||||@BLEOMEDAC@@@@@BLEOMEDAC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@52@76.73@54.34@@@@@@@@@@3.47@@@@@@@@@@@@@@@@8/15/2017@52@52@2411351@DRY SUBSTANCE WITHOUT SOLVANT@EURO@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920148@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@A04AA02@A04A@NO@UNTERACH, AUSTRIA@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920148@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@@@@@@@@@Novartis acquires Ebewe in US$1.2 billion deal. [Novartis, 19 May 2009]@@@@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@FDA, 21 May 2008@5/21/2008@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@@@@@APPROVED@@@@@@@@@@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@EBEWE PHARMA@NOVARTIS@SANDOZ@@@EBEWE PHARMA|NOVARTIS|SANDOZ||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@4@MG@4 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16067014@Onco@@@@@@@@@@@ABP 798, Experimental, Concentrate for solution for infusion, ABP 798 at a dose of 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20Rituximab, Active Comparator, Concentrate for solution for infusion, Rituximab at a dose of 375 mg/m2 administered as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20@@@@@THOUSAND OAKS, CALIFORNIA@2/1/2018@@@@16067014@Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)@Both@@@@@@@@@@@NCT02747043@250@@@@@@@4/1/2016@@20130109@@@Males and females ≥ 18 and < 80 years of age  -  Histological confirmed, Grade 1, 2, or 3a follicular B-cell NHL expressing CD20 within 3 months before randomization  -  Stage 2, 3, or 4 (per Cotswold's Modification of Ann Arbor Staging System) with measurable disease (per International Working Group)  -  subjects must have a baseline scan (computed tomography [CT]) of the neck (if palpable lymph node > 1.0 cm), chest, abdomen, and pelvis to assess disease burden within 28 days before randomization  -  subjects must have had a baseline bone marrow biopsy within 3 months before randomization  -  Low tumor burden based on the Groupe d'Etudes des Lymphomes Folliculaires (GELF) criteria  -  largest nodal or extranodal mass < 7 cm  -  no more than 3 nodal sites with diameter > 3 cm  -  no spleen enlargement  -  no significant serous effusions by CT  -  normal lactate dehydrogenase (LDH)  -  no B symptoms@MONO@ADULTS@Phase 3@III@@@@@@@@@@-@@@@@-||||@AMGEN@@@@@AMGEN||||@New Zealand@@@@@New Zealand|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@ABP 798@@@@@ABP 798||||@Other@@@@@Other||||@Risk difference of objective response rate@@@@@Risk difference of ORR@Serum concentrations@@@@@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917991@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@J06BA02@J06B@YES@DEERFIELD, ILLINOIS@@@@@14917991@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@YES@-@@NO REVIEW@@@@@-@-@-@-@B-cell CLL: For patients with hypogammaglobulinemia and/or recurrent bacterial infections due to B-cell CLL, a dose of 400 mg/kg every 3 to 4 weeks is recommended.@Jul-99@@@-@@@Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death.18 Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.@NO LABELLED TRIAL@No@-@-@@@-@DISCONTINUED@@@@NO LABELLED TRIAL@-@@@@-@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD@@@@@GAMMAGARD||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@1@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@33240019@INJECTABLE PREPARATION, 10 ML@EURO@@@@@@@@0.5@G@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918936@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will first undergo standard surgery to reduce their tumor burden. Patients will then receive limited doses of two existing drugs to improve the immune system environment and modify the tumor vasculature. Following the preparatory treatments, the patients in this ovarian cancer trial will receive a series of three immunizations with DCVax-L, each two weeks apart, while continuing to receive the low doses of two drugs intended to keep the immune system and the tumor microenvironment in a beneficial condition. The second study, which will be a follow-on to the first study but covered by a separate IND filing, will compare two treatment arms continuing further with the drug and DCVax-L regimen, and adding the adoptive transfer of DCVax®-L primed, and expanded T cells. SOURCE: Northwest@@-@-@-@BETHESA, MARYLAND@@@DCVax products are being developed to activate all aspects of the immune response, both cellular and antibody, thus potentially providing a broader and longer lasting immune and clinical response. Northwest Biotherapeutics' products are deigned as pure, activated DC loaded with the immunogen as would naturally occur, and that are capable of migrating to lymph nodes. The intended result is a very robust, and full immune response consisting of both a specific cellular T cell response and a specific antibody response against the cancer associated antigen.@@14918936@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@First-patient in, December 2007. SOURCE: Northwest, 27 December 2007@-@@@@-@-@@@@@-||||@NORTHWEST BIOTHERAPEUTICS@@@@@NORTHWEST BIOTHERAPEUTICS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@DCVAX-L@@@@@DCVAX-L||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15059275@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive either single oral dose of MLN9708 (4.0mg) or placebo on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progression [clinicaltrials.gov]@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@5/1/2019@@MLN-9708, formerly MLN-2238, is a second-generation proteasome inhibitor. In vitro, non-clinical studies have shown that proteasome inhibition can be cytotoxic to a variety of cancer cell types. MLN9708 is currently under clinical investigation.@@15059275@The purpose of this phase 3, randomized, double-blind, multicenter study is to compare Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma.@@-@-@@NO REVIEW@@@@-@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]       >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]@-@NCT01564537@703@-@-@@@-@@8/1/2012@-@TOURMALINE-MM1@@-@Diagnosed Multiple Myeloma according to standard criteriaMeasurable disease as specified in study protocolEastern Cooperative Oncology Group (ECOG)performance status of 0 to 2@ADULT@@III@III@@-@-@Trial registered [Millennium, 22 March 2012]@-@@@@COMBO@-@LENALIDOMIDE@DEXAMETHASONE@@@-|LENALIDOMIDE|DEXAMETHASONE||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Myeloma@@@@@Myeloma|||||||||@MLN-9708@@@@@MLN-9708||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@RESPONSE@@@@RELAPSED@REFRACTORY@@@@DOUBLE-BLIND@PARALLELL ASSIGNMENT@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16387358@Onco@@@@@300f1015ntsdm@@@@@@@@L01XC07@L01X@@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16387358@Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations@@YES@@@@@@@@@FIRST-LINE@@152@The recommended dose of Avastin when used in addition to erlotinib is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.It is recommended that the treatment with Avastin in addition to erlotinib is continued until disease progression.@EMA, 2 June 2016@6/2/2016@@No@@@@JO25567@No@@@EGFR activating mutations@@II@APPROVED@@@@@@@@@COMBO@BEVACIZUMAB@ERLOTINIB@@@@BEVACIZUMAB|ERLOTINIB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AVASTIN@TARCEVA@@@@AVASTIN|TARCEVA|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@REPONSE RATE@DISEASE CONTROL RATE@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@MULTI-CENTRE@@@76.5@kg@60746.72656@@@16@month@16 month@60746.73@60746.73@124.82@1@1.1511@913.75@@@@@@@@@@@@2.28@21@@mg/kg@15@1@@@@@@@@@@@8/2/2017@913.75@913.75@9261110T@SOLUTION FOR PERFUSION 16 ML@EURO@@@@@@@@400@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922840@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@@@NO@MADISON, NEW JERSEY@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14922840@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@@@NO REVIEW@@@@100%@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenousinjection.@EMA, June 2006@@@@@@In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. Leucovorin may be fatal if given intrathecally. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@REFOLINON@@@@@REFOLINON||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@GB£@@@@@@@@15@MG@7.5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16639039@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE23@L01X@@BASEL, SWITZERLAND@7/1/2011@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639039@Dabrafenib is indicated in monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.@Both@Yes@17-Jun-16@6/17/2016@NO REVIEW@@@@@@@NCT01153763@92@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@EMA, 26 August 2013@8/26/2013@6/6/2014@No@@8/1/2010@@BRF113710@No@@Must be at least 18 years of age; Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay; Is treatment naive or has received prior treatment for metastatic melanoma; Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment; Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication; Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication; Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; Adequate organ function.@BRAF V600 mutation@ADULTS@II@APPROVED@@Positive recommendation. 17 June 2016 [https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-dabrafenib-tafinlar.pdf]@SNS@@@@@@MONO@DABRAFENIB@@@@@DABRAFENIB||||@NOVARTIS @@@@@NOVARTIS ||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@@@@@TAFINLAR||||@Other@@@@@Other||||@OVERALL RESPONSE RATE@@@@@PROGRESSION FREE SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@SINGLE GROUP@OPEN LABEL@@@@1@1@48480.0624@@@6.9@month@6.9 month@48480.06@48480.06@231@28@1.1511@1078@1179.27@1085.54@@@@@@@@@@0.77@1@@mg@300@1@@@@@@@@@@@8/4/2017@38.5@38.5@701613@CAPSULE@EURO@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16384752@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384752@Indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alphatherapy@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@532@The recommended dosage of Glivec is 400 mg/day for adult patients in chronic phase CML.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@60@1.1511@1048.07@1172.57@1078.07@@@@@@@@@@0.17@1@@mg@400@1@@@@@@@@@@@8/1/2017@17.47@17.47@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924939@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Nexavar with AMG-386 or placebo@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@AMG 386 is a recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins.  AMG 386 is designed to bind angiopoietins 1 and 2, thereby inhibiting Tie2 dependent stimulation of endothelial cells. Angiopoietins, together with vascular endothelial growth factors (“VEGFs”), are key cytokines that regulate neovascularization. In 2007, we initiated four phase 2 studies of AMG 386 for the treatment of RCC, metastatic breast cancer, ovarian cancer and gastric cancer@@14924939@Combo with Nexavar@@-@-@@NO REVIEW@@@@-@Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-108, AMG-317, AMG-386, AMG-479 and AMG-655, for US$200 mil.@-@NCT00467025@150@-@-@@@-@@5/1/2007@-@20060159@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@SORAFENIB@@@@-|SORAFENIB|||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@AMG-386@NEXAVAR@@@@AMG-386|NEXAVAR|||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@@@TK Inhibitor|Angiogenesis Inhibitor|VEGF||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@CROSSOVER@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918719@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@@@NO@LAKE FOREST, ILLINOIS@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14918719@Leucovorin is used in cytotoxic therapy as an antidote to folic acid antagonists such as methotrexate. Leucovorin is effective in the treatment of megaloblastic anaemia.@@NO@@@NO REVIEW@@@@100%@Acquired through takeover of Mayne Pharma@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenousinjection.@EMA, March 2003@@@@@@Leucovorin rescue: Depending upon the dose of methotrexate administered, dosage regimens of leucovorin calcium vary. Up to 120 mg leucovorin calcium are generally given, usually in divided doses over 12-24 hours by intramuscular injection, bolus intravenous injection or intravenous infusion in normal saline. This is followed by 12-15 mg intramuscularly or 15 mg orally every 6 hours for 48 hours. Rescue therapy is usually started 24 hours after the commencement of methotrexate administration. Megaloblastic anaemia (folate deficiency): 15 mg (one tablet) leucovorin per day.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@GENERIC@@@@@GENERIC||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916480@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients in cohorts 1-5 will receive a test dose of 25 mg on Day 1 with the remainder of the scheduled dose on Day 2. In cohort 6, patients will receive the highest weekly dose previously tolerated on Day 1 and all subsequent infusions. The test dose of 25 mg will not be given on Day 1. Within a cohort, dose escalation may occur on Day 8, Day 15, Day 22, and Day 29. A cohort will be identified based on the highest scheduled dose level. Responding patients will receive four additional infusions every other week at the highest cohort specific dose level. For phase Ib, a dose administration schedule will be chosen based on the maximum tolerated dose, demonstrated antitumor activity, and antigen saturation of bone marrow blasts. Ten patients will be treated in each of three cohorts, testing the antitumor activity of SGN-33 in 1) MDS/Chronic MyeloMonocytic Leukemia, 2) untreated AML, and 3) relapsed AML. SOURCE: clinicaltrials.gov@@-@-@-@SEATTLE, WASHINGTON@@@@@14916480@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00283114@60@-@-@@@-@@9/1/2005@-@SG033-0001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@LINTUZUMAB@@@@@LINTUZUMAB||||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@Acute Myeloid Leukaemia@@@Haematological Malignancy|Myelodysplastic Syndrome|Acute Myeloid Leukaemia|||||||@SGN-33@@@@@SGN-33||||@mAb@Humanised@CD33@@@mAb|Humanised|CD33||@SAFETY@PHARMACOKINETICS@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924624@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@LONDON, UNITED KINGDOM@@@BGC 945 (ONX 0801) is designed to work by combining two proven approaches to improving outcomes for cancer patients. These include receptor-mediated targeting of tumor cells and inhibition of thymidylate synthase, a key enzyme involved in cell growth and division. BGC 945 (ONX 0801) targets malignant cells that overexpress the alpha-folate receptor, which is located on the cell's surface. Once BGC 945 (ONX 0801) enters the cell via this receptor, the compound inhibits, or switches off, thymidylate synthase (TS). BGC 945 (ONX 0801) is distinct from currently marketed TS inhibitors, such as pemetrexed, 5 fluorouracil, and raltitrexed, due to its selective tumor cell-specific uptake by the alpha-folate receptor. The alpha-folate receptor is overexpressed in a number of tumor types with significant unmet needs, including ovarian cancer, lung cancer, breast cancer, and colorectal cancer.@@14924624@-@@-@-@@NO REVIEW@@@@-@Onyx has in-licensed BGC 945 from BTG. Onyx will obtain a worldwide license for BGC 945 and all of its related patents. Onyx will receive exclusive worldwide marketing rights and will be responsible for all product development and commercialization activities. BTG will receive a $13 million upfront payment, and payments of up to $72 million upon the attainment of certain global development and regulatory milestones, plus additional milestone payments upon the achievement of certain marketing approvals and commercial milestones. BTG will also receive royalties on future product sales. [Onyx, 6.11.2008]@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Trial to commence in 2009. [Onyx, 6.11.2008]@-@@@@-@-@@@@@-||||@ONYX PHARMACEUTICALS@BTG INTERNATIONAL@@@@ONYX PHARMACEUTICALS|BTG INTERNATIONAL|||@@@@@@|||||||||@Other@@@@@Other|||||||||@ONX-801@BCG-945@@@@ONX-801|BCG-945|||@TS Inhibitor@@@@@TS Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917386@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917386@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Adult soft tissue sarcoma: For adult soft tissue sarcomas dacarbazine is given in daily doses of 250 mg/m2 body surface area i.v. (days 1-5) in combination with doxorubicin every 3 weeks (ADIC regimen). Restriction of food intake for 4-6 hours prior to treatment may reduce the severity of the nausea and vomiting which occurs in most patients particularly during the first two days of treatment. Because severe gastrointestinal and haematological disturbances can occur an extremely careful benefit-risk analysis has to be made before every course of therapy with dacarbazine.@@@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@DETIMEDAC@@@@@DETIMEDAC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1807@320@415.56@330.78@@@@@@@@@@0.16@@@@@@@@@@@@@@@@8/15/2017@32@32@4613627@VIAL@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921984@Onco@@@@@@@@@@@Solution, IV, 40 mg/m2, 3-week cycle, study will be completed once all subjects have progressed or 15 months after the Last Patient First Visit, which ever comes first; versus Solution, IV, loading dose 400 mg/m2 then 250mg/m2, weekly, study will be completed once all subjects have progressed or 15 months after the Last Patient First Visit, which ever comes first. [clinicaltrials.gov]@@L01C@L01C@-@NEW YORK, NEW YORK@@@Ixabepilone is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to ß-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of  ß-II and  ß-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.@@14921984@Triple-negative (ER, PR, HER2) locally advanced non-resectable and/or metastatic breast cancer@@-@-@@NO REVIEW@@@June 2008-March 2011@-@-@FIRST-LINE@NCT00633464@80@-@-@@@-@@@-@CA163-139@@-@-@@@II@II@@-@-@Trial registered. [BMS, 5.03.2008]@-@@@@BOTH@IXABEPILONE@CETUXIMAB@@@@IXABEPILONE|CETUXIMAB|||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IXEMPRA@BMS-247550@ERBITUX@@@IXEMPRA|BMS-247550|ERBITUX||@Epothilone@@@@@Epothilone||||@RECIST@@@@@PROGRESSION-FREE SURVIVAL@TIME TO RESPONSE@DURATION OF RESPONSE@@@METASTATIC@TRIPLE NEGATIVE@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16624613@Onco@@@@@300f1015ntsdm@@@@@@@@L01DB06@L01D@@NEW YORK, NEW YORK@@@Idarubicin is an antimitotic and cytotoxic agent which intercalates with DNA and interacts with topoisomerase II and has an inhibitory effect on nucleic acid synthesis. The compound has a high lipophilicity which results in an increased rate of cellular uptake compared with doxorubicin and daunorubicin. Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes. Studies in-vitro on human and murine anthracycline-resistant cells have shown a lower degree of cross-resistance for idarubicin compared with doxorubicin and daunorubicin. Cardiotoxicity studies in animals have indicated that idarubicin has a better therapeutic index than daunorubicin and doxorubicin. The main metabolite, idarubicinol, has shown in-vitro and in-vivo antitumoral activity in experimental models. In the rat, idarubicinol, administered at the same doses as the parent drug, is clearly less cardiotoxic than idarubicin.@@16624613@Acute myeloblastic leukaemia as a first-line treatment in paediatric patients.@@NO@25-Jan-17@1/25/2017@@@@@100%@@FIRST-LINE@@@The recommended dose is 10 to 12 mg/m²/day for 3 days@ANSM, 10 July 2015@7/10/2015@4/2/2007@@@@@@No@@@PAEDIATRIC@@@APPROVED@@ASMR V in paediatric patients [http://www.has-sante.fr/portail/upload/docs/evamed/CT-15601_ZAVEDOS_PIC_EI_LAM_pediatrie_Avis2_CT15601.pdf]@HAUTE AUTORITÉ DE SANTÉ@@@@@@COMBO@IDARUBICIN HCL@CYTARABINE@@@@IDARUBICIN HCL|CYTARABINE|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@ZAVEDOS@DEPOCYTE@@@@ZAVEDOS|DEPOCYTE|||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@43.39@54.5@46.29@@@@@@@@@@4.34@@@@@@@@@@@@@@@@8/1/2017@43.39@43.39@3.40E+12@CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918675@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918675@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Adult soft tissue sarcoma: For adult soft tissue sarcomas dacarbazine is given in daily doses of 250 mg/m2 body surface area i.v. (days 1-5) in combination with doxorubicin every 3 weeks (ADIC regimen). Restriction of food intake for 4-6 hours prior to treatment may reduce the severity of the nausea and vomiting which occurs in most patients particularly during the first two days of treatment. Because severe gastrointestinal and haematological disturbances can occur an extremely careful benefit-risk analysis has to be made before every course of therapy with dacarbazine.@EMA, November 1997@@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.299@90@@@@@@@@@@@@0.09@@@@@@@@@@@@@@@@7/28/2017@9@9@7.32E+15@POWDER FOR SOLUTION FOR INJECTION VIAL@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16396675@Onco@@@@@300f1020ntsdm@@@@@@Experimental: Lenalidomide / Dexamethasone until disease progression Experimental: Lenalidomide / Dexamethasone for 18 cycles Active Comparator: Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles@@L04AX04@L04A@@SUMMIT, NEW JERSEY@6/1/2016@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396675@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@20-Oct-16@@NO REVIEW@@@@@@FIRST-LINE@NCT00689936@1623@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 11 February 2015@2/11/2015@@YES@@8/1/2008@@CC5013MM020, 200700482339@No@@Must understand and voluntarily sign informed consent form. Age ≥ 18 years at the time of signing consent. Previously untreated. ECOG performance status of 0, 1, or 2. Able to adhere to the study visit schedule and other protocol requirements. Females of childbearing potential (FCBP)^2@@ADULTS@III@APPROVED@@Added to the reimbursement list on 20 October 2016 [http://www.gazzettaufficiale.it/eli/id/2016/10/28/16A07750/sg;jsessionid=aYtec5ixDvhYP72a9v3pbw__.ntc-as2-guri2a]@SSN@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@DURATION OF RESPONSE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@164331.8467@@@26@month@26 month@164331.85@164331.85@207.8@21@1.1229@5818.41@9602.71@6080.3@@@@@@@@@@11.08@28@@mg@25@21@@@@@@@@@@@6/7/2017@277.07@277.07@38016046@HARD CAPSULE@EURO@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15045767@Onco@@@@@300f1037ntsdm@@@@@@Provenge or placebo@@@@@SEATTLE, WASHINGTON@@@Sipuleucel–T contains mature, autologous antigen Antigen Presenting Cells (APCs). APCs are obtained from the patient via a standard leukapheresis Leukapheresis procedure approximately two days before each scheduled infusion. The patient's APCs are then transported to a Dendreon manufacturing facility where they are co-cultured with a recombinant fusion protein containing prostatic acid phosphatase (PAP). The activated, antigen-loaded APCs (now sipuleucel–T) are then delivered to the physician's office (infusion site) for infusion into the patient. Sipuleucel–T is then infused into the patient, where it can potentially stimulate a T cell response against prostate cancer cells. The process is performed three times over the course of a four-week period, upon which treatment is completed.@@15045767@Androgen dependent prostate cancer@@@@@NO REVIEW@@@@@@@NCT00005947@170@@EMA, 17 September 2013@9/17/2013@@@@6/1/2005@@PROTECT@No@@170 MEN WITH NON-METASTATIC ADPC@@@III; P-11 / DEN-D9901, NCI-G00-1789;@APPROVED@@@SNS@Researchers evaluated cumulative product release parameters including CD54 upregulation and the number of total nucleated cells (TNCs) among patients treated with sipuleucel-T (n=146). Results showed that Provenge patients experienced improved survival if they received more cells across the three doses (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received Provenge as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022). SOURCE: Dendreon, 14 February 2008@@@@@MONO@SIPULEUCEL-T@@@@@SIPULEUCEL-T||||@DENDREON@@@@@DENDREON||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROVENGE@@@@@PROVENGE||||@Vaccine@Immunotherapy@@@@Vaccine|Immunotherapy|||@PSADT@@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INTRAVENOUS@EURO@@@@@@@@@@250 ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16384763@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384763@Indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alphatherapy@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@@532@The recommended dosage of Glivec is 400 mg/day for adult patients in chronic phase CML.@@@@@@@@@No@@@ADULT@@@APPROVED@@@NHI@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@1@0.0091@2090.74@2465.5@@@@@@@@@@@20.91@1@@mg@400@1@@@@@@@@@@@8/30/2017@2090.74@2090.74@4291011F1028@TABLET@YEN@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921960@Onco@@@@@300f1008ntsdm@@@@@@@@L02BA01@L02B@YES@LONDON, UNITED KINGDOM@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14921960@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@@NHI@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NOLVADEX@@@@@NOLVADEX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.0091@246.94@291.2@@@@@@@@@@@12.35@@@@@@@@@@@@@@@@8/30/2017@246.94@246.94@4291003F2054@FILM COATED TABLET@YEN@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921219@Onco@@@@@@@@@@@Genasense plus Abraxane paclitaxel and Temodar temozolomide@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@6/1/2009@@Genasense (oblimersen sodium) Injection is a drug that inhibits the production of a protein known as Bcl-2. By reducing production of Bcl-2 in cancer cells, it seeks to restore the basic biological process whereby cancer cells can be readily killed by treatment with current methods of anticancer therapy. Genta's clinical trials programs focus on treating cancer patients with Genasense along with the administration of anticancer therapy with the intention of potentiating the cancer-killing effects of treatment. Genta is developing Genasense Injection with the intention of potentiating the cancer-killing activity of standard anticancer therapies. In a typical example, Genasense might be administered for several days and then be immediately followed by regular doses of chemotherapy. This sequence would then be repeated, depending upon the particular type of chemotherapy regimen and indication. In other applications, Genasense might be administered concurrent with or after conventional chemotherapy, again depending on the chemotherapy and indication. Genasense has the potential to be used in combination with most types of anticancer therapy.@@14921219@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00409383@28@-@Confirmatory trial in response to failed EMEA application.@@@-@@11/1/2006@-@GM108@@-@-@@@I@III@@-@-@To date, 6 patients (43%) have achieved major objective responses: one with complete response (CR) after 6 cycles of treatment, and 5 with at least a partial response after only one treatment cycle.  Three additional patients have maintained stable disease (SD) after at least three treatment cycles, for an overall clinical benefit response (CR+PR+SD) of 64%. SOURCE: Genta/ASCO, 30 May 2008Preliminary Phase III data from 7 evaluable patients showed that Genasense + Abraxane paclitaxel and Temodar temoxolomide produced 3 partial responses and 2 cases of stable disease. Two other patients progressed. SOURCE: Chemotherapy Foundation Symposium, November 2007.@No dose-limiting toxicity was observed.  The most commonly observed side-effects were similar to those encountered with the chemotherapy drugs used alone, including leukopenia, thrombocytopenia, and hair loss.  @@@@COMBO@OBLIMERSEN SODIUM@PACLITAXEL, ALBUMIN-BOUND@TEMOZOLOMIDE@@@OBLIMERSEN SODIUM|PACLITAXEL, ALBUMIN-BOUND|TEMOZOLOMIDE||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@GENASENSE@ABRAXANE@TEMODAR@@@GENASENSE|ABRAXANE|TEMODAR||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920815@Onco@@@@@300f1015ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920815@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@Nov-96@@NO REVIEW@@@@@@@@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@Feb-97@@1/19/1998@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@LABEL@No@@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@2135.16@2135.16@@1@1.1511@8.71@11.54@9.29@@@@@@@@@@4.36@@@@@@@@@@@@@@@@8/1/2017@8.71@8.71@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15358224@Onco@@@@@300f1008ntsdm@@@@@@The recommended daily dose of TARCEVA is 150 mg taken orally@@L01XE03@L01X@-@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@15358224@Indicated as monotherapy for the first-line treatment of patients with locally advanced (stage III b, not amenable to curative therapy) or metastatic (stage IV) non-small celllung cancer (NSCLC) with EGFR activating mutations.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@>> Abbott signed a deal with Genentech and OSI to develop a molecular gene test to identify extra copies of EGFR in NSCLC for Tarceva. [Abbott, 10 March 2008]     >> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]       >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]        >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@FIRST-LINE@JO22903@102@The recommended daily dose is 150 mg taken at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.@@@@@@@@@No@@@@@II@APPROVED@@@NHI@@@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@SINGLE ARM@@@@@1@@3320128.923@@@11.8@month@11.8 month@3320128.92@3320128.92@9250.62@1@0.0091@6167.08@7272.5@@@@@@@@@@@61.67@1@@mg@150@1@@@@@@@@@@@8/30/2017@6167.08@6167.08@4291016F2027@FILM-COATED TABLET (BLISTER PVC/ALU)@YEN@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
15318132@Onco@@@@@300f1012ntsdm@@@@@@120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.@@M05BX04@M05B@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.@@15318132@Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.@@NA@15-Oct-13@10/15/2013@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@@@2862@The recommended dose of XGEVA for the prevention of skeletal related events is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.@EMA, 15 July 2011@7/15/2011@@No@@@@@No@@@@@III@APPROVED@@@GKV@Denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time points. These improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy, and in post-menopausal women with low bone mass. [Amgen, 14 July 2008]          Trial registered. [Amgen, 02.02.2006]@@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Bone Loss@@@@Supportive Care|Bone Loss||||||||@XGEVA@@@@@XGEVA||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@@@@@@@@@@@@@@@@@@@@@1@1@10172.7181@@@27.6@month@27.6 month@10172.72@10172.72@12.12@1@1.1511@339.3@439.97@350.69@@@@@@@@@@2.83@28@@mg@120@1@@@@@@@@@@@8/1/2017@339.3@339.3@9199606@SOLUTION FOR INJECTION, 1.7 ML@EURO@@@@@@@@120@MG@120 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918969@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@HAYWARD, CALIFORNIA@@@KOS-953 is a proprietary formulation of 17-AAG developed by Kosan to improve patient tolerability and provide greater stability compared to the original drug product.  In addition to the Phase I single-agent study in multiple myeloma reported today, the formulation is also currently being evaluated in a Phase Ib clinical trial of KOS-953 administered in combination with bortezomib (Velcade), a recently approved agent to treat relapsed-refractory myeloma. @@14918969@-@@-@-@@NO REVIEW@@@@-@BMS acquires Kosan Biosciences for US$190 million. SOURCE: BMS, 29 May 2008@-@-@30@-@-@@@-@@@-@N/A@@-@-@@@II@WITHDRAWN@@-@-@Preliminary data: tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma. One of the 6 evaluable patients with a BRAF mutation (V600E) showed evidence of anti-melanoma activity. An additional patient with BRAF mutation continues on study but was too early to assess for efficacy. The safety profile has been manageable. Accrual is continuing toward the goal of enrolling a total of 30 evaluable patients (with continued BRAF mutation analysis). SOURCE: KosaN/ASCO, June 2007@-@@@@-@TANESPIMYCIN@@@@@TANESPIMYCIN||||@KOSAN BIOSCIENCES@BMS@@@@KOSAN BIOSCIENCES|BMS|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@KOS-953@@@@@KOS-953||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@-@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923910@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01BB03@L01B@NO@BRENTFORD, UNITED KINGDOM@@@@@14923910@Indicated primarily for the treatment of acute leukaemias especially acute myelogenous leukaemia and acute lymphoblastic leukaemia. Lanvis is also used in the treatment of chronic granulocytic leukaemia.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Adults: The usual dosage of Lanvis is between 100 and 200 mg/m2 body surface area, per day. Children: Similar dosages to those used in adults, with appropriate correction for body surface area, have been used.@@@@@@@It is an active cytotoxic agent for use only under the direction of physicians experienced in the administration of such agents. Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, immunisations with live organism vaccines are not recommended. Hepatic Effects: not recommended for maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity associated with vascular endothelial damage@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@TIOGUANINE@@@@@TIOGUANINE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Chronic Myeloid Leukaemia@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Chronic Myeloid Leukaemia||||||@THIOGUANIN ASPEN@@@@@THIOGUANIN ASPEN||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@1.1511@150@200.63@155.42@@@@@@@@@@0.15@@@@@@@@@@@@@@@@8/1/2017@6@6@1688872@TABLET@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16396664@Onco@@@@@300f1018ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396664@Indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.@Both@YES@@@NO REVIEW@@@@@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@TGA, 16 March 2016@3/16/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@125987.2597@@@37.6@week@37.6 week@125987.26@125987.26@478.68@21@0.779@5361.16@5407.68@@@@@@@@@@@25.53@28@@mg@25@21@@@@@@@@@@@8/1/2017@255.29@255.29@2922-1419-HB-CJ@HARD CAPSULE@A$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14918204@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01DB07@L01D@YES@BASEL, SWITZERLAND@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14918204@Mitoxantrone is indicated in the treatment of metastatic breast cancer, non-Hodgkin's lymphoma and adult acute non-lymphocytic leukaemia. Mitoxantrone has also been used in the palliation of non-resectable primary hepatocellular carcinoma.@@NO@@@NO REVIEW@@@@@G Gam is the French arm of Hexal, purchased by Novartis in February 2005.@@@@HRPC: based on data from two Phase 3 comparative trials of mitoxantrone injection plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m2 given as a short intravenous infusion every 21 days.@@@@@@@HRPC: functional cardiac changes such as decreases in LVEF and congestive heart failure may occur in patients with HRPC treated with mitoxantrone. In a randomised comparative trial of mitoxantrone plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone had a cardiac event defined as any decrease in LVEF below the normal range, CHF (n = 3), or myocardial ischemia. Two patients had a prior history of cardiac disease. The total mitoxantrone dose administered to patients with cardiac effects ranged from > 48 to 212 mg/m2. Among 112 patients evaluable for safety on the mitoxantrone + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. The range of total mitoxantrone doses administered to these patients is not available.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@MITOXANTRONE@@@@@MITOXANTRONE||||@NOVARTIS@G GAM@@@@NOVARTIS|G GAM|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919066@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dose Level 1, 2 OR 3 PO for at least 7 days @@L01CA04@L01C@-@-@11/1/2008@@Vinorelbine is an antineoplastic active substance of the vinca alkaloid family, but in contrast to all other vinca alkaloids the catharanthine portion of vinorelbine has undergone a structural modification. On the molecular level it affects the dynamic equilibrium of tubulin in the microtubular system of the cell. Vinorelbine inhibits tubulin polymerisation and binds preferentially to mitotic microtubules, only affecting axonal microtubules at high concentrations. Spiralisation of the tubulin is induced to a lesser degree than with vincristine. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.@@14919066@Non-haematological malignancies for wich there are no currently accepted therapies@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00641160@12@-@-@@@-@@3/1/2008@-@MT-CL002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@VINORELBINE TARTRATE@@@@@VINORELBINE TARTRATE||||@METRONOME THERAPEUTICS@@@@@METRONOME THERAPEUTICS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@-@@@@@-||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@SAFETY@ADVERSE EVENTS@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918717@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@LAKE FOREST, ILLINOIS@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918717@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@NO@@@NO REVIEW@@@@100%@Acquired via takeover of Mayne Pharma@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, August 1985@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.299@24@@@@@@@@@@@@0.02@@@@@@@@@@@@@@@@7/28/2017@4.8@4.8@9.12E+15@SOLUTION FOR INJECTION, VIAL@GB£@@@@@@@@250@MG@250 MG/10 ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916488@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days. @@-@-@-@BASEL, SWITZERLAND@11/1/2009@@A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins. @@14916488@Combo with Gemzar for advanced incurable malignant solid tumours@@-@-@@NO REVIEW@@@@-@-@-@NCT00550199@40@-@EMEA PDCO recommended product-specific waiver. SOURCE: EMEA PDCO, January 2008Orphan designation was granted by the European Commission for panobinostat lactate for the treatment of cutaneous T cell lymphoma. [There is discussion of current treatments, the numbers or persons affected with this condition in the EU, and the mode of action & state of development of panobinostat lactate for the treatment of this condition. Panobinostat lactate was not authorised anywhere in the world for cutaneous T-cell lymphoma, or designated as orphan medicinal product elsewhere for this condition, at the time of submission. Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.] SOURCE: EMEA COMP, 6 November 2007@11/6/2007@@-@@11/1/2007@-@SCRI REFMAL 120,@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@PANOBINOSTAT@GEMCITABINE@@@@PANOBINOSTAT|GEMCITABINE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LBH-589@GEMZAR@@@@LBH-589|GEMZAR|||@HDAC@@@@@HDAC||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916643@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive Vectibix alone.@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the bindingof ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-inducedreceptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth,induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, andinternalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits thegrowth and survival of selected human tumor cell lines expressing EGFR.@@14916643@Metastatic or recurrent SCCHN@@@@@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@SECOND-LINE@NCT00446446@50@@@@@@@5/1/2007@@PRISM@@PATENT STATUS REMAINS IN DISPUTE; AMGEN LICENSED THE SCHLESSINGER PATENT ('866) UNTIL 2017 IN SEPTEMBER 2006 FROM YEDA.@@@@II@II@@@@RESULTS PENDING@@@@@MONO@PANITUMUMAB@@@@@PANITUMUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@VECTIBIX@@@@@VECTIBIX||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@RESPONSE RATE@@@@@@@@@@METASTATIC@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923373@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923373@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOX@@@@@TAMOX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@30@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918829@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14918829@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@@@@@For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg daily for two or three days is advisable together with a high fluid intake. Otherwise similar considerations to the above recommendations for treating patients with gout govern the regulation of dosage for maintenance purposes in secondary hyperuricemia.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Covered; preferred@MEDICARE@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@QUALITEST@@@@@QUALITEST||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@500@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@US$@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924620@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@BEMA fentanyl versus placebo in doses from 200mcg to 12mcg@@N02AB03@N02A@-@RALEIGH, NORTH CAROLINA@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals. @@14924620@Breakthrough cancer pain@@-@-@@NO REVIEW@@@@-@Meda licensed European rights in August 2006. In September 2007, a licensing agreement was signed for the U.S. distribution rights.@-@-@81@-@-@@@-@@@-@-@@-@81 patients on stable background opioid medication@@@III@III@@-@-@A total of 394 BTP episodes were treated with BEMA™ Fentanyl and 197 with placebo. Lack of effective pain relief leading to withdrawal during the initial open label titration phase was infrequent (3.3% of patients). In the double blind portion of the study, the primary endpoint – sum of pain intensity differences at 30 minutes (SPID30) – was significantly greater with BEMA Fentanyl than placebo (p=0.004). Additionally, SPID values were significant in favor of BEMA Fentanyl at all time points from 15 minutes through 60 minutes, the last assessment time. SOURCE: BioDelivery/APS, 8 May 2008@-@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@BIODELIVERY SCIENCES@MEDA AB@@@@BIODELIVERY SCIENCES|MEDA AB|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ONSOLIS@BEMA@@@@ONSOLIS|BEMA|||@Opioid Analgesic@@@@@Opioid Analgesic||||@SPID@@@@@@@@@@-@@@@@PLACEBO-CONTROLLED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924134@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Abraxane plus carboplatin@@L01CD01@L01C@-@SUMMIT, NEW JERSEY@@@Abraxane is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel protein-bound particles for injectable suspension) is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.@@14924134@Recurrent platinum-sensitive overian or primary peritoneal cancer@@-@-@@NO REVIEW@@@@-@>>Celgene acquires Abraxis for US$2.9 billion [Celgene 30 June 2010 http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight= ]>> Abraxis BioScience has entered into an agreement with AstraZeneca to re-acquire the exclusive rights to market Abraxane in the United States. [Abraxis, 28.11.2008]       >> AstraZeneca paid US$200 mil to co-promote Abraxane in the U.S., whilst Abraxis bought AstraZeneca's anaesthetic/analgesia portfolio. India/certain Asia rights licensed to Biocon in August 2007.@SECOND-LINE@NCT00466986@40@-@-@@@-@@11/1/2005@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING; completion in June 2009.@-@@@@COMBO@PACLITAXEL PROTEIN BOUND PARTICLES@CARBOPLATIN@@@@PACLITAXEL PROTEIN BOUND PARTICLES|CARBOPLATIN|||@CELGENE@ABRAXIS@@@@CELGENE|ABRAXIS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ABRAXANE@@@@@ABRAXANE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918699@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@@@YES@LAKE FOREST, ILLINOIS@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14918699@Indicated in a wide variety of disorders amenable to glucocorticoid therapy, as well as an adjunct in the control of cerebral oedema.@@@@@NO REVIEW@@@@100%@Acquired through the takeover of Mayne@@@N/A@Intravenous Administration: IV dosage of dexamethasone phosphate is variable, depending on the condition being treated. It usually ranges from 0.5-24 mg daily. The duration of therapy is dependent on the clinical response of the patient and as soon as improvement is indicated, the dosage should be adjusted to the minimum required to maintain the desired clinical response. Withdrawal of the drug on completion of therapy should be gradual.@EMA, May 2000@@@@@@The lowest effective dose of corticosteroid should be used to control the condition under treatment for the minimum period. Frequent patient review is required to appropriately titrate the dose against disease activity. When dose reduction is possible, it should occur gradually. Too rapid a reduction of dexamethasone dosage following prolonged treatment can lead to acute adrenal insufficiency, hypotension and death. A 'withdrawal syndrome' may also occur including fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and loss of weight.@NO LABELLED TRIAL@No@@@-@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@ADJUVANT@DEXAMETHASONE SODIUM PHOSPHATE@@@@@DEXAMETHASONE SODIUM PHOSPHATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Brain Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Brain Cancer||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@1@year@1 year@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@8@MG@8 MG/2 ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16384686@Onco@@@@@300f1020ntsdm@@@@@@@@L01CD02@L01C@@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@16384686@TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.@@YES@8-Oct-10@10/8/2010@NO REVIEW@@@@100%@@SECOND-LINE@@@For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent. Docetaxel is administered as a one-hour infusion every three weeks.@N/A@@@@@@@@No@@@@@@APPROVED@@@SSN@@@@@@MONO@DOCETAXEL@@@@@DOCETAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@LOCALLY ADVANCED@UNRESECTABLE@@@@@@@@@1.75@m²@3438.349687@@@12.3@week@12.3 week@3438.35@3438.35@39.93@1@1.1229@127.79@210.9@133.54@@@@@@@@@@6.39@21@@mg/m²@75@1@@@@@@@@@@@6/7/2017@127.79@127.79@32391017@CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION, 0.5 ML@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919607@Onco@@@@@300f1012ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@HOLZKIRCHEN, GERMANY@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14919607@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@@@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@APPROVED@@@GKV@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@UNCONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@58.65@85.14@61.2@@@@@@@@@@5.87@@@@@@@@@@@@@@@@8/1/2017@11.73@11.73@6326205@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917100@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@@@@@@14917100@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@NO@@@NO REVIEW@@@@100%@Merger between Kyowa Hakko and Kirin Pharma announced in October 2007.@@@@Malignant lymphomas: Used alone the recommended dosage regime is 15 x 10³ IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 10³ IU (15 vials). Dosage should be reduced in the elderly. The dose may need to be adjusted when bleomycin is used in combination chemotherapy.@EMA, July 2006@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@KYOWA HAKKO KOGYO@KIRIN PHARMA@@@@KYOWA HAKKO KOGYO|KIRIN PHARMA|||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||||@BLEO-KYOWA@@@@@BLEO-KYOWA||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@408.6@408.6@@10@1.2961@190.6@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@19.06@19.06@4.68E+15@INJECTION POWDER FOR RECONSTITUTION@GB£@@@@@@@@15000@IU@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916016@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Patients will receive external radiotherapy with or without nimotuzab@@-@-@-@ONTARIO, CANADA@@@Nimotuzumab is a humanized monoclonal antibody (mAb) that targets the epidermal growth factor receptor (EGFR), a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy. Nimotuzumab has been administered to >1,800 patients worldwide through clinical trials, compassionate use programs and commercial sales and, to date (11/26/2007), there have been no reports of any severe incidents of rash. Incidents of certain other side-effects commonly observed with EGFR-targeting monoclonal antibodies or small molecules are rare.@@14916016@First-line therapy@@-@-@@NO REVIEW@@@@-@YM BioSciences and its licensees are committed to the clinical development and subsequent marketing of nimotuzumab. These include Daiichi-Sankyo Co. Ltd. in Japan, Oncoscience AG in Europe, Kuhnil Pharmaceutical Co., Ltd. in South Korea and Innogene Kalbiotech Pte Ltd. in South East Asia. In addition, as of November 30, 2007 eight other companies around the globe were involved either in a consortium with YM, its licensees or certain of the other licensees, or unilaterally in a number of trials in multiple indications. The other licensees for nimotuzumab include Biocon BioPharmaceuticals Ltd. (BBPL) in India, Biotech Pharmceutical Co. Ltd. in China, Delta Laboratories in Columbia, Eske Group in Peru, Eurofarma Laboratorios Ltda. in Brazil, Ferozsons Labs in Pakistan, Laboratorio Elea S.A.C.I.F.yA. in Argentina and Laboratorios PiSA in Mexico. @FIRST-LINE@NCT00369447@104@-@-@@@-@@@-@YMB1000-010@@-@-@@@I/II@II@@-@-@Median survival was 60 weeks. SOURCE: YM Biosciences/ASCO, 2 June 2008  Partial Response or Stable Disease seen in every one of the 13 patients so far enrolled in this study. SOURCE: YM Biosciences/World Conference on Lung Cancer, 4 September 2007@-@@@@COMBO@NIMOTUZUMAB@@@@@NIMOTUZUMAB||||@YM BIOSCIENCES@ONCOSCIENCE@DAIICHI SANKYO@@@YM BIOSCIENCES|ONCOSCIENCE|DAIICHI SANKYO||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@THERALOC@@@@@THERALOC||||@mAb@EGFR@@@@mAb|EGFR|||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918602@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14918602@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@HEUMANN@@@@@HEUMANN||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@100@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917408@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917408@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90%@Teva acquires Barr. SOURCE: Teva, 21 July 2008@@@@Malignant Melanoma: Dacarbazine can be administered as single agent in doses of 200 to 250 mg/m² body surface area/day as an i.v. injection for 5 days every 3 weeks. As an alternative to an intravenous bolus injection dacarbazine can be administered as a short-term infusion (over 15 - 30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as intravenous infusion.@13-Dec-06@12/13/2006@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@PLIVA@BARR PHARMACEUTICALS@TEVA PHARMACEUTICAL@@@PLIVA|BARR PHARMACEUTICALS|TEVA PHARMACEUTICAL||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@DTIC-DOME@@@@@DTIC-DOME||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@10@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14917382@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917382@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@@@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@DETIMEDAC@@@@@DETIMEDAC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1807@160@213.27@165.74@@@@@@@@@@0.16@@@@@@@@@@@@@@@@8/15/2017@16@16@4613610@VIAL@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16669287@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC12@L01X@@SEATTLE, WASHINGTON@8/1/2014@@@@16669287@Classical HL at high risk of relapse or progression as post-auto-HSCT consolidation@Both@NA@@@NO REVIEW@@@@@@@NCT01100502@329@The recommended dose is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.@FDA, 17 August 2015@8/17/2015@@Yes@@4/1/2010@@SGN35-005, 2009-016947-20@No@@Patients with HL who have received ASCT in the previous 30-45 days; Patients at high risk of residual HL post ASCT; Histologically-confirmed HL; ECOG of 0 or 1; Adequate organ function@@ADULTS@III@APPROVED@@@NA@@@@@@MONO@BRENTUXIMAB@@@@@BRENTUXIMAB||||@SEATTLE GENETICS@MILLENNIUM PHARMACEUTICALS@@@@SEATTLE GENETICS|MILLENNIUM PHARMACEUTICALS|||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@ADCETRIS@@@@@ADCETRIS||||@Other@CD30@@@@Other|CD30|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@Incidence of Adverse Events@@@@RELAPSED@@@@@RANDOMISED@DOUBLE BLIND@PARALLEL ASSIGNMENT@@@76.5@kg@1169100.619@@@42.9@month@42.9 month@1169100.62@1169100.62@895.97@1@1@6832@@@@@@@@@@@@136.64@21@@mg/kg@1.8@1@@@@@@@@@@@8/2/2017@6832@6832@51144-0050-01@LYOPHILISATE FOR SOLUTION FOR INJECTION@US$@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922979@Onco@@@@@@@@@@@>> Cohorts 1-4 received gemcitabine and erlotinib plus escalating doses of motesanib (50, 100, 125 mg once daily and 75 mg twice daily, respectively) from day 9 of the first cycle. Cohorts 5 and 6 were given erlotinib plus motesanib (100 and 125 mg once daily, respectively).     >> Patients in the control group received once-weekly gemcitabine (1000 mg/m2 iv for 7-8 weeks for the first cycle, and subsequent cycles of 3/4 weeks) and once-daily erlotinib (100 mg) from day 1.@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Motesanib diphosphate is a highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis and lymphangiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (“VEGFR1-3”). It is also under investigation for its potential direct anti-tumor activity by targeting platelet-derived growth factor receptor (“PDGFR”) and stem cell factor receptor (“c-kit”) signaling, which may also confer direct anti-tumor activity. In February 2008, Amgen announced that Takeda will become the worldwide partner for motesanib diphosphate in addition to an exclusive collaboration on up to 13 other programs in the Japanese market. @@14922979@Motesanib in combination with Gemzar and Tarceva in solid tumour in patients with no previous VEGF, Gemzar or Tarceva therapy.@@-@-@@NO REVIEW@@@-@-@Motesanib was the unofficial key to the wide-ranging, two-part R&D deal with Amgen signed in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-@-@-@-@-@-@@@-@@@-@-@@-@Patients had previously not received any Gemzar, Tarceva or angiogenesis inhibitor therapy@@@I@I@@-@-@MTD in the 1-4 cohorts was 100mg once-daily. Pharmacokinetic parametre values of 50-125mg once daily were not affected by Tarceva and Gemzar. 1 confirmed partial response was seen in an NSCLC patient. [Amgen / ASCO, 2.06.2008]@78% of patients experienced adverse events related to motesanib, with grade IV events including febrile neutropaenia (in 2 patients) and pulmonary embolism in 2 patients. Grade III events included deep vein thrombosis in 2 patients, congestive heart failure in 1 patient and cholecystitis in 1 patient.@@@@COMBO@MOTESANIB DIPHOSPHATE@ERLOTINIB@GEMCITABINE@@@MOTESANIB DIPHOSPHATE|ERLOTINIB|GEMCITABINE||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AMG-706@@@@@AMG-706||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@MAXIMUM TOLERATED DOSE@PHARMACOKINETICS@@@@RESPONSE RATE@@@@@-@@@@@ACTIVE CONTROL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916615@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Two dose levels of PX-12@@-@-@-@BELLEVUE, WASHINGTON@@@PX-12 is a small molecule designed to inhibit thioredoxin-1. Increased levels of thioredoxin-1 have been noted in many types of cancer cells, including hepatoma, lung cancers, squamous cervical carcinoma, primary gastric cancers and colorectal carcinomas. Increased levels of thioredoxin-1 are associated with decreased sensitivity to a variety of common chemotherapy agents and may cause or contribute to drug resistance. @@14916615@Progression following Gemzar or Gemzar-containing regimen@@-@-@@NO REVIEW@@@@-@Oncothyreon will restructure to focus on development of PX-478 and PX-866 following the transfer of manufacturing responsibilities of Stimuvax to Merck KGaA. [Oncothyreon, 20.12.2008]@SECOND-LINE@NCT00417287@80@-@FDA SPA AND FAST-TRACK GRANTED.@@@-@@@-@PX-12-II-01@@-@-@@@II@II@@-@-@PX-12 reduced plasma Trx-1 levels in all patients with initial levels greater than 18 ng/mL, the upper limit of the normal range. Patients with normal Trx-1 levels remained in the normal range following PX-12 treatment. Thirty-three percent of patients with elevated Trx-1 levels achieved stable disease with PX-12 treatment. No patients achieved stable disease if their starting Trx-1 levels were within the normal range. SOURCE: Oncothyreon/AACR, 16 April 2008@-@@@@MONO@-@@@@@-||||@ONCOTHYREON@@@@@ONCOTHYREON||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@PX-12@@@@@PX-12||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917572@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L02AE02@L02A@NO@OSAKA, JAPAN@@@This is a synthetic nonapeptide analogue of naturally occurring gonadotrophin releasing hormone (GnRH) which possesses greater potency than the natural hormone. It is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy. Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Oestradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.@@14917572@Treatment of metastatic prostate cancer; metastatic breast cancer; uterine fibroids; precocious puberty; and endometriosis@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@One injection every four weeks.@@@@No@@@@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@TAKEDA PHARMACEUTICAL@@@@@TAKEDA PHARMACEUTICAL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ENANTONE MONATS DEPOT@@@@@ENANTONE MONATS DEPOT||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.1807@381.14@492.87@393.85@@@@@@@@@@33.88@@@@@@@@@@@@@@@@8/15/2017@127.05@127.05@3891933@PREFILLED SYRINGE 1 ML@EURO@@@@@@@@3.75@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922665@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive galiximab 500MG/M2 IV once weekly@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@12/1/2011@@A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies. @@14922665@Previously untreated follicular NHL@@-@-@@NO REVIEW@@@@-@Mitsubishi Pharma discontinued its involvement in the Asian development of the drgu in March 2003.@FIRST-LINE@NCT00651443@20@-@The trial is being conducted under a US FDA Special Protocol Assessment, granted in July 2006. @@@-@@4/1/2008@-@114-NH-103@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@GALIXIMAB@@@@@GALIXIMAB||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@IDEC-114@ANTI-CD80 MAB@@@@IDEC-114|ANTI-CD80 MAB|||@mAb@Humanised@CD80@@@mAb|Humanised|CD80||@MECHANISM OF ACTION@@@@@@@@@@-@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16641006@Onco@@@@@300f1008ntsdm@@@@@KEYNOTE-010@@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@9/1/2015@@KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking  antibody indicated for the treatment of patients with unresectable or  metastatic melanoma and disease progression following ipilimumab  and, if BRAF V600 mutation positive, a BRAF inhibitor@@16641006@Unresectable, advanced or relapsed non-small-cell lung cancer (NSCLC), second-line treatment.@Both@NA@@@NO REVIEW@@@@@@SECOND-LINE@NCT01905657@1034@2 mg/kg administered intravenously over 30 minutes every3 weeks. Patients should be treated with KEYTRUDA until disease progression or unacceptabletoxicity.@MHLW, 19 December 2016@12/19/2016@@Yes@@8/1/2013@@3475-010, 2012-004391-19, 132355@No@@Life expectancy of at least 3 months; Histologically- or cytologically-confirmed diagnosis of non-small cell lung cancer (NSCLC) that is PD-L1 positive per central laboratory review; At least one bi-dimensional measurable lesion; Radiographic progression after treatment with at least 2 cycles of a platinum-containing doublet; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1@@ADULTS@II/III@APPROVED@@@NHI@ORR@@@@@MONO@PEMBROLIZUMAB@@@@@PEMBROLIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@OVERALL SURVIVAL@PROGRESSION FREE SURVIVAL@@@@@@@@@UNRESECTABLE@ADVANCED@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN-LABEL@@@76.5@kg@3294234.424@@@4.27@month@4.27 month@3294234.42@3294234.42@25364.4@1@0.0091@348138.77@410541@@@@@@@@@@@3481.39@21@@mg/kg@2@1@@@@@@@@@@@8/30/2017@348138.77@348138.77@4291435A2025@SOLUTION FOR INJECTION - 4 ML@YEN@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
16668396@Onco@@@@@300f1020ntsdm@@@@@@Ibrutinib: 420 mg daily or 840 mg daily@@L01XE27@L01X@@BEERSE, BELGIUM@6/1/2013@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16668396@Indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy,@@YES@26-Nov-15@11/26/2015@NO REVIEW@@@@@@SECOND-LINE@NCT01105247@133@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 21 October 2014@10/21/2014@@YES@@4/1/2010@@PCYC-1102-CA@No@@@@@II@APPROVED@@@SSN@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@PHARMACYCLICS@@@@JANSSEN PHARMACEUTICAL|PHARMACYCLICS|||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE GROUP ASSIGNMENT@@@1@1@55352.40497@@@9@month@9 month@55352.4@55352.4@202.2@120@1.1229@8088.2@13348.76@8452.26@@@@@@@@@@0.48@1@@mg@420@1@@@@@@@@@@@6/7/2017@67.4@67.4@43693023@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15394367@Onco@@@@@300f1020ntsdm@@@@@@521 patients were randomised to treatment with Teysuno (25 mg/m2 orally twice daily for 21 days followed by a 7-day rest period) and cisplatin (75 mg/m2 intravenous infusion once every 4 weeks); and 508 patients were randomised to treatment with 5-FU (1000 mg/m2/24 hours as a continuous intravenous infusion on Days 1 through 5 repeated every 4 weeks) and cisplatin (100 mg/m2 as an intravenous infusion on Day 1 repeated every 4 weeks).@@L01BC53@L01B@@@@@Teysuno is an oral fluoropyrimidine anti-cancer medicinal product@@15394367@Indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin@Both@@@@@@@@100%@@@@1029@The recommended standard dose of Teysuno when administered in combination with cisplatin is25 mg/m2 (expressed as tegafur content) twice daily, morning and evening, for 21 consecutive daysfollowed by 7 days rest (1 treatment cycle). This treatment cycle is repeated every 4 weeks.@EMA, 14 March 2011@3/14/2011@@@@@@FLAGS@No@@@@ADULTS@III@APPROVED@@@SSN@@@@@@COMBO@GIMERACIL / OTERACIL / TEGAFUR@CISPLATIN@@@@GIMERACIL / OTERACIL / TEGAFUR|CISPLATIN|||@NORDIC PHARMA@@@@@NORDIC PHARMA||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TEYSUNO@GENERIC@@@@TEYSUNO|GENERIC|||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMIZED@CONTROLLED@OPEN-LABEL@@@1.75@m²@1841.612322@@@4.8@month@4.8 month@1841.61@1841.61@12.61@42@1.1229@161.46@266.48@168.73@@@@@@@@@@0.19@28@@mg/m²@50@21@@@@@@@@@@@6/7/2017@3.84@3.84@42291031@HARD CAPSULE@EURO@@@@@@@@20@MG@5.8 MG|15.8 MG|20 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14916700@Onco@@@@@300f1012ntsdm@@@@@@Caelyx versus Xeloda@@L01DB01@L01D@-@KENILWORTH, NEW JERSEY@@@The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.@@14916700@Versus Xeloda in first-line mBC@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@FIRST-LINE@NCT00266799@346@-@-@@@-@@1/1/2006@-@PELICAN@@-@-@@@IV@IV@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@DOXORUBICIN, PEGYLATED LIPOSOMAL @@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL ||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CAELYX@@@@@CAELYX||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922505@Onco@@@@@@@@@@@Vectibix monotherapy plus BSC versus BSC alone in patients with mCRC.@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the bindingof ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-inducedreceptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth,induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, andinternalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits thegrowth and survival of selected human tumor cell lines expressing EGFR.@@14922505@Biomarker analysis of 408 trial - Vectibix monotherapy in patients with non-mutated/wild-type KRAS tumours@@@@@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@THIRD-LINE@NCT00113763@463@@@@@@@@@408 TRIAL@@PATENT STATUS REMAINS IN DISPUTE; AMGEN LICENSED THE SCHLESSINGER PATENT ('866) UNTIL 2017 IN SEPTEMBER 2006 FROM YEDA.@@@@III 20020408@III@@@@The data showed the relative effect of Vectibix versus BSC was significantly greater in patients with non-mutated versus mutated KRAS (HR = 0.45 vs. HR = 0.99). Median PFS in patients without the mutation treated with Vectibix plus BSC was 12.3 weeks versus 7.3 weeks, respectively. When the analysis standardized the time to tumor assessment, the median PFS was 16 weeks versus 8 weeks, respectively (HR= 0.49 vs. 1.07). When the treatment arms were combined (non-mutated vs. mutated) overall survival was longer in patients with non-mutated compared with mutated KRAS (HR = 0.67). No differences in overall survival were observed between Vectibix and BSC in either KRAS subgroup, potentially due to a high rate of crossover from BSC to Vectibix after progression, and similar efficacy of Vectibix in these patients. In patients with tumors carrying non-mutated KRAS genes, the analysis demonstrated that in Vectibix treated patients clinically meaningful inferior symptom control and QoL scores could be excluded compared to BSC, and that a clinically meaningful difference in favour of Vectibix was observed at most time points. In contrast, a clinically significant worsening of symptom control and QoL scores could not be excluded in patients with mutated KRAS tumors treated with Vectibix compared to BSC. The data is presented at the ASCO GI meeting on 26 January. SOURCE: Amgen, 24 January 2008@@@@@MONO@PANITUMUMAB@@@@@PANITUMUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@@@@@VECTIBIX||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@BIOMARKER@@@@@@@@@@METASTATIC@@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920156@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@ICELAND@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920156@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@@@Regimen 1: 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43): Weekly Camptosar 125mg/m2 IV over 90 minutes on days 1, 8, 15 and 22, followed by 100mg/m2 on week 5 and 75mg/m2 on week 6@FDA, 29 February 2008@2/29/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@COMBO@IRINOTECAN@@@@@IRINOTECAN||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@5.5@month@5.5 month@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@18111-0002-02@INJECTION - 2 ML@US$@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920088@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@ICELAND@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920088@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@@@Regimen 2: 6-wk cycle with infusional 5-FU/LV (next cycle begins on day 43): Camptosar 180mg/m2 IV over 90 minutes on days 1, 15 and 29, followed by dose level 1 (150mg/m2) and 2 (120mg/m2)@FDA, 29 February 2008@2/29/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@COMBO@IRINOTECAN@@@@@IRINOTECAN||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@5.6@month@5.6 month@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@18111-0002-03@INJECTION - 5 ML@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921082@Onco@@@@@300f1015ntsdm@@@@@@ARM1: Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles) with Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles) ARM2: Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles) with Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles) and Bevacizumab 15 mg/kg D1 (D1=D22, until progression). SOURCE: clinicaltrials.gov@@L01XC07@L01X@-@BASEL, SWITZERLAND@11/1/2012@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14921082@Avastin plus pemetrexed and cisplatin@@-@-@@NO REVIEW@@@@-@-@-@NCT00651456@445@-@-@@@-@@2/1/2008@-@IFCT-GFPC-ELCWP-0701@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@COMBO@BEVACIZUMAB@PEMETREXED@@@@BEVACIZUMAB|PEMETREXED|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Mesothelioma@@@@@Mesothelioma|||||||||@AVASTIN@ALIMTA@@@@AVASTIN|ALIMTA|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921105@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Drug: zalutumumab - Eight weekly infusions. Drug: cisplatin - Infusions.Procedure: Radiotherapy - Daily in the treatment period @@-@-@-@COPENHAGEN, DENMARK@@@Zalutumumab is a fully human, high-affinity antibody targeted at the Epidermal Growth Factor receptor (EGFr) and is in clinical development to treat head and neck cancer, non small cell lung cancer (NSCLC) and colorectal cancer. EGFr is a receptor molecule found on the surface of many cancer cells. Activation of EGFr by the appropriate growth factor molecule promotes the growth of tumor cells. @@14921105@Frontline against squamous cell head and neck cancer@@-@-@@NO REVIEW@@@@-@No licensing partner@FIRST-LINE@NCT00401401@-@-@The US FDA has placed a partial clinical hold on trial. The FDA has requested an updated analysis of safety data since the Genmab's last annual report which covered the period through July 29, 2008. [Genmab 3 June 2009]@6/3/2009@@-@@1/1/2007@-@Hx-EGFr-203@@-@PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY, OROPHARYNX, HYPOPHARYN OR LARYNX.@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@ZALUTUMUMAB@CISPLATIN@@@@ZALUTUMUMAB|CISPLATIN|||@GENMAB@MEDAREX@@@@GENMAB|MEDAREX|||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@HUMAX-EGFR@@@@@HUMAX-EGFR||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@SAFETY@TIME TO PROGRESSION@@@@@@@@@LOCALLY ADVANCED@@@@@OPEN-LABEL@RANDOMISED@UNCONTROLLED@DOSE ESCALATION@PARALLEL ASSIGNMENT@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921401@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Yondelis alone@@L01CX01@L01C@-@NEW BRUNSWICK, NEW JERSEY@@@Yondelis (trabectedin, ET-743) was originally isolated from the marine tunicate Ecteinascidia turbinata. Yondelis has a novel mechanism of action. It is a unique anti cancer agent that binds into the minor groove of the DNA and interacts with DNA repair enzymes and transcription factors, interfering with different cell cycle processes. In addition to STS, Yondelis is being developed in a pivotal Phase III trial in ovarian cancer and in Phase II in prostate and breast cancers. Yondelis was designated Orphan Drug for STS by the European Commission (E.C.) in 2001 and by the U.S. FDA in 2004 and for ovarian cancer by the E.C. in 2003 and by the U.S. FDA in 2005.@@14921401@-@@-@-@@NO REVIEW@@@@-@>> PharmaMar, the biotech arm of Zeltia, has regained the Japanese rights to the drug and received US$10 million from the previous licence holder. Yondelis had been licensed to Ortho Biotech Products (OBI), a subsidiary of Johnson & Johnson since 2001. [Zeltia, 11 July 2008]              >> PharmaMar (Zeltia) maintains European rights, Ortho Biotech U.S. rights and Janssen Cilag for the rest of the world.@-@NCT00072670@50@-@-@@@-@@1/1/2004@-@ET-B-025-02@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@TRABECTEDIN@@@@@TRABECTEDIN||||@JOHNSON & JOHNSON@JANSSEN CILAG@ORTHO BIOTECH@@@JOHNSON & JOHNSON|JANSSEN CILAG|ORTHO BIOTECH||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@YONDELIS@@@@@YONDELIS||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@PSA@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922253@Onco@@@@@@@@@@@ARQ-197 (120MG capsule twice daily) versus gemcitabine (1000MG/M2 once weekly for 4 weeks for the first 28 days cycle; subsequently 1000MG/M2 once weekly for 3 weeks with no drug administered in the 4th week).@@-@-@-@WOBURN, MASSACHUSSETTS@@@ARQ 197 is a selective inhibitor of c-Met, a receptor tyrosine kinase. When abnormally activated, c-Met plays multiple roles in aspects of human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis. Pre-clinical data have demonstrated that ARQ 197 inhibits c-Met activation in a wide range of human tumor cell lines, including clear cell sarcoma, and shows anti-tumor activity against several human tumor xenografts. In clinical studies to date, treatment with ARQ 197 has been well tolerated and has resulted in tumor responses and prolonged stable disease across broad ranges of tumors and doses.@@14922253@ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma @@-@-@@NO REVIEW@@@@-@>> Daiichi Sankyo and ArQule will jointly develop and launch ARQ-197 worldwide except Japan, China, South Korea and Taiwan. Daiichi Sankyo will also become the first partner in ArQule's kinase inhibitor programme (AKIP). Daiichi will pay US$75 million upfront in cash for the two collaborations and tiered royalties on any sales. [Daiichi Sankyo, 11.11.2008]         >> Kyowa Hakko holds rights to ARQ-197 in Japan and parts of Asia@-@NCT00558207@72@-@-@@@-@@11/1/2007@-@ARQ 197-205@@-@Histologically or cytologically confirmed locally advanced or metastatic unresectable pancreatic adenocarcinoma @@@II@II@@-@-@Trial registered. Completion expected in November 2008. [Arqule, 12.11.2007]@-@@@@MONO@-@GEMCITABINE@@@@-|GEMCITABINE|||@ARQULE@KYOWA HAKKO KOGYO@KIRIN PHARMA@DAIICHI-SANKYO@@ARQULE|KYOWA HAKKO KOGYO|KIRIN PHARMA|DAIICHI-SANKYO|@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ARQ-197@GEMZAR@@@@ARQ-197|GEMZAR|||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14919194@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are stratified according to participating centre location (North America vs Europe), lactate dehydrogenase (less than ULN vs ULN or greater), and metastatic sites (liver only vs liver and other sites). Patients are randomised to one of two treatment arms. Arm I: Patients receive interleukin-2 (IL-2) subcutaneously (SC) twice daily on days 1 and 2 of weeks 1 and 3 and days 1-5 of weeks 2 and 4. Patients also receive histamine dihydrochloride SC over 10-30 minutes on days 1-5 of weeks 1-4.  Arm II: Patients receive IL-2 as in arm I. In both arms, treatment repeats every 6 weeks for at least 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 3 years and then every 6 months thereafter.@@-@-@-@-@@@Ceplene is EpiCept's registration-stage compound for the treatment of AML.Ceplene is based on the naturally occurring molecule histamine, and isdesigned to prevent or inhibit oxidative stress, thus protecting criticalimmune cells.  Research has demonstrated that oxidative stress suppresses theimmune system's ability to destroy cancer cells, including malignant AMLcells.@@14919194@Stage IV melanoma metastatic to the liver@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Maxim Pharmaceuticals in January 2006.@-@NCT00039234@224@-@-@@@-@@9/1/2002@-@MAXIM-MP-8899-0104,  @@2018 [Orphan exclusivity]@-@@@MSKCC-03057; @III@@-@-@November 2004; primary endpoint of increased survival time with the combination therapy compared with IL-2 alone was not met. Trial will continue under compassionate use.@-@@@@COMBO@HISTAMINE DIHYDROCHLORIDE@@@@@HISTAMINE DIHYDROCHLORIDE||||@EPICEPT@@@@@EPICEPT||||@@@@@@|||||||||@Melanoma / Skin Cancer@Liver Cancer@@@@Melanoma / Skin Cancer|Liver Cancer||||||||@CEPLENE@@@@@CEPLENE||||@Other@@@@@Other||||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@SAFETY@@RESPONSE RATE@SAFETY@@@@METASTATIC@@@@@RANDOMISED@ACTIVE CONTROL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16639052@Onco@@@@@300f1018ntsdm@@@@@@@@L01XE23@L01X@@LONDON, UNITED KINGDOM@7/1/2011@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK. Mekinist is indicated as a single-agent oral treatment for unresectable or metastatic melanoma in adult patients with BRAF V600E or V600K mutations.@@16639052@TAFINLAR as monotherapy is indicated for the treatment of patients with BRAF V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma.@Both@NO@1-Dec-13@12/1/2013@NO REVIEW@@@@@@@NCT01153763@92@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@TGA, 27 August 2013@8/27/2013@@No@@8/1/2010@@BRF113710@No@@Must be at least 18 years of age; Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay; Is treatment naive or has received prior treatment for metastatic melanoma; Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment; Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication; Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication; Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; Adequate organ function.@BRAF V600 mutation@ADULTS@II@APPROVED@@@PBS@@@@@@MONO@DABRAFENIB@@@@@DABRAFENIB||||@GSK@@@@@GSK||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@@@@@TAFINLAR||||@Other@@@@@Other||||@OVERALL RESPONSE RATE@@@@@PROGRESSION FREE SURVIVAL@@@@@ADVANCED@METASTATIC@@@@SINGLE GROUP@OPEN LABEL@@@@1@1@60247.98515@@@6.9@month@6.9 month@60247.99@60247.99@287.07@120@0.779@8612.17@8760.05@8682.11@@@@@@@@@@0.96@1@@mg@300@1@@@@@@@@@@@8/1/2017@71.77@71.77@3188-0575-GE-NV@CAPSULE@A$@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916606@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@CTCL patients will receive 1000 mg/m2 of PXD101 IV. PTCL patients will receive 1000 mg/m2 of PXD101 IV.@@-@-@-@COPENHAGEN, DENMARK@@@Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a singleagent,or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade (bortezomib) for injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.@@14916606@Treating T-cell lymphomas (peripheral and cutaneous)@@-@-@@NO REVIEW@@@@-@TopoTarget licenses back global rights in exchange for US$26-mil. Payment to CuraGen, 5 mil newly issued shares, and a 10% milestone payment on first US$60 mil of rvenues generated whether in sales or partnership deals. SOURCE: TopoTarget, 22 April 2008@SEVENTH-LINE@NCT00274651@68@-@-@@@-@@@-@PXD101-CLN-6@@-@-@@@II@II@@-@-@4 of 14 patients achieved an objective response for an objective response rate of 29% including one CR and 3 partial responses (PR). Time to response ranged from 8-57 days. As demonstrated by a decrease in SWAT score, 77% of evaluable patients showed an improvement in skin burden of CTCL. 5 out of 6 patients with significant pruritus at baseline had a clinically meaningful reduction in pruritus scores. The CTCL arm is now enrolling up to 34 patients to further refine the magnitude of the objective RR. In the PTCL arm, 2 of 11 patients achieved an objective response including one CR and one PR, with best responses not yet determined in 2 patients whose treatment is ongoing. The degree of activity observed in the first phase of this study meets the predefined criteria to expand enrollment of the PTCL arm to a total of 34 patients. [TopoTarget/ASCO, June 2007]@-@@@@MONO@BELINOSTAT@@@@@BELINOSTAT||||@TOPOTARGET@@@@@TOPOTARGET||||@@@@@@|||||||||@Haematological Malignancy@CTCL@@@@Haematological Malignancy|CTCL||||||||@PXD-101@@@@@PXD-101||||@HDAC@@@@@HDAC||||@COMPLETE RESPONSE@PARTIAL RESPONSE@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921465@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921465@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@YES@-@@NO REVIEW@@@@100%@-@-@-@-@In combination chemotherapy the usual dose (25-30 mg/m²) is usually maintained, while the frequency of administration is reduced e.g. day 1 and 5 every 3 weeks or day 1 and 8 every 3 weeks according to treatment protocol.@N/A@@@NO@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@EXPIRED@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@COMBO@VINORELBINE TARTRATE@CISPLATIN@@@@VINORELBINE TARTRATE|CISPLATIN|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@-@@@@@@@@@@ADVANCED@REFRACTORY@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@4227.39@4227.39@11.58@1@1.1229@101.62@167.71@106.19@@@@@@@@@@2.03@@@@@@@@@@@@@@@@6/7/2017@101.62@101.62@27865094@PREPARATION FOR INJECTION (5 ML)@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921097@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AZD-2281 given orally twice daily. BRCA identified by using Myriad Genetics BRACAnalysis test@@-@-@-@LONDON, UNITED KINGDOM@@@A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. PARP inhibitor AZD2281 selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.@@14921097@BRCA1 or 2 positive advanced ovarian cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@-@NCT00494442@40@-@-@@@-@@6/1/2007@-@ICEBERG-2@@-@40 PATIENTS WITH ADVANCED BRCA1 OR BRCA2-POSITIVE OVARIAN CANCER@@@KU36-58 @II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@AZD-2281@@@@@AZD-2281||||@PARP Inhibitor@@@@@PARP Inhibitor||||@RESPONSE RATE@TIME TO PROGRESSION@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@NON-COMPARATIVE@INTERNATIONAL@MULTI-CENTRE@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921109@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@COPENHAGEN, DENMARK@@@HuMax-CD4 is a high affinity human antibody that targets the CD4 receptor on T-lymphocytes. Genmab has run two Phase II studies using HuMax-CD4 to treat CTCL, one in early stage patients and the other for patients with advanced disease, both of which achieved positive results. Thirty-eight CTCL patients with MF, the most common form of CTCL, were treated in these studies. Genmab has US Orphan Drug designation for HuMax-CD4 to treat MF patients and is making plans for a pivotal study with HuMax-CD4 under an FDA Fast Track designation for patients who have failed available therapies.@@14921109@T-cell lymphoma in the skin@@-@-@@NO REVIEW@@@@-@Genmab licensed global rights licensed to Merck Serono in August 2005, but regained in June 2007.@-@NCT00071071@N/A@-@-@@@-@@@-@Hx-CD4-007@@-@-@@@III@DISCONTINUED@@-@-@>> Development discontinued as part of a strategic review of Genmab's pipeline. Patient recruitment in CTCL was slow and the small market potential meant that Genmab did not consider this worth the investment. [Genmab, 8.10.2008]      >> 22 patients with CTCL received infusions of 4, 8, or 14 mg/kg zanolimumab once weekly for 12 weeks. In the two highest dose groups, 5 out of 12 patients (42%) had a clinical response. A partial response was observed in one of six patients (16%) in the 8 mg/kg dose group and four of six patients (67%) in the 14 mg/kg dose group. No responses were observed at the 4 mg/kg dose level, and this dose will not be used in the second part of the study. [Genmab, December 2007]@-@@@@MONO@ZANOLIMUMAB@@@@@ZANOLIMUMAB||||@GENMAB@MEDAREX@@@@GENMAB|MEDAREX|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@CTCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|CTCL||||||@HUMAX-CD4@@@@@HUMAX-CD4||||@mAb@Human@CD4@@@mAb|Human|CD4||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919775@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@GALASHIELS, UNITED KINGDOM@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919775@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Jan-91@1/1/1991@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@PROSTRAKAN@ELFAR@@@@PROSTRAKAN|ELFAR|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@500@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16384818@Onco@@@@@300f1020ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384818@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@YES@@@NO REVIEW@@@@100%@-@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@N/A@@@YES@@@@@No@@@PAEDIATRIC@@@APPROVED@@@SSN@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@23669.59191@@@1@year@1 year@23669.59@23669.59@64.85@120@1.1229@1907.3@3147.8@1993.15@@@@@@@@@@0.16@1@@mg/m²@340@1@@@@@@@@@@@6/7/2017@15.89@15.89@35372059@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921730@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oxaliplatin/5-FU/leucovorin plus vatalanib versus this therapy without vatalanib.@@-@-@-@LEVERKUSEN, GERMANY@10/1/2004@@"Vatalanib (PTK/ZK) is a ""small"" molecule tyrosine kinase inhibitor with broad specificity that targets all VEGF receptors (VEGFR), the platelet-derived growth factor receptor, and c-KIT. It is a multi-VEGFR inhibitor designed to block angiogenesis and lymphangiogenesis by binding the intracellular kinase domain of all three VEGFRs, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Vatalanib is a targeted drug that inhibits the activity of all known receptors that bind VEGF. The drug potently inhibits the formation of new blood vessels (angiogenesis). "@@14921730@Metastatic second-line colorectal cancer@@-@-@@NO REVIEW@@@@-@Following a modified agreement in January 2005, Novartis and Schering AG co-market vatalanib in Europe, North America and Japan for oncology indications, whilst Schering AG maintains marketing rights for Latin America, Africa, Australia and Novartis for A@SECOND-LINE@NCT00056446@830@-@-@@@-@@1/1/2003@-@CONFIRM-2@@-@-@@@III@DISCONTINUED@@-@-@July 2005; a review by the independent DSMB highlighted that there was a low probability that the trial will reach its primary endpoint of improvement in overall survival at final analysis. Results showed that the secondary endpoint of PFS was improved in favor of the vatalanib treatment arm and the greatest effect was observed in a subgroup of patients with high lactate dehydrogenase levels. Discontinued by Bayer Schering as part of strategic review in June 2007.@-@@@@COMBO@VATALANIB@@@@@VATALANIB||||@BAYER HEALTHCARE@NOVARTIS@@@@BAYER HEALTHCARE|NOVARTIS|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@PTK-787@ZK-222584@PTK/ZK@@@PTK-787|ZK-222584|PTK/ZK||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16396641@Onco@@@@@300f1014ntsdm@@@@@@Patients in the Revlimid/dexamethasone arm (n=170) took 25 mg of Revlimid orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone arm (n= 171)took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Patients in both treatment arms took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396641@Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.@@YES@@@NO REVIEW@@@@@@SECOND-LINE@@704@The recommended starting dose of REVLIMID® for multiple myeloma patients is 25 mg/day administered as a single 25 mg capsule on Days 121 of repeated 28day cycles.@@@@@@@@LABEL@No@@PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST ONE PRIOR TREATMENT WERE RANDOMIZED TO 2 ARMS: ARM1: REVLIMID (LENALIDOMIDE) PLUS ORAL PULSE HIGHDOSE DEXAMETHASONE THERAPY. ARM2: DEXAMETHASONE THERAPY ALONE.@@@III@APPROVED@@@RAMQ@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@TIME TO PROGRESSION@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@PLACEBO-CONTROLLED@@1@1@698587.0833@@@48.1@month@48.1 month@698587.08@698587.08@477.5@21@0.7881@8022@@@@@@@@@@@@25.47@28@@mg@25@21@@@@@@@@@@@7/19/2017@382@382@231769921@HARD CAPSULE@C$@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14916524@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Satraplatin with Xeloda@@-@-@-@MUNICH, GERMANY@12/1/2007@@Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is being studied in several cancer types and combinations. In clinical trials conducted by GPC Biotech and others, satraplatin has shown activity in prostate, lung and ovarian cancer.@@14916524@Combo with Xeloda@@-@-@@NO REVIEW@@@@-@Celgene terminated its co-development and license agreement with GPC Biotech for satraplatin in Europe, Turkey, the Middle East, Australia and New Zealand. All rights to these territories will be returned to GPC Biotech. SOURCE: GPC, 6 August 2008GPC licensed rights from Spectrum; GPC then sold European rights Pharmion; Japanese rights licensed from GPC by Yakult Honsha in June 2007 for US$10 million (at least 21% royalties). After a dispute between GPC and Spectrum, an arbitration panel concluded@-@NCT00329329@24@-@-@@@-@@3/1/2006@-@SAT1-05-02@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@SATRAPLATIN@CAPECITABINE@@@@SATRAPLATIN|CAPECITABINE|||@GPC BIOTECH@SPECTRUM@@@@GPC BIOTECH|SPECTRUM|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ORPLATNA@XELODA@@@@ORPLATNA|XELODA|||@Platinum@@@@@Platinum||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923375@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923375@@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOX 1A PHARMA@@@@@TAMOX 1A PHARMA||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@3.17@14.99@3.97@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.03@0.03@113827@FILM-COATED TABLET@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921751@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01XX32@L01X@-@CAMBRIDGE, MASSACHUSSETTS@11/1/2011@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@14921751@Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer@@-@-@@NO REVIEW@@@@-@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]      >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]      >> Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones.@THIRD-LINE@NCT00798720@33@-@-@@@-@@11/1/2008@-@CO08502@@-@Two prior systemic anti-cancer (cytotoxic or biologic) regimens for advanced/metastatic disease, including one (1) platinum-based chemotherapy @@@II@II@@-@-@Trial registered. [University of Wisconsin, 25.11.2008]@-@@@@COMBO@BORTEZOMIB@VORINOSTAT@@@@BORTEZOMIB|VORINOSTAT|||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@MERCK & CO@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|MERCK & CO||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@VELCADE@ZOLINZA@@@@VELCADE|ZOLINZA|||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@3-MONTH PROGRESSION-FREE SURVIVAL@@@@@RESPONSE RATE@OVERALL SURVIVAL@TOXICITY@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918149@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@CANONSBURG, PENNSYLVANIA@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14918149@Used in combination therapy with other approved chemotherapeutics in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy; used in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.@@YES@5-Dec@@NO REVIEW@@@@@Acquired through takeover of generics unit of Merck KGaA@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@Feb-97@@1/1/2000@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@4@@@@@@@@@@@@0.04@@@@@@@@@@@@@@@@8/2/2017@4@4@9195726R@INJECTABLE SOLUTION FOR PERFUSION, 5 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924135@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Avastin with Abraxane@@L01CD01@L01C@-@SUMMIT, NEW JERSEY@@@Abraxane is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel protein-bound particles for injectable suspension) is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.@@14924135@Recurrent, platinum-resistent primary epithelial ovarian or primary peritoneal carcinoma@@-@-@@NO REVIEW@@@@-@>>Celgene acquires Abraxis for US$2.9 billion [Celgene 30 June 2010 http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight= ]>> Abraxis BioScience has entered into an agreement with AstraZeneca to re-acquire the exclusive rights to market Abraxane in the United States. [Abraxis, 28.11.2008]       >> AstraZeneca paid US$200 mil to co-promote Abraxane in the U.S., whilst Abraxis bought AstraZeneca's anaesthetic/analgesia portfolio. India/certain Asia rights licensed to Biocon in August 2007.@-@NCT00407563@48@-@-@@@-@@1/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@PACLITAXEL PROTEIN BOUND PARTICLES@BEVACIZUMAB@@@@PACLITAXEL PROTEIN BOUND PARTICLES|BEVACIZUMAB|||@CELGENE@ABRAXIS@@@@CELGENE|ABRAXIS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ABRAXANE@AVASTIN@@@@ABRAXANE|AVASTIN|||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-GROUP@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16671830@Onco@@@@@300f1012ntsdm@@@@@The Nordic VII study@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671830@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX@@YES@@@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 18 December 2013@12/18/2013@@No@@@@@No@@@(EGFR)-expressing, RAS WILD-TYPE@@@APPROVED@@@GKV@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@35133.3069@@@7.9@month@7.9 month@35133.31@35133.31@146.21@1@1.1511@1149.62@1464.46@1186.53@@@@@@@@@@2.3@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/1/2017@1149.62@1149.62@493540@SOLUTION - INFUSION 100 ML@EURO@@@@@@@@500@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924850@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@8 mg/m2/day- dose could be reduced to 3.6 mg/m2/day) as a seven-day continuous infusion once every three weeks in patients with unresectable stage III or stage IV melanoma.@@-@-@-@TOKYO, JAPAN@@@A small-molecule proapoptotic agent with potential antineoplastic activity. Survivin inhibitor YM155 selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy. @@14924850@Unresectable stage III or IV malignant melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00281541@29@-@-@@@-@@11/1/2005@-@-@@-@-@@@II@II@@-@-@ASCO June 2007; out of 31 evaluable patients, 1 patient had a complete response, one patient had a partial response, seven patients achieved stable disease (mean duration of response was 109 days) and 23 patients had progressive disease. Common adverse effects included grade 3 arthralgia and back pain. 13 out of 34 patients (38.2%) experienced 18 serious adverse effects (grade 2 or higher), including pyrexia, myocardial infarction, sepsis, headache and acute renal failure. Astellas noted that it plans to conduct future studies of YM 155 in combination with other agents for the treatment of melanoma.@-@@@@MONO@-@@@@@-||||@ASTELLAS PHARMA@@@@@ASTELLAS PHARMA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@YM-155@@@@@YM-155||||@Survivin Suppressant@@@@@Survivin Suppressant||||@RECIST@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921381@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@All patients are to receive anti-infectious prophylactic supportive therapy as per institutional standards. Patients will be randomized in a ratio of 2:2:1 to receive up to 4 weekly i.v. infusions of rhMBL at a dose of 0.5 mg/kg or 1.0 mg/kg, or standard anti-infectious prophylactic therapy alone. A total of 20 patients will be treated in each of the rhMBL arms, and 10 patients will receive best standard supportive prophylactic therapy but not rhMBL.@@-@-@-@BRIDGEWATER, NEW JERSEY@@@@@14921381@Multiple myeloma receiving chemotherapy followed by stem cell transplant@@-@-@@NO REVIEW@@@@-@Enzon will spin-off its novel biotechnology business from Enzon in a transaction that will result in two independent and highly focused public companies. Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to current PEG royalty revenues, including PEG-Intron, Cimzia and Hematide, and the manufacturing facility in Indianapolis. SOURCE: Enzon, 7 May 2008Extra-Nordic rights licensed from NatImmune in October 2005. SOURCE: Enzon, 3 October 2005@-@NCT00388999@N/A@-@-@@@-@@9/1/2006@-@EZN-2232-01@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ENZON@@@@@ENZON||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@RHMBL@@@@@RHMBL||||@Other@@@@@Other||||@SAFETY@TOLERABILITY@@@@PHARMACOKINETICS@@@@@-@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917590@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AA01@L01A@NO@DEERFIELD, ILLINOIS@@@Cyclophosphamide is an antineoplastic agent which is converted in the body to an active alkylating metabolite. It also possesses marked immunosuppressant properties. The principal site of cyclophosphamide activation is the liver. The chemotherapeutic and immunosuppressant activity of cyclophosphamide is thought to be mediated by the cytotoxic intermediates produced by activation by mixed function oxidases in hepatic microsomes. Non-enzymatic cleavage, possibly taking place in the tumour cells, results in the formulation of highly cytotoxic forms of the drug.@@14917590@Cyclophosphamide has been used successfully to induce and maintain regressions in a wide range of neoplastic conditions, including leukaemias, lymphomas, soft tissue and osteogenic sarcomas, paediatric malignancies and adult solid tumours; in particular, breast and lung carcinomas. Cyclophosphamide is frequently used in combination chemotherapy regimens involving other cytotoxic drugs.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The recommended dose for cyclophosphamide tablets is 50-250 mg/m2 daily (doses towards the upper end of this range should be used only for short courses). The dose may be amended at the discretion of the physician.@@@@@@@Cyclophosphamide should be withheld in the presence of severe bone marrow depression and reduced doses should be used in the presence of lesser degrees of bone marrow depression. Regular blood counts should be performed in patients receiving cyclophosphamide. It should not normally be given to patients with severe infections and should be withdrawn if such infections become life threatening. Cyclophosphamide should be used with caution in debilitated patients and those with renal and/or hepatic failure. Cyclophosphamide is not recommended in patients with a plasma creatinine greater than 120 µmol/l (1.5 mg/100 ml) bilirubin greater than 17 µmol/l (1 mg/100 ml); or serum transaminases or alkaline phosphatase more than 2-3 times the upper limit of normal. In all such cases, dosage should be reduced.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@CYCLOPHOSPHAMIDE@@@@@CYCLOPHOSPHAMIDE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Breast Cancer@NSCLC@Sarcoma@Solid Tumours@Haematological Malignancy|Breast Cancer|NSCLC|Sarcoma|Solid Tumours|||||@ENDOXAN@@@@@ENDOXAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1807@15.7@30.83@16.89@@@@@@@@@@@@@@@@@@@@@@@@@@8/15/2017@0.31@0.31@334534@DRAGEES@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15045766@Onco@@@@@300f1012ntsdm@@@@@@Provenge or placebo@@L03AX17@L03A@-@SEATTLE, WASHINGTON@@@Sipuleucel–T contains mature, autologous antigen Antigen Presenting Cells (APCs). APCs are obtained from the patient via a standard leukapheresis Leukapheresis procedure approximately two days before each scheduled infusion. The patient's APCs are then transported to a Dendreon manufacturing facility where they are co-cultured with a recombinant fusion protein containing prostatic acid phosphatase (PAP). The activated, antigen-loaded APCs (now sipuleucel–T) are then delivered to the physician's office (infusion site) for infusion into the patient. Sipuleucel–T is then infused into the patient, where it can potentially stimulate a T cell response against prostate cancer cells. The process is performed three times over the course of a four-week period, upon which treatment is completed. @@15045766@Androgen dependent prostate cancer@@-@-@@NO REVIEW@@@@0%@-@-@NCT00005947@170@-@EC approves [Dendreon, 17 September 2013, http://investor.dendreon.com/releasedetail.cfm?ReleaseID=791072 ]  CHMP recommeds approval [Dendreon, 28 June 2013, http://files.shareholder.com/downloads/DNDN/2555916136x0x673510/b9719906-1f9c-4d06-b11c-5209a572eaf4/DNDN_News_2013_6_28_General.pdf ]@9/17/2013@@-@@@-@PROTECT@@-@170 MEN WITH NON-METASTATIC ADPC@@@III; P-11 / DEN-D9901, NCI-G00-1789; @DISCONTINUED@@-@GKV@Researchers evaluated cumulative product release parameters including CD54 upregulation and the number of total nucleated cells (TNCs) among patients treated with sipuleucel-T (n=146). Results showed that Provenge patients experienced improved survival if they received more cells across the three doses (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received Provenge as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022). SOURCE: Dendreon, 14 February 2008@-@@@@MONO@SIPULEUCEL-T@@@@@SIPULEUCEL-T||||@DENDREON@@@@@DENDREON||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROVENGE@@@@@PROVENGE||||@Vaccine@Immunotherapy@@@@Vaccine|Immunotherapy|||@PSADT@@@@@@@@@@-@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@@@@1@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@12/23/2014@@@11017564@PERFUSION / DISPERSION SOLUTION BAG - 250 ML@EURO@@@@@@@@50@MIE@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924759@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Docetaxel followed by capecitabine versus concomitant docetaxel/capecitabine@@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14924759@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00415285@100@-@-@@@-@@12/1/2006@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@DOCETAXEL@CAPECITABINE@@@@DOCETAXEL|CAPECITABINE|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAXOTERE@XELODA@@@@TAXOTERE|XELODA|||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@EARLY@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922289@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Amplimexon plus Gemzar@@-@-@-@TUCSON, ARIZONA@@@Amplimexon is a small molecule belonging to a class of compounds known as cyanoaziridines. AmpliMed's founding scientists, based at the Arizona Cancer Center of the University of Arizona in Tucson, Arizona, discovered the potential for Amplimexon as a cancer therapy and carried out extensive studies to determine the mechanisms by which it killed certain types of cancer cells. This led to the conduct of preclinical studies in order to select the best type of cancer to target in initial clinical studies. AmpliMed obtained orphan drug designation both in the United States and Europe for Amplimexon for several key indications, including malignant melanoma, multiple myeloma, ovarian cancer and pancreas cancer. In 2003, this work culminated in the FDA approving an IND for Amplimexon, enabling AmpliMed to initiate a series of clinical studies to explore the safety and efficacy of this exciting new drug in patients with cancer.@@14922289@Untreated pancreatic adenocarcinoma@@-@-@@NO REVIEW@@@@-@Handok licenses South Korean rights. [AmpliMed, 22.09.2008]@FIRST-LINE@NCT00327327@N/A@-@-@@@-@@@-@AMP-004@@-@-@@@I@I@@-@-@Trial started. SOURCE: AmpliMed, 1 May 2008@-@@@@COMBO@IMEXON@GEMCITABINE@@@@IMEXON|GEMCITABINE|||@AMPLIMED@@@@@AMPLIMED||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@AMPLIMEXON@GEMZAR@@@@AMPLIMEXON|GEMZAR|||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924208@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AVE1642 is administered to patients as a single agent for the first treatment cycle, and then in combination with docetaxel (75 mg/m(2)) for all additional cycles. Increasing doses of AVE1642 are tested in new cohorts of patients to establish the dose to be evaluated in combination with an array of chemotherapy agents in upcoming solid tumor studies. SOURCE: Immunogen@@-@-@-@-@@@Immunogen created AVE1642 and licensed it to sanofi-aventis, who advanced it into clinical testing in October 2006. AVE1642 is a “naked” (non-conjugated) antibody that binds to the IGF-1 receptor, to block a pathway used by cancer cells to survive exposure to chemotherapy agents. Thus, it is expected that AVE1642 will be used in combination with chemotherapeutic agents@@14924208@-@@-@-@@NO REVIEW@@@@-@AVE1642 is an anticancer compound that was developed by ImmunoGen and licensed to sanofi-aventis as part of a broader collaboration between the companies. ImmunoGen and sanofi-aventis have an ongoing collaboration to discover, develop, and commercialize novel anticancer products using ImmunoGen's antibody expertise as well as the Company's Tumor-Activated Prodrug (TAP) technology.@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Interim results from the evaluation of three different dose levels - 3, 6, and 12 mg/kg - in cohorts of four patients each, and finds AVE1642 to be well tolerated both as a single agent and in combination with docetaxel across these doses. The authors note that a substantial and sustained biological effect is seen with AVE1642 at doses above 3 mg/kg, and select the 6 mg/kg dose, given every three weeks, for future evaluation of the compound for the treatment of solid tumors. Encouraging evidence of anticancer activity was reported even though the study patients all had solid tumors that had failed to respond to previous treatments. Of particular note is a breast cancer patient who had previously been treated with taxanes and entered the study with skin metastases. She experienced a significant improvement in her metastases in response to treatment with docetaxel in combination with AVE1642. SOURCE: Immunogen/ASCO, 3 June 2008@-@@@@COMBO@-@DOCETAXEL@@@@-|DOCETAXEL|||@SANOFI-AVENTIS@IMMUNOGEN@@@@SANOFI-AVENTIS|IMMUNOGEN|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AVE-1642@TAXOTERE@@@@AVE-1642|TAXOTERE|||@mAb@CD33@@@@mAb|CD33|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917795@Onco@@@@@300f1008ntsdm@@@@@@Patients received Fareston 60MG, tamoxifen 40MG or tamoxifen 20MG.@@L02BA02@L02B@NO@@@@Toremifene is a nonsteroidal triphenylethylene derivative. As other members of this class, e.g. tamoxifen and clomifene, toremifene binds to oestrogen receptors and may produce oestrogenic, anti-oestrogenic or both effects, depending upon the duration of treatment, animal species, gender, target organ and variable selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly anti-oestrogenic in rats and man and oestrogenic in mice.@@14917795@First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with oestrogen receptor negative tumours.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@1157@The recommended dose is 60 mg, one tablet, daily. There is no relevant indication for use in children.@@@@@@@As with other anti-oestrogens, hypercalcaemia and tumour flare have been reported in some breast cancer patients with bone metastases during the first weeks of treatment. Tumour flare is a syndrome of diffuse musculoskeletal pain and erythema with increased size of tumor lesions that later regress.@LABEL@No@@@@@III 3 STUDIES@APPROVED@@@NHI@RR was 21.3% and 19.1%, 20.4% and 20.8%, and 31.3% and 37.3% for the Fareston (60MG) and tamoxifen (20MG, 40MG, 40MG) respectively. Median TTP was 5.6 and 5.8 months, 4.9 and 5.0 months, and 7.3 and 10.2 months respectively.@@@@@@TOREMIFENE CITRATE@@@@@TOREMIFENE CITRATE||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FARESTON@@@@@FARESTON||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@TIME TO PROGRESSION@@@@@@@@@METASTATIC@@@@@PROSPECTIVE@RANDOMISED@PLACEBO-CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@134.64@134.64@@1@0.0091@286.2@337.5@@@@@@@@@@@7.16@@@@@@@@@@@@@@@@8/30/2017@286.2@286.2@4291007F1021@TABLET@YEN@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918239@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@GERMANY@@@@@14918239@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@0.62@11.77@1.34@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@@@3683086@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922353@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Tarceva daily at 150mg continuously versus PF-299804 continuous dosing at 45mg daily. [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@2/1/2011@@This is an irreversible pan-ERBB inhibitor. PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo. Additionally, PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers. @@14922353@PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00769067@160@-@-@@@-@@11/1/2008@-@A7471028@@-@-@@@II@II@@-@-@Trial registered. [Pfizer, 07.10.2008]@-@@@@MONO@DACOMITINIB@ERLOTINIB@@@@DACOMITINIB|ERLOTINIB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PF-299804@TARCEVA@@@@PF-299804|TARCEVA|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@KRAS MUTATIONS@OVERALL SURVIVAL@PHARMACOKINETICS@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15413017@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"MDV9300, Experimental, 
"@@@@@@6/1/2018@@@@15413017@An International, Phase 2, Open-Label, Efficacy and Safety Study of MDV9300 in Patients With an Incomplete Response Following Salvage Therapy or Autologous Stem Cell Transplantation for Relapsed or Refractory CD20+ Diffuse Large B-Cell Lymphoma@Both@@@@@MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.@@@@@@NCT02653989@180@@@@@@@11/1/2015@@MDV9300-01@@@Age 18 years or older and willing and able to provide informed consent;  -  Histologically confirmed relapsed or refractory CD20+ DLBCL, transformed indolent lymphoma (follicular or other), or primary mediastinal large B-cell lymphoma;  -  Received prior treatment with a standard anthracycline and therapeutic anti-CD20 monoclonal antibody-based regimen;  -  For transplant-ineligible patients, salvage therapy just prior to MDV9300 treatment must have resulted in a PR or stable disease;  -  For post autologous stem cell transplant (ASCT) patients, salvage therapy plus ASCT just prior to MDV9300 treatment must have resulted in a PR or stable disease;  -  Adequate bone marrow reserve as defined per protocol;  -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. Patients with stable ECOG scores of 2 may be allowed with medical monitor approval.@MONO@ADULTS@Phase 2@II@@@@@@@@@@-@@@@@-||||@MEDIVATION@@@@@MEDIVATION||||@United States@@@@@United States|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@DLBCL@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|DLBCL|||||||@MDV9300@@@@@MDV9300||||@Other@@@@@Other||||@Best overall response rate@@@@@Duration of response (for responders)@PROGRESSION-FREE SURVIVAL@@@@RELAPSED@REFRACTORY@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924824@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SUMMIT, NEW JERSEY@@@Vidaza is a nucleoside analog of cytidine and is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. By inhibiting hypermethylation, Vidaza may restore normal expression to silent genes critical to cell differentiation and proliferation. Vidaza appears to exhibit its effects, inhibition of hypermethylation and direct toxicity, when cells are actively dividing.1 Because all cells are not in the same phase simultaneously, longer treatment time will expose more rapidly dividing cells to Vidaza. Vidaza also causes death of rapidly dividing cancer cells no longer responsive to normal growth control mechanisms.1 Cells that do not divide rapidly are relatively insensitive to Vidaza. @@14924824@Vidaza to restore hormone thx prostate@@-@-@@NO REVIEW@@@@-@Nippon Shinyaku licensed Japanese rights from Pharmion in November 2006. Celgene acquired Pharmion in November 2007.@-@NCT00384839@35@-@-@@@-@@4/1/2006@-@-@@-@35 PATIENTS WITH ADVANCED OR NON-ADVANCED PROSTATE CANCER WITH PSA PROGRESSION@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@AZACITIDINE@@@@@AZACITIDINE||||@CELGENE@PHARMION@@@@CELGENE|PHARMION|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@VIDAZA@@@@@VIDAZA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@SAFETY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916155@Onco@@@@@300f1020ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916155@Indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation could occur at any dose in patients not on a chronic regimen of opiates. September 2007: Dear Healthcare Professional letter issued to emphasise that it is not generic Actiq and ensure non-use in opioid non-tolerant patients or non-labelled indications.@@NO@-@@NO REVIEW@@@@100%@-@-@-@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@N/A@@@-@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@-@-@@@III@APPROVED@@@SSN@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@-@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.1807@17.6@29.04@18.39@@@@@@@@@@@@@@@@@@@@@@@@@@8/31/2017@5.87@5.87@35399132@SUBLINGUAL TABLET@EURO@@@@@@@@800@MCG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16396659@Onco@@@@@300f1018ntsdm@@@@@@10 mg once daily or 10 mg once daily for 21 days every 28 days. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396659@Revlimid is indicated for treatment of patients with transfusiondependent anaemia due to low or intermediate1 risk myelodysplastic syndromesassociated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.@@YES@13-Mar@@NO REVIEW@@@@@@@@148@The recommended starting dose of REVLIMID® for MDS patients is 10 mg daily for the first 21 days of repeated 28day cycles. Dosing is continued or modified based upon clinical and laboratory findings.@@@@No@@@@@No@@148 PATIENTS WHO HAD RBC TRANSFUSION DEPENDENT ANEMIA. RBCTRANSFUSION DEPENDENCE WAS DEFINED AS HAVING RECEIVED = 2 UNITS OF RBCS WITHIN 8 WEEKS PRIOR TO STUDY TREATMENT. THE STUDY ENROLLED PATIENTS WITH ABSOLUTE NEUTROPHIL COUNTS (ANC) = 500 CELLS/MM3,@@@III@APPROVED@@The PBAC recommended extending the current listing for lenalidomide to include treatment of transfusion-dependent, low risk/INT-1, 5q- myelodysplastic syndrome on the basis of acceptable cost effectiveness compared with best supportive care@PBS@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@@@@@@1@1@10722.31999@@@56@day@56 day@10722.32@10722.32@191.47@21@0.779@5361.16@5407.68@@@@@@@@@@@25.53@28@@mg@10@21@@@@@@@@@@@8/1/2017@255.29@255.29@2922-1419-HB-CJ@HARD CAPSULE@A$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922065@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@All patients will receive MLN9708 IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.The first stage of the study will be initiated at a starting dose of 0.125 mg/m2 [clinicaltrials.gov]@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@7/1/2010@@MLN-9708, formerly MLN-2238, is a second-generation proteasome inhibitor. In vitro, non-clinical studies have shown that proteasome inhibition can be cytotoxic to a variety of cancer cell types. MLN9708 is currently under clinical investigation.@@14922065@MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies@@-@-@@NO REVIEW@@@@-@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]       >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]@-@NCT00830869@74@-@-@@@-@@3/1/2009@-@C16001@@-@A diagnosis of a nonhematologic malignancy for which standard treatment is no longer effective. In the expanded cohort, enrollment will be limited to patients with a diagnosis of NSCLC, head and neck cancer (squamous cell cancer), soft tissue sarcoma, or prostate cancer. @ADULT@@I@I@@-@-@Trial registered [Millennium, 26.01.2009]@-@@@@MONO@-@@@@@-||||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Solid Tumours@NSCLC@Head & Neck Cancer@Sarcoma@Prostate Cancer@Solid Tumours|NSCLC|Head & Neck Cancer|Sarcoma|Prostate Cancer|||||@MLN-9708@MLN-2238@@@@MLN-9708|MLN-2238|||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@DOSE-LIMITING TOXICITY@ADVERSE EVENTS@@@@PHARMACOKINETICS@PHARMACODYNAMICS@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16396592@Onco@@@@@300f1012ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396592@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@NO@@@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@459@The recommended starting dose is lenalidomide 10 mg/day orally on days 121 of repeated 28day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 14 of repeated 28 day cycles, prednisone2 mg/kg orally on days 14 of repeated 28day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide alone, 10 mg/dayorally on days 121 of repeated 28day cycles given until disease progression.@EMA, 11 February 2015@2/11/2015@@Yes@@@@@No@@@@ADULTS@@APPROVED@@@GKV@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@312732.7488@@@27.4@month@27.4 month@312732.75@312732.75@375.25@21@1.1511@5253.5@6496.53@5292@@@@@@@@@@50.03@28@@mg@10@21@@@@@@@@@@@8/1/2017@250.17@250.17@1875255@HARD CAPSULE@EURO@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921411@Onco@@@@@@@@@@@Docetaxel and oblimersen versus doxetaxel alone@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@Genasense (oblimersen sodium) Injection is a drug that inhibits the production of a protein known as Bcl-2. By reducing production of Bcl-2 in cancer cells, it seeks to restore the basic biological process whereby cancer cells can be readily killed by treatment with current methods of anticancer therapy. Genta's clinical trials programs focus on treating cancer patients with Genasense along with the administration of anticancer therapy with the intention of potentiating the cancer-killing effects of treatment. Genta is developing Genasense Injection with the intention of potentiating the cancer-killing activity of standard anticancer therapies. In a typical example, Genasense might be administered for several days and then be immediately followed by regular doses of chemotherapy. This sequence would then be repeated, depending upon the particular type of chemotherapy regimen and indication. In other applications, Genasense might be administered concurrent with or after conventional chemotherapy, again depending on the chemotherapy and indication. Genasense has the potential to be used in combination with most types of anticancer therapy.@@14921411@Hormone refractory prostate cancer@@-@-@@NO REVIEW@@@APRIL 2004-@-@-@-@-@102@-@-@@@-@@@-@EORTC-30021, @@-@-@@@AVENTIS-AVE3139E/2501; @II@@-@-@Of 111 patients who were evaluable in this study, 24% had previously received estramustine (a combination of estrogen plus a chemotherapy agent), 26% had pretreatment elevation of serum lactate dehydrogenase (LDH), and 41% had previously progressed in each of three clinical parameters including prostate specific antigen (PSA), bone, and viscera. At baseline, more than 90% of patients had widely metastatic disease to bone and/or viscera. Following randomization, patients were treated with docetaxel (Taxotere®; sanofi aventis) either with (N= 54) or without Genasense (N=57). For patients who received Genasense plus docetaxel versus docetaxel alone, there were similar response rates as measured by RECIST criteria in patients with measurable disease (24% vs. 19%) or by PSA (37% vs. 46%). Neither progression- free nor overall survival has yet been reported. Occurrence of Grade 3-4 neutropenia (80% vs. 83%) and febrile neutropenia (11% vs. 9%) was similar, whereas Genasense was associated with an increase in Grade 3 thrombocytopenia (9% vs. 0%). SOURCE: Prostate Cancer Symposium, February 2007.@-@@@@COMBO@OBLIMERSEN SODIUM@DOCETAXEL@@@@OBLIMERSEN SODIUM|DOCETAXEL|||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@GENASENSE@TAXOTERE@@@@GENASENSE|TAXOTERE|||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@PSA@BUBLEY CRITERA@TOXIC EVENTS@@@TOXICITY@@@@@ADVANCED@REFRACTORY@@@@RANDOMISED@ACTIVE CONTROL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917549@Onco@@@@@300f1008ntsdm@@@@@@-@@L02BA01@L02B@YES@-@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14917549@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NA@-@@NO REVIEW@@@@-@-@-@-@-@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@-@@@-@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@-@No@-@-@@@-@DISCONTINUED@@-@NHI@RESULTS PENDING@-@@@@-@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@NICHI-IKO@@@@@NICHI-IKO||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOXIFEN NICHI-IKO@@@@@TAMOXIFEN NICHI-IKO||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@1@0.01111@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1/1/2015@@@4291003F2070@TABLETS@YEN@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918322@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01XX11@L01X@NO@HOLZKIRCHEN, GERMANY@@@Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. The low level of clinical side effects may be due to the fact that estramustine binds to a protein present in the tumour tissue, so resulting in accumulation of the drug at the target site. Estracyt also has weak oestrogenic and anti-gonadotrophic properties. Estramustine causes little or no bone marrow depression at usual therapeutic dosage. Estramustine is effective in patients who have not previously received drug therapy, as well as in those who have shown no response to conventional hormone treatment.@@14918322@Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyestradiol phosphate etc.) or by orchidectomy.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Dosage range may be from 1 to 10 capsules a day by mouth. The capsules should be taken not less than 1 hour before or 2 hours after meals. The capsules should not be taken with milk or milk products. Standard starting dosage is 4-6 capsules a day in divided doses with later adjustment according to response and gastrointestinal tolerance.@@@@@@@Use with caution in patients with moderate to severe bone marrow depression, thrombophlebitis, thrombosis, thromboembolic disorders, cardiovascular disease, coronary artery disease and congestive heart failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ESTRAMUSTINE PHOSPHATE SODIUM@@@@@ESTRAMUSTINE PHOSPHATE SODIUM||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Oestrogen@Nitrogen Mustard Analogue@@@@Oestrogen|Nitrogen Mustard Analogue|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@111.32@151.73@115.53@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@1.11@1.11@882715@HARD CAPSULE@EURO@@@@@@@@140@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384745@Onco@@@@@300f1018ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384745@Indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alphatherapy@@NO@@@NO REVIEW@@@@100%@@SECOND-LINE@@532@The recommended dosage of Glivec is 400 mg/day for adult patients in chronic phase CML.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@@PBS@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@30@0.779@2899.14@3047.02@2969.08@@@@@@@@@@0.24@1@@mg@400@1@@@@@@@@@@@8/1/2017@96.64@96.64@1632-1271-GE-AF@TABLET@A$@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14924639@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Panzem alone and in combination with Sutent@@-@-@-@ROCKVILLE, MARYLAND@@@Panzem is an orally active, well-tolerated compound that has antiproliferative, antiangiogenic and anti-inflammatory properties. Panzem attacks tumor cells through multiple mechanisms of action (MOA) and blocks the development of new blood vessels that feed tumor cells. Panzem's MOAs include the disruption of angiogenesis through the inhibition of hypoxia inducible factor-1 alpha (HIF-1a), a protein required for angiogenesis and cell survival under stress. The inhibition of angiogenesis is an important approach to the treatment of both cancer and rheumatoid arthritis. Initial development of 2ME2 has been focused on various oncology indications. While modest antitumor activity has been demonstrated across most clinical studies, there is no clear development path that would allow the Company to narrow the indications for the next series of larger randomized studies. Panzem for oncology is a drug candidate that needs to be developed in combination with other chemotherapeutic agents, requiring the conduct of further non-randomized trials to clarify specific combinations and indications. Conversely, Panzem has potential as a single agent in rheumatoid arthritis based on its antiangiogenic, antiiflammatory, and antiosteoclastic (bone resorption) properties.@@14924639@Combo with Sutent@@-@-@@NO REVIEW@@@@-@Entremed announces restructuring plan, including the loss of 60% of staff and core focus on development of ENMD-2076. [EntreMed, 19.12.2008]@SECOND-LINE@NCT00444314@-@-@-@@@-@@2/1/2007@-@-@@-@-@@@II@DISCONTINUED@@-@-@Development discontinued; modest antitumor activity has been shown across most of the clinical studies, yet there is not a clear development path that would narrow the indications for larger randomized studies. Additional trial costs, the high doses required for use in oncology, and manufacturing/process development expenditures would together require the commitment of a disproportionate amount of resources and limit clinical development efforts on the remainder of the pipeline. SOURCE: Entremed press release, 13 March 2008@-@@@@BOTH@2-METHOXYESTRADIOL@@@@@2-METHOXYESTRADIOL||||@ENTREMED@@@@@ENTREMED||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@PANZEM NCD@@@@@PANZEM NCD||||@2ME2@Angiogenesis Inhibitor@@@@2ME2|Angiogenesis Inhibitor|||@RESPONSE RATE@SAFETY@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916711@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@SUNNYVALE, CALIFORNIA@@@Motexafin gadolinium (MGd) is a small-molecule drug with a novel mechanism of action; it accumulates selectively in cancer cells due to their increased rates of metabolism. Once inside the cell, MGd induces apoptosis (programmed cell death) by disrupting redox-dependent pathways. MGd inhibits the enzyme thioredoxin reductase, which is a tumor growth promoter. This mechanism provides the opportunity to use MGd in a wide range of cancers. MGd is paramagnetic, and therefore is detectable by magnetic resonance imaging (MRI), allowing the visualization of the drug in tumors.@@14916711@CLL or small lymphocytic lymphoma@@-@-@@NO REVIEW@@@@-@Available for outlicensing.@SECOND-LINE@NCT00100711@27@-@FDA non-approvable letter for combo use with radiotherapy for NSCLC with brain metastases. SOURCE: Pharmacyclics, 21 December 2007NDA accepted with PDUFA date of 31 December. Pharmacyclics requested the FDA take into consideration the poor quality control in radiotherapy in France in its assessment of the clinical trial data. SOURCE: Pharmacyclics, 23 April 2007File over protest. SOURCE: Pharmacyclics, 4 April 2007FDA refusal to file the NDA, citing that the company's application is not sufficiently complete to permit a substantive review based on clinical studies that failed to demonstrate statistically significant differences between treatment arms in the primary endpoints. SOURCE: Pharmacyclics, 21 February 2007NDA of the two Phase III trials filed. SOURCE: Pharmacyclics, 22 December 2006@12/21/2007@@-@@10/1/2004@-@PCYC-0222@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@MOTEXAFIN GADOLINIUM@@@@@MOTEXAFIN GADOLINIUM||||@PHARMACYCLICS@@@@@PHARMACYCLICS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Non-Hodgkin's Lymphoma|||||||@XCYTRIN@@@@@XCYTRIN||||@Radiation Sensitiser@@@@@Radiation Sensitiser||||@COMPLETE RESPONSE@PARTIAL RESPONSE@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917073@Onco@@@@@300f1010ntsdm@@@@@@Patients received IFNy 0.2MG s.c for two days prior to ILP.@@L03AA@L03A@NO@INGELHEIM, GERMANY@@@Tasonermin affects the morphology and reduces proliferation of endothelial cells and modifiesexpression of specific cell surface and secretory proteins (including adhesion molecules and proteinsmodulating coagulation, interleukins and haematopoietic growth factors). These changes in turn leadto a procoagulant state resulting in microvascular thrombosis. Further, adherence and extravasation ofleukocytes is increased, leading to infiltration of the tumour by lymphocytes, monocytes, andgranulocytes. The reason for the differential sensitivity of the tumour vasculature (high) versus normalvasculature (low) are currently unknown.@@14917073@As an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated limb perfusion.@@YES@@@NO REVIEW@@@@100%@@@@39@Upper limb: 3MG dose by isolated limb perfusion; lower limb: 4MG total dose by isolate limb perfusion@EMA, 13 April 1999@4/13/1999@@@@@@152.53@No@@Patients with STS and malignant melnaoma@@@@APPROVED@@NO NICE REVIEW@NHS@20 patients completed a 1-year follow-up after ILP. 13 patients had recurrence or progression of the disease; 2 were excluded due to protocol violation; 2 received other chemotherapy or radiotherapy; one died and one was lost to follow-up. The median follow-up from ILP was 846 days. Violations primarily concerned deviations in the dose of melphalan; median dose here was 95mg (33-150mg). 10 patients underwent amputation giving a limb salvage rate of 29/39 (74%) during the follow-up. Complete response was seen in 28% of patients.@Systemic toxicity consisted of fever (100%), chills (51%), cardiac rhythm disturbances (62%), nausea and vomiting (31%) and fatigue (26%). Serious adverse events consisted of liver toxicity (18%), ARDS (13%), thrombocytopaenia (10%).@@@@ADJUVANT@TASONERMIN@INTERFERON@@@@TASONERMIN|INTERFERON|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@BEROMUN@@@@@BEROMUN||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@LIMB SALVAGE@@@@@@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@4@1.2961@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR INJECTION@GB£@@@@@@@@1@MG@1 MG/5 ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921759@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Drug given Daily x 14 days and 7 days of rest for 21 day cycle [clinicaltrials.gov]@@L01BB06@L01B@-@CAMBRIDGE, MASSACHUSSETTS@10/1/2011@@Clofarabine is a purine nucleoside anti-metabolite. Its antitumour activity is believed to be due to 3 mechanisms:   • DNA polymerase a inhibition resulting in termination of DNA chain elongation and/or DNA synthesis / repair.     • Ribonucleotide reductase inhibition with reduction of cellular deoxynucleotide triphosphate (dNTP) pools.     • Disruption of mitochondrial membrane integrity with the release of cytochrome C and other proapoptotic factors leading to programmed cell death even in non-dividing lymphocytes.@@14921759@Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS) @@-@-@@NO REVIEW@@@@-@In March 2001, Ilex licensed rights for the U.S. and Canada (and royalties elsewhere) from Bioenvision, which retained the lead role in developing and commercialising the drug elsewhere.Genzyme acquired rights in February 2004 from takeover of Ilex- befo@-@NCT00750334@48@-@-@@@-@@9/1/2008@-@CLOMDS01206@@-@Patients have been treated previously for MDS as follow: a.Patients must have had at least 1, but no more than 2, prior treatment regimens; b.Patients must not have refractory (i.e., disease progression or no evidence of response while on treatment) to more than 1 prior treatment regimen.@ADULT@@I@I@@-@-@Trial registered [Genzyme, 9.09.2008]@-@@@@MONO@CLOFARABINE@@@@@CLOFARABINE||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@CLOLAR@@@@@CLOLAR||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@MAXIMUM TOLERATED DOSE@@@@@PHARMACOKINETICS@FOOD EFFECT@RESPONSE RATE@@@-@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920944@Onco@@@@@300f1012ntsdm@@@@@@A 7.5 mg depot formulation of leuprolide injected once every 4 weeks@@L02AE02@L02A@NO@HOLZKIRCHEN, GERMANY@@@This is a synthetic nonapeptide analogue of naturally occurring gonadotrophin releasing hormone (GnRH) which possesses greater potency than the natural hormone. It is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy. Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Oestradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.@@14920944@Depot 7.5 mg is indicated in the palliative treatment of advanced prostatic cancer.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Sandoz is the generics subsidiary of Novartis.@@@56@The recommended dose is 7.5 mg, incorporated in a depot formulation.@@@@No@@@Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may occasionally develop during the first few weeks of Lupron Depot treatment. Cases of increasing bone pain, ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications.@@No@@56 PATIENTS WITH STAGE D2 PROSTATIC ADENOCARCINOMA AND NO PRIOR SYSTEMIC TREATMENT@@@N/A@APPROVED@@@GKV@Serum testosterone suppressed to the castrate range within 30 days of the initial depot injection in 94% (51/54) of patients for whom testosterone suppression was achieved and within 66 days in all 54 patients. Mean serum testosterone suppressed to castrate level by Week 3. The median dosing interval between injections was 28 days.@@@@@MONO@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@NOVARTIS@SANDOZ@@@@NOVARTIS|SANDOZ|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ELIGARD@@@@@ELIGARD||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@NON-COMPARATIVE@MULTI-CENTRE@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.1511@407.05@525.62@420.57@@@@@@@@@@18.09@@@@@@@@@@@@@@@@8/1/2017@135.68@135.68@2726008@DRY POWDER + SOLVENT@EURO@@@@@@@@7.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384833@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384833@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@NO@@@@@@@@@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@@@@Yes@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@76507.43163@@@36@month@36 month@76507.43@76507.43@69.87@60@1.1511@1048.07@1172.57@1078.07@@@@@@@@@@0.17@1@@mg@400@1@@@@@@@@@@@8/1/2017@17.47@17.47@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916526@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@BASEL, SWITZERLAND@@@R1507 is a fully human antibody created by Genmab under a collaboration with Roche. R1507 was selected from a large panel of antibodies and targets the Insulin-like Growth factor-1 Receptor (IGF-1R).  The IGF-1R molecule has been shown to be important in tumor growth and protecting tumor cells from being killed.  IGF-1R is over-expressed on a variety of tumors including breast, colon, prostate, lung, skin and pancreatic cancers and is a well validated target for an antibody therapeutic approach.  Roche filed an Investigational New Drug application with the US FDA for the antibody in December 2005. @@14916526@Patients With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.@@-@-@@NO REVIEW@@@@-@In-licensed from Genmab@-@NCT00642941@305@-@-@@@-@@12/1/2007@-@SARC011@@-@Patients >=2 years of age; progressive, recurrent or refractory Ewing's sarcoma, or recurrent or refractory osteosarcoma, synovial sarcoma, rhabdomyosarcoma, or other sarcomas of the following sub-types: alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma and myxoid liposarcoma. @PAEDIATRIC@@II@II@@-@-@Trial registered [Roche, 19.03.2008]@-@@@@MONO@-@@@@@-||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@R-1507@@@@@R-1507||||@mAb@@@@@mAb||||@-@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924495@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IL-21 in combination with Doxil@@-@-@-@SEATTLE, WASHINGTON@@@IL-21 has potent biological activity in regulating key classes of immune cells, including cytotoxic T cells and natural killer cells. These cell types play key roles in surveillance of the body to eliminate malignant and infected cells. Based upon the ability of IL-21 to inhibit tumor growth in a number of preclinical models, ZymoGenetics is developing IL-21 for the treatment of cancer, initially in renal cell carcinoma and metastatic melanoma. @@14924495@-@@-@-@@NO REVIEW@@@@-@>> ZymoGenetics announces the acquisition of ex-North American rights to Interleukin 21 (IL-21) from Novo Nordisk A/S, resulting in ZymoGenetics owning worldwide rights to IL-21. Novo Nordisk A/S agreed to license rest of world (ex-North American) development and commercialization rights for IL-21 to ZymoGenetics in exchange for potential regulatory approval milestones and royalties related to the ex-North American territory. In addition, upon licensing worldwide rights for IL-21 to a third party, Novo Nordisk A/S would receive a portion of related licensing fees if a certain threshold level were exceeded. [ZymoGenetics, 29.01.2009]            >> Novo Nordisk has exited all of its oncology interests as of February 2008.            >> Novo holds IL-21 rights outside of North America.@-@-@81@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@DOXORUBICIN@@@@-|DOXORUBICIN|||@ZYMOGENETICS@@@@@ZYMOGENETICS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@IL-21@@@@@IL-21||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@ANTIBODY FORMATION@BIOMARKER ASSESSMENTS@@ANTIBODY FORMATION@BIOMARKER@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919558@Onco@@@@@300f1015ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919558@@@NO@2-Jul@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@2-Apr@@4/24/2003@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@EUROGENERICS@@@@@EUROGENERICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@5.45@7.62@5.81@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.18@0.18@3.40E+12@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14917101@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@@@@@@14917101@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Malignant lymphomas: Used alone the recommended dosage regime is 15 x 10³ IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 10³ IU (15 vials). Dosage should be reduced in the elderly. The dose may need to be adjusted when bleomycin is used in combination chemotherapy.@@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||||@BLEOMEDAC@@@@@BLEOMEDAC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@52@76.73@54.34@@@@@@@@@@3.47@@@@@@@@@@@@@@@@8/15/2017@52@52@2411351@DRY SUBSTANCE WITHOUT SOLVANT@EURO@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16397630@Onco@@@@@300f1008ntsdm@@@@@@@@L01XX45@L01X@@@6/1/2014@@@@16397630@Kyprolis in combination dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.@Both@NA@@@NO REVIEW@Kyprolis with lenalidomide and low-dose dexamethasone (KRd) versus lenalidomide and low-dose dexamethasone alone (Rd)@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@NCT01080391@792@@MHLW, 4 July 2016@7/4/2016@@Yes@@7/1/2010@@PX-171-009@No@@Symptomatic multiple myelomaMeasurable disease, as defined by one or more of the following (assessed within 21 days prior to randomization): Serum M-protein ≥ 0.5 g/dL;Urine Bence-Jones protein ≥ 200 mg/24 hours; For IgA patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL)Prior treatment with at least one, but no more than three, regimens for multiple myeloma@@ADULTS@III@APPROVED@@@NHI@@@@@@COMBO@CARFILZOMIB@LENALIDOMIDE@DEXAMETHASONE@@@CARFILZOMIB|LENALIDOMIDE|DEXAMETHASONE||@ONO PHARMACEUTICAL@@@@@ONO PHARMACEUTICAL||||@World@@@@@World|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@KYPROLIS@REVLIMID@GENERIC@@@KYPROLIS|REVLIMID|GENERIC||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@MULTICENTER@@@1.75@m²@9174991.43@@@504@day@504 day@9174991.43@9174991.43@18204.35@1@0.0091@20336.74@23982@@@@@@@@@@@2033.67@28@1@mg/m²@24.67@6@28@11@mg/m²@27@6@28@@mg/m²@27@4@8/30/2017@20336.74@20336.74@4291433D1026@IV DRIP INFUSION@YEN@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
16159511@Onco@@@@@300f1014ntsdm@@@@@@Experimental: crizotinib 250mg orally continuous twice daily dosing Active Comparator: pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@12/1/2014@@@@16159511@XALKORI is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).@@@3-Feb-14@2/3/2014@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@SECOND-LINE@NCT00932893@347@The recommended dose of XALKORI is 250 mg orally, twice daily until disease progression or no longer tolerated by the patient. The recommended dose of XALKORI in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis is 250 mg orally, once daily.@Health Canada, 10 May 2012@5/10/2012@@@@9/1/2009@@PROFILE 1007@No@@Histologically or cytologically proven diagnosis of non-small cell lung cancer positive for the ALK fusion gene (test provided by a central laboratory). Must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug@(ALK)-positive@@III@APPROVED@@@RAMQ@The PROFILE 1007 study met its primary endpoint, demonstrating that crizotinib significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with ALK-positive advanced NSCLC. PROFILE 1007 is the first randomized Phase 3 study in ALK-positive advanced NSCLC patients. [Pfizer 19 June 2012 http://press.pfizer.com/press-release/pfizer-announces-positive-results-phase-3-study-profile-1007-evaluating-xalkori-crizot ]@The adverse events observed on crizotinib and chemotherapy in PROFILE 1007 were generally consistent with their respective known adverse event profiles.[Pfizer, June 2012]@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE RATE@OVERALL SURVIVAL@@@@ADVANCED@@@@@OPEN-LABEL@RANDOMISED@PARALLEL ASSIGNMENT@@@1@1@76116.04@@@7.7@month@7.7 month@76116.04@76116.04@325@60@0.7881@7800@@@@@@@@@@@@0.65@1@@mg@500@1@@@@@@@@@@@7/19/2017@130@130@238425660@CAPSULE@C$@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16392213@Onco@@@@@@@@@@@"RC48-ADC, Experimental, The phase I component has three dose levels of RC48-ADC (0.1mg/kg, 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg, 4.0 mg/m2 and 4.5 mg/kg) and is designed as a traditional dose-escalation study in which cohorts of 3 patients are evaluated for the incidence of dose-liming toxicity (DLT) at each dose level. Determine the recommended Phase II doses and regimens of RC48-ADC. Dosing interval is once two weeks.
"@@@@@CHINA@12/1/2016@@@@16392213@@Both@@@@@@@@@@MULTIPLE@NCT02881138@50@@@@@@@11/1/2015@@C001 CANCER@@@Inclusion Criteria:  -  Signed informed consent form;  -  Aged 18-65 years;  -  ECOG physical condition is 0 or 1;  -  Life expectancy greater than 12 weeks;  -  Patients with locally advanced or metastatic malignant solid tumors diagnosed by pathology and refractory to standard of care therapy, or for whom no standard of care therapy is available histology standard of care therapy, or for whom no standard of care therapy is available;  -  Documented Human epidermal growth factor receptor 2 (HER2)-positive as measured either by immunohistochemistry (IHC 2+ and by fluorescence in situ hybridization (FISH)or by immunohistochemistry (score, 3+);  -  Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1);  -  Adequate organ function as defined by the following criteria:  -  absolute neutrophil count(ANC) >= 1.5 x 10(9)/L;  -  platelets>=70*10(9)/L;  -  Total serum bilirubin <=1.5*ULN;  -  serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=3.0*upper limit of normal (ULN), or AST and ALT<=5*ULN if liver function abnormalities are due to underlying malignancy;  -  normal serum creatinine ;  -  international normalized ratio(INR) and activated partial thromboplastin time (aPTT) must be less than or equal to 1.5 times the upper limit of the normal range (ULN);  -  Women of child-bearing potential and men must agree to use adequate contraception (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug;  -  Left ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram.@HER2-POSITIVE@ADULTS@Phase 1@I@@@@@@@@@MONO@RC48-ADC@@@@@RC48-ADC||||@REMEGEN@@@@@REMEGEN||||@China@@@@@China|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@-@@@@@-||||@Other@@@@@Other||||@maximal tolerance dose (MTD) of RC48-ADC@@@@@Safety (the drug safety as assessed by NCI-CTCAE v4.0)@@@@@ADVANCED@METASTATIC@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916756@Onco@@@@@@@@@@@Yonderlis IV 1.1MG/M2 q3wk with Doxil/Caelyx 30MG/M2 versus Doxil 50MG/M2 q4wk@@L01CX01@L01C@-@MADRID, SPAIN@@@Yondelis (trabectedin, ET-743) was originally isolated from the marine tunicate Ecteinascidia turbinata. Yondelis has a novel mechanism of action. It is a unique anti cancer agent that binds into the minor groove of the DNA and interacts with DNA repair enzymes and transcription factors, interfering with different cell cycle processes. In addition to STS, Yondelis is being developed in a pivotal Phase III trial in ovarian cancer and in Phase II in prostate and breast cancers. Yondelis was designated Orphan Drug for STS by the European Commission (E.C.) in 2001 and by the U.S. FDA in 2004 and for ovarian cancer by the E.C. in 2003 and by the U.S. FDA in 2005.@@14916756@-@@-@-@@NO REVIEW@@@@-@>> PharmaMar, the biotech arm of Zeltia, has regained the Japanese rights to the drug and received US$10 million from the previous licence holder. Yondelis had been licensed to Ortho Biotech Products (OBI), a subsidiary of Johnson & Johnson since 2001. [Zeltia, 11 July 2008]              >> PharmaMar (Zeltia) maintains European rights, Ortho Biotech U.S. rights and Janssen Cilag for the rest of the world.@SECOND-LINE@NCT00113607@672@-@-@@@Orphan drug in Switzerland for ovarian cancer and soft tissue sarcoma. SOURCE: PharmaMar, 2 April 2008@@6/1/2007@-@OVA-301  @@-@PATIENTS WHO HAVE RELAPSED AFTER STANDARD FIRST-LINE PLATINUM-BASED CHEMO.@@@III@III@@-@-@>> PFS in the Yondelis/Doxil arm was 7.3 months versus 5.8 months in the Doxil arm alone. [PharmaMar/ESMO, 12.09.2008]>> IDMC recommended the trial should continue unchanged. [PharmaMar, October 2006]@-@@@@COMBO@TRABECTEDIN@DOXORUBICIN, LIPOSOMAL@@@@TRABECTEDIN|DOXORUBICIN, LIPOSOMAL|||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@YONDELIS@DOXIL@CAELYX@@@YONDELIS|DOXIL|CAELYX||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@OVERALL SURVIVAL@@@@@@@@@@RELAPSED@@@@@INTERNATIONAL@MULTI-CENTRE@PIVOTAL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15361179@Onco@@@@@300f1014ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361179@Indicated for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase@Both@NO@@@@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dosage of SPRYCEL (dasatinib) for chronic phase CML is 100 mg administered orally once daily (OD), either in the morning or in the evening.@@@@@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@49085.84729@@@14@month@14 month@49085.85@49085.85@115.27@60@0.7881@4841.45@@@@@@@@@@@@1.15@1@@mg@100@1@@@@@@@@@@@7/19/2017@80.69@80.69@229314560@FILM-COATED TABLET@C$@@@@@@@@70@MG@70 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922448@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AG013736, tablets 5 mg BID daily until tumor progression or toxicity @@-@-@-@NEW YORK, NEW YORK@12/1/2008@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14922448@Refractory to or not suitable candidates for 131-I treatment@@-@-@@NO REVIEW@@@@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@SECOND-LINE@NCT00094055@32@-@-@@@-@@9/1/2004@-@A4061014@@-@-@@@II@II@@-@-@7 out of 32 patients achieved partial responses, with a maximum tumour regression ranging from 36-67%. Two other patients had unconfirmed partial responses. Disease stabilisation (4-13 months) was seen in 15 patients. Median PROGRESSION-FREE SURVIVAL has not been reached. The agent was well tolerated with manageable toxicities, with the most common treatment-related adverse events being fatigue proteinuria, diarrhoea, nausea and hypertension. SOURCE: Pfizer/ASCO, 6 June 2006@-@@@@MONO@AXITINIB@@@@@AXITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@AG-013736@@@@@AG-013736||||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924228@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PHILIPSBURG, NEW JERSEY@@@CDX-1307 is a dendritic cell targeted immunotherapy designed to focus the immune system against hCG Beta, which is frequently expressed in epithelial tumors and has been associated with poor prognosis. The Phase 1 studies are open-label, dose-escalating clinical trials in patients with incurable breast, bladder, pancreatic, or colorectal cancer, all tumors that can express hCG Beta.@@14924228@-@@-@-@@NO REVIEW@@@@-@AVANT and Celldex announced a merger through which AVANT is the surviving name. SOURCE: Celldex, 22 October 2007@-@-@-@-@-@@@-@@@-@-@@-@-@@@DUKE COMPREHENSIVE CANCER CENTRE@I@@-@-@In one dose escalation scheme 25 patients have received CDX-1307 by local intradermal injection at up to 2.5mg, and in the other Phase 1 study 25 patients have received CDX-1307 systemically via intravenous injection at higher doses of up to 30 mg.CDX-1307 has been well tolerated at all doses and via both routes of administration without any Dose Limiting Toxicity. Despite advanced disease in the majority of patients, 2 patients experienced stable disease for at least 6 months and a minor response was seen in a patient with pancreatic cancer. Celldex expects to initiate a Phase 2 clinical trial of CDX-1307 in combination with selected TLR agonists in the second half of 2009. [Celldex, 4.11.2008]@This trial has enrolled seven patients to date without significant drug-related adverse events. @@@@MONO@-@@@@@-||||@CELLDEX THERAPEUTICS@AVANT IMMUNOTHERAPEUTICS@@@@CELLDEX THERAPEUTICS|AVANT IMMUNOTHERAPEUTICS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CDX-1307@@@@@CDX-1307||||@Other@@@@@Other||||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923265@Onco@@@@@300f1012ntsdm@@@@@@Patients will receive Avastin (15mg/kg IV) every 3 weeks, interferon alfa-2a 3 times weekly (3 Mio IU sc escalating to 18 Mio sc) and vinblastine (0.1mg/kg iv) every 3 weeks.@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14923265@First-line with Avastin in combo with stardard therapy for metastatic renal cell cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00520403@100-500@-@-@@@-@@10/1/2007@-@-@@-@-@@@II@II@@-@-@Not yet available@-@@@@COMBO@BEVACIZUMAB@INTERFERON@@@@BEVACIZUMAB|INTERFERON|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918910@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Rituxan with or withou Apomab@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918910@Indolent NHL progressed from Rituxan@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@80@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@FPI confirmed. SOURCE: Genentech, 10 April 2008Trial to start in Q1 2008 (delayed from initial plan of Q407). SOURCE: Genentech, January 2008.@-@@@@COMBO@-@RITUXIMAB@@@@-|RITUXIMAB|||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@APOMAB@RITUXAN@@@@APOMAB|RITUXAN|||@mAb@Human@@@@mAb|Human|||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16396587@Onco@@@@@300f1012ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396587@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@NO@@@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@459@The recommended starting dose is lenalidomide 10 mg/day orally on days 121 of repeated 28day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 14 of repeated 28 day cycles, prednisone2 mg/kg orally on days 14 of repeated 28day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide alone, 10 mg/dayorally on days 121 of repeated 28day cycles given until disease progression.@EMA, 11 February 2015@2/11/2015@@Yes@@@@@No@@@@ADULTS@@APPROVED@@@GKV@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@165117.0576@@@27.4@month@27.4 month@165117.06@165117.06@198.13@21@1.1511@5547.5@6856.89@5586@@@@@@@@@@26.42@28@@mg@10@21@@@@@@@@@@@8/1/2017@264.17@264.17@1875261@HARD CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918234@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14918234@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months).@@@@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9323851T@CONCENTRATE FOR SOLUTION FOR INFUSION (ONCO-TAIN VIAL), 40 ML@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16617764@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX52@L01X@@@@@VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patientswith chronic lymphocytic leukemia (CLL) with 17p deletion, as detected byan FDA approved test, who have received at least one prior therapy@@16617764@VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least oneprior therapy.@Both@NA@@@NO REVIEW@@@@@@SECOND-LINE@@106@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@FDA, 11 April 2016@4/11/2016@5/2/2016@@@@@@No@@@17p deletion@ADULTS@@APPROVED@@@@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLEXTA@@@@@VENCLEXTA||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@@@@@@@@@@@@@@@@1@1@166947.8435@@@12.1@month@12.1 month@166947.84@166947.84@453.62@10@1@120.45@@@@@@@@@@@@1.2@28@1@mg@92.5@28@1@@mg@400@1@@@@@@8/2/2017@12.05@12.05@00074-0561-14@FILM-COATED TABLET@US$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16396640@Onco@@@@@300f1014ntsdm@@@@@@Patients in the Revlimid/dexamethasone arm (n=170) took 25 mg of Revlimid orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone arm (n= 171)took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Patients in both treatment arms took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396640@Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.@@YES@@@NO REVIEW@@@@@@SECOND-LINE@@704@The recommended starting dose of REVLIMID® for multiple myeloma patients is 25 mg/day administered as a single 25 mg capsule on Days 121 of repeated 28day cycles.@@@@@@@@LABEL@No@@PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST ONE PRIOR TREATMENT WERE RANDOMIZED TO 2 ARMS: ARM1: REVLIMID (LENALIDOMIDE) PLUS ORAL PULSE HIGHDOSE DEXAMETHASONE THERAPY. ARM2: DEXAMETHASONE THERAPY ALONE.@@@III@APPROVED@@@RAMQ@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@TIME TO PROGRESSION@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@PLACEBO-CONTROLLED@@1@1@990274.623@@@48.1@month@48.1 month@990274.62@990274.62@676.87@28@0.7881@10108@@@@@@@@@@@@36.1@28@@mg@25@21@@@@@@@@@@@7/19/2017@361@361@230490228@HARD CAPSULE@C$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14923365@Onco@@@@@300f1014ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923365@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@@100%@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Unrestricted reimbursement.@RAMQ@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOFEN 10@@@@@TAMOFEN 10||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@C$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16398613@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XE27@L01X@@BEERSE, BELGIUM@@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16398613@Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion@Both@NA@@@NO REVIEW@@@@@@@@127@The recommended dose of IMBRUVICA for CLL and WM is 420 mg (three 140 mg capsules) orally once daily.@FDA, 28 July 2014@7/28/2014@@No@@@@@No@@All patients had a baseline ECOG performance status of 0 or 1. PFS and ORR were assessed by IRC.@@ADULTS@@APPROVED@@@@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@PHARMACYCLICS@@@@JANSSEN PHARMACEUTICAL|PHARMACYCLICS|||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@120@1@14803.88@@@@@@@@@@@@0.88@1@@mg@420@1@@@@@@@@@@@8/2/2017@123.37@123.37@57962-0140-12@CAPSULE@US$@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16396662@Onco@@@@@300f1018ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396662@Indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.@Both@YES@@@NO REVIEW@@@@@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@TGA, 16 March 2016@3/16/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@125987.2597@@@37.6@week@37.6 week@125987.26@125987.26@478.68@21@0.779@5361.16@5407.68@@@@@@@@@@@25.53@28@@mg@25@21@@@@@@@@@@@8/1/2017@255.29@255.29@2922-1419-HB-CJ@HARD CAPSULE@A$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14924494@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IL-21 in combination with Nexavar@@-@-@-@SEATTLE, WASHINGTON@@@IL-21 has potent biological activity in regulating key classes of immune cells, including cytotoxic T cells and natural killer cells. These cell types play key roles in surveillance of the body to eliminate malignant and infected cells. Based upon the ability of IL-21 to inhibit tumor growth in a number of preclinical models, ZymoGenetics is developing IL-21 for the treatment of cancer, initially in renal cell carcinoma and metastatic melanoma. @@14924494@Renal cell carcinoma@@-@-@@NO REVIEW@@@@-@>> ZymoGenetics announces the acquisition of ex-North American rights to Interleukin 21 (IL-21) from Novo Nordisk A/S, resulting in ZymoGenetics owning worldwide rights to IL-21. Novo Nordisk A/S agreed to license rest of world (ex-North American) development and commercialization rights for IL-21 to ZymoGenetics in exchange for potential regulatory approval milestones and royalties related to the ex-North American territory. In addition, upon licensing worldwide rights for IL-21 to a third party, Novo Nordisk A/S would receive a portion of related licensing fees if a certain threshold level were exceeded. [ZymoGenetics, 29.01.2009]            >> Novo Nordisk has exited all of its oncology interests as of February 2008.            >> Novo holds IL-21 rights outside of North America.@-@NCT00389285@45@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@SORAFENIB@@@@-|SORAFENIB|||@ZYMOGENETICS@@@@@ZYMOGENETICS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@IL-21@NEXAVAR@@@@IL-21|NEXAVAR|||@Immunotherapy@Interleukin@@@@Immunotherapy|Interleukin|||@SAFETY@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14925036@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Campath 30mg administered subcutaneously at varying intervals for up to 1 year  SOURCE: clinicaltrials.gov/North Shore Long Island Jewish Health System@@L01XC04@L01X@-@LEVERKUSEN, GERMANY@5/1/2009@@Alemtuzumab binds to CD52, an antigen present on the surface of B andT lymphocytes, a majority of monocytes, macrophages, NK cells, anda subpopulation of granulocytes. A proportion of bone marrow cells,including some CD34+ cells, express variable levels of CD52. The proposedmechanism of action is antibody-dependent cellular-mediatedlysis following cell surface binding of alemtuzumab to the leukemic cells.@@14925036@Maintenance trial@@-@-@@NO REVIEW@@@@-@ILEX Oncology (acquired by Genzyme) and LeukoSite (acquired by Millennium Pharma) entered into a distribution and development agreement with Schering AG (now Bayer Schering) in August 1999. The agreement grants Schering AG exclusive marketing and distribution rights to Campath in the United States, Europe and the rest of the world except Japan and East Asia, where LeukoSite and ILEX have retained these rights. Millenniusm sold Campath rights to ILEX in 2001 for US$140 million plus royalties. Initial rights licensed by LeukoSite from BTG.@-@NCT00587847@20@-@-@@@-@@5/1/2005@-@106.0621@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@ALEMTUZUMAB@@@@@ALEMTUZUMAB||||@BAYER HEALTHCARE@GENZYME@@@@BAYER HEALTHCARE|GENZYME|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@CAMPATH@MABCAMPATH@@@@CAMPATH|MABCAMPATH|||@mAb@Humanised@CD52@@@mAb|Humanised|CD52||@TIME TO PROGRESSION@@@@@INFECTIONS@@@@@REFRACTORY@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@15659.64@15659.64@42.9@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16670311@Onco@@@@@300f1020ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670311@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@20-Oct-16@10/20/2016@NO REVIEW@@@@@@FIRST-LINE@@459@@EMA, 11 February 2015@2/11/2015@@YES@@@@@No@@@@ADULTS@@APPROVED@@Added to the reimbursement list on 20 October 2016 [http://www.gazzettaufficiale.it/eli/id/2016/10/28/16A07750/sg;jsessionid=aYtec5ixDvhYP72a9v3pbw__.ntc-as2-guri2a]@SSN@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@710774.2429@@@27.4@month@27.4 month@710774.24@710774.24@852.86@21@1.1229@4776.03@7882.36@4991@@@@@@@@@@45.49@28@@mg@25@21@@@@@@@@@@@6/7/2017@227.43@227.43@38016010@HARD CAPSULE@EURO@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918109@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA01@L01X@YES@DEERFIELD, ILLINOIS@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14918109@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@YES@@@NO REVIEW@@@@@@@@@For monotherapy, the following two dosage regimens are recommended:- Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; - 15 to 20 mg/m²/day for five days, every 3 to 4 weeks. If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks.@@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Ovarian Cancer@Testicular Cancer@Bladder Cancer@@@Ovarian Cancer|Testicular Cancer|Bladder Cancer|||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916259@Onco@@@@@300f1008ntsdm@@@@@@Triweekly schedule @@L01CD01@L01C@-@SUMMIT, NEW JERSEY@9/1/2008@@Abraxane is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel protein-bound particles for injectable suspension) is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.@@14916259@-@@-@-@@NO REVIEW@@@@-@>>Celgene acquires Abraxis for US$2.9 billion [Celgene 30 June 2010 http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight= ]>> Abraxis BioScience has entered into an agreement with AstraZeneca to re-acquire the exclusive rights to market Abraxane in the United States. [Abraxis, 28.11.2008]       >> AstraZeneca paid US$200 mil to co-promote Abraxane in the U.S., whilst Abraxis bought AstraZeneca's anaesthetic/analgesia portfolio. India/certain Asia rights licensed to Biocon in August 2007.@-@NCT00661167@53@-@-@@@-@@4/1/2008@-@Taiho10041040@@-@-@@@II@II@@-@@RESULTS PENDING@-@@@@MONO@PACLITAXEL PROTEIN BOUND PARTICLES@@@@@PACLITAXEL PROTEIN BOUND PARTICLES||||@CELGENE@ABRAXIS@@@@CELGENE|ABRAXIS|||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@ABRAXANE@ABI-007@@@@ABRAXANE|ABI-007|||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14917275@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@DEERFIELD, ILLINOIS@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14917275@Used in combination therapy with other approved chemotherapeutics in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy; used in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.@@NO@7-Jun@@NO REVIEW@@@@100%@@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@1-Aug-93@8/1/1993@5/28/2003@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@CELLTOP@@@@@CELLTOP||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@40@1.1807@197.28@234.55@210.46@@@@@@@@@@0.2@@@@@@@@@@@@@@@@9/1/2017@4.93@4.93@3.40E+12@CAPSULE@EURO@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15045781@Onco@@@@@300f1015ntsdm@@@@@@@@L03AA02@L03A@@BERLIN, GERMANY@@@Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. NEUPOGEN containing rmetHuGCSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes. In some severe chronic neutropenia patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dosedependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.@@15045781@Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. It is indicated for the mobilisation of peripheral blood progenitor cells (PBPC). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. It is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.@@NO@@@NO REVIEW@@@@@@@@@@EMA, 24 July 2008@7/24/2008@@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@@FILGRASTIM@@@@@FILGRASTIM||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@RATIOGRASTIM@BIOSIMILAR@@@@RATIOGRASTIM|BIOSIMILAR|||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@61.29@75.55@65.38@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@61.29@61.29@3.40E+12@SOLUTION FOR PERFUSION AND INJECTION 0,5 ML (PREFILLED SYRINGE)@EURO@@@@@@@@300@MCG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15781621@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XE16@L01X@@NEW YORK, NEW YORK@@@@@15781621@XALKORI is indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive@Both@NA@@@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@@@50@The recommended dose of XALKORI is 250 mg orally, twice daily until disease progression or no longer tolerated by the patient.@FDA, 11 March 2016@3/11/2016@@Yes@@@@Study 1001@No@@@ROS1-positive@ADULTS@@APPROVED@@@NA@The current approval was based on a multicenter, single-arm trial in patients with metastatic ROS1 rearrangement-positive NSCLC.  All patients received crizotinib 250 mg orally twice daily. The efficacy outcome measures were objective response rate (ORR) according to RECIST v1.0 as evaluated by an independent radiology review (IRR) and as evaluated by the investigators. Duration of response (DoR) was an additional outcome measure.The trial enrolled 50 patients with an age range of 25-77 years whose tumors were prospectively determined to be ROS1-positive by fluorescence in situ hybridization (FISH; 96%) or reverse transcription polymerase chain reaction (RT-PCR; 4%) clinical trial assays. The ORR by IRR was 66% (95% CI: 51%, 79%) with a median DoR of 18 months. The ORR according to investigators was 72% (95% CI: 58%, 84%). [FDA, 11 March 2016,http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm]@The safety results of this trial were generally consistent with the safety profile of crizotinib evaluated in 1,669 patients with ALK-positive metastatic NSCLC. The most common adverse reactions of Xalkori are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy. [FDA, 11 March 2016,http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm]@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@METASTATIC@@@@@MULTICENTER@SINGLE-ARM@@@@1@1@354637.7273@@@18.3@month@18.3 month@354637.73@354637.73@637.14@60@1@15291.25@@@@@@@@@@@@1.27@1@@mg@500@1@@@@@@@@@@@8/2/2017@254.85@254.85@00069-8141-20@HARD CAPSULE@US$@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16617148@Onco@@@@@300f1037ntsdm@@@@@@Ibrutinib: 420 mg daily or 840 mg daily@@L01XE27@L01X@@BEERSE, BELGIUM@6/1/2013@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16617148@Treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo immunotherapy.@@YES@@@NO REVIEW@@@@@@FIRST-LINE@NCT01105247@133@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 21 October 2014@10/21/2014@1/11/2016@Yes@@4/1/2010@@PCYC-1102-CA@No@@@@@II@APPROVED@@@SNS@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE GROUP ASSIGNMENT@@@1@1@60069.74389@@@9@month@9 month@60069.74@60069.74@219.44@90@1.1511@6583.13@6904.6@6590.67@@@@@@@@@@0.52@1@@mg@420@1@@@@@@@@@@@8/4/2017@73.15@73.15@704172@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15394352@Onco@@@@@300f1008ntsdm@@@@@@Experimental: Lonsurf. 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Placebo: tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle.@@L01BC59@L01B@@@12/1/2014@@@@15394352@Unresectable advanced or recurrent colorectal cancer@Both@NA@30-May-14@5/30/2014@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@NCT01607957@800@35 mg/m²/dose orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.@MHLW, 1 March 2014@3/1/2014@@No@@5/24/2012@@TPU-TAS-102-301/2012-000109-66@No@@Has adenocarcinoma of the colon or rectum. Has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancerECOG performance status of 0 or 1Is able to take medications orally. Has adequate organ function (bone marrow, kidney and liver). Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.@@ADULTS@@APPROVED@@@NHI@@@@@@MONO@TIPIRACIL / TRIFLURIDINE@@@@@TIPIRACIL / TRIFLURIDINE||||@TAIHO@@@@@TAIHO||||@France@Germany@Italy@Japan@@United States|Australia|Austria|Belgium|Czech Republic||France|Germany|Italy|Japan@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@LONSURF@@@@@LONSURF||||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@@@@@METASTATIC@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@1.75@m²@1338342.742@@@7.1@month@7.1 month@1338342.74@1338342.74@6197.36@1@0.0091@2833.08@3340.9@@@@@@@@@@@141.65@28@@mg/m²@70@10@@@@@@@@@@@8/30/2017@2833.08@2833.08@4299100F2022@TABLET@YEN@@@@@@@@20@MG@9.42 MG|20 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14916089@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Not available@@L01XC06@L01X@-@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@14916089@Metastic and/or locally advanced soft tissue and bony sarcomas@@-@-@@NO REVIEW@@@@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]     >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@-@NCT00148109@45@-@-@@@-@@3/1/2005@-@UMCC 2004-078@@CURRENTLY IN DISPUTE; IMCLONE LOST PROCESS PATENT, EXPIRING IN 2017, TO YEDA IN 2006.@-@-@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@@@@BMS|IMCLONE|||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@RESPONSE RATE@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917407@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917407@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90%@@@@@Malignant Melanoma: Dacarbazine can be administered as single agent in doses of 200 to 250 mg/m² body surface area/day as an i.v. injection for 5 days every 3 weeks. As an alternative to an intravenous bolus injection dacarbazine can be administered as a short-term infusion (over 15 - 30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as intravenous infusion.@10-Jul-07@7/10/2007@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MADAUS@@@@@MADAUS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@DTIC-DOME@@@@@DTIC-DOME||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@1000@MG@1000 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14916669@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@L01XE15@L01X@-@-@@@PLX4032 is a novel, oral small molecule for treating melanoma and other cancers harboring the oncogenic BRAF mutation@@14916669@-@@YES@-@@NO REVIEW@@@@-@-@-@NCT00405587@25@-@-@@@-@@11/1/2006@-@PLX06-02@@-@-@@@I@I@@-@-@>>In the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.[Plexxikon 25 August 2010 http://www.plexxikon.com/view.cfm/78/Press-Releases ]>>RESULTS PENDING@Drug-related adverse events were predominantly mild in severity and included rash, joint pain, photosensitivity and fatigue. Among the 48 patients treated in the dose-escalation and extension cohorts, 18 patients developed cutaneous squamous cell carcinoma in sun exposed areas of the skin (primarily keratoacanthoma subtype) that were treated by excision, while treatment with PLX4032 was continued.@@@@MONO@VEMURAFENIB@@@@@VEMURAFENIB||||@PLEXXIKON@ROCHE@@@@PLEXXIKON|ROCHE|||@@@@@@|||||||||@Solid Tumours@Melanoma / Skin Cancer@@@@Solid Tumours|Melanoma / Skin Cancer||||||||@ZELBORAF@@@@@ZELBORAF||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@SAFETY@@@SAFETY@@@@@MALIGNANT@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917255@Onco@@@@@300f1010ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14917255@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@EMA, June 2000@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@"July 2007 consultation paper: ""for men willing to accept the adverse impact on overall survival and gynaecomastia in the hope of retaining sexual function, anti-androgen monotherapy with bicalutamide is appropriate. Men taking bicalutamide who do not maintain satisfactory sexual function should stop bicalutamide and be treated with androgen withdrawal."""@NHS@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@CASODEX@@@@@CASODEX||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@1459.92@1459.92@@28@1.2961@119.79@@@@@@@@@@@@0.09@@@@@@@@@@@@@@@@8/21/2017@4.28@4.28@2.08E+15@TABLET FILM COATED@GB£@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916683@Onco@@@@@300f1008ntsdm@@@@@@N/A@@-@-@-@BRENTFORD, UNITED KINGDOM@6/1/2008@@When administered intravenously, nelarabine works by preventing the cells from producing DNA, which causes them to self-destruct. Nelarabine is a water-soluble pro-drug of ara-G, a nucleoside (deoxyguanosine) analogue. When injected into the body, nelarabine is chemically converted to Ara-G and then its active form, ara-GTP. Accumulation of ara-GTP in cancer cells leads to inhibition of DNA synthesis, which results in programmed cell death. Nelarabine is cytotoxic to T-cells with high potency and selectivity, compared to other types of cells involved in the immune response (e.g. B-cells, monocytes, macrophages).@@14916683@Patients With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma. @@-@-@@NO REVIEW@@@@-@-@-@NCT00406757@12@-@-@@@Orphan drug@@6/1/2006@-@PGA105446@@-@"Histologic or cytogenetic documented diagnosis of T-ALL or T-LBL. 
Disease that is refractory to at least one prior chemotherapy regimen, or has relapsed following complete remission to at least one prior chemotherapy regimen. "@@@I@I@@-@@RESULTS PENDING@RESULTS PENDING@@@@MONO@NELARABINE@@@@@NELARABINE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Non-Hodgkin's Lymphoma|||||||@ATRIANCE@@@@@ATRIANCE||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@ADVERSE EVENTS@@@@@RESPONSE RATE@COMPLETE RESPONSE@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14919086@Onco@@@@@@@@@@@Velcade plus thalidomide plus dexamethasone versus thalidomide plus dexamethasone@@L01XX32@L01X@-@CAMBRIDGE, MASSACHUSSETTS@@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@14919086@Myeloma after autologous transplantation@@-@-@@NO REVIEW@@@4.5 YEARS@-@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]      >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]      >> Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones.@SECOND-LINE@NCT00256776@452@-@-@@@-@@@-@MMVAR@@-@-@@@III; EUDRACT: 2005-001628-35; EBMT-CLWP: 42206611 / @II@@-@-@Trial registered; completion expected in December 2009 [Millennium, 21.11.2005]@-@@@@COMBO@BORTEZOMIB@THALIDOMIDE@@@@BORTEZOMIB|THALIDOMIDE|||@MILLENNIUM PHARMACEUTICALS@JOHNSON & JOHNSON@TAKEDA PHARMACEUTICAL@@@MILLENNIUM PHARMACEUTICALS|JOHNSON & JOHNSON|TAKEDA PHARMACEUTICAL||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@VELCADE@THALOMID@@@@VELCADE|THALOMID|||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@TIME TO PROGRESSION@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14922336@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Abraxane administered weekly for 3 weeks at 30-minute IV infusion (150mg/m2) followed by 1 week rest. Avastin administered at 10mg/kg every 2 weeks without rest period.@@L01CD01@L01C@-@SUMMIT, NEW JERSEY@@@Abraxane is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel protein-bound particles for injectable suspension) is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.@@14922336@-@@-@-@@NO REVIEW@@@@-@>>Celgene acquires Abraxis for US$2.9 billion [Celgene 30 June 2010 http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight= ]>> Abraxis BioScience has entered into an agreement with AstraZeneca to re-acquire the exclusive rights to market Abraxane in the United States. [Abraxis, 28.11.2008]       >> AstraZeneca paid US$200 mil to co-promote Abraxane in the U.S., whilst Abraxis bought AstraZeneca's anaesthetic/analgesia portfolio. India/certain Asia rights licensed to Biocon in August 2007.@-@NCT00462423@50@-@-@@@-@@4/1/2007@-@ABRAXAVAST@@-@-@@@II@II@@-@-@RESULTS PENDING; completion due in April 2009.@-@@@@COMBO@PACLITAXEL PROTEIN BOUND PARTICLES@@@@@PACLITAXEL PROTEIN BOUND PARTICLES||||@CELGENE@ABRAXIS@@@@CELGENE|ABRAXIS|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ABRAXANE@@@@@ABRAXANE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-GROUP@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922131@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Forodesine hydrochloride administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). Patients will be evaluated after 1 full cycle of therapy (28 days).@@-@-@-@BIRMINGHAM, ALABAMA@@@Forodesine HCl is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in clinical trials for indications including T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). @@14922131@Fludarabine refractory CLL@@-@-@@NO REVIEW@@@@-@In February 2006, BioCryst announced an exclusive licensing agreement with Mundipharma to develop and commercialise forodesine HCL for use in the treatment of oncology in markets across Europe, Asia, Australia and certain neighbouring countries.@-@NCT00289549@30@-@-@@@-@@6/1/2005@-@BCX1777-Bo-05-204@@-@-@@@II@II@@-@-@An interim analysis was conducted - while this analysis showed that no partial or complete responses were observed, five out of 13 patients administered 200 mg of Forodesine HCl once-daily had substantial reductions in malignant lymphocytes, and at the time of the analysis, seven patients were still on study. [BioCryst, 22.12.2008]@Forodesine HCl was generally safe and well-tolerated at the 200 mg once-daily dose. @@@@MONO@FORODESINE@@@@@FORODESINE||||@BIOCRYST PHARMACEUTICALS@MUNDIPHARMA@@@@BIOCRYST PHARMACEUTICALS|MUNDIPHARMA|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@FODOSINE@BCX-1777@@@@FODOSINE|BCX-1777|||@PNP Inhibitor@@@@@PNP Inhibitor||||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15361167@Onco@@@@@300f1020ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361167@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.@Both@YES@@@@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dose for chronic phase CML is 100 mg dasatinib once daily, administered orally.@EMA, 6 December 2010@12/6/2010@@YES@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@56994.27106@@@14@month@14 month@56994.27@56994.27@133.84@30@1.1229@4015.34@6626.92@4196.07@@@@@@@@@@1.34@1@@mg@100@1@@@@@@@@@@@6/7/2017@133.84@133.84@37400114@FILM-COATED TABLET (BLISTER ALUMINIUM/ALUMINIUM)@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919341@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@CANONSBURG, PENNSYLVANIA@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919341@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@6-Sep@@NO REVIEW@@@@@Via takeover of generics unit of Merck KGaA@@@@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@1-Mar-06@3/1/2006@2/24/2011@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9284536T@SOLUTION TO DILUTE FOR PERFUSION, 50 ML@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16639056@Onco@@@@@300f1008ntsdm@@@@@@dabrafenib 150 mg twice dailydabrafenib plus trametinib placebo (dabrafenib 150 mg twice daily and trametinib placebo, trametinib 2 mg once daily)@@L01XE23@L01X@@BASEL, SWITZERLAND@8/1/2013@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639056@Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation@Both@NA@17-Jun-16@6/17/2016@NO REVIEW@@@@@@@NCT01584648@423@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@MHLW, 28 March 2016@3/28/2016@@Yes@@5/1/2012@@115306@No@@Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.The subject must have a radiologically measurable tumorThe subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).@BRAF V600 mutation@ADULTS@III@APPROVED@@@NHI@@@@@@COMBO@DABRAFENIB@TRAMETINIB@@@@DABRAFENIB|TRAMETINIB|||@NOVARTIS @@@@@NOVARTIS ||||@World@@@@@World|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@MEKINIST@@@@TAFINLAR|MEKINIST|||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@8424754.104@@@11.2@month@11.2 month@8424754.1@8424754.1@24730.74@1@0.0091@4121.79@4860.6@@@@@@@@@@@82.44@1@@mg@300@1@@@@@@@@@@@8/30/2017@4121.79@4121.79@4291046M1020@CAPSULE@YEN@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14923366@Onco@@@@@300f1014ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923366@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@@100%@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Unrestricted reimbursement.@RAMQ@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOFEN 20@@@@@TAMOFEN 20||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@30@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@C$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918670@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918670@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Adult soft tissue sarcoma: For adult soft tissue sarcomas dacarbazine is given in daily doses of 250 mg/m2 body surface area i.v. (days 1-5) in combination with doxorubicin every 3 weeks (ADIC regimen). Restriction of food intake for 4-6 hours prior to treatment may reduce the severity of the nausea and vomiting which occurs in most patients particularly during the first two days of treatment. Because severe gastrointestinal and haematological disturbances can occur an extremely careful benefit-risk analysis has to be made before every course of therapy with dacarbazine.@EMA, November 1997@@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@70@@@@@@@@@@@@0.07@@@@@@@@@@@@@@@@7/28/2017@70@70@7.32E+15@POWDER FOR SOLUTION FOR INFUSION VIAL@GB£@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16792814@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were randomized to receive MEKINIST 2 mg orally once daily or chemotherapy consisting of either dacarbazine 1,000 mg/m2 intravenously every 3 weeks or paclitaxel 175 mg/m2 intravenously every 3 weeks.@@L01XE25@L01X@@BASEL, SWITZERLAND@@@Mekinist is indicated as a single-agent oral treatment for unresectable or metastatic melanoma in adult patients with BRAF V600E or V600K mutations.@@16792814@Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.@@NA@@@NO REVIEW@@@@@@@@322@2 mg orally once daily until disease progression or unacceptable toxicity.@FDA, 29 May 2013@5/29/2013@@Yes@@@@@No@@@BRAF V600E or V600K mutations@@@APPROVED@@@@@@@@@MONO@TRAMETINIB@@@@@TRAMETINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@MEKINIST@@@@@MEKINIST||||@MEK Inhibitor@@@@@MEK Inhibitor||||@@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@MULTI-CENTER@RANDOMISED@OPEN-LABEL@ACTIVE CONTROLLED@@1@1@50992.93494@@@4.8@month@4.8 month@50992.93@50992.93@349.27@30@1@10478.23@@@@@@@@@@@@174.64@1@@mg@2@1@@@@@@@@@@@8/2/2017@349.27@349.27@00078-0668-15@FILM-COATED TABLET (BOTTLE)@US$@@@@@@@@2@MG@2 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16667750@Onco@@@@@300f1018ntsdm@@@@@@Active Comparator: Idelalisib + rituximab Participants will receive idelalisib plus rituximabInterventions: Drug: Idelalisib/Drug: RituximabPlacebo Comparator: Placebo + rituximab Participants will receive placebo to match idelalisib plus rituximabInterventions: Drug: Rituximab/Drug: Placebo to match idelalisib@@L01XX47@L01X@@FOSTER CITY, CALIFORNIA@4/1/2014@@Zydelig is a first-in-class inhibitor of PI3K delta, a protein that is over-expressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells.@@16667750@ZYDELIG in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) upon relapse in patients for whom chemo-immunotherapy is not considered suitable.@Both@NA@@@@@@730@0%@@SECOND-LINE@NCT01539512@220@The recommended maximum starting dose of Zydelig is 150 mg administered orally twice daily.Continue treatment until disease progression or unacceptable toxicity.@@@@No@@4/1/2012@@GS-US-312-0116@No@@Adult subjects with previously treated recurrent CLL who have measurable lymphadenopathyRequire therapy for CLLHave experienced CLL progression < 24 months since the completion of the last prior therapy@@ADULTS@III@APPROVED@@@@@@@@@COMBO@IDELALISIB@RITUXIMAB@@@@IDELALISIB|RITUXIMAB|||@GILEAD @@@@@GILEAD ||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ZYDELIG@MABTHERA@@@@ZYDELIG|MABTHERA|||@PI3K INHIBITOR@@@@@PI3K INHIBITOR||||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@@@@@RELAPSED@@@@@RANDOMISED@DOUBLE BLIND@PLACEBO-CONTROLLED@@@1@1@Invalid Factory Price@@@19.4@month@19.4 month@@@@60@0.779@@@@@@@@@@@@@@1@@mg@300@1@@@@@@@@@@@@@@@COATED TABLET@A$@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916026@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@XL-999 given weekly@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@VEGF/VEGFR is a potent stimulator of tumor angiogenesis and a validated target for cancer therapy. PDGFR and FGFR contribute to the development or stabilization of new tumor vasculature and also play a role in cancer cell proliferation. FGFR3 is highly expressed in some multiple myeloma patients, and inhibition of FGFR3 suppresses growth and/or survival of multiple myeloma cells grown in culture or in xenograft models. FLT3 is an important driver of leukemia cell proliferation in patients with acute myelogenous leukemia.  RET is mutationally activated in hereditary forms of medullary thyroid cancer and in sporadic forms of both medullary and papillary thyroid cancer. @@14916026@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00277316@72@-@-@@@-@@12/1/2005@-@XL999-201@@-@-@@@II@CLINICAL HOLD@@-@-@All trials suspended in November 2006 after preliminary review relateing to cardiovascular events showed 4 out of 14 patients enrolled in October experienced serious adverse cardiac events, similar to those seen in 12 of 117 dosed through the end of September. 15 of the 16 events occurred on the first administration of the drug.@-@@@@MONO@-@@@@@-||||@EXELIXIS@@@@@EXELIXIS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@XL-999@@@@@XL-999||||@TK Inhibitor@VEGF@PDGF@FGF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|FGF|Angiogenesis Inhibitor@RESPONSE RATE@SAFETY@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15354710@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were split into 2 groups. The first group took IBRANCE and letrozole together, while the second group took letrozole alone.@@L01XE33@L01X@NO@NEW YORK, NEW YORK@@@@@15354710@Treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.@Female@NA@@@NO REVIEW@@@@@@FIRST-LINE@@165@125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days@FDA, 02 Mar 2015@3/2/2015@@No@@@@@No@@@HR-positive, HER2-negative@ADULTS@@APPROVED@@@NA@In the trial, patients in the IBRANCE plus letrozole group lived approximately 20.2 months without their disease pregoressing, compared to approximately 10.2 months in the group receiving letrozole alone.[FDA, 3 February 2015]@IBRANCE may cause serious side effects, including low white blood cell counts, infections, and blood clots in the arteries of your lungs (pulmonary embolism).The most common side effects included low levels of infection-fighting white blood cells called neutrophils (neutropenia), low levels of white blood cells (leukopenia), fatigue, low red blood cell counts (anemia), and upper respiratory tract infections. [FDA, February 2015, https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100070/farydak-panobinostat]@@@@COMBO@PALBOCICLIB@LETROZOLE@@@@PALBOCICLIB|LETROZOLE|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IBRANCE@GENERIC@@@@IBRANCE|GENERIC|||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMIZED@OPEN-LABEL@MULTICENTER@@@1@1@300702.3662@@@20.2@month@20.2 month@300702.37@300702.37@489.42@21@1@10963.05@@@@@@@@@@@@5.22@28@@mg@125@21@@@@@@@@@@@8/2/2017@522.05@522.05@00069-0188-21@CAPSULE@US$@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16395631@Onco@@@@@300f1012ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16395631@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@GKV@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@130366.2497@@@37.6@week@37.6 week@130366.25@130366.25@495.31@21@1.1511@5547.5@6856.89@5586@@@@@@@@@@26.42@28@@mg@25@21@@@@@@@@@@@8/1/2017@264.17@264.17@1875261@HARD CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920805@Onco@@@@@300f1010ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920805@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@Nov-96@@NO REVIEW@@@@100%@@@@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@EMA, October 1995@@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@LABEL@No@@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@APPROVED@@NO NICE REVIEW@NHS@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@2091.36@2091.36@@5@1.299@45.84@@52.39@@@@@@@@@@4.58@@@@@@@@@@@@@@@@7/28/2017@9.17@9.17@4.72E+15@TABLET@GB£@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921463@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921463@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@YES@-@@NO REVIEW@@@@100%@-@-@-@-@As a single agent: The recommended regimen is :First three administrations: 60mg/m² of body surface area, administered once weekly. Subsequent administrations: Beyond the third administration, it is recommended to increase the dose of Navelbine soft capsules to 80mg/m² once weekly except in those patients for whom the neutrophil count dropped once below 500/mm3 or more than once between 500 and 1000/mm3 during the first three administrations at 60mg/m².@N/A@@@-@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@EXPIRED@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@BOTH@VINORELBINE TARTRATE@CISPLATIN@@@@VINORELBINE TARTRATE|CISPLATIN|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@-@@@@@@@@@@ADVANCED@REFRACTORY@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@31031.87@31031.87@85.02@1@1.1229@62.43@103.04@65.24@@@@@@@@@@2.08@@@@@@@@@@@@@@@@6/7/2017@62.43@62.43@27865118@CAPSULE@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921405@Onco@@@@@300f1015ntsdm@@@@@@Imatinib with chemotherapy@@L01XE01@L01X@-@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14921405@Ph+ ALL in paediatric patients@@NO@-@@NO REVIEW@@@@-@-@-@NCT00287105@40@-@-@@@-@@2/1/2006@-@ESPHALL@@-@-@PAEDIATRIC@@II/III; EUDRACT 2004-001647-30, PHRC/04-04, CIC0203/043; @III@@-@-@RESULTS PENDING@-@@@@COMBO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLEEVEC@GLIVEC@@@@GLEEVEC|GLIVEC|||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924132@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Abraxane monotherapy@@L01CD01@L01C@-@SUMMIT, NEW JERSEY@@@Abraxane is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel protein-bound particles for injectable suspension) is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.@@14924132@-@@-@-@@NO REVIEW@@@@-@>>Celgene acquires Abraxis for US$2.9 billion [Celgene 30 June 2010 http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight= ]>> Abraxis BioScience has entered into an agreement with AstraZeneca to re-acquire the exclusive rights to market Abraxane in the United States. [Abraxis, 28.11.2008]       >> AstraZeneca paid US$200 mil to co-promote Abraxane in the U.S., whilst Abraxis bought AstraZeneca's anaesthetic/analgesia portfolio. India/certain Asia rights licensed to Biocon in August 2007.@FIRST-LINE@NCT00284752@56@-@-@@@-@@8/1/2005@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING; completion in August 2007.@-@@@@MONO@PACLITAXEL PROTEIN BOUND PARTICLES@@@@@PACLITAXEL PROTEIN BOUND PARTICLES||||@CELGENE@ABRAXIS@@@@CELGENE|ABRAXIS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ABRAXANE@@@@@ABRAXANE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@PSA@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916145@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. Patient will also receive cisplatin, 75 mg/m2 as a 1- to 3-hour infusion on Day 1 of each cycle. SOURCE: clinicaltrials.gov@@-@-@-@-@7/1/2007@@S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.@@14916145@1st-line NSCLC@@-@-@@NO REVIEW@@@@-@sanofi-aventis returns its territory rights to Taiho Pharmaceutical for the development and commercialization of the oral anti-cancer agent S-1. Taiho will pursue further development of S-1 outside of Japan with gastric cancer included. SOURCE: Taiho, 18 July 2008@FIRST-LINE@NCT00651833@60@-@-@@@-@@2/1/2005@-@TPU-S1202@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@TEGAFUR GIMERACIL OTERACIL POTASSIUM @CISPLATIN@@@@TEGAFUR GIMERACIL OTERACIL POTASSIUM |CISPLATIN|||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@S-1@@@@@S-1||||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918266@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14918266@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@HEUMANN@@@@@HEUMANN||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@1.78@13.23@2.53@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@1564928@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15358232@Onco@@@@@300f1014ntsdm@@@@@@Experimental: Erlotinib. Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.Placebo Comparator: Placebo. Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.@@L01XE03@L01X@@BASEL, SWITZERLAND@11/1/2010@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@15358232@Tarceva is indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based first-linechemotherapy.@Both@YES@@@NO REVIEW@@@@@>> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]       >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]        >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@MAINTENANCE@NCT00556712@889@The recommended daily dose is 150 mg. Treatment should continue until disease progression or unacceptable toxicity occurs.@Health Canada, 16 April 2010@4/16/2010@@@@1/1/2006@@BO18192@No@@histologically documented, locally advanced , recurrent or metastatic NSCLC;measurable disease;no disease progression after 4 cycles of platinum-based chemotherapy.@@ADULTS@III@APPROVED@@@@@@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@CHUGAI PHARMACEUTICAL@@@@ROCHE|CHUGAI PHARMACEUTICAL|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@@6888@@@12.3@week@12.3 week@6888@6888@80@30@0.7881@2400@@@@@@@@@@@@0.53@1@@mg@150@1@@@@@@@@@@@7/19/2017@80@80@226902330@FILM-COATED TABLET (BLISTER PVC/ALU)@C$@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918124@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA01@L01X@YES@BASEL, SWITZERLAND@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14918124@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@@@@NO REVIEW@@@@@@@@@For monotherapy, the following two dosage regimens are recommended:- Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; - 15 to 20 mg/m²/day for five days, every 3 to 4 weeks. If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks.@1-Apr@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Ovarian Cancer@Testicular Cancer@Bladder Cancer@@@Ovarian Cancer|Testicular Cancer|Bladder Cancer|||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16396618@Onco@@@@@300f1010ntsdm@@@@@@10 mg once daily or 10 mg once daily for 21 days every 28 days. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396618@Indicated for the treatment of patients with transfusiondependent anaemia due to low or intermediate1risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.@@NO@@@NO REVIEW@@@@100%@@@@148@The recommended starting dose of lenalidomide is 10 mg orally once daily on days 121 of repeated 28day cycles. Dosing is continued or modified based upon clinical and laboratory findings.@EMA, 25 April 2013@4/25/2013@@Yes@@@@MDS003@No@@148 PATIENTS WHO HAD RBC TRANSFUSION DEPENDENT ANEMIA. RBCTRANSFUSION DEPENDENCE WAS DEFINED AS HAVING RECEIVED = 2 UNITS OF RBCS WITHIN 8 WEEKS PRIOR TO STUDY TREATMENT. THE STUDY ENROLLED PATIENTS WITH ABSOLUTE NEUTROPHIL COUNTS (ANC) = 500 CELLS/MM3,@@@III@APPROVED@@@NHS@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@OPEN-LABEL@SINGLE-ARM@MULTI-CENTRE@@@1@1@9799.999986@@@56@day@56 day@9800@9800@175@21@1.299@3675@@@@@@@@@@@@23.33@28@@mg@10@21@@@@@@@@@@@7/28/2017@175@175@2.99E+16@CAPSULE@GB£@@@@@@@@7.5@MG@7.5 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921174@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single agent Talvesta@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14921174@-@@-@-@@NO REVIEW@@@@-@Hana receives notice from Nasdaq that it has regained compliance with minimum US$1 bid price. SOURCE: Hana, 28 April 2008@-@NCT00112060@N/A@-@-@@@-@@@-@HBS101, HBS101.00@@-@-@@@I/II@CLINICAL HOLD@@-@-@Since 2004, the National Cancer Institute has been sponsoring a Phase 1 solid tumor trial with Talvesta, which has now been discontinued. As a result of observed toxicities, Hana has decided to conduct additional in vitro and in vivo toxicology studies to further characterize this novel antifolate. While no unexpected toxicity signals were seen in Hana's Phase 2 ALL trial, as a safety precaution, the company has proactively suspended enrollment in this study until additional toxicology and pharmacokinetic studies have been reviewed. Hana anticipates that clinical trials will resume subject to the results of the toxicology studies which will be completed by the end of 2007. SOURCE: Hana, 23 March 2007.@-@@@@MONO@TALOTREXIN@@@@@TALOTREXIN||||@HANA BIOSCIENCES@@@@@HANA BIOSCIENCES||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TALVESTA@PT-523@@@@TALVESTA|PT-523|||@Folic Acid Analogue@@@@@Folic Acid Analogue||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922540@Onco@@@@@300f1008ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14922540@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@@NHI@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@MEIJI SEIKA KAISHA@@@@@MEIJI SEIKA KAISHA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOXIFEN MEIJI@@@@@TAMOXIFEN MEIJI||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.0091@108.2@127.6@@@@@@@@@@@5.41@@@@@@@@@@@@@@@@8/30/2017@108.2@108.2@4291003F2089@TABLETS@YEN@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
15400328@Onco@@@@@300f1015ntsdm@@@@@@Investing arms: nilotinib 300mg bid or nilotinb 400 mg bidControl arm: imatinib 400mg QD@@L01XE08@L01X@@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@15400328@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.@Both@NO@6-Apr-11@4/6/2011@NO REVIEW@@@@@@FIRST-LINE@NCT00471497@846@The recommended dose of Tasigna is 300 mg twice daily. Treatment should be continued as long as the patient continues to benefit.@EMA, 23 September 2010@9/23/2010@2/22/2012@Yes@@@@ENEST@No@@Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome@ADULT@Adult@III@APPROVED@@ASMR IV@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@MOLECULAR RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@1@1@32430.06041@@@12@month@12 month@32430.06@32430.06@88.85@28@1.1511@621.96@711.12@651.96@@@@@@@@@@0.15@1@@mg@600@1@@@@@@@@@@@8/1/2017@22.21@22.21@3.40E+12@CAPSULE@EURO@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918091@Onco@@@@@300f1014ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14918091@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@Unrestricted reimbursement.@RAMQ@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@GENPHARM@@@@@GENPHARM||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GEN-BICALUTAMIDE@GENERIC@@@@GEN-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Factory Price@@@@@@@@@30@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@C$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
15361177@Onco@@@@@300f1014ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361177@Indicated for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase@Both@NO@@@@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dosage of SPRYCEL (dasatinib) for chronic phase CML is 100 mg administered orally once daily (OD), either in the morning or in the evening.@@@@@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@77893.14407@@@14@month@14 month@77893.14@77893.14@182.92@60@0.7881@2195.08@@@@@@@@@@@@1.83@1@@mg@100@1@@@@@@@@@@@7/19/2017@36.58@36.58@229312960@FILM-COATED TABLET@C$@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918672@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918672@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@EMA, November 1997@@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@70@@@@@@@@@@@@0.07@@@@@@@@@@@@@@@@7/28/2017@70@70@7.32E+15@POWDER FOR SOLUTION FOR INFUSION VIAL@GB£@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916031@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@350MG on days 1-5 of a repeated 14-day cycle@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@Principal Targets- Cell proliferation: EGFR and a variety of mutant forms of EGFR (e.g., T790M), HER2, Angiogenesis (VEGFR). EGFR and HER2 are targets for approved cancer therapies. Signaling through VEGF/VEGFR2 is the target of approved cancer therapies. EGFR is mutationally activated in a subset of NSCLC patients, and some EGFR mutations are associated with resistance to erlotinib and gefitinib.@@14916031@Previously untreated female Stage IIIb or Stage IV NSCLC@@-@-@@NO REVIEW@@@@-@XL647 is licensed to Symphony Evolution. GSK decided not to exercise an option for the drug in July 2007.@-@NCT00364780@42@-@-@@@-@@7/1/2006@-@XL647-201@@-@-@@@II@II@@-@-@September 2007; updated Phase II data showed 10 partial responses and 13 cases of stable disease in 34 evaluable patients. Responses were seen in patients with and without activating EGF receptor mutations. There were 16 serious adverse events in 8 patients (haemorrhage and duodenal ulcer, pneumonia, pulmonary embolism and haemotysis). Previous data showed 8 partial responses and 11 cases of stable disease in 30 evaluable patients.@-@@@@MONO@-@@@@@-||||@EXELIXIS@SYMPHONY EVOLUTION@@@@EXELIXIS|SYMPHONY EVOLUTION|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XL-647@@@@@XL-647||||@TK Inhibitor@EGFR@HER2@VEGF@Angiogenesis Inhibitor@TK Inhibitor|EGFR|HER2|VEGF|Angiogenesis Inhibitor@RESPONSE RATE@SAFETY@TOLERABILITY@@@TOLERABILITY@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16076430@Onco@@@@@@@@@@@Treatment Phase: Vemurafenib+Cobimetinib, Experimental, Participants with BRAF V600 mutation will receive vemurafenib 960 milligrams (mg) tablets orally twice daily (BID) on Days 1 to 28 along with cobimetinib 60 mg tablets orally once daily (OD) for 21 consecutive days (Days 1 to 21) of each 28-day cycle until disease progression, consent withdrawal, or the development of unacceptable toxicity.@@L01XE38@L01X@@BASEL, SWITZERLAND@2/1/2019@@@@16076430@A Single Arm, Open Label, Phase II, Multicenter Study to Assess The Detection of The BRAF V600 Mutation on cfDNA From Plasma in Patients With Advanced Melanoma@Both@@@@@Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.@@@@@@NCT02768207@208@@@@@@@4/1/2016@@ML29741@@@Pre-screening phase:  -  Participants with histologically confirmed melanoma, either unresectable Stage IIIc or Stage IV metastatic melanoma, as defined by American Joint Committee on Cancer (AJCC) 7th edition  -  Documentation of BRAF V600 test result mutation-positive status on melanoma tumor tissue using a validated tissue test  Treatment Phase:  -  Eastern cooperative oncology group (ECOG) performance status of 0-2  -  Adequate hematologic and end organ function obtained within 14 days prior to first dose of study drug treatment  -  Negative serum pregnancy test prior to commencement of dosing in women of childbearing potential  -  Absence of any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol and treatment regimen and follow-up after treatment discontinuation schedule  -  Female participants of childbearing potential and male participants with partners of childbearing potential must agree to always use 2 effective forms of contraception during the course of this study and for at least 3 months after completion of study therapy  -  Participants should be able to swallow tablets  -  Documentation of BRAF mutation positive status in melanoma tissue (archival or new)@BRAF V600 Mutation Positive@ADULTS@Phase 2@II@@@@@@@@@MONO@COBIMETINIB@@@@@COBIMETINIB||||@ROCHE@@@@@ROCHE||||@Belgium@Poland@@@@Belgium|Poland||||||||@Solid Tumours@Melanoma / Skin Cancer@@@@Solid Tumours|Melanoma / Skin Cancer||||||||@COTELLIC@@@@@COTELLIC||||@MEK Inhibitor@@@@@MEK Inhibitor||||@Number of participants with BRAF V600 mutation@@@@@Percentage of participants with objective response as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)@PROGRESSION-FREE SURVIVAL@@@@ADVANCED@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@Screening@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16668390@Onco@@@@@300f1015ntsdm@@@@@@Once daily@@L01XE27@L01X@@BEERSE, BELGIUM@5/1/2014@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16668390@Indicated for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy.@Both@@30-Nov-16@11/30/2016@NO REVIEW@@@@@@FIRST-LINE@NCT01614821@63@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 3 July 2015@7/3/2015@11/21/2014@Yes@@5/1/2012@@12-015@No@@Clinicopathological diagnosis of Waldenstrom's MacroglobulinemiaMeasurable disease; Have received at least one prior therapy for WM therapies@@ADULTS@@APPROVED@@30 November 2016 [http://www.has-sante.fr/portail/upload/docs/evamed/CT-15294_IMBRUVICA_Waldenstrom_PIC_INS_Avis2_CT15294.pdf]@Not reimbursed@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Waldenstrom's Macroglobinaemia@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Waldenstrom's Macroglobinaemia|||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@OVERALL RESPONSE RATE@@@@@SAFETY@PROGRESSION-FREE SURVIVAL@@@@@@@@@OPEN LABEL@MULTICENTER@SINGLE-ARM@@@1@1@Invalid Factory Price@@@1@month@1 month@@@@90@1.1511@@@@@@@@@@@@@@1@@mg@420@1@@@@@@@@@@@@@@3.40E+12@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922489@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Alimta alone@@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14922489@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00377520@51@-@-@@@-@@@-@8368H3E-US-JMGT  @@FEBRUARY 2009 (NCE); FEBRUARY 2011 (ORPHAN)@-@@@II@II@@-@-@Completion expected in September 2008.@-@@@@MONO@PEMETREXED@@@@@PEMETREXED||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@ALIMTA@@@@@ALIMTA||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@RESPONSE RATE@@@@@@@@@@ADVANCED@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER FOR INFUSION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920925@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Zosuquidar given in combination with gemtuzumab@@-@-@-@SAN DIEGO, CALIFORNIA@3/1/2008@@Zosuquidar (LY335979) is an oral P-glycoprotein modulator. Cancer cells develop several mechanisms of resistance to evade the toxic effects of anticancer drugs. One of these mechanisms involves a protein called multidrug resistance (MDR) transporter. MDR pumps substances out of the cell. In fact, MDR can pump anticancer agents out of the cancer cells. Therefore, the drugs cannot reach their target within the cancer cells and do not kill them. Zosuquidar does not have anticancer properties per se. However, it is an inhibitor of the MDR transporter and by blocking this transporter it is expected to help anticancer drugs to overcome this resistance mechanism and to exert their activity.@@14920925@Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia@@-@-@@NO REVIEW@@@@-@Kanisa licensed the drug from Eli Lilly. [Kanisa, August 2006]@SECOND-LINE@NCT00233909@55@-@-@@@-@@10/1/2005@-@KAN-979-02@@-@Morphologic evidence of acute myeloid leukemia in first relapse; Phase I: 18 years or older, Phase II: 50 years or older @@@I/II@II@@-@-@>> Trial completed [Kanisa, 28.03.2008]         >> Trial registered and commenced [Kanisa, 4.10.2005]@-@@@@COMBO@ZOSUQUIDAR@GEMTUZUMAB OZOGAMICIN@@@@ZOSUQUIDAR|GEMTUZUMAB OZOGAMICIN|||@KANISA PHARMACEUTICALS@LILLY@@@@KANISA PHARMACEUTICALS|LILLY|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@LY-335979@KAN-979@MYLOTARG@@@LY-335979|KAN-979|MYLOTARG||@Other@@@@@Other||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@RESPONSE RATE@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384823@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384823@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@NHS@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@24158.1747@@@1@year@1 year@24158.17@24158.17@66.19@30@1.299@1946.67@@@@@@@@@@@@0.16@1@@mg/m²@340@1@@@@@@@@@@@7/28/2017@64.89@64.89@7.32E+15@FILM-COATED TABLET@GB£@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919962@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01CA01@L01C@YES@UNITED STATES@@@Although the mechanism of action has not been definitely established, vinblastine appears to bind to or crystallise critical microtubular proteins of the mitotic spindle, thus preventing their proper polymerisation and causing metaphase arrest. In high concentrations, vinblastine also exerts complex effects on nucleic acid and protein synthesis. Vinblastine reportedly also interferes with amino acid metabolism by blocking cellular utilisation of glutamic acid and thus inhibits purine synthesis, the citric acid cycle, and the formation of urea. Vinblastine exerts some immunosuppressive activity.@@14919962@@@NO@@@NO REVIEW@@@@@@@@@Therapy should be initiated in adults with 3.7 mg/m2 dose, followed by doses of 5.5, 7.4, 9.25 and 11.1mg/m2 body surface area. After first dose, white blood cell counts should be made. Maximum dose should not exceed 18.5mg/m2 bsa. Dose should not increase if white blood cell count is reduced to 3,000 cells/mm3. For most patients, weekly dosing will stand at 5.5 to 7.4mg/m2 bsa.@@@@@@@Fatal if given intrathecally; for intravenous use only, and should be administered by experienced physicians.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@VINBLASTINE SULPHATE@@@@@VINBLASTINE SULPHATE||||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@Testicular Cancer@Choriocarcinoma@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Testicular Cancer|Choriocarcinoma|||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@43.07@@@@@@@@@@@@4.31@@@@@@@@@@@@@@@@8/2/2017@43.07@43.07@63323-0278-10@INJECTION (VIAL)@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384757@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384757@Indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alphatherapy@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@532@The recommended dosage of Glivec is 400 mg/day for adult patients in chronic phase CML.@@@@Yes@@@@@No@@@ADULT@@@APPROVED@@@GKV@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@@@@@@1@1@Invalid Average Duration of Use@@@@@@@@@90@1.1511@8200.95@10109.22@8239.45@@@@@@@@@@0.23@1@@mg@400@1@@@@@@@@@@@8/1/2017@91.12@91.12@1755203@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921318@Onco@@@@@300f1037ntsdm@@@@@@Caelyx plus cyclophosphamide plus Herceptin@@L01DB01@L01D@-@KENILWORTH, NEW JERSEY@@@The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.@@14921318@Caelyx plus cyclophosphamide and Herceptin@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00258960@49@-@-@@@-@@@-@GEICAM2004-05  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@DOXORUBICIN, PEGYLATED LIPOSOMAL @CARBOPLATIN@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL |CARBOPLATIN|||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CAELYX@@@@@CAELYX||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16063859@Onco@@@@@300f1037ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16063859@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX.@@YES@@@NO REVIEW@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@254@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 13 January 2012@1/13/2012@@No@@@@EMR 62 202-013@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@7/29/2011@@SNS@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@29384.2092@@@7.9@month@7.9 month@29384.21@29384.21@122.29@1@1.1511@192.3@247.74@199.84@@@@@@@@@@1.92@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/4/2017@192.3@192.3@658752@SOLUTION FOR INFUSION (VIAL) - 20 ML@EURO@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14967348@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Nilotinib versus imatinib@@-@-@-@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@14967348@Ph+ CML in chronic phase with suboptimal cytogenic response@@-@-@@NO REVIEW@@@@-@-@-@NCT00519090@586@-@-@@@-@@10/1/2007@-@ENEST @@-@-@@@CAMN107A2302;@III@@-@-@The difference in the rates of both MR4 and MR4.5 continued to be significantly higher for Tasigna, with the difference in favor of Tasigna increasing over time (MR4: 9-14% difference by one year, 17-24% difference by four years; MR4.5: 6-10% difference by one year, 14-17% difference by four years)[7]. Overall survival remained similar in all groups at four years, but fewer CML-related deaths occurred in both the Tasigna 300 mg twice daily (n=5) and 400 mg twice daily (n=4) arms versus Glivec (n=13)[7].[Novartis, 10 December 2012, http://www.novartis.com/newsroom/media-releases/en/2012/1663480.shtml ]@-@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@COMPLETE CYTOGENIC RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384755@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384755@Indicated for the treatment of adult with Ph+ CML in blast crisis.@@NO@@@NO REVIEW@@@@@@@@260@The recommended dose of Glivec is 600 mg/day for adult patients in blast crisis.@@@@Yes@@@@Study 0102@No@@@ADULT@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@BLAST PHASE@@@@@@@@@@1@1@19286.24857@@@6.05@month@6.05 month@19286.25@19286.25@104.81@30@1.1511@2096.14@2270.33@2126.14@@@@@@@@@@0.17@1@@mg@600@1@@@@@@@@@@@8/1/2017@69.87@69.87@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924171@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@rhApo2L/TRAIL is a soluble recombinant human protein that targets the pro-apoptotic death receptors DR4 and DR5, which are involved in the regulation of apoptosis (programmed cell death). rhApo2L/TRAIL is being evaluated as a potential cancer therapeutic. A phase 1b study of CRC initiated in 2006 is ongoing. Phase 2 studies were initiated in 2007 for the treatment of NSCLC in combination with chemotherapy both with and without bevacizumab and non-Hodgkin's lymphoma (“NHL”) as a monotherapy and in combination with rituximab.@@14924171@-@@-@-@@NO REVIEW@@@@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@IB@I@@-@-@Interim data from 24 patients found no dose-limiting toxicities in the four dosing cohorts. Four patients experienced a treatment-related serious adverse event. Best overall objective tumor response per the RECIST criteria was 58 percent. SOURCE: Amgen/ASCO, 31 May 2008@-@@@@COMBO@-@BEVACIZUMAB@CARBOPLATIN@PACLITAXEL@@-|BEVACIZUMAB|CARBOPLATIN|PACLITAXEL|@AMGEN@GENENTECH@@@@AMGEN|GENENTECH|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AMG-951@RH-APO2L/TRAIL@AVASTIN@@@AMG-951|RH-APO2L/TRAIL|AVASTIN||@Other@@@@@Other||||@RECIST@ADVERSE EVENTS@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918637@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@LAKE FOREST, ILLINOIS@@@@@14918637@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@NO@@@NO REVIEW@@@@100%@Via acquisition of Mayne Pharma@@@@Malignant lymphomas: Used alone the recommended dosage regime is 15 x 10³ IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 10³ IU (15 vials). Dosage should be reduced in the elderly. The dose may need to be adjusted when bleomycin is used in combination chemotherapy.@EMA, May 1998@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Testicular Cancer@Head & Neck Cancer@Haematological Malignancy@Non-Hodgkin's Lymphoma@@Testicular Cancer|Head & Neck Cancer|Haematological Malignancy|Non-Hodgkin's Lymphoma||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@15000@IU@15000 IU@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919828@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@M05BA03@M05B@NO@LAKE FOREST, ILLINOIS@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14919828@The treatment of tumour-induced hypercalcaemia. The prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, hypercalcaemia and bone pain) in patients with breast cancer with bone metastases or multiple myeloma with bone lesions, in addition to the specific treatment of the tumour. Paget's disease of bone.@@NO@@@NO REVIEW@@@@100%@Via takeover of Mayne@@@@Tumour-induced hypercalcaemia; please see label for dosing ranges; the total dose of pamidronate disodium may be administered either in a single infusion or in multiple infusions over 2-4 consecutive days. The maximum dose per treatment course is 90 mg for both initial and repeat courses.@EMA, June 2001@@@@@@Pamidronate should never be given as a bolus injection since severe local reactions and thrombophlebitis may occur. It should always be diluted and then given as a slow intravenous infusion. It should not be co-administered with other bisphosphonates. If other calcium lowering agents are used in conjunction with pamidronate, significant hypocalcaemia may result. Convulsions have been precipitated in some patients with tumour-induced hypercalcaemia due to the electrolyte changes associated with this condition and its effective treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Hypercalcaemia of Malignancy@@@@@Hypercalcaemia of Malignancy|||||||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@4.82E+15@SOLUTION FOR INFUSION - 10 ML@GB£@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921265@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@H02CA01@H02C@NO@CAMBRIDGE, MASSACHUSSETTS@@@@@14921265@(a) For the control of the manifestation of adrenal cortical hyperfunction in such conditions as hypercortisolism and primary aldosteronism. (b) For the treatment of postmenopausal advanced breast cancer following relapse to initial hormone therapy e.g. oestrogen receptor antagonists.@@NO@-@@NO REVIEW@@@@100%@Acquisition of Bioenvision by Genzyme completed in October 2007@-@-@-@POSTMENOPAUSAL BREAST CANCER – The daily dose given in divided doses should increase stepwise every three days from 240 mg to 480 mg to 720 mg to 960 mg. This dose should be maintained but if it cannot be tolerated it may be reduced to 720 mg/day. From the start of Trilostane therapy a physiological replacement dose of a glucocorticoid should be given, e.g. Hydrocortisone 30 mg/day in divided doses.@Jun-90@@@-@@@Pregnancy should be excluded before beginning treatment and nonhormonal contraceptive methods should be used during therapy where appropriate. As with all drugs that are metabolised by the liver and excreted by the kidney, caution should be exercised when treating patients with gross hepatic or renal impairment. It is advisable to monitor response when treating adrenal cortical hyperfunction, by regular assays of blood electrolytes and circulating corticosteroids, and adjust the dose accordingly. In some patients the suppression of aldosterone production may cause hyperkalaemia and hyponatraemia with subsequent hypotension – under these circumstances a mineralocorticoid should be given, e.g. Fludro-cortisone 0.1 mg/day@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@100%; no NICE review@NHS@NO LABELLED TRIAL@-@@@@-@TRILOSTANE @@@@@TRILOSTANE ||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MODRENAL@@@@@MODRENAL||||@Corticosteroid@@@@@Corticosteroid||||@-@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@100@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/23/2015@@@9.12E+15@CAPSULE@GB£@@@@@@@@120@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921190@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@TNFerade delivered once a week for five weeks by direct intratumoral injection by using endoscopy or Endoscopic Ultrasound. 5-FU (1000 mg/m2/day) will be delivered via continuous infusion for 96 hours during weeks 1 and 4. Cisplatin (75 mg/m2) will be delivered on Day 1 and Day 29 intravenously. The dose of radiation delivered will be 45 Gy in 1.8 Gy fractions for 5 weeks.@@-@-@-@-@@@@@14921190@Combo with 5-FU, cisplatin and radiation therapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00051480@N/A@-@-@@@-@@@-@GV-001.005@@-@-@@@II@II@@-@-@Overall patient survival for all dose levels is currently 83% at 18 months and 64% at 24 months, which compares favorably to six comparable recent studies showing one-year survival rates of 52% and five comparable recent studies showing two-year survival of 33%. Patients who received lower doses of TNFerade had lower risk of toxicity, while pathologic complete responses were achieved in 36 percent of resected patients who received the three highest doses. Study investigators concluded that TNFerade may reduce the rate of disease progression and recurrence in patients with locally advanced resectable esophageal cancer. SOURCE: GenVec, 23 May 2006@-@@@@COMBO@-@CISPLATIN@@@@-|CISPLATIN|||@GENVEC@@@@@GENVEC||||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@TNFERADE@@@@@TNFERADE||||@Gene Therapy@@@@@Gene Therapy||||@RESPONSE RATE@@@@@@@@@@LOCALLY ADVANCED@@@@@SINGLE-ARM@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921741@Onco@@@@@300f1015ntsdm@@@@@@-@@L01XX19@L01X@-@NEW YORK, NEW YORK@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14921741@Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants@@-@-@@NO REVIEW@@@@-@Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan@-@NCT00138060@75@-@-@@@-@@6/1/2005@-@COLOGEN@@-@"Has provided written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time without prejudice 
Ages between 18 and 85 years 
Histologically confirmed colorectal cancer 
No treatment for metastatic disease "@@@IV@IV@@-@BNF@RESULTS PENDING@-@@@@COMBO@IRINOTECAN@FLUOROURACIL@FOLFIRI@@@IRINOTECAN|FLUOROURACIL|FOLFIRI||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CAMPTOSAR@CAMPTO@5-FU@@@CAMPTOSAR|CAMPTO|5-FU||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RESPONSE RATE@-@@@@TOXICITY@PHARMACOKINETICS@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921534@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921534@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@YES@5-May@@NO REVIEW@@@@@@@@@In adults : Navelbine is usually given at 25-30mg/m² weekly. It may be administered by slow bolus (5-10 minutes) after dilution in 20-50 ml of sodium chloride 9 mg/ml (0.9%) solution for injection or in 5% glucose solution for injection. Administration should always be followed with at least 250 ml of an isotonic solution to flush the vein. Advanced non-small cell lung cancer and advanced breast cancer - In monotherapy the usual dose given is 25-30 mg/m² once weekly.@Apr-89@@@No@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@EXPIRED@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@MONO@VINORELBINE TARTRATE@@@@@VINORELBINE TARTRATE||||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@ADVANCED@REFRACTORY@@@@@@@@@@@Invalid Factory Price@@@1@year@1 year@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9137172T@INJECTABLE SOLUTION, 1 ML@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916393@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receiving FOLFIRI or irinotecan as second-line treatment for mCRC@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the bindingof ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-inducedreceptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth,induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, andinternalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits thegrowth and survival of selected human tumor cell lines expressing EGFR.@@14916393@Skin toxicities in patients receiving second-line FOLFIRI or irinotecan with Vectibix@@@@@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@SECOND-LINE@NCT00332163@100@@@@@@@4/1/2006@@STEPP@@PATENT STATUS REMAINS IN DISPUTE; AMGEN LICENSED THE SCHLESSINGER PATENT ('866) UNTIL 2017 IN SEPTEMBER 2006 FROM YEDA.@@@@II@II@@@@RESULTS PENDING (recruiting).@@@@@COMBO@PANITUMUMAB@LEUCOVORIN@FLOROURACIL@IRINOTECAN@@PANITUMUMAB|LEUCOVORIN|FLOROURACIL|IRINOTECAN|@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@Supportive Care@@@@Colorectal Cancer|Supportive Care||||||||@VECTIBIX@FOLFIRI@@@@VECTIBIX|FOLFIRI|||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@SKIN TOXICITIES@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@RANDOMISED@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15045772@Onco@@@@@300f1015ntsdm@@@@@@@@L03AA02@L03A@@JERUSALEM, ISRAEL@@@Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. NEUPOGEN containing rmetHuGCSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes. In some severe chronic neutropenia patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dosedependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.@@15045772@Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. It is indicated for the mobilisation of peripheral blood progenitor cells (PBPC). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. It is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.@@NO@@@NO REVIEW@@@@@@@@@@EMA, 16 September 2008@9/16/2008@3/4/2010@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@@FILGRASTIM@@@@@FILGRASTIM||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@TEVAGRISTIM@BIOSIMILAR@@@@TEVAGRISTIM|BIOSIMILAR|||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@98.09@118.83@104.64@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@98.09@98.09@3.40E+12@INJECTABLE SOLUTION FOR PERFUSION, 0.8 ML@EURO@@@@@@@@480@MCG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918272@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@BASEL, SWITZERLAND@@@@@14918272@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Sandoz is the generics subsidiary of Novartis.@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@NOVARTIS@SANDOZ@@@@NOVARTIS|SANDOZ|||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@3.46@15.36@4.27@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.03@0.03@860808@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921807@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV homoharringtonine with oral Gleevec@@-@-@-@GEELONG, AUSTRALIA@@@Omacetaxine mepesuccinate (formerly known as Ceflatonin, homoharringtonine or HHT) is a first-in-class small molecule with established clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, and induces apoptosis by inhibition of protein synthesis, particularly Mcl-1. As omacetaxine acts independently of tyrosine kinase inhibitors, it has therapeutic advantages for patients who have developed resistance to tyrosine kinase inhibitor therapy. Omacetaxine is administered subcutaneously.@@14921807@Chronic, accelerated and blast phase CML@@-@-@@NO REVIEW@@@@-@ChemGenex acquires global patent portfolio and full European rights to omacetaxine mepesuccinate from Stragen Pharma. Stragen remains supplier of the drug and significant shareholder in ChemGenex. SOURCE: ChemGenex, 10 June 2008Available for partnering. In June 2005, ChemGenex exclusively licensed the global rights to Stragen's patented manufacturing process for a semi-synthetic highly purified form of homoharringtonine. ChemGenex now has access to Stragen's manufacturing proces@-@-@77@-@>> FDA accepts NDA [10 November 2009 Chemgenex http://www.chemgenex.com/wt/page/pr_1257805219 ]>>FDA: Fast-track awarded in November 2006 for chronic, accelerated and blast-phase CML who have failed previous therapy. Orphan drug designation since March 2006.@11/10/2009@@-@@6/1/2005@-@CGX-635-CML-201@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OMACETAXINE MEPESUCCINATE@IMATINIB@@@@OMACETAXINE MEPESUCCINATE|IMATINIB|||@CHEMGENEX@@@@@CHEMGENEX||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@OMAPRO@GLEEVEC@@@@OMAPRO|GLEEVEC|||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@HAEMATOLOGIC RESPONSE@RESPONSE RATE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918842@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@J07BM01@J07B@@WHITEHOUSE STATION, NEW JERSEY@@@Gardasil is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response. HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN 1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.@@14918842@Vaginal and vulvar cancer@@NO@@@NO REVIEW@@@@@extra-Australia rights licensed from CSL@@@@@FDA, 12 September 2008@9/12/2008@@@@@@@No@FIRST PATENT EXPIRES IN 2017.@@@@@APPROVED@@@@RESULTS PENDING@@@@@@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@GARDASIL@@@@@GARDASIL||||@Vaccine@@@@@Vaccine||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@160.38@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/3/2017@160.38@160.38@00006-4045-00@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15412807@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"DFP-13318, Experimental, Stage 1: intravenous infusion once every 3 weeks
Stage 2: intravenous infusion once every 4 weeks
"@@@@@@12/1/2017@@@@15412807@A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors@Both@@@@@@@@@@@NCT02646852@72@@@@@@@1/1/2016@@D15-11073@@@Patients must have histologically (or cytologically)-confirmed diagnosis of solid tumor, refractory after standard therapy for the disease or for which conventional systemic therapy is not reliably effective or no effective therapy is available.  -  Aged ≥ 18 years.  -  ECOG Performance Status of 0 or 1.  -  Adequate clinical laboratory values defined as:  -  absolute neutrophil count ≥ 1.5x10^9/L  -  platelets ≥ 100x10^9/L  -  hemoglobin ≥ 9.0 g/dL (transfusions permissible)  -  plasma creatinine ≤ 1.5 x upper limit of normal (ULN) for the institution or calculated clearance ≥ 60 mL/min (Cockcroft-Gault formula)  -  bilirubin ≤ 1.5 x ULN  -  alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN (< 5 x ULN if documented hepatic metastases)  -  Serum sodium, potassium, magnesium and calcium within normal limits for the institution (supplements may be given to correct values)  -  Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.  -  Patients may have measurable or non-measurable disease as defined by RECIST 1.1.  -  Signed informed consent prior to the start of any study specific procedures.  -  Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.@@ADULTS@Phase 1@I@@@@@@@@@@-@@@@@-||||@DELTA-FLY PHARMA@@@@@DELTA-FLY PHARMA||||@United States@@@@@United States|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@DFP-13318@@@@@DFP-13318||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@@@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921804@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BASEL, SWITZERLAND@@@HCD122 is a fully human anti-CD40 antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases.  The antibody has a dual mechanism of action that involves blocking tumor cell growth and survival signals while recruiting immune effector cells to kill tumor cells through a process known as antibody-dependent cellular cytotoxicity (ADCC). @@14921804@Advanced Chronic Lymphocytic Leukemia That is Refractory or Relapsed After Prior Treatment@@-@-@@NO REVIEW@@@@-@>> XOMA and Novartis restructure their 2004 co-development deal; Novartis will pay US$6.2 million upfront and fund all future R&D plus additional milestones/royalties - Novartis receives control of the programme and expand into therapeutic areas beyond oncology. [Novartis, 11.11.2008]             >> HCD122 is the first product candidate selected under the multi-product antibody development and commercialization agreement for the treatment of cancer announced by Chiron (now Novartis) and Xoma, and initiated in March of 2004.@-@NCT00108108@40@-@-@@@-@@@-@CHCD122A2101@@-@-@@@I@DISCONTINUED@@-@-@>> Trial terminated [Novartis, 15.07.2008]>> Trial registered [Novartis, 14.04.2005]@-@@@@-@-@@@@@-||||@NOVARTIS@XOMA@@@@NOVARTIS|XOMA|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@HCD-122@@@@@HCD-122||||@mAb@CD40@@@@mAb|CD40|||@SAFETY@PHARMACOKINETICS@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918253@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@ULM, GERMANY@@@@@14918253@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@1.22@12.53@1.96@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@@@1675496@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921379@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Administered as a weekly 2-hour infusion@@-@-@-@BRIDGEWATER, NEW JERSEY@4/1/2009@@HIF-1 ALPHA ANTAGONIST@@14921379@Advanced Solid Tumors or Lymphoma @@-@-@@NO REVIEW@@@@-@Enzon will spin-off its novel biotechnology business from Enzon in a transaction that will result in two independent and highly focused public companies. Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to current PEG royalty revenues, including PEG-Intron, Cimzia and Hematide, and the manufacturing facility in Indianapolis. SOURCE: Enzon, 7 May 2008Extra-Nordic rights licensed from NatImmune in October 2005. SOURCE: Enzon, 3 October 2005@-@NCT00466583@40@-@-@@@-@@3/1/2007@-@EZN-2968-01@@-@Histologically or cytologically confirmed diagnosis of advanced and/or metastatic solid tumor or lymphoma (Hodgkin's or non-Hodgkin's) Patients who have failed standard therapy and have no known effective therapy available to them@ADULT@@I@I@@-@-@Trial registered. SOURCE: Enzon, 25 April 2007@-@@@@MONO@-@@@@@-||||@ENZON@@@@@ENZON||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@Solid Tumours@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Solid Tumours||||||@EZN-2968@@@@@EZN-2968||||@HIF-targeting@@@@@HIF-targeting||||@MAXIMUM TOLERATED DOSE@@@@@SAFETY@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16643266@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@16643266@Indicated for the treatment of wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use In combination with FOLFOX for first-line treatment.@@@@@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@FIRST-LINE@@656@The recommended dose of Vectibix is 6 mg/kg, administered as an intravenous infusion over 60 minutes, every 14 days.@FDA, 23 May 2014@5/23/2014@@No@@@@@No@@@@@@APPROVED@@@@@@@@@COMBO@PANITUMUMAB@OXALIPLATIN@LEUCOVORIN@FLUOURACIL@@PANITUMUMAB|OXALIPLATIN|LEUCOVORIN|FLUOURACIL|@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@FOLFOX@@@@VECTIBIX|FOLFOX|||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@76.5@kg@110472.3117@@@9.6@month@9.6 month@110472.31@110472.31@378.34@1@1@4615.89@@@@@@@@@@@@11.54@14@@mg/kg@6@1@@@@@@@@@@@8/2/2017@4615.89@4615.89@55513-0956-01@INJECTION - 20 ML@US$@@@@@@@@400@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916398@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Sprycel 70mg@@L01XE06@L01X@-@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14916398@Chronic phase CML@@NO@-@@NO REVIEW@@@@-@-@-@-@387@-@-@@@-@@@-@START-C  @@APRIL 2020 ('746); PATENT EXTENSION FILED.@387 PATIENTS WITH GLEEVEC-RESISTANT/INTOLERANT CML@@@CA180013@II@@-@-@ASH December 2006; interim results of 186 patients reported complete haematological response of 90% and major cytogenic response of 45%. An updated analysis of 387 patients showed91% CHR and 59% MCyR. Of the 288 patients with Gleevec-resistance, 52% achieved MCyR compared 80% of the 99 patients with intolerance.@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@INTERNATIONAL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920851@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@V03AF03@V03A@NO@MADISON, NEW JERSEY@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14920851@Leucovorin is used in cytotoxic therapy as an antidote to folic acid antagonists such as methotrexate. Leucovorin is effective in the treatment of megaloblastic anaemia.@@NO@@@NO REVIEW@@@@90%@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenous injection.@1-Mar-96@3/1/1996@4/22/1986@@@@Leucovorin rescue: Depending upon the dose of methotrexate administered, dosage regimens of leucovorin calcium vary. Up to 120 mg leucovorin calcium are generally given, usually in divided doses over 12-24 hours by intramuscular injection, bolus intravenous injection or intravenous infusion in normal saline. This is followed by 12-15 mg intramuscularly or 15 mg orally every 6 hours for 48 hours. Rescue therapy is usually started 24 hours after the commencement of methotrexate administration. Megaloblastic anaemia (folate deficiency): 15 mg (one tablet) leucovorin per day.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@LEDERFOLIN@@@@@LEDERFOLIN||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@5.76@8.99@6.22@@@@@@@@@@0.04@@@@@@@@@@@@@@@@8/4/2017@0.58@0.58@963470@TABLET@EURO@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921046@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01XX23@L01X@YES@NEW YORK, NEW YORK@@@@@14921046@Indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types.@@NO@@@NO REVIEW@@@@@@@@@The recommended treatment schedule is to start the patient at 2 to 6 g per day in divided doses, either three or four times a day. Doses are usually increased incrementally to 9 to 10 g per day. If severe side effects appear, the dose should be reduced until the maximum tolerated dose is achieved. If the patient can tolerate higher doses and improved clinical response appears possible, the dose should be increased until adverse reactions interfere. Experience has shown that the maximum tolerated dose (MTD) will vary from 2 to 16 g per day, but has usually been 9 to 10 g per day. The highest doses used in the studies to date were 18 to 19 g per day.@FDA, 08 July 1970@7/8/1970@@@@@Lysodren should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents. It should be temporarily discontinued immediately following shock or severe trauma since adrenal suppression is its prime action. Exogenous steroids should be administered in such circumstances, since the depressed adrenal may not immediately start to secrete steroids.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@MITOTANE@@@@@MITOTANE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@LYSODREN@@@@@LYSODREN||||@Other@@@@@Other||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1@479.95@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@4.8@4.8@00015-3080-60@TABLET@US$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918789@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@LAKE FOREST, ILLINOIS@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14918789@Methotrexate is indicated in the treatment of neoplastic disease, such as trophoblastic neoplasms and leukaemia, and the symptomatic treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy.@@NO@@@NO REVIEW@@@@100%@Via takeover of Mayne Pharma@@@@Leukaemia: Acute granulocytic leukaemia is rare in children but common in adults and it is not particularly sensitive to methotrexate but responds to other combination chemotherapy agents. Methotrexate is not generally a drug of choice for induction of remission of lymphoblastic leukaemia. After a remission is attained, methotrexate in a maintenance dosage of 20-30mg/m2 by I.M. injection has been administered twice weekly. Twice weekly doses appear to be more effective than daily drug administration. Alternatively, 2.5mg/kg has been administered I.V. every 14 days.@@@@@@@Methotrexate should be used with extreme caution in patients with haematological depression, renal impairment, diarrhoea, ulcerative disorders of the GI tract and psychiatric disorders. Hepatic toxicity has been observed, usually associated with chronic hepatic disease. Renal lesions may develop if the urinary flow is impeded and urinary pH is low, especially if large doses have been administered. The administration of low doses of methotrexate for prolonged periods may give rise, in particular, to hepatic toxicity. Particular care and possible cessation of treatment are indicated if stomatitis or GI toxicity occurs as haemorrhagic enteritis and intestinal perforation may result.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Sarcoma@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|Sarcoma|||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.299@35@@@@@@@@@@@@0.14@@@@@@@@@@@@@@@@7/28/2017@7@7@3.61E+15@INJECTION@GB£@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916813@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@L01DC01@L01D@YES@LAKE FOREST, ILLINOIS@@@@@14916813@It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's Disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. February 1996: has also been shown to be useful in the management of malignant pleural effusion and prevention of recurrent pleural effusions.@@NO@@@NO REVIEW@@@@@Acquired via Mayne@@@@Hodgkin's Disease—0.25 to 0.50 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly. After a 50% response, a maintenance dose of 1 unit daily or 5 units weekly intravenously or intramuscularly should be given. Pulmonary toxicity of Blenoxane appears to be dose-related with a striking increase when the total dose is over 400 units. Total doses over 400 units should be given with great caution.@@@@@@@It is recommended that Blenoxane be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Pulmonary fibrosis is the most severe toxicity associated with Blenoxane. The most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis. Its occurrence is higher in elderly patients and in those receiving greater than 400 units total dose, but pulmonary toxicity has been observed in young patients and those treated with low doses. A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in approximately 1% of lymphoma patients treated with Blenoxane.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@92.23@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@92.23@92.23@61703-0323-22@POWDER FOR INJECTION@US$@@@@@@@@30@U@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921983@Onco@@@@@300f1015ntsdm@@@@@@Infusion, I.V., Ixabepilone 40mg/m², trastuzumab 2mg/kg (loading dose=4mg/kg), cycle = 21days, duration of combination therapy approx 10 cycles. Trastuzumab might continue up to 38 months OR Infusion, I.V., docetaxel 100mg/m², trastuzumab 2mg/kg (loading dose=4mg/kg), cycle = 21days, duration of combination therapy approx 10 cycles. Trastuzumab might continue up to 38 months. SOURCE: clinicaltrials.gov@@L01C@L01C@-@NEW YORK, NEW YORK@3/1/2011@@Ixabepilone is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to ß-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of  ß-II and  ß-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.@@14921983@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00490646@80@-@-@@@-@@1/1/2008@-@CA163-140@@-@-@@@II/III@II@@-@-@RESULTS PENDING@-@@@@COMBO@IXABEPILONE@TRASTUZUMAB@@@@IXABEPILONE|TRASTUZUMAB|||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IXEMPRA@BMS-247550@HERCEPTIN@@@IXEMPRA|BMS-247550|HERCEPTIN||@Epothilone@@@@@Epothilone||||@RESPONSE RATE@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922347@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ARM A: Carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles/ paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles/ bevacizumab 15 mg/kg intravenously day 1 of each 21 day cycles x 6 cycles and then every 21 days until disease progression of unacceptable toxicity/ PF-3512676 0.2 mg/kg subcutaneously on Days 8, 15 of each 21 day cycle x 6 cycles then weekly until disease progression of unacceptable toxicity. ARM B: Paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles/ carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles/ bevacizumab 15 mg/kg intravenously day 1 of each 21 day cycles x 6 cycles and then every 21 days until disease progression of unacceptable toxicity. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@6/1/2009@@@@14922347@Locally advanced or metastatic NSCLC with carboplatin, paclitaxel and Avastin@@-@-@@NO REVIEW@@@@-@In May 2005, Pfizer licensed global rights for NSCLC and breast cancer from Coley; Pfizer subsequently bought Coley in November 2007. @FIRST-LINE@NCT00313768@140@-@-@@@-@@12/1/2005@-@A8501003@@-@-@@@II@DISCONTINUED@@-@-@June 2007; interim analysis of Phase III data by DSMC showed no evdience of clinical efficacy over standard cytotoxic chemo alone; risk-benefit profile did not justify continuation.@-@@@@COMBO@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PF-3512676@CPG-7909@@@@PF-3512676|CPG-7909|||@TLR-targeted@Immunotherapy@Vaccine@@@TLR-targeted|Immunotherapy|Vaccine||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916786@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@For patients electing to receive the drug on a long-term basis@@-@-@-@HAMILTON, BERMUDA@@@Xerecept (corticorelin acetate injection) is a synthetic preparation of the natural human peptide CRF. In preclinical studies, it has been demonstrated to be an inhibitor of swelling, or edema. The compound is being developed for its ability to reduce peritumoral brain edema (swelling in the brain due to a tumor), a dangerous complication of brain cancer. It has the potential to be safer than synthetic corticosteroids, the existing standard treatment for cerebral edema, that have serious adverse effects at the chronic high doses required for efficacy. @@14916786@Extended-Use for Patients in Studies NTI 0302, 0303, or Other Designated Studies@@-@-@@NO REVIEW@@@@-@Rights sold to Celtic Pharma in November 2005@-@NCT00226655@320@-@ORPHAN DRUG; FDA FILING EXPECTED IN 2008@@@ORPHAN DRUG; FDA FILING EXPECTED IN 2008@@@-@NTI0501@@-@-@@@OPEN-LABEL, EXTENDED USE OF XERECEPT@III@@-@-@June 2007 updated results; 20 patients (67%) reduced dexamethasone dosing and 8 (27%) discontinued dexamethasone out of the first 30 to complete 12 weeks of treatment. November 2006; results showed that of the 20 PBE patients with primary or secondary metastatic brain tumours who received at least four weeks of corticorelin therapy, 11 patients reduced their dexamethasone dosage and two patients did not take concomitant dexamethasone. Amelioration or resolution of steroid-related conditions was seen in 45% of patients with these conditions at baseline. @-@@@@-@CORTECORELIN ACETATE@@@@@CORTECORELIN ACETATE||||@CELTIC PHARMA@NEUROBIOLOGICAL TECHNOLOGIES@@@@CELTIC PHARMA|NEUROBIOLOGICAL TECHNOLOGIES|||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@XERECEPT@@@@@XERECEPT||||@Immunotherapy@Synthetic Peptide@@@@Immunotherapy|Synthetic Peptide|||@KARNOFSKY SCALE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918119@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA01@L01X@YES@BASEL, SWITZERLAND@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14918119@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@@@@NO REVIEW@@@@@@@@@For monotherapy, the following two dosage regimens are recommended:- Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; - 15 to 20 mg/m²/day for five days, every 3 to 4 weeks. If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks.@1-Apr@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Ovarian Cancer@Testicular Cancer@Bladder Cancer@@@Ovarian Cancer|Testicular Cancer|Bladder Cancer|||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918180@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XX05@L01X@NO@BASEL, SWITZERLAND@@@@@14918180@The treatment of chronic myeloid leukaemia. The treatment of cancer of the cervix in conjunction with radiotherapy.@@@@@NO REVIEW@@@@@Sandoz is the generics subsidiary of Novartis.@@@@Continuous therapy: Hydrea 20-30mg/kg should be given daily in single doses. Dosage should be based on the patient's actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts. Intermittent therapy: Hydrea 80mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Hydrea should be omitted.@1-Nov-05@11/1/2005@@@@@The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide therapy. If WBC falls below 2.5x109/L or platelet count to <100x109/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal. Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@HYDROXYCARBAMIDE@@@@@HYDROXYCARBAMIDE||||@NOVARTIS@SANDOZ@@@@NOVARTIS|SANDOZ|||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Cervical Cancer@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Cervical Cancer|||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@@@@@Anti-metabolite||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@20@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+24@CAPSULE@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916203@Onco@@@@@300f1010ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916203@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@NO NICE REVIEW@NHS@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.2961@21.05@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.02@7.02@2.69E+15@LOZENGE@GB£@@@@@@@@200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921965@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@LONDON, UNITED KINGDOM@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14921965@@@NO@@@NO REVIEW@@@@90%@@@@N/A@@1/1/1998@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@III; METASTATIC BREAST CANCER@DISCONTINUED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NOLVADEX@@@@@NOLVADEX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@30@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/2/2015@@@662007@TABLET@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14917406@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917406@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90%@Teva acquires Barr. SOURCE: Teva, 21 July 2008@@@@Malignant Melanoma: Dacarbazine can be administered as single agent in doses of 200 to 250 mg/m² body surface area/day as an i.v. injection for 5 days every 3 weeks. As an alternative to an intravenous bolus injection dacarbazine can be administered as a short-term infusion (over 15 - 30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as intravenous infusion.@13-Dec-06@12/13/2006@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@PLIVA@BARR PHARMACEUTICALS@TEVA PHARMACEUTICAL@@@PLIVA|BARR PHARMACEUTICALS|TEVA PHARMACEUTICAL||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@DTIC-DOME@@@@@DTIC-DOME||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@10@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14918676@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918676@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@NO@@@NO REVIEW@@@@100%@@@@@Adult soft tissue sarcoma: For adult soft tissue sarcomas dacarbazine is given in daily doses of 250 mg/m2 body surface area i.v. (days 1-5) in combination with doxorubicin every 3 weeks (ADIC regimen). Restriction of food intake for 4-6 hours prior to treatment may reduce the severity of the nausea and vomiting which occurs in most patients particularly during the first two days of treatment. Because severe gastrointestinal and haematological disturbances can occur an extremely careful benefit-risk analysis has to be made before every course of therapy with dacarbazine.@EMA, November 1997@@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.299@90@@@@@@@@@@@@0.09@@@@@@@@@@@@@@@@7/28/2017@9@9@7.32E+15@POWDER FOR SOLUTION FOR INJECTION VIAL@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921045@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01X@L01X@YES@@@@@@14921045@Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.@@YES@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 40% TO 60% DEPENDING ON REVENUES, PREVIOUSLY 60% FUNDED@@@@@Treatment should be started with 2-3 g of Lysodren per day and increased stepwise until mitotane plasma level reaches the therapeutic window with acceptable safety, which usually corresponds to a cumulative dose of 75 g. The total daily dose may be divided in two or three doses according to patient's convenience, and the treatment should be preferably taken during meals.@2-Aug-04@8/2/2004@3/1/2005@@@@Before the initiation of the treatment: All possible tumour tissues should be surgically removed from large metastatic masses before mitotane administration is instituted. This is necessary to minimise the possibility of infarction and haemorrhage in the tumour due to a rapid cytotoxic effect of mitotane. Shock, severe trauma or infection: Mitotane should be temporarily discontinued immediately following shock, severe trauma or infection, since adrenal suppression is its prime action. Exogenous steroids should be administered in such circumstances, since the depressed adrenal gland may not immediately start to secrete steroids. Because of an increased risk of acute adrenocortical insufficiency, patients should be instructed to contact their physician immediately if injury, infection, or other illness occurs. Patients should carry with them the card provided with the package leaflet indicating that they are prone to adrenal insufficiency and that in case of emergency care, adequate precautionary measures should be taken. Monitoring of plasma levels: Mitotane plasma levels should be monitored in order to adjust the Lysodren dose. It may be especially recommended in cases where administration of higher starting doses is considered necessary (e.g. in highly symptomatic patients) to reach the desired therapeutic levels more rapidly. The therapeutic window of mitotane lies between 14 mg/l and 20 mg/l. A dose adjustment may be necessary to achieve the correct therapeutic level and avoid specific adverse reactions. Mitotane plasma levels higher than 20 mg/l may be associated with severe undesirable effects and offer no further benefit in terms of efficacy.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@MITOTANE@@@@@MITOTANE||||@HRA PHARMA@@@@@HRA PHARMA||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@LYSODREN@@@@@LYSODREN||||@Other@@@@@Other||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@600@682.15@607.54@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@6@6@760629@TABLET@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919047@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@400mg Zolinza once-daily@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (ClassI) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removalof acetyl groups from the lysine residues of proteins, including histones and transcription factors. In somecancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenictranscription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones isassociated with a condensed chromatin structure and repression of gene transcription. Inhibition ofHDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in anopen chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation ofacetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. Themechanism of the antineoplastic effect of vorinostat has not been fully characterized.@@14919047@Advanced refractory CTCL@@-@-@@NO REVIEW@@@@-@-@-@-@74@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@July 2007 JCO; objective RR was 29.7%; median TTP was 4.9 months@-@@@@-@VORINOSTAT@@@@@VORINOSTAT||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@CTCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|CTCL||||||@ZOLINZA@@@@@ZOLINZA||||@HDAC@@@@@HDAC||||@RESPONSE RATE@@@@@@@@@@ADVANCED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916050@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@HOLZKIRCHEN, GERMANY@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14916050@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@5-FU HEXAL@@@@@5-FU HEXAL||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR INJECTION (20 ML)@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917098@Onco@@@@@300f1008ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@@@@@@14917098@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Merger between Kyowa Hakko and Kirin Pharma announced in October 2007.@@@@Malignant lymphomas: Used alone the recommended dosage regime is 15 x 10³ IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 10³ IU (15 vials). Dosage should be reduced in the elderly. The dose may need to be adjusted when bleomycin is used in combination chemotherapy.@@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHI@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@KYOWA HAKKO KOGYO@KIRIN PHARMA@@@@KYOWA HAKKO KOGYO|KIRIN PHARMA|||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||||@BLEO@@@@@BLEO||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@0.0091@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14919345@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@ULM, GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919345@@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@13.6@28.18@14.73@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.14@0.14@3572257@TABLET@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384684@Onco@@@@@300f1010ntsdm@@@@@@@@L01CD02@L01C@@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@16384684@TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.@@@@@NO REVIEW@@@@@@SECOND-LINE@@@For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent. Docetaxel is administered as a one-hour infusion every three weeks.@@@@@@@@@No@@@@@@APPROVED@@@NHS@@@@@@MONO@DOCETAXEL@@@@@DOCETAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@LOCALLY ADVANCED@UNRESECTABLE@@@@@@@@@1.75@m²@3392.003668@@@12.3@week@12.3 week@3392@3392@39.4@1@1.299@1008.54@@@@@@@@@@@@6.3@21@@mg/m²@75@1@@@@@@@@@@@7/28/2017@1008.54@1008.54@1.83E+16@CONCENTRATE FOR SOLUTION FOR INFUSION, 8 ML@GB£@@@@@@@@160@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16387797@Onco@@@@@300f1037ntsdm@@@@@@@@L02BG03@L02B@@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@16387797@Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.@@NO@@@NO REVIEW@@@@90%@@SECOND-LINE@@2579@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@EMA, 27 December 1996@12/27/1996@@@@@@@No@@@@@III@APPROVED@@@SNS@@@@@@ADJUVANT@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@EARLY@@@@@CONTROLLED@DOUBLE-BLIND@@@@1@1@1003.466666@@@24@month@24 month@1003.47@1003.47@1.37@28@1.1511@38.49@60.09@41.69@@@@@@@@@@1.37@1@@mg@1@1@@@@@@@@@@@8/4/2017@1.37@1.37@754465@FILM-COATED TABLET@EURO@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14916189@Onco@@@@@300f1010ntsdm@@@@@@"Patients are stratified according to stage of disease (locally advanced vs metastatic) and ECOG performance status (0 vs 1 vs 2). Patients are randomized to 1 of 3 treatment arms. 
>> Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.  
>> Arm II: Patients receive gemcitabine hydrochloride and capecitabine as in arm I. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sargramostim (GM-CSF) intradermally (ID) and telomerase peptide vaccine GV1001 ID on days 1, 3, and 5 in week 9, once a week in weeks 10-12 and 14, and then once a month in the absence of disease progression or unacceptable toxicity. Patients who develop disease progression while on vaccine therapy, discontinue vaccine therapy and then restart treatment with gemcitabine hydrochloride and capecitabine. Patients receive gemcitabine hydrochloride and capecitabine as above and continue treatment in the absence of further disease progression or unacceptable toxicity.  
>> Arm III: Patients receive gemcitabine hydrochloride and capecitabine as in arm I. Patients also receive GM-CSF ID and telomerase peptide vaccine GV1001 ID on days 1, 3, and 5 in week 1, once weekly in weeks 2, 3, 4 and 6, and then once a month in the absence of disease progression or unacceptable toxicity. 
Quality of life is assessed at baseline and at 8 weeks and then every 12 weeks during study treatment. [Gemvax]"@@-@-@-@SOUTH KOREA@@@-@@14916189@Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer@@-@-@@NO REVIEW@@@@-@KAEL Co, through its subsidiary VaxOnco, will acquire GemVax from Pharmexa, including GV-1001. Financial details not disclosed. [KAEL, 31.10.2008]@-@NCT00425360@1110@-@-@@@-@@9/1/2006@-@TELOVAC@@-@">> Histologically or cytologically confirmed pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas    
>> Locally advanced or metastatic disease precluding curative surgical resection "@@@III@III@@-@-@Trial registered [Gemvax, 19.01.2007]@-@@@@-@-@GEMCITABINE@CAPECITABINE@@@-|GEMCITABINE|CAPECITABINE||@KAEL CO.@PHARMEXA@@@@KAEL CO.|PHARMEXA|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@GV-1001@@@@@GV-1001||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@1-YEAR SURVIVAL@@@@@TIME TO PROGRESSION@QUALITY OF LIFE@OVERALL SURVIVAL@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918245@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@LEICHINGEN, GERMANY@@@@@14918245@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@ALIUD PHARMA@@@@@ALIUD PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@1.2@12.5@1.94@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@@@3399818@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924729@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Sprycel versus standard dose Gleevec (400mg)@@L01XE06@L01X@-@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14924729@Chronic phase Ph+ CML; trial started in September 2007@@NO@-@@NO REVIEW@@@@-@-@-@NCT00481247@518@-@-@@@-@@9/1/2007@-@-@@APRIL 2020 ('746); PATENT EXTENSION FILED.@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@CYTOGENIC RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15413038@Onco@@@@@300f1018ntsdm@@@@@@Olaratumab + Gemcitabine + Docetaxel (Dose Escalation), Experimental, Olaratumab intravenously (IV) on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.Olaratumab + Gemcitabine + Docetaxel, Experimental, Olaratumab IV on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.Placebo + Gemcitabine + Docetaxel, Placebo Comparator, Placebo IV on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.@@@@@INDIANAPOLIS, INDIANA@@@@@15413038@A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma@Both@@@@@Administered IV@@@@@@NCT02659020@196@@@@@@@@@15839@@@The participant may have no more than 2 prior lines of systemic therapies (neoadjuvant and adjuvant therapies will not be considered as a prior line of therapy) for advanced or metastatic disease and is suitable to receive gemcitabine and docetaxel therapy. All previous therapies must have completed ≥ 4 weeks (28 days) prior to enrollment (Phase 1b) / randomization (Phase 2).  -  Availability of tumor tissue is mandatory for study eligibility. The participant must have consented to provide archived formalin-fixed paraffin-embedded tumor tissue or be subject to a pre-treatment re-biopsy of primary or metastatic tumor tissue for future central pathology review and translational research (if archived tissue is unavailable).  -  The participant has adequate hematologic, organ, and coagulation function within 2 weeks (14 days) prior to enrollment (Phase 1b) or randomization (Phase 2).@COMBO@ADULTS@Phase 1/Phase 2@I@@@@@@@@@@OLARATUMAB@GEMCITABINE@DOCETAXEL@@@OLARATUMAB|GEMCITABINE|DOCETAXEL||@LILLY@@@@@LILLY||||@Australia@Germany@Hungary@Israel@Poland@Australia|Germany|Hungary|Israel|Poland|Spain|United Kingdom|United States||@Sarcoma@@@@@Sarcoma|||||||||@LY3012207@GENERIC@@@@LY3012207|GENERIC|||@mAb@@@@@mAb||||@Recommended Phase 2 Dose of Olaratumab: Number of Participants with Dose Limiting Toxicity (DLT)@Overall Survival (OS)@@@@Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Olaratumab@PK: Minimum Serum Concentration (Cmin) of Olaratumab@@@@@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@Double Blind (Subject,  Investigator)@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916237@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14916237@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@@@@@For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg daily for two or three days is advisable together with a high fluid intake. Otherwise similar considerations to the above recommendations for treating patients with gout govern the regulation of dosage for maintenance purposes in secondary hyperuricemia.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Covered; preferred@MEDICARE@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@HARVARD DRUG GROUP@@@@@HARVARD DRUG GROUP||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@100@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00904-2613-61@TABLET (UD)@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921695@Onco@@@@@300f1014ntsdm@@@@@@CPI-613 given twice weekly for three consecutive weeks. [Cornerstone]@@-@-@-@CRANBURY, NEW YORK@10/1/2009@@CPI-613 targets distinctive changes in the energy generating processes associated with the vast majority of solid tumor types, according to preclinical studies. CPI-613 has shown possible utility in multiple preclinical studies including studies conducted using human tumor biopsies from patients bearing lung, colon, pancreatic and breast tumors as well as cancer cell lines resistant to traditional chemotherapeutics. CPI-613 represents a subclass of compounds from Cornerstone’s AEMD platform which the company has named “Thioctans,” and which it believes kill cancer cells by an entirely new and highly selective mechanism. @@14921695@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00741403@40@-@-@@@FDA orphan drug for pancreatic cancer@@8/1/2008@-@CPI-613-002@@-@">> Karnofsky Performance Status (KPS) > 70%. 
>> Expected Survival > 3 months. 
>> Advanced or metastatic, histologically or cytologically documented solid tumors, lymphomas, for which there is no available therapy shown to provide clinical benefit."@@@I/II@II@@-@-@">> Trial registered. [Cornerstone, 25.08.2008]
>> FDA approves initiation of Phase I/II trial. [Cornerstone, 24 July 2008]"@-@@@@MONO@-@@@@@-||||@CORNERSTONE PHARMACEUTICALS@@@@@CORNERSTONE PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@Pancreatic Cancer@@@@Solid Tumours|Pancreatic Cancer||||||||@CPI-613@@@@@CPI-613||||@Other@@@@@Other||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922705@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Temsirolimus intravenously every week of each 28-day cycle (days 1, 8, 15 and 22) with gemcitabine intravenously every other week of each 28-day cycle. @@-@-@-@MADISON, NEW JERSEY@10/1/2009@@Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In invitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.@@14922705@Previously untreated metastatic pancreatic cancer@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@FIRST-LINE@NCT00593008@30@-@-@@@-@@10/1/2007@-@07-115@@2012 (EXCLUSIVITY); APRIL 2014 (EXTENSION)@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@TEMSIROLIMUS@GEMCITABINE@@@@TEMSIROLIMUS|GEMCITABINE|||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@TORISEL@GEMZAR@@@@TORISEL|GEMZAR|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@DOSE-LIMITING TOXICITY@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921594@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Provenge monotherapy@@-@-@-@SEATTLE, WASHINGTON@@@Sipuleucel–T contains mature, autologous antigen Antigen Presenting Cells (APCs). APCs are obtained from the patient via a standard leukapheresis Leukapheresis procedure approximately two days before each scheduled infusion. The patient's APCs are then transported to a Dendreon manufacturing facility where they are co-cultured with a recombinant fusion protein containing prostatic acid phosphatase (PAP). The activated, antigen-loaded APCs (now sipuleucel–T) are then delivered to the physician's office (infusion site) for infusion into the patient. Sipuleucel–T is then infused into the patient, where it can potentially stimulate a T cell response against prostate cancer cells. The process is performed three times over the course of a four-week period, upon which treatment is completed. @@14921594@Androgen dependent prostate cancer@@-@-@@NO REVIEW@@@@-@-@-@-@17 EVALUABLE @-@-@@@-@@@-@D9905@@-@-@@@II@II@@-@-@AUA May 2005; 71% (12 of 17) evaluable patients had prolongation in PSA doubling time post-treatment with Provenge. They had 52% increase in PSADT (5.2 months to 7.9 months).@-@@@@MONO@SIPULEUCEL-T@@@@@SIPULEUCEL-T||||@DENDREON@@@@@DENDREON||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROVENGE@@@@@PROVENGE||||@Vaccine@Immunotherapy@@@@Vaccine|Immunotherapy|||@PSADT@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923279@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@PARIS, FRANCE@@@@@14923279@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NO@@@NO REVIEW@@@@90%@Licensed from SRI International@@@@Initiation of therapy: is most conveniently carried out in hospital; 0.5ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact.@1-Jul-99@7/1/1999@3/22/1996@@@@Patients known to suffer from depression should be carefully monitored during treatment with Suprefact. Prostatic carcinoma: Monitoring of the effect of clinical effect of Suprefact is carried out by methods generally used in prostatic carcinoma. Initially serum testosterone levels rise and a clinical effect will not be seen until levels start to fall into therapeutic (castration) range. Disease flare (temporary deterioration of the patient's condition) has been reported at the beginning of the treatment. The incidence is variable, but of the order of the 10%. Symptoms are usually confined to transient increase in pain, but the exact nature depends on the site of the lesions. Neurological sequelae have been reported where secondary deposits impinge upon the spinal cord or CNS. Disease flare is prevented by the prophylactic use of an anti-androgen, e.g. cyproterone acetate, 300 mg daily. It is recommended that the treatment should be started at least 3 days before the first dose of Suprefact and continued for at least 3 weeks after commencement of the Suprefact therapy.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SUPREFACT DEPOT@@@@@SUPREFACT DEPOT||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@2@1.1511@171.55@226.16@179.09@@@@@@@@@@13.62@@@@@@@@@@@@@@@@8/4/2017@85.78@85.78@681155@SUBCUTANEOUS  IMPLANT@EURO@@@@@@@@6.3@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921215@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@12 monthly cycles of paclitaxel or Xyotax versus no treatment until relapse.@@-@-@-@SEATTLE, WASHINGTON@@@Opaxio (paclitaxel poliglumex, CT-2103), which was previously branded as Xyotax, is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, paclitaxel is rendered inactive, potentially sparing normal tissue's exposure to high levels of the active drug and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that Opaxio is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that Opaxio metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies. This is being studied in an ongoing phase III trial.@@14921215@Advanced (Stage III or IV) ovarian or primary peritoneal cancer.@@-@-@@NO REVIEW@@@@-@October 2006; Novartis licensed exclusive worldwide development and commercialisation rjghts of Xyotax for up to US$270 million. Novartis also agreed to make a US$15 million equity investment in CTI. CTI will have the option of co-detailing Xyotax in the @-@NCT00108745@-@-@-@@@-@@@-@GOG0212@@-@PATIENTS HAVING RECEIVED 4 TO 6 CYCLES OF PLATINUM-TAXANE THERAPY.@@@II@III@@-@-@RESULTS PENDING@-@@@@MONO@PACLITAXEL POLIGLUMEX@@@@@PACLITAXEL POLIGLUMEX||||@CELL THERAPEUTICS@NOVARTIS@@@@CELL THERAPEUTICS|NOVARTIS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@OPAXIO@XYOTAX@CT-2103@@@OPAXIO|XYOTAX|CT-2103||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@COMPLETE RESPONSE@QUALITY OF LIFE@@@@@@@@@ADVANCED@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924226@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ambrubicin with or without Herceptin@@-@-@-@SUMMIT, NEW JERSEY@12/1/2007@@Amrubicin is a third-generation, synthetic anthracycline analogue that has demonstrated substantial clinical efficacy in the treatment of small cell lung cancer. Amrubicin is a potent topoisomerase II inhibitor and is being studied as a single agent and in combination with anti-cancer therapies for a variety of solid tumors, including lung cancer. Amrubicin is currently approved and marketed in Japan for the treatment of lung cancer by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo Pharma, the original developer of the therapy. Dainippon Sumitomo Pharma also licensed the North American and European Union rights of Amrubicin to Pharmion Corporation, which was acquired by Celgene Corporation in March 2008. Amrubicin has been granted orphan-drug designation for the treatment of small cell lung cancer in both the U.S. and European Union.@@14924226@With or without Herceptin@@-@-@@NO REVIEW@@@@-@Nippon Kayaku licensed Japanese rights from Dainippon Sumitomo; Pharmion acquired North American and European rights to Calsed through takeover of Cabrellis in November 2006.@-@NCT00380835@66@-@-@@@-@@12/1/2006@-@-@@-@-@@@II@DISCONTINUED@@-@-@>> Trial discontinued [Celgene, 22.09.2008]            >> Trial registered [Pharmion, 26.09.2006]@-@@@@BOTH@AMRUBICIN@@@@@AMRUBICIN||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CALSED@@@@@CALSED||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@RECIST@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920087@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@CORONA, CALIFORNIA@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920087@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@@@Regimen 2: 6-wk cycle with infusional 5-FU/LV (next cycle begins on day 43): Camptosar 180mg/m2 IV over 90 minutes on days 1, 15 and 29, followed by dose level 1 (150mg/m2) and 2 (120mg/m2)@FDA, 22 February 2008@2/22/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@COMBO@IRINOTECAN@@@@@IRINOTECAN||||@WATSON PHARMACEUTICALS@@@@@WATSON PHARMACEUTICALS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@5.6@month@5.6 month@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@100@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922635@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@@@14922635@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@FDA agreed to amend SPA to accelerate the expected timing of final IMPACT results by one year (H2 2009 instead of 2010) - it will accept positive interim or final analysis from the trial to amend the BLA. SOURCE: Dendreon press release, 12 March 2008RECEIVED AN FDA SPA IN JUNE 2003 FOR THE TRIAL. THIS WILL BE USED TO REPLY TO FDA APPROVABLE LETTER.@3/12/2008@@-@@@-@2000-1@@-@-@@@-@I@@-@-@>> A total of 37 patients were treated. The median T cell proliferative stimulation index in response to the immunizing antigen increased from 1.3 at baseline to 19.7 at Week 4 (p=0.0002), 19.4 at Week 8 (p<0.0001) and 20.7 at Week 16 (p=0.02). Immune monitoring performed in three of four patients who underwent repeat treatment suggested an increase in immune response following the booster treatments. Five patients had prolonged disease stabilization ranging from 48 to 94 weeks, without the addition of other cancer therapy other than the continuation of bisphosphonates. In addition, one patient experienced a partial response lasting approximately six months. [Dendreon, 6.11.2008]           >> APC-8024 induced immune reaction against tumours; 2 of 11 breast cancer patients had disease stabilisation for nearly a year after other treatment failure. [Dendreon, 14 April 2008]@Results from the integrated analysis showed that treatment was generally well tolerated. The majority of side effects were mild, including infusion-related fatigue, fever and chills. @@@@-@LAPALEUCEL-T@@@@@LAPALEUCEL-T||||@DENDREON@@@@@DENDREON||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@APC-8024@NEUVENGE@@@@APC-8024|NEUVENGE|||@Vaccine@Immunotherapy@@@@Vaccine|Immunotherapy|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917069@Onco@@@@@300f1015ntsdm@@@@@@Patients received IFNy 0.2MG s.c for two days prior to ILP.@@L03AX11@L03A@NO@INGELHEIM, GERMANY@@@Tasonermin affects the morphology and reduces proliferation of endothelial cells and modifies expression of specific cell surface and secretory proteins (including adhesion molecules and proteins modulating coagulation, interleukins and haematopoietic growth factors). These changes in turn lead to a procoagulant state resulting in microvascular thrombosis. Further, adherence and extravasation of leukocytes is increased, leading to infiltration of the tumour by lymphocytes, monocytes, and granulocytes. The reason for the differential sensitivity of the tumour vasculature (high) versus normal vasculature (low) are currently unknown.@@14917069@As an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated limb perfusion.@@YES@NOT REIMBURSED@@NO REVIEW@@@@@@@@39@Upper limb: 3MG dose by isolated limb perfusion; lower limb: 4MG total dose by isolate limb perfusion@EMA, 13 April 1999@4/13/1999@9/1/2001@@@@@152.53@No@@Patients with STS and malignant melnaoma@@@@APPROVED@@NOT REIMBURSED@HAUTE AUTORITÉ DE SANTÉ@20 patients completed a 1-year follow-up after ILP. 13 patients had recurrence or progression of the disease; 2 were excluded due to protocol violation; 2 received other chemotherapy or radiotherapy; one died and one was lost to follow-up. The median follow-up from ILP was 846 days. Violations primarily concerned deviations in the dose of melphalan; median dose here was 95mg (33-150mg). 10 patients underwent amputation giving a limb salvage rate of 29/39 (74%) during the follow-up. Complete response was seen in 28% of patients.@Systemic toxicity consisted of fever (100%), chills (51%), cardiac rhythm disturbances (62%), nausea and vomiting (31%) and fatigue (26%). Serious adverse events consisted of liver toxicity (18%), ARDS (13%), thrombocytopaenia (10%).@@@@ADJUVANT@TASONERMIN@@@@@TASONERMIN||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@BEROMUN@@@@@BEROMUN||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@LIMB SALVAGE@@@@@@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9233680T@POWDER AND SOLVANT FOR INJECTABLE SOLUTION - 5 ML@EURO@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924950@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-706 alone in patients who have completed previously protocols and saw benefit in that protocol@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Motesanib diphosphate is a highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis and lymphangiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (“VEGFR1-3”). It is also under investigation for its potential direct anti-tumor activity by targeting platelet-derived growth factor receptor (“PDGFR”) and stem cell factor receptor (“c-kit”) signaling, which may also confer direct anti-tumor activity. In February 2008, Amgen announced that Takeda will become the worldwide partner for motesanib diphosphate in addition to an exclusive collaboration on up to 13 other programs in the Japanese market. @@14924950@Extension trial@@-@-@@NO REVIEW@@@@-@Motesanib was the unofficial key to the wide-ranging, two-part R&D deal with Amgen signed in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-@-@NCT00360867@100@-@-@@@-@@12/1/2005@-@20050130@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@MOTESANIB DIPHOSPHATE@@@@@MOTESANIB DIPHOSPHATE||||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AMG-706@@@@@AMG-706||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@SAFETY@ADVERSE EVENTS@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384820@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384820@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@YES@@@NO REVIEW@@@@90%@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@SNS@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@29392.58751@@@1@year@1 year@29392.59@29392.59@80.53@60@1.1511@1184.23@1289.75@1191.77@@@@@@@@@@0.2@1@@mg/m²@340@1@@@@@@@@@@@8/4/2017@19.74@19.74@779652@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14917781@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14917781@Indicated only for management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.@@NO@@@NO REVIEW@@@@@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@130@Initial dose: 200 mcg. Prescribe an initial supply of six 200 mcg units.@FDA, 4 November 1998@11/4/1998@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@SEPTEMBER 2006 (EXCLUSIVITY; FEBRUARY 2010)@@@@III@APPROVED@@Prior authorisation; specialty drug; quantity limit 120 for 30 days@MEDICARE@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@4105@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@136.83@136.83@63459-0512-30@LOZENGE@US$@@@@@@@@1200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916712@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Single-agent vatalanib assessed at 6-month survival rate.@@-@-@-@BASEL, SWITZERLAND@@@"Vatalanib (PTK/ZK) is a ""small"" molecule tyrosine kinase inhibitor with broad specificity that targets all VEGF receptors (VEGFR), the platelet-derived growth factor receptor, and c-KIT. It is a multi-VEGFR inhibitor designed to block angiogenesis and lymphangiogenesis by binding the intracellular kinase domain of all three VEGFRs, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Vatalanib is a targeted drug that inhibits the activity of all known receptors that bind VEGF. The drug potently inhibits the formation of new blood vessels (angiogenesis). "@@14916712@Patients who failed first-line Gemzar@@-@-@@NO REVIEW@@@@-@PTK/ZK was among 20 projects discontinued by Bayer Schering as part of its merger. SOURCE: Bayer, 19 June 2007Following a modified agreement in January 2005, Novartis and Schering AG will co-market vatalanib in Europe, North America and Japan for oncolo@SECOND-LINE@NCT00226005@65@-@-@@@-@@12/1/2005@-@PCRT04-001@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@VATALANIB@@@@@VATALANIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@PTK-787@ZK-222584@PTK/ZK@@@PTK-787|ZK-222584|PTK/ZK||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916164@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@21 day continuous IV administration of TLN-232 followed by a 7-day recovery period @@-@-@-@MONTREAL, CANADA@9/1/2010@@TLN-232 is a novel seven amino-acid peptide under development targeting solid tumours. It targets pyruvate kinase M2 (M2PK), a protein shown to be over-expressed in a number of different tumour types. M2PK is involved in tumour cell glycolysis, a process by which cancer cells generate the energy required for their rapid growth in the absence of oxygen.@@14916164@TLN-232 as Second-Line Therapy for Patients With Metastatic Melanoma@@-@-@@NO REVIEW@@@@-@Caprion (now Thallion) licensed CAP-232 in March 2006. A dispute over timely payments was resolved in January 2008.@SECOND-LINE@NCT00735332@49@-@-@@@-@@8/1/2008@-@TLN-232-202@@-@">> Histologically confirmed stage IV (M1a, M1b, and M1c) unresectable metastatic melanoma (cutaneous, mucosal or acral lentiginous) 
>> First progression after treatment by one first line systemic therapy for metastatic melanoma (immunotherapy or targeted therapy or chemotherapy or any combination of them) 
>> Measurable recurrent/progressive disease by radiological scan = 21 days prior to Day 1, Cycle 1 
>> Age = 18 years 
>> ECOG = 2 "@@@II@II@@-@-@Trial registered. [Thallion, 13.08.2008]@-@@@@-@-@@@@@-||||@THALLION PHARMACEUTICALS@CAPRION@@@@THALLION PHARMACEUTICALS|CAPRION|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TLN-232@CAP-232@@@@TLN-232|CAP-232|||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@SAFETY@TOLERABILITY@@@@METASTATIC@RELAPSED@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922365@Onco@@@@@300f1012ntsdm@@@@@@Panretin gel 3-4 times daily or matching vehicle gel.@@L01XX22@L01X@NO@FRAZER, PENNSYLVANIA@@@@@14922365@Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma; it is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using Panretin gel with systemic anti-KS treatment.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@268@Initially to be applied 2 times a day to cutaneous KS lesions. The application frequency can be gradually increased to 3 or 4 times a day according to individual lesion tolerance. If application site toxicity occurs, the application frequency can be reduced. Should severe irritation occur, application of drug can be temporarily discontinued for a few days until the symptoms subside.@EMA, 11 October 2000@10/11/2000@@@@@Panretin can cause fetal harm if significant absorption were to occur in a pregnant woman. 9-cis-Retinoic acid has been shown to be teratogenic in rabbits and mice. An increased incidence of fused sternebrae and limb and craniofacial defects occurred in rabbits given oral doses of 0.5 mg/kg/day (about five times the estimated daily human topical dose on a mg/m2 basis, assuming complete systemic absorption of 9-cis-retinoic acid, when Panretin gel is administered as a 60 g tube over 1 month in a 60 kg human) during the period of organogenesis.@STUDY 1@No@@@@@N/A@APPROVED@@@GKV@72 patients responded to Panretin, only 15% relapsed. Modified ACTG response was 36% on Panretin and 7% on vehicle gel, whilst Physician's Global/Subject Assessment was 47% and 11% respectively.@@@@@MONO@ALITRETINOIN@@@@@ALITRETINOIN||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Sarcoma@Kaposi's Sarcoma@@@@Sarcoma|Kaposi's Sarcoma||||||||@PANRETIN@@@@@PANRETIN||||@Retinoid@@@@@Retinoid||||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN-LABEL@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@1254.3@1594.71@1292.8@@@@@@@@@@20.91@@@@@@@@@@@@@@@@8/1/2017@1254.3@1254.3@2260679@GEL 60 G@EURO@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917012@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01AD02@L01A@YES@GALASHIELS, UNITED KINGDOM@@@@@14917012@"As palliative or supplementary treatment, usually in combination with radiotherapy and/or surgery as part of multiple drug regimens in: Brain tumours (primary or metastatic); Lung tumours (especially oat-cell carcinoma); Hodgkin's disease (resistant to conventional combination chemotherapy); Malignant melanoma (metastatic). Lomustine ""medac"" may also be of value as second-line treatment in Non-Hodgkin's lymphoma, myelomatosis, gastrointestinal tumours, carcinoma of the kidney, the testis, the ovary, the cervix uteri and the breast."@@YES@February 1999 (P) & May 2005 (H)@@NO REVIEW@@@@100%@@@@@"The recommended dose in patients with normally functioning bone marrow receiving Lomustine ""medac"" as their only chemotherapy is 120-130 mg/m² as a single dose every six to eight weeks (or as a divided dose over 3 days, e.g. 40 mg/m²/day)."@1-Dec-97@12/1/1997@12/31/1997@@@@CeeNU should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Bone marrow suppression, notably thrombocytopaenia and leukopaenia, which may contribute to bleeding and overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of CeeNU. Since the major toxicity is delayedbone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose. At the recommended dosage, courses of CeeNU should not be given more frequently than every 6 weeks. The bone marrow toxicity of CeeNU is cumulative and therefore dosage adjustment must be considered on the basis of nadir blood counts from prior dose@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@LOMUSTINE@@@@@LOMUSTINE||||@PROSTRAKAN@ORPHAN THERAPEUTICS@@@@PROSTRAKAN|ORPHAN THERAPEUTICS|||@@@@@@|||||||||@Brain Cancer@NSCLC@Melanoma / Skin Cancer@Haematological Malignancy@Hodgkin's Lymphoma@Brain Cancer|NSCLC|Melanoma / Skin Cancer|Haematological Malignancy|Hodgkin's Lymphoma|||||@BELUSTINE@@@@@BELUSTINE||||@Alkylating Agent@Nitrosourea@@@@Alkylating Agent|Nitrosourea|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@25.57@@@@@@@@@@@@0.64@@@@@@@@@@@@@@@@8/18/2017@25.57@25.57@9009994R@CAPSULE@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922989@Onco@@@@@@@@@@@-@@-@-@-@PARIS, FRANCE@@@DTS-201 consists of doxorubicin, a marketed cytotoxic agent effective against a wide variety of solid tumors, conjugated to a proprietary first generation peptide similar to the company's second generation Tumor-Selective Prodrug (TSP) technology. The product was discovered in 1996 by Pr André Trouet and his team at the Université Catholique de Louvain, Belgium and in-licensed from Medarex Inc in April 2003 for exclusive EU rights. DTS-201 is also known as Super-Leu-Dox or CPI-0004Na in the USA. DTS-201 completed Phase I clinical studies in Belgium and France in October 2007. DTS-201 is a prodrug designed to preferentially deliver doxorubicin to tumors as opposed to normal tissues. It consists of the tetrapeptide N-succinyl-ß-alanyl-L-leucyl-L-alanyl-L-leucine covalently linked to the aminoglycoside portion of doxorubicin. The DTS-201 concept is based on the inactivation of doxorubicin by the coupling of a tetrapeptidic sequence that prevents cellular uptake. DTS-201 is stable in blood but cleavable by some specific peptidases present in the tumor environment. Preclinical studies have demonstrated that DTS-201 was less toxic in vivo models than free doxorubicin and significantly more effective in a wide panel of human tumor xenograft models.@@14922989@-@@-@-@@NO REVIEW@@@-@-@In April of 2003, Diatos licensed from Medarex certain European rights to develop and commercialize DTS-201. Since in-licensing the product in early preclinical development, Diatos has completed preclinical development and initiated in July 2005 an open label Phase I clinical study with DTS-201 involving three leading oncology clinical centers in Belgium and France. @-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Trial started. SOURCE: Diatos, 5 August 2008@-@@@@MONO@DOXORUBICIN, PEPTIDE PRODRUG@@@@@DOXORUBICIN, PEPTIDE PRODRUG||||@DIATOS@MEDAREX@@@@DIATOS|MEDAREX|||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@DTS-201@@@@@DTS-201||||@Anthracycline@Topoisomerase II Inhibitor@@@@Anthracycline|Topoisomerase II Inhibitor|||@PSA@@@@@DURATION OF RESPONSE@PROGRESSION-FREE SURVIVAL@TIME TO PROGRESSION@@@REFRACTORY@@@@@OPEN-LABEL@MULTI-CENTRE@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920888@Onco@@@@@300f1014ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920888@Indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation.@@@@@@@@-@@@@@@The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient. The entire daily dose may be given at one time. These dosages are for initiation of therapy or for short courses of treatment. The dosage must be carefully adjusted according to the response of the patient and must be reduced as soon as there is an abrupt fall in the white blood cell count. Patients with Hodgkin's disease usually require 0.2 mg/kg daily, whereas patients with other lymphomas or chronic lymphocytic leukemia usually require only 0.1 mg/kg daily.@May-57@@@@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@NOT AVAILABLE@@@@@APPROVED@@@RAMQ@NO LABELLED TRIAL@@@@@@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Hodgkin's Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Hodgkin's Lymphoma|||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@26.76@26.76@@25@0.7881@33.3@@@@@@@@@@@@0.67@@@@@@@@@@@@@@@@7/19/2017@1.33@1.33@462625@TABLET@C$@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14923385@Onco@@@@@300f1018ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923385@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@@100%@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Restricted benefit: Treatment of hormone-dependent breast cancer. This drug is not PBS-subsidised for primary prevention of breast cancer.@PBS@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@GENPHARM@@@@@GENPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOXEN@@@@@TAMOXEN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@A$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916727@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@GEMCITABINE 1000 MG/M2/DAY ON DAYS 1 & 8 AND CARBOPLATIN AT AUC 2 ON DAYS 1 AND 8 EVERY 21 DAYS.@@@@@@5/1/2012@@@@14916727@AN OPEN-LABEL RANDOMIZED PHASE II TRIAL COMPARING GEMCITABINE AND CARBOPLATIN WITH AND WITHOUT P276-00 IN SUBJECTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER, WITH A PHASE I RUN-IN OF ESCALATING DOSE OF P276-00 ADDED TO GEMCITABINE AND CARBOPLATIN@@@@@@@@@@@@NCT01333137@140@@@@@@@4/1/2011@@P276-00/52/10@@@1. FEMALES OF AGE =18 YEARS.  2. HISTOLOGICALLY DOCUMENTED METASTATIC TRIPLE NEGATIVE BREAST CANCER (ANY TRIPLE NEGATIVE BREAST CANCER FOR PHASE I)  3. TWO OR FEWER CHEMOTHERAPY REGIMENS FOR ADVANCED DISEASE (NO LIMIT OF PRIOR REGIMENS FOR PHASE I)  4. ECOG PERFORMANCE SCORE OF 1 OR LESS  5. PRESENCE OF MEASURABLE DISEASE BY RECIST 1.1 CRITERIA (NOT FOR THE PHASE I PORTION)  6. ABILITY TO UNDERSTAND AND THE WILLINGNESS TO SIGN A WRITTEN INFORMED CONSENT DOCUMENT (ICD)  7. FULL RECOVERY FROM ALL PRIOR TREATMENT TOXICITIES TO COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE V.4) GRADE = 1@@@II@II@@@@Trial registered [Piramal Life Science 8 April 2011]@@@@@@P276-00@GEMCITABINE@CARBOPLATIN@@@P276-00|GEMCITABINE|CARBOPLATIN||@PIRAMAL LIFE SCIENCES LIMITED@@@@@PIRAMAL LIFE SCIENCES LIMITED||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@MEDIAN PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@OVERALL SURVIVAL  AT 6 MONTHS@@@@@@@@@RANDOMISED@EFFICACY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920587@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01XX05@L01X@NO@NEW YORK, NEW YORK@@@@@14920587@The treatment of chronic myeloid leukaemia. The treatment of cancer of the cervix in conjunction with radiotherapy.@@NO@@@NO REVIEW@@@@90%@@@@@Continuous therapy: Hydrea 20-30mg/kg should be given daily in single doses. Dosage should be based on the patient's actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts. Intermittent therapy: Hydrea 80mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Hydrea should be omitted.@1-May-98@5/1/1998@6/18/1998@@@@The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide therapy. If WBC falls below 2.5x109/L or platelet count to <100x109/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal. Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@HYDROXYCARBAMIDE@@@@@HYDROXYCARBAMIDE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Cervical Cancer@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Cervical Cancer|||||||@HYDREA@@@@@HYDREA||||@Anti-metabolite@@@@@Anti-metabolite||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1511@3.86@6.03@4.22@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@0.19@0.19@669473@CAPSULE@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14922439@Onco@@@@@300f1008ntsdm@@@@@@AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.@@-@-@-@NEW YORK, NEW YORK@11/1/2010@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14922439@-@@-@-@@NO REVIEW@@@@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@SECOND-LINE@NCT00569946@63@-@-@@@-@@12/1/2007@-@A4061035@@-@-@@@II@II@@-@@RESULTS PENDING@-@@@@MONO@AXITINIB@@@@@AXITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@AG-013736@@@@@AG-013736||||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14916212@Onco@@@@@300f1010ntsdm@@@@@@Stable doses of either long-acting oral opioid or transdermal fentanyl with Actiq (200, 400, 600, 800, 1200 and 1600mcg)@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916212@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@257@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@257 OPIOID-TOLERANT ADULT CANCER PATIENTS@@@III; TWO DOSE TITRATION STUDIES@APPROVED@@NO NICE REVIEW@NHS@95 of 127 patients (75%) titrated to a successful dose of Actiq (could be used consistently for at least 2 days without unacceptable side-effects). 11% and 14% withdrew due to adverse events or other reasons respectively.@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOSE-RANGING@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.2961@21.05@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.02@7.02@2.69E+15@LOZENGE@GB£@@@@@@@@400@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917247@Onco@@@@@300f1012ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14917247@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@@GKV@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@CASODEX@@@@@CASODEX||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1807@528.39@679.03@545.73@@@@@@@@@@0.12@@@@@@@@@@@@@@@@8/15/2017@17.61@17.61@5968143@FILM-COATED TABLET@EURO@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918209@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01DB07@L01D@YES@CANONSBURG, PENNSYLVANIA@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14918209@Mitoxantrone is indicated in the treatment of metastatic breast cancer, non-Hodgkin's lymphoma and adult acute non-lymphocytic leukaemia. Mitoxantrone has also been used in the palliation of non-resectable primary hepatocellular carcinoma.@@NO@6-Sep@@NO REVIEW@@@@@Acquired through takeover of generics unit of Merck KGaA@@@@HRPC: based on data from two Phase 3 comparative trials of mitoxantrone injection plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m2 given as a short intravenous infusion every 21 days.@5-May@@@@@@HRPC: functional cardiac changes such as decreases in LVEF and congestive heart failure may occur in patients with HRPC treated with mitoxantrone. In a randomised comparative trial of mitoxantrone plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone had a cardiac event defined as any decrease in LVEF below the normal range, CHF (n = 3), or myocardial ischemia. Two patients had a prior history of cardiac disease. The total mitoxantrone dose administered to patients with cardiac effects ranged from > 48 to 212 mg/m2. Among 112 patients evaluable for safety on the mitoxantrone + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. The range of total mitoxantrone doses administered to these patients is not available.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@MITOXANTRONE@@@@@MITOXANTRONE||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918746@Onco@@@@@@@@@@@Patients receive epratuzumab IV over 15-60 minutes on days 1, 8, 15, and 22.Patients are followed every 8 weeks for 10 months and then every 3 months for up to 4 years.@@-@-@-@MORRIS PLAINS, NEW JERSEY@@@Naked humanized antibody targeting CD22 receptors on B-lymphocytes.  Primary use is for the treatment of indolent and aggressive NHLs, and for autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren's Syndrome.  Every year there are 56,000 newly diagnosed cases of NHL and 25,000 deaths.  SLE afflicts up to 1.4 million in the U.S.  In May 2006, epratuzumab was licensed to UCB, S.A. for all autoimmune disease indications worldwide.  A Phase IIb clinical trial for SLE is currently enrolling patients.  Additionally, there are three NCI-sponsored trials in oncology ongoing.@@14918746@Low-grade follicular, B-cell NHL refractory to Rituxan@@-@-@@NO REVIEW@@@@-@UCB Pharma holds non-oncology rights, with option for a buy-in. North American rights were licensed to Amgen, but returned to Immunomedics in April 2004.@-@NCT00022685@30-100@-@-@@@-@@9/1/2001@-@NCI-G01-2004@@-@-@@@CDR0000068842, UCLA-0009041, IM-T-hLL2-07, UCLA-BB-IND-7124, @III@@-@-@RESULTS PENDING@-@@@@MONO@EPRATUZUMAB@@@@@EPRATUZUMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@LYMPHOCIDE@IMMU-102@@@@LYMPHOCIDE|IMMU-102|||@mAb@Humanised@CD22@@@mAb|Humanised|CD22||@SAFETY@RESPONSE RATE@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@REFRACTORY@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15413481@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Rociletinib and Trametinib Interventions: Rociletinib  Trametinib@@@@@@2/1/2018@@@@15413481@A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)@Both@@@@@@@884@@@@NCT02580708@89@@@@@@@9/1/2015@@CO-1686-033@@@Written informed consent on an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF before any study-specific evaluation•Histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon 20 insertion); measurable disease per RECIST 1.1Prior treatment with an EGFR TKI; in Phase 2, prior treatment with a T790M-directed EGFR TKI for patients in Group B. Previous chemotherapy is allowed; in Phase 2, immediate prior therapy must be EGFR TKIPatient willingness to undergo tumor biopsy at baseline and on treatment (optional for Phase 1; mandatory for Phase 2)Eastern Cooperative Oncology Group (ECOG) performance status 0-1; life expectancy at least 3 monthsAdequate hematological and biological function; LVEF ≥50%@EGFR MUTATION@ADULTS@Phase 1/2@I/II@@@@@@@@@COMBO@ROCILETINIB@TRAMETINIB@@@@ROCILETINIB|TRAMETINIB|||@CLOVIS ONCOLOGY@@@@@CLOVIS ONCOLOGY||||@United States@@@@@United States|||||||||@NSCLC@@@@@NSCLC|||||||||@CO-1686@MEKINIST@@@@CO-1686|MEKINIST|||@Other@@@@@Other||||@INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS@Objective response rate@@@@DURATION OF RESPONSE@DISEASE CONTROL RATE@PROGRESSION-FREE SURVIVAL@@@ADVANCED@METASTATIC@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918856@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01XA01@L01X@YES@@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14918856@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@NO@@@NO REVIEW@@@@@@@@@For advanced bladder cancer, Platinol-AQ should be administered at a dose of 100mg/m2 IV per cycle once every four weeks.@@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@US$@@@@@@@@@@100 ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16074382@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE35@L01X@@LONDON, UNITED KINGDOM@@@Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type.@@16074382@Indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).@Both@NA@15-Sep-16@9/15/2016@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@411@The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity.@EMA, 2 February 2016@2/2/2016@3/15/2016@No@@@@@No@@@EGFR T790M mutation-positive@ADULTS@@APPROVED@@No additionnal benefit. [G-BA, https://www.g-ba.de/downloads/39-261-2700/2016-09-15_AM-RL-XII_Osimertinib_D-219_BAnz.pdf]@GKV@The safety and efficacy of Tagrisso were demonstrated in two single-arm phase II trials involving a total of 411 patients with advanced EGFR T790M mutation-positive NSCLC whose disease progressed after treatment with EGFR-blocking therapies.Results from these two trials showed that a high proportion of patients (around 66%) responded and their tumour shrunk. This response appeared to be long-lasting. The benefits in terms of progression free survival and/or overall survival have not yet been determined.[EMA, 18 December 2015, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002448.jsp&mid=WC0b01ac058004d5c1]@The most common side effects of Tagrisso are diarrhoea and skin and nail conditions such as dry skin, rash and acne.[EMA, 18 December 2015, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002448.jsp&mid=WC0b01ac058004d5c1]@@@@MONO@OSIMERTINIB@@@@@OSIMERTINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAGRISSO@@@@@TAGRISSO||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@MULTICENTER@SINGLE-ARM@OPEN-LABEL@@@1@1@67858.096@@@9.7@month@9.7 month@67858.1@67858.1@230@30@1.1511@6900@8514.65@6938.5@@@@@@@@@@2.88@1@@mg@80@1@@@@@@@@@@@8/1/2017@230@230@11334371@TABLET@EURO@@@@@@@@80@MG@80 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16614933@Onco@@@@@@@@@@@"C-CAR011, Experimental, In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
"@@@@@UNITED STATES@8/1/2018@@@@16614933@A Phase I Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Adult Subjects With Relapsed/Refractory CD19+ B Cells Acute Lymphoblastic Leukemia(CALL-1)@Both@@@@@CD19-targeted chimeric antigen receptor T cells@@@@@SECOND/THIRD LINE@NCT03018093@20@@@@@@@2/1/2017@@CBMG2016003@@@-  Age 14-75 years old, male or female.  -  Volunteered to participate in this study and signed written informed consent form.  -  Histologically diagnosed as CD19+B-ALL according to the NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines (2016@CD19+B-ALL@ADULTS@Phase 1@I@@@@@@@@@MONO@C-CAR-011@@@@@C-CAR-011||||@CELLULAR BIOMEDICINE GROUP@@@@@CELLULAR BIOMEDICINE GROUP||||@@@@@@|||||||||@Acute Lymphocytic Leukaemia@@@@@Acute Lymphocytic Leukaemia|||||||||@-@@@@@-||||@Other@@@@@Other||||@Dose-limiting toxicity (DLT)@@@@@Overall response rate (ORR)@Overall survival (OS)@@@@RELAPSED@REFRACTORY@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917389@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@M05BA01@M05B@NO@@@@@@14917389@Paget's disease of bone: Effectiveness has been demonstrated primarily in patients with polyostotic Paget's disease with symptoms of pain and with clinically significant elevations of urinary hydroxyproline and serum alkaline phosphatase. In other circumstances in which there is extensive involvement of the skull or the spine with the prospect of irreversible neurological damage, or when a weight-bearing bone may be involved, the use of Didronel may also be considered.@@NO@3-Apr@@NO REVIEW@@@@@@@@@The recommended initial dose of Didronel for most patients is 5mg/kg body weight/day, for a period not exceeding six months. Doses above 10mg/kg should be reserved for use when there is an overriding requirement for suppression of increased bone turnover associated with Paget's disease or when the patient requires more prompt reduction of elevated cardiac output. Treatment with doses above 10mg/kg/day should be approached cautiously and should not exceed three months duration. Doses in excess of 20mg/kg/day are not recommended.@1-Mar-81@3/1/1981@@@@@Paget's Disease: In Paget's patients the response to therapy may be of slow onset and continue for months after Didronel therapy is discontinued. Dosage should not be increased prematurely. A 90-day drug-free interval should be provided between courses of therapy. Heterotopic Ossification: No specific warnings.@NO LABELLED TRIAL@No@@@@@@APPROVED@@35%; FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETIDRONATE@@@@@ETIDRONATE||||@PROCTER & GAMBLE@@@@@PROCTER & GAMBLE||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@DIDRONEL@@@@@DIDRONEL||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+12@TABLET@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918111@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA01@L01X@YES@DEERFIELD, ILLINOIS@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14918111@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@YES@@@NO REVIEW@@@@@@@@@For monotherapy, the following two dosage regimens are recommended:- Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; - 15 to 20 mg/m²/day for five days, every 3 to 4 weeks. If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks.@@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Ovarian Cancer@Testicular Cancer@Bladder Cancer@@@Ovarian Cancer|Testicular Cancer|Bladder Cancer|||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924207@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Avastin in combination with Xeloda and oxaliplatin@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14924207@Avastin in combination with Xeloda and Exolatin for patients with advanced colorectal cancer@@-@-@@NO REVIEW@@@@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008@-@NCT00159432@53@-@-@@@-@@2/1/2005@-@-@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@BEVACIZUMAB@CAPECITABINE@OXALIPLATIN@@@BEVACIZUMAB|CAPECITABINE|OXALIPLATIN||@ROCHE@GENENTECH@@@@ROCHE|GENENTECH|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@XELODA@ELOXATIN@@@AVASTIN|XELODA|ELOXATIN||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919174@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14919174@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@@@@@@@@@@The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months).@@@10/1/2007@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@No ASMR rating.@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@DAKOTA PHARM@@@@SANOFI-AVENTIS|DAKOTA PHARM|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@306@@@@@@@@@@@@3.06@@@@@@@@@@@@@@@@8/2/2017@306@306@9281087R@POWDER FOR SOLUTION FOR PERFUSION, 20 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919964@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@@@YES@LAKE FOREST, ILLINOIS@@@Vincristine is an antineoplastic drug with broad-spectrum anti-tumor activity in man. The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase. The drug is relatively marrow-sparing and is thus suitable for use in combination with other cancer chemotherapeutic agents.@@14919964@Vincristine sulfate injection is indicated in acute leukaemia. Vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas 4-6 (lymphocytic, mixed cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma 7, neuroblastoma 8, and Wilms' tumor 9.@@NO@@@NO REVIEW@@@@@Acquired via takeover of Mayne@@@@The drug is administered intravenously at weekly intervals. The usual dose of vincristine injection for children is 2 mg/m². For children weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of vincristine sulfate injection for adults is 1.4 mg/m². A 50% reduction in the dose of vincristine sulfate injection is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.@FDA, April 1988@@@@@@This preparation should be administered by individuals experienced in the administration of vincristine sulfate injection. It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissues during intravenous administration of vincristine sulfate injection may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. Fatal if given intrathecally.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@VINCRISTINE SULPHATE@@@@@VINCRISTINE SULPHATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Hodgkin's Lymphoma@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Hodgkin's Lymphoma||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@2@MG@1 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916570@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Reolysin with Gemzar@@-@-@-@CALGARY, CANADA@@@Reolysin, a proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of all human cancers. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders. Reovirus, an acronym for Respiratory Enteric Orphan virus, is generally believed to inhabit the respiratory and bowel systems in humans. Reovirus is found naturally in sewage and water supplies. By age 12, half of all children show evidence of reovirus exposure and by adulthood, most people have been exposed. However, the disease is non-pathogenic, meaning there are typically no symptoms from infections. The link to its cancer-killing ability was established after the reovirus was discovered to reproduce well in various cancer cell lines. Tumours bearing an activated Ras pathway are deficient in their ability to activate the anti-viral response mediated by the host cellular protein, PKR. Since PKR is responsible for preventing reovirus replication, tumour cells lacking the activity of PKR are susceptible to reovirus replication. As normal cells do not possess Ras activations, these cells are able to stop reovirus infection through normal PKR activity. In tumour cells with an activated Ras pathway, reovirus is able to freely replicate and eventually kill the host tumour cells. As cell death occurs, progeny virus particles are then free to infect surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there are no longer any tumour cells carrying an activated Ras pathway available.@@14916570@-@@-@-@@NO REVIEW@@@@-@-@-@-@20@-@-@@@-@@6/1/2007@-@REO-019@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@ONCOLYTICS BIOTECH@@@@@ONCOLYTICS BIOTECH||||@@@@@@|||||||||@Pancreatic Cancer@NSCLC@Ovarian Cancer@@@Pancreatic Cancer|NSCLC|Ovarian Cancer|||||||@REOLYSIN@@@@@REOLYSIN||||@Vaccine@@@@@Vaccine||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920141@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@N02AB03@N02A@@MONTVALE, NEW JERSEY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14920141@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@@@@NO REVIEW@@@@@Teva announces acquisition of Barr. SOURCE: Teva, 21 July 2008@@@@@@@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@BARR PHARMACEUTICALS@TEVA PHARMACEUTICAL@@@@BARR PHARMACEUTICALS|TEVA PHARMACEUTICAL|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@729.5@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@24.32@24.32@49884-0461-55@ORAL TRANSMUCOSAL LOZENGE@US$@@@@@@@@600@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916681@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive 2 intramuscular injections of TroVax at a 2 week interval followed by surgery 10 days later. Two further vaccinations are given at 4 and 8 weeks after surgery. Patients who show a response to the first four vaccinations are given 2 additional vaccinations 20 and 28 weeks post surgery. SOURCE: clinicaltrials.gov@@-@-@-@OXFORD, UNITED KINGDOM@12/1/2006@@TroVax is Oxford BioMedica's novel therapeutic cancer vaccine, which is being developed in collaboration with sanofi-aventis. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a Modified Vaccinia Ankara vector, which delivers the gene for 5T4 and stimulates a patient?s body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4 antigen. @@14916681@Colorectal cancer with removed liver metastases@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed global rights for TroVax in March 2007; co-fund Phase III trials and sanofi-aventis all future research and marketing@-@NCT00259844@20@-@-@@@-@@6/1/2004@-@PH2048@@Bavarian Nordic re-files patent infringement case against Oxford BioMedica. [Bavarian Nordic, 27.01.2009]@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@OXFORD BIOMEDICA@SANOFI-AVENTIS@@@@OXFORD BIOMEDICA|SANOFI-AVENTIS|||@@@@@@|||||||||@Colorectal Cancer@Liver Cancer@@@@Colorectal Cancer|Liver Cancer||||||||@TROVAX@MVA-5T4@@@@TROVAX|MVA-5T4|||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16160508@Onco@@@@@@@@@@@Experimental arm (arm A): Nintedanib, Experimental, Nintedanib 200 mg twice daily orally. Nintedanib will be given continuously until clinically relevant disease progression according to the investigator's assessment or until other criteria for treatment discontinuation are met as specified in the protocol. Dosing beyond RECIST 1.1 progression is allowed for the oral agent if the patient still derives benefit from the treatment.Standard arm (arm B): Ifosfamide, Active Comparator, Ifosfamide 3 g/m2 intravenously on days 1, 2 and 3 every 21 days for up to a maximum of 6 cycles.@@L01XE31@L01X@@INGELHEIM, GERMANY@1/1/2021@@@@16160508@A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease &quot;ANITA&quot;@Both@@@@@Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH & Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral@@@@@SECOND-LINE@NCT02808247@185@@@@@@@1/1/2017@@EORTC-1506-STBSG@@@@@ADULTS@Phase 2@II@@@@@@@@@COMBO@NINTEDANIB@IFOSFAMIDE@@@@NINTEDANIB|IFOSFAMIDE|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@OFEV@MITOXANA@@@@OFEV|MITOXANA|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@Progression-Free survival (PFS)@@@@@Progression-free survival rate at 12 weeks (binary)@OVERALL SURVIVAL@OBJECTIVE RESPONSE RATE@@@ADVANCED@METASTATIC@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924168@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-479 with either Vectibix or Gemzazr@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@@@14924168@Solid tumours@@-@-@@NO REVIEW@@@@-@Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-108, AMG-317, AMG-386, AMG-479 and AMG-655, for US$200 mil.@-@-@21@-@-@@@-@@@-@-@@-@-@@@-@I@@-@-@A partial response (by WHO criteria) was observed in a patient with metastatic colorectal cancer treated with AMG 479 and Vectibix. Another partial response (also by WHO criteria) was seen in a patient with hormone-resistant prostate cancer treated with AMG 479 and gemcitabine. Stable disease as a best response was noted in an additional six patients in the AMG 479 and Vectibix arm and in an additional seven patients in the AMG 479 and gemcitabine arm. SOURCE: Amgen/ASCO, 31 May 2008@There was one, grade 3, AMG 479-related, adverse event (high blood sugar) in the AMG 479 and Vectibix arm (n=10). There were no AMG 479 related adverse events greater than grade 3 in the AMG 479 and gemcitabine arm (n=11).@@@@COMBO@-@PANITUMUMAB@GEMCITABINE@@@-|PANITUMUMAB|GEMCITABINE||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AMG-479@VECTIBIX@GEMZAR@@@AMG-479|VECTIBIX|GEMZAR||@mAb@Human@@@@mAb|Human|||@SAFETY@PHARMACOKINETICS@MAXIMUM TOLERATED DOSE@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922945@Onco@@@@@300f1014ntsdm@@@@@@Patients will receive MabThera (750mg/m²) plus methotrexate (8g/m²) given at intervals up to week 22, plus cytarabine (2g/m²) at week 11 and week 22.@@L01XC02@L01X@-@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin’s lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@14922945@MabThera plus high dose methotrexate plus high dose cytarabine in patients with central nervous system non-Hodgkin's lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00517699@<100@-@-@@@-@@@-@-@@-@<100 patients with central nervous system non-Hodkin's lymphoma@@@II@II@@-@-@Trial registered. SOURCE: Roche, 16 August 2007@-@@@@COMBO@RITUXIMAB@METHOTREXATE@@@@RITUXIMAB|METHOTREXATE|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@RITUXAN@@@@@RITUXAN||||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918811@Onco@@@@@@@@@@@Alimta plus carboplatin versus Gemzar plus carboplatin@@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14918811@Alimta plus carboplatin versus Gemzar plus carboplatin in Stage IIIb or IV NSCLC@@-@-@@NO REVIEW@@@N/A@-@-@FIRST-LINE@-@446@-@>>CHMP gives following opinion: Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. First line treatment should be a platinum doublet with gemcitabine, paclitaxel or docetaxel. [EMEA 29 May 2009 http://www.emea.europa.eu/pdfs/human/opinion/Alimta_33182709en.pdf ]>>MMA IN EUROPE TO BE FILED IN H2 2007.@5/29/2009@@-@@@-@N/A@@-@446 PATIENTS CHEMOTHERAPY-NAÏVE PATIENTS@@@III@III@@-@-@ASCO June 2007 update on 384 patients; Alimta arm experienced fewer grade 3/4 thrombocytopaenia (48 versus 107), leukopaenia (44 versus 89) and granulocyopaenia (78 versus 98). No difference in survival to date.@-@@@@COMBO@PEMETREXED@CARBOPLATIN@@@@PEMETREXED|CARBOPLATIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALIMTA@@@@@ALIMTA||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER FOR INFUSION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16406119@Onco@@@@@300f1037ntsdm@@@@@@Drug: treatment crizotinib 250mg orally continuous twice daily dosingDrug: treatment pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE16@L01X@@NEW YORK, NEW YORK@11/1/2013@@@@16406119@XALKORI is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).@@YES@16-Jun-16@6/16/2016@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@FIRST-LINE@NCT01154140@343@The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) taken continuously.@EMA, 23 November 2015@11/23/2015@12/1/2013@No@@1/1/2011@@A8081014, 2010-021336-33, XALCORI@No@@Proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung - Positive for translocation or inversion events involving the ALK gene locus- No prior systemic treatment for locally advanced or metastatic disease; Patients with brain metastases only if treated and neurologically stable with no ongoing requirement for corticosteroids - Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures - 18 years of age or older with the exception of India which has an upper age limit of 65 years old@(ALK)-positive@@@APPROVED@@@SNS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@World@@@@@World|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OVERALL SURVIVAL@Objective response rate@DURATION OF RESPONSE@@@OBJECTIVE RESPONSE RATE@@@@@ADVANCED@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@57799.7073@@@10.9@month@10.9 month@57799.71@57799.71@174.34@60@1.1511@5230.2@5497.55@5237.74@@@@@@@@@@0.35@1@@mg@500@1@@@@@@@@@@@8/4/2017@87.17@87.17@694399@CAPSULE@EURO@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14920791@Onco@@@@@300f1012ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920791@Kytril Injection is indicated for a) the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and b) the prevention and treatment of postoperative nausea and vomiting. Kytril Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@@@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@APPROVED@@@GKV@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KEVATRIL@@@@@KEVATRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@UNCONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@23.35@40.51@24.79@@@@@@@@@@7.78@@@@@@@@@@@@@@@@8/1/2017@23.35@23.35@9219295@INJECTION SOLUTION AMPOULE, 3 ML@EURO@@@@@@@@3@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922838@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@@@NO@MADISON, NEW JERSEY@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14922838@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@@@NO REVIEW@@@@100%@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenousinjection.@EMA, June 2006@@@@@@In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. Leucovorin may be fatal if given intrathecally. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@REFOLINON@@@@@REFOLINON||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@GB£@@@@@@@@350@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920151@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@A04AA02@A04A@NO@@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920151@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@@@@NO REVIEW@@@@@@@@@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@FDA, 7 July 2008@7/7/2008@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@@@@@APPROVED@@@@@@@@@@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@APP PHARMACEUTICAL@FRESENIUS KABI@@@@APP PHARMACEUTICAL|FRESENIUS KABI|||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1@86.6@@@@@@@@@@@@86.6@@@@@@@@@@@@@@@@8/2/2017@8.66@8.66@63323-0317-01@INJECTION (VIAL)@US$@@@@@@@@0.1@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916013@Onco@@@@@300f1020ntsdm@@@@@@Vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3). [clinicaltrials.gov]@@-@-@-@LONDON, UNITED KINGDOM@4/1/2011@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@14916013@Postmenopausal Advanced Breast Cancer Patients@@-@-@@NO REVIEW@@@@-@-@-@NCT00752986@135@-@-@@@-@@9/1/2008@-@ZACFAST@@-@>> Post menopausal women with locally advanced or metatstatic breast cancer     >> Patients may have either measurable or non-measurable disease, as defined by RECIST criteria    >> One previous hormone therapy or one previuious chemotherapy for advanced disease are allowed (patients who have stable but evident disease after chemotherapy are eligible)@@@II@II@@-@-@Trial registered. [AstraZeneca, 15.09.2008]@-@@@@COMBO@VANDETANIB@FULVESTRANT@@@@VANDETANIB|FULVESTRANT|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZACTIMA@FASLODEX@@@@ZACTIMA|FASLODEX|||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@DISEASE-FREE SURVIVAL@@@@@TIME TO PROGRESSION@OVERALL SURVIVAL@ADVERSE EVENTS@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14923276@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@PARIS, FRANCE@@@@@14923276@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NO@-@@NO REVIEW@@@@100%@Licensed from SRI International@-@-@-@Initiation of therapy: is most conveniently carried out in hospital; 0.5ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact.@EMA, march 1986@@@-@@@Patients known to suffer from depression should be carefully monitored during treatment with Suprefact. Prostatic carcinoma: Monitoring of the effect of clinical effect of Suprefact is carried out by methods generally used in prostatic carcinoma. Initially serum testosterone levels rise and a clinical effect will not be seen until levels start to fall into therapeutic (castration) range. Disease flare (temporary deterioration of the patient's condition) has been reported at the beginning of the treatment. The incidence is variable, but of the order of the 10%. Symptoms are usually confined to transient increase in pain, but the exact nature depends on the site of the lesions. Neurological sequelae have been reported where secondary deposits impinge upon the spinal cord or CNS. Disease flare is prevented by the prophylactic use of an anti-androgen, e.g. cyproterone acetate, 300 mg daily. It is recommended that the treatment should be started at least 3 days before the first dose of Suprefact and continued for at least 3 weeks after commencement of the Suprefact therapy.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SUPREFACT@@@@@SUPREFACT||||@LH-RH Analog@@@@@LH-RH Analog||||@-@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@196.01@323.5@204.83@@@@@@@@@@31.11@@@@@@@@@@@@@@@@6/7/2017@196.01@196.01@25540030@PROLONGED RELEASE IMPLANT + SYRINGE@EURO@@@@@@@@6.3@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14924256@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01BC01@L01B@-@BRIDGEWATER, NEW JERSEY@@@This is a sustained-release formulation of cytarabine, designed for direct administration into the cerebrospinal fluid (CSF). Cytarabine is a cell-cycle phase specific antineoplastic agent, affecting cells only during the S-phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5'-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA synthesis. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.@@14924256@-@@YES@-@@NO REVIEW@@@@-@Enzon will spin-off its novel biotechnology business from Enzon in a transaction that will result in two independent and highly focused public companies. Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to current PEG royalty revenues, including PEG-Intron, Cimzia and Hematide, and the manufacturing facility in Indianapolis. SOURCE: Enzon, 7 May 2008Marketed by Enzon in U.S., Mundipharma in Europe@-@-@-@-@-@@@-@@@-@-@@FEBRUARY 2008; MAY 2013-JANUARY 2017 (LYMPHOMATOUS MENINGITIS)@-@@@-@IV@@-@-@-@-@@@@-@CYTARABINE LIPOSOME@@@@@CYTARABINE LIPOSOME||||@ENZON@@@@@ENZON||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@DEPOCYT@@@@@DEPOCYT||||@Anti-metabolite@@@@@Anti-metabolite||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917922@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01CB01@L01C@YES@UNITED STATES@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14917922@Refractory testicular tumours in combination therapy with other approved chemotherapeutics for patients who have already received surgical and chemoradiotherapy. Also approved as a first-line treatment in patients with SCLC.@@@@@NO REVIEW@@@@@@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@@@@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1@124.4@@@@@@@@@@@@0.12@@@@@@@@@@@@@@@@8/2/2017@12.44@12.44@63323-0104-05@INJECTION (VIAL) - 5 ML@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917246@Onco@@@@@300f1012ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14917246@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@@GKV@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@CASODEX@@@@@CASODEX||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1807@218.77@287.58@226.36@@@@@@@@@@0.15@@@@@@@@@@@@@@@@8/15/2017@7.29@7.29@7433133@FILM-COATED TABLET@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923259@Onco@@@@@300f1012ntsdm@@@@@@"Patients received AP 12009 for seven days every other week as second or third line therapy. After reaching the MTD with the 7-day on, 7-day off schedule, a second schedule with
4-day on, 10-day off cycles was initiated."@@-@-@-@-@@@TGF-beta 2 inhibitor@@14923259@Patients with advanced stage pancreatic carcinoma, malignant melanoma or colorectal carcinoma@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@"One patient, diagnosed with stage IV malignant melanoma, survived more than 60 weeks after the start of AP 12009 treatment. Another patient with stage IV pancreatic carcinoma and several liver metastases had a complete response and is still alive as of March 2008
148 weeks (34 months) after the start of treatment with AP 12009.SOURCE: Antisense/ASCO, 3 June 2008"@Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and fluid loss events (dehydration and hypokalemia) being the most common. The 210 unit/m2 dose produced more toxicities than seen in the CPX-1 Phase 1 clinical trial, resulting in only 40 percent of patients receiving >80 percent of the planned dose intensity. Treatment will be initiated at a lower dose in future studies. @@@@MONO@TRABEDERSEN@@@@@TRABEDERSEN||||@ANTISENSE PHARMA@@@@@ANTISENSE PHARMA||||@@@@@@|||||||||@Pancreatic Cancer@Melanoma / Skin Cancer@Colorectal Cancer@@@Pancreatic Cancer|Melanoma / Skin Cancer|Colorectal Cancer|||||||@AP-12009@@@@@AP-12009||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@MULTI-CENTRE@DOSE ESCALATION@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916065@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Pazopanib combo with lapatinib versus lapatinib alone@@-@-@-@BRENTFORD, UNITED KINGDOM@5/1/2010@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14916065@Tykerb + pazopanib in inflammatory breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00558103@320@-@-@@@-@@11/1/2007@-@VEG108838@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@BOTH@LAPATINIB@PAZOPANIB@@@@LAPATINIB|PAZOPANIB|||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TYKERB@GW-786034@@@@TYKERB|GW-786034|||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922810@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L01BB02@L01B@NO@BRENTFORD, UNITED KINGDOM@@@@@14922810@Indicated for the treatment of acute leukaemia. It may be utilised in remission induction and it is particularly indicated for maintenance therapy in: acute lymphoblastic leukaemia; acute myelogenous leukaemia. Purinethol may be used in the treatment of chronic granulocytic leukaemia.@@NO@-@@NO REVIEW@@@@100%@-@-@-@-@For adults and children the usual starting dose is 2.5 mg/kg bodyweight per day, or 50-75 mg/m2 body surface area per day, but the dose and duration of administration depend on the nature and dosage of other cytotoxic agents given in conjunction with Puri-Nethol.@N/A@@@-@@@Treatment with Puri-Nethol causes bone marrow suppression leading to leucopenia and thrombocytopenia and, less frequently, to anaemia. Full blood counts must be taken daily during remission induction and careful monitoring of haematological parameters should be conducted during maintenance therapy.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@MERCAPTOPURINE@@@@@MERCAPTOPURINE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Chronic Myeloid Leukaemia@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Chronic Myeloid Leukaemia||||||@PURINETHOL@@@@@PURINETHOL||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@1.1229@54.74@90.35@57.21@@@@@@@@@@0.04@@@@@@@@@@@@@@@@6/7/2017@2.19@2.19@10344012@TABLET@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16384840@Onco@@@@@300f1020ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384840@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@YES@@@@@@@100%@-@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@N/A@@@YES@@@@@No@@@@@@APPROVED@@@SSN@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@69614.92124@@@36@month@36 month@69614.92@69614.92@63.58@120@1.1229@1907.3@3147.8@1993.15@@@@@@@@@@0.16@1@@mg@400@1@@@@@@@@@@@6/7/2017@15.89@15.89@35372059@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15412598@Onco@@@@@@@@@@@Pembrolizumab plus Dinaciclib, Experimental, During the Dose Evaluation phase of the study, 12 participants will receive pembrolizumab 200 mg plus dinaciclib 7mg/m^2 on Day 1 of infusion Cycle 1, followed by pembrolizumab 200 mg plus dinaciclib 10 mg/m^2 on Day 8 of infusion Cycle 1. Participants will then receive pembrolizumab 200 mg plus dinaciclib 14mg/m^2 on Day 1 and Day 8 of infusion Cycles 2 through 35. The study design will be revised based on the number of DLTs in Cycle 1 and Cycle 2. If ≤4 DLTs occur, 30 participants per disease type will be enrolled in the Signal Detection Phase. If &gt;5 DLTs occur, a lower dose will be evaluated in up to 24 additional participants.@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@1/1/2020@@@@15412598@Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).@Both@@@@@200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35@@@@@@NCT02684617@138@@@@@@@3/1/2016@@3475-155@@@Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)  -  Women of childbearing potential and male participants must agree to use adequate contraception up to 120 days after study therapy  -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1  -  Must be able to provide biopsy specimens obtained ≤3 months for biomarker analysis  CLL Participants:  -  Must have a confirmed diagnosis of CLL defined by 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria  -  Must have received one prior therapy for CLL  -  Must meet one or more of the consensus criteria for initiating treatment  MM Participants:  -  Must have a confirmed diagnosis of active MM  -  Must have undergone prior treatment with ≥2 treatment lines of anti-myeloma therapy and failed last line of treatment (disease progression ≤60 days of completion of last therapy)  -  Must have failed prior anti-myeloma treatments that have included an immunomodulatory drug (IMiD) (pomalidomide, lenalidomide, or thalidomide) AND proteasome inhibitor (bortezomib or carfilzomib) alone or in combination.  DLBCL Participants:  -  Must have a confirmed diagnosis of DLBCL and have progressed following ≥2 lines of previous therapy, after autologous stem cell transplant, or not a candidate for autologous stem cell transplant  -  Must have measurable disease (≥1 lesion that is >15 mm in the longest diameter and by >10 mm in the short axis)@@ADULTS@Phase 1@I@@@@@@@@@@PEMBROLIZUMAB@@@@@PEMBROLIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Myeloma@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Myeloma|||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Number of participants with Dose Limiting Toxicity (DLT)@Number of participants with Adverse Events (AEs)@Number of participants discontinuiing study drug due to AEs@@@@@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16061250@Onco@@@@@300f1015ntsdm@@@@@@"Ibandronate 15-Minute Infusion, Experimental, Participants will receive ibandronate IV infusions over a 15-minute interval.
Ibandronate 60-Minute Infusion, Active Comparator, Participants will receive ibandronate IV infusions over a 60-minute interval.
"@@@@@BASEL, SWITZERLAND@6/1/2008@@@@16061250@Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer@Female@@@@@Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).@@@@@@NCT02716792@334@@@@@@@1/1/2006@@ML19188@@@For participants of childbearing potential: negative pregnancy test and ready to use effective contraceptive measures  -  Metastatic breast cancer with at least one bone metastasis  -  Karnofsky index >/= 60  -  Life expectancy >/= 6 months  -  Estimated creatinine clearance (Cockcroft and Gault formula) >/= 30 milliliters per minute (mL/min)@MONO@ADULTS@Phase 3@III@@@@@@@@@@IBANDRONATE@@@@@IBANDRONATE||||@ROCHE@@@@@ROCHE||||@France@@@@@France|||||||||@Breast Cancer@Bone Metastases@@@@Breast Cancer|Bone Metastases||||||||@BONDRONAT@@@@@BONDRONAT||||@Bisphosphonate@@@@@Bisphosphonate||||@Creatinine clearance (CrCl) Estimated by Cockcroft-Gault Formula@@@@@Number of Participants with Bone Pain According to Visual Analog Scale (VAS)@Number of Participants With of Skeletal Events (Vertebral and Non-Vertebral Fractures, Impending Fracture, Radiotherapy or Surgery to Bone)@@@@METASTATIC@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15413483@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Rociletinib and MPDL3280A Interventions:Drug: RociletinibDrug: MPDL3280A@@@@@@9/1/2018@@@@15413483@A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)@Both@@@@@@@974@@@@NCT02630186@93@@@@@@@1/1/2016@@CO-1686-032@@@ECOG performance status of 0 or 1Adequate hematological and biological function, confirmed by defined laboratory valuesHistologically or cytologically documented metastatic or unresectable, locally advanced or metastatic NSCLC, with one or more activating EGFR mutation (eg, G719X, exon 19 deletion, L858R, L861Q) and absence of exon 20 insertionMeasurable disease as defined by RECIST v1.1Biopsy of tumor tissue for central evaluation, within 60 days prior to the first day of study treatmentFor Phase 1 and Phase 2 Group B, progression after prior 1st or 2nd generation EGFR TKI (eg, erlotinib, gefitinib, afatinib). Previous chemotherapy for NSCLC is allowed.For Phase 2 Group A, EGFR TKI treatment-naïve and chemotherapy-naïve@EGFR MUTATION@ADULTS@Phase 1b/2@I/II@@@@Overall Survival@@@@@COMBO@ROCILETINIB@ATEZOLIZUMAB@@@@ROCILETINIB|ATEZOLIZUMAB|||@CLOVIS ONCOLOGY@@@@@CLOVIS ONCOLOGY||||@United States@@@@@United States|||||||||@NSCLC@@@@@NSCLC|||||||||@CO-1686@MPDL3280A@@@@CO-1686|MPDL3280A|||@Other@@@@@Other||||@INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS@MAXIMUM CONCENTRATION@@@@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@PROGRESSION-FREE SURVIVAL@@@ADVANCED@METASTATIC@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@PREVENTION@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916420@Onco@@@@@300f1015ntsdm@@@@@@Imatinib at a dose of 400mg in combination with Peg-Interferon-alpha2a (Peg-IFNa2a) or cytarabine (Ara-C)Versus imatinib at a dose of 600mg versus imatinib a dose of 400mg@@L01XE01@L01X@-@BASEL, SWITZERLAND@9/1/2007@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14916420@Previously untreated CML in chronic phase@@NO@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00219739@1106@-@-@@@-@@9/1/2003@-@SPIRIT030482@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLEEVEC@GLIVEC@@@@GLEEVEC|GLIVEC|||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920858@Onco@@@@@300f1015ntsdm@@@@@@@@V03AF03@V03A@@MADISON, NEW JERSEY@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14920858@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@Apr-99@@NO REVIEW@@@@@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@@Oct-88@@6/1/1999@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@LEDERFOLINE@@@@@LEDERFOLINE||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@14.82@19.79@15.81@@@@@@@@@@0.03@@@@@@@@@@@@@@@@8/1/2017@0.49@0.49@3.40E+12@SCORED TABLET@EURO@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15408208@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01AA09@L01A@@FRAZER, PENNSYLVANIA@@@@@15408208@Bendamustine hydrochloride is indicated for treatment of patients with Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.@Both@NA@@@NO REVIEW@@@@@@@@301@100 mg/m² infused intravenously over 10 minutes on Days 1 and 2 of a 28day cycle, up to 6 cycles.@FDA, 7 December 2015@12/7/2015@@No@@@@@No@@Previously-untreated patients with Binet Stage B or C (Rai Stages I -IV) CLL requiring treatment@@ADULTS@@APPROVED@@@@@@@@@MONO@BENDAMUSTINE HYDROCHLORIDE@@@@@BENDAMUSTINE HYDROCHLORIDE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@BENDEKA@@@@@BENDEKA||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@OPEN-LABEL@RANDOMIZED@CONTROLLED MULTICENTER@@@1.75@m²@49932.75@@@168@day@168 day@49932.75@49932.75@297.22@1@1@2377.75@@@@@@@@@@@@23.78@28@@mg/m²@100@2@@@@@@@@@@@8/2/2017@2377.75@2377.75@63459-0348-04@SOLUTION FOR INJECTION (VIAL) - 4 ML@US$@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16639038@Onco@@@@@300f1012ntsdm@@@@@@dabrafenib 150 mg twice dailydabrafenib plus trametinib placebo (dabrafenib 150 mg twice daily and trametinib placebo, trametinib 2 mg once daily)@@L01XE23@L01X@@BASEL, SWITZERLAND@8/1/2013@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639038@Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation@Both@NA@17-Mar-16@3/17/2016@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@NCT01584648@423@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@EMA, 25 August 2015@8/25/2015@10/1/2013@No@@5/1/2012@@115306@No@@Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.The subject must have a radiologically measurable tumorThe subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).@BRAF V600 mutation@ADULTS@III@APPROVED@@Considerable added benefit: 17 march 2016. [https://www.g-ba.de/downloads/39-261-2532/2016-03-17_AM-RL-XII_Dabrafenib-neues%20AWG_2015-10-01-D-182_BAnz.pdf]@GKV@@@@@@COMBO@DABRAFENIB@TRAMETINIB@@@@DABRAFENIB|TRAMETINIB|||@NOVARTIS @@@@@NOVARTIS ||||@World@@@@@World|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@MEKINIST@@@@TAFINLAR|MEKINIST|||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@72998.38287@@@11.2@month@11.2 month@72998.38@72998.38@214.29@120@1.1511@6428.57@7936.81@6467.07@@@@@@@@@@0.71@1@@mg@300@1@@@@@@@@@@@8/1/2017@53.57@53.57@7699865@HARD CAPSULE@EURO@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917982@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@M05BA01@M05B@NO@@@@@@14917982@Didronel is indicated for the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis.@@NO@@@NO REVIEW@@@@@@@@@Paget's Disease: Initial Treatment Regimens: 5 to 10 mg/kg/day, not to exceed 6 months, or 11 to 20 mg/kg/day, not to exceed 3 months. The recommended initial dose is 5 mg/kg/day for a period not to exceed 6 months. Doses above 10 mg/kg/day should be reserved for when 1) lower doses are ineffective or 2) there is an overriding need to suppress rapid bone turnover (especially when irreversible neurologic damage is possible) or reduce elevated cardiac output. Doses in excess of 20mg/kg/day are not recommended.@FDA, 1 September 1977@9/1/1977@@@@@Paget's Disease: In Paget's patients the response to therapy may be of slow onset and continue for months after Didronel therapy is discontinued. Dosage should not be increased prematurely. A 90-day drug-free interval should be provided between courses of therapy. Heterotopic Ossification: No specific warnings.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@ETIDRONATE@@@@@ETIDRONATE||||@PROCTER & GAMBLE@@@@@PROCTER & GAMBLE||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@DIDRONEL@@@@@DIDRONEL||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00149-0405-60@TABLET@US$@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922568@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arm 1: vorinostat 400 mg P.O. q.d. capsules once daily Arm 2: vorinostat 200 mg P.O. t.i.d. capsules three times daily. Treatment in 21 day cycles for up to 8 cycles. Arm 2: vorinostat 400 mg P.O. q.d. capsules once daily Arm 2: vorinostat 200 mg P.O. t.i.d. capsules three times daily. Treatment in 21 day cycles for up to 8 cycles. @@-@-@-@WHITEHOUSE STATION, NEW JERSEY@5/1/2008@@Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (ClassI) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removalof acetyl groups from the lysine residues of proteins, including histones and transcription factors. In somecancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenictranscription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones isassociated with a condensed chromatin structure and repression of gene transcription. Inhibition ofHDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in anopen chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation ofacetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. Themechanism of the antineoplastic effect of vorinostat has not been fully characterized.@@14922568@-@@-@-@@NO REVIEW@@@@-@-@-@-@80@-@-@@@-@@7/1/2007@-@2007_536@@-@-@@@II@II@@-@-@Endpoint over 2 years.@-@@@@MONO@VORINOSTAT@@@@@VORINOSTAT||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@ZOLINZA@@@@@ZOLINZA||||@HDAC@@@@@HDAC||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918716@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@LAKE FOREST, ILLINOIS@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918716@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@NO@@@NO REVIEW@@@@100%@Acquired via takeover of Mayne Pharma@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, August 1985@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@32@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@32@32@1.04E+16@SOLUTION FOR INFUSION, VIAL@GB£@@@@@@@@2.5@G@2.5 G/100 ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920801@Onco@@@@@300f1020ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920801@Kytril Injection is indicated for a) the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and b) the prevention and treatment of postoperative nausea and vomiting. Kytril Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.@@NO@-@@NO REVIEW@@@@100%@-@-@-@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@N/A@@@-@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@-@No@-@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@DISCONTINUED@@@SSN@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@-@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@-@@@@@UNCONTROLLED@@@@@@@Invalid Factory Price@@@@@-@-@@@3@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@28093045@INJECTABLE PREPARATION SYRINGE, 1 ML@EURO@@@@@@@@3@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14923370@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923370@@@NO@@@NO REVIEW@@@@@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@KADE@@@@@KADE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOKADIN@@@@@TAMOKADIN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@30@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919782@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@BAD VILBEL, GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919782@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Jan-91@1/1/1991@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@STADA ARZNEIMITTEL@BAYVIT@@@@STADA ARZNEIMITTEL|BAYVIT|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@500@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16385993@Onco@@@@@300f1014ntsdm@@@@@@@@L01XC07@L01X@YES@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16385993@AVASTIN in combination with fluoropyrimidine-based chemotherapy is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.@Both@NON-FORMULARY@8.06.2007@@@@@@0%@@FIRST-LINE@NCT00069095@1400@The recommended dose of Avastin is 7.5 mg/kg of body weight every 2 weekds@Health Canada, 9 September 2005@9/9/2005@@@@@Gastrointestinal perforations complicated by intra-abdominal abscesses or fistula formation with possible fatal outcome, wound healing complications, hemorrhage, arterial thromboembolic events when Avastin used in combination with chemotherapy, severe hypertension, reversible posterior leukoencephalopathy syndrome, neutropenia and infectionwhen Avastin used in combination with myelodispressive chemotherapy, proteinuria, congestive heart failure.@NO16966@No@@Adult patients ≥ 18 years of age with Metastatic colorectal cancer and ≥ 1 target lesion.@@ADULTS@III@APPROVED@@@@@@@@@COMBO@BEVACIZUMAB@CAPECITABINE@OXALIPLATINE@@@BEVACIZUMAB|CAPECITABINE|OXALIPLATINE||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@XELOX@@@@AVASTIN|XELOX|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@FACTORIAL ASSIGNMENT@@@76.5@kg@Invalid Factory Price@@@9.4@month@9.4 month@@@@1@0.7881@@@@@@@@@@@@@@21@@mg/kg@7.5@1@@@@@@@@@@@@@@@INJECTION@C$@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14923277@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@PARIS, FRANCE@@@@@14923277@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NO@@@NO REVIEW@@@@90%@Licensed from SRI International@@@@Initiation of therapy: is most conveniently carried out in hospital; 0.5ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact.@EMA, 1 January 1996@1/1/1996@8/28/1986@@@@Patients known to suffer from depression should be carefully monitored during treatment with Suprefact. Prostatic carcinoma: Monitoring of the effect of clinical effect of Suprefact is carried out by methods generally used in prostatic carcinoma. Initially serum testosterone levels rise and a clinical effect will not be seen until levels start to fall into therapeutic (castration) range. Disease flare (temporary deterioration of the patient's condition) has been reported at the beginning of the treatment. The incidence is variable, but of the order of the 10%. Symptoms are usually confined to transient increase in pain, but the exact nature depends on the site of the lesions. Neurological sequelae have been reported where secondary deposits impinge upon the spinal cord or CNS. Disease flare is prevented by the prophylactic use of an anti-androgen, e.g. cyproterone acetate, 300 mg daily. It is recommended that the treatment should be started at least 3 days before the first dose of Suprefact and continued for at least 3 weeks after commencement of the Suprefact therapy.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SUPREFACT@@@@@SUPREFACT||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@2@1.1511@34.24@53.45@37.04@@@@@@@@@@3.11@@@@@@@@@@@@@@@@8/4/2017@17.12@17.12@969626@INJECTABLE SOLUTION, 5.5 ML@EURO@@@@@@@@5.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14923003@Onco@@@@@@@@@@@Weekly infusion of epratuzumab for four weeks, followed by a weekly infusion of rituximab for four weeks. @@-@-@-@MORRIS PLAINS, NEW JERSEY@@@Naked humanized antibody targeting CD22 receptors on B-lymphocytes.  Primary use is for the treatment of indolent and aggressive NHLs, and for autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren's Syndrome.  Every year there are 56,000 newly diagnosed cases of NHL and 25,000 deaths.  SLE afflicts up to 1.4 million in the U.S.  In May 2006, epratuzumab was licensed to UCB, S.A. for all autoimmune disease indications worldwide.  A Phase IIb clinical trial for SLE is currently enrolling patients.  Additionally, there are three NCI-sponsored trials in oncology ongoing.@@14923003@Follicular or indolent NHL; combo with Rituxan@@-@-@@NO REVIEW@@@SEPTEMBER 2001-@-@UCB Pharma holds non-oncology rights, with option for a buy-in. North American rights were licensed to Amgen, but returned to Immunomedics in April 2004.@-@-@32@-@-@@@-@@@-@-@@-@-@@@II; EUROPEAN TRIAL@II@@-@-@20 patients (62%) displayed an objective response to treatment, with 25% of patients achieving a complete response and 37% achieving partial response. The median response duration was 16.5 months, and median time to progression was 11 months. SOURCE: Immunomedics, December 2005@-@@@@MONO@EPRATUZUMAB@@@@@EPRATUZUMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@LYMPHOCIDE@IMMU-102@@@@LYMPHOCIDE|IMMU-102|||@mAb@Humanised@CD22@@@mAb|Humanised|CD22||@RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@-@@@@@MULTI-CENTRE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16423938@Onco@@@@@@@@@@@"HBI-8000, Experimental, Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
"@@@@@UNITED STATES@3/1/2019@@@@16423938@A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)@Both@@@@@Oral, twice weekly@@@@@FIRST-LINE@NCT02955589@30@@@@@@@11/1/2016@@HBI-8000-210@@@-1. Histopathological, or cytological diagnosis of ATL confirmed as seropositive for anti-Human T-lymphotrophic Virus type-I (HTLV-I) antibody  2. Acute, lymphoma and unfavorable chronic types. The unfavorable chronic type is defined by the presence of at@@ADULTS@Phase 2@II@@@@@@@@@MONO@-@@@@@-||||@HUYA BIOSCIENCE@@@@@HUYA BIOSCIENCE||||@Japan@@@@@Japan|||||||||@T-Cell Lymphoma@@@@@T-Cell Lymphoma|||||||||@HBI-8000@@@@@HBI-8000||||@Other@@@@@Other||||@Objective Response Rate@@@@@Objective Response Rate by disease subtype@Median duration of progression-free survival (PFS)@@@@RELAPSED@REFRACTORY@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924723@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dastatinib monotherapy@@L01XE06@L01X@-@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14924723@Triple-negative breast cancer@@NO@-@@NO REVIEW@@@@-@-@-@NCT00371254@45@-@-@@@-@@12/1/2006@-@-@@APRIL 2020 ('746); PATENT EXTENSION FILED.@-@@@II@II@@-@-@Results expected in December 2008.@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@RELAPSED@TRIPLE NEGATIVE@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923056@Onco@@@@@300f1015ntsdm@@@@@@In arm 1, patients with duodeno-pancreatic tumors will be treated with 5FU/streptozotocin IV (5FU 400mg/m2/d  day1 to day5;streptozotocin 500mg/m2/d/IV day1 to day5;day1=day42) every 6 weeks, plus Avastin 7.5mg/kg IV every 3 weeks. In arm 2, patients with gastrointestinal tract tumors will be treated with Xeloda 1000mg/m2 po bid day 1 to day 14 plus Avastin 7.5mg/kg IV day1=day21 every 3 weeks.@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14923056@Avastin with chemotherapy in patients with progressive advanced/metastatic well-diferentiated endocrine tumors of the gastrointestinal tract.@@-@-@@NO REVIEW@@@@-@-@-@NCT00448136@<100@-@-@@@-@@6/1/2007@-@-@@-@-@@@II@II@@-@-@Not yet available@-@@@@MONO@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15048221@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ponatinib: 45 mg tablet taken orally once daily@@L01XE24@L01X@YES@CAMBRIDGE, MASSACHUSSETTS@10/1/2020@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@15048221@Treatment of adult patients with T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase). Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.@@NA@@@NO REVIEW@@@@@@@NCT01207440@440@@FDA, 14 December 2012@12/14/2012@@Yes@@9/1/2010@Arterial ThrombosisHepatoxicity@PACE@No@@@@@II@APPROVED@@@NA@showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to prior tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD's ongoing Phase 3 EPIC trial comparing ponatinib to imatinib in newly diagnosed chronic-phase CML patients. [Ariad, 30 August 2012, http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1730090&highlight= ]@The US FDA investigates reports of serious and life-threatening blood clots in patients taking Iclusig[FDA, 11 October 2013, http://www.fda.gov/Drugs/DrugSafety/ucm370945.htm ]The most common side effects observed in the study to date were consistent with the known safety profile of ridaforolimus and included stomatitis (e.g., mouth sores), fatigue, diarrhea and thrombocytopenia.@@@@MONO@PONATINIB@@@@@PONATINIB||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN LABEL@SINGLE-ARM@@@@1@1@Invalid Factory Price@@@531@day@531 day@@@@60@1@@@@@@@@@@@@@@1@@mg@45@1@@@@@@@@@@@@@@76189-0535-60@TABLET@US$@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921836@Onco@@@@@300f1014ntsdm@@@@@@"Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

All patients are followed at 4 weeks after completion of protocol therapy. Patients with ongoing complete response, partial response, or stable disease are followed every 3 months thereafter until relapse."@@-@-@-@BRENTFORD, UNITED KINGDOM@@@Ispinesib is a novel small molecule drug candidate that inhibits cell proliferation and promotes cancer cell death by specifically disrupting the function of a cytoskeletal protein known as kinesin spindle protein, or KSP. Current drugs that inhibit cell proliferation, such as paclitaxel and docetaxel, are standard treatments for many types of cancers, but these drugs also target other proteins that are essential to other important cellular functions and thus, their use is limited by side effects. @@14921836@-@@-@-@@NO REVIEW@@@@-@Part of wide-ranging 2001 partnership between Cytokinetics and GSK to discover and commercialise small moleculaes targeting mitotic kinesins in cancer; being positioned against Nexavar and Sutent@-@NCT00095953@25@-@-@@@-@@@-@CAN-NCIC-IND169@@-@-@@@II@II@@-@-@">> Cytokinetics is discontinuing research activities related to oncology. [Cytokinetics, 16.09.2008]
>> Analysis of first stage in 17 evaluable patients; stable disease in 6 patients; required 1 PR to proceed to second stage. [Cytokinetics, June 2007]"@-@@@@-@ISPINESIB@@@@@ISPINESIB||||@GSK@CYTOKINETICS@@@@GSK|CYTOKINETICS|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@SB-715992@@@@@SB-715992||||@KSP Inhibitor@@@@@KSP Inhibitor||||@PARTIAL RESPONSE@RECIST@STABLE DISEASE@@@STABLE DISEASE@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16384815@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384815@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@GKV@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@33924.59613@@@1@year@1 year@33924.6@33924.6@92.94@30@1.1511@2733.65@3407.95@2772.15@@@@@@@@@@0.23@1@@mg/m²@340@1@@@@@@@@@@@8/1/2017@91.12@91.12@1755195@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918965@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Administered as a three-hour intravenous infusion every three weeks@@-@-@-@HAYWARD, CALIFORNIA@@@KOS-1584 is Kosan's lead epothilone and is designed to be differentiated from other epothilones and to have a broad therapeutic index. KOS-1584 is a highly potent compound with favorable tissue distribution, long half-life and ease of formulation. Many cancers are treated with a taxane (the active ingredient in Taxol and Taxotere). Taxanes are cytotoxic agents with a mechanism of action that induces cell death by inhibiting cell division. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-sensitive and taxane-resistant tumors. Kosan's epothilones have demonstrated activity against a wide range of tumors and have the potential to overcome multi-drug resistance and to be synergistic with combination therapy@@14918965@-@@-@-@@NO REVIEW@@@@-@>> BMS acquires Kosan Biosciences for US$190 million. [BMS, 29 May 2008]      >> Partnership terminated due to reprioritisation at Roche. Kosan reacquires all rights. [Kosan, 25 October 2007]            >> Kosan and Roche established a global development and commercialization agreement for epothilones to treat cancer in September 2002.@-@-@45@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Antitumor activity was observed in 17% of 37 patients with advanced solid tumors who had been heavily pre-treated (median of five prior chemotherapy regimens). One confirmed partial response (44% tumor shrinkage by RECIST) was observed in a patient with non-small cell lung cancer. One patient with advanced refractory ovarian cancer had a 40% decrease in CA125 tumor marker, and four patients experienced stable disease over four or more cycles of treatment (greater than or equal to 16 weeks). Common toxicities were generally low-grade and typical of a cytotoxic agent and were most frequently gastrointestinal. SOURCE: Kosan@-@@@@MONO@-@@@@@-||||@KOSAN BIOSCIENCES@BMS@@@@KOSAN BIOSCIENCES|BMS|||@@@@@@|||||||||@Solid Tumours@Ovarian Cancer@NSCLC@@@Solid Tumours|Ovarian Cancer|NSCLC|||||||@KOS-1584@R-1645@@@@KOS-1584|R-1645|||@Epothilone@@@@@Epothilone||||@RECIST@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922451@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CP-751,871 IV every 3 weeks with daily dosing of Sutent [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@6/1/2011@@CP-751,871, a fully human monoclonal antibody, is a highly specific inhibitor of the IGF-1R pathway. The IGF-1R pathway is one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumour cells. @@14922451@CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp.@-@NCT00729833@45@-@-@@@-@@9/1/2008@-@A4021024@@-@>> Histologically or cytologically confirmed advanced solid tumors relapsed or refractory to standard therapy or for whom no standard therapy exists. >> ECOG Performance Status of 0, 1, or 2@@@I@I@@-@-@Trial registered. [Pfizer, 30.07.2007]@-@@@@COMBO@FIGITUMUMAB@SUNITINIB@@@@FIGITUMUMAB|SUNITINIB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CP-751,871@SUTENT@@@@CP-751,871|SUTENT|||@mAb@Human@@@@mAb|Human|||@MAXIMUM TOLERATED DOSE@@@@@SAFETY@PHARMACOKINETICS@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16387357@Onco@@@@@300f1015ntsdm@@@@@@@@L01XC07@L01X@@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16387357@Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations@@YES@@@@@@@@@FIRST-LINE@@152@The recommended dose of Avastin when used in addition to erlotinib is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.It is recommended that the treatment with Avastin in addition to erlotinib is continued until disease progression.@EMA, 2 June 2016@6/2/2016@@No@@@@JO25567@No@@@EGFR activating mutations@@II@APPROVED@@@@@@@@@COMBO@BEVACIZUMAB@ERLOTINIB@@@@BEVACIZUMAB|ERLOTINIB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AVASTIN@TARCEVA@@@@AVASTIN|TARCEVA|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@REPONSE RATE@DISEASE CONTROL RATE@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@MULTI-CENTRE@@@76.5@kg@66031.27628@@@16@month@16 month@66031.28@66031.28@135.68@1@1.1511@248.31@@@@@@@@@@@@2.48@21@@mg/kg@15@1@@@@@@@@@@@8/2/2017@248.31@248.31@9261104T@SOLUTION FOR PERFUSION  4 ML@EURO@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
15396681@Onco@@@@@300f1018ntsdm@@@@@@Ponatinib: 45 mg tablet taken orally once daily@@L01XE24@L01X@@CAMBRIDGE, MASSACHUSSETTS@10/1/2020@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@15396681@Iclusig is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid Ieukaemiawhose disease is resistant to, or who are intolerant of at least two priortyrosine kinase inhibitors; or where there is a T315I mutation.@@NO@1-Nov-15@11/1/2015@NO REVIEW@@@@100%@@@NCT01207440@440@The recommended starting dose of ICLUSIG is 45 mg once daily, taken at the same approximate time each day. Treatment should be continued as long as the patient does not show evidence of diseaseprogression or unacceptable toxicity.@TGA, 26 November 2014@11/26/2014@@No@@9/1/2010@@PACE@No@@@@@II@APPROVED@@@PBS@@@@@@MONO@PONATINIB@@@@@PONATINIB||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN LABEL@SINGLE-ARM@@@@1@1@46194.765@@@219@day@219 day@46194.77@46194.77@210.94@30@0.779@6328.05@6474.92@6397.99@@@@@@@@@@4.69@1@@mg@45@1@@@@@@@@@@@8/1/2017@210.94@210.94@1726-2074-GE-TS@FILM-COATED TABLET@A$@@@@@@@@45@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14924070@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@NEW YORK, NEW YORK@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14924070@VePesid (etoposide) is indicated in the management of: Small Cell Lung Cancer—VePesid Capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.@@NO@-@@NO REVIEW@@@@100%@-@-@-@-@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@N/A@@@-@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@VEPESID@@@@@VEPESID||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1229@116.11@191.63@121.34@@@@@@@@@@0.12@@@@@@@@@@@@@@@@6/7/2017@5.81@5.81@24639039@CAPSULE@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921307@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Group I: The first 30 patients to achieve and maintain a partial response (PR) or better receive autologous immunoglobulin idiotype-KLH conjugate vaccine subcutaneously (SC) on day 1 and sargramostim SC on days 1-4 beginning 26 weeks after the last dose of rituximab. Treatment repeats every 2 weeks for 14 weeks (8 immunizations).  Group II: All subsequent patients who achieve a PR or better receive autologous immunoglobulin idiotype-KLH conjugate vaccine and sargramostim SC as in group I beginning 13 weeks after the last dose of rituximab. Group III: Patients who are not eligible for group I or II and, in the investigator's opinion, are suitable candidates for immunization with autologous immunoglobulin idiotype-KLH conjugate vaccine and sargramostim SC receive the same treatment as groups I and II, beginning no more than 1 year after the last (fourth) dose of rituximab. SOURCE: clinicaltrials.gov@@-@-@-@FREMONT, CALIFORNIA@@@@@14921307@MyVax plus sargramostim after Rituxan@@-@-@@NO REVIEW@@@@-@-@-@NCT00071955@120@-@-@@@-@@3/1/2003@-@GENITOPE-2002-09@@-@-@@@II@CLINICAL HOLD@@-@-@After a review of the data from the pivotal Phase III trial, the FDA has communicated to Genitope that, in light of the Phase 3 clinical trial's failure to meet its primary endpoint, one or more additional Phase 3 clinical trials for MyVax personalized immunotherapy would be required before the FDA would accept a Biologics License Application for FDA review. Genitope has determined that it is not feasible at this time to pursue further clinical trials of MyVax personalized immunotherapy prior to receipt of FDA approval. Genitope is evaluating its alternatives with respect to the MyVax personalized immunotherapy program. SOURCE: Genitope press release, 10 March 2008@-@@@@COMBO@-@@@@@-||||@GENITOPE@@@@@GENITOPE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MYVAX@GTOP-99@@@@MYVAX|GTOP-99|||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923676@Onco@@@@@300f1008ntsdm@@@@@@-@@N02AB03@N02A@-@-@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals. @@14923676@Cancer pain@@-@-@@NO REVIEW@@@@-@"Hisamitsu has entered into an agreement with Kyowa Hakko for the joint sales in Japan of transdermal fentanyl cancer analgesic HFT-290. Under the terms of the agreement, each company will carry out independent distribution and marketing activities for the product, but will use the same brand name. SOURCE: Kyowa Hakko, 19 June 2008

Licensing deal signed in April 2005"@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@@-@-@@@@-@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@NIPPON SHINYAKU@HISAMITSU@KYOWA HAKKO KOGYO@KIRIN PHARMA@@NIPPON SHINYAKU|HISAMITSU|KYOWA HAKKO KOGYO|KIRIN PHARMA|@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@HFT-290@@@@@HFT-290||||@Opioid Analgesic@@@@@Opioid Analgesic||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TRANSDERMAL@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921843@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMN-107 continuous daily dosing@@-@-@-@BASEL, SWITZERLAND@9/1/2007@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@14921843@Gleevec resistant/intolerant CML in adult patients@@-@-@@NO REVIEW@@@@-@-@-@NCT00109707@800@-@-@@@-@@5/1/2004@-@CAMN107A2101@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924949@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-162 alone@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma. @@14924949@Relapsed or plateu-phase multiple myeloma@@-@-@@NO REVIEW@@@@-@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@-@NCT00259740@100@-@-@@@-@@11/1/2005@-@20050134@@-@-@@@Denosumab MM Phase 2 Study@II@@-@-@Trial registered. [Amgen, 29.11.2005]@-@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@AMG-162@@@@@AMG-162||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@COMPLETE RESPONSE@PARTIAL RESPONSE@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917405@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917405@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90%@@@@@Malignant Melanoma: Dacarbazine can be administered as single agent in doses of 200 to 250 mg/m² body surface area/day as an i.v. injection for 5 days every 3 weeks. As an alternative to an intravenous bolus injection dacarbazine can be administered as a short-term infusion (over 15 - 30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as intravenous infusion.@10-Jul-07@7/10/2007@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MADAUS@@@@@MADAUS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@DTIC-DOME@@@@@DTIC-DOME||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14917574@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L02AE02@L02A@NO@OSAKA, JAPAN@@@This is a synthetic nonapeptide analogue of naturally occurring gonadotrophin releasing hormone (GnRH) which possesses greater potency than the natural hormone. It is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy. Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Oestradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.@@14917574@Treatment of metastatic prostate cancer; metastatic breast cancer; uterine fibroids; precocious puberty; and endometriosis@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@One injection every four weeks.@@@@No@@@@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@TAKEDA PHARMACEUTICAL@@@@@TAKEDA PHARMACEUTICAL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ENANTONE MONATS DEPOT@@@@@ENANTONE MONATS DEPOT||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@130.42@175.87@135.22@@@@@@@@@@34.78@@@@@@@@@@@@@@@@8/15/2017@130.42@130.42@3891927@PREFILLED SYRINGE 1 ML@EURO@@@@@@@@3.75@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16384819@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384819@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@YES@@@NO REVIEW@@@@90%@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@SNS@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@28149.72637@@@1@year@1 year@28149.73@28149.73@77.12@120@1.1511@2268.31@2417.19@2275.85@@@@@@@@@@0.19@1@@mg/m²@340@1@@@@@@@@@@@8/4/2017@18.9@18.9@741975@CAPSULE@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15400323@Onco@@@@@300f1008ntsdm@@@@@@@@L01CX01@L01C@@@@@Yondelis (trabectedin, ET-743) was originally isolated from the marine tunicate Ecteinascidia turbinata. Yondelis has a novel mechanism of action. It is a unique anti cancer agent that binds into the minor groove of the DNA and interacts with DNA repair enzymes and transcription factors, interfering with different cell cycle processes. In addition to STS, Yondelis is being developed in a pivotal Phase III trial in ovarian cancer and in Phase II in prostate and breast cancers. Yondelis was designated Orphan Drug for STS by the European Commission (E.C.) in 2001 and by the U.S. FDA in 2004 and for ovarian cancer by the E.C. in 2003 and by the U.S. FDA in 2005.@@15400323@Malignant soft tissue tumors@@NA@1-Nov-15@11/1/2015@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@73@he recommended dose is 1.5 mg/m2 body surface area, administered as an intravenous infusion over 24 hours with a three-week interval between cycles@MHLW, 1 November 2015@11/1/2015@@@@@@@No@@@@@II@APPROVED@@@NHI@@@@@@MONO@TRABECTEDIN@@@@@TRABECTEDIN||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@YONDELIS@@@@@YONDELIS||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@3516234.867@@@5.6@month@5.6 month@3516234.87@3516234.87@20643.71@1@0.0091@41287.42@48688@@@@@@@@@@@165149.68@21@@mg/m²@1.5@1@@@@@@@@@@@8/30/2017@41287.42@41287.42@4291431D1027@INTRAVENOUS INFUSION@YEN@@@@@@@@0.25@MG@0.25 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14923172@Onco@@@@@300f1037ntsdm@@@@@@Savene mixed with specially formulated diluent@@@@NO@COPENHAGEN, DENMARK@@@The exact mechanism by which dexrazoxane exerts its cardioprotective effect has not been fully elucidated, however based on the available evidence the following mechanism has been suggested. The dose-dependent cardiotoxicity observed during anthracycline administration is due to anthracycline-induced iron-dependent free radical oxidative stress on the relatively unprotected cardiac muscle. Dexrazoxane, an analogue of EDTA (ethylene diamine tetra-acetic acid), is hydrolysed in cardiac cells to the ring-opened product ICRF-198. Both dexrazoxane (ICRF-187) and ICRF-198 are capable of chelating metal ions. It is generally thought that they can provide cardioprotection by scavenging metal ions thus preventing the Fe3+-anthracycline complex from redox cycling and forming reactive radicals.@@14923172@Indicated for the treatment of anthracycline extravasation@@@@@NO REVIEW@@@@100%@@@@36@Savene should be given once daily for 3 consecutive days. The recommended dose is: Day one: 1000 mg/m2, Day two: 1000 mg/m2 Day three: 500 mg/m2@@@@@@@Local examination should be performed on regular basis after treatment until resolution. If there is suspicion of extravasation by vesicant compounds other than anthracyclines through thesame IV access, e.g. vincristine, mitomycin, and vinorelbine, Savene would not be effective against the reaction from these compounds. Savene will be administered to patients undergoing cytotoxic therapy with anthracycline containing chemotherapy and its cytotoxic potential (especially resulting in reversible haematological toxicity with a nadir occurring on days 11-12) will therefore be added to that of the other chemotherapy administered. Haematological monitoring should therefore be undertaken regularly.@LABEL@No@@@@@N/A@APPROVED@@NO REVIEW@SNS@1 of the patients required surgery.@@@@@MONO@DEXRAZOXANE HCL@@@@@DEXRAZOXANE HCL||||@TOPOTARGET@@@@@TOPOTARGET||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@SAVENE@@@@@SAVENE||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@EXTRAVASATIONS@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@500@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921739@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Erwinia L-asparaginase administration will be given according to the protocol or non-protocol treatment plan under which the patient is currently being treated. Erwinase will be discontinued in any patient experiencing an allergic reaction or any Grade 3 or higher adverse event believed to be attributable to this agent. [clinicaltrials.gov]@@-@-@-@-@6/1/2009@@@@14921739@Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00693602@72@-@-@@@-@@6/1/2006@-@COMPASSIONATE ACCESS@@-@Patients on treatment for acute lymphoblastic leukemia or non-Hodgkins lymphoma receiving ALL-type therapy who have developed hypersensitivity to E. coli L-asparaginase or PEG-L-asparaginase or both. @-@@III@III@@-@-@Trial registered. [St Jude, 4.06.2008]@-@@@@-@ASPARAGINASE@@@@@ASPARAGINASE||||@EUSA PHARMA@@@@@EUSA PHARMA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Non-Hodgkin's Lymphoma|||||||@ERWINASE@@@@@ERWINASE||||@Enzyme@@@@@Enzyme||||@COMPASSIONATE USE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916741@Onco@@@@@@@@@@@Zybrestat 60MG/M2 for days 1, 8, 15 for 6 cycles with paclitaxel 200MG/M2 day 1 and carboplatin 6AUC on day 1; versus same-dose paclitaxel and carboplatin@@-@-@-@WALTHAM, MASSACHUSSETTS@12/1/2009@@@@14916741@with paclitaxel and carboplatin for anaplastic thyroid cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00507429@180@-@SPA and Fast-track agreement from FDA. SOURCE: Oxigene, 31 May 2007EMEA and FDA orphan drug. SOURCE: Oxigene@5/31/2007@@-@@7/1/2007@-@OXC4T4-302@@-@-@@@III@III@@-@-@>>Fosbretabulin, administered as a single agent to ATC patients who had progressed or relapsed following initial therapy, appeared to be well-tolerated with encouraging survival results. [Oxigene 17 March 2009]>>OXiGENE has initiated a total of four clinical trial sites in the United States and India, and anticipates initiating two to three additional sites prior to year-end. Additional regulatory submissions and reviews are in progress to support initiation of further study sites in the United States, Europe, Russia, and Israel beginning in January 2008. Based upon meetings with investigators from approximately 30 sites conducted this fall in India, the United States and Europe, OXiGENE anticipates having substantially all of the study's clinical trial sites initiated by mid-2008. As a result, OXiGENE expects to reach the planned interim analysis by mid-2009. SOURCE: Oxigene, 11 December 2007@-@@@@COMBO@COMBRETASTATIN A4 PRODRUG@PACLITAXEL@CARBOPLATIN@@@COMBRETASTATIN A4 PRODRUG|PACLITAXEL|CARBOPLATIN||@OXIGENE@@@@@OXIGENE||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@ZYBRESTAT@@@@@ZYBRESTAT||||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@PIVOTAL@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923894@Onco@@@@@300f1015ntsdm@@@@@@Thyrogen alone@@H01AB01@H01A@NO@CAMBRIDGE, MASSACHUSSETTS@@@@@14923894@Indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post-thyroidectomy patients maintained on hormone suppression therapy (THST). Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels. Thyrogen is also indicated for pre-therapeutic stimulation in low risk post-thyroidectomy patients maintained on THST for the ablation of thyroid remnant tissue (in combination) with 100 mCi (3.7 GBq) radioactive iodine (131I).@@YES@@@NO REVIEW@@@@@@@@358@The recommended dose regimen is two doses of 0.9 mg thyrotropin alfa administered at a 24-hour interval by intramuscular injection only.@1-Mar-00@3/1/2000@@@@@NONE@LABEL@No@@358 [WELL-DIFFERENTIATED THYROID CANCER]@@@III 2 STUDIES@APPROVED@@ASMR rating of III as a diagnostic@HAUTE AUTORITÉ DE SANTÉ@Total positive withdrawal scans: 79% and 85% detected in first and second trials respectively, 13% and 15% not detected respectively.@@@@@MONO@THYROTROPIN ALFA@@@@@THYROTROPIN ALFA||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@THYROGEN@@@@@THYROGEN||||@Other@@@@@Other||||@DIAGNOSTIC@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@677.28@677.28@@1@1.1511@371.45@@@@@@@@@@@@412.72@@@@@@@@@@@@@@@@8/2/2017@371.45@371.45@9206921R@POWDER FOR SOLUTION FOR INJECTION@EURO@@@@@@@@0.9@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924116@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@5 mg of oral prednisone given twice daily plus 120mg/m2 IV picoplatin in combination with 75mg/m2 docetaxel given every three weeks@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@11/1/2008@@Picoplatin is believed to have an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. @@14924116@Stage IV hormone-refractory prostate cancer@@-@-@@NO REVIEW@@@@-@Poniard granted exclusive rights to IV picoplatin from AnorMed (now part of Genzyme)@FIRST-LINE@NCT00448734@30@-@-@@@-@@6/1/2006@-@-@@-@30 PATIENTS WHO HAVE NOT RECEIVED PREVIOUS CHEMO.@@@II@II@@-@-@Enrolment completed in January 2008. Results expected in Q4 2008.@-@@@@COMBO@PICOPLATIN@DOCETAXEL@@@@PICOPLATIN|DOCETAXEL|||@PONIARD PHARMACEUTICALS@@@@@PONIARD PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@-@@@@@-||||@Platinum@@@@@Platinum||||@SAFETY@TIME TO PROGRESSION@PSA@@@PSA@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922572@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Nexavar with carboplatin and paclitaxel@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14922572@SCCHN@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@-@NCT00494182@43@-@-@@@-@@4/1/2007@-@2006-0940  @@DECEMBER 2010 (NCE); DECEMBER 2012 (ORPHAN); JUNE 2022 (EXTENSION)@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@COMBO@SORAFENIB TOSYLATE@CARBOPLATIN@PACLITAXEL@@@SORAFENIB TOSYLATE|CARBOPLATIN|PACLITAXEL||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16613314@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@16613314@Indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation.@@@@@NO REVIEW@@@@@@@@@The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient. The entire daily dose may be given at one time. These dosages are for initiation of therapy or for short courses of treatment. The dosage must be carefully adjusted according to the response of the patient and must be reduced as soon as there is an abrupt fall in the white blood cell count. Patients with Hodgkin's disease usually require 0.2 mg/kg daily, whereas patients with other lymphomas or chronic lymphocytic leukemia usually require only 0.1 mg/kg daily.@FDA, 18 March 1957@3/18/1957@@@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@NOT AVAILABLE@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Hodgkin's Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Hodgkin's Lymphoma|||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@1@608.19@@@@@@@@@@@@12.16@@@@@@@@@@@@@@@@8/2/2017@24.33@24.33@76388-0635-25@FILM-COATED TABLET@US$@@@@@@@@2@MG@2 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924875@Onco@@@@@@@@@@@Patients will be randomized to receive either Avastin (7.5mg/kg IV on day 1 of each 3 week cycle), in combo with Xeloda (1000mg/m² po bid on days 1-14 of each 3 week cycle), or Xeloda (1000mg/m² po bid on days 1-14 of each 3 week cycle) alone.@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14924875@Avastin in combination with Xeloda for elderly patients with metastatic colorectal cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00484939@100-500@-@-@@@-@@7/1/2007@-@-@@NOT YET AVAILABLE; POTENTIALLY 2018.@100-500 patients aged 70 and above@ELDERLY@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16387794@Onco@@@@@300f1012ntsdm@@@@@@@@L02BG03@L02B@@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@16387794@Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@2579@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@EMA, 27 December 1996@12/27/1996@@@@@@@No@@@@@III@APPROVED@@@GKV@@@@@@ADJUVANT@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@EARLY@@@@@CONTROLLED@DOUBLE-BLIND@@@@1@1@3535.068697@@@24@month@24 month@3535.07@3535.07@4.84@30@1.1511@145.28@194.66@150.55@@@@@@@@@@4.84@1@@mg@1@1@@@@@@@@@@@8/1/2017@4.84@4.84@7511985@FILM-COATED TABLET@EURO@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924580@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were randomly distributed in two study arms: a high dose (6 mg/kg) and a low dose group (2 mg adecatumumab/kg body weight). Within the groups patients were stratifiedaccording to their EpCAM expression of the primary tumor in high EpCAM and low to moderate EpCAM subgroups.@@-@-@-@DARMSTADT, GERMANY@@@Adecatumumab, also known as MT201, is a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors, and is Micromet's third candidate. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer.@@14924580@-@@-@-@@NO REVIEW@@@@-@Microment responsible for Phase Ib trial with docetaxel for metastatic breast cancer and monotherapy for solid tumours; Serono reimburses Micromet for its costs. SOURCE: Micromet, 5 December 2006@-@-@81@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Sera from 87 patients were analyzed for Immunogenicity at week 8/10, week 24 and 4 weeks after end of treatment. All sera except for one were termed negative(86 out of 87), one was false positive.@-@@@@MONO@ADECATUMUMAB@@@@@ADECATUMUMAB||||@MERCK SERONO@MICROMET@@@@MERCK SERONO|MICROMET|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MT-201@@@@@MT-201||||@mAb@Human@EPCAM@@@mAb|Human|EPCAM||@IMMUNOGENICITY@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15412809@Onco@@@@@@@@@@@the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating@@@@@@4/1/2017@@@@15412809@A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Esophageal Squamous Cell Carcinoma(ALTER1102)@Both@@@@@Experimental: Anlotinib. It should be continued until disease progression or intolerable toxicity or patients withdrawal of consentPlacebo Comparator@@-  Advanced esophageal squamous cell carcinoma with distant metastasis(Stage IV),at least one measurable lesion (by RECIST1.1)  -  Patients who at least have failed to a platinum-based chemotherapy treatment or chemotherapy containing paclitaxel.  Note: (@@@@NCT02649361@144@@@@@@@1/1/2016@@ALTN-11-II@@@Histological documentation of esophageal squamous cell carcinoma@@ADULTS@Phase 2@II@@@@Overall Survival@Objective Response Rate@@@@@ANLOTINIB@@@@@ANLOTINIB||||@@@@@@||||@China@@@@@China|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@Anlotinib, Experimental, Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consentPlacebo, Placebo Comparator, Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent@Progress free survival@@@@@@@@@@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917102@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01DC01@L01D@YES@@@@@@14917102@a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones. b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. c. Testicular teratoma d. Malignant effusions of serous cavities. e. Secondary indications in which Bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Malignant lymphomas: Used alone the recommended dosage regime is 15 x 10³ IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 10³ IU (15 vials). Dosage should be reduced in the elderly. The dose may need to be adjusted when bleomycin is used in combination chemotherapy.@@@@@@@Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course. If breathlessness or infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteriod and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases. Lung function tests which use 100% oxygen should not be used in patients who have been treated with Bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@BLEOMYCIN@@@@@BLEOMYCIN||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Head & Neck Cancer@Cervical Cancer@Oesophageal Cancer@Melanoma / Skin Cancer@Testicular Cancer@Head & Neck Cancer|Cervical Cancer|Oesophageal Cancer|Melanoma / Skin Cancer|Testicular Cancer|||||@BLEOMEDAC@@@@@BLEOMEDAC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@52@76.73@54.34@@@@@@@@@@3.47@@@@@@@@@@@@@@@@8/15/2017@52@52@2411351@DRY SUBSTANCE WITHOUT SOLVANT@EURO@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16396643@Onco@@@@@300f1014ntsdm@@@@@@Patients in the Revlimid/dexamethasone arm (n=170) took 25 mg of Revlimid orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone arm (n= 171)took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Patients in both treatment arms took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396643@Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.@@YES@@@NO REVIEW@@@@@@SECOND-LINE@@704@The recommended starting dose of REVLIMID® for multiple myeloma patients is 25 mg/day administered as a single 25 mg capsule on Days 121 of repeated 28day cycles.@@@@@@@@LABEL@No@@PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST ONE PRIOR TREATMENT WERE RANDOMIZED TO 2 ARMS: ARM1: REVLIMID (LENALIDOMIDE) PLUS ORAL PULSE HIGHDOSE DEXAMETHASONE THERAPY. ARM2: DEXAMETHASONE THERAPY ALONE.@@@III@APPROVED@@@RAMQ@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@TIME TO PROGRESSION@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@PLACEBO-CONTROLLED@@1@1@552743.3145@@@48.1@month@48.1 month@552743.31@552743.31@377.81@21@0.7881@8463@@@@@@@@@@@@20.15@28@@mg@25@21@@@@@@@@@@@7/19/2017@403@403@244060121@HARD CAPSULE@C$@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918737@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Breast Cancer: Intradermal administration of Lymphoseek: Inject 0.2 - 0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2 -.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2 - 0.4 in multiple divided injections or a single injection into the subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0 - 4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma patients intradermal administration of Lymphoseek: Inject 0.2 - 0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.  SOURCE: clinicaltrials.gov@@-@-@-@-@1/1/2009@@@@14918737@Lymphoseek and vital blue dye as lymphoid tissue targeting agents in patients with known melanoma or breast cancer who are undergoing lymph node mapping@@-@-@@NO REVIEW@@@@-@-@-@NCT00671918@238@-@Filing expected in H1 2009. SOURCE: Neoprobe, 9 June 2008EMEA PDCO recommended product-specific waiver. SOURCE: EMEA PDCO, January 2008Orphan designation was granted by the European Commission for panobinostat lactate for the treatment of cutaneous T cell lymphoma. [There is discussion of current treatments, the numbers or persons affected with this condition in the EU, and the mode of action & state of development of panobinostat lactate for the treatment of this condition. Panobinostat lactate was not authorised anywhere in the world for cutaneous T-cell lymphoma, or designated as orphan medicinal product elsewhere for this condition, at the time of submission. Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.] SOURCE: EMEA COMP, 6 November 2007@6/9/2008@@-@@4/1/2008@-@NEO3-05@@-@-@@@III@III@@-@-@Trial started. SOURCE: Neoprobe, 9 June 2008@-@@@@MONO@-@@@@@-||||@NEOPROBE@@@@@NEOPROBE||||@@@@@@|||||||||@Melanoma / Skin Cancer@Breast Cancer@@@@Melanoma / Skin Cancer|Breast Cancer||||||||@LYMPHOSEEK@@@@@LYMPHOSEEK||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384835@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384835@Indicated for the adjuvant treatment of adult patients who are at significant risk of relapse followingresection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrenceshould not receive adjuvant treatment.@@NO@@@@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The recommended dose of Glivec is 400 mg/day for the adjuvant treatment of adult patients followingresection of GIST. Optimal treatment duration is not yet established. Length of treatment in theclinical trial supporting this indication was 36 months@@@@Yes@@@@@No@@@@@@APPROVED@@@GKV@@@@@@ADJUVANT@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1@1@104776.0635@@@36@month@36 month@104776.06@104776.06@95.69@60@1.1511@1435.32@1816.59@1473.82@@@@@@@@@@0.24@1@@mg@400@1@@@@@@@@@@@8/1/2017@23.92@23.92@1755166@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922508@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Vorinostat and 5-FU infusion@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@6/1/2009@@Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (ClassI) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removalof acetyl groups from the lysine residues of proteins, including histones and transcription factors. In somecancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenictranscription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones isassociated with a condensed chromatin structure and repression of gene transcription. Inhibition ofHDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in anopen chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation ofacetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. Themechanism of the antineoplastic effect of vorinostat has not been fully characterized.@@14922508@Patients who have failed standard 5-FU regimens@@-@-@@NO REVIEW@@@@-@-@-@NCT00336141@77@-@-@@@-@@6/1/2006@-@3C-05-3@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@VORINOSTAT@FLUOROURACIL@@@@VORINOSTAT|FLUOROURACIL|||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ZOLINZA@5-FU@@@@ZOLINZA|5-FU|||@HDAC@@@@@HDAC||||@TOXICITY@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16074598@Onco@@@@@300f1018ntsdm@@@@@@Patients received OPDIVO (n=292) administered intravenously at 3 mg/kg every 2 weeks or docetaxel (n=290) administered intravenously at 75 mg/m2 every 3 weeks.@@L01XC17@L01X@@NEW YORK, NEW YORK@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16074598@OPDIVO, as monotherapy is indicated for the treatment of locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC) with progression on or after prior chemotherapy.@Both@YES@@@NO REVIEW@@@@@@SECOND-LINE@@582@The recommended dose of OPDIVO as a monotherapy is 3 mg/kg administered intravenously over 60 minutes every 2 weeks. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient.@TGA, 17 February 2016@2/17/2016@@No@@@@@No@@@@ADULTS@@APPROVED@@@@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@METASTATIC@NON-SQUAMOUS@@@@RANDOMIZED@OPEN-LABEL@@@@76.5@kg@24126.64277@@@2.33@month@2.33 month@24126.64@24126.64@340.44@1@0.779@2076.75@@@@@@@@@@@@20.77@14@@mg/kg@3@1@@@@@@@@@@@8/1/2017@2076.75@2076.75@2504-1868-IN-BQ@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL) - 10 ML@A$@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14921686@Onco@@@@@@@@@@@PAD versus vincristine, adriamycin and dexamethastone@@L01XX32@L01X@-@BEERSE, BELGIUM@@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@14921686@Second-line MM@@-@-@@NO REVIEW@@@STARTED IN OCTOBER 2006@-@Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones for extra-U.S. marketing rights since the US$15 mil deal (plus US$125 mil following European approval) between Ortho and Millennium in June 2003. Ortho also reimbursed around @SECOND-LINE@NCT00441168@212@-@-@@@-@@@-@CR011065  @@-@-@@@II@II@@-@-@IMW June 2007 update on 40 evaluable patients on PAD therapy; 29% CR increased to 57% after stem cell transplantation; survival at years 1 and 2 were 100% and 95%.@-@@@@COMBO@BORTEZOMIB@ADRIAMYCIN@DEXAMETHASONE@@@BORTEZOMIB|ADRIAMYCIN|DEXAMETHASONE||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@VELCADE@PAD@@@@VELCADE|PAD|||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@SAFETY@COMPLETE RESPONSE@PARTIAL RESPONSE@@@PARTIAL RESPONSE@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919605@Onco@@@@@300f1012ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@ULM, GERMANY@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14919605@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@@@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@APPROVED@@@GKV@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@UNCONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@12.56@26.87@13.66@@@@@@@@@@6.28@@@@@@@@@@@@@@@@8/1/2017@12.56@12.56@6607499@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916000@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients who meet all entry criteria will be administered 600 mg/m2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).@@-@-@-@TOKYO, JAPAN@4/1/2008@@@@14916000@Treatment of advanced stage malignancy of the kidney in patients who have not had previous immune-based therapies or treatment of advanced stage malignancies (cancerous growths) of the ovary, breast, colon, or hormone-refractory prostate in patients who have failed at least one but no more than two prior regimens of chemotherapy.@@-@-@@NO REVIEW@@@@-@Eisai acquired through takeover of MGI Pharma.@-@NCT00381173@20@-@-@@@-@@9/1/2006@-@ZYC3-002@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@CYCLOPHOSPHAMIDE@@@@-|CYCLOPHOSPHAMIDE|||@EISAI@MGI PHARMA@@@@EISAI|MGI PHARMA|||@@@@@@|||||||||@Kidney Cancer@Ovarian Cancer@Breast Cancer@Colorectal Cancer@HRPC@Kidney Cancer|Ovarian Cancer|Breast Cancer|Colorectal Cancer|HRPC|||||@ZYC-300@@@@@ZYC-300||||@Other@@@@@Other||||@SAFETY@TOLERABILITY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16669297@Onco@@@@@300f1018ntsdm@@@@@NEOSPHERE@FOUR ARM@@L01XC13@L01X@@BASEL, SWITZERLAND@2/1/2015@@Pertuzumab is a humanized antibody and the first in a new class of agents known as HER dimerization inhibitors (HDIs). HDIs block the ability of the HER2 receptor to collaborate with other HER receptor family members (HER1/EGFR, HER3, and HER4). In cancer cells, interfering with HER2's ability to collaborate with other HER family receptors blocks cell signaling and may ultimately lead to cancer cell growth inhibition and death of the cancer cell. HDIs, because of their unique mode of action, have the potential to work in a wide variety of tumors, including those that do not overexpress HER2@@16669297@Indicated, in combination with trastuzumab and chemotherapy, for the neoadjuvant treatment of patients with inflammatory or locally advanced HER2-positive breast cancer as part of a complete treatment regimen.@@YES@@@NO REVIEW@@@@0%@@@NCT00545688@417@The recommended initial dose of PERJETA is 840 mg, administered as a 60 min IV infusion, followed by, every 3 weeks, a 420 mg dose administered over 30-60 min. PERJETA should be administered for 3 to 6 cycles in combination with neoadjuvant trastuzumab and chemotherapy, as part of a treatment regimen for inflammatory or locally advanced HER2-positive breast cancer.@TGA, 20 May 2016@5/20/2016@@No@@12/1/2007@@WO20697@No@@locally advanced, inflammatory or early stage invasive breast cancer;HER2 positive (HER2+++ by IHC or FISH/CISH+).@@@II@APPROVED@@@@@@@@@NEOADJUVANT@PERTUZUMAB@TRASTUZUMAB@@@@PERTUZUMAB|TRASTUZUMAB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@PERJETA@HERCEPTIN@@@@PERJETA|HERCEPTIN|||@mAb@Humanised@HER2@@@mAb|Humanised|HER2||@PATHOLOGICAL COMPLETE RESPONSE@@@@@PROGRESSION FREE SURVIVAL@SAFETY@@@@ADVANCED@@@@@RANDOMISED@OPEN LABEL@PARALLEL ASSIGNMENT@@@1@1@16385.97333@@@13@week@13 week@16385.97@16385.97@180.07@1@0.779@3072.37@@@@@@@@@@@@7.32@21@1@mg@840@1@21@@mg@420@1@@@@@@8/1/2017@3072.37@3072.37@2639-2023-IN-RO@POWDER FOR INJECTION, VIAL - 14 ML@A$@@@@@@@@420@MG@420 MG/14 ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16161990@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC17@L01X@@NEW YORK, NEW YORK@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16161990@BRAF V600 wild-type unresectable or metastatic melanoma, as a single agent@Both@NA@@@NO REVIEW@@@@@@@@418@Modification on 13 September 2016: The currently approved recommended dosage regimens were modified to 240 mg intravenously (IV) every two weeks.  Initial dosing: 3 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity@FDA, 17 May 2016@5/17/2016@12/23/2014@Yes@@@@@No@@Disease characteristics were M1c stage disease (61%), cutaneous melanoma (74%), mucosal melanoma (11%), elevated LDH level (37%), PD-L1 greater than or equal to 5% tumor cell membrane expression (35%), and history of brain metastasis (4%). More patients in the OPDIVO arm had an ECOG performance status of 0 (71% vs. 58%).@@ADULTS@@APPROVED@@@@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@@@@@MULTICENTER@DOUBLE-BLIND@RANDOMIZED@@@1@1@67681.3269@@@5.1@month@5.1 month@67681.33@67681.33@436.31@1@1@2545.15@@@@@@@@@@@@25.45@14@@mg@240@1@@@@@@@@@@@8/2/2017@2545.15@2545.15@00003-3774-12@SOLUTION FOR INJECTION - 10 ML@US$@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16617144@Onco@@@@@300f1010ntsdm@@@@@@Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.@@L01XE27@L01X@@BEERSE, BELGIUM@5/1/2015@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16617144@IMBRUVICA as a single agent is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia@Both@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@NCT01722487@269@420 mg taken orally once daily (three 140 mg capsules once daily); Treatment should continue until disease progression or no longer tolerated by the patient.@EMA, 26 May 2016@5/26/2016@12/29/2014@Yes@@3/1/2013@@PCYC-1115-CA@No@@@@ADULTS@III@APPROVED@@@NHS@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@OVERALL RESPONSE RATE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@Invalid Average Duration of Use@@@@@@@@@120@1.299@6132@@@@@@@@@@@@0.37@1@@mg@420@1@@@@@@@@@@@7/28/2017@51.1@51.1@2.83E+16@CAPSULE@GB£@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924523@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01C@L01C@-@NEW YORK, NEW YORK@@@Ixabepilone is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to ß-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of  ß-II and  ß-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.@@14924523@Hormone-refractory prostate cancer@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@-@48@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@JCO 2005; 14 confirmed PSA responses; 72% of these responders had declines of greater than 80%; 2 patients achieved undectable PSA. Median PFS was 6 months and median survival was 18 months. Researchers concluded that further research is warranted.@-@@@@COMBO@IXABEPILONE@@@@@IXABEPILONE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@IXEMPRA@BMS-247550@@@@IXEMPRA|BMS-247550|||@Epothilone@@@@@Epothilone||||@PSA@@@@@@@@@@REFRACTORY@METASTATIC@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16395636@Onco@@@@@300f1012ntsdm@@@@@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@3/1/2017@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16395636@Treatment of adult patients with relapsed or refractory mantle cell lymphoma@Both@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@NCT00875667@254@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 28 January 2016@1/28/2016@@Yes@@4/1/2009@@CC5013MCL002@No@@Biopsy proven mantle cell lymphoma; Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease; Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2; Willing to follow pregnancy precaution@@ADULTS@II@APPROVED@@@GKV@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@RELAPSED@REFRACTORY@@@@RANDOMISED@MULTI-CENTRE@OPEN LAB EL@@@1@1@246914.4993@@@37.6@week@37.6 week@246914.5@246914.5@938.13@21@1.1511@5253.5@6496.53@5292@@@@@@@@@@50.03@28@@mg@25@21@@@@@@@@@@@8/1/2017@250.17@250.17@1875255@HARD CAPSULE@EURO@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16074592@Onco@@@@@300f1018ntsdm@@@@@@@@L01XC17@L01X@@NEW YORK, NEW YORK@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16074592@OPDIVO, as monotherapy is indicated for the treatment of patients with unresectable (Stage III) or metastatic (Stage IV) melanoma.@@YES@1-May-16@5/1/2016@NO REVIEW@@@@100%@@@@418@The recommended dose of OPDIVO as a monotherapy is 3 mg/kg administered intravenously over 60 minutes every 2 weeks. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient.@TGA, 11 January 2016@1/11/2016@@No@@@@@No@@@@@3@APPROVED@@@PBS@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@@@@@@76.5@kg@52809.38975@@@5.1@month@5.1 month@52809.39@52809.39@340.44@1@0.779@2076.75@@@@@@@@@@@@20.77@14@@mg/kg@3@1@@@@@@@@@@@8/1/2017@2076.75@2076.75@2504-1868-IN-BQ@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL) - 10 ML@A$@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15394371@Onco@@@@@300f1010ntsdm@@@@@@521 patients were randomised to treatment with Teysuno (25 mg/m2 orally twice daily for 21 days followed by a 7-day rest period) and cisplatin (75 mg/m2 intravenous infusion once every 4 weeks); and 508 patients were randomised to treatment with 5-FU (1000 mg/m2/24 hours as a continuous intravenous infusion on Days 1 through 5 repeated every 4 weeks) and cisplatin (100 mg/m2 as an intravenous infusion on Day 1 repeated every 4 weeks).@@L01BC53@L01B@@@@@Teysuno is an oral fluoropyrimidine anti-cancer medicinal product@@15394371@Indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin@Both@NO@@@@@@@100%@@@@1029@The recommended standard dose of Teysuno when administered in combination with cisplatin is25 mg/m2 (expressed as tegafur content) twice daily, morning and evening, for 21 consecutive daysfollowed by 7 days rest (1 treatment cycle). This treatment cycle is repeated every 4 weeks.@EMA, 14 March 2011@3/14/2011@@@@@@FLAGS@No@@@@ADULTS@III@APPROVED@@@NHS@@@@@@COMBO@GIMERACIL / OTERACIL / TEGAFUR@CISPLATIN@@@@GIMERACIL / OTERACIL / TEGAFUR|CISPLATIN|||@NORDIC PHARMA@@@@@NORDIC PHARMA||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TEYSUNO@GENERIC@@@@TEYSUNO|GENERIC|||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMIZED@CONTROLLED@OPEN-LABEL@@@1.75@m²@1417.99392@@@4.8@month@4.8 month@1417.99@1417.99@9.71@126@1.299@279.72@@@@@@@@@@@@0.15@28@@mg/m²@50@21@@@@@@@@@@@7/28/2017@2.22@2.22@2.04E+16@HARD CAPSULE@GB£@@@@@@@@15@MG@4.35 MG|11.8 MG|15 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14971350@Onco@@@@@300f1015ntsdm@@@@@@Combo with prednisone versus mitoxantrone and prednisone@@L01CD04@L01C@@PARIS, FRANCE@9/1/2009@@@@14971350@Combo with prednisone in patients previously treated with Taxotere regimen@@YES@@@NO REVIEW@@@@@@SECOND-LINE@NCT00417079@720@@EMA, 20 March 2011@3/20/2011@@@@12/1/2006@@TROPIC@No@@@@@III@APPROVED@@ASMR III@HAUTE AUTORITÉ DE SANTÉ@"the combination of cabazitaxel and prednisone/prednisolone significantly reduced the risk of death by 28% [HR=0.72 (95% CI: 0.61-0.84); P<0.0001] with an improvement in the median overall survival of 15.1 months vs. 12.7 months in the mitoxantrone combination arm. [Sanofi-Aventis 27 May 2010 http://en.sanofi-aventis.com/press/press_releases/2010/ppc_28560.asp ] The drug ""has good expectation in terms of recruitment."" Submission is scheduled in 2010. SOURCE: sanofi-aventis Q4 earnings call, 12 February 2008"@The most frequent grade 3/4 hematological adverse events with cabazitaxel were neutropenia (81.7%) assessed by laboratory values, leukopenia (68.2%), anemia (10.5%), and febrile neutropenia (7.5%); the most frequent grade 3/4 non-hematological adverse events were diarrhea (6.2%), fatigue (4.9%), and asthenia (4.6%). Discontinuation of treatment due to adverse events occurred in 18.3% of patients in the cabazitaxel arm and 8.4% of patients in the mitoxantrone arm. Most frequent treatment-emergent adverse events leading to discontinuation in the cabazitaxel arm were neutropenia (2.4%), hematuria (1.3%), diarrhea (1.1%) and fatigue (1.1%). Grade 3/4 peripheral neuropathy occurred in 0.5% of patients in the cabazitaxel arm vs. 0.3% in the mitoxantrone arm. Deaths due to adverse events were 4.9% in the cabazitaxel arm (predominantly due to neutropenia and its complications) vs. 1.9% in the mitoxantrone arm.@@@@COMBO@CABAZITAXEL@PREDNISONE@@@@CABAZITAXEL|PREDNISONE|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@JEVTANA@@@@@JEVTANA||||@Taxane@@@@@Taxane||||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@1.75@m²@65383.83888@@@15.1@month@15.1 month@65383.84@65383.84@142.36@1@1.1511@4100@@@@@@@@@@@@68.33@21@@mg/m²@25@1@@@@@@@@@@@8/2/2017@4100@4100@9365950T@SOLUTION FOR PERFUSION@EURO@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918138@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14918138@Used in combination therapy with other approved chemotherapeutics in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy; used in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.@@YES@6-Sep@@NO REVIEW@@@@@@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@5-Apr@@@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@SERB LABORATOIRES@@@@@SERB LABORATOIRES||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920825@Onco@@@@@300f1037ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920825@Kytril Injection is indicated for a) the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and b) the prevention and treatment of postoperative nausea and vomiting. Kytril Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.@@YES@@@NO REVIEW@@@@0%@@@@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@1-May-93@5/1/1993@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@APPROVED@@NO REVIEW@@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@UNCONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@120.5@173.07@128.04@@@@@@@@@@8.03@@@@@@@@@@@@@@@@8/4/2017@24.1@24.1@736488@INTRAVENOUS INJECTION AMPOULE, 3 ML@EURO@@@@@@@@3@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15358230@Onco@@@@@300f1018ntsdm@@@@@@Experimental: Erlotinib. Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.Placebo Comparator: Placebo. Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.@@L01XE03@L01X@@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@15358230@TARCEVA is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not progressed on first-line chemotherapy@Both@NO@@@NO REVIEW@@@@100%@>> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]       >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]        >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@MAINTENANCE@NCT00556712@889@The recommended daily dose is 150 mg. Treatment should continue until disease progression or unacceptable toxicity occurs.@TGA, 16 April 2010@4/16/2010@@@@@@BO18192@No@@histologically documented, locally advanced , recurrent or metastatic NSCLC;measurable disease;no disease progression after 4 cycles of platinum-based chemotherapy.@@ADULTS@III@APPROVED@@@PBS@@@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@CHUGAI PHARMACEUTICAL@@@@ROCHE|CHUGAI PHARMACEUTICAL|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@@4510.668382@@@2.8@month@2.8 month@4510.67@4510.67@52.96@30@0.779@1059.28@1172.86@1129.22@@@@@@@@@@0.35@1@@mg@150@1@@@@@@@@@@@8/1/2017@35.31@35.31@3197-0903-GE-RO@FILM COATED TABLET@A$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15356192@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX46@L01X@@LONDON, UNITED KINGDOM@@@Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumour DNA repair pathway deficiencies to preferentially kill cancer cells. It is the first PARP inhibitor to be approved for patients with germline BRCA-mutated advanced ovarian cancer@@15356192@Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy@@NA@@@@@@@@@FOURTH-LINE@@@Recommended dose is 400 mg taken twice daily. Continue treatment until disease progression or unacceptable toxicity.@FDA, 19 December 2014@12/19/2014@@No@@@@@No@@@@@@APPROVED@@@@Lynparza's efficacy was examined in a study where 137 participants with gBRCAm-associated ovarian cancer received the drug. The study was designed to measure objective response rate (ORR), or the percentage of participants who experienced partial shrinkage or complete disappearance of the tumor. Results showed 34 percent of participants experienced ORR for an average of 7.9 months.[FDA, 19 December 2014, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm]@Common side effects of Lynparza included nausea, fatigue, vomiting, diarrhea, distorted taste (dysgeusia), indigestion (dyspepsia), headache, decreased appetite, common cold-like symptoms (nasopharyngitis), cough, joint paint (arthralgia), musculoskeletal pain, muscle pain (myalgia), back pain, rash (dermatitis) and abdominal pain. Serious side effects included the development of myelodysplastic syndrome, a condition where the bone marrow is unable to produce enough functioning blood cells; acute myeloid leukemia, a bone marrow cancer; and lung inflammation.[FDA, 19 December 2014, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm]@@@@MONO@OLAPARIB@@@@@OLAPARIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@LYNPARZA@@@@@LYNPARZA||||@PARP Inhibitor@@@@@PARP Inhibitor||||@@@@@@@@@@@ADVANCED@@@@@@@@@@1@1@107984.7082@@@7.9@month@7.9 month@107984.71@107984.71@449.4@448@1@12583.2@@@@@@@@@@@@0.56@1@@mg@800@1@@@@@@@@@@@8/2/2017@28.09@28.09@00310-0657-58@HARD CAPSULE@US$@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921660@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Nexavar 800mg daily@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14921660@Lung adenocarcinoma@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@-@NCT00456716@24@-@-@@@-@@@-@CRC 0639   @@DECEMBER 2010 (NCE); DECEMBER 2012 (ORPHAN); JUNE 2022 (EXTENSION)@-@@@SWEDISH MEDICAL CENTRE; @II@@-@-@Completion expected in March 2008.@-@@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@ONYX@@@@BAYER HEALTHCARE|ONYX|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@RESPONSE RATE@OVERALL SURVIVAL@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919334@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@PETACH TIKVA, ISRAEL@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919334@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@6-Sep@@NO REVIEW@@@@@Via Ivax@@@@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@5-Oct@@5/1/2006@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9278122T@SOLUTION TO DILUTE FOR PERFUSION, 50 ML@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921173@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single agent Talvesta@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14921173@-@@-@-@@NO REVIEW@@@@-@Hana receives notice from Nasdaq that it has regained compliance with minimum US$1 bid price. SOURCE: Hana, 28 April 2008@-@NCT00129558@N/A@-@-@@@-@@@-@HBS103@@-@-@@@I/II@CLINICAL HOLD@@-@-@Since 2004, the National Cancer Institute has been sponsoring a Phase 1 solid tumor trial with Talvesta, which has now been discontinued. As a result of observed toxicities, Hana has decided to conduct additional in vitro and in vivo toxicology studies to further characterize this novel antifolate. While no unexpected toxicity signals were seen in Hana's Phase 2 ALL trial, as a safety precaution, the company has proactively suspended enrollment in this study until additional toxicology and pharmacokinetic studies have been reviewed. Hana anticipates that clinical trials will resume subject to the results of the toxicology studies which will be completed by the end of 2007. SOURCE: Hana, 23 March 2007.@-@@@@MONO@TALOTREXIN@@@@@TALOTREXIN||||@HANA BIOSCIENCES@@@@@HANA BIOSCIENCES||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Chronic Myeloid Leukaemia@Chronic Lymphocytic Leukaemia@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|Chronic Myeloid Leukaemia|Chronic Lymphocytic Leukaemia|||||@TALVESTA@PT-523@@@@TALVESTA|PT-523|||@Folic Acid Analogue@@@@@Folic Acid Analogue||||@DOSE RANGE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924967@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@8 patients with advanced lung cancer received single doses of 30 mCi/m2, 60 mCi/m2 or 90 mCi/m2 of the Rhenium-188/P2045 combination.@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@3/1/2006@@@@14924967@-@@-@-@@NO REVIEW@@@@-@Acquisition completed. SOURCE: Antisoma, 11 June 2008Antisoma acquired Xanthus in an all-share deal of GB£26.8 mil. SOURCE: Antisoma, 16 May 2008Xanthus acquired exclusive worldwide rights to P-2045 and other targeted cancer compounds from Schering AG on 6 September 2006.@-@NCT00100256@8@-@-@@@-@@1/1/2004@-@306509@@-@-@@@I@I@@-@-@While no radiographic responses were seen, five of the eight patients had stable disease at 8 weeks, all of whom entered the trial with progressive disease. Additionally, median event freesurvival was 3.1 months and median overall survival was 11.5 months. No symptomatic or laboratory dose-limiting toxicities were observed, and P2045 with Rhenium-188 was generally well tolerated. SOURCE: Bayer Schering, ASCO, 3 June 2007@-@@@@COMBO@-@@@@@-||||@XANTHUS PHARMACEUTICALS@BAYER HEALTHCARE@ANTISOMA@@@XANTHUS PHARMACEUTICALS|BAYER HEALTHCARE|ANTISOMA||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@P-2045@NEOTIDE@@@@P-2045|NEOTIDE|||@Somatostatin Analogue@Radiolabeled@@@@Somatostatin Analogue|Radiolabeled|||@MAXIMUM TOLERATED DOSE@SAFETY@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917988@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@J06BA02@J06B@YES@DEERFIELD, ILLINOIS@@@@@14917988@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@B-cell CLL: For patients with hypogammaglobulinemia and/or recurrent bacterial infections due to B-cell CLL, a dose of 400 mg/kg every 3 to 4 weeks is recommended.@Jul-99@@@@@@Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death.18 Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD S/D@@@@@GAMMAGARD S/D||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@371.25@480.36@383.64@@@@@@@@@@0.07@@@@@@@@@@@@@@@@8/1/2017@371.25@371.25@6198463@DRY MATTER + ORAL SOLUTION - 1 ML@EURO@@@@@@@@5000@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16670299@Onco@@@@@300f1015ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670299@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@25-Jan-17@1/25/2017@NO REVIEW@@@@0%@@FIRST-LINE@@459@The recommended starting dose is lenalidomide 10 mg/day orally on days 121 of repeated 28day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 14 of repeated 28 day cycles, prednisone2 mg/kg orally on days 14 of repeated 28day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide alone, 10 mg/dayorally on days 121 of repeated 28day cycles given until disease progression.@EMA, 11 February 2015@2/11/2015@9/1/2007@Yes@@@@@No@@@@ADULTS@@APPROVED@@25 January 2017: Insufficient SMR [http://www.has-sante.fr/portail/jcms/c_2746192/en/revlimid-myelome-multiple?xtmc=&xtcr=2]@Not reimbursed@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@68242.82798@@@27.4@month@27.4 month@68242.83@68242.83@81.89@1@1.1511@163.77@@@@@@@@@@@@10.92@28@@mg@10@21@@@@@@@@@@@8/2/2017@163.77@163.77@9298136R@CAPSULE@EURO@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
16617128@Onco@@@@@300f1010ntsdm@@@@@@Ibrutinib: 420 mg daily or 840 mg daily@@L01XE27@L01X@@BEERSE, BELGIUM@6/1/2013@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16617128@Treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo immunotherapy.@@NO@25-Jan-17@1/25/2017@NO REVIEW@@@@100%@@FIRST-LINE@NCT01105247@133@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 21 October 2014@10/21/2014@12/29/2014@Yes@@4/1/2010@@PCYC-1102-CA@No@@@@@II@APPROVED@@Recommended: 25 January 2017. Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults who have a 17p deletion or TP53 mutation, and in whom chemoimmunotherapy is unsuitable and only when the company provides ibrutinib with the discount agreed in the patient access scheme.  [https://www.nice.org.uk/guidance/TA429/chapter/1Recommendations]November 2016: Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:who have a 17p deletion or TP53 mutation (untreated patients), and in whom chemoimmunotherapy is unsuitable and only when the company provides ibrutinib with the discountagreed in the patient access scheme@NHS@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE GROUP ASSIGNMENT@@@1@1@41964.9552@@@9@month@9 month@41964.96@41964.96@153.3@120@1.299@6132@@@@@@@@@@@@0.37@1@@mg@420@1@@@@@@@@@@@7/28/2017@51.1@51.1@2.83E+16@CAPSULE@GB£@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918127@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@LAKE FOREST, ILLINOIS@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14918127@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@@@@NO REVIEW@@@@@Via takeover of Mayne Pharma (and Faulding)@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@1-Dec-02@12/1/2002@@@@@Haemopoietic depression is the most common toxic side effect of dacarbazine and involves primarily the leucocytes and platelets, although mild anaemia may sometimes occur. Leucopenia and thrombocytopenia may be severe enough to cause death. Possible bone marrow depression requires careful monitoring of white blood cells, red blood cells and platelet levels. Such toxicity may necessitate temporary suspension or cessation of therapy. Hepatic toxicity, accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death, have been reported. The incidence of such reactions has been low. This toxicity has been observed mostly when dacarbazine has been administered concomitantly with other anti-neoplastic drugs; however, it has also been reported in some patients treated with dacarbazine alone. Therefore frequent monitoring of liver size, function and blood counts (especially eosinophils) is required. It is recommended that dacarbazine be administered by physicians experienced in the use of cytotoxic therapy. Laboratory facilities should be available for blood monitoring. The drug can produce severe and possibly fatal, haematologic or hepatic toxicity and severe GI reactions and should be administered to patients preferably within the hospital setting, where they can be observed frequently during and after therapy, particulary with regards to the haemopoietic toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16396603@Onco@@@@@300f1010ntsdm@@@@@@Experimental: Lenalidomide / Dexamethasone until disease progression Experimental: Lenalidomide / Dexamethasone for 18 cycles Active Comparator: Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles@@L04AX04@L04A@@SUMMIT, NEW JERSEY@6/1/2016@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396603@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@NCT00689936@1623@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 11 February 2015@2/11/2015@@Yes@@8/1/2008@@CC5013MM020, 200700482339@No@@Must understand and voluntarily sign informed consent form. Age ≥ 18 years at the time of signing consent. Previously untreated. ECOG performance status of 0, 1, or 2. Able to adhere to the study visit schedule and other protocol requirements. Females of childbearing potential (FCBP)^2@@ADULTS@III@APPROVED@@@NHS@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@DURATION OF RESPONSE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@504145.2@@@26@month@26 month@504145.2@504145.2@637.5@21@1.299@3570@@@@@@@@@@@@34@28@@mg@25@21@@@@@@@@@@@7/28/2017@170@170@1.18E+16@CAPSULE@GB£@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16670309@Onco@@@@@300f1020ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670309@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@20-Oct-16@10/20/2016@NO REVIEW@@@@@@FIRST-LINE@@459@@EMA, 11 February 2015@2/11/2015@@YES@@@@@No@@@@ADULTS@@APPROVED@@Added to the reimbursement list on 20 October 2016 [http://www.gazzettaufficiale.it/eli/id/2016/10/28/16A07750/sg;jsessionid=aYtec5ixDvhYP72a9v3pbw__.ntc-as2-guri2a]@SSN@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@263249.7192@@@27.4@month@27.4 month@263249.72@263249.72@315.88@21@1.1229@5306.7@8758.17@5545.56@@@@@@@@@@16.85@28@@mg@25@21@@@@@@@@@@@6/7/2017@252.7@252.7@38016034@HARD CAPSULE@EURO@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922264@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Paclitaxel + Carboplatin + Bevacizumab With or Without Apomab @@-@-@-@SAN FRANCISCO, CALIFORNIA@3/1/2011@@@@14922264@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@FIRST-LINE@NCT00480831@120@-@-@@@-@@6/1/2007@-@APM4074g@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@PACLITAXEL@CARBOPLATIN@BEVACIZUMAB@@-|PACLITAXEL|CARBOPLATIN|BEVACIZUMAB|@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@APOMAB@AVASTIN@@@@APOMAB|AVASTIN|||@mAb@Human@@@@mAb|Human|||@PROGRESSION-FREE SURVIVAL@STABLE DISEASE@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15056598@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ibrutinib: 560 mg once daily continuous (without interruption) by mouth for 21-day cycles Temsirolimus: 175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycleSOURCE: clinicaltrials.gov@@L01XE27@L01X@-@BEERSE, BELGIUM@3/1/2017@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@15056598@A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy@@@@@NO REVIEW@@@@@@SECOND-LINE@NCT01646021@280@-@FDA approves [Pharmacyclics, 13 November 2013, http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=807003 ]US FDA grants breakthrough therapy designation for ibrutinib in MCL and Waldenström's macroglobulinemia[J&J, 12 February 2013, http://www.jnj.com/news/all/Ibrutinib-Receives-Two-Oncology-Breakthrough-Therapy-Designations-from-US-Food-and-Drug-Administration ]US FDA grants breakthrough therapy designation for ibrutinib in CLL and SLL[J&J, 8 April, 2013, http://www.jnj.com/news/product/ibrutinib-receives-third-oncology-breakthrough-therapy-designation-from-us-food-and-drug-administration ]@11/13/2013@@@@12/1/2012@-@CR014899@No@@@@@III@III@@@@RESULTS PENDING@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@PHARMACYCLICS@@@@JANSSEN PHARMACEUTICAL|PHARMACYCLICS|||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@RESPONSE@OVERALL SURVIVAL@@@@-@@@@@RANDOMISED@OPEN LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16617657@Onco@@@@@300f1008ntsdm@@@@@KEYNOTE-010@@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@9/1/2015@@KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking  antibody indicated for the treatment of patients with unresectable or  metastatic melanoma and disease progression following ipilimumab  and, if BRAF V600 mutation positive, a BRAF inhibitor@@16617657@Unresectable, advanced or relapsed non-small-cell lung cancer (NSCLC), second-line treatment.@Both@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@NCT01905657@1034@2 mg/kg administered intravenously over 30 minutes every3 weeks. Patients should be treated with KEYTRUDA until disease progression or unacceptabletoxicity.@MHLW, 19 December 2016@12/19/2016@@Yes@@8/1/2013@@3475-010, 2012-004391-19, 132355@No@@Life expectancy of at least 3 months; Histologically- or cytologically-confirmed diagnosis of non-small cell lung cancer (NSCLC) that is PD-L1 positive per central laboratory review; At least one bi-dimensional measurable lesion; Radiographic progression after treatment with at least 2 cycles of a platinum-containing doublet; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1@@ADULTS@II/III@APPROVED@@@NHI@ORR@@@@@MONO@PEMBROLIZUMAB@@@@@PEMBROLIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@OVERALL SURVIVAL@PROGRESSION FREE SURVIVAL@@@@@@@@@UNRESECTABLE@ADVANCED@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN-LABEL@@@76.5@kg@3389713.341@@@4.27@month@4.27 month@3389713.34@3389713.34@26099.55@1@0.0091@71645.82@84488@@@@@@@@@@@3582.29@21@@mg/kg@2@1@@@@@@@@@@@8/30/2017@71645.82@71645.82@4291435A1029@SOLUTION FOR INJECTION - 0.8 ML@YEN@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924276@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@After undertaking screening procedures, patients begin androgen suppression with a two-week lead-in of flutamide, followed by 9 monthly injections of leuprolide acetate. @@L02AE02@L02A@-@PARIS, FRANCE@12/1/2010@@Leuprolide acetate, an LH-RH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Eligard is a sterile polymeric matrix formulation of leuprolide acetate for subcutaneous injection. It is designed to deliver 7.5 mg of leuprolide acetate at a controlled rate over a one month therapeutic period.@@14924276@Eligard in combination with flutamide to treat men with localized prostate cancer after radiation therapy or radical prostatectomy@@-@-@@NO REVIEW@@@@-@-@-@NCT00223665@100@-@-@@@-@@1/1/1997@-@-@@-@100 male patients, 21 years and above@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@SANOFI-AVENTIS@QLT@@@@SANOFI-AVENTIS|QLT|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ELIGARD@@@@@ELIGARD||||@LH-RH Analog@@@@@LH-RH Analog||||@PSA@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920795@Onco@@@@@300f1020ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920795@Kytril Injection is indicated for a) the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and b) the prevention and treatment of postoperative nausea and vomiting. Kytril Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.@@NO@-@@NO REVIEW@@@@100%@-@-@-@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@N/A@@@-@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@-@No@-@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@DISCONTINUED@@@SSN@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@-@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@3@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@28093045@INJECTABLE PREPARATION SYRINGE, 1 ML@EURO@@@@@@@@3@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919108@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Odanacatib; 5mg oral, once daily for approximately 60 months versus placebo@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@1/1/2010@@Odanacatib is a highly selective, potent inhibitor of the cathepsin K enzyme.  Cathepsin K enzyme plays a key role in breaking down the protein in bone.  In cancer that has spread to the bones, tumor cells speed up the normal process of bone breakdown and formation, which in turn results in further tumor growth and bone destruction.  By inhibiting cathepsin K activity, odanacatib represents a potential novel therapeutic approach for metastatic bone disease that works differently from other commonly used medicines.@@14919108@Reducing the Risk of Bone Metastasis in Women With Breast Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00692458@4000@-@-@@@-@@8/1/2008@-@MK0822-029@@-@Confirmed primary State II or Stage III breast cancer Patient is not receiving adjuvant chemotherapy (e.g., cyclophosphamide, doxorubicin, carboplatin) at the time of randomization and has not received adjuvant chemotherapy for at least 6 weeks prior to the randomization visit (Visit 2). This inclusion criterion does not include hormone therapy, which is permitted.@@@III@III@@-@-@Trial registered. SOURCE: Merck, 4 June 2008@-@@@@MONO@ODANACATIB@@@@@ODANACATIB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Bone Metastases@Breast Cancer@@@@Bone Metastases|Breast Cancer||||||||@MK-822@@@@@MK-822||||@Other@@@@@Other||||@METASTASIS-FREE SURVIVAL@@@@@DISEASE-FREE SURVIVAL@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919764@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919764@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Jan-98@1/1/1998@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@FERRER FARMA@@@@@FERRER FARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@100@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14916709@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients randomised to receive either a 10mg/kg dose of Xcytrin every week, or a 15mg/kg dose every three weeks.@@-@-@-@SUNNYVALE, CALIFORNIA@@@Motexafin gadolinium (MGd) is a small-molecule drug with a novel mechanism of action; it accumulates selectively in cancer cells due to their increased rates of metabolism. Once inside the cell, MGd induces apoptosis (programmed cell death) by disrupting redox-dependent pathways. MGd inhibits the enzyme thioredoxin reductase, which is a tumor growth promoter. This mechanism provides the opportunity to use MGd in a wide range of cancers. MGd is paramagnetic, and therefore is detectable by magnetic resonance imaging (MRI), allowing the visualization of the drug in tumors.@@14916709@Single agent@@-@-@@NO REVIEW@@@@-@Available for outlicensing.@SECOND-LINE@NCT00129844@108@-@-@@@-@@@-@PCYC-0227@@-@-@@@II@II@@-@-@Data expected in H1 2008. SOURCE: Pharmacyclics, 21 December 2007ASCO 2007 from 58 evaluable patients; there was a confirmed RR of 5.2%, or 3 partial responses. 34.5% had stable disease. 1 of the responders received Xcytrin after having progressed through two prior lines of therapy: carboplatin, gemcitabine and bevacizumab, followed by erlotinib. The other two had previously failed either carboplatin/gemcitabine or cisplatin/vinorelbine. Median TTP was 7 weeks for all patients. 13% were free from progression at six months. Median survival was eight months, with 62% and 30% of patients alive at 6 and 12 months, respectively. The most common grade 3 or 4 adverse events were hypophosphatemia (24%), dyspnea (12%), fatigue (10%), hypoxia (7%), and finger blisters (5%).@-@@@@MONO@MOTEXAFIN GADOLINIUM@@@@@MOTEXAFIN GADOLINIUM||||@PHARMACYCLICS@@@@@PHARMACYCLICS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XCYTRIN@@@@@XCYTRIN||||@Radiation Sensitiser@@@@@Radiation Sensitiser||||@RESPONSE RATE@@@@@@@@@@RELAPSED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16159402@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC06@L01X@YES@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16159402@Erbitux, as a single agent, is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.@@NA@@@NO REVIEW@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@@@FDA, 2 October 2007@10/2/2007@@No@@@Infusion reactions such as airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, cardiac arrest ; Cardiopulmonary arrest and/or sudden death ; pulmonary toxicity leading to interstitial lung disease ; dermatologic toxicity including acneform rash, skin drying and fissuring, and inflammatory and infectious sequelae@@No@@@@@@APPROVED@@@@@@@@@MONO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@RECURRENT@METASTATIC@@@@@@@@@1.75@m²@66535.49786@@@5.8@month@5.8 month@66535.5@66535.5@377.16@1@1@1178.84@@@@@@@@@@@@5.89@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/2/2017@1178.84@1178.84@66733-0958-23@INJECTION@US$@@@@@@@@200@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916397@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Dasatinib 70mg given, escalating up to 100mg.@@L01XE06@L01X@-@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14916397@CML in blast crisis or Ph+ ALL@@NO@-@@NO REVIEW@@@@-@-@-@-@94@-@-@@@-@@@-@START-L@@APRIL 2020 ('746); PATENT EXTENSION FILED.@-@@@II@II@@-@-@ASCO June 2006; major haemotological and cytogenic response acehived in 44% and 46% of patients in the CML group and Ph+ALL group respectively. ASH December 2006 update; 29% patients achieved CHR; 46% achieved CCyR. Median PFS and OS were 3.0 and 5.3 months respectively.@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924552@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MORRIS PLAINS, NEW JERSEY@@@Naked humanized antibody targeting CD22 receptors on B-lymphocytes.  Primary use is for the treatment of indolent and aggressive NHLs, and for autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren's Syndrome.  Every year there are 56,000 newly diagnosed cases of NHL and 25,000 deaths.  SLE afflicts up to 1.4 million in the U.S.  In May 2006, epratuzumab was licensed to UCB, S.A. for all autoimmune disease indications worldwide.  A Phase IIb clinical trial for SLE is currently enrolling patients.  Additionally, there are three NCI-sponsored trials in oncology ongoing.@@14924552@Yttrium-90-labelled humanised antibody targeting CD22 for NHL@@-@-@@NO REVIEW@@@@-@UCB Pharma holds non-oncology rights, with option for a buy-in. North American rights were licensed to Amgen, but returned to Immunomedics in April 2004.@-@-@54 EVALUABLE @-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@EHA 2007; Objective RR was 59%, complete RR was 43% and 6 of the complete RR patients were disease-free for over a year (four patients were disease-free for over two years).@-@@@@-@EPRATUZUMAB@@@@@EPRATUZUMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@LYMPHOCIDE@IMMU-102@@@@LYMPHOCIDE|IMMU-102|||@mAb@Humanised@CD22@@@mAb|Humanised|CD22||@SAFETY@RESPONSE RATE@COMPLETE RESPONSE@@@COMPLETE RESPONSE@@@@@-@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921541@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921541@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@NO@6-Mar@@NO REVIEW@@@@@@@@@As a single agent: The recommended regimen is :First three administrations: 60mg/m² of body surface area, administered once weekly. Subsequent administrations: Beyond the third administration, it is recommended to increase the dose of Navelbine soft capsules to 80mg/m² once weekly except in those patients for whom the neutrophil count dropped once below 500/mm3 or more than once between 500 and 1000/mm3 during the first three administrations at 60mg/m².@1-Feb@@1/26/2006@@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@EXPIRED@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@BOTH@VINORELBINE TARTRATE@CISPLATIN@@@@VINORELBINE TARTRATE|CISPLATIN|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@ADVANCED@REFRACTORY@@@@@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@33130.11@33130.11@90.77@1@1.1511@49@61.38@52.27@@@@@@@@@@2.45@@@@@@@@@@@@@@@@8/1/2017@49@49@3.40E+12@SOFT CAPSULE@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922292@Onco@@@@@300f1012ntsdm@@@@@@"ARM A: Plerixafor (AMD3100) 240µg/kg administration as an SC injection 6 to 11 hours prior to initiation of apheresis. Daily administration for 2 up to 7 consecutive days 
ARM B: 10µg/kg of a nonpegylated form of G0CSF "@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@10/1/2009@@Mozobil, a novel small molecule CXCR4 chemokine antagonist, has been shown in multiple earlier studies to rapidly and effectively increase the number of stem cells in circulation in the blood. Once circulating in the blood, stem cells can be collected for use in a stem cell transplant. Mozobil has been granted special protocol assessment and orphan drug status in the United States and European Union and the pivotal trials have undergone Special Protocol Assessment by the FDA and Protocol Assistance by the EMEA. Genzyme intends to commercialize Mozobil through its existing global transplant business to hematologists and hematopoietic stem cell transplant centers in more than 50 countries throughout the world. Genzyme has been developing Mozobil since its acquisition of AnorMED, Inc. in 2006.@@14922292@Lymphoma and MM who have failed previous mobilisation@@-@-@@NO REVIEW@@@@-@Acquired via takeover of AnorMED@-@NCT00665314@30@-@-@@@-@@11/1/2007@-@AMD3100-EU23, @@-@-@@@II EudraCT number: 2006-00424729; @II@@-@-@RESULTS PENDING@-@@@@COMBO@PLERIXAFOR@@@@@PLERIXAFOR||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Myeloma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Myeloma|||||||@MOZOBIL@AMD-3100@@@@MOZOBIL|AMD-3100|||@CXCR4 Antagonist@@@@@CXCR4 Antagonist||||@NUMBER OF CD34+ CELLS@@@@@@@@@@-@@@@@RANDOMISED@SINGLE-ARM@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924497@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Combo with Gemzar and carboplatin@@-@-@-@DARMSTADT, GERMANY@@@IMO-2055 is designed to act as an agonist of TLR9 and has demonstrated activity as an immune modulator in preclinical models, both in vitro and in vivo.   IMO-2055 anticancer activity has been observed in preclinical mouse models when administered as a single agent.  IMO-2055 also has shown potentiation of anticancer activity when administered in combinations with certain chemotherapeutic agents, antibodies, and newer biologically targeted agents approved for use in cancer therapy.@@14924497@Combo with Gemzar and carboplatin@@-@-@@NO REVIEW@@@@-@Merck Serono licensed exclusive global development and marketing rights for IMO-2055 and IMO-2125 in exchange for US$40 mil. Upfront and up to US$381 mil in regulatory milestones and royalties. SOURCE: Idera, 19 December 2007@SECOND-LINE@-@N/A@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@The company enrolled 22 patients with advanced, previously treated solid tumors in the study before closing enrollment in July 2007. Patients received 3-week cycles of fixed-dose gemcitabine and carboplatin with three escalating doses and three dosage schedules of IMO-2055. Interim data from the 19 patients, 8 with NSCLC, suggest that it is feasible for the combination to be administered in patients with advanced solid tumors. The only dose-limiting toxicities observed in these patients were neutropaenia and thrombocytopaenia, which are common side effects observed with gemcitabine and carboplatin. In these 19 patients, the response rate, PFS and overall survival are 5%, 4.1 months, and 12.9 months, respectively. In the subset of eight patients with NSCLC, the response rate, PFS and overall survival are 13%, 6.5 months and 12.9 months, respectively. The company expects to announce final data of this study by the end of 2007. SOURCE: Idera, 6 September 2007@-@@@@COMBO@IMOXINE@GEMCITABINE@@@@IMOXINE|GEMCITABINE|||@MERCK SERONO@IDERA PHARMACEUTICALS@@@@MERCK SERONO|IDERA PHARMACEUTICALS|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@IMO-2055@GEMZAR@@@@IMO-2055|GEMZAR|||@TLR-targeted@@@@@TLR-targeted||||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384808@Onco@@@@@300f1018ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384808@Indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@@Dosing for children should be on the basis of body surface area (mg/m2). The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (@@@@Yes@@@@@No@@@PAEDIATRIC@@@APPROVED@@@PBS@@@@@@BOTH@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@@@@@@@@@@@1.2@m²@35978.3274@@@1@year@1 year@35978.33@35978.33@98.57@30@0.779@2899.14@3047.02@2969.08@@@@@@@@@@0.24@1@@mg/m²@340@1@@@@@@@@@@@8/1/2017@96.64@96.64@1632-1271-GE-AF@TABLET@A$@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16617766@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX52@L01X@@@@@VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patientswith chronic lymphocytic leukemia (CLL) with 17p deletion, as detected byan FDA approved test, who have received at least one prior therapy@@16617766@VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least oneprior therapy.@Both@NA@@@NO REVIEW@@@@@@SECOND-LINE@@106@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@FDA, 11 April 2016@4/11/2016@5/2/2016@@@@@@No@@@17p deletion@ADULTS@@APPROVED@@@@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLEXTA@@@@@VENCLEXTA||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@@@@@@@@@@@@@@@@1@1@2385.087996@@@12.1@month@12.1 month@2385.09@2385.09@6.48@50@1@43.02@@@@@@@@@@@@0.02@28@1@mg@92.5@28@1@@mg@400@1@@@@@@8/2/2017@0.86@0.86@00074-0566-11@FILM-COATED TABLET@US$@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924556@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@REDWOOD, CALIFORNIA@@@Volociximab is a chimeric monoclonal antibody that inhibits the functional activity of a5ß1 integrin, a protein found on activated endothelial cells that are involved in the formation of blood vessels. Volociximab is currently being investigated in Phase 2 clinical trials in patients with advanced solid tumors. PDL BioPharma and Biogen Idec have a broad collaboration for the joint development, manufacture and commercialization of volociximab.@@14924556@Stage IV melanoma@@-@-@@NO REVIEW@@@@-@Biogen Idec and PDL announced a broad collaboration for the joint development, manufacture and commercialization of three Phase II antibody products. The agreement provides for shared development and commercialization of daclizumab in multiple sclerosis and indications other than transplant and respiratory diseases, and for shared development and commercialization of M200 (volociximab) and HuZAF(TM) (fontolizumab) in all indications. Under terms of the agreement, PDL will receive an upfront payment of $40 million, and Biogen Idec will purchase $100 million of common stock from PDL. If multiple products were developed successfully in multiple indications and all milestones were achieved, PDL could receive certain development and commercialization milestone payments totaling up to $660 million. Of these, $560 million are related to development and $100 million are related to commercialization of collaboration products. Biogen Idec and PDL will share equally the costs of all development activities and all operating profits from each collaboration product within the United States and Europe. The companies will jointly oversee development, manufacturing and commercialization plans for collaboration products and intend to divide implementation responsibilities to leverage each company's capabilities and expertise. Each party will have co-promotion rights in the United States and Europe. Outside the United States and Europe, Biogen Idec will fund all incremental development and commercialization costs and pay a royalty to PDL on sales of collaboration products. [Biogen, 2.08.2005]@-@NCT-00369395@58@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@VOLOCIXIMAB@@@@@VOLOCIXIMAB||||@PDL BIOPHARMA@BIOGEN IDEC@@@@PDL BIOPHARMA|BIOGEN IDEC|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@M-200@@@@@M-200||||@mAb@Chimeric@Angiogenesis Inhibitor@@@mAb|Chimeric|Angiogenesis Inhibitor||@PROGRESSION-FREE SURVIVAL@SAFETY@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919251@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@ULM, GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919251@@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@4.2@16.3@5.04@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@3095219@TABLET@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922007@Onco@@@@@300f1014ntsdm@@@@@@Casodex as immediate hormonal therapy or adjuvant to radical prostatectomy or radiotherapy.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14922007@In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), Casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Casodex 150 mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.@@NO@@@NO REVIEW@@@@100%@@@@8113@The dosage is one 150 mg tablet to be taken orally once a day. Casodex 150 mg should be taken continuously for at least 2 years or until disease progression.@@@@@@@Casodex 150 mg should be used with caution in patients with moderate to severe hepatic impairment.@@No@@@@@III; THREE TRIALS@APPROVED@@Unrestricted reimbursement.@RAMQ@27.4% and 30.7% of all Casodex and placebotreated patients, respectively, had experienced objective disease progression. In the subgroup of locally advanced prostate cancer who did not receive treatment with radical prostatectomy or radiotherapy, immediate therapy with Casodex 150 mg significantly reduced the risk of objective disease progression (Hazard Ratio (HR)= 0.60; 95% CI 0.49 to 0.73). PFS events was 57.6% in the Casodex watchful waiting group, compared to 68.9% in the placebo group, whilst deaths were 49% and 57% respectively.@@@@@@BICALUTAMIDE@@@@@BICALUTAMIDE||||@NOVPHARM@@@@@NOVPHARM||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@NOVO-BICALUTAMIDE@GENERIC@@@@NOVO-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@DISEASE-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@@@@@100@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@C$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14920938@Onco@@@@@300f1014ntsdm@@@@@@NO LABELLED TRIAL@@L02AE02@L02A@NO@@@@This is a synthetic nonapeptide analogue of naturally occurring gonadotrophin releasing hormone (GnRH) which possesses greater potency than the natural hormone. It is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy. Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Oestradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.@@14920938@(i) Metastatic prostate cancer.(ii) Locally advanced prostate cancer, as an alternative to surgical castration.(iii) As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.(iv) As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.(v) Management of endometriosis, including pain relief and reduction of endometriotic lesions.(vi) Endometrial preparation prior to intrauterine surgical procedures including endometrial ablation or resection.(vii) Preoperative management of uterine fibroids to reduce their size and associated bleeding.@@NO@@@NO REVIEW@@@-@100%@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@Prostate Cancer: The usual recommended dose is 3.75mg administered as a single subcutaneous or intramuscular injection every month. The majority of patients will respond to a 3.75mg dose. Prostap therapy should not be discontinued when remission or improvement occurs. As with other drugs administered chronically by injection, the injection site should be varied periodically.@@@@No@@@Development or aggravation of diabetes may occur, therefore diabetic patients may require more frequent monitoring of blood glucose during treatment with PROSTAP.Hepatic dysfunction and jaundice with elevated liver enzyme levels have been reported. Therefore, close observation should be made and appropriate measures taken if necessary.Spinal fracture, paralysis, hypotension and worsening of depression have been reported.@NO LABELLED TRIAL@No@@@@@@APPROVED@@Unrestricted reimbursement.@RAMQ@NO LABELLED TRIAL@@@@@@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@LEUPLIN@@@@@LEUPLIN||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@14@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16160493@Onco@@@@@300f1014ntsdm@@@@@@Dabrafenib: 150 mg twice daily; Dacarbazine: 1000 mg/m2 every 3 weeks until initial progression@@L01XE25@L01X@@LONDON, UNITED KINGDOM@6/1/2013@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16160493@TAFINLAR (dabrafenib mesylate) is indicated as a monotherapy for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.@@NA@3-Feb-14@2/3/2014@NO REVIEW@@@@@@FIRST-LINE@NCT01227889@200@Monotherapy: 150 mg (two 75 mg capsules) given orally twice daily (corresponding to a total daily dose of 300 mg).@Health Canada, 28 August 2013@8/28/2013@@@@12/1/2010@@113683@No@@Has advanced (unresectable Stage III) or metastatic (Stage IV) melanoma that is BRAF mutation positive (V600E)Is treatment naive for advanced (unresectable) or metastatic melanoma, with the exception of Interleukin 2 (IL-2) which is allowed.Has measurable disease according to RECIST 1.1 criteria.@BRAF V600E mutation@@III@APPROVED@@@RAMQ@@@@@@MONO@DABRAFENIB@@@@@DABRAFENIB||||@NOVARTIS @@@@@NOVARTIS ||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@@@@@TAFINLAR||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@RESPONSE RATE@@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@CROSSOVER@@@1@1@39297.49785@@@5.1@month@5.1 month@39297.5@39297.5@253.33@120@0.7881@5066.67@@@@@@@@@@@@0.84@1@@mg@300@1@@@@@@@@@@@7/19/2017@42.22@42.22@2409607120@HARD CAPSULE@C$@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922215@Onco@@@@@@@@@@@ASA404 1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle versus Taxotere 75mg/m2 an hour for the first six cycles@@-@-@-@LONDON, UNITED KINGDOM@6/1/2011@@ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) that selectively disrupts established tumour blood vessels. It is currently in clinical trials for lung and prostate cancers. Antisoma has licensed the world-wide rights for ASA404 to Novartis AG. Novartis is now responsible for all further development work on the drug. Antisoma has an option to co-commercialise the drug with Novartis in the United States. @@14922215@Stage IIIB/IV NSCLC of squamous or non-squamous histology@@-@-@@NO REVIEW@@@@-@Novartis licensed global rights in April 2007; Antisoma has an option to co-commercialise the drug with Novartis in the United States. With the Phase III trial, Novartis assumes responsibility for the drug.@SECOND-LINE@NCT00738387@1000@-@Filings expected in 2011. SOURCE: Antisoma, 13 April 2008@4/13/2008@@-@@10/1/2008@-@ATTRACT-2@@-@>> Histologically confirmed non-small cell carcinoma of the lung of all histologies. (Histological or cytological specimens must be collected via surgical biopsy, brushing, washing or core needle aspiration of a defined lesion. Sputum cytology is not acceptable.)    >> Patients who have progressed while on or following a first-line chemotherapy regimen for Stage IIIb disease (malignant pleural effusion or pericardial effusion that have been confirmed cytologically) or Stage IV disease. Patients who have received bevacizumab and/or EGFR inhibitors in first-line will be eligible@@@III@DISCONTINUED@@-@-@>>Clinical programme terminated as interim results from the Phase III ATTRACT-2 study showed that the drug was not expected to meet the primary endpoint of improving overall survival when used in combination with chemotherapy [Novartis, 11.11.10, http://www.novartis.com/newsroom/media-releases/en/2010/1461276.shtml]>> Trial registered. [Novartis, 19.08.2008]    >> Trial to commence in H2 2008. [Novartis, 17 July 2008]@-@@@@COMBO@-@PACLITAXEL@CARBOPLATIN@@@-|PACLITAXEL|CARBOPLATIN||@ANTISOMA@NOVARTIS@@@@ANTISOMA|NOVARTIS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ASA-404@AS-1404@DMXAA@@@ASA-404|AS-1404|DMXAA||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@QUALITY OF LIFE@BIOMARKER@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15251981@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MSB0010718C (anti PD-L1) will be administered in study location using a protocol-defined dose escalation scheme until confirmed progression, unacceptable toxicity, or if any criterion for withdrawal from the trial or investigational medicinal product occurs@@@@@DARMSTADT, GERMANY@@@@@15251981@A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications@@@5-Jun@@-@@@@@Pfizer has entered into an agreement with Merck KGaA for the global development and commercialisation of Merck's programmed death-ligand 1 (PD-L1) inhibitor MSB0010718C@FIRST-LINE@NCT01772004@825@@@@@-@@@@@@@Subjects must have histologically or cytologically proven metastatic or locally advanced solid tumors, for which no standard therapy exists or standard therapy has failed. Availability of tumor archival material or fresh biopsies is optional for subjects in dose escalationDisease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for subjects with metastatic castrate-resistant prostate cancer (mCRPC) or metastatic breast cancer (MBC) who may be enrolled with objective evidence of disease without a measureable lesion@-@@@I@@@@Study registered [EMD Serono, 14 January 2013]@@@@@@ANTI PD-L1@@@@@ANTI PD-L1||||@MERCK SERONO@PFIZER@@@@MERCK SERONO|PFIZER|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@MSB0010718C@@@@@MSB0010718C||||@Other@@@@@Other||||@TOXICITY@@@@@ADVERSE EVENT@@@@@ADVANCED@METASTATIC@@@@OPEN LABEL@SINGLE GROUP ASSIGNMENT@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923382@Onco@@@@@300f1012ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@LEICHINGEN, GERMANY@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923382@@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III METASTATIC BREAST CANCER@APPROVED@@@GKV@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ALIUD PHARMA@@@@@ALIUD PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOXIFEN AL@@@@@TAMOXIFEN AL||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@3.19@15.02@3.99@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.03@0.03@3852034@TABLET@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924592@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@ONTARIO, CANADA@@@Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. NEUPOGEN containing rmetHuGCSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes. In some severe chronic neutropenia patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dosedependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.@@14924592@-@@-@-@@NO REVIEW@@@@-@>> Apotex and Intas have extended their business agreement to develop a biosimilar version of pegfilgrastim. Neupeg, a recombinant pegylated granulocyte colony stimulating factor is already manufactured and marketed in India and other countries by IBPL. [Apotex/Intas, 30.01.2009]    >> Apotex licensed European rights from Kwizda Pharma, which had been developing the biosimilar in collaboration with Intas. Apotex and Intas have concurrently agreed to extend the collaboration to North America. SOURCE: Apotex, 1 May 2008@-@-@-@-@N/A@@@-@@@-@-@@-@-@@@-@I@@-@-@-@-@@@@-@FILGRASTIM@@@@@FILGRASTIM||||@APOTEX@INTAS@@@@APOTEX|INTAS|||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@NEUKINE@BIOSIMILAR@@@@NEUKINE|BIOSIMILAR|||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921371@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are stratified according to risk score (3 [high-intermediate] vs 4 or 5 [high]). Chemotherapy: Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV, vincristine IV, and rituximab IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Sargramostim (GM-CSF) with or without autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId): Patients achieving complete remission (CR) or unconfirmed CR after chemotherapy and who have FavId® available are randomized to 1 of 2 treatment arms. Arm I: Patients receive FavId vaccine subcutaneously (SC) on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4. Arm II: Patients receive placebo SC on day 1 and GM-CSF SC as in arm I. In both arms, treatment repeats once a month for 6 months and then once every 2 months for 24 months (18 total vaccinations) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for up to 2 years.@@-@-@-@-@@@Specifid (mitumprotimut-T, formerly FavId) is a personalized, active immunotherapy designed to stimulate a patient's immune system to mount a specific and sustained response to the patient's cancer. specifid is based upon a recombinant protein, called idiotype (Id), which is derived from genetic material obtained from a patient's own tumor, then conjugated to keyhole limpet hemocyanin (KLH), a protein commonly use.@@14921371@Stage II/III or IV diffuse large b-cell lymphoma@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00324831@480@-@-@@@-@@@-@FAV-ID-11@@-@-@@@III@DISCONTINUED@@-@-@All development discontinued following failure of pivotal FAV-ID-06 trial. SOURCE: Favrille, 27 May 2008@-@@@@COMBO@MITUMPROTIMUT-T@@@@@MITUMPROTIMUT-T||||@FAVRILLE@@@@@FAVRILLE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@DLBCL@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|DLBCL|||||||@FAVLD@SPECIFID@@@@FAVLD|SPECIFID|||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916409@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@"ARM1: Sutent 50 mg capsule OD PO for 28 days followed by 14 days of rest until tumour progression. 
ARM2: Placebo 50 mg capsule OD PO for 28 days then 14 days rest until disease progression "@@L01XE04@L01X@-@NEW YORK, NEW YORK@@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14916409@Platinum (cisplatin)-refractory urothelial cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@-@NCT00578526@64@-@-@@@-@@2/1/2008@-@SPRUCE02@@-@-@@@II@II@@-@-@Endpoint at 4 months.@-@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@SINGLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14916533@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@MDV3100 daily until progression or dose-limiting toxicity [Medivation]@@-@-@-@SAN FRANCISCO, CALIFORNIA@12/1/2008@@MDV3100 is an investigational novel small molecule androgen receptor antagonist that is one of a series of small molecule compounds, known as the MDV300 series, that Medivation is developing to treat castration-resistant and hormone-sensitive prostate cancer. An increased number of androgen receptors present on prostate cancer cells is believed to play a major role in the growth of CRPC. Unlike currently available agents, MDV3100 has two modes of activity: (1) prevent the androgen receptor from entering the cell's nucleus and triggering further growth of the tumor and, importantly, (2) continue to inhibit the growth of the cancer even when the androgen receptor is overexpressed, as is the case in CRPC.@@14916533@MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00510718@100@-@-@@@-@@6/1/2007@-@S-3100-1-01@@-@Histologically or cytologically confirmed adenocarcinoma of the prostate; Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration).@@@I@I@@-@-@Trial registered [Medivation, 31.07.2007]@-@@@@-@-@@@@@-||||@MEDIVATION INC@@@@@MEDIVATION INC||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@MDV-3100@@@@@MDV-3100||||@Anti-androgen@@@@@Anti-androgen||||@SAFETY@@@@@PHARMACOKINETICS@PSA@@@@REFRACTORY@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916068@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy@@-@-@-@BRENTFORD, UNITED KINGDOM@9/1/2010@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14916068@Tykerb + pazopanib versus lapatinib alone and pazopanib alone in Stage IVB or recurrent or persistent cervical cancer with 0-1 prior chemo@@-@-@@NO REVIEW@@@@-@-@-@NCT00430781@180@-@-@@@-@@11/1/2006@-@VEG105281@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@BOTH@LAPATINIB@PAZOPANIB@@@@LAPATINIB|PAZOPANIB|||@GSK@@@@@GSK||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@TYKERB@GW-786034@@@@TYKERB|GW-786034|||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917417@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@L01AX04@L01A@YES@LEVERKUSEN, GERMANY@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917417@DTIC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTIC-Dome is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.@@@@@NO REVIEW@@@@@@@@@Malignant Melanoma: The recommended dosage is 2 to 4.5mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals. 2 An alternate recommended dosage is 250mg/square meter body surface/day I.V. for 5 days. Treatment may be repeated every 3 weeks.@FDA, 27 May 1975@5/27/1975@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@NOT AVAILABLE@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Melanoma / Skin Cancer@@@Haematological Malignancy|Hodgkin's Lymphoma|Melanoma / Skin Cancer|||||||@DTIC-DOME@@@@@DTIC-DOME||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Factory Price@@@@@@@@@12@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921406@Onco@@@@@@@@@@@Patients were randomised to receive 400 mg of oral Nexavar twice daily or placebo, in addition to two chemotherapeutic agents -- carboplatin and paclitaxel -- for up to 6 cycles. Subsequently, patients continued in a maintenance phase where Nexavar or placebo was administered as a single agent until study drug was discontinued due to progression of tumor or side effects.@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14921406@-@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@FIRST-LINE@-@900@-@-@@@-@@@-@ESCAPE@@DECEMBER 2010 (NCE); DECEMBER 2012 (ORPHAN); JUNE 2022 (EXTENSION)@-@@@III@III@@-@-@Trial stopped early following a planned interim analysis, where the independent DMC concluded that the study would not meet its primary endpoint of improved overall survival. Safety events were generally consistent with those previously reported. However, higher mortality was observed in the subset of patients with squamous cell carcinoma of the lung treated with sorafenib and carboplatin and paclitaxel versus those treated with carboplatin and paclitaxel alone. Full results expected at ASCO 2008 or World Lung Congress. SOURCE: Onyx and Global Insight, 18 February 2008@-@@@@COMBO@SORAFENIB TOSYLATE@CARBOPLATIN@PACLITAXEL@@@SORAFENIB TOSYLATE|CARBOPLATIN|PACLITAXEL||@BAYER HEALTHCARE@ONYX@@@@BAYER HEALTHCARE|ONYX|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923170@Onco@@@@@300f1014ntsdm@@@@@@Casodex as immediate hormonal therapy or adjuvant to radical prostatectomy or radiotherapy.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14923170@In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), Casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Casodex 150 mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.@@NO@@@NO REVIEW@@@@100%@@@@8113@The dosage is one 150 mg tablet to be taken orally once a day. Casodex 150 mg should be taken continuously for at least 2 years or until disease progression.@@@@@@@Casodex 150 mg should be used with caution in patients with moderate to severe hepatic impairment.@@No@@@@@III; THREE TRIALS@APPROVED@@Unrestricted reimbursement.@RAMQ@27.4% and 30.7% of all Casodex and placebotreated patients, respectively, had experienced objective disease progression. In the subgroup of locally advanced prostate cancer who did not receive treatment with radical prostatectomy or radiotherapy, immediate therapy with Casodex 150 mg significantly reduced the risk of objective disease progression (Hazard Ratio (HR)= 0.60; 95% CI 0.49 to 0.73). PFS events was 57.6% in the Casodex watchful waiting group, compared to 68.9% in the placebo group, whilst deaths were 49% and 57% respectively.@@@@@@BICALUTAMIDE@@@@@BICALUTAMIDE||||@SANDOZ@NOVARTIS@@@@SANDOZ|NOVARTIS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SANDOZ BICALUTAMIDE@GENERIC@@@@SANDOZ BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@DISEASE-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@@@@@30@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@C$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14922212@Onco@@@@@@@@@@@AV-951: 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of AV-951 for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive AV-951 once daily for 3 weeks followed by 1 week off. AV-951 dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both AV-951 and the FOLFOX6 chemotherapy regimen are co-administered, AV-951 will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen. Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15. [clinicaltrials.gov]@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@6/1/2009@@AV-951 is a novel, highly potent and specific inhibitor of VEGF receptors 1, 2 and 3. Angiogenesis inhibition has demonstrated benefit for patients with a wide range of cancer types, including renal cell carcinoma, metastatic breast cancer, colorectal cancer, and non-small cell lung cancer.  Due to its specificity, AVEO believes AV-951 may be more readily combined with standard chemotherapy as well as other targeted therapies, potentially increasing the breadth of its clinical utility.  AVEO's translational research effort, comprising its Human Response Platform (HRP), offers an opportunity to exploit AV-951's unique characteristics and will provide further insight into potential clinical settings, combinability with other anti-cancer agents, tumor subtypes and responsive patient populations.@@14922212@Advanced colorectal cancer and other gastrointestinal cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00660153@30@-@-@@@-@@6/1/2008@-@AV-951-103@@-@-@@@I@I@@-@-@>>Trial started. [AVEO, 25.08.2008]>>Trial registered. [AVEO, 15.04.2008]@-@@@@COMBO@-@@@@@-||||@AVEO PHARMACEUTICALS@@@@@AVEO PHARMACEUTICALS||||@Netherlands@@@@@Netherlands|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AV-951@@@@@AV-951||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921823@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity. SOURCE: clinicaltrials.gov/Lorus@@-@-@-@TORONTO, CANADA@@@LOR-2040 (formerly GTI-2040) is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. Through downregulation of R2, LOR-2040 has demonstrated strong antitumor and antimetastatic activity in a variety of tumor types in both in vivo and in vitro models and is under study in a multiple Phase I/II clinical program. R2 has been described as a malignant determinant that is elevated in a wide range of tumors, which can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential.@@14921823@Combo with oxaliplatin and Xeloda for unresectable colorectal cancer@@-@-@@NO REVIEW@@@@-@Global rights available for partnering@-@NCT00084643@20@-@-@@@-@@@-@CCC-PHI-41@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@ANTISENSE@CAPECITABINE@OXALIPLATIN@@@ANTISENSE|CAPECITABINE|OXALIPLATIN||@LORUS THERAPEUTICS@@@@@LORUS THERAPEUTICS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@LOR-2040@XELODA@ELOXATIN@@@LOR-2040|XELODA|ELOXATIN||@Antisense@@@@@Antisense||||@MAXIMUM TOLERATED DOSE@TOXICITY@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921566@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Doxil with multiday vinorelbine@@L01DB01@L01D@-@NEW BRUNSWICK, NEW JERSEY@@@The mechanism of action of doxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations. Doxil is doxorubicin HCl encapsulated in long-circulating Stealth liposomes. Liposomes are microscopic vesicles composed of a phospholipid bilayer that are capable of encapsulating active drugs. The Stealth liposomes of Doxil are formulated with surface-bound methoxypolyethylene glycol (MPEG), a process often referred to as pegylation, to protect liposomes from detection by the mononuclear phagocyte system (MPS) and to increase blood circulation time.@@14921566@-@@-@-@@NO REVIEW@@@@-@Doxil is a registered trademark of Alza Corporation, manufactured by Ben Venue Laboratories, distributed by Tibotec Therapeutics, a division of Ortho Biotec@-@NCT00159094@30@-@-@@@-@@10/1/2003@-@DO03-21-005  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@DOXORUBICIN, PEGYLATED LIPOSOMAL @VINORELBINE@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL |VINORELBINE|||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@DOXIL@@@@@DOXIL||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384750@Onco@@@@@300f1014ntsdm@@@@@@@@L01XE01@L01X@@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@16384750@Indicated for the treatment of adult with Ph+ CML in blast crisis.@@EXPENSIVE ITEM APPENDIX III (LIMITED WHOLESALE MARGIN)@@@NO REVIEW@@@@@@@@260@The recommended dose of Glivec is 600 mg/day for adult patients in blast crisis.@@@@Yes@@@@Study 0102@No@@@ADULT@@@APPROVED@@@RAMQ@@@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLEEVEC@@@@@GLEEVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@BLAST PHASE@@@@@@@@@@1@1@29279.00432@@@6.05@month@6.05 month@29279@29279@159.11@120@0.7881@3182.21@@@@@@@@@@@@0.27@1@@mg@600@1@@@@@@@@@@@7/19/2017@26.52@26.52@2253275120@TABLET@C$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14919440@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@M05BA03@M05B@NO@LAKE FOREST, ILLINOIS@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14919440@• Treatment of conditions associated with increased osteoclast activity: Tumour-induced hypercalcaemia • Osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer or multiple myeloma • Paget's disease of bone.@@YES@@@NO REVIEW@@@@@Via takeover of Mayne@@@@Osteolytic lesions and bone pain in multiple myeloma - The recommended dose is 90 mg every 4 weeks. Osteolytic lesions and bone pain in bone metastases associated with breast cancer - The recommended dose is 90 mg every 4 weeks. This dose may also be administered at 3 weekly intervals to coincide with chemotherapy if desired.@2-Jul@@@@@@Pamidronate should never be given as a bolus injection since severe local reactions and thrombophlebitis may occur. It should always be diluted and then given as a slow intravenous infusion. It should not be co-administered with other bisphosphonates. If other calcium lowering agents are used in conjunction with pamidronate, significant hypocalcaemia may result. Convulsions have been precipitated in some patients with tumour-induced hypercalcaemia due to the electrolyte changes associated with this condition and its effective treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Supportive Care@Breast Cancer@Haematological Malignancy@Myeloma@Bone Metastases@Supportive Care|Breast Cancer|Haematological Malignancy|Myeloma|Bone Metastases|||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918324@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01XX11@L01X@NO@HOLZKIRCHEN, GERMANY@@@Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. The low level of clinical side effects may be due to the fact that estramustine binds to a protein present in the tumour tissue, so resulting in accumulation of the drug at the target site. Estracyt also has weak oestrogenic and anti-gonadotrophic properties. Estramustine causes little or no bone marrow depression at usual therapeutic dosage. Estramustine is effective in patients who have not previously received drug therapy, as well as in those who have shown no response to conventional hormone treatment.@@14918324@Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyestradiol phosphate etc.) or by orchidectomy.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Dosage range may be from 1 to 10 capsules a day by mouth. The capsules should be taken not less than 1 hour before or 2 hours after meals. The capsules should not be taken with milk or milk products. Standard starting dosage is 4-6 capsules a day in divided doses with later adjustment according to response and gastrointestinal tolerance.@@@@@@@Use with caution in patients with moderate to severe bone marrow depression, thrombophlebitis, thrombosis, thromboembolic disorders, cardiovascular disease, coronary artery disease and congestive heart failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ESTRAMUSTINE PHOSPHATE SODIUM@@@@@ESTRAMUSTINE PHOSPHATE SODIUM||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Oestrogen@Nitrogen Mustard Analogue@@@@Oestrogen|Nitrogen Mustard Analogue|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@215.32@283.22@222.81@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@2.15@2.15@882684@HARD CAPSULE@EURO@@@@@@@@280@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916626@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@PRX302 at increasing volumes and/or number of deposits per gram of prostate@@-@-@-@VANCOUVER, CANADA@9/1/2008@@Protox’s lead drug developed from its PORxin platform, PRX302, is an engineered version of proaerolysin, a protein secreted by the bacteria Aeromonas hydrophilia. Proaerolysin contains two important regions that allow it to exert its effect. The first is a binding site that allows the molecule to attach to the surface of a cell and the second is an “activation tail” that must be removed before it is able to form a pore. Protox has engineered the tail on PRX302 so it can be cut off and activated by prostate specific antigen (PSA), an enzyme that is produced at high levels in the prostates of patients with prostate cancer and BPH. Once bound and activated, PRX302 combines with other activated PRX302 molecules to form a mushroom shaped structure that is able to perforate the cell membrane. The cell contents leak out through the resulting pore and the cell dies. PRX302 is injected locally into the prostate to treat prostate cancer and BPH using “molecular surgery” which is much less invasive and potentially safer than traditional surgery. In the case of prostate cancer, the goal is to reduce the size of the tumor or eliminate the tumor altogether. In the case of BPH, lower amounts of PRX302 are used to reduce the size of the prostate, thereby restoring normal urinary function. Protox is also developing second generation PORxin drug candidates with altered binding sites. Altering the binding site may further increase the drug’s specificity, providing greater flexibility to administer and treat an even wider range of diseases. These molecules are currently at the discovery stage.@@14916626@Recurrent, localised prostate cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00686088@30@-@-@@@-@@2/1/2008@-@PRX302-1-02@@-@"Completed a full course of radiation therapy for prostate cancer at least 2 years before enrollment. 
"@@@IIA@II@@-@-@">> Trial registered [Protox, 26.05.2008]            
>> Trial to start in Q1 08. [Protox, January 2008]"@-@@@@-@-@@@@@-||||@PROTOX THERAPEUTICS@@@@@PROTOX THERAPEUTICS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PORXIN@PRX-302@@@@PORXIN|PRX-302|||@Other@@@@@Other||||@SAFETY@@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14921824@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Lenalidomide combined with DTIC@@L04AX04@L04A@@SUMMIT, NEW JERSEY@11/1/2007@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14921824@Lenalidomide with DTIC; previously untreated with systemic chemotherapy@@@@@NO REVIEW@@@@@-@FIRST-LINE@NCT00179608@28@@@@@EMEA'S COMP issues positive opinion to grant ORPHAN DRUG status for CLL treatment@@9/1/2005@@CC5013MEL003@@@@@@I@I@@@@Endpoint during first 2 cycles (6 weeks) of treatment.@@@@@COMBO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@REVLIMID@DTIC@@@@REVLIMID|DTIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916622@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Talabostat with docetaxel versus docetaxel with placebo@@-@-@-@BOSTON, MASSACHUSSETTS@@@This is a substance being studied in the treatment of cancer, including certain types of lung, pancreas, and brain cancer. Talabostat may help the immune system block the growth of cancer cells. It may also increase the growth of new blood cells. It is a type of enzyme inhibitor. @@14916622@Stage IIIb/IV NSCLC with docetaxel@@-@-@@NO REVIEW@@@@-@DARA and Point to merge; DARA will become wholly-owned subsidiary, whilst Point will change its name to DARA BiosSciences. SOURCE: Point, 10 October 2007@MULTIPLE@NCT00080080@55@-@-@@@-@@@-@PTH-302@@-@55 PATIENTS ENROLLED AND 42 EVALUABLE.@@@II@CLINICAL HOLD@@-@-@All clinical trials for talabostat put on hold following the interim results for the two Phase III NSCLC trials which showed no increase in PFS or overall survival. SOURCE: Point, 21 May 2007Overall median PFS and survival was 4.0 months and 7.8 months, respectively. Median PFS was calculated at 4.9 months for the 37 second-line patients and 2.7 months for the 18 third-line patients in the study. Median survival was 10.0 months for second-line patients and 5.4 months for third-line patients. One-year survival was 38%. 6 of 42 patients demonstrated a clinical response to treatment—a 50% or greater reduction in the size of their tumour(s). 2 patients experienced a CR.@-@@@@COMBO@TALABOSTAT@DOCETAXEL@@@@TALABOSTAT|DOCETAXEL|||@DARA BIOSCIENCES@@@@@DARA BIOSCIENCES||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PT-100@TAXOTERE@@@@PT-100|TAXOTERE|||@Immunotherapy@@@@@Immunotherapy||||@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918003@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Stable doses of either long-acting oral opioid or transdermal fentanyl with Actiq (200, 400, 600, 800, 1200 and 1600mcg)@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14918003@Indicated only for management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.@@NO@@@NO REVIEW@@@@@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@257@Initial dose: 200 mcg. Prescribe an initial supply of six 200 mcg units.@FDA, 4 November 1998@11/4/1998@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@SEPTEMBER 2006 (EXCLUSIVITY; FEBRUARY 2010)@257 OPIOID-TOLERANT ADULT CANCER PATIENTS@@@III; TWO DOSE TITRATION STUDIES@APPROVED@@Prior authorisation; specialty drug; quantity limit 120 for 30 days@MEDICARE@95 of 127 patients (75%) titrated to a successful dose of Actiq (could be used consistently for at least 2 days without unacceptable side-effects). 11% and 14% withdrew due to adverse events or other reasons respectively.@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOSE-RANGING@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@2177@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@72.57@72.57@63459-0504-30@LOZENGE@US$@@@@@@@@400@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916552@Onco@@@@@300f1015ntsdm@@@@@@225 received orchiectomy/nilandron; 232 with orchiectomy/placebo.@@L02BB02@L02B@YES@PARIS, FRANCE@@@Nilutamide is an antiandrogen medication used in the treatment of advanced stage prostate cancer. This medication blocks the androgen receptor, preventing its interaction with testosterone. This leads to a decrease in dihydrotestosterone (DHT) production. Because most prostate cancer cells rely on DHT for growth and spread, nilutamide can prolong life in men with prostate cancer.@@14916552@Indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2). For maximum benefit, treatment must begin on the same day as or on the day after surgical castration.@@NO@@@NO REVIEW@@@@100%@@@@457@The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day.@@@5/19/1995@@@@Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials in patients exposed to nilutamide. A small study in Japanese subjects showed that 8 of 47 patients (17%) developed interstitial pneumonitis. Reports of interstitial changes including pulmonary fibrosis that led to hospitalisation and death have been reported rarely post-marketing.@LABEL@No@@@@@III@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@Nilandron and placebo: OS 27.3 and 23.6 months; PFS 21.1 and 14.9 months; CR or PR 41% and 24% respectively.@@@@@COMBO@NILUTAMIDE@@@@@NILUTAMIDE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ANANDRON@@@@@ANANDRON||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@DOUBLE-BLIND@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1807@104.04@126.11@110.99@@@@@@@@@@0.02@@@@@@@@@@@@@@@@9/1/2017@3.47@3.47@3.40E+12@TABLET@EURO@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919256@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14919256@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@60%@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@10-Jul-07@7/10/2007@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MADAUS@@@@@MADAUS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14922547@Onco@@@@@300f1010ntsdm@@@@@@Photofrin PDT versus Nd:YAG laser therapy@@L01XD01@L01X@NO@-@@@@@14922547@Photodynamic therapy with Photofrin is indicated for: - Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy. - Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). - Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy are not indicated. - Ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy.@@NO@-@@NO REVIEW@@@@100%@Licensed from QLT@-@-@211@Photodynamic therapy with Photofrin is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection at 2 mg/kg. Illumination with laser light 40–50 hours following injection constitutes the second stage of therapy. A second laser light application may be given 96-120 hours after injection, preceded by gentle debridement of residual tumor@-@@@-@@@Endobronchial Cancer: Patients should be assessed for the possibility that a tumor may be eroding into a pulmonary blood vessel. Patients at high risk for fatal massive hemoptysis (FMH) include those with large, centrally located tumors, those with cavitating tumors or those with extensive tumor extrinsic to the bronchus.@LABEL@@-@-@@@III TWO TRIALS [ENDOBRONCHIAL CANCER]@DISCONTINUED@@-@NHS@Objective tumour response rates (CR + PR), which demonstrate reduction of obstruction, were 59% for PDT and 58% for Nd:YAG at Week 1. The response rate at 1 month or later was 60% for PDT and 41% for Nd:YAG.@-@@@@MONO@PORFIRMER SODIUM@@@@@PORFIRMER SODIUM||||@SINCLAIR PHARMA@@@@@SINCLAIR PHARMA||||@@@@@@|||||||||@NSCLC@Oesophageal Cancer@@@@NSCLC|Oesophageal Cancer||||||||@PHOTOFRIN@@@@@PHOTOFRIN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@@@@1@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@12/29/2014@@@7.31E+15@INJECTION POWDER FOR RECONSTITUTION@GB£@@@@@@@@75@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15413021@Onco@@@@@@@@@@@Hypothyroxinemia induced patients, Experimental, Combined T3 and Methimazole treatment will be administered. This experimental treatment will be administered adjunct to standard oncological treatment for newly-diagnosed GBM patients e.g. radiation followed by Temozolomide.@@@@@@2/1/2017@@@@15413021@Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients@Both@@@@@Oral administration of T3 and Methimazole@@@@@@NCT02654041@30@@@@@@@1/1/2016@@MusliGBM002@@@Diagnosis of GBM, histologically or cytologically confirmed.  -  Newly-diagnosed subjects prior to beginning first-line conventional therapy.  -  Male or female subjects 18 years of age or older.  -  Ability to understand and willingness to sign a written informed consent document.  -  Ability and consent to comply with completion of a patient diary.  -  Subjects must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) with conventional techniques or as ≥10 mm (≥1 cm) with spiral CT scan, MRI, or calipers by clinical exam.  -  Allowable type and amount of prior therapy and medication  -  ECOG performance status ≤2 (KPS ≥60%, see Appendix A).  -  Life expectancy of greater than 6 months  -  Subjects must have adequate bone marrow, liver and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment:  -  Total bilirubin < 1.5 x the upper limit of normal (ULN).  -  Alanine transaminase (ALT) and aspartate aminotransferase (AST) < 2.5 xULN (< 5 x ULN for subjects with liver involvement of their cancer).  -  Alkaline phosphatase limit < 2.5 x ULN (<5 x ULN for subjects with liver involvement of their cancer)  -  Serum creatinine < 1.5 x the ULN. Glomerular filtration rate (GFR) ≥ 30 ml/min/1.73 m2 according to the MDRD (Modified diet in renal disease) abbreviated formula.  -  INR/PTT < 1.5 x ULN.  -  Platelet count > 100000 /mm3, Hemoglobin (Hb) > 9 g/dl, Absolute neutrophil count (ANC) > 1500/mm3  -  No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment.  -  No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the tumor.  -  No significant abnormalities in ECG per investigator judgment.  -  Non-pregnant, non-lactating female subjects.  -  Women of childbearing potential and men must agree to use adequate contraception since signing of the informed consent form until at least 3 months after the last study.@COMBO@ADULTS@Phase 2@II@@@@@@@@@@-@METHIMAZOLE@@@@-|METHIMAZOLE|||@MUSLI THYROPEUTICS@@@@@MUSLI THYROPEUTICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@T3@TAPAZOLE@@@@T3|TAPAZOLE|||@Other@@@@@Other||||@Response rate at 6 months (6 months PFS)@@@@@Response rate at 2 months (2 months PFS)@Response rate at 4 months (4 months PFS)@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@Supportive Care@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920796@Onco@@@@@300f1020ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920796@Kytril Injection is indicated for a) the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and b) the prevention and treatment of postoperative nausea and vomiting. Kytril Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.@@NO@-@@NO REVIEW@@@@100%@-@-@-@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@N/A@@@-@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@-@No@-@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@DISCONTINUED@@@SSN@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@-@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@3@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@28093045@INJECTABLE PREPARATION SYRINGE, 1 ML@EURO@@@@@@@@3@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16063861@Onco@@@@@300f1010ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16063861@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX.@@YES@@@@@@@100%@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@254@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 13 January 2012@1/13/2012@@No@@@@EMR 62 202-013@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@7/29/2011@@NHS@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@27214.3924@@@7.9@month@7.9 month@27214.39@27214.39@113.26@1@1.299@178.1@@@@@@@@@@@@1.78@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@7/28/2017@178.1@178.1@1.15E+16@SOLUTION FOR IV INFUSION - 20 ML@GB£@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916144@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2. SOURCE: clinicaltrials.gov@@-@-@-@-@11/1/2007@@S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.@@14916144@2nd-line NSCLC@@-@-@@NO REVIEW@@@@-@sanofi-aventis returns its territory rights to Taiho Pharmaceutical for the development and commercialization of the oral anti-cancer agent S-1. Taiho will pursue further development of S-1 outside of Japan with gastric cancer included. SOURCE: Taiho, 18 July 2008@SECOND-LINE@NCT00652561@57@-@-@@@-@@2/1/2005@-@TPU-S1203@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TEGAFUR GIMERACIL OTERACIL POTASSIUM @@@@@TEGAFUR GIMERACIL OTERACIL POTASSIUM ||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@S-1@@@@@S-1||||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924326@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Erbitux with Gemzar and platinum-based chemo.@@L01XC06@L01X@-@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@14924326@Treatment-naïve patients, combo with Gemzar and platinum-based therapy.@@-@-@@NO REVIEW@@@@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]     >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@-@-@-@-@@@-@@@-@-@@CURRENTLY IN DISPUTE; IMCLONE LOST PROCESS PATENT, EXPIRING IN 2017, TO YEDA IN 2006.@-@-@@II@II@@-@-@ASCO June 2007; favourable rates across the board observed.@-@@@@COMBO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@@@@BMS|IMCLONE|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@SAFETY@@RESPONSE RATE@SAFETY@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15402466@Onco@@@@@300f1018ntsdm@@@@@@Iressa 250 mg daily plus Best Supportive Care or placebo plus Best Supportive Care.@@L01XE02@L01X@@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@15402466@Treatment of patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) whose tumours express activating mutations of the EGFR tyrosine kinase.@@NO@1-Apr-07@4/1/2007@NO REVIEW@@@@@@SECOND-LINE@NCT00242801@1692@The recommended daily dose is one 250 mg tablet with or without food.@TGA, 28 April 2003@4/28/2003@@@@@@ISEL@No@@1692 PATIENTS WITH ADVANCED NSCLC RECEIVED EITHER IRESSA 250 MG DAILY PLUS BEST SUPPORTIVE CARE OR PLACEBO PLUS BEST SUPPORTIVE CARE. PATIENTS HAD RECEIVED 1 OR 2 PRIOR CHEMOTHERAPY REGIMENS AND HAD PROGRESSED WHILE RECEIVING OR WITHIN 90 DAYS OF THE LAST@@@III@APPROVED@@@PBS@@@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IRESSA@@@@@IRESSA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@EGFR MUTATION POSITIVE@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@1@1@9300.421984@@@7@month@7 month@9300.42@9300.42@43.68@30@0.779@1310.46@1432.83@1380.4@@@@@@@@@@0.17@1@@mg@250@1@@@@@@@@@@@8/1/2017@43.68@43.68@1823-1135-GE-AP@FILM-COATED TABLET@A$@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16396581@Onco@@@@@300f1012ntsdm@@@@@@Experimental: Lenalidomide / Dexamethasone until disease progression Experimental: Lenalidomide / Dexamethasone for 18 cycles Active Comparator: Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles@@L04AX04@L04A@@SUMMIT, NEW JERSEY@6/1/2016@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396581@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@NCT00689936@1623@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 11 February 2015@2/11/2015@@Yes@@8/1/2008@@CC5013MM020, 200700482339@No@@Must understand and voluntarily sign informed consent form. Age ≥ 18 years at the time of signing consent. Previously untreated. ECOG performance status of 0, 1, or 2. Able to adhere to the study visit schedule and other protocol requirements. Females of childbearing potential (FCBP)^2@@ADULTS@III@APPROVED@@@GKV@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@DURATION OF RESPONSE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@274973.3127@@@26@month@26 month@274973.31@274973.31@347.71@21@1.1511@5841.5@7217.24@5880@@@@@@@@@@18.54@28@@mg@25@21@@@@@@@@@@@8/1/2017@278.17@278.17@1875278@HARD CAPSULE@EURO@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15051153@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@BIBW-2992 versus Erbitux@@-@-@-@INGELHEIM, GERMANY@1/1/2009@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.@@15051153@Versus Erbitux in HNSCC@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00514943@80@-@-@@@-@@8/1/2007@-@1200.28@@-@-@@@II@II@@-@-@Endpoint is tumour shrinkage before crossover to Stage 2 of the trial (8 weeks after start of treatment).@-@@@@MONO@AFATINIB@CETUXIMAB@@@@AFATINIB|CETUXIMAB|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@BIBW-2992@TOVOK@ERBITUX@@@BIBW-2992|TOVOK|ERBITUX||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@TUMOUR SIZE@@@@@@@@@@METASTATIC@RELAPSED@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@CROSSOVER@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921314@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@30mg obatoclax, 1.0mg/m2 bortezomib; obatoclax 30 mg, bortezomib 1.3 mg/m2; Obatoclax 45 mg, Bortezomib 1.3 mg/m2; Obatoclax 45 mg over 24 hours, bortezomib 1.3 mg/m2; Obatoclax 60 mg over 24 hours, bortezomib 1.3 mg/m2 @@-@-@-@-@12/1/2010@@Obatoclax (GX15-070) is a small molecule indole bipyrrole drug compound that was discovered and is being developed at Gemin X. The attractive safety profile and mechanism of action of obatoclax offers the opportunity to treat many forms of cancer as both a single agent and in combination with current treatments. Obatoclax  is a pan-inhibitor of the pro-survival members of the Bcl-2 family of apoptosis regulators. Many of the cellular events that initiate malignant transformation of a normal cell (e.g., activation of oncogenes) also activate oncogenic stress pathways that usually cause the cell to self destruct by a process called apoptosis [3]. In order for these cells to survive and cause cancer, they typically must have acquired changes in other cellular pathways to prevent apoptosis. The Bcl-2 family of proteins are important regulators and executioners of the cellular decision to live or die. Moreover, this family of proteins also dictates whether or not many current cancer therapies are effective, because most of these treatments result in stress signals that ultimately must activate the cancer cell's apoptosis machinery.@@14921314@Relapsed or refractory mantle cell lymphoma; combo with Velcade@@-@-@@NO REVIEW@@@@-@-@-@NCT00407303@60@-@-@@@-@@10/1/2006@-@GEM012@@-@-@@@I/II@II@@-@-@Endpoint is between 4 weeks and 2 years.@-@@@@COMBO@OBATOCLAX MESYLATE@BORTEZOMIB@@@@OBATOCLAX MESYLATE|BORTEZOMIB|||@GEMIN X@@@@@GEMIN X||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@GX15-070@VELCADE@@@@GX15-070|VELCADE|||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917091@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14917091@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@GEPEPHARM@@@@@GEPEPHARM||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@BLEMINOL@@@@@BLEMINOL||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@100@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919365@Onco@@@@@300f1012ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@BAD VILBEL, GERMANY@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14919365@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@@@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@APPROVED@@@GKV@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@STADA ARZNEIMITTEL@@@@@STADA ARZNEIMITTEL||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@10.63@24.42@11.66@@@@@@@@@@5.32@@@@@@@@@@@@@@@@8/1/2017@10.63@10.63@688462@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918731@Onco@@@@@300f1020ntsdm@@@@@@Arenegry as a single-agent every 3 weeks@@-@-@-@MILAN, ITALY@10/1/2008@@NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumourvasculature. It consists of a tumour homing peptide (NGR) selectively binding tumour blood vessels, fused to the powerful human anticancer cytokine TNF. The resulting molecule has unique biological properties, including induction of tumour vascular permeability and normalisation, and a direct biological antitumour activity. NGR-hTNF is undergoing clinical development both as single agent and in combination with several different chemotherapeutic agents: currently, in addition to mesothelioma and colorectal cancer, single agent Phase II trials are ongoing in hepatocellular carcinoma and small-cell lung cancer; for colorectal cancer, it is also being tested in a Phase II trial in combination with Xelox. Also ongoing is a Phase I trial in combination with cisplatin, while a Phase I trial in combination with doxorubicin was successfully completed.@@14918731@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00484211@27@-@-@@@EMEA orphan drug [11 November 2009]; FDA orphan drug [12 October 2009]@@12/1/2006@-@NGR008@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@ARENEGYR@@@@@ARENEGYR||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15394366@Onco@@@@@300f1020ntsdm@@@@@@521 patients were randomised to treatment with Teysuno (25 mg/m2 orally twice daily for 21 days followed by a 7-day rest period) and cisplatin (75 mg/m2 intravenous infusion once every 4 weeks); and 508 patients were randomised to treatment with 5-FU (1000 mg/m2/24 hours as a continuous intravenous infusion on Days 1 through 5 repeated every 4 weeks) and cisplatin (100 mg/m2 as an intravenous infusion on Day 1 repeated every 4 weeks).@@L01BC53@L01B@@@@@Teysuno is an oral fluoropyrimidine anti-cancer medicinal product@@15394366@Indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin@Both@@@@@@@@100%@@@@1029@The recommended standard dose of Teysuno when administered in combination with cisplatin is25 mg/m2 (expressed as tegafur content) twice daily, morning and evening, for 21 consecutive daysfollowed by 7 days rest (1 treatment cycle). This treatment cycle is repeated every 4 weeks.@EMA, 14 March 2011@3/14/2011@@@@@@FLAGS@No@@@@ADULTS@III@APPROVED@@@SSN@@@@@@COMBO@GIMERACIL / OTERACIL / TEGAFUR@CISPLATIN@@@@GIMERACIL / OTERACIL / TEGAFUR|CISPLATIN|||@NORDIC PHARMA@@@@@NORDIC PHARMA||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TEYSUNO@GENERIC@@@@TEYSUNO|GENERIC|||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMIZED@CONTROLLED@OPEN-LABEL@@@1.75@m²@1841.726418@@@4.8@month@4.8 month@1841.73@1841.73@12.61@84@1.1229@322.94@532.98@337.47@@@@@@@@@@0.19@28@@mg/m²@50@21@@@@@@@@@@@6/7/2017@3.84@3.84@42291043@HARD CAPSULE@EURO@@@@@@@@20@MG@5.8 MG|15.8 MG|20 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918818@Onco@@@@@@@@@@@The first two out of three cohorts of six patients each received PBI-1402 once daily at doses ranging from 44mg/kg to 66mg/kg. SOURCE: Prometic@@-@-@-@-@@@@@14918818@Chemotherapy-induced anaemia@@-@-@@NO REVIEW@@@N/A@-@-@-@-@30@-@-@@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@2 patients out of 28 (7%) treated with PBI-1402 required a RBC transfusion, a response rate greater than 90% with regards to this clinical objective. SOURCE: ProMetic, 23 April 2008Additional PBI-1402 Phase II clinical results from CIA trials in 2008. SOURCE: Prometic, 28 March 2008Analysis of the compiled data from a total of 18 patients showed an overall statistically significant increase of the mean hematocrit values at weeks 4, 6 and 8, and of the hemoglobin values at week 8. At week 8, p values were 0.02 for hematocrit and hemoglobin.  More detailed results from the study have been submitted to the European Hematology Association for presentation at their June 2008 meeting in Copenhagen. SOURCE: ProMetic press release, 6 March 2008Results of the first 12 patients demonstrated that 83 percent of patients had a significant increase in red blood cell count from baseline (p=0.015), and 66 percent of patients had a significant increase in hemoglobin (p=0.038). For those who responded to treatment, the mean increase in hemoglobin level was 1.1g/dL from the baseline value of 9.8g/dL (p=0.0007).  In non-responders, PBI-1402 stabilized red blood cell count and hemoglobin level. No patients required blood transfusion, and one patient demonstrated hemoglobin content below 9g/dL (8.9g/dL).  PBI-1402 was generally well tolerated.  Two patients reported side effects deemed related to PBI-1402. These were of low grade and mainly involved the gastrointestinal tract/ SOURCE: Prometic/ASH, 9 December 2007@-@@@@MONO@-@@@@@-||||@PROMETIC@@@@@PROMETIC||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@PBI-1402@@@@@PBI-1402||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922380@Onco@@@@@@@@@@@Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity@@L01XE04@L01X@-@NEW YORK, NEW YORK@3/1/2008@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14922380@Inoperable liver cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@-@NCT00247676@160@-@-@@@-@@2/1/2006@-@A6181055@@JANUARY 2011 (NCE EXCLUSIVITY); FEBRUARY 2021 (GIST PATENT)@-@@@II@II@@-@-@Endpoint over 28 days beyond discontinuation of treatment@-@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14922480@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Avastin with single-agent chemo@@L01XC07@L01X@-@SAN FRANCISCO, CALIFORNIA@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14922480@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@NCT00476827@59@-@-@@@-@@5/1/2007@-@9597-07-4R0@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@II@II@@-@-@RESULTS PENDING; completion expected by May 2009.@-@@@@COMBO@BEVACIZUMAB@@@@@BEVACIZUMAB||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@SAFETY@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919339@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@CANONSBURG, PENNSYLVANIA@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919339@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@6-Sep@@NO REVIEW@@@@@Via takeover of generics unit of Merck KGaA@@@@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@1-Mar-06@3/1/2006@@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9284507T@DILUTED SOLUTION FOR PERFUSION, 25 ML@EURO@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919333@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@ULM, GERMANY@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919333@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@7-May@@NO REVIEW@@@@@@@@@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@1-Aug-06@8/1/2006@4/1/2007@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9290459T@SOLUTION TO DILUTE FOR PERFUSION, 16.7 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918714@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@LAKE FOREST, ILLINOIS@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918714@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@NO@@@NO REVIEW@@@@100%@Acquired via takeover of Mayne Pharma@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, August 1985@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.299@32@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@6.4@6.4@4.95E+15@SOLUTION FOR INJECTION, VIAL@GB£@@@@@@@@500@MG@500 MG/10 ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919439@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@M05BA03@M05B@NO@CANONSBURG, PENNSYLVANIA@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14919439@• Treatment of conditions associated with increased osteoclast activity: Tumour-induced hypercalcaemia • Osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer or multiple myeloma • Paget's disease of bone.@@NO@4-May@@NO REVIEW@@@@@Via takeover of generics unit of Merck KGaA@@@@Osteolytic lesions and bone pain in multiple myeloma - The recommended dose is 90 mg every 4 weeks. Osteolytic lesions and bone pain in bone metastases associated with breast cancer - The recommended dose is 90 mg every 4 weeks. This dose may also be administered at 3 weekly intervals to coincide with chemotherapy if desired.@3-Jul@@@@@@Pamidronate should never be given as a bolus injection since severe local reactions and thrombophlebitis may occur. It should always be diluted and then given as a slow intravenous infusion. It should not be co-administered with other bisphosphonates. If other calcium lowering agents are used in conjunction with pamidronate, significant hypocalcaemia may result. Convulsions have been precipitated in some patients with tumour-induced hypercalcaemia due to the electrolyte changes associated with this condition and its effective treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@65% - price to hospital €90@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Supportive Care@Breast Cancer@Haematological Malignancy@Myeloma@Bone Metastases@Supportive Care|Breast Cancer|Haematological Malignancy|Myeloma|Bone Metastases|||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+24@SOLUTION FOR PERFUSION 1 ML@EURO@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920380@Onco@@@@@300f1010ntsdm@@@@@@1MG dose@@-@-@NO@MORRIS PLAINS, NEW JERSEY@@@@@14920380@After reconstitution with sodium pertechnetate [99mTc] solution, CEA-Scan is indicated only in patients with histologically-demonstrated carcinoma of the colon or rectum for imaging of recurrence and/or metastases. CEA-Scan is employed, in the above mentioned patients, as an adjunct to standard non-invasive imaging techniques, such as ultrasonography or CT scan, in the following situations: - Patients with evidence of recurrence and/or metastatic carcinoma of the colon or rectum, who are undergoing an evaluation for extent of disease, such as prior to surgical resection and/or other therapy. -Patients with suspected recurrence and/or metastatic carcinoma of the colon or rectum in association with rising levels of carcinoembryonic antigen (CEA).@@-@-@@NO REVIEW@@@@-@-@-@-@222@The patient receives a single dose of 1 mg of CEA-Scan. It will contain the radioactive technetium isotope in an amount called 750-1000 Mbq.@APRIL 1996; MANUFACTURING AND COMMERCILISATION DISCONTINUED IN SEPTEMBER 2005@@@-@@@It is possible to have a serious allergic reaction to CEA-Scan. Therefore, your doctor should keep you under close observation for a short time after he has given you this drug.@LABEL@@-@-@-@@III@DISCONTINUED@@-@-@Imaging sensitivity of 78% (90/115), specificity of 86% (6/7), accuracy of 79% (96/122).@-@@@@ADJUVANT@ARCITUMOMAB@@@@@ARCITUMOMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CEA-SCAN@@@@@CEA-SCAN||||@mAb@Murine@Radiolabeled@Imaging@@mAb|Murine|Radiolabeled|Imaging|@IMAGING@@@@@@@@@@-@@@@@OPEN-LABEL@MULTI-CENTRE@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16074373@Onco@@@@@300f1014ntsdm@@@@@@@@L01XE13@L01X@@INGELHEIM, GERMANY@1/1/2012@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.@@16074373@GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of the lung with activating EGFR mutation(s).@@NA@4-May-16@5/4/2016@NO REVIEW@@@@@@FIRST-LINE@NCT00949650@334@Recommended dose: 40 mg orally, once daily. Treatment should be continued until disease progression or until no longer tolerated by the patient.@Health Canada, 17 January 2014@1/17/2014@@@@8/1/2009@@LUX-Lung 3@No@@Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology. EGFR mutation detected by central laboratory analysis of tumour biopsy material.@@@III@APPROVED@@@RAMQ@@@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GIOTRIF@@@@@GIOTRIF||||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE@DISEASE CONTROL@QUALITY OF LIFE@@@METASTATIC@@@@@PARALLEL ASSIGNMENT@@@@@1@1@20932.2912@@@11.1@month@11.1 month@20932.29@20932.29@62@28@0.7881@1736@@@@@@@@@@@@1.55@1@@mg@40@1@@@@@@@@@@@7/19/2017@62@62@241568228@FILM-COATED TABLET@C$@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14921575@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Davanat and 5-FU@@-@-@-@-@@@Davanat is a proprietary carbohydrate drug that is administered with chemotherapies and biologics to treat cancer. Davanat's mechanism of action is based on binding to lectins. Davanat targets specific lectin receptors (Galectins) on cancer cells. Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis.@@14921575@Gall bladder cancer and bile duct cancer; in combination with 5-FU@@-@-@@NO REVIEW@@@@-@>>Sanghyon licenses South Korean rights. [Pro-Pharmaceuticals, 14.08.2008}>>Pro-Pharmaceuticals and BioCancell formed partnership to target destruction of H19 genes in cancer cells by delivering siRNA through IV administration of Davanat and BC-819. [Pro-Pharmaceuticals, 19.05.2008}>>Pro-Pharmaceuticals partnered with an undisclosed company in July 2007 to develop Davanat with another drug.@FIRST-LINE@NCT00386516@42@-@-@@@-@@9/1/2006@-@DAVFU-007@@-@-@@@II@II@@-@-@Patient dosing started. SOURCE: Pro-Pharmaceuticals, 4 April 2007@-@@@@COMBO@-@FLUOROURACIL@@@@-|FLUOROURACIL|||@PRO-PHARMACEUTICALS@@@@@PRO-PHARMACEUTICALS||||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@DAVANAT@5-FU@@@@DAVANAT|5-FU|||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16639034@Onco@@@@@300f1015ntsdm@@@@@@dabrafenib 150 mg twice dailydabrafenib plus trametinib placebo (dabrafenib 150 mg twice daily and trametinib placebo, trametinib 2 mg once daily)@@L01XE23@L01X@@LONDON, UNITED KINGDOM@8/1/2013@@Dabrafenib is an  orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.@@16639034@Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation@Both@No@30-Nov-16@11/30/2016@@@@@100%@@@NCT01584648@423@The recommended dose of dabrafenib, either used as monotherapy or in combination with trametinib, is 150 mg (two 75 mg capsules) twice daily (corresponding to a total daily dose of 300 mg).@EMA, 25 August 2015@8/25/2015@10/7/2013@No@@5/1/2012@@115306@No@@Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.The subject must have a radiologically measurable tumorThe subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).@BRAF V600 mutation@ADULTS@III@APPROVED@@ASMR III. Same assessment as Mekinist [http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-10/mekinist_summary_ct14705.pdf]@HAS@@@@@@COMBO@DABRAFENIB@TRAMETINIB@@@@DABRAFENIB|TRAMETINIB|||@GSK@@@@@GSK||||@World@@@@@World|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAFINLAR@MEKINIST@@@@TAFINLAR|MEKINIST|||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@62454.18621@@@11.2@month@11.2 month@62454.19@62454.19@183.33@120@1.1511@5500@5745.39@5530@@@@@@@@@@0.61@1@@mg@300@1@@@@@@@@@@@8/1/2017@45.83@45.83@3.40E+12@CAPSULE@EURO@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916536@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Segment 1 (dose escalation of RAV12): Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, and 22 of course 1 and on days 1, 8, and 15 of each subsequent course. Patients also receive RAV12 IV once weekly on days 1, 8, and 15 or twice weekly on days 1, 4 or 5, 8, 11 or 12, 15, and 18 or 19 until the MTD is reached. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Segment 2 (efficacy): Once the MTD has been determined, patients receive RAV12 at the MTD and gemcitabine hydrochloride as in segment 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. SOURCE: clinicaltrials.gov@@-@-@-@-@2/1/2009@@@@14916536@Combo with Gemzar@@-@-@@NO REVIEW@@@@-@MacroGenics acquires Raven. SOURCE: MacroGenics, 17 July 2008Licensed from Spirogen in May 2003@FIRST-LINE@NCT00625586@81@-@-@@@-@@3/1/2008@-@RV12-2007-003@@-@-@@@II@II@@-@-@Trial initiated. SOURCE: Raven press release, 13 March 2008@-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@RAVEN BIOTECHNOLOGIES@MACROGENICS@@@@RAVEN BIOTECHNOLOGIES|MACROGENICS|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@RAV-12@GEMZAR@@@@RAV-12|GEMZAR|||@mAb@Chimeric@@@@mAb|Chimeric|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922630@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L02AE02@L02A@NO@OSAKA, JAPAN@@@This is a synthetic nonapeptide analogue of naturally occurring gonadotrophin releasing hormone (GnRH) which possesses greater potency than the natural hormone. It is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy. Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Oestradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.@@14922630@Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer. It offers an alternative treatment of prostatic cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient. In a controlled study comparing leuprolide acetate injection 1 mg/day given subcutaneously to DES (diethylstilbestrol), 3 mg/day, the survival rate for the two groups was comparable after two years treatment. The objective response to treatment was also similar for the two groups.@@NO@@@NO REVIEW@@@@0%@@@@@The recommended dose is 22.5 mg to be administered is one injection every three months (84 days).@@@@No@@@Isolated cases of worsening of signs and symptoms during the first weeks of treatment have been reported. Worsening of symptoms may contribute to paralysis with or without fatal complications.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@@NO LABELLED TRIAL@@@@@@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Prostate Cancer@Breast Cancer@@@@Prostate Cancer|Breast Cancer||||||||@PROCRIN@@@@@PROCRIN||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTABLE SUSPENSION@EURO@@@@@@@@22.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14917484@Onco@@@@@300f1012ntsdm@@@@@@Six monthly injections of Eligard 7.5mg@@L02AE02@L02A@NO@TOKYO, JAPAN@@@Leuprolide acetate, an LH-RH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Eligard is a sterile polymeric matrix formulation of leuprolide acetate for subcutaneous injection. It is designed to deliver 7.5 mg of leuprolide acetate at a controlled rate over a one month therapeutic period.@@14917484@Palliative treatment of advanced prostate cancer@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Sanofi-Synthelabo licensed North American rights from pre-merger Atrix in 2001@FIRST-LINE@@120@One injection every month@@@@No@@@Transient increase in serum testosterone concentrations during first week; contraindicated in children; cases of ureteral obstruction and spinal cord compression, possibly contributing to paralysis with or without fatal complications, have bene reported with LH-RH agonists@LABEL@No@@120 PATIENTS WITH ADVANCED PROSTATE CANCER (89 WITH STAGE C AND 31 WITH STAGE D)@@@@APPROVED@@@GKV@Mean serum PSA values reduced 94% from baseline by Month 6 in patients whose baseline values were elevated above normal limit. Mean testosterone concentration increased from 361.3 ng/dL at baseline to 574.6ng/dL at Day 3, then decreased to below baseline by Day 10 and was 21.8ng/dL on Day 28 by Month 6, it was 6.1ng/dL. Serum testosterone suppressed to below castrate threshold of under 50ngdL by Day 28 in 119 (94%) patients- all remaining attained the level by Day 42@@@@@MONO@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@ASTELLAS PHARMA@@@@@ASTELLAS PHARMA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ELIGARD@@@@@ELIGARD||||@LH-RH Analog@@@@@LH-RH Analog||||@PSA@SERUM TESTOSTERONE@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@355.97@461.04@367.88@@@@@@@@@@15.82@@@@@@@@@@@@@@@@8/15/2017@355.97@355.97@2726014@DRY POWDER + SOLVENT@EURO@@@@@@@@22.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919190@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@CANONSBURG, PENNSYLVANIA@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14919190@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.@@@2/1/2009@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@OXALIPLATIN@@@@@OXALIPLATIN||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@153@@@@@@@@@@@@3.06@@@@@@@@@@@@@@@@8/2/2017@153@153@9281070R@POWDER FOR SOLUTION FOR PERFUSION, 10 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919061@Onco@@@@@@@@@@@Yondelis 1.3mg/m2 as a 3-hour infusion every 3 weeks.@@L01CX01@L01C@-@MADRID, SPAIN@@@Yondelis (trabectedin, ET-743) was originally isolated from the marine tunicate Ecteinascidia turbinata. Yondelis has a novel mechanism of action. It is a unique anti cancer agent that binds into the minor groove of the DNA and interacts with DNA repair enzymes and transcription factors, interfering with different cell cycle processes. In addition to STS, Yondelis is being developed in a pivotal Phase III trial in ovarian cancer and in Phase II in prostate and breast cancers. Yondelis was designated Orphan Drug for STS by the European Commission (E.C.) in 2001 and by the U.S. FDA in 2004 and for ovarian cancer by the E.C. in 2003 and by the U.S. FDA in 2005.@@14919061@-@@-@-@@NO REVIEW@@@@-@>> PharmaMar, the biotech arm of Zeltia, has regained the Japanese rights to the drug and received US$10 million from the previous licence holder. Yondelis had been licensed to Ortho Biotech Products (OBI), a subsidiary of Johnson & Johnson since 2001. [Zeltia, 11 July 2008]              >> PharmaMar (Zeltia) maintains European rights, Ortho Biotech U.S. rights and Janssen Cilag for the rest of the world.@SECOND-LINE@-@44@-@-@@@-@@@-@N/A@@-@44 DEXAMETHASONE PRETREATED PATIENTS.@@@II@II@@-@-@ASCO June 2004 interim results; 1 complete response in 40 evaluable patients.@-@@@@MONO@TRABECTEDIN@@@@@TRABECTEDIN||||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@YONDELIS@@@@@YONDELIS||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@SINGLE-ARM@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923264@Onco@@@@@300f1008ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@PARIS, FRANCE@@@@@14923264@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Licensed from SRI International@@@@Initiation of therapy: is most conveniently carried out in hospital; 0.5ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact.@@@@@@@Patients known to suffer from depression should be carefully monitored during treatment with Suprefact. Prostatic carcinoma: Monitoring of the effect of clinical effect of Suprefact is carried out by methods generally used in prostatic carcinoma. Initially serum testosterone levels rise and a clinical effect will not be seen until levels start to fall into therapeutic (castration) range. Disease flare (temporary deterioration of the patient's condition) has been reported at the beginning of the treatment. The incidence is variable, but of the order of the 10%. Symptoms are usually confined to transient increase in pain, but the exact nature depends on the site of the lesions. Neurological sequelae have been reported where secondary deposits impinge upon the spinal cord or CNS. Disease flare is prevented by the prophylactic use of an anti-androgen, e.g. cyproterone acetate, 300 mg daily. It is recommended that the treatment should be started at least 3 days before the first dose of Suprefact and continued for at least 3 weeks after commencement of the Suprefact therapy.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHI@NO LABELLED TRIAL@@@@@@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SUPRECUR MP@@@@@SUPRECUR MP||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.0091@24760.75@29199@@@@@@@@@@@13755.97@@@@@@@@@@@@@@@@8/30/2017@24760.75@24760.75@2499405G1039@SUBCUTANEOUS INJECTION@YEN@@@@@@@@1.8@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921909@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@BMS-754807 Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, 24 months with Trastuzumab (Herceptin) IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly maintenance dose (dose escalation and dose expansion portions) [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@10/1/2010@@An orally bioavailable antagonist of human insulin-like growth factor type I receptor (IGF-1R) with potential antineoplastic activity. IGF-1R antagonist BMS-7548077 binds to IGF-1R, preventing IGF-1 ligand binding and activation of IGF-1R-mediated signaling pathways; inhibition of IGF-1R-mediated signaling pathways may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival@@14921909@BMS-754807 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced or Metastatic Her-2-Positive Breast Cancer@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00788333@48@-@-@@@-@@6/1/2009@-@CA191-004@@-@Subjects with locally advanced or metastatic Her-2-positive breast cancer who have failed at least one trastuzumab containing regimen Histologic or cytologic diagnosis of Her-2-positive breast cancer@@@I/II@II@@-@-@>> Phase II trial registered of BMS-754807 alone and in combination with Femara in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment. [BMS, 10.10.10]>>Trial registered [BMS, 7 November 2008]@-@@@@COMBO@-@TRASTUZUMAB@@@@-|TRASTUZUMAB|||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@BMS-754807@HERCEPTIN@@@@BMS-754807|HERCEPTIN|||@TK Inhibitor@@@@@TK Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@SAFETY@GLUCOSE METABOLISM@RESPONSE RATE@@@ADVANCED@METASTATIC@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916411@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@-@11/1/2008@@@@14916411@Pain in patients with advanced cancer who experience inadequate analgesia during optimsed chronic opioid therapy.@@-@-@@NO REVIEW@@@@-@Otsuka licensed U.S. rights for all indications in February 2007; Bayer holds rights in Canada and the UK.@SECOND-LINE@NCT00530764@336@-@BAYER RECEIVED APPROVAL IN CANADA IN AUGUST 2007@@@-@@11/1/2007@-@SPRAYGWCA0701@@-@-@@@II@II@@-@-@The Phase IIb trial evaluated three dose ranges of Sativex – a low dose (1-4 sprays per day), mid dose (6-10 sprays per day), and high dose (11-16 sprays per day) over a 5 week treatment period. In this study, the continuous response analysis showed statistically significant results in favor of Sativex for both the Sativex® low and mid dose groups versus placebo (p=0.008 and p=0.038, respectively). The low and mid dose Sativex groups, when combined, were also significantly superior to placebo for the primary outcome measure (p=0.006) and for the important secondary efficacy measure of reduction in sleep disruption (p=0.016).The results of this Phase IIb dose ranging study were consistent with a previous Phase IIa, 3-week clinical trial in 177 patients. In this prior study, Sativex showed a statistically significant improvement versus placebo in the continuous response analysis of improvement in average daily pain (p=0.044). [GWPharma, 23.11.10, http://www.gwpharm.co.uk/Sativex%20Enters%20Phase%20III%20Clinical%20Programme%20In%20Cancer%20Pain.aspx]@-@@@@MONO@-@@@@@-||||@OTSUKA PHARMACEUTICAL@GW PHARMACEUTICALS@@@@OTSUKA PHARMACEUTICAL|GW PHARMACEUTICALS|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@SATIVEX@@@@@SATIVEX||||@Cannabinoid@@@@@Cannabinoid||||@IVRS@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16670298@Onco@@@@@300f1015ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670298@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@25-Jan-17@1/25/2017@NO REVIEW@@@@0%@@FIRST-LINE@@459@The recommended starting dose is lenalidomide 10 mg/day orally on days 121 of repeated 28day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 14 of repeated 28 day cycles, prednisone2 mg/kg orally on days 14 of repeated 28day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide alone, 10 mg/dayorally on days 121 of repeated 28day cycles given until disease progression.@EMA, 11 February 2015@2/11/2015@9/1/2007@Yes@@@@@No@@@@ADULTS@@APPROVED@@25 January 2017: Insufficient SMR [http://www.has-sante.fr/portail/jcms/c_2746192/en/revlimid-myelome-multiple?xtmc=&xtcr=2]@Not reimbursed@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@97045.07669@@@27.4@month@27.4 month@97045.08@97045.08@116.45@1@1.1511@155.26@@@@@@@@@@@@15.53@28@@mg@10@21@@@@@@@@@@@8/2/2017@155.26@155.26@9298113R@CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
16423925@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"Phase 1b dose escalation, Experimental, In Phase 1b, patients with non-Hodgkin's lymphoma will receive escalating doses of Hu5F9-G4 in combination with ritixumab.
Phase 2 indolent lymphoma, Experimental, In Phase 2, patients with indolent lymphoma will receive Hu5F9-G4 in combination with ritixumab.
Phase 2 diffuse large B-cell lymphoma, Experimental, In Phase 2, patients with diffuse large B-cell lymphoma will receive Hu5F9-G4 in combination with ritixumab.
"@@@@@UNITED STATES@3/1/2018@@@@16423925@A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma@Both@@@@@Hu5F9-G4 infusions will be administered weekly.@@@@@-@NCT02953509@72@@@@@@@11/1/2016@@5F9003@@@- Phase 1b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard approved therapies  -  DLBCL Phase 2 cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL), relapsed or refractory to frontline or second line treatmen@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@-@RITUXIMAB@@@@-|RITUXIMAB|||@FORTY SEVEN, INC.@@@@@FORTY SEVEN, INC.||||@United States@@@@@United States|||||||||@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|B-Cell Lymphoma||||||||@HU5F9-G4@MABTHERA@@@@HU5F9-G4|MABTHERA|||@Other@@@@@Other||||@Dose-limiting toxicities (Number of participants with a DLT)@Objective response (defined by the Investigator according to the Lugano classification for lymphomas)@@@@@@@@@REFRACTORY@RELAPSED@@@@Non-Randomized@Safety Study@Single Group Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919442@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@M05BA03@M05B@NO@CANONSBURG, PENNSYLVANIA@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14919442@• Treatment of conditions associated with increased osteoclast activity: Tumour-induced hypercalcaemia • Osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer or multiple myeloma • Paget's disease of bone.@@NO@@@NO REVIEW@@@@@Via takeover of generics unit of Merck KGaA@@@@Tumour-induced hypercalcaemia; please see label for dosing ranges; the total dose of pamidronate disodium may be administered either in a single infusion or in multiple infusions over 2-4 consecutive days. The maximum dose per treatment course is 90 mg for both initial and repeat courses.@@@@@@@Pamidronate should never be given as a bolus injection since severe local reactions and thrombophlebitis may occur. It should always be diluted and then given as a slow intravenous infusion. It should not be co-administered with other bisphosphonates. If other calcium lowering agents are used in conjunction with pamidronate, significant hypocalcaemia may result. Convulsions have been precipitated in some patients with tumour-induced hypercalcaemia due to the electrolyte changes associated with this condition and its effective treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Hypercalcaemia of Malignancy@@@@@Hypercalcaemia of Malignancy|||||||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+24@SOLUTION FOR PERFUSION 1 ML@EURO@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16387364@Onco@@@@@300f1037ntsdm@@@@@@@@L01XC07@L01X@@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16387364@Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations@@YES@@@NO REVIEW@@@@@@FIRST-LINE@@152@The recommended dose of Avastin when used in addition to erlotinib is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.It is recommended that the treatment with Avastin in addition to erlotinib is continued until disease progression.@EMA, 2 June 2016@6/2/2016@@No@@@@JO25567@No@@@EGFR activating mutations@@II@APPROVED@@@SNS@@@@@@COMBO@BEVACIZUMAB@ERLOTINIB@@@@BEVACIZUMAB|ERLOTINIB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AVASTIN@TARCEVA@@@@AVASTIN|TARCEVA|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@REPONSE RATE@DISEASE CONTROL RATE@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@MULTI-CENTRE@@@76.5@kg@90868.46046@@@16@month@16 month@90868.46@90868.46@186.72@1@1.1511@341.71@408.32@349.25@@@@@@@@@@3.42@21@@mg/kg@15@1@@@@@@@@@@@8/4/2017@341.71@341.71@650602@INTRAVENOUS  INJECTION, 4 ML@EURO@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14920079@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@LAKE FOREST, ILLINOIS@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920079@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@@Once-every-3 week regimen: 350mg/m2 IV over 90 minutes, once every 3 weeks@FDA, 27 February 2008@2/27/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@687.466234@@@3.9@month@3.9 month@687.47@687.47@5.8@1@1@19.87@@@@@@@@@@@@0.2@21@@mg/m²@350@1@@@@@@@@@@@8/2/2017@19.87@19.87@61703-0349-09@INJECTION - 5 ML@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15402468@Onco@@@@@300f1008ntsdm@@@@@@Patients (=18 years, performance status [PS] 0-2) with locally advanced or metastatic NSCLC who had progressed or recurred following 1 or 2 prior chemotherapy regimens (at least 1 platinum-based) were randomized to receive gefitinib (250 mg/day orally) or docetaxel (75 mg/m2 iv every 3 weeks). SOURCE: AstraZeneca@@L01XE02@L01X@@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@15402468@@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@FIRST-LINE@NCT00322452@1329@The recommended daily dose of IRESSA (gefitinib) is one 250 mg tablet with or without food.@MHLW, 1 August 2002@8/1/2002@@@@@@IPASS@No@@PATIENTS WITH ADVANCED NSCLC@@@III@APPROVED@@@NHI@@@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IRESSA@@@@@IRESSA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@ADVANCED@EGFR MUTATION POSITIVE@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@1@1@1644821.696@@@9.5@month@9.5 month@1644821.7@1644821.7@5692.37@1@0.0091@5692.37@6712.7@@@@@@@@@@@22.77@1@@mg@250@1@@@@@@@@@@@8/30/2017@5692.37@5692.37@4291013F1027@TABLET@YEN@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924120@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV picoplatin once every 4 weeks in the FOLPI regimen with oxaliplatin in combination with 5-FU and leucovorin in the modified FOLFOX-6 regimen@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@6/1/2009@@Picoplatin is believed to have an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. @@14924120@First-line treatment of metastatic CRC@@-@-@@NO REVIEW@@@@-@Poniard granted exclusive rights to IV picoplatin from AnorMed (now part of Genzyme)@FIRST-LINE@-@100@-@-@@@-@@4/1/2006@-@-@@-@-@@@II@II@@-@-@Preliminary results to be presented at ASCO 2008. SOURCE: Poniard, 6 May 2008@-@@@@COMBO@PICOPLATIN@@@@@PICOPLATIN||||@PONIARD PHARMACEUTICALS@@@@@PONIARD PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@-@FOLFOX6@@@@-|FOLFOX6|||@Platinum@@@@@Platinum||||@SAFETY@@@@@@@@@@METASTATIC@@@@@TWO-ARM@RANDOMISED@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918733@Onco@@@@@300f1020ntsdm@@@@@@Arenegry as a single-agent every 3 weeks@@-@-@-@MILAN, ITALY@6/1/2007@@NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumourvasculature. It consists of a tumour homing peptide (NGR) selectively binding tumour blood vessels, fused to the powerful human anticancer cytokine TNF. The resulting molecule has unique biological properties, including induction of tumour vascular permeability and normalisation, and a direct biological antitumour activity. NGR-hTNF is undergoing clinical development both as single agent and in combination with several different chemotherapeutic agents: currently, in addition to mesothelioma and colorectal cancer, single agent Phase II trials are ongoing in hepatocellular carcinoma and small-cell lung cancer; for colorectal cancer, it is also being tested in a Phase II trial in combination with Xelox. Also ongoing is a Phase I trial in combination with cisplatin, while a Phase I trial in combination with doxorubicin was successfully completed.@@14918733@Patients previously treated with flyoropyrimidine, oxaliplatin and irinotecan regimens@@-@-@@NO REVIEW@@@@-@-@-@NCT00483080@27@-@-@@@-@@12/1/2006@-@NGR006@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ARENEGYR@@@@@ARENEGYR||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14917276@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@DEERFIELD, ILLINOIS@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14917276@Used in combination therapy with other approved chemotherapeutics in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy; used in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.@@YES@@@NO REVIEW@@@@100%@@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@1-Aug-93@8/1/1993@@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@CELLTOP@@@@@CELLTOP||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@4@@@@@@@@@@@@0.04@@@@@@@@@@@@@@@@8/18/2017@4@4@9156086R@INJECTABLE SOLUTION FOR PERFUSION, 5 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14917379@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917379@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Hodgkin's Disease: Dacarbazine is administered in a daily dose of 375 mg/m2 body surface area i.v. on day 1 and day 15 in combination with doxorubicin, bleomycin and vinblastine for each cycle of ABVD regimen.@@@@@@@It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 1. Hemopoietic depression is the most common toxicity with dacarbazine. 2. Hepatic necrosis has been reported. 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@DETIMEDAC@@@@@DETIMEDAC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@160@213.27@165.74@@@@@@@@@@0.16@@@@@@@@@@@@@@@@8/15/2017@160@160@4939429@VIAL@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923898@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01AC01@L01A@NO@@@@@@14923898@Thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumours: 1. Adenocarcinoma of the breast. 2. Adenocarcinoma of the ovary. 3. For controlling intracavitary effusions secondary to diffuse or localised neoplastic diseases of various serosal cavities. 4. For the treatment of superficial papillary carcinoma of the urinary bladder. While now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease.@@NO@@@NO REVIEW@@@@@@@@@Intravenous Administration: Thiotepa may be given by rapid intravenous administration in doses of 0.3 to 0.4 mg/kg. Doses should be given at 1 to 4 week intervals. Intracavitary Administration: The dosage recommended is 0.6 - 0.8 mg/kg. Administration is usually effected through the same tubing which is used to remove the fluid from the cavity involved. Intravesical Administration: Patients with papillary carcinoma of the bladder are dehydrated for 8 to 12 hours prior to treatment. Then 60 mg of thiotepa in 30 - 60 mL of Sodium Chloride Injection is instilled into the bladder by catheter@@@@@@@Death has occurred after intravesical administration, caused by bone-marrow depression from systematically absorbed drug. Death from septicemia and hemorrhage has occurred as a direct result of hematopoietic depression by thiotepa. Thiotepa is highly toxic to the hematopoietic system. A rapidly falling white blood cell or platelet count indicates the necessity for discontinuing or reducing the dosage of thiotepa. Weekly blood and platelet counts are recommended during therapy and for at least 3 weeks after therapy has been discontinued. Thiotepa can cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@THIOTEPA@@@@@THIOTEPA||||@WEST-WARD@@@@@WEST-WARD||||@@@@@@|||||||||@Ovarian Cancer@Hodgkin's Lymphoma@Bladder Cancer@Breast Cancer@Sarcoma@Ovarian Cancer|Hodgkin's Lymphoma|Bladder Cancer|Breast Cancer|Sarcoma|||||@THIOTEPA@@@@@THIOTEPA||||@Alkylating Agent@Ethylene Imine@@@@Alkylating Agent|Ethylene Imine|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00703-4303-01@POWDER FOR INJECTION FOR RECONSTITUTION@US$@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920765@Onco@@@@@300f1008ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@@@@@@14920765@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@Initiation of therapy: is most conveniently carried out in hospital; 0.5 ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact. One spray dose is introduced into each nostril 6 times a day@@@@@@@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to the castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHI@NO LABELLED TRIAL@@@@@@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@ITO LIFE SCIENCES@@@@@ITO LIFE SCIENCES||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ITORELIN NASAL@@@@@ITORELIN NASAL||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.0091@4956.98@5845.5@@@@@@@@@@@314.73@@@@@@@@@@@@@@@@8/30/2017@4956.98@4956.98@2499701R1060@NASAL SOLUTION 10 ML@YEN@@@@@@@@15.75@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924728@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Sprycel twice daily by for 28 days (per cycle).@@L01XE06@L01X@-@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14924728@Leiomyosarcoma, liposarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, giant cell tumour, epithelioid sarcoma etc.@@NO@-@@NO REVIEW@@@@-@-@-@NCT00464620@452@-@-@@@-@@5/1/2007@-@-@@APRIL 2020 ('746); PATENT EXTENSION FILED.@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-GROUP@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922433@Onco@@@@@@@@@@@ARM A: irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks ARM B: folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks@@L01XX19@L01X@-@NEW YORK, NEW YORK@12/1/2011@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14922433@Comparing Irinotecan In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone, As Adjuvant Treatment After Resection Of Liver Metastases For Colorectal Cancer.@@-@-@@NO REVIEW@@@@-@Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan@-@NCT00143403@321@-@-@@@-@@12/1/2001@-@A5961076@@-@Histologically proven adenocarcinoma of the colon or rectum with complete resection of primary tumour. Complete surgical resection (R0) of the liver metastasis(es) within a minimum of 3 weeks, and a maximum of 8 weeks prior to the first study treatment infusion. Exclusively hepatic metastasis (es) : absence of bone, lung and brain metastases.@@@III@III@@-@BNF@RESULTS PENDING@-@@@@ADJUVANT@IRINOTECAN@FLUOROURACIL@FOLFIRI@@@IRINOTECAN|FLUOROURACIL|FOLFIRI||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@Liver Cancer@@@@Colorectal Cancer|Liver Cancer||||||||@CAMPTOSAR@CAMPTO@5-FU@@@CAMPTOSAR|CAMPTO|5-FU||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@DISEASE-FREE SURVIVAL@-@@@@OVERALL SURVIVAL@SAFETY@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916116@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@75MG/M2 Vidaza plus MGCD0103 in 28-day cycles@@-@-@-@MONTREAL, CANADA@@@MGCD0103 is a rationally designed, oral, isoform-specific, small molecule HDAC inhibitor which has been designed to be a molecular-targeted cancer therapy. MethylGene has measured surrogate markers of MGCD0103 action, such as changes in histone deacetylase activity in white blood cells from treated patients and obtaining tumour biopsies when possible from patients before, during and after treatment. Histone acetylation is a molecular marker for monitoring drug effect (pharmacodynamics) and for development of pharmacogenomic and diagnostic applications. MGCD0103 inhibits a specific subset of HDAC isoforms. Using functional genomics, MethylGene has identified the specific HDAC isoforms which it believes plays a major role in cancer and it uses this information to rationally design and develop isoform-selective inhibitors to target these isoforms. @@14916116@-@@-@-@@NO REVIEW@@@@-@>> MethylGene announced that Celgene has terminated their licensing agreement for oncology histone deacetylase (HDAC) inhibitors, including MGCD0103. MethylGene will reacquire all rights to MGCD0103 and other HDAC and sirtuin inhibitors in territories licensed to Celgene including North America and the European Union. [MethylGene, 27.10.2008]      >> In January 2006, Pharmion licensed R&D, development and commercialisation rights of MethlyGene's HDACs in North America, Europe, Middle East and certain other markets.@SECOND-LINE@-@75@-@-@@@EMEA ORPHAN DRUG STATUS RECOMMMENDED FOR HODGKIN'S IN JULY 2007@@@-@TRIAL CL002@@-@-@@@II@CLINICAL HOLD@@-@-@FDA clinical hold. SOURCE: MethylGene, 18 August 2008@-@@@@MONO@-@@@@@-||||@METHYLGENE@@@@@METHYLGENE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MGCD-0103@@@@@MGCD-0103||||@HDAC@@@@@HDAC||||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923733@Onco@@@@@300f1037ntsdm@@@@@@Combination therapy with capecitabine, oxaliplatin and bevacizumab until disease progression versus capecitabine, oxaliplatin and bevacizumab for 6 cycles followed by bevacizumab until disease progression or a premature drop out of the study.@@L01XC07@L01X@-@BASEL, SWITZERLAND@6/1/2010@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14923733@Bevacizumab alone or combined with capecitabine and oxaliplatin as support therapy in metastatic colorectal cancer patients.@@-@-@@NO REVIEW@@@@-@-@-@NCT00335595@470@-@-@@@-@@7/1/2006@-@-@@-@-@@@III@III@@-@-@Not yet available@-@@@@COMBO@BEVACIZUMAB@CAPECITABINE@OXALIPLATIN@@@BEVACIZUMAB|CAPECITABINE|OXALIPLATIN||@ROCHE@SANOFI-AVENTIS@@@@ROCHE|SANOFI-AVENTIS|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@XELODA@ELOXATIN@@@AVASTIN|XELODA|ELOXATIN||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14918700@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918700@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@NO@@@NO REVIEW@@@@100%@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, July 2003@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@32@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@32@32@1.06E+16@SOLUTION FOR INFUSION VIAL, 100 ML@GB£@@@@@@@@2.5@G@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917312@Onco@@@@@300f1010ntsdm@@@@@@Cosmegen/vincristine versus Cosmegen/doxorubicin and vincristine versus Cosmegen/doxorubicin/cyclophosphamide/vincristine@@@@YES@WHITEHOUSE STATION, NEW JERSEY@@@@@14917312@Cosmegen, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer; aas a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. As a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.@@NO@@@NO REVIEW@@@@100%@@@@1439@Wilms' Tumor, Childhood Rhabdomyosarcoma and Ewing's Sarcoma Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents have been utilized in the treatment of Wilms' tumour, rhabdomyosarcoma and Ewing's sarcoma. The dose intensity per 2-week cycle for adults or children should not exceed 15 mcg/kg/day or 400-600 mcg/m2/day intravenously for five days. Calculation of the dosage for obese or edematous patients should be performed on the basis of surface area in an effort to more closely relate dosage to lean body mass.@@@@@@@Cosmegen should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. This drug is HIGHLY TOXIC and both powder and solution must be handled and administered with care. Inhalation of dust or vapors and contact with skin or mucous membranes, especially those of the eyes, must be avoided. Avoid exposure during pregnancy. Due to the toxic properties of dactinomycin (e.g., corrosivity, carcinogenicity, mutagenicity, teratogenicity), special handling procedures should be reviewed prior to handling and followed diligently. Dactinomycin is extremely corrosive to soft tissue. If extravasation occurs during intravenous use, severe damage to soft tissues will occur. In at least one instance, this has led to contracture of the arms.@LABEL@No@@@-@@III WILM'S TUMOUR@APPROVED@@100%; no NICE review@NHS@4-year relapse free survival and 4-year overall survival was 89% and 96% in patients on 10-week Cosmegen/vincristine therapy in patients with favourable histology. Rates shrank to 71% and 85% when radiation therapy preceded treatment of 65 weeks. In patients with unfavourable histology, rate was 53% and 52% for 65-week Cosmegen/doxorubicin/cyclophosphamide and vincristine therapy.@@@@@ADJUVANT@DACTINOMYCIN@VINCRISTINE@@@@DACTINOMYCIN|VINCRISTINE|||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Sarcoma@Solid Tumours@@@@Sarcoma|Solid Tumours||||||||@COSMEGEN LYOVAC@@@@@COSMEGEN LYOVAC||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@OVERALL SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@@@@@1@1.2961@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@0.5@MG@0.5 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924572@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@@@14924572@-@@-@-@@NO REVIEW@@@@-@-@-@-@150@-@-@@@-@@7/1/2007@-@-@@-@Patients with NSCLC, colorectal cancer, NHL or breast cancer.@@@IIB@II@@-@-@>>Ostarine treatment led to statistically significant increase in lean body mass (LBM) and improvement in muscle performance measured by stair climb in patients with cancer cachexia compared to baseline in both the Ostarine 1 mg and 3 mg treatment cohorts. IOstarine met the primary endpoint of LBM, measured by a dual energy X-ray absorptiometry (DEXA) scan, by demonstrating statistically significant increases in LBM compared to baseline in both the Ostarine 1 mg and 3 mg treatment cohorts. Specifically, the change from baseline in LBM for the placebo, 1 mg and 3 mg treatment groups was 0.1 kg (p=0.874 compared to baseline), 1.5 kg (p=0.001) and 1.3 kg (p=0.045), respectively, at the end of the 16-week trial. [GTx 11 June 2009 http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=1298375&highlight=  ]>>Trial started. Results expected in Q3 2008. SOURCE: Merck, July 2007@-@@@@-@OSTARINE@@@@@OSTARINE||||@MERCK & CO@GTX@@@@MERCK & CO|GTX|||@@@@@@|||||||||@Supportive Care@Cachexia@@@@Supportive Care|Cachexia||||||||@MK-2866@GTX-838@@@@MK-2866|GTX-838|||@SERMs@@@@@SERMs||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922843@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@@@NO@MADISON, NEW JERSEY@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14922843@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@@@NO REVIEW@@@@100%@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenousinjection.@EMA, June 2006@@@@@@In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. Leucovorin may be fatal if given intrathecally. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@REFOLINON@@@@@REFOLINON||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@30@MG@3 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922893@Onco@@@@@300f1014ntsdm@@@@@@Avastin in combination with Irinotecan and Capecitabine@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14922893@Avastin in combination with Irinotecan and Capecitabine for patients with previoulsy untreated metastatic colorectal cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00483834@50@-@-@@@-@@@-@-@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@II@II@@-@-@Not yet available@-@@@@COMBO@BEVACIZUMAB@IRINOTECAN@CAPECITABINE@@@BEVACIZUMAB|IRINOTECAN|CAPECITABINE||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@CAMPTOSAR@@@@AVASTIN|CAMPTOSAR|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14918774@Onco@@@@@@@@@@@Nexavar 400mg daily versus placebo@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14918774@-@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@FIRST-LINE@-@226@-@-@@@-@@@-@N/A@@-@-@@@III@III@@-@-@Nexavar (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those receiving placebo. Nexavar also significantly improved time to progression in these patients by 74 percent (HR=0.57; P=0.001). Median time to progression was 2.8 months in Nexavar-treated patients versus 1.4 months for those taking placebo. Median time to symptomatic progression was 3.5 months in patients treated with Nexavar versus 3.4 months for those taking placebo. Disease control rate (complete response + partial response + stable disease = 12 weeks) was 35 percent in Nexavar-treated patients versus 16 percent for those taking placebo. SOURCE: Onyx, 16 May 2008Trial halted in August 2007 after IDMC recommendation for all patients to receive Nexavar.@-@@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@Asia-Pacific@@@@@Asia-Pacific|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@OVERALL SURVIVAL@TIME TO PROGRESSION@PROGRESSION-FREE SURVIVAL@@@PROGRESSION-FREE SURVIVAL@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@
14921448@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@A04AD11@A04A@NO@DUBLIN, IRELAND@@@Nabilone is a synthetic cannabinoid which has been shown to have significant anti-emetic activity in patients undergoing chemotherapy for malignant neoplasms. The mode of action of Nabilone has been studied in cats and dogs. Although its anti-emetic action is not yet fully understood, it is apparent that there are a number of points in the control systems of the body at which Nabilone could block the emetic mechanism.@@14921448@Indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.@@NO@@@NO REVIEW@@@@100%@@@@@The usual adult dosage is 1 or 2 mg b.i.d. On the day of chemotherapy, the initial dose should be given 1 to 3 hours before the chemotherapeutic agent is administered. To minimise side effects, it is recommended that the lower starting dose be used and that the dose be increased as necessary. A dose of 1 or 2 mg the night before may be useful. The maximum recommended daily dose is 6 mg given in divided doses t.i.d. Cesamet may be administered 2 or 3 times daily during the entire course of each cycle of chemotherapy and, if needed, for 48 hours after the last dose of each cycle of chemotherapy.@@@@@@@• The effects of Cesamet may persist for a variable and unpredictable period of time following its oral administration. Adverse psychiatric reactions can persist for 48 to 72 hours following cessation of treatment. • Cesamet has the potential to affect the CNS, which might manifest itself in dizziness, drowsiness, euphoria “high”, ataxia, anxiety, disorientation, depression, hallucinations and psychosis. • Cesamet can cause tachycardia and orthostatic hypotension.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@NABILONE@@@@@NABILONE||||@CAMBRIDGE LABORATORIES@@@@@CAMBRIDGE LABORATORIES||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@NABILONE@@@@@NABILONE||||@Cannabinoid@@@@@Cannabinoid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@20@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@4.06E+15@CAPSULE@GB£@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919591@Onco@@@@@300f1015ntsdm@@@@@@@@L01XX19@L01X@YES@UNTERACH, AUSTRIA@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14919591@CAMPTO is indicated for the treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.@@YES@@@NO REVIEW@@@@@@SECOND-LINE@@@The recommended dosage of CAMPTO is 350 mg/m² administered as an intravenous infusion over a 30- to 90- minute period every three weeks.Treatment with CAMPTO should be continued until there is an objective progression of the disease or an unacceptable toxicity.@@@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@@No@@@@@@APPROVED@@No ASMR/SMR rating@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@EBEWE PHARMA@@@@@EBEWE PHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@Invalid Factory Price@@@3.9@month@3.9 month@@@@1@1.1511@@@@@@@@@@@@@@21@@mg/m²@350@1@@@@@@@@@@@@@@9330182T@DILUTED SOLUTION FOR PERFUSION, 2 ML@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16668389@Onco@@@@@300f1015ntsdm@@@@@@Once daily@@L01XE27@L01X@@BEERSE, BELGIUM@5/1/2014@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16668389@Indicated for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy.@Both@@30-Nov-16@11/30/2016@NO REVIEW@@@@@@FIRST-LINE@NCT01614821@63@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 3 July 2015@7/3/2015@11/21/2014@Yes@@5/1/2012@@12-015@No@@Clinicopathological diagnosis of Waldenstrom's MacroglobulinemiaMeasurable disease; Have received at least one prior therapy for WM therapies@@ADULTS@@APPROVED@@30 November 2016 [http://www.has-sante.fr/portail/upload/docs/evamed/CT-15294_IMBRUVICA_Waldenstrom_PIC_INS_Avis2_CT15294.pdf]@Not reimbursed@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Waldenstrom's Macroglobinaemia@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Waldenstrom's Macroglobinaemia|||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@OVERALL RESPONSE RATE@@@@@SAFETY@PROGRESSION-FREE SURVIVAL@@@@@@@@@OPEN LABEL@MULTICENTER@SINGLE-ARM@@@1@1@Invalid Factory Price@@@1@month@1 month@@@@120@1.1511@@@@@@@@@@@@@@1@@mg@420@1@@@@@@@@@@@@@@3.40E+12@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919036@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@J06BB04@J06B@YES@DEERFIELD, ILLINOIS@@@@@14919036@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@@@@NO REVIEW@@@@@@@@@B-cell CLL: For patients with hypogammaglobulinemia and/or recurrent bacterial infections due to B-cell CLL, a dose of 400 mg/kg every 3 to 4 weeks is recommended.@FDA, May 2005@@@@@@Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death.18 Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD S/D@@@@@GAMMAGARD S/D||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00944-2620-01@INJECTION (VIAL)@US$@@@@@@@@0.5@G@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916147@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive S-1/cisplatin or 5-FU/cisplatin@@-@-@-@-@@@S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.@@14916147@Gastric cancer@@-@-@@NO REVIEW@@@@-@sanofi-aventis returns its territory rights to Taiho Pharmaceutical for the development and commercialization of the oral anti-cancer agent S-1. Taiho will pursue further development of S-1 outside of Japan with gastric cancer included. SOURCE: Taiho, 18 July 2008@FIRST-LINE@NCT00400179@700@-@-@@@-@@@-@TPU S-1301  @@-@700 PATIENTS (300 PER TREATMENT ARM) WITH LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER THAN CANNOT BE REMOVED BY SURGERY. @@@III@III@@-@-@The study did not meet its primary end point of superior overall survival, although the survival curve of S-1/cisplatin group was above that of 5FU/cisplatin group and clinical safety profile was generally in favor of the S-1/cisplatin group. Taiho will pursue further developments of S-1 outside of Japan by more in-depth analysis of the data. SOURCE: Taiho, 18 July 2008Completion expected August 2008.@-@@@@COMBO@TEGAFUR GIMERACIL OTERACIL POTASSIUM @CISPLATIN@@@@TEGAFUR GIMERACIL OTERACIL POTASSIUM |CISPLATIN|||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@S-1@@@@@S-1||||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921740@Onco@@@@@@@@@@@2 mg/m^2 IV over 1 hour twice weekly x 12 weeks; 2 mg/m^2 IV over 1 hour once weekly x 24 weeks. SOURCE: IDM Pharma@@-@-@-@IRVINE, CALIFORNIA@2/1/2012@@IDM Pharma's lead product candidate, mifamurtide (MEPACT or L-MTP-PE), activates macrophages in vivo in order to increase their capacity to destroy cancer cells. IDM Pharma is developing L-MTP-PE for the treatment of osteosarcoma, the most common type of bone cancer affecting adolescents. IDM Pharma has received orphan drug status for L-MTP-PE for this indication in the United States and in Europe. A Phase 3 clinical trial of almost 800 patients was completed over a four-year period to support L-MTP-PE development. @@14921740@High-risk osteosarcoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00631631@100@-@>> EMEA preliminary consideration: CHMP considered that the data suggested a possible clinical benefit in terms of survival. However, the CHMP requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company is required to address a number of remaining questions relating to CMC. As a result of the CHMP's non-binding opinion, the Company was granted a clock stop, or time extension, to allow the Company additional time to respond to all the remaining questions regarding the MAA. The Company now expects to receive a final opinion from the CHMP in the third quarter and a final decision from the European Commission in the fourth quarter of 2008. [IDM, 28 January 2008.]>> MAA accepted for regulatory review in November 2006. [IDM, November 2006.]@1/28/2008@@YES@@2/1/2008@-@COMPASSIONATE ACCESS@@-@-@@@2007-0869@-@@-@-@Results to date are as follows:    -- Nine patients are alive with disease.    -- Nine patients have no evidence of disease.    -- Nine patients have died.    -- There are two patients for whom the status is unknown. SOURCE: IDM, 15 May 2008Compassionate access study initiated. SOURCE: IDM, 20 March 2008@-@@@@MONO@MIFAMURTIDE@@@@@MIFAMURTIDE||||@IDM PHARMA@@@@@IDM PHARMA||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@MEPACT@JUNOVAN@L-MTP-PE@@@MEPACT|JUNOVAN|L-MTP-PE||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917787@Onco@@@@@300f1012ntsdm@@@@@@Patients received Fareston 60MG, tamoxifen 40MG or tamoxifen 20MG.@@L02BA02@L02B@NO@DEERFIELD, ILLINOIS@@@Toremifene is a nonsteroidal triphenylethylene derivative. As other members of this class, e.g. tamoxifen and clomifene, toremifene binds to oestrogen receptors and may produce oestrogenic, anti-oestrogenic or both effects, depending upon the duration of treatment, animal species, gender, target organ and variable selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly anti-oestrogenic in rats and man and oestrogenic in mice.@@14917787@First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with oestrogen receptor negative tumours.@@NA@-@@NO REVIEW@@@@0%@-@-@-@1157@The recommended dose is 60 mg, one tablet, daily. There is no relevant indication for use in children.@Feb-96@@@-@@@As with other anti-oestrogens, hypercalcaemia and tumour flare have been reported in some breast cancer patients with bone metastases during the first weeks of treatment. Tumour flare is a syndrome of diffuse musculoskeletal pain and erythema with increased size of tumor lesions that later regress.@-@@-@-@@@III@DISCONTINUED@@-@GKV@RR was 21.3% and 19.1%, 20.4% and 20.8%, and 31.3% and 37.3% for the Fareston (60MG) and tamoxifen (20MG, 40MG, 40MG) respectively. Median TTP was 5.6 and 5.8 months, 4.9 and 5.0 months, and 7.3 and 10.2 months respectively.@-@@@@-@TOREMIFENE CITRATE@@@@@TOREMIFENE CITRATE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FARESTON@@@@@FARESTON||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@TIME TO PROGRESSION@@@@@@@@@METASTATIC@@@@@PROSPECTIVE@RANDOMISED@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@30@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@10/13/2014@@@7585989@TABLET@EURO@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16432030@Onco@@@@@300f1014ntsdm@@@@@@@@L01XE13@L01X@@INGELHEIM, GERMANY@10/1/2013@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.@@16432030@Indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology progressing after platinum-based chemotherapy@Both@NA@@@NO REVIEW@@@@@@SECOND-LINE@NCT01523587@795@The recommended starting dose of GIOTRIF is 40 mg orally once daily. GIOTRIF treatment should be continued until disease progression or until no longer tolerated by the patient@@@@@@3/1/2012@@LUX-Lung 8@No@@Diagnosis of advanced stage NSCLC squamous histology; Platinum-based doublet chemotherapy as 1st line treatment of Stage IIIB/IV NSCLC; Eligible to receive 2nd line therapy in the opinion of the investigator; Measurable disease according to RECIST 1.1; Adequate Performance Status; Availability of tumour tissue material for correlative studies. Archived tumour tissue is acceptable; Adequate organ function; Age = 18 years and above; Written informed consent that is consistent with ICH-GCP guidelines.@@ADULT@III@APPROVED@@@RAMQ@@@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GIOTRIF@@@@@GIOTRIF||||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@OBJECTIVE RESPONSE@DISEASE CONTROL@@@LOCALLY ADVANCED@METASTATIC@@@@PARALLEL ASSIGNMENT@RANDOMISED@OPEN LABEL@@@1@1@9164.94912@@@2.43@month@2.43 month@9164.95@9164.95@124@28@0.7881@1736@@@@@@@@@@@@3.1@1@@mg@40@1@@@@@@@@@@@7/19/2017@62@62@241566628@FILM-COATED TABLET@C$@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14920269@Onco@@@@@300f1014ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14920269@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@-@100%@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Unrestricted reimbursement.@RAMQ@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@GENPHARM@@@@@GENPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GEN-TAMOXIFEN@@@@@GEN-TAMOXIFEN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@30@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@C$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
15400326@Onco@@@@@300f1008ntsdm@@@@@@Investing arms: nilotinib 300mg bid or nilotinb 400 mg bidControl arm: imatinib 400mg QD@@L01XE08@L01X@@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@15400326@@Both@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@FIRST-LINE@NCT00471497@846@The recommended dose of Tasigna is 300 mg twice daily@@@@@@@@ENEST@No@@Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome@ADULT@Adult@III@APPROVED@@@NHI@@@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@MOLECULAR RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@1@1@4400161.056@@@12@month@12 month@4400161.06@4400161.06@12055.5@1@0.0091@4018.5@4738.8@@@@@@@@@@@20.09@1@@mg@600@1@@@@@@@@@@@8/30/2017@4018.5@4018.5@4291021M1020@CAPSULE@YEN@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14919196@Onco@@@@@@@@@@@All patients will receive MabThera 375mg/m² body surface area, as an IV infusion, every 8 weeks.@@L01XC02@L01X@-@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@14919196@MabThera maintenance therapy after a MabThera-containing induction regimen in first-line or relapsed patients with follicular non-Hodgkin's lymphoma. @@-@-@@NO REVIEW@@@@-@-@-@NCT00430352@>500@-@-@@@-@@10/1/2006@-@MAXIMA@@-@-@@@IV@IV@@-@-@Trial registered. SOURCE: Roche, 31 January 2007@-@@@@MONO@RITUXIMAB@@@@@RITUXIMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@RITUXAN@@@@@RITUXAN||||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922815@Onco@@@@@300f1020ntsdm@@@@@@Quadramet or placebo@@V10BX02@V10B@NO@KENILWORTH, NEW JERSEY@@@@@14922815@Indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.@@YES@-@@NO REVIEW@@@@100%@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@-@270@The recommended dose is 1.0 mCi/kg, administered intravenously over a period of one minute through a secure in-dwelling catheter and followed with a saline flush. Dose adjustment in patients at the extremes of weight have not been studied. Caution should be exercised when determining the dose in very thin or very obese patients.@EMA, February 1998@@@-@@@Causes bone marrow suppression. In clinical trials, white blood cell counts and platelet counts decreased to a nadir of approximately 40% to 50% of baseline in 123 (95%) of patients within 3 to 5 weeks after Quadramet, and tended to return to pretreatment levels by 8 weeks.@LABEL@No@-@270 [MAINLY PROSTATE CANCER]@@@III STUDY A + B@APPROVED@@@SSN@In study A, pain (the AUPC) decrease from baseline was significantly different in 1.0 mCi/kg and placebo groups at weeks 3 and 4. In study B, pain (the AUPC) decrease from baseline was significantly different in 1.0 mCi/kg and placebo groups at weeks 2, 3 and 4.@-@@@@MONO@SAMARIUM SM-153 LEXIDRONAM@@@@@SAMARIUM SM-153 LEXIDRONAM||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Supportive Care@Cancer Pain@Bone Metastases@@@Supportive Care|Cancer Pain|Bone Metastases|||||||@QUADRAMET@@@@@QUADRAMET||||@Radiolabeled@@@@@Radiolabeled||||@PAIN RELIEF@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@249.52@411.81@260.75@@@@@@@@@@@@@@@@@@@@@@@@@@6/7/2017@249.52@249.52@33111016@INJECTABLE SOLUTION@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16667502@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"Escalating Arm 1, Experimental, ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors.
Escalating Arm 2, Experimental, ABBV-621 via intravenous administration at escalating dose levels in participants with acute myeloid leukemia (AML).
Expansion Arm 1, Experimental, Additional participants with solid tumors will be enrolled in a dose expansion cohort that will further evaluate ABBV-621.
Expansion Arm 2, Experimental, Additional participants with colorectal cancer (CRC) will be enrolled in a dose expansion cohort that will further evaluate ABBV-621.
Expansion Arm 3, Experimental, Additional participants with AML will be enrolled in a dose expansion cohort that will further evaluate ABBV-621.
"@@@@@@11/1/2018@@@@16667502@An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies@Both@@@@@Intravenous@@@@@SECOND-LINE@NCT03082209@92@@@@@@@@@M15-913@@@Must have a diagnosis of a solid tumor, AML or non-Hodgkin lymphoma (NHL) that has relapsed, progressed, or failed to respond after at least one systemic therapy.  -  Must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, by computed tomography (CT) or magnetic resonance imaging (MRI) (excluding AML).  -  Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2.  -  Must have adequate hematologic, renal and hepatic function.@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@ABBVIE@@@@@ABBVIE||||@United States@@@@@United States|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ABBV-621@@@@@ABBV-621||||@Other@@@@@Other||||@Segment 1: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621@Segment 1: Maximum observed serum concentration (Cmax) of ABBV-621@Segment 1: Area under the serum concentration time curve (AUC) of ABBV-621@@@Segment 2: Dose limiting toxicity (DLT)@QTcF Change from Baseline@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922099@Onco@@@@@@@@@@@Imprime PGG 2.0, 4.0 or 6.0mg/kg and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Arm 2 looks at the same schedule without irinotecan. Number of Cycles: until progression or unacceptable toxicity develops@@-@-@-@EAGAN, MINNESOTA@8/1/2009@@Imprime PGG is a novel immunotherapy that can enhance the immune response against a number of disease indications. Imprime PGG works in concert with anti-tumor monoclonal antibodies to activate a large population of the body's immune cells (neutrophils) to kill cancer cells. Unlike other drugs that trigger a broad innate immune response, Imprime PGG selectively activates immune cells without inducing pro-inflammatory cytokines. This unique benefit reduces potential side effects of Imprime PGG. As a platform therapeutic in oncology, Imprime PGG has the potential to improve patient response rates for existing monoclonal antibody therapies in approved indications, create new indications for these drugs and enhance the efficacy of development-stage monoclonal antibody drugs.@@14922099@Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00545545@42@-@-@@@-@@10/1/2007@-@BT-CL-PGG-CRC0713@@-@Previously received treatment with 5-FU, alone or in combination with other anti-tumor medications; Prior treatment with capecitabine (Xeloda) will be considered to fulfill the requirement for prior treatment with 5-FU;@@@I/II@II@@-@-@>> A combination of Biothera's Imprime PGG and cetuximab (Erbitux) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients participating in a Phase Ib/IIa clinical trial. The sequential, dual-arm, open-label, dose-escalation study evaluated the safety and efficacy of Imprime PGG plus cetuximab and irinotecan (Arm #1) or Imprime PGG plus cetuximab alone (Arm #2). The 32-patient trial was conducted in Asia. In both arms of the trial, patients were dosed with 2 mg/kg, 4 mg/kg or 6 mg/kg of Imprime PGG in combination with standard doses of cetuximab and irinotecn. Imprime PGG was safe and well tolerated. All tumor responses and duration of responses were based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.0. [Biothera, 12.10.10 http://www.biothera.com/pharmaceutical/ESMOfinaldatarelease.htm]>> Enrolment completed in first arm. [Biothera, 8.10.2008]    >> Trial registered. [Biothera, 16.02.2007]@-@@@@COMBO@-@CETUXIMAB@@@@-|CETUXIMAB|||@BIOTHERA PHARMA@@@@@BIOTHERA PHARMA||||@Philippines@@@@@Philippines|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@IMPRIME PGG@ERBITUX@@@@IMPRIME PGG|ERBITUX|||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@PHARMACOKINETICS@RESPONSE RATE@@@@METASTATIC@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918276@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@ULM, GERMANY@@@@@14918276@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@1.8@13.26@2.56@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@2788104@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921491@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Lapatinib combo with paclitaxel as neadjuvant therapy@@-@-@-@BRENTFORD, UNITED KINGDOM@@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14921491@Newly diagnosed inflammatory breast cancer as a neoadjuvant therapy with paclitaxel@@-@-@@NO REVIEW@@@@-@-@-@NCT00111787@60@-@-@@@-@@4/1/2005@-@EGF102580@@17-Jul@-@@@II@II@@-@-@RESULTS PENDING@-@@@@NEOADJUVANT@LAPATINIB@PACLITAXEL@@@@LAPATINIB|PACLITAXEL|||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TYKERB@@@@@TYKERB||||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@COMPLETE RESPONSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923384@Onco@@@@@300f1018ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923384@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@@100%@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Restricted benefit: Treatment of hormone-dependent breast cancer. This drug is not PBS-subsidised for primary prevention of breast cancer.@PBS@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@APOTEX@@@@@APOTEX||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAMOXEN@@@@@TAMOXEN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@A$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916744@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14916744@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@@@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Unrestricted reimbursement.@RAMQ@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@APOTEX@@@@@APOTEX||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@APO-TAMOX@@@@@APO-TAMOX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@250@0.7934@87.5@@@@@@@@@@@@0.02@@@@@@@@@@@@@@@@8/18/2017@0.35@0.35@812390250@FILM COATED TABLET@C$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16668387@Onco@@@@@300f1015ntsdm@@@@@@Ibrutinib: 420 mg daily or 840 mg daily@@L01XE27@L01X@@BEERSE, BELGIUM@6/1/2013@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16668387@Treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo immunotherapy.@@YES@17-Jun-15@6/17/2015@NO REVIEW@@@@@@FIRST-LINE@NCT01105247@133@420 mg taken orally once daily (three 140 mg capsules once daily)@EMA, 21 October 2014@10/21/2014@11/21/2014@Yes@@4/1/2010@@PCYC-1102-CA@No@@@@@II@APPROVED@@17 June 2015: ASMR III. IMBRUVICA in monotherapy, like ZYDELIG in combination with rituximab, provides moderate clinical addedvalue (CAV III) in the therapeutic strategy for adult patients with CLL in the first line in patients with a 17p deletion or a TP53 mutation and who are unsuitable for chemoimmunotherapy. [http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-10/imbruvica_summary_ct14012.pdf]@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE GROUP ASSIGNMENT@@@1@1@Invalid Factory Price@@@9@month@9 month@@@@120@1.1511@@@@@@@@@@@@@@1@@mg@420@1@@@@@@@@@@@@@@3.40E+12@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924873@Onco@@@@@@@@@@@Eligible patients will receive one infusion of ofatumumab at 300 mg followed by 7 once weekly infusions at 2000 mg. Maintenance treatment will consist of 24 once monthly infusions of 2000 mg of ofatumumab. SOURCE: Genmab@@-@-@-@COPENHAGEN, DENMARK@@@Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.@@14924873@Ofatumumab retreatment and maintenance treatment study@@-@-@@NO REVIEW@@@@-@>> Amendment to the licensing deal agreed; Genmab has sold its co-promotion option rights to GSK. The sale of the co-promotion option does not affect the royalty or milestone revenue that Genmab may receive. GSK will now be fully responsible for the entire sales organisation for ofatumumab. Genmab will receive a one-time payment of US$4.5 million from GSK upon the FDA's acceptance for review of the filing of the first BLA for ofatumumab in an oncology indication in the United States in exchange for terminating its option to co-promote ofatumumab. [Genmab, 19.12.2008]      >> GlaxoSmithKline acquired an exclusive worldwide license to ofatumumab as well as any other antibodies with affinity for CD20 which Genmab may develop. GSK and Genmab will co-develop ofatumumab; Genmab has an option to co-promote ofatumumab in a targeted oncology setting in the United States and in the Nordic region. In addition, if Genmab exercises the co-promotion option, Genmab would have had the option to co-promote GSK's Bexxar and Arranon in the United States and Atriance in the relevant countries of the Nordic region. [Genmab, December 2006]@-@-@-@-@-@@@-@@@-@-@@-@Refractory CLL patients who participated in the ongoing Phase III CLL study and had disease progression following at least an objective response or stable disease during a 24 week treatment period of ofatumumab.@@@II@II@@-@-@Trial to start in 2008. [Genmab, 25 August 2008]@-@@@@MONO@OFATUMUMAB@@@@@OFATUMUMAB||||@GENMAB@MEDAREX@GSK@@@GENMAB|MEDAREX|GSK||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ARZERRA@@@@@ARZERRA||||@mAb@Human@CD20@@@mAb|Human|CD20||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@@
14918122@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA01@L01X@YES@BASEL, SWITZERLAND@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14918122@In combination with other chemotherapeutics and after appropriate surgigical and/or radiotherapeutic procedures, Platinol-AQ is indicated for for metastatic testicular tumours and metastatic ovarian tumours- an established combination for the latter is Platinol-AQ and Cytoxan. As a single agent, it is approved as a secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy but not received Platinol-AQ, and transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy.@@@@@NO REVIEW@@@@@@@@@For monotherapy, the following two dosage regimens are recommended:- Single dose of 50 to 120 mg/m² body surface every 3 to 4 weeks; - 15 to 20 mg/m²/day for five days, every 3 to 4 weeks. If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced. A typical dose is 20 mg/m² or more once every 3 to 4 weeks.@1-Apr@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Ovarian Cancer@Testicular Cancer@Bladder Cancer@@@Ovarian Cancer|Testicular Cancer|Bladder Cancer|||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@ADVANCED@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921015@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Different dose levels@@-@-@-@MORRIS PLAINS, NEW JERSEY@6/1/2003@@Radiolabeled humanized antibody targeting CEA-expressing tumors.  Primarily use for the treatment of inoperable metastatic solid tumors.  Every year there are 140,000 newly diagnosed and 65,000 deaths due to colorectal cancer; 180,000 new cases and 45,000 deaths due to breast cancer; 172,000 new case and 160,000 deaths due to lung cancer; 25,000 new case and 15,000 deaths due to ovarian cancer; and 29,000 new cases and 28,000 deaths due to pancreatic cancer.  Phase I clinical trials of yttrium-90-labeled labetuzumab have been completed as well as Phase II clinical trials of iodine-131-labeled labetuzumab for the treatment of patients with colorectal cancer that has metastasized to the liver.@@14921015@Colorectal or breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00041652@30@-@-@@@-@@2/1/2000@-@IM-T-hMN14-04@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@LABETUZUMAB@@@@@LABETUZUMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@IMMU-100@IMMU-101@@@@IMMU-100|IMMU-101|||@mAb@Humanised@Radiolabeled@@@mAb|Humanised|Radiolabeled||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918901@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-162 60MG or placebo every 6 months for 2 years@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma. @@14918901@Osteoporosis in breast cancer patients@@-@-@@NO REVIEW@@@@-@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@-@-@252@-@-@@@-@@@-@N/A@@-@-@@@III@III@@-@-@Denosumab met all primary and secondary bone mineral density endpoints@-@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Breast Cancer@Supportive Care@Bone Loss@@@Breast Cancer|Supportive Care|Bone Loss|||||||@AMG-162@@@@@AMG-162||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@BONE MINERAL DENSITY@@@@@@@@@@-@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919767@Onco@@@@@300f1037ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14919767@@@NO@@@NO REVIEW@@@@90%@@@@N/A@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@1-Jan-91@1/1/1991@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@NO REVIEW@SNS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@FERRER FARMA@@@@@FERRER FARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@500@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14918255@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@GERMANY@@@@@14918255@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@1.78@13.23@2.53@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@3683258@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919422@Onco@@@@@300f1018ntsdm@@@@@@@@L01BC05@L01B@NO@@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14919422@Non-Small Cell Lung Cancer: Gemcitabine, in combination with cisplatin, is indicated as a first-line treatment of patients with locally advanced (inoperable Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.Pancreatic Cancer: Gemcitabine is indicated for the treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is indicated for patients with 5-FU refractory pancreatic cancer.Bladder Cancer: Gemcitabine is indicated for treatment of advanced bladder cancer (muscle invasive Stage IV tumours with or without metastases) in combination with cisplatin therapy.Breast Cancer: Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless clinically contra-indicated.@@YES@@@NO REVIEW@@@@100%@@SECOND-LINE@@@@@@@@@@Gemzar can suppress bone marrow function as manifested by leukopaenia, thrombocytopaenia, and anaemia, can increase toxicity when prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing. Pulmonary toxicity, Hemolytic Uremic Syndrome (HUS) and/or renal failure, leading to death or requiring dialysis, despite discontinuation of therapy have been reported. Occurence of rare cases of Serious hepatotoxicity, including liver failure and death.@@No@@@@@@APPROVED@@@PBS@@@@@@COMBO@GEMCITABINE HYDROCHLORIDE@@@@@GEMCITABINE HYDROCHLORIDE||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Breast Cancer@NSCLC@Ovarian Cancer@Pancreatic Cancer@@Breast Cancer|NSCLC|Ovarian Cancer|Pancreatic Cancer||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@A$@@@@@@@@1000@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916576@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Infusion monotherapy@@-@-@-@CALGARY, CANADA@3/1/2009@@Reolysin, a proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of all human cancers. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders. Reovirus, an acronym for Respiratory Enteric Orphan virus, is generally believed to inhabit the respiratory and bowel systems in humans. Reovirus is found naturally in sewage and water supplies. By age 12, half of all children show evidence of reovirus exposure and by adulthood, most people have been exposed. However, the disease is non-pathogenic, meaning there are typically no symptoms from infections. The link to its cancer-killing ability was established after the reovirus was discovered to reproduce well in various cancer cell lines. Tumours bearing an activated Ras pathway are deficient in their ability to activate the anti-viral response mediated by the host cellular protein, PKR. Since PKR is responsible for preventing reovirus replication, tumour cells lacking the activity of PKR are susceptible to reovirus replication. As normal cells do not possess Ras activations, these cells are able to stop reovirus infection through normal PKR activity. In tumour cells with an activated Ras pathway, reovirus is able to freely replicate and eventually kill the host tumour cells. As cell death occurs, progeny virus particles are then free to infect surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there are no longer any tumour cells carrying an activated Ras pathway available.@@14916576@Histologically confirmed recurrent malignant glioma@@-@-@@NO REVIEW@@@@-@-@-@NCT00528684@44@-@-@@@-@@7/1/2006@-@REO-007@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ONCOLYTICS BIOTECH@@@@@ONCOLYTICS BIOTECH||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@REOLYSIN@@@@@REOLYSIN||||@Vaccine@@@@@Vaccine||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@SAFETY@IMMUNE RESPONSE@@SAFETY@IMMUNE RESPONSE@@@@MALIGNANT@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918704@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC02@L01B@YES@@@@Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. After intracellular conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.@@14918704@Fluorouracil may be used alone, or in combination, for the management of common malignancies particularly cancer of the colon and breast.@@NO@@@NO REVIEW@@@@100%@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@EMA, July 2003@@@@@@Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 300 - 500ml of 5% glucose or 0.9% NaCl injection and given over 4 hours. Alternatively the daily dose may be infused over 30 - 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 - 15g has been reached. Intravenousi Injection: l2mg/kg bodyweight may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course. Intra-arterial infusion: 5/7.5mg/kg bodyweight daily may be given by 24 hour continuous intra-arterial infusion.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@FLUOROURACIL@@@@@FLUOROURACIL||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Colorectal Cancer@Breast Cancer@@@@Colorectal Cancer|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@32@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@32@32@4.96E+15@SOLUTION FOR INFUSION VIAL, 50 ML@GB£@@@@@@@@2.5@G@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917545@Onco@@@@@300f1015ntsdm@@@@@@Patients receiving cisplatin over 50mg/m2 (mean dose of 80.2mg/m2) were given aprepitant 125mg, dexamethasone 12mg and ondansetraon 32mg IV on day 1, and aprepitant 80mg and dexamethasone 8mg for days 2-3.@@A04AD12@A04A@NO@WHITEHOUSE STATION, NEW JERSEY@@@@@14917545@Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Emend is given as part of combination therapy@@NO@@@NO REVIEW@@@@65%@Japanese rights with Ono.@@@1105@Emend is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg once daily in the morning on Days 2 and 3. Dosing is the same for Days 1-3 for highly and moderately emetogenic cancer chemotherapy.@1-Nov-03@11/1/2003@9/1/2004@@@@Emend should be used with caution in patients receiving concomitant orally administered medicinal products, including chemotherapy agents that are primarily metabolised through CYP3A4. Moderate inhibition of CYP3A4 by aprepitant, 125 mg/80 mg regimen, could result in elevated plasma concentrations of these concomitant medicinal products. Weak inhibition of CYP3A4 by a single 40 mg dose of aprepitant is not expected to alter the plasma concentrations of concomitant medicinal products that are primarily metabolised through CYP3A4 to a clinically significant degree.@@No@@@@@III; HIGHLY EMETOGENIC CHEMOTHERAPY; 2 RANDOMISED, PARALLEL ASSIGNMENT, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS.@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@Complete response was seen in 89% and 78% for the aprepitant and standard groups respectively for the acute phase, and 75% and 56% for the delayed phase.@@@@@COMBO@APREPITANT@CISPLATIN@@@@APREPITANT|CISPLATIN|||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Supportive Care@CINV@PONV@@@Supportive Care|CINV|PONV|||||||@EMEND@@@@@EMEND||||@NK1 Antagonist@@@@@NK1 Antagonist||||@COMPLETE RESPONSE@@@@@@@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@Invalid Dosage Value Phase 1@@@@@@71.16@71.16@@2@1.1807@36@46.1@38.4@@@@@@@@@@0.23@@@@@@@@@@@@@@@@9/1/2017@18@18@3.40E+12@CAPSULE@EURO@@@@@@@@80@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916725@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Alimta/cisplatin followed by chemoradiation versus Alimta/chemoradiation followed by consolidation therapy with Alimta and cisplatin@@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14916725@Unresectable, locally advanced NSCLC@@-@-@@NO REVIEW@@@@-@-@-@NCT00497315@100@-@-@@@-@@@-@PACCORA@@FEBRUARY 2009 (NCE); FEBRUARY 2011 (ORPHAN)@-@@@II@II@@-@-@Completion expected in February 2009.@-@@@@COMBO@PEMETREXED@CISPLATIN@@@@PEMETREXED|CISPLATIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALIMTA@@@@@ALIMTA||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@RESPONSE RATE@@@@@@@@@@LOCALLY ADVANCED@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER FOR INFUSION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916219@Onco@@@@@300f1010ntsdm@@@@@@Stable doses of either long-acting oral opioid or transdermal fentanyl with Actiq (200, 400, 600, 800, 1200 and 1600mcg)@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916219@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@257@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@257 OPIOID-TOLERANT ADULT CANCER PATIENTS@@@III; TWO DOSE TITRATION STUDIES@APPROVED@@NO NICE REVIEW@NHS@95 of 127 patients (75%) titrated to a successful dose of Actiq (could be used consistently for at least 2 days without unacceptable side-effects). 11% and 14% withdrew due to adverse events or other reasons respectively.@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOSE-RANGING@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.2961@21.05@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.02@7.02@2.69E+15@LOZENGE@GB£@@@@@@@@600@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917762@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01CB01@L01C@YES@UNITED STATES@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14917762@Refractory testicular tumours in combination therapy with other approved chemotherapeutics for patients who have already received surgical and chemoradiotherapy. Also approved as a first-line treatment in patients with SCLC.@@@@@NO REVIEW@@@@@@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@@@@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@62.19@@@@@@@@@@@@0.12@@@@@@@@@@@@@@@@8/2/2017@62.19@62.19@63323-0104-25@INJECTION@US$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922031@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Quarfloxacin alone@@-@-@-@SAN DIEGO, CALIFORNIA@6/1/2008@@Quarfloxin is a small-molecule targeted cancer therapeutic derived from the validated fluoroquinolone class of drugs. Rationally designed to selectively inhibit ribosomal RNA (rRNA) biogenesis in cancer cells, quarfloxin disrupts the interaction between the Nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA biogenesis and one that is amplified in cancer cells. As a result, quarfloxin selectively induces apoptotic cell death in cancers. Many commercialized cancer therapeutics act indirectly on rRNA Biogenesis through upstream modulators, but quarfloxin is the first agent to directly target this cancer-specific aberrant cell function.@@14922031@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00485966@25@-@-@@@-@@6/1/2007@-@C3-07-001@@-@-@@@II@DISCONTINUED@@-@-@>> Trial discontinued [Cylene, 3.11.2008]      >> Trial registered [Cylene, 11.06.2007]@-@@@@MONO@QUARFLOXIN@@@@@QUARFLOXIN||||@CYLENE PHARMACEUTICALS@@@@@CYLENE PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|||||||@CX-3543@@@@@CX-3543||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@-@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922444@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AG-013736 5 mg bid continuous dosing in 28 day cycles. @@-@-@-@NEW YORK, NEW YORK@6/1/2009@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14922444@Patients who have failed Nexavar therapy@@-@-@@NO REVIEW@@@@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@SECOND-LINE@NCT00282048@62@-@-@@@-@@3/1/2006@-@A4061023@@-@-@@@II@II@@-@-@Preliminary results showed overall median PROGRESSION-FREE SURVIVAL of 7.4 months. 13 patients (21%) had partial responses, 21 patients (34%) had stable disease, 16 patients (26%) had progressive disease, and tumour regression was experienced by 55% of patients. At a median follow-up of 8.1 months, the median overall survival was not reached. In patients receiving prior sunitinib therapy, one objective response was observed. Treatment-related grade 3/4 adverse events included hypertension, fatigue and hand-foot syndrome and nine patients (15%) withdrew because of adverse events. SOURCE: Pfizer/ASCO, 5 June 2007@-@@@@MONO@AXITINIB@@@@@AXITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@AG-013736@@@@@AG-013736||||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@RESPONSE RATE@@@@@@@@@@METASTATIC@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920588@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01XX05@L01X@NO@NEW YORK, NEW YORK@@@@@14920588@@@@@@NO REVIEW@@@@@@@@@Continuous therapy: Hydrea 20-30mg/kg should be given daily in single doses. Dosage should be based on the patient's actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts. Intermittent therapy: Hydrea 80mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Hydrea should be omitted.@FDA, 07 December 1967@12/7/1967@@@@@The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide therapy. If WBC falls below 2.5x109/L or platelet count to <100x109/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal. Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@HYDROXYUREA@@@@@HYDROXYUREA||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@HYDREA@@@@@HYDREA||||@Anti-metabolite@@@@@Anti-metabolite||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1@136.51@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@1.37@1.37@00003-0830-50@CAPSULE@US$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16387806@Onco@@@@@300f1010ntsdm@@@@@@@@L02BG03@L02B@@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@16387806@Treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy.@@NO@@@NO REVIEW@@@@100%@@SECOND-LINE@@375@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@EMA, 3 March 2000@3/3/2000@@@@@@@No@@@@@@APPROVED@@@NHS@@@@@@MONO@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@CONTROLLED@DOUBLE-BLIND@@@@1@1@374.61295@@@5.03@month@5.03 month@374.61@374.61@2.45@28@1.299@68.56@@@@@@@@@@@@2.45@1@@mg@1@1@@@@@@@@@@@7/28/2017@2.45@2.45@2.01E+15@FILM-COATED TABLET@GB£@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918263@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@LEICHINGEN, GERMANY@@@@@14918263@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@ALIUD PHARMA@@@@@ALIUD PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@1.78@13.23@2.53@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.04@0.04@3399830@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918261@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@GERMANY@@@@@14918261@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@ACIS@@@@@ACIS||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@3.46@15.36@4.27@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.03@0.03@108944@TABLET@EURO@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918722@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation. [clinicaltrials.gov]@@-@-@-@-@8/1/2009@@This is a first-in-class small molecule IDO inhibitor directed at disruption and elimination of tumour tolerance.@@14918722@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00739609@20@-@-@@@-@@8/1/2008@-@NLG2100@@-@>> A histological or cytological diagnosis of recurrent or refractory solid tumor malignancy. The patient's pathology must be reviewed and confirmed prior to enrollment (outside reviews acceptable). If no standard therapy exists for disease or subject refused standard therapy, subject would be considered eligible for enrollment.    >> Eastern Cooperative Oncology Group (ECOG) Performance Status = 2.@@@I@I@@-@-@Trial registered. [NewLink, 20.08.2008]@-@@@@-@-@@@@@-||||@NEWLINK GENETICS@@@@@NEWLINK GENETICS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@D-1MT@@@@@D-1MT||||@TK Inhibitor@@@@@TK Inhibitor||||@DOSE-LIMITING TOXICITY@@@@@SERUM KYNURENINE@BIOMARKER@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922750@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Campath with CHOP@@L01XC04@L01X@-@LEVERKUSEN, GERMANY@@@Alemtuzumab binds to CD52, an antigen present on the surface of B andT lymphocytes, a majority of monocytes, macrophages, NK cells, anda subpopulation of granulocytes. A proportion of bone marrow cells,including some CD34+ cells, express variable levels of CD52. The proposedmechanism of action is antibody-dependent cellular-mediatedlysis following cell surface binding of alemtuzumab to the leukemic cells.@@14922750@CHOP with Campth for T-Cell, null cell or natural killer (NK)-cell lymphoma@@-@-@@NO REVIEW@@@@-@ILEX Oncology (acquired by Genzyme) and LeukoSite (acquired by Millennium Pharma) entered into a distribution and development agreement with Schering AG (now Bayer Schering) in August 1999. The agreement grants Schering AG exclusive marketing and distribution rights to Campath in the United States, Europe and the rest of the world except Japan and East Asia, where LeukoSite and ILEX have retained these rights. Millenniusm sold Campath rights to ILEX in 2001 for US$140 million plus royalties. Initial rights licensed by LeukoSite from BTG.@-@NCT00161590@N/A@-@-@@@-@@7/1/2004@-@0204-157@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@ALEMTUZUMAB@@@@@ALEMTUZUMAB||||@BAYER HEALTHCARE@GENZYME@@@@BAYER HEALTHCARE|GENZYME|||@@@@@@|||||||||@Haematological Malignancy@T-Cell Lymphoma@@@@Haematological Malignancy|T-Cell Lymphoma||||||||@CAMPATH@MABCAMPATH@CHOP@@@CAMPATH|MABCAMPATH|CHOP||@mAb@Humanised@CD52@@@mAb|Humanised|CD52||@TOXICITY@@@@@OVERALL SURVIVAL@DISEASE-FREE SURVIVAL@CYTOMEGALOVIRUS REACTIVATION@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@15659.64@15659.64@42.9@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15338352@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01XX02@L01X@YES@@@@@@15338352@Indicated in the therapy of patients with acute lymphocytic leukemia. This agent is useful primarily in combination with other chemotherapeutic agents in the induction of remissions of the disease in pediatric patients. It should not be used as the sole induction agent unless combination therapy is deemed inappropriate. It is not recommended for maintenance therapy.@@NO@@@NO REVIEW@@@@100%@@@@@Regimen I: Prednisone 40 mg/square meter of body surface area per day orally in three divided doses for 15 days, followed by tapering of the dosage as follows: 20 mg/square meter for 2 days, 10 mg/square meter for 2 days, 5 mg/square meter for 2 days, 2.5 mg/square meter for 2 days and then discontinue. Vincristine sulfate 2 mg/square meter of body surface area intravenously once weekly on Days 1, 8, and 15 of the treatment period. The maximum single dose should not exceed 2.0 mg. Asparaginase 1,000 I.U./kg/day intravenously for ten successive days beginning on Day 22 of the treatment period. Regimen II: Prednisone 40 mg/square meter of body surface area per day orally in three divided doses for 28 days (the total daily dose should be to the nearest 2.5 mg), following which the dosage of prednisone should be discontinued gradually over a 14 day period. Vincristine sulfate 1.5 mg/square meter of body surface area intravenously weekly for four doses, on Days 1, 8, 15, and 22 of the treatment period. The maximum single dose should not exceed 2.0 mg. Asparaginase 6,000 I.U./square meter of body surface area intramuscularly on Days 4, 7, 10, 13, 16, 19, 22, 25, and 28 of the treatment period. When a remission is obtained with either of the above regimens, appropriate maintenance therapy must be instituted. Elspar should not be used as part of a maintenance regimen. The above regimens do not preclude a need for special therapy directed toward the prevention of central nervous system leukemia.@EMA, February 1994@@@@@@It is recommended that asparaginase be administered to patients only in a hospital setting under the supervision of a physician who is qualified by training and experience to administer cancer chemotherapeutic agents, because of the possibility of severe reactions, including anaphylaxis and sudden death. The physician must be prepared to treat anaphylaxis at each administration of the drug. In the treatment of each patient the physician must weigh carefully the possibility of achieving therapeutic benefit versus the risk of toxicity.@NO LABELLED TRIAL@No@@@PAEDIATRIC@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@ASPARAGINASE@@@@@ASPARAGINASE||||@EUSA PHARMA@@@@@EUSA PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ERWINASE@@@@@ERWINASE||||@Enzyme@@@@@Enzyme||||@@@@@@@@@@@@@@@@@@@@@1.75@m²@5792.85@@@3@week@3 week@5792.85@5792.85@275.85@5@1.299@3065@@@@@@@@@@@@@7@@IU/m²@6000@3@@@@@@@@@@@7/28/2017@613@613@1.02E+16@POWDER FOR SOLUTION FOR INJECTION@GB£@@@@@@@@10000@IU@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916247@Onco@@@@@300f1010ntsdm@@@@@@Stable doses of either long-acting oral opioid or transdermal fentanyl with Actiq (200, 400, 600, 800, 1200 and 1600mcg)@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916247@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@257@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@257 OPIOID-TOLERANT ADULT CANCER PATIENTS@@@III; TWO DOSE TITRATION STUDIES@APPROVED@@NO NICE REVIEW@NHS@95 of 127 patients (75%) titrated to a successful dose of Actiq (could be used consistently for at least 2 days without unacceptable side-effects). 11% and 14% withdrew due to adverse events or other reasons respectively.@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOSE-RANGING@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.2961@210.41@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.01@7.01@2.69E+15@LOZENGE@GB£@@@@@@@@1200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923873@Onco@@@@@300f1018ntsdm@@@@@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923873@Nolvadex is indicated for: 1. The treatment of breast cancer. 2. The treatment of anovulatory infertility.@@NO@@@NO REVIEW@@@@100%@@@@@Adults: The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some patients with advanced disease.@@@@@@@Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer. An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogenlike effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.@@No@@@@@@APPROVED@@Restricted benefit: Treatment of hormone-dependent breast cancer. This drug is not PBS-subsidised for primary prevention of breast cancer.@PBS@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@NOVOPHARM@@@@@NOVOPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TERRY WHITE CHEMISTS TAMOXIFEN@@@@@TERRY WHITE CHEMISTS TAMOXIFEN||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@A$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14919820@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@M05BA03@M05B@NO@MUMBAI, INDIA@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14919820@Treatment of conditions associated with increased osteoclast activity - Tumour-induced hypercalcaemia - Osteolytic lesions in patients with bone metastases associated with breast cancer - Multiple myeloma stage III@@NO@@@NO REVIEW@@@@100%@@@@@Tumour-induced hypercalcaemia; please see label for dosing ranges; the total dose of pamidronate disodium may be administered either in a single infusion or in multiple infusions over 2-4 consecutive days. The maximum dose per treatment course is 90 mg for both initial and repeat courses.@EMA, April 2004@@@@@@Pamidronate should never be given as a bolus injection since severe local reactions and thrombophlebitis may occur. It should always be diluted and then given as a slow intravenous infusion. It should not be co-administered with other bisphosphonates. If other calcium lowering agents are used in conjunction with pamidronate, significant hypocalcaemia may result. Convulsions have been precipitated in some patients with tumour-induced hypercalcaemia due to the electrolyte changes associated with this condition and its effective treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@WOCKHARDT@@@@@WOCKHARDT||||@@@@@@|||||||||@Hypercalcaemia of Malignancy@@@@@Hypercalcaemia of Malignancy|||||||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@4@1.299@104.41@@119.32@@@@@@@@@@1.74@@@@@@@@@@@@@@@@7/28/2017@26.1@26.1@9.47E+15@SOLUTION FOR INFUSION, AMPOULE - 1 ML@GB£@@@@@@@@15@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917071@Onco@@@@@300f1020ntsdm@@@@@@Patients received IFNy 0.2MG s.c for two days prior to ILP.@@L03AA@L03A@NO@INGELHEIM, GERMANY@@@Tasonermin affects the morphology and reduces proliferation of endothelial cells and modifies expression of specific cell surface and secretory proteins (including adhesion molecules and proteins modulating coagulation, interleukins and haematopoietic growth factors). These changes in turn lead to a procoagulant state resulting in microvascular thrombosis. Further, adherence and extravasation of leukocytes is increased, leading to infiltration of the tumour by lymphocytes, monocytes, and granulocytes. The reason for the differential sensitivity of the tumour vasculature (high) versus normal vasculature (low) are currently unknown.@@14917071@As an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated limb perfusion.@@YES@-@@NO REVIEW@@@@@-@-@-@39@Upper limb: 3MG dose by isolated limb perfusion; lower limb: 4MG total dose by isolate limb perfusion@EMA, 24 April 2002@4/24/2002@@-@@@-@152.53@No@-@Patients with STS and malignant melnaoma@@@-@APPROVED@@@@20 patients completed a 1-year follow-up after ILP. 13 patients had recurrence or progression of the disease; 2 were excluded due to protocol violation; 2 received other chemotherapy or radiotherapy; one died and one was lost to follow-up. The median follow-up from ILP was 846 days. Violations primarily concerned deviations in the dose of melphalan; median dose here was 95mg (33-150mg). 10 patients underwent amputation giving a limb salvage rate of 29/39 (74%) during the follow-up. Complete response was seen in 28% of patients.@Systemic toxicity consisted of fever (100%), chills (51%), cardiac rhythm disturbances (62%), nausea and vomiting (31%) and fatigue (26%). Serious adverse events consisted of liver toxicity (18%), ARDS (13%), thrombocytopaenia (10%).@@@@ADJUVANT@TASONERMIN@@@@@TASONERMIN||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@BEROMUN@@@@@BEROMUN||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@LIMB SALVAGE@@@@@@@@@-@@@@@OPEN-LABEL@NON-RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@N/A@@@@4@1.1807@7715.85@12734.24@8063.15@@@@@@@@@@1928.96@@@@@@@@@@@@@@@@8/31/2017@1928.96@1928.96@34483014@POWDER AND SOLVENT FOR SOLUTION FOR INFUSION - 5 ML@EURO@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16401514@Onco@@@@@@@@@@@"GD2 CAR-T cells, Experimental, The CAR-GD2-modified T cells can recognize and kill neuroblastoma through the recognition of GD2. This study will evaluate the efficacy and safety of CAR-GD2 T cells in treating refractory and/or recurrent neuroblastoma
"@@@@@CHINA@9/1/2020@@The CAR-GD2-modified T cells can recognize and kill neuroblastoma through the recognition of GD2.@@16401514@Single Arm and Multicenter Clinical Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) in Treatment of Relapsed or Refractory Neuroblastoma in Children@Both@@@@@GD2-specific Chimeric Antigen Receptor-modified T Cells@@@@@FIRST-LINE@NCT02919046@22@@@@@@@9/1/2016@@WM-CART-07@@@-Up to diagnostic criteria for relapsed or refractory neuroblastoma or high-risk patients，including:  -  Relapsed neuroblastoma : Children diagnosed with neuroblastoma who after standard treatment and remission, present lesions again and cannot reach comp@@CHILD@Phase 1/Phase 2@I/II@@@@@@@@@MONO@GD2 CAR-T CELLS@@@@@GD2 CAR-T CELLS||||@SINOBIOWAY CELL THERAPY@@@@@SINOBIOWAY CELL THERAPY||||@China@@@@@China|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@-@@@@@-||||@Other@@@@@Other||||@The overall efficiency of patients with neuroblastoma after autologous CAR-T cell therapy@The overall efficiency of patients with neuroblastoma after autologous CAR-T cell therapy@The overall efficiency of patients with neuroblastoma after autologous CAR-T cell therapy@@@Progression free survival@Overall survival@@@@REFRACTORY@RELAPSED@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15399116@Onco@@@@@300f1015ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@15399116@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX.@@YES@@@@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@254@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 13 January 2012@1/13/2012@1/1/2008@No@@@@EMR 62 202-013@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@7/29/2011@@HAUTE AUTORITÉ DE SANTÉ@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@31936.036@@@7.9@month@7.9 month@31936.04@31936.04@132.91@1@1.1511@209@@@@@@@@@@@@2.09@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/2/2017@209@209@9260599T@SOLUTION FOR PERFUSION  50 ML@EURO@@@@@@@@100@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
16159499@Onco@@@@@@@@@@@BGB-3111 and BGB-A317, Experimental, In the dose -escalation part, the dose levels and regimens will be evaluated.@@-@-@@@6/1/2018@@@@16159499@A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies@Both@@@@@@@@@@@NCT02795182@25@@@@@@@2/1/2016@@BGB-3111_BGB-A317_Study_001@@@-  Aged ≥ 18 years, able and willing to provide written informed consent and to comply with the study protocol.  -  Laboratory parameters as specified below:  -  Hematologic: platelet count > 50 x 10e9/L; absolute neutrophil count > 1.0 x109 cells/L;  -  @COMBO@Adult@Phase 1@I@@@@@@@@@-@-@-@@@@-|-|||@BEIGENE@@@@@BEIGENE||||@Australia@@@@@Australia|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@BGB-3111@BGB-A317@@@@BGB-3111|BGB-A317|||@Other@@@@@Other||||@Number of Participants With Adverse Events@@@@@PK@Area under the plasma concentration-time curve from time 0 to infinity time (AUC0-infinity)@@@@-@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16066130@Onco@@@@@300f1012ntsdm@@@@@@@@L01XX32@L01X@@BEERSE, BELGIUM@@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@16066130@Extension of the indication to allow patients who have received at least one prior therapy (instead of at least two) to be treated. Treatment of patients with multiple myeloma who have received at least one prior therapies and have demonstrated disease progression on the last therapy.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones for extra-U.S. marketing rights since the US$15 mil deal (plus US$125 mil following European approval) between Ortho and Millennium in June 2003. Ortho also reimbursed around@SECOND-LINE@@@The recommended starting dose of bortezomib is 1.3 mg/m2 body surface area twice weekly for two weeks (days 1, 4, 8, and 11) followed by a 10-day rest period (days 12-21). This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses. It is recommended that patients with a confirmed complete response receive 2 additional cycles beyond a confirmation. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles.@EMA, 20 April 2005@4/20/2005@@Yes@@@@@No@@@ADULT@@@APPROVED@@NO REVIEW@GKV@@@@@@MONO@BORTEZOMIB@@@@@BORTEZOMIB||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@VELCADE@@@@@VELCADE||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@26913.12@@@168@day@168 day@26913.12@26913.12@160.2@1@1.1511@1293.9@1643.25@1332.4@@@@@@@@@@369.69@21@@mg/m²@1.3@4@@@@@@@@@@@8/1/2017@1293.9@1293.9@822831@POWDER FOR INJECTABLE SUSPENSION@EURO@@@@@@@@3.5@MG@3.5 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921524@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921524@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@YES@5-May@@NO REVIEW@@@@@@@@@In combination chemotherapy the usual dose (25-30 mg/m²) is usually maintained, while the frequency of administration is reduced e.g. day 1 and 5 every 3 weeks or day 1 and 8 every 3 weeks according to treatment protocol.@Apr-89@@@No@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@EXPIRED@@@@@APPROVED@@1@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@COMBO@VINORELBINE TARTRATE@CISPLATIN@@@@VINORELBINE TARTRATE|CISPLATIN|||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@ADVANCED@REFRACTORY@@@@@@@@@@@Invalid Factory Price@@@1@year@1 year@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9137189T@INJECTABLE SOLUTION, 5 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918240@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@GERMANY@@@@@14918240@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Dosage in Adults: should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@1.18@12.48@1.92@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@@@3683092@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920821@Onco@@@@@300f1037ntsdm@@@@@@Kytril Injection at a dose of 40 mcg/kg was administered for 2, 4 or at least 6 cycles of chemotherapy@@A04AA02@A04A@NO@BASEL, SWITZERLAND@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14920821@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@YES@@@NO REVIEW@@@@0%@@@@512@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@EMA, 3 December 2001@12/3/2001@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@512 CANCER PATIENTS RECEIVED KYTRIL INJECTION, PROPHYLACTICALLY, FOR TWO CYCLES OF CHEMOTHERAPY, 224 PATIENTS RECEIVED IT FOR AT LEAST FOUR CYCLES, AND 108 PATIENTS RECEIVED IT FOR AT LEAST SIX CYCLES.@@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / REPEAT-CYCLE CHEMOTHERAPY@APPROVED@@NO REVIEW@@Kytril Injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no vomiting and no moderate or severe nausea in 24 hours) of 60% to 69%.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@KYTRIL@@@@@KYTRIL||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@UNCONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@39.03@60.93@42.25@@@@@@@@@@7.81@@@@@@@@@@@@@@@@8/4/2017@7.81@7.81@712224@INTRAVENOUS INJECTION AMPOULE, 1 ML@EURO@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15361168@Onco@@@@@300f1020ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361168@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.@Both@YES@@@@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dose for chronic phase CML is 100 mg dasatinib once daily, administered orally.@>> EMA, 6 December 2010@12/6/2010@@YES@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@DISCONTINUED@@@@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@Invalid Factory Price@@@14@month@14 month@71242.84@71242.84@167.31@60@1.0543@@@@@@@@@@@@@@1@@mg@100@1@@@@@@@@@@@3/31/2016@@@37400076@FILM-COATED TABLET (BLISTER ALUMINIUM/ALUMINIUM)@EURO@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919282@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-510 given to subjects with locally advanced/metastatic soft tissue sarcoma@@-@-@-@UNITED STATES@@@A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). @@14919282@ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00061659@88@-@-@@@-@@5/1/2003@-@M02-534@@-@-@@@II@II@@-@-@>> ABT-510 had a favourable safety profile, and the rate of disease control and OS times were encouraging. However, with low ORR and lack of dose response, the study failed to yield compelling evidence of strong single-agent activity in STS [JCO, Vol. 26, No.34, 1 December 2008].         >> Trial registered [Abbott, 2.06.2003]@-@@@@MONO@THROMBOSPONDIN@@@@@THROMBOSPONDIN||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@ABT-510@@@@@ABT-510||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916039@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Arm I: HLA-A2-positive patients receive GP2 peptide/GM-CSF vaccine intradermally (ID) every 3-4 weeks for a total of up to 6 inoculations. HLA-A2-negative patients receive AE37 peptide/GM-CSF vaccine ID every 3-4 weeks for a total of up to 6 inoculations. Arm II : Patients receive GM-CSF ID every 3-4 weeks for a total of up to 6 inoculations. SOURCE: clinicaltrials.gov@@-@-@-@TORONTO, CANADA@@@AE37 is designed to stimulate an immune response against the tumor-causing gene HER-2/neu, which occurs in a significant percentage of patients with breast cancer as well as other cancers. A robust immune response against HER-2/neu has the potential to destroy tumor cells even at sites in the body distant from the primary tumor.@@14916039@Peptide immunotherapeutic for patients with HER-2/neu positive breast cancer@@-@-@@NO REVIEW@@@@-@Antigen Express is a subsidiary of Generex.@-@NCT00524277@600@-@-@@@-@@1/1/2007@-@WRAMC-07-20029, @@-@-@@@WRAMC-9625-1186753655.52; @II@@-@-@First-patient in (FPI) in May 2007. SOURCE: Generex, 2 May 2007@-@@@@COMBO@-@@@@@-||||@GENEREX@ANTIGEN EXPRESS@@@@GENEREX|ANTIGEN EXPRESS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AE-37@@@@@AE-37||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RATE OF RELAPSE@@@@@@@@@@-@@@@@RANDOMISED@SINGLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924868@Onco@@@@@@@@@@@Patients receve supportive care plus talactoferrin or placebo@@-@-@-@HOUSTON, TEXAS@@@Talactoferrin, a novel dendritic cell activator (DCA), is a unique recombinant form of human lactoferrin, an important immunomodulatory protein. Lactoferrin, found in the highest concentration in milk, is expressed throughout the body in immune cells and on all body surfaces exposed to the external environment. Lactoferrin plays an important role in helping to establish the immune system, including the Gut Associated Lymphoid Tissue (GALT), in infants. Talactoferrin is produced in Aspergillus niger, a filamentous fungus, and is structurally identical to native human lactoferrin in all material respects, differing only in its glycosylation.@@14924868@Refractory Stage IIIB or IV NSCLC@@-@-@@NO REVIEW@@@@-@-@MULTIPLE@-@720@-@FDA confirmed that the Phase II trial provided the basis for moving forward with a large, pivotal Phase III trial in NSCLC and that the Phase II trial could provide supporting data for a BLA. The FDA also provided Fast Track designation for the development of talactoferrin as a first-line treatment in NSCLC. The FDA agreed that (i) the trial can be global without a requirement for any minimum number of patients from the U.S., provided that the standard of care is uniform across countries and that patients are appropriately stratified by region; (ii) it is appropriate to use carboplatin + paclitaxel (the chemotherapy used in Phase II) as the comparator arm even with the approval of Avastin, since Avastin's approval only applies to about 50% of patients with locally advanced or metastatic NSCLC and is associated with significant toxicities; (iii) PFS can be the primary endpoint for accelerated approval with the trial also powered to eventually look at overall survival for full approval; and (iv) a single pivotal trial powered for a high degree of statistical significance (p=0.01) for the PFS primary endpoint is acceptable. SPA package has been submitted.@@@-@@@-@-@@-@-@@@III@III@@-@-@Study to start H1 08 and complete in 2010. SOURCE: Agennix, January 2008.@-@@@@COMBO@TALACTOFERRIN ALFA@@@@@TALACTOFERRIN ALFA||||@AGENNIX@@@@@AGENNIX||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Immunotherapy@@@@@Immunotherapy||||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@REFRACTORY@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917385@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AX04@L01A@YES@@@@Dacarbazine is a cytostatic agent. The antineoplastic effect is due to an inhibition of cell growth which is independent of the cell cycle and due to an inhibition of DNA synthesis. An alkylating effect has also been shown and other cytostatic mechanisms may also be influenced by dacarbazine. Dacarbazine is considered not to show an antineoplastic effect by itself. However by microsomal N-demethylation it is quickly converted to 5-amino-imidazole-4-carboxamide and a methyl cation, which is responsible for the alkylating effect of the drug.@@14917385@Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of combination chemotherapy are: • Hodgkin's disease • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Adult soft tissue sarcoma: For adult soft tissue sarcomas dacarbazine is given in daily doses of 250 mg/m2 body surface area i.v. (days 1-5) in combination with doxorubicin every 3 weeks (ADIC regimen). Restriction of food intake for 4-6 hours prior to treatment may reduce the severity of the nausea and vomiting which occurs in most patients particularly during the first two days of treatment. Because severe gastrointestinal and haematological disturbances can occur an extremely careful benefit-risk analysis has to be made before every course of therapy with dacarbazine.@@@@@@@It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS). Hepatic necrosis has been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@DACARBAZINE@@@@@DACARBAZINE||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@DETIMEDAC@@@@@DETIMEDAC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@METASTATIC@MALIGNANT@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1807@160@213.27@165.74@@@@@@@@@@0.16@@@@@@@@@@@@@@@@8/15/2017@16@16@4613610@VIAL@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15361172@Onco@@@@@300f1010ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361172@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.@Both@NO@@@@@@@100%@@FIRST-LINE@NCT00481247@519@The recommended starting dose for chronic phase CML is 100 mg dasatinib once daily, administered orally.@EMA, 6 December 2010@12/6/2010@@Yes@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@@NHS@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@35555.73595@@@14@month@14 month@35555.74@35555.74@83.5@30@1.299@2504.96@@@@@@@@@@@@0.83@1@@mg@100@1@@@@@@@@@@@7/28/2017@83.5@83.5@1.54E+16@FILM-COATED TABLET@GB£@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922550@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Photofrin 2MG/KG followed by 2 non-thermal applications of 630NM laser light.@@L01XD01@L01X@NO@QUEBEC, CANADA@@@@@14922550@Photodynamic therapy with Photofrin is indicated for: - Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy. - Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). - Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy are not indicated. - Ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy.@@NO@@@NO REVIEW@@@@@Licensed from QLT@@@17@Photodynamic therapy with Photofrin is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection at 2 mg/kg. Illumination with laser light 40–50 hours following injection constitutes the second stage of therapy. A second laser light application may be given 96-120 hours after injection, preceded by gentle debridement of residual tumor@@@@@@@Oesophageal Cancer: If the esophageal tumor is eroding into the trachea or bronchial tree, the likelihood of tracheoesophageal or bronchoesophageal fistula resulting from treatment is sufficiently high that PDT is not recommended.@LABEL@No@N/A@@@@N/A@APPROVED@@@MEDICARE@Objective tumour response: 82% at week 1, 35% month 1, 94% any assessment. Improvement in dysphagia: 71% week1, 47% month 1, 76% any assessment.@@@@@MONO@PORFIRMER SODIUM@@@@@PORFIRMER SODIUM||||@PINNACLE BIOLOGICS@@@@@PINNACLE BIOLOGICS||||@@@@@@|||||||||@NSCLC@Oesophageal Cancer@@@@NSCLC|Oesophageal Cancer||||||||@PHOTOFRIN@@@@@PHOTOFRIN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@@@@@@SINGLE-ARM@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@20427@@@@@@@@@@@@272.36@@@@@@@@@@@@@@@@8/2/2017@20427@20427@76128-0155-75@POWDER FOR SOLUTION FOR INJECTION (VIAL)@US$@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916544@Onco@@@@@300f1015ntsdm@@@@@@225 received orchiectomy/nilandron; 232 with orchiectomy/placebo.@@L02BB02@L02B@YES@PARIS, FRANCE@@@Nilutamide is an antiandrogen medication used in the treatment of advanced stage prostate cancer. This medication blocks the androgen receptor, preventing its interaction with testosterone. This leads to a decrease in dihydrotestosterone (DHT) production. Because most prostate cancer cells rely on DHT for growth and spread, nilutamide can prolong life in men with prostate cancer.@@14916544@Indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2). For maximum benefit, treatment must begin on the same day as or on the day after surgical castration.@@NO@@@NO REVIEW@@@@100%@@@@457@The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day.@@@11/19/1987@@@@Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials in patients exposed to nilutamide. A small study in Japanese subjects showed that 8 of 47 patients (17%) developed interstitial pneumonitis. Reports of interstitial changes including pulmonary fibrosis that led to hospitalisation and death have been reported rarely post-marketing.@LABEL@No@@@@@III@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@Nilandron and placebo: OS 27.3 and 23.6 months; PFS 21.1 and 14.9 months; CR or PR 41% and 24% respectively.@@@@@COMBO@NILUTAMIDE@@@@@NILUTAMIDE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ANANDRON@@@@@ANANDRON||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@DOUBLE-BLIND@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@90@1.1807@111.66@135.07@119.12@@@@@@@@@@0.02@@@@@@@@@@@@@@@@9/1/2017@1.24@1.24@3.40E+12@TABLET@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922984@Onco@@@@@@@@@@@Intravenous CP-4126 was given at doses from 30 to 1600 mg/m2/day to 32 patients with different solid tumour indications. The maximum tolerated dose was determined at 1600 mg/m2/day, when administered as a 30 minutes infusion on days 1, 8 and 15 in a 4 week schedule. @@-@-@-@OSLO, NORWAY@@@CP-4126 is the elaidic acid ester of gemcitabine (Gemzar). Clavis Pharma aims to develop CP-4126 with substantial benefits over gemcitabine, including opportunities for oral administration. Despite the fact that gemcitabine has shown excellent anti-cancer activity in animal tumour models, the treatment response in man, is still modest (in pancreatic cancer patients treated with gemcitabine, life-expectancies is increased with 2.5 months). Clavis Pharma has shown in vitro and in vivo that CP-4126 has the potential to expand the therapeutic window compared to gemcitabine and give sustained effect at lower doses. A different tissue distribution may also offer opportunities for use in new indications. Excellent anti-tumour activity has been obtained after oral administration, with activity seen almost independent of the schedule of administration.@@14922984@-@@-@-@@NO REVIEW@@@-@-@-@-@-@-@-@-@@@EC orphan drug designation for pancreatic cancer in October 2009; FDA drug designation for pancreatic cancer January 2010. [7 January 2010 Clavis http://www.clavispharma.com/News+%26+Events/2010+Press+releases/573.cms ]@@@-@-@@-@-@@@I@I@@-@-@>> Intravenous CP-4126 provides prolonged presence of the therapeutically active agents in the blood plasma. CP-4126 itself was detected for 24 hours at concentrations known to stop cancer cell growth. The primary metabolite of CP-4126 - gemcitabine - was detected in plasma at similar or higher levels and for a longer duration than reported after injection of therapeutic doses of gemcitabine itself. [Clavis/ESMO 2008, 16.09.2008]@The most frequent toxicities observed were as expected for this type of cancer therapeutics@@@@MONO@GEMCITABINE, LVT ANALOGUE@@@@@GEMCITABINE, LVT ANALOGUE||||@CLAVIS PHARMA@@@@@CLAVIS PHARMA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CP-4126@@@@@CP-4126||||@Other@@@@@Other||||@PHARMACOKINETICS@SAFETY@@@@RESPONSE RATE@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923231@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L02AE01@L02A@NO@PARIS, FRANCE@@@@@14923231@For the treatment of advanced prostatic carcinoma (stage C or stage D) in which suppression of testosterone is indicated. Buserelin acts by blockade and subsequent down-regulation of pituitary LHRH receptor synthesis. Gonadotrophin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise.@@NO@Jan-91@@NO REVIEW@@@@@Licensed from SRI International@@@@Initiation of therapy: is most conveniently carried out in hospital; 0.5ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. Maintenance therapy: on the 8th day of treatment the patient is changed to intranasal administration of Suprefact.@1-Mar-86@3/1/1986@10/19/1986@@@@Patients known to suffer from depression should be carefully monitored during treatment with Suprefact. Prostatic carcinoma: Monitoring of the effect of clinical effect of Suprefact is carried out by methods generally used in prostatic carcinoma. Initially serum testosterone levels rise and a clinical effect will not be seen until levels start to fall into therapeutic (castration) range. Disease flare (temporary deterioration of the patient's condition) has been reported at the beginning of the treatment. The incidence is variable, but of the order of the 10%. Symptoms are usually confined to transient increase in pain, but the exact nature depends on the site of the lesions. Neurological sequelae have been reported where secondary deposits impinge upon the spinal cord or CNS. Disease flare is prevented by the prophylactic use of an anti-androgen, e.g. cyproterone acetate, 300 mg daily. It is recommended that the treatment should be started at least 3 days before the first dose of Suprefact and continued for at least 3 weeks after commencement of the Suprefact therapy.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@BUSERELIN ACETATE@@@@@BUSERELIN ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SUPREFACT@@@@@SUPREFACT||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@2@1.1511@23.03@30.56@24.57@@@@@@@@@@1.92@@@@@@@@@@@@@@@@8/1/2017@11.52@11.52@3.40E+12@SOLUTION FOR SC INJECTION, 6 ML@EURO@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916404@Onco@@@@@300f1018ntsdm@@@@@@107 patients received oral melphalan (0.15MG/KG/day x 7 followed by 0.05MG/KG/day) with prednisone; 203 received IV melphalan (16MG/M2 q 2 weeks x 4 over 6 weeks followed by 4 weeks) with prednisone.@@L01AA03@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.@@14916404@Alkeran Injection, at conventional intravenous dosage, is indicated in the treatment of multiple myeloma and ovarian cancer. Alkeran Injection, at high intravenous dosage, is indicated, with or without haematopoietic stem cell transplantation, for the treatment of multiple myeloma and childhood neuroblastoma. Alkeran Injection, administered by regional arterial perfusion, is indicated in the treatment of localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities.@@NO@5-May@@NO REVIEW@@@@100%@@@@310@Ovarian adenocarcinoma: When used intravenously as a single agent, a dose of 1 mg/kg body weight (approximately 40 mg/m2 body surface area) given at intervals of 4 weeks has often been used. When combined with other cytotoxic drugs, intravenous doses of between 0.3 and 0.4 mg/kg body weight (12 to 16 mg/m2 body surface area) have been used at intervals of 4 to 6 weeks.@TGA, 1 February 1996@2/1/1996@@@@@Melphalan should be administered under the supervision of a qualified physician experienced in the use of chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing IV to oral melphalan have shown more myelosuppression with the IV formulation.@LABEL@No@@@@@III@APPROVED@@Unrestricted reimbursement.@PBS@44% and 7% responded in the oral and IV groups respectively. Severe myelotoxicity and/or platelets occurred 28% and 11% respectively.@@@@@COMBO@MELPHALAN HYDROCHLORIDE@PREDNISONE@@@@MELPHALAN HYDROCHLORIDE|PREDNISONE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ALKERAN@@@@@ALKERAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@0.7915@56.51@71.18@60.76@@@@@@@@@@1.13@@@@@@@@@@@@@@@@9/1/2017@2.26@2.26@0115-1532-GE-AS@TABLET@A$@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14921798@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@>> ARM1: AMG 706 placebo 125mg QD until disease progression, consent withdrawal or unacceptable toxicity     >> ARM2: AMG 706 125mg PO QD until disease progression, consent withdrawal or unacceptable toxicity      >> ARM3: Bevacizumab 10 mg/kg IV every 14 days until disease progression, consent withdrawal or unacceptable toxicity@@-@-@-@THOUSAND OAKS, CALIFORNIA@12/1/2013@@Motesanib diphosphate is a highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis and lymphangiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (“VEGFR1-3”). It is also under investigation for its potential direct anti-tumor activity by targeting platelet-derived growth factor receptor (“PDGFR”) and stem cell factor receptor (“c-kit”) signaling, which may also confer direct anti-tumor activity. In February 2008, Amgen announced that Takeda will become the worldwide partner for motesanib diphosphate in addition to an exclusive collaboration on up to 13 other programs in the Japanese market. @@14921798@Combo with paclitaxel versus Avastin in subjects with HER-2 negative locally recurrent or metastatic breast cancer@@-@-@@NO REVIEW@@@@-@Motesanib was the unofficial key to the wide-ranging, two-part R&D deal with Amgen signed in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-@FIRST-LINE@NCT00356681@273@-@-@@@-@@12/1/2006@-@CIRGTORI 010@@-@>> Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease.     >> Measurable disease by RECIST guidelines.     >> Tumor (primary or metastatic) must be HER2 negative.@@@II@II@@-@-@Trial registered [Amgen, 24.07.2006]@-@@@@COMBO@MOTESANIB DIPHOSPHATE@PACLITAXEL@@@@MOTESANIB DIPHOSPHATE|PACLITAXEL|||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AMG-706@@@@@AMG-706||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@RESPONSE RATE@@@@@PROGRESSION-FREE SURVIVAL@@@@@METASTATIC@RELAPSED@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917458@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CA01@L01C@YES@@@@Although the mechanism of action has not been definitely established, vinblastine appears to bind to or crystallise critical microtubular proteins of the mitotic spindle, thus preventing their proper polymerisation and causing metaphase arrest. In high concentrations, vinblastine also exerts complex effects on nucleic acid and protein synthesis. Vinblastine reportedly also interferes with amino acid metabolism by blocking cellular utilisation of glutamic acid and thus inhibits purine synthesis, the citric acid cycle, and the formation of urea. Vinblastine exerts some immunosuppressive activity.@@14917458@Vinblastine sulphate is effective as a single agent, but its therapeutic effect is enhanced when used in combination with other antineoplastic drugs. Vinblastine sulphate has been used in the treatment of Hodgkin's disease (Stages III and IV); lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated); histiocytic lymphoma; advanced stages of mycosis fungoides; advanced carcinoma of the testis; Kaposi's sarcoma and Letterer-Siwe disease (histocytosis X). Vinblastine sulphate may be used in the treatment of choriocarcinoma resistant to other chemotherapeutic agents; carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.@@YES@5-May@@NO REVIEW@@@@100%@@@@@Vinblastine sulphate is given intravenously at weekly intervals according to the needs of the patient. Therapy is initiated by a single intravenous dose of 3.7MG/M2 bsa followed by doses of 5.5, 7.4, 9.25 and 11.1MG/M2 bsa. For most adult patients this dosage will be 5.5 mg/m2 - 7.4 mg/m2, however, leucopenia can be produced at 3.7 mg/m2, other patients may require 11.1 mg/m2 and, very rarely, 18.5 mg/m2.@1-Mar-82@3/1/1982@@@@@Fatal if given intrathecally; for intravenous use only, and should be administered by experienced physicians.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@VINBLASTINE SULPHATE@@@@@VINBLASTINE SULPHATE||||@EUROGENERICS@@@@@EUROGENERICS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@Testicular Cancer@Choriocarcinoma@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Testicular Cancer|Choriocarcinoma|||||@ELDISINE@@@@@ELDISINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@86.35@@@@@@@@@@@@21.59@@@@@@@@@@@@@@@@8/18/2017@86.35@86.35@9120668R@POWDER FOR INJECTABLE SOLUTION@EURO@@@@@@@@4@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916518@Onco@@@@@300f1037ntsdm@@@@@@Palonosetron 250 micrograms and 750 micrograms were compared with ondansetron 32 mg (half-life 4 hours) or dolasetron 100 mg (half-life 7.3 hours) administered intravenously on Day 1, without dexamethasone.@@A04AA05@A04A@NO@MILAN, ITALY@@@Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex.@@14916518@Aloxi is indicated for: the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.@@YES@@@NO REVIEW@@@@@@FIRST-LINE@@1132@250 micrograms palonosetron administered as a single intravenous bolus approximately 30 minutes before the start of chemotherapy. Aloxi should be injected over 30 seconds.@EMA, 11 October 2005@10/11/2005@@@@@As palonosetron may increase large bowel transit time, patients with a history of constipation or signs of subacute intestinal obstruction should be monitored following administration. Two cases of constipation with faecal impaction requiring hospitalisation have been reported in association with palonosetron 750 micrograms. At all dose levels tested, palonosetron did not induce clinically relevant prolongation of the QT interval. However, as for other 5-HT3 antagonists, caution should be exercised in the concomitant use of palonosetron with medicinal products that increase the QT interval or in patients who have or are likely to develop prolongation of the QT interval.@LABEL@No@@1132 [MODERATELY EMETOGENIC CHEMOTHERAPY]@@@III@APPROVED@@NO REVIEW@SNS@Complete response at 0-120 hours was 69.3% and 50.3% for Aloxi and ondansetron respectively.@@@@@MONO@PALONOSETRON HYDROCHLORIDE@@@@@PALONOSETRON HYDROCHLORIDE||||@ITALFARMACO@HELSINN HEALTHCARE@@@@ITALFARMACO|HELSINN HEALTHCARE|||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@ALOXI@@@@@ALOXI||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@EMETOGENIC RESPONSE@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@67@104.59@72.49@@@@@@@@@@@@@@@@@@@@@@@@@@8/23/2017@67@67@651499@INTRAVENOUS  INJECTION VIAL, 5 ML@EURO@@@@@@@@250@MCG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14916479@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Small groups of 3-6 patients will be treated with pre-specified doses of lenalidomide and SGN-33 and may receive up to eight 3-week Cycles of a combination of the two drugs. Patients will receive lenalidomide orally on a daily basis on Days 1-14 of each Cycle, followed by 1 week of rest. SGN-33 will be given intravenously on a weekly schedule; Days 1, 8, and 15 for Cycle 1 and Days 1 and 8 only for Cycles 2-8. Patients will be evaluated for toxicity, response and clinical benefit of treatment with the combination of the two drugs to determine if they are eligible for future Cycles of treatment. SOURCE: clinicaltrials.gov@@-@-@-@SEATTLE, WASHINGTON@5/1/2009@@@@14916479@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00502112@30@-@-@@@-@@7/1/2007@-@SG033-0002@@-@-@@@I@I@@-@-@Trial initiated. SOURCE: Seattle, 20 March 2008@-@@@@COMBO@LINTUZUMAB@LENALIDOMIDE@@@@LINTUZUMAB|LENALIDOMIDE|||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@SGN-33@REVLIMID@@@@SGN-33|REVLIMID|||@mAb@Humanised@CD33@@@mAb|Humanised|CD33||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16670300@Onco@@@@@300f1015ntsdm@@@@@@This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenancemonotherapy starting with lenalidomide 10 mg orally on days 1-21 of repeated 28-day cycles until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670300@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@25-Jan-17@1/25/2017@NO REVIEW@@@@0%@@FIRST-LINE@@459@The recommended starting dose is lenalidomide 10 mg/day orally on days 121 of repeated 28day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 14 of repeated 28 day cycles, prednisone2 mg/kg orally on days 14 of repeated 28day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide alone, 10 mg/dayorally on days 121 of repeated 28day cycles given until disease progression.@EMA, 11 February 2015@2/11/2015@9/1/2007@Yes@@@@@No@@@@ADULTS@@APPROVED@@25 January 2017: Insufficient SMR [http://www.has-sante.fr/portail/jcms/c_2746192/en/revlimid-myelome-multiple?xtmc=&xtcr=2]@Not reimbursed@@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@ALKERAN@GENERIC@@@REVLIMID|ALKERAN|GENERIC||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE BLIND@@@@1@1@45041.01653@@@27.4@month@27.4 month@45041.02@45041.02@54.05@1@1.1511@180.15@@@@@@@@@@@@7.21@28@@mg@10@21@@@@@@@@@@@8/2/2017@180.15@180.15@9298142R@CAPSULE@EURO@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918145@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CB01@L01C@YES@PETACH TIKVA, ISRAEL@@@Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly. Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2). It does not interfere with the synthesis of nucleinic acids.@@14918145@Used in combination therapy with other approved chemotherapeutics in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy; used in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.@@YES@@@NO REVIEW@@@@@@@@@The usual dose in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. In small cell lung cancer, the dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.@@@5/1/1999@@@@Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, haemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm3 or an absolute neutrophil count below 500/mm3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@ETOPOSIDE PHOSPHATE@@@@@ETOPOSIDE PHOSPHATE||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Testicular Cancer@SCLC@@@@Testicular Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@4@@@@@@@@@@@@0.04@@@@@@@@@@@@@@@@8/2/2017@4@4@9186437R@DILUTED SOLUTION FOR PERFUSION, 5 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14923958@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients given Trelstar or an approved GnRH agonist@@L02AE04@L02A@NO@CORONA, CALIFORNIA@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins.@@14923958@Indicated in the palliative treatment of advanced prostate cancer. It offers an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.@@@@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@@@227@The recommended dose is 11.25 mg incorporated in a long acting formulation administered every 84 days as a single intramuscular injection administered in either buttock.@FDA, 01 June 2000@6/1/2000@@@@@Initially, triptorelin, like other LHRH agonists, causes a transient increase in serum testosterone levels. As a result, isolated cases of worsening of signs and symptoms of prostate cancer during the first weeks of treatment have been reported with LHRH agonists. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, hematuria, or urethral or bladder outlet obstruction. Cases of spinal cord compression, which may contribute to paralysis with or without fatal complications, have been reported with LHRH agonists. If spinal cord compression or renal impairment develops, standard treatment of these complications should be instituted, and in extreme cases an immediate orchiectomy considered.@LABEL@No@@@@@III; ADVANCED PROSTATE CANCER@APPROVED@@@MEDICARE@Primary endpoints achieved: castration reached by Day 29 and maintenance of castration from Day 57 to Day 253@@@@@MONO@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@WATSON PHARMACEUTICALS@@@@@WATSON PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TRELSTAR LA@@@@@TRELSTAR LA||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@ACTIVE CONTROL@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@2439.72@@@@@@@@@@@@216.86@@@@@@@@@@@@@@@@8/2/2017@2439.72@2439.72@52544-0154-02@POWDER FOR SUSPENSION FOR INJECTION@US$@@@@@@@@11.25@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917585@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01AA01@L01A@NO@DEERFIELD, ILLINOIS@@@Cyclophosphamide is an antineoplastic agent which is converted in the body to an active alkylating metabolite. It also possesses marked immunosuppressant properties. The principal site of cyclophosphamide activation is the liver. The chemotherapeutic and immunosuppressant activity of cyclophosphamide is thought to be mediated by the cytotoxic intermediates produced by activation by mixed function oxidases in hepatic microsomes. Non-enzymatic cleavage, possibly taking place in the tumour cells, results in the formulation of highly cytotoxic forms of the drug.@@14917585@Cyclophosphamide has been used successfully to induce and maintain regressions in a wide range of neoplastic conditions, including leukaemias, lymphomas, soft tissue and osteogenic sarcomas, paediatric malignancies and adult solid tumours; in particular, breast and lung carcinomas. Cyclophosphamide is frequently used in combination chemotherapy regimens involving other cytotoxic drugs.@@YES@@@@@@@100%@@@@@The recommended dose for cyclophosphamide tablets is 50-250 mg/m2 daily (doses towards the upper end of this range should be used only for short courses). The dose may be amended at the discretion of the physician.@Apr-94@@11/1/2003@@@@Cyclophosphamide should be withheld in the presence of severe bone marrow depression and reduced doses should be used in the presence of lesser degrees of bone marrow depression. Regular blood counts should be performed in patients receiving cyclophosphamide. It should not normally be given to patients with severe infections and should be withdrawn if such infections become life threatening. Cyclophosphamide should be used with caution in debilitated patients and those with renal and/or hepatic failure. Cyclophosphamide is not recommended in patients with a plasma creatinine greater than 120 µmol/l (1.5 mg/100 ml) bilirubin greater than 17 µmol/l (1 mg/100 ml); or serum transaminases or alkaline phosphatase more than 2-3 times the upper limit of normal. In all such cases, dosage should be reduced.@NO LABELLED TRIAL@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@CYCLOPHOSPHAMIDE@@@@@CYCLOPHOSPHAMIDE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Breast Cancer@NSCLC@Sarcoma@Solid Tumours@Haematological Malignancy|Breast Cancer|NSCLC|Sarcoma|Solid Tumours|||||@ENDOXAN@@@@@ENDOXAN||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9167977R@POWDER FOR INJECTABLE SOLUTION IN VIAL@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16384273@Onco@@@@@300f1018ntsdm@@@@@@Eloxatin / 5-FU and leucovorin + / - Vectibix.@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@16384273@Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX.@@YES@@@NO REVIEW@@@@@@FIRST-LINE@NCT00364013@900@The recommended dose of Vectibix is 6 mg/kg of bodyweight given once every two weeks.@TGA, 14 May 2008@5/14/2008@@No@@7/1/2006@@PRIME@No@@@@@III@APPROVED@@@PBS@@@@@@COMBO@PANITUMUMAB@OXALIPLATIN@LEUCOVORIN@FLUOURACIL@@PANITUMUMAB|OXALIPLATIN|LEUCOVORIN|FLUOURACIL|@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@FOLFOX@@@@VECTIBIX|FOLFOX|||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@76.5@kg@74048.84698@@@10.2@month@10.2 month@74048.85@74048.85@238.68@1@0.779@2912@@@@@@@@@@@@7.28@14@@mg/kg@6@1@@@@@@@@@@@8/1/2017@2912@2912@3548-2612-IN-AN@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL) - 20 ML@A$@@@@@@@@400@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14918738@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@MUMBAI, INDIA@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14918738@Methotrexate is indicated in the treatment of neoplastic disease, such as trophoblastic neoplasms and leukaemia, and the symptomatic treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy.@@-@-@@NO REVIEW@@@@100%@-@-@-@-@Choriocarcinoma and Similar Trophoblastic Diseases: Methotrexate is administered intramuscularly in doses of 15-30mg daily for a five day course. Such courses may be repeated 3-5 times as required, with rest periods of one or more weeks interposed between courses until any manifesting toxic symptoms subside.@4-Apr@@@-@@@Methotrexate should be used with extreme caution in patients with haematological depression, renal impairment, diarrhoea, ulcerative disorders of the GI tract and psychiatric disorders. Hepatic toxicity has been observed, usually associated with chronic hepatic disease. Renal lesions may develop if the urinary flow is impeded and urinary pH is low, especially if large doses have been administered. The administration of low doses of methotrexate for prolonged periods may give rise, in particular, to hepatic toxicity. Particular care and possible cessation of treatment are indicated if stomatitis or GI toxicity occurs as haemorrhagic enteritis and intestinal perforation may result.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@-@NHS@NO LABELLED TRIAL@-@@@@-@METHOTREXATE@@@@@METHOTREXATE||||@WOCKHARDT@@@@@WOCKHARDT||||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@1@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@12/29/2014@@@9.56E+15@INJECTION VIAL 10 ML@GB£@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924792@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg by mouth (PO) twice daily (BID). These treaments will be administered in 6-week cycles for the duration of the study, up to 24 months. Subjects will be stratified by nephrectomy status, duration of response to sunitinib therapy, Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group, and RCC tumor histology.@@-@-@-@MADISON, NEW JERSEY@10/1/2010@@Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In invitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.@@14924792@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@SECOND-LINE@NCT00474786@440@-@-@@@-@@7/1/2007@-@-@@2012 (EXCLUSIVITY); APRIL 2014 (EXTENSION)@440 PATIENTS WHO HAVE FAILED PRIOR FIRST-LINE TREATMENT WITH SUNITINIB.@@@II/III@III@@-@-@RESULTS PENDING@-@@@@COMBO@TEMSIROLIMUS@@@@@TEMSIROLIMUS||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@TORISEL@@@@@TORISEL||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922594@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral clofarabine@@L01BB06@L01B@-@CAMBRIDGE, MASSACHUSSETTS@@@Clofarabine is a purine nucleoside anti-metabolite. Its antitumour activity is believed to be due to 3 mechanisms:   • DNA polymerase a inhibition resulting in termination of DNA chain elongation and/or DNA synthesis / repair.     • Ribonucleotide reductase inhibition with reduction of cellular deoxynucleotide triphosphate (dNTP) pools.     • Disruption of mitochondrial membrane integrity with the release of cytochrome C and other proapoptotic factors leading to programmed cell death even in non-dividing lymphocytes.@@14922594@Oral clofarabine@@-@-@@NO REVIEW@@@@-@In March 2001, Ilex licensed rights for the U.S. and Canada (and royalties elsewhere) from Bioenvision, which retained the lead role in developing and commercialising the drug elsewhere.Genzyme acquired rights in February 2004 from takeover of Ilex- befo@-@NCT00299156@30@-@-@@@-@@3/1/2006@-@2005-0536@@MAY 2009 (PATENT); DECEMBER 2011 (ORPHAN); JUNE 2012 (PAEDIATRIC)@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@CLOFARABINE@@@@@CLOFARABINE||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@CLOLAR@@@@@CLOLAR||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15412595@Onco@@@@@@@@@@@Enzalutamide plus androgen deprivation therapy (ADT), Experimental, Subjects will receive enzalutamide once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC) and provided by the site's pharmacy stock.Placebo plus androgen deprivation therapy (ADT), Placebo Comparator, Subjects will receive matching placebo once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC) and provided by the site's pharmacy stock.@@L02BB04@L02B@@TOKYO, JAPAN@4/1/2020@@@@15412595@A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)@Male@@@@@Experimental: Subjects will receive enzalutamide once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC) and provided by the site's pharmacy stock.Placebo Comparator: Placebo plus androgen deprivation therapy (ADT)@@@@@@NCT02677896@1100@@@@@@@2/1/2016@@9785-CL-0335@@@Subject is considered an adult according to local regulation at the time of signing informed consent.  Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.  Subject has metastatic prostate cancer documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan. Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.  Once randomized at day 1, subject must maintain ADT with an LHRH agonist or antagonist during study treatment or have a history of bilateral orchiectomy (i.e., medical or surgical castration).  Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.@Hormone Sensitive@ADULTS@Phase 3@III@@@@@@@@@@ENZALUTAMIDE@@@@@ENZALUTAMIDE||||@ASTELLAS PHARMA@@@@@ASTELLAS PHARMA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@XTANDI@@@@@XTANDI||||@Anti-androgen@@@@@Anti-androgen||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@TIME TO FIRST SYMPTOMATIC SKELETAL EVENT@@@@METASTATIC@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922819@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Quadramet or placebo@@V10BX02@V10B@NO@-@@@@@14922819@Indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.@@NO@-@@NO REVIEW@@@@-@EUSA to wholly acquire Cytogen. SOURCE: EUSA, 11 March 2008@-@-@270@The recommended dose is 1.0 mCi/kg, administered intravenously over a period of one minute through a secure in-dwelling catheter and followed with a saline flush. Dose adjustment in patients at the extremes of weight have not been studied. Caution should be exercised when determining the dose in very thin or very obese patients.@Mar-97@@@-@@@Causes bone marrow suppression. In clinical trials, white blood cell counts and platelet counts decreased to a nadir of approximately 40% to 50% of baseline in 123 (95%) of patients within 3 to 5 weeks after Quadramet, and tended to return to pretreatment levels by 8 weeks.@LABEL@@7-Feb@270 [MAINLY PROSTATE CANCER]@@@III STUDY A + B@DISCONTINUED@@-@MEDICARE@In study A, pain (the AUPC) decrease from baseline was significantly different in 1.0 mCi/kg and placebo groups at weeks 3 and 4. In study B, pain (the AUPC) decrease from baseline was significantly different in 1.0 mCi/kg and placebo groups at weeks 2, 3 and 4.@-@@@@MONO@SAMARIUM SM-153 LEXIDRONAM@@@@@SAMARIUM SM-153 LEXIDRONAM||||@EUSA PHARMA@CYTOGEN CORPORATION@@@@EUSA PHARMA|CYTOGEN CORPORATION|||@@@@@@|||||||||@Supportive Care@Cancer Pain@Bone Metastases@@@Supportive Care|Cancer Pain|Bone Metastases|||||||@QUADRAMET@@@@@QUADRAMET||||@Radiolabeled@@@@@Radiolabeled||||@PAIN RELIEF@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1/8/2015@@@57902-0860-01@INJECTION, VIAL@US$@@@@@@@@150@MCI@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920897@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920897@Leukeran is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia@@NO@@@NO REVIEW@@@@90%@@@@@Hodgkin's Disease: Used as a single agent in the palliative treatment of advanced disease a typical dosage is 0.2 mg/kg/day for 4-8 weeks. Leukeran is usually included in combination therapy and a number of regimes have been used. Leukeran has been used as an alternative to nitrogen mustard with a reduction in toxicity but similar therapeutic results. Non-Hodgkin's Lymphoma: Used as a single agent the usual dosage is 0.1-0.2 mg/kg/day for 4-8 weeks initially, maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment. Leukeran is useful in the management of patients with advanced diffuse lymphocytic lymphoma and those who have relapsed after radiotherapy. There is no significant difference in the overall response rate obtained with chlorambucil as a single agent and combination chemotherapy in patients with advanced non-Hodgkin's lymphocytic lymphoma. Chronic Lymphocytic Leukaemia: Treatment with Leukeran is usually started after the patient has developed symptoms or when there is evidence of impaired bone marrow function (but not bone marrow failure) as indicated by the peripheral blood count. Initially Leukeran is given at a dosage of 0.15 mg/kg/day until the total leucocyte count has fallen to 10,000 per µL. Treatment may be resumed 4 weeks after the end of the first course and continued at a dosage of 0.1 mg/kg/day.@2-Jul-02@7/2/2002@2/27/2003@@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@2.16@3.37@2.32@@@@@@@@@@0.02@@@@@@@@@@@@@@@@8/4/2017@0.04@0.04@779470@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919171@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14919171@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.@@@10/1/2007@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@DAKOTA PHARM@@@@SANOFI-AVENTIS|DAKOTA PHARM|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9281093T@CONCENTRATE FOR SOLUTION FOR PERFUSION, 10 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921816@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@7mg/m2 one-hour infusion on days 1, 8 and 15 of a 28-day scheudle@@-@-@-@BRENTFORD, UNITED KINGDOM@@@Ispinesib is a novel small molecule drug candidate that inhibits cell proliferation and promotes cancer cell death by specifically disrupting the function of a cytoskeletal protein known as kinesin spindle protein, or KSP. Current drugs that inhibit cell proliferation, such as paclitaxel and docetaxel, are standard treatments for many types of cancers, but these drugs also target other proteins that are essential to other important cellular functions and thus, their use is limited by side effects. @@14921816@Renal cell carcinoma@@-@-@@NO REVIEW@@@@-@Part of wide-ranging 2001 partnership between Cytokinetics and GSK to discover and commercialise small moleculaes targeting mitotic kinesins in cancer; being positioned against Nexavar and Sutent@-@NCT00354250@18-35@-@-@@@-@@12/1/2006@-@CCUM-14577A,@@-@18-35 PATIENTS WITH RENAL CELL CARCINOMA; 19 PTS WERE ACCRUED IN 6 MONTHS. BASELINE CHARACTERISTICS INCLUDED CLEAR CELL HISTOLOGY IN 74%, PAPILLARY IN 11%, AND UNCLASSIFIED IN 11%; 1 OR =2 PRIOR THERAPIES IN 37% AND 63%; PRIOR IMMUNOTHERAPY IN 53%, AND PR@@@NCI-7673;@DISCONTINUED@@-@-@>> Cytokinetics is discontinuing research activities related to oncology. [Cytokinetics, 16.09.2008]>> None of the 15 patients evaluable responded to treatment (95% CI: 0 - 21.8%). 7 patients (47%) experienced stable disease after 8 weeks. One patient experienced grade 3 neutropaenia. No other grade 3 or 4 toxicities were attributable to drug. Grade 1 and 2 toxicities included: fatigue (28%), anaemia (28%), leukopaenia (33%), elevated alkaline phosphatase (18%), anorexia (11%), hyponatraemia (11%), dyspnea (11%), headache (11%), and hypoalbuminemia (11%). Conclusion: treatment with weekly ispenesib in metastatic RCC does not lead to objective responses. [Cytokinetics/ASCO, June 2007]@-@@@@-@ISPINESIB@@@@@ISPINESIB||||@GSK@CYTOKINETICS@@@@GSK|CYTOKINETICS|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@SB-715992@@@@@SB-715992||||@KSP Inhibitor@@@@@KSP Inhibitor||||@STABLE DISEASE@RESPONSE RATE@RECIST@@@RECIST@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16423942@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Phase 1b dose escalation, Experimental, In Phase 1b, patients with advanced solid tumors will receive escalating doses of Hu5F9-G4 in combination with cetuximab.Phase 2 KRAS mutant, Experimental, In Phase 2, patients with advanced KRAS mutant colorectal cancer will receive Hu5F9-G4 in combination with cetuximab.Phase 2 KRAS wild-type, Experimental, In Phase 2, patients with advanced KRAS wild-type colorectal cancer will receive Hu5F9-G4 in combination with cetuximab.@@@@@UNITED STATES@5/1/2018@@@@16423942@A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer@Both@@@@@Hu5F9-G4 will be administered weekly.@@@@@FIRST-LINE@NCT02953782@112@@@@@@@11/1/2016@@5F9004@@@- Histological Diagnosis  -  Phase 1b only: Advanced solid malignancy with an emphasis on colorectal, head and neck, breast, pancreatic and ovarian cancers who have been treated with at least one regimen of prior systemic therapy, or who refuse systemic t@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@-@CETUXIMAB@@@@-|CETUXIMAB|||@FORTY SEVEN, INC.@@@@@FORTY SEVEN, INC.||||@United States@@@@@United States|||||||||@Colorectal Cancer@Solid Tumours@@@@Colorectal Cancer|Solid Tumours||||||||@HU5F9-G4@ERBITUX@@@@HU5F9-G4|ERBITUX|||@Other@@@@@Other||||@Dose-limiting toxicities (Number of participants with a DLT)@Objective response rate (as defined by RECIST Version 1.1)@@@@@@@@@ADVANCED@@@@@Non-Randomized@Safety Study@Single Group Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922541@Onco@@@@@300f1014ntsdm@@@@@@404 patients received Casodex 50mg once-daily, 409 received flutamide 250mg three-times daily, each in combination with goserelin acetate implant or leuprolide acetate depot.@@L02BB03@L02B@NO@LONDON, UNITED KINGDOM@@@Casodex is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Casodex can result in antiandrogen withdrawal syndrome in a subset of patients. Casodex is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.@@14922541@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@@@FIRST-LINE@@813@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@N/A@No@@813 PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED PROSTATE CANCER@@@III@APPROVED@@Unrestricted reimbursement.@RAMQ@Overall survival was not statistically significant; 52.7% of the Casodex/LHRH group had died, and 57.5% of the flutamide/LHRH group had died.@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@PHARMEL@@@@@PHARMEL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PHL-BICALUTAMIDE@GENERIC@@@@PHL-BICALUTAMIDE|GENERIC|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@MULTI-CENTRE@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@1459.92@1459.92@@30@0.7881@48.3@@@@@@@@@@@@0.03@@@@@@@@@@@@@@@@7/19/2017@1.61@1.61@228116330@TABLET@C$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14916222@Onco@@@@@300f1010ntsdm@@@@@@Actiq for breakthrough cancer pain@@N02AB03@N02A@YES@FRAZER, PENNSYLVANIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14916222@Indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.@@NO@@@NO REVIEW@@@@100%@Licensed from Kyowa Hakko; supplied by Abbott. Acquired through US$444 mil. takeover of Anesta Corp in 2000.@@@130@The initial dose of Actiq used should be 200 micrograms, titrating upwards as necessary through the range of available dosage strengths (200, 400, 600, 800, 1200 and 1600 micrograms). Patients should be carefully monitored until a dose is reached that provides adequate analgesia with acceptable side effects using a single dosage unit per episode of breakthrough pain. This is defined as the successful dose.@EMA, August 2002@@@@@@Must not be used in opioid non-tolerant patients; fentanyl is a Schedule II controlled substance; life-threatening hypoventilation can occur at any dose; contraindicated in acute or post-operative pain@LABEL@No@@@@@III@APPROVED@@NO NICE REVIEW@NHS@92 of 130 patients (71% achieved a successful dose during titration. The most successful doses were 400mcg (21%) and 800mcg (20%).@@@@@MONO@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@1.2961@21.05@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@7.02@7.02@2.69E+15@LOZENGE@GB£@@@@@@@@1200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920279@Onco@@@@@300f1018ntsdm@@@@@@Group A patients were all treated with Gleevec 400 mg daily. In Group B, 21 patients were treated with Gleevec 400 mg daily and 3 patients received lower doses.@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920279@Gleevec (imatinib mesylate) is indicated for use in the treatment of pediatric patients with newlydiagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase. Conditional approval was based on hematologic and cytogenetic response rates (surrogate endpoints) that are reasonably likely to predict clinical benefit. There are no controlled trials that demonstrate clinical benefit in pediatric patients. Patients should be advised about the conditional nature of the market authorization for Gleevec in this indication. Gleevec has been issued marketing authorization with conditions, pending the results of studies to verify its clinical benefit for the following indications: The treatment of adult patients with newly-diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase; The treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). Gleevec has been issued non-conditional approval for the following indications: The treatment of adult patients with Philadelphia chromosome-positive CML in blast crisis, accelerated phase or chronic phase (after failure of interferon-alpha therapy); The use as a single agent for induction phase therapy in adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL); The treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.@@NO@5-Mar-08@3/5/2008@NO REVIEW@@@@100%@@@@7@MDS/MPDL: The recommended dose of Gleevec is 400 mg/day for adult patients with MDS/MPD.@@@@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@AUGUST 2009 (PAEDIATRIC)@GROUP A: 7 PATIENTS SUFFERING FROM LIFE-THREATENING DISEASES ASSOCIATED WITH ABL, KIT OR PDGFR PROTEIN TYROSINE KINASES WITH MDS/MPD FROM THE PHASE II CLINICAL TRIAL + GROUP B: 24 PATIENTS WITH MDS/MPD FROM THE PUBLISHED CASE REPORTS AND A CLINICAL STUDY@ADULT@@II; OPEN LABEL, MULTICENTRE, PHASE 2 CLINICAL TRIAL + PUBLISHED CASE REPORTS + 1 CLINICAL STUDY@APPROVED@@Authority required: >> Initial PBS-subsidised treatment of a patient with a myelodysplastic or myeloproliferative disorder where:(1) there is confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement either by standard karyotyping, or FISH or PDGFRB fusion gene transcript; and (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:— cytarabine;— etoposide;— hydroxyurea.@PBS@Of the 31 patients: 45% achieved a complete haematological response CHR;  39% achieved a major cytogenetic response (including 10 with a complete cytogenetic response). 16 patients had a translocation, involving chromosome 5q33 (14 patients) or chromosome 4p12 (2 patients), resulting in a PDGFR gene re-arrangement, and responded haematologically (13 completely). Cytogenetic response was evaluated in 12 out of 14 patients, all of whom responded (10 patients completely). Only 1 out of the 14 patients without a translocation associated with PDGFR gene re-arrangement achieved a complete haematological response and none achieved a major cytogenetic response. Response durations of phase 2 study patients (Group A) ranged from 141+ days to 457+ days.@The adverse reactions were similar for Ph+ ALL as for Ph+ CML. The most frequently reported drug-related adverse reactions reported in the Ph+ ALL studies were mild nausea and vomiting, diarrhea, myalgia, muscle cramps and rash, which were easily manageable. Superficial edema was a common finding in all studies and were described primarily as periorbital or lower limb edemas. These edemas were rarely severe and may be managed with diuretics, other supportive measures, or in some patients by reducing the dose of Gleevec.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@GLEEVEC@@@@@GLEEVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@12.9@month@12.9 month@@@@60@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@A$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16421614@Onco@@@@@300f1020ntsdm@@@@@@@@L01XE38@L01X@@BASEL, SWITZERLAND@12/1/2017@@Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. In mice implanted with tumor cell lines expressing BRAF V600E, cobimetinib inhibited tumor cell growth.@@16421614@Indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation@Both@Yes@14-Sep-16@9/14/2016@NO REVIEW@@@@@@@NCT01689519@495@The recommended dose of Cotellic is 60 mg (3 tablets of 20 mg) once daily. Cotellic is taken on a 28 day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent Cotellic treatment cycle should start after the 7-day treatment break has elapsed. Treatment with Cotellic should continue until the patient no longer derives benefit or until the development of unacceptable toxicity.@EMA, 20 November 2015@11/20/2015@@No@@1/1/2013@@GO28141, 2012-003008-11@No@@@BRAF V600 mutation@ADULTS@III@APPROVED@@@SSN@The CHMP's recommendation is based primarily on results of the pivotal Phase III coBRIM study. These data showed that people who received the combination of Cotellic and Zelboraf lived over a year without their disease worsening (median progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf alone; hazard ratio=0.58, 95 percent confidence interval 0.46-0.72).2 The objective response rate was also higher for the combination arm compared to Zelboraf alone (70 vs. 50 percent; p<0.0001)[Roche, 25 September 2015, http://www.roche.com/media/store/releases/med-cor-2015-09-25.htm]@The most common adverse events in the combination arm of the pivotal study were diarrhoea, rash, nausea, fever, sun sensitivity, liver lab abnormalities, elevated creatine phosphokinase (CPK, an enzyme released by muscles) and vomiting.[Roche, 25 September 2015, http://www.roche.com/media/store/releases/med-cor-2015-09-25.htm]@@@@COMBO@COBIMETINIB@VEMURAFENIB@@@@COBIMETINIB|VEMURAFENIB|||@ROCHE@@@@@ROCHE||||@World@@@@@World|||||||||@Solid Tumours@Melanoma / Skin Cancer@@@@Solid Tumours|Melanoma / Skin Cancer||||||||@COTELLIC@ZELBORAF@@@@COTELLIC|ZELBORAF|||@MEK Inhibitor@@@@@MEK Inhibitor||||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@METASTATIC@UNRESECTABLE@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@1@69915.74913@@@12.3@month@12.3 month@69915.75@69915.75@186.88@63@1.1229@5232.7@8636.04@5468.23@@@@@@@@@@4.15@28@@mg@60@21@@@@@@@@@@@6/7/2017@83.06@83.06@44551012@FILM COATED TABLET@EURO@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918337@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918337@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@83.46@116.5@86.79@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@16.69@16.69@683536@PATCH (MATRIX)@EURO@@@@@@@@100@MCG@100 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921858@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received either Neulasta 6 mg, or Filgratrim 5 mcg/kg/day associated with a chemotherapy regimen that employed doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer.@@L03AA13@L03A@NO@THOUSAND OAKS, CALIFORNIA@@@Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Pegfilgrastim is a covalent conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20 kd polyethylene glycol (PEG) molecule. Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Similarly to filgrastim, neutrophils produced in response to pegfilgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As with other haematopoietic growth factors, G-CSF has shown in vitro stimulating properties on human endothelial cells. G-CSF can promote growth of myeloid cells, including malignant cells, in vitro and similar effects may be seen on some non-myeloid cells in vitro.@@14921858@Indicated to decrease the incidence of infection, as manifested by febrile neutropaenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropaenia.@@NO@@@NO REVIEW@@@@Precertification required. SOURCE: Aetna Preferred Drug Guide 2008@@@@157@The recommended dosage is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle.@FDA, 31 January 2002@1/31/2002@@@@@Rare cases of splenic rupture, including some fatal cases, have been reported following the administration of Neulasta. Adult respiratory distress syndrome (ARDS) has been reported in neutropenic patients with sepsis receiving Neulasta, and is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. Allergic reactions to Neulasta, including anaphylaxis, skin rash, and urticaria, have been reported. Severe sickle cell crises have been associated with the use of Neulasta in patients with sickle cell disease. Severe sickle cell crises, in some cases resulting in death, have also been associated with Filgrastim, the parent compound of pegfilgrastim.@STUDY 1@No@2015@157 WOMEN WITH BREAST CANCER WERE RANDOMISED TO RECEIVE A SINGLE SUBCUTANEOUS INJECTION OF NEULASTA 6 MG ON DAY 2 OF EACH CHEMOTHERAPY CYCLE OR DAILY SUBCUTANEOUS FILGRASTIM 5 MCG/KG/DAY BEGINNING ON DAY 2 OF EACH CHEMOTHERAPY CYCLE.@@@@APPROVED@@Covered; part B; quantity limit 1 for 30 days; specialty drug. Prior authorisation required. TIER 4.@MEDICARE@The results were similar between the two treatment groups@@@@@MONO@PEGFILGRASTIM@@@@@PEGFILGRASTIM||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@NEULASTA@@@@@NEULASTA||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@DURATION OF SEVERE NEUTROPAENIA@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@@@@@Invalid Dosage Value Phase 1@@@@@@10271.76@10271.76@@1@1@5940@@@@@@@@@@@@990@@@@@@@@@@@@@@@@8/2/2017@5940@5940@55513-0190-01@SOLUTION FOR INJECTION (PRE-FILLED SYRINGE) - 0.6 ML@US$@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922604@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Perifosine loading dose = 100 mg PO Every 6 Hours, followed by 50 mg PO Daily with docetaxel 75 mg/m^2 IV over 1 hour every 4 weeks. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@2/1/2009@@KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals. Published data suggest that the Akt pathway is frequently activated in renal cell cancer and that this tumor type may be particularly responsive to Akt inhibition.@@14922604@Relapsed epithelial ovarian cancer@@-@-@@NO REVIEW@@@@-@Keryx receives notice from Nasdaq that the company is not in compliance with the US$1 minimum bid price for continued listing and most reach this within 180 days. SOURCE: Keryx, 28 April 2008Keryx in-licensed North American rights for perifosine from Ae@SECOND-LINE@NCT00431054@20@-@-@@@-@@2/1/2007@-@2004-0970@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@PERIFOSINE@DOCETAXEL@@@@PERIFOSINE|DOCETAXEL|||@KERYX BIOPHARMACEUTICALS@AETERNA ZENTARIS@@@@KERYX BIOPHARMACEUTICALS|AETERNA ZENTARIS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@KRX-0401@TAXOTERE@@@@KRX-0401|TAXOTERE|||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16076432@Onco@@@@@@@@@@@Tocilizumab &amp; Gemcitabine and nab-Paclitaxel, Experimental, Tocilizumab:8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.Gemcitabine:1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.Nab-Paclitaxel:125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.Gemcitabine and nab-Paclitaxel, Active Comparator, Gemcitabine:1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.Nab-Paclitaxel:125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.@@-@-@@SUMMIT, NEW JERSEY@9/1/2018@@@@16076432@A Single Center, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.@Both@@@@@@@@@@FIRST-LINE@NCT02767557@140@@@@@@@10/1/2016@@GI1612@@@Signed informed consent  -  Histological or cytological pancreatic adenocarcinoma. Malignant unspecified tumor cells in cytological specimen are allowed after investigator assessment, mixed histology including adenosquamous carcinoma is allowed  -  Male or non-pregnant, non-lactating females who are ≥18 years of age at the time of signing the informed consent form (ICF)  -  Non-curable unresectable locally advanced or metastatic pancreatic carcinoma.  -  A modified Glasgow Prognostic Score (mGPS) criteria of 1 or 2 assessed within 14 days of randomization as defined below:  -  mGPS of 1: CRP > 10 mg/L and albumin ≥ 35 g/L  -  mGPS of 2: CRP > 10 mg/L and albumin < 35 g/L  -  No prior antineoplastic chemotherapy or anti-cancer drugs. Patients who have received neoadjuvant or adjuvant chemotherapy and who are diagnosed with loco regional recurrent or metastatic disease are not eligible  -  ECOG/WHO Performance Status (PS) 0-1  -  ≥ 4 weeks since prior major surgery, ≥ 2 weeks since prior minor surgery and ≥ 1 week since prior radiation therapy  -  Measurable disease using the RECIST1.1 criteria, defined as lesions that can be measured in at least one dimension and which have not been previously irradiated. Longest diameter ≥ 20 mm with conventional techniques or ≥ 10 mm with spiral CT scan or MRI  -  Fertile men and women of childbearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [ie, has had menses at any time during the preceding 24 consecutive months]) must use secure contraception methods as follows: intrauterine device, double-barrier contraception, as a condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository), vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female, or complete abstinence from sexual intercourse from before 2 months entering the study until 6 months after end of chemotherapy  -  Acceptable hematology parameters defined as:  -  Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L  -  Platelet count ≥ 100 x 10⁹/L  -  Haemoglobin ≥ 5.6 mmol/L  -  Acceptable liver function defined as:  -  Serum bilirubin < 1.5 x upper limit of normal (ULN)  -  ASAT/ALAT < 2.5 x ULN ( < 5 x ULN with known liver metastasis)  -  Acceptable renal function with a creatinine clearance ≥ 50 mL/min/ (eg, using the Cockroft-Gault formula)@@ADULTS@Phase 2@II@@@@@@@@@BOTH@PACLITAXEL@GEMCITABINE@TOCILIZUMAB@@@PACLITAXEL|GEMCITABINE|TOCILIZUMAB||@CELGENE@@@@@CELGENE||||@Denmark@@@@@Denmark|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@GENERIC@ACTEMRA@@@@GENERIC|ACTEMRA|||@Other@@@@@Other||||@Overall survival at 6 months@@@@@Performance status at 3 and 6 months assessed by investigator@Performance status at 3 and 6 months@@@@ADVANCED@METASTATIC@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921706@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients in Arm A will receive single agent IMC-A12 10 mg/kg over one hour every two weeks. A cycle is defined as four weeks of therapy. Patients will continue on study until progress or unacceptable toxicity develops. Patients in ARM B will receive IMC-A12 mg/kg 1 hour followed by cetuximab 500/mg/m2 i.v. over 2 hours. A cycle is defined by 4 weeks of therapy. Patients will continue on study until progression or unacceptable toxicity develops.@@-@-@-@NEW YORK, NEW YORK@6/1/2009@@IMC-A12 is a fully human IgG1 monoclonal antibody. It is designed to specifically target the human IGF-1R, thereby inhibiting certain ligands known as IGFs 1 and 2 from binding to and activating the receptor. This action blocks a signaling pathway that enhances tumor cell proliferation and survival. In 2007, ImClone completed enrollment into two Phase 1 studies of IMC-A12, which demonstrated favorable safety and pharmacokinetic profiles, as well as preliminary evidence of antitumor activity as a single agent when administered either weekly or every two weeks. In addition to this Phase 2 study of IMC-A12 in hormone expressing advanced breast cancer, Phase 2 studies of IMC-A12 in patients with soft tissue sarcoma (adults and adolescents) and advanced prostate, pancreatic, colorectal, liver, head and neck cancers, as well as a series of Phase 1/2 studies in pediatric malignancies and another evaluating the combination of IMC-A12 and temsirolimus, have begun to enroll patients.@@14921706@Squamous cell carcinoma of the head and neck; alone or in combo with Erbitux@@-@-@@NO REVIEW@@@@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]@-@NCT00617734@90@-@-@@@-@@1/1/2008@-@CP13-0706@@-@-@@@II@II@@-@-@Patient enrolment commenced. [ImClone, 9 April 2008]@-@@@@BOTH@-@CETUXIMAB@@@@-|CETUXIMAB|||@IMCLONE@LILLY@@@@IMCLONE|LILLY|||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@IMC-A12@ERBITUX@@@@IMC-A12|ERBITUX|||@TK Inhibitor@Human@@@@TK Inhibitor|Human|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920056@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@231 received Eulexin (250MG) + goserelin acetate (3.6MG) + radiation versus radiation alone@@@@YES@BASEL, SWITZERLAND@@@Flutamide is an anilide, nonsteroidal oral antiandrogen. In animal studies flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding in target tissues. When flutamide is given in combination with surgical or medical castration, suppression of both testicular and adrenal androgen activity is achieved.@@14920056@Eulexin Capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate.@@@@@NO REVIEW@@@@@Acquired through takeover of Eon Labs@@@466@The recommended dosage is 2 capsules 3 times a day at 8-hour intervals for a total daily dose of 750 mg.@@@@@@@"Hepatic Injury: There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide. Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with flutamide. Serum transaminase levels should be measured prior to starting treatment with flutamide. Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal. Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter. Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction, eg, nausea, vomiting, abdominal pain, fatigue, anorexia, ""flu-like"" symptoms, hyperbilirubinuria, jaundice, or right upper quadrant tenderness. If at any time a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, flutamide should be immediately discontinued with close follow-up of liver function tests until resolution."@LABEL@No@@@@@III; STAGE B2-C PROSTATIC CARCINOMA@APPROVED@@@MEDICARE@Eulexin combination associated with significantly lower rate of local failure compared to radiation alone (16% vs 33% at 4 years). The combination therapy also resulted in a trend toward reduction in the incidence of distant metastases (27% vs 36%). Median disease-free survival was significantly increased in patients who received complete hormonal therapy combined with radiation as compared to those patients who received radiation alone (4.4 vs 2. 6 years).@@@@@COMBO@FLUTAMIDE@GOSERELIN ACETATE@@@@FLUTAMIDE|GOSERELIN ACETATE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@ZOLADEX@@@@GENERIC|ZOLADEX|||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@LOCAL FAILURE@DISEASE-FREE SURVIVAL@@@@@@@@@METASTATIC@@@@@PLACEBO-CONTROLLED@@@@@@@Invalid Factory Price@@@@@@@@@180@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@US$@@@@@@@@125@MG@125 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16749484@Onco@@@@@300f1015ntsdm@@@@@@Arm I: Patients receive fludarabine IV over 15-30 minutes and cyclophosphamide IV over 15-30 minutes on days 1-3.  Arm II: Patients receive rituximab IV on day 0 during the first course of treatment and on day 1 during subsequent courses and fludarabine and cyclophosphamide as in arm I. SOURCE: clinicaltrials.gov@@L01XC02@L01X@@BASEL, SWITZERLAND@10/1/2011@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@16749484@In combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL.@Both@YES@27-Jan-10@1/27/2010@@@@@@@FIRST-LINE@NCT00281918@817@The recommended dosage of MabThera in combination with chemotherapy for previously untreated and relapsed/refractory patients is 375 mg/m2 body surface area administered on day 0 of the first treatment cycle followed by 500 mg/m2 body surface area administered on day 1 of each subsequent cycle for 6 cycles in total. The chemotherapy should be given after MabThera infusion.@EMA, 21 August 2009@8/21/2009@9/1/1998@No@@7/1/2003@@CLL-8@No@@Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Cumulative Illness Rating Scale (CIRS) score > 6; Life expectancy > 6 months; Bilirubin ≤ 2 times upper limit of normal (ULN); Alkaline phosphatase and transaminases ≤ 2 times ULN; Creatinine clearance ≥ 70 mL/min; Not pregnant or nursing; Negative pregnancy test@@ADULTS@Phase III@APPROVED@@25 May 2011: ASMR III (reassessment) [HAS, https://www.has-sante.fr/portail/upload/docs/application/pdf/2011-10/synthese_mabthera_ct-9841.pdf]27 January 2010: ASMR IV [HAS, https://www.has-sante.fr/portail/upload/docs/application/pdf/2011-03/mabthera_ct_7017.pdf]@HAUTE AUTORITÉ DE SANTÉ@Trial successfully met its primary endpoint by showing that patients treated with MabThera in combination with the current standard chemotherapy achieved a significant improvement in progression free survival, compared to patients treated with chemotherapy alone; PFS increased by 35%. SOURCE: Roche, 25 January 2008@@@@@COMBO@RITUXIMAB@FLUDARABINE@CYCLOPHOSPHAMIDE@@@RITUXIMAB|FLUDARABINE|CYCLOPHOSPHAMIDE||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@MABTHERA@FC@@@@MABTHERA|FC|||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@PROGRESSION-FREE SURVIVAL@@@@@EVENT FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@1.75@m²@5596.071428@@@168@day@168 day@5596.07@5596.07@33.31@1@1.1511@1566.9@@@@@@@@@@@@1.12@29@1@mg/m²@375@1@28@@mg/m²@500@1@@@@@@8/2/2017@1566.9@1566.9@9403691T@SOLUTION FOR SUBCUTANEOUS INJECTION BOTTLE - 11.7 ML@EURO@@@@@@@@1400@MG@120 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
14922917@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01BA01@L01B@YES@FORT LEE, NEW JERSEY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14922917@Neoplastic Diseases: indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Psoriasis: indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis: indicated in the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.@@@@@NO REVIEW@@@@@@@@@Leukemia: When used for induction, methotrexate in doses of 3.3 mg/m2 in combination with 60 mg/m2 of prednisone, given daily, produced remissions in 50% of patients treated, usually within a period of 4 to 6 weeks. Methotrexate in combination with other agents appears to be the drug of choice for securing maintenance of drug-induced remissions. When remission is achieved and supportive care has produced general clinical improvement, maintenance therapy is initiated, as follows: Methotrexate is administered 2 times weekly either by mouth or intramuscularly in total weekly doses of 30 mg/m2. It has also been given in doses of 2.5 mg/kg intravenously every 14 days. If and when relapse does occur, reinduction of remission can again usually be obtained by repeating the initial induction regimen.@@@@@@@1.Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks.2.Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. 3.Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs). 4.Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. 5.Methotrexate-induced lung disease is a potentially dangerous lesion, which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation. 6.Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. 7.Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. 8.Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication. 9.Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy. 10.Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. 11.Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@DAVA PHARMACEUTICALS@@@@@DAVA PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@RHEUMATREX@@@@@RHEUMATREX||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@24@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@67253-0580-46@TABLET@US$@@@@@@@@2.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919566@Onco@@@@@300f1015ntsdm@@@@@@100 mg/m²@@L01DB03@L01D@YES@LAKE FOREST, ILLINOIS@@@Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.@@14919566@Epirubicin is used in the treatment of a range of neoplastic conditions including • Breast, ovarian, gastric, lung and colorectal carcinomas • Malignant lymphomas • Leukaemias • Multiple myeloma. When administered intravesically, epirubicin has been shown to be beneficial in the treatment of • Papillary transitional cell carcinoma of the bladder • Carcinoma-in-situ • Prophylaxis of recurrences after transurethral resection.@@YES@@@NO REVIEW@@@@@Acquired through takeover of Mayne Pharma@FIRST-LINE@@565@High dose: Epirubicin as a single agent for the high dose treatment of lung cancer should be administered according to the following regimens: • Small cell lung cancer (previously untreated): 120 mg/m2 day 1, every 3 weeks. • Non-small cell lung cancer (squamous, large cell, and adenocarcinoma previously untreated): 135 mg/m2 day 1 or 45 mg/m2 day 1, 2 and 3 every 3 weeks. For high dose treatment, epirubicin may be given as an intravenous bolus over 3-5 minutes or as an infusion of up to 30 minutes duration. Breast Cancer: In the adjuvant treatment of early breast cancer patients with positive lymph nodes, intravenous doses of epirubicin ranging from 100 mg/m2 (as a single dose on day 1) to 120 mg/m2 (in two divided doses on days 1 and 8) every 3-4 weeks, in combination with intravenous cyclophosphamide and 5-fluorouracil and oral tamoxifen, are recommended. Lower doses (60-75 mg/m2 for conventional treatment and 105-120 mg/m2 for high dose treatment) are recommended for patients whose bone marrow function has been impaired by previous chemotherapy or radiotherapy, by age, or neoplastic bone marrow infiltration. The total dose per cycle may be divided over 2-3 successive days.@@@@@@@Occurrence of severe local tissue necrosis if extravasation during administration; intramuscular and subcutaneous routes of administration not allowed; during or after therapy occurrence of severe form of myocardial toxicity; cases of secondary acute myelogenous leukemia and refractory secondary leukaemia reported in patients treated with anthracyclines used in mono or combination therapy with DNA-damaging antineoplastic agents; cases of severe myelosuppression; advice of reduced dosage in patients with impaired hepatic function@GFEA-05@No@@565 PRE AND POSTMENOPAUSAL WOMEN WITH MORE THAN 4 NODES INVOLVED WITH TUMOR OR LESS THAN 4 POSITIVE NODES WITH NEGATIVE ESTROGEN ABND PROGESTERONE RECEPTORS AND A HISTOLOGIC TUMOR GRADE OF 2 OR 3. ALL 565 WOMEN RECEIVED A COMBINATION OF FLUOROURACIL, ELLE@@@III@APPROVED@@N/A@HAUTE AUTORITÉ DE SANTÉ@FEC-100 regimen showed a longer RFS after 5 years (65% for the FEC-100 regimen and 52% for the FEC-50 regimen - stratified logrank p=0,007) and after 10 years (49% of the FEC-100 regimen and 43% of the FEC-50 regimen - stratified logrank p=0,040 - unstratified logrank p=0,09) and a longer OS after 5 years (76% for the FEC-100 regimen and 65% for the FEC-50 regimen - stratified logrank p=0,007) and after 10 years (56% of the FEC-100 regimen and 50% of the FEC-50 regimen - stratified logrank p=0,023 - unstratified logrank p=0,039) - results based on Kaplan-Meier methods@@@@@COMBO@EPIRUBICIN HYDROCHLORIDE@@@@@EPIRUBICIN HYDROCHLORIDE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Breast Cancer@Ovarian Cancer@Stomach Cancer@NSCLC@SCLC@Breast Cancer|Ovarian Cancer|Stomach Cancer|NSCLC|SCLC|||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RELAPSE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@COMPARATIVE@OPEN-LABEL@MULTI-CENTRE@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9284306T@SOLUTION FOR PERFUSION 25 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918033@Onco@@@@@300f1015ntsdm@@@@@@260 patients received Gemzar 1000 mg/m2 was administered on Days 1, 8, and 15 of a 28-day cycle with cisplatin 100 mg/m2 administered on Day 1 of each cycle and another 262 patients received single-agent cisplatin 100 mg/m2 was administered on Day 1 of each 28-day cycle.@@L01BC05@L01B@NO@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14918033@Gemzar is indicated in combination with cisplatin for the treatment of non-small cell lung cancer.@@YES@@@NO REVIEW@@@@@@FIRST-LINE@@522@Combination use in NSCLC: the 4-week schedule, Gemzar should be administered intravenously at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15 of each 28-day cycle and Cisplatin should be administered intravenously at 100 mg/m2 on Day 1 after the infusion of Gemzar@1-Jun-96@6/1/1996@1/1/1997@@@@Gemzar can suppress bone marrow function as manifested by leukopaenia, thrombocytopaenia, and anaemia, can increase toxicity when prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing. Pulmonary toxicity, Hemolytic Uremic Syndrome (HUS) and/or renal failure, leading to death or requiring dialysis, despite discontinuation of therapy have been reported. Occurence of rare cases of Serious hepatotoxicity, including liver failure and death.@@No@@522 PATIENTS WITH INOPERABLE STAGE IIIA, IIIB, OR IV NSCLC WHO HAD NOT RECEIVED PRIOR CHEMOTHERAPY.@@@GEMZAR PLUS CISPLATIN VERSUS CISPLATIN@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@Median survival time on the Gemzar plus cisplatin arm was 9.0 months compared to 7.6 months on the single-agent cisplatin arm (p=0.008). Median TTP was 5.2 months on the Gemzar plus cisplatin arm compared to 3.7 months on the cisplatin arm (p=0.009). The objective RR on the Gemzar plus cisplatin arm was 26% compared to 10% with cisplatin (p<0.0001). No difference between treatment arms with regard to duration of response was observed.@@@@@COMBO@GEMCITABINE HYDROCHLORIDE@CISPLATIN@@@@GEMCITABINE HYDROCHLORIDE|CISPLATIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@OVERALL SURVIVAL@TIME TO PROGRESSION@RESPONSE RATE@DURATION OF RESPONSE@@RESPONSE RATE@DURATION OF RESPONSE@@@@ADVANCED@@@@@RANDOMISED@@@@@1.75@m²@861.49518@@@5.2@month@5.2 month@861.5@861.5@5.45@1@1.1511@5.81@@@@@@@@@@@@0.03@28@@mg/m²@1000@3@@@@@@@@@@@8/2/2017@5.81@5.81@9182209R@POWDER FOR SOLUTION IN PERFUSION (VIAL 10 ML)@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920067@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@YES@UNITED STATES@@@Idarubicin is an antimitotic and cytotoxic agent which intercalates with DNA and interacts with topoisomerase II and has an inhibitory effect on nucleic acid synthesis. The compound has a high lipophilicity which results in an increased rate of cellular uptake compared with doxorubicin and daunorubicin. Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes. Studies in-vitro on human and murine anthracycline-resistant cells have shown a lower degree of cross-resistance for idarubicin compared with doxorubicin and daunorubicin. Cardiotoxicity studies in animals have indicated that idarubicin has a better therapeutic index than daunorubicin and doxorubicin. The main metabolite, idarubicinol, has shown in-vitro and in-vivo antitumoral activity in experimental models. In the rat, idarubicinol, administered at the same doses as the parent drug, is clearly less cardiotoxic than idarubicin.@@14920067@>>Idamycin in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia in adults. >>Whenever intravenous idarubicin cannot be employed e.g. for medical, psychological or social reasons, oral idarubicin can be used for remission induction in patients with previously untreated, relapsed or refractory acute non-lymphocytic leukaemia. Zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents. As a single agent in the treatment of advanced breast cancer after failure of front line chemotherapy not including anthracyclines.@@@@@NO REVIEW@@@@@Fresenius Kabi has agreed to pay an initial sum of US$3.7 billion to acquire injectable generics specialist APP. Amongst other therapeutic specialities, the U.S. firm has several injectable drugs for oncology. SOURCE: Fresenius, 7 July 2008@@@@Idamycin 12 mg/m2 daily for 3 days by slow (10 to 15 min) intravenous injection in combination with cytarabine. The cytarabine may be given as 100 mg/m2 daily by continuous infusion for 7 days or as cytarabine 25mg/m2 intravenous bolus followed by cytarabine 200 mg/m2 daily for 5 days continuous infusion.@@@@@@@1. Idamycin should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration. 2. As is the case with other anthracyclines the use of Idamycin can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is morecommon in patients who have received prior anthracyclines or who have preexisting cardiac disease. 3. As is usual with antileukemic agents, severe myelosuppression occurs whenIdamycin is used at effective therapeutic doses. 4. It is recommended that Idamycin be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician andinstitution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.@LABEL@No@@@@@@APPROVED@@@MEDICARE@@@@@@@IDARUBICIN HCL@@@@@IDARUBICIN HCL||||@APP PHARMACEUTICAL@FRESENIUS KABI@@@@APP PHARMACEUTICAL|FRESENIUS KABI|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Breast Cancer@@@Haematological Malignancy|Acute Myeloid Leukaemia|Breast Cancer|||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@10@MG@1 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919355@Onco@@@@@300f1012ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@HYDERABAD, INDIA@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14919355@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Dr. Reddy's purchases Betapharm from 3i. SOURCE: Betapharm, 16 February 2006@@@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@@@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@APPROVED@@@GKV@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@BETAPHARM@DR. REDDY'S@@@@BETAPHARM|DR. REDDY'S|||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@12.56@26.87@13.66@@@@@@@@@@6.28@@@@@@@@@@@@@@@@8/1/2017@12.56@12.56@6621602@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922948@Onco@@@@@300f1012ntsdm@@@@@@100 mg/m²@@L01DB03@L01D@YES@GRAFELFING, GERMANY@@@Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.@@14922948@Epirubicin is used in the treatment of a range of neoplastic conditions including • Breast, ovarian, gastric, lung and colorectal carcinomas • Malignant lymphomas • Leukaemias • Multiple myeloma. When administered intravesically, epirubicin has been shown to be beneficial in the treatment of • Papillary transitional cell carcinoma of the bladder • Carcinoma-in-situ • Prophylaxis of recurrences after transurethral resection.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@>> Hikma Pharmaceuticals purchases Ribosepharm from Ratiopharm for US$45 million. [27.01.2007]      >> Ratiopharm acquires Ribosepharm. [8.11.2002]      >> Integrated with Klinge Pharma/Fujisawa. [Ribosepharm, 1996]@FIRST-LINE@@565@High dose: Epirubicin as a single agent for the high dose treatment of lung cancer should be administered according to the following regimens: • Small cell lung cancer (previously untreated): 120 mg/m2 day 1, every 3 weeks. • Non-small cell lung cancer (squamous, large cell, and adenocarcinoma previously untreated): 135 mg/m2 day 1 or 45 mg/m2 day 1, 2 and 3 every 3 weeks. For high dose treatment, epirubicin may be given as an intravenous bolus over 3-5 minutes or as an infusion of up to 30 minutes duration. Breast Cancer: In the adjuvant treatment of early breast cancer patients with positive lymph nodes, intravenous doses of epirubicin ranging from 100 mg/m2 (as a single dose on day 1) to 120 mg/m2 (in two divided doses on days 1 and 8) every 3-4 weeks, in combination with intravenous cyclophosphamide and 5-fluorouracil and oral tamoxifen, are recommended. Lower doses (60-75 mg/m2 for conventional treatment and 105-120 mg/m2 for high dose treatment) are recommended for patients whose bone marrow function has been impaired by previous chemotherapy or radiotherapy, by age, or neoplastic bone marrow infiltration. The total dose per cycle may be divided over 2-3 successive days.@@@@@@@Occurrence of severe local tissue necrosis if extravasation during administration; intramuscular and subcutaneous routes of administration not allowed; during or after therapy occurrence of severe form of myocardial toxicity; cases of secondary acute myelogenous leukemia and refractory secondary leukaemia reported in patients treated with anthracyclines used in mono or combination therapy with DNA-damaging antineoplastic agents; cases of severe myelosuppression; advice of reduced dosage in patients with impaired hepatic function@GFEA-05@No@@565 PRE AND POSTMENOPAUSAL WOMEN WITH MORE THAN 4 NODES INVOLVED WITH TUMOR OR LESS THAN 4 POSITIVE NODES WITH NEGATIVE ESTROGEN ABND PROGESTERONE RECEPTORS AND A HISTOLOGIC TUMOR GRADE OF 2 OR 3. ALL 565 WOMEN RECEIVED A COMBINATION OF FLUOROURACIL, ELLE@@@III@APPROVED@@@GKV@FEC-100 regimen showed a longer RFS after 5 years (65% for the FEC-100 regimen and 52% for the FEC-50 regimen - stratified logrank p=0,007) and after 10 years (49% of the FEC-100 regimen and 43% of the FEC-50 regimen - stratified logrank p=0,040 - unstratified logrank p=0,09) and a longer OS after 5 years (76% for the FEC-100 regimen and 65% for the FEC-50 regimen - stratified logrank p=0,007) and after 10 years (56% of the FEC-100 regimen and 50% of the FEC-50 regimen - stratified logrank p=0,023 - unstratified logrank p=0,039) - results based on Kaplan-Meier methods@@@@@ADJUVANT@EPIRUBICIN HYDROCHLORIDE@@@@@EPIRUBICIN HYDROCHLORIDE||||@RIBOSEPHARM@HIKMA PHARMACEUTICALS@@@@RIBOSEPHARM|HIKMA PHARMACEUTICALS|||@@@@@@|||||||||@Breast Cancer@Ovarian Cancer@Stomach Cancer@NSCLC@SCLC@Breast Cancer|Ovarian Cancer|Stomach Cancer|NSCLC|SCLC|||||@RIBOEPI@@@@@RIBOEPI||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RELAPSE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@COMPARATIVE@OPEN-LABEL@MULTI-CENTRE@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@458@590.04@473.13@@@@@@@@@@2.29@@@@@@@@@@@@@@@@8/1/2017@458@458@1494487@SOLUTION FOR INJECTION (100 ML)@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14971353@Onco@@@@@300f1012ntsdm@@@@@@Patients in the trial were treated with pemetrexed (500 mg/m2) plus best supportive care or placebo plus best supportive care. All patients were supplemented with vitamin B12, folic acid and dexamethasone. SOURCE: Lilly@@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14971353@ALIMTA is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose diseasehas not progressed immediately following platinum-based chemotherapy@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@MAINTENANCE@NCT00102804@663@In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose ofALIMTA is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first dayof each 21-day cycle.@EMA, 2 July 2009@7/2/2009@@@@@@5122@No@FEBRUARY 2009 (NCE); FEBRUARY 2011 (ORPHAN)@Patients with stage IIIB/IV NSCLC whose disease had not progressed after four cycles of platinum-based induction chemotherapy.@@@III@APPROVED@@@GKV@Patients treated with pemetrexed demonstrated increased efficacy with respect to progression-free survival compared to those treated by placebo (4.3 months vs. 2.6 months), and pemetrexed patients also achieved better tumor response (p < 0.001). When data was broken down by histology, it was comparable to previous pemetrexed trials evaluating histology -- patients with a non-squamous histology fared better than those with a squamous histology. Patients with non-squamous histology who were treated with pemetrexed achieved 4.5 months of median progression-free survival compared to 2.8 months for patients with squamous histology. Data to be presented at ASCO 2008. SOURCE: Lilly, 15 May 2008@No significant toxicity differences were identified between the two trial arms with the exception of grade 3/4 anemia (pemetrexed 4.5%, placebo 1.4%) and total serious adverse events due to the treatment (pemetrexed 4.3%, placebo 0%).@@@@MONO@PEMETREXED@@@@@PEMETREXED||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALIMTA@@@@@ALIMTA||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@ADVERSE EVENTS@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@1.75@m²@20480.10667@@@4@month@4 month@20480.11@20480.11@168.33@1@1.1511@404@521.77@417.43@@@@@@@@@@4.04@21@@mg/m²@500@1@@@@@@@@@@@8/1/2017@404@404@1812757@POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919650@Onco@@@@@300f1012ntsdm@@@@@@Oral doses of ondansetron 24 mg once a day, 8 mg twice a day, and 32 mg once a day. 66% of patients were treated with the ondansetron 24-mg  once-a-day , 55% with the ondansetron 8-mg twice-a-day , and 55% with the ondansetron 32-mg once-a-day@@A04AA01@A04A@NO@BAD VILBEL, GERMANY@@@Ondansetron is a potent, highly selective 5HTs receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomoting reflex by activating vagal afferents via 5HTs receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.@@14919650@Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2; prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy; prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; prevention of postoperative nausea and/or vomiting.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@357@Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin =50 mg/m2. Multiday, single-dose administration of a 24 mg dosage has not been studied. Pediatric Use: There is no experience with the use of a 24 mg dosage in pediatric patients. Geriatric Use: The dosage recommendation is the same as for the general population. Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is one 8-mg tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.@@@@@@@Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@357 ADULT CANCER PATIENTS RECEIVING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN =50 MG/M2.@@@CLINICAL TRIALS / CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING: HIGHLY EMETOGENIC CHEMOTHERAPY; 2 RANDOMISED, DOUBLE-BLIND, MONOTHERAPY TRIALS@APPROVED@@@GKV@First trial: Each of the 3 treatment groups was shown to be statistically significantly superior to a historical placebo control. 56% of patients receiving oral ondansetron 24 mg once a day experienced no nausea during the 24-hour study period, compared with 36% of patients in the oral ondansetron 8-mg twice-a-day group (p = 0.001) and 50% in the oral ondansetron 32-mg once-a-day group. Second trial, efficacy of the oral ondansetron 24-mg once-a-day regimen in the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2, was confirmed.@@@@@MONO@ONDANSETRON HYDROCHLORIDE@@@@@ONDANSETRON HYDROCHLORIDE||||@STADA ARZNEIMITTEL@@@@@STADA ARZNEIMITTEL||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@EMETIC EPISODES@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@32.02@51.47@33.73@@@@@@@@@@0.4@@@@@@@@@@@@@@@@8/1/2017@3.2@3.2@4818654@FILM-COATED TABLET@EURO@@@@@@@@8@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16160491@Onco@@@@@300f1020ntsdm@@@@@@dabrafenib 150 mg twice dailydabrafenib plus trametinib placebo (dabrafenib 150 mg twice daily and trametinib placebo, trametinib 2 mg once daily)@@L01XE25@L01X@@BASEL, SWITZERLAND@8/1/2013@@Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Trametinib inhibits growth of BRAF V600 mutant melanoma cell lines and demonstrates anti-tumour effects in BRAF V600 mutant melanoma animal models.@@16160491@Trametinib in combination with dabrafenib is Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation@Both@YES@14-Dec-16@12/14/2016@NO REVIEW@@@@@@@NCT01584648@423@The recommended dose of Mekinist, used as monotherapy or in combination with dabrafenib, is 2 mg given orally once daily@EMA, 25 August 2015@8/25/2015@@NO@@5/1/2012@@115306@No@@Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.The subject must have a radiologically measurable tumorThe subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).@BRAF V600 mutation@ADULTS@III@APPROVED@@14 December 2016: inclusion into the reimbursement list, Class H [http://www.gazzettaufficiale.it/eli/id/2017/01/03/16A09047/sg;jsessionid=JlQdc0TLom1RmbFWAhhvcg__.ntc-as5-guri2b]@SSN@@@@@@COMBO@TRAMETINIB@DABRAFENIB@@@@TRAMETINIB|DABRAFENIB|||@NOVARTIS @@@@@NOVARTIS ||||@United States@Argentina@Australia@Canada@France@United States|Argentina|Australia|Canada|France|Germany|Greece|Italy|Netherlands|Spain@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@MEKINIST@TAFINLAR@@@@MEKINIST|TAFINLAR|||@MEK Inhibitor@@@@@MEK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@52558.71777@@@11.2@month@11.2 month@52558.72@52558.72@154.29@30@1.1229@1157.14@1909.75@1209.22@@@@@@@@@@77.14@1@@mg@2@1@@@@@@@@@@@6/7/2017@38.57@38.57@43524026@FILM COATED TABLET@EURO@@@@@@@@0.5@MG@0.5 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16425245@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC24@L01X@@NEW BRUNSWICK, NEW JERSEY@@@CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including multiple myeloma and other cell types and tissues and has multiple functions, such asreceptor mediated adhesion, signaling, and modulation of cyclase@@16425245@Indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma whohave received at least one prior therapy.@Both@NA@@@NO REVIEW@@@@@@SECOND-LINE@@498@The recommended dose of DARZALEX is 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule: weekly from week 1 to 9, every three weeks from week 10 to 24, once per month from week 25 onward.@FDA, 21 November 2016@11/21/2016@@Yes@@@@@No@@@@ADULTS@@APPROVED@@@@The current approval was based on two randomized, open-label trials in which daratumumab was added to standard therapies. The POLLUX trial (also known as MMY3003), demonstrated substantial improvement in progression-free survival (PFS) when daratumumab was added to lenalidomide and dexamethasone compared with lenalidomide and dexamethasone alone. The estimated median PFS had not been reached in the daratumumab arm and was 18.4 months in the control arm (HR=0.37; 95% CI: 0.27, 0.52; p<0.0001), representing a 63% reduction in the risk of disease progression or death in patients treated with daratumumab.Similar results were observed in the CASTOR trial (also known as MMY3004), which compared the combination of daratumumab, bortezomib, and dexamethasone with bortezomib and dexamethasone. The estimated median PFS was not reached in the daratumumab arm and was 7.2 months in the control arm (HR=0.39; 95% CI: 0.28, 0.53; p<0.0001), representing a 61% reduction in the risk of disease progression or death for patients treated with daratumumab.[FDA, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm530249.htm]@The most frequently reported adverse reactions (greater than or equal to 20%) in MMY3003 were infusion reactions, diarrhea, nausea, fatigue, pyrexia, upper respiratory tract infection, muscle spasm, cough and dyspnea. The most frequently reported adverse reactions (greater than or equal to 20%) in MMY3004 were infusion reactions, diarrhea, peripheral edema, upper respiratory tract infection, peripheral sensory Neutropenia and thrombocytopenia have been added to the Warnings and Precautions of the DARZALEX label.[FDA, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm530249.htm]@@@@COMBO@DARATUMUMAB@BORTEZOMIB@DEXAMETHASONE@@@DARATUMUMAB|BORTEZOMIB|DEXAMETHASONE||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@DARZALEX@@@@@DARZALEX||||@mAb@Human@@@@mAb|Human|||@PROGRESSION FREE SURVIVAL@@@@@@@@@@@@@@@OPEN-LABEL@RANDOMIZED@ACTIVE-CONTROLLED@@@76.5@kg@Invalid Average Duration of Use@@@@@@@@@1@1@474.17@@@@@@@@@@@@4.74@7@9@mg/kg@16@1@21@5@mg/kg@16@1@28@@mg/kg@16@1@8/2/2017@474.17@474.17@57894-0502-05@SOLUTION FOR INJECTION (VIAL) - 5 ML@US$@@@@@@@@100@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918518@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@HOLZKIRCHEN, GERMANY@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14918518@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@@@@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Ovarian Cancer@NSCLC@Sarcoma@Kaposi's Sarcoma@@Ovarian Cancer|NSCLC|Sarcoma|Kaposi's Sarcoma||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@91.98@127.27@95.57@@@@@@@@@@3.07@@@@@@@@@@@@@@@@8/1/2017@91.98@91.98@1529228@CONCENTRATE FOR INFUSION SOLUTION, 5 ML@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921236@Onco@@@@@300f1010ntsdm@@@@@@Two phase titration (2-16 weeks, b=10) and maintenance (16-48 weeks, n=3) trial- Sensipar 70mg twice daily to 90mg 4 times daily in maintenance.@@H05BX01@H05B@NO@THOUSAND OAKS, CALIFORNIA@@@The calcium sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH secretion. Cinacalcet is a calcimimetic agent which directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels@@14921236@Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma.@@NO@NICE: January 2007 (hyperparathyroidism)@@Manufacturer's model: ICER of £35,600 per QALY gained. Assessment Group: ICER of £61,900 per additionaly QALY.@@@@100%@@@@13@Parathyroid Carcinoma: The recommended starting dose of Mimpara for adults is 30 mg twice per day. The dosage of Mimpara should be titrated every 2 to 4 weeks through sequential doses of 30 mg twice daily, 60 mg twice daily, 90 mg twice daily, and 90 mg three or four times daily as necessary to reduce serum calcium concentration to or below the upper limit of normal. The maximum dose used in clinical trials was 90 mg four times daily. Serum calcium should be measured within 1 week after initiation or dose adjustment of Mimpara. Once maintenance dose levels have been established, serum calcium should be measured every 2 to 3 months. After titration to the maximum dose of Mimpara, serum calcium should be periodically monitored; if clinically relevant reductions in serum calcium are not maintained, discontinuation of Mimpara therapy should be considered.@EMA, July 2004@@@@@@In three clinical studies of CKD patients on dialysis, 5% of the patients in both the Sensipar and placebo groups reported a history of seizure disorder at baseline. During the trials, seizures (primarily generalized or tonic-clonic) were observed in 1.4% (9/656) of Sensipar-treated patients and 0.4% (2/470) of placebo-treated patients. 5 of the 9 Sensipar-treated patients had a history of a seizure disorder and two were receiving anti-seizure medication at the time of their seizure. Both placebo-treated patients had a history of seizure disorder and were receiving anti-seizure medication at the time of their seizure. While the basis for the reported difference in seizure rate is not clear, the threshold for seizures is lowered by significant reductions in serum calcium levels. Therefore, serum calcium levels should be closely monitored in patients receiving Sensipar, particularly in patients with a history of a seizure disorder@@No@@@@@III; PARATHYROID CARCINOMA@APPROVED@@no carcinoma guidance as yet. January 2007 Guidance; cinacalcet is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Cinacalcet is recommended for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease (including those with calciphylaxis) only in those who have ‘very uncontrolled' plasma levels of intact parathyroid hormone (defined as greater than 85 pmol/litre [800 pg/ml]) that are refractory to standard therapy, and a normal or high adjusted serum calcium level; and in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery are considered to outweigh the benefits. Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma levels of intact parathyroid hormone of 30% or more is seen within 4 months of treatment, including dose escalation as appropriate.@NHS@Baseline mean (SD) serum calcium was 14.7 (1.8) mg/dL. The range of change from baseline to last measurement was –7.5 to 2.7 mg/dL during the titration phase and –7.4 to 0.9 mg/dL during the maintenance phase. No patients maintained a serum calcium level within the normal range.@@@@@MONO@CINACALCET HCL@@@@@CINACALCET HCL||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@MIMPARA@@@@@MIMPARA||||@Anti-Parathyroid Agent@@@@@Anti-Parathyroid Agent||||@SERUM CALCIUM@@@@@@@@@@@@@@@OPEN-LABEL@@@@@@@Invalid Dosage Value Phase 1@@@@@@1719.84@1719.84@@28@1.299@347.96@@@@@@@@@@@@0.14@@@@@@@@@@@@@@@@7/28/2017@12.43@12.43@8.96E+15@TABLET@GB£@@@@@@@@90@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916694@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@A weekly dose of 900 mg to be divided into three doses of 300 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 1,200 mg divided into four doses of 300 mg. A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg divided into four doses of 50 mg. A daily dose of 150 mg to be given in one dose at bedtime. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg to be given in one dose at bedtime. SOURCE: clinicaltrials.gov @@-@-@-@NEW YORK, NEW YORK@2/1/2008@@KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals. Published data suggest that the Akt pathway is frequently activated in renal cell cancer and that this tumor type may be particularly responsive to Akt inhibition.@@14916694@-@@-@-@@NO REVIEW@@@@-@Keryx receives notice from Nasdaq that the company is not in compliance with the US$1 minimum bid price for continued listing and most reach this within 180 days. SOURCE: Keryx, 28 April 2008Keryx in-licensed North American rights for perifosine from Ae@-@NCT00399789@120@-@-@@@-@@9/1/2004@-@Perifosine 201@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@PERIFOSINE@@@@@PERIFOSINE||||@KERYX BIOPHARMACEUTICALS@AETERNA ZENTARIS@@@@KERYX BIOPHARMACEUTICALS|AETERNA ZENTARIS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@KRX-0401@@@@@KRX-0401||||@Other@@@@@Other||||@GASTROINTESTINAL TOXICITY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16063867@Onco@@@@@300f1012ntsdm@@@@@@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16063867@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX.@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@254@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 13 January 2012@1/13/2012@@No@@@@EMR 62 202-013@No@@@(EGFR)-expressing, KRAS WILD-TYPE@@@APPROVED@7/29/2011@@GKV@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@35132.69568@@@7.9@month@7.9 month@35132.7@35132.7@146.21@1@1.1511@229.92@301.68@237.87@@@@@@@@@@2.3@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/1/2017@229.92@229.92@493528@SOLUTION FOR INFUSION 20 MG@EURO@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923487@Onco@@@@@300f1020ntsdm@@@@@@Starting dose of 650mg/m2/day with reduction to 500mg/m2/day were not tolerated; this was reduced to 300mg/m2/day (increased to 400mg/m2/day if there was no response after 8 weeks).@@L01XX25@L01X@YES@-@@@@@14923487@Indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.@@NO@27-Nov-03@11/27/2003@NO REVIEW@@@@100%@Global rights licensed by Eisai from Ligand in September 2006. Cephalon acquired European rights through takeover of Zeneus in December 2005.@SECOND-LINE@-@193@300 mg/m²/day as an initial dose with subsequent dosing depending on body surface area (please refer to label). Treatment should be continued as long as the patient is deriving benefit.@EMA, 29 March 2001@3/29/2001@@NO@@@Retinoids are associated with birth defects and must not be administered to pregnant women. About 70% of patients with CTCL who received an initial dose of =300 mg/m2/day had fasting triglyceride levels greater than 2.5 times the upper limit of normal. About 55% had values over 800 mg/dL with a median of about 1200 mg/dL in those patients. Acute pancreatitis has been reported in 4 patients with CTCL and in 6 patients with non-CTCL cancers; the cases were associated with marked elevations of fasting serum triglycerides, the lowest being 770 mg/dL in one patient. 1 patient with advanced non-CTCL cancer died of pancreatitis. Targretin induces biochemical evidence of or clinical hypothyroidism in about half of all patients treated, causing a reversible reduction in T4] and TSH levels. The incidence of decreases in TSH and total T4 were about 60% and 45%, respectively, in patients with CTCL receiving an initial dose of 300 mg/m2/day. A total of 18% of patients with CTCL receiving an initial dose of 300 mg/m2/day had reversible leukopaenia in the range of 1000 to <3000 WBC/mm3. Patients receiving an initial dose greater than 300 mg/m2/day  had an incidence of leukopenia of 43%.@LABEL@No@@@@@N/A@APPROVED@@@SSN@At 300mg/m2/day, 1/62 (1.6%) had CR and 19/62 (30%) had PR. Rate of relapse in the 20 patients with response was 30% (6/20) over 21 weeks.@-@@@@MONO@BEXAROTENE@@@@@BEXAROTENE||||@SIGMA TAU@@@@@SIGMA TAU||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@CTCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|CTCL||||||@TARGRETIN@@@@@TARGRETIN||||@Retinoid@@@@@Retinoid||||@COMPLETE RESPONSE@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@MULTI-CENTRE@HISTORICAL CONTROL@@@1.75@m²@57400.805@@@118@week@118 week@57400.81@57400.81@69.49@100@1.1229@992.75@1638.44@1037.43@@@@@@@@@@0.13@1@@mg/m²@300@1@@@@@@@@@@@6/7/2017@9.93@9.93@35710019@SOFT CAPSULE@EURO@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15111556@Onco@@@@@300f1020ntsdm@@@@@@Ofatumumab alone.@@L01XC10@L01X@-@COPENHAGEN, DENMARK@@@Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.@@15111556@Arzerra is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in patients who are refractory to fludarabine and alemtuzumab.@@YES@6-May-11@5/6/2011@NO REVIEW@@@@@>> Amendment to the licensing deal agreed; Genmab has sold its co-promotion option rights to GSK. The sale of the co-promotion option does not affect the royalty or milestone revenue that Genmab may receive. GSK will now be fully responsible for the entire sales organisation for ofatumumab. Genmab will receive a one-time payment of US$4.5 million from GSK upon the FDA's acceptance for review of the filing of the first BLA for ofatumumab in an oncology indication in the United States in exchange for terminating its option to co-promote ofatumumab. [Genmab, 19.12.2008]      >> GlaxoSmithKline acquired an exclusive worldwide license to ofatumumab as well as any other antibodies with affinity for CD20 which Genmab may develop. GSK and Genmab will co-develop ofatumumab; Genmab has an option to co-promote ofatumumab in a targeted oncology setting in the United States and in the Nordic region. In addition, if Genmab exercises the co-promotion option, Genmab would have had the option to co-promote GSK's Bexxar and Arranon in the United States and Atriance in the relevant countries of the Nordic region. [Genmab, December 2006]@SECOND-LINE@NCT00349349@154@Recommended dosage and schedule is 12 doses administered as follows:  • 300 mg initial dose, followed 1 week later by  • 2,000 mg weekly for 7 doses, followed 4 weeks later by  • 2,000 mg every 4 weeks for 4 doses. (2.1)@EMA, 19 April 2010@4/19/2010@@Orphan drug@@6/1/2006@-@Hx-CD20-406@No@@138 patients with refractory CLL were evaluable. About half of the patients (59) in the study were refractory to both fludarabine and alemtuzumab. The analysis also included a second group (79) who were refractory to fludarabine and considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes.@@@III@APPROVED@@Approved in June for reimbursement for CLL. According to the reimbursement document a cost-sharing scheme was negotiated with GSK, in which the company will pay for the equivalent of 50% of the cost of the entire treatment (12 infusions).[AIFA, in Italian,  http://antineoplastici.agenziafarmaco.it/Procedure_rimborso_arzerra.pdf ]@SSN@A total of 95 patients with fludarabine and alemtuzumab refractory CLL were treated in the study. The objective response rate (ORR), as determined by an Independent Review Committee, in the study was 51%. In addition to the 95 patients in the efficacy analysis the study also included 128 patients with relapsed or refractory CLL, who were not refractory to both fludarabine and alemtuzumab. Results from this concluded pivotal trial are consistent with the efficacy and safety data reported in the interim analysis and demonstrate the activity of single-agent ofatumumab in patients with heavily pretreated fludarabine and alemtuzumab-refractory chronic lymphocytic leukemia.  [Genmab 9 August 2010 http://www.genmab.com/Press%20Center/RecentNewsReleases/27GSKandGenmabAnnounceToplineResultsfromtheConcludedPivotalTrialofArzerrainRefractoryCLL.aspx ]>> At the interim analysis, the study met the primary endpoint in both populations and the results from the secondary endpoints also support the primary endpoint. An objective response rate of 51% (p<0.0001) consisting of 30 PR was achieved in the group of patients refractory to fludarabine and alemtuzumab. In the fludarabine refractory, alemtuzumab inappropriate patient group, an objective response rate of 44% (p<0.0001) was achieved, including 1 CR, and 34 PR. Achievement of the reported objective response rates are based on evaluations by an independent committee and are subject to review and confirmation by the regulatory authorities. [Genmab/GSK, 31 July 2008]>> Last patient to be included in the planned interim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20) in refractory CLL has now received the last scheduled treatment. In order to complete the database and allow for assessment of the responses by an independent committee, the final data will now be collected and analysed with the results expected in early August 2008. [Genmab, 29 May 2008]@There were no unexpected safety findings reported with the total study population (n=223). The most common adverse reactions (≥10%) occurring in patients treated with Arzerra were pyrexia (21%), anemia (18%), diarrhea (17%), neutropenia, fatigue (16%), dyspnea (15%), pneumonia (15%), chills (13%), rash (13%), nausea (13%), bronchitis (12%), peripheral edema (11%), back pain (10%) and upper respiratory tract infection (10%).  [Genmab 9 August 2010]>>Ofatumumab was generally well tolerated by CLL patients in the study. The most frequently reported adverse events (those that occurred at a greater than 15% frequency) were: pyrexia, diarrhea, fatigue, cough, neutropenia, anemia and pneumonia. There were no unexpected safety findings. None of the 14 patients tested for human anti-human antibodies (HAHA) demonstrated their presence at 12 months.@@@@MONO@OFATUMUMAB@@@@@OFATUMUMAB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|||||||@ARZERRA@@@@@ARZERRA||||@mAb@Human@CD20@@@mAb|Human|CD20||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@PIVOTAL@1@1@52719.43314@@@196@day@196 day@52719.43@52719.43@268.98@1@1.1229@2175.92@3591.14@2273.86@@@@@@@@@@2.18@8@1@mg@2300@1@11@7@mg@2000@1@28@@mg@2000@1@6/7/2017@2175.92@2175.92@39826033@CONCENTRATE FOR SOLUTION FOR INFUSION - 50 ML@EURO@@@@@@@@1000@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14916958@Onco@@@@@300f1018ntsdm@@@@@@Patients received either Aromasin (exemestane tablets) 25 mg once daily or megestrol acetate 40 mg four times daily.@@L02BG06@L02B@NO@NEW YORK, NEW YORK@@@Exemestane is an irreversible, steroidal aromatase inhibitor, structurally related to the natural substrate androstenedione. In post-menopausal women, oestrogens are produced primarily from the conversion of androgens into oestrogens through the aromatase enzyme in peripheral tissues. Oestrogen deprivation through aromatase inhibition is an effective and selective treatment for hormone dependent breast cancer in postmenopausal women. In postmenopausal women, Aromasin p.o. significantly lowered serum oestrogen concentrations starting from a 5 mg dose, reaching maximal suppression (>90%) with a dose of 10-25 mg. In postmenopausal breast cancer patients treated with the 25 mg daily dose, whole body aromatization was reduced by 98%. Exemestane does not possess any progestogenic or oestrogenic activity. A slight androgenic activity, probably due to the 17-hydro derivative, has been observed mainly at high doses. In multiple daily doses trials, Aromasin had no detectable effects on adrenal biosynthesis of cortisol or aldosterone, measured before or after ACTH challenge, thus demonstrating its selectivity with regard to the other enzymes involved in the steroidogenic pathway. Glucocorticoid or mineralocorticoid replacements are therefore not needed. A non dose-dependent slight increase in serum LH and FSH levels has been observed even at low doses: this effect is, however, expected for the pharmacological class and is probably the result of feedback at the pituitary level due to the reduction in oestrogen levels that stimulate the pituitary secretion of gonadotropins also in postmenopausal women.@@14916958@Adjuvant treatment of postmenopausal women with estrogenreceptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy; the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.@@NO@@@NO REVIEW@@@@100%@@SECOND-LINE@@769@The recommended dose of Aromasin in early and advanced breast cancer is one 25 mg tablet once daily after a meal. In postmenopausal women with early breast cancer who have been treated with 2–3 years of tamoxifen, treatment with Aromasin should continue in the absence of recurrence or contralateral breast cancer until completion of five years of adjuvant endocrine therapy. For patients with advanced breast cancer, treatment should continue until tumour progression is evident. For patients receiving Aromasin with a potent CYP 3A4 inducer such as rifampicin or phenytoin, the recommended dose is 50 mg once daily after a meal.@@@@@@@Aromasin Tablets may cause fetal harm when administered to a pregnant woman.@LABEL@No@@769 POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER WHO HAD DISEASE PROGRESSION AFTER TREATMENT WITH TAMOXIFEN FOR METASTATIC DISEASE OR AS ADJUVANT THERAPY, WERE RANDOMISED TO RECEIVE AROMASIN (N = 366) OR MEGESTROL ACETATE (N = 403). SOME PATIENTS ALSO@@@TREATMENT OF ADVANCED BREAST CANCER@APPROVED@@Unrestricted reimbursement.@PBS@The objective RRs observed in the two treatment arms showed that Aromasin was not different from megestrol acetate (15% for the Aromasin arm vs. 12.4% for the megestrol arm; CR was 2.2% and 1.2% and PR was 12.8% and 11.2% respectively). There were too few deaths occurring across treatment groups to draw conclusions on overall survival differences. Median time to tumor progression was 20.3 weeks for the Aromasin arm compared to 16.6 weeks for the megestrol arm (hazard ratio 0.84).@@@@@ADJUVANT@EXEMESTANE@@@@@EXEMESTANE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AROMASIN@@@@@AROMASIN||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@MULTI-CENTRE@COMPARATIVE@@1@1@244.506639@@@20.3@week@20.3 week@244.51@244.51@1.72@30@0.7915@51.62@66.06@55.5@@@@@@@@@@0.07@1@@mg@25@1@@@@@@@@@@@9/1/2017@1.72@1.72@0434-0946-GE-PF@TABLET@A$@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14923577@Onco@@@@@300f1020ntsdm@@@@@@In Study CA139-174 patients received paclitaxel at 135 mg/m2 as a 3-hour infusion every 3 weeks (intended dose intensity 45 mg/m2/week). If no dose limiting toxicity was observed, patients were to receive 155 mg/m2 and 175 mg/m2 in subsequent courses. Hematopoietic growth factors were not to be used initially. In Study CA139-281 patients received paclitaxel at 100 mg/m2 as a 3-hour infusion every 2 weeks (intended dose intensity 50 mg/m2/week).@@L01CD01@L01C@YES@NEW YORK, NEW YORK@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14923577@Paclitaxel is indicated, after failure of first-line or subsequent chemotherapy for the treatment of metastatic carcinoma of the ovary. Paclitaxel is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi's sarcoma.@@YES@@@NO REVIEW@@@@100%@@SECOND-LINE@@85@For patients with AIDS-related Kaposi's sarcoma, paclitaxel administered at a dose of 135 mg/m2 given intravenously over 3 hours every 3 weeks or at a dose of 100 mg/m2 given intravenously over 3 hours every 2 weeks is recommended (dose intensity 45-50 mg/m2 /week).@@@@@@@Taxol should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. Anaphylaxis and severe hypersensitivity reactions characterised by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2%-4% of patients in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H2 antagonists. Patients who experience severe hypersensitivity reactions should not be rechallenged with the drug. Taxol therapy should not be given to patients with solid tumours who have baseline neutrophil counts of less than 1,500 cells/mm3 and should not be given to patients with AIDS-related Kaposi's sarcoma if the baseline neutrophil count is less than 1000 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropaenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving Taxol.@CA139-174 / CA139-281@No@@Fifty-nine of the 85 patients enrolled in these studies had previously received systemic therapy, including interferon alpha (32%), DaunoXome (31%), DOXIL (2%) and doxorubicin containing chemotherapy (42%), with 64% having received prior anthracyclines. Eightyfive percent of the pretreated patients had progressed on, or could not tolerate, prior systemic therapy.@@@II@APPROVED@@@SSN@Although the planned dose intensity in the two studies was slightly different (45 mg/m2/week in Study CA139-174 and 50 mg/m2 /week in Study CA139-281), delivered dose intensity was 38-39 mg/m2/week in both studies, with a similar range (20-24 to 51-61). The efficacy of pacalitaxel was evaluated by assessing cutaneous tumor response according to the amended ACTG criteria and by seeking evidence of clinical benefit in patients in six domains of symptoms and/or conditions that are commonly related to AIDS-related Kaposi's sarcoma. Cutaneous Tumor Response (Amended ACTG Criteria) - The objective response rate was 59% (95% CI: 46 to 72%)( 35 of 59 patients) in patients with prior systemic therapy. Cutaneous responses were primarily defined as flattening of more than 50% of previously raised lesions. (See Table) The median time to response was 8.1 weeks and the median duration of response measured from the first day of treatment was 10.4 months (95% CI: 7.0 to 11.0 months) for the patients who had previously received systemic therapy. The median time to progression was 6.2 months (95% CI: 4.6 to 8.7 months). Additional Clinical Benefit - Most data on patient benefit were assessed retrospectively (plans for such analyses were not included in the study protocols). Nonetheless, clinical descriptions and photographs indicated clear benefit in some patients, including instances of improved pulmonary function in patients with pulmonary involvement, improved ambulation, resolution of ulcers, and decreased analgesic requirements in patients with KS involving the feet and resolution of facial lesions and edema in patients with KS involving the face, extremities and genitalia.@@@@@MONO@PACLITAXEL@@@@@PACLITAXEL||||@BMS@@@@@BMS||||@@@@@@|||||||||@Sarcoma@Kaposi's Sarcoma@@@@Sarcoma|Kaposi's Sarcoma||||||||@TAXOL@@@@@TAXOL||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@TIME TO PROGRESSION@OVERALL SURVIVAL@@@OVERALL SURVIVAL@@@@@@@@@@RANDOMISED@OPEN-LABEL@@@@@@Incorrect Average Duration of Use (Unit)@@@15@cycle@15 cycle@@@@1@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@28848024@INJECTABLE SOLUTION VIAL, 16.7 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14924963@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@400mg PO BID daily @@L01XE05@L01X@-@LEVERKUSEN, GERMANY@12/1/2010@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14924963@-@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@-@NCT00654238@55@-@-@@@-@@2/1/2006@-@802861@@DECEMBER 2010 (NCE); DECEMBER 2012 (ORPHAN); JUNE 2022 (EXTENSION)@Patients must have histologically confirmed thyroid cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Patients may have received multiple treatments of radioactive iodine, one prior biologic treatment, and at least half of the patients will have had no prior chemotherapy for metastatic disease. At least 3 weeks must have elapsed since prior treatment. ECOG performance status < 2 (Appendix 1).@@@II@II@@-@-@Treatment with Nexavar resulted in meaningful anti-tumor activity in the majority of patients with encouraging overall clinical benefit (both disease stabilization and partial responses) in patients with advanced thyroid cancer. SOURCE: Onyx/Bayer/ASCO, 2 June 2008@Nexavar was well-tolerated; the most common treatment-related adverse events included fatigue, rash, diarrhea, palmer-plantar erythema, musculoskeletal pain and weight loss. Patients enrolled in this study had been diagnosed with metastatic, iodine-refractory, unresectable or locally-advanced thyroid cancer. @@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@ONYX@@@@BAYER HEALTHCARE|ONYX|||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@RESPONSE RATE@@@@@TIME TO PROGRESSION@DURATION OF RESPONSE@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15059386@Onco@@@@@300f1015ntsdm@@@@@@1000MG abiraterone with prednisone/prednisolone@@L02BX03@L02B@-@NEW BRUNSWICK, NEW JERSEY@6/1/2011@@@@15059386@Castration-resistant prostate cancer in patients who failed docetaxel-based therapy@@NO@29 February 2013@@NO REVIEW@@@@100%@J&J acquired Cougar in 2009.[J&J May 21 2009 http://www.jnj.com/connect/news/all/20090521_160000 ]@@NCT00638690@1158@ZYTIGA 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily@EMA, 7 September 2011@9/7/2011@9/14/2011@No@@4/1/2008@Mineralocorticoid excess, Adrenocortical insufficiency, Hepatotoxicity@COU-AA-301@No@@@@@III@APPROVED@@ASMR III, 29 February 2013, http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-01/zytiga_ct_11654.pdf@HAUTE AUTORITÉ DE SANTÉ@Treatment with abiraterone acetate resulted in a 35 percent reduction in the risk of death (HR=0.65; 95 percent CI: 0.54, 0.77; p<0.0001) and a 36 percent increase in median survival (14.8 months vs. 10.9 months) compared with placebo.Patients who received abiraterone acetate and low-dose prednisone/prednisolone also showed significant improvements in secondary study endpoints when compared to the prednisone/prednisolone plus placebo group: time to PSA progression (TTPP) [median 10.2 months for abiraterone acetate vs. 6.6 months for placebo, HR=0.58 (95 percent CI: 0.46, 0.73); p<0.0001] and an increase in radiographic progression-free survival (rPFS) [median 5.6 months for abiraterone acetate vs. 3.6 months for placebo, HR=0.67 (95 percent CI: 0.58, 0.78); p<0.0001]. Total PSA response, defined as greater than or equal to a 50 percent decrease from baseline, was achieved in 38 percent of patients treated with abiraterone acetate vs. 10 percent in the prednisone/prednisolone plus placebo group [p<0.0001].[SOURCE: http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=516967]>>Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.These results will be presented at the upcoming European Society of Medical Oncologists meeting, which is held in Milan, October 8-12, 2010. They will also be submitted for publication in a peer reviewed journal.[SOURCE: http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=506329]>>Enrolment started. Phase III castration-resistant, chemotherapy-naïve prostate cancer trial to start in H2 2008. SOURCE: Cougar, 29 April 2008@@@@@COMBO@ABIRATERONE ACETATE@PREDNISONE@@@@ABIRATERONE ACETATE|PREDNISONE|||@JOHNSON & JOHNSON@COUGAR BIOTECHNOLOGY@@@@JOHNSON & JOHNSON|COUGAR BIOTECHNOLOGY|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ZYTIGA@@@@@ZYTIGA||||@Hormone Antagonist@@@@@Hormone Antagonist||||@OVERALL SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@1@1@43230.05743@@@14.8@month@14.8 month@43230.06@43230.06@96.03@120@1.1511@2881@3071.39@2911@@@@@@@@@@0.1@1@@mg@1000@1@@@@@@@@@@@8/1/2017@24.01@24.01@3.40E+12@TABLET@EURO@@@@@@@@250@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15360656@Onco@@@@@300f1010ntsdm@@@@@@Both everolimus and placebo administered by continuous oral dosing of two 5-mg tablets.@@L01XE10@L01X@@BASEL, SWITZERLAND@6/1/2014@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15360656@Indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.@@NO@21-Dec-16@12/21/2016@NO REVIEW@@@@100%@@SECOND-LINE@NCT00863655@724@The recommended dose of Afinitor is 10 mg to be taken once daily.@EMA, 30 July 2012@7/30/2012@@No@@6/1/2009@@BOLERO2@No@@@@@III@APPROVED@@21 December 2016: recommended. Everolimus, in combination with exemestane, is recommended within its marketing authorisation, as an option for treating advanced human epidermal growth factor receptor 2 (HER2)negative, hormonereceptorpositive breast cancer in postmenopausal women without symptomatic visceral disease that has recurred or progressed after a nonsteroidal aromatase inhibitor. Everolimus is recommended only if the company provides it with the discount agreed in the patient access scheme.[https://www.nice.org.uk/guidance/ta421/chapter/1Recommendations]August 2016: Not recommended (guidance). Everolimus, in combination with exemestane, is not recommended within its marketing authorisation for treating advanced human epidermal growth factor receptor 2 (HER2)negative hormonereceptorpositive breast cancer in postmenopausal women that has recurred or progressed after a nonsteroidal aromatase inhibitor.This guidance is not intended to affect the position of patientswhose treatment with everolimus was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop. [https://www.nice.org.uk/guidance/GIDTA10053/documents/appraisalconsultationdocument]July 2013: Not recommended (guidance). NICE's FAD:Everolimus, in combination with exemestane, is not recommended within its marketing authorisation for treating postmenopausal women with advanced human epidermal growth factor receptor 2 (HER2) negative hormonereceptorpositive breast cancer that has recurred or progressed following treatment with a nonsteroidal aromatase inhibitor. [5 July 2013, http://www.nice.org.uk/nicemedia/live/13866/64367/64367.pdf ]April 2013: NICE's preliminary guidance: not recommended. Everolimus, in combination with exemestane, is not recommended within its marketing authorisation for treating postmenopausal women with advanced human epidermal growth factor receptor 2 (HER2) negative hormonereceptorpositive breast cancer that has recurredor progressedfollowing treatment with a nonsteroidal aromatase inhibitor.[NICE, 15 April 2013 http://www.nice.org.uk/guidance/index.jsp?action=article&o=63215 ]@NHS@Updated findings from the BOLERO-2 study presented at SABCS showed treatment with everolimus plus hormonal therapy more than doubled progression-free survival (PFS) to 7.4 months compared to 3.2 months with hormonal therapy alone (hazard ratio=0.44 [95% confidence interval (CI): 0.36 to 0.53]; p<1x10-16) by local investigator assessment. Twelve month estimates of patients without disease progression were 31% and 10% in the everolimus and exemestane, and exemestane-alone arms, respectively. An additional analysis based on an independent central radiology review showed everolimus extended PFS to 11.0 months compared to 4.1 months (hazard ratio=0.36 [95% CI: 0.28 to 0.45]; p<1x10-16)[1].[Novartis, 8 December 2011, http://www.novartis.com/newsroom/media-releases/en/2011/1569858.shtml ]@@@@@COMBO@EVEROLIMUS@EXEMESTANE@@@@EVEROLIMUS|EXEMESTANE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AFINITOR@AROMASIN@@@@AFINITOR|AROMASIN|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@OVERALL SURVIVAL@RESPONSE@SAFETY@@@REFRACTORY@ADVANCED@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@53532.16@@@11@month@11 month@53532.16@53532.16@160@30@1.299@1200@@@@@@@@@@@@16@1@@mg@10@1@@@@@@@@@@@7/28/2017@40@40@2.41E+16@TABLET@GB£@@@@@@@@2.5@MG@2.5 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922248@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@10mg and 40mg IV AS-1411 plus cytarabine versus cytarabine alone@@-@-@-@LONDON, UNITED KINGDOM@@@Aptamers are short pieces of DNA or RNA that can fold into stable, three-dimensional structures capable of interacting with particular target proteins. AS1411 is the first aptamer to be tested as a treatment for cancer. It binds to the protein nucleolin, which is found on the surface of cancer cells. It is then internalised and has been shown to kill cancer cells from a variety of cell lines. The drug has also shown anti-cancer effects in animal models and promising signs of anti-cancer activity in the clinic. AS1411 was originally developed by Dr Paula Bates, Dr John Trent and Prof. Donald Miller at the University of Alabama and then at the University of Louisville. Antisoma added AS1411 to its pipeline when it acquired the Louisville-based company Aptamera Inc. in February 2005.@@14922248@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Aptamera in February 2005. Roche holds options to Antisoma products that entered the clinic before November 2007@-@NCT00512083@70@-@-@@@-@@8/1/2007@-@AS1411-C-201@@-@-@@@II@II@@-@-@Patient enrolment has been completed in the first (‘lower dose') stage of the trial, in which 33 patients were randomly assigned to be treated with either 10 mg/kg/day AS1411 plus cytarabine or cytarabine alone. Among 11 patients who received AS1411 plus cytarabine, one had a complete response (CR) and one had a complete response with incomplete recovery of platelet counts (CRp); a third patient had a ‘cytogenetic response' but had leukaemic blasts remaining. Among five patients who received cytarabine alone, none had a CR, none had a CRp and there were no cytogenetic responses. Patients who did not respond to cytarabine alone could be ‘crossed over' to receive AS1411 plus cytarabine; two of the first five patients crossed over, one of whom showed a 90% reduction in leukaemic blast count after treatment with the combination. SOURCE: Antisoma, 7 July 2008Preclinical data showed that AS1411 killed AML cells with high potency and associated this with down-regulation of the apoptosis-blocking protein Bcl-2. SOURCE: Antisoma/ASH, December 2007@The addition of AS1411 at this dose to cytarabine was well tolerated.@@@@COMBO@-@CYTARABINE@@@@-|CYTARABINE|||@ANTISOMA@@@@@ANTISOMA||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@AS-1411@@@@@AS-1411||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@SAFETY@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16641716@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16641716@Maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.@@NA@@@NO REVIEW@@@@@@MAINTENANCE@@@The recommended starting dose of REVLIMID is 10 mg once daily continuously (Days 128 of repeated 28day cycles) until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, the dose can be increased to 15 mg once daily if tolerated.@FDA, 22 February 2017@2/22/2017@@Yes@@@@@No@@@@@@APPROVED@@@@The current approval was based on two randomized, controlled trials evaluating the efficacy and safety of lenalidomide maintenance therapy for the treatment of multiple myeloma patients after autologous stem cell transplant (CALGB 100104 and IFM 2005-02 trials). These trials demonstrated approximately a 15-month (CALGB) and 18-month (IFM) progression-free survival advantage, at the time of the primary analysis, in patients treated with lenalidomide compared with patients receiving placebo (hazard ratio (HR) in CALGB=0.38; 95% CI: 0.27, 0.54; p<0.001 and HR in IFM=0.50; 95% CI: 0.39, 0.64; p<0.001). The median overall survival was 111 and 106 months for patients treated with lenalidomide compared with 84 and 88 months for patients receiving placebo in the CALGB and IFM trials, respectively.[FDA, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm]@The types, frequency, and severity of adverse events (AEs) observed in the two trials were similar to those previously described in the product label. Neutropenia, affecting 56% of the 517 patients treated with lenalidomide in both trials, was the most frequently reported grade 3/4 AE. An increased incidence of second primary malignancies was reported among patients treated with lenalidomide compared with those receiving placebo. The lenalidomide product label notes an increase in second primary malignancies in patients with multiple myeloma treated with lenalidomide.[FDA, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm]@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@@@@@@1@1@4177123.526@@@38@month@38 month@4177123.53@4177123.53@3614.03@28@1@17014.74@@@@@@@@@@@@243.07@1@30.42@mg@10@1@1@@mg@15@1@@@@@@8/2/2017@607.67@607.67@59572-0402-28@CAPSULE@US$@@@@@@@@2.5@MG@2.5 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917961@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@H02AB02@H02A@YES@CANONSBURG, PENNSYLVANIA@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14917961@Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Haematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anaemia), idiopathic thrombocytopaenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopaenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumour, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Acquired through takeover of Merck Generics.@@@N/A@Adults: Usually, daily oral dosages of 0.5 - 10 mg are sufficient. In some patients higher dosages may be temporarily required to control the disease. Once the disease is under control the dosage should be reduced or tapered off to the lowest suitable level under continuous monitoring and observation of the patient. For a short dexamethasone suppression test, 1mg dexamethasone is given at 11 p.m. and plasma cortisol measured the next morning. Patients who do not show a decrease in cortisol can be exposed to a longer test: 500 micrograms dexamethasone is given at 6 hourly intervals for 48 hours followed by 2mg every 6 hours for a further 48 hours. 24 hour-urine collections are made before, during and at the end of the test for determination of 17-hydroxycorticosteroids. Children: 0.01-0.1mg/kg of body weight daily.@@@@@@@Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity. Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@DEXAMETHASONE ACETATE@@@@@DEXAMETHASONE ACETATE||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Breast Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Breast Cancer||||||@FORTECORTIN@@@@@FORTECORTIN||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1511@1.68@13.11@2.43@@@@@@@@@@0.17@@@@@@@@@@@@@@@@8/1/2017@0.08@0.08@4862431@TABLET@EURO@@@@@@@@0.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920036@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14920036@It is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutics such as Paraplatin and cyclophosphamide. It is also indicated in the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have previously been treated with cisplatin.@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@@Single-Agent therapy; dosage of 360mg/m2 IV on day 1 every 4 weeks to treat recurrent ovarian carcinoma. In general, however, courses should not be repeated until neutrophil and platelet counts are at least 2,000 and 100,000 respectively. In combination with cyclophosphamide (600mg/m2 IV on day 1 every 4 weeks for 6 cycles) for previously untreated patients, 300mg/m2 IV on day every 4 weeks for 6 cycles should be used. Suggested dose adjustments include 125% from prior course if platelet and neutrophil counts are above 100,000 and 2,000 respectively; no adjustment if the counts are 50-100,000 or 500-2,000 respectively; and 75% if they are under 50,000 and 500 respectively.@@@@@@@Bone marrow suppression (leukopaenia, neutropaenia, and thrombocytopaenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during treatment and until recovery is achieved. Median nadir occurs at day 21 in patients receiving single-agent carboplatin. In general, single intermittent courses should not be repeated until leukocyte, neutrophil, and platelet counts have recovered. Since anaemia is cumulative, transfusions may be needed during treatment particularly in patients receiving prolonged therapy. Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial  dosages in these patients should be appropriately reduced and blood counts should be carefully monitored between courses. The use of Paraplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimise additive effects. Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents. It can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics.@LABEL@No@@Advanced ovarian cancer previously treated with chemotherapy@@@III@APPROVED@@@MEDICARE@Carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@8.25@@@@@@@@@@@@0.17@@@@@@@@@@@@@@@@8/2/2017@8.25@8.25@00703-4244-01@INJECTION - 5 ML@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917622@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@H02AB02@H02A@YES@INGELHEIM, GERMANY@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14917622@Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Haematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anaemia), idiopathic thrombocytopaenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopaenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumour, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.@@@@@NO REVIEW@@@@@Roxane is a U.S. subsidiary of Boehringer, acquired by the Germany company in 1978.@@@N/A@Adults: Usually, daily oral dosages of 0.5 - 10 mg are sufficient. In some patients higher dosages may be temporarily required to control the disease. Once the disease is under control the dosage should be reduced or tapered off to the lowest suitable level under continuous monitoring and observation of the patient. For a short dexamethasone suppression test, 1mg dexamethasone is given at 11 p.m. and plasma cortisol measured the next morning. Patients who do not show a decrease in cortisol can be exposed to a longer test: 500 micrograms dexamethasone is given at 6 hourly intervals for 48 hours followed by 2mg every 6 hours for a further 48 hours. 24 hour-urine collections are made before, during and at the end of the test for determination of 17-hydroxycorticosteroids. Children: 0.01-0.1mg/kg of body weight daily.@@@@@@@Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity. Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@DEXAMETHASONE SODIUM PHOSPHATE@@@@@DEXAMETHASONE SODIUM PHOSPHATE||||@BOEHRINGER INGELHEIM@ROXANE@@@@BOEHRINGER INGELHEIM|ROXANE|||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Brain Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Brain Cancer||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@@@@100@1@63.4@@@@@@@@@@@@0.32@@@@@@@@@@@@@@@@9/1/2017@0.63@0.63@00054-4183-25@TABLET@US$@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918794@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@V03AF03@V03A@NO@CANONSBURG, PENNSYLVANIA@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14918794@Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form.@@NO@@@NO REVIEW@@@@@Mylan acquired UDL Labs in March 1996.@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenous injection.@FDA, 01 Jun 1952@6/1/1952@@@@@In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. Leucovorin may be fatal if given intrathecally. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@MYLAN@UDL LABS@@@@MYLAN|UDL LABS|||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@GENERIC@@@@@GENERIC||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1@135.42@@@@@@@@@@@@0.54@@@@@@@@@@@@@@@@8/2/2017@2.71@2.71@51079-0581-06@TABLET@US$@@@@@@@@5@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920080@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX19@L01X@YES@UNITED STATES@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14920080@Camptosar is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.@@NO@@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@Fresenius Kabi has agreed to pay an initial sum of US$3.7 billion to acquire injectable generics specialist APP. Amongst other therapeutic specialities, the U.S. firm has several injectable drugs for oncology. SOURCE: Fresenius, 7 July 2008@SECOND-LINE@@@Once-every-3 week regimen: 350mg/m2 IV over 90 minutes, once every 3 weeks@FDA, 27 February 2008@2/27/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@@@@@APPROVED@@Covered; part B; specialty drug@MEDICARE@@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@APP PHARMACEUTICAL@FRESENIUS KABI@@@@APP PHARMACEUTICAL|FRESENIUS KABI|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@1.75@m²@1383.928@@@3.9@month@3.9 month@1383.93@1383.93@11.67@1@1@16@@@@@@@@@@@@0.4@21@@mg/m²@350@1@@@@@@@@@@@8/2/2017@16@16@63323-0193-02@INJECTION (SINGLE-DOSE) - 2 ML@US$@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923192@Onco@@@@@300f1010ntsdm@@@@@@Tamoxifen compared to ovarian ablation@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14923192@Adjuvant treatment of oestrogen-receptor positive early breast cancer; treatment of oestrogen-receptor positive locally advanced or metastatic breast cancer@@NO@@@NO REVIEW@@@@100%@@@@N/A@Adjuvant treatment of breast cancer, Adults (including elderly): The recommended dose is 20mg, given either in divided doses twice daily or as a single dose once daily. The current recommended treatment duration is five years; however the optimum duration has not been established. Treatment of locally advanced or metastatic breast cancer: The recommended dose is 20mg to 40mg, given either in divided doses twice daily or as a single dose once daily.@EMA, August 1999@@@@@@Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen; or within two months of cessation of therapy. A number of secondary primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.@LABEL@No@@@@@III; METASTATIC BREAST CANCER@APPROVED@@@NHS@The objective RR, time to treatment failure, and survival were similar with both treatments. In an overview analysis of survival data from the 3 studies, the hazard ratio for death (tamoxifen/ovarian ablation) was 1.00. Elevated serum and plasma oestrogens have been observed in premenopausal women receiving tamoxifen, but the data from the randomized studies do not suggest an adverse effect of this increase. A limited number of premenopausal patients with disease progression during tamoxifen therapy responded to subsequent ovarian ablation.@@@@@ADJUVANT@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ROSEMONT PHARMACEUTICALS@@@@@ROSEMONT PHARMACEUTICALS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SOLTAMOX@@@@@SOLTAMOX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@METASTATIC@ADVANCED@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@25.91@@29.61@@@@@@@@@@0.09@@@@@@@@@@@@@@@@7/28/2017@25.91@25.91@2.45E+15@ORAL SOLUTION, 150 ML (SUGAR FREE)@GB£@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15412299@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"Dose Escalation Group: MGN1703 + Ipilimumab, Experimental, Participants receive MGN1703 on Days 1, 8, and 15 of all cycles as an injection under the skin. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
Each cycle is 21 days long. Participants receive a total of 4 treatment cycles for a total of 12 weeks on treatment.
MTD Group: MGN1703 (subcutaneously) + Ipilimumab, Experimental, Dose expansion group consists of participants with advanced malignancy and cutaneous or subcutaneous manifestations.
MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
Each cycle is 21 days long.
MTD Group: MGN1703 (intratumoral injection + Ipilimumab, Experimental, Dose expansion group consists of participants with advanced malignancy and cutaneous or or subcutaneous manifestations.
MGN1703 given by intratumoral injection at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
Each cycle is 21 days long.
MTD Post XRT Group: MGN1703 (subcutaneously) + Ipilimumab, Experimental, Dose expansion group consists of participants with advanced malignancy treated with radiation (XRT) within the past 2 weeks.
MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
Each cycle is 21 days long.
"@@@@@BERLIN, GERMANY@3/1/2019@@@@15412299@A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies@Both@@@@@Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle. Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.@@@@@@NCT02668770@60@@@@@@@3/1/2016@@2015-0135@@@1. Patients must have a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist.  2. There is no limit on the number of prior treatment regimens.  3. Patients must be off prior chemotherapy, hormonal therapy, or biological therapy for at least 4 weeks or >3 half-lives whichever comes first. Patients with prostate cancer may continue to receive LHRH agonist (unless orchiectomy has been performed).  4. ECOG performance status </= 2 (Karnofsky >60%).  5. Patients must have adequate organ and marrow function as defined below within 7 days: WBC >/= 2500/mm^3. Absolute neutrophil count (ANC) >/= 1,500/mm^3. Absolute lymphocyte count (ALC) >/= 1,000/mm^3. Hemoglobin >/= 9g/dl. Platelets >/= 75,000/mm^3. Creatinine </= 2.0 x ULN or measured CrCl of >/= 50ml/m^2/1.73 m^2. Total bilirubin </= 2.0 mg/dL (unless previously diagnosed with Gilbert's Syndrome). AST(SGOT)/ALT(SGPT) </= 3 times the institutional upper limit of normal (patients with liver involvement will be allowed </= 5.0 X institutional upper normal limit).  6. Patients must have recovered from toxicity related to prior therapy to at least grade 1 (defined by CTCAE 4.0) or baseline level. Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis by the Principal Investigator.  7. As the effect of these drugs on the developing human fetus is not known, women of child-bearing potential and men must agree to use adequate contraception (abstinence; hormonal or barrier method of birth control) for the study and at least 2 months after completion.  8. Female patient of childbearing potential has a negative serum pregnancy test within 7 days of study enrollment.  9. Patients must be willing and able to review, understand, and provide written consent before study enrollment.  10. Plasma cortisol and adrenocorticotropic hormone (ACTH) levels not consistent with adrenal failure.  11. Measurable disease as defined by irRC or RECIST 1.1 criteria  12. Age >/= 18 years.@@ADULTS@Phase 1@I@@@@@@@@@@MGN1703@@@@@MGN1703||||@MOLOGEN@@@@@MOLOGEN||||@United States@@@@@United States|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@Maximum Tolerated Dose (MTD) of MGN1703 with Ipilimumab@@@@@Tumor Response@@@@@ADVANCED@@@@@NON-RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919485@Onco@@@@@300f1015ntsdm@@@@@@120 mg/m²@@L01DB03@L01D@YES@PARIS, FRANCE@@@Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.@@14919485@Epirubicin is used in the treatment of a range of neoplastic conditions including • Breast, ovarian, gastric, lung and colorectal carcinomas • Malignant lymphomas • Leukaemias • Multiple myeloma. When administered intravesically, epirubicin has been shown to be beneficial in the treatment of • Papillary transitional cell carcinoma of the bladder • Carcinoma-in-situ • Prophylaxis of recurrences after transurethral resection.@@YES@@@NO REVIEW@@@@@Dakota Pharm is a subsidiary of sanofi-aventis.@FIRST-LINE@@716@Conventional dose: When epirubicin is used as a single agent, the recommended dosage in adults is 60-90 mg/m2 body area. Epirubicin should be injected intravenously over 3-5 minutes. The dose should be repeated at 21-day intervals, depending upon the patient's haematomedullary status. If signs of toxicity, including severe neutropenia/neutropenic fever and thrombocytopaenia occur (which could persist at day 21), dose modification or postponement of the subsequent dose may be required.@@@12/1/2007@@@@Occurrence of severe local tissue necrosis if extravasation during administration; intramuscular and subcutaneous routes of administration not allowed; during or after therapy occurrence of severe form of myocardial toxicity; cases of secondary acute myelogenous leukemia and refractory secondary leukaemia reported in patients treated with anthracyclines used in mono or combination therapy with DNA-damaging antineoplastic agents; cases of severe myelosuppression; advice of reduced dosage in patients with impaired hepatic function@MA-5@No@@716 PREMENOPAUSAL AND PERIMENOPAUSAL WITH ONE OR MORE POSITIVE LYMPH NODES: 356 WOMEN RECEIVED A COMBINATION OF CYCLOPHOSPHAMIDE, ELLENCE AND FLUOROURACIL (CEF-120) AND WERE COMPARED TO 360 OTHER WOMEN WHO RECEIVED A COMBINATION OF CYCLOPHOSPHAMIDE, METHO@@@III@APPROVED@@N/A@HAUTE AUTORITÉ DE SANTÉ@CEF regimen showed a longer RFS after 5 years (62% for the CEF regimen and 53% for the CMF regimen - stratified logrank p=0,013) and after 10 years (51% of the CEF regimen and 44% of the CMF regimen - stratified logrank p=0,017 - unstratified logrank p=0,023) and a longer OS after 5 years (77% for the CEF regimen and 70% for the CMF regimen - stratified logrank p=0,043) and after 10 years (61% of the CEF regimen and 57% of the CMF regimen - stratified logrank p=0,100 - unstratified logrank p=0,18) - results based on Kaplan-Meier methods@@@@@COMBO@EPIRUBICIN HYDROCHLORIDE@@@@@EPIRUBICIN HYDROCHLORIDE||||@DAKOTA PHARM@SANOFI-AVENTIS@@@@DAKOTA PHARM|SANOFI-AVENTIS|||@@@@@@|||||||||@Haematological Malignancy@Myeloma@Bladder Cancer@Colorectal Cancer@@Haematological Malignancy|Myeloma|Bladder Cancer|Colorectal Cancer||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RELAPSE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@COMPARATIVE@OPEN-LABEL@MULTI-CENTRE@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9285263T@SOLUTION FOR PERFUSION 100 ML@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916764@Onco@@@@@@@@@@@150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy. [clinicaltrials.gov]@@L01XE03@L01X@-@SAN FRANCISCO, CALIFORNIA@9/1/2010@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14916764@Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]      >> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]      >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]       >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]"@-@NCT00491816@30@-@-@@@-@@7/1/2007@-@OSI3875s@@-@>> Female patient > 18 years of age          >> Histologically proven stage II or III adenocarcinoma of the breast           >> Patients must be candidates for neoadjuvant treatment (tumor size > 2 cm, T2, T3, T4 and/or clinical N1 or N2)           >> Estrogen Receptor negative, Progesterone Receptor negative and HER-2 negative disease (IHC 0 or 1+ and/or FISH negative)              >> Performance status of 2 or better             >> No prior chemotherapy or endocrine therapy@@@II@II@@-@-@Trial registered. [22.06.2007]@-@@@@NEOADJUVANT@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@COMPLETE RESPONSE@@@@@KI-67 CHANGE@TOXICITY@@@@METASTATIC@TRIPLE NEGATIVE@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917847@Onco@@@@@300f1010ntsdm@@@@@@Elitek was administered as an intravenous infusion over 30 minutes once (n=26) or twice (n=1) daily at a dose of 0.20 mg/kg/dose (total daily dose 0.20-0.40 mg/kg/day). Initiation of dosing was permitted at any time between 4 to 48 hours before the start of anti-tumor therapy and could be continued for 5 to 7 days after initiation of anti-tumor therapy. The dose of allopurinol varied according to local institutional practice.@@V03AF07@V03A@YES@PARIS, FRANCE@@@In humans, uric acid is the final step in the catabolic pathway of purines. The acute increase in plasma levels of uric acid subsequent to the lysis of large numbers of malignant cells and during cytoreductive chemotherapy may lead to impairment of renal function and renal failure resulting from the precipitation of crystals of uric acid in renal tubules. Rasburicase is a highly potent uricolytic agent that catalyses enzymatic oxidation of uric acid into allantoin, a water soluble product, easily excreted by the kidneys in the urine. The enzymatic oxidation of uric acid leads to stoichiometric formation of hydrogen peroxide. The increased of hydrogen peroxide over ambient levels can be eliminated by endogenous antioxidants and the only increased risk is for haemolysis in G6PD deficient and inherited anaemia patients.@@14917847@Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in patients with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.@@YES@NO NICE REVIEW@@NO REVIEW@@@@100%@@@@52@The recommended dose for Fasturtec is 0.20 mg/kg/day. Fasturtec is administered as a once daily 30 minute intravenous infusion in 50 ml of a sodium chloride 9 mg/ml (0.9%) solution. The duration of treatment with Fasturtec may be up to 7 days, the exact duration should be based upon adequate monitoring of uric acid levels in plasma and clinical judgment.@EMA, February 2001@@@@@@May cause severe hypersensitivity reactions including anaphylaxis, severe hemolysis when administered to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Elitek use has been associated with methemoglobinaemia.@STUDY 1@No@@52 PEDIATRIC PATIENTS WERE RANDOMISED TO RECEIVE EITHER ELITEK (N=27) OR ALLOPURINOL (N=25). PATIENTS WERE STRATIFIED AT RANDOMIZATION ON THE BASIS OF UNDERLYING MALIGNANT DISEASE (LEUKEMIA OR LYMPHOMA) AND BASELINE SERUM OR PLASMA URIC ACID LEVELS (<8.0@PAEDIATRIC@@@APPROVED@@NO NICE REVIEW@NHS@The uric acid AUC0-96 hr was significantly lower in the Elitek group (128 ± s.e. 14 mg·hr/dL) as compared to the allopurinol group (328 ± s.e. 26 mg·hr/dL).@@@@@MONO@RASBURICASE@@@@@RASBURICASE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@@@@Supportive Care|Haematological Malignancy||||||||@FASTURTEC@@@@@FASTURTEC||||@Detoxifying Agent@Urate Oxidase Enzyme@@@@Detoxifying Agent|Urate Oxidase Enzyme|||@URIC ACID CONCENTRATION@@@@@@@@@@EARLY@@@@@RANDOMISED@OPEN-LABEL@CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@2757.6@2757.6@@1@1.299@347.32@@@@@@@@@@@@46.31@@@@@@@@@@@@@@@@7/28/2017@347.32@347.32@4.85E+15@POWDER AND SOLVENT FOR CONCENTRATE FOR SOLUTION FOR INFUSION, 5 ML@GB£@@@@@@@@7.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15361206@Onco@@@@@300f1018ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361206@Treatment of adults aged 18 years or over with chronic, accelerated or myeloid or  lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior  therapy including imatinib; Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic  leukaemia with resistance or intolerance to prior therapy.@@NO@7-Jul@@Overall survival analysis: The base case analysis of dasatinib versus salvage chemotherapy in Ph+ ALL patients who have failed prior therapy estimated the incremental cost-effectiveness ratio to be in the range $75,000 - $105,000 per additional year of survival.  The base case analysis of dasatinib versus imatinib in Ph+ ALL patients who have failed prior therapy estimated the incremental cost-effectiveness ratio to be between $15,000 - $45,000 per additional year of survival.  Progression free analysis: The base case analysis of dasatinib versus imatinib in Ph+ ALL patients who have failed prior therapy estimated the incremental cost-effectiveness ratio to be between $45,000 - $75,000 per additional year of progression free survival.  The weighted comparative analysis of dasatinib versus salvage chemotherapy and imatinib in Ph+ ALL patients who have failed prior therapy estimated the incremental cost-effectiveness ratio to be between $75,000 - $105,000 per additional year of survival.@@@@@@@@PATIENTS WITH CML OR PH+ ALL RESISTANT TO OR INTOLERANT OF TREATMENT WITH IMATINIB. THE CHRONIC PHASE CML STUDY ENROLLED 186 PATIENTS (CA-180-013/17), THE ACCELERATED PHASE CML STUDY 107 PATIENTS (CA-180-005), AND THE MYELOID BLAST PHASE STUDY 74 PATIENTS (CA-180-006)@The recommended starting dosage for chronic phase CML is 100 mg once daily, administered orally, consistently either in the morning or in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@@@@@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-005/006/013/017@No@@PATIENTS WITH CML OR PH+ ALL RESISTANT TO OR INTOLERANT OF TREATMENT WITH IMATINIB. THE CHRONIC PHASE CML STUDY ENROLLED 186 PATIENTS (CA-180-013/17), THE ACCELERATED PHASE CML STUDY 107 PATIENTS (CA-180-005), AND THE MYELOID BLAST PHASE STUDY 74 PATIENTS (CA-180-006)@@@II@APPROVED@@>>The PBAC recommended the listing of dasatinib on the PBS for the treatment of patients with acute lymphoblastic leukaemia, expressing the Philadelphia chromosome or the transcript bcr-abl kinase, who are resistant to, or whose disease has relapsed on, prior therapy. [PBAC http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-dasatinib-sprycel-july07 ]@PBS@In chronic phase CML patients, the MCyR rate was 45% with a complete response (0% Ph+ cells) rate of 33%.@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@72049.80404@@@11@month@11 month@72049.8@72049.8@215.35@30@0.779@4614.57@4761.44@4684.51@@@@@@@@@@1.54@1@@mg@140@1@@@@@@@@@@@8/1/2017@153.82@153.82@3139-0614-GE-BQ@TABLET@A$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16614845@Onco@@@@@300f1010ntsdm@@@@@@Experimental: Ibrance + Letrozole. Ibrance, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).Active Comparator: Placebo + Letrozole Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).@@L01XE33@L01X@@NEW YORK, NEW YORK@2/1/2016@@@@16614845@IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.@Female@Yes@@@NO REVIEW@@@@@@@NCT01740427@650@The recommended dose is 125 mg of palbociclib once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days. The treatment withIBRANCE should be continued as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.When coadministered with palbociclib, the recommended dose of letrozole is 2.5 mg taken orally once daily continuously throughout the 28-day cycle. Please refer to the Summary of ProductCharacteristics of letrozole. Treatment of pre/perimenopausal women with the combination of palbociclib plus letrozole should always be combined with an LHRH agonist.@EMA, 9 November 2016@11/9/2016@@No@@2/1/2013@@A5481008, 2012-004601-27@No@@Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy; Confirmed diagnosis of ER positive breast cancer; No prior systemic anti-cancer therapy for advanced ER+ disease; Postmenopausal women; Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease; Eastern Cooperative Oncology Group [ECOG] 0-2; Adequate organ and marrow function; Patient must agree to provide tumor tissue@@ADULTS@Phase 3@APPROVED@@@NHS@@@@@@COMBO@PALBOCICLIB@LETROZOLE@@@@PALBOCICLIB|LETROZOLE|||@PFIZER@@@@@PFIZER||||@World@@@@@World|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@IBRANCE@GENERIC@@@@IBRANCE|GENERIC|||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@PROBABILITY OF PARTICIPANT SURVIVAL@OVERALL SURVIVAL@DURATION OF RESPONSE@@@ADVANCED@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@1@99340.82795@@@24.8@month@24.8 month@99340.83@99340.83@131.7@21@1.299@2950@@@@@@@@@@@@1.4@28@@mg@125@21@@@@@@@@@@@7/28/2017@140.48@140.48@3.37E+16@HARD CAPSULE@GB£@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919382@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@MUMBAI, INDIA@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919382@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@-@@NO REVIEW@@@@100%@-@-@-@-@First-line chemotherapy of breast carcinoma: When used in combination with doxorubicin (50 mg/m2), paclitaxel should be administered 24 hours after doxorubicin. The recommended dose of paclitaxel is 220 mg/m2 administered intravenously over a period of 3 hours, with a 3-week interval between course@6-Jul@@@-@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@-@NHS@NO LABELLED TRIAL@-@@@@-@PACLITAXEL@@@@@PACLITAXEL||||@WOCKHARDT@@@@@WOCKHARDT||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@1@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@12/29/2014@@@1.06E+16@CONC. INTRAVENOUS INFUSION 16.7 ML@GB£@@@@@@@@100.2@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916590@Onco@@@@@300f1015ntsdm@@@@@@Anzemet was administered intravenously at a dose of 1.8 mg/kg ; ondansetron was administered intravenously at a single dose of 32 mg@@A04AA04@A04A@NO@PARIS, FRANCE@@@Dolasetron mesilate and its major metabolite are selective serotonin 5-HT3 antagonists. The precise mode of action as an antiemetic is not known. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and are centrally located in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin can then activate 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. The effect of Anzemet in the management of cancer therapy induced nausea and vomiting is due to antagonism of 5-HT3 receptors on neurons either peripherally and/or centrally located.@@14916590@Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high dose cisplatin;  the prevention of postoperative nausea and vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, Anzemet Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low; the treatment of postoperative nausea and/or vomiting.@@YES@@@NO REVIEW@@@@@@@@609@Prevention of CINV: For adults, the recommended intravenous dosage of Anzemet Injection is 1.8 mg/kg given as a single dose approximately 30 minutes before chemotherapy. Alternatively, for most patients, a fixed dose of 100 mg can be administered over 30 seconds. The recommended intravenous dosage in pediatric patients 2 to 16 years of age is 1.8 mg/kg given as a single dose approximately 30 minutes before chemotherapy, up to a maximum of 100 mg. Prevention or Treatment of Postoperative Nausea and/or Vomiting: For adults, the recommended intravenous dosage of Anzemet Injection is 12.5 mg given as a single dose approximately 15 minutes before the cessation of anaesthesia (prevention) or as soon as nausea or vomiting presents (treatment). The recommended intravenous dosage in pediatric patients 2 to 16 years of age is 0.35 mg/kg, with a maximum dose of 12.5 mg, given as a single dose approximately 15 minutes before the cessation of anesthesia or as soon as nausea or vomiting presents.@Apr-97@@@@@@Anzemet can cause ECG interval changes, interval prolongation that could lead to cardiovascular consequences, including heart block or cardiac arrhythmias, cardiac conduction abnormality observed on an intra-operative cardiac rhythm monitor.@@No@@609 ADULT CANCER PATIENTS RECEIVING >70 MG/M2  CISPLATIN WERE RANDOMISED TO 2 ARMS TO COMPARE SINGLE INTRAVENOUS DOSES OF ANZEMET INJECTION WITH ONDANSETRON@@@CLINICAL STUDIES / PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / CISPLATIN BASED CHEMOTHERAPY/ STUDY 2@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@Anzemet Injection was shown to be equivalent to ondansetron  (44% for arm 1 treated with Anzemet vs 43% for arm 2 with ondansetron; nausea score for arm 1 = 10 vs 16 for arm 2)@@@@@MONO@DOLASETRON MESYLATE@@@@@DOLASETRON MESYLATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@ANZEMET@@@@@ANZEMET||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@@@@@@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+12@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16749460@Onco@@@@@300f1012ntsdm@@@@@@@@L01XC02@L01X@@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@16749460@Maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008Genentech opted-in in Q3 2006@FIRST-LINE@@1193@The recommended dose of MabThera used as a maintenance treatment for patients with previously untreated follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 2 months (starting 2 months after the last dose of induction therapy) until disease progression or for a maximum period of two years.@EMA, 25 October 2010@10/25/2010@@No@@@@@No@>> Sanofi-Aventis files litigation proceedings against Biogen and Genentech over patent infringement after Genentech ceased licensing deal with Sanofi-Aventis. [sanofi-aventis, 5.11.2008]    >> Patent Expiration: 2018@@@@III@APPROVED@@@GKV@@@@@@MAINTENANCE@RITUXIMAB@@@@@RITUXIMAB||||@ROCHE@GENENTECH@@@@ROCHE|GENENTECH|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MABTHERA@@@@@MABTHERA||||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@@@@@@@@@@@@@@@@PROSPECTIVE@OPEN-LABEL@MULTI-CENTER@@@1.75@m²@25536.24425@@@2@year@2 year@25536.24@25536.24@34.98@1@1.1511@1621.26@2044.49@1659.76@@@@@@@@@@3.24@60.83@@mg/m²@375@1@@@@@@@@@@@8/1/2017@1621.26@1621.26@8709904@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL) - 50 ML@EURO@@@@@@@@500@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917279@Onco@@@@@300f1010ntsdm@@@@@@Patients are stratified according to complete remission (first vs subsequent). Patients are randomized to one of two treatment arms. Arm I: Following consolidation chemotherapy or autologous stem cell transplantation, patients receive interleukin-2 subcutaneously followed by histamine dihydrochloride subcutaneously over 5-7 minutes twice daily on days 1-21. Treatment repeats every 6 weeks for 3 courses and then every 9 weeks for 7 courses in the absence of disease relapse or unacceptable toxicity. Arm II: Patients receive no further therapy following consolidation chemotherapy or autologous stem cell transplantation. Quality of life is assessed prior to study, and at visits 6, 7, 10, 11, 16, 17, and 22. Patients are followed for relapse and survival every 3 months for 2.5 years.@@L03AX14@L03A@-@@@@Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is based on the naturally occurring molecule histamine, and is designed to prevent or inhibit oxidative stress, thus protecting critical immune cells.  Research has demonstrated that oxidative stress suppresses the immune system's ability to destroy cancer cells, including malignant AML cells.@@14917279@Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60.@@NO@@@NO REVIEW@@@@100%@Acquired through takeover of Maxim Pharmaceuticals in January 2006.@@NCT00003991@360@IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of Ceplene; each dose of IL-2 is 16 400 IU/kg. Ceplene 0.5 ml solution is sufficient for a single dose. Ceplene is administered 1 to 3 minutes after each injection of IL-2. Each 0.5 ml Ceplene dose is injected slowly, over 5-15 minutes. >> Treatment cycles: Ceplene and IL-2 are administered for 10 treatment cycles: each cycle consists of a treatment period of 21 days (3 weeks) followed by a three-week or six-week treatment-free period. For cycles 1-3, each cycle consists of 3 weeks of treatment, followed by a 3-week treatment free period. For cycles 4-10, each cycle consists of 3 weeks of treatment, followed by a 6-week treatmentfree period.@EMA, 10 October 2008@10/10/2008@@Yes@@7/1/1998@Ceplene should be administered 1 to 3 minutes after IL-2 administration, and not concomitantly. Rapid subcutaneous injection or injection into a vascular space may result in severe hypotension, tachycardia, or syncope. Treatment with Ceplene in conjunction with IL-2 should be used with caution in patients with poorly compensated cardiac function. Patients with cardiac disease should be evaluated for ventricular ejection fraction and wall function by echocardiography or nuclear medicine stress test and then treated with caution.@MAXIM-MP-MA-0201@No@2018 [Orphan exclusivity]@@@@III@APPROVED@@@NHS@EpiCept released new data that confirm that leukemia-free survival (LFS) is a valid surrogate endpoint for overall survival (OS) in Acute Myeloid Leukemia (AML) patients in complete remission. The data were derived from the pivotal 320 patient, Phase III trial for Ceplene, which met its primary endpoint of increased LFS (p less than 0.01) among AML patients in their first remission. By performing a weighted linear regression analysis between estimates of LFS and OS at specific time points and between the estimated effects of Ceplene with IL-2 on LFS and OS, researchers found a high correlation between the country-specific Kaplan-Meier estimates of 24-month LFS and 36-month OS in both treated and untreated groups (R(2) = 0.71; P=0.0002). Similar correlations were also found between 24-month LFS and 48-month and 60-month OS. In addition, country-specific hazard ratios demonstrated that the treatment effect of Ceplene with IL-2 on LFS and OS were found to be highly correlated (R(2) = 0.84; P=0.004). [EpiCept/EHA, 12 June 2008]        ASH December 2007; the median leukaemia-free survival (LFS) of AML patients in first remission was 15 months for the Ceplene + IL-2 group versus 9.7 months in the control group (P=0.025). A Kaplan-Meier five-year estimate was supportive of the effect of Ceplene + IL-2 in maintaining LFS. In the AML population in first remission, this effect was shown in 34% of the treatment group versus 22 percent of the control group (P=0.024). Further, the median duration of the overall survival rate in the first remission patient group was 44 months for the Ceplene + IL-2 group versus 29 months for the control group, an improvement of 15 months. The Kaplan-Meier estimate analysis of patients alive at five years show a strong trend in favor of Ceplene + IL-2 (Kaplan-Meier, P=0.07), even though the trial was not initially powered to demonstrate a benefit in overall survival. These results were both durable and statistically significant.@@@@@@HISTAMINE DIHYDROCHLORIDE@@@@@HISTAMINE DIHYDROCHLORIDE||||@EPICEPT@@@@@EPICEPT||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@CEPLENE@@@@@CEPLENE||||@Other@@@@@Other||||@DISEASE-FREE SURVIVAL@RELAPSE RATE@OVERALL SURVIVAL@QUALITY OF LIFE@@OVERALL SURVIVAL@QUALITY OF LIFE@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.2961@73.83@@84.38@@@@@@@@@@147.66@@@@@@@@@@@@@@@@8/21/2017@73.83@73.83@UK_BNF_1073816522@SOLUTION FOR INJECTION, 0.5 ML@GB£@@@@@@@@0.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923315@Onco@@@@@300f1012ntsdm@@@@@@Patients received 50 mg Sutent on Schedule 4/2.Therapy was continued until the patients met withdrawal criteria or had progressive disease.@@L01XE04@L01X@NO@NEW YORK, NEW YORK@8/1/2004@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14923315@Gastrointestinal Stromal Tumor GIST: indicated for the treatment of GIST after disease progression on or intolerance to imatinib mesylate.  Advanced Renal Cell Carcinoma: indicated for the treatment of advanced renal cell carcinoma.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@SECOND-LINE@NCT00054886@63@The recommended dose for GIST and advanced RCC is one 50 mg oral dose taken once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2).@EMA, 19 July 2006@7/19/2006@@Yes@@1/1/2003@Pregnancy: inhibition of angiogenesis following administration of Sutent should be expected to result in adverse effects on pregnancy. Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant. Left Ventricular Dysfunction: In the presence of clinical manifestations of congestive heart failure (CHF), discontinuation of Sutent is recommended. The dose should be interrupted and/or reduced in patients without clinical evidence of CHF but with an ejection fraction <50% and >20% below baseline. QT Interval Prolongation and Torsade de Pointes: Sutent has been shown to prolong the QT interval in a dose dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Hypertension. Haemorrhagic Events: Tumour-related haemorrhage has been observed in patients treated with Sutent. Serious, sometimes fatal gastrointestinal complications including gastrointestinal perforation have occurred rarely in patients with intraabdominal malignancies treated with Sutent. Hypothyroidism.@RTKC-0511-014@No@@Patients can not have had prior treatment with any systemic therapy other than 1 prior cytokine-based treatment regimen or prior surgical resection of or irradiation to the only site of measurable disease.@@@II@APPROVED@@NO REVIEW@GKV@Twenty-five (40%) of 63 patients treated with SU11248 achieved partial responses; 17 additional patients (27%) demonstrated stable disease lasting  3 months. Median time to progression in the 63 patients was 8.7 months. Dosing was generally tolerated with manageable toxicities [Journal of Clinical Oncology, Vol 24, No 1 (January 1), 2006: pp. 16-24]@Median duration of blinded study treatment was two cycles for patients on Sutent (mean 3.0, range 1-9) and one cycle (mean 1.8, range 1-6) for patients on placebo. Dose reductions occurred in 23 patients (11%) on Sutent and none on placebo. Dose interruptions occurred in 59 patients (29%) on Sutent and 31 patients (30%) on placebo. The rates of treatment-emergent, non-fatal adverse reactions resulting in permanent discontinuation were 7% and 6% in the Sutent and placebo groups, respectively. Most treatment-emergent adverse reactions in both study arms were Grade 1 or 2 in severity. Grade 3 or 4 treatment-emergent adverse reactions were reported in 56% versus 51% of patients on Sutent versus placebo, respectively. Table 1 compares the incidence of common (=10%) treatment-emergent adverse reactions for patients receiving Sutent and reported more commonly in patients receiving Sutent than in patients receiving placebo.@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@RESPONSE RATE@@@@@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@2956.51@3681.11@2995.01@@@@@@@@@@3.94@@@@@@@@@@@@@@@@8/1/2017@98.55@98.55@4991140@HARD CAPSULE@EURO@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16061311@Onco@@@@@300f1037ntsdm@@@@@@Hycamtin was administered at a dose of 0.75 mg/m2/day IV over 30 minutes × 3 consecutive days starting on day 1 of a 21-day course in in combination with cisplatin (50 mg/m2 on day 1). Alone, cisplatin was administered at a dose of 50 mg/m2 IV on day 1 of a 21-day course.@@L01XX17@L01X@YES@BRENTFORD, UNITED KINGDOM@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@16061311@Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.@@YES@@@NO REVIEW@@@@@Merck KGaA licensed marketing and sales rights from SmithKline Beecham in June 2000 for the U.K. only.@SECOND-LINE@@147@Cervical Carcinoma: Initial dose- The recommended dose of topotecan is 0.75 mg/m2/day administered as 30 minute intravenous infusion daily on days 1, 2 and 3. Cisplatin is administered as an intravenous infusion on day 1 at a dose of 50 mg/m2/day and following the topotecan dose. This treatment schedule is repeated every 21 days for 6 courses or until progressive disease. Subsequent doses- Topotecan should not be re-administered unless the neutrophil count is more than or equal to 1.5 x 109/l, the platelet count is more than or equal to 100 x 109/l, and the haemoglobin level is more than or equal to 9g/dl (after transfusion if necessary). Patients who experience febrile neutropenia (neutrophil count less than 1 x 109/l with a temperature of 38°C or above) are recommended to have the dose of topotecan reduced by 20% to 0.60 mg/m2/day for subsequent courses.@1-Nov-96@11/1/1996@@@@@Bone marrow suppression (primarily neutropaenia) is the dose-limiting toxicity of Hycamtin. Cases of neutropenia, thrombocytopaenia and anaemia were reported. Hycamtin may cause fetal harm when administered to a pregnant woman.@LABEL@No@@147 ELIGIBLE WOMEN WERE RANDOMISED TO HYCAMTIN  PLUS CISPLATIN AND 146 ELIGIBLE WOMEN WERE RANDOMISED TO CISPLATIN. ALL PATIENTS HAD HISTOLOGICALLY CONFIRMED STAGE IV-B, RECURRENT, OR PERSISTENT CARCINOMA OF THE CERVIX CONSIDERED NOT AMENABLE TO CURATIVE@@@@APPROVED@@NO REVIEW@SNS@Median survival of eligible patients in the Hycamtin plus cisplatin treatment arm was 9.4 months (95% CI: 7.9 to 11.9) compared to 6.5 months (95% CI: 5.8 to 8.8) among patients randomised to cisplatin alone with a log rank p-value of 0.033 (significance level was 0.044 after adjusting for the interim analysis). The unadjusted hazard ratio for OS was 0.76 (95% CI: 0.59 to 0.98).@@@@@COMBO@TOPOTECAN HYDROCHLORIDE@CISPLATIN@@@@TOPOTECAN HYDROCHLORIDE|CISPLATIN|||@GSK@@@@@GSK||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@HYCAMTIN@@@@@HYCAMTIN||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@COMPARATIVE@RANDOMISED@@@@1.75@m²@924.44625@@@126@day@126 day@924.45@924.45@7.34@10@1.1511@391.3@459.9@398.84@@@@@@@@@@39.13@21@@mg/m²@0.75@3@@@@@@@@@@@8/4/2017@39.13@39.13@660763@CAPSULE@EURO@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15048227@Onco@@@@@300f1015ntsdm@@@@@@Experimental rm A:axitinib will be given at a starting dose of 5 mg twice daily [BID] with continuous dosingComparator: sorafenib will be given at a dose of 400 mg twice daily [BID] with continuous dosing@@L01XE17@L01X@-@NEW YORK, NEW YORK@7/1/2015@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth.@@15048227@INLYTA is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC) when one prior drug treatment for this disease has not worked or has stopped working.@@NO@@@NO REVIEW@@@@@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@SECOND-LINE@NCT00678392@723@The starting dose is 5 mg orally twice daily. Dose adjustments can  be made based on individual safety and tolerability.@EMA, 4 September 2012@9/4/2012@10/24/2012@@@9/1/2008@@AXIS@No@@@@@III@APPROVED@@ASMR IV, 9 January 2013@HAUTE AUTORITÉ DE SANTÉ@registrational Phase 3 AXIS trial, INLYTA significantly extended PFS with a median PFS of 6.7 months as compared to 4.7 months for those treated with sorafenib. The differences in PFS observed in the subgroups in the AXIS trial favored INLYTA over sorafenib, including in the ECOG PS 0 and ECOG PS 1 subgroups. [Pfizer, 17 October 2012 http://press.pfizer.com/press-release/pfizer-announces-top-line-results-phase-3-trial-inlyta-axitinib-treatment-naive-patien]Trial registered [Pfizer 12 March 2008]@@@@@MONO@AXITINIB@@@@@AXITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@INLYTA@@@@@INLYTA||||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@OBJECTIVE RESPONSE@@@@METASTATIC@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@1@1@25439.9424@@@6.8@month@6.8 month@25439.94@25439.94@123@56@1.1511@688.8@783.74@718.8@@@@@@@@@@12.3@1@@mg@10@1@@@@@@@@@@@8/1/2017@12.3@12.3@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916128@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@110mg 3x/week in 4-week cycles. The median number of cycles received to date is 2 (range: 1-4).@@-@-@-@MONTREAL, CANADA@@@MGCD0103 is a rationally designed, oral, isoform-specific, small molecule HDAC inhibitor which has been designed to be a molecular-targeted cancer therapy. MethylGene has measured surrogate markers of MGCD0103 action, such as changes in histone deacetylase activity in white blood cells from treated patients and obtaining tumour biopsies when possible from patients before, during and after treatment. Histone acetylation is a molecular marker for monitoring drug effect (pharmacodynamics) and for development of pharmacogenomic and diagnostic applications. MGCD0103 inhibits a specific subset of HDAC isoforms. Using functional genomics, MethylGene has identified the specific HDAC isoforms which it believes plays a major role in cancer and it uses this information to rationally design and develop isoform-selective inhibitors to target these isoforms. @@14916128@-@@-@-@@NO REVIEW@@@@-@>> MethylGene announced that Celgene has terminated their licensing agreement for oncology histone deacetylase (HDAC) inhibitors, including MGCD0103. MethylGene will reacquire all rights to MGCD0103 and other HDAC and sirtuin inhibitors in territories licensed to Celgene including North America and the European Union. [MethylGene, 27.10.2008]      >> In January 2006, Pharmion licensed R&D, development and commercialisation rights of MethlyGene's HDACs in North America, Europe, Middle East and certain other markets.@SECOND-LINE@-@12 TO 35@-@-@@@EMEA ORPHAN DRUG STATUS RECOMMMENDED FOR HODGKIN'S IN JULY 2007@@@-@TRIAL 010@@-@PATIENTS PREVIOUSLY TREATED WITH AUTOLOGOUS AND/OR ALLOGENEIC STEM CELL TRANSPLANT.@@@II@CLINICAL HOLD@@-@-@FDA clinical hold. SOURCE: MethylGene, 18 August 2008To date, 23 patients are enrolled in the 110mg cohort of whom 20 are evaluable for efficacy. In the 85mg cohort, 15 patients are currently enrolled and 10 are evaluable for efficacy. Data for the 110mg cohort showed eight patients with objective responses [two complete responses (CR) and six partial responses (PR)], resulting in a 35 percent objective response rate for all enrolled patients in this cohort. Tumor shrinkage was observed in 17 of 20 evaluable patients (85 percent) who had a CT scan. The median duration on study for all enrolled patients was four cycles. The two patients experiencing CRs completed 12 cycles of therapy and came off therapy as per protocol. The median duration of therapy for responders was six cycles. SOURCE: Methylgene/ASCO, 2 June 2008Interim data. CR and PR of 40% and a disease control rate of 45%. 75% of patients experienced a reduction in tumour size, with 60% experiencing a tumor reduction of greater than 30%. 7 pts have completed 2 cycles of therapy and are evaluable; 5 of these had tumour reduction ranging between 21% and 70% by CT, which is associated with a significant reduction in FDG-PET activity in 4 pts. 5 have had dose reductions/discontinuations due to mucositis, fatigue/nausea/diarrhoea, fatigue and pancreatitis/hypotension. Significant HDAC inhibition (>20% of total activity), was seen in PBMCs from 7/9 pts with samples. Treatment is ongoing in 14 pts; including those with tumour reduction. Criteria has been met to expand to 2nd stage of the study. SOURCE: Methylgene, ASCO 2007@The two patients experiencing CRs completed 12 cycles of therapy and came off therapy as per protocol. The median duration of therapy for responders was six cycles. The most common Grade 3 or greater toxicities at this starting dose level were thrombocytopenia (17 percent), pneumonia (17 percent), fatigue (17 percent) and neutropenia (17 percent).@@@@MONO@-@@@@@-||||@METHYLGENE@@@@@METHYLGENE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MGCD-0103@@@@@MGCD-0103||||@HDAC@@@@@HDAC||||@RESPONSE RATE@STABLE DISEASE@@@@@@@@@RELAPSED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919939@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@H02AB07@H02A@NO@@@@Prednisolone acetate is a synthetic adrenocorticoid with the general properties of prednisolone. Adrenocorticoids diffuse across cell membranes to complex with cytoplasmic receptors and subsequently stimulate synthesis of enzymes with anti-inflammatory effects. Glucocorticoids inhibit the oedema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation, deposition of collagen and scar formation. Prednisolone acetate has, on a weight to weight basis, a potency three to five times that of hydrocortisone.@@14919939@Indicated in the following conditions: Endocrine Disorders [Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcernia associated with cancer Nonsuppurative thyroiditis)] Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) [Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis] Collagen Diseases [During an exacerbation or as maintenance therapy in selected  cases of: Systemic lupus erythematosus Systemic-dermatomyositis (polymyositis) Acute rheumatic carditis] Dermatologic Diseases [Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis] Allergic States [Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions] Ophthalmic Diseases [Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic cornea marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis] Respiratory Diseases [Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis] Haematologic Disorders [Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopaenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia] Neoplastic Diseases For palliative management of: [Leukemias and lymphomas in adults Acute leukemia of childhood] Edematous States [To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis] Nervous System [Acute exacerbations of multiple sclerosis] Miscellaneous [Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement]@@NO@@@NO REVIEW@@@@@@@@@The initial dosage may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required.@@@@@@@In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination With other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@PREDNISONE@@@@@PREDNISONE||||@QUALITEST@@@@@QUALITEST||||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@48@1@34.5@@@@@@@@@@@@0.07@@@@@@@@@@@@@@@@8/2/2017@0.72@0.72@00603-5338-31@TABLET@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923926@Onco@@@@@300f1008ntsdm@@@@@@198 patients who received combination irinotecan/ infusional 5-FU/LV therapy given weekly were compared with 187 patients who received an infusional regimen of 5-FU/LV alone given daily for 5 days every 4 weeks.@@L01XX19@L01X@YES@@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14923926@Campto is indicated for the treatment of patients with advanced colorectal cancer: • in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, • as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.  Campto in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Campto in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Licensing deal between Daiichi and Yakult terminated upon expiration of patent. The two companies will independently pursure their irinotecan businesses. [Daiichi Saynko, 17.09.2007]@FIRST-LINE@@385@Regimen 1: 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43): Weekly Camptosar 125mg/m2 IV over 90 minutes on days 1, 8, 15 and 22, followed by 100mg/m2 on week 5 and 75mg/m2 on week 6@@@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR THE RECTUM RANDOMISED IN 2 ARMS. CONCOMITANT MEDICATIONS SUCH AS ANTIEMETICS, ATROPINE, AND LOPERAMIDE WERE GIVEN TO PATIENTS FOR PROPHYLAXIS AND/OR MANAGEMENT OF SYMPTOMS FROM TREATMENT. PATIENTS ALS@@@STUDY 2 OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FU/LV FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER@APPROVED@@@NHI@The combination of irinotecan/ infusional 5-FU/LV therapy resulted in significant improvements in objective tumour RRs (35% vs 22% p<0.005), TTP (6.7 months vs 4.4 months p=0.001), and survival (17.4 months vs 14.1 months p<0.05) when compared with infusional 5-FU/LV alone.@@@@@COMBO@IRINOTECAN@LEUCOVORIN@FLUOURACIL@@@IRINOTECAN|LEUCOVORIN|FLUOURACIL||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@TOPOTECIN@5-FU@@@@TOPOTECIN|5-FU|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@@@@@@ADVANCED@@@@@RANDOMISED@CONTROLLED@INTERNATIONAL@@@@@Invalid Dosage Value Phase 1@@@5.5@month@5.5 month@714422.22@714422.22@4270.61@1@0.0091@3880.45@4576@@@@@@@@@@@97.01@@@@@@@@@@@@@@@@8/30/2017@3880.45@3880.45@4240404A1091@INTRAVENOUS  INFUSION@YEN@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14916955@Onco@@@@@300f1008ntsdm@@@@@@Patients received either exemestane (25 mg/day) or tamoxifen (20 or 30 mg/day)@@L02BG06@L02B@NO@NEW YORK, NEW YORK@@@Exemestane is an irreversible, steroidal aromatase inhibitor, structurally related to the natural substrate androstenedione. In post-menopausal women, oestrogens are produced primarily from the conversion of androgens into oestrogens through the aromatase enzyme in peripheral tissues. Oestrogen deprivation through aromatase inhibition is an effective and selective treatment for hormone dependent breast cancer in postmenopausal women. In postmenopausal women, Aromasin p.o. significantly lowered serum oestrogen concentrations starting from a 5 mg dose, reaching maximal suppression (>90%) with a dose of 10-25 mg. In postmenopausal breast cancer patients treated with the 25 mg daily dose, whole body aromatization was reduced by 98%. Exemestane does not possess any progestogenic or oestrogenic activity. A slight androgenic activity, probably due to the 17-hydro derivative, has been observed mainly at high doses. In multiple daily doses trials, Aromasin had no detectable effects on adrenal biosynthesis of cortisol or aldosterone, measured before or after ACTH challenge, thus demonstrating its selectivity with regard to the other enzymes involved in the steroidogenic pathway. Glucocorticoid or mineralocorticoid replacements are therefore not needed. A non dose-dependent slight increase in serum LH and FSH levels has been observed even at low doses: this effect is, however, expected for the pharmacological class and is probably the result of feedback at the pituitary level due to the reduction in oestrogen levels that stimulate the pituitary secretion of gonadotropins also in postmenopausal women.@@14916955@Adjuvant treatment of postmenopausal women with estrogenreceptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy; the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@@4724@The recommended dose of Aromasin in early and advanced breast cancer is one 25 mg tablet once daily after a meal. In postmenopausal women with early breast cancer who have been treated with 2–3 years of tamoxifen, treatment with Aromasin should continue in the absence of recurrence or contralateral breast cancer until completion of five years of adjuvant endocrine therapy. For patients with advanced breast cancer, treatment should continue until tumour progression is evident. For patients receiving Aromasin with a potent CYP 3A4 inducer such as rifampicin or phenytoin, the recommended dose is 50 mg once daily after a meal.@@@@@@@Aromasin Tablets may cause fetal harm when administered to a pregnant woman.@IES@No@@4724 PATIENTS WHO REMAINED DISEASE-FREE AFTER RECEIVING ADJUVANT TAMOXIFEN THERAPY FOR 2 TO 3 YEARS WERE RANDOMISED TO RECEIVE 3 TO 2 YEARS OF AROMASIN (2352 PATIENTS) OR TAMOXIFEN (2372 PATIENTS) TO COMPLETE A TOTAL OF 5 YEARS OF HORMONAL THERAPY.@@@ADJUVANT TREATMENT IN EARLY BREAST CANCER: THE INTERGROUP EXEMESTANE STUDY 031 (IES); RANDOMISED, DOUBLE-BLIND, MULTICENTRE, MULTINATIONAL STUDY COMPARING EXEMESTANE TO TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER.@APPROVED@@@NHI@Overall survival was not significantly different in the 2 groups, with 116 deaths occurring in the Aromasin group and 137 in the tamoxifen group.@@@@@ADJUVANT@EXEMESTANE@@@@@EXEMESTANE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AROMASIN@@@@@AROMASIN||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@OVERALL SURVIVAL@@@@@@@@@@EARLY@@@@@RANDOMISED@DOUBLE-BLIND@MULTI-CENTRE@@@@@Invalid Dosage Value Phase 1@@@27@month@27 month@945.36@945.36@1.15@1@0.0091@366.59@432.3@@@@@@@@@@@14.66@@@@@@@@@@@@@@@@8/30/2017@366.59@366.59@4291012F1022@TABLETS@YEN@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921232@Onco@@@@@300f1012ntsdm@@@@@@Two phase titration (2-16 weeks, b=10) and maintenance (16-48 weeks, n=3) trial- Sensipar 70mg twice daily to 90mg 4 times daily in maintenance.@@H05BX01@H05B@NO@THOUSAND OAKS, CALIFORNIA@@@The calcium sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH secretion. Cinacalcet is a calcimimetic agent which directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels@@14921232@Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma.@@NO@6-Jun@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@13@Parathyroid Carcinoma: The recommended starting dose of Mimpara for adults is 30 mg twice per day. The dosage of Mimpara should be titrated every 2 to 4 weeks through sequential doses of 30 mg twice daily, 60 mg twice daily, 90 mg twice daily, and 90 mg three or four times daily as necessary to reduce serum calcium concentration to or below the upper limit of normal. The maximum dose used in clinical trials was 90 mg four times daily. Serum calcium should be measured within 1 week after initiation or dose adjustment of Mimpara. Once maintenance dose levels have been established, serum calcium should be measured every 2 to 3 months. After titration to the maximum dose of Mimpara, serum calcium should be periodically monitored; if clinically relevant reductions in serum calcium are not maintained, discontinuation of Mimpara therapy should be considered.@@@@@@@In three clinical studies of CKD patients on dialysis, 5% of the patients in both the Sensipar and placebo groups reported a history of seizure disorder at baseline. During the trials, seizures (primarily generalized or tonic-clonic) were observed in 1.4% (9/656) of Sensipar-treated patients and 0.4% (2/470) of placebo-treated patients. 5 of the 9 Sensipar-treated patients had a history of a seizure disorder and two were receiving anti-seizure medication at the time of their seizure. Both placebo-treated patients had a history of seizure disorder and were receiving anti-seizure medication at the time of their seizure. While the basis for the reported difference in seizure rate is not clear, the threshold for seizures is lowered by significant reductions in serum calcium levels. Therefore, serum calcium levels should be closely monitored in patients receiving Sensipar, particularly in patients with a history of a seizure disorder@LABEL@No@@@@@III; PARATHYROID CARCINOMA@APPROVED@@@GKV@Baseline mean (SD) serum calcium was 14.7 (1.8) mg/dL. The range of change from baseline to last measurement was –7.5 to 2.7 mg/dL during the titration phase and –7.4 to 0.9 mg/dL during the maintenance phase. No patients maintained a serum calcium level within the normal range.@@@@@MONO@CINACALCET HCL@@@@@CINACALCET HCL||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@MIMPARA@@@@@MIMPARA||||@Anti-Parathyroid Agent@@@@@Anti-Parathyroid Agent||||@SERUM CALCIUM@@@@@@@@@@@@@@@OPEN-LABEL@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@28@1.1511@363.5@470.56@375.65@@@@@@@@@@0.22@@@@@@@@@@@@@@@@8/1/2017@12.98@12.98@619142@FILM-COATED TABLET@EURO@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15356212@Onco@@@@@300f1020ntsdm@@@@@101-09@Experimental: Idelalisib Treatment with idelalisib will be continued until tumor progression or development of unacceptable toxicity.Intervention: Drug: Idelalisib@@L01XX47@L01X@@FOSTER CITY, CALIFORNIA@12/1/2015@@Zydelig is a first-in-class inhibitor of PI3K delta, a protein that is over-expressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells.@@15356212@Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.@Both@YES@13-Aug-15@8/13/2015@@@@1675@@@THIRD-LINE@NCT01282424@125@The recommended maximum starting dose of Zydelig is 150 mg administered orally twice daily.Continue treatment until disease progression or unacceptable toxicity.@EMA, 18 September 2014@9/18/2014@10/1/2015@NO@@5/1/2011@@@No@@Age ≥ 18 yearsKarnofsky performance score of ≥ 60 (Eastern Cooperative Oncology Group [ECOG] performance score of 0, 1, or 2)Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following: Follicular lymphoma (FL)/Small lymphocytic lymphoma (SLL) with absolute lymphocyte count/Lymphoplasmacytic lymphoma (LPL), with or without associated Waldenstroms Macroglobulinemia (WM)/Marginal zone lymphoma (MZL) (splenic, nodal, or extranodal)Prior treatment with ≥ 2 prior chemotherapy-based or immunotherapy-based regimens for iNHL@@ADULTS@II@APPROVED@@Included into the reimbursement list on 13 August 2015 [http://www.gazzettaufficiale.it/eli/id/2015/08/27/15A06564/sg;jsessionid=iu3IhZfKIpvPz3j9evM5hQ__.ntc-as1-guri2b]@SSN@Zydelig's accelerated approval in FL and SLL, two types of indolent non-Hodgkin lymphoma, is supported by data from a single-arm Phase 2 study (Study 101-09) of Zydelig monotherapy in patients refractory to rituximab and alkylating-agent-containing chemotherapy (FL: n=72; SLL: n=26). In the study, Zydelig achieved an overall response rate of 54 percent (range: 42-66 percent) and 58 percent (range: 37-77 percent), respectively, in FL and SLL patients. Of the responses seen in FL patients, 8 percent (n=6) were complete responses; all 15 responses in SLL patients were partial responses. The median duration of response was 11.9 months in SLL patients (range: 0.0, 14.7 months) and median duration of response was not reached in FL patients (range: 0.0, 14.8 months). Improvement in patient survival or disease related symptoms has not been established in these indications. Results of Study 116 and Study 101-09 were published in The New England Journal of Medicine in March 2014. - See more at: http://www.gilead.com/news/press-releases/2014/7/us-food-and-drug-administration-approves-gileads-zydelig-idelalisib-for-relapsed-chronic-lymphocytic-leukemia-follicular-lymphoma-and-small-lymphocytic-lymphoma#sthash.S9rICScm.dpuf[Gilead, 23 July 2014, http://www.gilead.com/news/press-releases/2014/7/us-food-and-drug-administration-approves-gileads-zydelig-idelalisib-for-relapsed-chronic-lymphocytic-leukemia-follicular-lymphoma-and-small-lymphocytic-lymphoma]@The most common adverse reactions (incidence ≥20 percent; all grades) in patients given Zydelig with or without rituximab are diarrhea, pyrexia, fatigue, nausea, cough, abdominal pain, chills and rash. The most common lab abnormalities (incidence ≥30 percent; all grades) in clinical studies were neutropenia, hypertriglyceridemia, hyperglycemia and ALT/AST elevations (indicators of liver function). - See more at: http://www.gilead.com/news/press-releases/2014/7/us-food-and-drug-administration-approves-gileads-zydelig-idelalisib-for-relapsed-chronic-lymphocytic-leukemia-follicular-lymphoma-and-small-lymphocytic-lymphoma#sthash.S9rICScm.dpuf[Gilead, 23 July 2014, http://www.gilead.com/news/press-releases/2014/7/us-food-and-drug-administration-approves-gileads-zydelig-idelalisib-for-relapsed-chronic-lymphocytic-leukemia-follicular-lymphoma-and-small-lymphocytic-lymphoma]@@@@MONO@IDELALISIB@@@@@IDELALISIB||||@GILEAD @@@@@GILEAD ||||@United States@France@Germany@Italy@Poland@United States|France|Germany|Italy|Poland|United Kingdom||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Follicular lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Follicular lymphoma|||||||@ZYDELIG@@@@@ZYDELIG||||@PI3K INHIBITOR@@@@@PI3K INHIBITOR||||@OVERALL RESPONSE RATE@@@@@DURATION OF RESPONSE@LYMPH NODE RESPONSE RATE@@@@RELAPSED@@@@@SINGLE ARM@MULTICENTER@@@@1@1@50693.33283@@@12.5@month@12.5 month@50693.33@50693.33@133.33@60@1.1229@4000@6601.6@4180.04@@@@@@@@@@0.44@1@@mg@300@1@@@@@@@@@@@6/7/2017@66.67@66.67@43620020@FILM-COATED TABLET@EURO@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16405993@Onco@@@@@300f1010ntsdm@@@@@@Active Comparator: Arm A. Drug: bendamustine•Experimental: Arm B. Drug: RO5072759 + Drug: bendamustine@@L01XC15@L01X@@BASEL, SWITZERLAND@9/1/2014@@Gazyvaro is designed to attack cells that have a certain marker on their surface. It kills targeted cells both directly and together with the body's immune system.@@16405993@Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during orup to 6 months after treatment with rituximab or a rituximab-containing regimen.@Both@YES@@@NO REVIEW@@@@100%@@SECOND-LINE@NCT01059630@414@Cycle 1: The recommended dose of Gazyvaro in combination with bendamustine is 1,000 mg administered onDay 1, Day 8 and Day 15 of the first 28 day treatment cycle.Cycles 2-6: The recommended dose of Gazyvaro in combination with bendamustine is 1,000 mg administered onDay 1 of each 28 day treatment cycle.Maintenance: Patients who respond to induction treatment (i.e. the initial 6 treatment cycles) with Gazyvaro incombination with bendamustine or have stable disease should continue to receive Gazyvaro 1,000 mgas single agent maintenance therapy once every 2 months for two years or until disease progression@EMA, 13 June 2016@6/13/2016@9/5/2014@Yes@@4/1/2010@@GAO4753g, GO01297@No@@History of histologically documented, CD20+, indolent NHL; Refractory to any previous regimen containing rituximab; Previously treated with a maximum of four unique chemotherapy containing treatment regimens; All patients must have at least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by CT scan)@@ADULTS@III@APPROVED@@October 2016: Rejected. Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is not recommended within its marketing authorisation for treating follicular lymphoma that did not respond orprogressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen. [NICE, https://www.nice.org.uk/guidance/GID-TA10020/documents/appraisal-consultation-document]@NHS@@@@@@@OBINUTUZUMAB@BENDAMUSTINE@@@@OBINUTUZUMAB|BENDAMUSTINE|||@ROCHE@@@@@ROCHE||||@World@@@@@World|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Follicular lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Follicular lymphoma|||||||@GAZYVARO@GENERIC@@@@GAZYVARO|GENERIC|||@CD20@@@@@CD20||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@COMPLETE RESPONSE@BEST RESPONSE@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@66131.40984@@@898@day@898 day@66131.41@66131.41@73.64@1@1.299@3312@@@@@@@@@@@@3.31@28@1@mg@1000@3@28@5@mg@1000@1@61@@mg@1000@1@7/28/2017@3312@3312@2.54E+16@CONCENTRATE FOR SOLUTION FOR INFUSION - 40 ML@GB£@@@@@@@@1000@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16750625@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XC02@L01X@@SAN FRANCISCO, CALIFORNIA@2/14/2011@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@16750625@First-line treatment of diffuse large B-cell, CD20-positive, non-Hodgkin's lymphoma in combination with CHOP or other anthracycline-based chemotherapy regimens.@Both@NA@@@NO REVIEW@@@@@@FIRST-LINE@NCT00499018@399@375 mg/m2 IV per infusion given on Day 1 of each cycle of chemotherapy for up to 8 infusions. Standard CHOP chemotherapy (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for eight cycles@FDA, 10 February2006@@@Yes@@7/10/2007@@IIL-DLCL04; EudraCT number 2007-000275-42@No@@Age 18-60; Histological confirmed diagnosis of Diffuse Large B-Cell Lymphoma CD20+ (newly diagnosis or shifted from low grade NHL and not previously treated) or of Follicular Lymphoma grade III according to REAL/WHO Classification; Advanced stage II, stage III and stage IV with at least two aa-IPI risk factors; Age-adjusted IPI 2-3; ECOG performance status 0-2; LVEF>45%, measured with echocardiography; Normal hepatic, renal and pulmonary functions; HIV, HCV and HBV negativity; HCV+ admitted only in histologically confirmed absence of replication marks; Positive serology for HBV (occult carriers: AntiHBcAg+, HbsAg-, AntiHBsAg+/-) admitted only upon negativity of weakly positive HBV-DNA test; Life expectancy > 3 months; Negative pregnancy test; Written Informed Consent;@@ADULTS@Phase III@APPROVED@@@NA@@@@@@COMBO@RITUXIMAB@CYCLOPHOSPHAMIDE@DOXORUBICIN@VINCRISTINE@PREDNISONE@RITUXIMAB|CYCLOPHOSPHAMIDE|DOXORUBICIN|VINCRISTINE|PREDNISONE@GENENTECH@BIOGEN IDEC@@@@GENENTECH|BIOGEN IDEC|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@DLBCL@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|DLBCL|||||||@RITUXAN@CHOP@@@@RITUXAN|CHOP|||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@@@@@@@@@@@@@@@@INTERVENTIONAL@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@1.75@m²@45603.075@@@168@day@168 day@45603.08@45603.08@271.45@1@1@868.63@@@@@@@@@@@@8.69@21@@mg/m²@375@1@@@@@@@@@@@8/2/2017@868.63@868.63@50242-0051-21@CONCENTRATE FOR SOLUTION FOR INFUSION - 10 ML@US$@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917623@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@H02AB02@H02A@YES@INGELHEIM, GERMANY@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14917623@Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Haematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anaemia), idiopathic thrombocytopaenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopaenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumour, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.@@@@@NO REVIEW@@@@@Roxane is a U.S. subsidiary of Boehringer, acquired by the Germany company in 1978.@@@N/A@Adults: Usually, daily oral dosages of 0.5 - 10 mg are sufficient. In some patients higher dosages may be temporarily required to control the disease. Once the disease is under control the dosage should be reduced or tapered off to the lowest suitable level under continuous monitoring and observation of the patient. For a short dexamethasone suppression test, 1mg dexamethasone is given at 11 p.m. and plasma cortisol measured the next morning. Patients who do not show a decrease in cortisol can be exposed to a longer test: 500 micrograms dexamethasone is given at 6 hourly intervals for 48 hours followed by 2mg every 6 hours for a further 48 hours. 24 hour-urine collections are made before, during and at the end of the test for determination of 17-hydroxycorticosteroids. Children: 0.01-0.1mg/kg of body weight daily.@@@@@@@Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity. Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@DEXAMETHASONE SODIUM PHOSPHATE@@@@@DEXAMETHASONE SODIUM PHOSPHATE||||@BOEHRINGER INGELHEIM@ROXANE@@@@BOEHRINGER INGELHEIM|ROXANE|||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Brain Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Brain Cancer||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@@@@100@1@53.54@@@@@@@@@@@@0.13@@@@@@@@@@@@@@@@9/1/2017@0.54@0.54@00054-4184-25@TABLET@US$@@@@@@@@4@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924456@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@L01DB06@L01D@YES@NEW YORK, NEW YORK@@@Idarubicin is an antimitotic and cytotoxic agent which intercalates with DNA and interacts with topoisomerase II and has an inhibitory effect on nucleic acid synthesis. The compound has a high lipophilicity which results in an increased rate of cellular uptake compared with doxorubicin and daunorubicin. Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes. Studies in-vitro on human and murine anthracycline-resistant cells have shown a lower degree of cross-resistance for idarubicin compared with doxorubicin and daunorubicin. Cardiotoxicity studies in animals have indicated that idarubicin has a better therapeutic index than daunorubicin and doxorubicin. The main metabolite, idarubicinol, has shown in-vitro and in-vivo antitumoral activity in experimental models. In the rat, idarubicinol, administered at the same doses as the parent drug, is clearly less cardiotoxic than idarubicin.@@14924456@Acute myeloblastic leukaemia without hyperleukocytosis, identifiable under the FAB classification, AML3 excepted, in patients over 60 years old, in the following circumstances: - contraindication to intravenous chemotherapy and/or long stay in hospital, - risks related to prolonged aplasia considered greater than potential benefits.@@NO@3-Mar-95@3/3/1995@NO REVIEW@@@@100%@Acquired via takeover of Pharmacia Corp.@-@-@-@Induction and consolidation therapy: the recommended dose is 20 mg/m²/week for 4 weeks;Salvage therapy: in nonresponding patients the dose can be increased to 40 mg/m²/week for 4 weeks.@N/A@@4/10/1995@-@@@The drug should not be given to patients with pre-existing bone marrow depression induced by previous drug therapy or radiotherapy unless the benefit warrants the risk. Pre-existing heart disease and previous therapy with anthracyclines, especially at high cumulative doses, or other potentially cardiotoxic agents are co-factors for increased risk of idarubicin-induced cardiac toxicity: the benefit to risk ratio of idarubicin therapy in such patients should be weighed before starting treatment with Zavedos. In absence of sufficient data, the use of oral idarubicin is not recommended in patients with prior total body irradiation or bone marrow transplantation.@NO LABELLED TRIAL@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@IDARUBICIN HCL@@@@@IDARUBICIN HCL||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@ZAVEDOS@@@@@ZAVEDOS||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@-@@@@@@@@@@RELAPSED@REFRACTORY@@@@-@@@@@1.75@m²@2751@@@8@week@8 week@2751@2751@49.13@1@1.1229@65.5@108.1@68.45@@@@@@@@@@6.55@7@4@mg/m²@20@1@7@@mg/m²@40@1@@@@@@6/7/2017@65.5@65.5@27441043@HARD CAPSULE@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921079@Onco@@@@@300f1015ntsdm@@@@@@Patients received melphalan, prednisone and thalidomide (MP-T) or vincristine, adriamycin and dexamethasone (VAD) followed by melphalan and transplantation (MEL 100).Thalidomide given at doses up to 400mg.@@L04AX02@L04A@-@SUMMIT, NEW JERSEY@@@The mechanism of action is not fully understood. It possesses immunomodulatory, anti-inflammatory and anti-angiogenic properties; the immunologic effects vary substantially under different conditions, but may be related to the suppression of excessive TNF-alpha production and down-modulation of selcted cell surface adhesion molecules involved in leukocyte migration.@@14921079@Newly diagnosed elderly multiple myeloma@@-@-@@NO REVIEW@@@@-@In November 2001, Celgene sold Pharmion exclusive licenses for thalidomide and S.T.E.P.S. in exchange for royalties. Celgene retained the rights for North America, China, Japan, Korea, and Taiwan. After revision of agreement in December 2004, Pharmion pay@FIRST-LINE@NCT00367185@447@-@-@@@-@@@-@IFM 99-06@@-@447 ELDERLY PATIENTS@ELDERLY@@III@III@@-@-@">> After a median follow-up of 51.5 months (IQR 34.4-63.2), median overall survival times were 33.2 months (13.8-54.8) for MP, 51.6 months (26.6-not reached) for MPT, and 38.3 months (13.0-61.6) for MEL100. The MPT regimen was associated with a significantly better overall survival than was the MP regimen (hazard ratio 0.59, 95% CI 0.46-0.81, p=0.0006) or MEL100 regimen (0.69, 0.49-0.96, p=0.027). No difference was seen for MEL100 versus MP (0.86, 0.65-1.15, p=0.32). ""The results of the trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma"" [Lancet. 2007 Oct 6;370(9594):1209-18]
>> Following an interim analysis, recruitment was stopped on the recommendation of the study's DSMB. At final analysis, the median OS in the MP-T arm was 53.6 months, compared to 32.2 and 38.6 months, respectively, for the MP and MEL 100 arms. The thalidomide combination was associated with more venous thrombosis and pulmonary embolism. Patients taking thalidomide were also at more risk of peripheral neuropathy, neutropaenia and constipation. [ASCO, June 2006]"@-@@@@COMBO@THALIDOMIDE@MELPHALAN@PREDNISONE@@@THALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@PHARMION@@@@CELGENE|PHARMION|||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@THALOMID@@@@@THALOMID||||@Immunotherapy@@@@@Immunotherapy||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15402496@Onco@@@@@300f1018ntsdm@@@@@@Drug: Bortezomib (VELCADE) 1.3 mg/m² by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.Drug: Doxorubicin hydrochloride (DOXIL/CAELYX) mg/m² by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.@@L01DB01@L01D@@BEERSE, BELGIUM@@@The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.@@15402496@CAELYX is indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.@Both@YES@@@NO REVIEW@@@@@@SECOND-LINE@NCT00103506@646@CAELYX is administered at 30 mg/m² on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m² on days 1, 4, 8, and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment.@TGA, 6 August 1997@8/6/1997@@No@@@@CR004117, DOXILMMY3001, 2004-001842-34@No@@Patients with multiple myeloma who have received at least 1 prior therapy and who have either responded and later had progressive disease or have progressed during their first therapy (primary refractory) are eligible for the studyPatients who may have received prior doxorubicin but not more than a cumulative dose of 240 milligram per meter square (mg/m^2) doxorubicin, DOXIL, or the equivalent amount of another anthracycline (i.e., 1 mg doxorubicin = 1 mg DOXIL/CAELYX = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin)Must have normal cardiac function, as evidenced by a left LVEF within institutional normal limits.@@ADULTS@III@APPROVED@@@PBS@@@@@@COMBO@DOXORUBICIN, PEGYLATED LIPOSOMAL@BORTEZOMIB@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL|BORTEZOMIB|||@JANSSEN-CILAG@@@@@JANSSEN-CILAG||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@CAELYX@VELCADE@@@@CAELYX|VELCADE|||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@TIME TO PROGRESSION@@@@@@@@@@PROGRESSIVE@@@@@RANDOMISED@PARALLEL GROUP@OPEN LABEL@MULTI-CENTRE@@1.75@m²@8533.487106@@@8.9@month@8.9 month@8533.49@8533.49@31.52@1@0.779@630.47@@@@@@@@@@@@12.61@21@@mg/m²@30@1@@@@@@@@@@@8/1/2017@630.47@630.47@0687-0405-IN-JC@SUSPENSION FOR I.V. INFUSION - 25 ML@A$@@@@@@@@50@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14920425@Onco@@@@@300f1037ntsdm@@@@@@This study included 12 patients with DFSP who were treated with Gleevec 800 mg daily@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920425@Glivec is indicated for the treatment of • adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. • adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. • adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. • adult patients with relapsed or refractory Ph+ ALL as monotherapy. • adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. • adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement. The effect of Glivec on the outcome of bone marrow transplantation has not been determined. Glivec is also indicated for the treatment of • adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). • adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with GIST and DFSP. The experience with Glivec in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.@@YES@@@NO REVIEW@@@@90%@@@@18@The recommended dose of Gleevec is 800 mg/day for adult patients with DFSP.@EMA, 9 January 2004@1/9/2004@7/13/2004@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@@Age range 23-75; DFSP was metastatic, locally recurrent following initial surgical resection and no considered amenable to further surgery at the time of study@ADULT@@II@APPROVED@@NO REVIEW@SNS@Twelve of these 18 patients either achieved a complete response (7 patients) or were made disease free by surgery after a partial response (5 patients, including one child) for a total complete response rate of 67%. A further 3 patients achieved a partial response, for an overall response rate of 83%. Of the 8 patients with metastatic disease, five responded (62%), three of them completely (37%). For the 10 study patients with the PDGF B gene rearrangement there were 4 complete and 6 partial responses@The adverse reactions were similar for Ph+ ALL as for Ph+ CML. The most frequently reported drug-related adverse reactions reported in the Ph+ ALL studies were mild nausea and vomiting, diarrhea, myalgia, muscle cramps and rash, which were easily manageable. Superficial edema was a common finding in all studies and were described primarily as periorbital or lower limb edemas. These edemas were rarely severe and may be managed with diuretics, other supportive measures, or in some patients by reducing the dose of Gleevec.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@Dermatofibrosarcoma protuberans@@@@Sarcoma|Dermatofibrosarcoma protuberans||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Dosage Value Phase 1@@@6.2@month@6.2 month@29776.15@29776.15@157.9@60@1.1511@1184.23@1289.75@1191.77@@@@@@@@@@0.2@@@@@@@@@@@@@@@@8/4/2017@19.74@19.74@779652@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14923248@Onco@@@@@300f1010ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14923248@Sprycel is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. It is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.@@NO@@@NO REVIEW@@@@100%@@@@78@The recommended starting dosage for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ALL is 70 mg twice daily administered orally, one tablet in the morning and one in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@EMA, 20 November 2006@11/20/2006@@Yes@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-0015@No@@42 with blastic phase and 36 with PH+ disease@@@II@APPROVED@@NICE final guidance: Dasatinib is not recommended for the treatment of chronic, accelerated or blast-crisis  phase CML in adults with imatinib intolerance or whose CML is resistant to treatment  with standard-dose imatinib. [NICE, January 2012, http://www.nice.org.uk/nicemedia/live/13645/57823/57823.pdf ]@NHS@The MaHR rate was 59% in accelerated phase patients, 32% in myeloid phase patients, 31% in lymphoid blast phase patients, and 42% in Ph+ ALL patients. The median durations of major haematologic response were 3.7 months in lymphoid blast CML and 4.8 months in Ph+ ALL.@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@14222.29433@@@4@month@4 month@14222.29@14222.29@116.9@30@1.299@2504.96@@@@@@@@@@@@0.83@1@@mg@140@1@@@@@@@@@@@7/28/2017@83.5@83.5@1.54E+16@FILM-COATED TABLET@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16639899@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"Fludarabine + Cyclophosphamide + CAR-NK Cells, Experimental, On Days -5, -4, and -3, participants receive Fludarabine and Cyclophosphamide. Participants also receive Mesna before and after the cyclophosphamide dose.
On Day 0, participants receive genetically modified NK cells as a cell infusion.
If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they receive AP1903 by vein and possibly steroids by mouth or by vein.
"@@L01BB05@L01B@@@5/1/2022@@@@16639899@Dose Escalation Study Phase I/II of Umbilical and Cord Blood-Derived CAR-Engineered NK Cells in Conjunction in Patients With Relapsed/Refractory B-Lymphoid Malignancies@Both@@@@@30 mg/m2 by vein on Days -5 to -3.@@@@@@NCT03056339@36@@@@@@@@@2016-0641@@@Inclusion Criteria:  1. Patients with history of B-lymphoid malignancies (ALL, CLL, NHL) who have received at least 2 lines of standard chemoimmunotherapy or targeted therapy and have persistent disease.  2. Patients with ALL, CLL, NHL with relapsed disease following standard therapy or a stem cell transplant.  3. Patients at least 3 weeks from last cytotoxic chemotherapy. Patients may continue tyrosine kinase inhibitors or other targeted therapies until at least two weeks prior to administration of lymphodepleting chemotherapy.  4. Karnofsky Performance Scale > 70.  5. Adequate hepatic function, as defined by SGPT < 3 X upper limit of normal; serum bilirubin and alkaline phosphatase < 2 X upper limit of normal, or considered not clinically significant by the study doctor or designee, serum creatinine of </= 2 mg/dl.  6. Able to provide written informed consent.  7. 18-65 years of age.  8. Availability of a CB unit matched with the patient at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens.  9. All participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor.@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@MONO@FLUDARABINE@@@@@FLUDARABINE||||@BELLICUM PHARMACEUTICALS@@@@@BELLICUM PHARMACEUTICALS||||@United States@@@@@United States|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|||||||@FLUDARA@@@@@FLUDARA||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@Optimal NK Cell Dose Level of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies@Toxicity of Chimeric antigen receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer (CB-NK) cells in patients with relapsed/refractory CD19+ B lymphoid malignancies@Efficacy of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies@@@Response of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies@@@@@RELAPSED@REFRACTORY@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920880@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@TOKYO, JAPAN@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14920880@Methotrexate is used in the treatment of adults with severe, active, classical or definite rheumatoid arthritis who are unresponsive or intolerant to conventional therapy. Methotrexate has also been used in the treatment of severe, uncontrolled psoriasis, which is not responsive to other therapy. Methotrexate has been used to produce regression in a wide range of neoplastic conditions including acute leukaemias, non-Hodgkin's lymphoma, soft-tissue and osteogenic sarcomas, and solid tumours particularly breast, lung, head and neck, bladder, cervical, ovarian, and testicular carcinoma.@@NO@Jan-91@@NO REVIEW@@@@@Eisai acquired French-based Biodim. SOURCE: Eisai, 21 February 2002@@@@Dosage for cancer treatment: A test dose of 5 - 10 mg parenterally is recommended, one week prior to therapy to detect idiosyncratic adverse events. Single doses, not exceeding 30 mg/m2, on not more than 5 consecutive days. A rest period of at least two weeks is recommended between treatments, in order to allow the bone marrow to return to normal. Doses in excess of 100 mg are usually given parenterally, when the injectable preparation should be used. Doses in excess of 70 mg/m2 should not be administered without leucovorin rescue (folinic acid rescue) or assay of serum methotrexate levels 24 - 48 hours after dosing. If methotrexate is administered in combination chemotherapy regimens, the dosage should be reduced, taking into consideration any overlapping toxicity of the other drug components.@Jul-77@@1/19/1973@@@@Methotrexate should be used with extreme caution in patients with haematological depression, renal impairment, diarrhoea, ulcerative disorders of the GI tract and psychiatric disorders. Hepatic toxicity has been observed, usually associated with chronic hepatic disease. Renal lesions may develop if the urinary flow is impeded and urinary pH is low, especially if large doses have been administered. The administration of low doses of methotrexate for prolonged periods may give rise, in particular, to hepatic toxicity. Particular care and possible cessation of treatment are indicated if stomatitis or GI toxicity occurs as haemorrhagic enteritis and intestinal perforation may result.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@EISAI@BIODIM@@@@EISAI|BIODIM|||@@@@@@|||||||||@Breast Cancer@Head & Neck Cancer@NSCLC@Bladder Cancer@Ovarian Cancer@Breast Cancer|Head & Neck Cancer|NSCLC|Bladder Cancer|Ovarian Cancer|||||@LEDERTREXATE@@@@@LEDERTREXATE||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@2.1@2.78@2.4@@@@@@@@@@0.42@@@@@@@@@@@@@@@@8/1/2017@2.1@2.1@3.40E+12@INJECTION SOLUTION AMPOULE, 2 ML@EURO@@@@@@@@5@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919225@Onco@@@@@300f1010ntsdm@@@@@@@@L01DB07@L01D@YES@MUMBAI, INDIA@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14919225@Mitoxantrone is indicated in the treatment of metastatic breast cancer, non-Hodgkin's lymphoma and adult acute non-lymphocytic leukaemia. Mitoxantrone has also been used in the palliation of non-resectable primary hepatocellular carcinoma.@@NO@@@NO REVIEW@@@@100%@@@@@Adult acute non-lymphocytic leukaemia: Single Agent Dosage in Relapse: The recommended dosage for remission induction is 12 mg/m2 of body surface area, given as a single intravenous dose daily for five consecutive days (total of 60 mg/m2). In clinical studies with a dosage of 12 mg/m2 daily for 5 days, patients who achieved a complete remission did so as a result of the first induction course.Combination Therapy: Mitoxantrone has been used in combination regimens for the treatment of acute non-lymphocytic leukaemia (ANLL). Most clinical experience has been with mitoxantrone combined with cytarabine. This combination has been used successfully for primary treatment of ANLL as well as in the treatment of relapse. An effective regimen for induction in previously untreated patients has been mitoxantrone 10-12 mg/m2 IV for 3 days combined with cytarabine 100 mg/m2 IV for 7 days (by continuous infusion). This is followed by second induction and consolidation courses as thought appropriate by the treating clinician. In clinical studies, duration of therapy in induction and consolidation courses with mitoxantrone have been reduced to 2 days, and that of cytarabine to 5 days. However, modification to the above regimen should be carried out by the treating clinician depending on individual patient factors.@EMA, October 2004@@@@@@There may be an increased risk of leukaemia when mitoxantrone is used as adjuvant treatment of non-metastatic breast cancer. In the absence of sufficient efficacy data, mitoxantrone must not be used as adjuvant treatment of non-metastatic breast cancer. Mitoxantrone should be used with caution in patients with myelosuppression or poor general condition. Cases of functional cardiac changes, including congestive heart failure and decreases in left ventricular ejection fraction have been reported during mitoxantrone therapy. These cardiac events have occurred most commonly in patients who have had prior treatment with anthracyclines, prior mediastinal/thoracic radiotherapy, or in patients with pre-existing heart disease. The concomitant administration of other cardiotoxic drugs may also increase the risk of cardiac toxicity. It is recommended that patients in these categories are treated with mitoxantrone at full cytotoxic dosage and schedule. However, added caution is required in these patients and careful regular cardiac examinations are recommended from the initiation of treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@MITOXANTRONE@@@@@MITOXANTRONE||||@WOCKHARDT@@@@@WOCKHARDT||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@20@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917187@Onco@@@@@300f1010ntsdm@@@@@@231 patients who received combination irinotecan/bolus 5-FU/LV therapy given weekly were compared with 226 patients who received a standard bolus regimen of 5-FU/LV alone given daily for 5 days every 4 weeks. The third arm (226 patients) was given an irinotecan-alone treatment on a weekly schedule.@@L01XX19@L01X@YES@NEW YORK, NEW YORK@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14917187@Indicated for the treatment of patients with advanced colorectal cancer in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.@@YES@5-Aug@@NICE: first-line combination combination with 5-FU/FA ICER £14,000 per QALY gained compared with 5-FU/FA@@@@100%@Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan@FIRST-LINE@@683@Regimen 1: 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43): 125 mg/m2 intravenous infusion over 90 minutes, days 1,8,15,22@EMA, September 1995@@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR THE RECTUM RANDOMISED IN 3 ARMS. CONCOMITANT MEDICATIONS SUCH AS ANTIEMETICS, ATROPINE, AND LOPERAMIDE WERE GIVEN TO PATIENTS FOR PROPHYLAXIS AND/OR MANAGEMENT OF SYMPTOMS FROM TREATMENT. PATIENTS ALS@@@STUDY 1 OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FU/LV FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER@APPROVED@@NICE recommendation in combination with 5-flourouracil and folinic acid as a front-line treatment for advanced colorectal cancer, or as a monotherapy in subsequent therapy@NHS@The combination of irinotecan/5-FU/LV therapy resulted in significant improvements in objective tumor RRs (39% vs 21% p<0.0001 / 18% for arm 3), TTP (7 months vs 4.3 months p=0.004 / 4.2 months for arm 3), and survival (14.8 months vs 12.6 months p<0.05 / 12 months for arm 3) when compared with 5-FU/LV alone and irinotecan alone control arm.@@@@@COMBO@IRINOTECAN@LEUCOVORIN@FLUOURACIL@@@IRINOTECAN|LEUCOVORIN|FLUOURACIL||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CAMPTO@5-FU@@@@CAMPTO|5-FU|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@@@@@@ADVANCED@@@@@RANDOMISED@CONTROLLED@INTERNATIONAL@@@1.75@m²@4530.716666@@@5.5@month@5.5 month@4530.72@4530.72@27.08@1@1.2961@130@@@@@@@@@@@@1.3@42@@mg/m²@125@4@@@@@@@@@@@8/21/2017@130@130@4.70E+15@CONCENTRATE FOR INTRAVENOUS INFUSION 5 ML@GB£@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917341@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L02AE04@L02A@NO@PARIS, FRANCE@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins.@@14917341@Men: Treatment of advanced, hormone-dependent prostate carcinoma. Women: Preoperative reduction of myoma size to reduce the symptoms of bleeding and pain in women with symptomatic uterine myomas. Symptomatic endometriosis confirmed by laparoscopy when suppression of the ovarian hormonogenesis is indicated to the extent that surgical therapy is not primarily indicated. Children: Treatment of confirmed central precocious puberty (girls under 9 years, boys under 10 years).@@NO@6-Aug@@NO REVIEW@@@@100%@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@@@@The dosage of one syringe, equivalent to 3.75 mg triptorelin, is injected every 28 days either subcutaneously (e.g. into the skin of the abdomen, the buttock or thigh) or deep intramuscularly. The injection site should be changed each time. Men: Once every four weeks an injection with one syringe, equivalent to 3.75 mg triptorelin. In order to continually suppress testosterone levels, it is important to comply with a 4-weekly administration.@1-Jun-96@6/1/1996@2/5/2010@@@@In adults the prolonged use of GnRH analogues may lead to bone loss which enhances the risk of osteoporosis. Prostate cancer  Initially, Decapeptyl SR like other GnRH analogues causes a transient increase in serum testosterone and consequent worsening of symptoms including increase in bone pain (and serum acid phosphatase levels). Continued treatment leads to suppression of testosterone (and dihydrotestosterone) and consequent improvement in the disease. During the first month of treatment, patients presenting with, or at particular risk of developing, urinary tract obstruction should be carefully monitored, as should those at risk of developing spinal cord compression. Consideration should be given to the use of an anti-androgen for three days prior to treatment, to counteract this initial rise in serum testosterone levels.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@IPSEN@DEBIOPHARM@@@@IPSEN|DEBIOPHARM|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@DECAPEPTYL@@@@@DECAPEPTYL||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@561.6@645.79@591.6@@@@@@@@@@24.96@@@@@@@@@@@@@@@@9/1/2017@561.6@561.6@3.40E+12@POWDER AND SOLVANT FOR INJECTABLE SOLUTION@EURO@@@@@@@@22.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14923418@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE03@L01X@-@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14923418@Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic nonsmallcell lung cancer (NSCLC) with EGFR activating mutations.@Both@NO@6-Jun-12@6/6/2012@NO REVIEW@@@@@>> Abbott signed a deal with Genentech and OSI to develop a molecular gene test to identify extra copies of EGFR in NSCLC for Tarceva. [Abbott, 10 March 2008]    >> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]      >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]       >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@FIRST-LINE@NCT00446225@174@The recommended daily dose is 150 mg taken at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.@EMA, 29 April 2010@4/29/2010@11/28/2005@No@@@@@No@@Histologically confirmed diagnosis of NSCLC, non epidermoid, stage IV or IIIB with pleural effusion, or N3 tumours not candidate for thoracic radiotherapy, harbouring deletions in the exon 19 or mutation in the exon 21 in the TK of the EGFR.Either measurable or evaluable disease.ECOG performance status < 2.@@ADULTS@III@APPROVED@@ASMR IV, 6 June 2012@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE@ONE YEAR SURVIVAL@OVERALL SURVIVAL@@@METASTATIC@@@@@OPEN LABEL@@@@@1@1@24355.39269@@@10.4@month@10.4 month@24355.39@24355.39@76.99@30@1.1511@1539.89@1702.12@1569.89@@@@@@@@@@0.51@1@@mg@150@1@@@@@@@@@@@8/1/2017@51.33@51.33@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919273@Onco@@@@@@@@@@@Patients are stratified according to receptor status (positive vs unknown), lymph node status (negative vs positive vs unknown), prior adjuvant chemotherapy (yes vs no), interval between last dose of aromatase inhibitor therapy and randomization (< 6 months vs 6 months-2 years), and duration of prior tamoxifen use (0 years vs < 2 years vs 2-4.5 years vs > 4.5 years). Patients are randomized to 1 of 2 treatment arms.Arm I: Patients receive oral letrozole once daily. Arm II: Patients receive oral placebo once daily. In both arms, treatment continues for 5 years in the absence of disease progression or unacceptable toxicity. Patients in arm II may then be offered oral letrozole once daily for up to 5 years. Quality of life is assessed at baseline, at 6 months, and then annually for 4.5 years.Double-blind, re-randomization: Patients who complete = 4.5 years of letrozole (arm I) and who did not experience recurrent disease or new primary breast cancer, including ductal carcinoma in situ, may participate in the double-blind, placebo-controlled, re-randomization portion of the study. Patients are stratified according to lymph node status at enrollment (negative vs positive vs unknown), prior adjuvant chemotherapy (yes vs no), and interval between last dose of letrozole and re-randomization (<6 months vs 6 months to 2 years). Common genetic single nucleotide polymorphisms for genes encoding proteins involved in pharmacokinetic and/or pharmacodynamic pathways for letrozole are analyzed in order to determine if these single nucleotide polymorphisms contribute to individual variation in toxicity and efficacy of letrozole therapy.Quality of life is assessed as during the first randomization. SOURCE: clinicaltrials.gov@@L02BG04@L02B@-@BASEL, SWITZERLAND@@@The elimination of oestrogen-mediated stimulatory effects is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone (E1) and oestradiol (E2). The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues.@@14919273@Letrozole After Tamoxifen in Treating Women With Breast Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00003140@4700@-@-@@@-@@8/1/1998@-@MA17@@-@-@@@III@III@@-@-@>> The analysis shows that women who started Femara several years after completing the recommended five years of tamoxifen reduced their risk of breast cancer coming back by 63% compared to those who did not start Femara. In addition, the risk of cancer spreading to other areas of the body was reduced by 61%. The median period before starting Femara was 31 months. The analysis evaluated the subset of 2,383 women who were in the placebo group when the MA-17 trial was unblinded (2003). Of these women, 1,579 chose to switch to Femara, while 804 chose not to start Femara. The safety analysis was consistent with many other Femara trials in various treatment settings, reinforcing that Femara is well tolerated. [Novartis/Journal of Clinical Oncology, 10 March 2008]          >> Trial registered. [1.11.1999]@-@@@@MONO@LETROZOLE@@@@@LETROZOLE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FEMARA@@@@@FEMARA||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916304@Onco@@@@@300f1015ntsdm@@@@@@Cyclophosphamide, methotrexate, and 5-FU (CMF) to no chemotherapy (19 trials with 7523 patients) and comparisons of doxorubicin-containing regimens with CMF as an active control (6 trials including 3510 patients).@@L01DB01@L01D@YES@NEW YORK, NEW YORK@@@Although not completely elucidated, the mechanism of action of doxorubicin is related to its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture studies have demonstrated rapid cell penetration and perinucleolar chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, mutagenesis and chromosomal aberrations. The specificity of doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastro-intestinal tract and gonads are the main normal tissues damaged.@@14916304@Doxorubicin has been used successfully in the treatment of neoplastic conditions such as acute leukaemia, soft tissue and osteogenic sarcomas, breast carcinoma, lymphomas, bronchogenic (lung) carcinoma. It has also been used in the treatment of paediatric malignancy. Doxorubicin is frequently used in combination chemotherapy regimen involving other cytotoxic drugs. Doxorubicin can be used in the treatment of non-metastatic transitional cell carcinoma, carcinoma in situ and papillary tumours of the bladder, by intravesical administration.@@YES@@@NO REVIEW@@@@@@@@11033@If it is used in combination with other antitumour agents with overlapping toxicity, such as high-dose i.v. cyclophosphamide or related anthracycline compounds such as daunorubicin, idarubicin and/or epirubicin, the dosage of doxorubicin should be reduced to 30 - 40 mg/m2 every three weeks. [IHS Global Insight assumption: 30mg/m2]@Jul-92@@@No@@@Severe local tissue necrosis will occur if there is extravasation during administration. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The probability of developing impaired myocardial function based on a combined index of signs, symptoms and decline in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20% at 500 mg/m2. The risk of developing CHF increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m2. Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) has been reported in patients treated with anthracyclines, including doxorubicin. The occurrence of refractory secondary AML or MDS is more common when anthracyclines are given in combination with DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. Dosage should be reduced in patients with impaired hepatic function. Severe myelosuppression may occur.@LABEL@No@EXPIRED@@@@LABEL: META ANALYSIS OF BREAST CANCER TRIALS@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@The doxorubicin-containing regimens would be considered as non-inferior to CMF if the upper 2-sided 95% confidence limit of the hazard ratio was less than 1.06, i.e., not more than 6% worse than CMF. A similar calculation for OS would require a non-inferiority margin of 1.02.@Cardiovascular: Cardiotoxicity, i.e., cardiomyopathy, congestive heart failure, supraventricular tachycardia. Routine ECG monitoring is recommended and caution should be exercised in patients with impaired cardiac function. Severe cardiac failure may occur suddenly, without premonitory ECG changes.   Vascular system: Phlebosclerosis.   Dermatological: Extravasation, skin necrosis, cellulitis, vesication, phlebitis, erythematous streaking along the vein proximal to the site of injection. Alopecia occurs frequently, including the interruption of beard growth, but all hair growth normally returns after treatment is stopped.@@@@COMBO@DOXORUBICIN@CYCLOPHOSPHAMIDE@FLUOURACIL@@@DOXORUBICIN|CYCLOPHOSPHAMIDE|FLUOURACIL||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Hodgkin's Lymphoma@Bladder Cancer@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|Hodgkin's Lymphoma|Bladder Cancer|Thyroid Cancer|Stomach Cancer|Sarcoma|Breast Cancer|Ovarian Cancer@ADRIBLASTINE@5-FU@@@@ADRIBLASTINE|5-FU|||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@DISEASE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@1@year@1 year@@@@@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15402485@Onco@@@@@300f1012ntsdm@@@@@@509 women with metastatic breast cancer were randomised to receive CAELYX (50 mg/m2 every four weeks, N=254) or doxorubicin (60 mg/m2 every three weeks, N=255).@@L01DB01@L01D@@BEERSE, BELGIUM@@@The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.@@15402485@Indicated as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@509@Breast cancer/Ovarian cancer: Caelyx is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.@EMA, 24 October 2000@10/24/2000@@No@@@Cardiac toxicity: It is recommended that all patients receiving Caelyx routinely undergo frequent ECG monitoring. Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the suspension of Caelyx therapy. However, reduction of the QRS complex is considered more indicative of cardiac toxicity. If this change occurs, the most definitive test for anthracycline myocardial injury, i.e., endomyocardial biopsy, must be considered.@@No@@@@@III@APPROVED@@@GKV@PLD and doxorubicin were comparable with respect to PFS [6.9 versus 7.8 months, respectively; hazard ratio (HR)=1.00; 95% confidence interval (CI) 0.82-1.22]. Subgroup results were consistent. Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR=3.16; 95%CI 1.58-6.31; P<0.001). Overall survival was similar (21 and 22 months for PLD and doxorubicin, respectively; HR=0.94; 95%CI 0.74-1.19).  [O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9; http://www.ncbi.nlm.nih.gov/pubmed/14998846]@Alopecia (overall, 66% versus 20%; pronounced, 54% versus 7%), nausea (53% versus 37%), vomiting (31% versus 19%) and neutropenia (10% versus 4%) were more often associated with doxorubicin than PLD. Palmar-plantar erythrodysesthesia (48% versus 2%), stomatitis (22% versus 15%) and mucositis (23% versus 13%) were more often associated with PLD than doxorubicin.@@@@MONO@DOXORUBICIN, PEGYLATED LIPOSOMAL@@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL||||@JANSSEN-CILAG@@@@@JANSSEN-CILAG||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CAELYX@@@@@CAELYX||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@PROGRESSION-FREE SURVIVAL@CARDIAC TOXICITY@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@SINGLE-ARM@@@@1.6@m²@17694.23339@@@6.9@month@6.9 month@17694.23@17694.23@84.31@1@1.1511@1475.43@1865.75@1513.93@@@@@@@@@@29.51@28@@mg/m²@50@1@@@@@@@@@@@8/1/2017@1475.43@1475.43@887150@CONCENTRATE FOR INFUSION SOLUTION - 25 ML@EURO@@@@@@@@50@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918661@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC01@L01B@YES@LAKE FOREST, ILLINOIS@@@Cytarabine (ARA-C) is metabolised in vivo to ARA-CTP phosphorylated compound. This competitively inhibits DNA polymerase and may also inhibit certain acid kinase enzymes. Primarily the drug acts as a false nucleoside and competes for enzymes involved in the conversion of cytidine nucleotide to deoxycytidine nucleotide and also incorporation into the DNA. Cytarabine has no effect on non proliferating cells nor on proliferating cells unless in the S phase. It is a cell cycle specific antineoplastic drug.@@14918661@In combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration is indicated in the prophylaxis and treatment of meningeal leukemia.@@NO@@@NO REVIEW@@@@100%@Via takeover of Mayne Pharma@@@@Induction: Adults Continuous Dosing: The usual dose in leukaemia, is 2 mg/kg by rapid intravenous injection daily for ten days. If after ten days neither therapeutic response not toxicity has been observed, the dose may be increased to 4 mg/kg until a therapeutic response or toxicity is evident. Daily blood counts should be taken. Almost all patients can be carried to toxicity with these doses. Alternatively, 0.5 to 1 mg/kg may be infused daily in 1-24 hours for ten days, and then at a rate of 2 mg/kg/day until toxicity is observed. Continue to toxicity or until remission occurs. Results from one hour infusions have been satisfactory in the majority of patients. Intermittent dosing: Cytarabine may be given as intermittent intravenous doses of 3-5 mg/kg daily, for five consecutive days. This course of treatment can be repeated after an interval of 2 to 9 days, and repeated until the therapeutic response or toxicity is exhibited. Evidence of bone marrow improvement has been reported to occur 7-64 days days after the beginning of therapy. In general, if a patient shows neither remission or toxicity after a trial period, then cautiously administered higher doses can be administered. Generally patients tolerate higher doses given by rapid intravenous injection rather than slow infusion. As a single agent for induction of remissions in patients with acute leukaemia, cytarabine has been given in doses of 200 mg/m2 by continuous intravenous infusion for five days at approximately 2 week intervals. Maintainance therapy: To maintain remission, doses of 1-1.5 mg/kg may be given intravenously or subcutaneously, once or twice weekly. Myelosuppression, anaemia and thrombocytopenia occur almost to all patients given daily infusions or injections. Myelosuppression is biphasic and nadirs at 7-9 and 15-24 days. Evidence of bone marrow improvement may be expected 7-64 (mean 28) days after the beginning of treatment.@EMA, September 1997@@@@@@Only physicians experienced in cancer chemotherapy should use Cytarabine for Injection USP. For induction therapy, patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of cytarabine is bone marrow suppression with leukopenia, thrombocytopenia, and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration, and hepatic dysfunction. The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. Before making this judgement or beginning treatment, the physician should be familiar with the following text.@NO LABELLED TRIAL@No@@@ALL@@@APPROVED@@100%; no NICE review@NHS@NO LABELLED TRIAL@@@@@@CYTARABINE@@@@@CYTARABINE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Chronic Myeloid Leukaemia@Lymphomatous Meningitis@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Chronic Myeloid Leukaemia|Lymphomatous Meningitis|||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@100@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15051156@Onco@@@@@300f1012ntsdm@@@@@@-@@-@-@-@INGELHEIM, GERMANY@@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. @@15051156@NSCLC With EGFR Activating Mutations@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00525148@80@-@FDA Fast-track designation. SOURCE: 14 February 2008@2/14/2008@@-@@@-@1200.22@@-@-@@@II@II@@-@-@">> Encouraging results were presented for LUX-Lung 2, a phase II trial studying patients with advanced NSCLC who harbour EGFR mutations. This result shows that the use of afatinib led to a high rate of tumour size reduction (objective response rate of 61%) and a long delay in the progression of cancer by over 1 year (PFS of 14 months) 3. These results help to underline afatinib’s potential benefit as a first or second line treatment in patients with EGFR mutations. Two phase III trials, LUX-Lung 3 and LUX-Lung 6 are currently underway to further evaluate afatinib as a first-line treatment in this patient group. [BI, 11.10.10 http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2010/11_october_2010_oncology.html]

>>Preliminary data from the Phase II LUX-Lung 2 trial of NSCLC patients with an EGFR mutation show a response rate of nearly two-thirds (63%) and a disease control rate of 97% in 38 evaluable first-line patients. [BI 3 August 2009  http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2009/03_august_2009.html ]

>>Preparing for Phase III trial in this setting. SOURCE: Boehringer Ingelheim, 14 February 2008

>>September 2007; BIBW 2992 was active against tumours resistant to first-generation inhibitors, and was more efficacious in lung cancer patients with specific mutations. Boehringer Ingelheim is finalising with the US FDA and EMEA details of phase III pivotal trials of BIBW 2992 in the treatment of lung cancer. SOURCE: Boehringer, September 2007"@The most commonly (greater than 5%) observed adverse events were Grade 3 and included diarrhea, skin-related adverse events and mouth ulcerations. 4 Comparable response rates (66%) and disease control (97%) rates were observed in the second-line setting. [BI 3 August 2009]@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@BIBW-2992@TOVOK@@@@BIBW-2992|TOVOK|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@COMPLETE RESPONSE@PARTIAL RESPONSE@RECIST@@@RECIST@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917307@Onco@@@@@300f1015ntsdm@@@@@@DaunoXome 40mg/m2 versus ABV (Adriamycin 10mg/m2, bleomycin 15U, vincristine 1.mg); both as IV every 2 weeks.@@L01DB02@L01D@YES@FOSTER CITY, CALIFORNIA@@@Daunorubicin is an anthracycline glycoside antibiotic and is a potent antileukaemic agent. It also has immunosuppressant effects. The exact mechanism of antineoplastic action is uncertain but may involve binding to DNA by intercalation between base pairs and inhibition of DNA and RNA synthesis by template disordering and steric obstruction. Daunorubicin is most active in the S-phase of cell division but is not cycle phase specific. Tumour cell cross-resistance has been observed between daunorubicin and doxorubicin.@@14917307@DaunoXome is indicated as a first line cytotoxic therapy for advanced HIV-associated Kaposi's sarcoma. DaunoXome is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.@@YES@@@NO REVIEW@@@@100%@Licensed from Gilead in May 2006. Gilead acquired it through takeover of NeXstar in 1999@FIRST-LINE@@60@DaunoXome should be administered intravenously over a 60 minute period at a dose of 40 mg/m2, with doses repeated every two weeks. Blood counts should be repeated prior to each dose, and therapy withheld if the absolute granulocyte count is less than 750 cells/mm3. Treatment should be continued until there is evidence of progressive disease (e.g., based on best response achieved: new visceral sites of involvement, or progression of visceral disease; development of 10 or more new, cutaneous lesions or a 25% increase in the number of lesions compared to baseline; a change in the character of 25% or more of all previously counted flat lesions to raised; increase in surface area of the indicator lesions), or until other intercurrent complications of HIV disease preclude continuation of therapy.@1-Aug-96@8/1/1996@@@@@1. Cardiac function should be monitored regularly in patients receiving DaunoXome because of the potential risk for cardiac toxicity and congestive heart failure. Cardiac monitoring is advised especially in those patients who have received prior anthracyclines or who have pre-existing cardiac disease or who have had prior radiotherapy encompassing the heart. 2. Severe myelosuppression may occur. 3. DaunoXome should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. 4. Dosage should be reduced in patients with impaired hepatic function. 5. A triad of back pain, flushing, and chest tightness has been reported in 13.8% of the patients (16/116) treated with DaunoXome in the Phase III clinical trial, and in 2.7% of treatment cycles (27/994). This triad generally occurs during the first five minutes of the infusion, subsides with interruption of the infusion, and generally does not recur if the infusion is then resumed at a slower rate.@LABEL@No@@@@@III; HIV-RELATED KAPOSI'S SARCOMA@APPROVED@@AMSR V@HAUTE AUTORITÉ DE SANTÉ@20 of 33 ABV responders responded to therapy by criteria more stringent than flattening of lesions. 11 of 27 DaunoXome responders responded to therapy by criteria other than flattening of lesions.@@@@@MONO@DAUNORUBICIN, LIPOSOMAL@@@@@DAUNORUBICIN, LIPOSOMAL||||@GILEAD SCIENCES@@@@@GILEAD SCIENCES||||@@@@@@|||||||||@Sarcoma@Kaposi's Sarcoma@@@@Sarcoma|Kaposi's Sarcoma||||||||@DAUNOXOME@@@@@DAUNOXOME||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@ACTG@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@RANDOMISED@PLACEBO-CONTROLLED@@@1.75@m²@5147.0475@@@365@day@365 day@5147.05@5147.05@14.1@1@1.1807@282.03@@@@@@@@@@@@2.82@14@@mg/m²@40@1@@@@@@@@@@@8/18/2017@282.03@282.03@9184467R@INJECTABLE LIPOSOMAL CONCENTRATE DISPERSION, 50 ML@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14917536@Onco@@@@@300f1018ntsdm@@@@@@Eloxatin + 5-FU/LV FOLFOX4 (267) arm received on Day 1: Eloxatin: 85 mg/m2 (2-hour infusion) + LV 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) and on Day 2: LV 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) - every 2 weeks Irinotecan + 5-FU/LV IFL (264) arm received on Day 1: irinotecan 125 mg/m2 as a 90–min infusion + LV 20 mg/m2 as a 15-min infusion or IV push, followed by 5-FU 500 mg/m2 IV bolus weekly x 4 - every 6 weeks Eloxatin + irinotecan IROX (264) arm received on Day 1: Eloxatin: 85 mg/m2 IV (2-hour infusion) + irinotecan 200 mg/m2 IV over 30 minutes - every 3 weeks@@L01XA03@L01X@YES@-@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14917536@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer. @@YES@-@@NO REVIEW@@@@100%@sanofi-aventis licensed U.S. and European rights from Debiopharm.@FIRST-LINE@-@795@The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.@-@@@-@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@-@@-@795  PATIENTS PREVIOUSLY UNTREATED FOR LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER WERE RANDOMISED TO 3 ARMS@@@COMBINATION THERAPY WITH ELOXATIN AND 5-FU/LV IN PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER; A NORTH AMERICAN, MULTICENTRE, OPEN-LABEL, RANDOMISED CONTROLLED STUDY COMPARED THE EFFICACY AND SAFETY OF TWO EXPERIMENTAL REGIMENS, ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FU/LV AND A COMBINATION OF ELOXATIN PLUS IRINOTECAN, TO AN APPROVED CONTROL REG@DISCONTINUED@@Authority required: Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid; Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour. Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer. Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.@PBS@Patients treated with the Eloxatin and 5-FU/LV combination had a significantly longer time to tumor progression based on investigator assessment (Median TTP = 8.7 months for the Eloxatin + 5-FU/LV arm compared to 6.9 months for the irinotecan + 5 FU/LV arm and 6.5 months for the ELOXATIN + irinotecan arm - hazard ratio = 0.74 and =<0.0014), longer OS (Median Survival ITT = 19.4 months for the ELOXATIN + 5-FU/LV arm compared to 14.6 months for the irinotecan + 5 FU/LV arm and 17.6 months for the Eloxatin + irinotecan arm - hazard ratio = 0.65 and =<0.0001), and a significantly higher confirmed RR based on investigator assessment (Complete response rate = 6.2% for the Eloxatin + 5-FU/LV arm compared to 2.4% for the irinotecan + 5 FU/LV arm and 3.3% for the Eloxatin + irinotecan arm ; Partial RR = 39% for the Eloxatin + 5-FU/LV arm compared to 30.2% for the irinotecan + 5 FU/LV arm and 31.2% for the Eloxatin + irinotecan arm ; Complete and partial RR = 45.2% for the Eloxatin + 5-FU/LV arm compared to 32.5% for the irinotecan + 5 FU/LV arm and 34.4% for the Eloxatin + irinotecan arm - p=0.0080).@The incidence of death within 30 days of last treatment, regardless of causality, was 3% in the Eloxatin/5-FU/LV arm; 5% in the irinotecan/5-FU/LV arm, and 3% in the Eloxatin/irinotecan arm. The most common adverse reactions were peripheral sensory neuropathy (82%%), parasthesias (77%), nausea (71%), diarrhea (56%), vomiting (41%) and fatigue (70%).@@@@COMBO@OXALIPLATIN@LEUCOVORIN@FLUOURACIL@@@OXALIPLATIN|LEUCOVORIN|FLUOURACIL||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ELOXATIN@5-FU@FOLFOX4@@@ELOXATIN|5-FU|FOLFOX4||@Platinum@@@@@Platinum||||@TIME TO PROGRESSION@OVERALL SURVIVAL@RESPONSE RATE@@@RESPONSE RATE@@@@@METASTATIC@@@@@MULTI-CENTRE@OPEN-LABEL@RANDOMISED@PLACEBO-CONTROLLED@@@@Invalid Factory Price@@@23.9@week@23.9 week@@@@1@0.8893@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3/1/2016@@@4542C5514011000036106@SOLUTION CONCENTRATE FOR I.V. INFUSION - 20 ML@A$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14917185@Onco@@@@@300f1010ntsdm@@@@@@198 patients who received combination irinotecan/ infusional 5-FU/LV therapy given weekly were compared with 187 patients who received an infusional regimen of 5-FU/LV alone given daily for 5 days every 4 weeks.@@L01XX19@L01X@YES@NEW YORK, NEW YORK@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14917185@Indicated for the treatment of patients with advanced colorectal cancer in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.@@YES@5-Aug@@NICE: first-line combination combination with 5-FU/FA ICER £14,000 per QALY gained compared with 5-FU/FA@@@@100%@Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan@FIRST-LINE@@385@Regimen 1: 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43): 125 mg/m2 intravenous infusion over 90 minutes, days 1,8,15,22@EMA, September 1995@@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR THE RECTUM RANDOMISED IN 2 ARMS. CONCOMITANT MEDICATIONS SUCH AS ANTIEMETICS, ATROPINE, AND LOPERAMIDE WERE GIVEN TO PATIENTS FOR PROPHYLAXIS AND/OR MANAGEMENT OF SYMPTOMS FROM TREATMENT. PATIENTS ALS@@@STUDY 2 OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FU/LV FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER@APPROVED@@NICE recommendation in combination with 5-flourouracil and folinic acid as a front-line treatment for advanced colorectal cancer, or as a monotherapy in subsequent therapy@NHS@The combination of irinotecan/ infusional 5-FU/LV therapy resulted in significant improvements in objective tumour RRs (35% vs 22% p<0.005), TTP (6.7 months vs 4.4 months p=0.001), and survival (17.4 months vs 14.1 months p<0.05) when compared with infusional 5-FU/LV alone.@@@@@COMBO@IRINOTECAN@LEUCOVORIN@FLUOURACIL@@@IRINOTECAN|LEUCOVORIN|FLUOURACIL||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CAMPTO@5-FU@@@@CAMPTO|5-FU|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@@@@@@ADVANCED@@@@@RANDOMISED@CONTROLLED@INTERNATIONAL@@@1.75@m²@4617.845833@@@5.5@month@5.5 month@4617.85@4617.85@27.6@1@1.2961@53@@@@@@@@@@@@1.33@42@@mg/m²@125@4@@@@@@@@@@@8/21/2017@53@53@8.09E+15@CONCENTRATE FOR INTRAVENOUS INFUSION 2 ML@GB£@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16614849@Onco@@@@@300f1015ntsdm@@@@@@Experimental: lenvatinib Intervention: Drug: lenvatinib 24 mg administered orally, once a dayExperimental: Placebo Intervention: Drug: Placebo 24 mg administered orally, once a day@@L01XE29@L01X@@TOKYO, JAPAN@3/1/2015@@@@16614849@Indicated for the treatment of adult patients with progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)@Both@YES@2-Dec-15@12/2/2015@@@@@@@MULTIPLE@NCT01321554@392@The recommended daily dose of LENVIMA is 24 mg  taken once daily with or without food. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.@EMA, 28 May 2015@5/28/2015@1/10/2017@Yes@@3/1/2011@@E7080-G000-303@No@@Subjects must have histologically or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes: a.Papillary thyroid cancer (PTC) i. Follicular variant ii. Variants (including but not limited to tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin's-like, trabecular, tumor with nodular fasciitis-like stroma, Hurthle cell variant of papillary carcinoma, poorly differentiated)b.Follicular thyroid cancer (FTC) i. Hurthle cell ii. Clear cell iii. Insular2.Measurable disease meeting the following criteria and confirmed by central radiographic review: a.At least 1 lesion of greater than or equal to 1.0 cm in the longest diameter for a non-lymph node or greater than or equal to 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of greater than or equal to 1.5 cmb.Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion@@ADULTS@III@APPROVED@@ASMR IV: 2 December 2015. [HAS, http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-05/lenvima_summary_ct14510.pdf]@HAUTE AUTORITÉ DE SANTÉ@The main study on which Lenvima's recommendation is based is a phase III trial including 392 patients with progressive DTC no longer responding to radioactive iodine, who were randomly assigned to receive either Lenvima or placebo. The study showed that patients treated with Lenvima lived on average 14.7 months longer without their disease progressing than patients treated with placebo.A large proportion of people receiving Lenvima during the studies needed to reduce the dose or interrupt treatment because of side effects (mainly high blood pressure and excess protein in the urine). Overall EMA's Committee for Medicinal Products for Human Use (CHMP) considered that Lenvima has a safety profile which is consistent with other similar therapies and that side effects were predictable and manageable. However, the CHMP has requested a further study to investigate the most appropriate starting dose of Lenvima to optimise the benefits and reduce risks for patients who will be treated with the medicine.The opinion adopted by the CHMP at its March 2015 meeting is an intermediary step on Lenvima's path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on EU-wide marketing authorisation. Once a marketing authorisation has been granted, a decision about price and reimbursement will then take place at the level of each Member State considering the potential role/use of this medicine in the context of the national health system of that country.[EMA, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/03/news_detail_002297.jsp&mid=WC0b01ac058004d5c1]@@@@@MONO@LENVATINIB@@@@@LENVATINIB||||@EISAI@@@@@EISAI||||@United States@Australia@Belgium@Brazil@Canada@United States|Australia|Belgium|Brazil|Canada|Chile|Denmark|France|Germany|Japan@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@LENVIMA@@@@@LENVIMA||||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@@@@@REFRACTORY@DIFFERENTIATED@@@@RANDOMIZED@DOUBLE BLIND@PLACEBO-CONTROLLED@MULTICENTER@@1@1@173295.8292@@@18.3@month@18.3 month@173295.83@173295.83@311.34@30@1.1511@1556.7@1719.28@1586.7@@@@@@@@@@12.97@1@@mg@24@1@@@@@@@@@@@8/1/2017@51.89@51.89@3.40E+12@CAPSULE@EURO@@@@@@@@4@MG@4 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14923586@Onco@@@@@300f1008ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14923586@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@First-line chemotherapy of breast carcinoma: When used in combination with doxorubicin (50 mg/m2), paclitaxel should be administered 24 hours after doxorubicin. The recommended dose of paclitaxel is 220 mg/m2 administered intravenously over a period of 3 hours, with a 3-week interval between course@@@@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHI@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAXOL@@@@@TAXOL||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.0091@18716.21@22071@@@@@@@@@@@187.16@@@@@@@@@@@@@@@@8/30/2017@18716.21@18716.21@4240406A2038@INJECTION 16,7 ML@YEN@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14921939@Onco@@@@@300f1010ntsdm@@@@@@Patients received either Nexavar 400 mg twice daily or to placebo.@@L01XE05@L01X@NO@LEVERKUSEN, GERMANY@@@Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis. Sorafenib inhibited tumor growth and angiogenesis of human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice.@@14921939@Hepatocellular carcinoma: Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma: Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.@@NO@4-Feb-09@2/4/2009@With discounting at 3.5% per annum, the comparison of sorafenib with best supportive care produced an ICER of £102,498. The deterministic sensitivity analyses demonstrated that estimates of treatment effectiveness and cost of sorafenib (dose intensity assumption) were the key drivers affecting the ICERs. The health state utility parameters affected the ICER marginally. The ICER was particularly sensitive to variations in estimates of the hazard ratio for overall survival, with ICERs ranging from £55,585 (HR for overall survival = 0.54) to £368,830 (HR for overall survival = 0.94). SOURCE: Assessment Group Model@@@@100%@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@SECOND-LINE@@769@The recommended daily dose of Nexavar is 400 mg (2 x 200 mg tablets) taken twice daily, without food (at least 1 hour before or 2 hours after eating).@EMA, 19 July 2006@7/19/2006@@@@@Women of childbearing potential should be advised to avoid becoming pregnant while on Nexavar. Nexavar should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.@STUDY 1@No@@769 PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WHO HAD RECEIVED ONE PRIOR SYSTEMIC THERAPY WERE STRATIFIED BY MSKCC (MEMORIAL SLOAN KETTERING CANCER CENTER) PROGNOSTIC RISK CATEGORY1 (LOW OR INTERMEDIATE) AND COUNTRY AND RANDOMIZED TO NEXAVAR 400 MG TWIC@@@III@APPROVED@@>>Final Appraisal Determination:1.1 Bevacizumab, sorafenib and temsirolimus are not recommended as first-line treatment options for people with advanced and/or metastatic renal cell carcinoma. 1.2 Sorafenib and sunitinib are not recommended as second-line treatment options for people with advanced and/or metastatic renal cell carcinoma. 1.3 People who are currently being treated with bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for advanced and/or metastatic renal cell carcinoma should have the option to continue their >>1.1 Sorafenib is not recommended for the treatment of advanced hepatocellular carcinoma in patients for whom surgical or locoregional therapies have failed or are not suitable.@NHS@The median PFS for patients on Nexavar was 167 days compared to 84 days for patients on placebo. The estimated hazard ratio (risk of progression with Nexavar compared to placebo) was 0.44 (95% CI: 0.35, 0.55).  The effect of Nexavar on PFS was consistent across different subsets, including age above or below 65 years, ECOG PS 0 or 1, MSKCC prognostic risk category1, whether the prior therapy was for progressive metastatic disease or for an earlier disease setting, time from diagnosis of less than or greater than 1.5 years.  The subsets also included patients with no prior IL-2 or interferon therapy, for whom the median PFS was 172 days on Nexavar compared to 85 days on placebo. OS was longer for Nexavar than placebo with a hazard ratio (Nexavar over placebo) of 0.72. This analysis did not meet the prespecified criteria for statistical significance. Additional analyses are planned as the survival data mature.@Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%),and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%.@@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@ONYX@@@@BAYER HEALTHCARE|ONYX|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@INTERNATIONAL@MULTI-CENTRE@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@1@1@21331.62543@@@167@day@167 day@21331.63@21331.63@127.73@112@1.299@3576.56@@@@@@@@@@@@0.16@1@@mg@800@1@@@@@@@@@@@7/28/2017@31.93@31.93@1.07E+16@FILM-COATED TABLET@GB£@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920952@Onco@@@@@300f1037ntsdm@@@@@@A single course of Leustatin Injection given by continuous intravenous infusion for 7 days at a dose of 0.09 mg/kg/day or a 7-day continuous intravenous infusion of Leustatin Injection at a comparable dose of 3.6 mg/m2/day.@@L01BB04@L01B@YES@NEW BRUNSWICK, NEW JERSEY@@@The selective toxicity cladribine towards certain normal and malignant lymphocyte and monocyte populations is based on the relative activities of deoxycytidine kinase, deoxynucleotidase and adenosine deaminase. It is postulated that cells with high deoxycytidine kinase and low deoxynucleotidase activities will be selectively killed by cladribine as toxic deoxynucleotides accumulate intracellularly. Cells containing high concentrations of deoxynucleotides are unable to properly repair single-strand DNA breaks. It can be distinguished from other chemotherapeutic agents affecting purine metabolism in that it is cytotoxic to both actively dividing and quiescent lymphocytes and monocytes, inhibiting both DNA synthesis and repair.@@14920952@Indicated for the primary or secondary treatment of patients with Hairy Cell Leukaemia (HCL); it is also indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (CLL) who have not responded to, or whose disease has progressed during or after, treatment with at least one standard alkylating-agent-containing regimen.@@YES@@@NO REVIEW@@@@@Ortho Biotech Products@FIRST-LINE@@@HCL: The recommended treatment for Hairy Cell Leukaemia is a single course given by continuous intravenous infusion for 7 consecutive days at a dose of 0.09 mg/kg/day (3.6 mg/m²/day). Deviations from this dosage regimen are not advised. Physicians should consider delaying or discontinuing the drug if neurotoxicity or renal toxicity occurs. CLL: In patients with CLL, the recommended treatment consists of a continuous intravenous infusion for 2 hours on days 1 to 5 of a 28 day cycle at a dose of 0.12 mg/kg/day (4.8 mg/m2/day). The patient's response to therapy should be determined every two cycles of treatment. It is recommended that it be administered in responding patients for 2 cycles after maximum response has occurred, up to a maximum of 6 cycles.@1-Jul-97@7/1/1997@@@@@Severe bone marrow suppression, including neutropaenia, anaemia and thrombocytopaenia, has been commonly observed in patients treated with Leustatin especially at high doses. Fever (T = 100°F) was associated also with the use of Leustatin. Severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. Acute nephrotoxicity has been observed with high doses, especially when given concomitantly with other nephrotoxic agents/therapies. Leustatin Injection should not be given during pregnancy. Women of childbearing age should be advised to avoid becoming pregnant.@@No@@PATIENTS WITH HAIRY CELL LEUKEMIA WITH EVIDENCE OF ACTIVE DISEASE REQUIRING THERAPY. 60% OF THE PATIENTS HAD NOT RECEIVED PRIOR CHEMOTHERAPY FOR HAIRY CELL LEUKEMIA OR HAD UNDERGONE SPLENECTOMY AS THE ONLY PRIOR TREATMENT AND WERE RECEIVING LEUSTATIN AS A@@@N/A@APPROVED@@NO REVIEW@SNS@Among patients evaluable for efficacy (N=106), the combined complete RR was 66% and the combined overall RR was 88%. Among all patients (123), combined complete RR, including one more criterion, that is further requiring no evidence of splenomegaly (i.e., no palpable spleen on physical examination and = 13 cm on CT scan), was 54% and combined overall response rate (CR+GPR+PR) was 89%. The overall RR for patients without prior chemotherapy was 92%, compared with 84% for previously treated patients, with 78% for previously treated with splenectomy patients, with 83% for previously treated with interferon patients, with 55% for patients refractory to a-interferon, with 50% for previously treated with deoxycoformycin patients. The share of patients with no response or relapse for patients without prior chemotherapy was 14%, compared with 22% for previously treated patients, with 24% for previously treated with splenectomy patients, with 23% for previously treated with interferon patients, with 64% for patients refractory to a-interferon, with 66% for previously treated with deoxycoformycin patients. Normalisation of peripheral blood counts (Hemoglobin >12.0 g/dL, Platelets >100 x 109/L, Absolute Neutrophil Count ANC >1500 x 106/L) was achieved by 92% of evaluable patients. The median time to normalisation of peripheral counts was 9 weeks from the start of treatment (Range: 2 to 72). The median time to normalisation of Platelet Count was 2 weeks, the median time to normalisation of ANC was 5 weeks and the median time to normalisation of Hemoglobin was 8 weeks.@@@@@MONO@CLADRIBINE@@@@@CLADRIBINE||||@JOHNSON & JOHNSON@JANSSEN CILAG@@@@JOHNSON & JOHNSON|JANSSEN CILAG|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Hairy Cell Leukaemia@B-Cell Lymphoma@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Hairy Cell Leukaemia|B-Cell Lymphoma||||||@LEUSTATIN@@@@@LEUSTATIN||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@RESPONSE RATE@@@@@@@@@@@@@@@SINGLE-CENTRE@OPEN-LABEL@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@7@1.1511@2072.18@2213.21@2079.72@@@@@@@@@@29.6@@@@@@@@@@@@@@@@8/4/2017@296.03@296.03@674242@INTRAVENOUS  INJECTION, 10 ML@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15360718@Onco@@@@@300f1012ntsdm@@@@@@Everolimus plus BSC versus BSC plus placebo@@L01XE10@L01X@NO@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15360718@Patients who have progressed on VEGF therapy of Nexavar and/or Sutent@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@NCT00410124@416@The recommended dose for treatment of advanced renal cell carcinoma is 10 mg, to be taken once daily at the same time every day, either with orwithout food. Afinitor tablets should be swallowed whole with a glass of water. The tablets should not be chewed or crushed.Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.@EMA, 7 August 2009@8/7/2009@@No@@10/1/2006@@RECORD-1@No@@@@@III@APPROVED@@@GKV@Updated study findings show that patients receiving RAD001 had no tumor growth for nearly 5 months vs. 1.9 months for patients receiving placebo (hazard ratio = 0.33 with 95% CI 0.25 to 0.43; p-value < 0.001). In addition, after more than 10 months of treatment with RAD001, 25% of patients still had no tumor growth.Results presented at ASCO 2008The IDMC stopped the trial of more than 400 patients conducted in 12 countries because the study met its primary endpoint. The interim findings are being shared with investigators to allow them to offer everolimus to patients remaining on placebo. Full results of the trial will be submitted as a late-breaking abstract for presentation at the American Society of Clinical Oncology annual meeting in May. [Novartis, 28 February 2008]@Safety findings in the RECORD1 trial were consistent with those seen in prior Phase II studies. The most frequent adverse drug reactions in patients who took RAD001 included mouth sores (40%), feelings of tiredness/weakness (37%), and rash (25%). There was a low incidence (> 1% of patients listed) of grade 3 or 4 drugrelated adverse events: mouth sores (3%), lung inflammation (3%), infection (3%), tiredness/feelings of weakness (4%), diarrhea (1%), mucosal inflammation (1%) and shortness of breath (1%). The trial had a low rate of adverse drug reactions leading to discontinuation among patients who took RAD001 (6%). The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003.@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@AFINITOR@RAD-001@@@@AFINITOR|RAD-001|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@CROSSOVER@@@1@1@26469.81599@@@4.9@month@4.9 month@26469.82@26469.82@177.6@30@1.1511@1332.03@1689.99@1370.53@@@@@@@@@@17.76@1@@mg@10@1@@@@@@@@@@@8/1/2017@44.4@44.4@9911772@TABLET@EURO@@@@@@@@2.5@MG@2.5 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919453@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@H02AB07@H02A@NO@COLOMBES, FRANCE@@@Prednisolone acetate is a synthetic adrenocorticoid with the general properties of prednisolone. Adrenocorticoids diffuse across cell membranes to complex with cytoplasmic receptors and subsequently stimulate synthesis of enzymes with anti-inflammatory effects. Glucocorticoids inhibit the oedema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation, deposition of collagen and scar formation. Prednisolone acetate has, on a weight to weight basis, a potency three to five times that of hydrocortisone.@@14919453@Indicated in the following conditions: Endocrine Disorders [Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcernia associated with cancer Nonsuppurative thyroiditis)] Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) [Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis] Collagen Diseases [During an exacerbation or as maintenance therapy in selected  cases of: Systemic lupus erythematosus Systemic-dermatomyositis (polymyositis) Acute rheumatic carditis] Dermatologic Diseases [Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis] Allergic States [Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions] Ophthalmic Diseases [Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic cornea marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis] Respiratory Diseases [Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis] Haematologic Disorders [Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopaenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia] Neoplastic Diseases For palliative management of: [Leukemias and lymphomas in adults Acute leukemia of childhood] Edematous States [To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis] Nervous System [Acute exacerbations of multiple sclerosis] Miscellaneous [Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement]@@NO@5-Jan@@NO REVIEW@@@@@G Gam is the French arm of Hexal, purchased by Novartis in February 2005.@@@@The initial dosage may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required.@1-Aug-04@8/1/2004@7/18/2005@@@@In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination With other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PREDNISONE@@@@@PREDNISONE||||@BIOGARAN@G GAM@NOVARTIS@@@BIOGARAN|G GAM|NOVARTIS||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@1.37@1.85@1.67@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.05@0.05@3.40E+12@SCORED TABLET@EURO@@@@@@@@5@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14971365@Onco@@@@@300f1012ntsdm@@@@@@Aflibercept once every 2 weeks versus placebo together with irinotecan/5-FU (FOLFIRI) combination@@L01XX44@L01X@YES@PARIS, FRANCE@@@Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis.@@14971365@ZALTRAP, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen@@NA@15-Aug-13@8/15/2013@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@SECOND-LINE@NCT00561470@1200@4 mg/kg as an intravenous infusion over 1 hour every 2 weeks.@EMA, 5 February 2013@2/5/2013@3/1/2013@No@@11/1/2007@YES@VELOUR@No@@@@@EFC10262, AVE0005, EudraCT 2007-000820-42;@APPROVED@@15 August 2013: small additional benefit [G-BA, https://www.g-ba.de/downloads/39-261-1797/2013-08-15_AM-RL-XII_Aflibercept_BAnz.pdf]@GKV@The VELOUR trial showed that in patients previously treated with an oxaliplatin-containing regimen,  adding ZALTRAP to FOLFIRI significantly improved median survival from 12.06 months to 13.50  months (HR=0.817 (95% CI 0.714 to 0.935; p=0.0032), an 18 percent relative risk reduction. A significant improvement in progression-free survival from 4.67 months to 6.90 months (HR=0.758 95% CI 0.661 to 0.869; p=0.00007), a 24 percent relative risk reduction, was also observed. The overall response rate in the ZALTRAP plus FOLFIRI arm was 19.8% vs. 11.1% for FOLFIRI (p=0.0001).   [Sanofi 8 October 2012 http://en.sanofi.com/Images/31196_20121008_ZALTRAPVELOUR_en.pdf ]Trial met primary endpoint of improving overall survival. Full results to be presented at an upcoming medical meeting [Sanofi-Aventis, 26 April 2011, http://en.sanofi-aventis.com/binaries/20110426_VELOUR_en_tcm28-31928.pdf ]>>RESULTS PENDING@The most frequent adverse events reported with ZALTRAP in combination with FOLFIRI werediarrhea, asthenia/fatigue, stomatitis and ulceration, nausea, infection, hypertension,gastrointestinal and abdominal pains, vomiting, decreased appetite, decreased weight,epistaxis, alopecia, and dysphonia.@@@@COMBO@AFLIBERCEPT@IRINOTECAN@FLUOURACIL@@@AFLIBERCEPT|IRINOTECAN|FLUOURACIL||@SANOFI-AVENTIS@REGENERON PHARMACEUTICALS@@@@SANOFI-AVENTIS|REGENERON PHARMACEUTICALS|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ZALTRAP@5-FU@FOLFIRI@@@ZALTRAP|5-FU|FOLFIRI||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@76.5@kg@13761.50194@@@6.9@month@6.9 month@13761.5@13761.5@65.57@1@1.1511@600@769.57@619.6@@@@@@@@@@3@14@@mg/kg@4@1@@@@@@@@@@@8/1/2017@600@600@3800362@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL), 8 ML IN 200 ML@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16387341@Onco@@@@@300f1018ntsdm@@@@@@Patients in arm 1 (PC) received six cycles of paclitaxel 200 mg/m2 and carboplatin AUC=6.0, both by IV infusion on day 1. Patients in arm 2 (PC + Avastin) received six cycles of paclitaxel 200 mg/m2 and carboplatin AUC=6.0, both by IV infusion on day 1 in combination with Avastin at a dose of 15 mg/kg by IV infusion on day 1 and after completion or upon discontinuation of chemotherapy, they continued to receive Avastin alone until disease progression or until unacceptable toxicity.@@L01XC07@L01X@@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16387341@AVASTIN (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced,metastatic or recurrent, non-squamous non-small cell lung cancer.@@YES@@@NO REVIEW@@@@100%@@FIRST-LINE@NCT00021060@878@NSCLC: The recommended dose is 15 mg/kg, as an IV infusion every 3 weeks.@TGA, 24 February 2005@2/24/2005@@@@@@E4599@No@@CHEMOTHERAPY-NAÏVE PATIENTS WITH LOCALLY ADVANCED, METASTATIC OR RECURRENT NON-SQUAMOUS NSCLC WERE RANDOMISED TWO TREATMENT ARMS. 11% HAD RECURRENT DISEASE AND OF THE REMAINING 89% WITH NEWLY DIAGNOSED NSCLC, 12% HAD STAGE IIIB WITH MALIGNANT PLEURAL@@@III@APPROVED@@@PBS@@@@@@COMBO@BEVACIZUMAB@PACLITAXEL@CARBOPLATIN@@@BEVACIZUMAB|PACLITAXEL|CARBOPLATIN||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@ACTIVE CONTROL@OPEN-LABEL@MULTI-CENTRE@@76.5@kg@43451.77618@@@6.4@month@6.4 month@43451.78@43451.78@223.22@1@0.779@1634@@@@@@@@@@@@4.09@21@@mg/kg@15@1@@@@@@@@@@@8/1/2017@1634@1634@0537-0253-IN-RO@CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION - 16 ML@A$@@@@@@@@400@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14923196@Onco@@@@@300f1012ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14923196@Sprycel is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. It is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@PATIENTS WITH CML OR PH+ ALL RESISTANT TO OR INTOLERANT OF TREATMENT WITH IMATINIB. THE CHRONIC PHASE CML STUDY ENROLLED 186 PATIENTS (CA-180-013/17), THE ACCELERATED PHASE CML STUDY 107 PATIENTS (CA-180-005), AND THE MYELOID BLAST PHASE STUDY 74 PATIENTS (CA-180-006)@The recommended starting dosage for chronic phase CML is 100 mg once daily, administered orally, consistently either in the morning or in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@EMA, 20 November 2006@11/20/2006@@Yes@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-005/006/013/017@No@@PATIENTS WITH CML OR PH+ ALL RESISTANT TO OR INTOLERANT OF TREATMENT WITH IMATINIB. THE CHRONIC PHASE CML STUDY ENROLLED 186 PATIENTS (CA-180-013/17), THE ACCELERATED PHASE CML STUDY 107 PATIENTS (CA-180-005), AND THE MYELOID BLAST PHASE STUDY 74 PATIENTS (CA-180-006)@@@II@APPROVED@@@GKV@In chronic phase CML patients, the MCyR rate was 45% with a complete response (0% Ph+ cells) rate of 33%.@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@71094.72339@@@11@month@11 month@71094.72@71094.72@212.49@60@1.1511@4553.4@5638.42@4591.9@@@@@@@@@@1.52@1@@mg@140@1@@@@@@@@@@@8/1/2017@75.89@75.89@283475@FILM-COATED TABLET@EURO@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920064@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Idamycin 12MG/M2 (n=111) versus daunorubicin 45MG/M2 (n=119)@@L01DB06@L01D@YES@PETACH TIKVA, ISRAEL@@@Idarubicin is an antimitotic and cytotoxic agent which intercalates with DNA and interacts with topoisomerase II and has an inhibitory effect on nucleic acid synthesis. The compound has a high lipophilicity which results in an increased rate of cellular uptake compared with doxorubicin and daunorubicin. Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes. Studies in-vitro on human and murine anthracycline-resistant cells have shown a lower degree of cross-resistance for idarubicin compared with doxorubicin and daunorubicin. Cardiotoxicity studies in animals have indicated that idarubicin has a better therapeutic index than daunorubicin and doxorubicin. The main metabolite, idarubicinol, has shown in-vitro and in-vivo antitumoral activity in experimental models. In the rat, idarubicinol, administered at the same doses as the parent drug, is clearly less cardiotoxic than idarubicin.@@14920064@Idamycin in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia in adults.@@NO@@@NO REVIEW@@@@@@FIRST-LINE@@230@Idamycin 12 mg/m2 daily for 3 days by slow (10 to 15 min) intravenous injection in combination with cytarabine. The cytarabine may be given as 100 mg/m2 daily by continuous infusion for 7 days or as cytarabine 25mg/m2 intravenous bolus followed by cytarabine 200 mg/m2 daily for 5 days continuous infusion.@FDA, May 2002@@@@@@1. Idamycin should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration. 2. As is the case with other anthracyclines the use of Idamycin can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have preexisting cardiac disease. 3. As is usual with antileukemic agents, severe myelosuppression occurs when Idamycin is used at effective therapeutic doses. 4. It is recommended that Idamycin be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.@LABEL@No@@@@@III@APPROVED@@@MEDICARE@Idamycin 328 days versus daunorubicin 277 days@@@@@MONO@IDARUBICIN HCL@@@@@IDARUBICIN HCL||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@OVERALL SURVIVAL@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@329.4@@@@@@@@@@@@16.47@@@@@@@@@@@@@@@@8/2/2017@329.4@329.4@00703-4156-11@INJECTION (VIAL)@US$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16667505@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"LEE011 and everolimus, Experimental, This study will be conducted to determine the efficacy and safety of the combination of LEE011 and everolimus in subjects with advanced WDNETs of foregut origin (thymic, bronchopulmonary, gastric, duodenal, and pancreatic).
"@@@@@BASEL, SWITZERLAND@2/1/2019@@@@16667505@A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin@Both@@@@@All subjects will receive the oral combination of LEE011 and everolimus. Subjects will receive LEE011 300 mg daily, 3 weeks on and 1 week off, in combination with everolimus 2.5 mg daily. Subjects will continue treatment until meeting one of the criteria for removal from study.@@@@@@NCT03070301@42@@@@@@@@@16-1535@@@Patient has signed the Informed Consent prior to any screening procedures being performed and is able to comply with the protocol requirements.  -  Adults ≥ 18 years old  -  Histologic or cytologic diagnosis of a WDNET, low to intermediate grade, unresectable, of foregut origin (thymic, bronchopulmonary, gastric, duodenal, and pancreatic) confirmed by the enrolling institution  -  NOTE: Patients who have tumors with a Ki67 of 20% to 30% are eligible if the pathologist determines the tumor has the appearance of a well differentiated neuroendocrine tumor.  -  Note: If patients have a functional NET, they are permitted to continue on a somatostatin analog for hormonal symptom control  -  Patient has tissue available from a previous biopsy for the evaluation of potential predictive biomarkers. If tissue is not available, a new tumor specimen will need to be obtained prior to the start of study treatment.  -  Documented radiological evidence for disease progression (measurable or nonmeasurable) ≤12 months prior to enrollment  -  Disease that is currently not amenable to surgical resection with curative intent as determined by the treating investigator  -  Measurable disease as defined by RECIST v1.1  -  ECOG performance status 0 or 1 or KPS performance status 100 to 70  -  Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:  -  Absolute neutrophil count ≥1.5 x 10^9/L  -  Platelets ≥ 100 x 10^9/L  -  Hemoglobin ≥ 9.0 g/dL  -  INR ≤ 1.5  -  Serum creatinine <1.5mg/dL or creatinine clearance ≥ 50 mL/min  -  In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN. If a patient has liver metastases, ALT and AST <5 x ULN  -  Total bilirubin < ULN; or total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN in patients with well-documented Gilbert‟s Syndrome  -  Negative serum pregnancy test done ≤14 days prior to registration, for women of childbearing potential only  -  Patient with standard 12-lead ECG with the following parameters at screening (defined as the mean of the triplicate ECGs)  °QTcF interval at screening <450msec (using Fridericia‟s correction)  -  Must be able to swallow LEE011 and everolimus capsules/tablets  -  Recovered from adverse events (to grade 1 or less toxicity according to CTCAE 4.0) due to agents administered previously  *NOTE: Chemotherapy-induced alopecia and grade 2 neuropathy are acceptable  -  Women reproductive potential† must have a negative serum or urine β human chorionic gonadotropin (βhCG) pregnancy test. All women of reproductive potential, all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control (e.g. latex condoms) throughout the study and for 30 days after the last dose of study drug † A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).@@ADULTS@Phase 2@II@@@@@@@@@COMBO@-@EVEROLIMUS@@@@-|EVEROLIMUS|||@NOVARTIS@@@@@NOVARTIS||||@United States@@@@@United States|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@LEE011@AFINITOR@@@@LEE011|AFINITOR|||@Other@@@@@Other||||@Progression Free Survival (PFS)@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920955@Onco@@@@@300f1015ntsdm@@@@@@bendamustine group: 100 mg/m2 IV on D1 and D2 every 4 weeks (n=162);- chlorambucil group: 0.8 mg/kg per os on D1 and D15 every 4 weeks (n=157), a differentadministration regime to that used in France.@@L01AA09@L01A@NO@ULM, GERMANY@@@Bendamustine is an alkylating that is a bifunctional mechlorethamine derivative. Mechlorethamine and its derivatives dissociate into electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties. The bifunctional covalent linkage can lead to cell death via several pathways. The exact mechanism of action of bendamustine remains unknown. Bendamustine is active against both quiescent and dividing cells.@@14920955@First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.@@YES@6-Oct-10@10/6/2010@NO REVIEW@@@@@Ratiopharm acquired Ribosopharm. Cephalon acquired U.S. rights through takeover of Salmedix, which licensed it from Fujisawa (Astellas). It is marketed by MundiPharma as Ribomustin in Germany as a single or combination agent for indolent NHL, MM and CLL under the name Ribomustin. SymBio@FIRST-LINE@@319@100 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 4 weeks.@HMA, 15 July 2010@7/15/2010@10/1/2010@Yes@@@Myelosuppression Patients treated with Treanda are likely to experience myelosuppression. In the randomized CLL clinical study, patients receiving Treanda experienced Grade 3 or 4 neutropenia (24%), febrile neutropenia (3%), red blood cell transfusions (20%), and platelet transfusions (< 1%). In the event of treatment-related myelosuppression, monitor leukocytes, platelets, hemoglobin (Hgb), and neutrophils closely. In the randomized CLL clinical study hemoglobin and WBC differential counts were monitored weekly and platelet counts were monitored each cycle. Based on data from this study, hematologic nadirs should be expected in the third week of therapy and may require dose delays if recovery to the recommended values have notoccurred by day 28. Prior to the initiation of the next cycle of therapy, the ANC should be = 1 x 109/L and the platelet count should be = 75 x 109/L.Infections: Infection, including pneumonia and sepsis, has been reported in patients in clinical trials and in post-marketing reports. Infection has been associated with hospitalization, septic shock and death. Patients with myelosuppression following treatment with Treanda are more susceptible to infections. Patients with myelosuppression following Treanda treatment should be advised to contact a physician if they have symptoms or signs of infection.@NO LABELLED TRIAL@No@@chronic lymphocytic leukaemia, Binet stage B or C,patients aged under 75,patients who have not received any previous treatment for chronic lymphocytic leukaemia,WHO performance index ≤ 2,life expectancy of at least 3 months@@@@APPROVED@@ASMR III, compared tochlorambucil in terms of efficacy in the treatment of patients suffering from chroniclymphocytic leukaemia where combination chemotherapy including fludarabine is notsuitable.@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@BENDAMUSTINE@@@@@BENDAMUSTINE||||@RATIOPHARM@RIBOSEPHARM@ASTELLAS@@@RATIOPHARM|RIBOSEPHARM|ASTELLAS||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@LEVACT@@@@@LEVACT||||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@OVERALL PERCENTAGE RESPONSE@PROGRESSION-FREE SURVIVAL@@@@TIME TO PROGRESSION@DURATION OF REMISSION@@@@REFRACTORY@@@@@OPEN LABEL@RANDOMISED@@@@1.75@m²@5750.01@@@24@week@24 week@5750.01@5750.01@34.23@1@1.1511@273.81@@@@@@@@@@@@2.74@28@@mg/m²@100@2@@@@@@@@@@@8/2/2017@273.81@273.81@9353987T@POWDER FOR RECONSTITUTION FOR PERFUSION@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920272@Onco@@@@@300f1018ntsdm@@@@@@@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920272@Indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.@@NO@7-Jul@@The base case modelled incremental cost/extra discounted life year gained was estimated to be <$15,000 for newly diagnosed patients who go on to have a stem cell transplant; between $15,000 - $45,000 for newly diagnosed patients who do not go on to a stem cell transplant; and between $15,000 - $45,000 for relapsed/refractory patients. In the relapsed/refractory patients, the sensitivity analysis for the incremental cost per extra complete responder was as high as $100,000 to $200,000. The incremental cost/extra discounted life year gained was as high as $100,000 in the sensitivity analysis.@@@@100%@@@@411@The recommended dose of Glivec is 600 mg/day for adult patients with Ph+ ALL.@@@@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@AUGUST 2009 (PAEDIATRIC)@@ADULT@@@APPROVED@@The PBAC recommended the listing of imatinib for the treatment of acute lymphoblastic leukaemia (ALL) expressing the Philadelphia chromosome or transcript, bcr-abl tyrosine kinase (Ph +ve) in newly diagnosed patients in combination with chemotherapy on the basis of an acceptable cost-effectiveness ratio compared to chemotherapy alone.@PBS@Complete Haematologic response rate = 19% ; Major cytogenetic response rate = 35% ; Complete cytogenetic response rate = 21% ; Partial cytogenetic response rate = 14% for the 43 patients. The median duration of hematologic response was 3.4 months and the median duration of MCyR was 2.3 months.@The adverse reactions were similar for Ph+ ALL as for Ph+ CML. The most frequently reported drug-related adverse reactions reported in the Ph+ ALL studies were mild nausea and vomiting, diarrhea, myalgia, muscle cramps and rash, which were easily manageable. Superficial edema was a common finding in all studies and were described primarily as periorbital or lower limb edemas. These edemas were rarely severe and may be managed with diuretics, other supportive measures, or in some patients by reducing the dose of Gleevec.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@RELAPSED@REFRACTORY@@@@@@@@@1@1@12565.68452@@@2.85@month@2.85 month@12565.68@12565.68@144.96@60@0.779@1449.57@1576.95@1519.51@@@@@@@@@@0.24@1@@mg@600@1@@@@@@@@@@@8/1/2017@24.16@24.16@1632-1269-GE-AF@TABLET@A$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15358252@Onco@@@@@300f1018ntsdm@@@@@@@@L01XE03@L01X@-@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@15358252@Indicated for the first-line treatment of patients with advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with activating EGFR mutations.@Both@NO@@@NO REVIEW@@@@100%@>> Abbott signed a deal with Genentech and OSI to develop a molecular gene test to identify extra copies of EGFR in NSCLC for Tarceva. [Abbott, 10 March 2008]     >> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]       >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]        >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@FIRST-LINE@NCT00446225@174@The recommended daily dose is 150 mg taken at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.@@@@@@@@@No@@Histologically confirmed diagnosis of NSCLC, non epidermoid, stage IV or IIIB with pleural effusion, or N3 tumours not candidate for thoracic radiotherapy, harbouring deletions in the exon 19 or mutation in the exon 21 in the TK of the EGFR.Either measurable or evaluable disease.ECOG performance status < 2.@@ADULTS@III@APPROVED@@@PBS@@@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@CHUGAI PHARMACEUTICAL@@@@ROCHE|CHUGAI PHARMACEUTICAL|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE@ONE YEAR SURVIVAL@OVERALL SURVIVAL@@@METASTATIC@@@@@OPEN LABEL@@@@@1@@13817.76981@@@10.4@month@10.4 month@13817.77@13817.77@43.68@30@0.779@1310.46@1432.83@1380.4@@@@@@@@@@0.29@1@@mg@150@1@@@@@@@@@@@8/1/2017@43.68@43.68@3197-0904-GE-RO@FILM-COATED TABLET (BLISTER PVC/ALU)@A$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15048055@Onco@@@@@300f1012ntsdm@@@@@@Repeating dose of pertuzumab IV with Herceptin and Taxotere versus placebo/Herceptin/Taxotere@@L01XC13@L01X@@BASEL, SWITZERLAND@3/1/2012@@Pertuzumab is a humanized antibody and the first in a new class of agents known as HER dimerization inhibitors (HDIs). HDIs block the ability of the HER2 receptor to collaborate with other HER receptor family members (HER1/EGFR, HER3, and HER4). In cancer cells, interfering with HER2's ability to collaborate with other HER family receptors blocks cell signaling and may ultimately lead to cancer cell growth inhibition and death of the cancer cell. HDIs, because of their unique mode of action, have the potential to work in a wide variety of tumors, including those that do not overexpress HER2@@15048055@Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.@@NA@1-Oct-13@10/1/2013@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@NCT00567190@800@The initial PERJETA dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusion.@EMA, 5 March 2013@3/5/2013@4/1/2013@No@@12/1/2007@@CLEOPATRA@No@@@@@III@APPROVED@@Significant added value [G-BA, 1 October 2013, https://www.g-ba.de/downloads/39-261-1828/2013-10-01_AM-RL-XII_Pertuzumab_BAnz.pdf]@GKV@People who received pertuzumab in combination with Herceptin and chemotherapy experienced a 38 percentreduction in the risk of their disease worsening or death (progression-free survival, or PFS), (HR=0.62; pvalue=<0.0001). The median PFS improved by 6.1 months from 12.4 months for Herceptin andchemotherapy to 18.5 months for pertuzumab, Herceptin and chemotherapy. Overall survival (OS) data arecurrently immature, with a trend in favour of the pertuzumab combination.[Roche, 8 December 2011 http://www.roche.com/media/media_releases/med-cor-2011-12-08.htm ]FPI confirmed. SOURCE: Genentech, 10 April 2008First-patient in (FPI) in Q407, but not yet confirmed.@No new safety signals were observed and adverse events were consistent with those seen in previous studies of pertuzumab and Herceptin, either in combination or alone.[Roche, 8 December 2011]@@@@COMBO@PERTUZUMAB@TRASTUZUMAB@DOCETAXEL@@@PERTUZUMAB|TRASTUZUMAB|DOCETAXEL||@ROCHE@@@@@ROCHE||||@United States@@@@@United States|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@PERJETA@HERCEPTIN@TAXOTERE@@@PERJETA|HERCEPTIN|TAXOTERE||@mAb@Humanised@HER2@@@mAb|Humanised|HER2||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@1@1@65561.56857@@@18.5@month@18.5 month@65561.57@65561.57@116.51@1@1.1511@2358.75@2948.44@2397.25@@@@@@@@@@5.62@21@1@mg@840@1@21@@mg@420@1@@@@@@8/1/2017@2358.75@2358.75@9888530@CONCENTRATE FOR SOLUTION FOR INFUSION, 14 ML@EURO@@@@@@@@420@MG@420 MG/14 ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15360707@Onco@@@@@300f1008ntsdm@@@@@@Everolimus plus BSC versus BSC plus placebo@@L01XE10@L01X@NO@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15360707@Advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@NCT00410124@416@The recommended dose for treatment of advanced renal cell carcinoma is 10 mg, to be taken once daily at the same time every day, either with orwithout food. Afinitor tablets should be swallowed whole with a glass of water. The tablets should not be chewed or crushed.Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.@@@@Yes@@10/1/2006@@RECORD-1@No@@@@@III@APPROVED@@@NHI@Updated study findings show that patients receiving RAD001 had no tumor growth for nearly 5 months vs. 1.9 months for patients receiving placebo (hazard ratio = 0.33 with 95% CI 0.25 to 0.43; p-value < 0.001). In addition, after more than 10 months of treatment with RAD001, 25% of patients still had no tumor growth.Results presented at ASCO 2008>> The IDMC stopped the trial of more than 400 patients conducted in 12 countries because the study met its primary endpoint. The interim findings are being shared with investigators to allow them to offer everolimus to patients remaining on placebo. Full results of the trial will be submitted as a late-breaking abstract for presentation at the American Society of Clinical Oncology annual meeting in May. [Novartis, 28 February 2008]@Safety findings in the RECORD1 trial were consistent with those seen in prior Phase II studies. The most frequent adverse drug reactions in patients who took RAD001 included mouth sores (40%), feelings of tiredness/weakness (37%), and rash (25%). There was a low incidence (> 1% of patients listed) of grade 3 or 4 drugrelated adverse events: mouth sores (3%), lung inflammation (3%), infection (3%), tiredness/feelings of weakness (4%), diarrhea (1%), mucosal inflammation (1%) and shortness of breath (1%). The trial had a low rate of adverse drug reactions leading to discontinuation among patients who took RAD001 (6%). The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003.@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@AFINITOR@@@@@AFINITOR||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@CROSSOVER@@@1@1@2893031.089@@@4.01@month@4.01 month@2893031.09@2893031.09@23719.56@1@0.0091@5929.89@6992.8@@@@@@@@@@@2371.96@1@@mg@10@1@@@@@@@@@@@8/30/2017@5929.89@5929.89@4291023F2027@TABLET@YEN@@@@@@@@2.5@MG@2.5 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14923470@Onco@@@@@300f1010ntsdm@@@@@@Patients were randomised 1:1 to receive Tarceva (100 mg or 150 mg) or placebo once daily on a continuous schedule plus gemcitabine IV (1000 mg/m2, Cycle 1– Days 1, 8, 15, 22, 29, 36, and 43 of an 8 week cycle; Cycle 2 and subsequent cycles–Days 1, 8, and 15 of a 4 week cycle.  285 patients were randomised to receive gemcitabine plus Tarceva (261 patients in the 100 mg cohort and 24 patients in the 150 mg cohort) and 284 patients were randomised to receive gemcitabine plus placebo (260 patients in the 100 mg cohort and 24 patients in the 150 mg cohort). Too few patients were treated in the 150 mg cohort to draw conclusions. Tarceva or placebo was taken orally once daily until disease progression or unacceptable toxicity.@@L01XE03@L01X@NO@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14923470@Non-small cell lung cancer (NSCLC): Tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with EGFR- negative tumours. Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival advantage could be shown for patients with locally advanced disease.@@NO@@@NO REVIEW@@@@100%@>> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]       >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]        >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@FIRST-LINE@@569@Pancreatic Cancer: The recommended daily dose is 100 mg taken at least one hour before or two hours after the ingestion of food, in combination with gemcitabine. Treatment should continue until disease progression or unacceptable toxicity occurs.@EMA, 24 January 2007@1/24/2007@@@@@Pulmonary Toxicity: There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events, including fatalities, in patients receiving Tarceva for treatment of NSCLC, pancreatic cancer, or other advanced solid tumors. Myocardial infarction/ischemia. Cerebrovascular accident. Microangiopathic Haemolytic Anaemia with Thrombocytopaenia. Pregnancy: Women of childbearing potential should be advised to avoid pregnancy while on Tarceva . If Tarceva is used during pregnancy, the patient should be apprised of the potential hazard to the fetus or potential risk for loss of the pregnancy.@@No@@PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC PANCREATIC CANCER.@@@CLINICAL STUDIES / PANCREATIC CANCER - TARCEVA ADMINISTERED CONCURRENTLY WITH GEMCITABINE@APPROVED@@NO NICE REVIEW@NHS@Survival: median (months)/deaths: For the Tarceva+Gemcitabine arm= 6.4/ 250 For the Placebo+Gemcitabine arm=6.0/ 254 with hazard ratio=0.81; 95%CI=0.68-0.97; p=0.028@The most common adverse reactions in pancreatic cancer patients receiving Tarceva 100 mg plus gemcitabine were fatigue, rash, nausea, anorexia and diarrhea. In the Tarceva plus gemcitabine arm, Grade 3/4 rash and diarrhea were each reported in 5% of Tarceva plus gemcitabine-treated patients. The median time to onset of rash and diarrhea was 10 days and 15 days, respectively. Rash and diarrhea each resulted in dose reductions in 2% of patients, and resulted in study discontinuation in up to 1% of patients receiving Tarceva plus gemcitabine. The 150 mg cohort was associated with a higher rate of certain class-specific adverse reactions including rash and required more frequent dose reduction or interruption.@@@@COMBO@ERLOTINIB HYDROCHLORIDE@GEMCITABINE@@@@ERLOTINIB HYDROCHLORIDE|GEMCITABINE|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@TARCEVA@GENERIC@@@@TARCEVA|GENERIC|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@1@@4190.523144@@@3.8@month@3.8 month@4190.52@4190.52@36.26@30@1.299@1631.53@@@@@@@@@@@@0.36@1@@mg@100@1@@@@@@@@@@@7/28/2017@54.38@54.38@9.57E+15@FILM-COATED TABLET@GB£@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923354@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were randomised (2:1) to receive either 50 mg Sutent or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomised to placebo were then offered crossover to open-label Sutent, and patients randomised to Sutent were permitted to continue treatment per investigator judgment.@@L01XE04@L01X@NO@NEW YORK, NEW YORK@5/1/2008@@Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR? and PDGFRß), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRß, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRß- and VEGFR2-dependent tumor angiogenesis in vivo.@@14923354@Gastrointestinal Stromal Tumor GIST: indicated for the treatment of GIST after disease progression on or intolerance to imatinib mesylate.  Advanced Renal Cell Carcinoma: indicated for the treatment of advanced renal cell carcinoma.@@@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@SECOND-LINE@NCT00075218@357@The recommended dose for GIST and advanced RCC is one 50 mg oral dose taken once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2).@FDA, 26 January 2006@1/26/2006@@@@12/1/2003@Pregnancy: inhibition of angiogenesis following administration of Sutent should be expected to result in adverse effects on pregnancy. Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant. Left Ventricular Dysfunction: In the presence of clinical manifestations of congestive heart failure (CHF), discontinuation of Sutent is recommended. The dose should be interrupted and/or reduced in patients without clinical evidence of CHF but with an ejection fraction <50% and >20% below baseline. QT Interval Prolongation and Torsade de Pointes: Sutent has been shown to prolong the QT interval in a dose dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Hypertension. Haemorrhagic Events: Tumour-related haemorrhage has been observed in patients treated with Sutent. Serious, sometimes fatal gastrointestinal complications including gastrointestinal perforation have occurred rarely in patients with intraabdominal malignancies treated with Sutent. Hypothyroidism.@A6181004@No@JANUARY 2011 (NCE EXCLUSIVITY); FEBRUARY 2021 (GIST PATENT)@PATIENTS WITH GIST WHO HAD DISEASE PROGRESSION DURING PRIOR IMATINIB MESYLATE (IMATINIB) TREATMENT OR WHO WERE INTOLERANT OF IMATINIB. THE INTENT-TO-TREAT (ITT) POPULATION INCLUDED 312 PATIENTS. 207 PATIENTS WERE RANDOMISED TO THE SUTENT ARM, AND 105 PATI@@@III@APPROVED@@If life-threatening side-effects occur with imatinib not managed by maximum supportive treatment, then sunitinib should be considered prior to surgery, after discontinuing imatinib (GIST-2 and GIST-3). SOURCE: NCCN@MEDICARE@TTP: 27.3 (16.0, 32.1) for the Sutent arm vs 6.4 (4.4, 10.0) for the placebo arm p<0.0001 [median, weeks (95% CI)] PFS: 24.1 (11.1, 28.3) for the Sutent arm vs 6.0  (4.4, 9.9) for the placebo arm p<0.0001 [median, weeks (95% CI)] Objective RR: 6.8 (3.7, 11.1) for the Sutent arm vs 0 for the placebo arm p=0.006 (PR) [%, (95% CI)]  [Lancet. 2006 Oct 14;368(9544):1329-38]@Median duration of blinded study treatment was two cycles for patients on Sutent (mean 3.0, range 1-9) and one cycle (mean 1.8, range 1-6) for patients on placebo. Dose reductions occurred in 23 patients (11%) on Sutent and none on placebo. Dose interruptions occurred in 59 patients (29%) on Sutent and 31 patients (30%) on placebo. The rates of treatment-emergent, non-fatal adverse reactions resulting in permanent discontinuation were 7% and 6% in the Sutent and placebo groups, respectively. Most treatment-emergent adverse reactions in both study arms were Grade 1 or 2 in severity. Grade 3 or 4 treatment-emergent adverse reactions were reported in 56% versus 51% of patients on Sutent versus placebo, respectively. Table 1 compares the incidence of common (=10%) treatment-emergent adverse reactions for patients receiving Sutent and reported more commonly in patients receiving Sutent than in patients receiving placebo.@@@@MONO@SUNITINIB MALEATE@@@@@SUNITINIB MALEATE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@SUTENT@@@@@SUTENT||||@TK Inhibitor@VEGF@PDGF@SCF@@TK Inhibitor|VEGF|PDGF|SCF|@TIME TO PROGRESSION@@@@@PLASMA PROTEIN@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@REFRACTORY@@@@@RANDOMISED@DOUBLE-BLIND@CROSSOVER@@@1@1@65105.18592@@@24.1@week@24.1 week@65105.19@65105.19@385.92@28@1@16208.76@@@@@@@@@@@@11.58@42@@mg@50@28@@@@@@@@@@@8/2/2017@578.88@578.88@00069-0980-38@HARD CAPSULE@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16061304@Onco@@@@@300f1020ntsdm@@@@@@112 patients treated with Hycamtin received an initial dose of 1.5 mg/m2 given by intravenous infusion over 30 minutes for 5 consecutive days, starting on day 1 of a 21-day course. 114 patients treated with paclitaxel received 175 mg/m2 over 3 hours on day 1 of a 21-day course.@@L01XX17@L01X@YES@BRENTFORD, UNITED KINGDOM@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@16061304@Topotecan monotherapy is indicated for the treatment of  patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.@@YES@-@@NO REVIEW@@@@100%@Merck KGaA licensed marketing and sales rights from SmithKline Beecham in June 2000 for the U.K. only.@SECOND-LINE@-@226@Ovarian and Small Cell Lung Carcinoma- Initial dose- The recommended dose of topotecan is 1.5 mg/m2 body surface area/day administered by intravenous infusion over 30 minutes daily for 5 consecutive days with a 3 week interval between the start of each course. If well tolerated, treatment may continue until disease progression. Subsequent doses- Topotecan should not be re-administered unless the neutrophil count is  1 x 109/l, the platelet count is  100 x 109/l, and the haemoglobin level is  9 g/dl (after transfusion if necessary).@EMA, 19 May 1998@5/19/1998@@-@@@Bone marrow suppression (primarily neutropaenia) is the dose-limiting toxicity of Hycamtin. Cases of neutropenia, thrombocytopaenia and anaemia were reported. Hycamtin may cause fetal harm when administered to a pregnant woman.@LABEL@No@-@226 PATIENTS, WITH METASTATIC OVARIAN CARCINOMA, WHO HAD RECURRENT OVARIAN CANCER AFTER A PLATINUM-CONTAINING REGIMEN OR HAD NOT RESPONDED TO AT LEAST 1 PRIOR PLATINUM-CONTAINING REGIMEN, WERE RANDOMISED TO 2 ARMS: THE HYCAMTIN ARM AND THE PACLITAXEL ARM.@@@-@APPROVED@@-@SSN@The complete RR was of 5% for the Hycamtin arm compared to 3% for the paclitaxel arm. The partial RR was of 16% for the Hycamtin arm compared to 11% for the paclitaxel arm. The overall RR was of 21% for the Hycamtin arm compared to 14% for the paclitaxel arm - 95% CI was of 13 to 28% for the Hycamtin arm compared to 8 to 20% for the paclitaxel arm (p=0.20). The calculation for duration of response was based on the interval between first response and TTP. Median response duration was of 25.9 weeks for the Hycamtin arm (23 patients) compared to 21.6 weeks for the paclitaxel arm (16 patients) - 95% CI was of 22.1 to 32.9 weeks for the Hycamtin arm compared to 16 to 34 weeks for the paclitaxel arm (hazard ratio = 0.78 ; p=0.48). Median TTP was of 18.9 weeks for the Hycamtin arm compared to 14.7 weeks for the paclitaxel arm - 95% CI was of 12.1 to 23.6 weeks for the Hycamtin arm compared to 11.9 to 18.3 weeks for the paclitaxel arm (hazard ratio = 0.76 ; p=0.07). Median survival was of 63 weeks for the Hycamtin arm compared to 53 weeks for the paclitaxel arm - 95% CI was of 46.6 to 71.9 weeks for the Hycamtin arm compared to 42.3 to 68.7 weeks for the paclitaxel arm (hazard ratio = 0.97 ; p=0.87). The median time to response was 7.6 weeks (range 3.1 to 21.7) with Hycamtin compared to 6.0 weeks (range 2.4 to 18.1) with paclitaxel. Consequently, the efficacy of Hycamtin may not be achieved if patients are withdrawn from treatment prematurely.@-@@@@MONO@TOPOTECAN HYDROCHLORIDE@@@@@TOPOTECAN HYDROCHLORIDE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@HYCAMTIN@@@@@HYCAMTIN||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@ADVANCED@@@@@RANDOMISED@@@@@1.6@m²@2631.804@@@19@week@19 week@2631.8@2631.8@19.79@10@1.1229@346.29@571.52@361.88@@@@@@@@@@34.63@21@@mg/m²@1.5@5@@@@@@@@@@@6/7/2017@34.63@34.63@33306073@HARD CAPSULE@EURO@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14917831@Onco@@@@@300f1037ntsdm@@@@@@120 mg/m²@@L01DB03@L01D@YES@@@@Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.@@14917831@Epirubicin is used in the treatment of a range of neoplastic conditions including • Breast, ovarian, gastric, lung and colorectal carcinomas • Malignant lymphomas • Leukaemias • Multiple myeloma. When administered intravesically, epirubicin has been shown to be beneficial in the treatment of • Papillary transitional cell carcinoma of the bladder • Carcinoma-in-situ • Prophylaxis of recurrences after transurethral resection.@@YES@@@NO REVIEW@@@@90%@Acquired through takeover of Mayne Pharma@FIRST-LINE@@716@Conventional dose: When epirubicin is used as a single agent, the recommended dosage in adults is 60-90 mg/m2 body area. Epirubicin should be injected intravenously over 3-5 minutes. The dose should be repeated at 21-day intervals, depending upon the patient's haematomedullary status. If signs of toxicity, including severe neutropenia/neutropenic fever and thrombocytopaenia occur (which could persist at day 21), dose modification or postponement of the subsequent dose may be required.@1-Dec-95@12/1/1995@@@@@Occurrence of severe local tissue necrosis if extravasation during administration; intramuscular and subcutaneous routes of administration not allowed; during or after therapy occurrence of severe form of myocardial toxicity; cases of secondary acute myelogenous leukemia and refractory secondary leukaemia reported in patients treated with anthracyclines used in mono or combination therapy with DNA-damaging antineoplastic agents; cases of severe myelosuppression; advice of reduced dosage in patients with impaired hepatic function@MA-5@No@@716 PREMENOPAUSAL AND PERIMENOPAUSAL WITH ONE OR MORE POSITIVE LYMPH NODES: 356 WOMEN RECEIVED A COMBINATION OF CYCLOPHOSPHAMIDE, ELLENCE AND FLUOROURACIL (CEF-120) AND WERE COMPARED TO 360 OTHER WOMEN WHO RECEIVED A COMBINATION OF CYCLOPHOSPHAMIDE, METHO@@@III@APPROVED@@NO REVIEW@SNS@CEF regimen showed a longer RFS after 5 years (62% for the CEF regimen and 53% for the CMF regimen - stratified logrank p=0,013) and after 10 years (51% of the CEF regimen and 44% of the CMF regimen - stratified logrank p=0,017 - unstratified logrank p=0,023) and a longer OS after 5 years (77% for the CEF regimen and 70% for the CMF regimen - stratified logrank p=0,043) and after 10 years (61% of the CEF regimen and 57% of the CMF regimen - stratified logrank p=0,100 - unstratified logrank p=0,18) - results based on Kaplan-Meier methods@@@@@COMBO@EPIRUBICIN HYDROCHLORIDE@@@@@EPIRUBICIN HYDROCHLORIDE||||@KENFARMA@@@@@KENFARMA||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@Bladder Cancer@Colorectal Cancer@@Haematological Malignancy|Myeloma|Bladder Cancer|Colorectal Cancer||||||@FARMORUBICINE@@@@@FARMORUBICINE||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RELAPSE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@COMPARATIVE@OPEN-LABEL@MULTI-CENTRE@@@@Invalid Factory Price@@@168@day@168 day@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR INJECTION@EURO@@@@@@@@10@MG@10 MG/5ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919259@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@V03AF03@V03A@NO@CANONSBURG, PENNSYLVANIA@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14919259@Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form.@@NO@@@NO REVIEW@@@@@Mylan acquired UDL Labs in March 1996.@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenous injection.@FDA, 01 Jun 1952@6/1/1952@@@@@In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. Leucovorin may be fatal if given intrathecally. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@MYLAN@UDL LABS@@@@MYLAN|UDL LABS|||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@GENERIC@@@@@GENERIC||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1@228.12@@@@@@@@@@@@0.46@@@@@@@@@@@@@@@@8/2/2017@11.41@11.41@51079-0582-05@TABLET@US$@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16671430@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XE35@L01X@@LONDON, UNITED KINGDOM@@@Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type.@@16671430@Indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy@Both@NA@@@NO REVIEW@@@@@@@NCT012151981@419@The recommended dose of TAGRISSO is 80 mg tablet once a day until disease progression or unacceptable toxicity.@FDA, 30 March 2017@3/30/2017@@Yes@@@@@No@@trial conducted in patients with metastatic EGFR T790M mutation-positive NSCLC who had progressive disease following first-line EGFR TKI therapy. All patients were required to have EGFR T790M mutation-positive NSCLC identified by the cobas EGFR mutation test performed in a central laboratory.@EGFR T790M mutation-positive@ADULTS@@APPROVED@@@NA@In November 2015, osimertinib received accelerated approval for this indication based on an overall response rate (ORR) of 59% among 411 patients in two single-arm clinical trials. The current approval is based on AURA3 (NCT012151981), a randomized, multicenter open-label, active-controlled trial conducted in patients with metastatic EGFR T790M mutation-positive NSCLC who had progressive disease following first-line EGFR TKI therapy. All patients were required to have EGFR T790M mutation-positive NSCLC identified by the cobas EGFR mutation test performed in a central laboratory.AURA3 randomized 419 patients (2:1) to receive osimertinib (n=279) 80 mg orally once daily or platinum-based doublet chemotherapy (n=140). Patients in the chemotherapy arm received either pemetrexed, 500 mg/m2 with carboplatin AUC5, or pemetrexed, 500mg/m2 with cisplatin 75 mg/m2), on day 1 of every 21-day cycle for up to 6 cycles followed by pemetrexed maintenance therapy. Patients on the chemotherapy arm with radiological progression according to both investigator and blinded independent central review were offered osimertinib at progression.AURA3 demonstrated an improvement in investigator-assessed progression-free survival (PFS), with a hazard ratio of 0.30 (95% CI: 0.23, 0.41; p<0.001). The estimated median PFS was 10.1 months in the osimertinib arm and 4.4 months in the chemotherapy arm. Confirmed ORR, according to investigator assessment, was 65% (95% CI: 59%, 70%) and 29% (95% CI: 21%, 37%) in the osimertinib and chemotherapy arms, respectively (p<0.0001). Estimated median response durations were 11 months (95% CI: 8.6, 12.6) and 4.2 months (95% CI: 3.9, 5.9) in the osimertinib and chemotherapy arms, respectively.[FDA, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm549683.htm]@Serious adverse reactions were evaluated in 833 patients receiving osimertinib. The most serious adverse reactions were interstitial lung disease/pneumonitis (3.5%), QTc interval prolongation (0.7%), cardiomyopathy (1.9%), and keratitis (0.7%). The most common adverse reactions (occurring in at least 20% of patients) were diarrhea, rash, dry skin, nail toxicity, and fatigue. [FDA, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm549683.htm]@@@@MONO@OSIMERTINIB@@@@@OSIMERTINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAGRISSO@@@@@TAGRISSO||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@@@@@@@@@@@METASTATIC@@@@@MULTICENTER@RANDOMISED@OPEN LABEL@ACTIVE-CONTROLLED@@1@1@145314.0368@@@10.1@Month@10.1 Month@145314.04@145314.04@473.03@30@1@14190.75@@@@@@@@@@@@5.91@1@@mg@80@1@@@@@@@@@@@8/2/2017@473.03@473.03@00310-1350-30@FILM-COATED TABLET (BOTTLE)@US$@@@@@@@@80@MG@80 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924302@Onco@@@@@300f1015ntsdm@@@@@@Xeloda was administered at a dose of 1255 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles.@@L01BC06@L01B@YES@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924302@Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum based regimen.@@NO@6-Feb-08@2/6/2008@NO REVIEW@@@@100%@@FIRST-LINE@@162@800 –1000 mg/m2 when administered twice daily for 14 days followed by a 7-day rest period, or to 625 mg/m2 twice daily when administered continuously (see section 5.1)@EMA, 22 February 2007@2/22/2007@10/3/2005@No@@@Patients with moderate renal impairment at baseline require dose reduction. Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking Xeloda concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Xeloda can induce diarrhea, sometimes severe. Patients =80 years old may experience a greater incidence of grade 3 or 4 adverse events (diarrhea, nausea, hand-and-foot syndrome, and vomiting).  Xeloda may cause fetal harm when given to a pregnant woman.@LABEL@No@@PATIENTS WITH STAGE IV BREAST CANCER WERE ENROLLED. 135 HAD MEASURABLE DISEASE. RESISTANCE WAS DEFINED AS PROGRESSIVE DISEASE WHILE ON TREATMENT, WITH OR WITHOUT AN INITIAL RESPONSE, OR RELAPSE WITHIN 6 MONTHS OF COMPLETING TREATMENT WITH AN ANTHRACYC@@@BREAST CANCER MONOTHERAPY; OPEN-LABEL SINGLE-ARM TRIAL CONDUCTED IN 24 CENTRES IN THE US AND CANADA.@APPROVED@@Taking into account the absence of data showing a superiority of Xeloda versus 5 Fluorouracil, the Commission considers that Xeloda does not bring a ASMR compared to this comparator.@HAUTE AUTORITÉ DE SANTÉ@RR for patients resistant to both paclitaxel and anthracycline (n=43)  was of 25.6% (95% CI: 13.5-41.2) with a median duration of response of 154 days (95% CI: 63-233). The median TTP was 102 days and the median survival was 255 days. The objective RR in this population was supported by a RR of 18.5% (1 CR, 24 PRs) in the overall population of 135 patients with measurable disease, who were less resistant to chemotherapy. The median time to progression was 90 days and the median survival was 306 days.@@@@@COMBO@CAPECITABINE@DOCETAXEL@@@@CAPECITABINE|DOCETAXEL|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@XELODA@GENERIC@@@@XELODA|GENERIC|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@DURATION OF RESPONSE@@@@-@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@1.75@m²@2656.199624@@@10.5@month@10.5 month@2656.2@2656.2@8.32@120@1.1511@237.63@280.69@253.5@@@@@@@@@@@21@@mg/m²@1800@14@@@@@@@@@@@8/1/2017@1.98@1.98@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@500@MG@500 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920005@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@UNITED STATES@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14920005@It is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutics such as Paraplatin and cyclophosphamide. It is also indicated in the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have previously been treated with cisplatin.@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@@Single-Agent therapy; dosage of 360mg/m2 IV on day 1 every 4 weeks to treat recurrent ovarian carcinoma. In general, however, courses should not be repeated until neutrophil and platelet counts are at least 2,000 and 100,000 respectively. In combination with cyclophosphamide (600mg/m2 IV on day 1 every 4 weeks for 6 cycles) for previously untreated patients, 300mg/m2 IV on day every 4 weeks for 6 cycles should be used. Suggested dose adjustments include 125% from prior course if platelet and neutrophil counts are above 100,000 and 2,000 respectively; no adjustment if the counts are 50-100,000 or 500-2,000 respectively; and 75% if they are under 50,000 and 500 respectively.@@@@@@@Bone marrow suppression (leukopaenia, neutropaenia, and thrombocytopaenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during treatment and until recovery is achieved. Median nadir occurs at day 21 in patients receiving single-agent carboplatin. In general, single intermittent courses should not be repeated until leukocyte, neutrophil, and platelet counts have recovered. Since anaemia is cumulative, transfusions may be needed during treatment particularly in patients receiving prolonged therapy. Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial  dosages in these patients should be appropriately reduced and blood counts should be carefully monitored between courses. The use of Paraplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimise additive effects. Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents. It can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics.@LABEL@No@@Advanced ovarian cancer previously treated with chemotherapy@@@III@APPROVED@@@MEDICARE@Carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0151-01@POWDER FOR INJECTION@US$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920610@Onco@@@@@300f1014ntsdm@@@@@@Intron A doses of 30 million IU/m2 were administered subcutaneously three times per week (TIW). Doses were adjusted for patient tolerance. The average weekly dose delivered in the first 4 weeks was 150 million IU; at the end of 12 weeks this averaged 110 million IU/week; and by 24 weeks averaged 75 million IU/week.@@L03AB05@L03A@YES@KENILWORTH, NEW JERSEY@@@Intron A recombinant for Injection has been classified as an alpha interferon and is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of Escherichia coli bearing a genetically engineered plasmid containing an interferon alfa-2b gene from human leukocytes. The fermentation is carried out in a defined nutrient medium containing the antibiotic tetracycline hydrochloride at a concentration of 5 to 10 mg/L; the presence of this antibiotic is not detectable in the final product. The specific activity of interferon alfa-2b, recombinant is approximately 2.6 x 108 IU/mg protein as measured by the HPLC assay@@14920610@Approved for Basal cell carcinoma * chronic active hepatitis (B or C) * Chronic myelogenous leukemia * Condylomata accuminata * Cutaneous T cell lymphoma (CTCL) * Hairy cell leukemia * Kaposi's sarcoma (patients with AIDS) * Multiple myeloma * Non-Hodgkin's lymphoma * Renal cell carcinoma * Malignant Melanoma@@EXPENSIVE ITEM APPENDIX III (LIMITED WHOLESALE MARGIN)@1-Mar@@NO REVIEW@@@@@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@@@@AIDS-Related Kaposi's Sarcoma: The recommended dose of Intron A for Kaposi's Sarcoma is 30 million IU/m2/dose administered subcutaneously or intramuscularly three times a week until disease progression or maximal response has been achieved after 16 weeks of treatment.@@@@@@@Cardiovascular Disorders: Cardiovascular adverse experiences, which include hypotension, arrhythmia, or tachycardia of 150 beats per minute or greater, and rarely, cardiomyopathy and myocardial infarction have been observed. Transient cardiomyopathy was reported in approximately 2% of the AIDS-Related Kaposi's Sarcoma patients treated with Intron A. Hypotension may also occur. Cerebrovascular Disorders: Ischemic and hemorrhagic cerebrovascular events have been observed. Neuropsychiatric Disorders: depression and suicidal behavior including suicidal ideation, suicidal attempts, and completed suicides have been reported. Bone marrow toxicity: Intron A therapy suppresses bone marrow function and may result in severe cytopenias including very rare events of aplastic anemia. Ophthalmologic Disorders: Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots; optic neuritis and papilledema may be induced or aggravated. Endocrine Disorders: Infrequently, patients receiving Intron A therapy developed thyroid abnormalities, either hypothyroid or hyperthyroid. Diabetes mellitus has also been observed. Gastrointestinal Disorders: Hepatotoxicity, including fatality, has been observed in interferon alpha-treated patients. Pulmonary Disorders: Pulmonary infiltrates, pneumonitis and pneumonia, including fatality, have been observed. Autoimmune Disorders: Rare cases of autoimmune diseases including thrombocytopenia, vasculitis, Raynaud's phenomenon, rheumatoid arthritis, lupus erythematosus, and  rhabdomyolysis have been observed. Intron A therapy in patients with AIDS-Related Kaposi's Sarcoma should not be used for patients with rapidly progressive visceral disease. Chronic Hepatitis C and Chronic Hepatitis B patients with decompensated liver disease, autoimmune hepatitis or a history of autoimmune disease, and patients who are immunosuppressed transplant recipients should not be treated with Intron A. Combination treatment with Intron A and Rebetol (ribavirin) should not be used in patients with creatinine clearance <50 mL/min.@LABEL@No@@PATIENTS WITH AIDS-RELATED KS@@@AIDS-RELATED KAPOSI'S SARCOMA@APPROVED@@@RAMQ@44% of asymptomatic patients responded vs 7% of symptomatic patients. The median time to response was approximately 2 months and 1 month, respectively, for asymptomatic and symptomatic patients. The median duration of response was approximately 3 months and 1 month, respectively, for the asymptomatic and symptomatic patients. Baseline T4/T8 ratios were 0.46 for responders vs 0.33 for nonresponders.@@@@@MONO@INTERFERON ALPHA-2B@@@@@INTERFERON ALPHA-2B||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Sarcoma@Kaposi's Sarcoma@@@@Sarcoma|Kaposi's Sarcoma||||||||@INTRON A@@@@@INTRON A||||@Immunotherapy@Interferon@@@@Immunotherapy|Interferon|||@RESPONSE RATE@TIME TO RESPONSE@DURATION OF RESPONSE@@@DURATION OF RESPONSE@@@@@@@@@@@@@@@1.75@m²@30023.28@@@16@week@16 week@30023.28@30023.28@268.07@1@0.7881@357.42@@@@@@@@@@@@@7@@MIU/m²/dose@30@3@@@@@@@@@@@7/19/2017@357.42@357.42@22406941@SUBCUTANEOUS INJECTION - 1.2 ML@C$@@@@@@@@30@MIU@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16624045@Onco@@@@@300f1010ntsdm@@@@@@@@L01XX52@L01X@@UNITED STATES@10/1/2017@@Venetoclax is a potent, selective inhibitor of B-cell lymphoma (BCL)-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumour cell survival and has been associated with resistance to chemotherapeutics. Venetoclax binds directly to the BH3-binding groove of BCL-2, displacing BH3 motif-containing pro-apoptotic proteins like BIM, to initiate mitochondrial outer membrane permeabilization (MOMP), caspase activation, and programmed cell death. In non-clinical studies, venetoclax has demonstrated cytotoxic activity in tumour cells that overexpress BCL-2.@@16624045@Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.@Both@No@@@NO REVIEW@@@@@@@NCT02141282@120@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@EMA, 5 December 2016@12/5/2016@1/24/2017@Yes@@9/1/2014@@M14-032@No@@Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) criteria; Subject has relapsed/refractory disease with an indication for treatment; Subject has refractory disease or developed recurrence after therapy with a BCR PI; Subject must have an Eastern Cooperative Oncology Group performance score of equal to or less than 2; Subject must have adequate bone marrow function at Screening; Subject must have adequate coagulation profile, renal, and hepatic function, per laboratory reference range at Screening.@@ADULTS@II@APPROVED@@@NHS@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLYXTO@@@@@VENCLYXTO||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@DURATION OF RESPONSE@TIME TO PROGRESSION@PROGRESSION FREE SURVIVAL@@@RELAPSED@@@@@Non-Randomized@Single Group Assignment@NO MASKING@@@1@1@50041.35414@@@11.7@month@11.7 month@50041.35@50041.35@140.62@112@1.299@4190.79@@4789.47@@@@@@@@@@0.37@28@1@mg@92.5@28@1@@mg@400@1@@@@@@7/28/2017@37.42@37.42@3.38E+16@TABLET@GB£@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15048216@Onco@@@@@300f1012ntsdm@@@@@@Ponatinib: 45 mg tablet taken orally once daily@@L01XE24@L01X@YES@CAMBRIDGE, MASSACHUSSETTS@10/1/2020@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@15048216@Adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation@@NA@23-Jan-14@1/23/2014@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@NCT01207440@440@@EMA, 1 July 2013@7/1/2013@@Yes@@9/1/2010@Arterial ThrombosisHepatoxicity@PACE@No@@@@@II@APPROVED@@23 January 2014 Not quantifiable [https://www.g-ba.de/downloads/39-261-1898/2014-01-23_AM-RL-XII_Ponatinib_BAnz.pdf]@GKV@showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to prior tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD's ongoing Phase 3 EPIC trial comparing ponatinib to imatinib in newly diagnosed chronic-phase CML patients. [Ariad, 30 August 2012, http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1730090&highlight= ]@The most common side effects observed in the study to date were consistent with the known safety profile of ridaforolimus and included stomatitis (e.g., mouth sores), fatigue, diarrhea and thrombocytopenia.@@@@MONO@PONATINIB@@@@@PONATINIB||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN LABEL@SINGLE-ARM@@@@1@1@59287.57028@@@219@day@219 day@59287.57@59287.57@270.72@60@1.1511@5414.39@6693.73@5452.89@@@@@@@@@@6.02@1@@mg@45@1@@@@@@@@@@@8/1/2017@90.24@90.24@8807759@FILM-COATED TABLET@EURO@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15000377@Onco@@@@@300f1012ntsdm@@@@@@ARM1; Subjects in Group A will receive initial dose of 400 mg/m2 (over 2 hours) followed by weekly doses of 250 mg/m2 (over 1 hour). All doses will be given by IV infusionSubjects in both treatment groups (A nad B) will receive either Cisplatin (100 mg/m2 on day 1)+5-FU (100 mg/m2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) +5-FU (100 mg/m2 continuous IV from day 1 to day 4) every 3 weeks. ARM2; All doses will be given by IV infusion/Subjects in both treatment groups (A and B) will receive either Cisplatin (100 mg/m2 on day 1)+5-FU (100 mg/m2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) +5-FU (100 mg/m2 continuous IV from day 1 to day 4) every 3 weeks@@L01XC06@L01X@YES@DARMSTADT, GERMANY@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@15000377@Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.@@YES@18-Jun-05@6/18/2005@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@>> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@NCT00122460@440@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each. In patients with recurrent and/or metastatic squamous cell cancer of the head and neck, cetuximab is used in combination with platinum-based chemotherapy followed by cetuximab as maintenance therapy until disease progression.@EMA, 24 November 2008@11/24/2008@@No@@@Infusion reactions such as airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, cardiac arrest ; Cardiopulmonary arrest and/or sudden death ; pulmonary toxicity leading to interstitial lung disease ; dermatologic toxicity including acneform rash, skin drying and fissuring, and inflammatory and infectious sequelae@EXTREME@No@@PATIENTS WITH STAGE III/IV MH&N.@@@III@APPROVED@@@GKV@2.7 month increase in median overall survival for Erbitux compared to those in the control group (10.2 months versys 7.4 months); a 2.3 month gain was seen in median PFS (5.6 versus 3.3 months); and an 80% relative increase in tumour response rate (36% versus 20%) was seen. [ImClone/ESMO, 11.09.2008] >> The median overall survival for patients in the ERBITUX plus platinum-based chemotherapy arm was 10.1 months, and 7.4 months for patients treated with platinum-based chemotherapy alone (Hazard Ratio (HR), 0.797 (p = 0.036)).(1) ERBITUX plus platinum-based chemotherapy also conferred increased progression-free survival (PFS) and a higher response rate compared with chemotherapy alone. The median PFS values were 5.6 months and 3.3 months (HR = 0.538 (p less than 0.0001)) and the response rates were 35.6% and 19.5% (p = 0.0002) for patients treated with ERBITUX plus chemotherapy and chemotherapy alone, respectively. [BMS/ASCO, June 2007]@The toxicity profile in combination with platinumbased chemotherapy was manageable@@@@COMBO@CETUXIMAB@CISPLATIN@CARBOPLATIN@@@CETUXIMAB|CISPLATIN|CARBOPLATIN||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@OVERALL SURVIVAL@@@@@@@@@@RECURRENT@METASTATIC@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@1.75@m²@25079.90352@@@5.6@month@5.6 month@25079.9@25079.9@147.24@1@1.1511@229.92@301.68@237.87@@@@@@@@@@2.3@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/1/2017@229.92@229.92@493528@SOLUTION FOR INFUSION 20 MG@EURO@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16446250@Onco@@@@@300f1012ntsdm@@@@@@@@L01XX32@L01X@@@1/1/2014@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@16446250@VELCADE in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who areunsuitable for haematopoietic stem cell transplantation.@Both@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@NCT00722137@487@VELCADE 1 mg powder for solution for injection is administered via intravenous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and11, followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. Six VELCADE cycles are recommended, although for patients with a response firstdocumented at cycle 6, two additional VELCADE cycles may be given.@EMA, 30 Januray 2015@@@Yes@@5/1/2008@@LYM-3002@No@@Male or female patients 18 years or older (the patient must be at least the legal age limit to be able to give informed consent within the jurisdiction the study is taking place); Diagnosis of MCL (Stage II, III or IV) as evidenced by lymph node histology and either expression of cyclin D1 (in association with CD20 and CD5) or evidence of t(11;14) translocation, such as by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase chain reaction (PCR). Patients with a diagnosis of Stage I MCL will not be permitted to enter study; Paraffin embedded biopsy tissue block (preferably of lymph node origin) must be sent to the central laboratory for confirmation of MCL diagnosis prior to randomization. In China, a paraffin embedded lymph node biopsy tissue block must be sent for central confirmation of sample adequacy, prior to randomization: At least 1 measurable site of disease; No prior therapies for MCL; Not eligible for bone marrow transplantation as assessed by the treating physician (e.g., age or the presence of co-morbid conditions that may have a negative impact on the tolerability to transplantation); Eastern Cooperative Oncology Group ECOG status ≤2 (Attachment 1); Absolute neutrophil count (ANC) ≥1500 cells/µL, Platelets ≥100,000 cells/µL or ≥75,000 cells/µL if thrombocytopenia is considered by the investigator to be secondary to MCL (e.g., due to bone marrow infiltration or sequestration from splenomegaly), Alanine transaminase ≤3 x upper limit of normal (ULN); Aspartate transaminase ≤3 x ULN; Total bilirubin ≤1.5 x ULN; Calculated creatinine clearance ≥20 mL/min.@ADULT@ADULTS@III@APPROVED@@@GKV@@@@@@COMBO@BORTEZOMIB@RITUXIMAB@CYCLOPHOSPHAMIDE@DOXORUBICIN@PREDNISONE@BORTEZOMIB|RITUXIMAB|CYCLOPHOSPHAMIDE|DOXORUBICIN|PREDNISONE@JANSSEN CILAG@@@@@JANSSEN CILAG||||@World@@@@@World|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@VELCADE@MABTHERA@GENERIC@GENERIC@@VELCADE|MABTHERA|GENERIC|GENERIC|@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@TIME TO PROGRESSION@DURATION OF RESPONSE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1.75@m²@20184.84@@@126@day@126 day@20184.84@20184.84@160.2@1@1.1511@1293.9@1643.25@1332.4@@@@@@@@@@369.69@21@@mg/m²@1.3@4@@@@@@@@@@@8/1/2017@1293.9@1293.9@822831@POWDER FOR INJECTABLE SUSPENSION@EURO@@@@@@@@3.5@MG@3.5 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923536@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@-@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14923536@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@-@@NO REVIEW@@@-@1@-@-@-@-@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@-@@@-@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@Authority required: Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide; Advanced breast cancer after failure of prior therapy which includes an anthracycline; Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound; Primary treatment of ovarian cancer in combination with a platinum compound; Locally advanced or metastatic non-small cell lung cancer; Treatment of HER2 positive early breast cancer in combination with trastuzumab.@PBS@NO LABELLED TRIAL@-@@@@-@PACLITAXEL@@@@@PACLITAXEL||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Ovarian Cancer@NSCLC@Sarcoma@Kaposi's Sarcoma@@Ovarian Cancer|NSCLC|Sarcoma|Kaposi's Sarcoma||||||@TAXOL@@@@@TAXOL||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@1@0.8893@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@NO LONGER AVAILABLE@@4567J6494011000036102@SOLUTION CONCENTRATE FOR I.V. INFUSION, 50 ML@A$@@@@@@@@300@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14918074@Onco@@@@@300f1018ntsdm@@@@@@178 patients received Gemzar 1000 mg/m2 on Days 1 and 8 of a 21-day cycle and carboplatin AUC 4 administered after Gemzar on Day 1 of each cycle and another 178 patients received single-agent carboplatin AUC 5 administered on Day 1 of each 21-day cycle as the control arm.@@L01BC05@L01B@NO@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14918074@GEMZAR, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum–based therapy.@@YES@4-Apr@@NO REVIEW@@@@1@-@SECOND-LINE@-@356@When combination use in Ovarian cancer, Gemzar should be administered intravenously at a dose of 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle, and Carboplatin AUC 4 should be administered intravenously on Day 1 after Gemzar administration.@-@@@-@@@Gemzar can suppress bone marrow function as manifested by leukopaenia, thrombocytopaenia, and anaemia, can increase toxicity when prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing. Pulmonary toxicity, Hemolytic Uremic Syndrome (HUS) and/or renal failure, leading to death or requiring dialysis, despite discontinuation of therapy have been reported. Occurence of rare cases of Serious hepatotoxicity, including liver failure and death.@LABEL@@-@PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAD RELAPSED AT LEAST 6 MONTHS AFTER FIRST-LINE PLATINUM-BASED THERAPY WERE RANDOMISED TO RECEIVE EITHER GEMZAR AND CARBOPLATIN AUC 4 OR SINGLE-AGENT CARBOPLATIN AUC 5 AS THE CONTROL ARM.@@@III@DISCONTINUED@@Stage A progressive disease is defined by at least one of the following: persistent rise in lymphocyte count with doubling time less than 12 months; a downward trend in haemoglobin or platelets, or both; more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present; constitutional symptoms attributable to disease.@PBS@The addition of Gemzar to carboplatin resulted in statistically significant improvement in PFS and overall RR. Median PFS was 8.6 months for the Gemzar/Carboplatin arm and 5.8 months for the Carboplatin alone arm. Hazard ratio = 0.72, p=0.0038. Median overall survival was 18 months for the Gemzar/Carboplatin arm and 17.3 months for the Carboplatin alone arm. Hazard ratio = 0.98, Adjusted hazard ratio = 0.86, p=0.8977. Investigator reviewed: overall response rate was 47.2% for the Gemzar/Carboplatin arm and 30.9% for the Carboplatin alone arm, p=0.0016. Independently reviewed: overall RR was 46.3% for the Gemzar/Carboplatin arm and 35.6% for the Carboplatin alone arm, p=0.11.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@CARBOPLATIN@@@@GEMCITABINE HYDROCHLORIDE|CARBOPLATIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@@@@@1.6@m²@Invalid Factory Price@@@8.6@month@8.6 month@@@@1@0.8893@@@@@@@@@@@@@@21@@mg/m²@1000@2@@@@@@@@@@@@@@7246J4932011000036105@INJECTION@A$@@@@@@@@200@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916644@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Eloxatin / 5-FU and leucovorin + / - Vectibix.@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the bindingof ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-inducedreceptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth,induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, andinternalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits thegrowth and survival of selected human tumor cell lines expressing EGFR.@@14916644@Previously untreated mCRC; combo with oxaliplatin/5-FU/leucovorin@@@@@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@FIRST-LINE@NCT00364013@900@@@@@@@7/1/2006@@PRIME@@PATENT STATUS REMAINS IN DISPUTE; AMGEN LICENSED THE SCHLESSINGER PATENT ('866) UNTIL 2017 IN SEPTEMBER 2006 FROM YEDA.@@@@III@III@@@@Based upon the interim safety analysis, the DMC recommended that the PRIME study continue per protocol. SOURCE: Amgen/ASCO, 1 June 2008@Pooled safety data from a planned interim analysis, conducted by an independent Data Monitoring Committee (DMC), of 903 patients (455 Vectibix plus FOLFOX; 448 FOLFOX only), of which 99 percent received at least one cycle of therapy, showed the following pooled grade 3/4 adverse events: neutropenia (28 percent), diarrhea (11 percent), fatigue (4 percent), nausea (3 percent), dehydration (3 percent) and hypomagnesaemia, pulmonary embolism, febrile neutropenia and deep vein thrombosis (2 percent, respectively). Fifty-six percent of the pooled patient population had skin and subcutaneous tissue system organ class (SOC) events of any grade; 10 percent grade 3 and less than one percent grade 4.@@@@COMBO@PANITUMUMAB@OXALIPLATIN@LEUCOVORIN@FLUOURACIL@@PANITUMUMAB|OXALIPLATIN|LEUCOVORIN|FLUOURACIL|@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@FOLFOX@@@@VECTIBIX|FOLFOX|||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921852@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received either Neulasta 6 mg, or a placebo associated with a chemotherapy regimen that employed docetaxel 100 mg/m2 administered every 21 days for up to 4 cycles for the treatment of metastatic or non-metastatic breast cancer.@@L03AA13@L03A@NO@THOUSAND OAKS, CALIFORNIA@@@Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Pegfilgrastim is a covalent conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20 kd polyethylene glycol (PEG) molecule. Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Similarly to filgrastim, neutrophils produced in response to pegfilgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As with other haematopoietic growth factors, G-CSF has shown in vitro stimulating properties on human endothelial cells. G-CSF can promote growth of myeloid cells, including malignant cells, in vitro and similar effects may be seen on some non-myeloid cells in vitro.@@14921852@Indicated to decrease the incidence of infection, as manifested by febrile neutropaenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropaenia.@@NO@@@NO REVIEW@@@@Precertification required. SOURCE: Aetna Preferred Drug Guide 2008@@@@928@The recommended dosage is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle.@FDA, 31 January 2002@1/31/2002@@@@@Rare cases of splenic rupture, including some fatal cases, have been reported following the administration of Neulasta. Adult respiratory distress syndrome (ARDS) has been reported in neutropenic patients with sepsis receiving Neulasta, and is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. Allergic reactions to Neulasta, including anaphylaxis, skin rash, and urticaria, have been reported. Severe sickle cell crises have been associated with the use of Neulasta in patients with sickle cell disease. Severe sickle cell crises, in some cases resulting in death, have also been associated with Filgrastim, the parent compound of pegfilgrastim.@STUDY 3@No@2015@928 WOMEN WITH BREAST CANCER WERE RANDOMISED TO RECEIVE A SINGLE SUBCUTANEOUS INJECTION OF NEULASTA 6 MG OR PLACEBO ON DAY 2 OF EACH CHEMOTHERAPY CYCLE.@@@@APPROVED@@Covered; part B; quantity limit 1 for 30 days; specialty drug. Prior authorisation required. TIER 4.@MEDICARE@The incidence of febrile neutropaenia was lower for Neulasta-treated patients as compared to placebo-treated patients (1% versus 17%, p < 0.001). The incidence of hospitalisations (1% versus 14%) and IV anti-infective use (2% versus 10%) for the treatment of febrile neutropenia were also lower in the Neulasta-treated patients compared with the placebo-treated patients.@@@@@MONO@PEGFILGRASTIM@@@@@PEGFILGRASTIM||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@NEULASTA@@@@@NEULASTA||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@INCIDENCE OF FEBRILE NEUTROPAENIA@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@10271.76@10271.76@@1@1@5940@@@@@@@@@@@@990@@@@@@@@@@@@@@@@8/2/2017@5940@5940@55513-0190-01@SOLUTION FOR INJECTION (PRE-FILLED SYRINGE) - 0.6 ML@US$@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920866@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@MADISON, NEW JERSEY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14920866@Methotrexate is used in the treatment of adults with severe, active, classical or definite rheumatoid arthritis who are unresponsive or intolerant to conventional therapy. Methotrexate has also been used in the treatment of severe, uncontrolled psoriasis, which is not responsive to other therapy. Methotrexate has been used to produce regression in a wide range of neoplastic conditions including acute leukaemias, non-Hodgkin's lymphoma, soft-tissue and osteogenic sarcomas, and solid tumours particularly breast, lung, head and neck, bladder, cervical, ovarian, and testicular carcinoma.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@Dosage for cancer treatment: A test dose of 5 - 10 mg parenterally is recommended, one week prior to therapy to detect idiosyncratic adverse events. Single doses, not exceeding 30 mg/m2, on not more than 5 consecutive days. A rest period of at least two weeks is recommended between treatments, in order to allow the bone marrow to return to normal. Doses in excess of 100 mg are usually given parenterally, when the injectable preparation should be used. Doses in excess of 70 mg/m2 should not be administered without leucovorin rescue (folinic acid rescue) or assay of serum methotrexate levels 24 - 48 hours after dosing. If methotrexate is administered in combination chemotherapy regimens, the dosage should be reduced, taking into consideration any overlapping toxicity of the other drug components.@@@@@@@Methotrexate should be used with extreme caution in patients with haematological depression, renal impairment, diarrhoea, ulcerative disorders of the GI tract and psychiatric disorders. Hepatic toxicity has been observed, usually associated with chronic hepatic disease. Renal lesions may develop if the urinary flow is impeded and urinary pH is low, especially if large doses have been administered. The administration of low doses of methotrexate for prolonged periods may give rise, in particular, to hepatic toxicity. Particular care and possible cessation of treatment are indicated if stomatitis or GI toxicity occurs as haemorrhagic enteritis and intestinal perforation may result.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Breast Cancer@Head & Neck Cancer@NSCLC@Bladder Cancer@Ovarian Cancer@Breast Cancer|Head & Neck Cancer|NSCLC|Bladder Cancer|Ovarian Cancer|||||@METHOTREXAT LEDERLE@@@@@METHOTREXAT LEDERLE||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@86.74@120.65@90.17@@@@@@@@@@0.09@@@@@@@@@@@@@@@@8/1/2017@86.74@86.74@3027330@SOLUTION - INFUSION (40 ML)@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917816@Onco@@@@@300f1015ntsdm@@@@@@120 mg/m²@@L01DB03@L01D@YES@NEW YORK, NEW YORK@@@Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.@@14917816@Epirubicin is used in the treatment of a range of neoplastic conditions including • Breast, ovarian, gastric, lung and colorectal carcinomas • Malignant lymphomas • Leukaemias • Multiple myeloma. When administered intravesically, epirubicin has been shown to be beneficial in the treatment of • Papillary transitional cell carcinoma of the bladder • Carcinoma-in-situ • Prophylaxis of recurrences after transurethral resection.@@YES@@@NO REVIEW@@@@@@FIRST-LINE@@716@Conventional dose: When epirubicin is used as a single agent, the recommended dosage in adults is 60-90 mg/m2 body area. Epirubicin should be injected intravenously over 3-5 minutes. The dose should be repeated at 21-day intervals, depending upon the patient's haematomedullary status. If signs of toxicity, including severe neutropenia/neutropenic fever and thrombocytopaenia occur (which could persist at day 21), dose modification or postponement of the subsequent dose may be required.@@@12/1/2002@@@@Occurrence of severe local tissue necrosis if extravasation during administration; intramuscular and subcutaneous routes of administration not allowed; during or after therapy occurrence of severe form of myocardial toxicity; cases of secondary acute myelogenous leukemia and refractory secondary leukaemia reported in patients treated with anthracyclines used in mono or combination therapy with DNA-damaging antineoplastic agents; cases of severe myelosuppression; advice of reduced dosage in patients with impaired hepatic function@MA-5@No@@716 PREMENOPAUSAL AND PERIMENOPAUSAL WITH ONE OR MORE POSITIVE LYMPH NODES: 356 WOMEN RECEIVED A COMBINATION OF CYCLOPHOSPHAMIDE, ELLENCE AND FLUOROURACIL (CEF-120) AND WERE COMPARED TO 360 OTHER WOMEN WHO RECEIVED A COMBINATION OF CYCLOPHOSPHAMIDE, METHO@@@III@APPROVED@@N/A@HAUTE AUTORITÉ DE SANTÉ@CEF regimen showed a longer RFS after 5 years (62% for the CEF regimen and 53% for the CMF regimen - stratified logrank p=0,013) and after 10 years (51% of the CEF regimen and 44% of the CMF regimen - stratified logrank p=0,017 - unstratified logrank p=0,023) and a longer OS after 5 years (77% for the CEF regimen and 70% for the CMF regimen - stratified logrank p=0,043) and after 10 years (61% of the CEF regimen and 57% of the CMF regimen - stratified logrank p=0,100 - unstratified logrank p=0,18) - results based on Kaplan-Meier methods@@@@@COMBO@EPIRUBICIN HYDROCHLORIDE@@@@@EPIRUBICIN HYDROCHLORIDE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@Bladder Cancer@Colorectal Cancer@@Haematological Malignancy|Myeloma|Bladder Cancer|Colorectal Cancer||||||@FARMORUBICINE@@@@@FARMORUBICINE||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RELAPSE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@COMPARATIVE@OPEN-LABEL@MULTI-CENTRE@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9182480T@SOLUTION FOR PERFUSION 100 ML@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919677@Onco@@@@@300f1008ntsdm@@@@@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14919677@Indicated for the treatment of: 1. advanced ovarian carcinoma of epithelial origin in  (a) first line therapy (b) second line therapy, after other treatments have failed. 2. small cell carcinoma of the lung.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@@@Single-Agent Therapy: has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide:an effective combination for previously untreated patients consists of: Paraplatin—300 mg/m2 I.V. on day 1 every four weeks for six cycles. Cyclophosphamide—600 mg/m2 I.V. on day 1 every four weeks for six cycles. Intermittent courses of Paraplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.@@@@@@@Paraplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.@LABEL@No@@Advanced ovarian cancer previously treated with chemotherapy@@@III@APPROVED@@@NHI@Carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@SAWAI PHARMACEUTICAL@@@@@SAWAI PHARMACEUTICAL||||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.0091@2724.62@3213@@@@@@@@@@@54.49@@@@@@@@@@@@@@@@8/30/2017@2724.62@2724.62@4291403A1053@INFUSION SOLUTION 5 ML@YEN@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14920027@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@PETACH TIKVA, ISRAEL@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14920027@It is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutics such as Paraplatin and cyclophosphamide. It is also indicated in the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have previously been treated with cisplatin.@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@@Single-Agent therapy; dosage of 360mg/m2 IV on day 1 every 4 weeks to treat recurrent ovarian carcinoma. In general, however, courses should not be repeated until neutrophil and platelet counts are at least 2,000 and 100,000 respectively. In combination with cyclophosphamide (600mg/m2 IV on day 1 every 4 weeks for 6 cycles) for previously untreated patients, 300mg/m2 IV on day every 4 weeks for 6 cycles should be used. Suggested dose adjustments include 125% from prior course if platelet and neutrophil counts are above 100,000 and 2,000 respectively; no adjustment if the counts are 50-100,000 or 500-2,000 respectively; and 75% if they are under 50,000 and 500 respectively.@@@@@@@Bone marrow suppression (leukopaenia, neutropaenia, and thrombocytopaenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during treatment and until recovery is achieved. Median nadir occurs at day 21 in patients receiving single-agent carboplatin. In general, single intermittent courses should not be repeated until leukocyte, neutrophil, and platelet counts have recovered. Since anaemia is cumulative, transfusions may be needed during treatment particularly in patients receiving prolonged therapy. Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial  dosages in these patients should be appropriately reduced and blood counts should be carefully monitored between courses. The use of Paraplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimise additive effects. Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents. It can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics.@LABEL@No@@Advanced ovarian cancer previously treated with chemotherapy@@@III@APPROVED@@@MEDICARE@Carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00703-3248-11@INJECTION - 45 ML@US$@@@@@@@@450@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16793457@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@CHECKMATE-142@@@L01XC17@L01X@@NEW YORK, NEW YORK@3/11/2018@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16793457@Adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.@Both@NA@@@NO REVIEW@@@@@@@NCT02060188@74@240 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.@FDA, 31 July 2017@7/31/2017@12/23/2014@Yes@@3/7/2014@@CA209-142, 2013-003939-30 ( EudraCT Number )@No@@Men and women ≥ 18 years of age; Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; Histologically confirmed recurrent or metastatic colorectal cancer; Measurable disease by CT or MRI; Testing for MSI Status (by an accredited lab) 1.Subjects with microsatellite instability high (MSI-H) tumors will enroll in the MSI-H Cohort (mStage and cStage groups), the C3 Cohort, and the C5 Cohort. 2.Subjects with phenotypes that are non-microsatellite instability high (non-MSI-H) will enroll in the non- MSI-H Safety Cohort and the C6, C4 Cohorts; Adequate organ function as defined by study-specific laboratory tests@@ADULTS@II@APPROVED@@@NA@The approval was based on data from Study CA209142 (CHECKMATE 142; NCT 02060188), a multicenter, open-label, single arm study conducted in 53 patients with locally determined dMMR or MSI-H metastatic colorectal cancer (CRC) who had disease progression during, after, or were intolerant to prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This was a subset of the 74 patients who received at least one prior regimen for treatment of metastatic disease containing a fluoropyrimidine with oxaliplatin or irinotecan for treatment of metastatic disease. All patients received nivolumab 3 mg/kg by intravenous infusion every 2 weeks until unacceptable toxicity or radiographic progression.The objective response rate (ORR) as assessed by independent radiographic review committee using RECIST 1.1 was 28% (n=15) (95% CI: 17, 42) in the 53 patients who received prior fluoropyrimidine, oxaliplatin, and irinotecan. Responses lasted 6 or more months for 67% (95% CI: 38, 88) of patients. There was 1 complete response and 14 partial responses. The ORR was 32% (n=24) (95% CI: 22, 44) among the 74 patients in the overall population.Trials of nivolumab have not been conducted in pediatric patients. Efficacy for adolescent patients (12 years and older) with MSI-H or dMMR metastatic CRC is extrapolated from the results in the respective adult population.[FDA, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm]@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@Australia@Belgium@Canada@France@Ireland@Australia|Belgium|Canada|France|Ireland|Italy|Spain|United States||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@OBJECTIVE RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@PARALLEL ASSIGNMENT@NO MASKING@@@1@1@Incorrect Average Duration of Use (Unit)@@@@NA@NA@@@@1@1@2545.15@@@@@@@@@@@@25.45@14@@mg@240@1@@@@@@@@@@@8/2/2017@2545.15@2545.15@00003-3774-12@SOLUTION FOR INJECTION - 10 ML@US$@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16386020@Onco@@@@@300f1010ntsdm@@@@@@Experimental: Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil) Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.Experimental: Arm II (oxaliplatin, leucovorin calcium, fluorouracil) Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.Experimental: Arm III (bevacizumab) Patients receive bevacizumab as in arm I.@@L01XC07@L01X@YES@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16386020@Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.@Both@YES@15-Dec-10@12/15/2010@@@@@100%@@SECOND-LINE@NCT00025337@585@Avastin 10 mg/kg administred on a 2-weekly schedule.@EMA, 25 January 2008@1/25/2008@@No@@@Gastrointestinal perforations complicated by intra-abdominal abscesses or fistula formation with possible fatal outcome, wound healing complications, hemorrhage, arterial thromboembolic events when Avastin used in combination with chemotherapy, severe hypertension, reversible posterior leukoencephalopathy syndrome, neutropenia and infectionwhen Avastin used in combination with myelodispressive chemotherapy, proteinuria, congestive heart failure.@E3200@No@@Histologically confirmed adenocarcinoma of the colon or rectum; Advanced or metastatic disease: Must have received a fluoropyrimidine-based regimen and an irinotecan-based regimen, either alone or in combination, for advanced disease/May have relapsed within 6 months of adjuvant therapy with fluorouracil (5-FU) (or combination 5-FU and irinotecan) and progressed after single-agent irinotecan; Measurable disease; No known brain metastases; Performance status - ECOG 0-2; Absolute neutrophil count at least 1,500/mm^3; Platelet count at least 100,000/mm^3@@ADULTS@III@APPROVED@@NICE does not recommend bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for people with metastatic colorectal cancer.https://www.nice.org.uk/guidance/ta212@NHS@@@@@@COMBO@BEVACIZUMAB@OXALIPLATINE@LEUCOVORIN@5-FLOUROURACIL@@BEVACIZUMAB|OXALIPLATINE|LEUCOVORIN|5-FLOUROURACIL|@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@FOLFOX-4@@@@AVASTIN|FOLFOX-4|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@@@@@@RESPONSE DEFINED USING RECIST CRITERIA@PROGRESSION FREE SURVIVAL@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE-CONTROLLED@@@76.5@kg@28806.91213@@@7.5@month@7.5 month@28806.91@28806.91@126.28@1@1.299@924.4@@@@@@@@@@@@2.31@14@@mg/kg@10@1@@@@@@@@@@@7/28/2017@924.4@924.4@9.15E+15@CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION, 16 ML@GB£@@@@@@@@400@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922301@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@45 patients receive Velcade + Avastin and 45 receive Velcade + placebo@@L01XC07@L01X@-@SAN FRANCISCO, CALIFORNIA@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14922301@Multiple myeloma@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@SECOND-LINE@NCT00473590@90@-@-@@@-@@5/1/2007@-@AMBERAVF4064g@@NOT YET AVAILABLE; POTENTIALLY 2018.@90 PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@BEVACIZUMAB@BORTEZOMIB@@@@BEVACIZUMAB|BORTEZOMIB|||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@AVASTIN@VELCADE@@@@AVASTIN|VELCADE|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@MULTI-CENTRE@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917361@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@H02AB07@H02A@NO@CANONSBURG, PENNSYLVANIA@@@Prednisolone acetate is a synthetic adrenocorticoid with the general properties of prednisolone. Adrenocorticoids diffuse across cell membranes to complex with cytoplasmic receptors and subsequently stimulate synthesis of enzymes with anti-inflammatory effects. Glucocorticoids inhibit the oedema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation, deposition of collagen and scar formation. Prednisolone acetate has, on a weight to weight basis, a potency three to five times that of hydrocortisone.@@14917361@Indicated in the following conditions: Endocrine Disorders [Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcernia associated with cancer Nonsuppurative thyroiditis)] Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) [Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis] Collagen Diseases [During an exacerbation or as maintenance therapy in selected  cases of: Systemic lupus erythematosus Systemic-dermatomyositis (polymyositis) Acute rheumatic carditis] Dermatologic Diseases [Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis] Allergic States [Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions] Ophthalmic Diseases [Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic cornea marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis] Respiratory Diseases [Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis] Haematologic Disorders [Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopaenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia] Neoplastic Diseases For palliative management of: [Leukemias and lymphomas in adults Acute leukemia of childhood] Edematous States [To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis] Nervous System [Acute exacerbations of multiple sclerosis] Miscellaneous [Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement]@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial dosage may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required.@@@@@@@In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination With other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@PREDNISONE@@@@@PREDNISONE||||@MYLAN@@@@@MYLAN||||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@DECORTIN@@@@@DECORTIN||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1807@31.42@50.71@33.11@@@@@@@@@@@@@@@@@@@@@@@@@@8/15/2017@0.63@0.63@262846@TABLET@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921504@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are stratified according to prior treatment with adjuvant trastuzumab (Herceptin) (yes vs no), prior treatment with neoadjuvant or adjuvant taxane (yes vs no), disease-free interval (> 24 months vs = 24 months), and planned treatment with carboplatin (yes vs no). Patients are randomized to 1 of 2 treatment arms. Arm A: Induction therapy: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Maintenance therapy: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Arm B: Induction therapy: Patients receive trastuzumab and paclitaxel with or without carboplatin as in arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Maintenance therapy: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for 10 years.@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14921504@First-line combo with Herceptin in HER2-positive cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00520975@489@-@-@@@-@@11/1/2007@-@ECOG 1105@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@III@III@@-@-@FPI confirmed. SOURCE: Genentech, 10 April 2008First-patient in (FPI) due in Q1 2008 (SOURCE: Genentech Q307 SEC).@-@@@@COMBO@BEVACIZUMAB@TRASTUZUMAB@@@@BEVACIZUMAB|TRASTUZUMAB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AVASTIN@HERCEPTIN@@@@AVASTIN|HERCEPTIN|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917719@Onco@@@@@300f1018ntsdm@@@@@@arm1: 211 patients received a combination of cetuximab  and radiation therapy -  Starting one week before radiation, Erbitux was administered as a 400-mg/m2 initial dose, followed by 250 mg/m2 weekly for the duration of radiation therapy. The maximum infusion rate must not exceed 10 mg/min, equivalent to 5 ml/min of Erbitux 2 mg/ml. ; arm 2 : 213 patients were treated with radiation therapy alone@@L01XC06@L01X@YES@@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@14917719@Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease.@@YES@7-Mar@@The trial-based incremental discounted cost/extra life year gained was estimated to be between $45,000 – $75,000 and the trial-based incremental discounted cost/extra year of loco-regional control gained was estimated to be between $15,000- $45,000.  A modelled economic evaluation was presented. The resources included were similar to the preliminary economic evaluation with the only difference being ongoing consultations with an oncologist.   The base case modelled incremental discounted cost/extra life year gained was estimated to be between $15,000- $45,000 as was the base case modelled incremental discounted cost/extra year of loco-regional control gained.@@@@100%@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@@424@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@@@@No@@@Infusion reactions such as airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, cardiac arrest ; Cardiopulmonary arrest and/or sudden death ; pulmonary toxicity leading to interstitial lung disease ; dermatologic toxicity including acneform rash, skin drying and fissuring, and inflammatory and infectious sequelae@IMC-9815@No@@PATIENTS WITH STAGE III/IV SCC OF THE OROPHARYNX, HYPOPHARYNX, OR LARYNX WITH NO PRIOR THERAPY RANDOMISED (1:1) TO 2 REGIMENS. 90% OF PATIENTS HAD BASELINE KARNOFSKY PERFORMANCE STATUS =80; 60% HAD OROPHARYNGEAL, 25% LARYNGEAL, AND 15% HYPOPHARYNGEAL@@@TITLE: RANDOMISED TRIAL OF RADIATION THERAPY PLUS CETUXIMAB VS. RADIATION THERAPY@APPROVED@@The PBAC recommended listing for use in Stage III, IVa or IVb squamous cell cancer on the larynx, oropharynx or hypopharynx in combination with radiotherapy, on the basis of acceptable cost-effectiveness against radiotherapy alone, at the price proposed in the submission. [PBAC http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-cetuximab-mar07 ]@PBS@Updated 5-year survival results: the addition of Erbitux to radiation therapy resulted in a significant increase in median overall survival for patients with SCCHN, when compared to radiation therapy alone [49.0 vs. 29.3 months, respectively; p=0.018, Hazard Ratio (HR)=0.725, 95% CI (0.556-0.946)]. The overall survival rate at five years was 45 percent vs. 36 percent, respectively (p=0.018); survival rate at three years was 55 percent vs. 45 percent (p=0.05), respectively. These data are consistent with results in the current head and neck labeling for Erbitux which include the median overall survival rate [49.0 vs. 29.3 months, respectively; p=0.03, HR=0.74, 95% CI (0.57-0.97)]. [BMS/ASTRO, 22.09.2008] The median locoregional control was 24,4 months for patients enrolled in arm 1 (combination radiation therapy + cetuximab) compared as to 14,9months for patients in arm 2 (radiation therapy alone) - p=0,005 ; hazard ratio= 0,68. The median overall survival was 49 months for patients in arm 1 compared to 29,3 months for patients in arm 2 - p=0,032 : hazard ratio=0,74. [LABEL]@The most frequent side effects seen in 208 patients with cancer of the head and neck receiving ERBITUX in combination with radiation therapy versus 212 patients given radiation alone were acne-like rash (87%/10%), skin irritation in the radiation area (86%/90%), weight loss (84%/72%), and feeling weak (56%/49%). Commonly reported (=10%) serious side effects included: skin irritation in the radiation area (23%), acne-like rash (17%), and weight loss (11%)@@@@COMBO@CETUXIMAB@@@@@CETUXIMAB||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@CONTROLLED@MULTI-CENTRE@@@1.75@m²@9920.96875@@@6.4@week@6.4 week@9920.97@9920.97@221.45@1@0.779@1619.75@@@@@@@@@@@@3.24@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/1/2017@1619.75@1619.75@1352-0902-IN-SG@SOLUTION FOR IV INFUSION - 100 ML@A$@@@@@@@@500@MG@500 MG/100 ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15399694@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XE35@L01X@@LONDON, UNITED KINGDOM@@@Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type.@@15399694@Indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy@Both@NA@@@NO REVIEW@@@@@@@@411@The recommended dose of TAGRISSO is 80 mg tablet once a day until disease progression or unacceptable toxicity.@FDA, 13 November 2015@11/13/2015@@Yes@@@@@No@@@EGFR T790M mutation-positive@ADULTS@@APPROVED@@@NA@The approval was based on two multicenter, single-arm, open-label clinical trials in patients with metastatic EGFR T790M mutation-positive NSCLC who had progressed on prior systemic therapy, including an EGFR TKI (Study 1 and 2).  All patients were required to have EGFR T790M mutation-positive NSCLC as detected by the cobas® EGFR mutation test and received osimertinib 80 mg once daily. The major efficacy outcome measure was objective response rate (ORR) according to RECIST v1.1 as evaluated by a Blinded Independent Central Review (BICR). Duration of response (DOR) was an additional outcome measure.Study 1 (n=201) showed an ORR of 57% (95% CI: 50%, 64%). In Study 2 (n=210) the ORR was 61% (95% CI: 54%, 68%). The majority (96%) of patients in both trials had ongoing responses at the time of primary analysis and the median DOR had not been reached with duration of ongoing responses ranging from 1.1 to 5.6 months after a median duration of follow-up of 4.2 months (Study 1) and 4.0 months (Study 2).  The dose finding phase of Study 1 (n=63) showed an ORR of 51% and median DOR of 12.4 months.  [23 November 2015, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm]@Safety data was evaluated in 411 patients who received osimertinib at a dose of 80 mg daily. The most common adverse events were diarrhea (42%), rash (41%), dry skin (31%), nail toxicity (25%), eye disorders (18%), nausea (17%), decreased appetite (16%), and constipation (15%).  The majority of the above adverse events were grade 1-2. The most common Grade 3-4 adverse reactions were pneumonia and pulmonary embolism (2% each).The most common nonfatal serious adverse events (SAEs) included pneumonia and pulmonary embolus. Dose reductions due to adverse events occurred in 4.4% of patients. The most frequent adverse reaction leading to dose reductions or interruptions were prolonged QTc and neutropenia (2% each). Adverse events leading to discontinuation included ILD/pneumonitis (2%), and cerebrovascular accident (1%).  Fatal adverse events occurred in 3.2% of patients, including 4 cases of pneumonitis attributed to osimertinib.[23 November 2015, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm]@@@@MONO@OSIMERTINIB@@@@@OSIMERTINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAGRISSO@@@@@TAGRISSO||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@@@@@@@@@@@METASTATIC@@@@@MULTICENTER@SINGLE-ARM@OPEN-LABEL@@@1@1@117977.7329@@@4.1@month@4.1 month@117977.73@117977.73@946.05@30@1@14190.75@@@@@@@@@@@@11.83@1@@mg@80@1@@@@@@@@@@@8/2/2017@473.03@473.03@00310-1349-30@FILM-COATED TABLET (BOTTLE)@US$@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924775@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral doses of ondansetron 24 mg once a day, 8 mg twice a day, and 32 mg once a day. 66% of patients were treated with the ondansetron 24-mg  once-a-day , 55% with the ondansetron 8-mg twice-a-day , and 55% with the ondansetron 32-mg once-a-day@@A04AA01@A04A@NO@BRENTFORD, UNITED KINGDOM@@@Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about 30ng/ml are attained approximately 1.5 hours after an 8mg dose. For doses above 8mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses. Bioavailability, following oral administration, is slightly enhanced by the presence of food but unaffected by antacids. Studies in healthy elderly volunteers have shown slight, but clinically insignificant, age-related increases in both oral bioavailability (65%) and half-life (5 hours) of ondansetron. Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).  The disposition of ondansetron following oral, intramuscular(IM) and intravenous(IV) dosing is similar with a terminal half life of about 3 hours and steady state volume of distribution of about 140L. Equivalent systemic exposure is achieved after IM and IV administration of ondansetron.@@14924775@Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2; prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy; prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; prevention of postoperative nausea and/or vomiting.@@NO@@@NO REVIEW@@@@Co-pay Tier 3. SOURCE: Aetna Preferred Drug Guide 2008@@@@357@Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin =50 mg/m2. Multiday, single-dose administration of a 24 mg dosage has not been studied. Pediatric Use: There is no experience with the use of a 24 mg dosage in pediatric patients. Geriatric Use: The dosage recommendation is the same as for the general population. Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is one 8-mg tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.@@@@@@@Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@6-Dec@357 ADULT CANCER PATIENTS RECEIVING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN =50 MG/M2.@@@CLINICAL TRIALS / CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING: HIGHLY EMETOGENIC CHEMOTHERAPY; 2 RANDOMISED, DOUBLE-BLIND, MONOTHERAPY TRIALS@APPROVED@@Covered; preferred brand; quantity limit 2 for 30 days; step therapy@MEDICARE@First trial: Each of the 3 treatment groups was shown to be statistically significantly superior to a historical placebo control. 56% of patients receiving oral ondansetron 24 mg once a day experienced no nausea during the 24-hour study period, compared with 36% of patients in the oral ondansetron 8-mg twice-a-day group (p = 0.001) and 50% in the oral ondansetron 32-mg once-a-day group. Second trial, efficacy of the oral ondansetron 24-mg once-a-day regimen in the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2, was confirmed.@@@@@MONO@ONDANSETRON HYDROCHLORIDE@@@@@ONDANSETRON HYDROCHLORIDE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@ZOFRAN ODT@@@@@ZOFRAN ODT||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@EMETIC EPISODES@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@658.15@@@@@@@@@@@@5.48@@@@@@@@@@@@@@@@8/2/2017@21.94@21.94@00173-0569-00@ORODISPERSIBLE TABLET@US$@@@@@@@@4@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922926@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01BA01@L01B@YES@FORT LEE, NEW JERSEY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14922926@Neoplastic Diseases: indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Psoriasis: indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis: indicated in the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.@@@@@NO REVIEW@@@@@@@@@Choriocarcinoma and similar trophoblastic diseases: Methotrexate is administered orally or intramuscularly in doses of 15 to 30 mg daily for a five-day course. Such courses are usually repeated for 3 to 5 times as required, with rest periods of one or more weeks interposed between courses, until any manifesting toxic symptoms subside.@@@@@@@1.Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks.2.Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. 3.Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs). 4.Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. 5.Methotrexate-induced lung disease is a potentially dangerous lesion, which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation. 6.Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. 7.Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. 8.Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication. 9.Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy. 10.Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. 11.Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@DAVA PHARMACEUTICALS@@@@@DAVA PHARMACEUTICALS||||@@@@@@|||||||||@Endometrial Cancer@Breast Cancer@NSCLC@Head & Neck Cancer@@Endometrial Cancer|Breast Cancer|NSCLC|Head & Neck Cancer||||||@RHEUMATREX@@@@@RHEUMATREX||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@24@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@67253-0580-46@TABLET@US$@@@@@@@@2.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918698@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@@@YES@KENILWORTH, NEW JERSEY@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14918698@Indicated in a wide variety of disorders amenable to glucocorticoid therapy, as well as an adjunct in the control of cerebral oedema.@@@@@NO REVIEW@@@@100%@>> Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]>> Acquired through takeover of Organon in 2007@@@N/A@Adults: Usually, daily oral dosages of 0.5 - 10 mg are sufficient. In some patients higher dosages may be temporarily required to control the disease. Once the disease is under control the dosage should be reduced or tapered off to the lowest suitable level under continuous monitoring and observation of the patient. For a short dexamethasone suppression test, 1mg dexamethasone is given at 11 p.m. and plasma cortisol measured the next morning. Patients who do not show a decrease in cortisol can be exposed to a longer test: 500 micrograms dexamethasone is given at 6 hourly intervals for 48 hours followed by 2mg every 6 hours for a further 48 hours. 24 hour-urine collections are made before, during and at the end of the test for determination of 17-hydroxycorticosteroids. Children: 0.01-0.1mg/kg of body weight daily.@EMA, March 1990@@@@@@Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity. Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment.@NO LABELLED TRIAL@No@@@-@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@ADJUVANT@DEXAMETHASONE SODIUM PHOSPHATE@@@@@DEXAMETHASONE SODIUM PHOSPHATE||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Brain Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Brain Cancer||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@1@year@1 year@@@@20@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@GB£@@@@@@@@500@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917661@Onco@@@@@300f1037ntsdm@@@@@@Patients were randomised to Procrit 40,000 Units weekly (n = 174) or placebo (n = 170) SC. If hemoglobin had not increased by > 1 g/dL, after 4 weeks of therapy or the patient received RBC transfusion during the first 4 weeks of therapy, study drug was increased to 60,000 Units weekly. Forty-three percent of patients in the Epoetin alfa group required an increase in Procrit dose to 60,000 Units weekly@@B03XA01@B03X@YES@BEERSE, BELGIUM@@@Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment. The apparent molecular weight of erythropoietin is 32,000 to 40,000 dalton. The protein fraction of the molecule contributes about 58% and consists of 165 amino acids. The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein. Epoetin alfa obtained by gene technology is glycosylated and is identical in its amino acid and carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients. Epoetin alfa has the highest possible purity according to the present state of the art. In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.@@14917661@• Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). • It can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency) if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). • It can be used to reduce exposure to allogeneic blood transfusions in adult non-iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 1013 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml).@@YES@@@NO REVIEW@@@@60%@@@@344@Adult cancer patients with symptomatic anaemia receiving chemotherapy: The subcutaneous route of administration should be used. Epoetinum alfa therapy should be administered to patients with anaemia (e.g. Hb  11 g/dl [6.8 mmol/l]). The target haemoglobin concentration is approximately 12 g/dl (7.5 mmol/l).@HMA, 6 June 2006@6/6/2006@@@@@Chronic renal failure and cancer patients on epoetinum alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter. In all patients receiving epoetinum alfa, blood pressure should be closely monitored and controlled as necessary. Epoetinum alfa should be used with caution in the presence of untreated, inadequately treated or poorly controllable hypertension. It may be necessary to add or increase antihypertensive treatment. If blood pressure cannot be controlled, epoetinum alfa treatment should be discontinued. Epoetinum alfa should also be used with caution in the presence of epilepsy and chronic liver failure. There may be a moderate dosedependent rise in the platelet count within the normal range during treatment with epoetinum alfa. This regresses during the course of continued therapy. It is recommended that the platelet count is regularly monitored during the first 8 weeks of therapy.@@No@@344 ANEMIC CANCER PATIENTS.  61 PATIENTS (35 PATIENTS IN THE PLACEBO ARM AND 26 PATIENTS IN THE PROCRIT ARM) WERE TREATED WITH CONCOMITANT CISPLATIN CONTAINING REGIMENS AND 283 PATIENTS RECEIVED CONCOMITANT CHEMOTHERAPY REGIMENS THAT DID NOT CONTAIN CISPL@@@CLINICAL EXPERIENCE: RESPONSE TO PROCRIT / CANCER PATIENTS ON CHEMOTHERAPY /WEEKLY (QW) DOSING@APPROVED@@NO REVIEW@SNS@Reduced the proportion of patients transfused in day 29 through week 16 of the study as compared to placebo. 25 (14%) in the Procrit group received transfusions compared to 48 patients (28%) in the placebo group (p = 0.0010) between day 29 and week 16 or the last day on study.@@@@@COMBO@EPOETIN ALFA@@@@@EPOETIN ALFA||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@EPREX@@@@@EPREX||||@EPO@@@@@EPO||||@REDUCTION IN TRANSFUSIONS@@@@@@@@@@@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@16@week@16 week@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@5000@IU@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919961@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@FIFTH-LINE@@V10XA53@V10X@YES@BRENTFORD, UNITED KINGDOM@@@The therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) is an anti-neoplastic radioimmunotherapeutic monoclonal antibody-based regimen composed of the monoclonal antibody, Tositumomab, and the radiolabeled monoclonal antibody, Iodine I 131 Tositumomab. Possible mechanisms of action of the therapeutic regimen include induction of apoptosis, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity (ADCC) mediated by the antibody. Additionally, cell death is associated with ionizing radiation from the radioisotope.@@14919961@Bexxar is indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma, including patients with Rituximab-refractory non-Hodgkin's lymphoma. Determination of the effectiveness of the therapeutic regimen is based on overall response rates in patients whose disease is refractory to chemotherapy alone or to chemotherapy and Rituximab. The effects of the BEXXAR therapeutic regimen on survival are not known. The Bexxar therapeutic regimen is not indicated for the initial treatment of patients with CD20 positive non-Hodgkin's lymphoma.@@NO@@@NO REVIEW@@@@Not tiered. SOURCE: Aetna Preferred Drug 2008@@@@40@Recommended Dose: Dosimetric step • Tositumomab 450 mg intravenously in 50 ml 0.9% Sodium Chloride over 60 minutes. Reduce the rate of infusion by 50% for mild to moderate infusional toxicity; interrupt infusion for severe infusional toxicity. After complete resolution of severe infusional toxicity, infusion may be resumed with a 50% reduction in the rate of infusion. • Iodine I 131 Tositumomab (containing 5.0 mCi Iodine-131 and 35 mg Tositumomab) intravenously in 30 ml 0.9% Sodium Chloride over 20 minutes. Reduce the rate of infusion by 50% for mild to moderate infusional toxicity; interrupt infusion for severe infusional toxicity. After complete resolution of severe infusional toxicity, infusion may be resumed with a 50% reduction in the rate of infusion. Therapeutic step • Tositumomab 450 mg intravenously in 50 ml 0.9% Sodium Chloride over 60 minutes. Reduce the rate of infusion by 50% for mild to moderate infusional toxicity; interrupt infusion for severe infusional toxicity. After complete resolution of severe infusional toxicity, infusion may be resumed with a 50% reduction in the rate of infusion. • Iodine I 131 Tositumomab. Reduce the rate of infusion by 50% for mild to moderate infusional toxicity; interrupt infusion for severe infusional toxicity. After complete resolution of severe infusional toxicity, infusion may be resumed with a 50% reduction in the rate of infusion. • Patients with =150,000 platelets/mm3: The recommended dose is the activity of Iodine-131 calculated to deliver 75 cGy total body irradiation and 35 mg Tositumomab, administered intravenously over 20 minutes. • Patients with NCI Grade 1 thrombocytopenia (platelet counts =100,000 but <150,000 platelets/mm3): The recommended dose is the activity of Iodine-131 calculated to deliver 65 cGy total body irradiation and 35 mg Tositumomab, administered intravenously over 20 minutes.@FDA, 27 June 2003@6/27/2003@@@@@Hypersensitivity Reactions, including Anaphylaxis: Serious hypersensitivity reactions, including some with fatal outcome, have been reported with Bexxar. Medications for the treatment of severe hypersensitivity reactions should be available for immediate use. Patients who develop severe hypersensitivity reactions should have infusions of Bexxar discontinued and receive medical attention. Prolonged and Severe Cytopaenias: The majority of patients who received Bexxar experienced severe thrombocytopaenia and neutropaenia. Bexxar should not be administered to patients with >25% lymphoma marrow involvement and/or impaired bone marrow reserve. Pregnancy Category X: Bexxar can cause fetal harm when administered to a pregnant woman. Special requirements: Bexxar contains a radioactive component and should be administered only by physicians and other health care professionals qualified by training in the safe use and handling of therapeutic radionuclides. Bexxar should be administered only by physicians who are in the process of being or have been certified by GSK in dose calculation and administration of Bexxar.@STUDY 1@No@N/A@40 [NHL PROGRESSED AFTER 4 RITUXAN THERAPY]@@@III [FIRST-LINE ALL]@APPROVED@@@MEDICARE@The overall objective RR was 63% with a median duration of 25 months (range of 4 - 38+ months). The complete response in this subset of patients was 29%.@@@@@MONO@TOSITUMOMAB IODINE I-131@@@@@TOSITUMOMAB IODINE I-131||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@BEXXAR@@@@@BEXXAR||||@mAb@Murine@Radiolabeled@CD20@@mAb|Murine|Radiolabeled|CD20|@RESPONSE RATE@@@@@@@@@@@@@@@SINGLE-ARM@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00007-3262-01@SOLUTION FOR INJECTION - 20 ML@US$@@@@@@@@5.5@MCI@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916938@Onco@@@@@300f1020ntsdm@@@@@@Patients were treated with Arimidex 1 mg daily, or tamoxifen 20 mg daily, or a combination of the two treatments (treatment discontinued after 33 months)@@L02BG03@L02B@NO@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@14916938@Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.@@NO@@@NO REVIEW@@@@100%@-@@-@9366@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@EMA, 1 December 2003@12/1/2003@@@@@Arimidex can cause fetal harm when administered to a pregnant woman.@ATAC@No@@POSTMENOPAUSAL WOMEN WITH OPERABLE BREAST CANCER WERE RANDOMISED TO ADJUVANT TREATMENT WITH ARIMIDEX 1 MG DAILY (3125 PATIENTS), TAMOXIFEN 20 MG DAILY (3116 PATIENTS), OR A COMBINATION OF THE TWO TREATMENTS (3125 PATIENTS - TREATMENT DISCONTINUED AF@@@@APPROVED@@@SSN@DFS in the intent-to-treat population was statistically significantly improved [Hazard Ratio (HR) = 0.87, 95% CI: 0.78, 0.97, p=0.0127 in the Arimidex arm compared to the tamoxifen arm. In the hormone receptor-positive subpopulation representing about 84% of the trial patients, disease-free survival was also statistically significantly improved (HR =0.83, 95% CI: 0.73, 0.94, p=0.0049) in the Arimidex arm compared to the tamoxifen arm.@-@@@@ADJUVANT@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@DISEASE-FREE SURVIVAL@@@@@@@@@@EARLY@@@@@MULTI-CENTRE@DOUBLE-BLIND@RANDOMISED@@@1@1@1847.15915@@@5@year@5 year@1847.16@1847.16@1.01@28@1.1807@28.34@46.78@29.62@@@@@@@@@@1.01@1@@mg@1@1@@@@@@@@@@@8/31/2017@1.01@1.01@31809015@TABLET@EURO@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16733486@Onco@@@@@300f1010ntsdm@@@@@@Experimental: Cohort 1 Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.•Experimental: Cohort 2 Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.•Experimental: Cohort 3 Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@4/1/2021@@KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.@@16733486@Treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.@Both@YES@@@NO REVIEW@@@@100%@@THIRD-LINE@NCT02453594@210@200 mg for NSCLC that has not been previously treated with chemotherapy or for cHL.@EMA, 2 May 2017@5/2/2017@@No@@6/1/2015@@3475-087, 2014-004482-24 ( EudraCT Number ), 153005 ( Registry Identifier: JAPIC-CTI )@No@@Relapsed or refractory de novo classical Hodgkin lymphoma; Participant may have failed to achieve a response to, progressed after, or be ineligible for autologous stem cell transplant (auto-SCT); Participant may have failed to achieve a response or progressed after treatment with brentuximab vedotin or may be brentuximab vedotin naïve; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Measurable disease; Adequate organ function@@ADULTS@II@APPROVED@@@NHS@OVERALL SURVIVAL@@@@@MONO@PEMBROLIZUMAB@@@@@PEMBROLIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@OVERALL RESPONSE RATE@@@@@COMPLETE REMISSION RATE@PROGRESSION-FREE SURVIVAL@DURATION OF RESPONSE@@@REFRACTORY@RELAPSED@@@@NON-RANDOMIZED@SINGLE GROUP ASSIGNMENT@NO MASKING@@@1@1@86088.86705@@@11.3@month@11.3 month@86088.87@86088.87@250.48@1@1.299@2630@@@@@@@@@@@@26.3@21@@mg@200@1@@@@@@@@@@@7/28/2017@2630@2630@3.43E+16@SOLUTION FOR INFUSION (VIAL) - 4 ML@GB£@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920182@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Mitoxantrone and prednisone compared to prednisone alone@@L01DB07@L01D@YES@UNITED STATES@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14920182@Mitoxantrone Injection in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced HRPC; in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.@@NO@@@NO REVIEW@@@@@@@@161@HRPC: based on data from two Phase 3 comparative trials of mitoxantrone injection plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m2 given as a short intravenous infusion every 21 days.@@@@@@@HRPC: functional cardiac changes such as decreases in LVEF and congestive heart failure may occur in patients with HRPC treated with mitoxantrone. In a randomised comparative trial of mitoxantrone plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone had a cardiac event defined as any decrease in LVEF below the normal range, CHF (n = 3), or myocardial ischemia. Two patients had a prior history of cardiac disease. The total mitoxantrone dose administered to patients with cardiac effects ranged from > 48 to 212 mg/m2. Among 112 patients evaluable for safety on the mitoxantrone + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. The range of total mitoxantrone doses administered to these patients is not available.@@No@@161 PATIENTS WITH METASTATIC OR LOCALLY ADVANCED HRPC@@@CCI-NOV22@APPROVED@@Covered; part B; specialty drug@MEDICARE@A primary palliative response (defined as a 2-point decrease in pain intensity in a 6-point pain scale) was achieved in 29% of patients randomised to M + P compared to 12% of patients randomised to P alone (p = 0.011). 2 responders left the study after meeting primary response criterion for 2 consecutive cycles. A secondary palliative response was defined as a 50% or greater decrease in analgesic use, associated with stable pain intensity, and lasting a minimum of 6 weeks. An overall palliative response was achieved in 38% of patients randomised to M + P compared to 21% of patients on P (p = 0.025). The median duration of primary palliative response for M +P patients was 7.6 months compared to 2.1 months for P patients alone (p = 0.0009). The median duration of overall palliative response for M+P patients was 5.6 months compared to 1.9 months for P patients (p = 0.0004). Median TTP for M+P patients was 4.4 months compared to 2.3 months for all P patients (p =0.0001). Median time to death was 11.3 months for M+P patients and 10.8 months on P patients (p = 0.2324). 48 patients on the P arm crossed over to receive M + P. Of these, 30 patients had progressed on P, while 18 had SD on P. The clinical significance of a fall in PSA concentrations after chemotherapy is unclear- a PSA fall of 50% or greater for 2 consecutive follow-up assessments after baseline was reported in 33% of all M+P patients and 9% of P patients. These findings should be interpreted with caution since PSA responses were not defined prospectively@@@@@COMBO@MITOXANTRONE@PREDNISONE@@@@MITOXANTRONE|PREDNISONE|||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@PARTIAL RESPONSE@STABLE DISEASE@DURATION OF RESPONSE@TIME TO PROGRESSION@@DURATION OF RESPONSE@TIME TO PROGRESSION@@@@ADVANCED@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@563.25@@@@@@@@@@@@22.53@@@@@@@@@@@@@@@@8/2/2017@563.25@563.25@63323-0132-12@INJECTION@US$@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16676444@Onco@@@@@@@@@@@"Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab, Experimental, Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT will be declared the RP2D.
Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab, Experimental, Approximately 30 participants with advanced, platinum-sensitive ovarian cancer will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D for the combination. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles.
"@@@@@BASEL, SWITZERLAND@1/30/2019@@@@16676444@A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Solid Tumors and Advanced Gynecologic Cancers, With a Focus on Ovarian Cancer@Female@@@@@@@@@@@NCT03101280@48@@@@@@@@@WO39409@@@Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1  -  A life expectancy of at least 3 months  -  Have a histologically confirmed diagnosis of gynecological cancer (ovarian or endometrial) [Part 1] or high-grade serous or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (Part 2)  -  For Part 1, have received at least one line of prior therapy  -  For Part 2, have received at least one and no more than two lines of prior platinum-containing therapy and progressed after the most recent platinum therapy in a platinum-sensitive timeframe  -  Have disease that is measurable as defined by RECIST v1.1  -  Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue available for planned analyses  -  For Part 2 ONLY, have a CA125 measurement that is greater than 2 times the upper limit of normal (ULN)  -  For Part 2 ONLY, have disease that can be biopsied  -  For Part 2 ONLY, have a deleterious germline or somatic breast cancer susceptibility gene 1 (BRCA1) or BRCA2 mutation or tumors that are wild-type BRCA but show high levels of loss of heterozygosity (LOH) (tBRCAwt/LOHhigh) signature  -  Have adequate organ function@@ADULTS@Phase 1@I@@@@@@@@@COMBO@ATEZOLIZUMAB@RUCAPARIB@@@@ATEZOLIZUMAB|RUCAPARIB|||@ROCHE@@@@@ROCHE||||@Australia@United Kingdom@@@@Australia|United Kingdom||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@TECENTRIQ@CO-338@@@@TECENTRIQ|CO-338|||@Other@@@@@Other||||@Percentage of Participants With Adverse Events@Percentage of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]@Recommended Phase II Dose (RP2D) of Rucaparib for the Combination [Part 1]@@@Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)@Percentage of Participants With Objective Response of CR or PR as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (Cancer Antigen 125 [CA125] Response) Considerations@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16827900@Onco@@@@@300f1010ntsdm@@@@@@Experimental: Regorafenib. 160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)Placebo Comparator:  4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC@@L01XE21@L01X@@LEVERKUSEN, GERMANY@2/1/2016@@DAST (BAY 73-4506) is a novel oral substance for cancer therapy in the early stages of clinical development. The name DAST (Dual Acting Signal Transduction Inhibitor) stands for the dual mechanism of action of the active substance, which, by its inhibitory action on various enzymes (kinases), inhibits both the signalling pathways in cancer cell proliferation and also new blood vessel formation. In preclinical studies, DAST has proved to be effective in various tumor models, including pancreatic cancer, lung cancer, colon cancer, and breast cancer. Currently, two phase I clinical studies are being conducted with DAST. The first provisional data from these studies are very promising.@@16827900@Treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.@Both@YES@@@NO REVIEW@@@@100%@@SECOND-LINE@NCT01774344@573@The recommended dose of regorafenib is 160 mg (4 tablets of 40 mg) taken once daily for 3 weeks followed by 1 week off therapy. This 4-week period is considered a treatment cycle. Treatment should continue as long as benefit is observed or until unacceptable toxicity occurs@EMA, 2 August 2017@8/2/2017@@No@@5/1/2013@@15982, 2012-003649-14  EudraCT Number)@No@@Histological or cytological confirmation of HCC (hepatocellular carcinoma) or non-invasive diagnosis of HCC as per American Association for the Study of Liver Diseases criteria in patients with a confirmed diagnosis of cirrhosis; Barcelona Clinic Liver Cancer stage Category B or C that cannot benefit from treatments of established efficacy with higher priority such as resection, local ablation, chemoembolization or systemic sorafenib; Failure to prior treatment with sorafenib (defined as documented radiological progression according to the radiology charter). Randomization needs to be performed within 10 weeks after the last treatment with sorafenib; Tolerability of prior treatment with sorafenib defined as not less than 20 days at a minimum daily dose of 400 mg QD within the last 28 days prior to withdrawal; Liver function status Child-Pugh Class A. Child Pugh status should be calculated based on clinical findings and laboratory results during the screening period.@@ADULTS@III@APPROVED@@@NHS@@@@@@MONO@REGORAFENIB@@@@@REGORAFENIB||||@BAYER HEALTHCARE@ONYX@@@@BAYER HEALTHCARE|ONYX|||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@STIVARGA@@@@@STIVARGA||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@TIME TO PROGRESSION@OBJECTIVE TUMOUR RESPONSE RATE@@@@@@@@RANDOMISED@MULTICENTER@DOUBLE-BLIND@PLACEBO-CONTROLLED@@1@1@12607.86635@@@3.1@month@3.1 month@12607.87@12607.87@133.71@84@1.2961@3744@@@@@@@@@@@@1.11@28@@mg@160@21@@@@@@@@@@@8/21/2017@44.57@44.57@2.33E+16@TABLET@GB£@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16624028@Onco@@@@@300f1012ntsdm@@@@@@Experimental: Single arm Intervention: Drug: ABT-199@@L01XX52@L01X@@UNITED STATES@6/1/2017@@Venetoclax is a potent, selective inhibitor of B-cell lymphoma (BCL)-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumour cell survival and has been associated with resistance to chemotherapeutics. Venetoclax binds directly to the BH3-binding groove of BCL-2, displacing BH3 motif-containing pro-apoptotic proteins like BIM, to initiate mitochondrial outer membrane permeabilization (MOMP), caspase activation, and programmed cell death. In non-clinical studies, venetoclax has demonstrated cytotoxic activity in tumour cells that overexpress BCL-2.@@16624028@Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.@Both@NA@15-Jun-17@6/15/2017@NO REVIEW@@@@0%@@@NCT01889186@107@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@EMA, 5 December 2016@12/5/2016@1/1/2017@Yes@@6/1/2013@@M13-982, 2012-004027-20@No@@Subject must have diagnosis of CLL that meets published 2008 Modified IWCLL NCI-WG (International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group) Guidelines; Subject has an indication for treatment according to the 2008 Modified IWCLL NCI WG Guidelines; Subject has clinically measurable disease (lymphocytosis > 5 × 10^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam); Subject must be refractory or have relapsed after receiving at least one prior line of therapy (subjects that have progressed after 1 cycle of treatment or have completed at least 2 cycles of treatment for a given line of therapy) or previously untreated CLL (previously untreated CLL subjects must have received no prior chemotherapy or immunotherapy. Subjects with a history of emergency, loco-regional radiotherapy (e.g., for relief of compressive signs or symptoms) are eligible. In addition, subjects must meet the CLL diagnostic criteria above and must have > 5 × 109/L B Lymphocytes in the peripheral blood.); Subjects must have 17p deletion, assessed by local laboratory (in bone marrow or peripheral blood) or assessed by central laboratory (peripheral blood); Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.@17p Deletion or TP53 mutation@ADULTS@II@APPROVED@@15 June 2017, Benefit not quantifiable, [https://www.g-ba.de/downloads/39-261-2970/2017-06-15_AM-RL-XII_Venetoclax_D-266_BAnz.pdf]@@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLYXTO@@@@@VENCLYXTO||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@COMPLETE REMISSION@PARTIAL REMISSION@@@@@@@@@OPEN-LABEL@SINGLE-ARM@MULTICENTER@@@1@1@246526.8739@@@12@month@12 month@246526.87@246526.87@675.43@7@1.1511@628.04@805.02@648.52@@@@@@@@@@1.79@28@1@mg@92.5@28@1@@mg@400@1@@@@@@8/1/2017@89.72@89.72@12448786@FILM COATED TABLET@EURO@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16670296@Onco@@@@@300f1015ntsdm@@@@@@Experimental: Lenalidomide / Dexamethasone until disease progression Experimental: Lenalidomide / Dexamethasone for 18 cycles Active Comparator: Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles@@L04AX04@L04A@@SUMMIT, NEW JERSEY@6/1/2016@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16670296@Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant@Both@YES@25-Jan-17@1/25/2017@NO REVIEW@@@@@@FIRST-LINE@NCT00689936@1623@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles.@EMA, 11 February 2015@2/11/2015@9/1/2007@Yes@@8/1/2008@@CC5013MM020, 200700482339@No@@Must understand and voluntarily sign informed consent form. Age ≥ 18 years at the time of signing consent. Previously untreated. ECOG performance status of 0, 1, or 2. Able to adhere to the study visit schedule and other protocol requirements. Females of childbearing potential (FCBP)^2@@ADULTS@III@APPROVED@@25 January 2017: ASMR III [http://www.has-sante.fr/portail/upload/docs/evamed/CT-15763_REVLIMID_PIC_EI_myelome_multiple_Avis2_CT15763.pdf]@HAUTE AUTORITÉ DE SANTÉ@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@DURATION OF RESPONSE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@439140.1248@@@26@month@26 month@439140.12@439140.12@555.3@1@1.1511@148.08@@@@@@@@@@@@29.62@28@@mg@25@21@@@@@@@@@@@8/2/2017@148.08@148.08@9298159R@CAPSULE@EURO@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14924659@Onco@@@@@300f1020ntsdm@@@@@@Oral doses of ondansetron 24 mg once a day, 8 mg twice a day, and 32 mg once a day. 66% of patients were treated with the ondansetron 24-mg  once-a-day , 55% with the ondansetron 8-mg twice-a-day , and 55% with the ondansetron 32-mg once-a-day@@A04AA01@A04A@NO@BRENTFORD, UNITED KINGDOM@@@Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about 30ng/ml are attained approximately 1.5 hours after an 8mg dose. For doses above 8mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses. Bioavailability, following oral administration, is slightly enhanced by the presence of food but unaffected by antacids. Studies in healthy elderly volunteers have shown slight, but clinically insignificant, age-related increases in both oral bioavailability (65%) and half-life (5 hours) of ondansetron. Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).  The disposition of ondansetron following oral, intramuscular(IM) and intravenous(IV) dosing is similar with a terminal half life of about 3 hours and steady state volume of distribution of about 140L. Equivalent systemic exposure is achieved after IM and IV administration of ondansetron.@@14924659@Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2; prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy; prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; prevention of postoperative nausea and/or vomiting.@@NO@-@@NO REVIEW@@@@100%@-@-@-@357@Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin =50 mg/m2. Multiday, single-dose administration of a 24 mg dosage has not been studied. Pediatric Use: There is no experience with the use of a 24 mg dosage in pediatric patients. Geriatric Use: The dosage recommendation is the same as for the general population. Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is one 8-mg tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.@N/A@@@-@@@Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@-@No@-@357 ADULT CANCER PATIENTS RECEIVING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN =50 MG/M2.@@@CLINICAL TRIALS / CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING: HIGHLY EMETOGENIC CHEMOTHERAPY; 2 RANDOMISED, DOUBLE-BLIND, MONOTHERAPY TRIALS@APPROVED@@@SSN@First trial: Each of the 3 treatment groups was shown to be statistically significantly superior to a historical placebo control. 56% of patients receiving oral ondansetron 24 mg once a day experienced no nausea during the 24-hour study period, compared with 36% of patients in the oral ondansetron 8-mg twice-a-day group (p = 0.001) and 50% in the oral ondansetron 32-mg once-a-day group. Second trial, efficacy of the oral ondansetron 24-mg once-a-day regimen in the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2, was confirmed.@-@@@@MONO@ONDANSETRON HYDROCHLORIDE@@@@@ONDANSETRON HYDROCHLORIDE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@ZOFRAN@@@@@ZOFRAN||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@EMETIC EPISODES@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@36.31@59.92@37.94@@@@@@@@@@0.91@@@@@@@@@@@@@@@@6/7/2017@36.31@36.31@27612086@SYRUP 50 ML@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16749464@Onco@@@@@300f1010ntsdm@@@@@@@@L01XC02@L01X@@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@16749464@Maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy@@NO@22-Jun-11@6/22/2011@NO REVIEW@@@@100%@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008Genentech opted-in in Q3 2006@FIRST-LINE@@1193@The recommended dose of MabThera used as a maintenance treatment for patients with previously untreated follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 2 months (starting 2 months after the last dose of induction therapy) until disease progression or for a maximum period of two years.@EMA, 25 October 2010@10/25/2010@@No@@@@@No@@@@@III@APPROVED@@22 June 2011: Recommended. Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non‑Hodgkin's lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy. [NICE, https://www.nice.org.uk/guidance/ta226/chapter/1-Guidance]@NHS@@@@@@MAINTENANCE@RITUXIMAB@@@@@RITUXIMAB||||@ROCHE@GENENTECH@@@@ROCHE|GENENTECH|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MABTHERA@@@@@MABTHERA||||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@@@@@@@@@@@@@@@@PROSPECTIVE@OPEN-LABEL@MULTI-CENTER@@@1.75@m²@13752.86608@@@2@year@2 year@13752.87@13752.87@18.84@1@1.299@873.15@@@@@@@@@@@@1.75@60.83@@mg/m²@375@1@@@@@@@@@@@7/28/2017@873.15@873.15@7.70E+15@CONCENTRATE FOR SOLUTION FOR INFUSION, 50 ML@GB£@@@@@@@@500@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923667@Onco@@@@@300f1015ntsdm@@@@@@Patients were treated with either Taxotere (T) (75 mg/m2 on day 1) in combination with cisplatin (C) (75 mg/m2 on day 1) and fluorouracil (F) (750 mg/m2 per day for 5 days) or cisplatin (100 mg/m2 on day 1) and fluorouracil (1000 mg/m2 per day for 5 days).@@L01CD02@L01C@YES@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14923667@Breast Cancer: Taxotere is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable nodepositive breast cancer. NSCLC: Taxotere as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. Prostate Cancer: Taxotere in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Gastric Adenocarcinoma: Taxotere in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. Head and neck cancer: Taxotere in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN).@@YES@18-Apr-07@4/18/2007@@@@@@@SECOND-LINE@@@Gastric adenocarcinoma: The recommended dose of Taxotere is 75 mg/m2 as a 1 hour intravenous infusion, followed by cisplatin 75 mg/m2, as a 1 to 3 hour intravenous infusion (both on day 1 only), followed by fluorouracil 750 mg/m2 per day given as a 24-hour continuous intravenous infusion for 5 days, starting at the end of the cisplatin infusion. Treatment is repeated every three weeks. Premedication Regimen: All patients should be premedicated with oral corticosteroids such as dexamethasone 16 mg per day (e.g., 8 mg BID) for 3 days starting 1 day prior to Taxotere administration in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. For hormone-refractory metastatic prostate cancer, given the concurrent use of prednisone, the recommended premedication regimen is oral dexamethasone 8 mg, at 12 hours, 3 hours and 1 hour before the Taxotere infusion.@23-Oct-06@10/23/2006@3/1/1996@@@@@@No@@PATIENTS (N=445 PATIENTS WITH KPS>70) WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION, WHO HAD NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE WERE ENROLLED.@@@CLINICAL STUDIES/GASTRIC ADENOCARCINOMA@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@The hazard ratio (HR) for TTP was 1.47 (CF/TCF, 95% CI: 1.19-1.83) with a significantly longer TTP (p=0.0004) in the TCF arm. Approximately 75% of patients had died at the time of this analysis. Overall survival was significantly longer (p=0.0201) in the TCF arm with a HR of 1.29 (95% CI: 1.04-1.61).@@@@@COMBO@DOCETAXEL@CISPLATIN@FLUOROURACIL@@@DOCETAXEL|CISPLATIN|FLUOROURACIL||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@@@@@MULTI-CENTRE@OPEN-LABEL@RANDOMISED@@@@@Invalid Dosage Value Phase 1@@@@@@6683.91@6683.91@@1@1.1511@271.6@@@@@@@@@@@@3.4@@@@@@@@@@@@@@@@8/2/2017@271.6@271.6@9178099R@CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION, 2 ML@EURO@@@@@@@@80@MG@80 MG/2 ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918567@Onco@@@@@300f1012ntsdm@@@@@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (100 or 75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@HOLZKIRCHEN, GERMANY@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14918567@Indicated for the treatment of: 1. advanced ovarian carcinoma of epithelial origin in  (a) first line therapy (b) second line therapy, after other treatments have failed. 2. small cell carcinoma of the lung.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@FIRST-LINE@@789@Single-Agent Therapy: has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide:an effective combination for previously untreated patients consists of: Paraplatin—300 mg/m2 I.V. on day 1 every four weeks for six cycles. Cyclophosphamide—600 mg/m2 I.V. on day 1 every four weeks for six cycles. Intermittent courses of Paraplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.@@@@@@@Paraplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.@LABEL@No@@342 ADVANCED OVARIAN CANCER PATIENTS (SWOG) 447 ADVANCED OVARIAN CANCER PATIENTS (NCIC)@@@III; SWOG + NCIC@APPROVED@@@GKV@SWOG: Carboplatin versus cisplatin: 58% (48/83) versus 43% (33/76) respectively. Complete response: 10% (17/171) versus 10% (17/171). Median PFS: 49 versus 47 weeks. 2-year PFS: 21% versus 21%. 3-year PFS: 8% versus 14%. Median survival: 86 versus 79 weeks. 2-year survival: 40% versus 39%. 3-year survival: 18% versus 25%. NCIC: Carboplatin versus cisplatin: Clinical response  60% (48/80) versus 58% (49/85) respectively. Complete response: 11% (24/224) versus 15% (33/223). Median PFS: 59 versus 61 weeks. 2-year PFS: 31% versus 31%. 3-year PFS: 19% versus 23%. Median survival: 110 weeks versus 99 weeks. 2-year survival: 52% versus 48%. 3-year survival: 35% versus 33%.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Incorrect Average Duration of Use (Unit)@@@6@course@6 course@@@@1@1.1511@20.67@37.12@22.02@@@@@@@@@@0.41@@@@@@@@@@@@@@@@8/1/2017@20.67@20.67@1527749@INFUSION - SOLUTION, 5 ML@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920229@Onco@@@@@300f1012ntsdm@@@@@@311 received leuprolide + flutamide; 306 received leuprolide + placebo@@L02BB01@L02B@YES@LEICHINGEN, GERMANY@@@Flutamide is an anilide, nonsteroidal oral antiandrogen. In animal studies flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding in target tissues. When flutamide is given in combination with surgical or medical castration, suppression of both testicular and adrenal androgen activity is achieved.@@14920229@Treatment of advanced prostatic carcinoma in which suppression of testosterone effects is indicated; as initial treatment in combination with an LHRH agonist, as adjunctive therapy in patients already receiving LHRH agonist therapy; in surgically castrated patients; in the treatment of patients who have not responded to other form of hormonal manipulation or in patients who cannot tolerate such treatment. In combination with LHRH agonists for the management of locally confined B2-C2 (T2b-T4) prostate carcinoma as initial therapy; bulky primary tumors confined to the prostate (stage B2 or T2b) or extending beyond the capsule (stage C or T3-T4), with or without pelvic node involvement.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@617@One 250mg tablet three times daily at 8 hour intervals.@@@@@@@"Hepatic Injury: There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide. Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with flutamide. Serum transaminase levels should be measured prior to starting treatment with flutamide. Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal. Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter. Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction, eg, nausea, vomiting, abdominal pain, fatigue, anorexia, ""flu-like"" symptoms, hyperbilirubinuria, jaundice, or right upper quadrant tenderness. If at any time a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, flutamide should be immediately discontinued with close follow-up of liver function tests until resolution."@LABEL@No@@@@@III STAGE D2 METASTATIC CARCINOMA@APPROVED@@@GKV@Median survival reached at 3.5 years. The median actuarial survival time was 34.9 months for leuprolide and flutamide versus 27.9, months for leuprolide alone. This 7-month increment represents a 25% improvement in overall survival time with the flutamide therapy. Analysis of PFS showed a 2.6 month improvement in patients who received leuprolide plus flutamide, a 19% increment over leuprolide and placebo.@@@@@COMBO@FLUTAMIDE@LEUPROLIDE@@@@FLUTAMIDE|LEUPROLIDE|||@ALIUD PHARMA@@@@@ALIUD PHARMA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@@@@@@PLACEBO-CONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@84@1.1511@13.98@28.66@15.12@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.17@0.17@168797@TABLET@EURO@@@@@@@@250@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918054@Onco@@@@@300f1010ntsdm@@@@@@For the 63 patients in the Gemzar arm, the first cycle of Gemzar was administered intravenously at a dose of 1000 mg/m2 over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitated holding a dose) followed by a week of rest from treatment with Gemzar. Subsequent cycles consisted of injections once weekly for 3 consecutive weeks out of every 4 weeks. For the 63 patients in the 5-FU arm, 5-FU was administered intravenously at a weekly dose of 600 mg/m2 for 30 minutes.@@L01BC05@L01B@NO@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14918054@Non-Small Cell Lung Cancer: Gemcitabine, in combination with cisplatin, is indicated as a first-line treatment of patients with locally advanced (inoperable Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.  Pancreatic Cancer: Gemcitabine is indicated for the treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is indicated for patients with 5-FU refractory pancreatic cancer.  Bladder Cancer: Gemcitabine is indicated for treatment of advanced bladder cancer (muscle invasive Stage IV tumours with or without metastases) in combination with cisplatin therapy.  Breast Cancer: Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless clinically contra-indicated.@@YES@1-May@@Cost per QALY gained in front-line treatment from £7,200-£18,700 depending on comparator 5-FU regimen. ICER of £1,360-3,550 per QALY depending on 5-FU regimen@@@@100%@@FIRST-LINE@@126@When used as single-agent in pancreatic cancer, Gemzar should be administered by intravenous infusion at a dose of 1000 mg/m2 over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out of every 4 weeks.@@@@No@@@Gemzar can suppress bone marrow function as manifested by leukopaenia, thrombocytopaenia, and anaemia, can increase toxicity when prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing. Pulmonary toxicity, Hemolytic Uremic Syndrome (HUS) and/or renal failure, leading to death or requiring dialysis, despite discontinuation of therapy have been reported. Occurence of rare cases of Serious hepatotoxicity, including liver failure and death.@BURRIS TRIAL@No@@PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER WHO HAD RECEIVED NO PRIOR CHEMOTHERAPY.@@@MULTI-CENTRE (17 SITES IN US AND CANADA), PROSPECTIVE, SINGLE-BLINDED, TWO-ARM, RANDOMISED TRIAL THAT COMPARED GEMZAR TO 5-FLUOROURACIL (5-FU)@APPROVED@@1.1 Gemcitabine may be considered as a treatment option for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky performance score of 50 or more, where first line chemotherapy is to be used. 1.2 Gemcitabine is not recommended for patients who are suitable for potentially curative surgery, or patients with a Karnofsky (see Appendix D) score of less than 50. 1.3 There is insufficient evidence to support the use of gemcitabine as a second line treatment in patients with pancreatic adenocarcinoma [http://www.nice.org.uk/nicemedia/pdf/gemcitabineguidance.pdf]@NHS@Patients treated with Gemzar had statistically significant increases in clinical benefit response, survival, and TTP compared to 5-FU. No confirmed objective tumor responses were observed with either treatment. 22.2% (14 patients) on the Gemzar arm compared to 4.8% (3 patients) on the 5-FU arm were clinical benefit responders  (p=0.004) ; 1 patient on the Gemzar arm showed improvement in all 3 primary parameters (pain intensity, analgesic consumption, and performance status). 11 patients on the Gemzar arm and 2 patients on the 5-FU arm showed improvement in analgesic consumption and/or pain intensity with stable performance status. 2 patients on the Gemzar arm showed improvement in analgesic consumption or pain intensity with improvement in performance status. 1 patient on the 5-FU arm was stable with regard to pain intensity and analgesic consumption with improvement in performance status. No patient on either arm achieved a clinical benefit response based on weight gain. Median survival was 5.7 months for the Gemzar arm compared to 4.2 months for the 5-FU arm (p=0.0009) ; Median TTP was 2.1 months for the Gemzar arm compared to 0.9 months for the 5-FU arm (p=0.0013). [Eur J Cancer. 1997 Jan;33 Suppl 1:S18-22: http://www.ncbi.nlm.nih.gov/pubmed/9166095?ordinalpos=24&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]@@@@@MONO@GEMCITABINE HYDROCHLORIDE@@@@@GEMCITABINE HYDROCHLORIDE||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@ADVANCED@@@@@PROSPECTIVE@SINGLE-BLIND@TWO-ARM@RANDOMISED@@@@Invalid Dosage Value Phase 1@@@5.7@month@5.7 month@4589.71@4589.71@26.47@1@1.299@32.55@@@@@@@@@@@@0.16@@@@@@@@@@@@@@@@7/28/2017@32.55@32.55@4.77E+15@POWDER FOR INJECTABLE SOLUTION (VIAL)@GB£@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920563@Onco@@@@@300f1010ntsdm@@@@@@Hycamtin was administered at a dose of 0.75 mg/m2/day IV over 30 minutes × 3 consecutive days starting on day 1 of a 21-day course in in combination with cisplatin (50 mg/m2 on day 1). Alone, cisplatin was administered at a dose of 50 mg/m2 IV on day 1 of a 21-day course.@@L01XX17@L01X@YES@DARMSTADT, GERMANY@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@14920563@Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.@@NO@@@The ICERs for topotecan plus cisplatin compared with cisplatin alone for the cisplatin-naive population for the three utility scenarios were £25,309, £26,156 and £24,513 per QALY gained respectively. The ICERs for the licensed population for the three utility scenarios were £55,926, £59,406 and £54,352 per QALY gained respectively. The ERG used the third scenario in all subsequent exploratory analyses because they considered it the most appropriate.@@@@100%@Merck KGaA licensed marketing and sales rights from SmithKline Beecham in June 2000 for the U.K. only.@SECOND-LINE@@147@Cervical Carcinoma: Initial dose- The recommended dose of topotecan is 0.75 mg/m2/day administered as 30 minute intravenous infusion daily on days 1, 2 and 3. Cisplatin is administered as an intravenous infusion on day 1 at a dose of 50 mg/m2/day and following the topotecan dose. This treatment schedule is repeated every 21 days for 6 courses or until progressive disease. Subsequent doses- Topotecan should not be re-administered unless the neutrophil count is more than or equal to 1.5 x 109/l, the platelet count is more than or equal to 100 x 109/l, and the haemoglobin level is more than or equal to 9g/dl (after transfusion if necessary). Patients who experience febrile neutropenia (neutrophil count less than 1 x 109/l with a temperature of 38°C or above) are recommended to have the dose of topotecan reduced by 20% to 0.60 mg/m2/day for subsequent courses.@EMA, November 1996@@@@@@Bone marrow suppression (primarily neutropaenia) is the dose-limiting toxicity of Hycamtin. Cases of neutropenia, thrombocytopaenia and anaemia were reported. Hycamtin may cause fetal harm when administered to a pregnant woman.@LABEL@No@@147 ELIGIBLE WOMEN WERE RANDOMISED TO HYCAMTIN  PLUS CISPLATIN AND 146 ELIGIBLE WOMEN WERE RANDOMISED TO CISPLATIN. ALL PATIENTS HAD HISTOLOGICALLY CONFIRMED STAGE IV-B, RECURRENT, OR PERSISTENT CARCINOMA OF THE CERVIX CONSIDERED NOT AMENABLE TO CURATIVE@@@N/A@APPROVED@@1.1 Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they have not previously received cisplatin. 1.2 Women who have previously received cisplatin and are currently being treated with topotecan in combination with cisplatin for recurrent and stage IVB cervical cancer should have the option to continue their therapy until they and their clinicians consider it appropriate to stop. [NICE 22 October 2009 http://www.nice.org.uk/nicemedia/pdf/TA183Guidance.pdf ]@NHS@Median survival of eligible patients in the Hycamtin plus cisplatin treatment arm was 9.4 months (95% CI: 7.9 to 11.9) compared to 6.5 months (95% CI: 5.8 to 8.8) among patients randomised to cisplatin alone with a log rank p-value of 0.033 (significance level was 0.044 after adjusting for the interim analysis). The unadjusted hazard ratio for OS was 0.76 (95% CI: 0.59 to 0.98).@@@@@COMBO@TOPOTECAN HYDROCHLORIDE@CISPLATIN@@@@TOPOTECAN HYDROCHLORIDE|CISPLATIN|||@MERCK SERONO@GSK@@@@MERCK SERONO|GSK|||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@HYCAMTIN@@@@@HYCAMTIN||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@COMPARATIVE@RANDOMISED@@@@1.75@m²@2059.86375@@@126@day@126 day@2059.86@2059.86@16.35@1@1.299@348.76@@@@@@@@@@@@87.19@21@@mg/m²@0.75@3@@@@@@@@@@@7/28/2017@348.76@348.76@4.80E+15@POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION@GB£@@@@@@@@4@MG@4 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924027@Onco@@@@@300f1012ntsdm@@@@@@Patients received panitumumab at a dose of 6 mg/kg given once every 2 weeks plus best supportive care or BSC alone@@L01XC08@L01X@YES@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@14924027@Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@SECOND-LINE@NCT00113763@463@The recommended dose is 6 mg/kg administered over 60 minutes as an intravenous infusion every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.@EMA, 3 December 2007@12/3/2007@@No@@@Dermatologic findings (dermatitis, pustule formation and exfoliative rash), and deaths secondary to bacterial infection and sepsis occured at higher doses than the recommended dose. Severe infusion reactions occurred with the administration of Vectibix which were identified by reports of anaphylactic reaction, bronchospasm, fever, chills, and hypotension. Pulmonary fibrosis occurred in less than 1% of patients enrolled in clinical studies. It can cause diarrhea, and when used in combination with irinotecan, appears to increase the incidence and severity of chemotherapy-induced diarrhea. It can also cause electrolyte depletion.@"20020408 [""408 Trial""]"@No@@PATIENTS WITH EGFR-EXPRESSING MCRC WHO WERE REQUIRED TO HAVE PROGRESSED ON OR FOLLOWING TREATMENT WITH A REGIMEN(S) CONTAINING A FLUOROPYRIMIDINE, OXALIPLATIN, AND IRINOTECAN ((CONFIRMED FOR 75% OF PATIENTS), TO HAVE EGFR EXPRESSION DEFINED AS AT LEAS@@@III@APPROVED@@@GKV@Based upon IRC determination of disease progression, a statistically significant prolongation in PFS was observed in patients receiving Vectibix compared to those receiving BSC alone. The mean PFS was 96 days in the Vectibix arm and 60 days in the BSC-alone arm. In a series of sensitivity analyses, including one adjusting for potential ascertainment bias, ie, assessment for progressive disease at a nonstudy specified time point, PFS was still significantly prolonged among patients receiving Vectibix as compared to patients receiving BSC alone. There were 19 partial responses identified by the IRC in patients randomized to Vectibix for an overall response of 8% (95% CI: 5.0%, 12.6%). No patient in the control arm had an objective response identified by the IRC. The median duration of response was 17 weeks (95% CI: 16 weeks, 25 weeks). There was no difference in overall survival observed between the study arms.@In a single-arm study of 19 patients receiving Vectibix in combination with IFL, the incidence of NCI-CTC grade 3-4 diarrhea was 58%; in addition, grade 5 diarrhea occurred in 1 patient. In a single-arm study of 24 patients receiving Vectibix plus FOLFIRI, the incidence of NCI-CTC grade 3 diarrhea was 25%. Pulmonary fibrosis occurred in less than 1% (2/1,467) of patients in clinical trials of Vectibix. Following the initial fatality, patients with a history of interstitial pneumonitis, pulmonary fibrosis, and evidence of interstitial pneumonitis were excluded from clinical studies. Therefore, the estimated risk in such patients is uncertain. Permanently discontinue Vectibix therapy in patients developing interstitial lung disease, pneumonitis, or lung infiltrates. In the randomized, controlled clinical trial, median magnesium levels decreased by 0.1 mmol/L in the Vectibix arm. Additionally, hypomagnesemia (NCI-CTC grade 3 or 4) requiring electrolyte repletion occurred in 2% of patients 6 weeks or longer after the initiation of Vectibix. In some patients, hypomagnesemia was associated with hypocalcemia. Patients should be periodically monitored, and treated appropriately, for hypomagnesemia and hypocalcemia during and for 8 weeks after the completion of Vectibix therapy.@@@@MONO@PANITUMUMAB@@@@@PANITUMUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@@@@@VECTIBIX||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@INTERNATIONAL@RANDOMISED@CONTROLLED@@76.5@kg@15372.04114@@@96@day@96 day@15372.04@15372.04@160.13@1@1.1511@1953.6@2451.84@1992.1@@@@@@@@@@4.88@14@@mg/kg@6@1@@@@@@@@@@@8/1/2017@1953.6@1953.6@6078629@CONCENTRATE FOR INFUSION SOLUTION - 20 ML@EURO@@@@@@@@400@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924336@Onco@@@@@300f1037ntsdm@@@@@@Xeloda was administered at a dose of 1255 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles.@@L01BC06@L01B@YES@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924336@Xeloda is indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.@@YES@@@@@@@0%@@SECOND-LINE@@162@1250 mg/m2 administered twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 14 days followed by a 7-day rest period.@EMA, 22 February 2001@2/22/2001@5/16/2001@@@@Patients with moderate renal impairment at baseline require dose reduction. Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking Xeloda concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Xeloda can induce diarrhea, sometimes severe. Patients =80 years old may experience a greater incidence of grade 3 or 4 adverse events (diarrhea, nausea, hand-and-foot syndrome, and vomiting).  Xeloda may cause fetal harm when given to a pregnant woman.@LABEL@No@@PATIENTS WITH STAGE IV BREAST CANCER WERE ENROLLED. 135 HAD MEASURABLE DISEASE. RESISTANCE WAS DEFINED AS PROGRESSIVE DISEASE WHILE ON TREATMENT, WITH OR WITHOUT AN INITIAL RESPONSE, OR RELAPSE WITHIN 6 MONTHS OF COMPLETING TREATMENT WITH AN ANTHRACYC@@@BREAST CANCER MONOTHERAPY; OPEN-LABEL SINGLE-ARM TRIAL CONDUCTED IN 24 CENTRES IN THE US AND CANADA.@APPROVED@@NO REVIEW@@RR for patients resistant to both paclitaxel and anthracycline (n=43)  was of 25.6% (95% CI: 13.5-41.2) with a median duration of response of 154 days (95% CI: 63-233). The median TTP was 102 days and the median survival was 255 days. The objective RR in this population was supported by a RR of 18.5% (1 CR, 24 PRs) in the overall population of 135 patients with measurable disease, who were less resistant to chemotherapy. The median time to progression was 90 days and the median survival was 306 days.@The most common adverse events (>10%) in patients receiving Xeloda (%) were lymphopenia (94), anemia (72), diarrhea (57), hand-foot syndrome (57), nausea (53), fatigue (41), dermatitis (37), vomiting (37), neutropenia (26), stomatitis (24), thrombocytopenia (24), anorexia (23), hyperbilirubinemia (22), paresthesia (21), abdominal pain (20), constipation (15), eye irritation (15), and pyrexia (12). Grade 3/4 adverse events (>5%) in patients receiving Xeloda were lymphopenia (59), diarrhea (15), hand-foot syndrome (11), hyperbilirubinemia (11), fatigue (8), stomatitis (7), and dehydration (5).@@@@MONO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@DURATION OF RESPONSE@@@@-@@@@@ADVANCED@METASTATIC@@@@OPEN-LABEL@SINGLE-ARM@@@@1.6@m²@2354.762666@@@154@day@154 day@2354.76@2354.76@15.29@120@1.1511@344.04@410.75@351.58@@@@@@@@@@@21@@mg/m²@2500@14@@@@@@@@@@@8/4/2017@2.87@2.87@686782@FILM-COATED TABLET@EURO@@@@@@@@500@MG@500 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14918541@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@H02AB07@H02A@NO@CRAIGAVON, UNITED KINGDOM@@@Prednisolone acetate is a synthetic adrenocorticoid with the general properties of prednisolone. Adrenocorticoids diffuse across cell membranes to complex with cytoplasmic receptors and subsequently stimulate synthesis of enzymes with anti-inflammatory effects. Glucocorticoids inhibit the oedema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation, deposition of collagen and scar formation. Prednisolone acetate has, on a weight to weight basis, a potency three to five times that of hydrocortisone.@@14918541@Indicated in the following conditions: Endocrine Disorders [Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcernia associated with cancer Nonsuppurative thyroiditis)] Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) [Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis] Collagen Diseases [During an exacerbation or as maintenance therapy in selected  cases of: Systemic lupus erythematosus Systemic-dermatomyositis (polymyositis) Acute rheumatic carditis] Dermatologic Diseases [Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis] Allergic States [Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions] Ophthalmic Diseases [Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic cornea marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis] Respiratory Diseases [Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis] Haematologic Disorders [Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopaenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia] Neoplastic Diseases For palliative management of: [Leukemias and lymphomas in adults Acute leukemia of childhood] Edematous States [To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis] Nervous System [Acute exacerbations of multiple sclerosis] Miscellaneous [Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement]@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial dosage may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required.@@@@@@@In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination With other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@PREDNISONE@@@@@PREDNISONE||||@GALEN PHARMACEUTICALS@@@@@GALEN PHARMACEUTICALS||||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@7.18@20.06@8.1@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.14@0.14@1484661@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917599@Onco@@@@@300f1018ntsdm@@@@@@NO LABELLED TRIAL@@L01AA01@L01A@NO@NEW YORK, NEW YORK@@@Cyclophosphamide is an antineoplastic agent which is converted in the body to an active alkylating metabolite. It also possesses marked immunosuppressant properties. The principal site of cyclophosphamide activation is the liver. The chemotherapeutic and immunosuppressant activity of cyclophosphamide is thought to be mediated by the cytotoxic intermediates produced by activation by mixed function oxidases in hepatic microsomes. Non-enzymatic cleavage, possibly taking place in the tumour cells, results in the formulation of highly cytotoxic forms of the drug.@@14917599@Although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to Cytoxan treatment: 1. Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma. 2. Multiple myeloma. 3. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (Cytoxan given during remission is effective in prolonging its duration). 4. Mycosis fungoides (advanced disease). 5. Neuroblastoma (disseminated disease). 6. Adenocarcinoma of the ovary. 7. Retinoblastoma. 8. Carcinoma of the breast. Cytoxan is also used in non-malignant disease: it is useful in carefully selected cases of biopsy proven “minimal change” nephrotic syndrome in children but should not be used as primary therapy. In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, Cytoxan may induce a remission. Cytoxan is not indicated for the nephrotic syndrome in adults or for any other renal disease.@@NO@-@@-@@@-@-@-@-@-@-@When used as the only oncolytic drug therapy, the initial course of Cytoxan for patients with no hematologic deficiency usually consists of 40 to 50 mg/kg given intravenously in divided doses over a period of 2 to 5 days. Other intravenous regimens include 10 to 15 mg/kg given every 7 to 10 days or 3 to 5 mg/kg twice weekly. Many other regimens of intravenous and oral Cytoxan have been reported. Dosages must be adjusted in accord with evidence of antitumor activity and/or leukopenia. The total leukocyte count is a good, objective guide for regulating dosage. Transient decreases in the total white blood cell count to 2000 cells/mm3 (following short courses) or more persistent reduction to 3000 cells/mm3 (with continuing therapy) are tolerated without serious risk of infection if there is no marked granulocytopenia. When Cytoxan is included in combined cytotoxic regimens, it may be necessary to reduce the dose as well as that of the other drugs. Cytoxan and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system being used. Patients with compromised renal function may show some measurable changes in pharmacokinetic parameters of Cytoxan metabolism, but there is no consistent evidence indicating a need for dosage modification in patients with renal function impairment.@Nov-59@@@-@@@Carcinogenesis, Mutagenesis, and Impairment of Fertility: Second malignancies have developed in some patients treated with cyclophosphamide used alone or in association with other antineoplastic drugs and/or modalities. Most frequently, they have been urinary bladder, myeloproliferative, or lymphoproliferative malignancies. Second malignancies most frequently were detected in patients treated for primary myeloproliferative or lymphoproliferative malignancies or nonmalignant disease in which immune processes are believed to be involved pathologically. Urinary System: Hemorrhagic cystitis may develop in patients treated with cyclophosphamide. Rarely, this condition can be severe and even fatal. Fibrosis of the urinary bladder, sometimes extensive, also may develop with or without accompanying cystitis. Atypical urinary bladder epithelial cells may appear in the urine. These adverse effects appear to depend on the dose of cyclophosphamide and the duration of therapy. Such bladder injury is thought to be due to cyclophosphamide metabolites excreted in the urine. Forced fluid intake helps to assure an ample output of urine, necessitates frequent voiding, and reduces the time the drug remains in the bladder. This helps to prevent cystitis. Hematuria usually resolves in a few days after cyclophosphamide treatment is stopped, but it may persist. Medical and/or surgical supportive treatment may be required, rarely, to treat protracted cases of severe hemorrhagic cystitis. It is usually necessary to discontinue cyclophosphamide therapy in instances of severe hemorrhagic cystitis. Cardiac Toxicity: Although a few instances of cardiac dysfunction have been reported following use of recommended doses of cyclophosphamide, no causal relationship has been established. Acute cardiac toxicity has been reported with doses as low as 2.4 g/m2 to as high as 26 g/m2, usually as a portion of an intensive antineoplastic multi-drug regimen or in conjunction with transplantation procedures. In a few instances with high doses of cyclophosphamide, severe, and sometimes fatal, congestive heart failure has occurred after the first cyclophosphamide dose. Histopathologic examination has primarily shown hemorrhagic myocarditis. Hemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis. Pericarditis has been reported independent of any hemopericardium. No residual cardiac abnormalities, as evidenced by electrocardiogram or echocardiogram appear to be present in patients surviving episodes of apparent cardiac toxicity associated with high doses of cyclophosphamide. Cyclophosphamide has been reported to potentiate doxorubicin-induced cardiotoxicity. Infections: Treatment with cyclophosphamide may cause significant suppression of immune responses. Serious, sometimes fatal, infections may develop in severely immunosuppressed patients. Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop viral, bacterial, fungal, protozoan, or helminthic infections.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@-@PBS@NO LABELLED TRIAL@-@@@@-@CYCLOPHOSPHAMIDE@@@@@CYCLOPHOSPHAMIDE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Hodgkin's Lymphoma@Myeloma@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Hodgkin's Lymphoma|Myeloma|||||@ENDOXAN@@@@@ENDOXAN||||@Alkylating Agent@@@@@Alkylating Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@12.5MG/KGx42.941@@@@1@0.8893@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@L01AA011031GBX@POWDER FOR INJECTION (SOLVENT REQUIRED)@A$@@@@@@@@2@G@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15057869@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Brentuximab vedotin@@L01XC12@L01X@JC virus infection resulting in PML and death can occur in patients receiving Adcetris@SEATTLE, WASHINGTON@@@@@15057869@Treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates;@Both@NA@@@NO REVIEW@@@@@@@NCT00848926@102@The recommended dose is 1.8 mg/kg administered only as an intravenous infusion over 30 minutes every 3 weeks.@FDA, 19 August 2011@8/19/2011@@Yes@@@Progressive multifocal leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS.@SG035-0003@No@@Patients with relapsed or refractory Hodgkin lymphoma who have previously received autologous stem cell transplant.Histologically confirmed CD30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease of at least 1.5 cm as documented by spiral computed tomography.At US sites patients greater than or equal to 12 years of age may be enrolled. At non-US sites patients must be greater than or equal to 18 years of age.@@@II@APPROVED@@@@In the pivotal Hodgkin lymphoma clinical trial, 102 patients were enrolled who had relapsed after ASCT. Data demonstrated that 73 percent (95 percent CI 65, 83) of patients achieved an objective response following treatment with ADCETRIS, including 32 percent (95 percent CI 23, 42) with complete remissions and 40 percent with partial remissions (95 percent CI 32, 49). The median duration of objective response was 6.7 months (95 percent CI 4.0, 14.8; range 1.3 to 21.9+ months). [Seattle Genetics 19 August 2011 http://investor.seagen.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1598466&highlight= ]TRIAL REGISTERED [Millennium 8 April 2010 http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1410866&highlight= ]@Across both trials, brentuximab vedotin treatment was associated with generally manageable adverse events. The most common adverse events of any Grade in the pivotal Hodgkin lymphoma trial were peripheral sensory neuropathy (47 percent), fatigue (46 percent), nausea (42 percent), upper respiratory tract infection (37 percent) and diarrhea (36 percent). The most common adverse events of any Grade in the phase II systemic ALCL trial were peripheral sensory neuropathy (41 percent), nausea (40 percent), fatigue (38 percent), fever (34 percent) and diarrhea (29 percent).@@@@MONO@BRENTUXIMAB@@@@@BRENTUXIMAB||||@SEATTLE GENETICS@MILLENNIUM PHARMACEUTICALS@@@@SEATTLE GENETICS|MILLENNIUM PHARMACEUTICALS|||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@ADCETRIS@@@@@ADCETRIS||||@Other@CD30@@@@Other|CD30|||@Objective response rate@@@@@COMPLETE REMISSION RATE@@@@@RELAPSED@REFRACTORY@@@@OPEN LABEL@SINGLE GROUP ASSIGNMENT@@@@76.5@kg@182586.81@@@6.7@month@6.7 month@182586.81@182586.81@895.97@1@1@6832@@@@@@@@@@@@136.64@21@@mg/kg@1.8@1@@@@@@@@@@@8/2/2017@6832@6832@51144-0050-01@LYOPHILISATE FOR SOLUTION FOR INJECTION@US$@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916947@Onco@@@@@300f1012ntsdm@@@@@@Patients received 1 mg of Arimidex once daily or 20 mg of tamoxifen once daily.@@L02BG03@L02B@NO@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@14916947@First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer;@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@668@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@EMA, 3 March 2000@3/3/2000@@@@@Arimidex can cause fetal harm when administered to a pregnant woman.@@No@@POSTMENOPAUSAL WOMEN, BETWEEN THE AGES OF 30 AND 92 YEARS OLD AND WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER, WERE RANDOMISED TO RECEIVE ARIMIDEX (340 PATIENTS) OR TAMOXIFEN (328 PATIENTS).@@@@APPROVED@@@GKV@Arimidex was at least as effective as tamoxifen for objective tumor RR and TTP. Median TTP was 8.2 months for the Arimidex treatment group compared to 8.3 months for the Tamoxifen treatment group. 73% of the patients in the Arimidex treatment group progressed compared to 75% for the Tamoxifen treatment group [Hazard ratio=1.01, p=0.920]. The best objective RR (CR+PR) were 32.9% for the Arimidex treatment group compared to 32.6% in the Tamoxifen treatment group [Odds ratio:1.01].@@@@@MONO@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@TIME TO PROGRESSION@RESPONSE RATE@SAFETY@@@SAFETY@@@@@ADVANCED@@@@@DOUBLE-BLIND@CONTROLLED@@@@1@1@1146.268934@@@8.2@month@8.2 month@1146.27@1146.27@4.6@100@1.1807@459.59@592.05@474.77@@@@@@@@@@4.6@1@@mg@1@1@@@@@@@@@@@8/15/2017@4.6@4.6@7511991@FILM-COATED TABLET@EURO@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923881@Onco@@@@@300f1014ntsdm@@@@@@Patients received melphalan, prednisone and thalidomide (MP-T) or vincristine, adriamycin and dexamethasone (VAD) followed by melphalan and transplantation (MEL 100).Thalidomide given at doses up to 400mg.@@L04AX02@L04A@YES@@@@The mechanism of action is not fully understood. It possesses immunomodulatory, anti-inflammatory and anti-angiogenic properties; the immunologic effects vary substantially under different conditions, but may be related to the suppression of excessive TNF-alpha production and down-modulation of selcted cell surface adhesion molecules involved in leukocyte migration.@@14923881@Thalidomide Pharmion in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged  65 years or ineligible for high dose chemotherapy.@@@@@NO REVIEW@@@@100%@@FIRST-LINE@NCT00367185@447@Recommended posology in adults: The recommended oral dose is 200 mg per day. A maximum number of 12 cycles of 6 weeks should be used.@@@@@@@Birth Defects: Thalidomide can cause severe birth defects in humans. Thrombotic Events: The use of Thalomid in multiple myeloma results in an increased risk of venous thromboembolic events, such as deep venous thrombosis and pulmonary embolus. This risk increases significantly when thalidomide is used in combination with standard chemotherapeutic agents including dexamethasone. Drowsiness and Somnolence: Thalidomide frequently causes drowsiness and somnolence. Peripheral Neuropathy: Thalidomide is known to cause nerve damage that may be permanent. Peripheral neuropathy is a common, potentially severe, side effect of treatment with thalidomide that may be irreversible. Dizziness and Orthostatic Hypotension. Neutropenia: Decreased white blood cell counts, including neutropenia, have been reported in association with the clinical use of thalidomide. Increased HIV Viral Load.@IFM 99-06@No@@447 ELDERLY PATIENTS@ELDERLY@@III@APPROVED@@@RAMQ@"After a median follow-up of 51.5 months (IQR 34.4-63.2), median overall survival times were 33.2 months (13.8-54.8) for MP, 51.6 months (26.6-not reached) for MPT, and 38.3 months (13.0-61.6) for MEL100. The MPT regimen was associated with a significantly better overall survival than was the MP regimen (hazard ratio 0.59, 95% CI 0.46-0.81, p=0.0006) or MEL100 regimen (0.69, 0.49-0.96, p=0.027). No difference was seen for MEL100 versus MP (0.86, 0.65-1.15, p=0.32). ""The results of the trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma"" [Lancet. 2007 Oct 6;370(9594):1209-18]Following an interim analysis, recruitment was stopped on the recommendation of the study's DSMB. At final analysis, the median OS in the MP-T arm was 53.6 months, compared to 32.2 and 38.6 months, respectively, for the MP and MEL 100 arms. The thalidomide combination was associated with more venous thrombosis and pulmonary embolism. Patients taking thalidomide were also at more risk of peripheral neuropathy, neutropaenia and constipation. [ASCO, June 2006]"@The most frequently reported serious adverse events in multiple myeloma patients (occurring in =20% of patients treated with thalidomide/dexamethasone compared with dexamethasone alone) were: fatigue (79% vs 71%), hemoglobin (decreased) (78% vs 86%), hyperglycemia (73% vs 79%), hypocalcemia (72% vs 59%), constipation (55% vs 28%), sensory neuropathy (54% vs 28%), hyponatremia (43% vs 48%), muscle weakness (40% vs 37%), creatinine (35% vs 42%), leukocytes (decreased) (35% vs 29%), bone pain (30% vs 36%), neutrophils (decreased) (31% vs 24%), confusion (28% vs 12%), edema (57% vs 46%), dyspnea (42% vs 31%), thrombosis/embolism (23% vs 5%), anxiety/agitation (26% vs 14%), tremor (26% vs 6%), alkaline phosphatase (increased) (27% vs 28%), and rash/desquamation (30% vs 18%). Other serious reported adverse events in multiple myeloma controlled clinical trials thalidomide/dexamethasone vs. dexamethasone alone) were: hypokalemia (23% vs 23%), insomnia (23% vs 47%), depression (22% vs 24%), neuropathy-motor (22% vs 16%), fever (24% vs 20%), weight loss (23% vs 21%), weight gain (22% vs 13%), platelets (decreased) (24% vs 33%), anorexia (28% vs 25%), nausea (28% vs 23%), pain-other (25% vs 26%), headache (20% vs 23%), dry skin (21% vs 11%), and SGOT (increased) (25% vs 24%).@@@@COMBO@THALIDOMIDE@MELPHALAN@PREDNISONE@@@THALIDOMIDE|MELPHALAN|PREDNISONE||@FUJIMOTO PHARMACEUTICAL@@@@@FUJIMOTO PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@THALOMID@@@@@THALOMID||||@Immunotherapy@@@@@Immunotherapy||||@OVERALL SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@@@@@28@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@C$@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14921384@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L04AX03@L04A@YES@HOLZKIRCHEN, GERMANY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14921384@Neoplastic Diseases: indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Psoriasis: indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis: indicated in the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Leukemia: When used for induction, methotrexate in doses of 3.3 mg/m2 in combination with 60 mg/m2 of prednisone, given daily, produced remissions in 50% of patients treated, usually within a period of 4 to 6 weeks. Methotrexate in combination with other agents appears to be the drug of choice for securing maintenance of drug-induced remissions. When remission is achieved and supportive care has produced general clinical improvement, maintenance therapy is initiated, as follows: Methotrexate is administered 2 times weekly either by mouth or intramuscularly in total weekly doses of 30 mg/m2. It has also been given in doses of 2.5 mg/kg intravenously every 14 days. If and when relapse does occur, reinduction of remission can again usually be obtained by repeating the initial induction regimen.@@@@@@@1.Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks.2.Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. 3.Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs). 4.Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. 5.Methotrexate-induced lung disease is a potentially dangerous lesion, which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation. 6.Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. 7.Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. 8.Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication. 9.Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy. 10.Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. 11.Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@MTX HEXAL@@@@@MTX HEXAL||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@5.31@17.7@6.18@@@@@@@@@@0.07@@@@@@@@@@@@@@@@8/1/2017@0.53@0.53@1315421@TABLET@EURO@@@@@@@@7.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14924340@Onco@@@@@300f1010ntsdm@@@@@@Xeloda was administered at a dose of 1255 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles.@@L01BC06@L01B@YES@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924340@Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapyshould have included an anthracycline.@@NO@28-May-03@5/28/2003@NICE: combination therapy: £9,090 (0.78-0.98 QALYs); Monotherapy: £1,300 (0.73 QALYs)@@@@100%@@SECOND-LINE@@162@In combination with docetaxel, the recommended starting dose of capecitabine in the treatment of metastatic breast cancer is 1250 mg/m2 twice daily for 14 days followed by a 7- day rest period, combined with docetaxel at 75 mg/m2 as a 1 hour intravenous infusion every 3 weeks.@EMA, 2 January 2001@1/2/2001@@@@@Patients with moderate renal impairment at baseline require dose reduction. Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking Xeloda concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Xeloda can induce diarrhea, sometimes severe. Patients =80 years old may experience a greater incidence of grade 3 or 4 adverse events (diarrhea, nausea, hand-and-foot syndrome, and vomiting).  Xeloda may cause fetal harm when given to a pregnant woman.@LABEL@No@@PATIENTS WITH STAGE IV BREAST CANCER WERE ENROLLED. 135 HAD MEASURABLE DISEASE. RESISTANCE WAS DEFINED AS PROGRESSIVE DISEASE WHILE ON TREATMENT, WITH OR WITHOUT AN INITIAL RESPONSE, OR RELAPSE WITHIN 6 MONTHS OF COMPLETING TREATMENT WITH AN ANTHRACYC@@@BREAST CANCER MONOTHERAPY; OPEN-LABEL SINGLE-ARM TRIAL CONDUCTED IN 24 CENTRES IN THE US AND CANADA.@APPROVED@@1.1 In the treatment of locally advanced or metastatic breast cancer, capecitabine in combination with docetaxel is recommended in preference to single-agent docetaxel in people for whom anthracycline-containing regimens are unsuitable or have failed. 1.2 Capecitabine monotherapy is recommended as an option for people with locally advanced or metastatic breast cancer who have not previously received capecitabine in combination therapy and for whom anthracycline and taxane-containing regimens have failed or further anthracycline therapy is contraindicated. 1.3 The decision regarding treatment should be made jointly by the individual and the clinician(s) responsible for treatment. The decision should be made after an informed discussion between the clinician(s) and the patient; this discussion should take into account contraindications and the side-effect profile of the agents, alternative treatments for locally advanced or metastatic breast cancer, and the clinical condition and preferences of the individual. 1.4 The use of capecitabine to treat locally advanced or metastatic breast cancer should be supervised by oncologists who specialise in breast cancer. SOURCE: NICE@NHS@RR for patients resistant to both paclitaxel and anthracycline (n=43)  was of 25.6% (95% CI: 13.5-41.2) with a median duration of response of 154 days (95% CI: 63-233). The median TTP was 102 days and the median survival was 255 days. The objective RR in this population was supported by a RR of 18.5% (1 CR, 24 PRs) in the overall population of 135 patients with measurable disease, who were less resistant to chemotherapy. The median time to progression was 90 days and the median survival was 306 days.@The most common adverse events (>10%) in patients receiving Xeloda (%) were lymphopenia (94), anemia (72), diarrhea (57), hand-foot syndrome (57), nausea (53), fatigue (41), dermatitis (37), vomiting (37), neutropenia (26), stomatitis (24), thrombocytopenia (24), anorexia (23), hyperbilirubinemia (22), paresthesia (21), abdominal pain (20), constipation (15), eye irritation (15), and pyrexia (12). Grade 3/4 adverse events (>5%) in patients receiving Xeloda were lymphopenia (59), diarrhea (15), hand-foot syndrome (11), hyperbilirubinemia (11), fatigue (8), stomatitis (7), and dehydration (5).@@@@COMBO@CAPECITABINE@DOCETAXEL@@@@CAPECITABINE|DOCETAXEL|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XELODA@GENERIC@@@@XELODA|GENERIC|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@DURATION OF RESPONSE@@@@-@@@@@ADVANCED@METASTATIC@@@@OPEN-LABEL@SINGLE-ARM@@@@1.75@m²@2401.01386@@@186@day@186 day@2401.01@2401.01@12.91@120@1.299@265.55@@@@@@@@@@@@@21@@mg/m²@2500@14@@@@@@@@@@@7/28/2017@2.21@2.21@4.45E+15@FILM-COATED TABLET@GB£@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920456@Onco@@@@@300f1020ntsdm@@@@@@Triptorelin versus bilateral orchidectomy@@L02AE04@L02A@NO@-@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins.@@14920456@Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration. Treatment of metastatic prostate cancer. Treatment of endometriosis. Treatment of precocious puberty (onset before 8 years in girls and 9 years in boys).@@NO@-@@NO REVIEW@@@@100%@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@-@-@645@Prostate cancer: One intramuscular injection should be administered every 4 weeks (28 days). No dosage adjustment is necessary in the elderly.@N/A@@@-@@@In adults the prolonged use of GnRH analogues may lead to bone loss which enhances the risk of osteoporosis. Prostate cancer  Initially, Decapeptyl SR like other GnRH analogues causes a transient increase in serum testosterone and consequent worsening of symptoms including increase in bone pain (and serum acid phosphatase levels). Continued treatment leads to suppression of testosterone (and dihydrotestosterone) and consequent improvement in the disease. During the first month of treatment, patients presenting with, or at particular risk of developing, urinary tract obstruction should be carefully monitored, as should those at risk of developing spinal cord compression. Consideration should be given to the use of an anti-androgen for three days prior to treatment, to counteract this initial rise in serum testosterone levels.@LABEL@No@-@-@@@III; LOCALLY ADVANCED/METASTATIC PROSTATE CANCER@APPROVED@@@SSN@No significant difference in the median survival rates in the triptorelin group versus the orchidectomy group. A study assessing the pharmacodynamic equivalence between triptorelin 3-month and 28-day prolonged release formulations in patients with locally advanced or metastatic prostate cancer, found that equivalent testosterone suppression was achieved, whether 3 doses of Decapeptyl SR 3mg (n=68) or a single dose of Decapeptyl SR 11.25mg (n=63) was given.@-@@@@MONO@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@FERRING PHARMACEUTICALS@@@@@FERRING PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GONAPEPTYL DEPOT@@@@@GONAPEPTYL DEPOT||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@OVERALL SURVIVAL@@@@@@@@@METASTATIC@@@@@PLACEBO-CONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@100.35@165.61@104.87@@@@@@@@@@26.76@@@@@@@@@@@@@@@@6/7/2017@100.35@100.35@35562014@INJECTABLE PREPARATION, 2 ML@EURO@@@@@@@@3.75@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14923254@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14923254@Indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia  with resistance or intolerance to prior therapy.@@NO@@@NO REVIEW@@@@Co-pay Tier 3. SOURCE: Aetna Preferred Drug Guide 2008@@@@78@The recommended starting dosage for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ALL is 70 mg twice daily administered orally, one tablet in the morning and one in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@FDA, 28 June 2006@6/28/2006@@@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-0015@No@APRIL 2020 ('746); PATENT EXTENSION FILED.@42 with blastic phase and 36 with PH+ disease@@@II@APPROVED@@@MEDICARE@The MaHR rate was 59% in accelerated phase patients, 32% in myeloid phase patients, 31% in lymphoid blast phase patients, and 42% in Ph+ ALL patients. The median durations of major haematologic response were 3.7 months in lymphoid blast CML and 4.8 months in Ph+ ALL.@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@76099.57448@@@4@month@4 month@76099.57@76099.57@625.49@60@1@13403.35@@@@@@@@@@@@4.47@1@@mg@140@1@@@@@@@@@@@8/2/2017@223.39@223.39@00003-0528-11@FILM-COATED TABLET@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16380447@Onco@@@@@@@@@@@Alectinib, Experimental, Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.Crizotinib, Active Comparator, Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.@@L01XE36@L01X@@BASEL, SWITZERLAND@11/1/2019@@Alectinib is a tyrosine kinase inhibitor that targets ALK and RET.@@16380447@Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer@Both@@@@@Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.@@@@@FIRST-LINE@NCT02838420@183@@@@@@@7/1/2016@@YO29449@@@-  Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test. Sufficien@ALK POSITIVE@ADULTS@Phase 3@III@@@@@@@@@MONO@ALECTINIB@CRIZOTINIB@@@@ALECTINIB|CRIZOTINIB|||@ROCHE@@@@@ROCHE||||@China@South Korea@Thailand@@@China|South Korea|Thailand|||||||@NSCLC@@@@@NSCLC|||||||||@ALECENSA@@@@@ALECENSA||||@TK Inhibitor@@@@@TK Inhibitor||||@PFS as determined by Investigator using RECIST v1.1@@@@@PFS as determined by Independent Review Committee (IRC) using RECIST v1.1@Percentage of participants with objective response of complete response (CR) or partial response (PR) as determined by Investigator using RECIST v1.1@@@@@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921294@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@HOLZKIRCHEN, GERMANY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14921294@Neoplastic Diseases: indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Psoriasis: indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis: indicated in the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Lymphomas: In Burkitt's tumor, Stages I-II, methotrexate has produced prolonged remissions in some cases. Recommended dosage is 10 to 25 mg/day orally for 4 to 8 days. In Stage III, methotrexate is commonly given concomitantly with other antitumor agents. Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods. Lymphosarcomas in Stage llI may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily. Mycosis fungoides (cutaneous T cell lymphoma): Therapy with methotrexate as a single agent appears to produce clinical responses in up to 50% of patients treated. Dosage in early stages is usually 5 to 50 mg once weekly. Dose reduction or cessation is guided by patient response and hematologic monitoring. Methotrexate has also been administered twice weekly in doses ranging from 15 to 37.5 mg in patients who have responded poorly to weekly therapy. Combination chemotherapy regimens that include intravenous methotrexate administered at higher doses with leucovorin rescue have been utilized in advanced stages of the disease.@@@@@@@1.Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks.2.Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. 3.Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs). 4.Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. 5.Methotrexate-induced lung disease is a potentially dangerous lesion, which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation. 6.Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. 7.Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. 8.Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication. 9.Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy. 10.Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. 11.Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@MTX HEXAL@@@@@MTX HEXAL||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@110.2@150.31@114.37@@@@@@@@@@0.22@@@@@@@@@@@@@@@@8/1/2017@11.02@11.02@6151438@SOLUTION FOR INJECTION (2 ML)@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919640@Onco@@@@@300f1012ntsdm@@@@@@Oral doses of ondansetron 24 mg once a day, 8 mg twice a day, and 32 mg once a day. 66% of patients were treated with the ondansetron 24-mg  once-a-day , 55% with the ondansetron 8-mg twice-a-day , and 55% with the ondansetron 32-mg once-a-day@@A04AA01@A04A@NO@ULM, GERMANY@@@Ondansetron is a potent, highly selective 5HTs receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomoting reflex by activating vagal afferents via 5HTs receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.@@14919640@Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2; prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy; prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; prevention of postoperative nausea and/or vomiting.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@357@Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin =50 mg/m2. Multiday, single-dose administration of a 24 mg dosage has not been studied. Pediatric Use: There is no experience with the use of a 24 mg dosage in pediatric patients. Geriatric Use: The dosage recommendation is the same as for the general population. Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is one 8-mg tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.@@@@@@@Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@357 ADULT CANCER PATIENTS RECEIVING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN =50 MG/M2.@@@CLINICAL TRIALS / CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING: HIGHLY EMETOGENIC CHEMOTHERAPY; 2 RANDOMISED, DOUBLE-BLIND, MONOTHERAPY TRIALS@APPROVED@@@GKV@First trial: Each of the 3 treatment groups was shown to be statistically significantly superior to a historical placebo control. 56% of patients receiving oral ondansetron 24 mg once a day experienced no nausea during the 24-hour study period, compared with 36% of patients in the oral ondansetron 8-mg twice-a-day group (p = 0.001) and 50% in the oral ondansetron 32-mg once-a-day group. Second trial, efficacy of the oral ondansetron 24-mg once-a-day regimen in the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2, was confirmed.@@@@@MONO@ONDANSETRON HYDROCHLORIDE@@@@@ONDANSETRON HYDROCHLORIDE||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@EMETIC EPISODES@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@62.77@90.34@65.44@@@@@@@@@@0.52@@@@@@@@@@@@@@@@8/1/2017@2.09@2.09@5556647@FILM-COATED TABLET@EURO@@@@@@@@4@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15397601@Onco@@@@@300f1018ntsdm@@@@@@dabrafenib 150 mg twice dailydabrafenib plus trametinib placebo (dabrafenib 150 mg twice daily and trametinib placebo, trametinib 2 mg once daily)@@L01XE25@L01X@@BASEL, SWITZERLAND@8/1/2013@@Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Trametinib inhibits growth of BRAF V600 mutant melanoma cell lines and demonstrates anti-tumour effects in BRAF V600 mutant melanoma animal models.@@15397601@Mekinist in combination with dabrafenib is Treatment of patients with BRAF V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma.@Both@NO@1-Aug-15@8/1/2015@NO REVIEW@@@@@@@NCT01584648@423@The recommended dose of Mekinist, used as monotherapy or in combination with dabrafenib, is 2 mg given orally once daily@TGA, 6 March 2014@3/6/2014@@Yes@@5/1/2012@@115306@No@@Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.The subject must have a radiologically measurable tumorThe subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).@BRAF V600 mutation@ADULTS@III@APPROVED@@@PBS@@@@@@COMBO@TRAMETINIB@DABRAFENIB@@@@TRAMETINIB|DABRAFENIB|||@NOVARTIS @@@@@NOVARTIS ||||@United States@Argentina@Australia@Canada@France@United States|Argentina|Australia|Canada|France|Germany|Greece|Italy|Netherlands|Spain@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@MEKINIST@TAFINLAR@@@@MEKINIST|TAFINLAR|||@MEK Inhibitor@@@@@MEK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@95675.72516@@@11.2@month@11.2 month@95675.73@95675.73@280.85@30@0.779@2106.41@@2176.35@@@@@@@@@@140.43@1@@mg@2@1@@@@@@@@@@@8/1/2017@70.21@70.21@2116-2539-GE-NV@TABLET@A$@@@@@@@@0.5@MG@0.5 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14923596@Onco@@@@@300f1020ntsdm@@@@@@353 Patients in arm 1 received Aranesp at 500 mcg Q3W, 352 patients in arm 2 rceived Aranesp® 2.25 mcg/kg administered weekly as a SC injection. In both groups, the dose was reduced by 40% of the previous dose (e.g., for first dose reduction, to 300 mcg in the Q3W group and 1.35 mcg/kg in the QW group) if hemoglobin increased by more than 1 g/dL ina 14-day period. In arm 1, 254 patients (72%) required dose reductions (median time to first reduction at 6 weeks). In arm 2, 263 patients (75%) required dose reductions (median time to first reduction at 5 weeks).@@B03XA02@B03X@YES@MILAN, ITALY@@@Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. A primary growth factor for erythroid development, erythropoietin is produced in the kidney and released into the bloodstream in response to hypoxia. In responding to hypoxia, erythropoietin interacts with progenitor stem cells to increase red blood cell (RBC) production. Production of endogenous erythropoietin is impaired in patients with chronic renal failure (CRF), and erythropoietin deficiency is the primary cause of their anemia. Increased hemoglobin levels are not generally observed until 2 to 6 weeks after initiating treatment with Aranesp). In patients with cancer receiving concomitant chemotherapy, the etiology of anemia is multifactorial.@@14923596@Treatment of anaemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy.@@NO@-@@NO REVIEW@@@@100%@-@-@-@705@For cancer patients receiving chemotherapy : The recommended starting dose for Aranesp administered weekly is 2.25 mcg/kg as a SC injection. The recommended starting dose for Aranesp administered once-every-3-weeks (Q3W) is 500 mcg as a SC injection.@>> European Commission formally withdraws marketing authorisation for Neupopeg and Nespo. [EMEA, 05.12.2008]      >> Dompe Biotec issues voluntary withdrawal of marketing authorisation for commercial reasons. [Dompe Biotec, 10.11.2008]       >> European Commission approval. [EMEA, 8 June 2001]@6/8/2001@@-@@@When administered to target a hemoglobin of greater than 12 g/dL, Aranesp can increase mortality, serious cardiovascular and thromboembolic events, shorten time to tumor progression  in patients with advanced head and neck cancer receiving radiation therapy, shorten overall survival and increase deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy, can increase the risk of death in patients with active malignant disease receiving neither chemotherapy nor radiation therapy, can cause hypertension, seizures, pure red cell aplasia.@-@@-@705 ANEMIC (HGB = 11 G/DL) PATIENTS NON-MYELOID MALIGNANCIES RECEIVING MULTICYCLE CHEMOTHERAPY WERE RANDOMISED TO 2 ARMS (ARM 1 WITH ARANESP AT 500 MCG Q3W AND ARM 2 WITH ARANESP AT 2.25 MCG/KG).@@@(C2) CANCER PATIENTS RECEIVING CHEMOTHERAPY / ONCE-EVERY-3-WEEK (Q3W) DOSING@DISCONTINUED@@-@SSN@27% (95% CI: 22%, 32%) of patients in arm 1 and 34% (95% CI: 29%, 39%) in arm 2 required a RBC transfusion. The observed difference in the transfusion rates (arm 1-arm 2) was -6.7% (95% CI: -13.8%, 0.4%).@-@@@@MONO@DARBEPOIETIN ALFA@@@@@DARBEPOIETIN ALFA||||@DOMPE BIOTEC@@@@@DOMPE BIOTEC||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@NESPO@@@@@NESPO||||@EPO@@@@@EPO||||@KAPLAN-MEIER ESTIMATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@INTERNATIONAL@@@@@Invalid Dosage Value Phase 1@@@@@-@11168.4@11168.4@@1@1.0543@117.46@193.86@129.18@@@@@@@@@@@@@@@@@@@@@@@@@@@117.46@117.46@@INJECTION, PEN@EURO@@@@@@@@60@MCG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16749823@Onco@@@@@300f1012ntsdm@@@@@@@@L01XC02@L01X@@@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@16749823@Treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@322@The recommended dose of MabThera in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 bodysurface area per cycle, for up to 8 cycles.@EMA, 17 February 2017@2/17/2017@@No@@@@@No@@@@@@APPROVED@@@GKV@@@@@@COMBO@RITUXIMAB@CYCLOPHOSPHAMIDE@VINCRISTINE@PREDNISOLONE@@RITUXIMAB|CYCLOPHOSPHAMIDE|VINCRISTINE|PREDNISOLONE|@MUNDIPHARMA@@@@@MUNDIPHARMA||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@TRUXIMA@CVP@@@@TRUXIMA|CVP|||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@TIME TO TREATMENT FAILURE@@@@@@@@@@@@@@@RANDOMISED@OPEN-LABEL@@@@1.75@m²@13596.45@@@168@day@168 day@13596.45@13596.45@80.93@1@1.1511@1294.9@1644.48@1333.4@@@@@@@@@@2.59@21@@mg/m²@375@1@@@@@@@@@@@8/1/2017@1294.9@1294.9@12728936@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL) - 50 ML@EURO@@@@@@@@500@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16829133@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Active Comparator: Arm A Daunorubicin and Cytarabine. -Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.-Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.-Intervention: Drug: conventional chemotherapy (AraC + Daunorubicin),Experimental: Arm B Daunorubicin and Cytarabine and Mylotarg -Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.-Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.-Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1.Intervention: Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin).@@L01XC05@L01X@@MADISON, NEW JERSEY@7/1/2011@@Gemtuzumab ozogamicin (marketed as Mylotarg) is a monoclonal antibody used to treat acute myelogenous leukaemia. It is a monoclonal antibody to CD33 linked to a cytotoxic agent, calicheamicin. CD33 is expressed in most leukaemic blast cells but is not found on normal hematopoietic stem cells. When given to patients in first relapse, 15% of patients achieve a complete remission. In the United States, it was approved by the FDA for use in patients over the age of 60 with relapsed AML who are not considered candidates for standard chemotherapy. A notable complication of therapy with gemtuzumab is the increased risk of veno-occlusive disease in the absence of bone marrow transplantation. The onset of VOD can also be delayed and can occur at increased frequency following bone marrow transplantation.@@16829133@Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults.@Both@NA@@@NO REVIEW@@@@@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@FIRST-LINE@NCT00927498@271@A treatment course including MYLOTARG in combination therapy for adults with newly-diagnosed de novo CD33-positive AML consists of 1 induction cycle and 2 consolidation cycles. For the induction cycle, the recommended dose of MYLOTARG is 3 mg/m2 (up to one 4.5 mg vial) on Days 1, 4, and 7 in combination with daunorubicin and cytarabine. For patients requiring a second induction cycle, do NOT administer MYLOTARG during the second induction cycle.For the consolidation cycles, the recommended dose of MYLOTARG is 3 mg/m2 on Day 1 (up to one 4.5 mg vial) in combination with daunorubicin and cytarabine.@FDA, 1 September 2017@9/1/2017@@Yes@@12/1/2007@@ALFA-0701@No@@Patients with a morphologically proven diagnosis AML and both the two following criteria: Age > 50 years and £ 70 years. Not previously treated for their disease; ECOG performance status 0 to 3; Negative serology HIV, HBV and HBC (except post vaccination); Serum creatinin inf 2.5N; AST and ALT inf 2.5N; total bilirubin inf 2N; Cardiac function determined by radionucleide or echography within normal limits; Negative serum pregnancy test within one week before treatment for women of child bearing potential; Signed informed consent.@CD33-positive@ADULTS@III@APPROVED@@@@@@@@@COMBO@GEMTUZUMAB OZOGAMICIN@DAUNORUBICIN@CYTARABINE@@@GEMTUZUMAB OZOGAMICIN|DAUNORUBICIN|CYTARABINE||@WYETH@@@@@WYETH||||@France@@@@@France|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@MYLOTARG@DA@@@@MYLOTARG|DA|||@mAb@Humanised@CD33@@@mAb|Humanised|CD33||@EVENT FREE SURVIVAL@@@@@CR RATE@CUMULATIVE INSIDENCE OF RELAPSE@OVERALL SURVIVAL@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN-LABEL@MULTICENTER@@1.5@m²@Invalid Factory Price@@@15@day@15 day@@@@1@1@@@@@@@@@@@@@@7@1@mg/m²@3@3@4@@mg/m²@3@1@@@@@@@@@00008-4510-01@POWDER FOR SOLUTION FOR INFUSION (VIAL)@US$@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920431@Onco@@@@@300f1037ntsdm@@@@@@Patients were randomised to receive either 400 mg or 600 mg orally q.d.@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920431@Indicated for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).@@YES@@@NO REVIEW@@@@90%@@@@147@The recommended dose of Glivec is 400 mg/day for adult patients with unresectable and/or metastatic malignant GIST. At the time of analysis, the treatment duration was a median of 7 months.@EMA, 7 May 2009@5/7/2009@7/15/2004@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@@147 PATIENTS WITH UNRESECTABLE OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)@ADULT, CD 117 POSITIVE@@II@APPROVED@@NO REVIEW@SNS@There were no differences in RRs between the 2 dose groups. For the 99 responders to imatinib observed in the GIST study, the Kaplan-Meier estimate of median duration of response is 118 weeks (95% CI: 96, not reached) The median time to response was 12 weeks (range was 3-98 weeks).@The majority of Gleevec-treated patients experienced adverse reactions at some time. The most frequently reported adverse reactions were edema, nausea, diarrhea, abdominal pain, muscle cramps, fatigue, and rash. Most reactions were of mild-to-moderate severity. Drug was discontinued for adverse reactions in 7 patients (5%) in both dose levels studied. Superficial edema, most frequently periorbital or lower extremity edema, was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec. Severe (CTC Grade 3/4) superficial edema was observed in 3 patients (2%), including facial edema in one patient. Grade 3/4 pleural effusion or ascites was observed in 3 patients (2%)@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@OPEN-LABEL@INTERNATIONAL@RANDOMISED@@@1@1@16804.0796@@@7@month@7 month@16804.08@16804.08@78.93@30@1.1511@2367.75@2520.61@2375.29@@@@@@@@@@0.2@1@@mg@400@1@@@@@@@@@@@8/4/2017@78.93@78.93@779660@TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14920370@Onco@@@@@300f1012ntsdm@@@@@@77 patients were treated at a starting dose of 400 mg, the remaining 158 patients started at 600 mg.@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920370@Indicated for the treatment of adult patients with Ph+ CML in accelerated phase@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@235@The recommended dosage of Glivec is 600 mg/day for adult patients in accelerated phase CML. Treatment with Glivec continued until disease progression.@EMA, 7 November 2001@11/7/2001@@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@@PATIENTS WITH ACCELERATED PHASE DISEASE MET ONE OR MORE OF THE FOLLOWING CRITERIA: =15%-<30% BLASTS IN PB OR BM; =30% BLASTS + PROMYELOCYTES IN PB OR BM; =20% BASOPHILS IN PB; AND <100 X 109/L PLATELETS.@ADULT@@II; INTERNATIONAL, OPEN-LABEL, SINGLE-ARM STUDY CONDUCTED TO DETERMINE THE SAFETY AND EFFICACY OF GLEEVEC IN ACCELERATED PHASE DISEASE@APPROVED@@NO REVIEW@GKV@RRs in accelerated phase CML were higher for the 600-mg dose group than for the 400-mg group: haematologic response (75% vs. 64%), confirmed and unconfirmed major cytogenetic response (31% vs. 19%). Results for all 235 patients: CHR = 71% ; Major cytogenetic response = 21%@The majority of Gleevec-treated patients experienced adverse reactions at some time. Most reactions were of mild-to-moderate grade, but drug was discontinued for drug-related adverse reactions in 2.4% of newly diagnosed patients, 4% of patients in chronic phase after failure of interferon-alpha therapy, 4% in accelerated phase and 5% in blast crisis. The most frequently reported drug-related adverse reactions were edema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhea and rash. Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec. The frequency of severe superficial edema was 1.5%-6%. The overall safety profile of pediatric patients treated with Gleevec in 93 children studied was similar to that found in studies with adult patients, except that musculoskeletal pain was less frequent (20.5%) and peripheral edema was not reported. Nausea and vomiting were the most commonly reported individual adverse reactions with an incidence similar to that seen in adult patients. Although most patients experienced adverse reactions at some time during the study, the incidence of Grade 3/4 adverse reactions was low.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@ACCELERATED PHASE@@@@@INTERNATIONAL@OPEN-LABEL@SINGLE-ARM@@@1@1@95202.96897@@@22.9@month@22.9 month@95202.97@95202.97@136.68@90@1.1511@8200.95@10109.22@8239.45@@@@@@@@@@0.23@1@@mg@600@1@@@@@@@@@@@8/1/2017@91.12@91.12@1755203@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15996553@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@RADIANT-4@Experimental: Participants will receive everolimus 10mg once daily until disease progression, intolerable toxicity, or consent withdrawalPlacebo Comparator: Matching placebo to everolimus with same dose@@L01XE10@L01X@@BASEL, SWITZERLAND@8/1/2017@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15996553@Treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease.@Both@NA@@@NO REVIEW@@@@@@@NCT01524783@302@The recommended dose of AFINITOR Tablets is 10 mg, to be taken once daily at the same time every day. Continue treatment until disease progression or unacceptable toxicity occurs.@FDA, 26 February 2016@2/26/2016@@No@@3/1/2012@@CRAD001T2302, 2011-002887-26@No@@Pathologically confirmed, well differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumor of GI or lung originNo history of and no active symptoms related to carcinoid syndromeIn addition to treatmentnaive patients, patients previously treated with SSA, Interferon (IFN), one prior line of chemotherapy, and/or PRRT are allowed into the study. Pretreated patients must have progressed on or after the last treatmentRadiological documented disease progression within 6 months prior to randomizationMeasurable diseaseWHO performance status ≤1Adequate bone marrow, liver and renal function@@ADULTS@III@APPROVED@@@@The clinical trial enrolled 302 patients with unresectable, locally advanced or metastatic, well differentiated (low or intermediate grade), non-functional (no current or prior history of carcinoid symptoms), neuroendocrine tumors (NET) of gastrointestinal or lung origin. All patients were required to have evidence of disease progression within 6 months prior to randomization. The major efficacy outcome measure was progression-free survival (PFS) based on independent radiological assessment per RECIST. Median PFS were 11 months and 3.9 months in the everolimus and placebo arms, respectively [HR 0.48 (95% CI: 0.35, 0.67), p <0.001, stratified log rank test]. Overall response rates were 2% in the everolimus arm and 1% in the placebo arm. At the planned interim analysis, there was no statistically significant difference in overall survival between arms. [FDA, 26 February 2016, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488028.htm]@Safety data were evaluated in 300 patients who received at least one dose of investigational drug. The median exposure duration to everolimus was 9.3 months; 64% of patients were treated for greater than or equal to 6 months and 39% were treated for greater than or equal to12 months.Everolimus was discontinued for adverse reactions in 29% of patients and dose reduction or delay was required in 70% of everolimustreated patients. Serious adverse reactions occurred in 42% of everolimustreated patients and included 3 fatal events (cardiac failure, respiratory failure, and septic shock). The most common adverse reactions (incidence greater than or equal to 30%) were stomatitis, infections, diarrhea, peripheral edema, fatigue and rash. The most common laboratory abnormalities (incidence greater than or equal to 50%) were anemia, hypercholesterolemia, lymphopenia, elevated aspartate transaminase (AST) and fasting hyperglycemia.[FDA, 26 February 2016, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488028.htm]@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@World@@@@@World|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@AFINITOR@@@@@AFINITOR||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@ADVANCED@UNRESECTABLE@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@1@1@210833.3849@@@11@month@11 month@210833.38@210833.38@630.15@28@1@13233.17@@@@@@@@@@@@63.02@1@@mg@10@1@@@@@@@@@@@8/2/2017@472.61@472.61@00078-0620-51@TABLET@US$@@@@@@@@7.5@MG@7.5 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15402489@Onco@@@@@300f1018ntsdm@@@@@@509 women with metastatic breast cancer were randomised to receive CAELYX (50 mg/m2 every four weeks, N=254) or doxorubicin (60 mg/m2 every three weeks, N=255).@@L01DB01@L01D@@BEERSE, BELGIUM@@@The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.@@15402489@CAELYX, as monotherapy, is indicated for the treatment of metastatic breast cancer.@@YES@3-Jun@@NO REVIEW@@@@@@@@509@Breast cancer/Ovarian cancer: Caelyx is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.@TGA, 6 August 1997@8/6/1997@@No@@@@@No@@@@@III@APPROVED@@@PBS@PLD and doxorubicin were comparable with respect to PFS [6.9 versus 7.8 months, respectively; hazard ratio (HR)=1.00; 95% confidence interval (CI) 0.82-1.22]. Subgroup results were consistent. Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR=3.16; 95%CI 1.58-6.31; P<0.001). Overall survival was similar (21 and 22 months for PLD and doxorubicin, respectively; HR=0.94; 95%CI 0.74-1.19).  [O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9; http://www.ncbi.nlm.nih.gov/pubmed/14998846]@Alopecia (overall, 66% versus 20%; pronounced, 54% versus 7%), nausea (53% versus 37%), vomiting (31% versus 19%) and neutropenia (10% versus 4%) were more often associated with doxorubicin than PLD. Palmar-plantar erythrodysesthesia (48% versus 2%), stomatitis (22% versus 15%) and mucositis (23% versus 13%) were more often associated with PLD than doxorubicin.@@@@MONO@DOXORUBICIN, PEGYLATED LIPOSOMAL@@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL||||@JANSSEN-CILAG@@@@@JANSSEN-CILAG||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CAELYX@@@@@CAELYX||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@PROGRESSION-FREE SURVIVAL@CARDIAC TOXICITY@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@SINGLE-ARM@@@@1.6@m²@7939.097417@@@6.9@month@6.9 month@7939.1@7939.1@37.83@1@0.779@264.8@@@@@@@@@@@@13.24@28@@mg/m²@50@1@@@@@@@@@@@8/1/2017@264.8@264.8@0687-0706-HB-JC@SUSPENSION FOR I.V. INFUSION - 10 ML@A$@@@@@@@@20@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15360701@Onco@@@@@300f1018ntsdm@@@@@@Patients randomized to the treatment arm received AFINITOR Tablets at a starting dose of 4.5 mg/m2 daily, with subsequent dose adjustments as needed to achieve and maintain everolimus trough concentrations of 5 to 15 ng/mL as tolerated. AFINITOR/matched placebo treatment continued until disease progression or unacceptable toxicity.@@L01XE10@L01X@@BASEL, SWITZERLAND@10/1/2014@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15360701@Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection.@Both@NO@@@NO REVIEW@@@@@@@NCT00789828@117@The recommended starting dose is 4.5 mg/m2, once daily. Continue treatment until disease progression or unacceptable toxicity occurs.@@@@No@@8/1/2009@@CRAD001M2301/2007-006997-27@No@@Eligible patients had at least one SEGA lesion ≥ 1.0 cm in longest diameter on MRI based on local radiology assessment and one or more of the following: serial radiological evidence of SEGA growth, a new SEGA lesion ≥ 1 cm in longest diameter, or new or worsening hydrocephalus.@@@III@APPROVED@@@PBS@SEGA responses were observed in 27 of the 78 patients (35 percent, 95 percent CI: 24, 46) treated with everolimus. None of the 39 patients (0 percent, 95 percent CI: 0, 9) treated with placebo (p < 0.0001) demonstrated SEGA responses. With a median follow-up duration of 8.4 months for the overall study population, all responses were ongoing and the median response duration was 5.3 months (range: 2.1 to 8.4 months) in patients treated with everolimus. [FDA, 29 October 2012, http://www.cancer.gov/about-cancer/treatment/drugs/fda-everolimus]@In the randomized trial, the most common adverse reactions in patients receiving everolimus (incidence at least 20 percent) were stomatitis, respiratory tract infection, pyrexia, vomiting, rash, and behaviorial disturbances, including anxiety and aggression. The most common (at least 2 percent) grade 34 adverse reactions were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea. Serious adverse events were reported for 19 (24 percent) of the patients treated with everolimus and 5 (13 percent) of the patients who received the placebo during the doubleblind period of the randomized study[RC2] . The most common serious adverse event (reported in at least 3 patients and occurring more frequently in patients treated with everolimus) was pyrexia. Serious adverse events due to infections were more common in patients younger than 3 years of age; a total of 6 of 13 patients younger than 3 years who received everolimus had at least one serious adverse event due to infection, compared with 2 of 7 patients younger than 3 years who received placebo. No deaths occurred in either treatment group.[FDA, 29 October 2012, http://www.cancer.gov/aboutcancer/treatment/drugs/fdaeverolimus]@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@AFINITOR@@@@@AFINITOR||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RESPONSE RATE@@@@@RESPONSE RATE@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@RANDOMISED@@@1.2@m²@30894.74784@@@11@month@11 month@30894.75@30894.75@92.34@30@0.779@1282.5@1403.9@1352.44@@@@@@@@@@17.1@1@@mg/m²@4.5@1@@@@@@@@@@@8/1/2017@42.75@42.75@0077-0940-GE-NV@TABLET@A$@@@@@@@@2.5@MG@2.5 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16396651@Onco@@@@@300f1018ntsdm@@@@@@Patients in the Revlimid/dexamethasone arm (n=170) took 25 mg of Revlimid orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone arm (n= 171)took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Patients in both treatment arms took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396651@Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.@@YES@8-Nov@@NO REVIEW@@@@@@SECOND-LINE@@704@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on days 14, 912, and 1720 of each 28day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 14 every 28 days. Dosing is continued or modified based upon clinical and laboratory findings.@@@@Yes@@@@LABEL@No@@PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST ONE PRIOR TREATMENT WERE RANDOMIZED TO 2 ARMS: ARM1: REVLIMID (LENALIDOMIDE) PLUS ORAL PULSE HIGHDOSE DEXAMETHASONE THERAPY. ARM2: DEXAMETHASONE THERAPY ALONE.@@@III@APPROVED@@Recommended on a cost minimisation basis compared with bortezomib. The equi-effective doses to be based on 6 cycles of bortezomib.@PBS@@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@TIME TO PROGRESSION@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@PLACEBO-CONTROLLED@@1@1@344198.6111@@@48.1@month@48.1 month@344198.61@344198.61@235.27@21@0.779@6587.49@6634.01@@@@@@@@@@@12.55@28@@mg@25@21@@@@@@@@@@@8/1/2017@313.69@313.69@2922-1421-HB-CJ@HARD CAPSULE@A$@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14916017@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Patient will receive nimotuzumab plus irinotecan every 2 weeks. A 400 mg of nimotuzumab will be given once every 2 weeks for 12 weeks, whereas irinotecan will be administered at the same dose and schedule as the last dose and schedule given during the most recent pre-study irinotecan containing therapy. If  tumour shows no sign of further growth after 12 weeks of treatment, patient will continue receiving nimotuzumab 400 mg every 2 weeks for up to 18 months or as long as they benefit.@@-@-@-@ONTARIO, CANADA@@@Nimotuzumab is a humanized monoclonal antibody (mAb) that targets the epidermal growth factor receptor (EGFR), a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy. Nimotuzumab has been administered to >1,800 patients worldwide through clinical trials, compassionate use programs and commercial sales and, to date (11/26/2007), there have been no reports of any severe incidents of rash. Incidents of certain other side-effects commonly observed with EGFR-targeting monoclonal antibodies or small molecules are rare.@@14916017@Second-line therapy @@-@-@@NO REVIEW@@@@-@YM BioSciences and its licensees are committed to the clinical development and subsequent marketing of nimotuzumab. These include Daiichi-Sankyo Co. Ltd. in Japan, Oncoscience AG in Europe, Kuhnil Pharmaceutical Co., Ltd. in South Korea and Innogene Kalbiotech Pte Ltd. in South East Asia. In addition, as of November 30, 2007 eight other companies around the globe were involved either in a consortium with YM, its licensees or certain of the other licensees, or unilaterally in a number of trials in multiple indications. The other licensees for nimotuzumab include Biocon BioPharmaceuticals Ltd. (BBPL) in India, Biotech Pharmceutical Co. Ltd. in China, Delta Laboratories in Columbia, Eske Group in Peru, Eurofarma Laboratorios Ltda. in Brazil, Ferozsons Labs in Pakistan, Laboratorio Elea S.A.C.I.F.yA. in Argentina and Laboratorios PiSA in Mexico. @SECOND-LINE@NCT00493857,@100@-@-@@@-@@@-@YMB 1000-015@@-@100 PATIENTS WITH IRINOTECAN-REFRACTORY METASTATIC COLORECTAL CANCER@@@II@II@@-@-@Data on 58 evaluable patients of the 61 enrolled in the trial after being advised that the trial has now reached the point at which more than 50% of the patients have died:  The RR was 3.4% while the disease control rate reported was 50%, consisting of 27 patients with stable disease and two patients with partial response as determined using RECIST criteria. Median PFS was 12 weeks. Overall survival (Kaplan-Meier) in the evaluable patients was 9.3 months. Tissue samples from 17 patients were available for kRas analysis. Approximately 30% of the patients had mutated kRAS. PFS of 12 weeks was observed in patients with the mutation and 18 weeks in patients with wild type. SOURCE: YM, 4 August 2008  Accrual completed in the first 50-patient cohort. SOURCE: YM Biosciences, 20 December 2007@Only 22% of patients (15) were reported with rash, all of which was graded I/II. In contrast, Grade I/II rash was reported in 80% and Grade III/IV in 9.4% of patients in the cetuximab/irinotecan trial known as BOND 1. Neutropenia (4% vs. 9.4%), asthenia (5.2% vs. 13.9%) and diarrhea (7% vs. 21.2%) were lower in the nimotuzumab trial than in BOND 1. Two patients had Grade I hypomagnesemia, a condition affecting approximately 50% of patients treated with cetuximab.@@@@COMBO@NIMOTUZUMAB@IRINOTECAN@@@@NIMOTUZUMAB|IRINOTECAN|||@YM BIOSCIENCES@ONCOSCIENCE@DAIICHI SANKYO@@@YM BIOSCIENCES|ONCOSCIENCE|DAIICHI SANKYO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@THERALOC@@@@@THERALOC||||@mAb@EGFR@@@@mAb|EGFR|||@RESPONSE RATE@INCIDENCE OF RASH@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
16384175@Onco@@@@@300f1010ntsdm@@@@@@A total of 945 patients were randomised to receive nivolumab in combination with ipilimumab(n = 314), nivolumab monotherapy (n = 316), or ipilimumab monotherapy (n = 315). Patients in thecombination arm received nivolumab 1 mg/kg over 60 minutes and ipilimumab 3 mg/kg over90 minutes administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab3 mg/kg as monotherapy every 2 weeks.@@L01XC17@L01X@@NEW YORK, NEW YORK@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16384175@Indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.@Both@YES@27-Jul-16@7/27/2016@NO REVIEW@@@@100%@@@@945@The recommended dose is 1 mg/kg nivolumab administered as every 3 weeks for the first 4 doses in combination with 3 mg/kg ipilimumab administeredintravenously over 90 minutes. This is then followed by a second phase in which 3 mg/kg nivolumab is administered as an intravenous infusion over 60 minutes every 2 weeks.Treatment with OPDIVO, either as a monotherapy or in combination with ipilimumab, should becontinued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient.@EMA, 11 May 2016@5/11/2016@7/19/2015@No@@@@CA209067@No@@The study included adult patients with confirmed unresectable Stage III or Stage IV melanoma. Patients were to have ECOG performance status scoreof 0 or 1. Patients who had not received prior systemic anticancer therapy for unresectable or metastatic melanoma were enrolled. Prior adjuvant or neoadjuvant therapy was allowed if it wascompleted at least 6 weeks prior to randomisation. Patients with active autoimmune disease, ocular/uveal melanoma, or active brain or leptomeningeal metastases were excluded from the study.@ADULTS@ADULTS@III@APPROVED@@Recommended: 27 July 2016. Nivolumab in combination with ipilimumab is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with the discount agreed in the patient access scheme.[https://www.nice.org.uk/guidance/TA400/chapter/1-Recommendations)@NHS@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@@@@@@76.5@kg@73064.74236@@@15.5@month@15.5 month@73064.74@73064.74@154.98@1@1.299@439@@@@@@@@@@@@10.98@21@4@mg/kg@1@1@14@@mg/kg@3@1@@@@@@7/28/2017@439@439@2.99E+16@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL) - 4 ML@GB£@@@@@@@@40@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916605@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Belinostat plus standard doses of carboplatin and paclitaxel@@-@-@-@COPENHAGEN, DENMARK@12/1/2008@@Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a singleagent,or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade (bortezomib) for injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.@@14916605@-@@-@-@@NO REVIEW@@@@-@TopoTarget licenses back global rights in exchange for US$26-mil. Payment to CuraGen, 5 mil newly issued shares, and a 10% milestone payment on first US$60 mil of rvenues generated whether in sales or partnership deals. SOURCE: TopoTarget, 22 April 2008@-@NCT00421889@32@-@-@@@-@@9/1/2005@-@PXD101-CLN-8@@-@-@@@I/II@II@@-@-@>> In the phase I part where the data has now been finalized 23 patients were treated to find the recommended dose for phase II, which was belinostat 1000 mg/m2 i.v. once daily days 1-5 in combination with standard doses of carboplatin and paclitaxel administered on day 3 of each treatment cycle. In this group of heavily pretreated patients 2 confirmed partial remissions (PR) were documented in rectal cancer and in pancreatic cancer, respectively. Activity was observed in patients with primary tumour (CUP), ovarian, rectal, pancreatic and bladder cancer. 11 patients experienced stable disease (SD) ranging from 2 to +28 cycles. In the phase II part, 35 patients with ovarian cancer all had prior platinum-based therapy (14 and 21 patients hadplatinum-sensitive and platinum-resistant disease, respectively). Overall response rate criteria was 43%. 3 patients had complete remissions (CR) and 12 partial remissions (PR). Median duration of response was +5.3 months (range +1.2-+12.7 months) with 6 responses still ongoing. Median PFS in all 35 patients (11 patients censored for PD) is currently +5.4 months (range +0.1 to +13.9 months). [TopoTarget/ESMO 2008, 17.09.2008]>> Update; two patients acehived objective response. Second stage will proceed. [TopoTarget/ASCO, June 2007]@-@@@@COMBO@BELINOSTAT@CARBOPLATIN@PACLITAXEL@@@BELINOSTAT|CARBOPLATIN|PACLITAXEL||@TOPOTARGET@@@@@TOPOTARGET||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@PXD-101@@@@@PXD-101||||@HDAC@@@@@HDAC||||@PARTIAL RESPONSE@@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15394381@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE13@L01X@-@INGELHEIM, GERMANY@1/1/2012@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.@@15394381@GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).@@YES@12-Mar-15@3/12/2015@NO REVIEW@@@@90%@@FIRST-LINE@NCT00949650@332@Recommended dose: 40 mg orally, once daily. Treatment should be continued until disease progression or until no longer tolerated by the patient.@EMA, 25 September 2013@9/25/2013@@No@@8/1/2009@@LUX-Lung 3@No@@Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology. EGFR mutation detected by central laboratory analysis of tumour biopsy material.@@@III@APPROVED@@The AEMPS has recommended the use of Giotrif for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adult patients with epidermal growth factor receptor (EGFR)-activating mutations, who have not received prior therapy with tyrosine kinase inhibitors such as Tarceva (erlotinib; Roche, Switzerland) and Iressa (gefitinib; GlaxoSmithKline, UK).http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-afatinib-giotrif.pdf@SNS@Data from LUX-Lung 3 has shown that patients taking afatinib as a first-line treatment lived for almost one year without their tumour growing again (median progression-free survival (PFS) of 11.1 months) versus just over half a year (PFS of 6.9 months) for those treated with pemetrexed/cisplatin. In addition, NSCLC patients with tumours harbouring the two most common EGFR mutations (Del19 or L858R) taking afatinib lived for well over a year without tumour progression (PFS of 13.6 months) versus just over half a year (PFS of 6.9 months) for those in the comparator arm.1In addition, patients taking afatinib also experienced an improvement in lung cancer symptoms and a better quality of life compared to those receiving standard chemotherapy treatment.[BI, 15 July 2013, http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/15_july_2013_oncology.html ]Trial registered [BI, 29.07.2009]@The most common grade 3 drug-related adverse events observed in the afatinib treatment arm were diarrhoea (14%), rash (16%), and inflammation of the nail bed (paronychia) (11%). The most common drug-related grade 3 adverse events observed in the chemotherapy arm (pemetrexed/cisplatin) were neutropenia (15%), fatigue (13%), and leucopenia (8%). There was a low discontinuation rate associated with treatment-related adverse events in the trial (8% discontinuation rate for afatinib; 12% for chemotherapy). One percent of patients in the afatinib arm discontinued due to drug-related diarrhoea.@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GIOTRIF@@@@@GIOTRIF||||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE@DISEASE CONTROL@QUALITY OF LIFE@@@LOCALLY ADVANCED@METASTATIC@@@@PARALLEL ASSIGNMENT@@@@@1@1@18414.82126@@@11.1@month@11.1 month@18414.82@18414.82@54.54@28@1.1511@1909.02@2043.53@1916.56@@@@@@@@@@1.36@1@@mg@40@1@@@@@@@@@@@8/4/2017@68.18@68.18@699838@FILM-COATED TABLET@EURO@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921669@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@>> ARM1: Paclitaxel 80 mg/m^2 IV Once Weekly Over 1 Hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles; 5-Fluorouracil 500 mg/m^2 IV on day 1 every 3 weeks (+/- 7 days) for 4 cycles; Epirubicin 100 mg/m^2 IV on day 1 every 3 weeks (+/- 7 days) for 4 cycles; and Cyclophosphamide 500 mg/m^2 IV on day 1 every 3 weeks (+/- 7 days) for 4 cycles.        >> ARM2: same as above but with RAD-001 30 mg PO Weekly On Days 1, 8, & 15 for 12 cycles as well.@@-@-@-@BASEL, SWITZERLAND@7/1/2009@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921669@Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00499603@50@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@7/1/2007@-@CRAD001C24101@@-@>> Patients with histologic confirmation of invasive ER/PR and HER2/neu-negative breast carcinoma. Immunohistochemistry (IHC) must be used for ER/PR evaluation and IHC or FISH for determination of HER2/neu. ER/PR will be considered negative if equal or lower than 5% IHC staining and HER2/neu will be considered negative if IHC of 0% or negative FISH.       >> Patients must have intact primary tumors.       >> Age equal or greater than 18 years       >> Patients should have stage IIA (T1N1) to IIIC non inflammatory breast cancer.@@@II@II@@-@-@Trial registered [Novartis, 9.07.2007]@-@@@@NEOADJUVANT@EVEROLIMUS@PACLITAXEL@@@@EVEROLIMUS|PACLITAXEL|||@NOVARTIS@GENENTECH@@@@NOVARTIS|GENENTECH|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AFINITOR@RAD-001@FEC@@@AFINITOR|RAD-001|FEC||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RESPONSE RATE@@@@@@@@@@TRIPLE NEGATIVE@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16749459@Onco@@@@@300f1012ntsdm@@@@@@@@L01XC02@L01X@@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@16749459@Maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008Genentech opted-in in Q3 2006@FIRST-LINE@@1193@The recommended dose of MabThera used as a maintenance treatment for patients with previously untreated follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 2 months (starting 2 months after the last dose of induction therapy) until disease progression or for a maximum period of two years.@EMA, 25 October 2010@10/25/2010@@No@@@@@No@>> Sanofi-Aventis files litigation proceedings against Biogen and Genentech over patent infringement after Genentech ceased licensing deal with Sanofi-Aventis. [sanofi-aventis, 5.11.2008]    >> Patent Expiration: 2018@@@@III@APPROVED@@@GKV@@@@@@MAINTENANCE@RITUXIMAB@@@@@RITUXIMAB||||@ROCHE@GENENTECH@@@@ROCHE|GENENTECH|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@MABTHERA@@@@@MABTHERA||||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@@@@@@@@@@@@@@@@PROSPECTIVE@OPEN-LABEL@MULTI-CENTER@@@1.75@m²@25825.90262@@@2@year@2 year@25825.9@25825.9@35.38@2@1.1511@655.86@840.19@677.22@@@@@@@@@@3.28@60.83@@mg/m²@375@1@@@@@@@@@@@8/1/2017@327.93@327.93@8709896@CONCENTRATE FOR SOLUTION FOR INFUSION (VIAL) - 10 ML@EURO@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15116542@Onco@@@@@300f1015ntsdm@@@@@AVF4095g@Arm A: carboplatin, gemcitabine and Avastin for 6 months followed by maintenance Avastin; Arm B: carboplatin, gemcitabine and placebo for 6 months followed by maintenance placebo. Avastin dose is 15mg/kg every 3 weeks.@@L01XC07@L01X@-@BASEL, SWITZERLAND@8/1/2009@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@15116542@Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primaryperitoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.@@YES@1-Apr-15@4/1/2015@NO REVIEW@@@@@@SECOND-LINE@NCT00434642@487@Avastin is administered in combination with carboplatin and gemcitabine for 6 cycles and up to 10 cycles followed by continued use of Avastin assingle agent until disease progression.The recommended dose of Avastin is 15 mg/kg of body weightgiven once every 3 weeks as an intravenous infusion.@EMA, 24 October 2012@10/24/2012@4/1/2005@No@@4/1/2007@@@No@@@@@AVF4095G@APPROVED@@ASMR V, 1 April 2015http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-05/avastin_ovaire_summary_ct13974.pdf@HAUTE AUTORITÉ DE SANTÉ@The study met its primary endpoint of progression-free survival. The study showed that women who received a combination of Avastin and chemotherapy followed by the continued use of Avastin alone, lived longer without their disease worsening (progression-free survival or PFS), compared to women who received chemotherapy alone. No new safety findings were observed and adverse events were consistent with those seen in previous pivotal trials of Avastin. Full data from the OCEANS study will be submitted for presentation at an upcoming medical meeting. [Roche 8 February 2011 http://www.roche.com/media/media_releases/med-cor-2011-02-08.htm ]RESULTS PENDING@@@@@COMBO@BEVACIZUMAB@GEMCITABINE@CARBOPLATIN@@@BEVACIZUMAB|GEMCITABINE|CARBOPLATIN||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@AVASTIN@GEMZAR@@@@AVASTIN|GEMZAR|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RECURRENT@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@60@kg@40136.65813@@@12.4@month@12.4 month@40136.66@40136.66@106.42@1@1.1511@248.31@@@@@@@@@@@@2.48@21@@mg/kg@15@1@@@@@@@@@@@8/2/2017@248.31@248.31@9261104T@SOLUTION FOR PERFUSION  4 ML@EURO@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919224@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01DB07@L01D@YES@MUMBAI, INDIA@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14919224@Mitoxantrone is indicated in the treatment of metastatic breast cancer, non-Hodgkin's lymphoma and adult acute non-lymphocytic leukaemia. Mitoxantrone has also been used in the palliation of non-resectable primary hepatocellular carcinoma.@@NO@@@NO REVIEW@@@@100%@@@@@Adult acute non-lymphocytic leukaemia: Single Agent Dosage in Relapse: The recommended dosage for remission induction is 12 mg/m2 of body surface area, given as a single intravenous dose daily for five consecutive days (total of 60 mg/m2). In clinical studies with a dosage of 12 mg/m2 daily for 5 days, patients who achieved a complete remission did so as a result of the first induction course. Combination Therapy: Mitoxantrone has been used in combination regimens for the treatment of acute non-lymphocytic leukaemia (ANLL). Most clinical experience has been with mitoxantrone combined with cytarabine. This combination has been used successfully for primary treatment of ANLL as well as in the treatment of relapse. An effective regimen for induction in previously untreated patients has been mitoxantrone 10-12 mg/m2 IV for 3 days combined with cytarabine 100 mg/m2 IV for 7 days (by continuous infusion). This is followed by second induction and consolidation courses as thought appropriate by the treating clinician. In clinical studies, duration of therapy in induction and consolidation courses with mitoxantrone have been reduced to 2 days, and that of cytarabine to 5 days. However, modification to the above regimen should be carried out by the treating clinician depending on individual patient factors.@EMA, October 2004@@@@@@Leukaemia: When used in high doses (over 14mg/m2 per day for 3 days) such as indicated for leukaemia, severe myelosupression will occur. It should only administered by experienced chemo physicians. Blood and blood products must be available to support patients during the expected period of medullary hypoplasia and severe myelosupression. Particular care should be given to assuring full haemotologic recovery before any consolidation therapy. Acute congestive heart failure may occasionally occur in patients treated with mitoxantrone for ANLL. In firstline comparative trials of mitoxantrone + cytarabine vs. daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with congestive heart failure in 6.5% of patients on each arm. A causal relationship between drug therapy and cardiac effects is difficult to establish in this setting sincemyocardial function is frequently depressed by the anemia, fever and infection, and hemorrhage that often accompany the underlying disease.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@MITOXANTRONE@@@@@MITOXANTRONE||||@WOCKHARDT@@@@@WOCKHARDT||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CONCENTRATE FOR INFUSION@GB£@@@@@@@@20@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921054@Onco@@@@@300f1037ntsdm@@@@@@Randomized on a 1:1 basis to receive either Campath or chlorambucil. @@L01XC04@L01X@YES@LEVERKUSEN, GERMANY@11/1/2006@@Alemtuzumab binds to CD52, an antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. A proportion of bone marrow cells, including some CD34+ cells, express variable levels of CD52. The proposed mechanism of action is antibody-dependent cellular-mediated lysis following cell surface binding of alemtuzumab to the leukemic cells.@@14921054@MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate.@@YES@-@@NO REVIEW@@@@@ILEX Oncology (acquired by Genzyme) and LeukoSite (acquired by Millennium Pharma) entered into a distribution and development agreement with Schering AG (now Bayer Schering) in August 1999. The agreement grants Schering AG exclusive marketing and distribution rights to Campath in the United States, Europe and the rest of the world except Japan and East Asia, where LeukoSite and ILEX have retained these rights. Millenniusm sold Campath rights to ILEX in 2001 for US$140 million plus royalties. Initial rights licensed by LeukoSite from BTG.@FIRST-LINE@NCT00046683@284@MabCampath should be administered in escalating doses: 3 mg on day 1, 10 mg on day 2 and 30 mg on day 3 assuming that each dose is well tolerated. Thereafter, the recommended dose is 30 mg daily administered 3 times weekly on alternate days up to a maximum of 12 weeks. @EMEA approval [EMEA January 2008]@@@-@@7/1/2001@Occurrence of serious and, in rare instances fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia, of serious, and in some instances fatal, infusion reactions, and of serious, sometimes fatal bacterial, viral, fungal, and protozoan infections.@CAM307@No@-@# Histopathologically confirmed diagnosis of B-CLL with CD5, CD19, or CD23 positive clone. # Rai Stage I through IV disease with evidence of progression as evidenced by the presence of one or more of the following:1. Disease-related B symptoms (fever of greater than 38 celsius (100.5 F) for greater than or equal to 2 weeks without evidence of infection, night sweats without evidence of infection, weight loss >10% within previous 6 months. 2. Evidence of progression marrow failure as manifested by: a. decrease in hemoglobin to <11g/dL or b. decrease in platelet count to <100x10 to the ninth/L within the previous 6 months or c. decrease in absolute neutrophil count (ANC) to <1.0x10 to the ninth/L within the previous 6 months. 3. Progressive splenomegaly to >2 cm below the left costal margin or other organomegaly with progressive increase over 2 consecutive clinic visits greater than or equal to 2 weeks apart. 4. Progressive lymphadenopathy with at least 5 sites of involvement with either two nodes at least 2cm in longest diameter or one node greater than or equal to 5cm in longest diameter with progressive increase over 2 consecutive visits greater than or equal to weeks apart. 5. Progressive lymphocytes with an increase of >50% over a 2-month period, or an anticipated doubling time of less than 6 months. # Received no previous chemotherapy for B-CLL.@@@III@DISCONTINUED@@-@SNS@MabCampath was shown to be superior to chlorambucil as measured by the primary endpoint progression free survival. Overall response rate was 83.2% and 55.4% respectively, with complete response of 24.2% and 2.0% respectively. Time to alternative treatment was 23.3 months versus 14.7 months.@-@@@@MONO@ALEMTUZUMAB@@@@@ALEMTUZUMAB||||@BAYER HEALTHCARE@GENZYME@@@@BAYER HEALTHCARE|GENZYME|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|||||||@MABCAMPATH@@@@@MABCAMPATH||||@mAb@Humanised@CD52@@@mAb|Humanised|CD52||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@MULTI-CENTRE@OPEN-LABEL@NON-COMPARATIVE@@@@@Invalid Factory Price@@@11.7@week@11.7 week@@@@3@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/2/2015@@@650669@SOLUTION FOR PERFUSION (VIAL 1 ML)@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14918483@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@BAD VILBEL, GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918483@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@STADA ARZNEIMITTEL@@@@@STADA ARZNEIMITTEL||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@62.85@90.45@65.53@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@6.29@6.29@4789711@PATCH (MATRIX)@EURO@@@@@@@@50@MCG@50 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919227@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01DB07@L01D@YES@LAKE FOREST, ILLINOIS@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14919227@Mitoxantrone is indicated in the treatment of metastatic breast cancer, non-Hodgkin's lymphoma and adult acute non-lymphocytic leukaemia. Mitoxantrone has also been used in the palliation of non-resectable primary hepatocellular carcinoma.@@NO@@@NO REVIEW@@@@100%@@@@@Adult acute non-lymphocytic leukaemia: Single Agent Dosage in Relapse: The recommended dosage for remission induction is 12 mg/m2 of body surface area, given as a single intravenous dose daily for five consecutive days (total of 60 mg/m2). In clinical studies with a dosage of 12 mg/m2 daily for 5 days, patients who achieved a complete remission did so as a result of the first induction course. Combination Therapy: Mitoxantrone has been used in combination regimens for the treatment of acute non-lymphocytic leukaemia (ANLL). Most clinical experience has been with mitoxantrone combined with cytarabine. This combination has been used successfully for primary treatment of ANLL as well as in the treatment of relapse. An effective regimen for induction in previously untreated patients has been mitoxantrone 10-12 mg/m2 IV for 3 days combined with cytarabine 100 mg/m2 IV for 7 days (by continuous infusion). This is followed by second induction and consolidation courses as thought appropriate by the treating clinician. In clinical studies, duration of therapy in induction and consolidation courses with mitoxantrone have been reduced to 2 days, and that of cytarabine to 5 days. However, modification to the above regimen should be carried out by the treating clinician depending on individual patient factors.@EMA, September 2006@@@@@@Leukaemia: When used in high doses (over 14mg/m2 per day for 3 days) such as indicated for leukaemia, severe myelosupression will occur. It should only administered by experienced chemo physicians. Blood and blood products must be available to support patients during the expected period of medullary hypoplasia and severe myelosupression. Particular care should be given to assuring full haemotologic recovery before any consolidation therapy. Acute congestive heart failure may occasionally occur in patients treated with mitoxantrone for ANLL. In firstline comparative trials of mitoxantrone + cytarabine vs. daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with congestive heart failure in 6.5% of patients on each arm. A causal relationship between drug therapy and cardiac effects is difficult to establish in this setting sincemyocardial function is frequently depressed by the anemia, fever and infection, and hemorrhage that often accompany the underlying disease.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@MITOXANTRONE@@@@@MITOXANTRONE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CONCENTRATE FOR INFUSION@GB£@@@@@@@@20@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923980@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Drug: Lapatinib 1500 mg orally once a dayDrug: Letrozole 2.5 mg orally once a day@@L01XE07@L01X@NO@BRENTFORD, UNITED KINGDOM@6/1/2008@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14923980@TYKERB, a kinase inhibitor, is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.@Female@NO@@@NO REVIEW@@@NOVEMBER 2003-@Co-pay Tier 3. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@NCT00073528@1286@The recommended dose of TYKERB for hormone receptor positive, HER2 positive metastatic breast cancer is 1500 mg (6 tablets) given orally once daily continuously in combination with letrozole. When TYKERB is coadministered with letrozole, the recommended dose of letrozole is 2.5 mg once daily.@FDA, 29 January 2010@1/29/2010@@No@@12/1/2003@Decreases in left ventricular ejection fraction have been reported. Dose reduction in patients with severe hepatic impairment should be considered. Diarrhoea, including severe diarrhoea, has been reported during treatment. Lapatinib has been associated with interstitial lung disease and pneumonitis.@EGF30008@No@17-Jul@Subjects must have histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery [Singletary, 2002];Tumors that are ER+ and/or PgR+;Subjects will be considered ER+ or PgR+ if any assay [cytochemical, immunochemical, immunohistochemistry (IHC), or radioimmunoassay] of primary or secondary tumor tissue is positive;@@ADULTS@III@APPROVED@@TIER 4; prior authorisation required; dispensing limit applies; registered specialty drug.@MEDICARE@This study showed that for the primary endpoint of investigator-evaluated PFS in the HER2-positive population, PFS was statistically significantly longer in the letrozole plus lapatinib group compared with the letrozole plus placebo group. The HR was 0.71 (95% CI: 0.53, 0.96; stratified log rank p=0.019). Median PFS was 35.4 weeks in the letrozole plus lapatinib group compared with 13.0 weeks in the letrozole plus placebo group. As statistical significance was achieved in the HER2 positive population, testing was performed in the ITT population at the alpha 0.05 level as a secondary analysis. Investigator-evaluated PFS in the ITT population was also statistically significantly longer in the letrozole plus lapatinib group compared with the letrozole plus placebo group. The HR was 0.86 (95% CI: 0.76, 0.98; stratified log rank p=0.026). The median PFS was 47.0 weeks in the letrozole plus placebo group compared with 51.7 weeks in the letrozole plus lapatinib group. In the Safety population, 536 (86%) and 628 (96%) subjects reported AEs in the letrozole plus placebo and letrozole plus lapatinib groups, respectively. [J Clin Oncol. 2009 Nov 20;27(33):5538-46. Epub 2009 Sep 28.: http://www.ncbi.nlm.nih.gov/pubmed/19786658?dopt=Abstract]@The most frequently reported AEs were arthralgia, nausea, and diarrhea in the letrozole plus placebo group, and diarrhea, rash, and nausea in the letrozole plus lapatinib group. A total of 94 (15%) and 144 (22%) subjects had SAEs in the letrozole plus placebo and letrozole plus lapatinib groups, respectively. The most frequently reported SAEs were ejection fraction decreased, and vomiting in the letrozole plus placebo group, and ejection fraction decreased, diarrhea, and vomiting in the letrozole plus lapatinib. A total of 8 subjects in each treatment group had fatal SAEs. Three subjects had fatal events which were assessed as related to study medication, two subjects in the letrozole-placebo group (dyspnoea and myocardial infarction), and one subject in the letrozole-lapatinib group (hepatic function abnormal).@@@@COMBO@LAPATINIB@LETROZOLE@@@@LAPATINIB|LETROZOLE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TYKERB@FEMARA@@@@TYKERB|FEMARA|||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@PROGRESSION-FREE SURVIVAL@@@@@RESPONSE RATE@TOXICITIES@ERBB1/ERBB2 RECEPTOR@@@METASTATIC@ADVANCED@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@1@1@67369.58424@@@35.4@week@35.4 week@67369.58@67369.58@271.87@150@1@6796.77@@@@@@@@@@@@0.18@1@@mg@1500@1@@@@@@@@@@@8/2/2017@45.31@45.31@00078-0671-19@FILM-COATED TABLET@US$@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921277@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@HOLZKIRCHEN, GERMANY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14921277@Neoplastic Diseases: indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Psoriasis: indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis: indicated in the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Lymphomas: In Burkitt's tumor, Stages I-II, methotrexate has produced prolonged remissions in some cases. Recommended dosage is 10 to 25 mg/day orally for 4 to 8 days. In Stage III, methotrexate is commonly given concomitantly with other antitumor agents. Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods. Lymphosarcomas in Stage llI may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily. Mycosis fungoides (cutaneous T cell lymphoma): Therapy with methotrexate as a single agent appears to produce clinical responses in up to 50% of patients treated. Dosage in early stages is usually 5 to 50 mg once weekly. Dose reduction or cessation is guided by patient response and hematologic monitoring. Methotrexate has also been administered twice weekly in doses ranging from 15 to 37.5 mg in patients who have responded poorly to weekly therapy. Combination chemotherapy regimens that include intravenous methotrexate administered at higher doses with leucovorin rescue have been utilized in advanced stages of the disease.@@@@@@@1.Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks.2.Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. 3.Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs). 4.Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. 5.Methotrexate-induced lung disease is a potentially dangerous lesion, which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation. 6.Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. 7.Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. 8.Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication. 9.Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy. 10.Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. 11.Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@MTX HEXAL@@@@@MTX HEXAL||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@24.9@42.47@26.39@@@@@@@@@@1@@@@@@@@@@@@@@@@8/1/2017@24.9@24.9@9882993@SOLUTION - INJECTION (PREFILLED SYRINGE 1 ML)@EURO@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14925033@Onco@@@@@300f1015ntsdm@@@@@@The initial dose of Zofran Injection ranged from 0.04 to 0.87 mg/kg for a total dose of 2.16 to 12 mg. This was followed by the administration of Zofran Tablets ranging from 4 to 24 mg daily for 3 days@@A04AA01@A04A@NO@BRENTFORD, UNITED KINGDOM@@@Ondansetron is a potent, highly selective 5HTs receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomoting reflex by activating vagal afferents via 5HTs receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.@@14925033@Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2; prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy; prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; prevention of postoperative nausea and/or vomiting.@@NO@Nov-96@@NO REVIEW@@@@65%@@@@182@Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin =50 mg/m2. Multiday, single-dose administration of a 24 mg dosage has not been studied. Pediatric Use: There is no experience with the use of a 24 mg dosage in pediatric patients. Geriatric Use: The dosage recommendation is the same as for the general population. Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is one 8-mg tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.@1-Mar-90@3/1/1990@@@@@Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@182 PEDIATRIC PATIENTS 4 TO 18 YEARS OLD WITH CANCER WHO WERE GIVEN A VARIETY OF CISPLATIN OR NONCISPLATIN REGIMENS.@PAEDIATRIC@@PEDIATRIC STUDIES; THREE OPEN-LABEL, UNCONTROLLED, FOREIGN TRIALS@APPROVED@@65%; FREE PRICING IN HOSPITALS@HAUTE AUTORITÉ DE SANTÉ@58% of the 170 evaluable patients had a complete response (no emetic episodes) on day 1. Two studies showed the response rates for patients less than 12 years of age who received Zofran Tablets 4 mg 3 times a day to be similar to those in patients 12 to 18 years of age who received 8 mg 3 times daily. Thus, prevention of emesis in these pediatric patients was essentially the same as for patients older than 18 years of age. Overall, they were well tolerated in these paediatric patients.@@@@@MONO@ONDANSETRON HYDROCHLORIDE@@@@@ONDANSETRON HYDROCHLORIDE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@ZOPHREN@@@@@ZOPHREN||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN-LABEL@UNCONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+12@SOLUTION FOR INJECTION, PRE-FILLED SYRINGE, 4 ML@EURO@@@@@@@@8@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920093@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@90mg pamidronate or placebo as monthly 4-hour intravenous infusion for 9 months@@M05BA03@M05B@NO@ULM, GERMANY@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14920093@Hypercalcemia of Malignancy: in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget's Disease: Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget's disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase = 3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget's disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by = 50% in at least 50% of patients, and by = 30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget's disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma: Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated.@@NO@@@NO REVIEW@@@@@@@@392@The recommended dose of pamidronate disodium in patients with osteolytic bone lesions of multiple myeloma is 90 mg administered as a 4-hour infusion given on a monthly basis. Patients with marked Bence-Jones proteinuria and dehydration should receive adequate hydration prior to pamidronate disodium infusion.The recommended dose of pamidronate disodium inpatients with osteolytic bone metastases is 90 mg administered over a 2-hour infusion given every 3 to 4 weeks. Pamidronate disodium has been frequently used with doxorubicin, fluorouracil, cyclophosphamide, methotrexate, mitoxantrone, vinblastine, dexamethasone, prednisone, melphalan, vincristine, megesterol, and tamoxifen. It has been given less frequently with etoposide, cisplatin, cytarabine, paclitaxel, and aminoglutethimide.@FDA, February 2005@@@@@@Due to risk of significant deterioration in renal function which can progress to renal failure, single doses of pamidronate should not exceed 90mg. Bisphosphonates have been associated with renal toxicity. Serum creatinine should be assessed before treatment.@LABEL@No@5-Oct@392 PATIENTS WITH ADVANCED MULTIPLE MYELOMA@@@@APPROVED@@@@The proportion of patients developing any SRE was significantly smaller in the pamidronate disodium group (24% vs 41%, P<0.001), and the mean skeletal morbidity rate (#SRE/year) was significantly smaller for pamidronate disodium patients than for placebo patients (mean: 1.1 vs 2.1, P<.02). The times to the first SRE occurrence, pathologic fracture, and radiation to bone were significantly longer in the pamidronate disodium group (P=.001, .006, and .046, respectively). Fewer pamidronate disodium patients suffered any pathologic fracture (17% vs 30%, P=.004) or needed radiation to bone (14% vs 22%, P=.049).@@@@@MONO@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Bone Metastases@Myeloma@Breast Cancer@@@Bone Metastases|Myeloma|Breast Cancer|||||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@SKELETAL-RELATED EVENTS@@@@@@@@@@@@@@@DOUBLE-BLIND@RANDOMISED@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR PERFUSION@US$@@@@@@@@270@MG@9 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15360705@Onco@@@@@300f1008ntsdm@@@@@@Patients randomized to the treatment arm received AFINITOR Tablets at a starting dose of 4.5 mg/m2 daily, with subsequent dose adjustments as needed to achieve and maintain everolimus trough concentrations of 5 to 15 ng/mL as tolerated. AFINITOR/matched placebo treatment continued until disease progression or unacceptable toxicity.@@L01XE10@L01X@@BASEL, SWITZERLAND@10/1/2014@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15360705@Indicated for the treatment of pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.@Both@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@NCT00789828@117@The recommended starting dose is 3 mg/m2, once daily. Continue treatment until disease progression or unacceptable toxicity occurs.@@@@Yes@@8/1/2009@@CRAD001M2301/2007-006997-27@No@@Eligible patients had at least one SEGA lesion ≥ 1.0 cm in longest diameter on MRI based on local radiology assessment and one or more of the following: serial radiological evidence of SEGA growth, a new SEGA lesion ≥ 1 cm in longest diameter, or new or worsening hydrocephalus.@@@III@APPROVED@@@NHI@SEGA responses were observed in 27 of the 78 patients (35 percent, 95 percent CI: 24, 46) treated with everolimus. None of the 39 patients (0 percent, 95 percent CI: 0, 9) treated with placebo (p < 0.0001) demonstrated SEGA responses. With a median follow-up duration of 8.4 months for the overall study population, all responses were ongoing and the median response duration was 5.3 months (range: 2.1 to 8.4 months) in patients treated with everolimus. [FDA, 29 October 2012, http://www.cancer.gov/about-cancer/treatment/drugs/fda-everolimus]@In the randomized trial, the most common adverse reactions in patients receiving everolimus (incidence at least 20 percent) were stomatitis, respiratory tract infection, pyrexia, vomiting, rash, and behaviorial disturbances, including anxiety and aggression. The most common (at least 2 percent) grade 34 adverse reactions were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea. Serious adverse events were reported for 19 (24 percent) of the patients treated with everolimus and 5 (13 percent) of the patients who received the placebo during the doubleblind period of the randomized study[RC2] . The most common serious adverse event (reported in at least 3 patients and occurring more frequently in patients treated with everolimus) was pyrexia. Serious adverse events due to infections were more common in patients younger than 3 years of age; a total of 6 of 13 patients younger than 3 years who received everolimus had at least one serious adverse event due to infection, compared with 2 of 7 patients younger than 3 years who received placebo. No deaths occurred in either treatment group.[FDA, 29 October 2012, http://www.cancer.gov/aboutcancer/treatment/drugs/fdaeverolimus]@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@AFINITOR@@@@@AFINITOR||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RESPONSE RATE@@@@@RESPONSE RATE@@@@@@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@RANDOMISED@@@1.2@m²@1376534.493@@@5.3@month@5.3 month@1376534.49@1376534.49@8539.04@1@0.0091@5929.89@6992.8@@@@@@@@@@@2371.96@1@@mg/m²@3@1@@@@@@@@@@@8/30/2017@5929.89@5929.89@4291023F2027@TABLET@YEN@@@@@@@@2.5@MG@2.5 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
15299311@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L04AX06@L04A@@SUMMIT, NEW JERSEY@5/1/2013@@Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent.@@15299311@A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma@@@@@NO REVIEW@@@@@@@NCT01311687@426@@FDA, 8 February 2013@2/8/2013@@@@3/1/2011@@CC-4047-MM-003@No@@@@@III@APPROVED@@@@Study results demonstrated significantly improved median progression-free survival of 15.7 weeks (p<0.001) for patients with rrMM who were treated with pomalidomide plus low-dose dexamethasone, compared with 8.0 weeks (p<0.001) for those treated with high-dose dexamethasone only (data cutoff 07/09/12).1 Median overall survival was also significantly improved for the pomalidomide plus low-dose dexamethasone arm, compared with high-dose dexamethasone only, (median not reached vs. 34 weeks; p<0.001). [Celgene, 9 August, 2013, http://newsroom.celgene.com/press-release/oral-anti-cancer-therapy-pomalidomide-now-approved-european-commission-treatment-patie ]   The DSMB determined MM-003 met the primary endpoint of improvement in progression-free survival (PFS) at the PFS final analysis. Additionally, at the OS interim analysis, the study crossed the superiority boundary for overall survival (OS), a key secondary endpoint that the study was also powered to evaluate. Improvements in PFS and OS were both highly statistically significant and clinically meaningful. As a result, the DSMB recommended that patients who had not yet progressed in the high-dose dexamethasone arm should be crossed-over to the pomalidomide plus low-dose dexamethasone arm. [Celgene, 23 October 2012, http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1748565&highlight= ]@The most commonly reported Grade 3 or 4 adverse reactions included neutropenia, thrombocytopenia and infections. [Celgene 9 August 2013]  Safety results observed in MM-003 were consistent with previous studies of pomalidomide in relapsed/refractory multiple myeloma patients. Full data from the study are being prepared for submission to a future medical meeting for presentation. [Celgene, 23 Ocotber 2012]@@@@BOTH@POMALIDOMIDE@@@@@POMALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@POMALYST@CC-4047@@@@POMALYST|CC-4047|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@TIME TO DISEASE PROGRESSION@@@@@SAFETY@RESPONSE@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@PARALLEL ASSIGNMENT@@@@1@1@21639.97343@@@3.6@month@3.6 month@21639.97@21639.97@197.63@21@1@14525.78@@@@@@@@@@@@691.7@28@@mg@4@2@@@@@@@@@@@8/2/2017@691.7@691.7@59572-0501-21@CAPSULE@US$@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918454@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@GREIFSWALD, GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918454@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@RIEMSER ARZNEIMITTEL@@@@@RIEMSER ARZNEIMITTEL||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@20@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@PATCH, TRANSDERMAL@EURO@@@@@@@@25@MCG@25 MCG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16387366@Onco@@@@@300f1010ntsdm@@@@@@@@L01XC07@L01X@@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16387366@Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations@@YES@@@@@@@100%@@FIRST-LINE@@152@The recommended dose of Avastin when used in addition to erlotinib is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.It is recommended that the treatment with Avastin in addition to erlotinib is continued until disease progression.@EMA, 2 June 2016@6/2/2016@@No@@@@JO25567@No@@@EGFR activating mutations@@II@APPROVED@@@NHS@@@@@@COMBO@BEVACIZUMAB@ERLOTINIB@@@@BEVACIZUMAB|ERLOTINIB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AVASTIN@TARCEVA@@@@AVASTIN|TARCEVA|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@REPONSE RATE@DISEASE CONTROL RATE@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@MULTI-CENTRE@@@76.5@kg@64528.81278@@@16@month@16 month@64528.81@64528.81@132.6@1@1.299@242.66@@@@@@@@@@@@2.43@21@@mg/kg@15@1@@@@@@@@@@@7/28/2017@242.66@242.66@9.15E+15@CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION, 4 ML@GB£@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917733@Onco@@@@@300f1015ntsdm@@@@@@Ethyol 200mg/m2 with or without standard fractionated radiation.@@V03AF05@V03A@NO@KENILWORTH, NEW JERSEY@@@Ethyol is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite. This metabolite is believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. The ability of Ethyol to differentially protect normal tissues is attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of normal tissues relative to tumor tissue, which results in a more rapid generation of the active thiol metabolite as well as a higher rate constant for uptake into cells. The higher concentration of the thiol metabolite in normal tissues is available to bind to, and thereby detoxify, reactive metabolites of cisplatin. This thiol metabolite can also scavenge reactive oxygen species generated by exposure to either cisplatin or radiation.@@14917733@Indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer; to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands@@YES@@@NO REVIEW@@@@100%@>> Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009] >> Pinnacle Biologics purchased rights for Ethyol in Western Europe, Turkey and Israel. [Pinnacle, 20 February 2008]       >> AstraZeneca acquires MedImmune in US$15 billion deal. [AstraZeneca, 23.04.2007]      >> Schering-Plough licensed Latin America, Far East, and (in May 1993) European rights from U.S. Bioscience (acquired by MedImmune).@@@315@For Reduction of Moderate to Severe Xerostomia from Radiation of the Head and Neck: The recommended dose is 200 mg/m2 administered once daily as a 3-minute i.v. infusion, starting 15-30 minutes prior to standard fraction radiation therapy (1.8-2.0 Gy).@@@7/1/2000@@@@1. Limited data are currently available regarding the preservation of antitumor efficacy when Ethyol is administered prior to cisplatin therapy in settings other than advanced ovarian cancer. Although some animal data suggest interference is possible, in most tumor models the antitumor effects of chemotherapy are not altered by amifostine. Ethyol should not be used in patients receiving chemotherapy for other malignancies in which chemotherapy can produce a significant survival benefit or cure (e.g., certain malignancies of germ cell origin), except in the context of a clinical study. 2. Ethyol should not be administered in patients receiving definitive radiotherapy, except in the context of a clinical trial, since there are at present insufficient data to exclude a tumor-protective effect in this setting. 3. Patients who are hypotensive or in a state of dehydration should not receive Ethyol.@LABEL@No@@@@@III@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@In the acute group, the incidence of Grade 2 or higher xerostomia was 51% in Ethyol patients versus 78% in RT. In late-stage patients, the rate was 35% and 57% respectively.@@@@@MONO@AMIFOSTINE@@@@@AMIFOSTINE||||@SCHERING-PLOUGH@ASTRAZENECA@PINNACLE BIOLOGICS@@@SCHERING-PLOUGH|ASTRAZENECA|PINNACLE BIOLOGICS||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ETHYOL@@@@@ETHYOL||||@Detoxifying Agent@@@@@Detoxifying Agent||||@XEROSTOMIA@@@@@@@@@@@@@@@RANDOMISED@CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@152@@@@@@@@@@@@0.41@@@@@@@@@@@@@@@@8/2/2017@152@152@9219390R@POWDER FOR SOLUTION IN PERFUSION (VIAL 10 ML)@EURO@@@@@@@@375@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
15000099@Onco@@@@@300f1020ntsdm@@@@@@Experimental: crizotinib 250mg orally continuous twice daily dosing Active Comparator: pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice@@L01XE04@L01X@@NEW YORK, NEW YORK@12/1/2014@@@@15000099@XALKORI is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).@@YES@25-Mar-13@3/25/2013@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@SECOND-LINE@NCT00932893@347@The recommended dose of XALKORI is 250 mg orally, twice daily until disease progression or no longer tolerated by the patient. The recommended dose of XALKORI in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis is 250 mg orally, once daily.@EMA, 23 October 2012@10/23/2012@@NO@@9/1/2009@@PROFILE 1007@No@@Histologically or cytologically proven diagnosis of non-small cell lung cancer positive for the ALK fusion gene (test provided by a central laboratory). Must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug@(ALK)-positive@@III@APPROVED@@@SSN@The PROFILE 1007 study met its primary endpoint, demonstrating that crizotinib significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with ALK-positive advanced NSCLC. PROFILE 1007 is the first randomized Phase 3 study in ALK-positive advanced NSCLC patients. [Pfizer 19 June 2012 http://press.pfizer.com/press-release/pfizer-announces-positive-results-phase-3-study-profile-1007-evaluating-xalkori-crizot ]@The adverse events observed on crizotinib and chemotherapy in PROFILE 1007 were generally consistent with their respective known adverse event profiles.[Pfizer, June 2012]@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE RATE@OVERALL SURVIVAL@@@@ADVANCED@@@@@OPEN-LABEL@RANDOMISED@PARALLEL ASSIGNMENT@@@1@1@57574.95302@@@7.7@month@7.7 month@57574.95@57574.95@245.83@60@1.1229@5900@9737.36@6165.56@@@@@@@@@@0.49@1@@mg@500@1@@@@@@@@@@@6/7/2017@98.33@98.33@42549016@CAPSULE@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14920433@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920433@Indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.@@NO@@@NO REVIEW@@@@100%@@@@411@The recommended dose of Glivec is 600 mg/day for adult patients with Ph+ ALL.@EMA, November 2003@@@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@@@ADULT@@@APPROVED@@NO NICE REVIEW@NHS@Complete Haematologic response rate = 19% ; Major cytogenetic response rate = 35% ; Complete cytogenetic response rate = 21% ; Partial cytogenetic response rate = 14% for the 43 patients. The median duration of hematologic response was 3.4 months and the median duration of MCyR was 2.3 months.@The adverse reactions were similar for Ph+ ALL as for Ph+ CML. The most frequently reported drug-related adverse reactions reported in the Ph+ ALL studies were mild nausea and vomiting, diarrhea, myalgia, muscle cramps and rash, which were easily manageable. Superficial edema was a common finding in all studies and were described primarily as periorbital or lower limb edemas. These edemas were rarely severe and may be managed with diuretics, other supportive measures, or in some patients by reducing the dose of Gleevec.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@RELAPSED@REFRACTORY@@@@@@@@@1@1@8437.412848@@@2.85@month@2.85 month@8437.41@8437.41@97.33@30@1.299@1946.67@@@@@@@@@@@@0.16@1@@mg@600@1@@@@@@@@@@@7/28/2017@64.89@64.89@7.32E+15@FILM-COATED TABLET@GB£@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16384277@Onco@@@@@300f1008ntsdm@@@@@@Patients received panitumumab at a dose of 6 mg/kg given once every 2 weeks plus best supportive care or BSC alone@@L01XC08@L01X@@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@16384277@Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@SECOND-LINE@NCT00113763@463@The recommended dose of Vectibix is 6 mg/kg of bodyweight given once every two weeks.@MHLW, 16 April 2010@4/16/2010@@No@@@@"20020408 [""408 Trial""]"@No@@PATIENTS WITH EGFR-EXPRESSING MCRC WHO WERE REQUIRED TO HAVE PROGRESSED ON OR FOLLOWING TREATMENT WITH A REGIMEN(S) CONTAINING A FLUOROPYRIMIDINE, OXALIPLATIN, AND IRINOTECAN ((CONFIRMED FOR 75% OF PATIENTS), TO HAVE EGFR EXPRESSION DEFINED AS AT LEAS@@@III@APPROVED@@@NHI@@@@@@MONO@PANITUMUMAB@@@@@PANITUMUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@@@@@VECTIBIX||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@INTERNATIONAL@RANDOMISED@CONTROLLED@@76.5@kg@1975041.014@@@96@day@96 day@1975041.01@1975041.01@20573.34@1@0.0091@251003.76@295995@@@@@@@@@@@627.51@14@@mg/kg@6@1@@@@@@@@@@@8/30/2017@251003.76@251003.76@4291417A2027@IV INFUSION - 20 ML@YEN@@@@@@@@400@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918987@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@90 patients in the safety study and 81 in the dosing study; following enrollment, patients were HLA typed; A2 and A3 positive patients were then placed in the treatment arm while all other HLA types were placed in the observation arm. A total of 90 patients received NeuVax while 81 were in the observation arm of the study. @@-@-@-@SCOTTSDALE, ARIZONE@@@"NeuVax is a peptide-based immunotherapy that recruits the immune system to fight cancer and activates ""Killer T-cells"" to target tumors. NeuVax specifically targets cancer while leaving normal, healthy tissues unharmed. The key to NeuVax is a small peptide called E75 that is derived from HER2/neu, a protein expressed by tumors. Unlike existing monoclonal antibody therapy which requires frequent, ongoing, intravenous (I.V.) infusion, NeuVax can produce continuing activation of the immune system and therapeutic levels of Killer T-cells with a once monthly intradermal (under the skin) dosing schedule that is less expensive and more convenient for both the patient and physician."@@14918987@-@@-@-@@NO REVIEW@@@@-@-@-@-@171@-@October 2007; Apthera met with the FDA to review the development program of Apthera's NeuVax for the treatment of breast cancer. Apthera and FDA discussed issues relevant to the clinical studies conducted to date, the upcoming Special Protocol Assessment (SPA) submission process and the Company's planned Phase II/III study with NeuVax.@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Subset analysis review of 163 patients with breast cancer enrolled in the NeuVax trial to determine whether the level of HER2 expression affected response. Of the patients assessed, 92 underwent treatment. Within the treatment group, 56 (66 percent) were defined as HER2 low-expressors. The control group included 44 (67 percent) low-expressors. Low HER2 expressing patients maintained circulating, E75 peptide reactive T-cells after 1 year whereas patients with HER2 over-expressing tumors returned to pre-immunization levels. At a median follow-up of 30 months, disease recurrence was substantially reduced for treated patients with low HER2 expression. Low-expressors by IHC in the treatment arm of the study experienced 8 percent recurrence, compared with 21 percent for patients in the control arm. Furthermore, the mortality rate among low-expressors by IHC with recurrent disease was 0 percent among treated patients, versus 20 percent among controls (p=0.04). SOURCE: Apthera/AACR, 14 April 2008Toxicity was minimal with local reactions being 86% Grade I and 14% Grade II. Systemic toxicity was 16% Grade 0, 70% Grade I, 13% Grade II, and 1% Grade III. All patients demonstrated in vivo immunologic responses as well as in vivo DTH responses post-treatment. Clinical recurrence rate was 5.6% (5/90) for treated patients versus 14.8% (12/81) for the observation patients (p=0.04).@-@@@@-@E75@GM-CSF@@@@E75|GM-CSF|||@APTHERA@@@@@APTHERA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NEUVAX@@@@@NEUVAX||||@Vaccine@@@@@Vaccine||||@SAFETY@IMMUNE RESPONSE@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15044826@Onco@@@@@300f1015ntsdm@@@@@@Patients received panitumumab at a dose of 6 mg/kg given once every 2 weeks plus best supportive care or BSC alone@@L01XC08@L01X@YES@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@15044826@Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.@@YES@30-Apr-08@4/30/2008@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@SECOND-LINE@NCT00113763@463@The recommended dose is 6 mg/kg administered over 60 minutes as an intravenous infusion every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.@EMA, 3 December 2007@12/3/2007@9/1/2008@No@@@Dermatologic findings (dermatitis, pustule formation and exfoliative rash), and deaths secondary to bacterial infection and sepsis occured at higher doses than the recommended dose. Severe infusion reactions occurred with the administration of Vectibix which were identified by reports of anaphylactic reaction, bronchospasm, fever, chills, and hypotension. Pulmonary fibrosis occurred in less than 1% of patients enrolled in clinical studies. It can cause diarrhea, and when used in combination with irinotecan, appears to increase the incidence and severity of chemotherapy-induced diarrhea. It can also cause electrolyte depletion.@"20020408 [""408 Trial""]"@No@PATENT STATUS REMAINS IN DISPUTE; AMGEN LICENSED THE SCHLESSINGER PATENT ('866) UNTIL 2017 IN SEPTEMBER 2006 FROM YEDA.@PATIENTS WITH EGFR-EXPRESSING MCRC WHO WERE REQUIRED TO HAVE PROGRESSED ON OR FOLLOWING TREATMENT WITH A REGIMEN(S) CONTAINING A FLUOROPYRIMIDINE, OXALIPLATIN, AND IRINOTECAN ((CONFIRMED FOR 75% OF PATIENTS), TO HAVE EGFR EXPRESSION DEFINED AS AT LEAS@@@III@APPROVED@@ASMR V: 30 April 2008. [HAS, http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/vectibix_ct_5342.pdf]@HAUTE AUTORITÉ DE SANTÉ@Based upon IRC determination of disease progression, a statistically significant prolongation in PFS was observed in patients receiving Vectibix compared to those receiving BSC alone. The mean PFS was 96 days in the Vectibix arm and 60 days in the BSC-alone arm. In a series of sensitivity analyses, including one adjusting for potential ascertainment bias, ie, assessment for progressive disease at a nonstudy specified time point, PFS was still significantly prolonged among patients receiving Vectibix as compared to patients receiving BSC alone. There were 19 partial responses identified by the IRC in patients randomized to Vectibix for an overall response of 8% (95% CI: 5.0%, 12.6%). No patient in the control arm had an objective response identified by the IRC. The median duration of response was 17 weeks (95% CI: 16 weeks, 25 weeks). There was no difference in overall survival observed between the study arms.@In a single-arm study of 19 patients receiving Vectibix in combination with IFL, the incidence of NCI-CTC grade 3-4 diarrhea was 58%; in addition, grade 5 diarrhea occurred in 1 patient. In a single-arm study of 24 patients receiving Vectibix plus FOLFIRI, the incidence of NCI-CTC grade 3 diarrhea was 25%. Pulmonary fibrosis occurred in less than 1% (2/1,467) of patients in clinical trials of Vectibix. Following the initial fatality, patients with a history of interstitial pneumonitis, pulmonary fibrosis, and evidence of interstitial pneumonitis were excluded from clinical studies. Therefore, the estimated risk in such patients is uncertain. Permanently discontinue Vectibix therapy in patients developing interstitial lung disease, pneumonitis, or lung infiltrates. In the randomized, controlled clinical trial, median magnesium levels decreased by 0.1 mmol/L in the Vectibix arm. Additionally, hypomagnesemia (NCI-CTC grade 3 or 4) requiring electrolyte repletion occurred in 2% of patients 6 weeks or longer after the initiation of Vectibix. In some patients, hypomagnesemia was associated with hypocalcemia. Patients should be periodically monitored, and treated appropriately, for hypomagnesemia and hypocalcemia during and for 8 weeks after the completion of Vectibix therapy.@@@@MONO@PANITUMUMAB@@@@@PANITUMUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@@@@@VECTIBIX||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@INTERNATIONAL@RANDOMISED@CONTROLLED@@76.5@kg@11503.85143@@@96@day@96 day@11503.85@11503.85@119.83@1@1.1511@365.5@@@@@@@@@@@@3.66@14@@mg/kg@6@1@@@@@@@@@@@8/2/2017@365.5@365.5@9307183T@SOLVENT FOR PERFUSION - 5 ML@EURO@@@@@@@@100@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
15360113@Onco@@@@@300f1010ntsdm@@@@@@Experimental: CometriqPlacebo: Comparator@@L01XE26@L01X@@@12/1/2014@@Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, and metastatic progression of cancer.Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor)receptors. In addition, cabozantinib inhibits other tyrosine kinases including RET, the GAS6 receptor (AXL), the stem cell factor receptor (KIT), and Fms-like tyrosine kinase-3 (FLT3).@@15360113@Indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.@Both@NO@@@NO REVIEW@@@July 2008-december 2014@100%@@@NCT00704730@330@The recommended dose of COMETRIQ is 140 mg once daily, taken as one 80 mg orange capsule and three 20 mg grey capsules. Treatment should continue until the patient is no longer clinically benefiting fromtherapy or until unacceptable toxicity occurs.@EMA, 21 March 2014@3/21/2014@@Yes@@6/1/2008@@XL184-301@No@@The subject has a histologically confirmed diagnosis of MTC that cannot be removed by surgery, is locally advanced, or has spread in the body.The subject is at least 18 years old.The subject has an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.The subject has documented worsening of disease (progressive disease) at screening compared with a previous CT scan or MRI image done within 14 months of screening.@@ADULTS@III@APPROVED@@@NHS@The safety and effectiveness of Cometriq were established in a clinical study involving 330 patients with medullary thyroid cancer. Treatment with Cometriq increased the length of time a patient lived without the cancer progressing (progression-free survival) and, in some patients, reduced the size of tumors (response rate).Patients who were given Cometriq lived an average of 11.2 months without tumor growth compared with an average of four months in patients receiving a sugar pill (placebo). Results also showed that 27 percent of patients treated with Cometriq had reductions in tumor size lasting an average of nearly 15 months, while patients who received a placebo saw no reductions. Treatment with Cometriq did not extend patients' lives.[FDA, 29 November 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm]@The most common side effects were diarrhea; inflammation or sores of the mouth; redness, pain, or swelling of the digits (hand-foot syndrome); weight loss; loss of appetite; nausea; fatigue; oral pain; graying or loss of hair color; bad taste; new or worsening high blood pressure; abdominal pain and constipation. The most common laboratory abnormalities included increases in liver enzymes, low calcium and phosphorus, decreased white blood cells and platelets.[FDA, 29 November 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm]@@@@MONO@CABOZANTINIB@@@@@CABOZANTINIB||||@TMC PHARMA SERVICES@@@@@TMC PHARMA SERVICES||||@World@@@@@World|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@COMETRIQ@@@@@COMETRIQ||||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@OBJECTIVE RESPONSE RATE@@@@METASTATIC@UNRESECTABLE@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@1@Invalid Strength@@@11.2@month@11.2 month@@@@56@1.299@4800@@@@@@@@@@@@@1@@mg@140@1@@@@@@@@@@@7/28/2017@85.71@85.71@2.80E+16@HARD CAPSULE@GB£@@@@@@@@@@20 MG + 80 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924093@Onco@@@@@300f1020ntsdm@@@@@@Pazopanib versus placebo@@L01XE11@L01X@-@BRENTFORD, UNITED KINGDOM@@@Pazopanib is an investigational, oral, once-daily angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit. VEGF and PDGF are growth factors critical to the development and growth of blood vessels - a process known as angiogenesis. Angiogenesis plays a pivotal role in the growth and spread of several tumour types, with VEGF and PDGF overexpression linked to multiple cancers including cancers of the liver, lung, breast, kidney, bladder, ovaries, and colon. By inhibiting VEGFR, PDGFR, and c-kit pazopanib may stop or slow the rate of tumour growth and development. Pazopanib is currently being studied in a number of different tumour types; clinical trials are currently underway in renal cell carcinoma (Phase III), breast cancer (Phase III in inflammatory breast cancer), ovarian cancer, STS, NSCLC, cervical cancer and other solid tumours. It is being evaluated as a monotherapy, in combination with targeted therapies and in combination with cytotoxic chemotherapy.@@14924093@Votrient is used to treat advanced renal cell carcinoma (a type of kidney cancer). It is used in patients who have not received any previous treatment or in patients who have already been treated for their advanced disease with cytokines.@@YES@-@@NO REVIEW@@@@@-@-@NCT00334282@400@-@EMA, 15 June 2010@6/15/2010@@-@@3/1/2006@-@VEG105192@No@-@-@@@III@APPROVED@@@@>>Progression free survival in the pazopanib treated group was 9.2 months compared to 4.2 months in the placebo group.[GSK 1 June 2009] >> The complete results from the Phase III study will be presented at an upcoming medical conference. [GSK, 4 March 2009] >> Interim results: preliminary week 12 response rate was 27%; stable disease was observed in 46% of patients for a total disease control rate of 73%. The most frequent adverse events were diarrhea, fatigue, hair color change, nausea and hypertension, with a low incidence of hand-foot syndrome (10%), rash (12%), haemorrhage (9%), and mucositis (5%). [GSK/ASCO June 2007].@>>The majority of adverse events were mild to moderate, the most common (incidence =20%) being diarrhea, hypertension, hair color change, nausea, anorexia, and vomiting.  The most common grade 3/4 adverse events (incidence >3%) were diarrhea (4%), hypertension (4%), and asthenia (3%). The most common laboratory abnormalities (incidence =50%) were elevated levels of liver enzymes known as transaminase, with elevated ALT as the most common grade 3/4 event (12%).1 Investigator-reported serious adverse events included liver-related events (3%), arterial thrombotic events (3%) and hemorrhage (3%).4In this study, approximately 4% of patients on treatment compared to 3% of patients on placebo had a fatal event.  Investigators attributed death due to study drug in approximately 1.4% of patients in the treatment arm. [GSK 1 June 2009] >>The most common adverse events (AEs) associated with pazopanib treatment include diarrhoea, hypertension, hair colour change, nausea, anorexia and vomiting.@@@@MONO@PAZOPANIB@@@@@PAZOPANIB||||@GSK@@@@@GSK||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@VOTRIENT@GW-786034@@@@VOTRIENT|GW-786034|||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@1@1@30586.97773@@@9.2@month@9.2 month@30586.98@30586.98@109.31@30@1.1229@819.8@1353@856.7@@@@@@@@@@0.14@1@@mg@800@1@@@@@@@@@@@6/7/2017@27.33@27.33@39945011@FILM COATED TABLET@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921818@Onco@@@@@300f1020ntsdm@@@@@@Patients received either Neulasta 6 mg, or Filgratrim 5 mcg/kg/day associated with a chemotherapy regimen that employed doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer.@@L03AA13@L03A@NO@THOUSAND OAKS, CALIFORNIA@@@Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Pegfilgrastim is a covalent conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20 kd polyethylene glycol (PEG) molecule. Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Similarly to filgrastim, neutrophils produced in response to pegfilgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As with other haematopoietic growth factors, G-CSF has shown in vitro stimulating properties on human endothelial cells. G-CSF can promote growth of myeloid cells, including malignant cells, in vitro and similar effects may be seen on some non-myeloid cells in vitro.@@14921818@Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).@@NO@-@@NO REVIEW@@@@100%@-@-@-@157@One 6 mg dose (a single pre-filled syringe) of Neulasta is recommended for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy.@EMA, 22 August 2002@8/22/2002@@-@@@Rare cases of splenic rupture, including some fatal cases, have been reported following the administration of Neulasta. Adult respiratory distress syndrome (ARDS) has been reported in neutropenic patients with sepsis receiving Neulasta, and is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. Allergic reactions to Neulasta, including anaphylaxis, skin rash, and urticaria, have been reported. Severe sickle cell crises have been associated with the use of Neulasta in patients with sickle cell disease. Severe sickle cell crises, in some cases resulting in death, have also been associated with Filgrastim, the parent compound of pegfilgrastim.@STUDY 1@No@-@157 WOMEN WITH BREAST CANCER WERE RANDOMISED TO RECEIVE A SINGLE SUBCUTANEOUS INJECTION OF NEULASTA 6 MG ON DAY 2 OF EACH CHEMOTHERAPY CYCLE OR DAILY SUBCUTANEOUS FILGRASTIM 5 MCG/KG/DAY BEGINNING ON DAY 2 OF EACH CHEMOTHERAPY CYCLE.@@@-@APPROVED@@-@SSN@The mean days of severe neutropaenia of Neulasta-treated patients did not exceed that of Filgrastim-treated patients by more than one day in cycle 1 of chemotherapy. The rate of febrile neutropaenia were comparable for Neulasta and Filgrastim. Mean days of severe neutropaenia reached 1.8 days for the Neulasta treatment group and 1.6 days for the filgastrim treatment group (difference in means= 0.2 - 95% CI: -0.2, 0.6).@-@@@@MONO@PEGFILGRASTIM@@@@@PEGFILGRASTIM||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@NEULASTA@@@@@NEULASTA||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@DURATION OF SEVERE NEUTROPAENIA@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@902.51@1489.5@943.13@@@@@@@@@@150.42@@@@@@@@@@@@@@@@6/7/2017@902.51@902.51@35716036@SOLUTION FOR INJECTION 0.6 ML (PRE-FILLED SYRINGE WITH NEEDLE PROTECTION)@EURO@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922427@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@-@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14922427@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@-@@NO REVIEW@@@@60%@-@-@-@-@First-line chemotherapy of breast carcinoma: When used in combination with doxorubicin (50 mg/m2), paclitaxel should be administered 24 hours after doxorubicin. The recommended dose of paclitaxel is 220 mg/m2 administered intravenously over a period of 3 hours, with a 3-week interval between course@6/7/2004@@@-@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@-@-@@@-@DISCONTINUED@@NO REVIEW@SNS@NO LABELLED TRIAL@-@@@@-@PACLITAXEL@@@@@PACLITAXEL||||@NORTON HEALTHCARE@@@@@NORTON HEALTHCARE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@PAXENE@@@@@PAXENE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@1@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/2/2015@@@748210@INTRAVENOUS INJECTION VIAL, 25 ML@EURO@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15407470@Onco@@@@@300f1015ntsdm@@@@@@1000 MG IV ON DAYS 1, 8 AND 15 OF CYCLE 1 AND ON DAY 1 OF CYCLES 2-8 (21-DAY CYCLES) OR CYCLES 2-6 (28-DAY CYCLES); FOLLOWED BY 1000 MG IV EVERY 2 MONTHS IN RESPONDERS UNTIL DISEASE PROGRESSION, FOR UP TO 2 YEARS@@L01XC15@L01X@@BASEL, SWITZERLAND@5/1/2021@@Gazyvaro is designed to attack cells that have a certain marker on their surface. It kills targeted cells both directly and together with the body's immune system.@@15407470@Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy@Both@YES@18-Feb-15@2/18/2015@NO REVIEW@@@@@@FIRST-LINE@NCT01010061@787@@EMA, 23 July 2014@7/23/2014@@Yes@@12/1/2009@@BO21004 (Stage 1a)/2009-012476-28/CLL11@No@@Documented CD20+B-CLLPreviously untreated CLL requiring treatment according to the NCI criteria@@ADULTS@III@APPROVED@4/25/2013@ASMR III: 18 February 2015. [HAS, http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-10/gazyvaro__summary_ct13872.pdf]@HAUTE AUTORITÉ DE SANTÉ@GA101 demonstrated a statistically significant 86 percent reduction in the risk of disease worsening or death (HR=0.14, 95 percent CI 0.09-0.21, p<0.0001) when combined with chlorambucil compared to chlorambucil alone in previously untreated people with CLL and co-existing medical conditions. [Roche, 3 July 2013, http://www.roche.com/media/media_releases/med-cor-2013-07-03.htm ]@In CLL11, no new safety signals were detected for GA101. The most common Grade 3-4 adverse events (AEs) for GA101 were infusion-related reactions (IRRs) and low cell count of certain white blood cells (neutropenia) which did not result in an increased risk of infection. The incidence and severity of IRRs decreased after the first infusion and no Grade 3-4 IRRs have been reported beyond the first infusion.@@@@@OBINUTUZUMAB@CHLORAMBUCIL@@@@OBINUTUZUMAB|CHLORAMBUCIL|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@GAZYVARO@RITUXAN@@@@GAZYVARO|RITUXAN|||@CD20@@@@@CD20||||@PROGRESSION-FREE SURVIVAL@@@@@RESPONSE@SAFETY@@@@@@@@@RANDOMISED@SAFETY@PARALLEL ASSIGNMENT@OPEN LABEL@@1@1@25712.48@@@168@day@168 day@25712.48@25712.48@153.05@1@1.1511@3214.06@@@@@@@@@@@@3.21@28@1@mg@1000@3@28@@mg@1000@1@@@@@@8/2/2017@3214.06@3214.06@9406761T@SOLUTION FOR INFUSION@EURO@@@@@@@@1000@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@85@France
14917145@Onco@@@@@300f1012ntsdm@@@@@@231 patients who received combination irinotecan/bolus 5-FU/LV therapy given weekly were compared with 226 patients who received a standard bolus regimen of 5-FU/LV alone given daily for 5 days every 4 weeks. The third arm (226 patients) was given an irinotecan-alone treatment on a weekly schedule.@@L01XX19@L01X@YES@NEW YORK, NEW YORK@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14917145@CAMPTO is indicated for the treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.@@YES@19-Apr-06@4/19/2006@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan@SECOND-LINE@@683@The recommended dosage of CAMPTO is 350 mg/m² administered as an intravenous infusion over a 30- to 90- minute period every three weeks.Treatment with CAMPTO should be continued until there is an objective progression of the disease or an unacceptable toxicity.@HMA, June 1996@@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR THE RECTUM RANDOMISED IN 3 ARMS. CONCOMITANT MEDICATIONS SUCH AS ANTIEMETICS, ATROPINE, AND LOPERAMIDE WERE GIVEN TO PATIENTS FOR PROPHYLAXIS AND/OR MANAGEMENT OF SYMPTOMS FROM TREATMENT. PATIENTS ALS@@@III; STUDY 1 OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FU/LV FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER@APPROVED@@The special panel of experts (BfArM) recommended Campto irinotecan for off-label use in SCLC, but the G-BA went against the panel in its final verdict. There is no assessment in colorectal cancer.@GKV@The combination of irinotecan/5-FU/LV therapy resulted in significant improvements in objective tumor RRs (39% vs 21% p<0.0001 / 18% for arm 3), TTP (7 months vs 4.3 months p=0.004 / 4.2 months for arm 3), and survival (14.8 months vs 12.6 months p<0.05 / 12 months for arm 3) when compared with 5-FU/LV alone and irinotecan alone control arm.@@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CAMPTO@@@@@CAMPTO||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@@@@@@ADVANCED@@@@@RANDOMISED@CONTROLLED@INTERNATIONAL@@@1.75@m²@8453.205215@@@3.9@month@3.9 month@8453.21@8453.21@71.26@1@1.1807@97.73@134.54@101.5@@@@@@@@@@2.44@21@@mg/m²@350@1@@@@@@@@@@@8/15/2017@97.73@97.73@1114094@CONCENTRATE FOR INFUSION SOLUTION, 2 ML@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16624036@Onco@@@@@300f1012ntsdm@@@@@@@@L01XX52@L01X@@UNITED STATES@10/1/2017@@Venetoclax is a potent, selective inhibitor of B-cell lymphoma (BCL)-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumour cell survival and has been associated with resistance to chemotherapeutics. Venetoclax binds directly to the BH3-binding groove of BCL-2, displacing BH3 motif-containing pro-apoptotic proteins like BIM, to initiate mitochondrial outer membrane permeabilization (MOMP), caspase activation, and programmed cell death. In non-clinical studies, venetoclax has demonstrated cytotoxic activity in tumour cells that overexpress BCL-2.@@16624036@Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.@Both@NA@15-Jun-17@6/15/2017@NO REVIEW@@@@0%@@@NCT02141282@120@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@EMA, 5 December 2016@12/5/2016@1/1/2017@Yes@@9/1/2014@@M14-032@No@@Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) criteria; Subject has relapsed/refractory disease with an indication for treatment; Subject has refractory disease or developed recurrence after therapy with a BCR PI; Subject must have an Eastern Cooperative Oncology Group performance score of equal to or less than 2; Subject must have adequate bone marrow function at Screening; Subject must have adequate coagulation profile, renal, and hepatic function, per laboratory reference range at Screening.@@ADULTS@II@APPROVED@@15 June 2017, Benefit not quantifiable, [https://www.g-ba.de/downloads/39-261-2970/2017-06-15_AM-RL-XII_Venetoclax_D-266_BAnz.pdf]@@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLYXTO@@@@@VENCLYXTO||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@DURATION OF RESPONSE@TIME TO PROGRESSION@PROGRESSION FREE SURVIVAL@@@RELAPSED@@@@@Non-Randomized@Single Group Assignment@NO MASKING@@@1@1@599943.6437@@@11.7@month@11.7 month@599943.64@599943.64@1685.86@10@1.1511@448.6@578.15@463.43@@@@@@@@@@4.49@28@1@mg@92.5@28@1@@mg@400@1@@@@@@8/1/2017@44.86@44.86@12448740@FILM COATED TABLET@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920742@Onco@@@@@300f1012ntsdm@@@@@@Patients (=18 years, performance status [PS] 0-2) with locally advanced or metastatic NSCLC who had progressed or recurred following 1 or 2 prior chemotherapy regimens (at least 1 platinum-based) were randomized to receive gefitinib (250 mg/day orally) or docetaxel (75 mg/m2 iv every 3 weeks). SOURCE: AstraZeneca@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14920742@IRESSA is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@1466@The recommended posology of IRESSA is one 250 mg tablet once a day. If a dose of IRESSA is missed, it should be taken as soon as the patient remembers. If it is less than 12 hours to the next dose, the patient should not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose.@EMA, 24 June 2009@6/24/2009@@No@@@@INTEREST@No@@1,466 PATIENTS WITH ADVANCED NSCLC@@@III@APPROVED@@@GKV@Median survival for those taking Iressa was 7.6 months compared with eight months for patients receiving docetaxel. For patients with an EFGR gene mutation, average survival was 8.4 months for those on Iressa and 7.5 months for those receiving docetaxel. It marks the first time that an oral biologic therapy has proven this level of efficacy in a head-to-head trial. [Lancet. 2008;372:1809-1818, 22.11.2008]            1466 patients from 149 centers in 24 countries were randomized to gefitinib (n=733) or docetaxel (n=733); 323 patients were of Asian racial origin. In the gefitinib and docetaxel treatment arms, respectively, 54% and 55% had adenocarcinoma, 36% and 33% were female, and 20% and 21% were never-smokers. 30%, 58%, 12% and 25%, 63%, 12% had PS 0, 1, 2 in the gefitinib and docetaxel treatment arms, respectively and 15% and 17%, respectively, had undergone 2 prior chemotherapy regimens. 453 patients provided a tumour sample giving at least one evaluable biomarker. [AstraZeneca, June 2007]@In an assessment of quality of life, Iressa patients experienced far fewer side effects, with the most common being a rash and diarrhea. In contrast, patients taking docetaxel experienced low blood count, infection, and hair loss.@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IRESSA@@@@@IRESSA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@EGFR MUTATION POSITIVE@@@@RANDOMISED@OPEN-LABEL@@@@1@1@19694.36@@@7@month@7 month@19694.36@19694.36@92.5@30@1.1511@2775@3458.64@2813.51@@@@@@@@@@0.37@1@@mg@250@1@@@@@@@@@@@8/1/2017@92.5@92.5@1249285@FILM-COATED TABLET@EURO@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16617661@Onco@@@@@300f1037ntsdm@@@@@@Experimental: Arm A: Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study endsActive Comparator: Arm B: Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.@@L01XC17@L01X@@NEW YORK, NEW YORK@2/1/2015@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16617661@Indicated for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.@Both@YES@28-Nov-16@11/28/2016@NO REVIEW@@@@@@SECOND-LINE@NCT01673867@582@The recommended dose of OPDIVO is 3 mg/kg administered intravenously over 60 minutes every 2 weeks. Treatment should be continued as long as clinical benefit is observed or until treatmentis no longer tolerated by the patient.@EMA, 4 April 2016@4/4/2016@7/19/2015@No@@10/1/2012@@CA209-017, 2011-004792-36@No@@Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation therapy for locally advanced disease) and who will receive study therapy as second or third line of treatment for advanced disease; Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease; Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria; Eastern Cooperative Oncology Group (ECOG) performance status ≤1; A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient@ADULTS@ADULTS@III@APPROVED@@Recommended, 28 November 2016, [https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-nivolumab-Opdivo-cancer-pulmon-NMHNE.pdf]@SNS@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@OVERALL SURVIVAL@@@@@OBJECTIVE RESPONSE RATE@DURATION OF OBJECTIVE RESPONSE@@@@METASTATIC@NON-SQUAMOUS@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@76.5@kg@16554.93726@@@2.33@month@2.33 month@16554.94@16554.94@233.6@1@1.1511@1425@1540.15@1432.54@@@@@@@@@@14.25@14@@mg/kg@3@1@@@@@@@@@@@8/4/2017@1425@1425@706934@CONCENTRATE FOR SOLUTION FOR INFUSION - 10 ML@EURO@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14916866@Onco@@@@@300f1010ntsdm@@@@@@353 Patients in arm 1 received Aranesp at 500 mcg Q3W, 352 patients in arm 2 rceived Aranesp® 2.25 mcg/kg administered weekly as a SC injection. In both groups, the dose was reduced by 40% of the previous dose (e.g., for first dose reduction, to 300 mcg in the Q3W group and 1.35 mcg/kg in the QW group) if hemoglobin increased by more than 1 g/dL in a 14-day period. In arm 1, 254 patients (72%) required dose reductions (median time to first reduction at 6 weeks). In arm 2, 263 patients (75%) required dose reductions (median time to first reduction at 5 weeks).@@B03XA02@B03X@YES@THOUSAND OAKS, CALIFORNIA@@@Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. A primary growth factor for erythroid development, erythropoietin is produced in the kidney and released into the bloodstream in response to hypoxia. In responding to hypoxia, erythropoietin interacts with progenitor stem cells to increase red blood cell (RBC) production. Production of endogenous erythropoietin is impaired in patients with chronic renal failure (CRF), and erythropoietin deficiency is the primary cause of their anemia. Increased hemoglobin levels are not generally observed until 2 to 6 weeks after initiating treatment with Aranesp). In patients with cancer receiving concomitant chemotherapy, the etiology of anemia is multifactorial.@@14916866@Treatment of anaemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy.@@NO@28-May-08@5/28/2008@The manufacturer of darbepoetin alfa submitted an economic evaluation that included two scenarios. In the first, the use of darbepoetin alfa was considered over 25 weeks. The second included a time horizon of almost 3 years coupled with a treatment survival advantage (mean HR = 0.88). The associated ICERs for the two scenarios were approximately £160,000 and £24,000 per additional QALY gained, respectively.  In the base case of the Assessment Group's economic analysis, survival was assumed to be the same for both treatment and control arms (that is, a HR of 1 was used). This produced an ICER of more than £100,000 per additional QALY gained. The results of the sensitivity analysis demonstrated that erythropoietin analogues became more cost effective as the threshold haemoglobin concentration for initiating an erythropoietin analogue was reduced to lower levels, but the ICERs still remained high. The most favourable ICERs were obtained if a baseline haemoglobin concentration of 8 g/100 ml was assumed for all participants. These were in the range of £65,000–£80,000 per additional QALY gained. SOURCE: NICE guidance, 28 May 2008@@@@100%@@@@705@For cancer patients receiving chemotherapy : The recommended starting dose for Aranesp administered weekly is 2.25 mcg/kg as a SC injection. The recommended starting dose for Aranesp administered once-every-3-weeks (Q3W) is 500 mcg as a SC injection.@EMA, 8 June 2001@6/8/2001@@@@@When administered to target a hemoglobin of greater than 12 g/dL, Aranesp can increase mortality, serious cardiovascular and thromboembolic events, shorten time to tumor progression  in patients with advanced head and neck cancer receiving radiation therapy, shorten overall survival and increase deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy, can increase the risk of death in patients with active malignant disease receiving neither chemotherapy nor radiation therapy, can cause hypertension, seizures, pure red cell aplasia.@@No@@705 ANEMIC (HGB = 11 G/DL) PATIENTS NON-MYELOID MALIGNANCIES RECEIVING MULTICYCLE CHEMOTHERAPY WERE RANDOMISED TO 2 ARMS (ARM 1 WITH ARANESP AT 500 MCG Q3W AND ARM 2 WITH ARANESP AT 2.25 MCG/KG).@@@(C2) CANCER PATIENTS RECEIVING CHEMOTHERAPY / ONCE-EVERY-3-WEEK (Q3W) DOSING@APPROVED@@1 Erythropoietin analogues are not recommended for routine use in the management of cancer treatment-induced anaemia, except in the circumstances described below. 2 Erythropoietin analogues are recommended in combination with intravenous iron as an option for the management of cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer who have symptomatic anaemia with a haemoglobin level of 8 g/100 ml or lower. The use of erythropoietin analogues does not preclude the use of existing approaches to the management of anaemia, including blood transfusion where necessary. 3 Erythropoietin analogues in combination with intravenous iron may be considered for people who cannot be given blood transfusions and who have profound cancer treatment-related anaemia that is likely to have an impact on survival. 4 In the circumstances outlined in 2 and 3, the erythropoietin analogue with the lowest acquisition cost should be used. 5 People who are currently being treated with erythropoietin analogues for the management of cancer treatment-related anaemia but who do not fulfil the criteria in 2 and 3 should have the option to continue their therapy until they and their specialists consider it appropriate to stop.@NHS@27% (95% CI: 22%, 32%) of patients in arm 1 and 34% (95% CI: 29%, 39%) in arm 2 required a RBC transfusion. The observed difference in the transfusion rates (arm 1-arm 2) was -6.7% (95% CI: -13.8%, 0.4%).@@@@@MONO@DARBEPOIETIN ALFA@@@@@DARBEPOIETIN ALFA||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@ARANESP@@@@@ARANESP||||@EPO@@@@@EPO||||@KAPLAN-MEIER ESTIMATE@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@INTERNATIONAL@@@@@Invalid Dosage Value Phase 1@@@15@week@15 week@11168.4@11168.4@106.37@1@1.2961@440.43@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/21/2017@440.43@440.43@9.34E+15@SOLUTION FOR INJECTION, PRE-FILLED PEN - 0.6 ML@GB£@@@@@@@@300@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16623700@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"All Subjects, Experimental, Patients with advanced metastatic pancreatic cancer who have measurable disease
"@@@@@LEVERKUSEN, GERMANY@8/1/2019@@@@16623700@An Open-label, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343), an Anti-mesothelin Antibody Drug Conjugate, in Pretreated Mesothelin-expressing Advanced Pancreatic Cancer@Both@@@@@Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle@@@@@SECOND-LINE@NCT03023722@30@@@@@@@3/1/2017@@1.61E+09@@@Eligibility criteria for prescreening  -  Patients with advanced metastatic pancreatic cancer who have measurable disease; must not have had at least one and not more than two prior chemotherapy regimens for advanced disease (neoadjuvant chemotherapy would not be counted as a line of therapy). If prior radiation, measurable lesion outside radiation portal. ECOG performance status 0-1; Mesothelin positive. Must have normal organ function with LFTs <2.5 x ULN, no history of keratitis or corneal disease.  -  Written informed consent for prescreening.  -  Unresectable locally advanced or metastatic pancreatic cancer, confirmed by histology, and at least one but not more than two prior chemotherapy regimens with progression (neoadjuvant chemotherapy would not be counted as a line of therapy).  -  Availability of archival or fresh tissue for testing of mesothelin expression level.  Note: Archival tissue is preferred and fresh biopsy should only be obtained if no archival tissue is available and if in the investigator's judgement, there is no additional risk for the patient's safety. Patients with a sarcomatoid histology are not expected to have mesothelin overexpression and should not enter prescreening.  -  Age ≥ 18 years.  -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1  -  Life expectancy of at least 3 months.  -  No prior treatment with anetumab ravtansine (or any other mesothelin-based therapy)  Eligibility criteria for full study  -  Written informed consent for full study.  -  Histological documentation of overexpressing mesothelin at the moderate (2+) or stronger (3+) level in at least 30% of tumor cells as determined by IHC.  -  Unresectable locally advanced or metastatic pancreatic cancer and at least one but not more than two prior chemotherapy regimens with progression (neoadjuvant chemotherapy would not be counted as a line of therapy).  -  Patients must have at least 1 measurable lesion according to RECIST v 1.1  -  ECOG PS of 0 or 1  -  Life expectancy of at least 3 months.  -  Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements conducted within 7 days before starting study treatment:  -  Total bilirubin ≤ 1.5 x the upper limit of normal (ULN). Documented Gilbert syndrome is allowed if total bilirubin is mildly elevated (< 6 mg/dL).  -  ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement of their cancer).  -  ALP limit ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement of their cancer).  -  Extent of baseline tumor burden will not interfere with causal assessment of treatment-emergent hepatotoxicity, at the investigator's discretion.  -  Amylase and lipase ≤ 1.5 x ULN.  -  Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula (see Appendix 16.6).  -  Adequate coagulation, as assessed by the following laboratory test results:  -  International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN (CTCAE Grade ≤ 1).  -  Partial thromboplastin time (PTT) or activated PTT (aPTT) ≤ 1.5 x ULN (CTCAE Grade ≤ 1).  Note: Patients on stable dose of anti-coagulation therapy will be allowed to participate if they have no sign of bleeding or clotting and INR / PT and PTT / aPTT test results are compatible with the acceptable benefit-risk ratio at the investigator's discretion  -  Platelet count ≥ 75,000/mm3 , without platelet transfusion within 3 weeks before the start of study treatment.  -  Hemoglobin (Hb) ≥ 8 g/dL, without blood transfusion or erythropoietin within 6 weeks before the start of study treatment.  Note: Patients receiving chronic low-dose erythropoietin for chronic renal failure are allowed provided no dose adjustment is undertaken within 6 weeks before signing consent for full study and until safety follow-up visit and provided that they fulfill conditions of eligibility criteria (see also exclusion criterion number 18).  -  Absolute neutrophil count (ANC) ≥ 1000/mm3, without biologic response modifiers, such as G-CSF, within 6 weeks before the start of study treatment (see Section 8.1).  -  Left ventricular ejection fraction (LVEF) ≥ 50% or the lower limit of normal (LLN) according to local institution ranges of normality@Mesothelin-expressing@ADULTS@Phase 2@II@@@@@@@@@MONO@ANETUMAB RAVTANSINE@@@@@ANETUMAB RAVTANSINE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@United States@@@@@United States|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@BAY 94-9343@@@@@BAY 94-9343||||@Other@@@@@Other||||@Response rate as measured per RECIST 1.1 criteria@@@@@Time to Progression@Toxicity of Anetumab ravtansine assessed with National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03@@@@ADVANCED@METASTATIC@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918827@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BG04@L02B@NO@BASEL, SWITZERLAND@@@The elimination of oestrogen-mediated stimulatory effects is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone (E1) and oestradiol (E2). The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues.@@14918827@Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.@@NO@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@@@8000@Adult and Elderly Patients - The recommended dose is one 2.5 mg tablet administered once a day, without regard to meals. In patients with advanced disease, treatment with Femara should continue until tumor progression is evident. In the extended adjuvant setting, the optimal treatment duration with Femara is not known. The planned duration of treatment in the study was 5 years. However, at the time of the analysis , the median treatment duration was 24 months.@FDA, 25 July 1997@7/25/1997@@@@@May cause fetal harm when administered to pregnant women.@LABEL@No@DECEMBER 2008 (EXCLUSIVITY); JUNE 2011 (PATENT)@POSTMENOPAUSAL WOMEN WITH RESECTED, RECEPTOR-POSITIVE EARLY BREAST CANCER WERE RANDOMISED TO 4 ARMS: A. TAMOXIFEN FOR 5 YEARS ; B. FEMARA FOR 5 YEARS ; C. TAMOXIFEN FOR 2 YEARS FOLLOWED BY FEMARA FOR 3 YEARS ; D. FEMARA FOR 2 YEARS FOLLOWED BY TAMOX@@@ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN@APPROVED@@Covered; non-preferred@MEDICARE@Results from non-switching arms (arms A and B) together with data truncated 30 days after the switch in the two switching arms (arms C and D): DFS = 296 for the 4003 patients on Femara and 369 for the 4007 patients on tamoxifen (hazard ratio = 0.79 ; 95% CI = 0.68-0.92 ; p=0.002) ; Systemic DFS = 268 for the 4003 patients on Femara and 321 for the 4007 patients on tamoxifen (hazard ratio = 0.83 ; 95% CI = 0.70-0.97 ; p=0.022); Time to Distant Metastasis = 184 for the 4003 patients on Femara and 249 for the 4007 patients on tamoxifen (hazard ratio = 0.73 ; 95% CI = 0.60-0.88 ; p=0.001); Contralateral Breast Cancer = 19 for the 4003 patients on Femara and 31 for the 4007 patients on tamoxifen (hazard ratio = 0.61 ; 95% CI = 0.35-1.08 ; p=0.001) ; OS = 166 for the 4003 patients on Femara and 192 for the 4007 patients on tamoxifen (hazard ratio = 0.86 ; 95% CI = 0.70-1.06 ; p=0.155)@@@@@ADJUVANT@LETROZOLE@@@@@LETROZOLE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FEMARA@@@@@FEMARA||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@DISEASE-FREE SURVIVAL@TIME TO DISTANT METASTASIS@OVERALL SURVIVAL@@@OVERALL SURVIVAL@@@@@@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@@@@@Invalid Dosage Value Phase 1@@@@@@5288@5288@@30@1@702.08@@@@@@@@@@@@9.36@@@@@@@@@@@@@@@@8/2/2017@23.4@23.4@00078-0249-15@FILM-COATED TABLET@US$@@@@@@@@2.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918570@Onco@@@@@300f1012ntsdm@@@@@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (100 or 75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@ULM, GERMANY@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14918570@Indicated for the treatment of: 1. advanced ovarian carcinoma of epithelial origin in  (a) first line therapy (b) second line therapy, after other treatments have failed. 2. small cell carcinoma of the lung.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@789@Single-Agent Therapy: has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide:an effective combination for previously untreated patients consists of: Paraplatin—300 mg/m2 I.V. on day 1 every four weeks for six cycles. Cyclophosphamide—600 mg/m2 I.V. on day 1 every four weeks for six cycles. Intermittent courses of Paraplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.@@@@@@@Paraplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.@LABEL@No@@342 ADVANCED OVARIAN CANCER PATIENTS (SWOG) 447 ADVANCED OVARIAN CANCER PATIENTS (NCIC)@@@III; SWOG + NCIC@APPROVED@@@GKV@SWOG: Carboplatin versus cisplatin: 58% (48/83) versus 43% (33/76) respectively. Complete response: 10% (17/171) versus 10% (17/171). Median PFS: 49 versus 47 weeks. 2-year PFS: 21% versus 21%. 3-year PFS: 8% versus 14%. Median survival: 86 versus 79 weeks. 2-year survival: 40% versus 39%. 3-year survival: 18% versus 25%.NCIC: Carboplatin versus cisplatin: Clinical response  60% (48/80) versus 58% (49/85) respectively. Complete response: 11% (24/224) versus 15% (33/223). Median PFS: 59 versus 61 weeks. 2-year PFS: 31% versus 31%. 3-year PFS: 19% versus 23%. Median survival: 110 weeks versus 99 weeks. 2-year survival: 52% versus 48%. 3-year survival: 35% versus 33%.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Incorrect Average Duration of Use (Unit)@@@6@course@6 course@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@150@MG@10MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923616@Onco@@@@@300f1037ntsdm@@@@@@In Study CA139-174 patients received paclitaxel at 135 mg/m2 as a 3-hour infusion every 3 weeks (intended dose intensity 45 mg/m2/week). If no dose limiting toxicity was observed, patients were to receive 155 mg/m2 and 175 mg/m2 in subsequent courses. Hematopoietic growth factors were not to be used initially. In Study CA139-281 patients received paclitaxel at 100 mg/m2 as a 3-hour infusion every 2 weeks (intended dose intensity 50 mg/m2/week).@@L01CD01@L01C@YES@NEW YORK, NEW YORK@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14923616@Paclitaxel is indicated, after failure of first-line or subsequent chemotherapy for the treatment of metastatic carcinoma of the ovary. Paclitaxel is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi's sarcoma.@@YES@-@@NO REVIEW@@@@@-@SECOND-LINE@-@85@For patients with AIDS-related Kaposi's sarcoma, paclitaxel administered at a dose of 135 mg/m2 given intravenously over 3 hours every 3 weeks or at a dose of 100 mg/m2 given intravenously over 3 hours every 2 weeks is recommended (dose intensity 45-50 mg/m2 /week).@5/1/1994@@@-@@@Taxol should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. Anaphylaxis and severe hypersensitivity reactions characterised by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2%-4% of patients in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H2 antagonists. Patients who experience severe hypersensitivity reactions should not be rechallenged with the drug. Taxol therapy should not be given to patients with solid tumours who have baseline neutrophil counts of less than 1,500 cells/mm3 and should not be given to patients with AIDS-related Kaposi's sarcoma if the baseline neutrophil count is less than 1000 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropaenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving Taxol.@CA139-174 / CA139-281 @@-@Fifty-nine of the 85 patients enrolled in these studies had previously received systemic therapy, including interferon alpha (32%), DaunoXome (31%), DOXIL (2%) and doxorubicin containing chemotherapy (42%), with 64% having received prior anthracyclines. Eightyfive percent of the pretreated patients had progressed on, or could not tolerate, prior systemic therapy.@@@II@DISCONTINUED@@-@SNS@Although the planned dose intensity in the two studies was slightly different (45 mg/m2/week in Study CA139-174 and 50 mg/m2 /week in Study CA139-281), delivered dose intensity was 38-39 mg/m2/week in both studies, with a similar range (20-24 to 51-61). The efficacy of pacalitaxel was evaluated by assessing cutaneous tumor response according to the amended ACTG criteria and by seeking evidence of clinical benefit in patients in six domains of symptoms and/or conditions that are commonly related to AIDS-related Kaposi's sarcoma. Cutaneous Tumor Response (Amended ACTG Criteria) - The objective response rate was 59% (95% CI: 46 to 72%)( 35 of 59 patients) in patients with prior systemic therapy. Cutaneous responses were primarily defined as flattening of more than 50% of previously raised lesions. (See Table) The median time to response was 8.1 weeks and the median duration of response measured from the first day of treatment was 10.4 months (95% CI: 7.0 to 11.0 months) for the patients who had previously received systemic therapy. The median time to progression was 6.2 months (95% CI: 4.6 to 8.7 months). Additional Clinical Benefit - Most data on patient benefit were assessed retrospectively (plans for such analyses were not included in the study protocols). Nonetheless, clinical descriptions and photographs indicated clear benefit in some patients, including instances of improved pulmonary function in patients with pulmonary involvement, improved ambulation, resolution of ulcers, and decreased analgesic requirements in patients with KS involving the feet and resolution of facial lesions and edema in patients with KS involving the face, extremities and genitalia.@@@@@MONO@PACLITAXEL@@@@@PACLITAXEL||||@BMS@@@@@BMS||||@@@@@@|||||||||@Sarcoma@Kaposi's Sarcoma@@@@Sarcoma|Kaposi's Sarcoma||||||||@TAXOL@@@@@TAXOL||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@TIME TO PROGRESSION@OVERALL SURVIVAL@@@OVERALL SURVIVAL@@@@@-@@@@@RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@15 cycles@10515.75@10515.75@@1@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/2/2015@@@694471@INTRAVENOUS  INJECTION VIAL, 5 ML@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16392216@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Hyper-CVAD + Blinatumomab, Experimental, During Cycles 1 and 3:Cyclophosphamide 2 times each day by vein on Days 1-3. Mesna by vein non-stop to help prevent side effects on Days 1-3. Dexamethasone 1 time a day by vein on Days 1-4 and 11-14. Ofatumumab or rituximab by vein on Days 1 and 11. Methotrexate by vein on Day 2. Doxorubicin by vein non-stop for 1 day on Day 4. Vincristine by vein on Day 4 and 11. Cytarabine by vein on Day 7.During Cycles 2 and 4:Methotrexate by vein on Day 1. Ofatumumab or rituximab by vein on Days 1 and 8. Cytarabine by vein 2 times each day on Days 2 and 3.After Hyper-CVAD, Blinatumomab given nonstop for Weeks 1-4 every 6 weeks of Cycles 5-8.After 4 cycles of Blinatumomab, participants receive maintenance therapy for about 12 months.Participants take 6-mercaptopurine by mouth 3 times every day. Methotrexate taken every week. Vincristine by vein 1 time every month. Prednisone taken by mouth on Days 1-5 of every month.@@L01XC19@L01X@@THOUSAND OAKS, CALIFORNIA@11/1/2020@@Blinatumomab is a bispecific T-cell engager antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells.@@16392216@Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia (ALL)@Both@@@@@Cycles 1 + 3: 300 mg/m2 by vein over 3 hours every 12 hours for 6 doses Days 1,2,3 (total dose 1800 mg/m2).@@@@@FIRST-LINE@NCT02877303@60@@@@@@@11/1/2016@@2014-0845@@@Inclusion Criteria:  1. Patients at least 14 years of age with newly diagnosed, previously untreated B-lineage ALL, or having achieved CR with one course of induction chemotherapy.  2. Failure to one induction course of chemotherapy (these patients will be analyzed separately).  3. Performance status of 0-3  4. Adequate organ function with creatinine less than or equal to 2.0 mg/dL (unless considered tumor related), bilirubin less than or equal to 2.0 mg/dL (unless considered tumor related).  5. Adequate cardiac function as assessed by history and physical examination.  6. No active or co-existing malignancy with life expectancy less than 12 months.@@14 Years - N/A@Phase 2@II@@@@@@@@@COMBO@BLINATUMOMAB@CYCLOPHOSPHAMIDE@DEXAMETHASONE@OFATUMUMAB@@BLINATUMOMAB|CYCLOPHOSPHAMIDE|DEXAMETHASONE|OFATUMUMAB|@AMGEN@@@@@AMGEN||||@United States@@@@@United States|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@BLINCYTO@GENERIC@GENERIC@ARZERRA@@BLINCYTO|GENERIC|GENERIC|ARZERRA|@Other@@@@@Other||||@RELAPSE-FREE SURVIVAL@@@@@@@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921943@Onco@@@@@300f1018ntsdm@@@@@@Patients received either Nexavar 400 mg twice daily or to placebo.@@L01XE05@L01X@NO@LEVERKUSEN, GERMANY@@@Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis. Sorafenib inhibited tumor growth and angiogenesis of human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice.@@14921943@Sorafenib was TGA registered for the treatment of patients with advanced renal cell carcinoma on 27 September 2006.@@NO@8-Mar@@The economic evaluation produced an incremental cost per extra QALY gained in the range of $45,000 to $75,000.@@@@0%@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@SECOND-LINE@@769@The recommended daily dose of Nexavar is 400 mg (2 x 200 mg tablets) taken twice daily, without food (at least 1 hour before or 2 hours after eating).@TGA, 1 December 2005@12/1/2005@@@@@Women of childbearing potential should be advised to avoid becoming pregnant while on Nexavar. Nexavar should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.@STUDY 1@No@@769 PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WHO HAD RECEIVED ONE PRIOR SYSTEMIC THERAPY WERE STRATIFIED BY MSKCC (MEMORIAL SLOAN KETTERING CANCER CENTER) PROGNOSTIC RISK CATEGORY1 (LOW OR INTERMEDIATE) AND COUNTRY AND RANDOMIZED TO NEXAVAR 400 MG TWIC@@@III@APPROVED@@>> The PBAC therefore rejected the submission based on an unacceptably high and uncertain cost effectiveness ratio. There is high clinical uncertainty associated with the claimed survival advantage, but the place of sorafenib in the treatment algorithm is uncertain. [PBAC March 2008 http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-sorafenib-tosylate-mar08 ]  >> Overall, the PBAC accepted that there is a clinical need for additional treatment options for the management of renal cell carcinoma but that the data presented in the submission did not present, with an adequate degree of certainty, the extent of benefit that would be realised should sorafenib be listed on the PBS. The Committee considered that the conservative base case ICER estimate in the range $45,000 - $75,000 to be high and uncertain, with the possibility of the ICER being greater than $150,000. The PBAC therefore rejected the submission on the basis of uncertainty of the extent of gain in overall survival, and the resulting high and uncertain cost-effectiveness ratio. [PBAC November 2006 http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-sorafenib-nov06 ]@@The median PFS for patients on Nexavar was 167 days compared to 84 days for patients on placebo. The estimated hazard ratio (risk of progression with Nexavar compared to placebo) was 0.44 (95% CI: 0.35, 0.55).  The effect of Nexavar on PFS was consistent across different subsets, including age above or below 65 years, ECOG PS 0 or 1, MSKCC prognostic risk category1, whether the prior therapy was for progressive metastatic disease or for an earlier disease setting, time from diagnosis of less than or greater than 1.5 years.  The subsets also included patients with no prior IL-2 or interferon therapy, for whom the median PFS was 172 days on Nexavar compared to 85 days on placebo. OS was longer for Nexavar than placebo with a hazard ratio (Nexavar over placebo) of 0.72. This analysis did not meet the prespecified criteria for statistical significance. Additional analyses are planned as the survival data mature.@Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%),and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%.@@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@ONYX@@@@BAYER HEALTHCARE|ONYX|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@INTERNATIONAL@MULTI-CENTRE@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@1@1@32983.836@@@167@day@167 day@32983.84@32983.84@197.51@60@0.779@2962.62@@3032.56@@@@@@@@@@0.25@1@@mg@800@1@@@@@@@@@@@8/1/2017@49.38@49.38@2356-2372-GE-BN@FILM-COATED TABLET@A$@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14917419@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@H02AB02@H02A@YES@INGELHEIM, GERMANY@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14917419@Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Haematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anaemia), idiopathic thrombocytopaenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopaenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumour, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.@@@@@NO REVIEW@@@@@Roxane is a U.S. subsidiary of Boehringer, acquired by the Germany company in 1978.@@@N/A@Intravenous Administration: IV dosage of dexamethasone phosphate is variable, depending on the condition being treated. It usually ranges from 0.5-24 mg daily. The duration of therapy is dependent on the clinical response of the patient and as soon as improvement is indicated, the dosage should be adjusted to the minimum required to maintain the desired clinical response. Withdrawal of the drug on completion of therapy should be gradual.@@@@@@@Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity. Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@DEXAMETHASONE SODIUM PHOSPHATE@@@@@DEXAMETHASONE SODIUM PHOSPHATE||||@BOEHRINGER INGELHEIM@ROXANE@@@@BOEHRINGER INGELHEIM|ROXANE|||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Brain Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Brain Cancer||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@@@@1@1@19.92@@@@@@@@@@@@0.4@@@@@@@@@@@@@@@@9/1/2017@19.92@19.92@00054-3177-63@ORAL SOLUTION@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922813@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01BB02@L01B@NO@PETACH TIKVA, ISRAEL@@@@@14922813@Indicated for remission induction and maintenance therapy of acute lymphatic leukemia. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric patient or adult). ALL: Given as a single agent for remission induction, Purinethol induces complete remission in approximately 25% of paediatric patients and 10% of adults. However, reliance upon Purinethol alone is not justified for initial remission induction of ALL since combination chemotherapy with vincristine, prednisone, and L-asparaginase results in more frequent complete remission induction than with Purinethol alone or in combination. The duration of complete remission induced in ALL is so brief without the use of maintenance therapy that some form of drug therapy is considered essential. Purinethol, as a single agent, is capable of significantly prolonging complete remission duration; however, combination therapy has produced remission duration longer than that achieved with Purinethol alone. AML: As a single agent, it will induce complete remission in approximately 10% of pediatric patients and adults with acute myelogenous leukemia or its subclassifications. These results are inferior to those achieved with combination chemotherapy employing optimum treatment schedules.@@NO@@@NO REVIEW@@@@@@@@@The usual initial dosage for pediatric patients and adults is 2.5 mg/kg of body weight per day (100 to 200 mg in the average adult and 50 mg in an average 5-year-old child). A usual daily maintenance dose is 1.5 to 2.5 mg/kg/day as a single dose.@FDA, 11 September 1953@9/11/1953@@@@@Bone Marrow Toxicity: The most consistent, dose-related toxicity is bone marrow suppression. This may be manifest by anaemia, leukopaenia, thrombocytopaenia, or any combination of these. Any of these findings may also reflect progression of the underlying disease. Since mercaptopurine may have a delayed effect, it is important to withdraw the medication temporarily at the first sign of an abnormally large fall in any of the formed elements of the blood. There are individuals with an inherited deficiency of the enzyme TPMT who may be unusually sensitive to the myelosuppressive effects of mercaptopurine and prone to developing rapid bone marrow suppression following the initiation of treatment. Substantial dosage reductions may be required to avoid the development of life-threatening bone marrow suppression in these patients. This toxicity may be more profound in patients treated with concomitant allopurinol. This problem could be exacerbated by coadministration with drugs that inhibit TPMT, such as olsalazine, mesalazine, or sulphasalazine. Hepatotoxicity: Mercaptopurine is hepatotoxic in animals and humans. A small number of deaths have been reported that may have been attributed to hepatic necrosis due to administration of mercaptopurine.@NO LABELLED TRIAL@No@N/A@@PAEDIATRIC@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@MERCAPTOPURINE@@@@@MERCAPTOPURINE||||@TEVA PHARMACEUTICAL@GATE PHARMACEUTICAL@@@@TEVA PHARMACEUTICAL|GATE PHARMACEUTICAL|||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|||||||@PURINETHOL@@@@@PURINETHOL||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@57844-0522-06@SCORED TABLET@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917924@Onco@@@@@300f1018ntsdm@@@@@@Patients treated with a dose of 15-25 mg/m2 daily@@L01BB05@L01B@YES@LEVERKUSEN, GERMANY@@@Fludarabine phosphate is a water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine, 9ß-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. Fludarabine phosphate is rapidly dephosphorylated to 2F-ara-A which is taken up by cells and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2F-ara-ATP. This metabolite has been shown to inhibit ribonucleotide reductase, DNA polymerase a/d and e, DNA primase and DNA ligase thereby inhibiting DNA synthesis. Furthermore, partial inhibition of RNA polymerase II and consequent reduction in protein synthesis occur. While some aspects of the mechanism of action of 2F-ara-ATP are as yet unclear, it is assumed that effects on DNA, RNA and protein synthesis all contribute to inhibition of cell growth with inhibition of DNA synthesis being the dominant factor. In addition, in vitro studies have shown that exposure of CLL lymphocytes to 2F-ara-A triggers extensive DNA fragmentation and cell death characteristic of apoptosis.@@14917924@Fludarabine was TGA registered on 20 June 1995 for use as second-line therapy in patients with chronic lymphocytic leukaemia (CLL). Fludarabine was TGA registered on 6 April 2004 for the treatment of B-cell chronic lymphocytic leukaemia.@@NO@8-Mar@@A stepped economic evaluation was presented which produced an incremental discounted cost per extra discounted quality-adjusted life-year (QALY) gained of between $15,000 and $45,000.@@@@1@-@SECOND-LINE@-@31@The recommended dose is 40 mg fludarabine phosphate/m² body surface given daily for 5 consecutive days every 28 days by the oral route. This dose corresponds to 1.6 times the recommended intravenous dose of fludarabine phosphate (25 mg/m2 body surface per day).@-@@@-@@@Can severely suppress bone marrow function, notably anaemia, thrombocytopaenia and neutropaenia. Several instances of trilineage bone marrow hypoplasia or aplasia resulting in pancytopaenia, sometimes resulting in death, have been reported in adult patients. It was associated with severe neurologic effects, including blindness, coma, and death. Instances of life-threatening and sometimes fatal autoimmune hemolytic anemia have been reported to occur after one or more cycles of treatment with Fludara. There are clear dose-dependent toxic effects seen with Fludara. Fludara in combination with pentostatin is not recommended due to an unacceptably high incidence of fatal pulmonary toxicity for the treatment of refractory CLL. Transfusion-associated graft-versus-host disease has been observed rarely after transfusion of non-irradiated blood in Fludara treated patients.@-@@-@31 ADULT PATIENTS WITH CLL REFRACTORY TO AT LEAST ONE PRIOR STANDARD ALKYLATING-AGENT CONTAINING REGIMEN.@@@SOUTHWEST ONCOLOGY GROUP (SWOG) STUDY@DISCONTINUED@@The PBAC recommended the listing on fludarabine on the PBS for the treatment of B-cell chronic lymphocytic leukaemia in combination with an alkylating agent where the patient has advanced disease (Binet Stage B or C) or evidence of progressive disease on a cost-effectiveness basis against the main comparator, chlorambucil, at the price proposed. [PBAC http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-fludarabine-phosphate-mar08 ]@PBS@The response rates were obtained using standardised response criteria developed by the National Cancer Institute CLL Working Group3 and were achieved in heavily pre-treated patients. Overall objective RR was 32%, complete response rate was 13%, partial RR was 19%, median time to response was 21 weeks (range of 1 to 53 weeks), median duration of disease control was 65 weeks, median survival was 52 weeks. @-@@@@MONO@FLUDARABINE PHOSPHATE@@@@@FLUDARABINE PHOSPHATE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@FLUDARA@@@@@FLUDARA||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@RESPONSE RATE@TIME TO RESPONSE@DURATION OF RESPONSE@OVERALL SURVIVAL@@DURATION OF RESPONSE@OVERALL SURVIVAL@@@@ADVANCED@@@@@SINGLE-ARM@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@@@@5@0.8893@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@L01BB059185KGZ@POWDER FOR I.V. INJECTION@A$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16446628@Onco@@@@@300f1018ntsdm@@@@@@@@L01XX32@L01X@@BEERSE, BELGIUM@1/1/2014@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@16446628@VELCADE in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.@Both@YES@@@NO REVIEW@@@@0%@@FIRST-LINE@NCT00722137@487@VELCADE (bortezomib) for injection is administered at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11, followed by a 10 dayrest period on days 12-21. This 3 week period is considered a treatment cycle. Six VELCADE cycles are recommended, although for patients with a response first documented at cycle 6,two additional VELCADE cycles may be given;@TGA, 26 February 2016@2/26/2016@@Yes@@5/1/2008@@LYM-3002@No@@Male or female patients 18 years or older (the patient must be at least the legal age limit to be able to give informed consent within the jurisdiction the study is taking place); Diagnosis of MCL (Stage II, III or IV) as evidenced by lymph node histology and either expression of cyclin D1 (in association with CD20 and CD5) or evidence of t(11;14) translocation, such as by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase chain reaction (PCR). Patients with a diagnosis of Stage I MCL will not be permitted to enter study; Paraffin embedded biopsy tissue block (preferably of lymph node origin) must be sent to the central laboratory for confirmation of MCL diagnosis prior to randomization. In China, a paraffin embedded lymph node biopsy tissue block must be sent for central confirmation of sample adequacy, prior to randomization: At least 1 measurable site of disease; No prior therapies for MCL; Not eligible for bone marrow transplantation as assessed by the treating physician (e.g., age or the presence of co-morbid conditions that may have a negative impact on the tolerability to transplantation); Eastern Cooperative Oncology Group ECOG status ≤2 (Attachment 1); Absolute neutrophil count (ANC) ≥1500 cells/µL, Platelets ≥100,000 cells/µL or ≥75,000 cells/µL if thrombocytopenia is considered by the investigator to be secondary to MCL (e.g., due to bone marrow infiltration or sequestration from splenomegaly), Alanine transaminase ≤3 x upper limit of normal (ULN); Aspartate transaminase ≤3 x ULN; Total bilirubin ≤1.5 x ULN; Calculated creatinine clearance ≥20 mL/min.@ADULT@ADULTS@III@APPROVED@@@@@@@@@COMBO@BORTEZOMIB@RITUXIMAB@CYCLOPHOSPHAMIDE@DOXORUBICIN@PREDNISONE@BORTEZOMIB|RITUXIMAB|CYCLOPHOSPHAMIDE|DOXORUBICIN|PREDNISONE@JANSSEN CILAG@@@@@JANSSEN CILAG||||@World@@@@@World|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@VELCADE@MABTHERA@GENERIC@GENERIC@@VELCADE|MABTHERA|GENERIC|GENERIC|@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@TIME TO PROGRESSION@DURATION OF RESPONSE@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1.75@m²@25401.012@@@126@day@126 day@25401.01@25401.01@201.6@1@0.779@465.22@@@@@@@@@@@@465.22@21@@mg/m²@1.3@4@@@@@@@@@@@8/1/2017@465.22@465.22@3554-2614-IN-JC@POWDER FOR INJECTION@A$@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14922803@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L02AE02@L02A@NO@@@@This is a synthetic nonapeptide analogue of naturally occurring gonadotrophin releasing hormone (GnRH) which possesses greater potency than the natural hormone. It is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy. Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Oestradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.@@14922803@(i) Metastatic prostate cancer.  (ii) Locally advanced prostate cancer, as an alternative to surgical castration.  (iii) As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.  (iv) As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.  (v) Management of endometriosis, including pain relief and reduction of endometriotic lesions.  (vi) Endometrial preparation prior to intrauterine surgical procedures including endometrial ablation or resection.  (vii) Preoperative management of uterine fibroids to reduce their size and associated bleeding.@@NO@@@NO REVIEW@@@@100%@>> Takeda reacquires rights to Prostap following expiration of license agreement on 1 July 2009 [Takeda, 23 March 2009] >> Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@Prostate Cancer: The usual recommended dose is 3.75mg administered as a single subcutaneous or intramuscular injection every month. The majority of patients will respond to a 3.75mg dose. Prostap therapy should not be discontinued when remission or improvement occurs. As with other drugs administered chronically by injection, the injection site should be varied periodically.@EMA, 16 December 2004@12/16/2004@@No@@@Development or aggravation of diabetes may occur, therefore diabetic patients may require more frequent monitoring of blood glucose during treatment with PROSTAP.  Hepatic dysfunction and jaundice with elevated liver enzyme levels have been reported. Therefore, close observation should be made and appropriate measures taken if necessary.  Spinal fracture, paralysis, hypotension and worsening of depression have been reported.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@TAKEDA PHARMACEUTICAL@@@@@TAKEDA PHARMACEUTICAL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROSTAP@@@@@PROSTAP||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@1449.84@1449.84@@1@1.299@65.84@@75.24@@@@@@@@@@17.56@@@@@@@@@@@@@@@@7/28/2017@65.84@65.84@1.93E+16@POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, PRE-FILLED SYRINGE@GB£@@@@@@@@3.75@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14916721@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Vatalanib (1250mg continuous once daily dose) with Gemzar@@-@-@-@BASEL, SWITZERLAND@@@"Vatalanib (PTK/ZK) is a ""small"" molecule tyrosine kinase inhibitor with broad specificity that targets all VEGF receptors (VEGFR), the platelet-derived growth factor receptor, and c-KIT. It is a multi-VEGFR inhibitor designed to block angiogenesis and lymphangiogenesis by binding the intracellular kinase domain of all three VEGFRs, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Vatalanib is a targeted drug that inhibits the activity of all known receptors that bind VEGF. The drug potently inhibits the formation of new blood vessels (angiogenesis). "@@14916721@Advanced pancreatic cancer@@-@-@@NO REVIEW@@@@-@PTK/ZK was among 20 projects discontinued by Bayer Schering as part of its merger. SOURCE: Bayer, 19 June 2007Following a modified agreement in January 2005, Novartis and Schering AG will co-market vatalanib in Europe, North America and Japan for oncolo@-@NCT00185588@24@-@-@@@-@@10/1/2004@-@PANC0002,@@-@-@@@I/II@II@@-@-@Interim results from Phase I trial: 11 patients are evaluable for toxicity (5M/6F; median age 62 years, range 40-82 years; median KPS 90%). Thus far, 42 cycles have been given, with a median of four cycles per patient. Two patients have experienced DLT. The first patient (cohort 1) experienced grade 3 diarrhea and hypokalemia and grade 4 neutropenia occurring simultaneously and treated without sequelae. The second patient (cohort 3) developed grade 3 deep vein thrombosis. Beyond the first cycle, grade 3 toxicities included neutropenia (1), anemia (3), thrombocytopenia (1), hypertension (2), diarrhea (1), hypokalemia (1), thrombosis (1), and proteinuria (1). Three of eleven patients (27%) did not complete treatment to the first evaluation timepoint (2 cycles); two discontinued due to toxicity and one discontinued due to disease progression. Two of eleven patients (18%) had a partial response by RECIST. Six of eleven patients (55%) had stable disease as the best response ranging from 2-6 months. SOURCE: Novartis/ASCO, June 2006@-@@@@COMBO@VATALANIB@GEMCITABINE@@@@VATALANIB|GEMCITABINE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@PTK-787@ZK-222584@PTK/ZK@GEMZAR@@PTK-787|ZK-222584|PTK/ZK|GEMZAR|@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@MAXIMUM TOLERATED DOSE@RESPONSE RATE@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15361151@Onco@@@@@300f1015ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361151@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.@Both@NO@@@NO REVIEW@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dose for chronic phase CML is 100 mg dasatinib once daily, administered orally.@EMA, 6 December 2010@12/6/2010@@Yes@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@Not assessed@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@33675.88523@@@14@month@14 month@33675.89@33675.89@79.08@30@1.1511@3321.53@3521.17@3351.53@@@@@@@@@@0.79@1@@mg@100@1@@@@@@@@@@@8/1/2017@110.72@110.72@3.40E+12@FILM-COATED TABLET (IN BOTTLE)@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
16387359@Onco@@@@@300f1012ntsdm@@@@@@@@L01XC07@L01X@@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16387359@Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@152@The recommended dose of Avastin when used in addition to erlotinib is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.It is recommended that the treatment with Avastin in addition to erlotinib is continued until disease progression.@EMA, 2 June 2016@6/2/2016@@No@@@@JO25567@No@@@EGFR activating mutations@@II@APPROVED@@@GKV@@@@@@COMBO@BEVACIZUMAB@ERLOTINIB@@@@BEVACIZUMAB|ERLOTINIB|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AVASTIN@TARCEVA@@@@AVASTIN|TARCEVA|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@REPONSE RATE@DISEASE CONTROL RATE@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@MULTI-CENTRE@@@76.5@kg@88178.65192@@@16@month@16 month@88178.65@88178.65@181.19@1@1.1511@1326.38@1683.06@1364.88@@@@@@@@@@3.32@21@@mg/kg@15@1@@@@@@@@@@@8/1/2017@1326.38@1326.38@3159652@CONCENTRATE FOR INFUSION SOLUTION, 16 ML@EURO@@@@@@@@400@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920185@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Mitoxantrone and prednisone compared to prednisone alone@@L01DB07@L01D@YES@UNITED STATES@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14920185@Mitoxantrone Injection in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced HRPC; in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.@@NO@@@NO REVIEW@@@@@@@@161@HRPC: based on data from two Phase 3 comparative trials of mitoxantrone injection plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m2 given as a short intravenous infusion every 21 days.@@@@@@@HRPC: functional cardiac changes such as decreases in LVEF and congestive heart failure may occur in patients with HRPC treated with mitoxantrone. In a randomised comparative trial of mitoxantrone plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone had a cardiac event defined as any decrease in LVEF below the normal range, CHF (n = 3), or myocardial ischemia. Two patients had a prior history of cardiac disease. The total mitoxantrone dose administered to patients with cardiac effects ranged from > 48 to 212 mg/m2. Among 112 patients evaluable for safety on the mitoxantrone + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. The range of total mitoxantrone doses administered to these patients is not available.@@No@@161 PATIENTS WITH METASTATIC OR LOCALLY ADVANCED HRPC@@@CCI-NOV22@APPROVED@@Covered; part B; specialty drug@MEDICARE@A primary palliative response (defined as a 2-point decrease in pain intensity in a 6-point pain scale) was achieved in 29% of patients randomised to M + P compared to 12% of patients randomised to P alone (p = 0.011). 2 responders left the study after meeting primary response criterion for 2 consecutive cycles. A secondary palliative response was defined as a 50% or greater decrease in analgesic use, associated with stable pain intensity, and lasting a minimum of 6 weeks. An overall palliative response was achieved in 38% of patients randomised to M + P compared to 21% of patients on P (p = 0.025). The median duration of primary palliative response for M +P patients was 7.6 months compared to 2.1 months for P patients alone (p = 0.0009). The median duration of overall palliative response for M+P patients was 5.6 months compared to 1.9 months for P patients (p = 0.0004). Median TTP for M+P patients was 4.4 months compared to 2.3 months for all P patients (p =0.0001). Median time to death was 11.3 months for M+P patients and 10.8 months on P patients (p = 0.2324). 48 patients on the P arm crossed over to receive M + P. Of these, 30 patients had progressed on P, while 18 had SD on P. The clinical significance of a fall in PSA concentrations after chemotherapy is unclear- a PSA fall of 50% or greater for 2 consecutive follow-up assessments after baseline was reported in 33% of all M+P patients and 9% of P patients. These findings should be interpreted with caution since PSA responses were not defined prospectively@@@@@COMBO@MITOXANTRONE@PREDNISONE@@@@MITOXANTRONE|PREDNISONE|||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@PARTIAL RESPONSE@STABLE DISEASE@DURATION OF RESPONSE@TIME TO PROGRESSION@@DURATION OF RESPONSE@TIME TO PROGRESSION@@@@ADVANCED@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@637.5@@@@@@@@@@@@21.25@@@@@@@@@@@@@@@@8/2/2017@637.5@637.5@63323-0132-15@INJECTION@US$@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15394355@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Lonsurf. 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Placebo: tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle.@@L01BC59@L01B@@@12/1/2014@@@@15394355@Indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy@Both@NA@@@@@@@@@SECOND-LINE@NCT01607957@800@35 mg/m²/dose orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.@FDA, 22 September 2015@9/22/2015@@@@5/24/2012@@TPU-TAS-102-301/2012-000109-66@No@@Has adenocarcinoma of the colon or rectum. Has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancerECOG performance status of 0 or 1Is able to take medications orally. Has adequate organ function (bone marrow, kidney and liver). Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.@@ADULTS@III@APPROVED@@@@The primary endpoint of the study was overall survival and the secondary endpoint was progression-free survival. Patients treated with Lonsurf lived an average of 7.1 months compared to 5.3 months for those treated with placebo. On average, the time to disease progression was two months for patients on Lonsurf compared to 1.7 months for patients receiving placebo.[FDA, 22 September 2015, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm]@The most common side effects of treatment with Lonsurf are anemia, a decrease in infection-fighting white blood cells (neutropenia) or blood platelets (thrombocytopenia), physical weakness, extreme tiredness and lack of energy (fatigue), nausea, decreased appetite, diarrhea, vomiting, abdominal pain and fever.[FDA, 22 September 2015, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm]@@@@MONO@TIPIRACIL / TRIFLURIDINE@@@@@TIPIRACIL / TRIFLURIDINE||||@TAIHO@@@@@TAIHO||||@France@Germany@Italy@Japan@@United States|Australia|Austria|Belgium|Czech Republic||France|Germany|Italy|Japan@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@LONSURF@@@@@LONSURF||||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@@@@@METASTATIC@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@1.75@m²@93676.93746@@@7.1@month@7.1 month@93676.94@93676.94@433.78@40@1@5949.02@@@@@@@@@@@@9.92@28@@mg/m²@70@10@@@@@@@@@@@8/2/2017@148.73@148.73@64842-1025-02@FILM-COATED TABLET (BOTTLE)@US$@@@@@@@@15@MG@6.14 MG|15 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916483@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients received rituximab 375 mg/meter squared intravenously on day one and Treanda 90 mg/meter squared intravenously on days two and three of a 28-day cycle for up to six cycles. An additional dose of rituximab was given one week before the first cycle and four weeks after the last cycle. SOURCE: Cephalon@@-@-@-@FRAZER, PENNSYLVANIA@11/1/2008@@Bendamustine is an alkylating that is a bifunctional mechlorethamine derivative. Mechlorethamine and its derivatives dissociate into electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties. The bifunctional covalent linkage can lead to cell death via several pathways. The exact mechanism of action of bendamustine remains unknown. Bendamustine is active against both quiescent and dividing cells.@@14916483@-@@-@-@@NO REVIEW@@@@-@Cephalon acquired U.S. rights through takeover of Salmedix, which licensed it from Fujisawa (Astellas. It is marketed by MundiPharma as Ribomustin in Germany as a single or combination agent for indolent NHL, MM and CLL under the name Ribomustin. SymBio h@MULTIPLE@NCT00076349@66@-@This combination study is one of three studies in patients with NHL that Cephalon submitted to the FDA in December 2007 requesting approval of TREANDA for the treatment of patients with indolent NHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen. Cephalon anticipates a review decision on this application by the agency by October 31, 2008. SOURCE: Cephalon, 15 July 2008@7/15/2008@@-@@12/1/2003@-@SDX-105-02@@-@PATIENTS WITH RELAPSED INDOLENT OR MANTLE CELL NHL WHO HAVE HAD AT MAXIMUM OF 3 PRIOR CHEMO REGIMENS.@@@II@II@@-@-@Overall response rate was 92 percent with a complete response rate (CR) of 41 percent. A CR means that after treatment with the Treanda and rituximab combination, patients had no detectable evidence of disease. These responses were durable, with a median duration of 21 months overall (19 months for the mantle cell population). Additionally, the combination of Treanda and rituximab was associated with progression-free survival (PFS) of 23 months overall and for patients with mantle cell lymphoma. SOURCE: Cephalon, 15 July 2008@The most common adverse events in the trial included myelosuppression (a condition in which bone marrow activity is decreased), nausea, infection, fatigue, constipation, and diarrhea.@@@@COMBO@BENDAMUSTINE@RITUXIMAB@@@@BENDAMUSTINE|RITUXIMAB|||@CEPHALON@ASTELLAS PHARMA@@@@CEPHALON|ASTELLAS PHARMA|||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@TREANDA@RIBOMUSTIN@@@@TREANDA|RIBOMUSTIN|||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@N/A@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924798@Onco@@@@@300f1018ntsdm@@@@@@@@L02AE03@L02A@NO@LONDON, UNITED KINGDOM@@@Zoladex (D-Ser(But)6 Azgly10 LHRH) is a synthetic analogue of naturally occurring LHRH. On chronic administration Zoladex results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. This effect is reversible on discontinuation of therapy. Initially, Zoladex, like other LHRH agonists, may transiently increase serum testosterone concentration in men and serum estradiol concentration in women.@@14924798@Prostate cancer: Zoladex is indicated in the management of prostate cancer suitable for hormonal manipulation. Advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation. Zoladex 3.6 mg is indicated as an alternative to chemotherapy in the standard of care for pre/perimenopausal women with oestrogen receptor (ER) positive early breast cancer. Endometriosis: In the management of endometriosis, Zoladex alleviates symptoms, including pain, and reduces the size and number of endometrial lesions. Endometrial thinning: Zoladex is indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection. Uterine fibroids: In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery. Assisted reproduction: Pituitary downregulation in preparation for superovulation.@@NO@@@NO REVIEW@@@@100%@@@@124@One 3.6 mg depot of Zoladex injected subcutaneously into the anterior abdominal wall, every 28 days. No dosage adjustment is necessary for patients with renal or hepatic impairment, or in the elderly.@@@@@@@Males: the use of Zoladex in men at particular risk of developing ureteric obstruction or spinal cord compression should be considered carefully, and the patients monitored closely during the first month of therapy. Consideration should be given to the initial use of an anti-androgen (e.g. cyproterone acetate 300 mg daily for three days before and three weeks after commencement of Zoladex) at the start of LHRH analogue therapy since this has been reported to prevent the possible sequelae of the initial rise in serum testosterone. If spinal cord compression or renal impairment due to ureteric obstruction are present or develop, specific standard treatment of these complications should be instituted. Females: the use of LHRH agonists in women may cause a loss of bone mineral density. Following two years treatment for early breast cancer, the average loss of bone mineral density was 6.2% and 11.5% at the femoral neck and lumbar spine respectively. This loss has been shown to be partially reversible at the one year off treatment follow-up with recovery to 3.4% and 6.4% relative to baseline at the femoral neck and lumbar spine respectively, although this recovery is based on very limited data.@SWOG-8692 [INT-0075]@No@@124 PREMENOPAUSAL WOMEN WITH ADVANCED ESTROGEN RECEPTOR POSITIVE OR PROGESTERONE RECEPTOR POSITIVE BREAST CANCER WERE RANDOMISED TO 2 TREATMENT GROUPS: THE FIRST RECAIVED ZOLADEX, THE SECOND HAD OOPHORECTOMY.@@@CLINICAL STUDIES - BREAST CANCER: SWOG-8692 [INT-0075]@APPROVED@@Repeats: 5 (tablet), 3 (injection)@PBS@The best objective response (CR+PR) for the Zoladex group is 22% versus 12% for the oophorectomy group. The median time to treatment failure is 6.7 months for patients treated with Zoladex and 5.5 months for patients treated with oophorectomy. The median survival time for the Zoladex arm is 33.2 months and for the oophorectomy arm is 33.6 months. Subjective responses were observed with both treatments; 48% of the women in the Zoladex treatment group and 50% in the oophorectomy group had subjective responses.@@@@@MONO@GOSERELIN ACETATE@@@@@GOSERELIN ACETATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZOLADEX@@@@@ZOLADEX||||@LH-RH Analog@@@@@LH-RH Analog||||@RESPONSE RATE@TIME TO TREATMENT FAILURE@OVERALL SURVIVAL@@@OVERALL SURVIVAL@@@@@ADVANCED@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Dosage Value Phase 1@@@6.7@month@6.7 month@3275.23@3275.23@16.07@1@0.779@272.65@307.53@293.15@@@@@@@@@@75.74@@@@@@@@@@@@@@@@8/1/2017@272.65@272.65@3695-1193-GE-AP@SUBCUTANEOUS IMPLANT IN PRE-FILLED INJECTION SYRINGE@A$@@@@@@@@3.6@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15408109@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients in the study will be randomized to receive ofatumumab in combination with chlorambucil or chlorambucil alone. Patients receiving ofatumumab in combination with chlorambucil will receive one infusion of ofatumumab at 300 mg, one infusion at 1000 mg a week later, followed by up to 11 monthly infusions at 1000 mg. Patients will be evaluated for disease status one month following last treatment then every 3 months for 5 years. SOURCE: Genmab@@L01XC10@L01X@-@COPENHAGEN, DENMARK@3/1/2013@@Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.@@15408109@ARZERRA (ofatumumab) is indicated in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate;@Both@@@@NO REVIEW@@@@@>> Amendment to the licensing deal agreed; Genmab has sold its co-promotion option rights to GSK. The sale of the co-promotion option does not affect the royalty or milestone revenue that Genmab may receive. GSK will now be fully responsible for the entire sales organisation for ofatumumab. Genmab will receive a one-time payment of US$4.5 million from GSK upon the FDA's acceptance for review of the filing of the first BLA for ofatumumab in an oncology indication in the United States in exchange for terminating its option to co-promote ofatumumab. [Genmab, 19.12.2008]      >> GlaxoSmithKline acquired an exclusive worldwide license to ofatumumab as well as any other antibodies with affinity for CD20 which Genmab may develop. GSK and Genmab will co-develop ofatumumab; Genmab has an option to co-promote ofatumumab in a targeted oncology setting in the United States and in the Nordic region. In addition, if Genmab exercises the co-promotion option, Genmab would have had the option to co-promote GSK's Bexxar and Arranon in the United States and Atriance in the relevant countries of the Nordic region. [Genmab, December 2006]@FIRST-LINE@NCT00748189@447@Previously untreated CLL recommended dosage and schedule is: 300 mg on Day 1 followed by 1,000 mg on Day 8 (Cycle 1)/1,000 mg on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles until best response or a maximum of 12 cycles.@FDA, 17 April 2014@4/17/2014@@No@@12/1/2008@@OMB110911@No@@Patients with previously untreated CLL@@ADULTS@III@APPROVED@@@@Trial to start in 2008. [Genmab, 25 August 2008]@@@@@COMBO@OFATUMUMAB@CHLORAMBUCIL@@@@OFATUMUMAB|CHLORAMBUCIL|||@GENMAB@MEDAREX@GSK@@@GENMAB|MEDAREX|GSK||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ARZERRA@@@@@ARZERRA||||@mAb@Human@CD20@@@mAb|Human|CD20||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@@@@@@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@1@1@Invalid Factory Price@@@316@day@316 day@@@@10@1@@@@@@@@@@@@@@8@1@mg@1300@1@28@@mg@1000@1@@@@@@@@@00173-0808-05@CONCENTRATE FOR SOLUTION FOR INFUSION (WITH 2 FILTERS) - 5 ML@US$@@@@@@@@100@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916574@Onco@@@@@300f1010ntsdm@@@@@@Reolysin IV escalating doses with standard paclitaxel and carboplatin dose@@-@-@-@CALGARY, CANADA@@@Reolysin, a proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of all human cancers. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders. Reovirus, an acronym for Respiratory Enteric Orphan virus, is generally believed to inhabit the respiratory and bowel systems in humans. Reovirus is found naturally in sewage and water supplies. By age 12, half of all children show evidence of reovirus exposure and by adulthood, most people have been exposed. However, the disease is non-pathogenic, meaning there are typically no symptoms from infections. The link to its cancer-killing ability was established after the reovirus was discovered to reproduce well in various cancer cell lines. Tumours bearing an activated Ras pathway are deficient in their ability to activate the anti-viral response mediated by the host cellular protein, PKR. Since PKR is responsible for preventing reovirus replication, tumour cells lacking the activity of PKR are susceptible to reovirus replication. As normal cells do not possess Ras activations, these cells are able to stop reovirus infection through normal PKR activity. In tumour cells with an activated Ras pathway, reovirus is able to freely replicate and eventually kill the host tumour cells. As cell death occurs, progeny virus particles are then free to infect surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there are no longer any tumour cells carrying an activated Ras pathway available.@@14916574@Combo with paclitaxel and carboplatin@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@7/1/2007@-@REO-011@@-@-@@@I/II@II@@-@-@Fourteen patients have been treated to date: in nine evaluable late-stage head and neck cancer patients, eight of whom have refractory disease, four had durable partial responses and four others showed stable disease for periods of two, five plus, and eight cycles. Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response. Oncolytics is currently convening a group of experts in Europe and the U.S. to design a protocol for the Phase II/III trial, which will then be submitted to the FDA and EMEA for review. Following FDA and EMEA review, Oncolytics expects to file for approval for this trial early in 2009. [Oncolytics, 4.11.2008]@-@@@@COMBO@-@PACLITAXEL@CARBOPLATIN@@@-|PACLITAXEL|CARBOPLATIN||@ONCOLYTICS BIOTECH@@@@@ONCOLYTICS BIOTECH||||@@@@@@|||||||||@Head & Neck Cancer@Melanoma / Skin Cancer@NSCLC@Ovarian Cancer@@Head & Neck Cancer|Melanoma / Skin Cancer|NSCLC|Ovarian Cancer||||||@REOLYSIN@@@@@REOLYSIN||||@Vaccine@@@@@Vaccine||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@DOSE ESCALATION@NON-RANDOMISED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16671834@Onco@@@@@300f1010ntsdm@@@@@The Nordic VII study@@@L01XC06@L01X@@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671834@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX@@YES@29-Mar-17@3/29/2017@@@@@100%@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@FIRST-LINE@@@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 18 December 2013@12/18/2013@@No@@@@@No@@@(EGFR)-expressing, RAS WILD-TYPE@@@APPROVED@@29 March 2017: Recommended. Cetuximab is recommended, within its marketing authorisation, as an option for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults in combination with 5‑fluorouracil, folinic acid and oxaliplatin (FOLFOX). The drug is recommended only when the company provides it with the discount agreed in its patient access scheme. [NICE, https://www.nice.org.uk/guidance/ta439/chapter/1-Recommendations]@NHS@@@@@@COMBO@CETUXIMAB@FLUOROURACIL@LEUCOVORIN@OXALIPLATIN@@CETUXIMAB|FLUOROURACIL|LEUCOVORIN|OXALIPLATIN|@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@FOLFOX@@@@ERBITUX|FOLFOX|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@1.75@m²@27214.3924@@@7.9@month@7.9 month@27214.39@27214.39@113.26@1@1.299@890.5@@@@@@@@@@@@1.78@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@7/28/2017@890.5@890.5@1.15E+16@SOLUTION - INFUSION 100 ML@GB£@@@@@@@@500@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15004939@Onco@@@@@300f1020ntsdm@@@@@@Aflibercept once every 2 weeks versus placebo together with irinotecan/5-FU (FOLFIRI) combination@@L01XX44@L01X@YES@PARIS, FRANCE@@@Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis.@@15004939@ZALTRAP, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen@@YES@10-Sep-14@9/10/2014@NO REVIEW@@@@@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@SECOND-LINE@NCT00561470@1200@4 mg/kg as an intravenous infusion over 1 hour every 2 weeks.@EMA, 5 February 2013@2/5/2013@@No@@11/1/2007@YES@VELOUR@No@@@@@EFC10262, AVE0005, EudraCT 2007-000820-42;@APPROVED@@Inclusion in Class H on 10 September 2014 [gazetta ufficiale, http://www.gazzettaufficiale.it/eli/id/2014/09/26/14A07277/sg;jsessionid%3Dg10doumVY1spe1IYUxyc5g__.ntc-as2-guri2a]@SSN@The VELOUR trial showed that in patients previously treated with an oxaliplatin-containing regimen,  adding ZALTRAP to FOLFIRI significantly improved median survival from 12.06 months to 13.50  months (HR=0.817 (95% CI 0.714 to 0.935; p=0.0032), an 18 percent relative risk reduction. A significant improvement in progression-free survival from 4.67 months to 6.90 months (HR=0.758 95% CI 0.661 to 0.869; p=0.00007), a 24 percent relative risk reduction, was also observed. The overall response rate in the ZALTRAP plus FOLFIRI arm was 19.8% vs. 11.1% for FOLFIRI (p=0.0001).   [Sanofi 8 October 2012 http://en.sanofi.com/Images/31196_20121008_ZALTRAPVELOUR_en.pdf ]Trial met primary endpoint of improving overall survival. Full results to be presented at an upcoming medical meeting [Sanofi-Aventis, 26 April 2011, http://en.sanofi-aventis.com/binaries/20110426_VELOUR_en_tcm28-31928.pdf ]>>RESULTS PENDING@The most frequent adverse events reported with ZALTRAP in combination with FOLFIRI werediarrhea, asthenia/fatigue, stomatitis and ulceration, nausea, infection, hypertension,gastrointestinal and abdominal pains, vomiting, decreased appetite, decreased weight,epistaxis, alopecia, and dysphonia.@@@@COMBO@AFLIBERCEPT@IRINOTECAN@FLUOURACIL@@@AFLIBERCEPT|IRINOTECAN|FLUOURACIL||@SANOFI-AVENTIS@REGENERON PHARMACEUTICALS@@@@SANOFI-AVENTIS|REGENERON PHARMACEUTICALS|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ZALTRAP@5-FU@FOLFIRI@@@ZALTRAP|5-FU|FOLFIRI||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@76.5@kg@17387.6577@@@6.9@month@6.9 month@17387.66@17387.66@82.85@1@1.1229@758.1@1251.17@792.22@@@@@@@@@@3.79@14@@mg/kg@4@1@@@@@@@@@@@6/7/2017@758.1@758.1@42689036@PREPARATION FOR INJECTION, 4 ML@EURO@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16641727@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16641727@Maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.@@NA@@@NO REVIEW@@@@@@MAINTENANCE@@@The recommended starting dose of REVLIMID is 10 mg once daily continuously (Days 128 of repeated 28day cycles) until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, the dose can be increased to 15 mg once daily if tolerated.@FDA, 22 February 2017@2/22/2017@@Yes@@@@@No@@@@@@APPROVED@@@@The current approval was based on two randomized, controlled trials evaluating the efficacy and safety of lenalidomide maintenance therapy for the treatment of multiple myeloma patients after autologous stem cell transplant (CALGB 100104 and IFM 2005-02 trials). These trials demonstrated approximately a 15-month (CALGB) and 18-month (IFM) progression-free survival advantage, at the time of the primary analysis, in patients treated with lenalidomide compared with patients receiving placebo (hazard ratio (HR) in CALGB=0.38; 95% CI: 0.27, 0.54; p<0.001 and HR in IFM=0.50; 95% CI: 0.39, 0.64; p<0.001). The median overall survival was 111 and 106 months for patients treated with lenalidomide compared with 84 and 88 months for patients receiving placebo in the CALGB and IFM trials, respectively.[FDA, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm]@The types, frequency, and severity of adverse events (AEs) observed in the two trials were similar to those previously described in the product label. Neutropenia, affecting 56% of the 517 patients treated with lenalidomide in both trials, was the most frequently reported grade 3/4 AE. An increased incidence of second primary malignancies was reported among patients treated with lenalidomide compared with those receiving placebo. The lenalidomide product label notes an increase in second primary malignancies in patients with multiple myeloma treated with lenalidomide.[FDA, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm]@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@@@@@@1@1@417712.7067@@@38@month@38 month@417712.71@417712.71@361.4@100@1@60766.98@@@@@@@@@@@@24.31@1@30.42@mg@10@1@1@@mg@15@1@@@@@@8/2/2017@607.67@607.67@59572-0425-00@HARD CAPSULE@US$@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916161@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase. [SOURCE: clinicaltrials.gov]@@-@-@-@-@9/1/2010@@TM601, or chlorotoxin, is a synthetic polypeptide based on the amino acid sequences originally isolated from the venom of the scorpion Leiurus quinquestriatus.  Preclinical studies with labeled and unlabeled TM601 in animal models have revealed a number of important findings that support the premise for therapeutic benefits in brain tumors.  TM601, conjugated with a radioisotope, has been studied in several clinical indications including, glioma and melanoma.@@14916161@Intravenously Administered 131I-TM601 in Adult Patients With Progressive and/or Recurrent Malignant Melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00733798@58@-@-@@@>> FDA orphan drug designation for advanced melanoma. [TransMolecular, 24.12.2008]@@11/1/2008@-@TM601-011@@-@>> Have histologically proven Stage IIIc or IV malignant melanoma with documented progression during or following the most recent prior melanoma therapy.     >> Have measurable disease, defined as lesions that can be accurately measured in at least one dimension as > 20 mm with conventional techniques (CT) or > 10 mm with spiral CT scan or brain MRI.      >> Have failed at least 1 prior therapy for melanoma or refused first-line, standard therapy.@ADULT@@I/II@II@@-@-@Trial registered [TransMolecular, 11.08.2008]@-@@@@MONO@CHLOROTOXIN@@@@@CHLOROTOXIN||||@TRANSMOLECULAR@@@@@TRANSMOLECULAR||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TM-601@@@@@TM-601||||@Synthetic Peptide@@@@@Synthetic Peptide||||@SAFETY@6-MONTH PROGRESSION-FREE SURVIVAL@@@@RESPONSE RATE@TIME TO PROGRESSION@@@@MALIGNANT@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922040@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01CA02@L01C@YES@@@@Vincristine is an antineoplastic drug with broad-spectrum anti-tumor activity in man. The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase. The drug is relatively marrow-sparing and is thus suitable for use in combination with other cancer chemotherapeutic agents. Vincristine is poorly absorbed orally. The clearance of the drug after rapid intravenous injection follows a triphasic decay pattern: a very rapid steep descent (alpha phase); a narrow-middle region (beta-phase) and a much longer terminal region (gamma phase). The terminal phase half-life of the drug varies from 15-155 hours. Dosing with the drug more frequently than once weekly is therefore probably unnecessary. Vincristine is primarily excreted by the biliary route. Patients with impaired hepatic or biliary function, as evidenced by a raised serum alkaline phosphatase, have been shown to have a significantly prolonged vincristine elimination half-life.@@14922040@Vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of:  1. Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia 2. Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas.  3. Multiple myeloma.  4. Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.  5. Paediatric solid tumours, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumour, retinoblastoma and medulloblastoma. 6. Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.@@NO@@@NO REVIEW@@@@100%@@@@@The drug is administered intravenously at weekly intervals. The usual dose of vincristine injection for children is 2 mg/m². For children weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of vincristine sulfate injection for adults is 1.4 mg/m². A 50% reduction in the dose of vincristine sulfate injection is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.@@@@@@@This preparation should be administered by individuals experienced in the administration of vincristine sulfate injection. It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissues during intravenous administration of vincristine sulfate injection may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. Fatal if given intrathecally.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@VINCRISTINE SULPHATE@@@@@VINCRISTINE SULPHATE||||@GENUS PHARMA@@@@@GENUS PHARMA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||@ONCOVIN@@@@@ONCOVIN||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@12.41@@14.18@@@@@@@@@@12.41@@@@@@@@@@@@@@@@7/28/2017@12.41@12.41@UK_BNF_1069720169@INJECTION, VIAL - 1 ML@GB£@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918418@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@HOLZKIRCHEN, GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918418@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1511@260.52@340.36@269.42@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@13.03@13.03@4432624@TRANSDERMAL PATCH@EURO@@@@@@@@75@MCG@75 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917567@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients were randomised to Epogen 40,000 Units weekly (n = 174) or placebo (n = 170) SC. If hemoglobin had not increased by > 1 g/dL, after 4 weeks of therapy or the patient received RBC transfusion during the first 4 weeks of therapy, study drug was increased to 60,000 Units weekly. Forty-three percent of patients in the Epoetin alfa group required an increase in Epogen® dose to 60,000 Units weekly.@@B03XA01@B03X@YES@THOUSAND OAKS, CALIFORNIA@@@Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment. The apparent molecular weight of erythropoietin is 32,000 to 40,000 dalton. The protein fraction of the molecule contributes about 58% and consists of 165 amino acids. The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein. Epoetin alfa obtained by gene technology is glycosylated and is identical in its amino acid and carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients. Epoetin alfa has the highest possible purity according to the present state of the art. In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.@@14917567@Treatment of Anaemia of Chronic Renal Failure Patients: indicated for the treatment of anaemia associated with CRF, including patients on dialysis and patients not on dialysis. Epogen is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or haemoglobin determinations) and to decrease the need for transfusions in these patients. Non-dialysis patients with symptomatic anemia considered for therapy should have a haemoglobin less than 10 g/dL. It is not intended for patients who require immediate correction of severe anaemia. It may obviate the need for maintenance transfusions but is not a substitute for emergency transfusion. Treatment of Anaemia in Zidovudine-treated HIV-infected Patients Epogen is indicated for the treatment of anaemia related to therapy with zidovudine in HIV-infected patients. Epogen is indicated to elevate or maintain the red blood cell level (as manifested by the haematocrit or haemoglobin determinations) and to decrease the need for transfusions in these patients. Epogen is not indicated for the treatment of anemia in HIV- infected patients due to other factors such as iron or folate deficiencies, haemolysis, or gastrointestinal bleeding, which should be managed appropriately. Treatment of Anaemia in Cancer Patients on Chemotherapy: Epogen is indicated for the treatment of anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. Epogen is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months. Epogen is not indicated for the treatment of anaemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately. Procrit use has not been demonstrated in controlled clinical trials to improve symptoms of anaemia, quality of life, fatigue, or patient well-being. Epogen is not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy. Reduction of Allogeneic Blood Transfusion in Surgery Patients Epogen is indicated for the treatment of anemic patients (hemoglobin > 10 to 13 g/dL) who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Epogen is not indicated for anaemic patients who are willing to donate autologous blood@@NO@@@NO REVIEW@@@@Precertification required. SOURCE: Aetna Preferred Drug Guide 2008@@@@344@The initial recommended dose in adults is 150 Units/kg SC TIW or 40,000 Units SC Weekly. The initial recommended dose of in paediatric patients is 600 Units/kg IV weekly. Discontinue following the completion of a chemotherapy course.@FDA, 26 July 1999@7/26/1999@@@@@[updated November 2007] Renal failure: Patients experienced greater risks for death and serious cardiovascular events when administered ESAs to target higher versus lower haemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Dosing must be individualised to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL. Cancer: ESAs shortened overall survival and/or TTP in clinical studies in patients with advanced breast, head and neck, lymphoid, and NSCLC malignancies when dosed to target a haemoglobin of > 12 g/dL. The risks of shortened survival and tumour progression have not been excluded when ESAs are dosed to target a haemoglobin of < 12 g/dL. To minimise these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions. Use only for treatment of anaemia due to concomitant myelosuppressive chemotherapy. Discontinue following the completion of a chemotherapy course. Perisurgery: Procrit increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.@@No@4-Dec@344 ANAEMIC CANCER PATIENTS, AMONG WHICH 61 (35 PLACEBO ARM AND 26 IN THE EPOGEN ARM) PATIENTS WERE TREATED WITH CONCOMITANT CISPLATIN CONTAINING REGIMENS AND 283 PATIENTS RECEIVED CONCOMITANT CHEMOTHERAPY REGIMENS THAT DID NOT CONTAIN CISPLATINUM.@@@CLINICAL EXPERIENCE: RESPONSE TO EPOGEN / CANCER PATIENTS ON CHEMOTHERAPY / ADULT PATIENTS / WEEKLY (QW) DOSING@APPROVED@@@MEDICARE@Reduced the proportion of patients transfused in day 29 through week 16 of the study as compared to placebo. Twenty-five patients (14%) in the Epogen group received transfusions compared to 48 patients (28%) in the placebo group (p = 0.0010) between day 29 and week 16 or the last day on study.@@@@@MONO@EPOETIN ALFA@@@@@EPOETIN ALFA||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@EPOGEN@@@@@EPOGEN||||@EPO@@@@@EPO||||@REDUCTION IN TRANSFUSIONS@@@@@@@@@@@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@18743.76@18743.76@@10@1@331.6@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@33.16@33.16@55513-0126-10@INJECTION (VIAL)@US$@@@@@@@@2000@UI@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16793405@Onco@@@@@300f1010ntsdm@@@@@@•Experimental: Mekinist. •Active Comparator: Chemotherapy paclitaxel•Experimental: Crossover. Mekinist after documented progression on Chemotherapy Arm@@L01XE25@L01X@@BASEL, SWITZERLAND@10/1/2011@@Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Trametinib inhibits growth of BRAF V600 mutant melanoma cell lines and demonstrates anti-tumour effects in BRAFV600 mutant melanoma animal models.@@16793405@Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation@Both@NO@@@NO REVIEW@@@@100%@@@NCT01245062@322@2 mg once daily@EMA, 30 June 2014@6/30/2014@@No@@11/1/2010@@114267@No@@Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory; Received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy, biological or vaccine regimen is permitted. Prior use of sorafenib is allowed; Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Women of childbearing potential and men with reproductive potential must agree to use effective contraception during the study. Additionally women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1; Adequate screening organ function@BRAF V600E mutation@ADULTS@III@APPROVED@@@NHS@@@@@@MONO@TRAMETINIB@@@@@TRAMETINIB||||@NOVARTIS @@@@@NOVARTIS ||||@World@@@@@World|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@MEKINIST@@@@@MEKINIST||||@MEK Inhibitor@@@@@MEK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@CROSS OVER ASSIGNMENT@OPEN-LABEL@@@1@1@23359.488@@@4.8@month@4.8 month@23359.49@23359.49@160@7@1.299@1120@@@@@@@@@@@@80@1@@mg@2@1@@@@@@@@@@@7/28/2017@160@160@3.11E+16@FILM COATED TABLET@GB£@@@@@@@@2@MG@2 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919161@Onco@@@@@300f1020ntsdm@@@@@@NO LABELLED TRIAL@@-@-@YES@UNTERACH, AUSTRIA@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919161@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@-@@NO REVIEW@@@@100%@Novartis acquires Ebewe in US$1.2 billion deal. [Novartis, 19 May 2009]@-@-@-@First-line chemotherapy of breast carcinoma: When used in combination with doxorubicin (50 mg/m2), paclitaxel should be administered 24 hours after doxorubicin. The recommended dose of paclitaxel is 220 mg/m2 administered intravenously over a period of 3 hours, with a 3-week interval between course@N/A@@@-@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@@-@-@@@-@APPROVED@@1@SSN@NO LABELLED TRIAL@-@@@@-@PACLITAXEL@@@@@PACLITAXEL||||@EBEWE PHARMA@NOVARTIS@SANDOZ@@@EBEWE PHARMA|NOVARTIS|SANDOZ||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@300@MG@6 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14924317@Onco@@@@@300f1020ntsdm@@@@@@Patients received either Xeloda 1250 mg/m2 twice daily for 14 days followed by 1 week without treatment and docetaxel 75 mg/m2 as a 1-hour intravenous infusion administered in 3-week cycles, or docetaxel 100 mg/m2 as a 1-hour intravenous infusion administered in 3-week cycles.@@L01BC06@L01B@YES@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924317@Xeloda is indicated for the treatment of first-line treatment of advanced gastric cancer in combination with a platinum-based regimen@@YES@-@@NO REVIEW@@@@100%@-@FIRST-LINE@-@511@In combination treatment, the recommended starting dose of capecitabine should be reduced to 800 - 1000 mg/m2 when administered twice daily for 14 days followed by a 7-day rest period, or to 625 mg/m2 twice daily when administered continuously.@N/A@@@-@@@Patients with moderate renal impairment at baseline require dose reduction. Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking Xeloda concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Xeloda can induce diarrhea, sometimes severe. Patients =80 years old may experience a greater incidence of grade 3 or 4 adverse events (diarrhea, nausea, hand-and-foot syndrome, and vomiting).  Xeloda may cause fetal harm when given to a pregnant woman.@LABEL@No@-@PATIENTS WITH METASTATIC BREAST CANCER RESISTANT TO, OR RECURRING DURING OR AFTER AN ANTHRACYCLINE-CONTAINING THERAPY, OR RELAPSING DURING OR RECURRING WITHIN 2 YEARS OF COMPLETING AN ANTHRACYCLINE-CONTAINING ADJUVANT THERAPY WERE RANDOMIZED TO RECEIV; OPEN-LABEL, MULTICENTRE, RANDOMISED TRIAL IN 75 CENTRES IN EUROPE, NORTH AMERICA, SOUTH AMERICA, ASIA, AND AUSTRALIA.@@@III; BREAST CANCER COMBINATION THERAPY@APPROVED@@-@SSN@Xeloda in combination with docetaxel resulted in statistically significant improvement in TTP, OS and objective RR compared to monotherapy with docetaxel: Median TTP was of 186 days (95% CI: 165-198) for the combination therapy compared to 128 days (95% CI: 105-136) for the monotherapy with docetaxel (p=0.0001, hazard ratio: 0.643). Overall survival was of 442 days (95% CI: 375-497) for the combination therapy compared to 352 days (95% CI: 298-387) for the monotherapy with docetaxel (p=0.0126, hazard ratio: 0.775). RR was of 32% for the combination therapy compared to 22% for the monotherapy with docetaxel (p=0.009).@-@@@@COMBO@CAPECITABINE@DOCETAXEL@@@@CAPECITABINE|DOCETAXEL|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@XELODA@GENERIC@@@@XELODA|GENERIC|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@TIME TO PROGRESSION@OVERALL SURVIVAL@RESPONSE RATE@@@RESPONSE RATE@@@@@ADVANCED@@@@@OPEN-LABEL@MULTI-CENTRE@RANDOMISED@@@1.75@m²@3627.593165@@@10.5@month@10.5 month@3627.59@3627.59@11.36@60@1.1229@48.68@80.34@50.87@@@@@@@@@@@21@@mg/m²@1800@14@@@@@@@@@@@6/7/2017@0.81@0.81@35219017@FILM COATED TABLET (BLISTER PVDC/PVC)@EURO@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921256@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01DC03@L01D@YES@@@@Mitomycin-C Kyowa is an antitumour antibiotic that is activated in the tissues to an alkylating agent which disrupts deoxyribonucleic acid (DNA) in cancer cells by forming a complex with DNA and also acts by inhibiting division of cancer cells by interfering with the biosynthesis of DNA.@@14921256@Recommended for certain types of cancer in combination with other drugs or after primary therapy has failed. It has been successfully used to improve subjective and objective symptoms in a wide range of neoplastic conditions. 1. As a single agent in the treatment of superficial bladder cancer. In addition it has been shown that post-operative instillations of Mitomycin-C can reduce recurrence rates in newly diagnosed patients with superficial bladder cancer. 2. As a single agent and in combination with other drugs in metastatic breast cancer. 3. In combination with other agents in advanced squamous cell carcinoma of the uterine cervix. 4. It shows a degree of activity as part of combination therapy in carcinoma of the stomach, pancreas and lung (particularly non-small cell). 5. It shows a degree of activity as a single agent and in combination in liver cancer when given by the intra-arterial route. 6. It has a possible role in combination with other cytotoxic drugs in colo-rectal cancer. 7. It shows a degree of activity as a single agent or part of combination therapy in cancer of the head and neck. 8. It shows a degree of activity as a single agent in cancer of the prostate. 9. It has a possible role in skin cancer. 10. It has a degree of activity in leukaemia and non-solid tumours. 11. It has a possible role in sarcomas. 12. It has been successfully used in combination with surgery, pre-operatively (oesophageal squamous cell carcinoma) and post-operatively (gastric cancer). 13. It has shown to be effective when used in combination with radiotherapy.@@NO@@@NO REVIEW@@@@100%@Merger between Kyowa Hakko and Kirin Pharma announced in October 2007.@@@@Intravenously, the dose should be given as slowly as possible and with great care in order to avoid extravasation. The usual dose is in the range of 4 – 10mg (0.06-0.15mg/kg) given at 1 – 6 weekly intervals depending on whether other drugs are given in combination and on bone marrow recovery. In a number of combination schedules, the dose is 10mg/m2 of body surface area, the course being repeated at intervals for as long as required. A course ranging from 40-80mg (0.58 –1.2mg/kg) is often required for a satisfactory response when used alone or in combination. A higher dosage course may be given when used alone or as part of a particular combination schedule and total cumulative doses exceeding 2mg/kg have been given.@EMA, November 1992@@@@@@Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Bone marrow suppression, notably thromboytopaenia and leukopaenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic side effects. HUS has been reported in patients receiving systemic mitomycin.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@MITOMYCIN@@@@@MITOMYCIN||||@KYOWA HAKKO KOGYO@KIRIN PHARMA@@@@KYOWA HAKKO KOGYO|KIRIN PHARMA|||@@@@@@|||||||||@NSCLC@Pancreatic Cancer@Liver Cancer@Colorectal Cancer@@NSCLC|Pancreatic Cancer|Liver Cancer|Colorectal Cancer||||||@MITOMYCIN C@@@@@MITOMYCIN C||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@5.15@@5.88@@@@@@@@@@2.58@@@@@@@@@@@@@@@@7/28/2017@5.15@5.15@UK_BNF_31836473@INJECTION POWDER FOR RECONSTITUTION@GB£@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920933@Onco@@@@@300f1015ntsdm@@@@@@Leukine was given SC at 250 mcg/m2/day once a day (n=10) or twice a day (n=21) until completion of the phereses. Phereses were begun on day 5 of Leukine administration and continued until the targeted MNC count of 9 x 108/kg or CD34+ cell count of 1 x 106/kg was reached.@@L03AA09@L03A@NO@LEVERKUSEN, GERMANY@@@Sargramostim, a yeast-derived, recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF), is a multilineage growth factor that accelerates myeloid recovery. Like other CSFs, LEUKINE stimulates neutrophils to produce antibacterial activity. Unlike other CSFs, it also stimulates monocytes/macrophages to provide antibacterial and antifungal activity.@@14920933@Use Following Induction Chemotherapy in Acute Myelogenous Leukaemia (AML): indicated for use following induction chemotherapy in older adult patients with AML to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death. Use in Mobilisation and Following Transplantation of Autologous Peripheral Blood Progentior Cells: indicated for the mobilisation of haematopoietic progenitor cells into peripheral blood for collection by leukapheresis.  Use in Myeloid Reconstitution After Autologous Bone Marrow Transplantation (BMT): indicated for acceleration of myeloid recovery in patients with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukaemia (ALL) and Hodgkin's disease undergoing autologous BMT. Use in Myeloid Reconstitution After Allogeneic BMT: indicated for acceleration of myeloid recovery in patients undergoing allogeneic BMT from HLA-matched related donors. Use in BMT Failure or Engraftment Delay: indicated in patients who have undergone allogeneic or autologous BMT in whom engraftment is delayed or has failed.@@NO@@@NO REVIEW@@@@@@@@@Neutrophil Recovery Following Chemotherapy in AML: The recommended dose is 250 mcg/m2/day administered intravenously over a 4 hour period starting approximately on day 11 or four days following the completion of induction chemotherapy, if the day 10 bone marrow is hypoplastic with <5% blasts. If a second cycle of induction chemotherapy is necessary, it should be administered approximately four days after the completion of chemotherapy if the bone marrow is hypoplastic with <5% blasts. Mobilisation of Peripheral Blood Progenitor Cells: The recommended dose is 250 mcg/m2/day administered IV over 24 hours or SC once daily. Post Peripheral Blood Progenitor Cell Transplantation: The recommended dose is 250 mcg/m2/day administered IV over 24 hours or SC once daily beginning immediately following infusion of progenitor cells and continuing until an ANC>1500 cells/mm3 for three consecutive days is attained.  Myeloid Reconstitution After Autologous or Allogeneic Bone Marrow Transplantation: The recommended dose is 250 mcg/m2/day administered IV over a 2-hour period beginning two to four hours after bone marrow infusion, and not less than 24 hours after the last dose of chemotherapy or radiotherapy. Bone Marrow Transplantation Failure or Engraftment Delay: The recommended dose is 250 mcg/m2/day for 14 days as a 2-hour IV infusion. The dose can be repeated after 7 days off therapy if engraftment has not occurred. If engraftment still has not occurred, a third course of 500 mcg/m2/day for 14 days may be tried after another 7 days off therapy.@TEMPORARY USE (ATU) ONLY.@@@@@@Pediatric use: Because Leukine contains benzyl alcohol, it should not be administered to premature infants. Fluid Retention: Edema, capillary leak syndrome, pleural and/or pericardial effusion have been reported in patients after Leukine administration. Respiratory Symptoms: Sequestration of granulocytes in the pulmonary circulation following Leukine infusion and dyspnea have been reported. Cardiovascular Symptoms: Occasional transient supraventricular arrhythmia has been reported during Leukine administration, particularly in patients with a previous history of cardiac arrhythmia. Renal and Hepatic Dysfunction: In patients with preexisting renal or hepatic dysfunction, administration of Leukine has induced elevation of serum creatinine or bilirubin and hepatic enzymes.@@No@@PATIENTS UNDERGOING PBPC (PERIPHERAL BLOOD PROGENITOR CELLS) TRANSPLANT@@@MOBILISATION AND ENGRAFTMENT OF PBPC; 2ND RETROSPECTIVE REVIEW, DATA FROM A SINGLE TRANSPLANT CENTRE@APPROVED@@Temporary use (ATU) only.@HAUTE AUTORITÉ DE SANTÉ@There was no difference in CD34+ cell count in patients receiving Leukine once or twice a day. The median time to neutrophil recovery was 12 days and to platelet recovery was 23 days.@@@@@MONO@SARGRAMOSTIM@@@@@SARGRAMOSTIM||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Supportive Care@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@Supportive Care|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|||||@LEUKINE@@@@@LEUKINE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@TIME TO NEUTROPHIL RECOVERY@@@@@@@@@@@@@@@RETROSPECTIVE@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+24@INJECTABLE SOLUTION, 1 ML@EURO@@@@@@@@500@MCG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14917206@Onco@@@@@300f1018ntsdm@@@@@@198 patients who received combination irinotecan/ infusional 5-FU/LV therapy given weekly were compared with 187 patients who received an infusional regimen of 5-FU/LV alone given daily for 5 days every 4 weeks. @@L01XX19@L01X@YES@-@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14917206@Campto is indicated for the treatment of patients with advanced colorectal cancer: • in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, • as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.  Campto in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Campto in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.@@YES@-@@NO REVIEW@@@@100%@Licensing deal between Daiichi and Yakult terminated upon expiration of patent. The two companies will independently pursure their irinotecan businesses. [Daiichi Saynko, 17.09.2007]@SECOND-LINE@-@385@Once-every-3 week regimen: 350mg/m2 IV over 90 minutes, once every 3 weeks@-@@@-@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@@-@PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR THE RECTUM RANDOMISED IN 2 ARMS. CONCOMITANT MEDICATIONS SUCH AS ANTIEMETICS, ATROPINE, AND LOPERAMIDE WERE GIVEN TO PATIENTS FOR PROPHYLAXIS AND/OR MANAGEMENT OF SYMPTOMS FROM TREATMENT. PATIENTS ALS@@@STUDY 2 OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FU/LV FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER@DISCONTINUED@@Authority required: Metastatic colorectal cancer in patients with a WHO performance status of 2 or less. In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.@PBS@The combination of irinotecan/ infusional 5-FU/LV therapy resulted in significant improvements in objective tumour RRs (35% vs 22% p<0.005), TTP (6.7 months vs 4.4 months p=0.001), and survival (17.4 months vs 14.1 months p<0.05) when compared with infusional 5-FU/LV alone.@-@@@@MONO@IRINOTECAN@@@@@IRINOTECAN||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CAMPTOSAR@@@@@CAMPTOSAR||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@@@@@@ADVANCED@@@@@RANDOMISED@CONTROLLED@INTERNATIONAL@@@@@Invalid Factory Price@@@3.9@month@3.9 month@@@@1@0.8893@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@L01XX194451GPF100MG5ML@CONCENTRATE FOR INJECTION - 5 ML@A$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15361156@Onco@@@@@300f1015ntsdm@@@@@DASISION@Patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily@@L01XE06@L01X@@NEW YORK, NEW YORK@12/1/2013@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361156@Indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.@Both@NO@@@NO REVIEW@@@@@@FIRST-LINE@NCT00481247@519@The recommended starting dose for chronic phase CML is 100 mg dasatinib once daily, administered orally.@EMA, 6 December 2010@12/6/2010@10/1/2011@Yes@@8/1/2007@@CA180-056/2006-005712-27@No@@Male & Female ≥18 years/Chronic Phase Ph+ CML/Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-2@@ADULTS@III@APPROVED@@Not assessed@HAUTE AUTORITÉ DE SANTÉ@@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RATE OF CONFIRMED COMPLETE CYTOGENETIC RESPONSE@@@@@@@@@@CHRONIC PHASE@PH+@@@@OPEN-LABEL@MULTICENTER@RANDOMISED@@@1@1@33675.88523@@@14@month@14 month@33675.89@33675.89@79.08@30@1.1511@3321.53@3521.17@3351.53@@@@@@@@@@0.79@1@@mg@100@1@@@@@@@@@@@8/1/2017@110.72@110.72@3.40E+12@FILM-COATED TABLET IN BLISTER PACK@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14916993@Onco@@@@@300f1010ntsdm@@@@@@Eighty-four patients were treated with 650 mg/m2/day of nelarabine administered intravenously over 1 hour daily for 5 consecutive days repeated every 21 days.@@L01BB07@L01B@YES@BRENTFORD, UNITED KINGDOM@@@When administered intravenously, nelarabine works by preventing the cells from producing DNA, which causes them to self-destruct. Nelarabine is a water-soluble pro-drug of ara-G, a nucleoside (deoxyguanosine) analogue. When injected into the body, nelarabine is chemically converted to Ara-G and then its active form, ara-GTP. Accumulation of ara-GTP in cancer cells leads to inhibition of DNA synthesis, which results in programmed cell death. Nelarabine is cytotoxic to T-cells with high potency and selectivity, compared to other types of cells involved in the immune response (e.g. B-cells, monocytes, macrophages).@@14916993@Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.@@NO@@@NO REVIEW@@@@100%@@@@151@Children and adolescents (aged 21 years and younger): The recommended dose of nelarabine for children is 650 mg/m2 administered intravenously over one hour daily for 5 consecutive days, repeated every 21 days. In clinical studies, the 650 mg/m2 and 1,500 mg/m2 have both been used in patients in the age range 16 to 21 years. Efficacy and safety were similar for both regimens. The prescribing physician should consider which regimen is appropriate when treating patients in this age range.@EMA, August 2007@@@Yes@@@NEUROLOGICAL ADVERSE EVENTS: Severe neurological events have been reported with the use of nelarabine. These events have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of events associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barré Syndrome. Full recovery from these events has not always occurred with cessation of nelarabine. Therefore, close monitoring for neurological events is strongly recommended, and nelarabine must be discontinued at the first sign of neurological events of NCI CTCAE Grade 2 or greater.@COG-P9673 [PAEDIATRIC]@No@@151 patients 21 years of age, 149 of whom had relapsed or refractory T-cell acute lymphoblastic leukaemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL); 39 of whom had received two or more prior induction regimens and 31 whom had received one prior induction regimen@PAEDIATRIC@@Childrens Oncology Group@APPROVED@@NO REVIEW@NHS@Of the 39 patients who had received two or more prior induction regimens, 5 (13%) [95% CI: 4%–27%] achieved a complete response (bone marrow blast counts 5%, no other evidence of disease, and full recovery of peripheral blood counts) and 9 (23%) [95% CI: 11%–39%] achieved complete responses with or without full haematological recovery. Duration of response in both classifications of response ranged between 4.7 and 36.4 weeks and median overall survival was 13.1 weeks [95% CI: 8.7–17.4] and survival at one year was 14% [95% CI: 3%–26%]. Thirteen (42%) of the 31 patients treated with one prior induction regimen achieved a complete response overall. Nine of these 31 patients failed to respond to prior induction (refractory patients). Four (44%) of the nine refractory patients experienced a complete response to nelarabine.@The safety profile from pivotal clinical trials at the recommended doses of nelarabine in adults (1,500 mg/m2) and children (650 mg/m2) is based on data from 103 adults and 84 paediatric patients respectively. The most frequently occurring adverse events were fatigue; gastrointestinal disorders; haematological disorders; respiratory disorders; nervous system disorders; and pyrexia. Neurotoxicity is the dose limiting toxicity associated with nelarabine therapy.@@@@MONO@NELARABINE@@@@@NELARABINE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@T-Cell Lymphoma@@@Haematological Malignancy|Acute Lymphocytic Leukaemia|T-Cell Lymphoma|||||||@ATRIANCE@@@@@ATRIANCE||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@COMPLETE RESPONSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@MULTI-CENTRE@@@@1.2@m²@7586.057142@@@46@day@46 day@7586.06@7586.06@164.91@6@1.2961@1332@@@@@@@@@@@@0.89@21@@mg/m²@650@5@@@@@@@@@@@8/21/2017@222@222@1.22E+16@SOLUTION FOR INTRAVENOUS  INFUSION, 50 ML@GB£@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16432019@Onco@@@@@300f1012ntsdm@@@@@@Experimental: Patients receive afatinib tablets once dailyActive Comparator: Patients receive erlotinib tablets once daily@@L01XE13@L01X@@INGELHEIM, GERMANY@10/1/2013@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.@@16432019@Giotrif as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.@Both@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@NCT01523587@795@The recommended dose is 40 mg once daily. GIOTRIF treatment should be continued until disease progression or until no longer tolerated by the patient@EMA, 25 February 2016@2/25/2016@@No@@3/1/2012@@LUX-Lung 8@No@@Diagnosis of advanced stage NSCLC squamous histology; Platinum-based doublet chemotherapy as 1st line treatment of Stage IIIB/IV NSCLC; Eligible to receive 2nd line therapy in the opinion of the investigator; Measurable disease according to RECIST 1.1; Adequate Performance Status; Availability of tumour tissue material for correlative studies. Archived tumour tissue is acceptable; Adequate organ function; Age = 18 years and above; Written informed consent that is consistent with ICH-GCP guidelines.@@ADULT@III@APPROVED@@@GKV@@@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GIOTRIF@@@@@GIOTRIF||||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@OBJECTIVE RESPONSE@DISEASE CONTROL@@@LOCALLY ADVANCED@METASTATIC@@@@PARALLEL ASSIGNMENT@RANDOMISED@OPEN LABEL@@@1@1@7637.796521@@@2.63@month@2.63 month@7637.8@7637.8@95.48@28@1.1511@2005.07@2514.93@2043.57@@@@@@@@@@2.39@1@@mg@40@1@@@@@@@@@@@8/1/2017@71.61@71.61@2.48E+06@FILM-COATED TABLET@EURO@@@@@@@@30@MG@30 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919832@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01CA02@L01C@YES@LAKE FOREST, ILLINOIS@@@Vincristine is an antineoplastic drug with broad-spectrum anti-tumor activity in man. The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase. The drug is relatively marrow-sparing and is thus suitable for use in combination with other cancer chemotherapeutic agents. Vincristine is poorly absorbed orally. The clearance of the drug after rapid intravenous injection follows a triphasic decay pattern: a very rapid steep descent (alpha phase); a narrow-middle region (beta-phase) and a much longer terminal region (gamma phase). The terminal phase half-life of the drug varies from 15-155 hours. Dosing with the drug more frequently than once weekly is therefore probably unnecessary. Vincristine is primarily excreted by the biliary route. Patients with impaired hepatic or biliary function, as evidenced by a raised serum alkaline phosphatase, have been shown to have a significantly prolonged vincristine elimination half-life.@@14919832@Vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of:  1. Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia 2. Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas.  3. Multiple myeloma.  4. Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.  5. Paediatric solid tumours, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumour, retinoblastoma and medulloblastoma. 6. Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.@@YES@@@NO REVIEW@@@@100%@Acquired via takeover of Mayne@@@@The drug is administered intravenously at weekly intervals. The usual dose of vincristine injection for children is 2 mg/m². For children weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of vincristine sulfate injection for adults is 1.4 mg/m². A 50% reduction in the dose of vincristine sulfate injection is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.@EMA, October 1995@@@@@@This preparation should be administered by individuals experienced in the administration of vincristine sulfate injection. It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissues during intravenous administration of vincristine sulfate injection may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. Fatal if given intrathecally.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@VINCRISTINE SULPHATE@@@@@VINCRISTINE SULPHATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Chronic Lymphocytic Leukaemia@Sarcoma@@Haematological Malignancy|Chronic Myeloid Leukaemia|Chronic Lymphocytic Leukaemia|Sarcoma||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@26.66@@@@@@@@@@@@13.33@@@@@@@@@@@@@@@@7/28/2017@26.66@26.66@1.50E+16@SOLUTION FOR INJECTION, VIAL, 2 ML@GB£@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14918552@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@H02AB07@H02A@NO@HOLZKIRCHEN, GERMANY@@@Prednisolone acetate is a synthetic adrenocorticoid with the general properties of prednisolone. Adrenocorticoids diffuse across cell membranes to complex with cytoplasmic receptors and subsequently stimulate synthesis of enzymes with anti-inflammatory effects. Glucocorticoids inhibit the oedema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation, deposition of collagen and scar formation. Prednisolone acetate has, on a weight to weight basis, a potency three to five times that of hydrocortisone.@@14918552@Indicated in the following conditions: Endocrine Disorders [Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcernia associated with cancer Nonsuppurative thyroiditis)] Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) [Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis] Collagen Diseases [During an exacerbation or as maintenance therapy in selected  cases of: Systemic lupus erythematosus Systemic-dermatomyositis (polymyositis) Acute rheumatic carditis] Dermatologic Diseases [Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis] Allergic States [Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions] Ophthalmic Diseases [Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic cornea marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis] Respiratory Diseases [Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis] Haematologic Disorders [Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopaenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia] Neoplastic Diseases For palliative management of: [Leukemias and lymphomas in adults Acute leukemia of childhood] Edematous States [To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis] Nervous System [Acute exacerbations of multiple sclerosis] Miscellaneous [Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement]@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@The initial dosage may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required.@@@@@@@In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination With other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@PREDNISONE@@@@@PREDNISONE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@12.28@26.51@13.37@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.12@0.12@2.46E+06@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916959@Onco@@@@@300f1018ntsdm@@@@@@Patients received either exemestane (25 mg/day) or tamoxifen (20 or 30 mg/day)@@L02BG06@L02B@NO@NEW YORK, NEW YORK@@@Exemestane is an irreversible, steroidal aromatase inhibitor, structurally related to the natural substrate androstenedione. In post-menopausal women, oestrogens are produced primarily from the conversion of androgens into oestrogens through the aromatase enzyme in peripheral tissues. Oestrogen deprivation through aromatase inhibition is an effective and selective treatment for hormone dependent breast cancer in postmenopausal women. In postmenopausal women, Aromasin p.o. significantly lowered serum oestrogen concentrations starting from a 5 mg dose, reaching maximal suppression (>90%) with a dose of 10-25 mg. In postmenopausal breast cancer patients treated with the 25 mg daily dose, whole body aromatization was reduced by 98%. Exemestane does not possess any progestogenic or oestrogenic activity. A slight androgenic activity, probably due to the 17-hydro derivative, has been observed mainly at high doses. In multiple daily doses trials, Aromasin had no detectable effects on adrenal biosynthesis of cortisol or aldosterone, measured before or after ACTH challenge, thus demonstrating its selectivity with regard to the other enzymes involved in the steroidogenic pathway. Glucocorticoid or mineralocorticoid replacements are therefore not needed. A non dose-dependent slight increase in serum LH and FSH levels has been observed even at low doses: this effect is, however, expected for the pharmacological class and is probably the result of feedback at the pituitary level due to the reduction in oestrogen levels that stimulate the pituitary secretion of gonadotropins also in postmenopausal women.@@14916959@Adjuvant treatment of postmenopausal women with estrogenreceptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy; the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.@@NO@@@NO REVIEW@@@@100%@@SECOND-LINE@@4724@The recommended dose of Aromasin in early and advanced breast cancer is one 25 mg tablet once daily after a meal. In postmenopausal women with early breast cancer who have been treated with 2–3 years of tamoxifen, treatment with Aromasin should continue in the absence of recurrence or contralateral breast cancer until completion of five years of adjuvant endocrine therapy. For patients with advanced breast cancer, treatment should continue until tumour progression is evident. For patients receiving Aromasin with a potent CYP 3A4 inducer such as rifampicin or phenytoin, the recommended dose is 50 mg once daily after a meal.@@@@@@@Aromasin Tablets may cause fetal harm when administered to a pregnant woman.@IES@No@@4724 PATIENTS WHO REMAINED DISEASE-FREE AFTER RECEIVING ADJUVANT TAMOXIFEN THERAPY FOR 2 TO 3 YEARS WERE RANDOMISED TO RECEIVE 3 TO 2 YEARS OF AROMASIN (2352 PATIENTS) OR TAMOXIFEN (2372 PATIENTS) TO COMPLETE A TOTAL OF 5 YEARS OF HORMONAL THERAPY.@@@ADJUVANT TREATMENT IN EARLY BREAST CANCER: THE INTERGROUP EXEMESTANE STUDY 031 (IES); RANDOMISED, DOUBLE-BLIND, MULTICENTRE, MULTINATIONAL STUDY COMPARING EXEMESTANE TO TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER.@APPROVED@@Unrestricted reimbursement.@PBS@Overall survival was not significantly different in the 2 groups, with 116 deaths occurring in the Aromasin group and 137 in the tamoxifen group.@@@@@ADJUVANT@EXEMESTANE@@@@@EXEMESTANE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AROMASIN@@@@@AROMASIN||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@OVERALL SURVIVAL@@@@@@@@@@EARLY@@@@@RANDOMISED@DOUBLE-BLIND@MULTI-CENTRE@@@1@1@3140.21545@@@1825@day@1825 day@3140.22@3140.22@1.72@30@0.7915@51.62@66.06@55.5@@@@@@@@@@0.07@1@@mg@25@1@@@@@@@@@@@9/1/2017@1.72@1.72@0434-0946-GE-PF@TABLET@A$@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15996556@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@RADIANT-4@Experimental: Participants will receive everolimus 10mg once daily until disease progression, intolerable toxicity, or consent withdrawalPlacebo Comparator: Matching placebo to everolimus with same dose@@L01XE10@L01X@@BASEL, SWITZERLAND@8/1/2017@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15996556@Treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease.@Both@NA@@@NO REVIEW@@@@@@@NCT01524783@302@The recommended dose of AFINITOR Tablets is 10 mg, to be taken once daily at the same time every day. Continue treatment until disease progression or unacceptable toxicity occurs.@FDA, 26 February 2016@2/26/2016@@No@@3/1/2012@@CRAD001T2302, 2011-002887-26@No@@Pathologically confirmed, well differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumor of GI or lung originNo history of and no active symptoms related to carcinoid syndromeIn addition to treatmentnaive patients, patients previously treated with SSA, Interferon (IFN), one prior line of chemotherapy, and/or PRRT are allowed into the study. Pretreated patients must have progressed on or after the last treatmentRadiological documented disease progression within 6 months prior to randomizationMeasurable diseaseWHO performance status ≤1Adequate bone marrow, liver and renal function@@ADULTS@III@APPROVED@@@@The clinical trial enrolled 302 patients with unresectable, locally advanced or metastatic, well differentiated (low or intermediate grade), non-functional (no current or prior history of carcinoid symptoms), neuroendocrine tumors (NET) of gastrointestinal or lung origin. All patients were required to have evidence of disease progression within 6 months prior to randomization. The major efficacy outcome measure was progression-free survival (PFS) based on independent radiological assessment per RECIST. Median PFS were 11 months and 3.9 months in the everolimus and placebo arms, respectively [HR 0.48 (95% CI: 0.35, 0.67), p <0.001, stratified log rank test]. Overall response rates were 2% in the everolimus arm and 1% in the placebo arm. At the planned interim analysis, there was no statistically significant difference in overall survival between arms. [FDA, 26 February 2016, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488028.htm]@Safety data were evaluated in 300 patients who received at least one dose of investigational drug. The median exposure duration to everolimus was 9.3 months; 64% of patients were treated for greater than or equal to 6 months and 39% were treated for greater than or equal to12 months.Everolimus was discontinued for adverse reactions in 29% of patients and dose reduction or delay was required in 70% of everolimustreated patients. Serious adverse reactions occurred in 42% of everolimustreated patients and included 3 fatal events (cardiac failure, respiratory failure, and septic shock). The most common adverse reactions (incidence greater than or equal to 30%) were stomatitis, infections, diarrhea, peripheral edema, fatigue and rash. The most common laboratory abnormalities (incidence greater than or equal to 50%) were anemia, hypercholesterolemia, lymphopenia, elevated aspartate transaminase (AST) and fasting hyperglycemia.[FDA, 26 February 2016, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488028.htm]@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@World@@@@@World|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@AFINITOR@@@@@AFINITOR||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@ADVANCED@UNRESECTABLE@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@1@1@158125.0387@@@11@month@11 month@158125.04@158125.04@472.61@28@1@13233.17@@@@@@@@@@@@47.26@1@@mg@10@1@@@@@@@@@@@8/2/2017@472.61@472.61@00078-0567-51@TABLET@US$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920131@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01BB04@L01B@YES@BEDFORD, OHIO@@@The selective toxicity cladribine towards certain normal and malignant lymphocyte and monocyte populations is based on the relative activities of deoxycytidine kinase, deoxynucleotidase and adenosine deaminase. It is postulated that cells with high deoxycytidine kinase and low deoxynucleotidase activities will be selectively killed by cladribine as toxic deoxynucleotides accumulate intracellularly. Cells containing high concentrations of deoxynucleotides are unable to properly repair single-strand DNA breaks. It can be distinguished from other chemotherapeutic agents affecting purine metabolism in that it is cytotoxic to both actively dividing and quiescent lymphocytes and monocytes, inhibiting both DNA synthesis and repair.@@14920131@Indicated for the treatment of active hairy cell leukaemia  as defined by clinically significant anaemia, neutropaenia, thrombocytopaenia or disease-related symptoms.@@YES@@@NO REVIEW@@@@@@@@@Recommended dose and schedule is a single course given by continuous infusion for 7 days at a dose of 0.09mg/kg/day. If patients do not respond, it is unlikely that they will benefit from additional courses. Therapy should be delayed or discontinued if neurotoxicity or renal toxicity occurs.@@@@@@@Severe bone marrow suppression, including neutropaenia, anaemia and thrombocytopaenia, has been commonly observed, especially at high doses. At initiation of treatment, most patients in the clinical studies had haematologic impairment as a manifestation of active Hairy Cell Leukemia. Following treatment, further haematologic impairment occurred before recovery of peripheral blood counts began. During the first two weeks after treatment initiation, mean Platelet Count, ANC, and Haemoglobin concentration declined and subsequently increased with normalisation of mean counts by Day 12, Week 5 and Week 8, respectively. The myelosuppressive effects were most notable during the first month following treatment. Forty-four percent (44%) of patients received transfusions with RBCs and 14% received transfusions with platelets during Month 1. Careful haematologic monitoring, especially during the first 4 to 8 weeks after treatment, is recommended. Fever (T ³ 100°F) was associated in approximately two-thirds of patients (131/196) in the first month of therapy. Virtually all of these patients were treated empirically with parenteral antibiotics. Overall, 47% (93/196) of all patients had fever in the setting of neutropaenia (ANC ² 1000), including 62 patients (32%) with severe neutropaenia (i.e., ANC ² 500).@@No@@@@@NO LABELLED TRIAL@APPROVED@@Covered; part B; specialty drug@MEDICARE@NO LABELLED TRIAL@@@@@@CLADRIBINE@@@@@CLADRIBINE||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Hairy Cell Leukaemia@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Hairy Cell Leukaemia|||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@@@@@@@@@@@@@@@@NO LABELLED TRIAL@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0115-01@SOLUTION FOR INJECTION (VIAL, NOVAPLUS) - 10 ML@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921885@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received SC administration of Neupogen (4 to 8 mcg/kg/day‚ days 4 to 17) or placebo after receiving standard dose chemotherapy with cyclophosphamide‚ doxorubicin‚ and etoposide.@@L03AA02@L03A@NO@THOUSAND OAKS, CALIFORNIA@@@Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. NEUPOGEN containing rmetHuGCSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes. In some severe chronic neutropenia patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dosedependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.@@14921885@To decrease the incidence of infection‚ as manifested by febrile neutropaenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropaenia with fever; reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML; to reduce the duration of neutropaenia and neutropaenia-related clinical sequelae‚ eg‚ febrile neutropaenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation; the mobilisation of haematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilisation allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilisation or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care. Also indicated for chronic administration to reduce the incidence and duration of sequelae of neutropaenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropaenia‚ cyclic neutropaenia‚ or idiopathic neutropaenia.@@NO@@@NO REVIEW@@@@Injectable medication that may be covered under the medical benefit. SOURCE: Aetna Preferred Drug Guide 2008@@@@210@Cancer Patients Receiving Myelosuppressive Chemotherapy: The recommended starting dose is 5 mcg/kg/day‚ administered as a single daily injection by SC bolus injection‚ by short IV infusion (15 to 30 minutes)‚ or by continuous SC or continuous IV infusion. It should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. It should be administered daily for up to 2 weeks‚ until the ANC has reached 10‚000/mm3 following the expected chemotherapy-induced neutrophil nadir. Cancer Patients Receiving Bone Marrow Transplant: The recommended dose following BMT is 10 mcg/kg/day given as an IV infusion of 4 or 24 hours‚ or as a continuous 24-hour SC infusion. For patients receiving BMT‚ the first dose should be administered at least 24 hours after cytotoxic chemotherapy and at least 24 hours after bone marrow infusion. Peripheral Blood Progenitor Cell Collection and Therapy in Cancer Patients: The recommended dose for the mobilisation of PBPC is 10 mcg/kg/day SC‚ either as a bolus or a continuous infusion. It is recommended that it be given for at least 4 days before the first leukapheresis procedure and continued until the last leukapheresis. Patients With Severe Chronic Neutropaenia: Starting Dose for the Congenital Neutropaenia: The recommended daily starting dose for the Congenital Neutropaenia is 6 mcg/kg BID SC every day. The recommended daily starting dose for the Idiopathic or Cyclic Neutropaenia is 5 mcg/kg as a single injection SC every day. Chronic daily administration is required to maintain clinical benefit.@FDA, 20 February 1991@2/20/1991@@@@@Allergic-type reactions occurring on initial or subsequent treatment have been reported in < 1 in 4000 patients treated with Neupogen. These have generally been characterised by systemic symptoms involving at least 2 body systems‚ most often skin (rash‚ urticaria‚ facial edema)‚ respiratory (wheezing‚ dyspnea)‚ and cardiovascular (hypotension‚ tachycardia). Rare cases of splenic rupture have been reported following the administration in both healthy donors and patients. Some of these cases were fatal. Adult respiratory distress syndrome (ARDS) has been reported in neutropenic patients with sepsis receiving Neupogen, and is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. Severe sickle cell crises, in some cases resulting in death, have been associated with the use of Neupogen in patients with sickle cell disease. MDS (myelodysplastic syndrome) and AML (Acute Myeloid Leukemia) have been reported to occur in the natural history of congenital neutropenia without cytokine therapy. Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with Neupogen for SCN (Severe Chronic Neutropaenia).@LABEL@No@2006@210 PATIENTS WITH SMALL CELL LUNG CANCER RANDOMISED TO RECEIVE NEUPOGEN (N = 99) OR PLACEBO (N = 111)@@@III; CANCER PATIENTS RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY@APPROVED@@@MEDICARE@The requirements for in-patient hospitalisation and antibiotic use were also significantly decreased during the first cycle of chemotherapy; incidence of hospitalization was 69% (77/111) for placebo-treated patients in cycle 1‚ versus 52% (51/99) for Neupogen-treated patients (p = 0.032). The incidence of IV antibiotic usage was 60% (67/111) for placebo-treated patients in cycle 1‚ versus 38% (38/99) for Neupogen-treated patients (p = 0.003).@@@@@MONO@FILGRASTIM@@@@@FILGRASTIM||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@NEUPOGEN@@@@@NEUPOGEN||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@DURATION OF HOSPITALISATION@DECREASED IV ANTIBIOTIC USAGE@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@324.3@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@324.3@324.3@55513-0924-01@PREPARATION FOR INJECTION (SYRINGE)@US$@@@@@@@@300@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917869@Onco@@@@@300f1008ntsdm@@@@@@Femara 2.5 mg & tamoxifen 20 mg@@L02BG04@L02B@NO@BASEL, SWITZERLAND@@@The elimination of oestrogen-mediated stimulatory effects is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone (E1) and oestradiol (E2). The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues.@@14917869@Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer. Treatment of early invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy. First-line treatment in postmenopausal women with advanced breast cancer. Advanced breast cancer in postmenopausal women in whom tamoxifen or other anti-oestrogen therapy has failed. Pre-operative therapy in postmenopausal women with localised hormone receptor positive breast cancer, to allow subsequent breast-conserving surgery in women not originally considered candidates for breast-conserving surgery. Subsequent treatment after surgery should be in accordance with standard of care.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@FIRST-LINE@@916@Adult and elderly patients - The recommended dose of Femara is 2.5 mg once daily. In the adjuvant setting, treatment with Femara should continue for 5 years or until tumour relapse occurs, whichever comes first. Following standard adjuvant tamoxifen therapy, treatment with Femara should continue for 3 years or until tumour relapse occurs, whichever comes first. Currently there is a lack of long-term data, therefore the optimal duration of therapy has not yet been established. In patients with metastatic disease, treatment with Femara should continue until tumour progression is evident.@@@@@@@May cause fetal harm when administered to pregnant women.@LABEL@No@@POSTMENOPAUSAL PATIENTS WITH LOCALLY ADVANCED (STAGE IIIB OR LOCO-REGIONAL RECURRENCE NOT AMENABLE TO TREATMENT WITH SURGERY OR RADIATION) OR METASTATIC BREAST CANCER.@@@FIRST-LINE BREAST CANCER; RANDOMISED, DOUBLE-BLINDED, MULTINATIONAL TRIAL COMPARED FEMARA WITH TAMOXIFEN@APPROVED@@@NHI@Femara was superior to tamoxifen in TTP and rate of objective tumour response: median TTP = 9.4 months for the 453 patients on Femara vs. 6 months for the 454 patients on tamoxifen (hazard ratio = 0.72 ; 95% CI = 0.62-0.83 ; p<0.0001); Objective RR:  complete RR + partial RR = 145 of the 453 patients on Femara vs. 95 of the 454 patients on tamoxifen (hazard ratio = 1.77 ; 95% CI = 1.31-2.39 ; p<0.0002) ; complete RR = 42 of the 453 patients on Femara vs. 15 of the 454 patients on tamoxifen (hazard ratio = 2.99 ; 95% CI = 1.63-5.47 ; p<0.0004); median duration of objective response = 18 months for the patients on Femara (n=145) vs. 16 months for the patients on tamoxifen (n=95); OS = 35 months for the patients on Femara (n=458) vs. 32 months for the patients on tamoxifen (n=458) - p=0.5136@@@@@ADJUVANT@LETROZOLE@@@@@LETROZOLE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FEMARA@@@@@FEMARA||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@TIME TO PROGRESSION@RESPONSE RATE@DURATION OF RESPONSE@OVERALL SURVIVAL@@DURATION OF RESPONSE@OVERALL SURVIVAL@@@@@@@@@RANDOMISED@DOUBLE-BLIND@MULTI-CENTRE@@@@@Invalid Dosage Value Phase 1@@@32@month@32 month@210513.75@210513.75@216.29@1@0.0091@464.36@547.6@@@@@@@@@@@185.74@@@@@@@@@@@@@@@@8/30/2017@464.36@464.36@4291015F1026@TABLET@YEN@@@@@@@@2.5@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
16387420@Onco@@@@@300f1008ntsdm@@@@@@85 patients received bevacizumab as a single agent and 82 received bevacizumab plus irinotecan. The dose of irinotecan depended on whether the patient was taking anticonvulsant therapy. Patients who progressed in the bevacizumab arm were allowed to begin using irinotecan as well.@@L01XC07@L01X@-@BASEL, SWITZERLAND@9/1/2007@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16387420@Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients 37 following prior therapy as a single agent.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009] >> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]           >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]         >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@SECOND-LINE@NCT00345163@167@The recommended dose is 10 mg/kg every 2 weeks.@MHLW, 17 June 2013@6/17/2013@@@@7/1/2006@@AVF3708g@No@NOT YET AVAILABLE; POTENTIALLY 2018.@@@@II@APPROVED@@@NHI@Duration of treatment was 16 weeks in the bevacizumab-alone arm and 22 weeks in the bevacizumab/irinotecan arm. Overall survival rates were 9.2 months and 8.7 months, respectively, while 6-month PFS was 42.6% and 50.3%, respectively. An objective response was seen in 28% of patients receiving bevacizumab alone and 38% of those receiving the dual therapy. [Genentech, 05.06.2008]       Data to be presented at ASCO 2008. [Genentech, 10.04.2008]        36% (31/85) of GBM patients treated with Avastin alone, and 51% (42/82) of patients treated with Avastin in combination with chemotherapy (irinotecan), lived without the disease advancing within six months. Genentech is planning Phase III in front-line GBM in 2008, though the Phase II results will also be submitted to the FDA under the accelerated approval process. [Genentech, November 2007]@Side effects traditionally associated with the use of bevacizumab -- including infections, venous-thromboembolic events, and wound healing complications -- were relatively infrequent, occurring in 9.5%, 2.4%, and 3.6% of patients, respectively. However, each of these adverse events was seen more frequently in the group receiving dual bevacizumab/CPT-11 compared with the arm receiving bevacizumab alone.@@@@COMBO@BEVACIZUMAB@IRINOTECAN@@@@BEVACIZUMAB|IRINOTECAN|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@6-MONTH PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@RELAPSED@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@76.5@kg@2305945.315@@@4.2@month@4.2 month@2305945.32@2305945.32@18050.85@1@0.0091@35393.82@41738@@@@@@@@@@@353.94@15@@mg/kg@10@1@@@@@@@@@@@8/30/2017@35393.82@35393.82@4291413A1022@CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION, 4 ML@YEN@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14918508@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918508@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Sanofi acquired Sterling Winthrop in 1992. Winthrop is now a subsidiary of sanofi-aventis.@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@WINTHROP@SANOFI-AVENTIS@@@@WINTHROP|SANOFI-AVENTIS|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1511@96.58@133.09@100.32@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@4.83@4.83@3980163@PATCH (MATRIX)@EURO@@@@@@@@25@MCG@25 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917240@Onco@@@@@300f1018ntsdm@@@@@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14917240@Indicated for the treatment of: 1. advanced ovarian carcinoma of epithelial origin in  (a) first line therapy (b) second line therapy, after other treatments have failed. 2. small cell carcinoma of the lung.@@NO@@@NO REVIEW@@@@100%@@SECOND-LINE@@@Single-Agent Therapy: has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide:an effective combination for previously untreated patients consists of: Paraplatin—300 mg/m2 I.V. on day 1 every four weeks for six cycles. Cyclophosphamide—600 mg/m2 I.V. on day 1 every four weeks for six cycles. Intermittent courses of Paraplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.@@@@@@@Paraplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.@LABEL@No@@Advanced ovarian cancer previously treated with chemotherapy@@@III@APPROVED@@Unrestricted reimbursement.@PBS@Carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@CARBOPLATIN EBEWE@@@@@CARBOPLATIN EBEWE||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@0.7915@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION, AQUEOUS@A$@@@@@@@@50@MG@50 MG/5 ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14919857@Onco@@@@@300f1010ntsdm@@@@@@@@L01XX19@L01X@YES@NEW DELHI, INDIA@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14919857@Campto is indicated for the treatment of patients with advanced colorectal cancer: • in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, • as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.  Campto in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Campto in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.@@NO@5-Aug@@@@@@100%@Dabur Pharma will change its name to Fresenius Kabi Oncology. [Dabur, 29.10.2008]@FIRST-LINE@@@Regimen 1: 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43): Weekly Camptosar 125mg/m2 IV over 90 minutes on days 1, 8, 15 and 22, followed by 100mg/m2 on week 5 and 75mg/m2 on week 6@EMA, 12 March 2008@3/12/2008@@@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@LABEL@No@@@@@@APPROVED@@NICE recommendation in combination with 5-flourouracil and folinic acid as a front-line treatment for advanced colorectal cancer, or as a monotherapy in subsequent therapy@NHS@@@@@@COMBO@IRINOTECAN@@@@@IRINOTECAN||||@DABUR PHARMA@FRESENIUS KABI ONCOLOGY@@@@DABUR PHARMA|FRESENIUS KABI ONCOLOGY|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@-@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@5.5@month@5.5 month@@@@@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917492@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Anzemet was administered intravenously at a dose of 1.8 mg/kg ; ondansetron was administered intravenously at a single dose of 32 mg@@A04AA04@A04A@NO@PARIS, FRANCE@@@Dolasetron mesilate and its major metabolite are selective serotonin 5-HT3 antagonists. The precise mode of action as an antiemetic is not known. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and are centrally located in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin can then activate 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. The effect of Anzemet in the management of cancer therapy induced nausea and vomiting is due to antagonism of 5-HT3 receptors on neurons either peripherally and/or centrally located.@@14917492@Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high dose cisplatin;  the prevention of postoperative nausea and vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, Anzemet Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low; the treatment of postoperative nausea and/or vomiting.@@NO@@@NO REVIEW@@@@@@@@609@Prevention of CINV: For adults, the recommended intravenous dosage of Anzemet Injection is 1.8 mg/kg given as a single dose approximately 30 minutes before chemotherapy. Alternatively, for most patients, a fixed dose of 100 mg can be administered over 30 seconds. The recommended intravenous dosage in pediatric patients 2 to 16 years of age is 1.8 mg/kg given as a single dose approximately 30 minutes before chemotherapy, up to a maximum of 100 mg. Prevention or Treatment of Postoperative Nausea and/or Vomiting: For adults, the recommended intravenous dosage of Anzemet Injection is 12.5 mg given as a single dose approximately 15 minutes before the cessation of anaesthesia (prevention) or as soon as nausea or vomiting presents (treatment). The recommended intravenous dosage in pediatric patients 2 to 16 years of age is 0.35 mg/kg, with a maximum dose of 12.5 mg, given as a single dose approximately 15 minutes before the cessation of anesthesia or as soon as nausea or vomiting presents.@FDA, 11 September 1997@9/11/1997@@@@@Anzemet can cause ECG interval changes, interval prolongation that could lead to cardiovascular consequences, including heart block or cardiac arrhythmias, cardiac conduction abnormality observed on an intra-operative cardiac rhythm monitor.@@No@11-Jul@609 ADULT CANCER PATIENTS RECEIVING >70 MG/M2  CISPLATIN WERE RANDOMISED TO 2 ARMS TO COMPARE SINGLE INTRAVENOUS DOSES OF ANZEMET INJECTION WITH ONDANSETRON@@@CLINICAL STUDIES / PREVENTION OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / CISPLATIN BASED CHEMOTHERAPY/ STUDY 2@APPROVED@@@MEDICARE@Anzemet Injection was shown to be equivalent to ondansetron  (44% for arm 1 treated with Anzemet vs 43% for arm 2 with ondansetron; nausea score for arm 1 = 10 vs 16 for arm 2)@@@@@MONO@DOLASETRON MESYLATE@@@@@DOLASETRON MESYLATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@ANZEMET@@@@@ANZEMET||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1@477.53@@@@@@@@@@@@0.96@@@@@@@@@@@@@@@@9/1/2017@95.51@95.51@30698-0121-05@FILM-COATED TABLET (BOTTLE)@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15414000@Onco@@@@@300f1020ntsdm@@@@@@Lapatinib and Herceptin versus lapatinib monotherapy@@L01XE07@L01X@-@BRENTFORD, UNITED KINGDOM@@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@15414000@in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy@@YES@-@@NO REVIEW@@@@@-@-@NCT00320385@270@The recommended dose of Tyverb is 1000 mg (i.e. four tablets) once daily continuously.The recommended dose of trastuzumab is 4 mg/kg administered as an intravenous (IV) loading dose,followed by 2 mg/kg IV weekly (see section 5.1). Please refer to the full prescribing information oftrastuzumab.@EMA, 14 August 2013@8/14/2013@@-@@11/1/2005@-@EGF104900@No@17-Jul@-@@@III@APPROVED@@-@@The combination of lapatinib + trastuzumab was associated with an 8.3 month increase in median OS versus lapatinib monotherapy (17.2 months vs. 8.9 months; n=150; HR=0.62; 95 per cent Confidence Interval 0.42, 0.90).[GSK, 14 August 2013, http://www.gsk.com/media/press-releases/2013/gsk-receives-marketing-authorisation-from-the-european-commissio.html ]Patients who received lapatinib plus trastuzumab in this study experienced a statistically significant increase in median progression-free survival versus Tykerb alone (12 weeks vs. 8.1 weeks); 27 percent reduction in the risk of disease progression [Hazard Ratio: 0.73; p=0.008]; response rate of 10.3 percent versus 6.9 percent. Response rate is a clinical term that is calculated by complete and partial disappearance of the tumor; double the overall clinical benefit rate versus Tykerb alone (24.7 percent vs. 12.4 percent; p=0.01). Clinical benefit rate is calculated by the response rate and the rate of durable stable disease (greater than or equal to 6 months); a trend in improved overall survival [Hazard Ratio: 0.75; p=0.106]. The study also demonstrated the activity of Tykerb as a single agent in this patient population, with patients on this arm achieving a median progression free survival of 8.1 weeks and an overall clinical benefit rate of 12.4 percent. Data to be presented at ASCO 2008. SOURCE: GSK, 16 May 2008@Within the EGF104900 trial, the incidence of AEs was similar in both treatment groups (94 per cent vs. 90 per cent). The most frequent adverse reactions (> 25 per cent) during the trial were diarrhoea and nausea. Additional adverse events which affected > 10 per cent of patients included fatigue, vomiting, rash, dyspnoea, anorexia and headache. Serious adverse events, including diarrhoea, decreased cardiac function and hepatobiliary disorders, were experienced by 26 per cent of patients@@@@COMBO@LAPATINIB@TRASTUZUMAB@@@@LAPATINIB|TRASTUZUMAB|||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TYKERB@HERCEPTIN@@@@TYKERB|HERCEPTIN|||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@CROSSOVER@@1@1@5306.735952@@@12@week@12 week@5306.74@5306.74@63.18@70@1.1229@1105.57@1824.63@1155.33@@@@@@@@@@0.06@1@@mg@1000@1@@@@@@@@@@@6/7/2017@15.79@15.79@38633044@TABLET@EURO@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14917833@Onco@@@@@300f1037ntsdm@@@@@@100 mg/m²@@L01DB03@L01D@YES@@@@Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.@@14917833@Epirubicin is used in the treatment of a range of neoplastic conditions including • Breast, ovarian, gastric, lung and colorectal carcinomas • Malignant lymphomas • Leukaemias • Multiple myeloma. When administered intravesically, epirubicin has been shown to be beneficial in the treatment of • Papillary transitional cell carcinoma of the bladder • Carcinoma-in-situ • Prophylaxis of recurrences after transurethral resection.@@YES@@@NO REVIEW@@@@90%@Acquired through takeover of Mayne Pharma@FIRST-LINE@@565@High dose: Epirubicin as a single agent for the high dose treatment of lung cancer should be administered according to the following regimens: • Small cell lung cancer (previously untreated): 120 mg/m2 day 1, every 3 weeks. • Non-small cell lung cancer (squamous, large cell, and adenocarcinoma previously untreated): 135 mg/m2 day 1 or 45 mg/m2 day 1, 2 and 3 every 3 weeks. For high dose treatment, epirubicin may be given as an intravenous bolus over 3-5 minutes or as an infusion of up to 30 minutes duration. Breast Cancer: In the adjuvant treatment of early breast cancer patients with positive lymph nodes, intravenous doses of epirubicin ranging from 100 mg/m2 (as a single dose on day 1) to 120 mg/m2 (in two divided doses on days 1 and 8) every 3-4 weeks, in combination with intravenous cyclophosphamide and 5-fluorouracil and oral tamoxifen, are recommended. Lower doses (60-75 mg/m2 for conventional treatment and 105-120 mg/m2 for high dose treatment) are recommended for patients whose bone marrow function has been impaired by previous chemotherapy or radiotherapy, by age, or neoplastic bone marrow infiltration. The total dose per cycle may be divided over 2-3 successive days.@1-Dec-95@12/1/1995@@@@@Occurrence of severe local tissue necrosis if extravasation during administration; intramuscular and subcutaneous routes of administration not allowed; during or after therapy occurrence of severe form of myocardial toxicity; cases of secondary acute myelogenous leukemia and refractory secondary leukaemia reported in patients treated with anthracyclines used in mono or combination therapy with DNA-damaging antineoplastic agents; cases of severe myelosuppression; advice of reduced dosage in patients with impaired hepatic function@GFEA-05@No@@565 PRE AND POSTMENOPAUSAL WOMEN WITH MORE THAN 4 NODES INVOLVED WITH TUMOR OR LESS THAN 4 POSITIVE NODES WITH NEGATIVE ESTROGEN ABND PROGESTERONE RECEPTORS AND A HISTOLOGIC TUMOR GRADE OF 2 OR 3. ALL 565 WOMEN RECEIVED A COMBINATION OF FLUOROURACIL, ELLE@@@III@APPROVED@@NO REVIEW@SNS@FEC-100 regimen showed a longer RFS after 5 years (65% for the FEC-100 regimen and 52% for the FEC-50 regimen - stratified logrank p=0,007) and after 10 years (49% of the FEC-100 regimen and 43% of the FEC-50 regimen - stratified logrank p=0,040 - unstratified logrank p=0,09) and a longer OS after 5 years (76% for the FEC-100 regimen and 65% for the FEC-50 regimen - stratified logrank p=0,007) and after 10 years (56% of the FEC-100 regimen and 50% of the FEC-50 regimen - stratified logrank p=0,023 - unstratified logrank p=0,039) - results based on Kaplan-Meier methods@@@@@COMBO@EPIRUBICIN HYDROCHLORIDE@@@@@EPIRUBICIN HYDROCHLORIDE||||@KENFARMA@@@@@KENFARMA||||@@@@@@|||||||||@Breast Cancer@Ovarian Cancer@Stomach Cancer@NSCLC@SCLC@Breast Cancer|Ovarian Cancer|Stomach Cancer|NSCLC|SCLC|||||@FARMORUBICINE@@@@@FARMORUBICINE||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RELAPSE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@COMPARATIVE@OPEN-LABEL@MULTI-CENTRE@@@@Invalid Factory Price@@@126@day@126 day@@@@50@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR INJECTION@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921848@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received either Neulasta 6 mg, or a placebo associated with a chemotherapy regimen that employed docetaxel 100 mg/m2 administered every 21 days for up to 4 cycles for the treatment of metastatic or non-metastatic breast cancer.@@L03AA13@L03A@NO@THOUSAND OAKS, CALIFORNIA@@@Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Pegfilgrastim is a covalent conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20 kd polyethylene glycol (PEG) molecule. Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Similarly to filgrastim, neutrophils produced in response to pegfilgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As with other haematopoietic growth factors, G-CSF has shown in vitro stimulating properties on human endothelial cells. G-CSF can promote growth of myeloid cells, including malignant cells, in vitro and similar effects may be seen on some non-myeloid cells in vitro.@@14921848@Indicated to decrease the incidence of infection, as manifested by febrile neutropaenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropaenia.@@NO@@@NO REVIEW@@@@Precertification required. SOURCE: Aetna Preferred Drug Guide 2008@@@@928@The recommended dosage is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle.@FDA, 31 January 2002@1/31/2002@@@@@Rare cases of splenic rupture, including some fatal cases, have been reported following the administration of Neulasta. Adult respiratory distress syndrome (ARDS) has been reported in neutropenic patients with sepsis receiving Neulasta, and is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. Allergic reactions to Neulasta, including anaphylaxis, skin rash, and urticaria, have been reported. Severe sickle cell crises have been associated with the use of Neulasta in patients with sickle cell disease. Severe sickle cell crises, in some cases resulting in death, have also been associated with Filgrastim, the parent compound of pegfilgrastim.@STUDY 3@No@2015@928 WOMEN WITH BREAST CANCER WERE RANDOMISED TO RECEIVE A SINGLE SUBCUTANEOUS INJECTION OF NEULASTA 6 MG OR PLACEBO ON DAY 2 OF EACH CHEMOTHERAPY CYCLE.@@@@APPROVED@@Covered; part B; quantity limit 1 for 30 days; specialty drug. Prior authorisation required. TIER 4.@MEDICARE@The incidence of febrile neutropaenia was lower for Neulasta-treated patients as compared to placebo-treated patients (1% versus 17%, p < 0.001). The incidence of hospitalisations (1% versus 14%) and IV anti-infective use (2% versus 10%) for the treatment of febrile neutropenia were also lower in the Neulasta-treated patients compared with the placebo-treated patients.@@@@@MONO@PEGFILGRASTIM@@@@@PEGFILGRASTIM||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@NEULASTA@@@@@NEULASTA||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@INCIDENCE OF FEBRILE NEUTROPAENIA@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@10271.76@10271.76@@1@1@5940@@@@@@@@@@@@990@@@@@@@@@@@@@@@@8/2/2017@5940@5940@55513-0190-01@SOLUTION FOR INJECTION (PRE-FILLED SYRINGE) - 0.6 ML@US$@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15059376@Onco@@@@@300f1020ntsdm@@@@@@MDX-010 in combination With a MDX-1379 (melanoma peptide vaccine), and melanoma vaccine monotherapy@@L01XC11@L01X@YES@PRINCETON, NEW JERSEY@@@Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that plays a critical role in regulating natural immune responses. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.@@15059376@Yervoy is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody  indicated for the treatment of unresectable or metastatic melanoma.@Both@YES@6-Feb-13@2/6/2013@NO REVIEW@@@@@>>BMS acquires Medarex in July 2009>>BMS and Medarex announced a worldwide collaboration to develop and commercialize MDX-010. The collaboration also includes MDX-1379, an investigational gp100 peptide vaccine, which will be developed for potential use in combination with MDX-010 in melanoma. BMS and Medarex have agreed to jointly continue to investigate the development of MDX-010 in additional tumor types. BMS and Medarex will share in the costs of developing MDX-010 and MDX-1379 in the United States and Europe based on a pre-agreed percentage allocation.  BMS will be responsible for all development outside of these territories. Medarex will receive an initial cash payment of $50 million, of which $25 million will be a purchase of Medarex's common stock by Bristol-Myers Squibb at a premium to the market price.  Medarex could receive up to $205 million if all regulatory milestones are met, and up to $275 million in sales- related milestones.  Medarex will have an option to co-promote and share profits with BMS in the United States based on a pre-agreed percentage split. Bristol-Myers Squibb will receive an exclusive license ex-US and pay royalties to Medarex. [BMS, 8.11.2004]@SECOND-LINE@NCT00094653@750@YERVOY 3 mg/kg administered intravenously over 90 minutes every 3 weeks for a total of four doses.@EMA, 14 July 2011@7/14/2011@@NO@@9/1/2004@YES@MDX010-20@No@-@Diagnosed with malignant melanoma Measurable unresectable Stage III or IV melanoma HLA-A*0201 positive Previous treatment with & failure/relapse/inability to tolerate IL-2, dacarbazine and/or temozolomide@@ADULTS@III@APPROVED@@-@SSN@>>Long-term follow-up from this study demonstrated that treatment with Yervoy plus DTIC resulted in a four-year survival rate of 19.0% compared to 9.6% for DTIC alone. Additionally, the overall survival data appeared relatively stable between years three and four for patients treated with YERVOY plus DTIC (21.2% at three years and 19.0% at four years). The three and four-year survival rates for patients treated with placebo plus DTIC were 12.1% and 9.6%, respectively. [BMS, 29 September 2012 http://news.bms.com/press-release/rd-news/new-four-and-five-year-survival-data-yervoy-ipilimumab-treatment-naive-and-pre ]>>Trial results presented at ASCO 2010. '[O]verall survival (OS) was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab. The results were statistically significant for patients receiving ipilimumab alone (hazard ratio 0.66, p=0.0026) or ipilimumab in combination with a gp100 peptide vaccine (hazard ratio 0.68, p=0.0004) when compared to those patients who received the control therapy of gp100 alone. Forty-four to 46 percent of patients treated with ipilimumab were alive at one year compared to 25 percent of patients treated with the control arm. At two years, 22 to 24 percent of patients treated with ipilimumab were alive compared to 14 percent of patients treated with the control arm.' [BMS 5 June 2010 http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20100605005041/en&t=634115742159696703 ]>>RESULTS PENDING@As in other studies of ipilimumab, the most common side effects reported in the study were immune-related and based on the mechanism of action. These immune-related adverse events were sometimes severe and life-threatening, and most often affected the gastrointestinal, skin, liver, or endocrine systems.@@@@MONO@IPILIMUMAB@@@@@IPILIMUMAB||||@MEDAREX@BMS@@@@MEDAREX|BMS|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@YERVOY@@@@@YERVOY||||@mAb@Human@CTLA4 Receptor Antagonist@@@mAb|Human|CTLA4 Receptor Antagonist||@RESPONSE RATE@OVERALL SURVIVAL@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@MULTI-CENTRE@@@76.5@kg@70422.075@@@12@week@12 week@70422.08@70422.08@838.36@1@1.1229@15342.5@25321.26@16033.08@@@@@@@@@@76.71@21@@mg/kg@3@1@@@@@@@@@@@6/7/2017@15342.5@15342.5@41275025@PREPARATION FOR INJECTION, 40 ML@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14917873@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14917873@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@MIBE@@@@@MIBE||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@FENTADOLON@@@@@FENTADOLON||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@42.03@64.13@44.06@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@8.41@8.41@1914475@PATCH (MATRIX)@EURO@@@@@@@@50@MCG@50 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921635@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@One-hour infusion on days 1 and 15 of a 28-day schedule, first without and then with G-CSF.@@-@-@-@SAN FRANCISCO, CALIFORNIA@3/1/2009@@Ispinesib is a novel small molecule drug candidate that inhibits cell proliferation and promotes cancer cell death by specifically disrupting the function of a cytoskeletal protein known as kinesin spindle protein, or KSP. Current drugs that inhibit cell proliferation, such as paclitaxel and docetaxel, are standard treatments for many types of cancers, but these drugs also target other proteins that are essential to other important cellular functions and thus, their use is limited by side effects. @@14921635@-@@-@-@@NO REVIEW@@@@-@Part of wide-ranging 2001 partnership between Cytokinetics and GSK to discover and commercialise small moleculaes targeting mitotic kinesins in cancer. Agreement extended in July 2007 until June 2008.@-@NCT00343564@100@-@-@@@-@@4/1/2006@-@CY 2121@@-@-@@@I/II@II@@-@-@>> Cytokinetics is discontinuing research activities related to oncology. [Cytokinetics, 16.09.2008]>> At the interim analysis point, 46 patients had been enrolled and 43 patients were treated. Of the treated patients, 43 were evaluable for safety and 28 were evaluable for efficacy. The authors concluded that the pattern of onset and recovery of neutropenia supports a dosing schedule for SB-743921 of days 1 and 15 of a 28-day cycle. The MTD of SB-743921 was 6 mg/m2 when given days 1 and 15 every 28 days without G-CSF support. This represents a greater dose density (0.43 mg/m2/day) than on the previously studied schedule; i.e., 4 mg/m2 once every 21 days (0.19 mg/m2/day). The only DLT observed without G-CSF was neutropenia; therefore further dose escalation with empiric, prophylactic G-CSF is ongoing and the trial is currently enrolling at 8 mg/m2. The declines from baseline seen in neutrophil counts on day 8 and 22 without G-CSF were not observed with 6 mg/m2 plus G-CSF suggesting further dose escalation with G-CSF may be possible. [Cytokinetics/10th International Conference on Malignant Lymphoma, 5 June 2008]@Grade 3 and 4 toxicities other than neutropenia were uncommon; in particular, no evidence of neuropathy or alopecia was observed. To date, one objective partial response has been observed at the MTD without G-CSF in a patient with Hodgkin lymphoma. @@@@BOTH@ISPINESIB@@@@@ISPINESIB||||@CYTOKINETICS@GSK@@@@CYTOKINETICS|GSK|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@SB-743921@@@@@SB-743921||||@KSP Inhibitor@@@@@KSP Inhibitor||||@DOSE-LIMITING TOXICITY@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@OPEN-LABEL@NON-RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15408696@Onco@@@@@300f1037ntsdm@@@@@@Experimental arm: BIBF 1120 2 times daily along with standard therapy of docetaxelPlacebo comparator: placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel@@L01XE31@L01X@@INGELHEIM, GERMANY@12/1/2013@@Nintedanib is an oral triple angiokinase inhibitor that targets three growth factor receptors simultaneously: vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR alpha and beta), and fibroblast growth factor receptors (FGFR 1-3). All three receptors are crucially involved in the formation and maintenance of new blood vessels (angiogenesis); their blockade may lead to the inhibition of angiogenesis, which plays a critical role in tumour growth and spread@@15408696@Indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.@Both@YES@21-Dec-15@12/21/2015@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 40% TO 60% DEPENDING ON REVENUES@@SECOND-LINE@NCT00805194@1314@The recommended dose of nintedanib is 200 mg twice daily administered approximately 12 hours apart, on days 2 to 21 of a standard 21 day docetaxel treatment cycle.@EMA, 21 Novermber 2014@@12/16/2015@No@@12/1/2008@@LUME-Lung 1@No@@histologically or cytologically confirmed, locally advanced and/or metastatic NSCLC of stage IIIB or IV or recurrent NSCLC;relapse or failure of one first line prior chemotherapy;@@ADULTS@III@APPROVED@@Considered as a new alternative [AEMPS, https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-nintedanib-Vargatef.pdf]@SNS@The combination of nintedanib plus docetaxel demonstrated a statistically significant prolonged progression-free survival (PFS), versus placebo (3.4 vs. 2.7 months, respectively) regardless of tumour histology, reducing the risk of renewed tumour growth by 21%.Overall survival was significantly prolonged in adenocarcinoma patients treated with nintedanib plus docetaxel versus placebo plus docetaxel (12.6 vs. 10.3 months respectively).1 The results demonstrated that patients with adenocarcinoma who have failed initial treatment with chemotherapy received on average a 20% extension of overall survival. In addition, the data demonstrated that the earlier adenocarcinoma patients failed first line chemotherapy, the bigger the benefit nintedanib provided, as patients who progressed within 9 months (T<9 months) after start of their first-line treatment, achieved a median overall survival benefit of 3 months (10.9 vs. 7.9 months).[BI, 14 October 2013, http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/14_october_2013_oncology.html ]@The most common adverse events (AEs) in LUME-Lung 1 were gastrointestinal side effects and reversible liver enzyme elevations which were manageable by supportive treatment or dose reduction (adverse events nintedanib vs. placebo: nausea 24% vs. 18%, vomiting 17% vs. 9%, diarrhoea 42% vs. 22%and liver enzyme elevation 29% vs. 8%). Withdrawal due to adverse events was similar in both arms, as were Grade 3, bleeding or thromboembolic events.@@@@COMBO@NINTEDANIB@DOCETAXEL@@@@NINTEDANIB|DOCETAXEL|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@VARGATEF@GENERIC@@@@VARGATEF|GENERIC|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@ADVANCED@@@@@RANDOMISED@PARALLED ASSIGNMENT@DOUBLE-BLIND@@@1@1@9748.733384@@@4.2@month@4.2 month@9748.73@9748.73@76.31@120@1.1511@2403.85@2558.15@2411.39@@@@@@@@@@0.2@21@@mg@400@20@@@@@@@@@@@8/4/2017@20.03@20.03@704655@SOFT CAPSULE@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14923160@Onco@@@@@300f1015ntsdm@@@@@@67 patients were randomised at baseline to receive, double-blind, doses of 10 mg, 20 mg or 30 mg Sandostatin LAR Depot every 28 days and 26 patients continued, unblinded, on their previous Sandostatin Injection regimen (100-300 mcg t.i.d.). In any given month after steady-state levels of octreotide were reached, approximately 35% to 40% of the patients who received  LAR Depot required supplemental subcutaneous Sandostatin Injection therapy usually for a few days, to control exacerbation of carcinoid symptoms. In any given month the percentage of patients randomised to subcutaneous Injection, who required supplemental treatment with an increased dose of Injection, was similar to the percentage of patients randomised to LAR Depot.@@H01CB02@H01C@NO@BASEL, SWITZERLAND@@@Octreotide is a synthetic octapeptide analog of naturally occurring somatostatin with similar pharmacological effects, but with a longer duration of action. It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the gastroenteropancreatic (GEP) endocrine system, stomach, intestine and pancreas (for example, gastrin, insulin and glucagon).@@14923160@Acromegaly: indicated for long-term maintenance therapy in acromegalic patients for whom medical treatment is appropriate and who have been shown to respond to and can tolerate Sandostatin (octreotide acetate) Injection. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal. Sandostatin LAR Depot can be used in patients who have had an inadequate response to surgery or in those for whom surgical resection is not an option. It may also be used in patients who have received radiation and have had an inadequate therapeutic response. Carcinoid Tumors: indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors in patients in whom initial treatment with Sandostatin. Vasoactive Intestinal Peptide Tumors (VIPomas): indicated for long-term treatment of the profuse watery diarrhoea associated with VIP-secreting tumors in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated and In patients with acromegaly, carcinoid syndrome and VIPomas.@@NO@Aug-99@@NO REVIEW@@@@@manufactured by: Sandoz GmbH, Schaftenau, Austria (Subsidiary of Novartis Pharma AG, Basle, Switzerland)@@@93@@@@10/1/1998@@@@Gallbladder abnormalities: including biliary abnormalities with gallstones, microlithiasis, sediment, sludge and dilatation.@@No@@93 PATIENTS WITH MALIGNANT CARCINOID SYNDROME, WHO HAD PREVIOUSLY BEEN SHOWN TO BE RESPONSIVE TO SANDOSTATIN INJECTION.@@@CLINICAL TRIALS / CARCINOID SYNDROME@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@Over the six-month treatment period approximately 50%-70% of patients who completed the trial on Sandostatin LAR Depot required subcutaneous Sandostatin Injection supplemental therapy to control exacerbation of carcinoid symptoms although steady-state serum LAR Depot levels had been reached.@@@@@MONO@OCTREOTIDE ACETATE@@@@@OCTREOTIDE ACETATE||||@NOVARTIS@SANDOZ@@@@NOVARTIS|SANDOZ|||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@SANDOSTATINE@@@@@SANDOSTATINE||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@GROWTH HORMONE LEVEL@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@6@1.1511@33.89@43.62@36.15@@@@@@@@@@112.97@@@@@@@@@@@@@@@@8/1/2017@5.65@5.65@3.40E+12@INJECTABLE SOLUTION, 1 ML@EURO@@@@@@@@0.05@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918372@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@ICELAND@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918372@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1511@241.43@316.23@249.74@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@12.07@12.07@4683094@PATCH (MATRIX)@EURO@@@@@@@@100@MCG@100 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921502@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arm A: AC+Avastin (4 cycles) followed by paclitaxel, Avastin (4 cycles), the Avastin for 18 courses. Arm B: AC (4 cycles) followed by paclitaxel, Avastin (4 cycles), then Avastin for 22 courses. Avastin dose was 10mg/kg every 2 weeks.@@L01XC07@L01X@-@SAN FRANCISCO, CALIFORNIA@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14921502@Adjuvant HER2-negative@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@NCT00119262@212@-@-@@@-@@10/1/2005@-@ECOG-E2104@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@II@II@@-@-@Enrolment completed in Q4 2006. SABCS December 2007; standard anthracycline-based chemotherapy (doxorubicin) can be added to Avastin after surgical removal of the breast tumour, without a concerning increase in the incidence of cardiac adverse events typically associated with this form of chemotherapy. These data support the commencement of phase III adjuvant breast cancer clinical programme which will include over 10,000 patients with early stage breast cancer. Trial design informed set-up of ECOG-5103.@-@@@@ADJUVANT@BEVACIZUMAB@@@@@BEVACIZUMAB||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Breast Cancer@HER2-@@@@Breast Cancer|HER2-||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@CARDIAC DYSFUNCTION@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916972@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Patients received either exemestane (25 mg/day) or tamoxifen (20 or 30 mg/day)@@L02BG06@L02B@NO@NEW YORK, NEW YORK@@@Exemestane is an irreversible, steroidal aromatase inhibitor, structurally related to the natural substrate androstenedione. In post-menopausal women, oestrogens are produced primarily from the conversion of androgens into oestrogens through the aromatase enzyme in peripheral tissues. Oestrogen deprivation through aromatase inhibition is an effective and selective treatment for hormone dependent breast cancer in postmenopausal women. In postmenopausal women, Aromasin p.o. significantly lowered serum oestrogen concentrations starting from a 5 mg dose, reaching maximal suppression (>90%) with a dose of 10-25 mg. In postmenopausal breast cancer patients treated with the 25 mg daily dose, whole body aromatization was reduced by 98%. Exemestane does not possess any progestogenic or oestrogenic activity. A slight androgenic activity, probably due to the 17-hydro derivative, has been observed mainly at high doses. In multiple daily doses trials, Aromasin had no detectable effects on adrenal biosynthesis of cortisol or aldosterone, measured before or after ACTH challenge, thus demonstrating its selectivity with regard to the other enzymes involved in the steroidogenic pathway. Glucocorticoid or mineralocorticoid replacements are therefore not needed. A non dose-dependent slight increase in serum LH and FSH levels has been observed even at low doses: this effect is, however, expected for the pharmacological class and is probably the result of feedback at the pituitary level due to the reduction in oestrogen levels that stimulate the pituitary secretion of gonadotropins also in postmenopausal women.@@14916972@Adjuvant treatment of postmenopausal women with estrogenreceptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy; the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.@@@@@NO REVIEW@@@@@@SECOND-LINE@@4724@The recommended dose of Aromasin in early and advanced breast cancer is one 25 mg tablet once daily after a meal. In postmenopausal women with early breast cancer who have been treated with 2–3 years of tamoxifen, treatment with Aromasin should continue in the absence of recurrence or contralateral breast cancer until completion of five years of adjuvant endocrine therapy. For patients with advanced breast cancer, treatment should continue until tumour progression is evident. For patients receiving Aromasin with a potent CYP 3A4 inducer such as rifampicin or phenytoin, the recommended dose is 50 mg once daily after a meal.@@@@@@@Aromasin Tablets may cause fetal harm when administered to a pregnant woman.@IES@No@@4724 PATIENTS WHO REMAINED DISEASE-FREE AFTER RECEIVING ADJUVANT TAMOXIFEN THERAPY FOR 2 TO 3 YEARS WERE RANDOMISED TO RECEIVE 3 TO 2 YEARS OF AROMASIN (2352 PATIENTS) OR TAMOXIFEN (2372 PATIENTS) TO COMPLETE A TOTAL OF 5 YEARS OF HORMONAL THERAPY.@@@ADJUVANT TREATMENT IN EARLY BREAST CANCER: THE INTERGROUP EXEMESTANE STUDY 031 (IES); RANDOMISED, DOUBLE-BLIND, MULTICENTRE, MULTINATIONAL STUDY COMPARING EXEMESTANE TO TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER.@APPROVED@@Unrestricted reimbursement.@RAMQ@Overall survival was not significantly different in the 2 groups, with 116 deaths occurring in the Aromasin group and 137 in the tamoxifen group.@@@@@ADJUVANT@EXEMESTANE@@@@@EXEMESTANE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AROMASIN@@@@@AROMASIN||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@OVERALL SURVIVAL@@@@@@@@@@EARLY@@@@@RANDOMISED@DOUBLE-BLIND@MULTI-CENTRE@@@@@Invalid Dosage Value Phase 1@@@@@@945.36@945.36@@30@0.7934@155.35@@@@@@@@@@@@0.21@@@@@@@@@@@@@@@@8/18/2017@5.18@5.18@224270530@TABLET@C$@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
15394394@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE13@L01X@-@INGELHEIM, GERMANY@1/1/2012@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.@@15394394@GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKInaïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).@@NA@17-Apr-14@4/17/2014@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@FIRST-LINE@NCT00949653@333@Recommended dose: 40 mg orally, once daily@MHLW, 17 April 2014@4/17/2014@@@@8/1/2009@@LUX-Lung 3@No@@Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology. EGFR mutation detected by central laboratory analysis of tumour biopsy material.@@@III@APPROVED@@@NHI@Data from LUX-Lung 3 has shown that patients taking afatinib as a first-line treatment lived for almost one year without their tumour growing again (median progression-free survival (PFS) of 11.1 months) versus just over half a year (PFS of 6.9 months) for those treated with pemetrexed/cisplatin. In addition, NSCLC patients with tumours harbouring the two most common EGFR mutations (Del19 or L858R) taking afatinib lived for well over a year without tumour progression (PFS of 13.6 months) versus just over half a year (PFS of 6.9 months) for those in the comparator arm.1In addition, patients taking afatinib also experienced an improvement in lung cancer symptoms and a better quality of life compared to those receiving standard chemotherapy treatment.[BI, 15 July 2013, http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/15_july_2013_oncology.html ]Trial registered [BI, 29.07.2009]@The most common grade 3 drug-related adverse events observed in the afatinib treatment arm were diarrhoea (14%), rash (16%), and inflammation of the nail bed (paronychia) (11%). The most common drug-related grade 3 adverse events observed in the chemotherapy arm (pemetrexed/cisplatin) were neutropenia (15%), fatigue (13%), and leucopenia (8%). There was a low discontinuation rate associated with treatment-related adverse events in the trial (8% discontinuation rate for afatinib; 12% for chemotherapy). One percent of patients in the afatinib arm discontinued due to drug-related diarrhoea.@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GIOTRIF@@@@@GIOTRIF||||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE@DISEASE CONTROL@QUALITY OF LIFE@@@LOCALLY ADVANCED@METASTATIC@@@@PARALLEL ASSIGNMENT@@@@@1@1@3404638.259@@@11.3@month@11.3 month@3404638.26@3404638.26@9905.82@1@0.0091@4952.91@5840.7@@@@@@@@@@@247.65@1@@mg@40@1@@@@@@@@@@@8/30/2017@4952.91@4952.91@4291030F1020@FILM-COATED TABLET@YEN@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
16387786@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received 1 mg of Arimidex once daily or 20 mg of tamoxifen once daily.@@L02BG03@L02B@NO@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@16387786@First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer;@@NO@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@@668@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@FDA, 01 September 2000@9/1/2000@@@@@Arimidex can cause fetal harm when administered to a pregnant woman.@@No@9-Dec@POSTMENOPAUSAL WOMEN, BETWEEN THE AGES OF 30 AND 92 YEARS OLD AND WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER, WERE RANDOMISED TO RECEIVE ARIMIDEX (340 PATIENTS) OR TAMOXIFEN (328 PATIENTS).@@@@APPROVED@@@MEDICARE@Arimidex was at least as effective as tamoxifen for objective tumor RR and TTP. Median TTP was 8.2 months for the Arimidex treatment group compared to 8.3 months for the Tamoxifen treatment group. 73% of the patients in the Arimidex treatment group progressed compared to 75% for the Tamoxifen treatment group [Hazard ratio=1.01, p=0.920]. The best objective RR (CR+PR) were 32.9% for the Arimidex treatment group compared to 32.6% in the Tamoxifen treatment group [Odds ratio:1.01].@@@@@MONO@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@TIME TO PROGRESSION@RESPONSE RATE@SAFETY@@@SAFETY@@@@@ADVANCED@METASTATIC@@@@DOUBLE-BLIND@CONTROLLED@@@@1@1@3968.714068@@@8.2@month@8.2 month@3968.71@3968.71@15.91@30@1@477.37@@@@@@@@@@@@15.91@1@@mg@1@1@@@@@@@@@@@8/2/2017@15.91@15.91@00310-0201-30@FILM-COATED TABLET@US$@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924313@Onco@@@@@300f1012ntsdm@@@@@@Xeloda was administered at a dose of 1255 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles.@@L01BC06@L01B@YES@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924313@Xeloda is indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@162@1250 mg/m2 administered twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 14 days followed by a 7-day rest period.@@@@@@@Patients with moderate renal impairment at baseline require dose reduction. Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking Xeloda concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Xeloda can induce diarrhea, sometimes severe. Patients =80 years old may experience a greater incidence of grade 3 or 4 adverse events (diarrhea, nausea, hand-and-foot syndrome, and vomiting).  Xeloda may cause fetal harm when given to a pregnant woman.@LABEL@No@@PATIENTS WITH STAGE IV BREAST CANCER WERE ENROLLED. 135 HAD MEASURABLE DISEASE. RESISTANCE WAS DEFINED AS PROGRESSIVE DISEASE WHILE ON TREATMENT, WITH OR WITHOUT AN INITIAL RESPONSE, OR RELAPSE WITHIN 6 MONTHS OF COMPLETING TREATMENT WITH AN ANTHRACYC@@@BREAST CANCER MONOTHERAPY; OPEN-LABEL SINGLE-ARM TRIAL CONDUCTED IN 24 CENTRES IN THE US AND CANADA.@APPROVED@@@GKV@RR for patients resistant to both paclitaxel and anthracycline (n=43)  was of 25.6% (95% CI: 13.5-41.2) with a median duration of response of 154 days (95% CI: 63-233). The median TTP was 102 days and the median survival was 255 days. The objective RR in this population was supported by a RR of 18.5% (1 CR, 24 PRs) in the overall population of 135 patients with measurable disease, who were less resistant to chemotherapy. The median time to progression was 90 days and the median survival was 306 days.@The most common adverse events (>10%) in patients receiving Xeloda (%) were lymphopenia (94), anemia (72), diarrhea (57), hand-foot syndrome (57), nausea (53), fatigue (41), dermatitis (37), vomiting (37), neutropenia (26), stomatitis (24), thrombocytopenia (24), anorexia (23), hyperbilirubinemia (22), paresthesia (21), abdominal pain (20), constipation (15), eye irritation (15), and pyrexia (12). Grade 3/4 adverse events (>5%) in patients receiving Xeloda were lymphopenia (59), diarrhea (15), hand-foot syndrome (11), hyperbilirubinemia (11), fatigue (8), stomatitis (7), and dehydration (5).@@@@MONO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@DURATION OF RESPONSE@@@@-@@@@@ADVANCED@METASTATIC@@@@OPEN-LABEL@SINGLE-ARM@@@@1.6@m²@2389.942837@@@154@day@154 day@2389.94@2389.94@15.52@120@1.1511@349.18@452.46@360.88@@@@@@@@@@@21@@mg/m²@2500@14@@@@@@@@@@@8/1/2017@2.91@2.91@410399@FILM-COATED TABLET@EURO@@@@@@@@500@MG@500 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922522@Onco@@@@@300f1010ntsdm@@@@@@120 mg/m²@@L01DB03@L01D@YES@NEW YORK, NEW YORK@@@Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.@@14922522@Epirubicin is used in the treatment of a range of neoplastic conditions including • Breast, ovarian, gastric, lung and colorectal carcinomas • Malignant lymphomas • Leukaemias • Multiple myeloma. When administered intravesically, epirubicin has been shown to be beneficial in the treatment of • Papillary transitional cell carcinoma of the bladder • Carcinoma-in-situ • Prophylaxis of recurrences after transurethral resection.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@716@Conventional dose: When epirubicin is used as a single agent, the recommended dosage in adults is 60-90 mg/m2 body area. Epirubicin should be injected intravenously over 3-5 minutes. The dose should be repeated at 21-day intervals, depending upon the patient's haematomedullary status. If signs of toxicity, including severe neutropenia/neutropenic fever and thrombocytopaenia occur (which could persist at day 21), dose modification or postponement of the subsequent dose may be required.@EMA, May 2004@@@@@@Occurrence of severe local tissue necrosis if extravasation during administration; intramuscular and subcutaneous routes of administration not allowed; during or after therapy occurrence of severe form of myocardial toxicity; cases of secondary acute myelogenous leukemia and refractory secondary leukaemia reported in patients treated with anthracyclines used in mono or combination therapy with DNA-damaging antineoplastic agents; cases of severe myelosuppression; advice of reduced dosage in patients with impaired hepatic function@MA-5@No@@716 PREMENOPAUSAL AND PERIMENOPAUSAL WITH ONE OR MORE POSITIVE LYMPH NODES: 356 WOMEN RECEIVED A COMBINATION OF CYCLOPHOSPHAMIDE, ELLENCE AND FLUOROURACIL (CEF-120) AND WERE COMPARED TO 360 OTHER WOMEN WHO RECEIVED A COMBINATION OF CYCLOPHOSPHAMIDE, METHO@@@III@APPROVED@@NO NICE REVIEW@NHS@CEF regimen showed a longer RFS after 5 years (62% for the CEF regimen and 53% for the CMF regimen - stratified logrank p=0,013) and after 10 years (51% of the CEF regimen and 44% of the CMF regimen - stratified logrank p=0,017 - unstratified logrank p=0,023) and a longer OS after 5 years (77% for the CEF regimen and 70% for the CMF regimen - stratified logrank p=0,043) and after 10 years (61% of the CEF regimen and 57% of the CMF regimen - stratified logrank p=0,100 - unstratified logrank p=0,18) - results based on Kaplan-Meier methods@@@@@COMBO@EPIRUBICIN HYDROCHLORIDE@@@@@EPIRUBICIN HYDROCHLORIDE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@Bladder Cancer@Colorectal Cancer@@Haematological Malignancy|Myeloma|Bladder Cancer|Colorectal Cancer||||||@PHARMORUBICIN@@@@@PHARMORUBICIN||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RELAPSE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@COMPARATIVE@OPEN-LABEL@MULTI-CENTRE@@@@Invalid Dosage Value Phase 1@@@168@day@168 day@4260.6@4260.6@25.36@1@1.299@21.24@@@@@@@@@@@@2.12@@@@@@@@@@@@@@@@7/28/2017@21.24@21.24@4.85E+15@SOLUTION FOR INJECTION - 5 ML@GB£@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14921205@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ifosfamide at 2.0g/m2 and standard IV regimen of Mesnex or IV plus oral regimen of Mesnex.@@V03AF01@V03A@NO@DEERFIELD, ILLINOIS@@@@@14921205@Indicated as a prophylactic agent in reducing the incidence of ifosfamide-inducing haemorrhagic cystitis.@@@@@NO REVIEW@@@@@@@@50@Intravenous Schedule: Mesnex is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. The total daily dose of mesna is 60% of the ifosfamide dose. The recommended dosing schedule is Ifosfamide 1.2 g/m2 (0 hours), - (4 hours), - (8 hours) and Mesnex 240mg/m2 (0 hours) 240mg/m2 (4 hours), 240mg/m2 (8 hours). Intravenous and Oral Dosing Mesnex Injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration. Mesnex Tablets are given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide. The total daily dose of mesna is 100% of the ifosfamide dose. The recommended dosing schedule is Ifosfamide 1.2 g/m2 (0 hours) –– (2 hours) –– (6 hours), Mesnex Injection 240 mg/m2 (0 hours) –– (2 hours) –– (6 hours) and Mesnex Tablets –– (0 hours) 480 mg/m2 (2 hours) 480 mg/m2 (6 hours). Patients who vomit within two hours of taking oral mesna should repeat the dose or receive intravenous mesna. The efficacy and safety of this ratio of IV and PO mesna has not been established as being effective for daily doses of Ifex higher than 2.0 g/m2. The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is adjusted (either increased or decreased), the ratio of Mesnex to Ifex should be maintained.@@@@@@@Allergic reactions to mesna ranging from mild hypersensitivity to systemic anaphylactic reactions have been reported. Patients with autoimmune disorders who were treated with cyclophosphamide and mesna appeared to have a higher incidence of allergic reactions. The majority of these patients received mesna orally. Mesnex has been developed as an agent to reduce the risk of ifosfamide induced haemorrhagic cystitis. It will not prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide therapy. Mesnex does not prevent haemorrhagic cystitis in all patients. Up to 6% of patients treated with mesna have developed haematuria (>50 RBC/hpf or WHO grade 2 and above). As a result, a morning specimen of urine should be examined for the presence of haematuria (microscopic evidence of red blood cells) each day prior to ifosfamide therapy. If haematuria develops when Mesnex is given with ifosfamide according to the recommended dosage schedule, depending on the severity of the hematuria, dosage reductions or discontinuation of ifosfamide therapy may be initiated. In order to reduce the risk of hematuria, Mesnex must be administered with each dose of ifosfamide as outlined in@MED-504@No@@@@@@APPROVED@@@MEDICARE@3.7% of standard IV regimen patients developed haematuria compared to 4.3% on IV+oral regimen.@@@@@MONO@MESNA@@@@@MESNA||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@MESNEX@@@@@MESNEX||||@Detoxifying Agent@@@@@Detoxifying Agent||||@HAEMATURIA@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@@@@@100@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@@@10 ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917612@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Cyclophosphamide, methotrexate, and 5-FU (CMF) to no chemotherapy (19 trials with 7523 patients) and comparisons of doxorubicin-containing regimens with CMF as an active control (6 trials including 3510 patients).@@L01DB01@L01D@YES@@@@Although not completely elucidated, the mechanism of action of doxorubicin is related to its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture studies have demonstrated rapid cell penetration and perinucleolar chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, mutagenesis and chromosomal aberrations. The specificity of doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastro-intestinal tract and gonads are the main normal tissues damaged.@@14917612@Adriamycin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.@@YES@@@NO REVIEW@@@@@@@@11033@The most commonly used dose schedule when used as a single agent is 60 to 75 mg/m2 as a single intravenous injection administered at 21-day intervals. The lower dosage should be given to patients with inadequate marrow reserves due to old age, or prior therapy, or neoplastic marrow infiltration. [IHS Global Insight Assumption: 60mg/m2]@FDA, August 1974@@@No@@@Severe local tissue necrosis will occur if there is extravasation during administration. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The probability of developing impaired myocardial function based on a combined index of signs, symptoms and decline in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20% at 500 mg/m2. The risk of developing CHF increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m2. Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) has been reported in patients treated with anthracyclines, including doxorubicin. The occurrence of refractory secondary AML or MDS is more common when anthracyclines are given in combination with DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. Dosage should be reduced in patients with impaired hepatic function. Severe myelosuppression may occur.@LABEL@No@EXPIRED@@@@LABEL: META ANALYSIS OF BREAST CANCER TRIALS@APPROVED@@@MEDICARE@The doxorubicin-containing regimens would be considered as non-inferior to CMF if the upper 2-sided 95% confidence limit of the hazard ratio was less than 1.06, i.e., not more than 6% worse than CMF. A similar calculation for OS would require a non-inferiority margin of 1.02.@Cardiovascular: Cardiotoxicity, i.e., cardiomyopathy, congestive heart failure, supraventricular tachycardia. Routine ECG monitoring is recommended and caution should be exercised in patients with impaired cardiac function. Severe cardiac failure may occur suddenly, without premonitory ECG changes.   Vascular system: Phlebosclerosis.   Dermatological: Extravasation, skin necrosis, cellulitis, vesication, phlebitis, erythematous streaking along the vein proximal to the site of injection. Alopecia occurs frequently, including the interruption of beard growth, but all hair growth normally returns after treatment is stopped.@@@@MONO@DOXORUBICIN@@@@@DOXORUBICIN||||@WEST-WARD@@@@@WEST-WARD||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Hodgkin's Lymphoma@Bladder Cancer@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|Hodgkin's Lymphoma|Bladder Cancer|Thyroid Cancer|Stomach Cancer|Sarcoma|Breast Cancer|Ovarian Cancer@ADRIAMYCIN@@@@@ADRIAMYCIN||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@DISEASE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@@@@1@1@35@@@@@@@@@@@@0.7@@@@@@@@@@@@@@@@9/1/2017@35@35@00143-9547-01@SOLUTION FOR INJECTION - 25 ML@US$@@@@@@@@50@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16623470@Onco@@@@@300f1012ntsdm@@@@@@Experimental: Arm A: Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study endsActive Comparator: Arm B: Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.@@L01XC17@L01X@@NEW YORK, NEW YORK@2/1/2015@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@16623470@Indicated for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.@Both@NA@20-Oct-16@10/20/2016@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@NCT01673867@582@The recommended dose of OPDIVO is 3 mg/kg administered intravenously over 60 minutes every 2 weeks. Treatment should be continued as long as clinical benefit is observed or until treatmentis no longer tolerated by the patient.@EMA, 4 April 2016@4/4/2016@7/19/2015@No@@10/1/2012@@CA209-057, 2012-002472-14@No@@Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation therapy for locally advanced disease) and who will receive study therapy as second or third line of treatment for advanced disease; Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease; Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria; Eastern Cooperative Oncology Group (ECOG) performance status ≤1; A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient@ADULTS@ADULTS@III@APPROVED@@Considerable added benefit: 20 October 2016 [G-BA, https://www.g-ba.de/downloads/39-261-2733/2016-10-20_AM-RL-XII_Nivolumab-nAWG-NSCLC_D-231_BAnz.pdf]@GKV@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@OVERALL SURVIVAL@@@@@OBJECTIVE RESPONSE RATE@DURATION OF OBJECTIVE RESPONSE@@@@METASTATIC@NON-SQUAMOUS@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@76.5@kg@13302.0373@@@2.33@month@2.33 month@13302.04@13302.04@187.7@1@1.1511@458@590.04@473.13@@@@@@@@@@11.45@14@@mg/kg@3@1@@@@@@@@@@@8/1/2017@458@458@11024601@CONCENTRATE FOR SOLUTION FOR INFUSION - 4 ML@EURO@@@@@@@@40@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15368670@Onco@@@@@300f1010ntsdm@@@@@KEYNOTE-006@Experimental: Pembrolizumab Every 2 Weeks. Participants receive pembrolizumab, 10 mg intravenously (IV), once every 2 weeks for up to 2 yearsExperimental: Pembrolizumab Every 3 Weeks. Participants receive pembrolizumab, 10 mg IV, once every 3 weeks for up to 2 yearsActive Comparator: Ipilimumab. Participants receive ipilimumab, 3 mg/kg IV, once every 3 weeks for a total of 4 doses@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@@@KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking  antibody indicated for the treatment of patients with unresectable or  metastatic melanoma and disease progression following ipilimumab  and, if BRAF V600 mutation positive, a BRAF inhibitor.@@15368670@KEYTRUDA as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.@Both@YES@25-Nov-15@11/25/2015@@@@@100%@@FIRST-LINE@NCT01866319@556@The recommended dose of KEYTRUDA is 2 mg/kg administered intravenously over 30 minutes every 3 weeks. Patients should be treated with KEYTRUDA until disease progression or unacceptabletoxicity.@EMA, 17 July 2015@7/17/2015@@No@@8/1/2013@@3475-006/2012-004907-10@No@@Histologically-confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy (excluding uveal or ocular melanoma)At least one measurable lesionNo prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma (first line) or one prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma (second line)Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1Archived tissue sample or new biopsy sampleFemale participants of childbearing potential and male participants must agree to use effective contraception from Visit 1 to 120 days after the last dose of study drug; male participants must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug@@ADULTS@III@APPROVED@6/4/2014@25 November 2015: Recommended. Pembrolizumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma that has not been previously treated with ipilimumab, in adults, only when the company provides pembrolizumab with the discount agreed in the patient access scheme. [NICE, https://www.nice.org.uk/guidance/ta366/chapter/1-Guidance]@NHS@The European Commission's approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of KEYTRUDA in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.[Merck, 22 July 2015, http://www.mercknewsroom.com/news-release/oncology-newsroom/european-commission-approves-mercks-anti-pd-1-therapy-keytruda-pembro]@The safety analysis supporting the European approval of KEYTRUDA was based on 1,012 advanced melanoma patients across three doses (2 mg/kg every three weeks or 10 mg/kg every two or three weeks) in studies KEYNOTE-001 and KEYNOTE-002 combined. The most common adverse reactions (&gt;10%) with KEYTRUDA were diarrhea (15%), nausea (12%), pruritus (25%), rash (25%), arthralgia (13%) and fatigue (33%). The majority of adverse reactions reported were of Grade 1 or 2 severity. The most serious adverse reactions were immune-related adverse reactions and severe infusion-related reactions.[Merck, 22 July 2015, http://www.mercknewsroom.com/news-release/oncology-newsroom/european-commission-approves-mercks-anti-pd-1-therapy-keytruda-pembro]@@@@MONO@PEMBROLIZUMAB@@@@@PEMBROLIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@United States@Australia@Austria@Belgium@Canada@United States|Australia|Austria|Belgium|Canada|Chile|Colombia|France|Germany|Israel@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@OVERALL RESPONSE RATE@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@76.5@kg@27975.07255@@@4.8@month@4.8 month@27975.07@27975.07@191.61@1@1.299@1315@@@@@@@@@@@@26.3@21@@mg/kg@2@1@@@@@@@@@@@7/28/2017@1315@1315@3.00E+16@POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION@GB£@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923489@Onco@@@@@300f1010ntsdm@@@@@@Starting dose of 650mg/m2/day with reduction to 500mg/m2/day were not tolerated; this was reduced to 300mg/m2/day (increased to 400mg/m2/day if there was no response after 8 weeks).@@L01XX25@L01X@YES@TOKYO, JAPAN@@@@@14923489@Indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.@@NO@@@NO REVIEW@@@@100%@Global rights licensed by Eisai from Ligand in September 2006. Cephalon acquired European rights through takeover of Zeneus in December 2005.@SECOND-LINE@@193@300 mg/m²/day as an initial dose with subsequent dosing depending on body surface area (please refer to label). Treatment should be continued as long as the patient is deriving benefit.@EMA, 29 March 2001@3/29/2001@@No@@@Retinoids are associated with birth defects and must not be administered to pregnant women. About 70% of patients with CTCL who received an initial dose of =300 mg/m2/day had fasting triglyceride levels greater than 2.5 times the upper limit of normal. About 55% had values over 800 mg/dL with a median of about 1200 mg/dL in those patients. Acute pancreatitis has been reported in 4 patients with CTCL and in 6 patients with non-CTCL cancers; the cases were associated with marked elevations of fasting serum triglycerides, the lowest being 770 mg/dL in one patient. 1 patient with advanced non-CTCL cancer died of pancreatitis. Targretin induces biochemical evidence of or clinical hypothyroidism in about half of all patients treated, causing a reversible reduction in T4] and TSH levels. The incidence of decreases in TSH and total T4 were about 60% and 45%, respectively, in patients with CTCL receiving an initial dose of 300 mg/m2/day. A total of 18% of patients with CTCL receiving an initial dose of 300 mg/m2/day had reversible leukopaenia in the range of 1000 to <3000 WBC/mm3. Patients receiving an initial dose greater than 300 mg/m2/day  had an incidence of leukopenia of 43%.@LABEL@No@@@@@N/A@APPROVED@@@NHS@At 300mg/m2/day, 1/62 (1.6%) had CR and 19/62 (30%) had PR. Rate of relapse in the 20 patients with response was 30% (6/20) over 21 weeks.@@@@@MONO@BEXAROTENE@@@@@BEXAROTENE||||@EISAI@CEPHALON@@@@EISAI|CEPHALON|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@CTCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|CTCL||||||@TARGRETIN@@@@@TARGRETIN||||@Retinoid@@@@@Retinoid||||@COMPLETE RESPONSE@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@MULTI-CENTRE@HISTORICAL CONTROL@@@1.75@m²@54206.25@@@118@week@118 week@54206.25@54206.25@65.63@100@1.299@937.5@@@@@@@@@@@@0.13@1@@mg/m²@300@1@@@@@@@@@@@7/28/2017@9.38@9.38@4.33E+15@SOFT CAPSULE@GB£@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16446267@Onco@@@@@300f1012ntsdm@@@@@@Velcade dexamethasone, thalidomide (VcTD) versus TD alone@@L01XX32@L01X@@@3/1/2013@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@16446267@VELCADE in combination with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@NCT00507416@257@VELCADE 1 mg powder for solution for injection is administered via intravenous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 28 day treatment cycle. This 4-week period is considered a treatment cycle. At least 72 hoursshould elapse between consecutive doses of VELCADE. Dexamethasone is administered orally at 40 mg on days 1, 2, 3, 4, 8, 9, 10 and 11 of the VELCADE treatment cycle. Thalidomide is administered orally at 50 mg daily on days 1-14 and if tolerated the dose is increasedto 100 mg on days 15-28, and thereafter may be further increased to 200 mg daily from cycle 2 (see Table 4).Four treatment cycles of this combination are administered. It is recommended that patients with at least partial response receive 2 additional cycles.@EMA, 31 July 2013@7/31/2013@@Yes@@6/1/2007@@UPFRONTC05009@No@@@@@III@APPROVED@@@GKV@Results from first 256 patients: as induction therapy prior to stem cell transplantation (SCT), the VcTD arm demonstrated a complete remission (CR, including immunofixation positive and negative) rate of 36 percent compared to 9 percent in the TD arm (p<0.001). Following transplantation, the VcTD arm demonstrated a complete remission (CR, including immunofixation positive and negative) rate of 57 percent compared to 28 percent in the TD arm (p<0.001). Successful stem cell mobilization occurred in more than 90 percent of patients in both arms. SOURCE: Millennium, ASH December 2007@@@@@COMBO@BORTEZOMIB@DEXAMETHASONE@THALIDOMIDE@@@BORTEZOMIB|DEXAMETHASONE|THALIDOMIDE||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@VELCADE@GENERIC@GENERIC@@@VELCADE|GENERIC|GENERIC||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@COMPLETE RESPONSE@@@@@@@@@@@@@@@MULTI-CENTRE@RANDOMISED@@@@1.75@m²@20184.84@@@168@day@168.0 day@20184.84@20184.84@120.15@1@1.1511@1293.9@1643.25@1332.4@@@@@@@@@@369.69@28@@mg/m²@1.3@4@@@@@@@@@@@8/1/2017@1293.9@1293.9@822831@POWDER FOR INJECTABLE SUSPENSION@EURO@@@@@@@@3.5@MG@3.5 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16396644@Onco@@@@@300f1008ntsdm@@@@@@Patients in the Revlimid/dexamethasone arm (n=170) took 25 mg of Revlimid orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone arm (n= 171)took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Patients in both treatment arms took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16396644@@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@@704@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on days 14, 912, and 1720 of each 28day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 14 every 28 days. Dosing is continued or modified based upon clinical and laboratory findings.@MHLW, 1 July 2010@7/1/2010@@@@@@LABEL@No@@PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST ONE PRIOR TREATMENT WERE RANDOMIZED TO 2 ARMS: ARM1: REVLIMID (LENALIDOMIDE) PLUS ORAL PULSE HIGHDOSE DEXAMETHASONE THERAPY. ARM2: DEXAMETHASONE THERAPY ALONE.@@@III@APPROVED@@@NHI@RESULTS PENDING@@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@TIME TO PROGRESSION@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@PLACEBO-CONTROLLED@@1@1@71154276.55@@@48.1@month@48.1 month@71154276.55@71154276.55@48635.55@1@0.0091@6484.74@7647.1@@@@@@@@@@@2593.9@28@@mg@25@21@@@@@@@@@@@8/30/2017@6484.74@6484.74@4291024M2020@CAPSULE@YEN@@@@@@@@2.5@MG@2.5 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924475@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received up to four doses of Hematide administered subcutaneously every three weeks.@@-@-@-@OSAKA, JAPAN@@@Hematide is a novel, synthetic pegylated peptide-based erythropoiesis stimulating agent (ESA) that acts on the erythropoietin receptor to stimulate the production of red blood cells. @@14924475@CKD or cancer-related anaemia@@-@-@@NO REVIEW@@@@-@Takeda initially licensed Japanese rights in February 2006; followed up with a global deal in June 2006; Affymax and Takeda will co-develop and co-market in the U.S. Takeda paid US$105 mil. upfront and could pay another US$430 mil.@-@-@30@-@-@@@-@@@-@-@@-@30 PATIENTS WITH CKD OR CANCER-RELATED ANAEMIA@@@II@DISCONTINUED@@-@-@>Takeda and Affymax suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia. [Takeda, 29.08.2008]>The mean Hgb level was 10.2 g/dL at study entry and increased to over 11 g/dL following an initial dose of Hematide. In the maintenance-conversion study, 90 patients previously treated with epoetin alfa were switched to Hematide once every 4 weeks. The mean baseline Hgb level, which was 11.5 g/dL at baseline, was maintained within +/- 1.0 g/dL at the end of 6 months of treatment. 6% of patients reported adverse events possibly related to Hematide such as fatigue, rash and hypertension and 0.7% of patients reported serious adverse events possibly related to Hematide (1 transient ischaemic attack in a patient with history of atrial fibrillation, and one moderate infusion reaction in a patient who responded to outpatient intervention). ASH December 2006; preliminary results from the first two cohorts of patients (15 patients who received a dose of 0.1 mg/kg and 15 patients who received a dose of 0.15 mg/kg) showed that Hematide increased both reticulocyte and hemoglobin levels. A pronounced reticulocyte response was observed following each dose of Hematide, and at least 50% of patients in both dose groups had haemoglobin increases =1 g/dL by week 7, which appeared to be sustained through week 13. Hemoglobin values achieved levels of =11 g/dL in at least 50 percent of patients by week 10 and were sustained through week 13. [Affymax/ERAC, June 2007]@-@@@@MONO@-@@@@@-||||@TAKEDA PHARMACEUTICAL@AFFYMAX@@@@TAKEDA PHARMACEUTICAL|AFFYMAX|||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@HEMATIDE@AF-37702@@@@HEMATIDE|AF-37702|||@EPO@Synthetic Peptide@@@@EPO|Synthetic Peptide|||@SAFETY@@@@@@@@@@-@@@@@MULTI-CENTRE@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917431@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@BEERSE, BELGIUM@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14917431@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@DUROGESIC SMAT@@@@@DUROGESIC SMAT||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1807@44.62@67.4@46.73@@@@@@@@@@@@@@@@@@@@@@@@@@8/15/2017@8.92@8.92@574965@TRANSDERMAL PATCH@EURO@@@@@@@@50@MCG@50 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16063903@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX52@L01X@@@@@Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.@@16063903@Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.@Both@NA@@@NO REVIEW@@@@@@SECOND-LINE@@106@Initiate therapy with VENCLEXTA at 20 mg once daily for 7 days, followed by a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg.@FDA, 11 April 2016@4/11/2016@@Yes@@@@@No@@@17p deletion@ADULTS@@APPROVED@@@@The approval was based on the results of a phase 2, single-arm trial of venetoclax for the treatment of patients with CLL harboring the 17p deletion who had received at least one prior therapy. The major efficacy outcome measure was overall response rate (ORR) according to the 2008 Modified IWCLL NCI-WG Guidelines for Tumor Response as evaluated by an independent review committee (IRC). Duration of response (DOR) was an additional outcome measure.  The trial enrolled 106 patients who had received at least one prior therapy with 17p deletion, as detected by an FDA-approved CLL fluorescence in situ hybridization (FISH) probe kit.  Patients had a median of 2.5 prior treatments (range 1-10). The ORR by IRC was 80% (95% CI: 71%, 87%) with 8% complete remission (including 2% complete remission with incomplete marrow recovery).  Minimal residual disease (MRD) was evaluated in peripheral blood and bone marrow for patients who achieved CR or CRi, following treatment with venetoclax.  Three percent of the patients in the intent-to-treat population achieved a complete remission (CR or CRi) and were also negative for MRD in the bone marrow and peripheral blood.  The median time to first response was 0.8 months (range: 0.1 to 8.1 months).  Median duration of response (DOR) has not been reached with approximately 12 months median follow-up. The DOR ranged from 2.9 to more than 19.0 months.[FDA, 11 April 2016, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm495351.htm]@Safety data were evaluated in 240 patients with previously-treated CLL who were treated with single-agent venetoclax at a target dose of 400 mg orally daily. The most common (greater than or equal to 20%) adverse reactions of any grade were neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue. Serious adverse reactions were reported in 44% of patients, and the most common (greater than or equal to 2%) serious adverse reactions were pneumonia, febrile neutropenia, pyrexia, autoimmune hemolytic anemia, anemia, and tumor lysis syndrome (TLS). Due to a rapid reduction in tumor volume, TLS is an important identified risk when initiating venetoclax. The risk of TLS is reduced with stratification by tumor burden, prophylaxis with hydration and anti-hyperuricemics, frequent blood chemistry monitoring and correction of electrolyte abnormalities. In patients with higher risk features, hospitalization for IV hydration, electrolyte monitoring, and aggressive correction of electrolyte abnormalities may be required. In 66 patients with CLL starting with a daily dose of 20 mg and increasing over 5 weeks to a daily dose of 400 mg, the rate of TLS was 6% with no clinical events. All events were laboratory TLS and occurred in patients who had a lymph node(s) greater than or equal to 5 cm or ALC greater than or equal to 25 x 109/L.  [FDA, 11 April 2016, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm495351.htm]@@@@@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLEXTA@@@@@VENCLEXTA||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@@@@@@@@@@@OPEN-LABEL@SINGLE-ARM@MULTICENTER@@@1@1@16986.34406@@@12.1@month@12.1 month@16986.34@16986.34@46.15@2@1@17.2@@@@@@@@@@@@0.86@24@1@mg@92.5@1@7@@mg@400@1@@@@@@8/2/2017@8.6@8.6@00074-0561-11@FILM-COATED TABLET (UNIT DOSE BLISTER)@US$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917438@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@BEERSE, BELGIUM@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14917438@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@DUROGESIC SMAT@@@@@DUROGESIC SMAT||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1807@96.58@133.09@100.32@@@@@@@@@@@@@@@@@@@@@@@@@@8/15/2017@4.83@4.83@575114@TRANSDERMAL PATCH@EURO@@@@@@@@25@MCG@25 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922876@Onco@@@@@300f1010ntsdm@@@@@@Patients in the Revlimid/dexamethasone arm (n=170) took 25 mg of Revlimid orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone arm (n= 171)took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Patients in both treatment arms took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.@@L04AX04@L04A@YES@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14922876@Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.@@NO@1-Jan-09@1/1/2009@When the ERG's approach to modelling overall survival was used, for the comparison of lenalidomide with dexamethasone in people who has received one prior therapy only, the ICER was more than £69,000 per QALY gained. For the comparisons with dexamethasone in people who had received one prior therapy, and where that therapy was thalidomide, the ICERs were above £56,000 per QALY gained. [NICE, 28.10.2008]@@@@100%@@SECOND-LINE@@704@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on days 14, 912, and 1720 of each 28day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 14 every 28 days. Dosing is continued or modified based upon clinical and laboratory findings.@EMA, 14 June 2007@6/14/2007@@Yes@@@Thalidomide, of which Revlimid is an analogue, is a known human teratogen that causes lifethreatening human birth defects. Revlimid may cause fetal harm when administered to aDVT and pulmonary embolism: this drug has demonstrated a significantly increased risk of DVT and PE in patients with multiple myeloma who were treated with Revlimid combination therapy.@LABEL@No@@PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST ONE PRIOR TREATMENT WERE RANDOMIZED TO 2 ARMS: ARM1: REVLIMID (LENALIDOMIDE) PLUS ORAL PULSE HIGHDOSE DEXAMETHASONE THERAPY. ARM2: DEXAMETHASONE THERAPY ALONE.@@@III@APPROVED@@Not recommended: November 2016. Lenalidomide in combination with dexamethasone is not recommended for treating multiple myeloma in adults: whose condition has relapsed for the first time, who have had 1 prior treatment with bortezomib, when thalidomide is contraindicated or not suitable and, when stem cell transplantation is not suitable. [NICE, https://www.nice.org.uk/guidance/GID-TAG452/documents/appraisal-consultation-document]Revlimid in first relapse:1 Appraisal Committee's preliminary recommendations1.1 Lenalidomide in combination with dexamethasone is not recommended for treating multiple myeloma in people:whose multiple myeloma has relapsed for the first time, andwho have received 1 prior treatment with bortezomib, andfor whom thalidomide is contraindicated or cannot be tolerated andfor whom bone marrow transplantation is not appropriate.[NICE, March 2014 http://www.nice.org.uk/guidance/index.jsp?action=article&amp;o=66926]&gt;&gt;Revlimid in people who have received two or more therapies: Lenalidomide in combination with dexamethasone is recommended, within its licensed indication, as an option for the treatment of multiple myeloma in people who have received two or more prior therapies, under the following circumstances 1.1 The NHS will cover the cost of the drug for the first 2 years (26 cycles of 28 days) of treatment; the drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for longer than 2 years will be met by the manufacturer. 1.2 People currently receiving lenalidomide for the treatment of multiple myeloma, but who have not received two or more prior therapies, should have the option to continue therapy until they and their clinicians consider it appropriate to stop. [NICE preliminary recommendations, 30.01.2009] &gt;&gt; Lenalidomide in combination with dexamethasone is not recommended for the treatment of multiple myeloma in people who have received at least one prior therapy. People currently receiving lenalidomide for the treatment of multiple myeloma should have the option to continue therapy until they and their clinicians consider it appropriate to stop. [NICE appraisal committee preliminary recommendations, 28.10.2008] &gt;&gt; NICE guidance due in January 2009@NHS@Analyses of both studies showed that the combination of Revlimid/dexamethasone was significantly superior to dexamethasone alone for TTP.@In the lenalidomide/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of lenalidomide compared to 21% in the placebo/dexamethasone treatment group. Of these patients who had one dose interruption with or without a dose reduction, 50% in the lenalidomide/dexamethasone treatment group underwent at least one additional dose interruption with or without a dose reduction compared to 21% in the placebo/dexamethasone treatment group. Other adverse events reported in multiple myeloma patients (REVLIMID® (lenalidomide)/dexamethasone vs dexamethasone/placebo): constipation (39% vs 19%), fatigue (38% vs 37%), insomnia (32% vs 37%), muscle cramp (30% vs 21%), diarrhea (29% vs 25%), neutropenia (28% vs 5%), anemia (24% vs 17%), asthenia (23% vs 25%), pyrexia (23% vs 19%), nausea (22% vs 19%), headache (21% vs 21%), peripheral edema (21% vs 19%), dizziness (21% vs 15%), dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and muscle weakness (15% vs 15%).@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@TIME TO PROGRESSION@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@PLACEBO-CONTROLLED@@1@1@932668.62@@@48.1@month@48.1 month@932668.62@932668.62@637.5@21@1.299@3570@@@@@@@@@@@@34@28@@mg@25@21@@@@@@@@@@@7/28/2017@170@170@1.18E+16@HARD CAPSULE@GB£@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14924003@Onco@@@@@300f1012ntsdm@@@@@@Ifosfamide at 2.0g/m2 and standard IV regimen of Mesnex or IV plus oral regimen of Mesnex.@@V03AF01@V03A@NO@DEERFIELD, ILLINOIS@@@@@14924003@Indicated as a prophylactic agent in reducing the incidence of ifosfamide-inducing haemorrhagic cystitis.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@50@Intravenous Schedule: Mesnex is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. The total daily dose of mesna is 60% of the ifosfamide dose. The recommended dosing schedule is Ifosfamide 1.2 g/m2 (0 hours), - (4 hours), - (8 hours) and Mesnex 240mg/m2 (0 hours) 240mg/m2 (4 hours), 240mg/m2 (8 hours). Intravenous and Oral Dosing Mesnex Injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration. Mesnex Tablets are given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide. The total daily dose of mesna is 100% of the ifosfamide dose. The recommended dosing schedule is Ifosfamide 1.2 g/m2 (0 hours) –– (2 hours) –– (6 hours), Mesnex Injection 240 mg/m2 (0 hours) –– (2 hours) –– (6 hours) and Mesnex Tablets –– (0 hours) 480 mg/m2 (2 hours) 480 mg/m2 (6 hours). Patients who vomit within two hours of taking oral mesna should repeat the dose or receive intravenous mesna. The efficacy and safety of this ratio of IV and PO mesna has not been established as being effective for daily doses of Ifex higher than 2.0 g/m2. The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is adjusted (either increased or decreased), the ratio of Mesnex to Ifex should be maintained.@@@@@@@Allergic reactions to mesna ranging from mild hypersensitivity to systemic anaphylactic reactions have been reported. Patients with autoimmune disorders who were treated with cyclophosphamide and mesna appeared to have a higher incidence of allergic reactions. The majority of these patients received mesna orally. Mesnex has been developed as an agent to reduce the risk of ifosfamide induced haemorrhagic cystitis. It will not prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide therapy. Mesnex does not prevent haemorrhagic cystitis in all patients. Up to 6% of patients treated with mesna have developed haematuria (>50 RBC/hpf or WHO grade 2 and above). As a result, a morning specimen of urine should be examined for the presence of haematuria (microscopic evidence of red blood cells) each day prior to ifosfamide therapy. If haematuria develops when Mesnex is given with ifosfamide according to the recommended dosage schedule, depending on the severity of the hematuria, dosage reductions or discontinuation of ifosfamide therapy may be initiated. In order to reduce the risk of hematuria, Mesnex must be administered with each dose of ifosfamide as outlined in@MED-504@No@@@@@@APPROVED@@@GKV@3.7% of standard IV regimen patients developed haematuria compared to 4.3% on IV+oral regimen.@@@@@MONO@MESNA@@@@@MESNA||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@UROMITEXAN@@@@@UROMITEXAN||||@Detoxifying Agent@@@@@Detoxifying Agent||||@HAEMATURIA@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@41.38@63.3@43.38@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@8.28@8.28@4887388@INJECTION MULTIDOSE IN BOTTLE, 10 ML@EURO@@@@@@@@1000@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918400@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@HOLZKIRCHEN, GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918400@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@12.76@27.12@13.86@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@2.55@2.55@6326168@TRANSDERMAL PATCH@EURO@@@@@@@@12@MCG@12 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918478@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@BAD VILBEL, GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918478@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@STADA ARZNEIMITTEL@@@@@STADA ARZNEIMITTEL||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@16.66@32.05@17.89@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@3.33@3.33@4789361@PATCH (MATRIX)@EURO@@@@@@@@25@MCG@25 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16380437@Onco@@@@@300f1012ntsdm@@@@@@Patients are given vinflunine plus Gemzar or placebo plus Gemzar@@L01CA@L01C@-@CASTRES, FRANCE@6/1/2008@@Vinflunine is a second-generation Vinca alkaloid distinguished from other related compounds by differences in tubulin binding affinities and its effects upon microtubule dynamics. Although in vitro studies have demonstrated that vinflunine is consistently the least potent of the Vinca alkaloids, in vivo studies in a range of transplantable murine and human tumor models in mice have shown that vinflunine was markedly superior to vinorelbine and the other Vinca alkaloids in terms of increase in life span and inhibition of tumor growth. The potential of vinflunine as a component of combination chemotherapy has also been demonstrated. Preliminary evidence from phase I and phase II studies indicated that vinflunine was a promising anticancer agent with manageable toxicity, at least comparable in efficacy to the most active currently available agents. Antitumor activity has been observed in patients with advanced transitional cell cancer of the bladder, metastatic breast cancer and non-small cell lung cancer. Phase III trials are ongoing in non-small cell lung and bladder cancer, with programs planned in advanced breast cancer and ovarian cancer.@@16380437@Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@BMS gained exclusive rights to market the drug in the US, Canada, Japan, South Korea, and select South-East Asian markets in April 2004 from Pierre Fabre. Pierre Fabre retained responsibility for the development and marketing of Javlor in all other territ@SECOND-LINE@NCT00389155@450@The recommended dose is 320 mg/m² vinflunine as a 20 minute intravenous infusion every 3 weeks.@EMA, 10 August 2009@8/10/2009@@No@@11/1/2006@@@No@@450 PATIENTS WHO ARE INELIGIBLE FOR CISPLATIN THERAPY@@@II/III@APPROVED@@@GKV@At ASCO, May-June 2003, results were presented from a phase II trial in patients with advanced transitional cell cancer of the  bladder. Patients were treated with vinflunine at 350 mg/m2 every 21 days; this dose was reduced to 320 mg/m2 every 21 days, after one episode of fatal neutropenic sepsis. Preliminary efficacy data showed that among 48 evaluable patients, nine had partial responses, 26 had stable disease and 16 had disease progression. Grade 3 and 4 neutropenia occurred in 30% and 37% of patients, respectively; other grade 3 and 4 toxicities included constipation (7%), myalgia (4%), vomiting (7%). 17% of patients experienced grade 2 alopecia. Results from the Phase III trial are pending.@@@@@MONO@VINFLUNINE@@@@@VINFLUNINE||||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@JAVLOR@@@@@JAVLOR||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@@@1.75@m²@27870.78912@@@6.9@month@6.9 month@27870.79@27870.79@132.8@1@1.1511@249@325.8@257.55@@@@@@@@@@4.98@21@@mg/m²@320@1@@@@@@@@@@@8/1/2017@249@249@5376371@CONCENTRATE FOR INFUSION SOLUTION, 2 ML@EURO@@@@@@@@50@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14919963@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@L01CA02@L01C@YES@LAKE FOREST, ILLINOIS@@@Vincristine is an antineoplastic drug with broad-spectrum anti-tumor activity in man. The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase. The drug is relatively marrow-sparing and is thus suitable for use in combination with other cancer chemotherapeutic agents.@@14919963@Vincristine sulfate injection is indicated in acute leukaemia. Vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas 4-6 (lymphocytic, mixed cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma 7, neuroblastoma 8, and Wilms' tumor 9.@@NO@@@NO REVIEW@@@@@Acquired via takeover of Mayne@@@@The drug is administered intravenously at weekly intervals. The usual dose of vincristine injection for children is 2 mg/m². For children weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of vincristine sulfate injection for adults is 1.4 mg/m². A 50% reduction in the dose of vincristine sulfate injection is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.@FDA, April 1988@@@@@@This preparation should be administered by individuals experienced in the administration of vincristine sulfate injection. It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissues during intravenous administration of vincristine sulfate injection may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. Fatal if given intrathecally.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@VINCRISTINE SULPHATE@@@@@VINCRISTINE SULPHATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Hodgkin's Lymphoma@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Hodgkin's Lymphoma||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@5.75@@@@@@@@@@@@5.75@@@@@@@@@@@@@@@@8/2/2017@5.75@5.75@61703-0309-06@INJECTION (VIAL) - 1 ML@US$@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15059391@Onco@@@@@300f1020ntsdm@@@@@@Experimental: abiraterone acetate plus prednisone/prednisolone 1000mg Daily/5mg Twice DailyPlacebo Comparator: placebo plus prednisone/prednisolone 1000mg Daily/5mg Twice Daily@@L02BX03@L02B@-@NEW BRUNSWICK, NEW JERSEY@2/1/2014@@@@15059391@In combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.@@-@-@@NO REVIEW@@@@@J&J acquired Cougar in 2009.[J&J May 21 2009 http://www.jnj.com/connect/news/all/20090521_160000 ]@-@NCT00887198@1000@ZYTIGA 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily@EMA, 11 January 2013@1/11/2013@@-@@4/1/2009@Mineralocorticoid excess, Adrenocortical insufficiency, Hepatotoxicity@COU-AA-302@No@-@-@@@III@APPROVED@@-@@>> The results were published in The New England Journal of Medicine in December 2012. The data demonstrated a statistically significant improvement in rPFS in the abiraterone acetate plus prednisone/prednisolone arm (ZYTIGA arm) of the study compared to the placebo plus prednisone/prednisolone (control) arm.  Additionally, treatment with ZYTIGA plus prednisone/prednisolone resulted in a longer OS than with placebo (median OS in the ZYTIGA arm was not reached because progression events occurred more slowly in the ZYTIGA arm compared to the control arm. At the time of the interim analysis, statistical significance for OS was not reached.[J&J, 11 January 2013, http://www.jnj.com/connect/news/all/zytiga-approved-in-the-eu-for-use-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-before-chemotherapy ]>>The Independent Data Monitoring Committee (IDMC) unanimously recommended unblinding the study based on a planned interim analysis in which differences in radiographic progression-free survival, overall survival, and secondary endpoints were observed that constitute evidence of clinical benefit as well as continued evidence of favorable safety in patients receiving abiraterone acetate plus prednisone as compared to those receiving placebo plus prednisone.  Based on these results, the IDMC also recommended that patients in the placebo arm be offered treatment with ZYTIGA.These results will be presented at an upcoming medical meeting and will also be submitted for publication in a peer-reviewed journal.[J&J, 8 March 2012 http://www.jnj.com/connect/news/all/study-unblinded-zytiga-abiraterone-acetate-plus-prednisone-for-asymptomatic-or-mildly-symptomatic-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer ]>>Trial registered [Cougar, 18 April 2009]@-@@@@COMBO@ABIRATERONE ACETATE@PREDNISONE@@@@ABIRATERONE ACETATE|PREDNISONE|||@JOHNSON & JOHNSON@COUGAR BIOTECHNOLOGY@@@@JOHNSON & JOHNSON|COUGAR BIOTECHNOLOGY|||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@ZYTIGA@@@@@ZYTIGA||||@Hormone Antagonist@@@@@Hormone Antagonist||||@OVERALL SURVIVAL@PROGRESSION FREE SURVIVAL@@@@@@@@@ASYMPTOMATIC@MILDLY SYMPTOMATIC@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@1@1@124354.53@@@35.3@month@35.3 month@124354.53@124354.53@115.82@120@1.1229@3474.61@5734.49@3631.01@@@@@@@@@@0.12@1@@mg@1000@1@@@@@@@@@@@6/7/2017@28.96@28.96@41427016@TABLET@EURO@@@@@@@@250@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16061292@Onco@@@@@300f1015ntsdm@@@@@@112 patients treated with Hycamtin received an initial dose of 1.5 mg/m2 given by intravenous infusion over 30 minutes for 5 consecutive days, starting on day 1 of a 21-day course. 114 patients treated with paclitaxel received 175 mg/m2 over 3 hours on day 1 of a 21-day course.@@L01XX17@L01X@YES@BRENTFORD, UNITED KINGDOM@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@16061292@Topotecan monotherapy is indicated for the treatment of  patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.@@NO@@@NO REVIEW@@@@@Merck KGaA licensed marketing and sales rights from SmithKline Beecham in June 2000 for the U.K. only.@SECOND-LINE@@226@Ovarian and Small Cell Lung Carcinoma- Initial dose- The recommended dose of topotecan is 1.5 mg/m2 body surface area/day administered by intravenous infusion over 30 minutes daily for 5 consecutive days with a 3 week interval between the start of each course. If well tolerated, treatment may continue until disease progression. Subsequent doses- Topotecan should not be re-administered unless the neutrophil count is  1 x 109/l, the platelet count is  100 x 109/l, and the haemoglobin level is  9 g/dl (after transfusion if necessary).@1-Nov-96@11/1/1996@5/30/2008@@@@Bone marrow suppression (primarily neutropaenia) is the dose-limiting toxicity of Hycamtin. Cases of neutropenia, thrombocytopaenia and anaemia were reported. Hycamtin may cause fetal harm when administered to a pregnant woman.@LABEL@No@@226 PATIENTS, WITH METASTATIC OVARIAN CARCINOMA, WHO HAD RECURRENT OVARIAN CANCER AFTER A PLATINUM-CONTAINING REGIMEN OR HAD NOT RESPONDED TO AT LEAST 1 PRIOR PLATINUM-CONTAINING REGIMEN, WERE RANDOMISED TO 2 ARMS: THE HYCAMTIN ARM AND THE PACLITAXEL ARM.@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@The complete RR was of 5% for the Hycamtin arm compared to 3% for the paclitaxel arm. The partial RR was of 16% for the Hycamtin arm compared to 11% for the paclitaxel arm. The overall RR was of 21% for the Hycamtin arm compared to 14% for the paclitaxel arm - 95% CI was of 13 to 28% for the Hycamtin arm compared to 8 to 20% for the paclitaxel arm (p=0.20). The calculation for duration of response was based on the interval between first response and TTP. Median response duration was of 25.9 weeks for the Hycamtin arm (23 patients) compared to 21.6 weeks for the paclitaxel arm (16 patients) - 95% CI was of 22.1 to 32.9 weeks for the Hycamtin arm compared to 16 to 34 weeks for the paclitaxel arm (hazard ratio = 0.78 ; p=0.48). Median TTP was of 18.9 weeks for the Hycamtin arm compared to 14.7 weeks for the paclitaxel arm - 95% CI was of 12.1 to 23.6 weeks for the Hycamtin arm compared to 11.9 to 18.3 weeks for the paclitaxel arm (hazard ratio = 0.76 ; p=0.07). Median survival was of 63 weeks for the Hycamtin arm compared to 53 weeks for the paclitaxel arm - 95% CI was of 46.6 to 71.9 weeks for the Hycamtin arm compared to 42.3 to 68.7 weeks for the paclitaxel arm (hazard ratio = 0.97 ; p=0.87). The median time to response was 7.6 weeks (range 3.1 to 21.7) with Hycamtin compared to 6.0 weeks (range 2.4 to 18.1) with paclitaxel. Consequently, the efficacy of Hycamtin may not be achieved if patients are withdrawn from treatment prematurely.@@@@@MONO@TOPOTECAN HYDROCHLORIDE@@@@@TOPOTECAN HYDROCHLORIDE||||@GSK@@@@@GSK||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@HYCAMTIN@@@@@HYCAMTIN||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RESPONSE RATE@DURATION OF RESPONSE@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@ADVANCED@@@@@RANDOMISED@@@@@1.6@m²@5415.152@@@19@week@19 week@5415.15@5415.15@40.72@10@1.1511@178.13@212.24@190.03@@@@@@@@@@71.25@21@@mg/m²@1.5@5@@@@@@@@@@@8/1/2017@17.81@17.81@3.40E+12@CAPSULE@EURO@@@@@@@@0.25@MG@0.25 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14917344@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@H02AB02@H02A@YES@PARIS, FRANCE@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14917344@Dexamethasone Injection is indicated in acute conditions in which oral glucocorticoid therapy is not feasible such as: Shock: of haemorrhagic, traumatic, surgical or septic origin; cerebral oedema associated with cerebral neoplasm; inflammatory diseases of joints and soft tissue such as rheumatoid arthritis. Short term management of acute self-limited allergic conditions such as angioneurotic oedema or acute exacerbations of chronic allergic disorders such as bronchial asthma or serum sickness. High doses of dexamethasone are intended for the adjunctive treatment of shock where massive doses of corticosteroids are needed. There is a lack of evidence that use of corticosteroids in septic shock affects mortality in the long term. Use must be accompanied by the appropriate concomitant systemic antibiotic treatment and supportive measures which the patient's condition may require.@@NO@Aug-93@@NO REVIEW@@@@65%@@@@N/A@Intravenous Administration: IV dosage of dexamethasone phosphate is variable, depending on the condition being treated. It usually ranges from 0.5-24 mg daily. The duration of therapy is dependent on the clinical response of the patient and as soon as improvement is indicated, the dosage should be adjusted to the minimum required to maintain the desired clinical response. Withdrawal of the drug on completion of therapy should be gradual.@1-Dec-97@12/1/1997@3/19/1959@@@@Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity. Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment.@NO LABELLED TRIAL@No@@@-@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@DEXAMETHASONE ACETATE@@@@@DEXAMETHASONE ACETATE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Breast Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Breast Cancer||||||@DECTANCYL@@@@@DECTANCYL||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1807@3.04@3.99@3.34@@@@@@@@@@0.2@@@@@@@@@@@@@@@@9/1/2017@0.1@0.1@3.40E+12@TABLET@EURO@@@@@@@@0.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919512@Onco@@@@@300f1015ntsdm@@@@@@Cyclophosphamide, methotrexate, and 5-FU (CMF) to no chemotherapy (19 trials with 7523 patients) and comparisons of doxorubicin-containing regimens with CMF as an active control (6 trials including 3510 patients).@@L01DB01@L01D@YES@@@@Although not completely elucidated, the mechanism of action of doxorubicin is related to its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture studies have demonstrated rapid cell penetration and perinucleolar chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, mutagenesis and chromosomal aberrations. The specificity of doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastro-intestinal tract and gonads are the main normal tissues damaged.@@14919512@Doxorubicin has been used successfully in the treatment of neoplastic conditions such as acute leukaemia, soft tissue and osteogenic sarcomas, breast carcinoma, lymphomas, bronchogenic (lung) carcinoma. It has also been used in the treatment of paediatric malignancy. Doxorubicin is frequently used in combination chemotherapy regimen involving other cytotoxic drugs. Doxorubicin can be used in the treatment of non-metastatic transitional cell carcinoma, carcinoma in situ and papillary tumours of the bladder, by intravesical administration.@@YES@5-Dec@@NO REVIEW@@@@@G Gam is the French arm of Hexal, purchased by Novartis in February 2005.@@@11033@If it is used in combination with other antitumour agents with overlapping toxicity, such as high-dose i.v. cyclophosphamide or related anthracycline compounds such as daunorubicin, idarubicin and/or epirubicin, the dosage of doxorubicin should be reduced to 30 - 40 mg/m2 every three weeks. [IHS Global Insight assumption: 30mg/m2]@3-May@@8/1/2004@No@@@Severe local tissue necrosis will occur if there is extravasation during administration. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The probability of developing impaired myocardial function based on a combined index of signs, symptoms and decline in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20% at 500 mg/m2. The risk of developing CHF increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m2. Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) has been reported in patients treated with anthracyclines, including doxorubicin. The occurrence of refractory secondary AML or MDS is more common when anthracyclines are given in combination with DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. Dosage should be reduced in patients with impaired hepatic function. Severe myelosuppression may occur.@LABEL@No@EXPIRED@@@@III; META ANALYSIS OF BREAST CANCER TRIALS@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@The doxorubicin-containing regimens would be considered as non-inferior to CMF if the upper 2-sided 95% confidence limit of the hazard ratio was less than 1.06, i.e., not more than 6% worse than CMF. A similar calculation for OS would require a non-inferiority margin of 1.02.@Cardiovascular: Cardiotoxicity, i.e., cardiomyopathy, congestive heart failure, supraventricular tachycardia. Routine ECG monitoring is recommended and caution should be exercised in patients with impaired cardiac function. Severe cardiac failure may occur suddenly, without premonitory ECG changes.   Vascular system: Phlebosclerosis.   Dermatological: Extravasation, skin necrosis, cellulitis, vesication, phlebitis, erythematous streaking along the vein proximal to the site of injection. Alopecia occurs frequently, including the interruption of beard growth, but all hair growth normally returns after treatment is stopped.@@@@COMBO@DOXORUBICIN@CYCLOPHOSPHAMIDE@METHOTREXATE@FLUOURACIL@@DOXORUBICIN|CYCLOPHOSPHAMIDE|METHOTREXATE|FLUOURACIL|@G GAM@NOVARTIS@@@@G GAM|NOVARTIS|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Hodgkin's Lymphoma@Bladder Cancer@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|Hodgkin's Lymphoma|Bladder Cancer|Thyroid Cancer|Stomach Cancer|Sarcoma|Breast Cancer|Ovarian Cancer@GENERIC@5-FU@@@@GENERIC|5-FU|||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@DISEASE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@1@year@1 year@@@@1@1.1511@4@@@@@@@@@@@@0.4@@@@@@@@@@@@@@@@8/2/2017@4@4@9251270R@LYOPHILIZATE FOR PARENTERAL USE@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14923203@Onco@@@@@300f1012ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14923203@Sprycel is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. It is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@78@The recommended starting dosage for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ALL is 70 mg twice daily administered orally, one tablet in the morning and one in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@EMA, 20 November 2006@11/20/2006@@Yes@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-0015@No@@42 with blastic phase and 36 with PH+ disease@@@II@APPROVED@@@GKV@The MaHR rate was 59% in accelerated phase patients, 32% in myeloid phase patients, 31% in lymphoid blast phase patients, and 42% in Ph+ ALL patients. The median durations of major haematologic response were 3.7 months in lymphoid blast CML and 4.8 months in Ph+ ALL.@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@32315.78336@@@4@month@4 month@32315.78@32315.78@265.61@60@1.1511@2276.7@2847.87@2315.2@@@@@@@@@@1.9@1@@mg@140@1@@@@@@@@@@@8/1/2017@37.95@37.95@283469@FILM-COATED TABLET@EURO@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918894@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-869 with chemotherapy@@-@-@-@UNITED STATES@@@ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 µmol/L) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. The inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 = 2, 4, and 7 nmol/L for PDGFR-ß, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nmol/L for human endothelial cells). ABT-869 is not a general antiproliferative agent because, in most cancer cells, >1,000-fold higher concentrations of ABT-869 are required for inhibition of proliferation. However, ABT-869 exhibits potent antiproliferative and apoptotic effects on cancer cells whose proliferation is dependent on mutant kinases, such as FLT3. In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50% inhibition, 15 mg/kg). In tumor growth studies, ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED50 = 1.5–5 mg/kg, twice daily) and is also effective (>50% inhibition) in orthotopic breast and glioma models. Reduction in tumor size and tumor regression was observed in epidermoid carcinoma and leukemia xenograft models, respectively. In combination, ABT-869 produced at least additive effects when given with cytotoxic therapies. @@14918894@-@@-@-@@NO REVIEW@@@@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008Part of a partnership signed in June 2007 with Genentech which also includes ABT-869. They will co-develop the drugs and co-promote in the U.S., with Abbott holding overseas rights.@-@-@-@-@EMEA has granted Orphan Drug status to ABT869 to treat advanced liver cancer. @@@EMEA has granted Orphan Drug status to ABT869 to treat advanced liver cancer. @@@-@N/A@@-@-@@@II@II@@-@-@Trial to start H1 2008. SOURCE: Abbott/Genentech, January 2008.@-@@@@COMBO@-@@@@@-||||@ABBOTT@GENENTECH@@@@ABBOTT|GENENTECH|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ABT-869@@@@@ABT-869||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16667514@Onco@@@@@@@@@@@"Part I: Dose Escalation, Experimental, Participants will receive obinutuzumab 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by RO7082859 IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of RO7082859 will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. RO7082859 dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.
Part II: Dose Escalation, Experimental, Part II (multiple participant cohorts) will start when either RO7082859 flat dose of 810 mcg is reached or a RO7082859-related greater than or equal to (&gt;/=) Grade 2 AE or DLT occurs, whichever comes first. Participants will receive obinutuzumab 1000 mg single dose IV infusion on Day -7 (pre-treatment) followed by RO7082859 IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of RO7082859 will be administered on Day 1 of every 2 week cycle until either the MTD/OBD is defined.
Part III: Dose Expansion, Experimental, Part III will start once OBD is defined. Participants will receive obinutuzumab 1000 mg single dose IV infusion on Day -7 (pre-treatment) followed by RO7082859 IV infusion at OBD on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, RO7082859 will be administered at OBD on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression.
"@@@@@BASEL, SWITZERLAND@11/1/2018@@@@16667514@A Multicenter, Open-Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Doses of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma@Both@@@@@RO7082859 will be administered at a dose and as per the schedule specified in the respective arms.@@@@@@NCT03075696@140@@@@@@@@@NP30179@@@Depending upon study part, a history or status of: 1) a histologically-confirmed hematological malignancy that is expected to express cluster of differentiation (CD)20; 2) relapse after or failure to respond to at least one prior treatment regimen; and 3) no available treatment options that are expected to prolong survival (e.g., standard chemotherapy or autologous stem cell transplant [SCT])  -  Participant must have at least one measureable target lesion (>/=1.5 centimeters [cm]) in its largest dimension by computerized tomography [CT] scan)  -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1  -  Life expectancy of >/=12 weeks  -  AEs from prior anti-cancer therapy must have resolved to Grade less than or equal to (</=) 1  -  Participants must have peripheral B-cell counts at or below 500 cells per microliter (cells/mcL) at screening  -  Adequate liver, hematological and renal function  -  Negative serologic or polymerase chain reaction (PCR) test results for acute or chronic Hepatitis B virus (HBV) infection  -  Negative test results for Hepatitis C virus (HCV) and human immunodeficiency virus (HIV)@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@ROCHE@@@@@ROCHE||||@Australia@Canada@Denmark@Italy@Spain@Australia|Canada|Denmark|Italy|Spain|||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@RO7082859@@@@@RO7082859||||@Other@@@@@Other||||@Part I and II: Percentage of Participants With Dose Limiting Toxicities (DLTs)@Part I, II and III: Percentage of Participants With Adverse Events (AEs)@Part II: MTD or OBD of RO7082859@@@Part I, II and III: Cmax of Obinutuzumab@Part I, II and III: Cmin of Obinutuzumab@@@@RELAPSED@REFRACTORY@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917394@Onco@@@@@300f1008ntsdm@@@@@@Patients were randomised to Procrit 40,000 Units weekly (n = 174) or placebo (n = 170) SC. If hemoglobin had not increased by > 1 g/dL, after 4 weeks of therapy or the patient received RBC transfusion during the first 4 weeks of therapy, study drug was increased to 60,000 Units weekly. Forty-three percent of patients in the Epoetin alfa group required an increase in Procrit dose to 60,000 Units weekly@@L01DB01@L01D@YES@BEERSE, BELGIUM@@@Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment. The apparent molecular weight of erythropoietin is 32,000 to 40,000 dalton. The protein fraction of the molecule contributes about 58% and consists of 165 amino acids. The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein. Epoetin alfa obtained by gene technology is glycosylated and is identical in its amino acid and carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients. Epoetin alfa has the highest possible purity according to the present state of the art. In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.@@14917394@• Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). • It can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency) if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). • It can be used to reduce exposure to allogeneic blood transfusions in adult non-iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 1013 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml).@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@Manufactured by: Amgen Inc.@@@344@Adult cancer patients with symptomatic anaemia receiving chemotherapy: The subcutaneous route of administration should be used. Epoetinum alfa therapy should be administered to patients with anaemia (e.g. Hb  11 g/dl [6.8 mmol/l]). The target haemoglobin concentration is approximately 12 g/dl (7.5 mmol/l).@@@@@@@Chronic renal failure and cancer patients on epoetinum alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter. In all patients receiving epoetinum alfa, blood pressure should be closely monitored and controlled as necessary. Epoetinum alfa should be used with caution in the presence of untreated, inadequately treated or poorly controllable hypertension. It may be necessary to add or increase antihypertensive treatment. If blood pressure cannot be controlled, epoetinum alfa treatment should be discontinued. Epoetinum alfa should also be used with caution in the presence of epilepsy and chronic liver failure. There may be a moderate dosedependent rise in the platelet count within the normal range during treatment with epoetinum alfa. This regresses during the course of continued therapy. It is recommended that the platelet count is regularly monitored during the first 8 weeks of therapy.@LABEL@No@@344 ANEMIC CANCER PATIENTS.  61 PATIENTS (35 PATIENTS IN THE PLACEBO ARM AND 26 PATIENTS IN THE PROCRIT ARM) WERE TREATED WITH CONCOMITANT CISPLATIN CONTAINING REGIMENS AND 283 PATIENTS RECEIVED CONCOMITANT CHEMOTHERAPY REGIMENS THAT DID NOT CONTAIN CISPL@@@CLINICAL EXPERIENCE: RESPONSE TO PROCRIT / CANCER PATIENTS ON CHEMOTHERAPY /WEEKLY (QW) DOSING@APPROVED@@@NHI@Reduced the proportion of patients transfused in day 29 through week 16 of the study as compared to placebo. 25 (14%) in the Procrit group received transfusions compared to 48 patients (28%) in the placebo group (p = 0.0010) between day 29 and week 16 or the last day on study.@@@@@COMBO@DOXORUBICIN@@@@@DOXORUBICIN||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@DOXIL@@@@@DOXIL||||@EPO@@@@@EPO||||@REDUCTION IN TRANSFUSIONS@@@@@@@@@@@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@10808.88@10808.88@@1@0.0091@84207.25@99301@@@@@@@@@@@4210.36@@@@@@@@@@@@@@@@8/30/2017@84207.25@84207.25@4235402A1025@INJECTION@YEN@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14922286@Onco@@@@@@@@@@@ARM1: Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day courseARM2: Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course [Celgene]@@-@-@-@SUMMIT, NEW JERSEY@3/1/2011@@Amrubicin is a third-generation, synthetic anthracycline analogue that has demonstrated substantial clinical efficacy in the treatment of small cell lung cancer. Amrubicin is a potent topoisomerase II inhibitor and is being studied as a single agent and in combination with anti-cancer therapies for a variety of solid tumors, including lung cancer. Amrubicin is currently approved and marketed in Japan for the treatment of lung cancer by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo Pharma, the original developer of the therapy. Dainippon Sumitomo Pharma also licensed the North American and European Union rights of Amrubicin to Pharmion Corporation, which was acquired by Celgene Corporation in March 2008. Amrubicin has been granted orphan-drug designation for the treatment of small cell lung cancer in both the U.S. and European Union.@@14922286@Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy@@-@-@@NO REVIEW@@@@-@Nippon Kayaku licensed Japanese rights from Dainippon Sumitomo; Pharmion acquired North American and European rights to Calsed through takeover of Cabrellis in November 2006.@SECOND-LINE@NCT00547651@620@-@NDA and MAA expected in 2009. [Celgene, 04.09.2008]@@@>> FDA fast-track designation for SCLC after first-line chemotherapy. [Celgene, 04.09.2008]          >> FDA orphan drug designation. [Celgene, 25.03.2008]        >> SPA agreed with FDA and EMEA. [Celgene, 18.10.2007]@@9/1/2007@-@AMR PH GL 2007 CL 001@@-@Histological or cytological diagnosis of SCLC at study entry according to the International Association for the Study of Lung Cancer (IASLC) histopathologic classification. Mixed or combined subtypes according to the IASLC are not allowed; SCLC that is either sensitive (defined as a response to first-line platinum-based chemotherapy, with subsequent progression >/= 90 days after completing chemotherapy) or refractory (defined as no objective response to prior platinum-based therapy or progression < 90 days after completing prior platinum-based therapy); Extensive or limited disease; patients with limited disease who are candidates for local or regional salvage radiation therapy must have been offered such treatment prior to participation in this study; Radiographically documented progression after first-line treatment with platinum-based chemotherapy; No more than 1 prior chemotherapy regimen.@@@III@III@@-@-@Trial registered [Celgene, 18.10.2007]@-@@@@MONO@AMRUBICIN@TOPOTECAN@@@@AMRUBICIN|TOPOTECAN|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@CALSED@HYCAMTIN@@@@CALSED|HYCAMTIN|||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@OVERALL SURVIVAL@@@@@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@QUALITY OF LIFE@@@REFRACTORY@RELAPSED@@@@HEAD-TO-HEAD@RANDOMISED@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919667@Onco@@@@@300f1008ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919667@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@@@@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHI@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Ovarian Cancer@NSCLC@Sarcoma@Kaposi's Sarcoma@@Ovarian Cancer|NSCLC|Sarcoma|Kaposi's Sarcoma||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.0091@4571.57@5391@@@@@@@@@@@152.39@@@@@@@@@@@@@@@@8/30/2017@4571.57@4571.57@4240406A1040@INJECTION 5 ML@YEN@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
15051138@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@1000 MG IV ON DAYS 1, 8 AND 15 OF CYCLE 1 AND ON DAY 1 OF CYCLES 2-8 (21-DAY CYCLES) OR CYCLES 2-6 (28-DAY CYCLES); FOLLOWED BY 1000 MG IV EVERY 2 MONTHS IN RESPONDERS UNTIL DISEASE PROGRESSION, FOR UP TO 2 YEARS@@L01XC15@L01X@@SAN FRANCISCO, CALIFORNIA@5/1/2021@@Gazyva is designed to attack cells that have a certain marker on their surface. It kills targeted cells both directly and together with the body's immune system.@@15051138@Indicated in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.@Both@NA@@@NO REVIEW@@@@@"Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009] >> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]           >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]         >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@FIRST-LINE@NCT01010061@787@Recommended dose for 6 cycles (28-day cycles):• 100 mg on day 1 Cycle 1• 900 mg on day 2 Cycle 1• 1000 mg on day 8 and 15 of Cycle 1• 1000 mg on day 1 of Cycles 2–6@FDA, 1 November 2013@11/1/2013@@No@@12/1/2009@@BO21004 (Stage 1a)/2009-012476-28/CLL11@No@@Documented CD20+B-CLLPreviously untreated CLL requiring treatment according to the NCI criteria@@ADULTS@III@APPROVED@@@@GA101 demonstrated a statistically significant 86 percent reduction in the risk of disease worsening or death (HR=0.14, 95 percent CI 0.09-0.21, p<0.0001) when combined with chlorambucil compared to chlorambucil alone in previously untreated people with CLL and co-existing medical conditions. [Roche, 3 July 2013, http://www.roche.com/media/media_releases/med-cor-2013-07-03.htm ]@In CLL11, no new safety signals were detected for GA101. The most common Grade 3-4 adverse events (AEs) for GA101 were infusion-related reactions (IRRs) and low cell count of certain white blood cells (neutropenia) which did not result in an increased risk of infection. The incidence and severity of IRRs decreased after the first infusion and no Grade 3-4 IRRs have been reported beyond the first infusion.@@@@@OBINUTUZUMAB@CHLORAMBUCIL@@@@OBINUTUZUMAB|CHLORAMBUCIL|||@GENENTECH @ROCHE@@@@GENENTECH |ROCHE|||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@GAZYVA@RITUXAN@@@@GAZYVA|RITUXAN|||@CD20@@@@@CD20||||@PROGRESSION-FREE SURVIVAL@@@@@RESPONSE@SAFETY@@@@@@@@@RANDOMISED@SAFETY@PARALLEL ASSIGNMENT@OPEN LABEL@@1@1@47738.08@@@168@day@168 day@47738.08@47738.08@284.16@1@1@5967.26@@@@@@@@@@@@5.97@28@1@mg@1000@3@28@@mg@1000@1@@@@@@8/2/2017@5967.26@5967.26@50242-0070-01@CONCENTRATE FOR SOLUTION FOR INFUSION - 40 ML@US$@@@@@@@@1000@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922163@Onco@@@@@300f1018ntsdm@@@@@@Eloxatin + 5-FU/LV FOLFOX4 (1123): Day 1: Eloxatin: 85 mg/m2 (2-hour infusion) + LV: 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) ; Day 2: LV: 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) - every 2 weeks for 12 cycles5-FU/LV alone (1123): Day 1: LV: 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) ; Day 2: LV: 200 mg/m2 (2-hour infusion), followed by 5-FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) - every 2 weeks for 12 cycles@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14922163@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@NO REVIEW@@@@100%@sanofi-aventis licensed U.S. and European rights from Debiopharm.@FIRST-LINE@@2246@The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months).@@@@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@@No@@2246 PATIENTS WERE RANDOMISED; 1123 PATIENTS PER STUDY ARM. PATIENTS IN THE STUDY WERE BETWEEN 18 AND 75 YEARS OF AGE, HAD HISTOLOGICALLY PROVEN STAGE II  OR III  COLON CARCINOMA (WITH THE INFERIOR POLE OF THE TUMOR ABOVE THE PERITONEAL REFLECTION, I.E.,@@@COMBINATION ADJUVANT THERAPY WITH ELOXATIN AND INFUSIONAL 5-FU/LV IN PATIENTS WITH STAGE II OR III COLON CANCER@APPROVED@@Authority required: Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid; Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour. Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.@PBS@In the overall study population DFS was statistically significantly improved in the Eloxatin combination arm compared to infusional 5-FU/LV alone: 4-year disease-free survival rate (95% CI) is 75.9% (73.4 - 78.5) for the FOLFOX4 arm and is 69.1% (66.3 - 71.9) for the infusional 5-FU/LV alone arm (hazard ratio=0.75 - p=0.002). A statistically significant improvement in DFS was noted in Stage III patients, but not in Stage II patients: 4-year disease-free survival rate (95% CI) is 69.7% (66.2 - 73.3) for the FOLFOX4 arm stage III patients and is 61% (57.1 - 64.8) for the infusional 5-FU/LV alone arm stage III patients (hazard ratio=0.75 - p=0.002). 4-year DFS rate (95% CI) is 85.1% (81.7- 88.6) for the FOLFOX4 arm stage II patients and is 81.3% (77.6 - 85.1) for the infusional 5-FU/LV alone arm stage II patients (hazard ratio=0.80 - p=0.179).@The incidence of death within 28 days of last treatment, regardless of causality, was 0.5% in both Eloxatin and 5-FU/LV arms. In the Eloxatin arm, 3 deaths were due to sepsis/neutropaenic sepsis, 2 from intracerebral bleeding and one from eosinophilic pneumonia. The most common adverse reactions were peripheral sensory neuropathy (92%), nausea (74%), diarrhea (56%), vomiting (47%) and fatigue (44%).@@@@ADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@INTERPHARMA@@@@@INTERPHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@OXALIPLATIN EBEWE@@@@@OXALIPLATIN EBEWE||||@Platinum@@@@@Platinum||||@DISEASE-FREE SURVIVAL@@@@@@@@@@@@@@@INTERNATIONAL@MULTI-CENTRE@RANDOMISED@@@@@Invalid Factory Price@@@6@month@6 month@@@@1@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@POWDER FOR INFUSION@A$@@@@@@@@50@MG@50MG/10ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16624046@Onco@@@@@300f1010ntsdm@@@@@@@@L01XX52@L01X@@UNITED STATES@10/1/2017@@Venetoclax is a potent, selective inhibitor of B-cell lymphoma (BCL)-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumour cell survival and has been associated with resistance to chemotherapeutics. Venetoclax binds directly to the BH3-binding groove of BCL-2, displacing BH3 motif-containing pro-apoptotic proteins like BIM, to initiate mitochondrial outer membrane permeabilization (MOMP), caspase activation, and programmed cell death. In non-clinical studies, venetoclax has demonstrated cytotoxic activity in tumour cells that overexpress BCL-2.@@16624046@Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.@Both@No@@@NO REVIEW@@@@@@@NCT02141282@120@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@EMA, 5 December 2016@12/5/2016@1/24/2017@Yes@@9/1/2014@@M14-032@No@@Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) criteria; Subject has relapsed/refractory disease with an indication for treatment; Subject has refractory disease or developed recurrence after therapy with a BCR PI; Subject must have an Eastern Cooperative Oncology Group performance score of equal to or less than 2; Subject must have adequate bone marrow function at Screening; Subject must have adequate coagulation profile, renal, and hepatic function, per laboratory reference range at Screening.@@ADULTS@II@APPROVED@@@NHS@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLYXTO@@@@@VENCLYXTO||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@DURATION OF RESPONSE@TIME TO PROGRESSION@PROGRESSION FREE SURVIVAL@@@RELAPSED@@@@@Non-Randomized@Single Group Assignment@NO MASKING@@@1@1@50040.51829@@@11.7@month@11.7 month@50040.52@50040.52@140.62@7@1.299@130.96@@149.67@@@@@@@@@@0.37@28@1@mg@92.5@28@1@@mg@400@1@@@@@@7/28/2017@18.71@18.71@3.38E+16@TABLET@GB£@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14920042@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14920042@It is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutics such as Paraplatin and cyclophosphamide. It is also indicated in the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have previously been treated with cisplatin.@@NO@@@NO REVIEW@@@@@@SECOND-LINE@@@Single-Agent therapy; dosage of 360mg/m2 IV on day 1 every 4 weeks to treat recurrent ovarian carcinoma. In general, however, courses should not be repeated until neutrophil and platelet counts are at least 2,000 and 100,000 respectively. In combination with cyclophosphamide (600mg/m2 IV on day 1 every 4 weeks for 6 cycles) for previously untreated patients, 300mg/m2 IV on day every 4 weeks for 6 cycles should be used. Suggested dose adjustments include 125% from prior course if platelet and neutrophil counts are above 100,000 and 2,000 respectively; no adjustment if the counts are 50-100,000 or 500-2,000 respectively; and 75% if they are under 50,000 and 500 respectively.@@@@@@@Bone marrow suppression (leukopaenia, neutropaenia, and thrombocytopaenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during treatment and until recovery is achieved. Median nadir occurs at day 21 in patients receiving single-agent carboplatin. In general, single intermittent courses should not be repeated until leukocyte, neutrophil, and platelet counts have recovered. Since anaemia is cumulative, transfusions may be needed during treatment particularly in patients receiving prolonged therapy. Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial  dosages in these patients should be appropriately reduced and blood counts should be carefully monitored between courses. The use of Paraplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimise additive effects. Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents. It can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics.@LABEL@No@@Advanced ovarian cancer previously treated with chemotherapy@@@III@APPROVED@@@MEDICARE@Carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@34.22@@@@@@@@@@@@0.23@@@@@@@@@@@@@@@@8/2/2017@34.22@34.22@00409-1129-11@INJECTION - 15 ML@US$@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920276@Onco@@@@@300f1018ntsdm@@@@@@In the Gleevec arm, patients were treated initially with 400 mg daily. Dose escalations were allowed from 400 mg daily to 600 mg daily, then from 600 mg daily to 800 mg daily. In the IFN/Ara-C arm, patients were treated with a target dose of interferon-alfa (IFN) of 5 MIU/m2/day subcutaneously in combination with subcutaneous cytarabine (Ara-C) 20 mg/m2/day for 10 days/month.@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920276@Adult patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is notconsidered as the first line of treatment.@@NO@5-Mar-08@3/5/2008@NO REVIEW@@@@100%@@FIRST-LINE@@1106@The recommended dose of Gleevec is 400 mg/day for adult patients in chronic phase CML. Treatment with Glivec continued until disease progression.@@@@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@AUGUST 2009 (PAEDIATRIC)@PATIENTS WITH NEWLY DIAGNOSED PH+ CML IN CHRONIC PHASE WERE RANDOMISED IN A GLEEVEC ALONE ARM (533 PATIENTS) AND IFN/ARA-C ARM (533 PATIENTS). PATIENTS WERE ALLOWED TO CROSS OVER TO THE ALTERNATIVE TREATMENT ARM IF THEY FAILED TO SHOW A COMPLETE HEM@ADULT@@III@APPROVED@@Authority required: Treatment of patients in the accelerated phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. >> Treatment of patients in the blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia.>>Continuing treatment of patients with chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, where the patient has previously received PBS-subsidised treatment with imatinib mesylate of: (a) the accelerated phase of chronic myeloid leukaemia; or(b) the blast phase of chronic myeloid leukaemia.>> Initial treatment of patients in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia.. >> Continuing treatment of patients who have received initial treatment with imatinib mesylate as a pharmaceutical benefit for the chronic phase of chronic myeloid leukaemia and who have demonstrated either a major cytogenetic response or less than 1% bcr-abl level in the blood in the preceding 12 months.@PBS@Complete haematologic response, major cytogenetic response and complete cytogenetic response are statistically significantly higher in the Gleevec arm compared to the IFN + Ara-C arm. CHR rate = 95.3% in the Gleevec arm compared to 55.7% in the IFN + Ara-C arm. Major Cytogenetic Response = 83.4% in the Gleevec arm compared to 16.3% in the IFN + Ara-C arm. Complete cytogenetic response = 68.4% in the Gleevec arm compared to 5.4% in the IFN + Ara-C arm. Major Molecular response at 12 months = 40% in the Gleevec arm compared to 2% in the IFN + Ara-C arm.@The majority of Gleevec-treated patients experienced adverse reactions at some time. Most reactions were of mild-to-moderate grade, but drug was discontinued for drug-related adverse reactions in 2.4% of newly diagnosed patients, 4% of patients in chronic phase after failure of interferon-alpha therapy, 4% in accelerated phase and 5% in blast crisis. The most frequently reported drug-related adverse reactions were edema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhea and rash. Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec. The frequency of severe superficial edema was 1.5%-6%. The overall safety profile of pediatric patients treated with Gleevec in 93 children studied was similar to that found in studies with adult patients, except that musculoskeletal pain was less frequent (20.5%) and peripheral edema was not reported. Nausea and vomiting were the most commonly reported individual adverse reactions with an incidence similar to that seen in adult patients. Although most patients experienced adverse reactions at some time during the study, the incidence of Grade 3/4 adverse reactions was low.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@OPEN-LABEL@MULTI-CENTRE@RANDOMISED@@@1@1@241025.9955@@@82@month@82 month@241026@241026@96.64@60@0.779@1449.57@1576.95@1519.51@@@@@@@@@@0.24@1@@mg@400@1@@@@@@@@@@@8/1/2017@24.16@24.16@1632-1269-GE-AF@TABLET@A$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15361216@Onco@@@@@300f1020ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361216@Sprycel is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. It is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.@@YES@25.05.2007@@NO REVIEW@@@@@-@@-@PATIENTS WITH CML OR PH+ ALL RESISTANT TO OR INTOLERANT OF TREATMENT WITH IMATINIB. THE CHRONIC PHASE CML STUDY ENROLLED 186 PATIENTS (CA-180-013/17), THE ACCELERATED PHASE CML STUDY 107 PATIENTS (CA-180-005), AND THE MYELOID BLAST PHASE STUDY 74 PATIENTS (CA-180-006)@The recommended starting dosage for chronic phase CML is 100 mg once daily, administered orally, consistently either in the morning or in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@EMA, 20 November 2006@11/20/2006@@YES@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-005/006/013/017@No@-@PATIENTS WITH CML OR PH+ ALL RESISTANT TO OR INTOLERANT OF TREATMENT WITH IMATINIB. THE CHRONIC PHASE CML STUDY ENROLLED 186 PATIENTS (CA-180-013/17), THE ACCELERATED PHASE CML STUDY 107 PATIENTS (CA-180-005), AND THE MYELOID BLAST PHASE STUDY 74 PATIENTS (CA-180-006)@@@II@APPROVED@@Classification H: Risk-sharing Agreement for acute lymphocytic leukaemia and chronic myeloid leukaemia: one package is free for every new patient registered. SOURCE: AIFA@@In chronic phase CML patients, the MCyR rate was 45% with a complete response (0% Ph+ cells) rate of 33%.@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@62693.69803@@@11@month@11 month@62693.7@62693.7@187.38@30@1.1229@4015.34@6626.92@4196.07@@@@@@@@@@1.34@1@@mg@140@1@@@@@@@@@@@6/7/2017@133.84@133.84@37400114@FILM-COATED TABLET (BLISTER ALUMINIUM/ALUMINIUM)@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15117113@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@PD-332991 was administered 125 mg/d capsules orally for 3 out of 4 weeks in repeated cyclesDrug: letrozole was adminstered 2.5 mg/d tablets orally on a continuous regimen. SOURCE: Pfizer@@-@-@-@NEW YORK, NEW YORK@7/1/2018@@Palbociclib is an investigational oral targeted agent that selectively inhibits cyclin-dependent kinases (CDKs) 4 and 6 to regain cell cycle control and block tumor cell proliferation.@@15117113@Phase 1/2, Open-Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Letrozole Plus PD 0332991 (Oral CDK 4/6 Inhibitor) And Letrozole Single Agent For The First-Line Treatment Of ER Positive, HER2 Negative Advanced Breast Cancer In Postmenopausal Women@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00721409@177@-@-@@@-@@9/1/2008@-@PALOMA -1@@-@-@@@II@II@@-@-@For women treated with the combination of palbociclib plus letrozole, the median PFS was 20.2 months, a statistically significant improvement compared to the 10.2 months of PFS in women who received letrozole alone (HR=0.488 [95% CI: 0.319, 0.748]; p=0.0004).  an initial assessment of overall survival (OS), a secondary endpoint, was also performed. Based on the events at the time of the assessment, a median OS of 37.5 months was observed in the combination arm versus 33.3 months for those who received letrozole alone, a difference of 4.2 months (HR = 0.813, 95% CI: 0.492, 1.345). This OS observation at the time of final PFS analysis was not statistically significant. A follow-up OS analysis will be conducted following the accrual of additional events. [Pfizer, 6 April 2014 http://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_novel_cdk_4_6_inhibitor_palbociclib_plus_letrozole_significantly_prolonged_progression_free_survival_in_patients_with_advanced_breast_cancer ]@The combination of palbociclib and letrozole was generally well-tolerated and the safety profile of the combination was consistent with previously reported data. The most common adverse events in the palbociclib plus letrozole arm were neutropenia (a decrease of the neutrophil count), leukopenia (a decrease in the total white blood cell count), fatigue and anemia. The neutropenia observed with the combination in this study was non-cumulative and clinically manageable. No cases of febrile neutropenia were reported in either arm of the study. Neutropenia is an on-target, anti-proliferative side effect of palbociclib and signifies inhibition of CDK4 and its effect on bone marrow.[Pfizer, 6 April 2014]@@@@COMBO@PALBOCICLIB@@@@@PALBOCICLIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@PD-332991@@@@@PD-332991||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@SAFETY@@@@OVERALL SURVIVAL@@@@@ADVANCED@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924439@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01DB06@L01D@YES@NEW YORK, NEW YORK@@@Idarubicin is an antimitotic and cytotoxic agent which intercalates with DNA and interacts with topoisomerase II and has an inhibitory effect on nucleic acid synthesis. The compound has a high lipophilicity which results in an increased rate of cellular uptake compared with doxorubicin and daunorubicin. Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes. Studies in-vitro on human and murine anthracycline-resistant cells have shown a lower degree of cross-resistance for idarubicin compared with doxorubicin and daunorubicin. Cardiotoxicity studies in animals have indicated that idarubicin has a better therapeutic index than daunorubicin and doxorubicin. The main metabolite, idarubicinol, has shown in-vitro and in-vivo antitumoral activity in experimental models. In the rat, idarubicinol, administered at the same doses as the parent drug, is clearly less cardiotoxic than idarubicin.@@14924439@Acute myeloblastic leukaemia without hyperleukocytosis, identifiable under the FAB classification, AML3 excepted, in patients over 60 years old, in the following circumstances: - contraindication to intravenous chemotherapy and/or long stay in hospital, - risks related to prolonged aplasia considered greater than potential benefits.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Acquired via takeover of Pharmacia Corp.@@@@Induction and consolidation therapy: the recommended dose is 20 mg/m²/week for 4 weeks;Salvage therapy: in nonresponding patients the dose can be increased to 40 mg/m²/week for 4 weeks.@@@@@@@The drug should not be given to patients with pre-existing bone marrow depression induced by previous drug therapy or radiotherapy unless the benefit warrants the risk. Pre-existing heart disease and previous therapy with anthracyclines, especially at high cumulative doses, or other potentially cardiotoxic agents are co-factors for increased risk of idarubicin-induced cardiac toxicity: the benefit to risk ratio of idarubicin therapy in such patients should be weighed before starting treatment with Zavedos. In absence of sufficient data, the use of oral idarubicin is not recommended in patients with prior total body irradiation or bone marrow transplantation.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@IDARUBICIN HCL@@@@@IDARUBICIN HCL||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@ZAVEDOS@@@@@ZAVEDOS||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@@@@@@@@@@@RELAPSED@REFRACTORY@@@@@@@@@1.75@m²@11137.98@@@8@week@8 week@11137.98@11137.98@198.89@1@1.1511@265.19@346.27@274.25@@@@@@@@@@26.52@7@4@mg/m²@20@1@7@@mg/m²@40@1@@@@@@8/1/2017@265.19@265.19@52669@INJECTION SOLUTION VIAL@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15360696@Onco@@@@@300f1018ntsdm@@@@@@Drug: Everolimus A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.Drug: Placebo a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.@@L01XE10@L01X@@BASEL, SWITZERLAND@3/1/2014@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15360696@Progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (NETs) of pancreatic origin.@Both@NO@14-Mar@@NO REVIEW@@@@@@@NCT00510068@410@The recommended dose of AFINITOR Tablets is 10 mg, to be taken once daily at the same time every day. Continue treatment until disease progression or unacceptable toxicity occurs.@TGA, 27 March 2013@3/27/2013@@Yes@@7/1/2007@@CRAD001C2324/RADIANT-3@No@@Patients must have advanced (unresectable or metastatic) biopsyproven pancreatic NETMeasurable disease by radiologic assessmentAdequate blood workPerformance Status 02 : Ability to be out of bed most of the time@@ADULTS@III@APPROVED@@Recommended@PBS@Results from the trial showed that everolimus more than doubled median PFS from 4.6 to 11.0 months when compared with placebo and reduced the risk of cancer progression by 65% (hazard ratio=0.35 [95% confidence interval (CI), 0.27 to 0.45]; p<0.001) in patients with advanced pancreatic NET. After 18 months, 34% of patients treated with everolimus (95% CI, 26 to 43) were alive and progression-free versus 9% of those treated with placebo (95% CI, 4 to 16), showing a more prolonged benefit for patients treated with everolimus.[Novartis 9 February 2011 http://www.novartis.com/newsroom/media-releases/en/2011/1487280.shtml ]@In the study, everolimus maintained a safety profile consistent with the prescribing information and previous studies of the drug. The most frequent all grade, drugrelated adverse events (>=20%) were stomatitis/oral mucositis/ulcers (64% everolimus vs. 17% placebo; includes stomatitis, aphthous stomatitis, mouth ulceration and tongue ulceration), rash (49% vs. 10%), diarrhea (34% vs. 10%), fatigue (31% vs. 14%), infections (23% vs. 6%), nausea (20% vs. 18%), peripheral edema (20% vs. 3%) and decreased appetite (20% vs. 7%); most were grade one or two. Grade three and four adverse events (>=5%) include stomatitis/oral mucositis/ulcers (7% vs. 0%; includes stomatitis, aphthous stomatitis, mouth ulceration and tongue ulceration), anemia (6% vs. 0%) and hyperglycemia (5% vs. 2%). Median exposure to everolimus was 2.3fold longer than exposure to placebo (38 vs. 16 weeks)[1].@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@Pancreatic Cancer@@@@Carcinoid / Neuroendocrine Tumour|Pancreatic Cancer||||||||@AFINITOR@@@@@AFINITOR||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@UNRESECTABLE@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@1@1@57212.496@@@11@month@11 month@57212.5@57212.5@171@30@0.779@2565@2711.87@2634.94@@@@@@@@@@17.1@1@@mg@10@1@@@@@@@@@@@8/1/2017@85.5@85.5@0077-0942-GE-NV@TABLET@A$@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15394278@Onco@@@@@300f1012ntsdm@@@@@@Experimental arm: BIBF 1120 2 times daily along with standard therapy of docetaxelPlacebo comparator: placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel@@L01XE31@L01X@@INGELHEIM, GERMANY@12/1/2013@@Nintedanib is an oral triple angiokinase inhibitor that targets three growth factor receptors simultaneously: vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR alpha and beta), and fibroblast growth factor receptors (FGFR 1-3). All three receptors are crucially involved in the formation and maintenance of new blood vessels (angiogenesis); their blockade may lead to the inhibition of angiogenesis, which plays a critical role in tumour growth and spread@@15394278@Indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinomatumour histology after first-line chemotherapy.@Both@NA@18-Jun-15@6/18/2015@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@NCT00805194@1314@The recommended dose of nintedanib is 200 mg twice daily administered approximately 12 hours apart, on days 2 to 21 of a standard 21 day docetaxel treatment cycle.@EMA, 21 Novermber 2014@@1/1/2015@No@@12/1/2008@@LUME-Lung 1@No@@histologically or cytologically confirmed, locally advanced and/or metastatic NSCLC of stage IIIB or IV or recurrent NSCLC;relapse or failure of one first line prior chemotherapy;@@ADULTS@III@APPROVED@@Minor additional benefit: 18 June 2015 [G-BA, https://www.g-ba.de/downloads/39-261-2262/2015-06-18_AM-RL-XII_Nintedanib_2015-01-01-D-147_BAnz.pdf]@GKV@The combination of nintedanib plus docetaxel demonstrated a statistically significant prolonged progression-free survival (PFS), versus placebo (3.4 vs. 2.7 months, respectively) regardless of tumour histology, reducing the risk of renewed tumour growth by 21%.Overall survival was significantly prolonged in adenocarcinoma patients treated with nintedanib plus docetaxel versus placebo plus docetaxel (12.6 vs. 10.3 months respectively).1 The results demonstrated that patients with adenocarcinoma who have failed initial treatment with chemotherapy received on average a 20% extension of overall survival. In addition, the data demonstrated that the earlier adenocarcinoma patients failed first line chemotherapy, the bigger the benefit nintedanib provided, as patients who progressed within 9 months (T<9 months) after start of their first-line treatment, achieved a median overall survival benefit of 3 months (10.9 vs. 7.9 months).[BI, 14 October 2013, http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/14_october_2013_oncology.html ]@The most common adverse events (AEs) in LUME-Lung 1 were gastrointestinal side effects and reversible liver enzyme elevations which were manageable by supportive treatment or dose reduction (adverse events nintedanib vs. placebo: nausea 24% vs. 18%, vomiting 17% vs. 9%, diarrhoea 42% vs. 22%and liver enzyme elevation 29% vs. 8%). Withdrawal due to adverse events was similar in both arms, as were Grade 3, bleeding or thromboembolic events.@@@@COMBO@NINTEDANIB@DOCETAXEL@@@@NINTEDANIB|DOCETAXEL|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@VARGATEF@GENERIC@@@@VARGATEF|GENERIC|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@ADVANCED@@@@@RANDOMISED@PARALLED ASSIGNMENT@DOUBLE-BLIND@@@1@1@8945.548048@@@4.2@month@4.2 month@8945.55@8945.55@70.03@60@1.1511@1102.9@1405.39@1138.34@@@@@@@@@@0.18@21@@mg@400@20@@@@@@@@@@@8/1/2017@18.38@18.38@10061362@SOFT CAPSULE@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917750@Onco@@@@@300f1015ntsdm@@@@@@All patients received a dose of 52 mg/m2 daily * 5 IV infusion. There was no dose modification during the remission induction phase of treatment (maximum of 2 cycles).@@L01BB06@L01B@NO@CAMBRIDGE, MASSACHUSSETTS@1/1/2006@@Clofarabine is a purine nucleoside anti-metabolite. Its antitumour activity is believed to be due to 3 mechanisms:    • DNA polymerase a inhibition resulting in termination of DNA chain elongation and/or DNA synthesis / repair.      • Ribonucleotide reductase inhibition with reduction of cellular deoxynucleotide triphosphate (dNTP) pools.      • Disruption of mitochondrial membrane integrity with the release of cytochrome C and other proapoptotic factors leading to programmed cell death even in non-dividing lymphocytes.@@14917750@Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients  21 years old at initial diagnosis@@YES@13-Dec-06@12/13/2006@NO REVIEW@@@@@In March 2001, Ilex licensed rights for the U.S. and Canada (and royalties elsewhere) from Bioenvision, which retained the lead role in developing and commercialising the drug elsewhere. Genzyme acquired rights in February 2004 from takeover of Ilex- befo@THIRD-LINE@NCT00042341@61@Adults (including the elderly): There are currently insufficient data to establish the safety and efficacy of clofarabine in adult patients. Paediatric patients: The recommended dose is 52 mg/m2 of body surface area administered by intravenous infusion over 2 hours daily for 5 consecutive days. Body surface area must be calculated using the actual height and weight of the patient before the start of each cycle. Treatment cycles should be repeated every 2 to 6 weeks@EMA, 29 May 2006@5/29/2006@11/1/2006@Yes@@5/1/2002@Can increase the risk of infection, including severe sepsis, as a result of bone marrow suppression; should be discontinued immediately in the event of clinically significant signs or symptoms of SIRS or capillary leak syndrome. Severe bone marrow suppression, including neutropenia, anemia, and thrombocytopenia, has been observed in patients treated with Clolar.@CLO-212@No@@ALL PATIENTS HAD DISEASE THAT HAD RELAPSED AFTER AND/OR WAS REFRACTORY TO TWO OR MORE PRIOR THERAPIES. 93.8% HAD RECEIVED 2 TO 4 PRIOR REGIMENS AND 30.6% OF THE PATIENTS HAD UNDERGONE AT LEAST 1 PRIOR TRANSPLANT.@PAEDIATRIC@@II@APPROVED@@ASMR II, 13 December 2006@HAUTE AUTORITÉ DE SANTÉ@Administration of clofarabine resulted in a dramatic and rapid reduction in peripheral leukaemia cells in 31 of the 33 patients (94%) who had a measurable absolute blast count at baseline. The 12 patients who achieved an overall remission (CR + CRp) had a median survival time of 66.6 weeks as of the data collection cut-off date. Responses were seen in different immunophenotypes of ALL, including pre-B cell and T-cell. Although transplantation rate was not a study endpoint, 10/61 patients (16%) went on to receive a HSCT after treatment with clofarabine (3 after achieving a CR, 2 after a CRp, 3 after a PR, 1 patient that was considered a treatment failure by the IRRP and 1 that was considered not evaluable by the IRRP). Response durations are confounded in patients who received a HSCT.@One hundred and twenty nine patients (98% of the total population) experienced at least one adverse event considered by the study investigator to be related to clofarabine. Those most frequently reported were nausea (61% of patients), vomiting (61%), febrile neutropenia (32%), headache (24%), pyrexia (21%), pruritus (21%) and dermatitis (20%). Although 76 patients (58%) experienced at least one serious clofarabine-related adverse event, only 2 patients discontinued treatment because of an adverse reaction; both with hyperbilirubinaemia, one after receiving 52 mg/m2/day and one after 70 mg/m2/day clofarabine. However, the deaths of 4 patients were considered by the study investigator to be related to treatment with clofarabine: one patient experienced clofarabine-related acute vascular leak syndrome that contributed to cardiac arrest; one patient died from respiratory distress and hepatocellular damage; one patient from septic shock and multi-organ failure; and one patient from multi-organ failure.@@@@MONO@CLOFARABINE@@@@@CLOFARABINE||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@EVOLTRA@@@@@EVOLTRA||||@Anti-metabolite@Purine Analogue@@@@Anti-metabolite|Purine Analogue|||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@SINGLE-ARM@NON-RANDOMISED@UNCONTROLLED@OPEN-LABEL@@1.2@m²@31747.95@@@42@day@42 day@31747.95@31747.95@755.9@1@1.1511@1356.75@@@@@@@@@@@@67.84@28@@mg/m²@52@5@@@@@@@@@@@8/2/2017@1356.75@1356.75@9294954T@SOLUTION FOR PERFUSION  (20 ML)@EURO@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
15354719@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: lenvatinib Intervention: Drug: lenvatinib 24 mg administered orally, once a dayExperimental: Placebo Intervention: Drug: Placebo 24 mg administered orally, once a day@@L01XE29@L01X@NO@TOKYO, JAPAN@3/1/2015@@@@15354719@indicated for differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.@Both@NA@@@@@@@@@MULTIPLE@NCT01321554@392@The recommended daily dose of LENVIMA is 24 mg (two 10 mg capsules and one 4 mg capsule) orally taken once daily with or without food. Continue LENVIMA until disease progression or until unacceptable toxicity occurs.@FDA, 13 February 2015@2/13/2015@@Yes@@3/1/2011@@E7080-G000-303@No@@Subjects must have histologically or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes: a.Papillary thyroid cancer (PTC) i. Follicular variant ii. Variants (including but not limited to tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin's-like, trabecular, tumor with nodular fasciitis-like stroma, Hurthle cell variant of papillary carcinoma, poorly differentiated)b.Follicular thyroid cancer (FTC) i. Hurthle cell ii. Clear cell iii. Insular2.Measurable disease meeting the following criteria and confirmed by central radiographic review: a.At least 1 lesion of greater than or equal to 1.0 cm in the longest diameter for a non-lymph node or greater than or equal to 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of greater than or equal to 1.5 cmb.Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion@@ADULTS@III@APPROVED@@@@In the Phase 3 SELECT trial, which included 392 patients, LENVIMA demonstrated a highly statistically significant improvement in PFS in patients with RAI-R DTC compared with placebo. The median PFS, or delay in the length of time during and after treatment in which the disease did not worsen, with LENVIMA and placebo was 18.3 months and 3.6 months, respectively (HR 0.21; 95% CI: 0.16-0.28; p<0.001). In addition, an overall response rate, the sum of partial and complete response rates, of 65% was seen in patients treated with LENVIMA versus 2% with placebo, which included a complete response achieved in 2% of patients treated with LENVIMA versus 0% with placebo. Based on RECIST v1.1 criteria, a partial response is defined as a minimum 30% decrease in the sum of diameters of target lesions and a complete response is defined as a complete disappearance of tumors.[FDA, 13 February 2015, http://eisai.mediaroom.com/2015-02-13-FDA-Approves-Eisais-LENVIMA-lenvatinib-for-the-Treatment-of-Patients-with-Locally-Recurrent-or-Metastatic-Progressive-Radioactive-Iodine-Refractory-Differentiated-Thyroid-Cancer]@Serious risks seen in patients in the Phase 3 SELECT clinical trial were hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, proteinuria, renal failure and impairment, gastrointestinal perforation and fistula formation, QT interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events,  impairment of exogenous thyroid suppression and embryofetal toxicity. The most common adverse reactions observed in greater than or equal to 30% of LENVIMA-treated patients, in order of decreasing frequency, were: hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, weight decreased, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia (PPE) syndrome, abdominal pain, and dysphonia. The most common serious adverse reactions (at least 2%) were pneumonia (4%), hypertension (3%), and dehydration (3%).[FDA, 13 February 2015, http://eisai.mediaroom.com/2015-02-13-FDA-Approves-Eisais-LENVIMA-lenvatinib-for-the-Treatment-of-Patients-with-Locally-Recurrent-or-Metastatic-Progressive-Radioactive-Iodine-Refractory-Differentiated-Thyroid-Cancer]@@@@MONO@LENVATINIB@@@@@LENVATINIB||||@EISAI@@@@@EISAI||||@United States@Australia@Belgium@Brazil@Canada@United States|Australia|Belgium|Brazil|Canada|Chile|Denmark|France|Germany|Japan@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@LENVIMA@@@@@LENVIMA||||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL RESPONSE RATE@@@@@REFRACTORY@DIFFERENTIATED@@@@RANDOMIZED@DOUBLE BLIND@PLACEBO-CONTROLLED@MULTICENTER@@1@1@646783.183@365000@@18.3@month@18.3 month@646783.18@646783.18@1162@5@1@2420.83@@@@@@@@@@@@48.42@1@@mg@24@1@@@@@@@@@@@8/2/2017@484.17@484.17@62856-0710-05@HARD CAPSULE@US$@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14937970@Onco@@@@@300f1020ntsdm@@@@@@Patients received panitumumab at a dose of 6 mg/kg given once every 2 weeks plus best supportive care or BSC alone@@L01XC08@L01X@YES@THOUSAND OAKS, CALIFORNIA@@@Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.@@14937970@Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.@@YES@16-Jan-09@1/16/2009@NO REVIEW@@@@@Acquired through takeover of Abgenix, with which it was co-developing the drug, in December 2005. Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline,@SECOND-LINE@NCT00113763@463@The recommended dose is 6 mg/kg administered over 60 minutes as an intravenous infusion every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.@EMA, 3 December 2007@12/3/2007@@No@@@Dermatologic findings (dermatitis, pustule formation and exfoliative rash), and deaths secondary to bacterial infection and sepsis occured at higher doses than the recommended dose. Severe infusion reactions occurred with the administration of Vectibix which were identified by reports of anaphylactic reaction, bronchospasm, fever, chills, and hypotension. Pulmonary fibrosis occurred in less than 1% of patients enrolled in clinical studies. It can cause diarrhea, and when used in combination with irinotecan, appears to increase the incidence and severity of chemotherapy-induced diarrhea. It can also cause electrolyte depletion.@"20020408 [""408 Trial""]"@No@@PATIENTS WITH EGFR-EXPRESSING MCRC WHO WERE REQUIRED TO HAVE PROGRESSED ON OR FOLLOWING TREATMENT WITH A REGIMEN(S) CONTAINING A FLUOROPYRIMIDINE, OXALIPLATIN, AND IRINOTECAN ((CONFIRMED FOR 75% OF PATIENTS), TO HAVE EGFR EXPRESSION DEFINED AS AT LEAS@@@III@APPROVED@@Monitoring system, including computerised card system, is now in place [AIFA, 16 January 2009] >> Vectibix will be subject to official registry of oncology drugs for monitoring of prescriptions. [AIFA Decision No. 241, 17 December 2008]@SSN@Based upon IRC determination of disease progression, a statistically significant prolongation in PFS was observed in patients receiving Vectibix compared to those receiving BSC alone. The mean PFS was 96 days in the Vectibix arm and 60 days in the BSC-alone arm. In a series of sensitivity analyses, including one adjusting for potential ascertainment bias, ie, assessment for progressive disease at a nonstudy specified time point, PFS was still significantly prolonged among patients receiving Vectibix as compared to patients receiving BSC alone. There were 19 partial responses identified by the IRC in patients randomized to Vectibix for an overall response of 8% (95% CI: 5.0%, 12.6%). No patient in the control arm had an objective response identified by the IRC. The median duration of response was 17 weeks (95% CI: 16 weeks, 25 weeks). There was no difference in overall survival observed between the study arms.@In a single-arm study of 19 patients receiving Vectibix in combination with IFL, the incidence of NCI-CTC grade 3-4 diarrhea was 58%; in addition, grade 5 diarrhea occurred in 1 patient. In a single-arm study of 24 patients receiving Vectibix plus FOLFIRI, the incidence of NCI-CTC grade 3 diarrhea was 25%. Pulmonary fibrosis occurred in less than 1% (2/1,467) of patients in clinical trials of Vectibix. Following the initial fatality, patients with a history of interstitial pneumonitis, pulmonary fibrosis, and evidence of interstitial pneumonitis were excluded from clinical studies. Therefore, the estimated risk in such patients is uncertain. Permanently discontinue Vectibix therapy in patients developing interstitial lung disease, pneumonitis, or lung infiltrates. In the randomized, controlled clinical trial, median magnesium levels decreased by 0.1 mmol/L in the Vectibix arm. Additionally, hypomagnesemia (NCI-CTC grade 3 or 4) requiring electrolyte repletion occurred in 2% of patients 6 weeks or longer after the initiation of Vectibix. In some patients, hypomagnesemia was associated with hypocalcemia. Patients should be periodically monitored, and treated appropriately, for hypomagnesemia and hypocalcemia during and for 8 weeks after the completion of Vectibix therapy.@@@@MONO@PANITUMUMAB@@@@@PANITUMUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VECTIBIX@@@@@VECTIBIX||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@INTERNATIONAL@RANDOMISED@CONTROLLED@@76.5@kg@12072.4344@@@96@day@96 day@12072.43@12072.43@125.75@1@1.1229@1534.26@2532.15@1603.32@@@@@@@@@@3.84@14@@mg/kg@6@1@@@@@@@@@@@6/7/2017@1534.26@1534.26@38347035@CONCENTRATE FOR SOLUTION FOR INFUSION - 20 ML@EURO@@@@@@@@400@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15373319@Onco@@@@@300f1020ntsdm@@@@@@Drug: Regorafenib: 160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off) plus Best Supportive Care.  Drug: Placebo: matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off) plus Best Supportive Care[clinicaltrials.gov]@@L01XE21@L01X@-@LEVERKUSEN, GERMANY@6/1/2013@@DAST (BAY 73-4506) is a novel oral substance for cancer therapy in the early stages of clinical development. The name DAST (Dual Acting Signal Transduction Inhibitor) stands for the dual mechanism of action of the active substance, which, by its inhibitory action on various enzymes (kinases), inhibits both the signalling pathways in cancer cell proliferation and also new blood vessel formation. In preclinical studies, DAST has proved to be effective in various tumor models, including pancreatic cancer, lung cancer, colon cancer, and breast cancer. Currently, two phase I clinical studies are being conducted with DAST. The first provisional data from these studies are very promising.@@15373319@Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.@Both@NO@@@NO REVIEW@@@@100%@-@@NCT01103323@754@The recommended dose of regorafenib is 160 mg (4 tablets of 40 mg) taken once daily for 3 weeks followed by 1 week off therapy. This 4-week period is considered a treatment cycle.@EMA, 30 August 2013@8/30/2013@@No@@4/1/2010@-@CORRECT@No@@>>Progression during or within 3 months following the last administration of approved standard therapies. Patients treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy >>Patients with measurable or non measurable disease >>Eastern Cooperative Oncology Group (ECOG) Performance Status of </= 1@@ADULTS@III@APPROVED@@@SSN@>>In the CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial, Stivarga plus best supportive care (BSC) significantly improved OS [HR=0.77 (95% CI, 0.64-0.94), two-sided p=0.0102] and PFS [HR=0.49 (95% CI, 0.42-0.58), two-sided p<0.0001] compared to placebo plus BSC. Median OS was 6.4 months with Stivarga versus 5.0 months with placebo; median PFS was 2.0 months with Stivarga versus 1.7 months with placebo. No difference in overall response rate was observed. Five patients (1%) in the regorafenib arm and one patient (0.4%) in the placebo arm experienced partial responses.  [Onxy, 27 September 2012 http://www.onyx.com/view.cfm/635/bayers-stivarga-regorafenib-tablets-approved-by-us-fda-for-treatment-of-metastatic-colorectal-cancer ] >>Trial registered. [Bayer, 8 April 2010]@The most frequently observed adverse drug reactions greater than or equal to 30% in patients receiving Stivarga were asthenia/fatigue, decreased appetite and food intake, hand-foot-skin reaction (HFSR)/palmar-plantar erythrodysesthesia (PPE), diarrhea, mucositis, weight loss, infection, hypertension and dysphonia. The most serious adverse drug reactions in patients receiving Stivarga included hepatotoxicity, hemorrhage, and gastrointestinal perforation. Full results from the study were presented at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) (January 2012), and updated results at the 48th ASCO Annual Meeting (June 2012) [Onyx, 27 September 2012]@@@@MONO@REGORAFENIB@@@@@REGORAFENIB||||@BAYER HEALTHCARE@ONYX@@@@BAYER HEALTHCARE|ONYX|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@STIVARGA@@@@@STIVARGA||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@1@1@4313.640505@@@1.9@month@1.9 month@4313.64@4313.64@74.64@84@1.1229@2090@3449.34@2184.07@@@@@@@@@@0.62@28@@mg@160@21@@@@@@@@@@@6/7/2017@24.88@24.88@42925026@COATED-TABLET@EURO@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918693@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@@@YES@KENILWORTH, NEW JERSEY@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14918693@Dexamethasone can be used for all forms of general and local glucocorticoid injection therapy and all acute conditions in which intravenous glucocorticoids may be life-saving.@@@@@NO REVIEW@@@@100%@>> Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]>> Acquired through takeover of Organon in 2007@@@N/A@For acute life-threatening situations (e.g. anaphylaxis, acute severe asthma) substantially higher dosages may be needed. Cerebral oedema (adults): initial dose 8-16 mg iv followed by 5 mg iv or im every 6 hours, until a satisfactory result has been obtained. In brain surgery these dosages may be necessary until several days after the operation. Thereafter, the dosage has to be tapered off gradually.@EMA, March 1989@@@@@@Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity. Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@DEXAMETHASONE SODIUM PHOSPHATE@@@@@DEXAMETHASONE SODIUM PHOSPHATE||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Brain Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Brain Cancer||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@1@year@1 year@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@8@MG@8 MG/2 ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917181@Onco@@@@@300f1037ntsdm@@@@@@231 patients who received combination irinotecan/bolus 5-FU/LV therapy given weekly were compared with 226 patients who received a standard bolus regimen of 5-FU/LV alone given daily for 5 days every 4 weeks. The third arm (226 patients) was given an irinotecan-alone treatment on a weekly schedule.@@L01XX19@L01X@YES@NEW YORK, NEW YORK@@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14917181@Campto is indicated for the treatment of patients with advanced colorectal cancer: • in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, • as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.  Campto in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Campto in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.@@YES@-@@NO REVIEW@@@@@Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan@FIRST-LINE@-@683@Regimen 2: 6-wk cycle with infusional 5-FU/LV (next cycle begins on day 43): Camptosar 180mg/m2 IV over 90 minutes on days 1, 15 and 29, followed by dose level 1 (150mg/m2) and 2 (120mg/m2)@3/1/1997@@@-@@@Can induce both early and late forms of diarrhea. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally occurring more than 24 hours after administration) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia. Severe myelosuppression may also occur.@-@@-@PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR THE RECTUM RANDOMISED IN 3 ARMS. CONCOMITANT MEDICATIONS SUCH AS ANTIEMETICS, ATROPINE, AND LOPERAMIDE WERE GIVEN TO PATIENTS FOR PROPHYLAXIS AND/OR MANAGEMENT OF SYMPTOMS FROM TREATMENT. PATIENTS ALS@@@III; STUDY 1 OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FU/LV FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER@DISCONTINUED@@NO REVIEW@SNS@The combination of irinotecan/5-FU/LV therapy resulted in significant improvements in objective tumor RRs (39% vs 21% p<0.0001 / 18% for arm 3), TTP (7 months vs 4.3 months p=0.004 / 4.2 months for arm 3), and survival (14.8 months vs 12.6 months p<0.05 / 12 months for arm 3) when compared with 5-FU/LV alone and irinotecan alone control arm.@-@@@@COMBO@IRINOTECAN@LEUCOVORIN@FLUOURACIL@@@IRINOTECAN|LEUCOVORIN|FLUOURACIL||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CAMPTO@5-FU@@@@CAMPTO|5-FU|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TIME TO PROGRESSION@OVERALL SURVIVAL@@@@@@@@@ADVANCED@@@@@RANDOMISED@CONTROLLED@INTERNATIONAL@@@@@Invalid Factory Price@@@5.6@month@5.6 month@10832.96@10832.96@63.6@1@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/2/2015@@@675629@VIAL (2 ML)@EURO@@@@@@@@40@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15399689@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ixazomib + Lenalidomide + Dexamethasone: patients will receive single oral dose of ixazomib (4.0mg) on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progressionPlacebo + Lenalidomide + Dexamethasone: Patients will receive single oral dose of Placebo on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progression@@L01XX50@L01X@@CAMBRIDGE, MASSACHUSSETTS@10/1/2015@@Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.@@15399689@Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.@Both@NA@@@NO REVIEW@@@@@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]       >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]       >> Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones.@SECOND-LINE@NCT01564537@837@The recommended starting dose of NINLARO is 4 mg administered orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle.The recommended starting dose of lenalidomide is 25 mg administered daily on Days 1 through 21 of a 28-day treatment cycle.The recommended starting dose of dexamethasone is 40 mg administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle.Treatment should be continued until disease progression or unacceptable toxicity.@FDA, 20 November 2015@11/20/2015@@Yes@@8/1/2012@@C16010@No@@Multiple myeloma diagnosed according to standard criteria either currently or at the time of initial diagnosis NOTE: The initial diagnosis must be symptomatic MM, although the relapsed disease does not need to be symptomatic.Patients must have measurable disease defined by at least 1 of the following 3 measurements: • Serum M-protein ≥ 1 g/dL ( ≥10 g/L). • Urine M-protein ≥ 200 mg/24 hours. • Serum free light chain assay: involved free light chain level ≥ 10 mg/dL ( ≥ 100 mg/L), provided that the serum free light chain ratio is abnormal. Patients with relapsed and/or refractory MM who have received 1 to 3 prior therapies. NOTE: This patient population includes the following 3 categories of patients: • Patients who relapsed from their previous treatment(s) but were not refractory to any previous treatment. • Patients who were refractory to all lines of previous treatment(s) (ie, patients who have never responded to any therapies received). • Patients who were relapsed from at least 1 previous treatment AND additionally were refractory to at least 1 previous treatment. For the purposes of this study, refractory disease is defined as disease progression on treatment or progression within 60 days after the last dose of a given therapy. A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation, followed by maintenance is considered 1 line of therapy. Autologous and allogenic transplants are permitted.@@ADULTS@III@APPROVED@@@@The trial showed a statistically significant improvement in PFS. The median PFS on the combination arm of ixazomib, lenalidomide and dexamethasone was 20.6 months (95% CI: 17.0, NE) compared to a median PFS of 14.7 months (95% CI: 12.9, 17.6) on the combination arm of placebo, lenalidomide and dexamethasone (PFS HR 0.74, 95% CI: 0.59, 0.94; p value=0.012).[FDA, 20 November 2015, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm473804.htm]@The more common (>20%) adverse reactions associated with an increased rate on the ixazomib combination arm compared to the placebo combination arm were diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea, peripheral edema, vomiting, and back pain.[FDA, 20 November 2015, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm473804.htm]@@@@COMBO@IXAZOMIB@LENALIDOMIDE@DEXAMETHASONE@@@IXAZOMIB|LENALIDOMIDE|DEXAMETHASONE||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@United States@Australia@Austria@Japan@Netherlands@United States|Australia|Austria|Japan|Netherlands|Turkey|United Kingdom|France|Germany|Israel@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@NINLARO@REVLIMID@GENERIC@@@NINLARO|REVLIMID|GENERIC||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@OVERALL RESPONSE RATE@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@368469.6256@@@20.6@month@20.6 month@368469.63@368469.63@588.07@1@1@3156@@@@@@@@@@@@1372.17@28@@mg@4@3@@@@@@@@@@@8/2/2017@3156@3156@63020-0078-01@CAPSULE (UNIT-DOSE BLISTER)@US$@@@@@@@@2.3@MG@2.3 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15394378@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE13@L01X@-@INGELHEIM, GERMANY@1/1/2012@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.@@15394378@GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).@@NO@19-Feb-14@2/19/2014@NO REVIEW@@@@@@FIRST-LINE@NCT00949650@330@Recommended dose: 40 mg orally, once daily. Treatment should be continued until disease progression or until no longer tolerated by the patient.@EMA, 25 September 2013@9/25/2013@7/31/2014@@@8/1/2009@@LUX-Lung 3@No@@Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology. EGFR mutation detected by central laboratory analysis of tumour biopsy material.@@@III@APPROVED@@ASMR V@HAUTE AUTORITÉ DE SANTÉ@Data from LUX-Lung 3 has shown that patients taking afatinib as a first-line treatment lived for almost one year without their tumour growing again (median progression-free survival (PFS) of 11.1 months) versus just over half a year (PFS of 6.9 months) for those treated with pemetrexed/cisplatin. In addition, NSCLC patients with tumours harbouring the two most common EGFR mutations (Del19 or L858R) taking afatinib lived for well over a year without tumour progression (PFS of 13.6 months) versus just over half a year (PFS of 6.9 months) for those in the comparator arm.1In addition, patients taking afatinib also experienced an improvement in lung cancer symptoms and a better quality of life compared to those receiving standard chemotherapy treatment.[BI, 15 July 2013, http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/15_july_2013_oncology.html ]Trial registered [BI, 29.07.2009]@The most common grade 3 drug-related adverse events observed in the afatinib treatment arm were diarrhoea (14%), rash (16%), and inflammation of the nail bed (paronychia) (11%). The most common drug-related grade 3 adverse events observed in the chemotherapy arm (pemetrexed/cisplatin) were neutropenia (15%), fatigue (13%), and leucopenia (8%). There was a low discontinuation rate associated with treatment-related adverse events in the trial (8% discontinuation rate for afatinib; 12% for chemotherapy). One percent of patients in the afatinib arm discontinued due to drug-related diarrhoea.@@@@MONO@AFATINIB@PEMETREXED@CISPLATIN@@@AFATINIB|PEMETREXED|CISPLATIN||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GIOTRIF@ALIMTA@@@@GIOTRIF|ALIMTA|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE@DISEASE CONTROL@QUALITY OF LIFE@@@LOCALLY ADVANCED@METASTATIC@@@@PARALLEL ASSIGNMENT@@@@@1@1@20555.96811@@@11.1@month@11.1 month@20555.97@20555.97@60.89@28@1.1511@1704.79@1870.76@1734.79@@@@@@@@@@1.52@1@@mg@40@1@@@@@@@@@@@8/1/2017@60.89@60.89@3.40E+12@FILM COATED TABLET@EURO@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
15044843@Onco@@@@@300f1015ntsdm@@@@@@TYKERB 1250MG once daily plus Xeloda 2000MG/M2/day on days 1-14 every 21 days or Xeloda 2500MG/M2/day on days 1-14 every 21 days alone.@@L01XE07@L01X@NO@BRENTFORD, UNITED KINGDOM@@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@15044843@Indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting@@NO@16-Jul-08@7/16/2008@NO REVIEW@@@@100%@@SECOND-LINE@NCT00078572@399@The recommended dose of Tyverb is 1250 mg (i.e. five tablets) once daily continuously.@EMA, 10 June 2008@6/10/2008@4/16/2012@No@@@Decreases in left ventricular ejection fraction have been reported. Dose reduction in patients with severe hepatic impairment should be considered. Diarrhoea, including severe diarrhoea, has been reported during treatment. Lapatinib has been associated with interstitial lung disease and pneumonitis.@100151@No@@@@@III@APPROVED@@ASMR III, 16 July 2008, http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-09/tyverb_ct_5358.pdf@HAUTE AUTORITÉ DE SANTÉ@Independent: median TTP was 27.1 and 18.6 weeks in the Tykerb and control group respectively. RR was 23.7% and 13.9% respectively; investigator RR results were 31.8% and 17.4% respectively. The interim analysis of time to progression met specified criteria for early reporting on the basis of superiority in the combination-therapy group. The hazard ratio for the independently assessed time to progression was 0.49 (95% confidence interval, 0.34 to 0.71; P<0.001), with 49 events in the combination-therapy group and 72 events in the monotherapy group. The median time to progression was 8.4 months in the combination-therapy group as compared with 4.4 months in the monotherapy group. This improvement was achieved without an increase in serious toxic effects or symptomatic cardiac events. [N Engl J Med. 2006 Dec 28;355(26):2733-43; http://www.ncbi.nlm.nih.gov/pubmed/17192538?dopt=Abstract]@Decreases in Left Ventricular Ejection Fraction: Due to potential cardiac toxicity with HER2 (ErbB2) inhibitors, LVEF was monitored in clinical trials at approximately 8-week intervals. LVEF decreases were defined as signs or symptoms of deterioration in left ventricular cardiac function that are =Grade 3 (NCI CTCAE), or a =20% decrease in left ventricular cardiac ejection fraction relative to baseline which is below the institution's lower limit of normal. Among 198 patients who received lapatinib/capecitabine combination treatment, 3 experienced Grade 2 and one had Grade 3 LVEF adverse reactions (NCI CTC 3.0). Interstitial Lung Disease/Pneumonitis: Lapatinib has been associated with interstitial lung disease and pneumonitis in monotherapy or in combination with other chemotherapies@@@@COMBO@LAPATINIB@CAPECITABINE@@@@LAPATINIB|CAPECITABINE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TYVERB@XELODA@@@@TYVERB|XELODA|||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@@@@@1@1@14976.76802@@@6.6@month@6.6 month@14976.77@14976.77@74.61@140@1.1511@2088.96@2262.72@2118.96@@@@@@@@@@0.06@1@@mg@1250@1@@@@@@@@@@@8/1/2017@14.92@14.92@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14920868@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L04AX03@L04A@YES@MADISON, NEW JERSEY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14920868@Neoplastic Diseases: indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Psoriasis: indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis: indicated in the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@@@@Lymphomas: In Burkitt's tumor, Stages I-II, methotrexate has produced prolonged remissions in some cases. Recommended dosage is 10 to 25 mg/day orally for 4 to 8 days. In Stage III, methotrexate is commonly given concomitantly with other antitumor agents. Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods. Lymphosarcomas in Stage llI may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily. Mycosis fungoides (cutaneous T cell lymphoma): Therapy with methotrexate as a single agent appears to produce clinical responses in up to 50% of patients treated. Dosage in early stages is usually 5 to 50 mg once weekly. Dose reduction or cessation is guided by patient response and hematologic monitoring. Methotrexate has also been administered twice weekly in doses ranging from 15 to 37.5 mg in patients who have responded poorly to weekly therapy. Combination chemotherapy regimens that include intravenous methotrexate administered at higher doses with leucovorin rescue have been utilized in advanced stages of the disease.@@@@@@@1.Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks.2.Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. 3.Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs). 4.Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. 5.Methotrexate-induced lung disease is a potentially dangerous lesion, which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation. 6.Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. 7.Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. 8.Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication. 9.Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy. 10.Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. 11.Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@METHOTREXAT LEDERLE@@@@@METHOTREXAT LEDERLE||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@23.97@41.29@25.42@@@@@@@@@@0.08@@@@@@@@@@@@@@@@8/1/2017@0.8@0.8@4907932@TABLET@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15358229@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Erlotinib. Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.Placebo Comparator: Placebo. Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.@@L01XE03@L01X@@SAN FRANCISCO, CALIFORNIA@11/1/2010@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@15358229@Tarceva is indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based first-line chemotherapy.@Both@NA@@@NO REVIEW@@@@@>> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]       >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]        >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@MAINTENANCE@NCT00556712@889@The recommended daily dose is 150 mg. Treatment should continue until disease progression or unacceptable toxicity occurs.@FDA, 16 April 2010@4/16/2010@@No@@1/1/2006@@BO18192@No@@histologically documented, locally advanced , recurrent or metastatic NSCLC;measurable disease;no disease progression after 4 cycles of platinum-based chemotherapy.@@ADULTS@III@WITHDRAWN@@@NA@@@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@1@22214.86898@@@2.8@month@2.8 month@22214.87@22214.87@260.85@30@1@7825.37@@@@@@@@@@@@1.74@1@@mg@150@1@@@@@@@@@@@5/2/2017@260.85@260.85@50242-0064-01@FILM-COATED TABLET@US$@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918401@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N01AH01@N01A@YES@HOLZKIRCHEN, GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918401@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@22.61@39.57@24.02@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@2.26@2.26@7524752@SOLUTION FOR INJECTION 10 ML@EURO@@@@@@@@500@MCG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921255@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@@@YES@BRUSSELS, BELGIUM@@@Mitomycin-C Kyowa is an antitumour antibiotic that is activated in the tissues to an alkylating agent which disrupts deoxyribonucleic acid (DNA) in cancer cells by forming a complex with DNA and also acts by inhibiting division of cancer cells by interfering with the biosynthesis of DNA.@@14921255@Recommended for certain types of cancer in combination with other drugs or after primary therapy has failed. It has been successfully used to improve subjective and objective symptoms in a wide range of neoplastic conditions. 1. As a single agent in the treatment of superficial bladder cancer. In addition it has been shown that post-operative instillations of Mitomycin-C can reduce recurrence rates in newly diagnosed patients with superficial bladder cancer. 2. As a single agent and in combination with other drugs in metastatic breast cancer. 3. In combination with other agents in advanced squamous cell carcinoma of the uterine cervix. 4. It shows a degree of activity as part of combination therapy in carcinoma of the stomach, pancreas and lung (particularly non-small cell). 5. It shows a degree of activity as a single agent and in combination in liver cancer when given by the intra-arterial route. 6. It has a possible role in combination with other cytotoxic drugs in colo-rectal cancer. 7. It shows a degree of activity as a single agent or part of combination therapy in cancer of the head and neck. 8. It shows a degree of activity as a single agent in cancer of the prostate. 9. It has a possible role in skin cancer. 10. It has a degree of activity in leukaemia and non-solid tumours. 11. It has a possible role in sarcomas. 12. It has been successfully used in combination with surgery, pre-operatively (oesophageal squamous cell carcinoma) and post-operatively (gastric cancer). 13. It has shown to be effective when used in combination with radiotherapy.@@@@@NO REVIEW@@@@@@@@@Intravenously, the dose should be given as slowly as possible and with great care in order to avoid extravasation. The usual dose is in the range of 4 – 10mg (0.06-0.15mg/kg) given at 1 – 6 weekly intervals depending on whether other drugs are given in combination and on bone marrow recovery. In a number of combination schedules, the dose is 10mg/m2 of body surface area, the course being repeated at intervals for as long as required. A course ranging from 40-80mg (0.58 –1.2mg/kg) is often required for a satisfactory response when used alone or in combination. A higher dosage course may be given when used alone or as part of a particular combination schedule and total cumulative doses exceeding 2mg/kg have been given.@@@@@@@Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Bone marrow suppression, notably thromboytopaenia and leukopaenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic side effects. HUS has been reported in patients receiving systemic mitomycin.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@MITOMYCIN@@@@@MITOMYCIN||||@UCB PHARMA@@@@@UCB PHARMA||||@@@@@@|||||||||@NSCLC@Pancreatic Cancer@Liver Cancer@Colorectal Cancer@@NSCLC|Pancreatic Cancer|Liver Cancer|Colorectal Cancer||||||@MITEM@@@@@MITEM||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@EURO@@@@@@@@5@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916545@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01DC03@L01D@YES@FELLBACH, GERMANY@@@Mitomycin-C Kyowa is an antitumour antibiotic that is activated in the tissues to an alkylating agent which disrupts deoxyribonucleic acid (DNA) in cancer cells by forming a complex with DNA and also acts by inhibiting division of cancer cells by interfering with the biosynthesis of DNA.@@14916545@Recommended for certain types of cancer in combination with other drugs or after primary therapy has failed. It has been successfully used to improve subjective and objective symptoms in a wide range of neoplastic conditions. 1. As a single agent in the treatment of superficial bladder cancer. In addition it has been shown that post-operative instillations of Mitomycin-C can reduce recurrence rates in newly diagnosed patients with superficial bladder cancer. 2. As a single agent and in combination with other drugs in metastatic breast cancer. 3. In combination with other agents in advanced squamous cell carcinoma of the uterine cervix. 4. It shows a degree of activity as part of combination therapy in carcinoma of the stomach, pancreas and lung (particularly non-small cell). 5. It shows a degree of activity as a single agent and in combination in liver cancer when given by the intra-arterial route. 6. It has a possible role in combination with other cytotoxic drugs in colo-rectal cancer. 7. It shows a degree of activity as a single agent or part of combination therapy in cancer of the head and neck. 8. It shows a degree of activity as a single agent in cancer of the prostate. 9. It has a possible role in skin cancer. 10. It has a degree of activity in leukaemia and non-solid tumours. 11. It has a possible role in sarcomas. 12. It has been successfully used in combination with surgery, pre-operatively (oesophageal squamous cell carcinoma) and post-operatively (gastric cancer). 13. It has shown to be effective when used in combination with radiotherapy.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Use in patients with bladder tumours: In the treatment of superficial bladder tumours the usual dose is 20-40mg dissolved in 20-40ml of diluent, instilled into the bladder through a urethral catheter, weekly or three times a week for a total of 20 doses. The dose should be retained by the patient for a minimum of one hour. During this one-hour period the patient should be rotated every 15 minutes to ensure that the Mitomycin-C comes into contact with all areas of the bladder urothelium.@@@@@@@Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Bone marrow suppression, notably thromboytopaenia and leukopaenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic side effects. HUS has been reported in patients receiving systemic mitomycin.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@MITOMYCIN@@@@@MITOMYCIN||||@BIOSYN ARZNEIMITTEL@@@@@BIOSYN ARZNEIMITTEL||||@@@@@@|||||||||@Bladder Cancer@Breast Cancer@Cervical Cancer@Stomach Cancer@@Bladder Cancer|Breast Cancer|Cervical Cancer|Stomach Cancer||||||@AMETYCINE@@@@@AMETYCINE||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1807@100.65@138.24@104.52@@@@@@@@@@5.03@@@@@@@@@@@@@@@@8/15/2017@100.65@100.65@1102694@DRY SUBSTANCE FOR INJECTION VIAL@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917649@Onco@@@@@300f1020ntsdm@@@@@@Patients were randomised to Procrit 40,000 Units weekly (n = 174) or placebo (n = 170) SC. If hemoglobin had not increased by > 1 g/dL, after 4 weeks of therapy or the patient received RBC transfusion during the first 4 weeks of therapy, study drug was increased to 60,000 Units weekly. Forty-three percent of patients in the Epoetin alfa group required an increase in Procrit dose to 60,000 Units weekly@@B03XA01@B03X@YES@BEERSE, BELGIUM@@@Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment. The apparent molecular weight of erythropoietin is 32,000 to 40,000 dalton. The protein fraction of the molecule contributes about 58% and consists of 165 amino acids. The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein. Epoetin alfa obtained by gene technology is glycosylated and is identical in its amino acid and carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients. Epoetin alfa has the highest possible purity according to the present state of the art. In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.@@14917649@• Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). • It can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency) if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). • It can be used to reduce exposure to allogeneic blood transfusions in adult non-iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 1013 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml).@@NO@-@@NO REVIEW@@@@100%@-@-@-@344@Adult cancer patients with symptomatic anaemia receiving chemotherapy: The subcutaneous route of administration should be used. Epoetinum alfa therapy should be administered to patients with anaemia (e.g. Hb  11 g/dl [6.8 mmol/l]). The target haemoglobin concentration is approximately 12 g/dl (7.5 mmol/l).@N/A@@@-@@@Chronic renal failure and cancer patients on epoetinum alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter. In all patients receiving epoetinum alfa, blood pressure should be closely monitored and controlled as necessary. Epoetinum alfa should be used with caution in the presence of untreated, inadequately treated or poorly controllable hypertension. It may be necessary to add or increase antihypertensive treatment. If blood pressure cannot be controlled, epoetinum alfa treatment should be discontinued. Epoetinum alfa should also be used with caution in the presence of epilepsy and chronic liver failure. There may be a moderate dosedependent rise in the platelet count within the normal range during treatment with epoetinum alfa. This regresses during the course of continued therapy. It is recommended that the platelet count is regularly monitored during the first 8 weeks of therapy.@LABEL@No@-@344 ANEMIC CANCER PATIENTS.  61 PATIENTS (35 PATIENTS IN THE PLACEBO ARM AND 26 PATIENTS IN THE PROCRIT ARM) WERE TREATED WITH CONCOMITANT CISPLATIN CONTAINING REGIMENS AND 283 PATIENTS RECEIVED CONCOMITANT CHEMOTHERAPY REGIMENS THAT DID NOT CONTAIN CISPL@@@CLINICAL EXPERIENCE: RESPONSE TO PROCRIT / CANCER PATIENTS ON CHEMOTHERAPY /WEEKLY (QW) DOSING@APPROVED@@@SSN@Reduced the proportion of patients transfused in day 29 through week 16 of the study as compared to placebo. 25 (14%) in the Procrit group received transfusions compared to 48 patients (28%) in the placebo group (p = 0.0010) between day 29 and week 16 or the last day on study.@-@@@@COMBO@EPOETIN ALFA@@@@@EPOETIN ALFA||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@EPREX@@@@@EPREX||||@EPO@@@@@EPO||||@REDUCTION IN TRANSFUSIONS@@@@@@@@@@-@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@16407.3@16407.3@@1@1.1807@30.05@49.59@31.4@@@@@@@@@@@@@@@@@@@@@@@@@@8/31/2017@30.05@30.05@27015167@INJECTION PREFILLED SYRINGE, 0.3 ML@EURO@@@@@@@@3000@IU@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14917668@Onco@@@@@300f1037ntsdm@@@@@@Patients were randomised to Procrit 40,000 Units weekly (n = 174) or placebo (n = 170) SC. If hemoglobin had not increased by > 1 g/dL, after 4 weeks of therapy or the patient received RBC transfusion during the first 4 weeks of therapy, study drug was increased to 60,000 Units weekly. Forty-three percent of patients in the Epoetin alfa group required an increase in Procrit dose to 60,000 Units weekly@@B03XA01@B03X@YES@BEERSE, BELGIUM@@@Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment. The apparent molecular weight of erythropoietin is 32,000 to 40,000 dalton. The protein fraction of the molecule contributes about 58% and consists of 165 amino acids. The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein. Epoetin alfa obtained by gene technology is glycosylated and is identical in its amino acid and carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients. Epoetin alfa has the highest possible purity according to the present state of the art. In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.@@14917668@• Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). • It can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency) if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). • It can be used to reduce exposure to allogeneic blood transfusions in adult non-iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 1013 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml).@@YES@@@NO REVIEW@@@@60%@@@@344@Adult cancer patients with symptomatic anaemia receiving chemotherapy: The subcutaneous route of administration should be used. Epoetinum alfa therapy should be administered to patients with anaemia (e.g. Hb  11 g/dl [6.8 mmol/l]). The target haemoglobin concentration is approximately 12 g/dl (7.5 mmol/l).@HMA, 1 June 1993@6/1/1993@@@@@Chronic renal failure and cancer patients on epoetinum alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter. In all patients receiving epoetinum alfa, blood pressure should be closely monitored and controlled as necessary. Epoetinum alfa should be used with caution in the presence of untreated, inadequately treated or poorly controllable hypertension. It may be necessary to add or increase antihypertensive treatment. If blood pressure cannot be controlled, epoetinum alfa treatment should be discontinued. Epoetinum alfa should also be used with caution in the presence of epilepsy and chronic liver failure. There may be a moderate dosedependent rise in the platelet count within the normal range during treatment with epoetinum alfa. This regresses during the course of continued therapy. It is recommended that the platelet count is regularly monitored during the first 8 weeks of therapy.@@No@@344 ANEMIC CANCER PATIENTS.  61 PATIENTS (35 PATIENTS IN THE PLACEBO ARM AND 26 PATIENTS IN THE PROCRIT ARM) WERE TREATED WITH CONCOMITANT CISPLATIN CONTAINING REGIMENS AND 283 PATIENTS RECEIVED CONCOMITANT CHEMOTHERAPY REGIMENS THAT DID NOT CONTAIN CISPL@@@CLINICAL EXPERIENCE: RESPONSE TO PROCRIT / CANCER PATIENTS ON CHEMOTHERAPY /WEEKLY (QW) DOSING@APPROVED@@NO REVIEW@SNS@Reduced the proportion of patients transfused in day 29 through week 16 of the study as compared to placebo. 25 (14%) in the Procrit group received transfusions compared to 48 patients (28%) in the placebo group (p = 0.0010) between day 29 and week 16 or the last day on study.@@@@@COMBO@EPOETIN ALFA@@@@@EPOETIN ALFA||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@EPREX@@@@@EPREX||||@EPO@@@@@EPO||||@REDUCTION IN TRANSFUSIONS@@@@@@@@@@@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@16@week@16 week@@@@1@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@EURO@@@@@@@@1000@IU@1000 IU@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16406133@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Ofatumumab, Fludarabine, Cyclophosphamide. Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cyclesActive Comparator: Fludarabine, Cyclophosphamide. Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles@@L01XC10@L01X@@COPENHAGEN, DENMARK@12/1/2014@@Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.@@16406133@ARZERRA is indicated in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL.@Both@@@@NO REVIEW@@@@@>> Amendment to the licensing deal agreed; Genmab has sold its co-promotion option rights to GSK. The sale of the co-promotion option does not affect the royalty or milestone revenue that Genmab may receive. GSK will now be fully responsible for the entire sales organisation for ofatumumab. Genmab will receive a one-time payment of US$4.5 million from GSK upon the FDA's acceptance for review of the filing of the first BLA for ofatumumab in an oncology indication in the United States in exchange for terminating its option to co-promote ofatumumab. [Genmab, 19.12.2008]      >> GlaxoSmithKline acquired an exclusive worldwide license to ofatumumab as well as any other antibodies with affinity for CD20 which Genmab may develop. GSK and Genmab will co-develop ofatumumab; Genmab has an option to co-promote ofatumumab in a targeted oncology setting in the United States and in the Nordic region. In addition, if Genmab exercises the co-promotion option, Genmab would have had the option to co-promote GSK's Bexxar and Arranon in the United States and Atriance in the relevant countries of the Nordic region. [Genmab, December 2006]@@NCT00824265@365@The recommended dosage and schedule in combination with fludarabine and cyclophosphamide is: 300 mg on Day 1 followed 1 week later by 1,000 mg on Day 8 (Cycle 1) followed by 1,000 mg on Day 1 of subsequent 28-day cycles for a maximum of 6 cycles.@FDA, 30 August 2016@8/30/2016@@No@@3/1/2009@@110913@No@@Confirmed and active CLL requiring treatment; at least one previous treatment for CLL and having achieved a complete or partial remission/response but after a period of 6 or more months, shows evidence of disease progression; fully active at a minimum or fully capable of selfcare and up and about more than 50% of waking hours; age 18yrs or older; signed written informed consent.@@ADULTS@III@APPROVED@@@@Approval for this indication by the FDA is based on results from the Phase III COMPLEMENT 2 study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL. Top-line results from COMPLEMENT 2 were reported in April 2015.The study met the primary endpoint with a median progression free survival in patients receiving ofatumumab in combination with FC of 28.9 months, compared to 18.8 months in patients receiving FC alone (HR =0.67, p=0.0032). Secondary endpoints included overall response rate, overall survival, patient reported outcomes, time to response, duration of response, time to progression, time to next therapy, safety assessments and quality of life. The safety profile observed in this study was consistent with other trials of ofatumumab and no new safety signals were observed. [https://globenewswire.com/news-release/2016/08/31/868285/0/en/Genmab-Announces-U-S-FDA-Approval-of-Arzerra-ofatumumab-in-Combination-with-Fludarabine-and-Cyclophosphamide-for-Relapsed-CLL.html]@@@@@COMBO@OFATUMUMAB@FLUDARABINE@CYCLOPHOSPHAMIDE@@@OFATUMUMAB|FLUDARABINE|CYCLOPHOSPHAMIDE||@GENMAB@MEDAREX@GSK@@@GENMAB|MEDAREX|GSK||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ARZERRA@FLUDARA@ENDOXAN@@@ARZERRA|FLUDARA|ENDOXAN||@mAb@Human@CD20@@@mAb|Human|CD20||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@TIME TO RESPONSE@DURATION OF RESPONSE@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@MULTICENTER@@1@1@40308.337@@@176@day@176 day@40308.34@40308.34@229.02@1@1@5521.69@@@@@@@@@@@@5.52@8@1@mg@1300@1@28@@mg@1000@1@@@@@@8/2/2017@5521.69@5521.69@00078-0690-61@SOLUTION FOR INJECTION - 50 ML@US$@@@@@@@@1000@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924915@Onco@@@@@300f1014ntsdm@@@@@@Administration of Zoladex (3.6 mg depot) and flutamide capsules (250 mg t.i.d.) prior to and during radiation@@L02AE03@L02A@NO@LONDON, UNITED KINGDOM@@@Zoladex (D-Ser(But)6 Azgly10 LHRH) is a synthetic analogue of naturally occurring LHRH. On chronic administration Zoladex results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. This effect is reversible on discontinuation of therapy. Initially, Zoladex, like other LHRH agonists, may transiently increase serum testosterone concentration in men and serum estradiol concentration in women.@@14924915@Zoladex is indicated:  • In the treatment of metastatic prostate cancer where Zoladex has demonstrated comparable survival benefits to surgical castrations  • In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Zoladex has demonstrated comparable survival benefits to an anti-androgen  • As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival and overall survival  • As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival  • As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Zoladex has demonstrated improved disease-free survival@@NO@@@NO REVIEW@@@@@@@@466@Adult males (including the elderly): one depot of Zoladex LA injected subcutaneously into the anterior abdominal wall every 12 weeks. Children: Zoladex LA is not indicated for use in children.@@@@@@@Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostatic cancer, may occasionally develop during the first few weeks of Zoladex treatment. A small number of patients may experience a temporary increase in bone pain, which can be managed symptomatically. As with other LHRH agonists, isolated cases of ureteral obstruction and spinal cord compression have been observed.@@No@@466 PATIENTS WITH BULKY PRIMARY TUMORS CONFINED TO THE PROSTATE (STAGE B2) OR EXTENDING BEYOND THE CAPSULE (STAGE C), WITH OR WITHOUT PELVIC NODE INVOLVEMENT. 231 PATIENTS RECEIVED A COMBINATION THERAPY OF ZOLADEX + FLUTAMIDE + RADIATION, AND 235 PATIENTS@@@CLINICAL STUDIES - STAGE B2-C PROSTATIC CARCINOMA@APPROVED@@Unrestricted reimbursement.@RAMQ@Patients who received the combination therapy showed a significantly lower rate of local failure compared to radiation alone (16% vs 33% at 4 years, P<0.001). The combination therapy also resulted in a trend toward reduction in the incidence of distant metastases (27% vs 36% at 4 years, P=0.058). Median disease-free survival was significantly increased in patients who received complete hormonal therapy combined with radiation as compared to those patients who received radiation alone (4.4 vs 2.6 years, P<0.001). Inclusion of normal PSA level as a criterion for disease-free survival also resulted in significantly increased median disease-free survival in patients receiving the combination therapy (2.7 vs 1.5 years, P<0.001).@@@@@COMBO@GOSERELIN ACETATE@@@@@GOSERELIN ACETATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ZOLADEX LA@@@@@ZOLADEX LA||||@LH-RH Analog@@@@@LH-RH Analog||||@INCIDENCE OF DISTANT METASTASES@DISEASE-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@MULTI-CENTRE@CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@4714.58@4714.58@@1@0.7881@1113@@@@@@@@@@@@103.06@@@@@@@@@@@@@@@@7/19/2017@1113@1113@22259051@SUBCUTANEOUS  IMPLANT@C$@@@@@@@@10.8@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14968148@Onco@@@@@300f1010ntsdm@@@@@AVF4095g@Arm A: carboplatin, gemcitabine and Avastin for 6 months followed by maintenance Avastin; Arm B: carboplatin, gemcitabine and placebo for 6 months followed by maintenance placebo. Avastin dose is 15mg/kg every 3 weeks.@@L01XC07@L01X@-@BASEL, SWITZERLAND@8/1/2009@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14968148@Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primaryperitoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.@@YES@22-May-13@5/22/2013@NO REVIEW@@@@100%@@SECOND-LINE@NCT00434642@487@Avastin is administered in combination with carboplatin and gemcitabine for 6 cycles and up to 10 cycles followed by continued use of Avastin assingle agent until disease progression.The recommended dose of Avastin is 15 mg/kg of body weightgiven once every 3 weeks as an intravenous infusion.@EMA, 24 October 2012@10/24/2012@@@@4/1/2007@@@No@@@@@AVF4095G@APPROVED@@NICE does not recommend bevacizumab given with gemcitabine and carboplatin for treating adults with the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube or primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor inhibitors.https://www.nice.org.uk/guidance/ta285@NHS@The study met its primary endpoint of progression-free survival. The study showed that women who received a combination of Avastin and chemotherapy followed by the continued use of Avastin alone, lived longer without their disease worsening (progression-free survival or PFS), compared to women who received chemotherapy alone. No new safety findings were observed and adverse events were consistent with those seen in previous pivotal trials of Avastin. Full data from the OCEANS study will be submitted for presentation at an upcoming medical meeting. [Roche 8 February 2011 http://www.roche.com/media/media_releases/med-cor-2011-02-08.htm ]RESULTS PENDING@@@@@COMBO@BEVACIZUMAB@GEMCITABINE@CARBOPLATIN@@@BEVACIZUMAB|GEMCITABINE|CARBOPLATIN||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@AVASTIN@GEMZAR@@@@AVASTIN|GEMZAR|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RECURRENT@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@60@kg@37354.84553@@@12.4@month@12.4 month@37354.85@37354.85@99.04@1@1.299@924.4@@@@@@@@@@@@2.31@21@@mg/kg@15@1@@@@@@@@@@@7/28/2017@924.4@924.4@9.15E+15@CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION, 16 ML@GB£@@@@@@@@400@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16407029@Onco@@@@@300f1012ntsdm@@@@@@Experimental: Lonsurf. 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Placebo: tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle.@@L01BC59@L01B@@@12/1/2014@@@@16407029@Indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies includingfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.@Both@NA@2-Feb-17@2/2/2017@Small Added benefit: 2 February 2017 [G-BA, https://www.g-ba.de/downloads/39-261-2852/2017-02-02_AM-RL-XII_Trifluridin-Tipiracil_D-252.pdf]Minor additional benefit: 16 November 2016. [IQWiG, https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/trifluridin-tipiracil-kombination-bei-darmkrebs-zusatznutzen-nur-fur-manche-patienten.7643.html]@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@NCT01607957@800@The recommended starting dose of Lonsurf in adults is 35 mg/m2/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long as benefit is observed or untilunacceptable toxicity occurs@EMA, 25 April 2016@4/25/2016@8/15/2016@No@@5/24/2012@@TPU-TAS-102-301/2012-000109-66@No@@Has adenocarcinoma of the colon or rectum. Has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancerECOG performance status of 0 or 1Is able to take medications orally. Has adequate organ function (bone marrow, kidney and liver). Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.@ADULTS@ADULTS@@APPROVED@@@GKV@The decision from the EC follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the approval of LONSURF in February 2016.1 Both the CHMP opinion and the EC decisions were based on data from the international, double-blind, placebo-controlled Phase III RECOURSE study, which investigated the efficacy and safety of LONSURF with best supportive care (BSC) compared to placebo with BSC in 800 patients with previously treated mCRC. The study met the primary endpoint of statistically significant improvement in overall survival (OS).[Servier, http://www.servier.com/content/patients-advanced-metastatic-colorectal-cancer-europe-now-have-new-treatment-option-lonsurf%C2%AE]@@@@@MONO@TIPIRACIL / TRIFLURIDINE@@@@@TIPIRACIL / TRIFLURIDINE||||@SERVIER @@@@@SERVIER ||||@France@Germany@Italy@Japan@@United States|Australia|Austria|Belgium|Czech Republic||France|Germany|Italy|Japan@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@LONSURF@@@@@LONSURF||||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@@@@@METASTATIC@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@1.75@m²@30312.23706@@@7.1@month@7.1 month@30312.24@30312.24@140.36@60@1.1511@2887.5@3596.53@2926@@@@@@@@@@3.21@28@@mg/m²@70@10@@@@@@@@@@@8/1/2017@48.13@48.13@11862153@FILM-COATED TABLET@EURO@@@@@@@@15@MG@6.14 MG|15 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16379634@Onco@@@@@300f1010ntsdm@@@@@@@@L01XC24@L01X@@BEERSE, BELGIUM@@@CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells,including multiple myeloma and other cell types and tissues and has multiple functions, such asreceptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity.Daratumumab is an IgG1k human monoclonal antibody (mAb) that binds to CD28 and inhibitsthe growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediatedcross linking as well as by immune-mediated tumor cell lysis through complement dependentcytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC) and antibodydependent cellular phagocytosis (ADCP). Myeloid derived suppressor cells (MDSCs) and asubset of regulatory T cells (CD38+Tregs) express CD38 and are susceptible to daratumumabmediated cell lysis.@@16379634@DARZALEX as monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.@Both@NA@@@NO REVIEW@@@@100%@@@@106@The recommended dose of DARZALEX is 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule: weekly from week 1 to 8, every two weeks from week 9 to 24, once per month from week 25 onward.@EMA, 20 May 2016@5/20/2016@7/19/2016@Yes@@@@@No@@@@ADULTS@@APPROVED@9/9/2015@@NHS@Darzalex has been shown to be effective at treating multiple myeloma in patients whose disease had progressed despite at least two previous treatments. These patients have limited treatment options and Darzalex, which works in a different way to existing treatments, represents an alternative. Darzalex's safety profile is considered acceptable and manageable.Although there were limitations in the studies, including lack of control group and low number of patients, the Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Darzalex's benefits are greater than its risks and recommended that it be approved for use in the EU. Darzalex has been given ‘conditional approval'. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary.[EMA, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004077/WC500207298.pdf]@The most common side effects with Darzalex (which may affect around 1 in 2 people) are infusion-related reactions such as breathing problems, cough, runny or blocked nose and chills. Other frequent side effects (affecting at least 1 in 5 patients) are tiredness, pyrexia (fever), nausea (feeling sick), back pain, upper respiratory tract infections (such as colds), anaemia (low red blood cell counts), neutropenia (low levels of neutrophils, a type of white blood cell) and thrombocytopenia (low blood platelet counts). For the full list of all side effects and restrictions with Darzalex, see the package leaflet.[EMA, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004077/WC500207298.pdf]@@@@MONO@DARATUMUMAB@@@@@DARATUMUMAB||||@JANSSEN BIOTECH@@@@@JANSSEN BIOTECH||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@DARZALEX@@@@@DARZALEX||||@mAb@Human@@@@mAb|Human|||@OVERALL RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@76.5@kg@69549.29568@@@7.4@month@7.4 month@69549.3@69549.3@309@1@1.299@315@@360@@@@@@@@@@3.15@7@8@mg/kg@16@1@14@8@mg/kg@16@1@28@@mg/kg@16@1@7/28/2017@315@315@3.29E+16@CONCENTRATE FOR SOLUTION FOR INFUSION - 5 ML@GB£@@@@@@@@100@MG@20 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15360690@Onco@@@@@300f1018ntsdm@@@@@@Both everolimus and placebo administered by continuous oral dosing of two 5-mg tablets.@@L01XE10@L01X@@BASEL, SWITZERLAND@6/1/2014@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15360690@Postmenopausal women with hormone receptor-positive, HER2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.@@NO@13-Jul@@NO REVIEW@@@@@@SECOND-LINE@NCT00863655@724@The recommended dose of Afinitor is 10 mg to be taken once daily.@TGA, 14 October 2013@10/14/2013@@No@@6/1/2009@@BOLERO2@No@@@@@III@APPROVED@@Recommended@PBS@Updated findings from the BOLERO-2 study presented at SABCS showed treatment with everolimus plus hormonal therapy more than doubled progression-free survival (PFS) to 7.4 months compared to 3.2 months with hormonal therapy alone (hazard ratio=0.44 [95% confidence interval (CI): 0.36 to 0.53]; p<1x10-16) by local investigator assessment. Twelve month estimates of patients without disease progression were 31% and 10% in the everolimus and exemestane, and exemestane-alone arms, respectively. An additional analysis based on an independent central radiology review showed everolimus extended PFS to 11.0 months compared to 4.1 months (hazard ratio=0.36 [95% CI: 0.28 to 0.45]; p<1x10-16)[1].[Novartis, 8 December 2011, http://www.novartis.com/newsroom/media-releases/en/2011/1569858.shtml ]@@@@@COMBO@EVEROLIMUS@EXEMESTANE@@@@EVEROLIMUS|EXEMESTANE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AFINITOR@AROMASIN@@@@AFINITOR|AROMASIN|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@OVERALL SURVIVAL@RESPONSE@SAFETY@@@REFRACTORY@ADVANCED@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@57212.496@@@11@month@11 month@57212.5@57212.5@171@30@0.779@2565@2711.87@2634.94@@@@@@@@@@17.1@1@@mg@10@1@@@@@@@@@@@8/1/2017@85.5@85.5@0077-0942-GE-NV@TABLET@A$@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
15400338@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE08@L01X@YES@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@15400338@Tasigna is indicated for the treatment of adults with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available.@Both@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@321@In patients with chronic- or accelerated-phase CML who cannot tolerate other treatments or whose disease does not respond to them, the recommended dose is 400 mg twice a day.@EMA, 28 November 2007@11/28/2007@@Yes@@@Tasigna prolongs the QT interval. Sudden deaths have been reported in patients receiving nilotinib. Tasigna should not be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be corrected prior to Tasigna administration and should be periodically monitored. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided. Patients should avoid food 2 hours before and 1 hour after taking dose. Use with caution in patients with hepatic impairment. ECGs should be obtained to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, as well as following any dose adjustments.@@No@@The definition of imatinib resistance included failure to achieve a complete hematologic response (by 3 months), cytogenetic response (by 6 months) or major cytogenetic response (by 12 months) or progression of disease after a previous cytogenetic or hematologic response. Imatinib intolerance was defined as discontinuation of treatment due to toxicity and lack of a major cytogenetic response at time of study entry.@ADULT@Adult@II@APPROVED@@@GKV@The MCyR rate in 320 CP patients was 49%. Most responders achieved their MCyR rapidly within 3 months (median 2.8 months) of starting Tasigna treatment and these were sustained (median duration has not been reached). Among 156 patients with MCyR 43 patients (27.6%) lost their MCyR. Patients with a CHR at baseline achieved a MCyR faster (1 vs. 2.8 months). Of CP patients without a baseline CHR, 70% achieved a CHR and median time to CHR was 1 month and median duration of CHR has not been reached. The overall confirmed HR rate in 119 AP patients was 42%. Most responders achieved a HR early with Tasigna treatment (median 1.0 months) and these have been durable (median duration has not been reached). No patients have had a loss of CHR. The MCyR rate was 27% with a median time to response of 2.0 months.@@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@OPEN-LABEL@SINGLE ARM@MULTI-CENTRE@@@1@1@86383.51179@@@18.4@month@18.4 month@86383.51@86383.51@154.35@392@1.1511@15126.45@18597.8@15164.95@@@@@@@@@@0.19@1@@mg@800@1@@@@@@@@@@@8/1/2017@38.59@38.59@10918472@HARD CAPSULE@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918340@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918340@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@1 A PHARMA@@@@@1 A PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@129.49@174.7@134.27@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@12.95@12.95@683499@PATCH (MATRIX)@EURO@@@@@@@@75@MCG@75 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16671852@Onco@@@@@300f1010ntsdm@@@@@@Drug: CetuximabCetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Number of Cycles: until progression or unacceptable toxicity developsDrug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops@@L01XC06@L01X@@NEW YORK, NEW YORK@5/1/2006@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671852@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy@Both@YES@29-Mar-17@3/29/2017@@@@@100%@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@NCT00154102@1221@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 18 December 2013@12/18/2013@@No@@5/1/2004@@EMR 62 202-013@No@@Diagnosis of histologically confirmed adenocarcinoma of the colon or rectumInoperable metastatic diseaseImmunohistochemical evidence of epidermal growth factor receptor expression in tumor tissuePresence of at least 1 bi-dimensionally measurable index lesion.@(EGFR)-expressing, RAS WILD-TYPE@ADULTS@III@APPROVED@@29 March 2017: Cetuximab is recommended, within its marketing authorisation, as an option for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults in combination with 5‑fluorouracil, folinic acid and irinotecan (FOLFIRI). The drug is recommended only when the company provides it with the discount agreed in its patient access scheme. [NICE, https://www.nice.org.uk/guidance/ta439/chapter/1-Recommendations]@NHS@@@@@@COMBO@CETUXIMAB@IRINOTECAN@@@@CETUXIMAB|IRINOTECAN|||@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@GENERIC@@@@ERBITUX|GENERIC|||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL TIME@BEST OVERALL RESPONSE RATE@@@@METASTATIC@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1.75@m²@39064.2759@@@11.4@month@11.4 month@39064.28@39064.28@112.66@1@1.299@890.5@@@@@@@@@@@@1.78@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@7/28/2017@890.5@890.5@1.15E+16@SOLUTION - INFUSION 100 ML@GB£@@@@@@@@500@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15361226@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.@@L01XX39@L01X@-@CAMBRIDGE, MASSACHUSSETTS@12/1/2015@@The cyclic peptide structure of romidepsin is unique among members of a new class of cancer drugs known as histone deacetylase, or HDAC, inhibitors. HDAC inhibition has been shown to increase acetylation of histones and other proteins, which is associated with anti-tumor activity including chromatin remodeling, tumor suppressor gene transcription, growth inhibition, and apoptosis. Preclinical studies suggest that romidepsin is among the most potent inhibitors of both Class I and Class II HDACs.@@15361226@Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy@Both@@@@NO REVIEW@@@@@Global rights licensed from Fujisawa (Astellas) in April 2004@@NCT00426764@131@14 mg/m2 administered intravenously (IV) over a 4-hour period on days 1, 8, and 15 of a 28-day cycle. Repeat cycles every 28 days provided that the patient continues to benefit from and tolerates the drug.@FDA, 16 June 2011@6/16/2011@@Yes@@6/1/2007@@@No@@Histologically confirmed PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, extranodal natural killer (NK)/T-cell lymphoma nasal type, enteropathy- type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, cutaneous γδ T-cell lymphoma (excludes mycosis fungoides or Sezary syndrome), transformed mycosis fungoides, hepatosplenic T-cell lymphoma, anaplastic large cell lymphoma (ALCL; anaplastic lymphoma kinase [ALK]-1 negative), or patients with ALK 1 expressing ALCL (ALK-1 positive) who have relapsed disease after autologous stem cell transplant (ASCT);@@ADULTS@II@APPROVED@@@@@@@@@MONO@ROMIDEPSIN@@@@@ROMIDEPSIN||||@GLOUCESTER PHARMACEUTICALS@@@@@GLOUCESTER PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@CTCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|CTCL||||||@ISTODAX@@@@@ISTODAX||||@HDAC@@@@@HDAC||||@COMPLETE RESPONSE@@@@@@@@@@PERIPHERAL@RELAPSED@@@@OPEN-LABEL@MULTICENTER@@@@1.75@m²@Invalid Factory Price@@@2.43@month@2.43 month@@@@2@1@@@@@@@@@@@@@@28@@mg/m²@14@3@@@@@@@@@@@@@@46026-0983-01@POWDER FOR SOLUTION FOR INJECTION (WITH DIULENT) - 2 ML@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15402482@Onco@@@@@300f1012ntsdm@@@@@@Hycamtin vs. Caelyx; 239 patients received an initial dose of Doxil 50 mg/m2 infused over one hour every 4 weeks and 235 patients received an initial dose of topotecan 1.5 mg/m2 infused daily for 5 consecutive days every 3 weeks.@@L01DB01@L01D@@BEERSE, BELGIUM@@@The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.@@15402482@Indicated for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@@474@Breast cancer/Ovarian cancer: Caelyx is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.@@@@No@@@Cardiac toxicity: It is recommended that all patients receiving Caelyx routinely undergo frequent ECG monitoring. Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the suspension of Caelyx therapy. However, reduction of the QRS complex is considered more indicative of cardiac toxicity. If this change occurs, the most definitive test for anthracycline myocardial injury, i.e., endomyocardial biopsy, must be considered.@30-49@No@@474 PATIENTS WITH EPITHELIAL OVARIAN CANCER AFTER PLATINUM-BASED CHEMOTHERAPY. PATIENTS WERE STRATIFIED ACCORDING TO PLATINUM SENSITIVITY AND THE PRESENCE OF BULKY DISEASE (PRESENCE OF TUMOR MASS GREATER THAN 5 CM IN SIZE). PLATINUM SENSITIVITY IS DEFINED@WOMEN@@III@APPROVED@11/29/1999@@GKV@There was no statistically significant difference in TTP between the two treatment arms. Median TTP: 4.1 months for the Doxil arm and 4.2 months for the topotecan arm. p=0.617, hazard ratio=0.955. 95% CI for hazard ratio: 0.762 - 1.196@@@@@MONO@DOXORUBICIN, PEGYLATED LIPOSOMAL@@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL||||@JANSSEN-CILAG@@@@@JANSSEN-CILAG||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@CAELYX@@@@@CAELYX||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@@@@@RANDOMISED@MULTI-CENTRE@@@@1.6@m²@10513.96477@@@4.1@month@4.1 month@10513.96@10513.96@84.31@1@1.1511@1475.43@1865.75@1513.93@@@@@@@@@@29.51@28@@mg/m²@50@1@@@@@@@@@@@8/1/2017@1475.43@1475.43@887150@CONCENTRATE FOR INFUSION SOLUTION - 25 ML@EURO@@@@@@@@50@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16074375@Onco@@@@@300f1012ntsdm@@@@@@Experimental: necitumumab + gemcitabine + cisplatinActive Comparator: gemcitabine + cisplatin@@@@@INDIANAPOLIS, INDIANA@6/1/2013@@@@16074375@Portrazza in combination with gemcitabine and cisplatin chemotherapy is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.@Both@NA@1-Apr-16@4/1/2016@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@NCT00981058@1093@The recommended dose of Portrazza is 800 mg (flat dose) administered as an intravenous infusion over 60 minutes on Days 1 and 8 of each 3-week cycle. Portrazza is administered in addition to gemcitabine and cisplatin-based chemotherapy for up to 6 cycles of treatment followed by Portrazza as a single agent in patients whose disease has not progressed, until disease progression or unacceptable toxicity.@EMA, 15 February 2016@2/15/2016@@No@@1/1/2010@@13909, CP11-0806, I4X-IE-JFCC, 2009-013838-25@No@@Histologically or cytologically confirmed squamous NSCLCHas Stage IV disease at the time of study entryMeasurable or nonmeasurable disease at the time of study entry as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) (patients with only truly nonmeasurable disease are not eligible)Has resolution to Grade ≤ 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia)@@ADULTS@III@APPROVED@@@GKV@@@@@L01XC22@COMBO@NECITUMUMAB@GEMCITABINE@CISPLATIN@@@NECITUMUMAB|GEMCITABINE|CISPLATIN||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PORTRAZZA@GENERIC@GENERIC@@@PORTRAZZA|GENERIC|GENERIC||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@OBJECTIVE RESPONSE RATE@TIME TO TREATMENT FAILURE@@@METASTATIC@LOCALLY ADVANCED@@@@RANDOMIZED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@7432.836132@@@5.7@month@5.7 month@7432.84@7432.84@42.87@1@1.1511@450.16@580.13@465.04@@@@@@@@@@0.56@21@@mg@800@2@@@@@@@@@@@8/1/2017@450.16@450.16@11645898@CONCENTRATE FOR SOLUTION FOR INFUSION - 50 ML@EURO@@@@@@@@800@MG@16 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920885@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@@@YES@TOKYO, JAPAN@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14920885@Methotrexate is used in the treatment of adults with severe, active, classical or definite rheumatoid arthritis who are unresponsive or intolerant to conventional therapy. Methotrexate has also been used in the treatment of severe, uncontrolled psoriasis, which is not responsive to other therapy. Methotrexate has been used to produce regression in a wide range of neoplastic conditions including acute leukaemias, non-Hodgkin's lymphoma, soft-tissue and osteogenic sarcomas, and solid tumours particularly breast, lung, head and neck, bladder, cervical, ovarian, and testicular carcinoma.@@@@@NO REVIEW@@@@@Eisai acquired French-based Biodim. SOURCE: Eisai, 21 February 2002@@@@Dosage for cancer treatment: A test dose of 5 - 10 mg parenterally is recommended, one week prior to therapy to detect idiosyncratic adverse events. Single doses, not exceeding 30 mg/m2, on not more than 5 consecutive days. A rest period of at least two weeks is recommended between treatments, in order to allow the bone marrow to return to normal. Doses in excess of 100 mg are usually given parenterally, when the injectable preparation should be used. Doses in excess of 70 mg/m2 should not be administered without leucovorin rescue (folinic acid rescue) or assay of serum methotrexate levels 24 - 48 hours after dosing. If methotrexate is administered in combination chemotherapy regimens, the dosage should be reduced, taking into consideration any overlapping toxicity of the other drug components.@1-Nov-91@11/1/1991@@@@@Methotrexate should be used with extreme caution in patients with haematological depression, renal impairment, diarrhoea, ulcerative disorders of the GI tract and psychiatric disorders. Hepatic toxicity has been observed, usually associated with chronic hepatic disease. Renal lesions may develop if the urinary flow is impeded and urinary pH is low, especially if large doses have been administered. The administration of low doses of methotrexate for prolonged periods may give rise, in particular, to hepatic toxicity. Particular care and possible cessation of treatment are indicated if stomatitis or GI toxicity occurs as haemorrhagic enteritis and intestinal perforation may result.@NO LABELLED TRIAL@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@EISAI@BIODIM@@@@EISAI|BIODIM|||@@@@@@|||||||||@Breast Cancer@Head & Neck Cancer@NSCLC@Bladder Cancer@Ovarian Cancer@Breast Cancer|Head & Neck Cancer|NSCLC|Bladder Cancer|Ovarian Cancer|||||@LEDERTREXATE@@@@@LEDERTREXATE||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919733@Onco@@@@@300f1037ntsdm@@@@@@Cyclophosphamide, methotrexate, and 5-FU (CMF) to no chemotherapy (19 trials with 7523 patients) and comparisons of doxorubicin-containing regimens with CMF as an active control (6 trials including 3510 patients).@@L01DB01@L01D@YES@@@@Although not completely elucidated, the mechanism of action of doxorubicin is related to its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture studies have demonstrated rapid cell penetration and perinucleolar chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, mutagenesis and chromosomal aberrations. The specificity of doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastro-intestinal tract and gonads are the main normal tissues damaged.@@14919733@Doxorubicin has been used successfully in the treatment of neoplastic conditions such as acute leukaemia, soft tissue and osteogenic sarcomas, breast carcinoma, lymphomas, bronchogenic (lung) carcinoma. It has also been used in the treatment of paediatric malignancy. Doxorubicin is frequently used in combination chemotherapy regimen involving other cytotoxic drugs. Doxorubicin can be used in the treatment of non-metastatic transitional cell carcinoma, carcinoma in situ and papillary tumours of the bladder, by intravesical administration.@@YES@@@NO REVIEW@@@@90%@@@@11033@If it is used in combination with other antitumour agents with overlapping toxicity, such as high-dose i.v. cyclophosphamide or related anthracycline compounds such as daunorubicin, idarubicin and/or epirubicin, the dosage of doxorubicin should be reduced to 30 - 40 mg/m2 every three weeks. [IHS Global Insight assumption: 30mg/m2]@1-Feb-93@2/1/1993@@No@@@Severe local tissue necrosis will occur if there is extravasation during administration. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The probability of developing impaired myocardial function based on a combined index of signs, symptoms and decline in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20% at 500 mg/m2. The risk of developing CHF increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m2. Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) has been reported in patients treated with anthracyclines, including doxorubicin. The occurrence of refractory secondary AML or MDS is more common when anthracyclines are given in combination with DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. Dosage should be reduced in patients with impaired hepatic function. Severe myelosuppression may occur.@LABEL@No@EXPIRED@@@@III; META ANALYSIS OF BREAST CANCER TRIALS@APPROVED@@NO REVIEW@SNS@The doxorubicin-containing regimens would be considered as non-inferior to CMF if the upper 2-sided 95% confidence limit of the hazard ratio was less than 1.06, i.e., not more than 6% worse than CMF. A similar calculation for OS would require a non-inferiority margin of 1.02.@Cardiovascular: Cardiotoxicity, i.e., cardiomyopathy, congestive heart failure, supraventricular tachycardia. Routine ECG monitoring is recommended and caution should be exercised in patients with impaired cardiac function. Severe cardiac failure may occur suddenly, without premonitory ECG changes. Vascular system: Phlebosclerosis. Dermatological: Extravasation, skin necrosis, cellulitis, vesication, phlebitis, erythematous streaking along the vein proximal to the site of injection. Alopecia occurs frequently, including the interruption of beard growth, but all hair growth normally returns after treatment is stopped.@@@@COMBO@DOXORUBICIN@CYCLOPHOSPHAMIDE@METHOTREXATE@FLUOURACIL@@DOXORUBICIN|CYCLOPHOSPHAMIDE|METHOTREXATE|FLUOURACIL|@TEDEC@@@@@TEDEC||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@GENERIC@5-FU@@@@GENERIC|5-FU|||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@DISEASE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@1@year@1 year@@@@50@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR INJECTION@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14923887@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Symptomatic patients were randomised with newly diagnosed multiple myeloma to Thalomid plus dexamethasone (Thal + Dex; N = 103) versus dexamethasone alone (Dex alone; N=104). The Thalomid dose was 200 mg daily and the dexamethasone dose was 40 mg orally once daily on days 1-4, 9-12, and 17-20 every 28-days. Each group was treated for four 28-day cycles.@@L04AX02@L04A@YES@SUMMIT, NEW JERSEY@@@The mechanism of action is not fully understood. It possesses immunomodulatory, anti-inflammatory and anti-angiogenic properties; the immunologic effects vary substantially under different conditions, but may be related to the suppression of excessive TNF-alpha production and down-modulation of selcted cell surface adhesion molecules involved in leukocyte migration.@@14923887@Multiple Myeloma: Thalomid (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma. Erythema Nodosum Leprosum: Thalomid (thalidomide) is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Thalomid (thalidomide) is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.@@NO@Oct-98@@NO REVIEW@@@@Co-pay Tier 3. SOURCE: Aetna Preferred Drug Guide 2008@@FIRST-LINE@NCT00033332@207@Multiple Myeloma: Thalomid (thalidomide) is administered in combination with dexamethasone in 28-day treatment cycles. The dose of Thalomid (thalidomide) is 200 mg administered orally once daily with water, preferably at bedtime and at least 1-hour after the evening meal. The dose of dexamethasone is 40 mg daily administered orally on days 1-4, 9-12, and 17-20 every 28 days.@FDA, 25 May 2006@5/25/2006@@@@@Birth Defects: Thalidomide can cause severe birth defects in humans. Thrombotic Events: The use of Thalomid in multiple myeloma results in an increased risk of venous thromboembolic events, such as deep venous thrombosis and pulmonary embolus. This risk increases significantly when thalidomide is used in combination with standard chemotherapeutic agents including dexamethasone. Drowsiness and Somnolence: Thalidomide frequently causes drowsiness and somnolence. Peripheral Neuropathy: Thalidomide is known to cause nerve damage that may be permanent. Peripheral neuropathy is a common, potentially severe, side effect of treatment with thalidomide that may be irreversible. Dizziness and Orthostatic Hypotension. Neutropenia: Decreased white blood cell counts, including neutropenia, have been reported in association with the clinical use of thalidomide. Increased HIV Viral Load.@E1A00@No@20-Oct@NEWLY DIAGNOSED PATIENTS WERE TREATED.@@@III@APPROVED@@Thalomid is recommended under Category 1 as a primary induction therapy for nontransplant candidates with melphalan and prednisone or under Category 2A with dexamethasone. It is also recommended under Category 2A as a primary induction therapy for transplant patients with dexamethasone or under Category 2B with Velcade and dexamethasone. In salvage therapy, it is recommended as a monotherapy, or with dexamethasone, or with DTPACE, under Category 2A. SOURCE: NCCN  Thalomid is subject to the S.T.E.P.S. (System for Thalidomide Education and Prescribing Safety) programme, a proprietary education and restrictive distribution program for Thalomid. STEPS is a restricted distribution system included as part of the prescribing information because of the toxicity associated with fetal exposure to Thalomid and to minimise the risk of fetal exposure to Thalomid. Celgene has patents which encompass managed delivery programs for products or drugs that are either teratogens (causing birth defects) or have other adverse effects that make them contraindicated for certain patients. Celgene Hematology Oncology Consultants and Customer Care representatives work with patients, prescribers and pharmacists. Thalomid may only be prescribed by licensed prescribers registered with STEPS. Effective contraception must be used for at least 4 weeks before beginning therapy, during therapy, and for 4 weeks following discontinuation. Two reliable forms of contraceptive methods must be used. Male patients must always use condoms during any sexual contact. Pregnancy tests must occur weekly during the first 4 weeks, then repeated at 24 weeks.  Prior authorisation; specialty drug; quantity limit 30 for 30 days@MEDICARE@Response rates based on serum or urine paraprotein measurements were significantly higher in the combination arm (51.5% compared with 35.6% for dexamethasone alone).@The most frequently reported serious adverse events in multiple myeloma patients (occurring in =20% of patients treated with thalidomide/dexamethasone compared with dexamethasone alone) were: fatigue (79% vs 71%), hemoglobin (decreased) (78% vs 86%), hyperglycemia (73% vs 79%), hypocalcemia (72% vs 59%), constipation (55% vs 28%), sensory neuropathy (54% vs 28%), hyponatremia (43% vs 48%), muscle weakness (40% vs 37%), creatinine (35% vs 42%), leukocytes (decreased) (35% vs 29%), bone pain (30% vs 36%), neutrophils (decreased) (31% vs 24%), confusion (28% vs 12%), edema (57% vs 46%), dyspnea (42% vs 31%), thrombosis/embolism (23% vs 5%), anxiety/agitation (26% vs 14%), tremor (26% vs 6%), alkaline phosphatase (increased) (27% vs 28%), and rash/desquamation (30% vs 18%). Other serious reported adverse events in multiple myeloma controlled clinical trials thalidomide/dexamethasone vs. dexamethasone alone) were: hypokalemia (23% vs 23%), insomnia (23% vs 47%), depression (22% vs 24%), neuropathy-motor (22% vs 16%), fever (24% vs 20%), weight loss (23% vs 21%), weight gain (22% vs 13%), platelets (decreased) (24% vs 33%), anorexia (28% vs 25%), nausea (28% vs 23%), pain-other (25% vs 26%), headache (20% vs 23%), dry skin (21% vs 11%), and SGOT (increased) (25% vs 24%).@@@@COMBO@THALIDOMIDE@DEXAMETHASONE@@@@THALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@THALOMID@@@@@THALOMID||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@OPEN-LABEL@@@@@Incorrect Average Duration of Use (Unit)@@@4@cycle@4 cycle@25899.92@25899.92@6474.98@84@1@26530.49@@@@@@@@@@@@1.58@@@@@@@@@@@@@@@@8/2/2017@315.84@315.84@59572-0220-96@CAPSULE@US$@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14923237@Onco@@@@@300f1020ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14923237@Sprycel is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. It is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.@@YES@25.05.2007@@NO REVIEW@@@@@-@@-@78@The recommended starting dosage for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ALL is 70 mg twice daily administered orally, one tablet in the morning and one in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@11/20/2006@@@YES@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-0015@@-@42 with blastic phase and 36 with PH+ disease@@@II@DISCONTINUED@@Classification H: Risk-sharing Agreement for acute lymphocytic leukaemia and chronic myeloid leukaemia: one package is free for every new patient registered. SOURCE: AIFA@@The MaHR rate was 59% in accelerated phase patients, 32% in myeloid phase patients, 31% in lymphoid blast phase patients, and 42% in Ph+ ALL patients. The median durations of major haematologic response were 3.7 months in lymphoid blast CML and 4.8 months in Ph+ ALL.@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@Invalid Factory Price@@@4@month@4 month@-@@@56@1.0543@@@@@@@@@@@@@@1@@mg@140@1@@@@@@@@@@@@@@37400037@FILM COATED TABLET@EURO@@@@@@@@70@MG@70 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15361196@Onco@@@@@300f1020ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@15361196@Sprycel is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. It is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.@@YES@25.05.2007@@NO REVIEW@@@@@-@@-@78@The recommended starting dosage for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ALL is 70 mg twice daily administered orally, one tablet in the morning and one in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@EMA, 20 November 2006@11/20/2006@@YES@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-0015@No@-@42 with blastic phase and 36 with PH+ disease@@@II@APPROVED@@Classification H: Risk-sharing Agreement for acute lymphocytic leukaemia and chronic myeloid leukaemia: one package is free for every new patient registered. SOURCE: AIFA@@The MaHR rate was 59% in accelerated phase patients, 32% in myeloid phase patients, 31% in lymphoid blast phase patients, and 42% in Ph+ ALL patients. The median durations of major haematologic response were 3.7 months in lymphoid blast CML and 4.8 months in Ph+ ALL.@-@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@28497.13547@@@4@month@4 month@28497.14@28497.14@234.23@30@1.1229@4015.34@6626.92@4196.07@@@@@@@@@@1.67@1@@mg@140@1@@@@@@@@@@@6/7/2017@133.84@133.84@37400138@FILM COATED TABLET@EURO@@@@@@@@80@MG@80 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14921950@Onco@@@@@300f1037ntsdm@@@@@@Patients received either Nexavar 400 mg twice daily or to placebo.@@L01XE05@L01X@NO@LEVERKUSEN, GERMANY@@@Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis. Sorafenib inhibited tumor growth and angiogenesis of human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice.@@14921950@Indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.@@YES@@@NO REVIEW@@@@90%@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@SECOND-LINE@@769@The recommended daily dose of Nexavar is 400 mg (2 x 200 mg tablets) taken twice daily, without food (at least 1 hour before or 2 hours after eating).@EMA, 19 July 2006@7/19/2006@4/1/2010@@@@Women of childbearing potential should be advised to avoid becoming pregnant while on Nexavar. Nexavar should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.@STUDY 1@No@@769 PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WHO HAD RECEIVED ONE PRIOR SYSTEMIC THERAPY WERE STRATIFIED BY MSKCC (MEMORIAL SLOAN KETTERING CANCER CENTER) PROGNOSTIC RISK CATEGORY1 (LOW OR INTERMEDIATE) AND COUNTRY AND RANDOMIZED TO NEXAVAR 400 MG TWIC@@@III@APPROVED@@NO REVIEW@SNS@The median PFS for patients on Nexavar was 167 days compared to 84 days for patients on placebo. The estimated hazard ratio (risk of progression with Nexavar compared to placebo) was 0.44 (95% CI: 0.35, 0.55).  The effect of Nexavar on PFS was consistent across different subsets, including age above or below 65 years, ECOG PS 0 or 1, MSKCC prognostic risk category1, whether the prior therapy was for progressive metastatic disease or for an earlier disease setting, time from diagnosis of less than or greater than 1.5 years.  The subsets also included patients with no prior IL-2 or interferon therapy, for whom the median PFS was 172 days on Nexavar compared to 85 days on placebo. OS was longer for Nexavar than placebo with a hazard ratio (Nexavar over placebo) of 0.72. This analysis did not meet the prespecified criteria for statistical significance. Additional analyses are planned as the survival data mature.@Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%),and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%.@@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@INTERNATIONAL@MULTI-CENTRE@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@1@1@20332.96543@@@167@day@167 day@20332.97@20332.97@121.75@112@1.1511@3409.12@3603.63@3416.66@@@@@@@@@@0.15@1@@mg@800@1@@@@@@@@@@@8/4/2017@30.44@30.44@656938@FILM-COATED TABLET@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16074360@Onco@@@@@@@@@@@Eribulin mesylate plus PEGPH20 (Phase 1b), Experimental, Recommended Phase 2 dose (RP2D) will be assessed in the below dose levels:RP2D level 1: PEGPH20 (3.0 microgram per killogram (μg/kg)) plus eribulin mesylate (1.4 milligrams per square meter (mg/m2)) orRP2D level 0: PEGPH20 (1.6 μg/kg) plus eribulin mesylate (1.4 mg/m2) orRP2D level -1: PEGPH20 (1.6 μg/kg) plus eribulin mesylate (1.1 mg/m2)Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. If no more than 1 of 6 subjects in this third cohort has a DLT, the Phase 2 part will proceed with dose level -1 as the RP2D. Otherwise, alternative doses will be explored prior to the start of Phase 2.Eribulin mesylate plus PEGPH20 (Phase 2), Experimental, Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.Eribulin mesylate (Phase 2), Experimental, Participants will receive eribulin mesylate at 1.4 mg/m2.@@L01XX41@L01X@@TOKYO, JAPAN@8/1/2018@@The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression@@16074360@A Randomized, Open-label, Multicenter, Phase 1b/2 Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)@Both@@@@@Eribulin mesylate will be administered at 1.4 mg/m2 or 1.1 mg/m2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle@@@@@@NCT02753595@96@@@@@@@6/1/2016@@E7389-M000-219@@@Histological adenocarcinoma of the breast. - Females or males, aged ≥18 years at the time of signing the informed consent form (ICF). -  Human epidermal growth factor receptor 2-negative (defined as immunohistochemistry (IHC) <2+ or fluorescence in situ hybridization (FISH) negative) breast cancer previously treated with 0 to 1 line of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting. Hormonal therapy and bone metastases treatment (eg, bisphosphonates, denosumab, etc.) are not considered forms of systemic anticancer therapy.   -  Archived tissue sample or new biopsy sample:  Metastatic breast cancer tissue with High-Hyaluronan (HA)-high levels based on available tumor tissue in formaldehyde fixed-paraffin embedded (FFPE) block or minimum of 5 (10 preferred) unstained core biopsy slides that meet specific tissue sample requirements. Fine needle aspirates (FNA) or brushing biopsies will not be acceptable.  (NOTE: HA status is not a requirement for enrollment in Phase 1b).   -  Phase 2 participants must be determined to be HA-high based on a clinical trial assay from a central laboratory (details in a separate Laboratory Manual). Tumor samples must meet the requirements noted in the previous criteria (see Study Laboratory Manual).  -  Presence of measureable disease meeting the following criteria:  1. At least 1 lesion of ≥10 mm in long axis diameter for non-lymph nodes or ≥15 mm in short axis diameter for lymph nodes that is serially measurable according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) using computerized tomography (CT) or magnetic resonance imaging (MRI).  2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of subsequent progressive disease (substantial size increase of ≥20%) to be deemed a target lesion.   -  Life expectancy of ≥3 months.   - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.   - Adequate renal function as evidenced by serum creatinine ≤1.5 milligram/deciliter (mg/dL) or calculated creatinine clearance ≥50 mL/minute according to the Cockcroft and Gault formula.   -  Adequate bone marrow function, defined as:  1. Absolute neutrophil count (ANC) ≥1.5 × 10^9/liter (L) and  2. Hemoglobin (Hgb) ≥9.0 gram/deciliter (g/dL); can be corrected by growth factor or transfusion and  3. Platelet count ≥100 × 10^9/L.   -  Adequate liver function, defined as:  1. Total bilirubin ≤1.5 × upper limit of normal (ULN), except for unconjugated hyperbilirubinemia or Gilbert's syndrome.  2. Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN if participant has liver metastases). If ALP is >3 × ULN (in the absence of liver metastases) or >5 × ULN (in the presence of liver metastases) and participants are also known to have bone metastases, the liver specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.   -  Willing and able to comply with all aspects of the treatment protocol.  13. Provide written informed consent.@COMBO@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@@ERIBULIN MESYLATE@PEGYLATED RECOMBINANT HUMAN HYALURONIDASE@@@@ERIBULIN MESYLATE|PEGYLATED RECOMBINANT HUMAN HYALURONIDASE|||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@HALAVEN@PEGPH20@@@@HALAVEN|PEGPH20|||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@Recommended Phase 2 dose (RP2D)@Objective response rate@@@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@METASTATIC@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16421613@Onco@@@@@300f1020ntsdm@@@@@@@@L01XX45@L01X@@THOUSAND OAKS, CALIFORNIA@6/1/2014@@@@16421613@Kyprolis in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy@Both@Yes@14-Sep-16@9/14/2016@NO REVIEW@Kyprolis with lenalidomide and low-dose dexamethasone (KRd) versus lenalidomide and low-dose dexamethasone alone (Rd)@@@@@SECOND-LINE@NCT01080391@792@When combined with lenalidomide and dexamethasone, Kyprolis is administered intravenously as a 10 minute infusion, on two consecutive days, each week for three weeks (days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (days 17 to 28) as shown in table 1. Each 28-day period is considered one treatment cycle. Kyprolis is administered at a starting dose of 20 mg/m2 (maximum dose 44 mg) in cycle 1 on days 1 and 2. If tolerated, the dose should be increased on day 8 of cycle 1 to 27 mg/m2 (maximum dose 60 mg). From cycle 13, the day 8 and 9 doses of Kyprolis are omitted.@EMA, 19 November 2015@11/19/2015@@Orphan Drug@@7/1/2010@@PX-171-009@No@@Symptomatic multiple myelomaMeasurable disease, as defined by one or more of the following (assessed within 21 days prior to randomization): Serum M-protein ≥ 0.5 g/dL;Urine Bence-Jones protein ≥ 200 mg/24 hours; For IgA patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL)Prior treatment with at least one, but no more than three, regimens for multiple myeloma@@ADULTS@III@APPROVED@@@SSN@The EC approved Kyprolis based on data from the pivotal Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and DexamethSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial. The study showed that patients treated with Kyprolis in combination with lenalidomide and dexamethasone (regimen referred to as KRd) had increased median time to progressive disease (PD) or death by 8.7 months compared to patients treated with lenalidomide and dexamethasone (regimen referred to as Rd). The median progression-free survival (PFS) was 26.3 months in the KRd arm compared to 17.6 months in the Rd arm (HR: 0.69;  95 percent CI: 0.57 to 0.83; p=0.0001). The most common adverse events (AEs) in the Kyprolis arm included pneumonia (1 percent), myocardial infarction (0.8 percent) and upper respiratory tract infection (0.8 percent). Discontinuation of treatment due to AEs occurred in 15 percent of patients in the KRd arm versus 18 percent of patients in the Rd arm.  Kyprolis received an accelerated assessment from the European Medicines Agency (EMA), and  orphan drug designation in 2008, given to medicines intended for the treatment, prevention or diagnosis of a disease that is life threatening and has a prevalence in the EU of no more than five in 10,000 people. Approval from the EC grants a centralized marketing authorization with unified labeling in the 28 countries that are members of the EU. Norway, Iceland and Liechtenstein, as members of the European Economic Area (EEA), will take corresponding decisions on the basis of the decision of the EC.[Amgen, 19 November 2015]@@@@@COMBO@CARFILZOMIB@LENALIDOMIDE@DEXAMETHASONE@@@CARFILZOMIB|LENALIDOMIDE|DEXAMETHASONE||@AMGEN@@@@@AMGEN||||@World@@@@@World|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@KYPROLIS@REVLIMID@GENERIC@@@KYPROLIS|REVLIMID|GENERIC||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@MULTICENTER@@@1.75@m²@86259.04535@@@504@day@504 day@86259.05@86259.05@171.15@1@1.1229@1147.18@1893.3@1198.82@@@@@@@@@@19.12@28@1@mg/m²@24.67@6@28@11@mg/m²@27@6@28@@mg/m²@27@4@6/7/2017@1147.18@1147.18@44553016@POWDER FOR SOLUTION FOR INFUSION@EURO@@@@@@@@60@MG@60 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14919854@Onco@@@@@300f1010ntsdm@@@@@@Cyclophosphamide, methotrexate, and 5-FU (CMF) to no chemotherapy (19 trials with 7523 patients) and comparisons of doxorubicin-containing regimens with CMF as an active control (6 trials including 3510 patients).@@L01DB01@L01D@YES@LAKE FOREST, ILLINOIS@@@Although not completely elucidated, the mechanism of action of doxorubicin is related to its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture studies have demonstrated rapid cell penetration and perinucleolar chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, mutagenesis and chromosomal aberrations. The specificity of doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastro-intestinal tract and gonads are the main normal tissues damaged.@@14919854@Doxorubicin has been used successfully in the treatment of neoplastic conditions such as acute leukaemia, soft tissue and osteogenic sarcomas, breast carcinoma, lymphomas, bronchogenic (lung) carcinoma. It has also been used in the treatment of paediatric malignancy. Doxorubicin is frequently used in combination chemotherapy regimen involving other cytotoxic drugs. Doxorubicin can be used in the treatment of non-metastatic transitional cell carcinoma, carcinoma in situ and papillary tumours of the bladder, by intravesical administration.@@YES@@@NO REVIEW@@@@100%@Acquired via Mayne (which acquired it via Faulding)@@@11033@The most commonly used dose schedule when used as a single agent is 60 to 75 mg/m2 as a single intravenous injection administered at 21-day intervals. The lower dosage should be given to patients with inadequate marrow reserves due to old age, or prior therapy, or neoplastic marrow infiltration. [IHS Global Insight Assumption: 60mg/m2]@EMA, July 2001@@@No@@@Severe local tissue necrosis will occur if there is extravasation during administration. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The probability of developing impaired myocardial function based on a combined index of signs, symptoms and decline in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20% at 500 mg/m2. The risk of developing CHF increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m2. Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) has been reported in patients treated with anthracyclines, including doxorubicin. The occurrence of refractory secondary AML or MDS is more common when anthracyclines are given in combination with DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. Dosage should be reduced in patients with impaired hepatic function. Severe myelosuppression may occur.@LABEL@No@EXPIRED@@@@LABEL: META ANALYSIS OF BREAST CANCER TRIALS@APPROVED@@1@NHS@The doxorubicin-containing regimens would be considered as non-inferior to CMF if the upper 2-sided 95% confidence limit of the hazard ratio was less than 1.06, i.e., not more than 6% worse than CMF. A similar calculation for OS would require a non-inferiority margin of 1.02.@Cardiovascular: Cardiotoxicity, i.e., cardiomyopathy, congestive heart failure, supraventricular tachycardia. Routine ECG monitoring is recommended and caution should be exercised in patients with impaired cardiac function. Severe cardiac failure may occur suddenly, without premonitory ECG changes. Vascular system: Phlebosclerosis. Dermatological: Extravasation, skin necrosis, cellulitis, vesication, phlebitis, erythematous streaking along the vein proximal to the site of injection. Alopecia occurs frequently, including the interruption of beard growth, but all hair growth normally returns after treatment is stopped.@@@@MONO@DOXORUBICIN@@@@@DOXORUBICIN||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Hodgkin's Lymphoma@Bladder Cancer@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|Hodgkin's Lymphoma|Bladder Cancer|Thyroid Cancer|Stomach Cancer|Sarcoma|Breast Cancer|Ovarian Cancer@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@DISEASE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@1@year@1 year@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14919830@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01CA02@L01C@YES@LAKE FOREST, ILLINOIS@@@Vincristine is an antineoplastic drug with broad-spectrum anti-tumor activity in man. The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase. The drug is relatively marrow-sparing and is thus suitable for use in combination with other cancer chemotherapeutic agents. Vincristine is poorly absorbed orally. The clearance of the drug after rapid intravenous injection follows a triphasic decay pattern: a very rapid steep descent (alpha phase); a narrow-middle region (beta-phase) and a much longer terminal region (gamma phase). The terminal phase half-life of the drug varies from 15-155 hours. Dosing with the drug more frequently than once weekly is therefore probably unnecessary. Vincristine is primarily excreted by the biliary route. Patients with impaired hepatic or biliary function, as evidenced by a raised serum alkaline phosphatase, have been shown to have a significantly prolonged vincristine elimination half-life.@@14919830@Vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of:  1. Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia 2. Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas.  3. Multiple myeloma.  4. Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.  5. Paediatric solid tumours, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumour, retinoblastoma and medulloblastoma. 6. Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.@@NO@@@NO REVIEW@@@@100%@Acquired via takeover of Mayne@@@@The drug is administered intravenously at weekly intervals. The usual dose of vincristine injection for children is 2 mg/m². For children weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of vincristine sulfate injection for adults is 1.4 mg/m². A 50% reduction in the dose of vincristine sulfate injection is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.@EMA, October 1995@@@@@@This preparation should be administered by individuals experienced in the administration of vincristine sulfate injection. It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissues during intravenous administration of vincristine sulfate injection may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. Fatal if given intrathecally.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@VINCRISTINE SULPHATE@@@@@VINCRISTINE SULPHATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Chronic Lymphocytic Leukaemia@Sarcoma@@Haematological Malignancy|Chronic Myeloid Leukaemia|Chronic Lymphocytic Leukaemia|Sarcoma||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@5@MG@1 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922834@Onco@@@@@300f1014ntsdm@@@@@@NO LABELLED TRIAL@@L04AX03@L04A@YES@MADISON, NEW JERSEY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14922834@Methotrexate is used in the treatment of adults with severe, active, classical or definite rheumatoid arthritis who are unresponsive or intolerant to conventional therapy. Methotrexate has also been used in the treatment of severe, uncontrolled psoriasis, which is not responsive to other therapy. Methotrexate has been used to produce regression in a wide range of neoplastic conditions including acute leukaemias, non-Hodgkin's lymphoma, soft-tissue and osteogenic sarcomas, and solid tumours particularly breast, lung, head and neck, bladder, cervical, ovarian, and testicular carcinoma.@@NO@@@NO REVIEW@@@@@@@@@Dosage for cancer treatment: A test dose of 5 - 10 mg parenterally is recommended, one week prior to therapy to detect idiosyncratic adverse events. Single doses, not exceeding 30 mg/m2, on not more than 5 consecutive days. A rest period of at least two weeks is recommended between treatments, in order to allow the bone marrow to return to normal. Doses in excess of 100 mg are usually given parenterally, when the injectable preparation should be used. Doses in excess of 70 mg/m2 should not be administered without leucovorin rescue (folinic acid rescue) or assay of serum methotrexate levels 24 - 48 hours after dosing. If methotrexate is administered in combination chemotherapy regimens, the dosage should be reduced, taking into consideration any overlapping toxicity of the other drug components.@@@@@@@Methotrexate should be used with extreme caution in patients with haematological depression, renal impairment, diarrhoea, ulcerative disorders of the GI tract and psychiatric disorders. Hepatic toxicity has been observed, usually associated with chronic hepatic disease. Renal lesions may develop if the urinary flow is impeded and urinary pH is low, especially if large doses have been administered. The administration of low doses of methotrexate for prolonged periods may give rise, in particular, to hepatic toxicity. Particular care and possible cessation of treatment are indicated if stomatitis or GI toxicity occurs as haemorrhagic enteritis and intestinal perforation may result.@NO LABELLED TRIAL@No@@@@@@APPROVED@@1@RAMQ@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Breast Cancer@Head & Neck Cancer@NSCLC@Bladder Cancer@Ovarian Cancer@Breast Cancer|Head & Neck Cancer|NSCLC|Bladder Cancer|Ovarian Cancer|||||@RATIO-METHOTREXATE@@@@@RATIO-METHOTREXATE||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@0.7881@63.25@@@@@@@@@@@@0.25@@@@@@@@@@@@@@@@7/19/2017@0.63@0.63@2244798100@TABLET@C$@@@@@@@@2.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada
14919835@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01CA02@L01C@YES@LAKE FOREST, ILLINOIS@@@Vincristine is an antineoplastic drug with broad-spectrum anti-tumor activity in man. The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase. The drug is relatively marrow-sparing and is thus suitable for use in combination with other cancer chemotherapeutic agents. Vincristine is poorly absorbed orally. The clearance of the drug after rapid intravenous injection follows a triphasic decay pattern: a very rapid steep descent (alpha phase); a narrow-middle region (beta-phase) and a much longer terminal region (gamma phase). The terminal phase half-life of the drug varies from 15-155 hours. Dosing with the drug more frequently than once weekly is therefore probably unnecessary. Vincristine is primarily excreted by the biliary route. Patients with impaired hepatic or biliary function, as evidenced by a raised serum alkaline phosphatase, have been shown to have a significantly prolonged vincristine elimination half-life.@@14919835@Vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of:  1. Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia 2. Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas.  3. Multiple myeloma.  4. Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.  5. Paediatric solid tumours, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumour, retinoblastoma and medulloblastoma. 6. Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.@@YES@@@NO REVIEW@@@@100%@Acquired via takeover of Mayne@@@@The drug is administered intravenously at weekly intervals. The usual dose of vincristine injection for children is 2 mg/m². For children weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of vincristine sulfate injection for adults is 1.4 mg/m². A 50% reduction in the dose of vincristine sulfate injection is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.@EMA, October 1995@@@@@@This preparation should be administered by individuals experienced in the administration of vincristine sulfate injection. It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissues during intravenous administration of vincristine sulfate injection may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. Fatal if given intrathecally.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@VINCRISTINE SULPHATE@@@@@VINCRISTINE SULPHATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@13.47@@@@@@@@@@@@13.47@@@@@@@@@@@@@@@@7/28/2017@13.47@13.47@1.50E+16@SOLUTION FOR INJECTION, VIAL, 1 ML@GB£@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14917696@Onco@@@@@300f1020ntsdm@@@@@@ARM1; Subjects in Group A will receive initial dose of 400 mg/m2 (over 2 hours) followed by weekly doses of 250 mg/m2 (over 1 hour). All doses will be given by IV infusionSubjects in both treatment groups (A nad B) will receive either Cisplatin (100 mg/m2 on day 1)+5-FU (100 mg/m2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) +5-FU (100 mg/m2 continuous IV from day 1 to day 4) every 3 weeks. ARM2; All doses will be given by IV infusion/Subjects in both treatment groups (A and B) will receive either Cisplatin (100 mg/m2 on day 1)+5-FU (100 mg/m2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) +5-FU (100 mg/m2 continuous IV from day 1 to day 4) every 3 weeks@@L01XC06@L01X@YES@NEW YORK, NEW YORK@@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@14917696@Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.@@YES@18-Jun-05@6/18/2005@NO REVIEW@@@@0%@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]     >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@@NCT00122460@440@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each. In patients with recurrent and/or metastatic squamous cell cancer of the head and neck, cetuximab is used in combination with platinum-based chemotherapy followed by cetuximab as maintenance therapy until disease progression.@EMA, 24 November 2008@11/24/2008@@NO@@@Infusion reactions such as airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, cardiac arrest ; Cardiopulmonary arrest and/or sudden death ; pulmonary toxicity leading to interstitial lung disease ; dermatologic toxicity including acneform rash, skin drying and fissuring, and inflammatory and infectious sequelae@EXTREME@No@@PATIENTS WITH STAGE III/IV MH&N.@@@III@APPROVED@@Classification H. Post-marketing monitoring system: centres utilising the drug must compile records of usage indicating the eligibility of the patients for follow-up. [AIFA]@@2.7 month increase in median overall survival for Erbitux compared to those in the control group (10.2 months versys 7.4 months); a 2.3 month gain was seen in median PFS (5.6 versus 3.3 months); and an 80% relative increase in tumour response rate (36% versus 20%) was seen. [ImClone/ESMO, 11.09.2008] >> The median overall survival for patients in the ERBITUX plus platinum-based chemotherapy arm was 10.1 months, and 7.4 months for patients treated with platinum-based chemotherapy alone (Hazard Ratio (HR), 0.797 (p = 0.036)).(1) ERBITUX plus platinum-based chemotherapy also conferred increased progression-free survival (PFS) and a higher response rate compared with chemotherapy alone. The median PFS values were 5.6 months and 3.3 months (HR = 0.538 (p less than 0.0001)) and the response rates were 35.6% and 19.5% (p = 0.0002) for patients treated with ERBITUX plus chemotherapy and chemotherapy alone, respectively. [BMS/ASCO, June 2007]@The toxicity profile in combination with platinumbased chemotherapy was manageable@@@@COMBO@CETUXIMAB@CISPLATIN@CARBOPLATIN@@@CETUXIMAB|CISPLATIN|CARBOPLATIN||@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@OVERALL SURVIVAL@@@@@@@@@@RECURRENT@METASTATIC@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@1.75@m²@19590.9476@@@5.6@month@5.6 month@19590.95@19590.95@115.02@1@1.1229@179.6@296.41@187.68@@@@@@@@@@1.8@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@6/7/2017@179.6@179.6@36584035@SOLUTION FOR INFUSION - 20 ML@EURO@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918398@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N01AH01@N01A@YES@HOLZKIRCHEN, GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918398@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@5.56@18.02@6.44@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.56@0.56@7524746@SOLUTION FOR INJECTION (2 ML)@EURO@@@@@@@@100@MCG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15400320@Onco@@@@@300f1037ntsdm@@@@@REGARD@Experimental: IMC-1121B (ramucirumab) Placebo Comparator: Placebo@@L01XC@L01X@@NEW YORK, NEW YORK@3/1/2014@@IMC-1121B is a fully human IgG1 monoclonal antibody designed to bind to the extracellular domain of VEGFR-2 found on tumor vasculature, thereby inhibiting certain ligands known as vascular endothelial growth factors from binding to and activating the receptor. This action blocks a signaling pathway key to new blood vessel formation in growing tumors, which has been shown to starve tumors of their nutrient supply and result in significant tumor growth inhibition in pre-clinical models.@@15400320@Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer orgastro-oesophageal junction adenocarcinoma with disease progression after prior platinum orfluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.@Both@YES@18-Dec-15@12/18/2015@NO REVIEW@@@AUGUST 2009 - MARCH 2014@@@@NCT00917384@355@The recommended dose of ramucirumab as a single agent is 8 mg/kg every 2 weeks. It is recommended that treatment be continued until disease progression or until unacceptable toxicityhas occurred.@EMA, 19 December 2014@12/19/2014@12/1/2015@Yes@@8/1/2009@@@No@@Histologically or cytologically confirmed gastric carcinoma, including gastric adenocarcinoma or GEJ adenocarcinomaMetastatic disease or locally recurrent, unresectable disease with measurable lymph node metastasesMeasurable disease and/or evaluable disease. Measurable disease is defined as at least one unidimensionally-measurable target lesion [≥ 2 centimeter (cm) with conventional techniques or ≥ 1 cm by spiral computed tomography (CT)], as defined by Response using Response Evaluation Criteria in Solid Tumors (RECIST).@@ADULTS@@APPROVED@@Recommended; The AEMPS has decided to recommend Cyramza in patients who have not received taxanes as a first-line treatment and in patients who are not candidates for chemotherapy. http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-ramucirumab-Cyramza.pdf@SNS@@@@@@MONO@RAMUCIRUMAB@@@@@RAMUCIRUMAB||||@IMCLONE@LILLY@@@@IMCLONE|LILLY|||@United States@Argentina@Australia@Bosnia and Herzegovina@Brazil@United States|Argentina|Australia|Bosnia and Herzegovina|Brazil|Canada|Chile|Colombia|Croatia|Czech Republic@Stomach Cancer@@@@@Stomach Cancer|||||||||@CYRAMZA@@@@@CYRAMZA||||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@mAb@Human@TK Inhibitor|Angiogenesis Inhibitor|VEGF|mAb|Human@OVERALL SURVIVAL@RESPONSE RATE@@@@PROGRESSION-FREE SURVIVAL@OBJECTIVE RESPONSE@SAFETY@@@ADVANCED@METASTATIC@@@@DOUBLE BLIND@PARALLEL ASSIGNMENT@@@@76.5@kg@16669.36714@@@2.1@month@2.1 month@16669.37@16669.37@260.97@1@1.1511@2985@3162.55@2992.54@@@@@@@@@@5.97@14@@mg/kg@8@1@@@@@@@@@@@8/4/2017@2985@2985@705113@CONCENTRATE FOR SOLUTION FOR INFUSION - 50 ML@EURO@@@@@@@@500@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14921073@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles @@L01BA04@L01B@-@INDIANAPOLIS, INDIANA@12/1/2009@@Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant c@@14921073@A Phase II Study of Pemetrexed as Second-Line Treatment in Patients With Pancreatic Cancer Progressing Despite Therapy With Gemcitabine@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00864513@24@-@-@@@-@@10/1/2007@Pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia, and anaemia (or pancytopenia) (see section 4.8). Myelosuppression is usually the dose-limiting toxicity. Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to 1500 cells/mm3 and platelet count returns to 100,000 cells/mm3. Dose reductions for subsequent cycles are based on nadir ANC, platelet count, and maximum non-haematologic toxicity seen from the previous cycle@IIT2007022, 2007-022 @@-@Histologically confirmed adenocarcinoma of the pancreas Prior treatment for distant or locally advanced disease with gemcitabine-based therapy@@@II@II@@-@-@Trial commences (clinicaltrial.gov 17 March 2009)@-@@@@MONO@PEMETREXED@@@@@PEMETREXED||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ALIMTA@@@@@ALIMTA||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@PROGRESSION-FREE SURVIVAL@@@@@RESPONSE RATE@TIME TO PROGRESSION@SAFETY@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@POWDER FOR INFUSION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918690@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01DB02@L01D@YES@@@@Daunorubicin is an anthracycline glycoside antibiotic and is a potent antileukaemic agent. It also has immunosuppressant effects. The exact mechanism of antineoplastic action is uncertain but may involve binding to DNA by intercalation between base pairs and inhibition of DNA and RNA synthesis by template disordering and steric obstruction. Daunorubicin is most active in the S-phase of cell division but is not cycle phase specific. Tumour cell cross-resistance has been observed between daunorubicin and doxorubicin.@@14918690@Daunorubicin is indicated for the following: Inducing remissions of acute myelogenous and lymphocytic leukaemias.@@@@@NO REVIEW@@@@100%@Sanofi acquired Sterling Winthrop in 1992. Winthrop is now a subsidiary of sanofi-aventis.@@@@ADULTS: 40 - 60 mg/m² on alternate days for a course of up to three injections for the induction of remissions.  Acute myelogenous leukaemia: The recommended dose is 45 mg/m² Acute lymphocytic leukaemia: The recommended dose is 45 mg/m² CHILDREN: Over 2 years - Same as for adults. Under 2 years or if less than 0.5 m² surface area: 1 mg/kg/day. ELDERLY: Daunorubicin should be used with care in patients with inadequate bone marrow reserves due to old age. A reduction of up to 50% in dosage is recommended.@EMA, June 1994@@@@@@1. Cerubidine must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration. 2. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m2 in adults, 300 mg/m2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age. 3. Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage. 4. It is recommended that Cerubidine be administered only by physicians who are experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection. 5. Dosage should be reduced in patients with impaired hepatic or renal function.@NO LABELLED TRIAL@No@@@@@@APPROVED@@100%; no NICE review@NHS@NO LABELLED TRIAL@@@@@@DAUNORUBICIN@@@@@DAUNORUBICIN||||@WINTHROP@SANOFI-AVENTIS@@@@WINTHROP|SANOFI-AVENTIS|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@10@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@GB£@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
15318123@Onco@@@@@300f1010ntsdm@@@@@@120 mg of denosumab, administered subcutaneously once monthly with a loading dose at days 8 and 15 of month one. SOURCE: Amgen@@M05BX04@M05B@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.@@15318123@Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.@@NO@@@NO REVIEW@@@@100%@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@@@529@The recommended dose of XGEVA for the treatment of giant cell tumour of bone is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm with additional 120 mg doses on days 8 and 15 of treatment of the first month of therapy.@EMA, 1 August 2014@8/1/2014@@No@@7/1/2006@@@No@@@@@II; Denosumab GCT Phase 2 Study;@APPROVED@@@NHS@Interim results met the primary and all secondary endpoints. The primary endpoint was tumor response (elimination of greater than or equal to 90 percent of giant cells or no radiographic progression of the target lesion). Out of 35 patients enrolled in the study, 25 were eligible for this interim analysis, with 24 receiving denosumab and 15 being eligible for efficacy analysis based on availability of pre- and post-radiology and histology assessments. Thirteen of 15 patients (87 percent) had tumor response to denosumab treatment. Of those, 9 of 9 had a histologic response which showed almost complete or complete elimination of giant cells. In addition, 4 of 6 patients had a radiographic response demonstrating no further progression. The two patients who did not meet radiographic response criteria were considered stable by investigators. Three subjects reported evidence of new bone formation and repair visible by radiology. SOURCE: Amgen/ASCO, 31 May 2008@In this study, denosumab appeared generally well-tolerated. The most frequent adverse events reported were headache (3 (13 percent)) and nasopharyngitis (3 (13 percent)). No treatment-related serious adverse events related to denosumab or deaths were reported, and no neutralizing anti-denosumab antibodies were observed.@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@XGEVA@@@@@XGEVA||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@1@1@2639.298948@@@6@month@6 month@2639.3@2639.3@14.46@1@1.299@309.86@@@@@@@@@@@@2.58@28@1@mg@120@3@28@@mg@120@1@@@@@@7/28/2017@309.86@309.86@1.94E+16@SOLUTION FOR INJECTION, 1.7 ML@GB£@@@@@@@@120@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922181@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Participants will receive a single dose of Avastin 2 weeks before they are scheduled to start the combination of carboplatin, Abraxane and Avastin. Before the dose of Avastin is given, a perfusion CT scan and blood work will be performed. The perfusion CT scan and blood draw will be repeated 12 days after teh Avastin dose (2 days before beginning study treatment). The combination of carboplatin, Abraxane and Avastin will be given in 3 week cycles and all drugs will be given as infusions. On day 1, Avastin, Abraxane and carboplatin wil be given. On Day 8 and 15, Abraxane will be given. Participants can receive up to 6 cycles of carboplatin, Abraxane and Avastin if their disease does not get worse and they do not experience intolerable side effects. The following assessment procedures will be performed on day 1 of each cycle: physical exam; routine urine test (every other cycle); Performance status assessment. Routine blood tests will be performed on days 1, 8 and 15.  Additional procedures performed after cycles 2 and 4 and at 6 months after beginning study treatment are as follows: CT scan, PET scan, perfusion CT and blood work. After 6 cycles of carboplatin, Abraxane and Avastin, participants will receive Avastin alone for three weeks. Participants can continue to receive Avastin as long as they do not experience unacceptable side effects. [clinicaltrials.gov]@@L01CD01@L01C@-@SUMMIT, NEW JERSEY@4/1/2011@@Abraxane is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel protein-bound particles for injectable suspension) is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.@@14922181@Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer@@-@9-Sep-08@9/9/2008@NO REVIEW@@@@-@>>Celgene acquires Abraxis for US$2.9 billion [Celgene 30 June 2010 http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight= ]>> Abraxis BioScience has entered into an agreement with AstraZeneca to re-acquire the exclusive rights to market Abraxane in the United States. [Abraxis, 28.11.2008]       >> AstraZeneca paid US$200 mil to co-promote Abraxane in the U.S., whilst Abraxis bought AstraZeneca's anaesthetic/analgesia portfolio. India/certain Asia rights licensed to Biocon in August 2007.@FIRST-LINE@NCT00642759@36@-@-@@@-@@4/1/2008@-@AVF4298s@@-@>> Histologically confirmed diagnosis of non-small cell lung carcinoma of non-squamous histology >> AJCC stage IIIB or Stage IV >> Measurable disease by RECIST criteria, and must have at least one target lesion 2cm or greater in diameter for optimal perfusion CT scanning >> No prior chemotherapy treatment or VEGF inhibitor treatment, although prior treatment with EGFR inhibitors will be allowed@@@II; ABX203-LC07US@II@@Abraxane may be substituted for either paclitaxel or docetaxel in patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or for patients in who standard premedications are contraindicated. [NCCN, 9.09.2008]@-@Trial registered. [Abraxis, 21.03.2008]@-@@@@COMBO@PACLITAXEL PROTEIN BOUND PARTICLES@BEVACIZUMAB@CARBOPLATIN@@@PACLITAXEL PROTEIN BOUND PARTICLES|BEVACIZUMAB|CARBOPLATIN||@CELGENE@ABRAXIS@@@@CELGENE|ABRAXIS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ABRAXANE@AVASTIN@@@@ABRAXANE|AVASTIN|||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@PROGRESSION-FREE SURVIVAL@@@@@SAFETY@RESPONSE RATE@OVERALL SURVIVAL@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919359@Onco@@@@@300f1012ntsdm@@@@@@Patients received either Kytril Injection, 40 mcg/kg or the combination of chlorpromazine and dexamethasone. They were all treated with ifosfamide =3 g/m2/day for two or three days.@@A04AA02@A04A@NO@HOLZKIRCHEN, GERMANY@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14919359@Kytril tablets are indicated for the prevention of nausea and vomiting induced by cytostatic therapy@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@88@Adults The dose of Kytril is 1mg twice a day or 2mg once a day during cytostatic therapy. The first dose of Kytril should be administered within one hour before the start of cytostatic therapy. Concomitant use of dexamethasone: The efficacy of Kytril may be enhanced by the addition of dexamethasone. Maximum Dose and Duration of Treatment: Kytril is also available as ampoules for intravenous administration. The maximum dose of Kytril administered orally and/or intravenously over 24 hours should not exceed 9mg.@@@@@@@Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@88 PEDIATRIC PATIENTS RECEIVED EITHER KYTRIL INJECTION 20 MCG/KG OR CHLORPROMAZINE PLUS DEXAMETHASONE@PAEDIATRIC@@CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING / PEDIATRIC STUDIES@APPROVED@@@GKV@22% of Kytril Injection patients achieved complete response (no vomiting and no moderate or severe nausea in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of vomiting episodes with Kytril Injection was 1.5; with chlorpromazine it was 7.0.@@@@@MONO@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@RESPONSE RATE@EMETIC EPISODES@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@31.69@51.05@33.39@@@@@@@@@@6.34@@@@@@@@@@@@@@@@8/1/2017@6.34@6.34@1888826@FILM-COATED TABLET@EURO@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15400340@Onco@@@@@300f1020ntsdm@@@@@@@@L01XE08@L01X@YES@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@15400340@Tasigna is indicated for the treatment of adults with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available.@Both@-@08.08.2008@@NO REVIEW@@@@@-@SECOND-LINE@-@321@In patients with chronic- or accelerated-phase CML who cannot tolerate other treatments or whose disease does not respond to them, the recommended dose is 400 mg twice a day.@EMA, 28 November 2007@11/28/2007@@EC orphan drug designation for CML. SOURCE: EMEA, 22 May 2006@@@Tasigna prolongs the QT interval. Sudden deaths have been reported in patients receiving nilotinib. Tasigna should not be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be corrected prior to Tasigna administration and should be periodically monitored. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided. Patients should avoid food 2 hours before and 1 hour after taking dose. Use with caution in patients with hepatic impairment. ECGs should be obtained to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, as well as following any dose adjustments.@@No@-@The definition of imatinib resistance included failure to achieve a complete hematologic response (by 3 months), cytogenetic response (by 6 months) or major cytogenetic response (by 12 months) or progression of disease after a previous cytogenetic or hematologic response. Imatinib intolerance was defined as discontinuation of treatment due to toxicity and lack of a major cytogenetic response at time of study entry.@ADULT@Adult@II@APPROVED@@Classification H. Post-marketing monitoring system for chronic myeloid leukaemia: centres utilising the drug must compile records of usage indicating the eligibility of the patients for follow-up. [AIFA]@@The MCyR rate in 320 CP patients was 49%. Most responders achieved their MCyR rapidly within 3 months (median 2.8 months) of starting Tasigna treatment and these were sustained (median duration has not been reached). Among 156 patients with MCyR 43 patients (27.6%) lost their MCyR. Patients with a CHR at baseline achieved a MCyR faster (1 vs. 2.8 months). Of CP patients without a baseline CHR, 70% achieved a CHR and median time to CHR was 1 month and median duration of CHR has not been reached. The overall confirmed HR rate in 119 AP patients was 42%. Most responders achieved a HR early with Tasigna treatment (median 1.0 months) and these have been durable (median duration has not been reached). No patients have had a loss of CHR. The MCyR rate was 27% with a median time to response of 2.0 months.@-@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@@@@@@@@@@@CHRONIC PHASE@@@@@OPEN-LABEL@SINGLE ARM@MULTI-CENTRE@@@1@1@74753.56932@@@18.4@month@18.4 month@74753.57@74753.57@133.57@112@1.1229@2804.99@4629.36@2931.25@@@@@@@@@@0.17@1@@mg@800@1@@@@@@@@@@@6/7/2017@25.04@25.04@38328062@HARD CAPSULE@EURO@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14918652@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01BC01@L01B@YES@LAKE FOREST, ILLINOIS@@@Cytarabine (ARA-C) is metabolised in vivo to ARA-CTP phosphorylated compound. This competitively inhibits DNA polymerase and may also inhibit certain acid kinase enzymes. Primarily the drug acts as a false nucleoside and competes for enzymes involved in the conversion of cytidine nucleotide to deoxycytidine nucleotide and also incorporation into the DNA. Cytarabine has no effect on non proliferating cells nor on proliferating cells unless in the S phase. It is a cell cycle specific antineoplastic drug.@@14918652@Cytarabine may be used alone or in combination with other antineoplastic agents. It is indicated alone or in combination for induction of remission and/or maintainance in patients with acute myeloid leukaemia, acute non-lymphoblastic leukaemias, acute lymphoblastic leukaemias, acute lymphocytic leukaemia, erythroleukaemia, blast crises of chronic myeloid leukaemia, diffuse histiocytic lymphomas (non-hodgkin's lymphomas of high malignancy), meningeal leukaemia and meningeal neoplasms. Clinicians should refer to the current literature on combination therapy before initiating treatment.@@NO@@@NO REVIEW@@@@100%@Via takeover of Mayne Pharma@@@@Leukaemic Meningitis: Therapy for established meningitis employs a wide variety of dose regimens but a recommended total daily dose not exceeding 100 mg, alternating with methotrexate (given either systemically or intrathecally) is recommended. Cytarabine has been given intrathecally at doses of 10-30 mg/m2 three times a week until cerebro-spinal fluid findings return to normal.@EMA, September 1997@@@@@@Only physicians experienced in cancer chemotherapy should use Cytarabine for Injection USP. For induction therapy, patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of cytarabine is bone marrow suppression with leukopenia, thrombocytopenia, and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration, and hepatic dysfunction. The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. Before making this judgement or beginning treatment, the physician should be familiar with the following text.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@NO LABELLED TRIAL@@@@@@CYTARABINE@@@@@CYTARABINE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Lymphomatous Meningitis@@@@@Lymphomatous Meningitis|||||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.299@100@@@@@@@@@@@@0.04@@@@@@@@@@@@@@@@7/28/2017@20@20@4.68E+15@SUSPENSION FOR INJECTION, 5 ML@GB£@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16637331@Onco@@@@@300f1012ntsdm@@@@@@ixazomib + Lenalidomide + Dexamethasone: patients will receive single oral dose of ixazomib (4.0mg) on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progressionPlacebo + Lenalidomide + Dexamethasone: Patients will receive single oral dose of Placebo on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progression@@L01XX50@L01X@@CAMBRIDGE, MASSACHUSSETTS@10/1/2015@@Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.@@16637331@NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.@Both@NA@6-Jul-17@7/6/2017@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]       >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]       >> Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones.@SECOND-LINE@NCT01564537@837@The recommended starting dose of NINLARO is 4 mg administered orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle.The recommended starting dose of lenalidomide is 25 mg administered daily on Days 1 to 21 of a 28-day treatment cycle.The recommended starting dose of dexamethasone is 40 mg administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle.Treatment should be continued until disease progression or unacceptable toxicity.@EMA, 21 November 2016@11/21/2016@1/15/2017@Yes@@8/1/2012@@C16010@No@@Multiple myeloma diagnosed according to standard criteria either currently or at the time of initial diagnosis NOTE: The initial diagnosis must be symptomatic MM, although the relapsed disease does not need to be symptomatic.Patients must have measurable disease defined by at least 1 of the following 3 measurements: • Serum M-protein ≥ 1 g/dL ( ≥10 g/L). • Urine M-protein ≥ 200 mg/24 hours. • Serum free light chain assay: involved free light chain level ≥ 10 mg/dL ( ≥ 100 mg/L), provided that the serum free light chain ratio is abnormal. Patients with relapsed and/or refractory MM who have received 1 to 3 prior therapies. NOTE: This patient population includes the following 3 categories of patients: • Patients who relapsed from their previous treatment(s) but were not refractory to any previous treatment. • Patients who were refractory to all lines of previous treatment(s) (ie, patients who have never responded to any therapies received). • Patients who were relapsed from at least 1 previous treatment AND additionally were refractory to at least 1 previous treatment. For the purposes of this study, refractory disease is defined as disease progression on treatment or progression within 60 days after the last dose of a given therapy. A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation, followed by maintenance is considered 1 line of therapy. Autologous and allogenic transplants are permitted.@ADULTS@ADULTS@III@APPROVED@@06 July 2017, Benefit not quantifiable, [https://www.g-ba.de/downloads/39-261-2994/2017-07-06_AM-RL-XII_Ixazomib_D-272_BAnz.pdf]@GKV@The European Commission followed the CHMP's recommendation to approve NINLARO based on data from the pivotal Phase 3 TOURMALINE-MM1 trial, which demonstrated that NINLARO plus lenalidomide and dexamethasone increased the length of progression-free survival by about six months, or 40 percent, in patients with relapsed and refractory multiple myeloma when compared with placebo, lenalidomide and dexamethasone. The study also showed that the progression-free survival benefit observed in the NINLARO regimen extended across pre-specified subgroups of patients. Follow-up analyses for overall survival are planned for 2017.[https://www.takeda.com/news/2016/20161124_7626.html]@@@@@COMBO@IXAZOMIB@LENALIDOMIDE@DEXAMETHASONE@@@IXAZOMIB|LENALIDOMIDE|DEXAMETHASONE||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@United States@Australia@Austria@Japan@Netherlands@United States|Australia|Austria|Japan|Netherlands|Turkey|United Kingdom|France|Germany|Israel@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@NINLARO@REVLIMID@GENERIC@@@NINLARO|REVLIMID|GENERIC||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@OVERALL RESPONSE RATE@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@315230.6683@@@20.6@month@20.6 month@315230.67@315230.67@503.11@3@1.1511@8100@9985.49@8138.5@@@@@@@@@@1173.91@28@@mg@4@3@@@@@@@@@@@8/1/2017@2700@2700@11531686@HARD CAPSULE@EURO@@@@@@@@2.3@MG@2.3 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14921456@Onco@@@@@300f1010ntsdm@@@@@@Patients treated with Navelbine (30 mg/m2) weekly or 5-fluorouracil (5-FU) (425 mg/m2 IV bolus) plus leucovorin (LV) (20 mg/m2 IV bolus) daily for 5 days every 4 weeks. A total of 211 patients were randomized at a 2:1 ratio to Navelbine (143) or 5-FU/LV (68).@@L01CA04@L01C@YES@CASTRES, FRANCE@@@Navelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine. Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.@@14921456@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@YES@2-Dec@@NO REVIEW@@@@100%@@FIRST-LINE@@211@In adults : Navelbine is usually given at 25-30mg/m² weekly. It may be administered by slow bolus (5-10 minutes) after dilution in 20-50 ml of sodium chloride 9 mg/ml (0.9%) solution for injection or in 5% glucose solution for injection. Administration should always be followed with at least 250 ml of an isotonic solution to flush the vein. Advanced non-small cell lung cancer and advanced breast cancer - In monotherapy the usual dose given is 25-30 mg/m² once weekly.@EMA, May 1996@@@No@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequently monitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@@No@EXPIRED@Stage IV NSCLC, no prior chemotherapy, and Karnofsky Performance Status =70@@@III@APPROVED@@NICE; the guidance recommends that: Vinorelbine by itself should not be used as the first treatment for advanced breast cancer. Vinorelbine on its own should be one option for treating advanced breast cancer when initial treatment with chemotherapy using drugs called anthracyclines has not worked or is unsuitable for the patient. The patient and the doctor who is responsible for the cancer treatment should choose the follow-up treatment together, after they have discussed the benefits and possible side effects of the drugs available. NICE has looked at the evidence that is available and decided that at the moment it can't recommend routine use of vinorelbine together with other chemotherapy drugs (combination therapy).@NHS@Navelbine showed improved survival time compared to 5-FU/LV. In an intent-to-treat analysis, the median survival time was 30 weeks versus 22 weeks for patients receiving Navelbine versus 5-FU/LV, respectively (P = 0.06). The 1-year survival rates were 24% (±4% SE) for Navelbine and 16% (±5% SE) for the 5-FU/LV group, using the Kaplan-Meier product-limit estimates. The median survival time with 5-FU/LV was similar to or slightly better than that usually observed in untreated patients with advanced NSCLC, suggesting that the difference was not related to some unknown detrimental effect of 5-FU/LV therapy. The response rates (all partial responses) for Navelbine and 5-FU/LV were 12% and 3%, respectively.@@@@@MONO@VINORELBINE TARTRATE@@@@@VINORELBINE TARTRATE||||@PIERRE FABRE@@@@@PIERRE FABRE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@NAVELBINE@@@@@NAVELBINE||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@OVERALL SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@@@@@@@Invalid Dosage Value Phase 1@@@30@week@30 week@3272.06@3272.06@15.58@10@1.299@1399.79@@@@@@@@@@@@2.8@@@@@@@@@@@@@@@@7/28/2017@139.98@139.98@4.80E+15@CONCENTRATE FOR INTRAVENOUS INFUSION@GB£@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922762@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were randomised to Procrit 40,000 Units weekly (n = 174) or placebo (n = 170) SC. If hemoglobin had not increased by > 1 g/dL, after 4 weeks of therapy or the patient received RBC transfusion during the first 4 weeks of therapy, study drug was increased to 60,000 Units weekly. Forty-three percent of patients in the Epoetin alfa group required an increase in Procrit dose to 60,000 Units weekly@@B03XA01@B03X@YES@BRIDGEWATER, NEW JERSEY@@@Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment. The apparent molecular weight of erythropoietin is 32,000 to 40,000 dalton. The protein fraction of the molecule contributes about 58% and consists of 165 amino acids. The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein. Epoetin alfa obtained by gene technology is glycosylated and is identical in its amino acid and carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients. Epoetin alfa has the highest possible purity according to the present state of the art. In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.@@14922762@Treatment of Anaemia of Chronic Renal Failure Patients: indicated for the treatment of anaemia associated with CRF, including patients on dialysis and patients not on dialysis. Procrit is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or haemoglobin determinations) and to decrease the need for transfusions in these patients. Non-dialysis patients with symptomatic anemia considered for therapy should have a haemoglobin less than 10 g/dL. It is not intended for patients who require immediate correction of severe anaemia. It may obviate the need for maintenance transfusions but is not a substitute for emergency transfusion. Treatment of Anaemia in Zidovudine-treated HIV-infected Patients Procrit is indicated for the treatment of anaemia related to therapy with zidovudine in HIV-infected patients. Procrit is indicated to elevate or maintain the red blood cell level (as manifested by the haematocrit or haemoglobin determinations) and to decrease the need for transfusions in these patients. Procrit is not indicated for the treatment of anemia in HIV- infected patients due to other factors such as iron or folate deficiencies, haemolysis, or gastrointestinal bleeding, which should be managed appropriately. Treatment of Anaemia in Cancer Patients on Chemotherapy: Procrit is indicated for the treatment of anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. Procrit is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months. Procrit is not indicated for the treatment of anaemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately. Procrit use has not been demonstrated in controlled clinical trials to improve symptoms of anaemia, quality of life, fatigue, or patient well-being. Procrit is not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy. Reduction of Allogeneic Blood Transfusion in Surgery Patients Procrit is indicated for the treatment of anemic patients (hemoglobin > 10 to 13 g/dL) who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Procrit is not indicated for anaemic patients who are willing to donate autologous blood@@NO@@@NO REVIEW@@@@Injectable medication that may be covered under the medical benefit. SOURCE: Aetna Preferred Drug Guide 2008@Manufactured by: Amgen Inc.@@@344@The initial recommended dose in adults is 150 Units/kg SC TIW or 40,000 Units SC Weekly. The initial recommended dose of in paediatric patients is 600 Units/kg IV weekly. Discontinue following the completion of a chemotherapy course.@FDA, 01 June 1989@6/1/1989@@@@@[updated November 2007] Renal failure: Patients experienced greater risks for death and serious cardiovascular events when administered ESAs to target higher versus lower haemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Dosing must be individualised to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL. Cancer: ESAs shortened overall survival and/or TTP in clinical studies in patients with advanced breast, head and neck, lymphoid, and NSCLC malignancies when dosed to target a haemoglobin of > 12 g/dL. The risks of shortened survival and tumour progression have not been excluded when ESAs are dosed to target a haemoglobin of < 12 g/dL. To minimise these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions. Use only for treatment of anaemia due to concomitant myelosuppressive chemotherapy. Discontinue following the completion of a chemotherapy course. Perisurgery: Procrit increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.@@No@4-Dec@344 ANEMIC CANCER PATIENTS.  61 PATIENTS (35 PATIENTS IN THE PLACEBO ARM AND 26 PATIENTS IN THE PROCRIT ARM) WERE TREATED WITH CONCOMITANT CISPLATIN CONTAINING REGIMENS AND 283 PATIENTS RECEIVED CONCOMITANT CHEMOTHERAPY REGIMENS THAT DID NOT CONTAIN CISPL@@@CLINICAL EXPERIENCE: RESPONSE TO PROCRIT / CANCER PATIENTS ON CHEMOTHERAPY /WEEKLY (QW) DOSING@APPROVED@@@MEDICARE@Reduced the proportion of patients transfused in day 29 through week 16 of the study as compared to placebo. 25 (14%) in the Procrit group received transfusions compared to 48 patients (28%) in the placebo group (p = 0.0010) between day 29 and week 16 or the last day on study.@@@@@COMBO@EPOETIN ALFA@@@@@EPOETIN ALFA||||@ORTHO BIOTECH@JOHNSON & JOHNSON@@@@ORTHO BIOTECH|JOHNSON & JOHNSON|||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@PROCRIT@@@@@PROCRIT||||@EPO@@@@@EPO||||@REDUCTION IN TRANSFUSIONS@@@@@@@@@@@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@8939.04@8939.04@@4@1@1961.6@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@490.4@490.4@59676-0320-04@INJECTION (VIAL)@US$@@@@@@@@20000@UI@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16446635@Onco@@@@@300f1018ntsdm@@@@@@Velcade with melphalan and prednisone (MP) versus MP alone@@L01XX32@L01X@@@7/1/2007@@Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.@@16446635@VELCADE, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dosechemotherapy.@@YES@9-Jul@@NO REVIEW@@@@@@FIRST-LINE@NCT00111319@682@@TGA, December 2008@@@No@@12/1/2004@@@No@@Symptomatic multiple myeloma or asymptomatic multiple myeloma with related organ or tissue damage. Asymptomatic multiple myeloma-related organ or tissue damage can include presence of asymptomatic lytic bone lesion or plasmacytoma, or presence of anemia, renal function impairment, or hypercalcemia, as long as the criteria for pre-treatment clinical laboratory values indicated below are met. PATIENTS INELIGIBLE FOR STEM CELL TRANSPLANT.@@@III@APPROVED@@Recommended on a cost minimisation basis compared with thalidomide. Extend the current Authority required listing to include use as first line therapy in combination with a corticosteroid and melphalan or cyclophosphamide in the treatment of multiple myeloma in patients who meet certain criteria.@PBS@@@@@@COMBO@BORTEZOMIB@MELPHALAN@PREDNISONE@@@BORTEZOMIB|MELPHALAN|PREDNISONE||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@VELCADE@ALKERAN@GENERIC@@@VELCADE|ALKERAN|GENERIC||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@TIME TO PROGRESSION@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@COMPLETE RESPONSE@@PROGRESSION-FREE SURVIVAL@COMPLETE RESPONSE@@@@@@@@@RANDOMISED@MULTI-CENTRE@INTERNATIONAL@@@1.75@m²@55035.526@@@54@week@54 week@55035.53@55035.53@145.6@1@0.779@1395.66@@@@@@@@@@@@465.22@42@4@mg/m²@1.3@8@42@@mg/m²@1.3@4@@@@@@8/1/2017@1395.66@1395.66@3554-2616-IN-JC@POWDER FOR SOLUTION FOR INFUSION/INJECTION@A$@@@@@@@@3@MG@3 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14920382@Onco@@@@@300f1012ntsdm@@@@@@Patients were treated with Gleevec 340 mg/m2/day, with no interruptions in the absence of dose limiting toxicity.@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920382@Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is notconsidered as the first line of treatment.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@51@Pediatric Patients with Ph+ CML: The recommended dose of Gleevec for children with newly diagnosed Ph+ CML is 340 mg/m2/day (not to exceed 600 mg).@EMA, 7 November 2001@11/7/2001@@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@@PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED AND UNTREATED CML IN CHRONIC PHASE WERE TREATED WITH GLEEVEC@PAEDIATRIC@@II; STUDY 2108@APPROVED@@NO REVIEW@GKV@CHR was observed in 78% of patients after 8 weeks of therapy. CCyR was 65%, comparable to the results observed in adults. PCyR was observed in 16%. The majority of patients who achieved a CCyR developed the CCyR between months 3 and 10 with a median time to response of 6.74 months.@The majority of Gleevec-treated patients experienced adverse reactions at some time. Most reactions were of mild-to-moderate grade, but drug was discontinued for drug-related adverse reactions in 2.4% of newly diagnosed patients, 4% of patients in chronic phase after failure of interferon-alpha therapy, 4% in accelerated phase and 5% in blast crisis. The most frequently reported drug-related adverse reactions were edema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhea and rash. Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec. The frequency of severe superficial edema was 1.5%-6%. The overall safety profile of pediatric patients treated with Gleevec in 93 children studied was similar to that found in studies with adult patients, except that musculoskeletal pain was less frequent (20.5%) and peripheral edema was not reported. Nausea and vomiting were the most commonly reported individual adverse reactions with an incidence similar to that seen in adult patients. Although most patients experienced adverse reactions at some time during the study, the incidence of Grade 3/4 adverse reactions was low.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@OPEN-LABEL@MULTI-CENTRE@SINGLE-ARM@@@1.2@m²@19053.8972@@@6.74@month@6.74 month@19053.9@19053.9@92.94@90@1.1511@8200.95@10109.22@8239.45@@@@@@@@@@0.23@1@@mg/m²@340@1@@@@@@@@@@@8/1/2017@91.12@91.12@1755203@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14922386@Onco@@@@@300f1008ntsdm@@@@@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@NEW YORK, NEW YORK@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14922386@Indicated for the treatment of: 1. advanced ovarian carcinoma of epithelial origin in  (a) first line therapy (b) second line therapy, after other treatments have failed. 2. small cell carcinoma of the lung.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@SECOND-LINE@@@Single-Agent Therapy: has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide:an effective combination for previously untreated patients consists of: Paraplatin—300 mg/m2 I.V. on day 1 every four weeks for six cycles. Cyclophosphamide—600 mg/m2 I.V. on day 1 every four weeks for six cycles. Intermittent courses of Paraplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.@@@@@@@Paraplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.@LABEL@No@@Advanced ovarian cancer previously treated with chemotherapy@@@III@APPROVED@@@NHI@Carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@BMS@@@@@BMS||||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@PARAPLATIN@@@@@PARAPLATIN||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@350842.06@350842.06@@1@0.0091@3506.48@4135@@@@@@@@@@@70.13@@@@@@@@@@@@@@@@8/30/2017@3506.48@3506.48@4291403A1088@INJECTION 5 ML@YEN@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan
14924304@Onco@@@@@300f1012ntsdm@@@@@@Patients received either Xeloda 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks) or IV bolus 5-FU 425 mg/m2 and 20 mg/m2 IV leucovorin on days 1 to 5, given as 4-week cycles for a total of 6 cycles (24 weeks). All patients with normal renal function or mild renal impairment began treatment at the full starting dose of 1250 mg/m2 orally twice daily. The starting dose was reduced in patients with moderate renal impairment (calculated creatinine clearance 30 to 50 mL/min) at baseline. Subsequently, for all patients, doses were adjusted when needed according to toxicity.@@L01BC06@L01B@YES@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924304@Xeloda is indicated for the treatment of, for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C), colon cancer@@YES@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@1987@1250 mg/m2 administered twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 14 days followed by a 7-day rest period. Adjuvant treatment inpatients with stage III colon cancer is recommended for a total of 6 months.@EMA, 22 February 2001@2/22/2001@@@@@Patients with moderate renal impairment at baseline require dose reduction. Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking Xeloda concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Xeloda can induce diarrhea, sometimes severe. Patients =80 years old may experience a greater incidence of grade 3 or 4 adverse events (diarrhea, nausea, hand-and-foot syndrome, and vomiting).  Xeloda may cause fetal harm when given to a pregnant woman.@LABEL@No@@PATIENTS WITH DUKES' C COLON CANCER WITH AT LEAST ONE POSITIVE LYMPH NODE AND TO HAVE UNDERGONE (WITHIN 8 WEEKS PRIOR TO RANDOMISATION) COMPLETE RESECTION OF THE PRIMARY TUMOR WITHOUT MACROSCOPIC OR MICROSCOPIC EVIDENCE OF REMAINING TUMOUR WERE RANDO@@@III@APPROVED@@@GKV@DFS was of 66% for the Xeloda treatment group compared to 62.9% for the 5-FU/LV treatment group. The hazard ratio for DFS for Xeloda compared to 5-FU/LV was 0.87 (95% C.I. 0.76 – 1.00). Because the upper 2-sided 95% confidence limit of hazard ratio was less than 1.20, XELODA was non-inferior to 5-FU/LV. The choice of the non-inferiority margin of 1.20 corresponds to the retention of approximately 75% of the 5-FU/LV effect on DFS. The comparison of overall survival did not reach statistical significance for the test of difference (HR 0.88, 95% C.I. 0.74 – 1.05; p = 0.169).@In Xeloda monotherapy for colon cancer in the adjuvant setting, the most common adverse events for all grades (>10%) in patients receiving either XELODA or 5-FU/LV (%;%) were hand-foot syndrome (60;9), diarrhea (47;65), nausea (34;47), stomatitis (22;60), fatigue (16;16), lethargy (16;15), vomiting (15;21), abdominal pain (14;16), asthenia (10;10), anorexia (9;11), constipation (9;11), and alopecia (6;22). Grade 3/4 adverse events (> 5%) in patients receiving either XELODA or 5-FU/LV were hand-foot syndrome (17;<1), diarrhea (12;14), stomatitis (2;14), andneutropenia(<1;5).@@@@ADJUVANT@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@DISEASE-FREE SURVIVAL@@@@@-@@@@@@@@@@MULTI-CENTRE@RANDOMISED@CONTROLLED@@@1.75@m²@2865.408896@@@24@week@24 week@2865.41@2865.41@17.06@60@1.1511@52.63@77.52@54.98@@@@@@@@@@@21@@mg/m²@2500@14@@@@@@@@@@@8/1/2017@0.88@0.88@410407@FILM-COATED TABLET@EURO@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16432243@Onco@@@@@300f1037ntsdm@@@@@RADIANT-4@Experimental: Participants will receive everolimus 10mg once daily until disease progression, intolerable toxicity, or consent withdrawalPlacebo Comparator: Matching placebo to everolimus with same dose@@L01XE10@L01X@@BASEL, SWITZERLAND@8/1/2017@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@16432243@Afinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease@Both@YES@@@NO REVIEW@@@@90%@@@NCT01524783@302@The recommended dose is 10 mg everolimus once daily. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.@EMA, 28 April 2016@4/28/2016@@No@@3/1/2012@@CRAD001T2302, 2011-002887-26@No@@Pathologically confirmed, well differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumor of GI or lung origin. No history of and no active symptoms related to carcinoid syndrome. In addition to treatmentnaive patients, patients previously treated with SSA, Interferon (IFN), one prior line of chemotherapy, and/or PRRT are allowed into the study. Pretreated patients must have progressed on or after the last treatment; Radiological documented disease progression within 6 months prior to randomization; Measurable disease; WHO performance status ≤1; Adequate bone marrow, liver and renal function@@ADULTS@III@APPROVED@@@SNS@@@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@AFINITOR@@@@@AFINITOR||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@1@1@56511.00121@@@11@month@11 month@56511@56511@168.9@30@1.1511@2533.55@2693.04@2541.09@@@@@@@@@@16.89@1@@mg@10@1@@@@@@@@@@@8/4/2017@84.45@84.45@663792@TABLET@EURO@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
16671843@Onco@@@@@300f1010ntsdm@@@@@@Biological: cetuximabProcedure: quality-of-life assessment@@L01XC06@L01X@@NEW YORK, NEW YORK@3/1/2006@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671843@Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.@Both@YES@@@@@@@100%@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@THIRD-LINE@NCT00079066@572@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 18 December 2013@12/18/2013@@No@@8/1/2003@@CO17, CAN-NCIC-CO17, AGITG-CAN-NCIC-CO17, BMS-CA225-025, IMCL-CAN-NCIC-CO17, CDR0000353486@No@@@(EGFR)-expressing, RAS WILD-TYPE@ADULTS@III@APPROVED@@@NHS@@@@@@MONO@CETUXIMAB@@@@@CETUXIMAB||||@IMCLONE@MERCK SERONO@@@@|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@OVERALL SURVIVAL@@@@@TIME TO PROGRESSION@OBJECTIVE RESPONSE RATE@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@@@@1.75@m²@12994.5322@@@3.7@month@3.7 month@12994.53@12994.53@115.47@1@1.299@890.5@@@@@@@@@@@@1.78@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@7/28/2017@890.5@890.5@1.15E+16@SOLUTION - INFUSION 100 ML@GB£@@@@@@@@500@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
16733479@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Pembrolizumab Q2W. Participants receive pembrolizumab, 10 mg/kg intravenously (IV), Q2W for up to 2 years. With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.Experimental: Pembrolizumab Q3W. Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years. With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.Active Comparator: Ipilimumab. Participants receive ipilimumab, 3 mg/kg IV Q3W for a total of 4 doses.@@L01XC18@L01X@@WHITEHOUSE STATION, NEW JERSEY@3/24/2015@@KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking  antibody indicated for the treatment of patients with unresectable or  metastatic melanoma and disease progression following ipilimumab  and, if BRAF V600 mutation positive, a BRAF inhibitor.@@16733479@The US Food and Drug Administration (FDA) expanded the label to include the approval of pembrolizumab (Keytruda® Injection, Merck Sharp & Dohme Corp.) for the treatment of patients with unresectable or metastatic melanoma. This expansion now includes the initial treatment of patients with unresectable or metastatic melanoma with pembrolizumab.@Both@NA@@@NO REVIEW@@@@@@FIRST-LINE@NCT01866319@834@200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity@FDA, 18 December 2015@12/18/2015@@Yes@@8/28/2013@@3475-006; 2012-004907-10 (EudraCT Number)@No@@Histologically-confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy (excluding uveal or ocular melanoma); At least one measurable lesion; No prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma (first line) or one prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma (second line); Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Archived tissue sample or new biopsy sample; Female participants of childbearing potential must agree to use effective contraception from Visit 1 to 120 days after the last dose of study drug; male participants must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug@@ADULTS@III@APPROVED@@@NA@The trial enrolled 834 patients with unresectable or metastatic melanoma who had not received ipilimumab and who had received no more than one line of prior systemic therapy. Patients were randomized (1:1:1) to pembrolizumab 10 mg/kg intravenously every 2 weeks (Q2W), or pembrolizumab 10 mg/kg every 3 weeks (Q3W), or to ipilimumab 3 mg/kg intravenously Q3W for up to 4 doses. Patients treated with pembrolizumab were treated until disease progression.  The trial met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) as assessed by a blinded independent central review (BICR) per RECIST v1.1.  The pembrolizumab 10 mg/kg Q2W and Q3W arms demonstrated statistically significant improvements in OS compared to the ipilimumab arm with hazard ratios (HR) of 0.63 (95% CI: 0.47, 0.83; p<0.001) and 0.69 (95% CI: 0.52, 0.90; p=0.004), respectively.  Median OS was not reached in either pembrolizumab arm.  As compared to the ipilimumab arm, a significant improvement in PFS was observed in the pembrolizumab 10 mg/kg Q2W and Q3W arms with HR of 0.58 [95% CI 0.46, 0.72]; p<0.001 and 0.58 [95% CI: 0.47, 0.72]; p<0.001, respectively.  Median PFS was 5.5 and 4.1 months in the pembrolizumab 10 mg/kg Q2W and Q3W arms, respectively, and was 2.8 months in the ipilimumab arm.  The overall response rates were 34 %, 33 %, and 12% for patients in the pembrolizumab 10 mg/kg Q2W, 10 mg/kg Q3W, and ipilimumab arms, respectively. Median response durations were not reached for any treatment arm. [FDA, http://wayback.archive-it.org/7993/20170111231607/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm]@Safety data was evaluated in 1567 patients with unresectable or metastatic melanoma who received pembrolizumab at 2 mg/kg Q3W, or 10 mg/kg delivered either Q2W or Q3W. The most serious risks of pembrolizumab are immune-mediated adverse reactions (imARs), including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. Other clinically significant imARs included arthritis, exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and inflammatory foci in brain parenchyma resulting in partial seizures.  The most common adverse events reported included fatigue, pruritus, rash, constipation, nausea, diarrhea, and decreased appetite. [FDA, http://wayback.archive-it.org/7993/20170111231607/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm]@@@@MONO@PEMBROLIZUMAB@@@@@PEMBROLIZUMAB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@KEYTRUDA@@@@@KEYTRUDA||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@PROGRESSION FREE SURVIVAL@OVERALL SURVIVAL@@@@OVERALL RESPONSE RATE@@@@@UNRESECTABLE@METASTATIC@@@@RANDOMIZED@PARALLEL ASSIGNMENT@NO MASKING@@@1@1@52028.83906@@@4.1@month@4.1 month@52028.84@52028.84@417.21@1@1@2190.37@@@@@@@@@@@@43.81@21@@mg@200@1@@@@@@@@@@@8/2/2017@2190.37@2190.37@00006-3029-02@POWDER FOR INJECTION@US$@@@@@@@@50@MG@50 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14918346@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@N02AB03@N02A@YES@GERMANY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14918346@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@The initial Durogesic DTrans dose should be based on the patient's opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.@@@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@ABZ PHARMA@@@@@ABZ PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@17.66@33.31@18.91@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@3.53@3.53@2239685@PATCH (MATRIX)@EURO@@@@@@@@25@MCG@25 MCG/HOUR@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16398344@Onco@@@@@300f1012ntsdm@@@@@@@@L01XX24@L01X@@@@@Oncaspar is the only FDA-approved pegylated formulation of L-asparaginase, the enzyme that depletes the amino acid asparagine. For the last 25 years, L-asparaginase has been an important component in the treatment of acute lymphoblastic leukemia (ALL). While normal cells can produce asparagine, leukemic cells are unable to produce enough asparagine to survive on their own.  L-asparaginase is given to ALL patients to ensure depletion  of asparagine that is circulating in the blood.2 Depletion (starving the leukemic cells) of asparagine ultimately results in leukemic cell death.  Oncaspar allows patients to gain the full benefits of asparaginase therapy with enhanced patient convenience over native L-asparaginase (nonpegylated form). Through the process of pegylation, the half-life of L-asparaginase is significantly increased 1,2,4  and the L-asparaginase activity is sustained.@@16398344@Indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@118@The recommended dose of Oncaspar in patients with a body surface area ≥0.6 m2 and who are ≤21 years of age is 2500 U (equivalent to 3.3 ml Oncaspar)/m² body surface area every 14 days.Children with a body surface area <0.6 m² should receive 82.5 U (equivalent to 0.1 ml Oncaspar)/kg body weight every 14 days.@EMA, 14 January 2016@1/14/2016@@Yes@@@@@No@@118 PEDIATRIC PATIENTS AGED 1 TO 9 YEARS WITH PREVIOUSLY UNTREATED STANDARD-RISK ALL WERE RANDOMISED 1: I TO ONCASPAR OR NATIVE E. COLI L-ASPARAGINASE AS PART OF COMBINATION THERAPY.@PAEDIATRIC@@@APPROVED@@@GKV@Patients treated with pegaspargase had more rapid clearance of lymphoblasts from day 7 and day 14 bone marrow aspirates and more prolonged asparaginase activity than those treated with native asparaginase. In the first delayed intensification phase, 26% of native asparaginase patients had high-titer antibodies, whereas 2% of pegaspargase patients had those levels. High-titer antibodies were associated with low asparaginase activity in the native arm, but not in the pegaspargase arm. Adverse events, infections, and hospitalization were similar between arms. Event-free survival at 3 years was 82%. [Blood.  2002 Mar 15;99(6):1986-94; http://www.ncbi.nlm.nih.gov/pubmed/11877270]@@@@@COMBO@PEGASPARGASE@@@@@PEGASPARGASE||||@BAXALTA@@@@@BAXALTA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@ONCASPAR@@@@@ONCASPAR||||@Enzyme@@@@@Enzyme||||@@@@@@@@@@@@@@@@OPEN-LABEL@MULTI-CENTRE@RANDOMISED@ACTIVE CONTROL@@1.2@m²@34413.74@@@12@month@12 month@34413.74@34413.74@94.29@1@1.1511@1650.01@2079.73@1688.51@@@@@@@@@@@14@@IU/m²@2500@1@@@@@@@@@@@8/1/2017@1650.01@1650.01@11643103@SOLUTION FOR INFUSION/INJECTION (VIAL) - 5 ML@EURO@@@@@@@@3750@IU@3750 IU@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
15109297@Onco@@@@@300f1020ntsdm@@@@@@-@@L01XE13@L01X@-@INGELHEIM, GERMANY@1/1/2012@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.@@15109297@GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).@@YES@26-Nov-14@11/26/2014@NO REVIEW@@@@@-@FIRST-LINE@NCT00949650@331@Recommended dose: 40 mg orally, once daily. Treatment should be continued until disease progression or until no longer tolerated by the patient.@EMA, 25 September 2013@9/25/2013@@NO@@8/1/2009@-@LUX-Lung 3@No@-@Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology. EGFR mutation detected by central laboratory analysis of tumour biopsy material.@@@III@APPROVED@@-@SSN@Data from LUX-Lung 3 has shown that patients taking afatinib as a first-line treatment lived for almost one year without their tumour growing again (median progression-free survival (PFS) of 11.1 months) versus just over half a year (PFS of 6.9 months) for those treated with pemetrexed/cisplatin. In addition, NSCLC patients with tumours harbouring the two most common EGFR mutations (Del19 or L858R) taking afatinib lived for well over a year without tumour progression (PFS of 13.6 months) versus just over half a year (PFS of 6.9 months) for those in the comparator arm.1In addition, patients taking afatinib also experienced an improvement in lung cancer symptoms and a better quality of life compared to those receiving standard chemotherapy treatment.[BI, 15 July 2013, http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/15_july_2013_oncology.html ]Trial registered [BI, 29.07.2009]@The most common grade 3 drug-related adverse events observed in the afatinib treatment arm were diarrhoea (14%), rash (16%), and inflammation of the nail bed (paronychia) (11%). The most common drug-related grade 3 adverse events observed in the chemotherapy arm (pemetrexed/cisplatin) were neutropenia (15%), fatigue (13%), and leucopenia (8%). There was a low discontinuation rate associated with treatment-related adverse events in the trial (8% discontinuation rate for afatinib; 12% for chemotherapy). One percent of patients in the afatinib arm discontinued due to drug-related diarrhoea.@@@@MONO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GIOTRIF@@@@@GIOTRIF||||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@PROGRESSION-FREE SURVIVAL@@@@@OBJECTIVE RESPONSE@DISEASE CONTROL@QUALITY OF LIFE@@@LOCALLY ADVANCED@METASTATIC@@@@PARALLEL ASSIGNMENT@@@@@1@1@51895.2013@@@11.1@month@11.1 month@51895.2@51895.2@153.71@28@1.1229@2151.94@3551.56@2248.8@@@@@@@@@@3.84@1@@mg@40@1@@@@@@@@@@@6/7/2017@76.86@76.86@43023035@FILM COATED TABLET@EURO@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
15116544@Onco@@@@@300f1012ntsdm@@@@@AVF4095g@Arm A: carboplatin, gemcitabine and Avastin for 6 months followed by maintenance Avastin; Arm B: carboplatin, gemcitabine and placebo for 6 months followed by maintenance placebo. Avastin dose is 15mg/kg every 3 weeks.@@L01XC07@L01X@-@BASEL, SWITZERLAND@8/1/2009@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@15116544@Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primaryperitoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@SECOND-LINE@NCT00434642@487@Avastin is administered in combination with carboplatin and gemcitabine for 6 cycles and up to 10 cycles followed by continued use of Avastin assingle agent until disease progression.The recommended dose of Avastin is 15 mg/kg of body weightgiven once every 3 weeks as an intravenous infusion.@EMA, 24 October 2012@10/24/2012@@@@4/1/2007@@@No@@@@@AVF4095G@APPROVED@@@GKV@The study met its primary endpoint of progression-free survival. The study showed that women who received a combination of Avastin and chemotherapy followed by the continued use of Avastin alone, lived longer without their disease worsening (progression-free survival or PFS), compared to women who received chemotherapy alone. No new safety findings were observed and adverse events were consistent with those seen in previous pivotal trials of Avastin. Full data from the OCEANS study will be submitted for presentation at an upcoming medical meeting. [Roche 8 February 2011 http://www.roche.com/media/media_releases/med-cor-2011-02-08.htm ]RESULTS PENDING@@@@@COMBO@BEVACIZUMAB@GEMCITABINE@CARBOPLATIN@@@BEVACIZUMAB|GEMCITABINE|CARBOPLATIN||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@AVASTIN@GEMZAR@@@@AVASTIN|GEMZAR|||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RECURRENT@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@60@kg@58962.78907@@@12.4@month@12.4 month@58962.79@58962.79@156.33@1@1.1511@364.78@472.18@376.97@@@@@@@@@@3.65@21@@mg/kg@15@1@@@@@@@@@@@8/1/2017@364.78@364.78@3159646@CONCENTRATE FOR INFUSION SOLUTION, 4 ML@EURO@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920345@Onco@@@@@300f1015ntsdm@@@@@@77 patients were treated at a starting dose of 400 mg, the remaining 158 patients started at 600 mg.@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920345@Indicated for the treatment of adult patients with Ph+ CML in accelerated phase@@NO@@@NO REVIEW@@@@@@@@235@The recommended dosage of Glivec is 600 mg/day for adult patients in accelerated phase CML. Treatment with Glivec continued until disease progression.@2-Feb@@11/22/2004@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@@PATIENTS WITH ACCELERATED PHASE DISEASE MET ONE OR MORE OF THE FOLLOWING CRITERIA: =15%-<30% BLASTS IN PB OR BM; =30% BLASTS + PROMYELOCYTES IN PB OR BM; =20% BASOPHILS IN PB; AND <100 X 109/L PLATELETS.@ADULT@@II; INTERNATIONAL, OPEN-LABEL, SINGLE-ARM STUDY CONDUCTED TO DETERMINE THE SAFETY AND EFFICACY OF GLEEVEC IN ACCELERATED PHASE DISEASE@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RRs in accelerated phase CML were higher for the 600-mg dose group than for the 400-mg group: haematologic response (75% vs. 64%), confirmed and unconfirmed major cytogenetic response (31% vs. 19%). Results for all 235 patients: CHR = 71% ; Major cytogenetic response = 21%@The majority of Gleevec-treated patients experienced adverse reactions at some time. Most reactions were of mild-to-moderate grade, but drug was discontinued for drug-related adverse reactions in 2.4% of newly diagnosed patients, 4% of patients in chronic phase after failure of interferon-alpha therapy, 4% in accelerated phase and 5% in blast crisis. The most frequently reported drug-related adverse reactions were edema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhea and rash. Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec. The frequency of severe superficial edema was 1.5%-6%. The overall safety profile of pediatric patients treated with Gleevec in 93 children studied was similar to that found in studies with adult patients, except that musculoskeletal pain was less frequent (20.5%) and peripheral edema was not reported. Nausea and vomiting were the most commonly reported individual adverse reactions with an incidence similar to that seen in adult patients. Although most patients experienced adverse reactions at some time during the study, the incidence of Grade 3/4 adverse reactions was low.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@ACCELERATED PHASE@@@@@INTERNATIONAL@OPEN-LABEL@SINGLE-ARM@@@1@1@73000.84171@@@22.9@month@22.9 month@73000.84@73000.84@104.81@30@1.1511@2096.14@2270.33@2126.14@@@@@@@@@@0.17@1@@mg@600@1@@@@@@@@@@@8/1/2017@69.87@69.87@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16387409@Onco@@@@@300f1037ntsdm@@@@@@@@L01XC07@L01X@@BASEL, SWITZERLAND@2/1/2013@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@16387409@Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix@Female@YES@@@NO REVIEW@@@@@@@NCT00803062@452@Avastin is administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin or paclitaxel and topotecan.The recommended dose of Avastin is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.It is recommended that treatment be continued until progression of the underlying disease or untilunacceptable toxicity@EMA, 30 March 2015@3/30/2015@@No@@4/1/2009@@NCI-2009-01084, NCI-2009-01084, CDR0000628746, GOG-0240, GOG-0240, U10CA180868, U10CA027469@No@@@@Adult@III@APPROVED@@@SNS@@@@@@@BEVACIZUMAB@PACLITAXEL@CISPLATIN/TOPOTECAN@@@BEVACIZUMAB|PACLITAXEL|CISPLATIN/TOPOTECAN||@ROCHE@@@@@|ROCHE|||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@TUMOUR RESPONSE@@@PROGRESSION-FREE SURVIVAL@@@@@RECURRENT@METASTATIC@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@60@kg@36970.99127@@@8.3@month@8.3 month@36970.99@36970.99@146.45@1@1.1511@341.71@408.32@349.25@@@@@@@@@@3.42@21@@mg/kg@15@1@@@@@@@@@@@8/4/2017@341.71@341.71@650602@INTRAVENOUS  INJECTION, 4 ML@EURO@@@@@@@@100@MG@25 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
15399690@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ixazomib + Lenalidomide + Dexamethasone: patients will receive single oral dose of ixazomib (4.0mg) on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progressionPlacebo + Lenalidomide + Dexamethasone: Patients will receive single oral dose of Placebo on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days until disease progression@@L01XX50@L01X@@CAMBRIDGE, MASSACHUSSETTS@10/1/2015@@Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.@@15399690@Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.@Both@NA@@@NO REVIEW@@@@@>> Takeda acquisition of Millennium completed. [Millennium, 14 May 2008]       >> Takeda acquired Millennium Pharma on 10 April 2008 in a US$8.8 bil. deal. Millennium Pharma will continue to operate as a standalone unit. [Takeda, 10 April 2008]       >> Ortho Biotech and Janssen-Cilag pay double-digit royalties and other milestones.@SECOND-LINE@NCT01564537@837@The recommended starting dose of NINLARO is 4 mg administered orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle.The recommended starting dose of lenalidomide is 25 mg administered daily on Days 1 through 21 of a 28-day treatment cycle.The recommended starting dose of dexamethasone is 40 mg administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle.Treatment should be continued until disease progression or unacceptable toxicity.@FDA, 20 November 2015@11/20/2015@@Yes@@8/1/2012@@C16010@No@@Multiple myeloma diagnosed according to standard criteria either currently or at the time of initial diagnosis NOTE: The initial diagnosis must be symptomatic MM, although the relapsed disease does not need to be symptomatic.Patients must have measurable disease defined by at least 1 of the following 3 measurements: • Serum M-protein ≥ 1 g/dL ( ≥10 g/L). • Urine M-protein ≥ 200 mg/24 hours. • Serum free light chain assay: involved free light chain level ≥ 10 mg/dL ( ≥ 100 mg/L), provided that the serum free light chain ratio is abnormal. Patients with relapsed and/or refractory MM who have received 1 to 3 prior therapies. NOTE: This patient population includes the following 3 categories of patients: • Patients who relapsed from their previous treatment(s) but were not refractory to any previous treatment. • Patients who were refractory to all lines of previous treatment(s) (ie, patients who have never responded to any therapies received). • Patients who were relapsed from at least 1 previous treatment AND additionally were refractory to at least 1 previous treatment. For the purposes of this study, refractory disease is defined as disease progression on treatment or progression within 60 days after the last dose of a given therapy. A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation, followed by maintenance is considered 1 line of therapy. Autologous and allogenic transplants are permitted.@@ADULTS@III@APPROVED@@@@The trial showed a statistically significant improvement in PFS. The median PFS on the combination arm of ixazomib, lenalidomide and dexamethasone was 20.6 months (95% CI: 17.0, NE) compared to a median PFS of 14.7 months (95% CI: 12.9, 17.6) on the combination arm of placebo, lenalidomide and dexamethasone (PFS HR 0.74, 95% CI: 0.59, 0.94; p value=0.012).[FDA, 20 November 2015, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm473804.htm]@The more common (>20%) adverse reactions associated with an increased rate on the ixazomib combination arm compared to the placebo combination arm were diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea, peripheral edema, vomiting, and back pain.[FDA, 20 November 2015, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm473804.htm]@@@@COMBO@IXAZOMIB@LENALIDOMIDE@DEXAMETHASONE@@@IXAZOMIB|LENALIDOMIDE|DEXAMETHASONE||@MILLENNIUM PHARMACEUTICALS@TAKEDA PHARMACEUTICAL@@@@MILLENNIUM PHARMACEUTICALS|TAKEDA PHARMACEUTICAL|||@United States@Australia@Austria@Japan@Netherlands@United States|Australia|Austria|Japan|Netherlands|Turkey|United Kingdom|France|Germany|Israel@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@NINLARO@REVLIMID@GENERIC@@@NINLARO|REVLIMID|GENERIC||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@OVERALL RESPONSE RATE@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@368469.6256@@@20.6@month@20.6 month@368469.63@368469.63@588.07@3@1@9468@@@@@@@@@@@@1372.17@28@@mg@4@3@@@@@@@@@@@8/2/2017@3156@3156@63020-0078-02@CAPSULE (UNIT-DOSE BLISTER)@US$@@@@@@@@2.3@MG@2.3 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921725@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@One-way and 2-way sensitivity analyses were conducted to examine the effect of uncertainty in our model parameters on the estimates. Sensitivity analyses for rates estimated from time-to-event curves were conducted using data points 10% before and after the original point estimate. For example, if the observed survival at 60 months was the original point estimate, survival at 54 and 66 months for the sensitivity analyses were used. For other proportions and continuous variables, the investigators used ± 20% of the expected value. Finally, because they considered ABMT to be a unique decision point in the model, they assessed the effect of having a more durable third remission, as might be expected with ABMT, and less durable, as might be expected with radioimmunotherapy.@@L01XC02@L01X@-@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@14921725@Cost-Effectiveness of Extended Adjuvant Rituximab for US Patients Aged 65-70 Years with Follicular Lymphoma in Second Remission@@-@-@@-@@@@-@-@-@-@-@-@-@@@-@@@-@COST-EFFECTIVENESS@@>> Sanofi-Aventis files litigation proceedings against Biogen and Genentech over patent infringement after Genentech ceased licensing deal with Sanofi-Aventis. [sanofi-aventis, 5.11.2008]    >> Patent Expiration: 2018@Study was restricted to US patients aged 65-70 years (the age range with the most cases of FL5) in their second remission from FL.@@@-@-@@-@-@Disease-free and OS estimates for patients with FL aged 65-70 years in their second remission were calculated for patients treated with extended adjuvant rituximab and observation. After 5 years, DFS is expected to be 47% and 22%, and OS is estimated to be 73% and 61% for extended adjuvant rituximab and observation, respectively, during the second remission. Thediscounted incremental cost-effectiveness ratio (ICER) for the addition of adjuvant rituximab is estimated to be $19,522/QALY gained. The unadjusted ICER is $16,586/QALY gained.One-way and 2-way sensitivity analyses were completed to assess the stability of the model. Using the actual RFS rates reported 10% before and after 4 years since randomisation, thedifference in OS is smaller. The adjuvant and observation groups are expected to have 39% and 32% survival rates, respectively, under these assumptions. In contrast, the originalmodel assumed 60% and 32% DFS after 4 years of follow-up. This smaller benefit in DFS translated to an adjusted ICER of $181,105, which is higher than values generally accepted as cost-effective in the United States. The lowest (most costeffective regimen) ICER, $6,991, was predicted if the cost of the rituximab was decreased by 20%. Another important variable was the proportion of patients choosing further aggressive salvage therapy after their second relapse.  Because previously published data is not available, the authors relied upon expert opinion to estimate that 80% of patients in this age range would choose and be eligible for further aggressive treatments. However, if 96% of patients undergo further therapy, the ICER increases to $32,381, while if only 64% are able to take further aggressive therapy, the ICER declines to $12,576. Finally, the durability of the third remission also affects the ICER. Patients with longer subsequent remissions, as might be expected with ABMT, have an increased ICER to $32,066, while patients with shorter subsequent remissions, as might be expected with radioimmunotherapy, have a decreased ICER of $11,093. A lower DFS rate and more patients choosing further aggressive treatments resulted in the most expensive 2-way analysis, with an ICER of $258,833/QALY. Conversely, if 20% less was spent for the rituximab and subsequent remissions are less durable, then the model becomes dominant, and adjuvanttreatment is both less expensive and improves health. SOURCE: Clinical Lymphoma & Myeloma, Vol. 8, No. 3, 166-170 2008.@-@@@@ADJUVANT@RITUXIMAB@@@@@RITUXIMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Follicular lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Follicular lymphoma|||||||@RITUXAN@MABTHERA@@@@RITUXAN|MABTHERA|||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@COST-EFFECTIVENESS@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924057@Onco@@@@@300f1010ntsdm@@@@@@Patients will receive 6x monthly cycles of combination treatment (MabThera and chlorambucil), after up to 6 cycles of chlorambucil alone. MabThera will be administered on day 1 of each cycle, at a dose of 375mg/m2 IV in cycle 1, and 500mg/m2 in subsequent cycles, and chlorambucil will be administered on days 1-7 of each cycle at a dose of 10mg/m2/day po. @@L01XC02@L01X@-@BASEL, SWITZERLAND@@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin’s lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@14924057@Previously untreat patients with B-cell chronic lymphocytic leukemia@@-@-@@NO REVIEW@@@@-@-@-@NCT00532129@<100@-@-@@@-@@9/1/2007@-@-@@-@<100 previously untreated patients with CD20-positive B-Cell Chronic Lymphocytic Leukemia @@@II@II@@-@-@Trial registered. SOURCE: Roche, 18 September 2007@-@@@@-@RITUXIMAB@@@@@RITUXIMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@RITUXAN@@@@@RITUXAN||||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923209@Onco@@@@@300f1012ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14923209@Sprycel is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. It is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@78@The recommended starting dosage for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ALL is 70 mg twice daily administered orally, one tablet in the morning and one in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@EMA, 20 November 2006@11/20/2006@@Yes@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-0015@No@@42 with blastic phase and 36 with PH+ disease@@@II@APPROVED@@@GKV@The MaHR rate was 59% in accelerated phase patients, 32% in myeloid phase patients, 31% in lymphoid blast phase patients, and 42% in Ph+ ALL patients. The median durations of major haematologic response were 3.7 months in lymphoid blast CML and 4.8 months in Ph+ ALL.@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@25852.62669@@@4@month@4 month@25852.63@25852.63@212.49@30@1.1511@4553.4@5638.42@4591.9@@@@@@@@@@1.52@1@@mg@140@1@@@@@@@@@@@8/1/2017@151.78@151.78@4658392@FILM-COATED TABLET@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
16749820@Onco@@@@@300f1010ntsdm@@@@@@Experimental: Fludarabine+Cyclophosphamide+Rituximab (FCR) Active Comparator: Fludarabine+Cyclophosphamide (FC)@@L01XC02@L01X@@@5/29/2013@@Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Mechanism of Action: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line. Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.@@16749820@in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL@Both@NO@@@@@@@100%@@SECOND-LINE@NCT00090051@552@@EMA, 17 February 2017@2/17/2017@@No@@8/23/2004@@102-14. BO17072@No@@Age ≥18 years; Established diagnosis of B-cell CLL by NCI Working Group criteria; ≤1 previous line of chemotherapy; Expected survival >6 months; Acceptable hematologic status, liver function, renal function, and pulmonary function; Negative serum pregnancy test for both pre-menopausal women and for women who are < 2 years after the onset of menopause; Written informed consent@@ADULTS@Phase III@APPROVED@@28 July 2010: Recommended. [NICE, https://www.nice.org.uk/guidance/ta193/chapter/1-Guidance]@NHS@Trial successfully met its primary endpoint by showing that patients treated with MabThera in combination with the current standard chemotherapy achieved a significant improvement in progression free survival, compared to patients treated with chemotherapy alone; PFS increased by 35%. SOURCE: Roche, 25 January 2008@@@@@COMBO@RITUXIMAB@FLUDARABINE@CYCLOPHOSPHAMIDE@@@RITUXIMAB|FLUDARABINE|CYCLOPHOSPHAMIDE||@NAPP@@@@@NAPP||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@TRUXIMA@FC@@@@TRUXIMA|FC|||@mAb@Chimeric@CD20@@@mAb|Chimeric|CD20||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1.75@m²@7858.4@@@168@day@168 day@7858.4@7858.4@46.78@1@1.299@785.84@@@@@@@@@@@@1.57@29@1@mg/m²@375@1@28@@mg/m²@500@1@@@@@@7/28/2017@785.84@785.84@3.42E+16@SOLUTION FOR INFUSION (VIAL) - 50 ML@GB£@@@@@@@@500@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922727@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home. In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@@@KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals. Published data suggest that the Akt pathway is frequently activated in renal cell cancer and that this tumor type may be particularly responsive to Akt inhibition.@@14922727@-@@-@-@@NO REVIEW@@@@-@Keryx receives notice from Nasdaq that the company is not in compliance with the US$1 minimum bid price for continued listing and most reach this within 180 days. SOURCE: Keryx, 28 April 2008Keryx in-licensed North American rights for perifosine from Ae@SECOND-LINE@NCT00590954@N/A@-@-@@@-@@@-@06-044@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@PERIFOSINE@@@@@PERIFOSINE||||@KERYX BIOPHARMACEUTICALS@AETERNA ZENTARIS@@@@KERYX BIOPHARMACEUTICALS|AETERNA ZENTARIS|||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@KRX-0401@@@@@KRX-0401||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14920113@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@185 patients on 90mg pamidronate (unfused over 2 hours every 3 to 4 weeks for 24 months) compared to 197 patients on placebo.@@M05BA03@M05B@NO@BEDFORD, OHIO@@@Pamidronate disodium is a potent inhibitor of osteoclastic bone resorption. It binds strongly to hydroxyapatite crystals and inhibits the formation and dissolution of these crystals in vitro. Inhibition of osteoclastic bone resorption in vivo may be at least partly due to binding of the drug to the bone mineral. Pamidronate suppresses the accession of osteoclast precursors onto the bone. However, the local and direct antiresorptive effect of bone-bound bisphosphonate appears to be the predominant mode of action in vitro and in vivo. Experimental studies have demonstrated that pamidronate inhibits tumour-induced osteolysis when given prior to or at the time of inoculation or transplantation with tumour cells. Biochemical changes reflecting the inhibitory effect of Aredia on tumour-induced hypercalcaemia, are characterised by a decrease in serum calcium and phosphate and secondarily by decreases in urinary excretion of calcium, phosphate, and hydroxyproline.@@14920113@Hypercalcemia of Malignancy: in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget's Disease: Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget's disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase = 3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget's disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by = 50% in at least 50% of patients, and by = 30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget's disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma: Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated.@@NO@@@NO REVIEW@@@@@@@@382@The recommended dose of pamidronate disodium in patients with osteolytic bone lesions of multiple myeloma is 90 mg administered as a 4-hour infusion given on a monthly basis. Patients with marked Bence-Jones proteinuria and dehydration should receive adequate hydration prior to pamidronate disodium infusion.The recommended dose of pamidronate disodium inpatients with osteolytic bone metastases is 90 mg administered over a 2-hour infusion given every 3 to 4 weeks. Pamidronate disodium has been frequently used with doxorubicin, fluorouracil, cyclophosphamide, methotrexate, mitoxantrone, vinblastine, dexamethasone, prednisone, melphalan, vincristine, megesterol, and tamoxifen. It has been given less frequently with etoposide, cisplatin, cytarabine, paclitaxel, and aminoglutethimide.@@@@@@@Due to risk of significant deterioration in renal function which can progress to renal failure, single doses of pamidronate should not exceed 90mg. Bisphosphonates have been associated with renal toxicity. Serum creatinine should be assessed before treatment.@LABEL@No@5-Oct@@@@@APPROVED@@@MEDICARE@The complete + partial response rate was 33% in pamidronate disodium patients and 18% in placebo patients treated with chemotherapy (P=.001). No difference was seen between pamidronate disodium and placebo in hormonally-treated patients. Any SRE rate was 46% in chemo patients and 55% in hormonal therapy. ECOG PS was +0.81 and +0.95 in the pamidronate chemo and hormonal therapy patients respectively, compared to +1.19 and +0.90 on placebo.@@@@@MONO@PAMIDRONATE DISODIUM@@@@@PAMIDRONATE DISODIUM||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Bone Metastases@Myeloma@Breast Cancer@@@Bone Metastases|Myeloma|Breast Cancer|||||||@GENERIC@@@@@GENERIC||||@Bisphosphonate@@@@@Bisphosphonate||||@SKELETAL-RELATED EVENTS@RESPONSE RATE@@@@@@@@@@@@@@DOUBLE-BLIND@RANDOMISED@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION FOR PERFUSION@US$@@@@@@@@30@MG@3 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15048225@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ponatinib: 45 mg tablet taken orally once daily@@L01XE24@L01X@YES@CAMBRIDGE, MASSACHUSSETTS@10/1/2020@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@15048225@Treatment of adult patients with T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.@@NA@@@NO REVIEW@@@@@@@NCT01207440@440@@FDA, 14 December 2012@12/14/2012@@Yes@@9/1/2010@Arterial ThrombosisHepatoxicity@PACE@No@@@@@II@APPROVED@@@NA@showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to prior tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD's ongoing Phase 3 EPIC trial comparing ponatinib to imatinib in newly diagnosed chronic-phase CML patients. [Ariad, 30 August 2012, http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1730090&highlight= ]@The US FDA investigates reports of serious and life-threatening blood clots in patients taking Iclusig[FDA, 11 October 2013, http://www.fda.gov/Drugs/DrugSafety/ucm370945.htm ]The most common side effects observed in the study to date were consistent with the known safety profile of ridaforolimus and included stomatitis (e.g., mouth sores), fatigue, diarrhea and thrombocytopenia.@@@@MONO@PONATINIB@@@@@PONATINIB||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@@@@@@OPEN LABEL@SINGLE-ARM@@@@1@1@44714.69997@@@81@day@81 day@44714.7@44714.7@552.03@30@1@16561@@@@@@@@@@@@12.27@1@@mg@45@1@@@@@@@@@@@8/2/2017@552.03@552.03@76189-0534-30@TABLET@US$@@@@@@@@45@MG@45 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14917999@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@N02AB03@N02A@YES@NEW BRUNSWICK, NEW JERSEY@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14917999@Management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.@@NO@@@NO REVIEW@@@@@Manufactured by Alza and distributed by Janssen Pharmaceutica Products (both subsidiaries of J&J)@@@@Each patch can be worn for 72 hours, and the next patch should be applied to a different skin site. Dosing is individualised according to WHO scale, with daily dosing ranging from 25mcg/h to 100mcg depending on the dosage of the previous analgesic. Please refer to label for scale.@FDA, 7 August 1990@8/7/1990@@@@@Using damaged or cut patches can lead to the rapid release of the contents of the patch and absorption of a potentially fatal dose of fentanyl. It should be administered to children only if they are opioid-tolerant and 2 years of age or older. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Death and other serious medical problems have occurred when people were accidentally exposed to it. It has been reported as being abused by other methods and routes of administration. Respiratory depression is the chief hazard of opioid agonists, including fentanyl. Respiratory depression is more likely to occur in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration. Duragesic should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. The concomitant use of Duragesic with other central nervous system depressants, including but not  limited to other opioids, sedatives, hypnotics, tranquilisers (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation or potentially result in coma. The concomitant with potent cytochrome P450 3A4 inhibitors (ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.@NO LABELLED TRIAL@No@6-Nov@@@@@APPROVED@@Covered; non-preferred; quantity limit 20 for 30 days@MEDICARE@NO LABELLED TRIAL@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@JOHNSON & JOHNSON@JANSSEN CILAG@@@@JOHNSON & JOHNSON|JANSSEN CILAG|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@DURAGESIC@@@@@DURAGESIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1@198.17@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@39.63@39.63@50458-0091-05@TRANSDERMAL PATCH - 3.75 CM²@US$@@@@@@@@25@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16384151@Onco@@@@@300f1037ntsdm@@@@@@Ibrutinib: 560 mg once dailySOURCE: clinicaltrials.gov@@L01XE27@L01X@@BEERSE, BELGIUM@3/1/2014@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16384151@Indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).@@YES@14-Apr-16@4/14/2016@NO REVIEW@@@@@@@NCT01236391@115@560 mg taken orally once daily (four 140 mg capsules once daily)@EMA, 21 October 2014@10/21/2014@1/11/2016@Yes@@2/1/2011@@PCYC-1104-CA@No@@@@@II@APPROVED@@The AEMPS has recommended Imbruvica as another therapeutic option for the refractory or relapsed condition, depending on patients [http://www.redaccionmedica.com/contenido/images/IPTibrutinibimbrubicaLCM.pdf]@SNS@Efficacy results demonstrated a 65.8% overall response rate (95% CI: 56.2, 74.5); 17% of patients achieved a complete response and 49% of patients achieved a partial response.  The median duration of response was 17.5 months (95% CI: 15.8, not reached). [Pharmacyclics, 13 November 2013, http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=807003@Safety was evaluated in the same 111 patients. The most common Grade 3 or 4 nonhematological adverse reactions (greater than or equal to 5%) were: pneumonia (7%), abdominal pain (5%), atrial fibrillation, diarrhea (5%), fatigue (5%), and skin infections (5%). Five percent of patients had Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, and hematuria). Treatmentemergent Grade 3 or 4 cytopenias (adverse reactions and laboratory abnormalities combined) were reported in 41% of patients@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@SAFETY@PATIENT REPORTED OUTCOMES@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN LABEL@PARALLEL ASSIGNMENT@@@1@1@155736.3731@@@17.5@month@17.5 month@155736.37@155736.37@292.58@90@1.1511@6583.13@6904.6@6590.67@@@@@@@@@@0.52@1@@mg@560@1@@@@@@@@@@@8/4/2017@73.15@73.15@704172@CAPSULE@EURO@@@@@@@@140@MG@140 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14924654@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@FAC+placebo or FAC+Zinecard.@@V03AF02@V03A@NO@NEW YORK, NEW YORK@@@The exact mechanism by which dexrazoxane exerts its cardioprotective effect has not been fully elucidated, however based on the available evidence the following mechanism has been suggested. The dose-dependent cardiotoxicity observed during anthracycline administration is due to anthracycline-induced iron-dependent free radical oxidative stress on the relatively unprotected cardiac muscle. Dexrazoxane, an analogue of EDTA (ethylene diamine tetra-acetic acid), is hydrolysed in cardiac cells to the ring-opened product ICRF-198. Both dexrazoxane (ICRF-187) and ICRF-198 are capable of chelating metal ions. It is generally thought that they can provide cardioprotection by scavenging metal ions thus preventing the Fe3+-anthracycline complex from redox cycling and forming reactive radicals.@@14924654@Zinecard is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. It is not recommended for use with the initiation of doxorubicin therapy.@@@@@NO REVIEW@@@@@@@@N/A@The recommended dosage ratio of Zinecard:doxorubicin is 10:1 (eg, 500 mg/m2 Zinecard:50 mg/m2 doxorubicin). In patients with moderate to severe renal dysfunction (creatinine clearance values < 40 mL/min), the recommended dosage ratio of Zinecard:doxorubicin is 5:1 (eg. 250 mg/m2 Zinecard:50 mg/m2 doxorubicin).@FDA, 26 May 1995@5/26/1995@@@@@Zinecard may add to the myelosuppression caused by chemotherapeutic agents. There is some evidence that the use of dexrazoxane concurrently with the initiation of fluorouracil, doxorubicin and cyclophosphamide (FAC) therapy interferes with the antitumor efficacy of the regimen, and this use is not recommended. In the largest of three breast cancer trials, patients who received dexrazoxane starting with their first cycle of FAC therapy had a lower response rate (48% vs 63%; p=0.007) and shorter time to progression than patients who did not receive dexrazoxane. Therefore, Zinecard should only be used in those patients who have received a cumulative doxorubicin dose of 300 mg/m2 and are continuing with doxorubicin therapy. Although clinical studies have shown that patients receiving FAC with Zinecard may receive a higher cumulative dose of doxorubicin before experiencing cardiac toxicity than patients receiving FAC without Zinecard the use of Zinecard in patients who have already received a cumulative dose of doxorubicin of 300 mg/m2 without Zinecard, does not eliminate the potential for anthracycline induced cardiac toxicity. Therefore, cardiac function should be carefully monitored. Secondary malignancies (primarily acute myeloid leukemia) have been reported in patients treated chronically with oral razoxane. Razoxane is the racemic mixture, of which dexrazoxane is the S(+)-enantiomer. In these patients, the total cumulative dose of razoxane ranged from 26 to 480 grams and the duration of treatment was from 42 to 319 weeks. One case of T-cell lymphoma, a case of B-cell lymphoma and six to eight cases of cutaneous basal cell or squamous cell carcinoma have also been reported in patients treated with razoxane.@LABEL@No@DECEMBER 2007; SEPTEMBER 2010 (PREVENTION OF CARDIOTOXICITY)@@@@III@APPROVED@@@MEDICARE@The difference in decline from baseline in LVEF was evident beginning with a cumulative doxorubicin dose of 150 mg/m2 and reached statistical significance in patients who received =400 mg/m2 of doxorubicin. Patients unprotected by Zinecard had a 13 times greater risk of developing congestive heart failure. Overall, 3% of patients treated with Zinecard developed CHF compared with 22% of patients not receiving Zinecard.@@@@@@DEXRAZOXANE HCL@@@@@DEXRAZOXANE HCL||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@Supportive Care@@@@Breast Cancer|Supportive Care||||||||@ZINECARD@@@@@ZINECARD||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@LVEF@@@@@@@@@@@@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@@@@3382.08@3382.08@@1@1@234.88@@@@@@@@@@@@0.94@@@@@@@@@@@@@@@@8/2/2017@234.88@234.88@00013-8717-62@POWDER FOR SOLUTION FOR INJECTION (SDV)@US$@@@@@@@@250@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14924864@Onco@@@@@300f1012ntsdm@@@@@@Administration of Zoladex (3.6 mg depot) and flutamide capsules (250 mg t.i.d.) prior to and during radiation@@L02AE03@L02A@NO@LONDON, UNITED KINGDOM@@@Zoladex (D-Ser(But)6 Azgly10 LHRH) is a synthetic analogue of naturally occurring LHRH. On chronic administration Zoladex results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. This effect is reversible on discontinuation of therapy. Initially, Zoladex, like other LHRH agonists, may transiently increase serum testosterone concentration in men and serum estradiol concentration in women.@@14924864@• In the treatment of metastatic prostate cancer • In the treatment of locally advanced prostate cancer, as an alternative to surgical castration • As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer • As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer • As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@466@Adult males (including the elderly): one depot of Zoladex LA injected subcutaneously into the anterior abdominal wall every 12 weeks. Children: Zoladex LA is not indicated for use in children.@Jan-87@@@No@@@Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostatic cancer, may occasionally develop during the first few weeks of Zoladex treatment. A small number of patients may experience a temporary increase in bone pain, which can be managed symptomatically. As with other LHRH agonists, isolated cases of ureteral obstruction and spinal cord compression have been observed.@@No@@466 PATIENTS WITH BULKY PRIMARY TUMORS CONFINED TO THE PROSTATE (STAGE B2) OR EXTENDING BEYOND THE CAPSULE (STAGE C), WITH OR WITHOUT PELVIC NODE INVOLVEMENT. 231 PATIENTS RECEIVED A COMBINATION THERAPY OF ZOLADEX + FLUTAMIDE + RADIATION, AND 235 PATIENTS@@@CLINICAL STUDIES - STAGE B2-C PROSTATIC CARCINOMA@APPROVED@@@GKV@Patients who received the combination therapy showed a significantly lower rate of local failure compared to radiation alone (16% vs 33% at 4 years, P<0.001). The combination therapy also resulted in a trend toward reduction in the incidence of distant metastases (27% vs 36% at 4 years, P=0.058). Median disease-free survival was significantly increased in patients who received complete hormonal therapy combined with radiation as compared to those patients who received radiation alone (4.4 vs 2.6 years, P<0.001). Inclusion of normal PSA level as a criterion for disease-free survival also resulted in significantly increased median disease-free survival in patients receiving the combination therapy (2.7 vs 1.5 years, P<0.001).@@@@@COMBO@GOSERELIN ACETATE@@@@@GOSERELIN ACETATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ZOLADEX@@@@@ZOLADEX||||@LH-RH Analog@@@@@LH-RH Analog||||@INCIDENCE OF DISTANT METASTASES@DISEASE-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@MULTI-CENTRE@CONTROLLED@@@@@@Invalid Dosage Value Phase 1@@@52@week@52 week@1717.52@1717.52@4.72@1@1.1511@396.37@512.12@409.56@@@@@@@@@@36.7@@@@@@@@@@@@@@@@8/1/2017@396.37@396.37@6604609@PREFILLED SYRINGE WITH IMPLANT@EURO@@@@@@@@10.8@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918550@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@H02AB07@H02A@NO@HOLZKIRCHEN, GERMANY@@@Prednisolone acetate is a synthetic adrenocorticoid with the general properties of prednisolone. Adrenocorticoids diffuse across cell membranes to complex with cytoplasmic receptors and subsequently stimulate synthesis of enzymes with anti-inflammatory effects. Glucocorticoids inhibit the oedema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation, deposition of collagen and scar formation. Prednisolone acetate has, on a weight to weight basis, a potency three to five times that of hydrocortisone.@@14918550@Indicated in the following conditions: Endocrine Disorders [Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcernia associated with cancer Nonsuppurative thyroiditis)] Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) [Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis] Collagen Diseases [During an exacerbation or as maintenance therapy in selected  cases of: Systemic lupus erythematosus Systemic-dermatomyositis (polymyositis) Acute rheumatic carditis] Dermatologic Diseases [Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis] Allergic States [Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions] Ophthalmic Diseases [Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic cornea marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis] Respiratory Diseases [Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis] Haematologic Disorders [Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopaenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia] Neoplastic Diseases For palliative management of: [Leukemias and lymphomas in adults Acute leukemia of childhood] Edematous States [To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis] Nervous System [Acute exacerbations of multiple sclerosis] Miscellaneous [Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement]@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@The initial dosage may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required.@@@@@@@In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination With other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@PREDNISONE@@@@@PREDNISONE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@6.46@19.15@7.36@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.13@0.13@2461159@TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14923216@Onco@@@@@300f1018ntsdm@@@@@@The maximum imatinib dose had been 400–600 mg/day in about one-half of the patients and >600 mg/day in the other half.@@L01XE06@L01X@NO@NEW YORK, NEW YORK@@@Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.@@14923216@Treatment of adults aged 18 years or over with chronic, accelerated or myeloid or  lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior  therapy including imatinib; Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic  leukaemia with resistance or intolerance to prior therapy.@@NO@7-Jul@@Overall survival analysis: The base case analysis of dasatinib versus salvage chemotherapy in Ph+ ALL patients who have failed prior therapy estimated the incremental cost-effectiveness ratio to be in the range $75,000 - $105,000 per additional year of survival.  The base case analysis of dasatinib versus imatinib in Ph+ ALL patients who have failed prior therapy estimated the incremental cost-effectiveness ratio to be between $15,000 - $45,000 per additional year of survival.  Progression free analysis: The base case analysis of dasatinib versus imatinib in Ph+ ALL patients who have failed prior therapy estimated the incremental cost-effectiveness ratio to be between $45,000 - $75,000 per additional year of progression free survival.  The weighted comparative analysis of dasatinib versus salvage chemotherapy and imatinib in Ph+ ALL patients who have failed prior therapy estimated the incremental cost-effectiveness ratio to be between $75,000 - $105,000 per additional year of survival.@@@@@@@@PATIENTS WITH CML OR PH+ ALL RESISTANT TO OR INTOLERANT OF TREATMENT WITH IMATINIB. THE CHRONIC PHASE CML STUDY ENROLLED 186 PATIENTS (CA-180-013/17), THE ACCELERATED PHASE CML STUDY 107 PATIENTS (CA-180-005), AND THE MYELOID BLAST PHASE STUDY 74 PATIENTS (CA-180-006)@The recommended starting dosage for chronic phase CML is 100 mg once daily, administered orally, consistently either in the morning or in the evening. In clinical trials of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 100 mg twice daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting dosage.@@@@@@@Myelosuppression: Treatment is associated with severe thrombocytopaenia, neutropaenia, and anaemia. Their occurrence is more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Sprycel temporarily or dose reduction. Bleeding Related Events: in addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe CNS haemorrhages, including fatalities, occurred in <1% of patients. Severe gastrointestinal hemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions. Fluid Retention: Sprycel is associated with fluid retention. In all clinical studies, severe fluid retention was reported in 8% of patients, including pleural and pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalised edema were each reported in <1% of patients.@CA-180-005/006/013/017@No@@PATIENTS WITH CML OR PH+ ALL RESISTANT TO OR INTOLERANT OF TREATMENT WITH IMATINIB. THE CHRONIC PHASE CML STUDY ENROLLED 186 PATIENTS (CA-180-013/17), THE ACCELERATED PHASE CML STUDY 107 PATIENTS (CA-180-005), AND THE MYELOID BLAST PHASE STUDY 74 PATIENTS (CA-180-006)@@@II@APPROVED@@>>The PBAC recommended the listing of dasatinib on the PBS for the treatment of patients with acute lymphoblastic leukaemia, expressing the Philadelphia chromosome or the transcript bcr-abl kinase, who are resistant to, or whose disease has relapsed on, prior therapy. [PBAC http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-dasatinib-sprycel-july07 ] >>Authority required: Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has active leukaemia (as defined by presence on current pathology assessments of either the Philadelphia chromosome on cytogenetic or FISH analysis, or the presence of the transcript BCR-ABL greater than 1% on the international scale) and who has failed an adequate trial of imatinib. [PBS]@PBS@In chronic phase CML patients, the MCyR rate was 45% with a complete response (0% Ph+ cells) rate of 33%.@@@@@MONO@DASATINIB@@@@@DASATINIB||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@SPRYCEL@@@@@SPRYCEL||||@TK Inhibitor@bcr-abl@PDGF@@@TK Inhibitor|bcr-abl|PDGF||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@SINGLE-ARM@MULTI-CENTRE@@@@1@1@109358.8422@@@11@month@11 month@109358.84@109358.84@326.86@60@0.779@2801.64@2948.51@2871.58@@@@@@@@@@2.33@1@@mg@140@1@@@@@@@@@@@8/1/2017@46.69@46.69@3139-0615-GE-BQ@TABLET@A$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
14923123@Onco@@@@@300f1037ntsdm@@@@@@67 patients were randomised at baseline to receive, double-blind, doses of 10 mg, 20 mg or 30 mg Sandostatin LAR Depot every 28 days and 26 patients continued, unblinded, on their previous Sandostatin Injection regimen (100-300 mcg t.i.d.). In any given month after steady-state levels of octreotide were reached, approximately 35% to 40% of the patients who received  LAR Depot required supplemental subcutaneous Sandostatin Injection therapy usually for a few days, to control exacerbation of carcinoid symptoms. In any given month the percentage of patients randomised to subcutaneous Injection, who required supplemental treatment with an increased dose of Injection, was similar to the percentage of patients randomised to LAR Depot.@@H01CB02@H01C@NO@BASEL, SWITZERLAND@@@Octreotide is a synthetic octapeptide analog of naturally occurring somatostatin with similar pharmacological effects, but with a longer duration of action. It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the gastroenteropancreatic (GEP) endocrine system, stomach, intestine and pancreas (for example, gastrin, insulin and glucagon).@@14923123@Acromegaly: indicated for long-term maintenance therapy in acromegalic patients for whom medical treatment is appropriate and who have been shown to respond to and can tolerate Sandostatin (octreotide acetate) Injection. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal. Sandostatin LAR Depot can be used in patients who have had an inadequate response to surgery or in those for whom surgical resection is not an option. It may also be used in patients who have received radiation and have had an inadequate therapeutic response. Carcinoid Tumors: indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors in patients in whom initial treatment with Sandostatin. Vasoactive Intestinal Peptide Tumors (VIPomas): indicated for long-term treatment of the profuse watery diarrhoea associated with VIP-secreting tumors in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated and In patients with acromegaly, carcinoid syndrome and VIPomas.@@YES@@@NO REVIEW@@@@90%@manufactured by: Sandoz GmbH, Schaftenau, Austria (Subsidiary of Novartis Pharma AG, Basle, Switzerland)@@@93@@1-Mar-93@3/1/1993@5/20/1993@@@@Gallbladder abnormalities: including biliary abnormalities with gallstones, microlithiasis, sediment, sludge and dilatation.@@No@@93 PATIENTS WITH MALIGNANT CARCINOID SYNDROME, WHO HAD PREVIOUSLY BEEN SHOWN TO BE RESPONSIVE TO SANDOSTATIN INJECTION.@@@CLINICAL TRIALS / CARCINOID SYNDROME@APPROVED@@NO REVIEW@SNS@Over the six-month treatment period approximately 50%-70% of patients who completed the trial on Sandostatin LAR Depot required subcutaneous Sandostatin Injection supplemental therapy to control exacerbation of carcinoid symptoms although steady-state serum LAR Depot levels had been reached.@@@@@MONO@OCTREOTIDE ACETATE@@@@@OCTREOTIDE ACETATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@SANDOSTATIN@@@@@SANDOSTATIN||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@GROWTH HORMONE LEVEL@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@3.47@5.42@3.78@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@0.69@0.69@772657@AMPOULE, 1 ML@EURO@@@@@@@@50@MCG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919641@Onco@@@@@300f1012ntsdm@@@@@@Oral doses of ondansetron 24 mg once a day, 8 mg twice a day, and 32 mg once a day. 66% of patients were treated with the ondansetron 24-mg  once-a-day , 55% with the ondansetron 8-mg twice-a-day , and 55% with the ondansetron 32-mg once-a-day@@A04AA01@A04A@NO@ULM, GERMANY@@@Ondansetron is a potent, highly selective 5HTs receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomoting reflex by activating vagal afferents via 5HTs receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.@@14919641@Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2; prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy; prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; prevention of postoperative nausea and/or vomiting.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@357@Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin =50 mg/m2. Multiday, single-dose administration of a 24 mg dosage has not been studied. Pediatric Use: There is no experience with the use of a 24 mg dosage in pediatric patients. Geriatric Use: The dosage recommendation is the same as for the general population. Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is one 8-mg tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Tablet or one 8-mg ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.@@@@@@@Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.@@No@@357 ADULT CANCER PATIENTS RECEIVING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN =50 MG/M2.@@@CLINICAL TRIALS / CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING: HIGHLY EMETOGENIC CHEMOTHERAPY; 2 RANDOMISED, DOUBLE-BLIND, MONOTHERAPY TRIALS@APPROVED@@@GKV@First trial: Each of the 3 treatment groups was shown to be statistically significantly superior to a historical placebo control. 56% of patients receiving oral ondansetron 24 mg once a day experienced no nausea during the 24-hour study period, compared with 36% of patients in the oral ondansetron 8-mg twice-a-day group (p = 0.001) and 50% in the oral ondansetron 32-mg once-a-day group. Second trial, efficacy of the oral ondansetron 24-mg once-a-day regimen in the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin =50 mg/m2, was confirmed.@@@@@MONO@ONDANSETRON HYDROCHLORIDE@@@@@ONDANSETRON HYDROCHLORIDE||||@RATIOPHARM@@@@@RATIOPHARM||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@GENERIC@@@@@GENERIC||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@EMETIC EPISODES@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@111.32@151.73@115.53@@@@@@@@@@0.46@@@@@@@@@@@@@@@@8/1/2017@3.71@3.71@5556653@FILM-COATED TABLET@EURO@@@@@@@@8@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918049@Onco@@@@@300f1020ntsdm@@@@@@260 patients received Gemzar 1000 mg/m2 was administered on Days 1, 8, and 15 of a 28-day cycle with cisplatin 100 mg/m2 administered on Day 1 of each cycle and another 262 patients received single-agent cisplatin 100 mg/m2 was administered on Day 1 of each 28-day cycle.@@L01BC05@L01B@NO@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14918049@Non-Small Cell Lung Cancer: Gemcitabine, in combination with cisplatin, is indicated as a first-line treatment of patients with locally advanced (inoperable Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.  Pancreatic Cancer: Gemcitabine is indicated for the treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is indicated for patients with 5-FU refractory pancreatic cancer.  Bladder Cancer: Gemcitabine is indicated for treatment of advanced bladder cancer (muscle invasive Stage IV tumours with or without metastases) in combination with cisplatin therapy.  Breast Cancer: Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless clinically contra-indicated.@@YES@-@@NO REVIEW@@@@100%@-@FIRST-LINE@-@522@Combination use in NSCLC: the 4-week schedule, Gemzar should be administered intravenously at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15 of each 28-day cycle and Cisplatin should be administered intravenously at 100 mg/m2 on Day 1 after the infusion of Gemzar@N/A@@@-@@@Gemzar can suppress bone marrow function as manifested by leukopaenia, thrombocytopaenia, and anaemia, can increase toxicity when prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing. Pulmonary toxicity, Hemolytic Uremic Syndrome (HUS) and/or renal failure, leading to death or requiring dialysis, despite discontinuation of therapy have been reported. Occurence of rare cases of Serious hepatotoxicity, including liver failure and death.@-@No@-@522 PATIENTS WITH INOPERABLE STAGE IIIA, IIIB, OR IV NSCLC WHO HAD NOT RECEIVED PRIOR CHEMOTHERAPY.@@@GEMZAR PLUS CISPLATIN VERSUS CISPLATIN@APPROVED@@@SSN@Median survival time on the Gemzar plus cisplatin arm was 9.0 months compared to 7.6 months on the single-agent cisplatin arm (p=0.008). Median TTP was 5.2 months on the Gemzar plus cisplatin arm compared to 3.7 months on the cisplatin arm (p=0.009). The objective RR on the Gemzar plus cisplatin arm was 26% compared to 10% with cisplatin (p<0.0001). No difference between treatment arms with regard to duration of response was observed.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@CISPLATIN@@@@GEMCITABINE HYDROCHLORIDE|CISPLATIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@OVERALL SURVIVAL@TIME TO PROGRESSION@RESPONSE RATE@DURATION OF RESPONSE@@RESPONSE RATE@DURATION OF RESPONSE@@@@ADVANCED@@@@@RANDOMISED@@@@@1.75@m²@4537.3068@@@5.2@month@5.2 month@4537.31@4537.31@28.69@1@1.1229@30.6@50.5@31.98@@@@@@@@@@0.15@28@@mg/m²@1000@3@@@@@@@@@@@6/7/2017@30.6@30.6@29452024@INJECTABLE PREPARATION@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
14922208@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arm A: FOLFOX4 for 6 months followed by observation; Arm B: FOLFOX4 + Avastin (5mg/kg every 2 weeks) for 6 months followed by Avastin for 6 months; and, Arm C: XELOX + Avastin (7.5mg/kg every 3 weeks) for 6 months followed by Avastin for 6 months@@L01XC07@L01X@-@BASEL, SWITZERLAND@4/1/2007@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14922208@Newly diagnosed high-risk Stage II colon cancer or Stage III adult colon cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00112918@3450@-@Submission expected in 2010 or earlier@@@-@@10/1/2004@-@AVANT@@NOT YET AVAILABLE; POTENTIALLY 2018.@-@@@CDR0000427299, UCLA-0412086-01, ROCHE-BO17920A;@III@@-@-@>>The study did not meet its primary endpoint of improving disease-free survival in stage III colon cancer. In line with the previously reported NSABP C-08 study results that also evaluated Avastin in the early-stage setting, the AVANT study shows that standard chemotherapy plus one year of Avastin is not effective in reducing the risk of relapses in early-stage colon cancer. Unlike the C-08 results, preliminary efficacy data from AVANT numerically favour chemotherapy alone (the control arm). Roche is evaluating the data from these two studies to help define the next steps for the ongoing Avastin adjuvant programme.[Roche, 18 September, 2010 http://www.roche.com/investors/ir_update/inv-update-2010-09-18b.htm]>>Enrolment completed Q2 2007; efficacy analysis is event-driven@Adverse events were consistent with those previously observed in pivotal trials of Avastin across tumour types for approved indications.@@@@BOTH@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@THREE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14916942@Onco@@@@@300f1015ntsdm@@@@@@Patients received 1 mg of Arimidex once daily or 20 mg of tamoxifen once daily.@@L02BG03@L02B@NO@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@14916942@First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer;@@NO@24-Jan-01@1/24/2001@NO REVIEW@@@@100%@@FIRST-LINE@@668@The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumour progression.@EMA, 3 March 2000@3/3/2000@@@@@Arimidex can cause fetal harm when administered to a pregnant woman.@@No@@POSTMENOPAUSAL WOMEN, BETWEEN THE AGES OF 30 AND 92 YEARS OLD AND WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER, WERE RANDOMISED TO RECEIVE ARIMIDEX (340 PATIENTS) OR TAMOXIFEN (328 PATIENTS).@@@@APPROVED@@ASMR Vhttp://www.has-sante.fr/portail/upload/docs/application/pdf/ct010022.pdf@HAUTE AUTORITÉ DE SANTÉ@Arimidex was at least as effective as tamoxifen for objective tumor RR and TTP. Median TTP was 8.2 months for the Arimidex treatment group compared to 8.3 months for the Tamoxifen treatment group. 73% of the patients in the Arimidex treatment group progressed compared to 75% for the Tamoxifen treatment group [Hazard ratio=1.01, p=0.920]. The best objective RR (CR+PR) were 32.9% for the Arimidex treatment group compared to 32.6% in the Tamoxifen treatment group [Odds ratio:1.01].@@@@@MONO@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@TIME TO PROGRESSION@RESPONSE RATE@SAFETY@@@SAFETY@@@@@ADVANCED@@@@@DOUBLE-BLIND@CONTROLLED@@@@1@1@274.684785@@@8.2@month@8.2 month@274.68@274.68@1.1@90@1.1807@99.12@120.04@105.74@@@@@@@@@@1.1@1@@mg@1@1@@@@@@@@@@@9/1/2017@1.1@1.1@3.40E+12@FILM COATED TABLET@EURO@@@@@@@@1@MG@1 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918968@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@30 patients in the dose-escalating phase and 41 patients treated at 340 mg/m2 of tanespimycin and 1.3 mg/m2 of bortezomib. Of the 41 patients in the 340 mg/m2 of tanespimycin and 1.3 mg/m2 of bortezomib dose group, 19 were treated with the prior Cremophor-containing formulation of tanespimycin (tanespimycin injection) and 22 were treated with the recently introduced tanespimycin injectable suspension formulation (52 evaluable total). SOURCE: Kosan@@-@-@-@HAYWARD, CALIFORNIA@@@KOS-953 is a proprietary formulation of 17-AAG developed by Kosan to improve patient tolerability and provide greater stability compared to the original drug product.  In addition to the Phase I single-agent study in multiple myeloma reported today, the formulation is also currently being evaluated in a Phase Ib clinical trial of KOS-953 administered in combination with bortezomib (Velcade), a recently approved agent to treat relapsed-refractory myeloma. @@14918968@-@@-@-@@NO REVIEW@@@@-@BMS acquires Kosan Biosciences for US$190 million. SOURCE: BMS, 29 May 2008@-@-@71@-@-@@@-@@@-@N/A@@-@-@@@IB@I@@-@-@In the bortezomib-naive group, the overall response rate (complete, partial and minor responses) was 47% (9 out of 19 evaluable patients), including 2 complete responses (CR), 1 near-complete response, 2 partial responses (PR) and 4 minor responses (MR). The response rates were similar between the tanespimycin injection (45%, 5 out of 11 patients; 2 CR, 1 PR, 2 MR) and the injectable suspension (50%, 4 out of 8 patients; 1 CR, 1PR, 2 MR) groups. In the bortezomib-pretreated group, the overall response rate was 47% (7 out of 15 evaluable patients; 1 CR, 2 PR, 4 MR). In this group, 14 patients received the Cremophor-containing formulation and 1 patient received the injectable suspension formulation. In the bortezomib-refractory group, the overall response rate was 17% (3 out of 18 evaluable patients; 3 PR). All responding bortezomib-refractory patients received the Cremophor-containing formulation. Five patients received the injectable suspension formulation and 13 received the Cremophor-containing formulation. To date, the response rate at the 340 mg/m2 dose is lower than that in the earlier, dose-escalating group that received doses of tanespimycin between 100 and 275 mg/m2.The combination of tanespimycin and bortezomib was well-tolerated. There was no increase in toxicity with the injectable suspension formulation compared to the Cremophor-containing formulation observed with the tanespimycin plus bortezomib combination dosed at 340 mg/m2 and 1.3 mg/m2, respectively. Common toxicities were similar for the two tanespimycin formulations. Common tanespimycin toxicities (primarily Grade 1-2) were gastrointestinal (diarrhea, nausea, vomiting), fatigue, reversible increased liver function tests (LFT), dizziness, headache, insomnia and musculoskeletal malaise. Grade 3 tanespimycin toxicities were limited to diarrhea, fatigue and increased LFT. No cardiovascular toxicity was observed. Common toxicities associated with bortezomib included thrombocytopenia (Grade 3-4 at 1.3 mg/m2) and neuropathy (Grade 1-2, at 1.3 mg/m2). A lower than anticipated rate of neuropathy was observed in the tanespimycin plus bortezomib combination, and no patient experienced a Grade 3 neuropathy. In prior bortezomib trials (the SUMMIT and CREST trials), 13% Grade 3 neuropathy was observed. This observation supports the hypothesis that treatment with tanespimycin exerts a neuroprotective effect. SOURCE: Kosan/ASH, 8 December 2007@-@@@@COMBO@TANESPIMYCIN@BORTEZOMIB@@@@TANESPIMYCIN|BORTEZOMIB|||@KOSAN BIOSCIENCES@BMS@@@@KOSAN BIOSCIENCES|BMS|||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@KOS-953@VELCADE@@@@KOS-953|VELCADE|||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919343@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01CD01@L01C@YES@UNTERACH, AUSTRIA@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919343@Ovarian carcinoma: in the first-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin. In the second-line chemotherapy of ovarian cancer, Taxol is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum containing therapy. Breast carcinoma: In the adjuvant setting, Taxol is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Taxol is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, Taxol is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline containing therapy. Advanced non-small cell lung carcinoma: Taxol, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy. AIDS-related Kaposi's sarcoma: Taxol is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.@@YES@@@NO REVIEW@@@@@Novartis acquires Ebewe in US$1.2 billion deal. [Novartis, 19 May 2009]@@@@175 mg/m² administered over a period of 3 hours, with a 3 week interval between courses.@1-Mar-06@3/1/2006@12/1/2007@@@@Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients must be pretreated with corticosteroids, antihistamines and H2 antagonists. Taxol should be given before cisplatin when used in combination.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PACLITAXEL@@@@@PACLITAXEL||||@EBEWE PHARMA@NOVARTIS@SANDOZ@@@EBEWE PHARMA|NOVARTIS|SANDOZ||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9285406T@DILUTED SOLUTION FOR PERFUSION, 5 ML@EURO@@@@@@@@30@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14918067@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@260 patients received Gemzar 1000 mg/m2 was administered on Days 1, 8, and 15 of a 28-day cycle with cisplatin 100 mg/m2 administered on Day 1 of each cycle and another 262 patients received single-agent cisplatin 100 mg/m2 was administered on Day 1 of each 28-day cycle.@@L01BC05@L01B@NO@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14918067@Gemzar is indicated in combination with cisplatin for the treatment of non-small cell lung cancer.@@@@@NO REVIEW@@@@No tiering. SOURCE: Aetna Preferred Drug Guide 2008@@@@522@Combination use in NSCLC: the 4-week schedule, Gemzar should be administered intravenously at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15 of each 28-day cycle and Cisplatin should be administered intravenously at 100 mg/m2 on Day 1 after the infusion of Gemzar@FDA, 25 August 1998@8/25/1998@@@@@Gemzar can suppress bone marrow function as manifested by leukopaenia, thrombocytopaenia, and anaemia, can increase toxicity when prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing. Pulmonary toxicity, Hemolytic Uremic Syndrome (HUS) and/or renal failure, leading to death or requiring dialysis, despite discontinuation of therapy have been reported. Occurence of rare cases of Serious hepatotoxicity, including liver failure and death.@@No@NOVEMBER 2007 (PAEDIATRIC); JULY 2009 (OVARIAN CANCER); EXTENSIONS TO 2013. Lilly sued Teva//Sicor over its ANDA in February 2006, and the case goes to trial in July 2009.@522 PATIENTS WITH INOPERABLE STAGE IIIA, IIIB, OR IV NSCLC WHO HAD NOT RECEIVED PRIOR CHEMOTHERAPY.@@@GEMZAR PLUS CISPLATIN VERSUS CISPLATIN@APPROVED@@@MEDICARE@No significant difference was observed in QOL between the Gemzar plus cisplatin arm and the single-agent cisplatin arm.@@@@@COMBO@GEMCITABINE HYDROCHLORIDE@CISPLATIN@@@@GEMCITABINE HYDROCHLORIDE|CISPLATIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@QUALITY OF LIFE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@@@@@1.75@m²@21973.31682@@@5.2@month@5.2 month@21973.32@21973.32@138.93@1@1@740.95@@@@@@@@@@@@0.74@28@@mg/m²@1000@3@@@@@@@@@@@8/2/2017@740.95@740.95@00002-7502-01@POWDER FOR INJECTION@US$@@@@@@@@1000@MG@1000 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14922872@Onco@@@@@300f1010ntsdm@@@@@@Patients in the Revlimid/dexamethasone arm (n=170) took 25 mg of Revlimid orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone arm (n= 171)took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Patients in both treatment arms took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.@@L04AX04@L04A@YES@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14922872@Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.@@NO@1-Jan-09@1/1/2009@When the ERG's approach to modelling overall survival was used, for the comparison of lenalidomide with dexamethasone in people who has received one prior therapy only, the ICER was more than £69,000 per QALY gained. For the comparisons with dexamethasone in people who had received one prior therapy, and where that therapy was thalidomide, the ICERs were above £56,000 per QALY gained. [NICE, 28.10.2008]@@@@100%@@SECOND-LINE@@704@The recommended starting dose of lenalidomide is 25 mg orally once daily on days 121 of repeated 28day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on days 14, 912, and 1720 of each 28day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 14 every 28 days. Dosing is continued or modified based upon clinical and laboratory findings.@EMA, 14 June 2007@6/14/2007@@Yes@@@Thalidomide, of which Revlimid is an analogue, is a known human teratogen that causes lifethreatening human birth defects. Revlimid may cause fetal harm when administered to aDVT and pulmonary embolism: this drug has demonstrated a significantly increased risk of DVT and PE in patients with multiple myeloma who were treated with Revlimid combination therapy.@LABEL@No@@PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST ONE PRIOR TREATMENT WERE RANDOMIZED TO 2 ARMS: ARM1: REVLIMID (LENALIDOMIDE) PLUS ORAL PULSE HIGHDOSE DEXAMETHASONE THERAPY. ARM2: DEXAMETHASONE THERAPY ALONE.@@@III@APPROVED@@Not recommended: November 2016. Lenalidomide in combination with dexamethasone is not recommended for treating multiple myeloma in adults: whose condition has relapsed for the first time, who have had 1 prior treatment with bortezomib, when thalidomide is contraindicated or not suitable and, when stem cell transplantation is not suitable. [NICE, https://www.nice.org.uk/guidance/GID-TAG452/documents/appraisal-consultation-document]Revlimid in first relapse:1 Appraisal Committee's preliminary recommendations1.1 Lenalidomide in combination with dexamethasone is not recommended for treating multiple myeloma in people:whose multiple myeloma has relapsed for the first time, andwho have received 1 prior treatment with bortezomib, andfor whom thalidomide is contraindicated or cannot be tolerated andfor whom bone marrow transplantation is not appropriate.[NICE, March 2014 http://www.nice.org.uk/guidance/index.jsp?action=article&amp;o=66926]&gt;&gt;Revlimid in people who have received two or more therapies: Lenalidomide in combination with dexamethasone is recommended, within its licensed indication, as an option for the treatment of multiple myeloma in people who have received two or more prior therapies, under the following circumstances 1.1 The NHS will cover the cost of the drug for the first 2 years (26 cycles of 28 days) of treatment; the drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for longer than 2 years will be met by the manufacturer. 1.2 People currently receiving lenalidomide for the treatment of multiple myeloma, but who have not received two or more prior therapies, should have the option to continue therapy until they and their clinicians consider it appropriate to stop. [NICE preliminary recommendations, 30.01.2009] &gt;&gt; Lenalidomide in combination with dexamethasone is not recommended for the treatment of multiple myeloma in people who have received at least one prior therapy. People currently receiving lenalidomide for the treatment of multiple myeloma should have the option to continue therapy until they and their clinicians consider it appropriate to stop. [NICE appraisal committee preliminary recommendations, 28.10.2008] &gt;&gt; NICE guidance due in January 2009@NHS@Analyses of both studies showed that the combination of Revlimid/dexamethasone was significantly superior to dexamethasone alone for TTP.@In the lenalidomide/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of lenalidomide compared to 21% in the placebo/dexamethasone treatment group. Of these patients who had one dose interruption with or without a dose reduction, 50% in the lenalidomide/dexamethasone treatment group underwent at least one additional dose interruption with or without a dose reduction compared to 21% in the placebo/dexamethasone treatment group. Other adverse events reported in multiple myeloma patients (REVLIMID® (lenalidomide)/dexamethasone vs dexamethasone/placebo): constipation (39% vs 19%), fatigue (38% vs 37%), insomnia (32% vs 37%), muscle cramp (30% vs 21%), diarrhea (29% vs 25%), neutropenia (28% vs 5%), anemia (24% vs 17%), asthenia (23% vs 25%), pyrexia (23% vs 19%), nausea (22% vs 19%), headache (21% vs 21%), peripheral edema (21% vs 19%), dizziness (21% vs 15%), dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and muscle weakness (15% vs 15%).@@@@COMBO@LENALIDOMIDE@DEXAMETHASONE@@@@LENALIDOMIDE|DEXAMETHASONE|||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@GENERIC@@@@REVLIMID|GENERIC|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@TIME TO PROGRESSION@@@@@@@@@@@@@@@RANDOMISED@MULTI-CENTRE@DOUBLE-BLIND@PLACEBO-CONTROLLED@@1@1@345636.018@@@48.1@month@48.1 month@345636.02@345636.02@236.25@21@1.299@3969@@@@@@@@@@@@12.6@28@@mg@25@21@@@@@@@@@@@7/28/2017@189@189@1.18E+16@HARD CAPSULE@GB£@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14922802@Onco@@@@@300f1037ntsdm@@@@@@311 received leuprolide + flutamide; 306 received leuprolide + placebo@@L02BB01@L02B@YES@@@@Flutamide is an anilide, nonsteroidal oral antiandrogen. In animal studies flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding in target tissues. When flutamide is given in combination with surgical or medical castration, suppression of both testicular and adrenal androgen activity is achieved.@@14922802@Treatment of advanced prostatic carcinoma in which suppression of testosterone effects is indicated; as initial treatment in combination with an LHRH agonist, as adjunctive therapy in patients already receiving LHRH agonist therapy; in surgically castrated patients; in the treatment of patients who have not responded to other form of hormonal manipulation or in patients who cannot tolerate such treatment. In combination with LHRH agonists for the management of locally confined B2-C2 (T2b-T4) prostate carcinoma as initial therapy; bulky primary tumors confined to the prostate (stage B2 or T2b) or extending beyond the capsule (stage C or T3-T4), with or without pelvic node involvement.@@NO@@@NO REVIEW@@@@90%@@FIRST-LINE@@617@One 250mg tablet three times daily at 8 hour intervals.@1-Mar-93@3/1/1993@5/24/1994@@@@"Hepatic Injury: There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide. Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with flutamide. Serum transaminase levels should be measured prior to starting treatment with flutamide. Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal. Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter. Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction, eg, nausea, vomiting, abdominal pain, fatigue, anorexia, ""flu-like"" symptoms, hyperbilirubinuria, jaundice, or right upper quadrant tenderness. If at any time a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, flutamide should be immediately discontinued with close follow-up of liver function tests until resolution."@@No@@@@@III; STAGE D2 METASTATIC CARCINOMA@APPROVED@@NO REVIEW@SNS@Median survival reached at 3.5 years. The median actuarial survival time was 34.9 months for leuprolide and flutamide versus 27.9, months for leuprolide alone. This 7-month increment represents a 25% improvement in overall survival time with the flutamide therapy. Analysis of PFS showed a 2.6 month improvement in patients who received leuprolide plus flutamide, a 19% increment over leuprolide and placebo.@@@@@COMBO@FLUTAMIDE@LEUPROLIDE@@@@FLUTAMIDE|LEUPROLIDE|||@PRASFARMA@@@@@PRASFARMA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROSTACUR@@@@@PROSTACUR||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@OVERALL SURVIVAL@PROGRESSION-FREE SURVIVAL@@@@@@@@@@@@@@PLACEBO-CONTROLLED@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@90@1.1511@34.41@53.72@37.27@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@0.38@0.38@693812@TABLET@EURO@@@@@@@@250@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919406@Onco@@@@@300f1018ntsdm@@@@@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14919406@Indicated for the treatment of: 1. advanced ovarian carcinoma of epithelial origin in  (a) first line therapy (b) second line therapy, after other treatments have failed. 2. small cell carcinoma of the lung.@@NO@@@NO REVIEW@@@@100%@@SECOND-LINE@@@Single-Agent Therapy: has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide:an effective combination for previously untreated patients consists of: Paraplatin—300 mg/m2 I.V. on day 1 every four weeks for six cycles. Cyclophosphamide—600 mg/m2 I.V. on day 1 every four weeks for six cycles. Intermittent courses of Paraplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.@@@@@@@Paraplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.@LABEL@No@@Advanced ovarian cancer previously treated with chemotherapy@@@III@APPROVED@@Unrestricted reimbursement.@PBS@Carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@@@@@1@0.779@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@SOLUTION, AQUEOUS@A$@@@@@@@@450@MG@450 MG/45 ML@@@@@@@@@@@@@@@@@@@@@@@@23@Australia
16671805@Onco@@@@@300f1037ntsdm@@@@@@Biological: cetuximabProcedure: quality-of-life assessment@@L01XC06@L01X@@NEW YORK, NEW YORK@3/1/2006@@Erbitux is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.@@16671805@Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer as monotherapy in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.@Both@YES@@@@@@@@>> Acquisition completed. [Lilly, 24.11.2008]          >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]        >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]      >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@THIRD-LINE@NCT00079066@572@In all indications, Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each.@EMA, 17 July 2008@7/17/2008@@No@@8/1/2003@@CO17, CAN-NCIC-CO17, AGITG-CAN-NCIC-CO17, BMS-CA225-025, IMCL-CAN-NCIC-CO17, CDR0000353486@No@@@(EGFR)-expressing, KRAS WILD-TYPE@ADULTS@III@APPROVED@@@SNS@@@@@@MONO@CETUXIMAB@@@@@CETUXIMAB||||@BMS@IMCLONE@MERCK SERONO@@@BMS|IMCLONE|MERCK SERONO||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ERBITUX@@@@@ERBITUX||||@mAb@Chimeric@TK Inhibitor@EGFR@@mAb|Chimeric|TK Inhibitor|EGFR|@OVERALL SURVIVAL@@@@@TIME TO PROGRESSION@OBJECTIVE RESPONSE RATE@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@@@@1.75@m²@14030.5926@@@3.7@month@3.7 month@14030.59@14030.59@124.67@1@1.1511@192.3@247.74@199.84@@@@@@@@@@1.92@7@1@mg/m²@400@1@7@@mg/m²@250@1@@@@@@8/4/2017@192.3@192.3@658752@SOLUTION FOR INFUSION (VIAL) - 20 ML@EURO@@@@@@@@100@MG@5 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14919461@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@H02AB07@H02A@NO@SOUTH CROYDON, AUSTRALIA@@@Prednisolone acetate is a synthetic adrenocorticoid with the general properties of prednisolone. Adrenocorticoids diffuse across cell membranes to complex with cytoplasmic receptors and subsequently stimulate synthesis of enzymes with anti-inflammatory effects. Glucocorticoids inhibit the oedema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation, deposition of collagen and scar formation. Prednisolone acetate has, on a weight to weight basis, a potency three to five times that of hydrocortisone.@@14919461@Indicated in the following conditions: Endocrine Disorders [Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcernia associated with cancer Nonsuppurative thyroiditis)] Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) [Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis] Collagen Diseases [During an exacerbation or as maintenance therapy in selected  cases of: Systemic lupus erythematosus Systemic-dermatomyositis (polymyositis) Acute rheumatic carditis] Dermatologic Diseases [Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis] Allergic States [Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions] Ophthalmic Diseases [Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic cornea marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis] Respiratory Diseases [Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis] Haematologic Disorders [Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopaenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia] Neoplastic Diseases For palliative management of: [Leukemias and lymphomas in adults Acute leukemia of childhood] Edematous States [To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis] Nervous System [Acute exacerbations of multiple sclerosis] Miscellaneous [Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement]@@NO@october 20004@@NO REVIEW@@@@@Sigma acquires Arrow. [Sigma, 22.08.2005]@@@@The initial dosage may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required.@1-Aug-04@8/1/2004@5/19/2005@@@@In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination With other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@PREDNISONE@@@@@PREDNISONE||||@ARROW GENERICS@SIGMA PHARMACEUTICAL@@@@ARROW GENERICS|SIGMA PHARMACEUTICAL|||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@20@1.1511@1.82@2.42@2.12@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.09@0.09@3.40E+12@SCORED TABLET@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919843@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@L01CA04@L01C@YES@LAKE FOREST, ILLINOIS@@@Vinorelbine is an antineoplastic active substance of the vinca alkaloid family, but in contrast to all other vinca alkaloids the catharanthine portion of vinorelbine has undergone a structural modification. On the molecular level it affects the dynamic equilibrium of tubulin in the microtubular system of the cell. Vinorelbine inhibits tubulin polymerisation and binds preferentially to mitotic microtubules, only affecting axonal microtubules at high concentrations. Spiralisation of the tubulin is induced to a lesser degree than with vincristine. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.@@14919843@As a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer. - Treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.@@NO@2-Dec@@NO REVIEW@@@@100%@@@@@In adults : Navelbine is usually given at 25-30mg/m² weekly. It may be administered by slow bolus (5-10 minutes) after dilution in 20-50 ml of sodium chloride 9 mg/ml (0.9%) solution for injection or in 5% glucose solution for injection. Administration should always be followed with at least 250 ml of an isotonic solution to flush the vein. Advanced non-small cell lung cancer and advanced breast cancer - In monotherapy the usual dose given is 25-30 mg/m² once weekly. - In combination chemotherapy the usual dose (25-30 mg/m²) is usually maintained, while the frequency of administration is reduced e.g. day 1 and 5 every 3 weeks or day 1 and 8 every 3 weeks according to treatment protocol.@EMA, October 1995@@@@@@Vinorelbine should be administered in carefully adjusted doses by or under the supervision of a chemo-experienced physician. Patients treated with vinorelbine should be frequentlymonitored for myelosuppression both during and after therapy. Granulocytopaenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocytecount recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results reviewed prior to administering each dose of vinorelthose@NO LABELLED TRIAL@No@@@@@@APPROVED@@NICE; the guidance recommends that: Vinorelbine by itself should not be used as the first treatment for advanced breast cancer. Vinorelbine on its own should be one option for treating advanced breast cancer when initial treatment with chemotherapy using drugs called anthracyclines has not worked or is unsuitable for the patient. The patient and the doctor who is responsible for the cancer treatment should choose the follow-up treatment together, after they have discussed the benefits and possible side effects of the drugs available. NICE has looked at the evidence that is available and decided that at the moment it can't recommend routine use of vinorelbine together with other chemotherapy drugs (combination therapy).@NHS@NO LABELLED TRIAL@@@@@@VINORELBINE TARTRATE@@@@@VINORELBINE TARTRATE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@NSCLC@Breast Cancer@@@@NSCLC|Breast Cancer||||||||@GENERIC@@@@@GENERIC||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CONCENTRATE FOR INFUSION@GB£@@@@@@@@50@MG@10MG/ML@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom
14923478@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were randomised 2:1 to receive Tarceva 150 mg or placebo (488 Tarceva, 243 placebo) orally once daily until disease progression or unacceptable toxicity.@@L01XE03@L01X@NO@SAN FRANCISCO, CALIFORNIA@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14923478@Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.@@NA@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009] >> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]           >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]       >> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]       >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]        >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]"@SECOND/THIRD LINE@NCT00036647@731@The recommended daily dose is 150 mg. Treatment should continue until disease progression or unacceptable toxicity occurs.@FDA, 18 November 2004@11/18/2004@@No@@@Pulmonary Toxicity: There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events, including fatalities, in patients receiving Tarceva for treatment of NSCLC, pancreatic cancer, or other advanced solid tumors. Myocardial infarction/ischemia. Cerebrovascular accident. Microangiopathic Haemolytic Anaemia with Thrombocytopaenia. Pregnancy: Women of childbearing potential should be advised to avoid pregnancy while on Tarceva . If Tarceva is used during pregnancy, the patient should be apprised of the potential hazard to the fetus or potential risk for loss of the pregnancy.@@No@9 November 2018 (NCE)@PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC AFTER FAILURE OF AT LEAST ONE CHEMOTHERAPY REGIMEN.@@@CLINICAL STUDIES / NON-SMALL CELL LUNG CANCER (NSCLC) – TARCEVA ADMINISTERED AS A SINGLE AGENT@WITHDRAWN@@In first-line NSCLC, erlotinib +/- chemotherapy is recommended if patient has known active EGFR mutation or gene amplification and never a smoker. In patients who have experience disease progression either during or after first-line therapy, single-agent docetaxel or pemetrexed, or TK inhibitor, erlotinib are established second-line agents. Erlotinib has proven superior to BSC with significantly improved survival and delayed time to symptom deterioration here. In third-line therapy, erlotinib has proven statistically superior to BSC with respect to survival.@MEDICARE@Survival:Months/median: For the Tarceva arm: 6.7 and for the arm placebo=4.7 with Hazard Ratio=0.73, 95% CI 0.61–0.86,  p<0.001.@The most common adverse reactions in patients receiving single-agent Tarceva 150 mg were rash and diarrhea. Grade 3/4 rash and diarrhea occurred in 9% and 6%, respectively, in Tarceva-treated patients. Rash and diarrhea each resulted in study discontinuation in 1% of Tarceva-treated patients. Six percent and 1% of patients needed dose reduction for rash and diarrhea, respectively. The median time to onset of rash was 8 days, and the median time to onset of diarrhea was 12 days.@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@OVERALL SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@1@1@34911.67652@@@9.9@week@9.9 week@34911.68@34911.68@503.78@30@1@2518.88@@@@@@@@@@@@3.36@1@@mg@150@1@@@@@@@@@@@5/2/2017@83.96@83.96@50242-0062-01@FILM-COATED TABLET@US$@@@@@@@@25@MG@25 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
16642682@Onco@@@@@300f1020ntsdm@@@@@@Experimental: CometriqPlacebo: Comparator@@L01XE26@L01X@@@12/1/2014@@Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, and metastatic progression of cancer.Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor)receptors. In addition, cabozantinib inhibits other tyrosine kinases including RET, the GAS6 receptor (AXL), the stem cell factor receptor (KIT), and Fms-like tyrosine kinase-3 (FLT3).@@16642682@Indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.@Both@NO@@@NO REVIEW@@@July 2008-december 2014@0%@@@NCT00704730@330@The recommended dose of COMETRIQ is 140 mg once daily, taken as one 80 mg orange capsule and three 20 mg grey capsules. Treatment should continue until the patient is no longer clinically benefiting fromtherapy or until unacceptable toxicity occurs.@EMA, 21 March 2014@3/21/2014@2/14/2017@YES@@6/1/2008@@XL184-301@No@@The subject has a histologically confirmed diagnosis of MTC that cannot be removed by surgery, is locally advanced, or has spread in the body.The subject is at least 18 years old.The subject has an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.The subject has documented worsening of disease (progressive disease) at screening compared with a previous CT scan or MRI image done within 14 months of screening.@@ADULTS@III@APPROVED@@@@The safety and effectiveness of Cometriq were established in a clinical study involving 330 patients with medullary thyroid cancer. Treatment with Cometriq increased the length of time a patient lived without the cancer progressing (progression-free survival) and, in some patients, reduced the size of tumors (response rate).Patients who were given Cometriq lived an average of 11.2 months without tumor growth compared with an average of four months in patients receiving a sugar pill (placebo). Results also showed that 27 percent of patients treated with Cometriq had reductions in tumor size lasting an average of nearly 15 months, while patients who received a placebo saw no reductions. Treatment with Cometriq did not extend patients' lives.[FDA, 29 November 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm]@The most common side effects were diarrhea; inflammation or sores of the mouth; redness, pain, or swelling of the digits (hand-foot syndrome); weight loss; loss of appetite; nausea; fatigue; oral pain; graying or loss of hair color; bad taste; new or worsening high blood pressure; abdominal pain and constipation. The most common laboratory abnormalities included increases in liver enzymes, low calcium and phosphorus, decreased white blood cells and platelets.[FDA, 29 November 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm]@@@@MONO@CABOZANTINIB@@@@@CABOZANTINIB||||@IPSEN@@@@@IPSEN||||@World@@@@@World|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@COMETRIQ@@@@@COMETRIQ||||@TK Inhibitor@@@@@TK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@OBJECTIVE RESPONSE RATE@@@@METASTATIC@UNRESECTABLE@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@1@1@Invalid Strength@@@11.2@month@11.2 month@@@@112@1.1229@9112.14@14960@9520.14@@@@@@@@@@@1@@mg@140@1@@@@@@@@@@@6/7/2017@81.36@81.36@43339062@HARD CAPSULE (84 X 20 MG + 28 X 80 MG)@EURO@@@@@@@@@@20 MG + 80 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy
16692930@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Arm A: AP26113 will be administered to eligible patients with locally advanced or metastatic ALK+ NSCLC at a dose of 90 mg QD, continuously.Experimental: Arm B: AP26113 will be administered to eligible patients with locally advanced or metastatic ALK+ NSCLC at a dose of 90 mg QD for 7 days, then 180 mg QD, continuously.@@@@@CAMBRIDGE, MASSACHUSETTS@11/1/2016@@@@16692930@Indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.@Both@NA@@@@@@@@@@NCT02094573@218@The recommended dosing regimen for ALUNBRIG is: 90 mg orally once daily for the first 7 days; if 90 mg is tolerated during the first 7 days, increase the dose to 180 mg orally once daily.Administer ALUNBRIG until disease progression or unacceptable toxicity.@FDA, 28 April 2017@4/28/2017@@Yes@@3/1/2014@@AP26113-13-201@No@@Have histologically or cytologically confirmed locally advanced or metastatic NSCLC that is ALK+. Must meet one of the following two criteria:  a.Have documented ALK rearrangement by a positive result from the Vysis® ALK Break-Apart fluorescence in situ hybridization (FISH) Probe Kit; or b.Have documented ALK positivity by a different test and tissue available for the Vysis® FISH test. Tissue should be derived preferably from a biopsy taken after progression with crizotinib. If such a sample is not available, testing may be performed with archived tumor tissue; Had progressive disease while on crizotinib, as assessed by the investigator or treating physician; Have at least 1 measurable lesion per RECIST v1.1. Note: Previously irradiated lesions may not be used for target lesions, unless there is unambiguous radiological progression after radiotherapy. Brain lesions may not be used as target lesions if they were: 1) previously treated with whole brain radiation therapy (WBRT) within 3 months, or 2) previously treated by stereotactic radiosurgery (SRS) or surgical resection; Recovered from toxicities related to prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0) grade ≤2; Are a male or female patient ≥18 years old; Have a life expectancy ≥3 months.@ALK-positive@ADULTS@II@APPROVED@@@NA@Approval was based on a non-comparative, two-arm, open-label, multicenter clinical trial demonstrating a clinically meaningful and durable overall response rate (ORR) in patients with locally advanced or metastatic ALK-positive NSCLC who had progressed on crizotinib (the ALTA Trial; NCT02094573). All patients had tumors with a documented ALK rearrangement based on an FDA-approved test or a different test with adequate archival tissue to confirm ALK arrangement by the Vysis® ALK Break-Apart fluorescence in situ hybridization Probe Kit test. A total of 222 patients were randomized to brigatinib orally either 90 mg once daily (n=112) or 180 mg once daily following a 7-day lead-in at 90 mg once daily (n=110).ORR was assessed by an independent review committee according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. ORR was 48% (95% CI: 39%, 58%) in the 90 mg arm and 53% (95% CI: 43%, 62%) in the 180 mg arm. After a median duration of follow-up of 8 months, median duration of response (DOR) was 13.8 months in both arms. In patients with measurable brain metastases at baseline, intracranial ORR was 42% (95% CI: 23%, 63%) in the 90 mg arm (n=26) and 67% (95% CI: 41%, 87%) in the 180 mg arm (n=18). Median intracranial DOR was not estimable in the 90 mg arm and was 5.6 months in the 180 mg arm. Among patients who exhibited an intracranial response, 78% of patients in the 90 mg arm and 68% of patients in the 180 mg arm maintained an intracranial response for at least 4 months.[https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm]@Safety was evaluated in 219 patients who received at least one dose of brigatinib in the ALTA trial. The most common adverse reactions, occurring in at least 25% of patients taking brigatinib, were nausea, diarrhea, fatigue, cough, and headache. The most common serious adverse reactions were pneumonia and ILD/pneumonitis. Fatal adverse reactions occurred in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis (1 patient each). Visual disturbances also occurred in patients receiving brigatinib. Adverse reactions leading to permanent discontinuation of brigatinib occurred in 2.8% and 8.2% of patients receiving 90 mg and 180 mg, respectively.Patients receiving brigatinib should be monitored for new or worsening respiratory symptoms, hypertension, bradycardia, visual symptoms, and elevations in amylase, lipase, blood glucose, and creatine phosphokinase.[https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm]@@@@@BRIGATINIB@@@@@BRIGATINIB||||@ARIAD PHARMACEUTICALS@@@@@ARIAD PHARMACEUTICALS||||@World@@@@@World|||||||||@NSCLC@@@@@NSCLC|||||||||@ALUNBRIG@@@@@ALUNBRIG||||@Other@@@@@Other||||@OBJECTIVE RESPONSE RATE@@@@@OVERALL SURVIVAL@PROGRESSION FREE SURVIVAL@@@@METASTATIC@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN LABEL@@@1@1@197714.3783@@@13.8@month@13.8 month@197714.38@197714.38@471.04@180@1@14250@@@@@@@@@@@@2.64@7@1@mg@90@7@1@@mg@180@1@@@@@@8/2/2017@79.17@79.17@76189-0113-18@TABLET@US$@@@@@@@@30@MG@30 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15045756@Onco@@@@@300f1037ntsdm@@@@@@Both everolimus and placebo administered by continuous oral dosing of two 5-mg tablets.@@L01XE10@L01X@@BASEL, SWITZERLAND@6/1/2014@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@15045756@Indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.@@YES@@@NO REVIEW@@@@90%@@SECOND-LINE@NCT00863655@724@The recommended dose of Afinitor is 10 mg to be taken once daily.@EMA, 30 July 2012@7/30/2012@@No@@6/1/2009@@BOLERO2@No@@@@@III@APPROVED@@@SNS@Updated findings from the BOLERO-2 study presented at SABCS showed treatment with everolimus plus hormonal therapy more than doubled progression-free survival (PFS) to 7.4 months compared to 3.2 months with hormonal therapy alone (hazard ratio=0.44 [95% confidence interval (CI): 0.36 to 0.53]; p<1x10-16) by local investigator assessment. Twelve month estimates of patients without disease progression were 31% and 10% in the everolimus and exemestane, and exemestane-alone arms, respectively. An additional analysis based on an independent central radiology review showed everolimus extended PFS to 11.0 months compared to 4.1 months (hazard ratio=0.36 [95% CI: 0.28 to 0.45]; p<1x10-16)[1].[Novartis, 8 December 2011, http://www.novartis.com/newsroom/media-releases/en/2011/1569858.shtml ]@@@@@COMBO@EVEROLIMUS@EXEMESTANE@@@@EVEROLIMUS|EXEMESTANE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AFINITOR@AROMASIN@@@@AFINITOR|AROMASIN|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@OVERALL SURVIVAL@RESPONSE@SAFETY@@@REFRACTORY@ADVANCED@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@1@1@56511.00121@@@11@month@11 month@56511@56511@168.9@30@1.1511@2533.55@2693.04@2541.09@@@@@@@@@@16.89@1@@mg@10@1@@@@@@@@@@@8/4/2017@84.45@84.45@663792@TABLET@EURO@@@@@@@@5@MG@5 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14922369@Onco@@@@@300f1015ntsdm@@@@@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (100 or 75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@NEW YORK, NEW YORK@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14922369@Indicated for the treatment of: 1. advanced ovarian carcinoma of epithelial origin in  (a) first line therapy (b) second line therapy, after other treatments have failed. 2. small cell carcinoma of the lung.@@YES@@@NO REVIEW@@@@@@FIRST-LINE@@789@Single-Agent Therapy: has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide:an effective combination for previously untreated patients consists of: Paraplatin—300 mg/m2 I.V. on day 1 every four weeks for six cycles. Cyclophosphamide—600 mg/m2 I.V. on day 1 every four weeks for six cycles. Intermittent courses of Paraplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.@1-Mar-89@3/1/1989@1/1/2002@@@@Paraplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.@LABEL@No@@342 ADVANCED OVARIAN CANCER PATIENTS (SWOG) 447 ADVANCED OVARIAN CANCER PATIENTS (NCIC)@@@III; SWOG + NCIC@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@SWOG: Carboplatin versus cisplatin: 58% (48/83) versus 43% (33/76) respectively. Complete response: 10% (17/171) versus 10% (17/171). Median PFS: 49 versus 47 weeks. 2-year PFS: 21% versus 21%. 3-year PFS: 8% versus 14%. Median survival: 86 versus 79 weeks. 2-year survival: 40% versus 39%. 3-year survival: 18% versus 25%. NCIC: Carboplatin versus cisplatin: Clinical response  60% (48/80) versus 58% (49/85) respectively. Complete response: 11% (24/224) versus 15% (33/223). Median PFS: 59 versus 61 weeks. 2-year PFS: 31% versus 31%. 3-year PFS: 19% versus 23%. Median survival: 110 weeks versus 99 weeks. 2-year survival: 52% versus 48%. 3-year survival: 35% versus 33%.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@BMS@@@@@BMS||||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@PARAPLATIN@@@@@PARAPLATIN||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Incorrect Average Duration of Use (Unit)@@@6@course@6 course@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9137195R@INJECTABLE SOLUTION FOR PERFUSION VIAL, 15 ML@EURO@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14921279@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@HOLZKIRCHEN, GERMANY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14921279@Neoplastic Diseases: indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Psoriasis: indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis: indicated in the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Lymphomas: In Burkitt's tumor, Stages I-II, methotrexate has produced prolonged remissions in some cases. Recommended dosage is 10 to 25 mg/day orally for 4 to 8 days. In Stage III, methotrexate is commonly given concomitantly with other antitumor agents. Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods. Lymphosarcomas in Stage llI may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily. Mycosis fungoides (cutaneous T cell lymphoma): Therapy with methotrexate as a single agent appears to produce clinical responses in up to 50% of patients treated. Dosage in early stages is usually 5 to 50 mg once weekly. Dose reduction or cessation is guided by patient response and hematologic monitoring. Methotrexate has also been administered twice weekly in doses ranging from 15 to 37.5 mg in patients who have responded poorly to weekly therapy. Combination chemotherapy regimens that include intravenous methotrexate administered at higher doses with leucovorin rescue have been utilized in advanced stages of the disease.@@@@@@@1.Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks.2.Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. 3.Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs). 4.Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. 5.Methotrexate-induced lung disease is a potentially dangerous lesion, which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation. 6.Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. 7.Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. 8.Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication. 9.Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy. 10.Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. 11.Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@MTX HEXAL@@@@@MTX HEXAL||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@11.04@24.94@12.09@@@@@@@@@@0.22@@@@@@@@@@@@@@@@8/1/2017@11.04@11.04@4507440@SOLUTION FOR INJECTION (2 ML)@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14920286@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients were randomised to receive either 400 mg or 600 mg orally q.d.@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920286@Indicated for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).@@NO@@@NO REVIEW@@@@Co-pay tier 2. SOURCE: Aetna Preferred Drug Guide 2008@@@@147@The recommended dose of Glivec is 400 mg/day for adult patients with unresectable and/or metastatic malignant GIST. At the time of analysis, the treatment duration was a median of 7 months.@FDA, 22 February 2002@2/22/2002@@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@AUGUST 2009 (PAEDIATRIC)@PATIENTS WITH UNRESECTABLE OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)@ADULT, CD 117 POSITIVE@@II@APPROVED@@Patients with marginally resectable or resectable GIST lesions with risk of significant morbidity should be treated with imatinib. Close monitoring is essential, because some patients may rapidly become unresectable. Surgery is recommended if bleeding and/or symptoms are present. PET scans allow rapid assessment of imatinib therapy. Baseline CT with or without MRI followed by subsequent PET scans about 2-4 weeks after therapy should be considered to assess therapeutic effect. If there is no progression, resection should be considered, if possible (GIST-2). In stable and responding patients, imatinib therapy should be continued until maximal response, which may take 3-6 months. If there is progression, as confirmed with CT scan, surgery is recommended after discontinuing imatinib (GIST-2). Imatinib dosing can be stopped right before surgery and resumed as soon as the patient is able to tolerate oral medications following surgery. SOURCE: NCCN@MEDICARE@There were no differences in RRs between the 2 dose groups. For the 99 responders to imatinib observed in the GIST study, the Kaplan-Meier estimate of median duration of response is 118 weeks (95% CI: 96, not reached) The median time to response was 12 weeks (range was 3-98 weeks).@The majority of Gleevec-treated patients experienced adverse reactions at some time. The most frequently reported adverse reactions were edema, nausea, diarrhea, abdominal pain, muscle cramps, fatigue, and rash. Most reactions were of mild-to-moderate severity. Drug was discontinued for adverse reactions in 7 patients (5%) in both dose levels studied. Superficial edema, most frequently periorbital or lower extremity edema, was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec. Severe (CTC Grade 3/4) superficial edema was observed in 3 patients (2%), including facial edema in one patient. Grade 3/4 pleural effusion or ascites was observed in 3 patients (2%)@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Sarcoma@GIST@@@@Sarcoma|GIST||||||||@GLEEVEC@@@@@GLEEVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@OPEN-LABEL@INTERNATIONAL@RANDOMISED@@@1@1@79746.80449@@@7@month@7 month@79746.8@79746.8@374.55@90@1@8427.44@@@@@@@@@@@@0.94@1@@mg@400@1@@@@@@@@@@@8/2/2017@93.64@93.64@00078-0401-34@TABLET@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
15398316@Onco@@@@@300f1015ntsdm@@@@@@Drug: Lapatinib 1500 mg orally once a dayDrug: Letrozole 2.5 mg orally once a day@@L01XE07@L01X@@BRENTFORD, UNITED KINGDOM@6/1/2008@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@15398316@Indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy.@Female@NO@3-Nov-10@11/3/2010@NO REVIEW@@@@100%@@FIRST-LINE@NCT00073528@1286@The recommended dose of Tyverb is 1500 mg (i.e. six tablets) once daily continuously.@EMA, 18 February 2010@2/18/2010@6/21/2012@No@@12/1/2003@@EGF30008@No@@Subjects must have histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery [Singletary, 2002];Tumors that are ER+ and/or PgR+;Subjects will be considered ER+ or PgR+ if any assay [cytochemical, immunochemical, immunohistochemistry (IHC), or radioimmunoassay] of primary or secondary tumor tissue is positive;@@ADULTS@III@APPROVED@@ASMR V, 3 November 2010, http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/tyverb_ct_8653.pdf@HAUTE AUTORITÉ DE SANTÉ@Endpoint is 6 months.@@@@@COMBO@LAPATINIB@LETROZOLE@@@@LAPATINIB|LETROZOLE|||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TYVERB@FEMARA@@@@TYVERB|FEMARA|||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@ADVANCED@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@1@1@22186.0638@@@35.4@week@35.4 week@22186.06@22186.06@89.53@84@1.1511@1253.45@1394.56@1283.45@@@@@@@@@@0.06@1@@mg@1500@1@@@@@@@@@@@8/1/2017@14.92@14.92@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France
16624035@Onco@@@@@300f1012ntsdm@@@@@@@@L01XX52@L01X@@UNITED STATES@10/1/2017@@Venetoclax is a potent, selective inhibitor of B-cell lymphoma (BCL)-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumour cell survival and has been associated with resistance to chemotherapeutics. Venetoclax binds directly to the BH3-binding groove of BCL-2, displacing BH3 motif-containing pro-apoptotic proteins like BIM, to initiate mitochondrial outer membrane permeabilization (MOMP), caspase activation, and programmed cell death. In non-clinical studies, venetoclax has demonstrated cytotoxic activity in tumour cells that overexpress BCL-2.@@16624035@Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.@Both@NA@15-Jun-17@6/15/2017@NO REVIEW@@@@0%@@@NCT02141282@120@Week 1: 20 mg daily, week 2: 50 mg daily, week 3: 100 mg daily, week 4: 200 mg daily, week 5 onwards: 400 mg daily. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed@EMA, 5 December 2016@12/5/2016@1/1/2017@Yes@@9/1/2014@@M14-032@No@@Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) criteria; Subject has relapsed/refractory disease with an indication for treatment; Subject has refractory disease or developed recurrence after therapy with a BCR PI; Subject must have an Eastern Cooperative Oncology Group performance score of equal to or less than 2; Subject must have adequate bone marrow function at Screening; Subject must have adequate coagulation profile, renal, and hepatic function, per laboratory reference range at Screening.@@ADULTS@II@APPROVED@@15 June 2017, Benefit not quantifiable, [https://www.g-ba.de/downloads/39-261-2970/2017-06-15_AM-RL-XII_Venetoclax_D-266_BAnz.pdf]@@@@@@@MONO@VENETOCLAX@@@@@VENETOCLAX||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@VENCLYXTO@@@@@VENCLYXTO||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@OVERALL RESPONSE RATE@@@@@DURATION OF RESPONSE@TIME TO PROGRESSION@PROGRESSION FREE SURVIVAL@@@RELAPSED@@@@@Non-Randomized@Single Group Assignment@NO MASKING@@@1@1@599943.6437@@@11.7@month@11.7 month@599943.64@599943.64@1685.86@14@1.1511@628.04@805.02@648.52@@@@@@@@@@4.49@28@1@mg@92.5@28@1@@mg@400@1@@@@@@8/1/2017@44.86@44.86@12448757@FILM COATED TABLET@EURO@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14917791@Onco@@@@@300f1037ntsdm@@@@@@Patients received Fareston 60MG, tamoxifen 40MG or tamoxifen 20MG.@@L02BA02@L02B@NO@@@@Toremifene is a nonsteroidal triphenylethylene derivative. As other members of this class, e.g. tamoxifen and clomifene, toremifene binds to oestrogen receptors and may produce oestrogenic, anti-oestrogenic or both effects, depending upon the duration of treatment, animal species, gender, target organ and variable selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly anti-oestrogenic in rats and man and oestrogenic in mice.@@14917791@First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with oestrogen receptor negative tumours.@@NO@@@NO REVIEW@@@@90%@>> Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009] >> Acquired through takeover of Organon in 2007@@@1157@The recommended dose is 60 mg, one tablet, daily. There is no relevant indication for use in children.@EMA,14 February 1996@2/14/1996@1/22/1997@@@@As with other anti-oestrogens, hypercalcaemia and tumour flare have been reported in some breast cancer patients with bone metastases during the first weeks of treatment. Tumour flare is a syndrome of diffuse musculoskeletal pain and erythema with increased size of tumor lesions that later regress.@LABEL@No@@@@@III 3 STUDIES@APPROVED@@NO REVIEW@SNS@RR was 21.3% and 19.1%, 20.4% and 20.8%, and 31.3% and 37.3% for the Fareston (60MG) and tamoxifen (20MG, 40MG, 40MG) respectively. Median TTP was 5.6 and 5.8 months, 4.9 and 5.0 months, and 7.3 and 10.2 months respectively.@@@@@@TOREMIFENE CITRATE@@@@@TOREMIFENE CITRATE||||@ORION PHARMA@SCHERING-PLOUGH@@@@ORION PHARMA|SCHERING-PLOUGH|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FARESTON@@@@@FARESTON||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@TIME TO PROGRESSION@@@@@@@@@METASTATIC@@@@@PROSPECTIVE@RANDOMISED@PLACEBO-CONTROLLED@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@75.18@117.36@81.34@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@0.75@0.75@679357@TABLET@EURO@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14920478@Onco@@@@@300f1015ntsdm@@@@@@Initial dose at 8 mg/kg as an intravenous infusion over 90 minutes. Subsequent doses at 6 mg/kg as an intravenous infusion over 30−90 minutes everythree weeks.@@L01XC03@L01X@YES@BASEL, SWITZERLAND@@@Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2@@14920478@Metastatic Breast Cancer (MBC): Herceptin is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2: a) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. b) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. c) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. d) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer, not previously treated with trastuzumab.   Early Breast Cancer (EBC): Herceptin is indicated for the treatment of patients with HER2 positive early breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). Herceptin should only be used in patients whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.  Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.@@YES@4-Oct-06@10/4/2006@NO REVIEW@@@@@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008@@NCT00045032@3752@EBC 3-weekly schedule: In the HERA trial, Herceptin was initiated after completions of standard chemotherapy (most commonly, anthracycline-containing regimens or anthracyclines plus a taxane). Initial loading dose of 8 mg/kg body weight, followed by 6 mg/kg body weight 3 weeks later and then 6 mg/kg repeated at 3-weekly intervals administered as infusions over approximately 90 minutes. Patients with early breast cancer should be treated for 1 year or until disease recurrence. If the patient misses a dose of Herceptin by one week or less, then the usual dose of Herceptin (6 mg/kg) should be given as soon as possible (do not wait until the next planned cycle). Subsequent maintenance Herceptin doses of 6 mg/kg should then be given every 3 weeks, according to the previous schedule. If the patient misses a dose of Herceptin by more than one week, a re-loading dose of Herceptin should be given (8 mg/kg over approximately 90 minutes). Subsequent maintenance Herceptin doses of 6 mg/kg should then be given every 3 weeks from that point.@22-May-06@5/22/2006@12/1/2000@@@@Cardiomyopathy: Herceptin can cause left ventricular cardiac dysfunction and congestive heart failure (CHF) with disabling cardiac failure, death, and mural thrombosis leading to stroke. The risk of cardiac dysfunction was increased in geriatric patients. Pulmonary Toxicity: Herceptin administration can result in serious infusion reactions and pulmonary toxicity. Severe reactions which include bronchospasm, hypoxia, and severe hypotension were reported. Pulmonary toxicity includes dyspnea, pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.@HERA@No@@PATIENTS WHO WERE REQUIRED TO SHOW HER2 OVEREXPRESSION (3+ BY IHC) OR GENE AMPLIFICATION (BY FISH) WERE RANDOMISED PRIOR TO A PRE-SPECIFIED INTERIM ANALYSIS. THE DATA FROM BOTH ARMS IN STUDY 1 AND TWO OF THE THREE STUDY ARMS IN STUDY 2 WERE POOLED. H@@@HERA (BO16348); NCCTG N9831; NSABP B-31@APPROVED@@In the adjuvant treatment of HER2-positive breast cancer, Herceptin makes a major improvement in therapeutic effectiveness versus standard of care and has been allocated an ASMR rating of I (Transparency Commission).@HAUTE AUTORITÉ DE SANTÉ@Among the 1880 patients who received AC => paclitaxel, the number of events reported were 261 for DFS and 92 for OS. Among the 1872 patients who received AC => paclitaxel + Herceptin, the number of events reported were 133 for DFS and 62 for OS. Hazard ratio (95% CI) is 0.48 (0.39-0.59) for DFS (p<0.0001) and 0.67 for OS (log-rank test non significant).@The following non-cardiac adverse reactions of Grade 2-5 occurred at an incidence of at least 2% greater among patients randomized to Herceptin plus chemotherapy as compared to chemotherapy alone: arthralgia (31% vs. 28%), fatigue (28% vs. 22%), infection (22% vs. 14%), hot flashes (17% vs. 15%), anemia (13% vs. 7%), dyspnea (12% vs. 4%), rash/desquamation (11% vs. 7%), neutropenia (7% vs. 5%), headache (6% vs. 4%), and insomnia (3.7% vs. 1.5%). The majority of these events were Grade 2 in severity.@@@@ADJUVANT@TRASTUZUMAB@@@@@TRASTUZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@HERCEPTIN@@@@@HERCEPTIN||||@mAb@Humanised@TK Inhibitor@HER2@@mAb|Humanised|TK Inhibitor|HER2|@DISEASE-FREE SURVIVAL@@@@@@@@@@EARLY@@@@@RANDOMISED@OPEN-LABEL@@@@60@kg@22311.13029@@@52@week@52 week@22311.13@22311.13@61.29@1@1.1511@499.29@@@@@@@@@@@@3.33@1@1@mg/kg@8@1@21@@mg/kg@6@1@@@@@@8/2/2017@499.29@499.29@9220097R@POWDER FOR PERFUSION, 15 ML@EURO@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
14919504@Onco@@@@@300f1015ntsdm@@@@@@Carboplatin (300mg/m2) and cyclophosphamide (600mg/m2) versus cisplatin (100 or 75mg/m2) and cyclophosphamide.@@L01XA02@L01X@YES@PARIS, FRANCE@@@Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.@@14919504@Indicated for the treatment of: 1. advanced ovarian carcinoma of epithelial origin in  (a) first line therapy (b) second line therapy, after other treatments have failed. 2. small cell carcinoma of the lung.@@YES@@@NO REVIEW@@@@@Dakota Pharm is a subsidiary of sanofi-aventis.@FIRST-LINE@@789@Single-Agent Therapy: has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide:an effective combination for previously untreated patients consists of: Paraplatin—300 mg/m2 I.V. on day 1 every four weeks for six cycles. Cyclophosphamide—600 mg/m2 I.V. on day 1 every four weeks for six cycles. Intermittent courses of Paraplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.@1-Nov-03@11/1/2003@1/1/2008@@@@Paraplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.@LABEL@No@@342 ADVANCED OVARIAN CANCER PATIENTS (SWOG) 447 ADVANCED OVARIAN CANCER PATIENTS (NCIC)@@@III; SWOG + NCIC@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@SWOG: Carboplatin versus cisplatin: 58% (48/83) versus 43% (33/76) respectively. Complete response: 10% (17/171) versus 10% (17/171). Median PFS: 49 versus 47 weeks. 2-year PFS: 21% versus 21%. 3-year PFS: 8% versus 14%. Median survival: 86 versus 79 weeks. 2-year survival: 40% versus 39%. 3-year survival: 18% versus 25%. NCIC: Carboplatin versus cisplatin: Clinical response  60% (48/80) versus 58% (49/85) respectively. Complete response: 11% (24/224) versus 15% (33/223). Median PFS: 59 versus 61 weeks. 2-year PFS: 31% versus 31%. 3-year PFS: 19% versus 23%. Median survival: 110 weeks versus 99 weeks. 2-year survival: 52% versus 48%. 3-year survival: 35% versus 33%.@@@@@COMBO@CARBOPLATIN@CYCLOPHOSPHAMIDE@@@@CARBOPLATIN|CYCLOPHOSPHAMIDE|||@DAKOTA PHARM@SANOFI-AVENTIS@@@@DAKOTA PHARM|SANOFI-AVENTIS|||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@RESPONSE RATE@COMPLETE RESPONSE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@ADVANCED@RELAPSED@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Incorrect Average Duration of Use (Unit)@@@6@course@6 course@@@@1@1.1511@19@@@@@@@@@@@@0.04@@@@@@@@@@@@@@@@8/2/2017@19@19@9239151R@INJECTABLE SOLUTION FOR PERFUSION VIAL, 45 ML@EURO@@@@@@@@450@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France
16395670@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients with a creatinine clearance >60 mL/min were given lenalidomide at a dose of 25 mg once daily for 21 days every 28 days. Patients with a creatinine clearance ≥30 mL/min and <60 mL/min were given lenalidomide at a dose of 10 mg once daily for 21 days every 28 days. Treatment was continued until disease progression, unacceptable toxicity, or withdrawal of consent.@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@16395670@Indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.@Both@NA@@@NO REVIEW@@@@@@SECOND-LINE@@134@The recommended starting dose of REVLIMID is 10 mg daily. Treatment is continued or modified based upon clinical and laboratory findings.@FDA, 5 June 2013@6/5/2013@@Yes@@@@@No@@The trial included patients who were at least 18 years of age with biopsyproven MCL with measurable disease by CT scan. Patients were required to have received prior treatment with an anthracycline or mitoxantrone, cyclophosphamide, rituximab, and bortezomib, alone or in combination. Patients were required to have documented refractory disease (defined as without any response of PR or better during treatment with bortezomib or a bortezomibcontaining regimen), or relapsed disease (defined as progression within one year after treatment with bortezomib or a bortezomibcontaining regimen). At enrollment patients were to have an absolute neutrophil counts (ANC) ≥1500/ mm3, platelet counts ≥ 60,000/mm3, serum SGOT/AST or SGPT/ALT ≤3x upper limit of normal (ULN) unless there was documented evidence of liver involvement by lymphoma, serum total bilirubin ≤1.5 x ULN except in cases of Gilbert's syndrome or documented liver involvement by lymphoma, and calculated creatinine clearance (CockcroftGault formula) >30 mL/min.@@ADULTS@@APPROVED@@@@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@@Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@OVERALL RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@SINGLE ARM@MULTI-CENTRE@OPEN LAB EL@@@1@1@27108.2397@@@2.2@month@2.2 month@27108.24@27108.24@405.11@21@1@12761.07@@@@@@@@@@@@40.51@1@@mg@10@1@@@@@@@@@@@8/2/2017@607.67@607.67@59572-0415-21@HARD CAPSULE@US$@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14919788@Onco@@@@@300f1037ntsdm@@@@@@100 mg/m²@@L01DB03@L01D@YES@LAKE FOREST, ILLINOIS@@@Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.@@14919788@Epirubicin is used in the treatment of a range of neoplastic conditions including • Breast, ovarian, gastric, lung and colorectal carcinomas • Malignant lymphomas • Leukaemias • Multiple myeloma. When administered intravesically, epirubicin has been shown to be beneficial in the treatment of • Papillary transitional cell carcinoma of the bladder • Carcinoma-in-situ • Prophylaxis of recurrences after transurethral resection.@@YES@@@NO REVIEW@@@@90%@Acquired through takeover of Mayne Pharma@FIRST-LINE@@565@High dose: Epirubicin as a single agent for the high dose treatment of lung cancer should be administered according to the following regimens: • Small cell lung cancer (previously untreated): 120 mg/m2 day 1, every 3 weeks. • Non-small cell lung cancer (squamous, large cell, and adenocarcinoma previously untreated): 135 mg/m2 day 1 or 45 mg/m2 day 1, 2 and 3 every 3 weeks. For high dose treatment, epirubicin may be given as an intravenous bolus over 3-5 minutes or as an infusion of up to 30 minutes duration. Breast Cancer: In the adjuvant treatment of early breast cancer patients with positive lymph nodes, intravenous doses of epirubicin ranging from 100 mg/m2 (as a single dose on day 1) to 120 mg/m2 (in two divided doses on days 1 and 8) every 3-4 weeks, in combination with intravenous cyclophosphamide and 5-fluorouracil and oral tamoxifen, are recommended. Lower doses (60-75 mg/m2 for conventional treatment and 105-120 mg/m2 for high dose treatment) are recommended for patients whose bone marrow function has been impaired by previous chemotherapy or radiotherapy, by age, or neoplastic bone marrow infiltration. The total dose per cycle may be divided over 2-3 successive days.@8-May-06@5/8/2006@12/21/2006@@@@Occurrence of severe local tissue necrosis if extravasation during administration; intramuscular and subcutaneous routes of administration not allowed; during or after therapy occurrence of severe form of myocardial toxicity; cases of secondary acute myelogenous leukemia and refractory secondary leukaemia reported in patients treated with anthracyclines used in mono or combination therapy with DNA-damaging antineoplastic agents; cases of severe myelosuppression; advice of reduced dosage in patients with impaired hepatic function@GFEA-05@No@@565 PRE AND POSTMENOPAUSAL WOMEN WITH MORE THAN 4 NODES INVOLVED WITH TUMOR OR LESS THAN 4 POSITIVE NODES WITH NEGATIVE ESTROGEN ABND PROGESTERONE RECEPTORS AND A HISTOLOGIC TUMOR GRADE OF 2 OR 3. ALL 565 WOMEN RECEIVED A COMBINATION OF FLUOROURACIL, ELLE@@@III@APPROVED@@NO REVIEW@SNS@FEC-100 regimen showed a longer RFS after 5 years (65% for the FEC-100 regimen and 52% for the FEC-50 regimen - stratified logrank p=0,007) and after 10 years (49% of the FEC-100 regimen and 43% of the FEC-50 regimen - stratified logrank p=0,040 - unstratified logrank p=0,09) and a longer OS after 5 years (76% for the FEC-100 regimen and 65% for the FEC-50 regimen - stratified logrank p=0,007) and after 10 years (56% of the FEC-100 regimen and 50% of the FEC-50 regimen - stratified logrank p=0,023 - unstratified logrank p=0,039) - results based on Kaplan-Meier methods@@@@@COMBO@EPIRUBICIN HYDROCHLORIDE@@@@@EPIRUBICIN HYDROCHLORIDE||||@HOSPIRA@@@@@HOSPIRA||||@@@@@@|||||||||@Breast Cancer@Ovarian Cancer@Stomach Cancer@NSCLC@SCLC@Breast Cancer|Ovarian Cancer|Stomach Cancer|NSCLC|SCLC|||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RELAPSE-FREE SURVIVAL@OVERALL SURVIVAL@@@@@@@@@@@@@@RANDOMISED@COMPARATIVE@OPEN-LABEL@MULTI-CENTRE@@@@Invalid Dosage Value Phase 1@@@126@day@126 day@@@@1@1.1511@45.1@70.4@48.77@@@@@@@@@@0.45@@@@@@@@@@@@@@@@8/4/2017@45.1@45.1@654367@INJECTABLE SOLUTION, 50 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14918828@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@V03AF03@V03A@NO@BEDFORD, OHIO@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14918828@Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form.@@NO@@@NO REVIEW@@@@@@@@@Advanced Colorectal Cancer: Either of the following two regimens is recommended: 1. Leucovorin is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 2. Leucovorin is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenous injection.@FDA, 01 Jun 1952@6/1/1952@@@@@In the treatment of accidental overdosages of folic acid antagonists, intravenous leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting toxicity decreases. In the treatment of accidental overdosages of intrathecally adminstered folic acid antagonists, do not adminster leucovorin intrathecally. Leucovorin may be fatal if given intrathecally. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@GENERIC@@@@@GENERIC||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0009-01@INJECTION (VIAL)@US$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
14921292@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01BA01@L01B@YES@HOLZKIRCHEN, GERMANY@@@Methotrexate is an antimetabolite which acts principally by competitively inhibiting the enzyme, dihydrofolate reductase. In the process of DNA synthesis and cellular replication, folic acid must be reduced to tetrahydrofolic acid by this enzyme, and inhibition by methotrexate interferes with tissue cell reproduction. Actively proliferating tissues such as malignant cells are generally more sensitive to this effect of methotrexate. It also inhibits antibody synthesis.@@14921292@Neoplastic Diseases: indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides, (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Psoriasis: indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis: indicated in the management of selected adults with severe, active, rheumatoid arthritis (ARC criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Novartis purchases Hexal and Eon Labs in a 5.65 billion euro deal. [Novartis, 21.02.2005]@@@@Lymphomas: In Burkitt's tumor, Stages I-II, methotrexate has produced prolonged remissions in some cases. Recommended dosage is 10 to 25 mg/day orally for 4 to 8 days. In Stage III, methotrexate is commonly given concomitantly with other antitumor agents. Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods. Lymphosarcomas in Stage llI may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily. Mycosis fungoides (cutaneous T cell lymphoma): Therapy with methotrexate as a single agent appears to produce clinical responses in up to 50% of patients treated. Dosage in early stages is usually 5 to 50 mg once weekly. Dose reduction or cessation is guided by patient response and hematologic monitoring. Methotrexate has also been administered twice weekly in doses ranging from 15 to 37.5 mg in patients who have responded poorly to weekly therapy. Combination chemotherapy regimens that include intravenous methotrexate administered at higher doses with leucovorin rescue have been utilized in advanced stages of the disease.@@@@@@@1.Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks.2.Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration. 3.Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some NSAIDs). 4.Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. 5.Methotrexate-induced lung disease is a potentially dangerous lesion, which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation. 6.Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. 7.Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. 8.Like other cytotoxic drugs, methotrexate may induce “tumor lysis syndrome” in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication. 9.Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy. 10.Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. 11.Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@METHOTREXATE@@@@@METHOTREXATE||||@HEXAL@NOVARTIS@@@@HEXAL|NOVARTIS|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@MTX HEXAL@@@@@MTX HEXAL||||@Anti-metabolite@Folic Acid Analogue@@@@Anti-metabolite|Folic Acid Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@1.1511@72.07@102.11@75.05@@@@@@@@@@0.29@@@@@@@@@@@@@@@@8/1/2017@7.21@7.21@7523600@SOLUTION FOR INJECTION (1 ML)@EURO@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14925065@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@M04AA01@M04A@NO@@@@@@14925065@Indicated in the management of patients with signs and symptomas of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephroptahy; the management of patients with leukaemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment should be discontinued when the potential for overproduction of uric acid is no longer presents; and, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. This is not an innocuous drug. It is not recommended for the treatment of asymptomatic hyperuricemia.@@NO@@@NO REVIEW@@@@90%@@@@@Dosage in Adults: Zyloric should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor (see Dosage in renal impairment). The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used. Dosage in children: Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.@EMA, 1 December 1966@12/1/1966@2/1/1967@@@@Zyloric should be withdrawn immediately when a skin rash or other evidence of sensitivity occurs. Reduced doses should be used in patients with hepatic or renal impairment. Patients under treatment for hypertension or cardiac insufficiency, for example with diuretics or ACE inhibitors, may have some concomitant impairment of renal function and allopurinol should be used with care in this group. Asymptomatic hyperuricaemia per se is generally not considered an indication for use of Zyloric. Fluid and dietary modification with management of the underlying cause may correct the condition. Acute gouty attacks: Allopurinol treatment should not be started until an acute attack of gout has completely subsided, as further attacks may be precipitated.@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@FAES FARMA, S.A.@@@@@FAES FARMA, S.A.||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@ZYLORIC@@@@@ZYLORIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@2@3.12@2.14@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@0.02@0.02@849612@TABLET@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain
14920381@Onco@@@@@300f1012ntsdm@@@@@@Patients were treated with Gleevec 340 mg/m2/day, with no interruptions in the absence of dose limiting toxicity.@@L01XE01@L01X@NO@BASEL, SWITZERLAND@@@Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from CML patients in blast crisis. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGFand SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation.@@14920381@Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is notconsidered as the first line of treatment.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@51@Pediatric Patients with Ph+ CML: The recommended dose of Gleevec for children with newly diagnosed Ph+ CML is 340 mg/m2/day (not to exceed 600 mg).@EMA, 7 November 2001@11/7/2001@@Yes@@@Women of childbearing potential should be advised to avoid becoming pregnant.@@No@@PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED AND UNTREATED CML IN CHRONIC PHASE WERE TREATED WITH GLEEVEC@PAEDIATRIC@@II; STUDY 2108@APPROVED@@NO REVIEW@GKV@CHR was observed in 78% of patients after 8 weeks of therapy. CCyR was 65%, comparable to the results observed in adults. PCyR was observed in 16%. The majority of patients who achieved a CCyR developed the CCyR between months 3 and 10 with a median time to response of 6.74 months.@The majority of Gleevec-treated patients experienced adverse reactions at some time. Most reactions were of mild-to-moderate grade, but drug was discontinued for drug-related adverse reactions in 2.4% of newly diagnosed patients, 4% of patients in chronic phase after failure of interferon-alpha therapy, 4% in accelerated phase and 5% in blast crisis. The most frequently reported drug-related adverse reactions were edema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhea and rash. Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec. The frequency of severe superficial edema was 1.5%-6%. The overall safety profile of pediatric patients treated with Gleevec in 93 children studied was similar to that found in studies with adult patients, except that musculoskeletal pain was less frequent (20.5%) and peripheral edema was not reported. Nausea and vomiting were the most commonly reported individual adverse reactions with an incidence similar to that seen in adult patients. Although most patients experienced adverse reactions at some time during the study, the incidence of Grade 3/4 adverse reactions was low.@@@@MONO@IMATINIB MESYLATE@@@@@IMATINIB MESYLATE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@GLIVEC@@@@@GLIVEC||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@CHRONIC PHASE@@@@@OPEN-LABEL@MULTI-CENTRE@SINGLE-ARM@@@1.2@m²@19053.8972@@@6.74@month@6.74 month@19053.9@19053.9@92.94@30@1.1511@2733.65@3407.95@2772.15@@@@@@@@@@0.23@1@@mg/m²@340@1@@@@@@@@@@@8/1/2017@91.12@91.12@1755195@FILM-COATED TABLET@EURO@@@@@@@@400@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14918299@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@H02AB02@H02A@YES@CRAIGAVON, UNITED KINGDOM@@@Dexamethasone is a synthetic glucocorticoid whose anti-inflammatory potency is 7 times greater than prednisolone. Like other glucocorticoids, dexamethasone also has anti-allergic, antipyretic and immunosuppressive properties. Dexamethasone has practically no water and salt-retaining properties and is, therefore, particularly suitable for the use in patients with cardiac failure or hypertension. Because of its long biological half-life (36-54 hours), dexamethasone is especially suitable in conditions where continuous glucocorticoid action is desired.@@14918299@Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Haematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anaemia), idiopathic thrombocytopaenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopaenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumour, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.@@@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@N/A@Adults: Usually, daily oral dosages of 0.5 - 10 mg are sufficient. In some patients higher dosages may be temporarily required to control the disease. Once the disease is under control the dosage should be reduced or tapered off to the lowest suitable level under continuous monitoring and observation of the patient. For a short dexamethasone suppression test, 1mg dexamethasone is given at 11 p.m. and plasma cortisol measured the next morning. Patients who do not show a decrease in cortisol can be exposed to a longer test: 500 micrograms dexamethasone is given at 6 hourly intervals for 48 hours followed by 2mg every 6 hours for a further 48 hours. 24 hour-urine collections are made before, during and at the end of the test for determination of 17-hydroxycorticosteroids. Children: 0.01-0.1mg/kg of body weight daily.@@@@@@@Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity. Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@DEXAMETHASONE ACETATE@@@@@DEXAMETHASONE ACETATE||||@GALEN PHARMACEUTICALS@@@@@GALEN PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Anaemia@Haematological Malignancy@Breast Cancer@@Supportive Care|Anaemia|Haematological Malignancy|Breast Cancer||||||@GENERIC@@@@@GENERIC||||@Corticosteroid@@@@@Corticosteroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@53.96@79.21@56.36@@@@@@@@@@0.13@@@@@@@@@@@@@@@@8/1/2017@0.54@0.54@745645@TABLET@EURO@@@@@@@@4@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany
14916519@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@L01XA01@L01X@YES@BEDFORD, OHIO@@@Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent. Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.@@14916519@Platinol is indicated as therapy to be employed as follows: Metastatic Testicular Tumors: In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors: In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Platinol and Cytoxan (cyclophosphamide). Platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Platinol therapy. Advanced Bladder Cancer: Platinol is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.@@NO@@@NO REVIEW@@@@@@@@@Metastatic ovarian tumours; the usual dose is 75-100mg/m2 IV per cycle once every 4 weeks when used sequentially with Cytoxan (which is dosed at 600mg/m2 IV once every four weeks. As a single-agent, it should be administered at 100mg/m2 IV per cycle once every 4 weeks.@@@@@@@Platinol-AQ produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, it should not be given more frequently than once every 3 to 4 weeks. Elderly patients may be more susceptible to nephrotoxicity. There are reports of severe neuropathies in patients in whom regimens are employed using higher doses or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral neuropathy. Loss of motor function has also been reported. Anaphylactic-like reactions have been reported within minutes of administration to patients with prior exposure, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@CISPLATIN@@@@@CISPLATIN||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@ADVANCED@METASTATIC@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0112-99@SOLUTION FOR INJECTION (VIAL) - 100 ML@US$@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States
